DRAMP_ID	Sequence	Sequence_Length	Name	Source	Activity	Patent_No	Patent_Type	Publication_Date	Also_Publication_As	Patent_Title	Abstract
DRAMP04719	VNPGVVVRISQKGLDYASQQGTAALQXXLKHIKIPDYL	38	Sequence 3 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04720	IIGGRESRPHSRPYMAYLQIQXPA	24	Sequence 4 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04721	KVFERXELARTLKRL	15	Sequence 5 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04722	VNPGVVVRISQKGLDYASQQGTAALQXXLKNIKIPDYL	38	Sequence 6 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04723	TCRYLLVRSLQTFSQAXFTXRRXYRGNLVSINNFNINYRI	40	Sequence 7 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04724	KNLRRXXRKXXHIIKKYG	18	Sequence 1 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04725	KNLRRIIRKIIHIIKKYG	18	Sequence 2 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04726	KNLRRGIRKIIHIIKKYG	18	Sequence 3 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04727	KNLRRTIRKIIHIIKKYG	18	Sequence 4 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04728	KNLRRSIRKIIHIIKKYG	18	Sequence 5 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04729	KNLRREIRKIIHIIKKYG	18	Sequence 6 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04730	KNLRRDIRKIIHIIKKYG	18	Sequence 7 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04731	KNLRRAIRKIIHIIKKYG	18	Sequence 8 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04732	KNLRRIGRKIIHIIKKYG	18	Sequence 10 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04733	KNLRRITRKIIHIIKKYG	18	Sequence 11 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04734	KNLRRISRKIIHIIKKYG	18	Sequence 12 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04735	KNLRRIERKIIHIIKKYG	18	Sequence 13 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04736	KNLRRIDRKIIHIIKKYG	18	Sequence 14 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04737	KNLRRIARKIIHIIKKYG	18	Sequence 15 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04738	KNLRRIIRKGIHIIKKYG	18	Sequence 17 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04739	KNLRRIIRKTIHIIKKYG	18	Sequence 18 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04740	KNLRRIIRKSIHIIKKYG	18	Sequence 19 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04741	KNLRRIIRKEIHIIKKYG	18	Sequence 20 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04742	KNLRRIIRKDIHIIKKYG	18	Sequence 21 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04743	KNLRRIIRKAIHIIKKYG	18	Sequence 22 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04744	KNLRRIIRKIGHIIKKYG	18	Sequence 24 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04745	KNLRRIIRKITHIIKKYG	18	Sequence 25 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04746	KNLRRIIRKISHIIKKYG	18	Sequence 26 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04747	KNLRRIIRKIEHIIKKYG	18	Sequence 27 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04748	KNLRRIIRKIDHIIKKYG	18	Sequence 28 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04749	KNLRRIIRKIAHIIKKYG	18	Sequence 29 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04750	KNLRRIIRKGIRIIKKYG	18	Sequence 32 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04751	KRLRRIIRKGIHIIKKYG	18	Sequence 34 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04752	RRLRRIIRKGIRIIKKYG	18	Sequence 36 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04753	MRIHYLLFALLFLFLVPVPGHGGIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	67	Sequence 2 from Patent US 20020115602	Synthetic construct	Antimicrobial	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04754	TLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	41	Sequence 3 from Patent US 20020115602	Synthetic construct	Antimicrobial	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04755	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	45	Sequence 4 from Patent US 20020115602	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04756	WCFAVCRRGRCRYKCRR	17	Sequence 1 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04757	WCFAVCYRGRCRRKCRR	17	Sequence 2 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04758	FRWCFRVCYKGRCRYKCR	18	Sequence 3 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04759	RRWCFRVCYKGFCRYKCR	18	Sequence 4 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04760	RRWCFRVCYRGFCRYFCR	18	Sequence 5 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04761	RRWCFIVCRRGACYRRCR	18	Sequence 6 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04762	RRWCFIVCRRGRCYVACRR	19	Sequence 7 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04763	RVWCRRRCYRGFCRYFCR	18	Sequence 8 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04764	RVWCRYRCYRGFCRRFCR	18	Sequence 9 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04765	RRWCRRVCYAGFCYRKCR	18	Sequence 10 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04766	RRWCFRVCYRGRFCYRKCR	19	Sequence 11 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04767	KWCFRVCYRGICYRRCR	17	Sequence 12 from Patent US 20020156017	Tachypleus tridentatus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04768	RRWCFRVCYRGFCYRKCR	18	Sequence 13 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04769	WCFXVCXRGXCRXKCRR	17	Sequence 14 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04770	XRWCFRVCYXGXCXXXCR	18	Sequence 15 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04771	RRWCFXVCXRGXCYXXCRX	19	Sequence 16 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04772	RXWCXXXCYRGFCXXXCR	18	Sequence 17 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04773	RRWCXRVCYXGFCYRKCR	18	Sequence 18 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04774	RRWCFRVCYRGXFCYRKCR	19	Sequence 19 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04775	GIGKFLKSAKKFGKAFVKILNS	22	Sequence 3 from Patent US 20020162135	Synthetic construct	Antimicrobial	US 2002/0162135 A1	Patent Application	2002##10##31	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Expression of antimicrobial peptide via the plastid genome to control phytopathogenic bacteria.	This invention provides a novel method to confer disease resistance to plants. Plant plastids are transformed using a plastid vector which contains heterologous DNA sequences coding for a cytotoxic antimicrobial peptide. Transgenic plants are capable of fighting off phytopathogenic bacterial infection.
DRAMP04776	RQRDPQQQAEQAQKRAQRRETE	22	Sequence 9 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04777	PRHMQIAQQRAERRAEKEKRKQQKR	25	Sequence 10 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04778	SEQIDNMAWFHVSVCNAVFVVIIIIMLLMFVPVVRG	36	Sequence 11 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04779	MGHHHHHHHHHHSSGHIEGRHM	22	Sequence 16 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04780	RSGRGECRRQCLRRHEGQPWETQECMRRCRRRG	33	Sequence 23 from Patent US 20020168392	Maize	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04781	VKEDHQFETRGEILECYRLCQQQ	23	Sequence 26 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04782	QKHRSQILGCYLXCQQL	17	Sequence 27 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04783	LDPIRQQQLCQMRCQQQEKDPRQQQQCK	28	Sequence 28 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04784	MAWFHVSVCNAVFVVIIIIMLLMFVPVVRGRQRDPQQQYEQCQKRCQRRETEPRHMQICQQRCERRYEKEKRKQQKR	77	Sequence 30 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04785	RVIRVVQRACRAIRHIVRRIRQGLRRIL	28	Sequence 1 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04786	RVIRVVQRACRAIRHIVRRIRQGLRRILRVV	31	Sequence 2 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04787	RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV	31	Sequence 3 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04788	RVVRVVRRVVRR	12	Sequence 4 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04789	RRVVRRVRRVVRRVVRVVRRVVRR	24	Sequence 5 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04790	VRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	36	Sequence 6 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04791	RRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	42	Sequence 7 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04792	RVVRVVRRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	48	Sequence 8 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04793	RVVRVVRRWVRR	12	Sequence 9 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04794	RRWVRRVRRVWRRVVRVVRRWVRR	24	Sequence 10 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04795	VRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	36	Sequence 11 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04796	RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWRVV	48	Sequence 12 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04797	RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	48	Sequence 12 from Patent US 6835713	Synthetic construct	Antimicrobial, Antibacterial	US 6835713 B2	Granted Patent	2004##12##28	US20020169279	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04798	MAVMKSRTVIVAAVLLAVVILSSLCPCYEAGGCTIGKPPKTPAPKRPCFSPYSEDHCDRQNCRFVCMSHGYSDGGWCDEREVRKMCCCYH	90	Sequence 2 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04799	MAVMKSRTVIVAAVLLAVVILSSLCPCYEAGGCIGKPPKTPAPKRPCFSPYSEDHCDRQNCRFVCMSHGYSDGGWCDEREVRKMCCCYH	89	Sequence 6 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04800	MMALNGGWRKTFVSILTTCFLVVVVIVSLSCEAKGGVVPRLRPPFCFPYDREYCTPFHCGKVCQEYNFPAKNGGYCDKRGDPWKCCCPY	89	Sequence 10 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04801	MAKFFNYTIVQGLLMLSMVLLASCVIHAHIISGETEEVSNIGSPTVMVTMGANRKIIGDNKNLLCYLKALEYCCERTKQCYDDIKKCLEHCHG	93	Sequence 14 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04802	MMTKCQKRASIQGLWLLSMVLLASSSLVCASMAVDGQTKEDINATSVTSMNMTRSSSASYNMTGGGGELNRGPCVVRSGFYWCQNIGYPTMSECLKNCES	100	Sequence 18 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04803	MARCLKSCSVHGLWLLSMILLASCVVHAHIINGRQSNTGSLTMTTTGEASMIIGDEKDAICYIKAALYCCKRTIQCYQDIAQCLRNCRKNV	91	Sequence 22 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04804	MIVGHGIDI	9	Sequence 6 from Patent US 20030068802	Streptococcus pneumoniae	Antimicrobial	US 2003/0068802 A1	Patent Application	2003##4##10	Unknown	Use of streptococcus pneumoniae acyl carrier protein synthase crystal structure in diagnostics, antimicrobial drug design, and biosensors.	Provided are methods of purifying and crystallizing Streptococcus pneumoniae acyl carrier protein synthase (AcpS) enzyme, crystals of AcpS, the use of such crystals to determine the three-dimensional structure of AcpS enzymes, and the three-dimensional structure of AcpS. The three-dimensional crystal structure of AcpS can be used in medical diagnostics to produce antibodies that permit detection of Streptococcus pneumoniae both in vitro and in vivo. The three-dimensional crystal structure of AcpS can also be used in pharmaceutical discovery and development to identify and design compounds that inhibit the biochemical activity of AcpS enzyme in bacteria. Inhibitory compounds identified in this way can be optimized by structure/activity studies to develop antibacterial pharmaceutical compounds useful for the prevention or treatment of bacterial infections.
DRAMP04805	FIHHIFRGIVHAGRSIGRFLTG	22	Sequence 1 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04806	FFHHIFRGIVHVGKTIHRLVTG	22	Sequence 2 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04807	FFHHIFRGIVHVGKTIHKLVTG	22	Sequence 3 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04808	FFRHLFRGAKAIFRGARQGXRAHKVVSRYRNRDVPETDNNQEEP	44	Sequence 4 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04809	HIFR	4	Sequence 5 from Patent US 20030083247	Synthetic construct	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04810	GIGKFLHSAGKFGKAFVGEIMKS	23	Sequence 1 from Patent US 20030092612	Xenopus laevis	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04811	GIGKFLHSAKKFGKAFVGEIMNS	23	Sequence 2 from Patent US 20030092612	Xenopus laevis	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04812	GIGKFLKKAKKFGKAFVKILKX	22	Sequence 3 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04813	GIGKFLKKAKKFGKAFVKILKK	22	Sequence 4 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04814	KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK	37	Sequence 5 from Patent US 20030092612	Silk moth	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04815	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG	36	Sequence 6 from Patent US 20030092612	Silk moth	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04816	MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG	38	Sequence 7 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04817	ACYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 8 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04818	CYCRIPACIAGERRYGTCIYQGRLWAFCC	29	Sequence 9 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04819	DCYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 10 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04820	VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR	33	Sequence 11 from Patent US 20030092612	Rabbit	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04821	RLCRVVIRVCR	11	Sequence 12 from Patent US 20030092612	Cow	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04822	KWKLFKKIGIGAVLKVLTTGLPALIX	26	Sequence 13 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04823	KWKGIGAVLKVLTTGX	16	Sequence 14 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04824	KWKLFKKIGIGAVLKVLTTGLPALKLTK	28	Sequence 1 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04825	KWKSFIKKLTTAVKKVLTTGLPALIS	26	Sequence 2 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04826	KWKSFIKKLTSAAKKVVTTAKPLALIS	27	Sequence 3 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04827	KWKSFIKKLTKAAKKVVTTAKKPLIV	26	Sequence 4 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04828	KWKKFIKSLTKSAAKTVVKTAKKPLIV	27	Sequence 5 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04829	KWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	32	Sequence 6 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04830	KLFKKIGIGAVLKVLKVLTTGLPALKLTLK	30	Sequence 7 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04831	KWKFKKIGIGAVLKVLKVLTTGLPALKLTLK	31	Sequence 8 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04832	KLWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	33	Sequence 9 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04833	KWKSFIKKLTSAAKKVTTAAKPLTK	25	Sequence 10 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04834	KWKKFIKKIGIGAVLKVLTTGLPALKLTKK	30	Sequence 11 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04835	KKWKKFIKKIGIGAVLTTPGAKK	23	Sequence 12 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04836	GWGSFFKKAAHVGKHVGKAALTHYL	25	Sequence 13 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04837	KGWGSFFKKAAHVGKHVGKAALTHYL	26	Sequence 15 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04838	ALWKTMLKKAAHVGKHVGKAALTHYL	26	Sequence 17 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04839	SIGSAFKKAAHVGKHVGKAALTHYL	25	Sequence 18 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04840	GWGSFFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 19 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04841	ALWKTMLKKAAHVGKHVGKAALGAAARRRK	30	Sequence 20 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04842	SIGSAFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 21 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04843	RQRVEELSKFSKKGAAARRRK	21	Sequence 22 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04844	ALWKTMLKKLGTMALHAGKAALGAAADTISQTQ	33	Sequence 23 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04845	SIGSAFKKALPVAKKIGKAALPIAKAALP	29	Sequence 24 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04846	KWKSFIKKLTSAAKKVVTTAKPLISS	26	Sequence 25 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04847	HVIGRFIHHFFCCFFHHIFRGIVH	24	Sequence 6 from Patent US 20030105281	Synthetic construct	Antimicrobial	US 2003/0105281 A1	Patent Application	2003##6##5	WO2002014345A2, WO2002014345A3, WO2002014346A2, WO2002014346A8	Antimicrobial peptides isolated from mast cells.	"Antimicrobial peptides (endobiotic peptides) isolated from mast cells are described, along with compositions containing the same and methods of use thereof. Such peptides obtained from fish mast cells are referred to as ""piscidins"" herein."
DRAMP04848	KWKSFIKNLTKGGSKILTTGLPALIS	26	Sequence 3 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04849	KWKKFIKNLTKGGSKILTTGLPALIS	26	Sequence 4 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04850	KWKSFIKNLEKVLKPGGLLSNIVTSL	26	Sequence 5 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04851	KWKSFIKNLEKVLKKGPILANLVSIV	26	Sequence 6 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04852	KWKEFIKKLTTAVKKVLTTGLPALIS	26	Sequence 7 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04853	KWKKFIKELQKVLAPGGLLSNIVTSL	26	Sequence 8 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04854	KWKSFIKKLTSVLKKVVTTALPALIS	26	Sequence 9 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04855	KWKSFIKNLTKVLKKVVTTALPALIS	26	Sequence 10 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04856	KWKLFKKKGTGAVLTVLTTGLPALIS	26	Sequence 11 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04857	KWKSFIKKLTSVLKKVVTTAKPLISS	26	Sequence 12 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04858	KKKSFIKLLTSAKVSVLTTAKPLISS	26	Sequence 13 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04859	KWKKFIKELQKVLKPGGLLSNIVTSL	26	Sequence 14 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04860	KKWWRRVLSGLKTGPALSNV	20	Sequence 15 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04861	KKWWRRVLKGLSSGPALSNV	20	Sequence 16 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04862	KKWWRRALQALKNGPALSNV	20	Sequence 17 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04863	KKWWRRVLSGLKTAGPAIQSVLNK	24	Sequence 18 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04864	KKWWRRALQGLKTAGPAIQSVLNK	24	Sequence 19 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04865	KKWWKAQKAVNSGPNALQTLAQ	22	Sequence 20 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04866	KKWWKAKKFANSGPNALQTLAQ	22	Sequence 21 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04867	KKWWKFIKKAVNSGTTGLQTLAS	23	Sequence 22 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04868	KKSFFKKLTSVASSVLS	17	Sequence 23 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04869	WKVFKSFIKKASSFAQSVLD	20	Sequence 24 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04870	KWKSFIKK	8	Sequence 34 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04871	KKWWRRXXXGLKTAGPAIQSVLNK	24	Sequence 35 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04872	KWKLFKKIGIGAVLKVLTTGLPALIS	26	Sequence 36 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04873	KWKLFKKIGIGAVLKVLTTGLPALKKTK	28	Sequence 37 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04874	KKWWRRXLXXLXXXGPAXXSXVXXX	25	Sequence 38 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04875	KKWWKXXXKXXNSGXXXLQTLAX	23	Sequence 39 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04876	YNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	34	Sequence 1 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04877	YKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	35	Sequence 2 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04878	TRCYKFGGFCHYNICPGNSRFMSNCHPENLRCCKN	35	Sequence 3 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04879	ARCYKFGGFCYNSMCPPHTKFIGNCHPDHLHCCIN	35	Sequence 4 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04880	DHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKY	35	Sequence 5 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04881	ERCHKKGGYCYFYCFSSHKKIGSCFPEWPRCCKN	34	Sequence 6 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04882	YYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRR	35	Sequence 7 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04883	FFCRIRGGRCAVLNCLGKEEQIGRCSNSGRKCCRK	35	Sequence 8 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04884	VSCIRNGGICQYRCIGLRHKIGTCGSPFKCCK	32	Sequence 9 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04885	VSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKR	34	Sequence 10 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04886	RACYREGGECLRCIGLFHKIGTCNFRFKCCKF	32	Sequence 11 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04887	ITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCKI	34	Sequence 12 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04888	VTCMSYGGSCQRSCNGSFRLGGHCGHPKIRCCRR	34	Sequence 13 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04889	VSCCMIGGICRYLCKGNILQNGNCGVTSLNCCKR	34	Sequence 14 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04890	VTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKK	35	Sequence 15 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04891	GHCLNLSGVCRRDVCKVVEDQIGACRRRMKCCRA	34	Sequence 16 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04892	KQCIALKGVCRDKLCSTLDDTIGICNEGKKCCRR	34	Sequence 18 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04893	KQCISLKGICKDLACT	16	Sequence 19 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04894	KKCVQRKNACHYFECPWLYYSVGTCYKGKGKCCQK	35	Sequence 20 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04895	IKCLQGNNNCHIQKCPWFLLQVSTCYKGKGRCCQK	35	Sequence 21 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04896	IQCFQKNNTCHTNQCPYFQDEIGTCYDKRGKCCQK	35	Sequence 22 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04897	IACIENKDTCRLKNCPRLHNVVGTCYEGKGKCCHK	35	Sequence 23 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04898	TICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVS	35	Sequence 24 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04899	TVCLMQQGHCRLFMCRSGERKGDICSDPWNRCCVP	35	Sequence 25 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04900	DECPSEYYHCRLKCNADEHAIRYCADFSICCKL	33	Sequence 26 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04901	QDCSKHRHCRMKCKANEYAVRYCEDWTICCRV	32	Sequence 27 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04902	KKCLNDVGICKKKCKPEEMHVKNGWAMCGKQRDCCVP	37	Sequence 28 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04903	KKCANTLGNCRKMCRDGEKQTEPATSKCPIGKLCCVL	37	Sequence 29 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04904	RRCLMGLGRCRDHCNVDEKEIQKCKMKKCCVG	32	Sequence 30 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04905	KRCLVGFGKCKDSCLADETQMQHCKAKKCCIG	32	Sequence 31 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04906	RRCYYGTGRCRKSCKEIERKKEKCGEKHICCVP	33	Sequence 32 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04907	RTCFYGLGKCRRICRANEKKKERCGERTFCCLR	33	Sequence 33 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04908	RICGYGTARCRKKCRSQEYRIGRCPNTYACCLR	33	Sequence 34 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04909	NPCELYQGMCRNACREYEIQYLTCPNDQKCCLK	33	Sequence 35 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04910	IACELYQGLCRNACQKYEIQYLSCPKTRKCCLK	33	Sequence 36 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04911	LRCMGNSGICRASCKKNEQPYLYCRNCQSCCLQ	33	Sequence 37 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04912	LQCMGNRGFCRSSCKKSEQAYFYCRTFQMCCLQ	33	Sequence 38 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04913	KKCFNKVTGYCRKKCKVGERYEIGCLSGKLCCAN	34	Sequence 39 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04914	KRCFSNVEGYCRKKCRLVEISEMGCLHGKYCC	32	Sequence 40 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04915	KKCWNNYVQGHCRKICRVNEVPEALCENGRYCCLN	35	Sequence 41 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04916	KSCWIIKGHCRKNCKPGEQVKKPCKNGDYCCIP	33	Sequence 42 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04917	KACWVLRGHCRKHCRSGERVRKPCSNGDYCC	31	Sequence 43 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04918	KKCWNRSGHCRKQCKDGEAVKDTCKNLRACCIP	33	Sequence 44 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04919	KRCLKILGHCRRHCKDGEMDHGSCKYYRVCCVP	33	Sequence 45 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04920	VECWMDGHCRLLCKDGEDSIIRCRNRKRCCVP	32	Sequence 46 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04921	QKCWKNNVGHCRRRCLDTERYILLCRNKLSCCIS	34	Sequence 47 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04922	KCWKNSLGYCRVRCQEEERYIYLCKNKVSCCIH	33	Sequence 48 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04923	KRCWKGQGACQTYCTRQETYMHLCPDASLCCLS	33	Sequence 49 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04924	KRCWNGQGACRTFCTRQETFMHLCPDASLCCLS	33	Sequence 50 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04925	MKCWGKSGRCRTTCKESEVYYILCKTEAKCCVD	33	Sequence 55 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04926	DTCWKLKGICRNTCQKEEIYHIFCGIQSLCCLE	33	Sequence 56 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04927	RECRIGNGQCKNQCHENEIRIAYCIRPGTHCCLQ	34	Sequence 57 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04928	KECKMRRGHCKLQCSEKELRISFCIRPGTHCC	32	Sequence 58 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04929	KSCTAIGGRCKNQCDDSEFRISYCARPTTHCCVT	34	Sequence 59 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04930	DRCTKRYGRCKRDCLESEKQIDICSLPRKICCTE	34	Sequence 60 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04931	VDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	34	Sequence 61 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04932	VNCKKSEGQCQEYCNFMETQVGYCSKKKEPCCLH	34	Sequence 62 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04933	ERCEKVRGICKTFCDDVEYDYGYCIKWRSQCCV	33	Sequence 63 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04934	ERCEKVRGMCKTVCDIDEYDYGYCIRWRNQCCI	33	Sequence 64 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04935	KRECQLVRGACKPECNSWEYVYYYCNVNPCCAV	33	Sequence 65 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04936	HKCSLVRGTCKSECNSWEYKYNYCHTEPCCVV	32	Sequence 66 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04937	ETCRLGRGKCRRTCIESEKIAGWCKLNFFCCRE	33	Sequence 67 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04938	ETCRLGRGKCRRACIESEKIVGWCKLNFFCCRE	33	Sequence 68 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04939	ESCKLGRGKCRKECLENEKPDGNCRLNFLCCRQ	33	Sequence 69 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04940	TNCFLYLARTAIHRALISKRMEGHCEAECLTFEVKIGGCRAELAPFCCKN	50	Sequence 70 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04941	FLCKKMNGQCEAECFTFEQKIGTCQANFLCCRK	33	Sequence 71 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04942	EKCSRVNGRCTASCLKNEELVALCQKNLKCCVT	33	Sequence 72 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04943	EKCSRINGRCTASCLKNEELVALCWKNLKCCVT	33	Sequence 73 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04944	EKCNKLKGTCKNNCGKNEELIALCQKSLKCCRT	33	Sequence 74 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04945	EICERPNGSCRDFCLETEIHVGRCLNSRPCCLP	33	Sequence 75 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04946	KLCLDQKDTCPDSRTCLEGTQPCHPHHPNCCES	33	Sequence 76 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04947	RPCEKMGGICKSQKTHGCSILPAECKSRYKHCCRL	35	Sequence 77 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04948	CRSWGTCSIAAICFDSLSRRGQCGPVKDPCCPL	33	Sequence 78 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04949	LTCIANRGFCWHSCIQGFQLAGHCGHPKVRLLH	33	Sequence 80 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04950	LVCRRKGGRCYIKCPDNTDZIGMCRLPFKCCKRQ	34	Sequence 81 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04951	LSCWMKZGICQYRCFGNTHKIGSCGAPFLKCCKR	34	Sequence 82 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04952	XCRRLCYKQRCVTYCRGR	18	Sequence 1 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04953	XCRRLCYKQRCVTYCRGX	18	Sequence 2 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04954	XCKRLCYKQRCVTYCRGR	18	Sequence 3 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04955	XCHRLCYKQRCVTYCRGR	18	Sequence 4 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04956	XCRKLCYKQRCVTYCRGR	18	Sequence 5 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04957	XCRHLCYKQRCVTYCRGR	18	Sequence 6 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04958	XCRRYCYKQRCVTYCRGR	18	Sequence 7 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04959	XCRRVCYKQRCVTYCRGR	18	Sequence 8 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04960	XCRRICYKQRCVTYCRGR	18	Sequence 9 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04961	XCRRMCYKQRCVTYCRGR	18	Sequence 10 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04962	XCRRFCYKQRCVTYCRGR	18	Sequence 11 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04963	XCRRWCYKQRCVTYCRGR	18	Sequence 12 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04964	XCRRLCLKQRCVTYCRGR	18	Sequence 13 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04965	XCRRLCVKQRCVTYCRGR	18	Sequence 14 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04966	XCRRLCIKQRCVTYCRGR	18	Sequence 15 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04967	XCRRLCMKQRCVTYCRGR	18	Sequence 16 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04968	XCRRLCFKQRCVTYCRGR	18	Sequence 17 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04969	XCRRLCWKQRCVTYCRGR	18	Sequence 18 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04970	XCRRLCYRQRCVTYCRGR	18	Sequence 19 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04971	XCRRLCYHQRCVTYCRGR	18	Sequence 20 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04972	XCRRLCYKNRCVTYCRGR	18	Sequence 21 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04973	XCRRLCYKQKCVTYCRGR	18	Sequence 22 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04974	XCRRLCYKQHCVTYCRGR	18	Sequence 23 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04975	XCRRLCYKQRCLTYCRGR	18	Sequence 24 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04976	XCRRLCYKQRCYTYCRGR	18	Sequence 25 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04977	XCRRLCYKQRCITYCRGR	18	Sequence 26 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04978	XCRRLCYKQRCMTYCRGR	18	Sequence 27 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04979	XCRRLCYKQRCFTYCRGR	18	Sequence 28 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04980	XCRRLCYKQRCWTYCRGR	18	Sequence 29 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04981	XCRRLCYKQRCVGYCRGR	18	Sequence 30 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04982	XCRRLCYKQRCVSYCRGR	18	Sequence 31 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04983	XCRRLCYKQRCVAYCRGR	18	Sequence 32 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04984	XCRRLCYKQRCVTLCRGR	18	Sequence 33 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04985	XCRRLCYKQRCVTVCRGR	18	Sequence 34 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04986	XCRRLCYKQRCVTICRGR	18	Sequence 35 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04987	XCRRLCYKQRCVTMCRGR	18	Sequence 36 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04988	XCRRLCYKQRCVTFCRGR	18	Sequence 37 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04989	XCRRLCYKQRCVTWCRGR	18	Sequence 38 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04990	XCRRLCYKQRCVTYCKGR	18	Sequence 39 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04991	XCRRLCYKQRCVTYCHGR	18	Sequence 40 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04992	XCRRLCYKQRCVTYCRTR	18	Sequence 41 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04993	XCRRLCYKQRCVTYCRSR	18	Sequence 42 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04994	XCRRLCYKQRCVTYCRAR	18	Sequence 43 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04995	XCRRLCYKQRCVTYCRGK	18	Sequence 44 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04996	XCKHICFKNRCWSVCKGR	18	Sequence 45 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04997	XCRHLCYKNKCVTYCRGK	18	Sequence 46 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04998	XCRRVCYRQRCVGICHTR	18	Sequence 47 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04999	XCHKMCLKQHCYAWCRGR	18	Sequence 48 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05000	XCHRLCIHQRCVTYCKAK	18	Sequence 49 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05001	XCRRYCMRQRCVTYCRGR	18	Sequence 50 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05002	XCHKFCLKNKCFSYCKTR	18	Sequence 51 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05003	XCKRLCYKQRCVTYCRGX	18	Sequence 52 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05004	XCHRLCYKQRCVTYCRGX	18	Sequence 53 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05005	XCRKLCYKQRCVTYCRGX	18	Sequence 54 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05006	XCRHLCYKQRCVTYCRGX	18	Sequence 55 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05007	XCRRYCYKQRCVTYCRGX	18	Sequence 56 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05008	XCRRVCYKQRCVTYCRGX	18	Sequence 57 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05009	XCRRICYKQRCVTYCRGX	18	Sequence 58 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05010	XCRRMCYKQRCVTYCRGX	18	Sequence 59 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05011	XCRRFCYKQRCVTYCRGX	18	Sequence 60 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05012	XCRRWCYKQRCVTYCRGX	18	Sequence 61 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05013	XCRRLCLKQRCVTYCRGX	18	Sequence 62 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05014	XCRRLCVKQRCVTYCRGX	18	Sequence 63 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05015	XCRRLCIKQRCVTYCRGX	18	Sequence 64 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05016	XCRRLCMKQRCVTYCRGX	18	Sequence 65 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05017	XCRRLCFKQRCVTYCRGX	18	Sequence 66 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05018	XCRRLCWKQRCVTYCRGX	18	Sequence 67 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05019	XCRRLCYRQRCVTYCRGX	18	Sequence 68 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05020	XCRRLCYHQRCVTYCRGX	18	Sequence 69 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05021	XCRRLCYKNRCVTYCRGX	18	Sequence 70 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05022	XCRRLCYKQKCVTYCRGX	18	Sequence 71 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05023	XCRRLCYKQHCVTYCRGX	18	Sequence 72 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05024	XCRRLCYKQRCLTYCRGX	18	Sequence 73 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05025	XCRRLCYKQRCYTYCRGX	18	Sequence 74 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05026	XCRRLCYKQRCITYCRGX	18	Sequence 75 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05027	XCRRLCYKQRCMTYCRGX	18	Sequence 76 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05028	XCRRLCYKQRCFTYCRGX	18	Sequence 77 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05029	XCRRLCYKQRCWTYCRGX	18	Sequence 78 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05030	XCRRLCYKQRCVGYCRGX	18	Sequence 79 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05031	XCRRLCYKQRCVSYCRGX	18	Sequence 80 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05032	XCRRLCYKQRCVAYCRGX	18	Sequence 81 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05033	XCRRLCYKQRCVTLCRGX	18	Sequence 82 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05034	XCRRLCYKQRCVTVCRGX	18	Sequence 83 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05035	XCRRLCYKQRCVTICRGX	18	Sequence 84 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05036	XCRRLCYKQRCVTMCRGX	18	Sequence 85 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05037	XCRRLCYKQRCVTFCRGX	18	Sequence 86 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05038	XCRRLCYKQRCVTWCRGX	18	Sequence 87 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05039	XCRRLCYKQRCVTYCKGX	18	Sequence 88 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05040	XCRRLCYKQRCVTYCHGX	18	Sequence 89 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05041	XCRRLCYKQRCVTYCRTX	18	Sequence 90 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05042	XCRRLCYKQRCVTYCRSX	18	Sequence 91 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05043	XCRRLCYKQRCVTYCRAX	18	Sequence 92 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05044	XCKHICFKNRCWSVCKGX	18	Sequence 94 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05045	XCRHLCYKNKCVTYCRGX	18	Sequence 95 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05046	XCRRVCYRQRCVGICHTX	18	Sequence 96 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05047	XCHKMCLKQHCYAWCRGX	18	Sequence 97 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05048	XCHRLCIHQRCVTYCKAX	18	Sequence 98 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05049	XCRRYCMRQRCVTYCRGX	18	Sequence 99 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05050	XCHKFCLKNKCFSYCKTX	18	Sequence 100 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05051	PGPIPN	6	Sequence 1 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05052	TTMPLW	6	Sequence 2 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05053	AVESTVATLEASPEVIESPPE	21	Sequence 3 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05054	AVESTVATLEDSPEVIESPPE	21	Sequence 4 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05055	DMPIQAFLLYQQPVLGPVR	19	Sequence 7 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05056	MAIPPKKNQDKTEIPTINTIASGEPTSTPTIEAVESTVATLEASPEVIESPPEINTVQVTSTAV	64	Sequence 8 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05057	MAIPPKKNQDKTEIPTINTIASGEPTSTPTTEAVESTVATLEDSPEVIESPPEINTVQVTSTAV	64	Sequence 10 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05058	TEIPTINTIASGEPTSTPTIEAVESTVATLEASPEVIESPPEINTVQVTSTAV	53	Sequence 12 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05059	TEIPTINTIASGEPTSTPTTEAVESTVATLEDSPEVIESPPEINTVQVTSTAV	53	Sequence 14 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05060	DPAA	4	Sequence 3 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05061	DKHMIEGRMKSCCRSTLGRNCYNLCRVRGAQKLCAGVCRCKLTSSGKCPTGFPK	54	Sequence 8 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05062	DKHMIEGRKSCCRSTLGRNCYNLCRVRGAQKLCAGVCRCKLTSSGKCPTGFPKMIEGRETSSATETTTETATKSEEAAKETATEHDEL	88	Sequence 11 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05063	ILKKWPWWPWRRK	13	Sequence 1 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05064	ILKPWKWPWWPWRRKK	16	Sequence 2 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05065	ILKPWKWPWWPWRR	14	Sequence 3 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05066	ILPWKKWPWWRWRR	14	Sequence 4 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05067	ILKKWPWWPWRR	12	Sequence 5 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05068	ILPWKWPWWPWRKWR	15	Sequence 6 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05069	ILPWKWPWWPWRRWR	15	Sequence 7 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05070	ILPWKWPWWPWKKWK	15	Sequence 8 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05071	PWKWPWWPWRR	11	Sequence 9 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05072	ILPWKWPWRR	10	Sequence 10 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05073	ILPWKWPWWPWWPWRR	16	Sequence 11 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05074	ILPWKWPWWPWWKKPWRR	18	Sequence 12 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05075	ILPWICPWRPSKAN	14	Sequence 13 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05076	IVPWKWTLWPWRR	13	Sequence 14 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05077	TLPCLWPWWPWSI	13	Sequence 15 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05078	ILPWKWPWWPWRR	13	Sequence 16 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05079	ILKKWPWWPWKRR	13	Sequence 17 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05080	ILKKWPWWPWKWKK	14	Sequence 18 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05081	ILPWKWPWYVRR	12	Sequence 19 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05082	IKWPWYVWL	9	Sequence 20 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05083	ILPWKWFFPPWPWRR	15	Sequence 21 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05084	ILPWKWPPWPPWPWRR	16	Sequence 22 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05085	ILKKWPWWRWRR	12	Sequence 27 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05086	ILKKFPFFPFRRK	13	Sequence 28 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05087	ILKKFPFFPFKKK	13	Sequence 29 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05088	ILKKWAWWPWRRK	13	Sequence 30 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05089	ILKKWPWWAWRRK	13	Sequence 31 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05090	ILKKWPWWPWKKK	13	Sequence 32 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05091	ILRRWPWWPWRRR	13	Sequence 33 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05092	WWKKWPWWPWRRK	13	Sequence 34 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05093	FFKKWPWWPWRRK	13	Sequence 35 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05094	FFKKFPFFPFRRK	13	Sequence 36 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05095	FFKKFPFFPFKKK	13	Sequence 37 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05096	ILKKWPWWPWWPWRRK	16	Sequence 38 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05097	ILKKWPWWPWRWWRR	15	Sequence 39 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05098	ILKKWPWWPWRRWWK	15	Sequence 40 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05099	ILKKWPWWPWPPRRK	15	Sequence 41 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05100	ILKKWPWWPWPPFFRRK	17	Sequence 42 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05101	MFLKAVVLTVALVAITGTQAEVTSDQVANV	30	Sequence 1 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05102	AYLDEELQTELYEIKHQILQTMGVLSLQGSMLSVGDKVSTNGQSVNFDTIKEMCTFRAGGNIAVPRTPEENEAIASIAKKYNNYVYLGMIEDQ	93	Sequence 3 from Patent US 20040037781	Rat	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05103	AHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGP	93	Sequence 6 from Patent US 20040037781	Homo sapiens	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05104	DVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDS	96	Sequence 11 from Patent US 20040037781	Homo sapiens	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05105	AYLDEELQTELYEIKHQILQTMGVLSLQGSMLSVGDKVFSTNGQSVNFDTIKEMCTRAGGNIAVPRTPEENEAIASIAKKYNNYVYLGMIED	92	Sequence 15 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05106	TPGDFHYLDGASVNYTNWYPG	21	Sequence 16 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05107	SPGDFRYSDGTPVNYTNWYRG	21	Sequence 17 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05108	NQGRHFCGGALIHARFVMTAASCFQ	25	Sequence 1 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05109	RHFCGGALIHARFVMTAASC	20	Sequence 2 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05110	NQGRHFSGGALIHARFVMTAASCFQ	25	Sequence 3 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05111	RHFSGGALIHARFVMTAASC	20	Sequence 4 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05112	NQGRHFCGGALIHARFVMTAASSFQ	25	Sequence 5 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05113	RHFCGGALIHARFVMTAASS	20	Sequence 6 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05114	NQGRHFSGGALIHARFVMTAASSFQ	25	Sequence 7 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05115	RHFSGGALIHARFVMTAASS	20	Sequence 8 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05116	NQGRHFCGGALIHARFVMTAARCFQ	25	Sequence 10 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05117	NQGRHFCGGALIHARFVMTAAKCFQ	25	Sequence 11 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05118	RHFCGGALIHARFVMTAAHC	20	Sequence 12 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05119	RHFCGGALIHARFVMTAARC	20	Sequence 13 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05120	RHFCGGALIHARFVMTAAKC	20	Sequence 14 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05121	NQGRHFSGGALIHARFVMTAAHCFQ	25	Sequence 15 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05122	NQGRHFSGGALIHARFVMTAARCFQ	25	Sequence 16 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05123	NQGRHFSGGALIHARFVMTAAKCFQ	25	Sequence 17 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05124	NQGRHFCGGALIHARFVMTAAHSFQ	25	Sequence 18 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05125	NQGRHFCGGALIHARFVMTAARSFQ	25	Sequence 19 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05126	NQGRHFCGGALIHARFVMTAAKSFQ	25	Sequence 20 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05127	RHFSGGALIHARFVMTAAHC	20	Sequence 21 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05128	RHFSGGALIHARFVMTAARC	20	Sequence 22 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05129	RHFSGGALIHARFVMTAAKC	20	Sequence 23 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05130	RHFCGGALIHARFVMTAAHS	20	Sequence 24 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05131	RHFCGGALIHARFVMTAARS	20	Sequence 25 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05132	RHFCGGALIHARFVMTAAKS	20	Sequence 26 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05133	NQGRHFCAGALIHARFVMTAASCFQ	25	Sequence 27 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05134	NQGRHFCGAALIHARFVMTAASCFQ	25	Sequence 28 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05135	NQGRHFCAAALIHARFVMTAASCFQ	25	Sequence 29 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05136	NQGRHFSAGALIHARFVMTAASCFQ	25	Sequence 30 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05137	NQGRHFSGAALIHARFVMTAASCFQ	25	Sequence 31 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05138	NQGRHFSAAALIHARFVMTAASCFQ	25	Sequence 32 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05139	NQGRHFCAGALIHARFVMTAASSFQ	25	Sequence 33 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05140	NQGRHFCGAALIHARFVMTAASSFQ	25	Sequence 34 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05141	NQGRHFCAAALIHARFVMTAASSFQ	25	Sequence 35 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05142	NQGRHFCGGALIHARFVMTAATCFQ	25	Sequence 36 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05143	NQGRHFCGGALIHARFLMTAASCFQ	25	Sequence 37 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05144	NQGRHFCGGALIHARFIMTAASCFQ	25	Sequence 38 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05145	NQGRHFCGGALIHARFAMTAASCFQ	25	Sequence 39 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05146	NQGRHYCGGALIHARFVMTAASCFQ	25	Sequence 40 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05147	NQGRHFCGGALIHARYVMTAASCFQ	25	Sequence 41 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05148	NQGRHFCGGALIHARFVMTAASCYQ	25	Sequence 42 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05149	RHFSAGALIHARFVMTAASC	20	Sequence 43 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05150	RHFSGAALIHARFVMTAASC	20	Sequence 44 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05151	RHFSAAALIHARFVMTAASC	20	Sequence 45 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05152	RHFSGGALIHARFLMTAASC	20	Sequence 46 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05153	RHFSGGALIHARFIMTAASC	20	Sequence 47 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05154	RHFSGGALIHARFAMTAASC	20	Sequence 48 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05155	RHYSGGALIHARFVMTAASC	20	Sequence 49 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05156	RHFSGGALIHARYVMTAASC	20	Sequence 50 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05157	RHFCAGALIHARFVMTAASS	20	Sequence 51 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05158	RHFCGAALIHARFVMTAASS	20	Sequence 52 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05159	RHFCAAALIHARFVMTAASS	20	Sequence 53 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05160	RHFCGGALIHARFLMTAASS	20	Sequence 54 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05161	RHFCGGALIHARFIMTAASS	20	Sequence 55 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05162	RHFCGGALIHARFAMTAASS	20	Sequence 56 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05163	RHYCGGALIHARFVMTAASS	20	Sequence 57 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05164	RHFCGGALIHARYVMTAASS	20	Sequence 58 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05165	MKVFFLFAVLFCLVQTNSVHISHQEARGPSFRICVDFLGPRWARGCSTGN	50	Sequence 3 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05166	MKVFFLFAVLFCLVQTNSVHISHQEARGPSFKICVGFLGPRWARGCSTGN	50	Sequence 4 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05167	MKVFFLFAVLFCLVQTNSGDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	80	Sequence 9 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05168	MKVFFLFAVLFCLVQTNSGDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	80	Sequence 10 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05169	MRQRLLPSVTSLLLVALLFPEPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	62	Sequence 11 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05170	MRQRLLPSVTSLLLVALLFPEPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	62	Sequence 12 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05171	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQVHISHQEARGPSFRICVDFLGPRWARGCSTGN	79	Sequence 13 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05172	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQVHISHQEARGPSFKICVGFLGPRWARGCSTGN	79	Sequence 14 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05173	NSVHISHQEARGPSFRICVDFLGPRWARGCSTGN	34	Sequence 15 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05174	NSVHISHQEARGPSFKICVGFLGPRWARGCSTGN	34	Sequence 16 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05175	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQEPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	89	Sequence 17 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05176	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQEPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	89	Sequence 18 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05177	NSGDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	64	Sequence 21 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05178	NSGDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	64	Sequence 22 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05179	PASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	41	Sequence 23 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05180	PASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	41	Sequence 24 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05181	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQ	47	Sequence 25 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05182	VHISHQEARGPSFRICVDFLGPRWARGCSTGN	32	Sequence 26 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05183	VHISHQEARGPSFKICVGFLGPRWARGCSTGN	32	Sequence 27 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05184	EPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	42	Sequence 28 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05185	EPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	42	Sequence 29 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05186	GDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	62	Sequence 30 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05187	GDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	62	Sequence 31 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05188	GNFLTGLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	47	Sequence 63 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05189	GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	41	Sequence 64 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05190	KWRRWI	6	Sequence 1 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05191	KWRRWV	6	Sequence 3 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05192	KWIKWR	6	Sequence 5 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05193	KWVKWI	6	Sequence 7 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05194	KWIKWI	6	Sequence 9 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05195	KWIKWIKWI	9	Sequence 11 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05196	KFIKFIKFI	9	Sequence 13 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05197	KWRRWVRWI	9	Sequence 15 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05198	IWRVWRRWK	9	Sequence 17 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05199	KFRRFVRFI	9	Sequence 19 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05200	KPRRPVRPI	9	Sequence 21 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05201	KWIRWVRWI	9	Sequence 23 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05202	ACNFQSCWATCQAQHSIYFRRAFCDRSQCKCVFVRG	36	Sequence 2 from Patent US 20040087771	Pseudacanthotermes spinig	Antimicrobial	US 2004/0087771 A1	Patent Application	2004##5##6	CA2410575A1, EP1294880A2, WO2002000706A2, WO2002000706A3	Antimicrobial peptides of the family of defensins, polynucleotides encoding said peptides, transformed vectors and organisms containing them.	The invention concerns novel antimicrobial peptides of the family of defensins, in particular antifungal, called termicines, polynucleotides encoding said peptides, vectors containing them for transforming a host organism and the method for transforming said organism. The invention also concerns transformed organisms, in particular yeast producing termicine, or plant cells and plants, the termicines produced by the transformed plats providing them with resistence to fungus-mediated diseases. The invention further concerns the use of termicines as medicine and pharmaceutical compositions containing them.
DRAMP05203	SLDKRACNFQSCWATCQAQHSIYFRRAFCDRSQCKCVFVRG	41	Sequence 4 from Patent US 20040087771	Synthetic construct	Antimicrobial	US 2004/0087771 A1	Patent Application	2004##5##6	CA2410575A1, EP1294880A2, WO2002000706A2, WO2002000706A3	Antimicrobial peptides of the family of defensins, polynucleotides encoding said peptides, transformed vectors and organisms containing them.	The invention concerns novel antimicrobial peptides of the family of defensins, in particular antifungal, called termicines, polynucleotides encoding said peptides, vectors containing them for transforming a host organism and the method for transforming said organism. The invention also concerns transformed organisms, in particular yeast producing termicine, or plant cells and plants, the termicines produced by the transformed plats providing them with resistence to fungus-mediated diseases. The invention further concerns the use of termicines as medicine and pharmaceutical compositions containing them.
DRAMP05204	SRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKL	32	Sequence 1 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05205	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	37	Sequence 2 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05206	RLCRIVVIRVCR	12	Sequence 4 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05207	QLRYREAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVCPRPTRQPPELCDFKEKQCVGTVTLNPSIHSLDISCNEIQSV	96	Sequence 6 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05208	GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSEFFQS	37	Sequence 12 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05209	GRFKRFRKKFKKLFKKLSPVIPLLHLG	27	Sequence 14 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05210	GLRKRLRKFRNKIKEKLKKIGQKIQGFVPKLAPRTDY	37	Sequence 15 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05211	RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLGPFPGRR	46	Sequence 16 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05212	RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPL	60	Sequence 17 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05213	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFPGKR	42	Sequence 18 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05214	RGGRLCYCRRRFCICVG	17	Sequence 19 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05215	LFEAIEGFIFL	11	Sequence 20 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05216	GILGFVFTLT	10	Sequence 21 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05217	QYIKANSKFIGITE	14	Sequence 22 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05218	VYDFFVWL	8	Sequence 23 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05219	ILPWKWPWWPWRRG	14	Sequence 19 from Patent US 7658928	Synthetic construct	Antimicrobial	US 7658928 B2	Granted Patent	2010##2##9	CA2418854A1, EP1309345A2, US20040170642, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05220	LFEAIEGFI	9	Sequence 22 from Patent US 7658928	Synthetic construct	Antimicrobial	US 7658928 B2	Granted Patent	2010##2##9	CA2418854A1, EP1309345A2, US20040170642, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05221	SLRCGSCRRIIQHLMDKLGDQPDENTVIEEASKVCSKMRLLKGLCKSIMKKFLRTIAEDIVAGKTSRVICVDIKMCKSKPVGFI	84	Sequence 23 from Patent US 20040204575	Bos taurus	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05222	GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKEKTGLI	83	Sequence 24 from Patent US 20040204575	Sus scrofa	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05223	GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPL	83	Sequence 25 from Patent US 20040204575	Homo sapiens	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05224	MTSWAVLLITSVLL	14	Sequence 28 from Patent US 20040204575	Bos taurus	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05225	MRLVVCLVFLASFALVCQAQGYQGGYTRPFPRPPYGGGYHPVPVCTSCHRLSPLQARACCRQLGRCCDAKQTYG	74	Sequence 1 from Patent US 20040235738	Penaeus monodon	Antimicrobial	US 2004/0235738 A1	Patent Application	2004##11##25	US7670836, US20080032385	Novel antimicrobial peptide isolated from penaeus monodon.	"The present invention provides an antimicrobial peptide, monodoncin, which is isolated and purified from Penaeus monodon and is capable of being mass produced by molecular cloning techniques in a heterologous expression system, such as yeast. Monodoncin demonstrates a wide-range of bacteriostatic and bactericidal effects on G(-) and G(+) bacteria as well as fungicidal activities, and can be used in combination with conventional antibiotics as ""cocktail therapy"" to improve the therapeutic effects of the conventional antibiotics."
DRAMP05226	KKAAAXAAAAAXAAXAAXAAAKKKK	25	Sequence 1 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05227	KKAAAXAAAAAXAAWAAXAAAKKKK	25	Sequence 2 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05228	KKAAAFAAAAAFAAWAAFAAAKKKK	25	Sequence 3 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05229	KKAAAWAAAAAWAAWAAWAAAKKKK	25	Sequence 4 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05230	KKAAALAAAAALAAWAALAAAKKKK	25	Sequence 5 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05231	KKAAAIAAAAAIAAWAAIAAAKKKK	25	Sequence 6 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05232	KKAAAYAAAAAYAAWAAYAAAKKKK	25	Sequence 7 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05233	KKAAASAAAAASAAWAASAAAKKKK	25	Sequence 8 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05234	KKAFAAAAAFAAWAAFAKKKK	21	Sequence 9 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05235	KKKKKKAAFAAWAAFAA	17	Sequence 10 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05236	RRRAAFAAWAAFAARRR	17	Sequence 11 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05237	KKAAAAFAAFAAWFAAFAAAAKKKK	25	Sequence 12 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05238	KKAAAMAAAAAMAAWAAMAAAKKKK	25	Sequence 13 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05239	KKAAALAAAAACAAWAALAAAKKKK	25	Sequence 14 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05240	KKATALVGAASLTAWVGLASAKKKK	25	Sequence 15 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05241	KKAAAFAAAAAFAAXAAFAAAKKKK	25	Sequence 16 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05242	KKAAAWAAAAAWAAXAAWAAAKKKK	25	Sequence 17 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05243	KKAAALAAAAALAAXAALAAAKKKK	25	Sequence 18 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05244	KKAAAIAAAAAIAAXAAIAAAKKKK	25	Sequence 19 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05245	KKAAAYAAAAAYAAXAAYAAAKKKK	25	Sequence 20 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05246	KKAFAAAAAFAAXAAFAKKKK	21	Sequence 21 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05247	KKKKKAAAFAAXAAFA	16	Sequence 22 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05248	RRRAAAFAAXAAFARRR	17	Sequence 23 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05249	KKAAAAFAAFAAXFAAFAAAAKKKK	25	Sequence 24 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05250	KKAAAMAAAAAMAAXAAMAAAKKKK	25	Sequence 25 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05251	KKAAALAAAAACAAXAALAAAKKKK	25	Sequence 26 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05252	KKATALVGAASLTAXVGLASAKKKK	25	Sequence 27 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05253	KKAAAVAAAAAVAAWAAVAAAKKKK	25	Sequence 28 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05254	KKAAAAAAAAAAAAWAAAAAAKKKK	25	Sequence 29 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05255	KKAAATAAAAATAAWAATAAAKKKK	25	Sequence 30 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05256	KKAAAGAAAAAGAAWAAGAAAKKKK	25	Sequence 31 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05257	KKAAANAAAAANAAWAANAAAKKKK	25	Sequence 32 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05258	KKKKKKAAAFAAAAAFAAWAAFAAA	25	Sequence 33 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05259	KKKAAAFAAWAAFAKKK	17	Sequence 34 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05260	RRRRRRAAFAAWAAFAA	17	Sequence 36 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05261	KKKKKKAAAAFWAAAAF	17	Sequence 37 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05262	KKKKKKAAFAAFAAFAA	17	Sequence 38 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05263	KKKKKKAAWAAWAAWAA	17	Sequence 39 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05264	KKAAAVAAAAAVAAXAAVAAAKKKK	25	Sequence 40 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05265	KKAAAAAAAAAAAAXAAAAAAKKKK	25	Sequence 41 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05266	GWFKKAWRKVKHAGRRVLDTAKGVGRHYLNNWLNRYRG	38	Sequence 5 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05267	GWFKKAWRKVKNAGRVLKGVGIHYGVGLIG	30	Sequence 6 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05268	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNXLNRYRZ	38	Sequence 9 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05269	GXFKKAXRKVKNAGRRVLKGVGIHYGVGLIZ	31	Sequence 10 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05270	MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	64	Sequence 2 from Patent US 20050004355	Synthetic construct	Antimicrobial	US 2005/0004355 A1	Patent Application	2005##1##6	CA2290781A1, CN1260834A, EP0980431A1, US6143498, US6420116, US7223840, WO1998051794A1	Antimicrobial peptide.	The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.
DRAMP05271	MRLHHLLLALLFLVLSAWSGFTQGVGNPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRK	63	Sequence 3 from Patent US 20050004355	Synthetic construct	Antimicrobial	US 2005/0004355 A1	Patent Application	2005##1##6	CA2290781A1, CN1260834A, EP0980431A1, US6143498, US6420116, US7223840, WO1998051794A1	Antimicrobial peptide.	The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.
DRAMP05272	ITFTG	5	Sequence 1 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05273	ACGGACAGATGCAGATTGG	19	Sequence 2 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05274	CCGAGGCCAGTTGAGATCAGTC	22	Sequence 3 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05275	ASPTYRLYSASPASPASPASPLYS	24	Sequence 5 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05276	GSRGKHTFVRPTLVF	15	Sequence 6 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05277	FISYSSPSHMGARMR	15	Sequence 7 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05278	AATTTAATACGACTCACTATAGGCAAACGACTGTCCTGGCCGT	43	Sequence 8 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05279	VAPIAKYLATALAKWALKQGFAKLKS	26	Sequence 1 from Patent US 20050043508	Synthetic construct	Antimicrobial	US 2005/0043508 A1	Patent Application	2005##2##24	US7041647	Synthetic peptide having an ionophoric and antimicrobial activity.	This invention provides a novel synthetic peptide (P1) of 26 amino acids, which inhibits the microbial growing. Peptide P1 also shows ionophoric activity in rat liver mitochondria. Furthermore, this invention provides pharmaceutical compositions and compositions for agricultural use, which contain the peptide of the invention.
DRAMP05280	GNNRPVYIPQPRPPHPRI	18	Sequence 1 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05281	KKAAAKAAAAAKAAWAAKAAAKKKK	25	Sequence 2 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05282	KRRWPWWPWKKLI	13	Sequence 7 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05283	ILKKIPIIPIRRK	13	Sequence 9 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05284	ILKKYPYYPYRRK	13	Sequence 10 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05285	ILKKWPWPWRRK	12	Sequence 11 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05286	ILKKYPWYPWRRK	13	Sequence 12 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05287	ILKKFPWFPWRRK	13	Sequence 13 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05288	ILKKFPFWPWRRK	13	Sequence 14 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05289	ILRYVYYVYRRK	12	Sequence 15 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05290	ILRWPWWPWWPWRRK	15	Sequence 16 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05291	WWRWPWWPWRRK	12	Sequence 17 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05292	ILRRWPWWPWRRK	13	Sequence 18 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05293	ILRRWPWWPWRK	12	Sequence 19 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05294	ILKWPWWPWRRK	12	Sequence 20 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05295	ILKKWPWWPWRK	12	Sequence 21 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05296	ILKWPWWPWRK	11	Sequence 22 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05297	ILRWPWWPWRRK	12	Sequence 23 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05298	KRRWPWWPWRLI	12	Sequence 24 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05299	ILWPWWPWRRK	11	Sequence 25 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05300	ILRWPWWPWRRKIMILKKAGS	21	Sequence 28 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05301	ILRWPWWPWRRKMILKKAGS	20	Sequence 29 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05302	ILRWPWWPWRRKDMILKKAGS	21	Sequence 30 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05303	ILRWPWRRWPWRRK	14	Sequence 31 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05304	ILRWPWWPWRRKILMRWPWWPWRRKMAA	28	Sequence 32 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05305	KRKWPWWPWRLI	12	Sequence 33 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05306	ILKWVWWVWRRK	12	Sequence 34 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05307	LKKWPWWPWRRK	12	Sequence 38 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05308	PWWPWRRK	8	Sequence 39 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05309	ILKKWPWWPWRRKMILKKAGS	21	Sequence 40 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05310	ILKKWPWWPWRRMILKKAGS	20	Sequence 41 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05311	ILKKWPWWPWRRIMILKKAGS	21	Sequence 42 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05312	WWPWRRK	7	Sequence 43 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05313	ILKKWPW	7	Sequence 44 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05314	ILKKWPWWPWRRKM	14	Sequence 45 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05315	ILKKWPWWPWRRM	13	Sequence 46 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05316	ILKKWPWWPWRRIM	14	Sequence 47 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05317	ILKKWWWPWRK	11	Sequence 48 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05318	ILKKWPWWWRK	11	Sequence 49 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05319	WRIWKPKWRLPKW	13	Sequence 50 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05320	CLRWPWWPWRRK	12	Sequence 51 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05321	ILKKWVWWVWRRK	13	Sequence 55 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05322	ILKKWPWWVWRRK	13	Sequence 56 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05323	ILKKWVWWPWRRK	13	Sequence 57 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05324	ILRWVWWVWRRK	12	Sequence 58 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05325	KRRWVWWVWRLI	12	Sequence 59 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05326	ILRRWVWWVWRRK	13	Sequence 60 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05327	ILRWWVWWVWWRRK	14	Sequence 61 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05328	RLWVWWVWRRK	11	Sequence 62 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05329	RLWVWWVWRR	10	Sequence 63 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05330	RLGGGWVWWVWRR	13	Sequence 64 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05331	RLWWVVWWRR	10	Sequence 65 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05332	RLVVWWVVRR	10	Sequence 66 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05333	RLFVWWVFRR	10	Sequence 67 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05334	RLVVWVVWRR	10	Sequence 68 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05335	WVRLWWRRVW	10	Sequence 71 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05336	IKKWPWWPWRRK	12	Sequence 72 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05337	ILKKPWWPWRRK	12	Sequence 73 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05338	ILKKWWWPWRRK	12	Sequence 74 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05339	ILKKWPWWWRRK	12	Sequence 75 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05340	ILKKWPWWPRRK	12	Sequence 76 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05341	ILKKWPWWPWK	11	Sequence 78 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05342	ILKKWPWWPWR	11	Sequence 79 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05343	LWPWWPWRRK	10	Sequence 80 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05344	LRWWWPWRRK	10	Sequence 81 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05345	LRWPWWPW	8	Sequence 82 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05346	WPWWPWRRK	9	Sequence 83 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05347	RWWWPWRRK	9	Sequence 84 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05348	ALRWPWWPWRRK	12	Sequence 85 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05349	IARWPWWPWRRK	12	Sequence 86 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05350	ILAWPWWPWRRK	12	Sequence 87 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05351	ILRAPWWPWRRK	12	Sequence 88 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05352	ILRWAWWPWRRK	12	Sequence 89 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05353	ILRWPAWPWRRK	12	Sequence 90 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05354	ILRWPWAPWRRK	12	Sequence 91 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05355	ILRWPWWAWRRK	12	Sequence 92 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05356	ILRWPWWPARRK	12	Sequence 93 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05357	ILRWPWWPWARK	12	Sequence 94 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05358	ILRWPWWPWRAK	12	Sequence 95 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05359	ILRWPWWPWRRA	12	Sequence 96 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05360	RRIWKPKWRLPKR	13	Sequence 97 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05361	WRWWKPKWRWPKW	13	Sequence 98 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05362	WRWWKVAWRWVKW	13	Sequence 100 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05363	WRWWKVWRWVKW	12	Sequence 101 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05364	WRWWKVVWRWVKW	13	Sequence 102 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05365	WXWWXVAWXWVXW	13	Sequence 103 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05366	WXWWXPXWXWPXW	13	Sequence 104 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05367	KKWWRRALQALKNGLPALIS	20	Sequence 109 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05368	KWKSFIKKLTSAAKKVLTTGLPALIS	26	Sequence 115 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05369	KWKLFIKKLTPAVKKVLLTGLPALIS	26	Sequence 116 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05370	GKPRPYSPIPTSPRPIRY	18	Sequence 117 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05371	RLARIVVIRVAR	12	Sequence 118 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05372	MSDVIIPFLTSAVTAFIVAYLLDRWYIKRRR	31	Sequence 1 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05373	MRKFVTTLTASPRNKKVGNHRLEISPFVSLRRYYYFNTAICIENPVTREFAIDDSYGSLSTNQNCAQYRQYFSLGGYKEVSLEEIHAV	88	Sequence 6 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05374	MIQLSERQQDLLQVAEKYEQCHIEFYTAQSRLFGTEIMGEVVKTSLGTLKIAHPEEDLFEVALAYLASKKDILTAQERKDVLFYIQNNLC	90	Sequence 7 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05375	MMMDKQVEEVKKHYPIVEDWSVIVARKEDDCMTVTDAVPFILAGYKNVSYEMDDIVVLCSEPIGLTWEDVRFLKNHEGSVSFEEIGYEDKAMVYHVDLG	99	Sequence 9 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05376	MMTEDQKFKYLTKIEELEAGCFSDWTKEDITGDLKYLKKGIIEESIELIRAVNGLTYSEELHDFTQEIIEELDISPL	77	Sequence 10 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05377	MDWTKMTFMGTVDEVKEIWNGLEEAGRLYAVWLSDDHVYGIVDVNEEGLFCLGWVSDISPESLQNMLGGGAELFESYEDVLSEHGGSIAIRVEV	94	Sequence 11 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05378	MDKLAAGGLYLLFLLLAGIIVTH	23	Sequence 14 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05379	MVIIKYTTKTQPTPVKEMFISPQHYAKWRSHMGSKLTSVKPIKGGR	46	Sequence 18 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05380	MFKLLTLFKRNKITSAEEYYTQAIHICEQFDRSTQKYTSM	40	Sequence 19 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05381	MFKYTDRSVRQYIERQQRSAMLEQEQAEKDKKERRKAGLLFFGTIVVLVAVVAVYIVPQSLDAMWHENYEKPAQEAARN	79	Sequence 20 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05382	MTLAGYRVDSCNGCGKAYLVGESHDRKKCAECASK	35	Sequence 22 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05383	MKKRYKVTALFEDGTSQCLVVGNFSSPTNAWCAAMRNLTPEGIARVQHYNVEEISK	56	Sequence 23 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05384	LNQVEVLREEYVEGYVVQMWRRNPSNAPVIEVFTEDNLEEGIIPEYVTANDDTFDRIVDAVEFGYLEELELV	72	Sequence 24 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05385	KGLKKLLKGLKKLLKL	16	Sequence 1 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05386	KGLKKGLKLLKKLLKL	16	Sequence 2 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05387	KGLKKLLKLGKKLLKL	16	Sequence 3 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05388	KGLKKLGKLLKKLLKL	16	Sequence 4 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05389	KGLKKLLKLLKKGLKL	16	Sequence 5 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05390	KGLKKLLKLLKKLGKL	16	Sequence 6 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05391	KCLKKLLKLGKKLLKL	16	Sequence 7 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05392	KCLKKGLKLLKKLLKL	16	Sequence 8 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05393	KCLKKLLKGLKKLLKL	16	Sequence 9 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05394	KCLKKLGKLLKKLLKL	16	Sequence 10 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05395	KCLKKLGKLLKKLGKL	16	Sequence 11 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05396	KCLKKGLKLLKKLLKG	16	Sequence 12 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05397	KGLKKLLKLLKKLLKL	16	Sequence 13 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05398	KCLKKLLKLGKKLLKLC	17	Sequence 14 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05399	KCLKKGLKLLKKLLKLC	17	Sequence 15 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05400	KCLKKLLKLLKKLGKLC	17	Sequence 16 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05401	KCLKKLLKLLKKGLKLC	17	Sequence 17 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05402	KCLKKLLKGLKKLLKLC	17	Sequence 18 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05403	KCLKKLGKLLKKLLKLC	17	Sequence 19 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05404	KCLKKLGKLLKKLLKGC	17	Sequence 20 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05405	CLKKLLKLGKKLLKLC	16	Sequence 21 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05406	CLKKGLKLLKKLLKLC	16	Sequence 22 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05407	CLKKLLKLLKKLGKLC	16	Sequence 23 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05408	CLKKLLKLLKKGLKLC	16	Sequence 24 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05409	CLKKLLKGLKKLLKLC	16	Sequence 25 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05410	CLKKLGKLLKKLLKLC	16	Sequence 26 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05411	KGLKKGLKGLKKLLKL	16	Sequence 40 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05412	KGLKKLLKALKKLLKL	16	Sequence 41 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05413	KGGKKLLKGLKKLLKL	16	Sequence 43 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05414	MKTLTFYTLLLCAALYSNFFDCKAVADAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	66	Sequence 6 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05415	ELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFS	36	Sequence 7 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05416	DAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFS	38	Sequence 8 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05417	ELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	38	Sequence 9 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05418	DAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	40	Sequence 10 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05419	RLLRKWWWKRLL	12	Sequence 1 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05420	RRLLRKWWWKRLL	13	Sequence 2 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05421	RRRLLRKWWWKRLL	14	Sequence 3 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05422	LLRKWWWKRLL	11	Sequence 4 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05423	KFAKKFAKKFAKKFAK	16	Sequence 1 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05424	KFAKKFAKKFAKKFAKKFAK	20	Sequence 2 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05425	KFAKKFAKKFAKKFAKKFAKKFAK	24	Sequence 3 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05426	KFAKKFAKKFAKKFAKKFAKKFAKKFAK	28	Sequence 4 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05427	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	32	Sequence 5 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05428	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	48	Sequence 6 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05429	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	68	Sequence 7 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05430	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	84	Sequence 8 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05431	RFARRFARRFARRFARRFARRFAR	24	Sequence 9 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05432	RFARRFARRFARRFARRFARRFARRFAR	28	Sequence 10 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05433	RFARRFARRFARRFARRFARRFARRFARRFAR	32	Sequence 11 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05434	FAKKFAKKFAKKFAKKFAKKFAKK	24	Sequence 12 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05435	AKKFAKKFAKKFAKKFAKKFAKKF	24	Sequence 13 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05436	KKFAKKFAKKFAKKFAKKFAKKFA	24	Sequence 14 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05437	LKKLLKKLLKKLLKKLLKKL	20	Sequence 15 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05438	LKKLLKKLLKKLLKKLLKKLLKKL	24	Sequence 16 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05439	LKKLLKKLLKKLLKKLLKKLLKKLLKKL	28	Sequence 17 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05440	LKKLLKKLLKKLLKKLLKKLLKKLLKKLLKKL	32	Sequence 18 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05441	KFAFKFAFKFAFKFAFKFAFKFAFKFAF	28	Sequence 19 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05442	KFFKKFFKKFFKKFFKKFFKKFFKKFFK	28	Sequence 20 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP18754	RCICRRGFC	9	Sequence 34 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP05444	KAAKKAAKKAAKKAAKKAAKKAAKKAAK	28	Sequence 22 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05445	KKAKKKAKKKAKKKAKKKAKKKAKKKAK	28	Sequence 23 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05446	KFKKFKKFKKFKKFK	15	Sequence 24 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05447	KFKKFKKFKKFKKFKKFK	18	Sequence 25 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05448	KFKKFKKFKKFKKFKKFKKFK	21	Sequence 26 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05449	KFKKFKKFKKFKKFKKFKKFKKFK	24	Sequence 27 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05450	KFKKFKKFKKFKKFKKFKKFKKFKKFK	27	Sequence 28 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05451	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	30	Sequence 29 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05452	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	36	Sequence 30 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05453	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	48	Sequence 31 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05454	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	63	Sequence 32 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05455	FKAFKA	6	Sequence 33 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05456	FKAFKAFKAFKA	12	Sequence 34 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05457	FKAFKAFKAFKAFKAFKA	18	Sequence 35 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05458	FKAFKAFKAFKAFKAFKAFKA	21	Sequence 36 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05459	FKAFKAFKAFKAFKAFKAFKAFKA	24	Sequence 37 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05460	FKAFKAFKAFKAFKAFKAFKAFKAFKA	27	Sequence 38 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05461	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	30	Sequence 39 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05462	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	51	Sequence 40 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05463	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	63	Sequence 41 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05464	LKLK	4	Sequence 42 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05465	LKLKLKLKLK	10	Sequence 43 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05466	LKLKLKLKLKLKLKLK	16	Sequence 44 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05467	LKLKLKLKLKLKLKLKLK	18	Sequence 45 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05468	LKLKLKLKLKLKLKLKLKLK	20	Sequence 46 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05469	LKLKLKLKLKLKLKLKLKLKLK	22	Sequence 47 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05470	LKLKLKLKLKLKLKLKLKLKLKLK	24	Sequence 48 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05471	LKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLK	36	Sequence 49 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05472	LKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLK	48	Sequence 50 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05473	LRLRLRLRLRLRLR	14	Sequence 51 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05474	LRLRLRLRLRLRLRLRLR	18	Sequence 52 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05475	LRLRLRLRLRLRLRLRLRLRLR	22	Sequence 53 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05476	KGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGK	33	Sequence 54 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05477	KGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGK	45	Sequence 55 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05478	KTKKTKKTKKTKKTKKTKKTK	21	Sequence 56 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05479	KFAK	4	Sequence 57 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05480	KFAKKFAK	8	Sequence 58 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05481	KFAKKFAKKFAK	12	Sequence 59 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05482	LKLKLKLKLKLKLK	14	Sequence 60 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05483	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	80	Sequence 61 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05484	KFKKFKKFK	9	Sequence 62 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05485	KFKKFKKFKKFK	12	Sequence 63 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05486	KGKKGKKGKKGKKGKKGKKGK	21	Sequence 64 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05487	FAKKFAKKFKKFAKKFAKFAFAF	23	Sequence 65 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05488	FKLRAKIKVRLRAKIKL	17	Sequence 66 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05489	KFAKKFAKKFAKKAAK	16	Sequence 67 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05490	KFAKKFAKKAAKKAAK	16	Sequence 68 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05491	KFAKKAAKKFAKKAAK	16	Sequence 69 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05492	RVVRQWPIGRVVRRVVRRVVR	21	Sequence 1 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05493	KVVKQWPIGKVVKKVVKKVVK	21	Sequence 2 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05494	RLLRQWPIGRLLRRLLRRLLR	21	Sequence 3 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05495	KLLKQWPIGKLLKKLLKKLLK	21	Sequence 4 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05496	RVLRQWPIGRVLRRVLRRVLR	21	Sequence 5 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05497	KVLKQWPIGKVLKKVLKKVLK	21	Sequence 6 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05498	RLVRQWPIGRLVRRLVRRLVR	21	Sequence 7 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05499	KLVKQWPIGKLVKKLVKKLVK	21	Sequence 8 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05500	RVVKQWPIGRVVKRVVKRVVK	21	Sequence 9 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05501	KVVRQWPIGKVVRKVVRKVVR	21	Sequence 10 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05502	RLLKQWPIGRLLKRLLKRLLK	21	Sequence 11 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05503	KLLRQWPIGKLLRKLLRKLLR	21	Sequence 12 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05504	RVLKQWPIGRVLKRVLKRVLK	21	Sequence 13 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05505	KVLRQWPIGKVLRKVLRKVLR	21	Sequence 14 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05506	RLVKQWPIGRLVKRLVKRLVK	21	Sequence 15 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05507	KLVRQWPIGKLVRKLVRKLVR	21	Sequence 16 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05508	KLVRQFPVGKLVRKLVRKLVR	21	Sequence 17 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05509	RVVRNWPIGRVVRRVVRRVVR	21	Sequence 18 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05510	KVVKNWPIGKVVKKVVKKVVK	21	Sequence 19 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP10738	KRWKHIRRI	9	Sequence 764 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10739	WIVWIRKRI	9	Sequence 765 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10740	RRWVIRIYK	9	Sequence 766 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10741	WFWRRKMIR	9	Sequence 767 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10742	RYRRWVRKR	9	Sequence 768 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10743	RKWWWKWRR	9	Sequence 769 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10744	RIWMFKIFR	9	Sequence 770 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10745	IVRVGIFRL	9	Sequence 771 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10746	IIRLIKWWR	9	Sequence 772 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10747	WVRRYQMRR	9	Sequence 773 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10748	WQVVMRYRR	9	Sequence 774 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10749	KKWKVWRFG	9	Sequence 775 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10750	WRYWWTRRI	9	Sequence 776 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10751	RIRKGWKWG	9	Sequence 777 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10752	KKRRGNRVR	9	Sequence 778 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10753	VMRKLRRRW	9	Sequence 779 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10754	RNRTHWWRK	9	Sequence 780 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10755	RFTWWWRKF	9	Sequence 781 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10756	KRIRYKRWH	9	Sequence 782 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10757	RWRRYGRVY	9	Sequence 783 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10758	TVVKKRVKK	9	Sequence 784 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10759	RKYRRRYRR	9	Sequence 785 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10760	YFRWWKRWI	9	Sequence 786 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10761	WWQWIVWRK	9	Sequence 787 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10762	RKRLYRWIK	9	Sequence 788 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10763	GWWKNWRWW	9	Sequence 789 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10764	KWWWYWYRR	9	Sequence 790 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10765	RFKWFIRRF	9	Sequence 791 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10766	RIRRLWNIV	9	Sequence 792 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10767	ARWMWRRWR	9	Sequence 793 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10768	LVRWVWGKR	9	Sequence 794 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10769	KRWLKWWRV	9	Sequence 795 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10770	FVYRGWRRK	9	Sequence 796 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10771	RRRWKIYKW	9	Sequence 797 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10772	KRWWQWRWF	9	Sequence 798 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10773	KRVKVRWVT	9	Sequence 799 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10774	RFKYWRWWQ	9	Sequence 800 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10775	KRQWWRVFK	9	Sequence 801 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10776	FKIVWWRRR	9	Sequence 802 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10777	QWWWKYRWK	9	Sequence 803 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10778	RWLRIRKVY	9	Sequence 804 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10779	RYKRVVYRH	9	Sequence 805 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10780	KVRWKWWGW	9	Sequence 806 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10781	IWKVRIFKR	9	Sequence 807 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10782	AIWHKTRRL	9	Sequence 808 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10783	IRQRVRWRW	9	Sequence 809 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10784	MKVWIRWRI	9	Sequence 810 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10785	QRRWWGRFK	9	Sequence 811 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10786	NKRVWFIYR	9	Sequence 812 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10787	RVVNWKGGL	9	Sequence 813 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10788	RYRRFRVRW	9	Sequence 814 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10789	KKVRRVIWW	9	Sequence 815 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10790	WFTRWKWRW	9	Sequence 816 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10791	KWVWFRWRK	9	Sequence 817 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10792	KYLRSVIFY	9	Sequence 818 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10793	FKRSWVQIV	9	Sequence 819 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10794	RWWFIRKWW	9	Sequence 820 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10795	IRRWKRVWW	9	Sequence 821 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10796	QKWYRQRRN	9	Sequence 822 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10797	VWRKWYRVK	9	Sequence 823 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10798	KKKLWRKFR	9	Sequence 824 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10799	RRWWWWRFN	9	Sequence 825 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10800	WFFKSKVYW	9	Sequence 826 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10801	RVVNLNWRW	9	Sequence 827 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10802	RWRRNWMTK	9	Sequence 828 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10803	WKIWKIRWF	9	Sequence 829 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10804	WWFWVIRKY	9	Sequence 830 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10805	RYVKIRWVR	9	Sequence 831 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10806	RIWILSWRW	9	Sequence 832 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10807	KSWRKLFIW	9	Sequence 833 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10808	VWVRWKIWY	9	Sequence 834 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10809	KKRRFKRRY	9	Sequence 835 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10810	RFWKKIRRH	9	Sequence 836 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10811	RKVWWRVFY	9	Sequence 837 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10812	YWRRKWRRK	9	Sequence 838 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10813	KRIRRWKWW	9	Sequence 839 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10814	YWRYLWIRF	9	Sequence 840 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10815	IIYKWRWYW	9	Sequence 841 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10816	QTVYLIFRR	9	Sequence 842 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10817	AKKIKWLVW	9	Sequence 843 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10818	YRFVRRWIV	9	Sequence 844 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10819	VWRRYWWYR	9	Sequence 845 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10820	ARKWKYWRF	9	Sequence 846 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10821	RKRVIKRWR	9	Sequence 847 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10822	RSFWWMWFK	9	Sequence 848 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10823	WRINIFKRI	9	Sequence 849 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10824	RWRVLKRRK	9	Sequence 850 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10825	RWWVIWWWK	9	Sequence 851 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10826	KLIRIWWWW	9	Sequence 852 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10827	FKRKRWWGI	9	Sequence 853 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10828	VWHWWRWRW	9	Sequence 854 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10829	WKRWLIIGR	9	Sequence 855 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10830	AYRWWTRFK	9	Sequence 856 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10831	SWWWIWLKK	9	Sequence 857 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10832	FVIWKYIRV	9	Sequence 858 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10833	RWVRTRRRR	9	Sequence 859 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10834	RRSWWYKRR	9	Sequence 860 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10835	RKYVWWKSI	9	Sequence 861 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10836	WWKRYIVKK	9	Sequence 862 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10837	WFIRVWRYR	9	Sequence 863 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10838	WKMWLRKHW	9	Sequence 864 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10839	RRFFWKKGI	9	Sequence 865 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10840	KRWTFWSRR	9	Sequence 866 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10841	AVQRWRWVV	9	Sequence 867 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10842	IWKYGWRYK	9	Sequence 868 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10843	IIKWWRRWR	9	Sequence 869 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10844	AFRKVKRWG	9	Sequence 870 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10845	MGFTRKWQF	9	Sequence 871 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10846	NWIRWRKWR	9	Sequence 872 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10847	RIGRKLRIR	9	Sequence 873 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10848	RWWRWRHVI	9	Sequence 874 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10849	RLVSKRRRK	9	Sequence 875 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10850	RRKYWKKYR	9	Sequence 876 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10851	IILWWYRRK	9	Sequence 877 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10852	IYFWWWRIR	9	Sequence 878 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10853	HKRKWWRFR	9	Sequence 879 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10854	IGRFWRRWL	9	Sequence 880 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10855	RIRRVLVYV	9	Sequence 881 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10856	WWLRGRRWL	9	Sequence 882 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10857	VRIRKRRWR	9	Sequence 883 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10858	WWRRKWWRR	9	Sequence 884 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10859	WWWRSFRKR	9	Sequence 885 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10860	VGQKWRKRT	9	Sequence 886 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10861	FRRRYRVYR	9	Sequence 887 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10862	RIRRKRKGR	9	Sequence 888 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10863	WKWVTRMYI	9	Sequence 889 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10864	KVVRKKRLR	9	Sequence 890 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10865	RKRRKHWRY	9	Sequence 891 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10866	RVTRTWQRW	9	Sequence 892 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10867	RRRITRKRI	9	Sequence 893 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10868	RLILIKKKW	9	Sequence 894 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10869	WKRRWSRSR	9	Sequence 895 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10870	MWWWFLWRR	9	Sequence 896 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10871	RWVRIWKKK	9	Sequence 897 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10872	KRRVWRMWR	9	Sequence 898 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10873	WHWWIRWWR	9	Sequence 899 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10874	WWRRLRWLV	9	Sequence 900 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10875	KWWIWKRRR	9	Sequence 901 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10876	RYGRKWMIW	9	Sequence 902 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10877	RVKKIKLFI	9	Sequence 903 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10878	RIRYIQRVW	9	Sequence 904 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10879	RLIRWWRKR	9	Sequence 905 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10880	QRGRWLRRG	9	Sequence 906 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10881	RRRRWIRKK	9	Sequence 907 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10882	LGRRWRYRR	9	Sequence 908 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10883	FKIVHVKVR	9	Sequence 909 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10884	FRKKYRVRR	9	Sequence 910 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10885	WKYKYRIRL	9	Sequence 911 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10886	HVRRWWRII	9	Sequence 912 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10887	RFKWWRRYW	9	Sequence 913 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10888	RRRRMRKKI	9	Sequence 914 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10889	RRIRGRVGR	9	Sequence 915 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10890	AFWRWIRFK	9	Sequence 916 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10891	VKKRKIVIY	9	Sequence 917 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10892	KRVKWTWRK	9	Sequence 918 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10893	TGVGRGYRI	9	Sequence 919 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10894	LSWKWWRRV	9	Sequence 920 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10895	IKTFIKRWR	9	Sequence 921 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10896	KMRLKWKRR	9	Sequence 922 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10897	WRWYVTRRK	9	Sequence 923 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10898	IYRRRRKLR	9	Sequence 924 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10899	VWWKWWRWW	9	Sequence 925 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10900	KYKKGWRVV	9	Sequence 926 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10901	KWRRWYYWR	9	Sequence 927 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10902	RRWVFGRRY	9	Sequence 928 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10903	GFTWKKKRR	9	Sequence 929 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10904	YKKIRIKRR	9	Sequence 930 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10905	VWIRRIKRR	9	Sequence 931 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10906	WWKWIRKIV	9	Sequence 932 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10907	WRRKWWSRW	9	Sequence 933 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10908	VTRRRTRIK	9	Sequence 934 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10909	RKRWFVYIW	9	Sequence 935 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10910	IIKWKRIMI	9	Sequence 936 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10911	FNRWWWKKI	9	Sequence 937 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10912	RYKSRRVRR	9	Sequence 938 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10913	VKVIKKFVR	9	Sequence 939 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10914	KWKWLQGRR	9	Sequence 940 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10915	KVRWWYNIK	9	Sequence 941 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10916	FWFRIRKLK	9	Sequence 942 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10917	KRRKQRKYR	9	Sequence 943 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10918	AKNSKRRLW	9	Sequence 944 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10919	RNRRIFRYS	9	Sequence 945 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10920	RWTKWFLVR	9	Sequence 946 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10921	RIRRTRRTR	9	Sequence 947 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10922	KIRWWRISI	9	Sequence 948 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10923	YKGRWGRRW	9	Sequence 949 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10924	MYYRIKQKW	9	Sequence 950 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10925	WRIQRWRWQ	9	Sequence 951 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10926	IRRWSYRRW	9	Sequence 952 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10927	VRIWKIIWW	9	Sequence 953 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10928	RWRWWWLWK	9	Sequence 954 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10929	TKRRWIWIT	9	Sequence 955 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10930	RRWHYWKGW	9	Sequence 956 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10931	WRIRKWWMR	9	Sequence 957 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10932	KRRTRWWVR	9	Sequence 958 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10933	RKWRVWKRR	9	Sequence 959 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10934	WRVWKIRVR	9	Sequence 960 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10935	KYWGIGGWR	9	Sequence 961 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10936	RLISRRRKK	9	Sequence 962 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10937	VSRRIVRRM	9	Sequence 963 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10938	ITKWWRKRR	9	Sequence 964 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10939	KWKIQLWKI	9	Sequence 965 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10940	KKWTWWYVI	9	Sequence 966 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10941	SWKKNRKIW	9	Sequence 967 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10942	HKRQYRKWF	9	Sequence 968 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10943	IFKWFYRRK	9	Sequence 969 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10944	ILKWKWPWWKWRR	13	Sequence 973 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10945	ILPWKWRWWKWRR	13	Sequence 974 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10946	FLPKKFRWWKYRK	13	Sequence 975 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10947	FIKWKFRWWKWRK	13	Sequence 976 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10948	KWPWWPWRR	9	Sequence 977 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10949	KWPWWPWRK	9	Sequence 978 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10950	KFPWWPWRR	9	Sequence 979 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10951	KKPWWPWRR	9	Sequence 980 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10952	KWRWWPWRR	9	Sequence 981 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10953	KWPKWPWRR	9	Sequence 982 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10954	KWPWKPWRR	9	Sequence 983 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10955	KWPWWKWRR	9	Sequence 984 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10956	KWPWWPKRR	9	Sequence 985 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10957	KFRWWPWRR	9	Sequence 987 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10958	KFRWWKWRR	9	Sequence 988 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10959	KWRWWKKRR	9	Sequence 989 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10960	KKKWWKWRR	9	Sequence 990 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10961	KFHWWIWRK	9	Sequence 991 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10962	KFHWWKWRK	9	Sequence 992 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10963	KFKWWKYRK	9	Sequence 993 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10964	KFKFFKYRK	9	Sequence 994 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10965	KFKFFKFRK	9	Sequence 995 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10966	PWWPWRR	7	Sequence 996 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10967	KWWPWRR	7	Sequence 997 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10968	RWWPWRR	7	Sequence 999 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10969	PKWPWRR	7	Sequence 1000 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10970	PWKPWRR	7	Sequence 1001 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10971	PWWPKRR	7	Sequence 1003 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10972	PWWPWRK	7	Sequence 1004 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10973	RWWKWRR	7	Sequence 1005 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10974	RWWKWRK	7	Sequence 1006 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10975	RFWKWRR	7	Sequence 1007 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10976	RWWIKRR	7	Sequence 1008 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10977	RWWIYRR	7	Sequence 1009 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10978	RFFKFRR	7	Sequence 1010 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10979	KWWKWKK	7	Sequence 1011 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10980	KFFKFKK	7	Sequence 1012 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10981	RWRWKRWWW	9	Sequence 1013 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10982	RWRRWKWWW	9	Sequence 1014 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10983	RWWRWRKWW	9	Sequence 1015 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10984	RWRRKWWWW	9	Sequence 1016 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10985	RWRWWKRWY	9	Sequence 1017 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10986	RRKRWWWWW	9	Sequence 1018 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10987	RWRIKRWWW	9	Sequence 1019 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10988	KIWWWWRKR	9	Sequence 1020 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10989	RWRRWKWWL	9	Sequence 1021 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10990	KRWWKWIRW	9	Sequence 1022 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10991	KRWWWWWKR	9	Sequence 1023 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10992	IRWWKRWWR	9	Sequence 1024 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10993	IKRWWRWWR	9	Sequence 1025 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10994	RRKWWWRWW	9	Sequence 1026 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10995	RKWWRWWRW	9	Sequence 1027 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10996	KRWWWWRFR	9	Sequence 1028 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10997	IKRWWWRRW	9	Sequence 1029 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10998	KRWWWVWKR	9	Sequence 1030 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10999	KWRRWKRWW	9	Sequence 1031 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11000	WRWWKIWKR	9	Sequence 1032 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11001	WRWRWWKRW	9	Sequence 1033 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11002	WKRWKWWKR	9	Sequence 1034 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11003	RIKRWWWWR	9	Sequence 1035 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11004	IWKRWWRRW	9	Sequence 1036 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11005	KWWKIWWKR	9	Sequence 1037 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11006	RKRWLWRWW	9	Sequence 1038 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11007	KRWRWWRWW	9	Sequence 1039 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11008	KKRWLWWWR	9	Sequence 1040 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11009	RWWRKWWIR	9	Sequence 1041 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11010	KWWRWWRKW	9	Sequence 1042 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11011	KRWWIRWWR	9	Sequence 1043 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11012	KIWWWWRRR	9	Sequence 1044 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11013	RRRKWWIWW	9	Sequence 1045 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11014	RRRWWWWWW	9	Sequence 1046 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11015	RWWIRKWWR	9	Sequence 1047 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11016	KRWWKWWRR	9	Sequence 1048 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11017	KRWWRKWWR	9	Sequence 1049 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11018	RRIWRWWWW	9	Sequence 1050 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11019	IRRRKWWWW	9	Sequence 1051 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11020	KRKIWWWIR	9	Sequence 1052 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11021	RKIWWWRIR	9	Sequence 1053 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11022	KRWWIWRIR	9	Sequence 1054 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11023	RWFRWWKRW	9	Sequence 1055 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11024	WRWWWKKWR	9	Sequence 1056 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11025	WKRWWKKWR	9	Sequence 1057 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11026	WKRWRWIRW	9	Sequence 1058 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11027	WRWWKWWRR	9	Sequence 1059 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11028	WKKWWKRRW	9	Sequence 1060 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11029	WRWYWWKKR	9	Sequence 1061 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11030	WRRWWKWWR	9	Sequence 1062 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11031	IRMWVKRWR	9	Sequence 1063 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11032	RIWYWYKRW	9	Sequence 1064 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11033	FRRWWKWFK	9	Sequence 1065 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11034	RVRWWKKRW	9	Sequence 1066 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11035	RLKKVRWWW	9	Sequence 1067 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11036	RWWLKIRKW	9	Sequence 1068 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11037	LRWWWIKRI	9	Sequence 1069 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11038	TRKVWWWRW	9	Sequence 1070 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11039	KRFWIWFWR	9	Sequence 1071 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11040	KKRWVWVIR	9	Sequence 1072 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11041	KRWVWYRYW	9	Sequence 1073 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11042	IRKWRRWWK	9	Sequence 1074 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11043	RHWKTWWKR	9	Sequence 1075 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11044	RRFKKWYWY	9	Sequence 1076 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11045	RIKVIWWWR	9	Sequence 1077 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11046	RKRLKWWIY	9	Sequence 1078 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11047	LVFRKYWKR	9	Sequence 1079 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11048	RRRWWWIIV	9	Sequence 1080 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11049	KKRWVWIRY	9	Sequence 1081 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11050	RWRIKFKRW	9	Sequence 1082 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11051	KWKIFRRWW	9	Sequence 1083 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11052	IWKRWRKRL	9	Sequence 1084 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11053	RRRKWWIWG	9	Sequence 1085 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11054	RWLVLRKRW	9	Sequence 1086 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11055	RKWIWRWFL	9	Sequence 1087 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11056	KRRRIWWWK	9	Sequence 1088 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11057	IWWKWRRWV	9	Sequence 1089 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11058	LRWRWWKIK	9	Sequence 1090 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11059	RWKMWWRWV	9	Sequence 1091 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11060	VKRYYWRWR	9	Sequence 1092 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11061	RWYRKRWSW	9	Sequence 1093 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11062	KRKLIRWWW	9	Sequence 1094 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11063	RWRWWIKII	9	Sequence 1095 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11064	KFRKRVWWW	9	Sequence 1096 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11065	IWIWRKLRW	9	Sequence 1097 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11066	LRFILWWKR	9	Sequence 1098 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11067	RVWFKRRWW	9	Sequence 1099 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11068	RRWFVKWWY	9	Sequence 1100 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11069	KWWLVWKRK	9	Sequence 1101 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11070	RWILWWWRI	9	Sequence 1102 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11071	KRWLTWRFR	9	Sequence 1103 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11072	RKWRWRWLK	9	Sequence 1104 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11073	IRRRWWWIV	9	Sequence 1105 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11074	IKWWWRMRI	9	Sequence 1106 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11075	RWKIFIRWW	9	Sequence 1107 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11076	IRQWWRRWW	9	Sequence 1108 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11077	RRRKTWYWW	9	Sequence 1109 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11078	RRWWMRWWV	9	Sequence 1110 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11079	RRFKFIRWW	9	Sequence 1112 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11080	INRKRRLRW	9	Sequence 1113 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11081	RRMKKLRRK	9	Sequence 1114 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11082	RKVRWKIRV	9	Sequence 1115 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11083	VRIVRVRIR	9	Sequence 1116 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11084	IKRVKRRKR	9	Sequence 1117 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11085	RVKTWRVRT	9	Sequence 1118 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11086	RVFVKIRMK	9	Sequence 1119 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11087	IRGRIIFWV	9	Sequence 1120 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11088	ATWIWVFRR	9	Sequence 1121 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11089	KKSKQLWKR	9	Sequence 1122 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11090	MINRVRLRW	9	Sequence 1123 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11091	GGIRRLRWY	9	Sequence 1124 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11092	RLVHWIRRV	9	Sequence 1125 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11093	AWKIKKGRI	9	Sequence 1126 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11094	FVVMKRIVW	9	Sequence 1127 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11095	GIKWRSRRW	9	Sequence 1128 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11096	RWMVSKIWY	9	Sequence 1129 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11097	IVVRVWVVR	9	Sequence 1130 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11098	RWIGVIIKY	9	Sequence 1131 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11099	WIRKRSRIF	9	Sequence 1132 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11100	GWKILRKRK	9	Sequence 1133 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11101	YQRLFVRIR	9	Sequence 1134 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11102	AVWKFVKRV	9	Sequence 1135 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11103	IRKKRRRWT	9	Sequence 1136 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11104	ILRVISKRR	9	Sequence 1137 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11105	AWRFKNIRK	9	Sequence 1138 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11106	HYKFQRWIK	9	Sequence 1139 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11107	RRIRRVRWG	9	Sequence 1140 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11108	VLVKKRRRR	9	Sequence 1141 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11109	RWRGIVHIR	9	Sequence 1142 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11110	WRNRKVVWR	9	Sequence 1143 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11111	KFWWWNYLK	9	Sequence 1144 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11112	KRIMKLKMR	9	Sequence 1145 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11113	IRRRKKRIK	9	Sequence 1146 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11114	RKWMGRFLM	9	Sequence 1147 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11115	RRVQRGKWW	9	Sequence 1148 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11116	WHGVRWWKW	9	Sequence 1149 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11117	WVRFVYRYW	9	Sequence 1150 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11118	RKRTKVTWI	9	Sequence 1151 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11119	IRRIVRRKI	9	Sequence 1152 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11120	KIRRKVRWG	9	Sequence 1153 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11121	AIRRWRIRK	9	Sequence 1154 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11122	WRFKVLRQR	9	Sequence 1155 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11123	RSGKKRWRR	9	Sequence 1156 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11124	FMWVYRYKK	9	Sequence 1157 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11125	RGKYIRWRK	9	Sequence 1158 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11126	WVKVWKYTW	9	Sequence 1159 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11127	VVLKIVRRF	9	Sequence 1160 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11128	GKFYKVWVR	9	Sequence 1161 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11129	SWYRTRKRV	9	Sequence 1162 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11130	KNRGRWFSH	9	Sequence 1163 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11131	AFRGSRHRM	9	Sequence 1164 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11132	GRNGWYRIN	9	Sequence 1165 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11133	AGGMRKRTR	9	Sequence 1166 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11134	ATRKGYSKF	9	Sequence 1167 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11135	SSGVRWSWR	9	Sequence 1168 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11136	RVWRNGYSR	9	Sequence 1169 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11137	WGRTRWSSR	9	Sequence 1170 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11138	GKRVWGRGR	9	Sequence 1171 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11139	SFNWKRSGK	9	Sequence 1172 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11140	WGRGGWTNR	9	Sequence 1173 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11141	ANRWGRGIR	9	Sequence 1174 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11142	WGGHKRRGW	9	Sequence 1175 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11143	WHGGQKWRK	9	Sequence 1176 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11144	FVWQKGTNR	9	Sequence 1177 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11145	HGVWGNRKR	9	Sequence 1178 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11146	TRGWSLGTR	9	Sequence 1179 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11147	GRRVMNQKR	9	Sequence 1180 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11148	RNKFGGNWR	9	Sequence 1181 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11149	GVRVQRNSK	9	Sequence 1182 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11150	NQKWSGRRR	9	Sequence 1183 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11151	RQNGVWRVF	9	Sequence 1184 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11152	GRMRLWNGR	9	Sequence 1185 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11153	WHYRSQVGR	9	Sequence 1186 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11154	GWNTMGRRW	9	Sequence 1187 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11155	RRMGNGGFR	9	Sequence 1188 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11156	SKNVRTWRQ	9	Sequence 1189 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11157	ARGRWINGR	9	Sequence 1190 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11158	GSRRSVWVF	9	Sequence 1191 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11159	WSQNVRTRI	9	Sequence 1192 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11160	GMRRWRGKN	9	Sequence 1193 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11161	RGRTSNWKM	9	Sequence 1194 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11162	WGKRRGWNT	9	Sequence 1195 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11163	AMLGGRQWR	9	Sequence 1197 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11164	QRNKGLRHH	9	Sequence 1198 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11165	ARGKSIKNR	9	Sequence 1199 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11166	NRRNGQMRR	9	Sequence 1200 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11167	RGRRQIGKF	9	Sequence 1201 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11168	ASKRVGVRN	9	Sequence 1202 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11169	GRIGGKNVR	9	Sequence 1203 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11170	NKTGYRWRN	9	Sequence 1204 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11171	VSGNWRGSR	9	Sequence 1205 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11172	GWGGKRRNF	9	Sequence 1206 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11173	KNNRRWQGR	9	Sequence 1207 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11174	GRTMGNGRW	9	Sequence 1208 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11175	GRQISWGRT	9	Sequence 1209 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11176	GGRGTRWHG	9	Sequence 1210 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11177	GVRSWSQRT	9	Sequence 1211 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11178	GSRRFGWNR	9	Sequence 1212 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11179	LVRAIQVRAVIR	12	Sequence 1213 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11180	VQRWLIVWRIRK	12	Sequence 1214 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11181	IVWKIKRWWVGR	12	Sequence 1215 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11182	RFWKVRVKYIRF	12	Sequence 1216 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11183	VQLRIRVAV	9	Sequence 1217 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11184	VQLRIWVRR	9	Sequence 1218 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11185	WNRVKWIRR	9	Sequence 1219 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11186	RIKWIVRFR	9	Sequence 1220 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11187	AIRVVRARLVRR	12	Sequence 1221 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11188	IRWRIRVWVRRI	12	Sequence 1222 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11189	RRWVVWRIVQRR	12	Sequence 1223 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11190	IFWRRIVIVKKF	12	Sequence 1224 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11191	VRLRIRVAV	9	Sequence 1225 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11192	RQVIVRRW	8	Sequence 1226 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11193	VLIRWNGKK	9	Sequence 1227 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11194	LRIRWIFKR	9	Sequence 1228 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11195	KRIVRRLVARIV	12	Sequence 1229 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11196	VRLIVAVRIWRR	12	Sequence 1230 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11197	IVVWRRQLVKNK	12	Sequence 1231 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11198	VRLRIRWWVLRK	12	Sequence 1232 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11199	LRIRVIVWR	9	Sequence 1234 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11200	IRVWVLRQR	9	Sequence 1235 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11201	RIRVIVLKK	9	Sequence 1236 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11202	RRIVKKFQIVRR	12	Sequence 1237 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11203	VQWRIRVRVIKK	12	Sequence 1238 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11204	KKQVSRVKVWRK	12	Sequence 1239 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11205	LIQRIRVRNIVK	12	Sequence 1240 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11206	KQFRIRVRV	9	Sequence 1241 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11207	FRIRVRVIR	9	Sequence 1242 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11208	WRWRVRVWR	9	Sequence 1243 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11209	IRVRVIWRK	9	Sequence 1244 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11210	RRVIVKKFRIRR	12	Sequence 1245 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11211	KQFRNRLRIVKK	12	Sequence 1246 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11212	KRWRWIVRNIRR	12	Sequence 1247 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11213	VQFRIRVIVIRK	12	Sequence 1248 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11214	KRFRIRVRV	9	Sequence 1249 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11215	IVVRRVIRK	9	Sequence 1250 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11216	IWVIRRVWR	9	Sequence 1251 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11217	FQVVKIKVR	9	Sequence 1252 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11218	VIWIRWR	7	Sequence 1253 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11219	IVWIWRR	7	Sequence 1254 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11220	WIVIWRR	7	Sequence 1255 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11221	RRWIVWI	7	Sequence 1256 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11222	RWWRIVI	7	Sequence 1257 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11223	WIRVIRW	7	Sequence 1258 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11224	IIRRWWV	7	Sequence 1259 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11225	IRWVIRW	7	Sequence 1260 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11226	ILRWKWRWWRWRR	13	Sequence 1261 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11227	RWRWWRWRR	9	Sequence 1262 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11228	KWKWWKWKK	9	Sequence 1263 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11229	RWWRWRR	7	Sequence 1264 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11230	RIRVAV	6	Sequence 1265 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11231	WKWPWWPW	8	Sequence 1266 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11232	KIWVIRWWR	9	Sequence 1267 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11233	FFWLIKGAIHAGKAIHGLIHRRRH	24	Sequence 1 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11234	FFWLIKGAIHAGKAIHGLIH	20	Sequence 2 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11235	FIGLLISAGKAIHDLIRRRH	20	Sequence 3 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11236	FIGLLISAGKAIHDLI	16	Sequence 4 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11237	KRRLIARILRLAARALVKKR	20	Sequence 1 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11238	KRKLIFLAAFLAALALFKKR	20	Sequence 2 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11239	KRRLAAFRAFRGALKSVLKK	20	Sequence 3 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11240	KRRLIARILRLAIRALVKKR	20	Sequence 4 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11241	KRRLILRILRLAIRALVKKR	20	Sequence 5 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11242	KRRLILRILRLAIRILVKKR	20	Sequence 6 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11243	KRRLIFRILKLFFRFLVKKR	20	Sequence 7 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11244	KRRILIRILKLIIKLILKKR	20	Sequence 8 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11245	KRRKLIKILKLIIKLIRKKR	20	Sequence 9 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11246	KRRKLIKILKLIAKLIRKKR	20	Sequence 10 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11247	KRRKAIKILKLIAKLIRKKR	20	Sequence 11 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11248	KRRKAIKILKLIAKAIRKKR	20	Sequence 12 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11249	KRRLALFRAFRLALKSVLKK	20	Sequence 13 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11250	KRRLALFRLFRLALKLVLKK	20	Sequence 14 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11251	KRRLFLFRLFRLFLRLFLKK	20	Sequence 15 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11252	KRRKLAFRAFRFALKAVLKK	20	Sequence 16 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11253	KRRKLAFRLFRLFLKLVLKK	20	Sequence 17 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11254	RKKRLKLLKRLV	12	Sequence 1 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11255	RKKRLKLLKRLL	12	Sequence 2 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11256	RKKRVKLLKRLV	12	Sequence 3 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11257	RKKKVKLLKRLV	12	Sequence 4 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11258	RKKRLKVVKRLV	12	Sequence 5 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11259	RKKRLRVVRRLV	12	Sequence 6 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11260	RKKKLKVVKRLV	12	Sequence 7 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11261	RKKKLKIIKRLI	12	Sequence 8 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11262	RKKKIKIIKRLI	12	Sequence 9 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11263	RKKKIKIIKKII	12	Sequence 10 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11264	RKKKAKIIKKII	12	Sequence 11 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11265	RKKKLKFFKRLF	12	Sequence 12 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11266	RKKKFKFFKRLF	12	Sequence 13 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11267	RKKKFKFFKRFF	12	Sequence 14 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11268	RKKKFKIFKRLF	12	Sequence 15 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11269	KRKKLLKRLL	10	Sequence 16 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11270	KRKKLLKRLI	10	Sequence 17 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11271	KKKKIIKRLI	10	Sequence 18 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11272	RKKRKKLLKRLL	12	Sequence 19 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11273	RKKRKKLIKRLI	12	Sequence 20 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11274	RKKRKKLLKRLI	12	Sequence 21 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11275	RKKKKKIIKKLI	12	Sequence 22 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11276	KKKKKKIIKKII	12	Sequence 23 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11277	RKRAARLLKRLV	12	Sequence 24 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11278	RKRFARFAKRAV	12	Sequence 25 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11279	KKKAARALKRAL	12	Sequence 26 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11280	KFKRWLA	7	Sequence 1 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11281	KFRAWVR	7	Sequence 3 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11282	KWKIWLK	7	Sequence 5 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11283	KKWRAWLKWLAKK	13	Sequence 7 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11284	KKWRKWLRAIAKK	13	Sequence 9 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11285	KKFRRFVRFIAKK	13	Sequence 11 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11286	KKWRRWLKWLAKK	13	Sequence 13 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11287	RCICGRGICRCICGRGIC	18	Sequence 11 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11288	RCICGKGICRCICGRGIC	18	Sequence 12 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11289	RCICGKGICRCICGKGIC	18	Sequence 13 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11290	RGGRLCYCRRRFCVCVGR	18	Sequence 14 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11291	RGGRLCYCRRRFCVCV	16	Sequence 15 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11292	RGGGLCYCRRRFCVCVGR	18	Sequence 16 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11293	RGGRLCYCRGWICFCVGR	18	Sequence 17 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11294	RGGRLCYCRPRFCVCVGR	18	Sequence 18 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11295	GICRCICGKGICRCICGR	18	Sequence 21 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP18753	RCICRRGVC	9	Sequence 33 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP11297	GFCWYVCVYRNGVRVCYRRCN	21	Sequence 2 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11298	GACWYVCVYRNGVRVCYRRCN	21	Sequence 3 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11299	GFCAYVCVYRNGVRVCYRRCN	21	Sequence 4 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11300	GFCEYVCVYRNGVRVCYRRCN	21	Sequence 5 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11301	GFCGYVCVYRNGVRVCYRRCN	21	Sequence 6 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11302	GFCSYVCVYRNGVRVCYRRCN	21	Sequence 7 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11303	GFCTYVCVYRNGVRVCYRRCN	21	Sequence 8 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11304	GFCYYVCVYRNGVRVCYRRCN	21	Sequence 9 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11305	GFCWKVCVYRNGVRVCYRRCN	21	Sequence 10 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11306	GFCWNVCVYRNGVRVCYRRCN	21	Sequence 11 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11307	GFCWRVCVYRNGVRVCYRRCN	21	Sequence 12 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11308	GFCWYACVYRNGVRVCYRRCN	21	Sequence 13 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11309	GFCWYECVYRNGVRVCYRRCN	21	Sequence 14 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11310	GFCWYGCVYRNGVRVCYRRCN	21	Sequence 15 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11311	GFCWYLCVYRNGVRVCYRRCN	21	Sequence 16 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11312	GFCWYNCVYRNGVRVCYRRCN	21	Sequence 17 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11313	GFCWYRCVYRNGVRVCYRRCN	21	Sequence 18 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11314	GFCWYSCVYRNGVRVCYRRCN	21	Sequence 19 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11315	GFCWYWCVYRNGVRVCYRRCN	21	Sequence 20 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11316	GFCWYVCAYRNGVRVCYRRCN	21	Sequence 21 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11317	GFCWYVCGYRNGVRVCYRRCN	21	Sequence 22 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11318	GFCWYVCHYRNGVRVCYRRCN	21	Sequence 23 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11319	GFCWYVCSYRNGVRVCYRRCN	21	Sequence 24 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11320	GFCWYVCYYRNGVRVCYRRCN	21	Sequence 25 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11321	GFCWYVCVIRNGVRVCYRRCN	21	Sequence 26 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11322	GFCWYVCVKRNGVRVCYRRCN	21	Sequence 27 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11323	GFCWYVCVRRNGVRVCYRRCN	21	Sequence 28 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11324	GFCWYVCVYRNGARVCYRRCN	21	Sequence 29 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11325	GFCWYVCVYRNGGRVCYRRCN	21	Sequence 30 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11326	GFCWYVCVYRNGKRVCYRRCN	21	Sequence 31 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11327	GFCWYVCVYRNGLRVCYRRCN	21	Sequence 32 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11328	GFCWYVCVYRNGPRVCYRRCN	21	Sequence 33 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11329	GFCWYVCVYRNGQRVCYRRCN	21	Sequence 34 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11330	GFCWYVCVYRNGRRVCYRRCN	21	Sequence 35 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11331	GFCWYVCVYRNGSRVCYRRCN	21	Sequence 36 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11332	GFCWYVCVYRNGVRACYRRCN	21	Sequence 37 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11333	GFCWYVCVYRNGVRGCYRRCN	21	Sequence 38 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11334	GFCWYVCVYRNGVRHCYRRCN	21	Sequence 39 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11335	GFCWYVCVYRNGVRKCYRRCN	21	Sequence 40 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11336	GFCWYVCVYRNGVRNCYRRCN	21	Sequence 41 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11337	GFCWYVCVYRNGVRQCYRRCN	21	Sequence 42 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11338	GFCWYVCVYRNGVRRCYRRCN	21	Sequence 43 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11339	GFCWYVCVYRNGVRSCYRRCN	21	Sequence 44 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11340	GFCWYVCVYRNGVRTCYRRCN	21	Sequence 45 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11341	GFCWYVCVYRNGVRVCHRRCN	21	Sequence 46 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11342	GFCWYVCVYRNGVRVCKRRCN	21	Sequence 47 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11343	GFCWYVCVYRNGVRVCNRRCN	21	Sequence 48 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11344	GFCWYVCVYRNGVRVCRRRCN	21	Sequence 49 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11345	GFCWYVCVYRNGVRVCYRRCH	21	Sequence 50 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11346	GFCWYVCVYRNGVRVCYRRCK	21	Sequence 51 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11347	GFCWYVCVYRNGVRVCYRRCR	21	Sequence 52 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11348	GFCWYVCVYRNGVRVCYRRCS	21	Sequence 53 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11349	GFCWYVCVYRNGVRVCYRRCT	21	Sequence 54 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11350	RFCWYVCVYRNGVRVCYRRCR	21	Sequence 55 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11351	GFCFYVCVYRNGVRVCRRRCN	21	Sequence 56 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11352	GFCAHVCVYRNGVRVCYRRCN	21	Sequence 57 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11353	GFCARVCVYRNGVRVCYRRCN	21	Sequence 58 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11354	GFCFYVCVRRNGVRVCYRRCN	21	Sequence 59 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11355	GFCGHVCVYRNGVRVCYRRCN	21	Sequence 60 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11356	GFCGRVCVYRNGVRVCYRRCN	21	Sequence 61 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11357	GFCSYVCVYRNGVRACYRRCN	21	Sequence 62 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11358	GFCSRVCVYRNGVRVCYRRCN	21	Sequence 63 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11359	GFCYRVCVYRNGVRVCYRRCN	21	Sequence 64 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11360	GFCWFVCVYRNGVRQCYRRCN	21	Sequence 65 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11361	GFCWHVCVYRNGVRSCYRRCN	21	Sequence 66 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11362	GFCWHVCVYRNGVRVCRRRCN	21	Sequence 67 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11363	GFCWKVCVYRNGVRVCSRRCN	21	Sequence 68 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11364	GFCWNVCVYRNGVRSCYRRCN	21	Sequence 69 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11365	GFCWNVCVYRNGVRVCHRRCN	21	Sequence 70 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11366	GFCWRVCVYRNGVRPCYRRCN	21	Sequence 71 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11367	GFCWRACVYRNGVRVCYRRCN	21	Sequence 72 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11368	GFCWRVCGYRNGVRVCYRRCN	21	Sequence 73 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11369	GFCWRVCHYRNGVRVCYRRCN	21	Sequence 74 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11370	GFCWRVCSYRNGVRVCYRRCN	21	Sequence 75 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11371	GFCWRVCVYRNGVRVCHRRCN	21	Sequence 76 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11372	GFCWRVCVYRNGVRVCNRRCN	21	Sequence 77 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11373	GFCWSVCVYRNGVRSCYRRCN	21	Sequence 78 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11374	GFCWYACVYRNGARVCYRRCN	21	Sequence 79 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11375	GFCWYACVYRNGKRVCYRRCN	21	Sequence 80 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11376	GFCWYACVYRNGVRACYRRCN	21	Sequence 81 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11377	GFCWYACVYRNGVRVCHRRCN	21	Sequence 82 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11378	GFCWYMCGYRNGVRVCYRRCN	21	Sequence 83 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11379	GFCWYVCAYRNGVRACYRRCN	21	Sequence 84 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11380	GFCWYVCSYRNGKRVCYRRCN	21	Sequence 85 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11381	GFCWYVCVKRNGARVCYRRCN	21	Sequence 86 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11382	GFCWYVCVKRNGVRSCYRRCN	21	Sequence 87 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11383	GFCWYVCVYKNGVRSCYRRCN	21	Sequence 88 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11384	GFCWYVCVYKNGVRVCHRRCN	21	Sequence 89 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11385	GFCWYVCVYPNGGRVCYRRCN	21	Sequence 90 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11386	GFCWYVCVYRRGVRQCYRRCN	21	Sequence 91 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11387	GFCWYVCVYRNGARVCCRRCN	21	Sequence 92 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11388	GFCWYVCVYRNGGRKCYRRCN	21	Sequence 93 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11389	GFCWYVCVYRNGVRLCHRRCN	21	Sequence 94 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11390	AFCWNVCVYRNGVRVCHRRCN	21	Sequence 95 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11391	DFCWNVCVYRNGVRVCHRRCN	21	Sequence 96 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11392	FFCWNVCVYRNGVRVCHRRCN	21	Sequence 97 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11393	HFCWNVCVYRNGVRVCHRRCN	21	Sequence 98 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11394	IFCWNVCVYRNGVRVCHRRCN	21	Sequence 99 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11395	KFCWNVCVYRNGVRVCHRRCN	21	Sequence 100 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11396	MFCWNVCVYRNGVRVCHRRCN	21	Sequence 101 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11397	QFCWNVCVYRNGVRVCHRRCN	21	Sequence 102 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11398	RFCWNVCVYRNGVRVCHRRCN	21	Sequence 103 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11399	SFCWNVCVYRNGVRVCHRRCN	21	Sequence 104 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11400	TFCWNVCVYRNGVRVCHRRCN	21	Sequence 105 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11401	VFCWNVCVYRNGVRVCHRRCN	21	Sequence 106 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11402	WFCWNVCVYRNGVRVCHRRCN	21	Sequence 107 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11403	YFCWNVCVYRNGVRVCHRRCN	21	Sequence 108 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11404	GGCWNVCVYRNGVRVCHRRCN	21	Sequence 109 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11405	GHCWNVCVYRNGVRVCHRRCN	21	Sequence 110 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11406	GICWNVCVYRNGVRVCHRRCN	21	Sequence 111 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11407	GLCWNVCVYRNGVRVCHRRCN	21	Sequence 112 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11408	GMCWNVCVYRNGVRVCHRRCN	21	Sequence 113 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11409	GPCWNVCVYRNGVRVCHRRCN	21	Sequence 114 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11410	GVCWNVCVYRNGVRVCHRRCN	21	Sequence 115 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11411	GWCWNVCVYRNGVRVCHRRCN	21	Sequence 116 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11412	GYCWNVCVYRNGVRVCHRRCN	21	Sequence 117 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11413	GFLQYVCVYRNGVRVCHRRCN	21	Sequence 118 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11414	GFCAYACVKRNGVRVCYRRCN	21	Sequence 119 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11415	GFCAKVCVYRNGVRSCYRRCN	21	Sequence 120 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11416	GFCARVCVYRNGVRACYRRCN	21	Sequence 121 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11417	GFCARVCVYRNGVRSCYRRCN	21	Sequence 122 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11418	GFCARVCVYRNGVRTCYRRCN	21	Sequence 123 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11419	GFCARVCSYRNGVRVCYRRCN	21	Sequence 124 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11420	GFCARVCVKRNGVRVCYRRCN	21	Sequence 125 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11421	GFCAWVCVYRNGVRQCYRRCN	21	Sequence 126 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11422	GFCAYVCVRRNGVRSCYRRCN	21	Sequence 127 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11423	GFCFYVCAYRNGVRSCYRRCN	21	Sequence 128 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11424	GFCFHVCVYRNGVRSCYRRCN	21	Sequence 129 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11425	GFCFNVCVYRNGVRSCYRRCN	21	Sequence 130 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11426	GFCFNVCVYRNGVRVCHRRCN	21	Sequence 131 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11427	GFCFRVCVYRNGVRKCYRRCN	21	Sequence 132 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11428	GFCFRVCVYRNGVRQCYRRCN	21	Sequence 133 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11429	GFCFRVCVYRNGVRSCYRRCN	21	Sequence 134 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11430	GFCFRVCVYRNGVRVCHRRCN	21	Sequence 135 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11431	GFCFRVCVYRNGVRVCQRRCN	21	Sequence 136 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11432	GFCFYVCVKRNGVRVCHRRCN	21	Sequence 137 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11433	GFCGHVCVYRNGVRVCYRRCA	21	Sequence 138 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11434	GFCGHVCVYRNGVRVCYRRCK	21	Sequence 139 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11435	GFCGHVCVYRNGVRVCYRRCL	21	Sequence 140 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11436	GFCGHVCVYRNGVRVCYRRCM	21	Sequence 141 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11437	GFCGHVCVYRNGVRVCYRRCP	21	Sequence 142 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11438	GFCGHVCVYRNGVRVCYRRCR	21	Sequence 143 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11439	GFCGHVCVYRNGVRVCYRRCS	21	Sequence 144 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11440	GFCGHVCVYRNGVRVCYRRCY	21	Sequence 145 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11441	GFCGHVCVYRNGVRACYRRCN	21	Sequence 146 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11442	GFCGHVCVYRNGVRFCYRRCN	21	Sequence 147 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11443	GFCGHVCVYRNGVRGCYRRCN	21	Sequence 148 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11444	GFCGHVCVYRNGVRHCYRRCN	21	Sequence 149 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11445	GFCGHVCVYRNGVRICYRRCN	21	Sequence 150 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11446	GFCGHVCVYRNGVRLCYRRCN	21	Sequence 151 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11447	GFCGHVCVYRNGVRMCYRRCN	21	Sequence 152 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11448	GFCGHVCVYRNGVRNCYRRCN	21	Sequence 153 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11449	GFCGHVCVYRNGVRQCYRRCN	21	Sequence 154 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11450	GFCGHVCVYRNGVRRCYRRCN	21	Sequence 155 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11451	GFCGHVCVYRNGVRSCYRRCN	21	Sequence 156 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11452	GFCGHVCVYRNGVRTCYRRCN	21	Sequence 157 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11453	GFCGHVCVYRNGVRWCYRRCN	21	Sequence 158 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11454	GFCGHVCVYRNGVRYCYRRCN	21	Sequence 159 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11455	GFCGHVCVYRNGVRVCFRRCN	21	Sequence 160 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11456	GFCGHVCVYRNGVRVCGRRCN	21	Sequence 161 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11457	GFCGHVCVYRNGVRVCIRRCN	21	Sequence 162 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11458	GFCGHVCVYRNGVRVCLRRCN	21	Sequence 163 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11459	GFCGHVCVYRNGVRVCMRRCN	21	Sequence 164 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11460	GFCGHVCVYRNGVRVCTRRCN	21	Sequence 165 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11461	GFCGHVCVYRNGVRVCVRRCN	21	Sequence 166 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11462	GFCGHVCVYRNGVRVCWRRCN	21	Sequence 167 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11463	GFCGKVCVYRNGVRHCYRRCN	21	Sequence 168 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11464	GFCGRVCVYRNGVRLCYRRCN	21	Sequence 169 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11465	GFCGRVCVYRNGVRRCYRRCN	21	Sequence 170 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11466	GFCGRVCVYRNGVRTCYRRCN	21	Sequence 171 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11467	GFCGRVCVRRNGVRVCYRRCN	21	Sequence 172 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11468	GFCGSVCVYRNGVRACYRRCN	21	Sequence 173 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11469	GFCGSVCVYRNGVRKCYRRCN	21	Sequence 174 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11470	GFCGSVCVYRNGVRRCYRRCN	21	Sequence 175 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11471	GFCGYVCVRRNGVRSCYRRCN	21	Sequence 176 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11472	GFCINVCVYRNGVRVCHRRCN	21	Sequence 177 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11473	GFCLHVCVYRNGVRQCYRRCN	21	Sequence 178 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11474	GFCLKVCVYRNGVRKCYRRCN	21	Sequence 179 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11475	GFCLRVCVYRNGVRQCYRRCN	21	Sequence 180 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11476	GFCLRVCVYRNGVRSCYRRCN	21	Sequence 181 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11477	GFCMEVCVYRNGVRVCTRRCN	21	Sequence 182 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11478	GFCMHVCVYRNGVRSCYRRCN	21	Sequence 183 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11479	GFCMNVCVYRNGVRVCHRRCN	21	Sequence 184 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11480	GFCMRVCVYRNGVRTCYRRCN	21	Sequence 185 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11481	GFCMSVCVYRNGVRQCYRRCN	21	Sequence 186 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11482	GFCMSVCVYRNGVRRCYRRCN	21	Sequence 187 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11483	GFCNRVCVYRNGVRICYRRCN	21	Sequence 188 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11484	GFCSKVCVYRNGVRRCYRRCN	21	Sequence 189 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11485	GFCSRVCVYRNGVRICYRRCN	21	Sequence 190 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11486	GFCTNVCVYRNGVRACYRRCN	21	Sequence 191 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11487	GFCTRVCVYRNGVRRCYRRCN	21	Sequence 192 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11488	GFCTRVCVYRNGVRTCYRRCN	21	Sequence 193 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11489	GFCTSVCVYRNGVRHCYRRCN	21	Sequence 194 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11490	GFCTYVCVKRNGVRKCYRRCN	21	Sequence 195 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11491	GFCVHVCVYRNGVRPCYRRCN	21	Sequence 196 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11492	GFCVHVCVYRNGVRVCHRRCN	21	Sequence 197 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11493	GFCVKVCVYRNGVRQCYRRCN	21	Sequence 198 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11494	GFCVNVCVYRNGVRVCHRRCN	21	Sequence 199 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11495	GFCVRVCVYRNGVRGCYRRCN	21	Sequence 200 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11496	GFCVRVCVYRNGVRPCYRRCN	21	Sequence 201 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11497	GFCVRVCVYRNGVRQCYRRCN	21	Sequence 202 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11498	GFCVRVCVYRNGVRRCYRRCN	21	Sequence 203 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11499	GFCVRVCVYRNGVRTCYRRCN	21	Sequence 204 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11500	GFCYHVCVYRNGVRYCYRRCN	21	Sequence 205 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11501	GFCYKVCVYRNGVRSCYRRCN	21	Sequence 206 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11502	GFCYNVCVYRNGVRRCYRRCN	21	Sequence 207 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11503	GFCYNVCVYRNGVRVCHRRCN	21	Sequence 208 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11504	GFCYRVCVYRNGVRTCYRRCN	21	Sequence 209 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11505	GFCYRVCVYRNGVRVCHRRCN	21	Sequence 210 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11506	GFCYRVCVYRNGVRVCSRRCN	21	Sequence 211 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11507	GFCYWVCVYRNGVRSCYRRCN	21	Sequence 212 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11508	GFCWHVCVYRNGARSCYRRCN	21	Sequence 213 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11509	GFCWHVCVYRNGSRSCYRRCN	21	Sequence 214 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11510	GFCWHVCVYRNGVRSCSRRCN	21	Sequence 215 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11511	GFCWHVCAYRNGKRVCYRRCN	21	Sequence 216 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11512	GFCWHVCAYRNGVRSCYRRCN	21	Sequence 217 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11513	GFCWHVCARRNGVRVCYRRCN	21	Sequence 218 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11514	GFCWHVCHYRNSVRVCYRRCN	21	Sequence 219 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11515	GFCWHVCVSRNGVRKCYRRCN	21	Sequence 220 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11516	GFCWKVCVSRNGVRVCSRRCN	21	Sequence 221 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11517	GFCWNVCVYRNAVRVCHRRCN	21	Sequence 222 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11518	GFCWNVCVYRNDVRVCHRRCN	21	Sequence 223 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11519	GFCWNVCVYRNEVRVCHRRCN	21	Sequence 224 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11520	GFCWNVCVYRNFVRVCHRRCN	21	Sequence 225 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11521	GFCWNVCVYRNHVRVCHRRCN	21	Sequence 226 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11522	GFCWNVCVYRNKVRVCHRRCN	21	Sequence 227 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11523	GFCWNVCVYRNRVRVCHRRCN	21	Sequence 228 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11524	GFCWNVCVYRNYVRVCHRRCN	21	Sequence 229 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11525	GFCWNVCVYRAGVRVCHRRCN	21	Sequence 230 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11526	GFCWNVCVYRGGVRVCHRRCN	21	Sequence 231 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11527	GFCWNVCVYRHGVRVCHRRCN	21	Sequence 232 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11528	GFCWNVCVYRQGVRVCHRRCN	21	Sequence 233 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11529	GFCWNVCVYRRGVRVCHRRCN	21	Sequence 234 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11530	GFCWNVCVYRNGARVCHRRCN	21	Sequence 235 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11531	GFCWNVCVYRNGFRVCHRRCN	21	Sequence 236 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11532	GFCWNVCVYRNGHRVCHRRCN	21	Sequence 237 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11533	GFCWNVCVYRNGQRVCHRRCN	21	Sequence 238 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11534	GFCWNVCVYRNGRRVCHRRCN	21	Sequence 239 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11535	GFCWNVCVYRNGTRVCHRRCN	21	Sequence 240 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11536	GFCWNVCVYRNGWRVCHRRCN	21	Sequence 241 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11537	GFCWNVCVYRNGYRVCHRRCN	21	Sequence 242 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11538	GFCWNVCVYRNGVRACHRRCN	21	Sequence 243 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11539	GFCWNVCVYRNGVRCCHRRCN	21	Sequence 244 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11540	GFCWNVCVYRNGVRFCHRRCN	21	Sequence 245 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11541	GFCWNVCVYRNGVRGCHRRCN	21	Sequence 246 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11542	GFCWNVCVYRNGVRHCHRRCN	21	Sequence 247 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11543	GFCWNVCVYRNGVRICHRRCN	21	Sequence 248 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11544	GFCWNVCVYRNGVRLCHRRCN	21	Sequence 249 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11545	GFCWNVCVYRNGVRMCHRRCN	21	Sequence 250 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11546	GFCWNVCVYRNGVRNCHRRCN	21	Sequence 251 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11547	GFCWNVCVYRNGVRRCHRRCN	21	Sequence 252 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11548	GFCWNVCVYRNGVRWCHRRCN	21	Sequence 253 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11549	GFCWNVCVYRNGVRYCHRRCN	21	Sequence 254 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11550	GFCWNACVYRNGVRNCYRRCN	21	Sequence 255 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11551	GFCWNACVYRNGVRSCYRRCN	21	Sequence 256 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11552	GFCWNACVYRNGVRVCHRRCN	21	Sequence 257 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11553	GFCWNACVKRNGVRVCYRRCN	21	Sequence 258 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11554	GFCWNCCVYRNGVRVCHRRCN	21	Sequence 259 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11555	GFCWNFCVYRNGVRVCHRRCN	21	Sequence 260 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11556	GFCWNHCVYRNGVRVCHRRCN	21	Sequence 261 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11557	GFCWNICVYRNGVRVCHRRCN	21	Sequence 262 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11558	GFCWNLCVYRNGVRVCHRRCN	21	Sequence 263 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11559	GFCWNMCVYRNGVRVCHRRCN	21	Sequence 264 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11560	GFCWNQCVYRNGVRVCHRRCN	21	Sequence 265 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11561	GFCWNTCVYRNGVRVCHRRCN	21	Sequence 266 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11562	GFCWNWCVYRNGVRVCHRRCN	21	Sequence 267 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11563	GFCWNYCVYRNGVRVCHRRCN	21	Sequence 268 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11564	GFCWNVCAYRNGARVCYRRCN	21	Sequence 269 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11565	GFCWNVCAYRNGVRSCYRRCN	21	Sequence 270 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11566	GFCWNVCAYRNGVRVCHRRCN	21	Sequence 271 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11567	GFCWNVCFYRNGVRVCHRRCN	21	Sequence 272 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11568	GFCWNVCGYRNGVRVCHRRCN	21	Sequence 273 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11569	GFCWNVCIYRNGVRVCHRRCN	21	Sequence 274 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11570	GFCWNVCLYRNGVRVCHRRCN	21	Sequence 275 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11571	GFCWNVCWYRNGVRVCHRRCN	21	Sequence 276 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11572	GFCWNVCYYRNGVRVCHRRCN	21	Sequence 277 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11573	GFCWNVCVYRNGVRVCHRRCA	21	Sequence 278 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11574	GFCWNVCVYRNGVRVCHRRCC	21	Sequence 279 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11575	GFCWNVCVYRNGVRVCHRRCF	21	Sequence 280 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11576	GFCWNVCVYRNGVRVCHRRCG	21	Sequence 281 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11577	GFCWNVCVYRNGVRVCHRRCH	21	Sequence 282 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11578	GFCWNVCVYRNGVRVCHRRCI	21	Sequence 283 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11579	GFCWNVCVYRNGVRVCHRRCK	21	Sequence 284 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11580	GFCWNVCVYRNGVRVCHRRCL	21	Sequence 285 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11581	GFCWNVCVYRNGVRVCHRRCM	21	Sequence 286 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11582	GFCWNVCVYRNGVRVCHRRCP	21	Sequence 287 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11583	GFCWNVCVYRNGVRVCHRRCQ	21	Sequence 288 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11584	GFCWNVCVYRNGVRVCHRRCR	21	Sequence 289 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11585	GFCWNVCVYRNGVRVCHRRCS	21	Sequence 290 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11586	GFCWNVCVYRNGVRVCHRRCW	21	Sequence 291 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11587	GFCWNVCVYRNGVRVCHRRCY	21	Sequence 292 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11588	GFCWNVCVYRNGVRVCHRDCN	21	Sequence 293 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11589	GFCWNVCVYRNGVRVCHRHCN	21	Sequence 294 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11590	GFCWNVCVYRNGVRVCHRKCN	21	Sequence 295 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11591	GFCWNVCVYRNGVRVCHRMCN	21	Sequence 296 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11592	GFCWNVCVYRNGVRVCHRTCN	21	Sequence 297 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11593	GFCWNVCVYRNGVRVCHRYCN	21	Sequence 298 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11594	GFCWNVCVARNGVRVCHRRCN	21	Sequence 299 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11595	GFCWNVCVDRNGVRVCHRRCN	21	Sequence 300 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11596	GFCWNVCVFRNGVRVCHRRCN	21	Sequence 301 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11597	GFCWNVCVGRNGVRVCHRRCN	21	Sequence 302 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11598	GFCWNVCVHRNGVRVCHRRCN	21	Sequence 303 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11599	GFCWNVCVIRNGVRVCHRRCN	21	Sequence 304 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11600	GFCWNVCVKRNGVRVCHRRCN	21	Sequence 305 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11601	GFCWNVCVMRNGVRVCHRRCN	21	Sequence 306 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11602	GFCWNVCVQRNGVRVCHRRCN	21	Sequence 307 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11603	GFCWNVCVRRNGVRVCHRRCN	21	Sequence 308 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11604	GFCWNVCVSRNGVRVCHRRCN	21	Sequence 309 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11605	GFCWNVCVTRNGVRVCHRRCN	21	Sequence 310 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11606	GFCWNVCVVRNGVRVCHRRCN	21	Sequence 311 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11607	GFCWNVCVWRNGVRVCHRRCN	21	Sequence 312 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11608	GFCWRVCVYRNGARKCYRRCN	21	Sequence 313 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11609	GFCWRVCVYRNGARVCSRRCN	21	Sequence 314 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11610	GFCWRVCVYRNGVRKCHRRCN	21	Sequence 315 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11611	GFCWRVCVYRNGVRSCHRRCN	21	Sequence 316 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11612	GFCWRVCVYRNGVRSCSRRCN	21	Sequence 317 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11613	GFCWRACVYRNSVRVCYRRCN	21	Sequence 318 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11614	GFCWRACVYRNGVRACYRRCN	21	Sequence 319 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11615	GFCWRACVYRNGVRSCYRRCN	21	Sequence 320 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11616	GFCWRACVYRNGVRVCHRRCN	21	Sequence 321 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11617	GFCWRACVKRNGVRVCYRRCN	21	Sequence 322 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11618	GFCWRCCVYRNGVRSCYRRCN	21	Sequence 323 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11619	GFCWRSCVYRNGVRVCHRRCN	21	Sequence 324 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11620	GFCWRVCAYRNGVRSCYRRCN	21	Sequence 325 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11621	GFCWRVCGYRNGVRVCHRRCN	21	Sequence 326 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11622	GFCWRVCHYRNSVRVCYRRCN	21	Sequence 327 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11623	GFCWRVCHYRNGKRVCYRRCN	21	Sequence 328 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11624	GFCWRVCSYRNGARVCYRRCN	21	Sequence 329 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11625	GFCWRVCSYRNGSRVCYRRCN	21	Sequence 330 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11626	GFCWRVCSYRNGVRKCYRRCN	21	Sequence 331 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11627	GFCWRVCSRRNGVRVCYRRCN	21	Sequence 332 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11628	GFCWRVCSSRNGVRVCYRRCN	21	Sequence 333 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11629	GFCWRVCVRRNGARVCYRRCN	21	Sequence 334 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11630	GFCWRVCVRRNGVRVCHRRCN	21	Sequence 335 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11631	GFCWRVCVSRNGVRVCHRRCN	21	Sequence 336 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11632	GFCWRVCVSRNGVRVCSRRCN	21	Sequence 337 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11633	GFCWYACVYRNSKRVCYRRCN	21	Sequence 338 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11634	GFCWYACVYRNGARSCYRRCN	21	Sequence 339 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11635	GFCWYACVYRNGKRACYRRCN	21	Sequence 340 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11636	GFCWYACVYRNGKRVCHRRCN	21	Sequence 341 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11637	GFCWYACVYRNGVRKCHRRCN	21	Sequence 342 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11638	GFCWYACAYRNGVRACYRRCN	21	Sequence 343 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11639	GFCWYRCHYSNGVRVCYRRCN	21	Sequence 344 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11640	GFCWYSCVRRNGVRSCYRRCN	21	Sequence 345 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11641	GFCWYTCVKRNGLRVCYRRCN	21	Sequence 346 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11642	GFCWYVCAYKNGVRVCHRRCN	21	Sequence 347 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11643	GFCWYVCAYRNGVRACHRRCN	21	Sequence 348 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11644	GFCWYVCAYRNGVRSCHRRCN	21	Sequence 349 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11645	GFCWYVCARRNGARVCYRRCN	21	Sequence 350 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11646	GFCWYVCARRNGVRSCYRRCN	21	Sequence 351 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11647	GFCWYVCFYRNHVRVCHRRCN	21	Sequence 352 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11648	GFCWYVCVFRNGVRACHRRCN	21	Sequence 353 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11649	GFCWYVCVKRNGARVCSRRCN	21	Sequence 354 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11650	GFCWYVCVRRNGVRSCSRRCN	21	Sequence 355 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11651	GFCWYVCVYKNGKRSCYRRCN	21	Sequence 356 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11652	GFCWYVCVYRNGKRACHRRCN	21	Sequence 357 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11653	RFCWNVCVYRHGVRVCHRRCN	21	Sequence 358 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11654	RFCWNVCVYRNGVRVCHRHCN	21	Sequence 359 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11655	GFCAYACVKRNGARVCYRRCN	21	Sequence 360 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11656	GFCAHVCVYRNGARKCYRRCN	21	Sequence 361 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11657	GFCAHVCVKRNGARVCYRRCN	21	Sequence 362 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11658	GFCARVCAKRNGVRVCYRRCN	21	Sequence 363 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11659	GFCARVCVKRNGVRSCYRRCN	21	Sequence 364 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11660	GFCARVCVRRNGVRKCYRRCN	21	Sequence 365 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11661	GFCARVCVRRNGVRSCYRRCN	21	Sequence 366 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11662	GFCFYACVRRNGVRSCYRRCN	21	Sequence 367 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11663	GFCFYVCASRNGVRSCYRRCN	21	Sequence 368 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11664	GFCFHVCAYRNGVRVCHRRCN	21	Sequence 369 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11665	GFCFHVCSYRNGVRKCYRRCN	21	Sequence 370 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11666	GFCFNACVYRNGVRSCYRRCN	21	Sequence 371 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11667	GFCFNVCARRNGVRVCYRRCN	21	Sequence 372 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11668	GFCFRVCVYRNGVRKCHRRCN	21	Sequence 373 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11669	GFCFRVCVYRNGVRSCSRRCN	21	Sequence 374 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11670	GFCFRACVKRNGVRVCYRRCN	21	Sequence 375 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11671	GFCFRSCVYRNGARVCYRRCN	21	Sequence 376 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11672	GFCFRSCVRRNGVRVCYRRCN	21	Sequence 377 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11673	GFCFRVCAYRNGVRKCYRRCN	21	Sequence 378 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11674	GFCFRVCAYRNGVRVCHRRCN	21	Sequence 379 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11675	GFCFRVCASRNGVRVCYRRCN	21	Sequence 380 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11676	GFCFRVCVKRNGVRKCYRRCN	21	Sequence 381 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11677	GFCFYVCVRRNGVRSCHRRCN	21	Sequence 382 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11678	GFCGHVCVYRNGVRMCYRRCH	21	Sequence 383 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11679	GFCGKVCVRRNGLRVCYRRCN	21	Sequence 384 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11680	GFCGRVCVYRNGKRACYRRCN	21	Sequence 385 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11681	GFCGRVCVYRNGKRSCYRRCN	21	Sequence 387 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11682	GFCGRVCVRRNGVRKCYRRCN	21	Sequence 388 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11683	GFCTRVCVRRNGLRVCYRRCN	21	Sequence 389 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11684	GFCWHVCVYKNGKRSCYRRCN	21	Sequence 390 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11685	GFCWHACVRRNGVRSCYRRCN	21	Sequence 391 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11686	GFCWHVCAYRNGKRACYRRCN	21	Sequence 392 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11687	GFCWHVCAKRNGLRVCYRRCN	21	Sequence 393 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11688	GFCWHVCARRNGARVCYRRCN	21	Sequence 394 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11689	GFCWHVCARRNGVRVCHRRCN	21	Sequence 395 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11690	GFCWHVCSKRNGLRVCYRRCN	21	Sequence 396 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11691	GFCWHVCVRRNGARKCYRRCN	21	Sequence 397 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11692	GFCWHVCVRRNGARSCYRRCN	21	Sequence 398 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11693	GFCWHVCVRRNGARVCSRRCN	21	Sequence 399 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11694	GFCWHVCVSRNGLRKCYRRCN	21	Sequence 400 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11695	GFCWKACVYKNGVRVCHRRCN	21	Sequence 401 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11696	GFCWKACVYRNGARSCYRRCN	21	Sequence 402 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11697	GFCWKACAYRNGARVCYRRCN	21	Sequence 403 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11698	GFCWKVCVKRNGARKCYRRCN	21	Sequence 404 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11699	GFCWKVCVRRNGARVCSRRCN	21	Sequence 405 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11700	GFCWNACAYRNGKRVCYRRCN	21	Sequence 406 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11701	GFCWNACARRNGVRVCYRRCN	21	Sequence 407 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11702	GFCWNACVRRNGVRSCYRRCN	21	Sequence 408 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11703	GFCWNFCVYRYGVRVCHRRCN	21	Sequence 409 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11704	GFCWNVCAYRQGVRVCHRRCN	21	Sequence 410 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11705	GFCWNVCAYRNGKRACYRRCN	21	Sequence 411 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11706	GFCWNVCVRRNGARSCYRRCN	21	Sequence 412 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11707	GFCWRVCVYRNSKRVCHRRCN	21	Sequence 413 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11708	GFCWRVCVYKNGKRVCHRRCN	21	Sequence 414 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11709	GFCWRACVYRNGKRSCYRRCN	21	Sequence 415 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11710	GFCWRACVYRNGVRACHRRCN	21	Sequence 416 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11711	GFCWRACAYRNGKRVCYRRCN	21	Sequence 417 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11712	GFCWRACAYRNGVRACYRRCN	21	Sequence 418 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11713	GFCWRACAYRNGVRVCHRRCN	21	Sequence 419 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11714	GFCWRACARRNGVRVCYRRCN	21	Sequence 420 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11715	GFCWRACHYRNGVRSCYRRCN	21	Sequence 421 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11716	GFCWRACVRRNGVRKCYRRCN	21	Sequence 422 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11717	GFCWRSCVYRNGARSCYRRCN	21	Sequence 423 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11718	GFCWRVCAYRNSVRSCYRRCN	21	Sequence 424 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11719	GFCWRVCAYSNGKRVCYRRCN	21	Sequence 425 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11720	GFCWRVCAYRNGARVCHRRCN	21	Sequence 426 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11721	GFCWRVCAYRNGKRACYRRCN	21	Sequence 427 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11722	GFCWRVCAYRNGKRVCHRRCN	21	Sequence 428 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11723	GFCWRVCAYRNGVRACHRRCN	21	Sequence 429 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11724	GFCWRVCAYRNGVRSCHRRCN	21	Sequence 430 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11725	GFCWRVCAKRNGVRKCYRRCN	21	Sequence 431 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11726	GFCWRVCAKRNGVRSCYRRCN	21	Sequence 432 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11727	GFCWRVCAKRNGVRVCHRRCN	21	Sequence 433 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11728	GFCWRVCARRNGVRSCYRRCN	21	Sequence 434 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11729	GFCWRVCASRNGLRVCYRRCN	21	Sequence 435 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11730	GFCWRVCGYRNSKRVCYRRCN	21	Sequence 436 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11731	GFCWRVCHYRNSKRVCYRRCN	21	Sequence 437 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11732	GFCWRVCHYKNGKRVCYRRCN	21	Sequence 438 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11733	GFCWRVCHYSNGKRVCYRRCN	21	Sequence 439 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11734	GFCWRVCSKRNGVRKCYRRCN	21	Sequence 440 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11735	GFCWRVCVKRNGARKCYRRCN	21	Sequence 441 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11736	GFCWRVCVKRNGVRSCSRRCN	21	Sequence 442 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11737	GFCWRVCVRRNGARKCYRRCN	21	Sequence 443 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11738	GFCWRVCVRRNGARSCYRRCN	21	Sequence 444 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11739	GFCWRVCVRRNGLRKCYRRCN	21	Sequence 445 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11740	GFCWRVCVRRNGLRVCHRRCN	21	Sequence 446 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11741	GFCWRVCVRRNGVRSCSRRCN	21	Sequence 447 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11742	GFCWRVCVRRNGVRVCSRHCN	21	Sequence 448 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11743	GFCWRVCVSRNGARVCSRRCN	21	Sequence 449 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11744	GFCWYACAKRNGLRVCYRRCN	21	Sequence 450 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11745	GFCWYACVSRNGLRSCYRRCN	21	Sequence 451 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11746	GFCWYVCAYSNGVRSCHRRCN	21	Sequence 452 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11747	GFCWYVCARRNGLRSCYRRCN	21	Sequence 453 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11748	GFCWYVCVKRNGARKCHRRCN	21	Sequence 454 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11749	GFCARVCVKRNGARKCYRRCN	21	Sequence 455 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11750	GFCARVCVKRNGARVCHRRCN	21	Sequence 456 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11751	GFCARVCVSRNGLRKCYRRCN	21	Sequence 457 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11752	GFCAYVCVSRNGARSCHRRCN	21	Sequence 458 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11753	GFCFHVCARRNGVRKCYRRCN	21	Sequence 459 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11754	GFCFHVCARRNGVRVCHRRCN	21	Sequence 460 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11755	GFCFHVCVKRNGVRKCSRRCN	21	Sequence 461 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11756	GFCFKVCSYRNGLRKCYRRCN	21	Sequence 462 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11757	GFCFKVCSKRNGVRKCYRRCN	21	Sequence 463 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11758	GFCFNVCARRNGVRVCSRRCN	21	Sequence 464 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11759	GFCFRVCVYRNGARKCSRRCN	21	Sequence 465 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11760	GFCFRACAYRNGVRVCHRRCN	21	Sequence 466 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11761	GFCFRACTSRNGVRVCYRRCN	21	Sequence 467 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11762	GFCFRACVKRNGARVCYRRCN	21	Sequence 468 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11763	GFCFRACVRRNGVRVCHRRCN	21	Sequence 469 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11764	GFCFRACVSRNGVRSCYRRCN	21	Sequence 470 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11765	GFCFRSCARRNGVRVCYRRCN	21	Sequence 471 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11766	GFCFRSCASRNGVRVCYRRCN	21	Sequence 472 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11767	GFCFRVCAYRNGARSCYRRCN	21	Sequence 473 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11768	GFCFRVCAYRNGARVCHRRCN	21	Sequence 474 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11769	GFCFRVCAYRNGARVCSRRCN	21	Sequence 475 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11770	GFCFRVCAYRNGVRKCHRRCN	21	Sequence 476 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11771	GFCFRVCAKRNGARVCYRRCN	21	Sequence 477 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11772	GFCFRVCAKRNGVRKCYRRCN	21	Sequence 478 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11773	GFCFRVCAKRNGVRVCHRRCN	21	Sequence 479 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11774	GFCFRVCASRNGVRKCYRRCN	21	Sequence 480 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11775	GFCFRVCSYRNGARSCYRRCN	21	Sequence 481 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11776	GFCFRVCSYRNGLRKCYRRCN	21	Sequence 482 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11777	GFCFRVCSKRNGARVCYRRCN	21	Sequence 483 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11778	GFCFRVCSKRNGVRVCHRRCN	21	Sequence 484 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11779	GFCFRVCSRRNGLRVCYRRCN	21	Sequence 485 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11780	GFCFRVCSSRNGARVCYRRCN	21	Sequence 486 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11781	GFCFRVCSSRNGVRKCYRRCN	21	Sequence 487 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11782	GFCFRVCVKRNGARSCYRRCN	21	Sequence 488 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11783	GFCFRVCVRRNGVRKCSRRCN	21	Sequence 489 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11784	GFCFYVCVSRNGARKCHRRCN	21	Sequence 490 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11785	GFCGKVCVKRNGLRKCYRRCN	21	Sequence 491 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11786	GFCGRVCVYRNSKRSCYRRCN	21	Sequence 492 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11787	GFCGRVCVYKNGKRACYRRCN	21	Sequence 493 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11788	GFCSYSCAYRNGSRSCYRRCN	21	Sequence 494 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11789	GFCSNSCVKRNGVRVCSRRCN	21	Sequence 495 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11790	GFCTNVCAKRNGARVCYRRCN	21	Sequence 496 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11791	GFCWHACVRRNGARSCYRRCN	21	Sequence 497 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11792	GFCWHACVRRNGLRKCYRRCN	21	Sequence 498 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11793	GFCWHACVRRNGLRVCHRRCN	21	Sequence 499 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11794	GFCWHVCAYKNGVRACHRRCN	21	Sequence 500 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11795	GFCWHVCARRNGLRVCSRRCN	21	Sequence 501 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11796	GFCWKRCVYRNGLRKCHRRCN	21	Sequence 502 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11797	GFCWKSCVRRNGLRSCYRRCN	21	Sequence 503 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11798	GFCWKVCARRNGARSCYRRCN	21	Sequence 504 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11799	GFCWKVCSSRNGLRSCYRRCN	21	Sequence 505 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11800	GFCWKVCVSRNGARKCSRRCN	21	Sequence 506 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11801	GFCWNVCARRNGLRVCHRRCN	21	Sequence 507 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11802	GFCWNVCVRRNGLRKCHRRCN	21	Sequence 508 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11803	GFCWRVCVYSNGKRSCHRRCN	21	Sequence 509 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11804	GFCWRACVYKNSKRVCYRRCN	21	Sequence 510 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11805	GFCWRACVYKNGVRACHRRCN	21	Sequence 511 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11806	GFCWRACAYRNGKRACYRRCN	21	Sequence 512 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11807	GFCWRACAYRNGKRSCYRRCN	21	Sequence 513 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11808	GFCWRACASRNGVRVCHRRCN	21	Sequence 514 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11809	GFCWRACSRRNGLRVCYRRCN	21	Sequence 515 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11810	GFCWRACVKRNGARVCSRRCN	21	Sequence 516 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11811	GFCWRACVKRNGLRSCYRRCN	21	Sequence 517 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11812	GFCWRACVRRNGARSCYRRCN	21	Sequence 518 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11813	GFCWRACVRRNGLRSCYRRCN	21	Sequence 519 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11814	GFCWRACVSRNGARSCYRRCN	21	Sequence 520 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11815	GFCWRACVSRNGLRVCSRRCN	21	Sequence 521 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11816	GFCWRRCVRRNGARSCYRRCN	21	Sequence 522 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11817	GFCWRVCAYKNGKRSCYRRCN	21	Sequence 523 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11818	GFCWRVCARRNGLRVCHRRCN	21	Sequence 524 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11819	GFCWRVCASRNGARVCSRRCN	21	Sequence 525 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11820	GFCWRVCGYKNGVRACHRRCN	21	Sequence 526 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11821	GFCWRVCGYRNGKRACHRRCN	21	Sequence 527 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11822	GFCWRVCSYSNSKRVCYRRCN	21	Sequence 528 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11823	GFCWRVCSRRNGLRSCYRRCN	21	Sequence 529 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11824	GFCWRVCVRRNGLRSCSRRCN	21	Sequence 530 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11825	GFCWRVCVSRNGARKCSRRCN	21	Sequence 531 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11826	GFCWRVCVSRNGLRSCSRRCN	21	Sequence 532 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11827	GLCWRVCAYSNGKRACYRRCN	21	Sequence 533 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11828	GFCFNVCVSRNGARKCHRRCN	21	Sequence 534 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11829	GFCFRACARRNGVRSCYRRCN	21	Sequence 535 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11830	GFCFRACSKRNGLRVCYRRCN	21	Sequence 536 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11831	GFCFRACVKRNGLRKCYRRCN	21	Sequence 537 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11832	GFCFRACVKRNGLRVCHRRCN	21	Sequence 538 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11833	GFCFRVCAKRNGARSCYRRCN	21	Sequence 539 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11834	GFCFRVCASRNGVRKCHRRCN	21	Sequence 540 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11835	GFCFRVCSKRNGARKCYRRCN	21	Sequence 541 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11836	GFCGHRCSRRNGVRKCYRRCN	21	Sequence 542 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11837	GFCSHRCSYRNSVRACYRRCN	21	Sequence 543 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11838	GFCSRVCSYRNGSRACHRRCN	21	Sequence 544 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11839	GFCWRACASRNGLRVCSRRCN	21	Sequence 545 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11840	GFCSNRCHYSNGSRACHRRCN	21	Sequence 546 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11841	GFCWGAVNYTSNCRACKRRCN	21	Sequence 547 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11842	GSCWGAVNYTSNCRACKRRCN	21	Sequence 548 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11843	MASRAAGLAARLARLALR	18	Sequence 1 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11844	MASRAAGLAARLARLALRA	19	Sequence 2 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11845	MASRAAGLAARLARLALRAL	20	Sequence 3 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11846	ASRAAGLAARLARLALR	17	Sequence 4 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11847	MVSRAAGLAARLARLALR	18	Sequence 5 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11848	MVSRAAGLAARLARLALRA	19	Sequence 6 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11849	MVSRAAGLAARLARLALRAL	20	Sequence 7 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11850	MASRAAGLARRLARLARR	18	Sequence 8 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11851	MASRAAGLARRLARLARRA	19	Sequence 9 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11852	MASRAAGLARRLARLARRAL	20	Sequence 10 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11853	MAARAAGLAARLAALALR	18	Sequence 11 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11854	MAARAAGLAARLAALALRA	19	Sequence 12 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11855	MAARAAGLAARLAALALRAL	20	Sequence 13 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11856	SRAAGLAARLARLAL	15	Sequence 14 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11857	MGECVRGRCPSGMCCSQFGYCGKGPKYCG	29	Sequence 15 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11858	MASRAARLAARLARLALR	18	Sequence 16 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11859	MASRAARLAARLARLALRA	19	Sequence 17 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11860	ASRAARLAARLARLALR	17	Sequence 18 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11861	MVSRAARLAARLARLALR	18	Sequence 19 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11862	MVSRAARLAARLARLALRA	19	Sequence 20 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11863	MVSRAARLAARLARLALRAL	20	Sequence 21 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11864	MASRAARLARRLARLARR	18	Sequence 22 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11865	MASRAARLARRLARLARRA	19	Sequence 23 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11866	MASRAARLARRLARLARRAL	20	Sequence 24 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11867	MAARAARLAARLAALALR	18	Sequence 25 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11868	MAARAARLAARLAALALRA	19	Sequence 26 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11869	MAARAARLAARLAALALRAL	20	Sequence 27 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11870	SRAARLAARLARLAL	15	Sequence 28 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11871	RLARLARRLARLA	13	Sequence 29 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11872	LLKALKKLLKKLL	13	Sequence 1 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11873	LRFLKKILKHLF	12	Sequence 2 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11874	LRALAKALKHKL	12	Sequence 3 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11875	LKALRKALKHLA	12	Sequence 4 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11876	LRFLKKILKKLF	12	Sequence 5 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11877	LRFLKKALKKLF	12	Sequence 6 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11878	LRFAKKALKKLF	12	Sequence 7 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11879	LRFIKKILKKLI	12	Sequence 8 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11880	LRIIKKILKKLI	12	Sequence 9 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11881	LRIIRRILRRLI	12	Sequence 10 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11882	LRILRRLLRRLF	12	Sequence 11 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11883	LRFLRRILRRLL	12	Sequence 12 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11884	LRFARRALRRLF	12	Sequence 13 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11885	LRKLKKILKKLF	12	Sequence 14 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11886	LRKAKKIAKKLF	12	Sequence 15 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11887	APKAMKLLKKLLKLQKKGI	19	Sequence 1 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11888	APKAMRLLRRLLRLQKKGI	19	Sequence 2 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11889	APKAMXXXXXXXXLQKKGI	19	Sequence 3 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11890	NQVSLTCLVK	10	Sequence 1 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11891	TCRVDHRGLTF	11	Sequence 2 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11892	HEAL	4	Sequence 3 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11893	GQYGNLWFAY	10	Sequence 4 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11894	AQYGNLWFAY	10	Sequence 5 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11895	GAYGNLWFAY	10	Sequence 6 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11896	GQAGNLWFAY	10	Sequence 7 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11897	GQYANLWFAY	10	Sequence 8 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11898	GQYGALWFAY	10	Sequence 9 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11899	GQYGNAWFAY	10	Sequence 10 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11900	GQYGNLAFAY	10	Sequence 11 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11901	GQYGNLWAAY	10	Sequence 12 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11902	GQYGNLWFAA	10	Sequence 13 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11903	AQVSLTCLVK	10	Sequence 14 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11904	NAVSLTCLVK	10	Sequence 15 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11905	NQASLTCLVK	10	Sequence 16 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11906	NQVALTCLVK	10	Sequence 17 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11907	NQVSATCLVK	10	Sequence 18 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11908	NQVSLACLVK	10	Sequence 19 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11909	NQVSLTALVK	10	Sequence 20 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11910	NQVSLTCAVK	10	Sequence 21 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11911	NQVSLTCLAK	10	Sequence 22 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11912	NQVSLTCLVA	10	Sequence 23 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11913	NQVSLTCSVK	10	Sequence 24 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11914	NQVSATCSVK	10	Sequence 25 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11915	MSTAVSKCAT	10	Sequence 26 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11916	ACRVDHRGLTF	11	Sequence 27 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11917	TARVDHRGLTF	11	Sequence 28 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11918	TCAVDHRGLTF	11	Sequence 29 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11919	TCRADHRGLTF	11	Sequence 30 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11920	TCRVAHRGLTF	11	Sequence 31 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11921	TCRVDARGLTF	11	Sequence 32 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11922	TCRVDHAGLTF	11	Sequence 33 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11923	TCRVDHRALTF	11	Sequence 34 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11924	TCRVDHRGATF	11	Sequence 35 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11925	TCRVDHRGLAF	11	Sequence 36 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11926	TCRVDHRGLTA	11	Sequence 37 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11927	CRVD	4	Sequence 38 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11928	HRGL	4	Sequence 39 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11929	TCLV	4	Sequence 40 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11930	QYGN	4	Sequence 41 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11931	VDHRGL	6	Sequence 42 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11932	VSLTCL	6	Sequence 43 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11933	GNLWFA	6	Sequence 44 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11934	MAQFLLFVYSLIIFLSLFFGEAAFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP	69	Sequence 1 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11935	CFGEAAFETTEPMLTTYLILCVSEADCPKVVKPNYTMCAGGICWQSVQGSNQGP	54	Sequence 2 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11936	TQFLLFIYSLIIFLSLFLGEAALERTRTTMLTSYNIGCKSDADCPKAIEPHYTRCVDGHCWLYFGEGPKLHN	72	Sequence 3 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11937	MAQFLLFIYSLIIFLSLFLGEAWFKRTETGEIIWVVRCVTDTDCPKMGEPQYFKCLNGVCLEHIRELP	68	Sequence 4 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11938	GEAALERTETTMHNVQPSHFIPCFTAADCPMIDEPHYIECVTGFCWALMRNLH	53	Sequence 5 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11939	MAQVIMFVGALIIFLSLFLVETKKTDIPCDSRNDCPQQILPRYVLCVNGLCRIYFP	56	Sequence 6 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11940	MAQFLLFIYSLIIFLSLFFGEAAYERTEPIMHNGEPINLIPCVTVADCPRMDEPLHMTCLVGACWPCIRSLY	72	Sequence 7 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11941	MAQFLLFIYSLIIFLSPFLGEAVFKRTETGEIIWTLPCATDTDCPKMGEPMYFKCLNGFCLEHIRELHD	69	Sequence 8 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11942	MAQILKLVYAFTIFLFIFLVVTNGQECKDDGDCPTNMCLPSLVSKCINFICECTHSMSTD	60	Sequence 9 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11943	MAQIIMFFYALIIFLSPFLVDRRSFPSSFVSPKSYTSEIPCKATRDCPYELYYETKCVDSLCTYW	65	Sequence 10 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11944	MAQIIPFLGALIIFLSLFLVESKQTNIPCKSAEDCPKPIYPRYVLCSYGFCRIFFP	56	Sequence 11 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11945	MAQFLMFIYVLIIFLYLFYVEAAMFELTKSTIRCVTDADCPNVVKPLKPKCVDGFCEYT	59	Sequence 12 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11946	MAQFLLFVYFIIIIVSLFLVEAREPTKIPCVSDSDCHKVKKPLLLTCIDGICQYTLEATPFD	62	Sequence 13 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11947	MAHILMFVYALIIFLSPFLIGRKGGPPGGRTYIPCISDDDCIVAQPPYVLLCVNNFCTYFKDDDLPQR	68	Sequence 14 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11948	MVQYLMFLYAFIIFLSLFVVQKAQIYITFFTIFSIFVFYTTFYHLTLTTFFSFHNAGYLPCSSDDDCPKEMKPVVVKCIHNFCEHFMVGEYEGP	94	Sequence 15 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11949	FFDHLFFFCGLAETKRTNIPCFSDDDCPKTCPPLVFEVR	39	Sequence 16 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11950	MTQFLFFIFVLMIFLSPFLVEMEKTHVRCITADDCPKVERPLKMKCIGNYCHYFLNNF	58	Sequence 17 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11951	MAKIANFVYSMIIFLSLFLVATKAEWYYPCNTDSDCPQNMCPPDMEPRCWTGYCSSCYIRWGK	63	Sequence 18 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11952	MQRLDNMAKNVKFIYVIILLLFIFLVIIVCDSAFVPNSGPCTTDKDCKQVKGYIARCRKGYCMQSVKRTWSSYSR	75	Sequence 20 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11953	MAATRKFIYVLSHFLFLFLVTKITDARVCKSDKDCKDIIIYRYILKCRNGECVKIKI	57	Sequence 21 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11954	MVKILKFIYVMIIFLSLFLVATNVNAINKCSQDSHCPKDMCKKPSKPRCVVSPKLPLSSKSGVCTCV	67	Sequence 22 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11955	MAKIVKFIYVMIILIFLFLVSTNIDAIRNKCFRPSDCPPSMYCDAGFQIGCVRKICTCLRILAPIDFVPT	70	Sequence 23 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11956	MQKEKNMAKTFEFVYAMIIFILLFLVENNFAAYIIECQTDDDCPKSQLEMFAWKCVKNGCHLFGMYEDDDDP	72	Sequence 24 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11957	MVKTLKLVNYMIFFLSIFLVVKNVDGDDVVFQYVFDGCRIDADCPISGLQLLKWMCINNECEFNHVRPRYV	71	Sequence 25 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11958	MAKTLNFVCAMILFISLFLVSKNVALYIIECKTDADCPISKLNMYNWRCIKSSCHLYKVIQFMV	64	Sequence 26 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11959	MVEIVKFVYIINIFIFLFLVATNVEAKFTRCFRDSDCPKTLCHSPGKAKCMHHSICKCIFFGYNI	65	Sequence 27 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11960	MTKILMLFYAMIVFHSIFLVASYTDECSTDADCEYILCLFPIIKRCIHNHCKCVPMGSIEPMSTIPNGVHKFHIINN	77	Sequence 28 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11961	MVKTFKFIYSIIIFLSPFLVVMNVDGELIKCTMDADCPTSLNRKWLCINNICRKMCVTNV	60	Sequence 29 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11962	MAESPKFVYVLILFISIFNVIIVCDFAFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR	62	Sequence 30 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11963	MAKTTKLIYVMILFLSLFLVAKNVTAQIRCNDAFECRRSAICNFPNKWKCNDHKCECV	58	Sequence 31 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11964	ETPKLVYVLILFLSIIFSIIVSNSFPDKIFIGDCKTDKDCKPKRGVNFRCRKGKCYPR	58	Sequence 32 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11965	MQRTKNMAETLKFVYVLILFISLFLVLIVCDSAFVANTETCITDKDCPNGRNYIGRCRKGHCQQRLVR	68	Sequence 33 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11966	MSKILKFVYVPILYFSILLVLTIHDQVYFNNNSPPCVTDKDCPRPQFRKSNVRCRNGHCVNLGN	64	Sequence 34 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11967	MVKTPKLVYVLILFLSIFLSMIVSNSSFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI	61	Sequence 35 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11968	MAKILKFVYVPILYFSILLVLTIYDQAYFNDPRPCVSDKDCPRPKFQKSNVRCRKGYCVNLDG	63	Sequence 36 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11969	MAKILKFVYVPILYLSILLVLTIYDQVYFNNSPPCVTDKDCPRPQFRKSNVRCRNGYCVNLGN	63	Sequence 37 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11970	MAKIMKYVNVPILFLSILLVLMSYGSNYSPTPFPCLTDKDCTRRKGFSVTCRKGFCVEFKHF	62	Sequence 38 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11971	MAKTIKCLNVLILFLYMFLVLTLLDFGSSTTPTPCRTDQDCPRKKKFSVTCRKGFCAEIRHVY	63	Sequence 39 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11972	GETLKSVYLLILFISLFLVIIVSHSVTSPWVLKQHCVTDKDCPQMGKIKIRCRNGECVQGF	61	Sequence 40 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11973	MQIGKNMVETQKLVYVILLFLSIFLFTNSPLSQIIFSECKTDKDCPKYQRANIRCRKGQCVRI	63	Sequence 41 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11974	MVETPKFVYNLILLIYIFLFIIICDSTYLPTTRICITDKDCPSVKNYIGRCRKGYCQASKLR	62	Sequence 42 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11975	MVQTPKLVYVIVLLLSIFLGMTICNSSFSHFFEGACKSDKDCPKLHRSNVRCRKGQCVQI	60	Sequence 43 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11976	MTETLKFVYILILFIFIFLVLMVCDSAFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR	62	Sequence 44 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11977	MADTLKFVHVLILLISIFLVIIVSSFIFLPCITDKDCQTLKKNKGKGRCRKGFCVDGLIG	60	Sequence 45 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11978	ILFLSIFLCIIVSNSSFSKTFDRACKTDKDCPKLRGVNVRCRKDQCVTV	49	Sequence 46 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11979	MTETLKFVYVLILFISIFLVIIVCESSFFPSSPVCKTDKDCPQLRGYTARCRKTQCLLIPRG	62	Sequence 47 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11980	LVIIVCDSIHFHVSRPCMTDDDCAPEKYYNIRCRKGFCVQIRKY	44	Sequence 48 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11981	LVIILCDSAYFPNSRPCKTDKNCAQVKNYISKCLKGLCVQEE	42	Sequence 49 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11982	VYILILFICIFLVMIVCDSAYLPLSRSCITDKDCSRVKNYNARCRKGYCQYLQY	54	Sequence 50 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11983	MAEIIKFICLTILFLSLFLVAAEEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR	63	Sequence 51 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11984	MAETLKFVYVMILFLSIFLVITISNSNPYIINILCKTDKDCPKVQGANIRCRSGKCVQV	59	Sequence 52 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11985	MTHISKFVFALIIFLSIYVGVNDCKRIPCKDNNDCNNNWQLLACRFEREVPRCINSICKCMPM	63	Sequence 53 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11986	MTYISKVVYALIIFLSIYVGVNDCMLVTCEDHFDCRQNVQQVGCSFREIPQCINSICKCMKG	62	Sequence 54 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11987	MTHIFKFVYALIIFLSIYVAVNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR	63	Sequence 55 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11988	MKSQNHAKFISFYKNDLFKIFQNNDSHFKVFFALIIFLYTYLHVTNGVFVSCNSHIHCRVNNHKIGCNIPEQYLLCVNLFCLWLDY	86	Sequence 56 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11989	MNHISKFVYALIIFLSVYLVVLDGRPVSCKDHYDCRRKVKIVGCIFPQEKPMCINSMCTCIREIVP	66	Sequence 57 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11990	MAQISKFVYALIIFFSLILAVTNAGLFRCKVDIDCPQILCFDEQIAKCIARMCECDYE	58	Sequence 58 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11991	MDLVHMFVYAFIIFLSIPLPPARSDFPCKTKDDCAQQIDYIAECIIGFCRYFTPFEHPF	59	Sequence 59 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11992	MTQISISFYALIIFFSLFLVVTNGRNKTCNYSSECLFHNCPLGWVMKCFTYFCACSRL	58	Sequence 60 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11993	MHTRKNMDLVHMFVYAFTIFLSIPLPPVRSDFPCKTKVDCPQHKKYIAECIFGFCRHFKPLEHPF	65	Sequence 61 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11994	MQRRKNMAQILLFAYVFIISISLFLVVTNGVKIPCVKDTDCPTLPCPLYSKCVDGFCKMLSI	62	Sequence 62 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11995	LHMLIYAFIIFLSIPLPPTRKTIPCKTKVDCPQQIYYVVECLDGFCDYWRD	51	Sequence 63 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11996	MQTMRNMNLVYMFVYAFIIFLSIHFPPRIKCNTEADCPQRFDNIVECLFGICHFYIK	57	Sequence 64 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11997	MARVISLFYALIIFLFLFLVATNGDLSPCLRSGDCSKDECPSHLVPKCIGLTCYCI	56	Sequence 65 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11998	FLWIIIPSILLIVSDRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	48	Sequence 66 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11999	SQILMFVSVLIIFLSLFLADTKQTNIPCENKRDCPQPLYPKFVTCFEGLCRMHYPLKKI	59	Sequence 67 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12000	MAQILMFVYFLIIFLSLFLVESIKIFTEHRCRTDADCPARELPEYLKCQGGMCRLLIKKD	60	Sequence 68 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12001	MAQLIIFVYALIIFLYLLFVEAQITKLPCVTVDDCPKVEKPIPMVAKCFGKSFSRHCHYFYF	62	Sequence 69 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12002	MFVYVLIIFLSLFLIEASIKTKIACVTDNDCPRAIKPVVMWCINNYCHYYLYGYQ	55	Sequence 70 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12003	MAQNKYLFCAFIIFLSLFFVLTKSSIPCKTRTQCPEKMCRLPKFVWCIDGSCVCA	55	Sequence 71 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12004	MTLLLKFLYALIIFISLLFVVTNGAQFLCSDDSDCPRDLCVRNSLTLRCVNYICQCR	57	Sequence 72 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12005	MQRKTNMTQFIFFIYVLMIFLSLFLVESEKLDIRCATVDDCPKVTKPVVMMCTGKFCHYFFVRKQIL	67	Sequence 73 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12006	MARISLFVYALIIFFSLFFVLTNGELEIRCVSDADCPLFPLPLHNRCIDDVCHLFTS	57	Sequence 74 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12007	MAQILKFVDALILFLSLFFILINGDRIPCATDADGPPKILPIIHKCINNFCKLKLYN	57	Sequence 75 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12008	MNQIPMFGYTLIIFFSLFPVITNGDRIPCVTNGDCPVMRLPLYMRCITYSCELFFDGPNLCAVERI	66	Sequence 76 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12009	MAHFLMFVYALITCLSLFLVEMGHLSIHCVSVDDCPKVEKPITMKCINNYCKYFVDHKL	59	Sequence 77 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12010	MVHILMFVYALIFSNFIFLVEANMVVLGCVSDDDCPKVPLPRFLKCIANLCCLVRKKDL	59	Sequence 78 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12011	MVKTLKFVYYMILFLSLFLFIKNVDGAFVKCETDDDCPKYNGFRKYECVNNWCRLTGLH	59	Sequence 79 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12012	MSKTIMFLYAMTLFLFLLHIEKSSGVLIDCKTVKDCPTSYTKIYRCEDNKCRFSFVIGL	59	Sequence 80 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12013	MTETLKFVVTKKKTLKFVYAMILFLSFFLIASEVGAHFGCETDADCPRSTDKNFFLRCINKKCEWAAKRH	70	Sequence 81 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12014	MTKIFKFIHAMILFLSLFLVAESYFADILCKVHEDCPQKSTHKYYCIDDECFLYYWEAP	59	Sequence 82 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12015	MAEIIKFVYTMILLLSLFLVTTKVGAYIACQSEIDCPPNYSFLFAIRCIKQKCVTVGRYL	60	Sequence 83 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12016	MTKTLKFICIMILFLSLFLVAESFATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV	65	Sequence 84 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12017	MQMEKNMTKTLKFIYVMILFLSLFLVAESFFVDIMCKVHEDCPQKSTHKYYCVDDKCFLYYWEGKP	66	Sequence 85 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12018	MANTHKLVSMILFIFLFLVANNVEGYVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	59	Sequence 86 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12019	MAHKLVYTIILFIFLFLVANNVEGDIVCITDNDCPPNTLVQGYRCIDGKCESVFLSYR	58	Sequence 87 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12020	MAKTLNFMFALILFISLFLVSKNVAIDIFVCQTDADCPKSELSMYTWKCIDNECNLFKVMQQMV	64	Sequence 88 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12021	MAKTCKLVFALILFVSLYLVSMSAELGGPCRSDEECPQLSLRFFAIKCRENVCIYVDLDPYKPRAEKNQFLH	72	Sequence 89 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12022	MKRGKNMSKILKFIYATLVLYLFLVVTKASDDECKIDGDCPISWQKFHTYKCINQKCKWVLRFHEY	66	Sequence 90 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12023	MAKTLKFFYTIILFLSLFLVLQRKLTGCEVDGDCPKVFKLKVMILFIKCINNKCVRGLLSQTGTQCPDFFFLKRTLPRFYF	81	Sequence 91 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12024	MIKILTFLYALVLFLSLFIFSIAAQNLMKCNTDDECPKFDDKFPLSFKCINDGCRMVINDKYKHKTVQKLL	71	Sequence 92 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12025	MAKIVKYVYVIIIFLSLFLVATKIEGYYYKCFKDSDCVKLLCRIPLRPKCMYRHICKCKVVLTQNNYVLT	70	Sequence 93 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12026	MSNTLMFVITFIVLVTLFLGPKNVYAFQPCVTTADCMKTLKTDENIWYECINDFCIPFPIPKGRK	65	Sequence 94 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12027	MAEILKFIYNAILFVSLYFIVIYGELVCDTDDDCLKFFPDNPYPMECINSICLSLTD	57	Sequence 95 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12028	MARTLKFVYAVILFLSLFLVAKGDDVKIKCVVAANCPDLMYPLVYKCLNGICVQFTLTFPFV	62	Sequence 96 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12029	MSQIFMFAYVLIIFLSLFHVETNIHKIGCKTSEDCPYLGKCIEDFCQFKK	50	Sequence 97 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12030	MAKIVYFVYSMIIFLSLFLVTTKAAERIYRCLDHSHCPTFMCSPGLKPKCMNPKVCKCVPVQSRKYYALT	70	Sequence 98 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12031	MAQKFMFFYALIIFLSSFYVIINTIDPPHHITNHEIPCKYNHDCPTILDYISICPYHYCEFWRTY	65	Sequence 99 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12032	MIETLKFVYAMILFLSLFLITSEVGGLYIGCETDRDYPPLANKTFYLKCIDKKCEWTVTDSLSTRSGRMQKLSI	74	Sequence 100 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12033	MVRTLKFVYVIILILSLFLVAKGGGKKIYCENAASCPRLMYPLVYKCLDNKCVKFMMKSRFV	62	Sequence 101 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12034	MAEIVKYVYVIIIFPSLILFATNIEAIIRCFHDADCVHKICHPPQIRKCVSKICKCRLMITQKDYVLT	68	Sequence 102 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12035	MAKIVNFVYSMIIFVSLFLVATKGGSKPFLTRPYPCNTGSDCPQNMCPPGYKPGCEDGYCNHCYKRW	67	Sequence 103 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12036	EDFLYSMIIFLSLFLVATKSEPGGHRCSTDSFCPPNMCPPGMTPKCVRFRCKCVPIGWKNLSHVLA	66	Sequence 104 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12037	MAEILKFVYIVILFISILLVVETEQYCVDDADCQKLYPFHRQLSLKCIRAFCVKLVGQANDDLFPSTVHAADATGLGIDAK	81	Sequence 105 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12038	MAKIVNFIYSMIIFLSLFLVETNAQCIYPACFKDHMCRQLKCSPGRTPKCVNYQCRCSPQALGSYHLLT	69	Sequence 106 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12039	MAKTLKFVYAMIIFLSLFLMATNIDSALIECQIDDDCPPIKFAKYLCINYKCRKICLGE	59	Sequence 107 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12040	MAGTLNFVYAMILFLSLFLVARGEEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVKLEPPYDMSITPNSVHK	75	Sequence 108 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12041	MVEKMVGILKFVCPFLFLYFLLLSMLVISGKHDYHMFFQRIPCPKDKILDCNLLECWCK	59	Sequence 109 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12042	MTKTLIFIYALFIVVSLFLVVTSETRIPCVSRNDCPKRPYPLFMKCIDNFCEIWKIGKE	59	Sequence 110 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12043	MAQRFMFIYALIIFLSQFFVVINTSMSIYITFKKFIIDFIHNVYHPSITSNFSLFNNAGDIPNNSNRNSPKEDVFCNSNDDCPTILYYVSKCVYNFCEYW	100	Sequence 111 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12044	MEDIVKFVYVIIIFLSIFIIATNMEAKTICIGDSDCRNERCMPGIKPVCSEGWCDCIGFIP	61	Sequence 112 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12045	MAKTLKVMYTMVLFFSLFLVAKNVDAYVWCETVEDCFKSQYFIFDCINNQCINVGKNPKEPRYPGIPRDQ	70	Sequence 113 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12046	MIKVVKFIYVMIIILSLFQLSINAREKVNCLDDADCLEVSCLNGSNAECVGNSCVCVFVFYRENFDEQFRR	71	Sequence 114 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12047	MNPNIRLFYDLIIFLSLLLVLTDGSVPCLTSFGCPRSTCYPPSTPNCILRICECI	55	Sequence 115 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12048	MGETLKFVYTMSIFLSLFLVVTSIVGEEWNSHSWNSEFYLKKSCSSDFDCPRTMCIKLSLARCFNDFCHCY	71	Sequence 116 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12049	MARILKNVYTIIHFLIINFLLLFHVLNVRRQTEPPGPLIPCEFDYDCPLIDCIRTSDSRCINGNCHCRE	69	Sequence 117 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12050	MQMRKNMAQILFYVYALLILFSPFLVARIMVVNPNNPCVTDADCQRYRHKLATRMVCNIGFCLMDFTHDPYAPSLP	76	Sequence 118 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12051	MQIGRKKMGETPKLVYVIILFLSIFLCTNSSFSQMINFRGCKRDKDCPQFRGVNIRCRSGFCTPIDS	67	Sequence 119 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12052	MAKFVNFVYSMIIFLSLLVVAMNAKRNYQCDPCFGHPDDMINFCPPGTAPKCFHGLIKCVPIMRGTNRMFA	71	Sequence 120 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12053	MDAILKFIYAMFLFLFLFVTTRNVEALFECNRDFVCGNDDECVYPYAVQCIHRYCKCLKSRN	62	Sequence 121 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12054	MAVILKFVYIMIIFLFLLYVVNGTRCNRDEDCPFICTGPQIPKCVSHICFCLSSGKEAY	59	Sequence 122 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12055	MQKARNMAKLVKLVYVIIVFYTLFLVATEIVSGIPCNDDVDCPQTLCEQLIADFKYMIDFKSECVSRMCACTGSPV	76	Sequence 123 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12056	MAHILKFVYATILVLFLFFVATKVDGAVHKECKTDVDCRQIWFVTKCINHECQPIL	56	Sequence 124 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12057	MAKLVKFVYVIIVFYTLFLVGTEIVSGHACTVNADCEQSMCDPFCVGGYHFTPICVIGWCVCVGNRVAPVL	71	Sequence 125 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12058	MIQILIFVYALIIFISLFLVVTSETHIPCVHHDDCPKRPYPRFMKCVDNFCETWIIGWE	59	Sequence 126 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12059	MLRRKNTVQILMFVSALLIYIFLFLVITSSANIPCNSDSDCPWKIYYTYRCNDGFCVYKSIDPSTIPQYMTDLIFPR	77	Sequence 127 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12060	MAQTLMLVYALIIFTSLFLVVISRQTDIPCKSDDACPRVSSHHIECVKGFCTYWKLD	57	Sequence 128 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12061	MQRKKNMGQILIFVFALINFLSPILVEMTTTTIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	61	Sequence 129 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12062	MVKTFNFVCTMVLLFFLFLTAKKVYAYHLCKTRFDCPRTYLLFFPRMWKCINRRCRYVYFFE	62	Sequence 130 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12063	MAQIFKFFYVMTIFIYLFLVSTTVDAGMRCNHVSDCPKDTFCWLDSHMQCIKHQCKCVRIFEPIDPA	67	Sequence 131 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12064	MAISYKFVYAIIFFIFLFLVANNVEGYIVCITDNDCPENTEVRQYECIEGRCRLSRVLNP	60	Sequence 132 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12065	MAQILILFYVMTIFIYLFLVSTNVDAGIRCRNVYDCPKATYCRAGSHRVQCIKHQCKCVRIFESIDPA	68	Sequence 133 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12066	LSKTLKFFYAMILFLSLFLVAKEIEGCEDDSDCPQIFNFHPFICKCINNECEKVILQKGYMSMKPKILHKRYTRKNEFLH	80	Sequence 134 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12067	MAEIVKLIYVMIIFFYVFLVSMNVDASDECVKVSDCSPTKYCLPGRRMICSKGKCKCLRNMFIPIPE	67	Sequence 135 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12068	MAHKFVYAIILFIFLFLVAKNVKGYVVCRTVDDCPPDTRDLRYRCLNGKCKSYRLSYG	58	Sequence 136 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12069	DKTLKFVYIMILFLSIFYILIVCDSNAFGMTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK	64	Sequence 137 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12070	MAKFSMFVYALINFLSLFLVETAITNIRCVSDDDCPKVIKPLVMKCIGNYCYFFMIYEGP	60	Sequence 138 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12071	MAQILFYVYALIILFSPFLAALVIIDHHKPCVSDTDCAFYLDIPPTVKYCSDGLCAWYFPDNPLP	65	Sequence 139 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12072	MAQILMFFYSLIIFISLLTSHPCISDDDCPEALSPQFPKCIHNVCVYFVEE	51	Sequence 142 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12073	MAETLKFVYVLILFISILFVVIVCDSSYIPISHPCTTVKDCPEVKNYKSRCLKGLCISGRLR	62	Sequence 143 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12074	MQRRKKSMAKMLKFFFAIILLLSLFLVATEVGGAYIECEVDDDCPKPMKNSHPDTYYKCVKHRCQWAWK	69	Sequence 144 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12075	MFVYDLILFISLILVVTGINAEADTSCHSFDDCPWVAHHYRECIEGLCAYRILY	54	Sequence 145 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12076	MQIRKIMSGVLKFVYAIILFLFLFLVAREVGGLETIECETDGDCPRSMIKMWNKNYRHKCIDGKCEWIKKLP	72	Sequence 146 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12077	MQRVKKMSETLKFVYVLILFISIFHVVIVCDSIYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR	68	Sequence 147 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12078	MAKTLNYVYVLILFISIFLSITVYGYIPGIVNKPCKTDKDCPKKPPHNIRCRKGQCVEIL	60	Sequence 148 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12079	MAQSLIFVYALIIFLFLFRVEAEHLKIRCVTDDDCPKVEKPLYMYCGNHWCAYKLHFV	58	Sequence 149 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12080	MAGIPCYFYGSIIFLSLFLLAAFFEKGYMIPCATSDDCLKNMCRPPLTPRCIEHNCKCK	59	Sequence 150 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12081	FFGSSIPSILLIVSDRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	48	Sequence 151 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12082	AEIFKFVYKWILFVSLFLVIVAKEDDIECVTDADCYEKLPALQRAVMKCIQGFCKIHI	58	Sequence 152 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12083	MAQLSYIFYAFIIFLCVFFVPTKSNSIPCTTHAQCPGDMCELPQIVWCVVGFCECA	56	Sequence 153 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12084	AWNLKFVYVMVLFFSLLIVVINIDAYRSCKTDDDCPDYLCTSPKIGKCMDNDCYCI	56	Sequence 154 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12085	MVEALKLVNVLILFLSIFLSIIVSTSSFPWKLYPCVTDKDCPRKNRHVVKCRKGYCVGVQII	62	Sequence 155 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12086	MQSVENMAEVIKFVNVIIIFISLFPFAMTVDANMVICTQDFDCQTKICPFDLQPKCTILFEFLLSLCGCV	70	Sequence 156 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12087	MAAIIKFIYTMFLFIFLFVVPTKVDALAGCITDADCVIKKCSSSCRIKCIDFRCLCPTGF	60	Sequence 157 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12088	MARILSFFYALLIFVSLFLVTTNGSLPDAPPCLFTPECPPDMCPTDLTLKCINLSCQCTIEYDIDPDVVPS	71	Sequence 158 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12089	MANITKFVYIAILFLSLFFIGMNDAAILECREDSHCVTKIKCVLPRKPECRNNACTCYKGGFSFHH	66	Sequence 159 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12090	MAQIPRYFYAFIIFLYLFHVATTNRFLYRIGCDTSNDCPSYMCPPPLSPRCTKFYCKCI	59	Sequence 160 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12091	MAEILKFVYIVILFISILLVVETEQCVYDADCEKIYPLHRQHLFKCIKAFCVRSS	55	Sequence 161 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12092	MARILYFFYTLLIFVSLFMIAINGSLPDAPPCLFTPECPPDMCPTDLTLKCINLTCQCTSEYDID	65	Sequence 162 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12093	MAKIIKFVYVMIIIISFFLVATNAKDDCLVDADCVTLVCEFDERPQCVINTCRCRPLRFSGFYYEQLH	68	Sequence 163 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12094	MQKRRNMAAILKFVYIMIIYLFVLLVAVKAFEECKEDADCHPVCSVPGCSNICTLPDVPTCIDNNCFCI	69	Sequence 164 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12095	MARTLKFVYSMILFLSLFLVANGLKIFCIDVADCPKDLYPLLYKCIYNKCIVFTRIPFPFDWI	63	Sequence 165 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12096	KIINFVYNMIIFFSLFLVATNAGGCNPCLVTCPDDLLNRCPPGMEPICEYGVIKCYPIGKETNRVLT	67	Sequence 166 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12097	MARILCFFYGLLIFVSLFMVATNQSIPDVLPCLFSNECPPDLCPTDLFAKCINLTCQCTAEYDLD	65	Sequence 167 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12098	MASILKFVYIMIIYLSVLLVVIEGYPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT	65	Sequence 168 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12099	MGEMFKFIYTFILFVHLFLVVIFEDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK	61	Sequence 169 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12100	MQIGSNMAETMKLVYVIILFLSIFLGITLSNSAFSHFIPGCKTDKDCPKFYGSNVRCRKGKCVQLG	66	Sequence 170 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12101	MGEIMKFVYVMIIYLFMFNVATGSEFIFTKKLTSCDSSKDCRSFLCYSPKFPVCKRGICECI	62	Sequence 171 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12102	MANVTKFVYIAIYFLSLFFIAKNDATATFCHDDSHCVTKIKCVLPRTPQCRNEACGCYHSNKFR	64	Sequence 172 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12103	MAYISRIFYVLIIFLSLFFVVINGVKSLLLIKVRSFIPCQRSDDCPRNLCVDQIIPTCVWAKCKCKNYND	70	Sequence 173 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12104	MAVVIKFVNVMLIFISLFPFAMNVDANIISCTQDFDCQTKICPFHLKPKCIVLEILPHSLSGGICGCD	68	Sequence 174 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12105	MAEILKCFYTMNLFIFLIILPAKIRGEHIQCVIDDDCPKSLNKLLIIKCINHVCQYVGNLPDFASQIPKSTKMPYKGE	78	Sequence 175 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12106	MAHIFNYVYALLVFLSLFLMVTNGIHIGCDKDRDCPKQMCHLNQTPKCLKNICKCV	56	Sequence 176 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12107	MFKILLFTSSIIVFLSLFFVTYEDFWNVCAYNSDCQSYPCDLGESRNCTLNRCICVYNI	59	Sequence 177 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12108	MGEILKFVYNVILFGSLYLLVIYAERECDTDADCQKKFPGSNQHLLWCNNGFCDCRTH	58	Sequence 178 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12109	MXNLRILIILIIFIFIFLVLIVCDSTFIHFSIPCITDKDCSILQNYKARCRKGYCLRRKIR	61	Sequence 179 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12110	MVQIGCFFYALIILLSPFLVATHQSIDDVIPCVLNTDCPRDMCPIHLFPKCINLLCRCSYWEDN	64	Sequence 180 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12111	MYREKNMAKTLKFVYVIVLFLSLFLAAKNIDGRVSYNSFIALPVCQTAADCPEGTRGRTYKCINNKCRYPKLLKPIQ	77	Sequence 181 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12112	AFFIFLSIAHRPPANTIPCFGTKDKCPFNLYYKVECIDGFCYYPV	45	Sequence 182 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12113	MVKTPKLVYVLILFLSICFSITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR	62	Sequence 183 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12114	MQIVKNMVKTPKLVYVLILFLSIFFSITVSNSFNSKIVFTDCKTDKDCQNHRGFNFRCRKGNCVAKIR	68	Sequence 184 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12115	MAKTLMFIYIVILLTCVLAVIDINAFSFPCKTNSDCPSYLCHYPKNPECVERECICW	57	Sequence 185 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12116	FIVLLSQFLVVINGSIPCETTADCPVAVPPEYYKCMYKVCVLIR	44	Sequence 186 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12117	MAHIIMFVYALIYALIIFSSLFVRDGIPCLSDDECPEMSHYSFKCNNKICEYDLGEMSDDDYYLEMSRE	69	Sequence 187 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12118	MTEILKFVCIMIIFLSSFIVSQNIDAGGNRKCFRDSDCPKFMCPSYLAVKCIGRLCRCGRPELQVELNPK	70	Sequence 188 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12119	MTEILKFVCVMIIFISSFIVSKSLNGGGKDKCFRDSDCPKHMCPSSLVAKCINRLCRCRRPELQVQLNP	69	Sequence 189 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12120	VNFIYSMIIFLFLFPVATKTQFLPNYYEFYHCYNHSDCQGSMCPTGSKPKCVDQVCECILIRM	63	Sequence 190 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12121	KKKIIIVLCTLFYHLSNNFQLFDNTDTATCITDADCPYDGKCIDGFCRFNVKNNNQV	57	Sequence 191 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12122	MAKIFNYVYALIMFLSLFLMGTSGMKNGCKHTGHCPRKMCGAKTTKCRNNKCQCV	55	Sequence 192 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12123	MARTLQFVYVMILFFSLFLVAKGDDVKIKCVSAIDCMDLFNLLPIVYKCINNICVYEQSSQRLI	64	Sequence 193 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12124	MDEILKFVFCMIIFLSLFLIATKVGGEHNECETDADCPKHTTIFFVMKCIDHICRCMKTSI	61	Sequence 194 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12125	FKVLNIVYAMIIFLSISFSITNSFKMFCRYDEDCPPRMCRLPQVPQCNEFICDCGMPVYKPYQNKYIKK	69	Sequence 195 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12126	MAEIGKYIYVIIFFISLFFITTSVEGWRCKTKYDCIKIRFCKFPTIARCTKPDFLFLEYDRGFCTCDD	68	Sequence 196 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12127	MQRLENTTEVVMLIYVMIIFLCLLLVTMNVNAVIKCFQDSDCPKYMCMFPLKPKCVYILVFPPPWTAQCICD	72	Sequence 197 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12128	MAQISKSFYALIIFLSLILVVTGIKLIKCTVSDDCPMNFRCPPNTFVRCISDLCTCRSLLDEQS	64	Sequence 198 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12129	MQIGKNMVETLKLVYVIILFFSIFLCIAVSNSSFSEIIDSACKTDKDCPKLHKVNVRCRKGKCVAI	66	Sequence 199 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12130	MAKVTKFGYIIIHFLSLFFLAMNVAGGRECHANSHCVGKITCVLPQKPECWNYACVCYDSNKYR	64	Sequence 200 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12131	MAKIIKFVYIMILCVSLLLIVEAGGKECVTDVDCEKIYPGNKKPLICSTGYCYSLYEEPPRYHK	64	Sequence 201 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12132	ERTLKLVLLDALETQIVQKACVILLPNRSVCTNPYVNVYESSPKEIMCIHEHVCLPYLRAYTNYIPS	67	Sequence 202 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12133	MAEIIKFVYILILCVSLLLIGEASGKECVTDADCENLYYGNKWPLICSNIGYCLSSYEEPPHK	63	Sequence 203 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12134	KIMKFVHAMILFLFLFAINVTAFRDPCNFDFDCRNSNCTAPYVATCMYEHCYC	53	Sequence 204 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12135	MGQIEKFVYSLIIILSLALVVTCNGIPICQTYMDCPSDMCTRPKHAYCVSYKCYCV	56	Sequence 205 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12136	MAEIIKFVYIMILCVSLLLIAEASGKECVTDADCENLYPGNKKPMFCNNTGYCMSLYKEPSRYM	64	Sequence 206 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12137	YAMILFISMFLAARNVDAYLKCKTVHDCPKSQVVYKCVGNYCRAVKIRRWNLS	53	Sequence 207 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12138	TRAKVHKFIYIMIVFLSIFHVVNSYVVMCEKDSDCVDSFCVPPNVPKCRVVCKCLPK	57	Sequence 208 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12139	MNTILKFIFVVFLFLSIFLSAGNSKSYGPCTTLQDCETHNWFEVCSCIDFECKCWSLL	58	Sequence 209 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12140	MTKILKCVYAMILFLPLFVVAMEVGRRANVECESDKDCQEHWSEFFIIQCIDNICVPSERPL	62	Sequence 210 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12141	NAILFVSLYLLVIYGDRECDTDTECQKKFPGVNAHHLWCDNGNCVSYPK	49	Sequence 211 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12142	MDKTIKFTYVMIIFVYLFLIATNVEAYKNRCFRDSDCPKEMCNHPKIPKCVNNAYCKCVVAMYFPPK	67	Sequence 212 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12143	MAEIIKFVYIMILFVSLLLIVEAGGNECVTDVDCEKLYPGNKKPLICNIGYCLSLYKEPPRYM	63	Sequence 213 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12144	MAEIVKFVYVMIIFASPFLFSMNLDSENICDGDYDCNPNEWWCPPNYVLKCINYQCSCIGFTPAIYALD	69	Sequence 214 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12145	MDAVLKFVYTMILYLFLLHVIAEDFPFHKCEKDEDCLEICADDQMAMCILNVCFCY	56	Sequence 215 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12146	MTTILKFAYVMIICLFLLQVAAQEVLEKEIFPCQTDGECDHMCVTPGIPKCVANMCFCFDNL	62	Sequence 216 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12147	MRKSMATILKFVYVIMLFIYSLFVIESFGHRFLIYNNCKNDTECPNDCGPHEQAKCILYACYCVE	65	Sequence 217 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12148	MAKVTKFVYIAIHILSLFFIAMNDAVIFECSEDSHCVTKIKCVLPRKPECRNTQCTCYRGYKGSFTLHH	69	Sequence 218 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12149	MAGILKFFYIAIIYVSLYLVVIEGKDGCKTNFDCLIKYPDHNEDILQCIGGHCLCLTN	58	Sequence 219 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12150	MAEILKILYVFIIFLSLILAVISQHPFTPCETNADCKCRNHKRPDCLWHKCYCY	54	Sequence 220 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12151	MAEILKFVYNATLFFSLYLVVYNSKLWCDTDADCQEKFPGPSKYPIKCMKGICKCVIN	58	Sequence 221 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12152	MPEMIQFDYLMILFIFLIFVVTNIMAWRPDCKENNDCPTFYCATWINTCIKFKCYCIRPWG	61	Sequence 222 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12153	MRINRTPAIFKFVYTIIIYLFLLRVVAKDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF	61	Sequence 223 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12154	MVGTLKFLRVHISFLTILLMIIICAFYFIPDSGPCVTNKDCEQEIGYIVKCDTNTGFCVKILQRS	65	Sequence 224 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12155	EILKFIFVIIILFLSISLVSADFDLHNDSYDYLYEFQECEVDNDCPQDPLPMKCINYICVVHNEEPSDNL	70	Sequence 225 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12156	MAATFKLVYVMILLISLYHVAGNFEDISIECMFSIDCPQIKSNIFRFKCIEDRCKIEFIYQRKKYEI	67	Sequence 226 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12157	MTTFLKVAYIMIICVFVLHLAAQVDSQKRWHGCKEDRDCDNICSVHAVTKCIGNMCRCLANVK	63	Sequence 227 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12158	MTTILKFAYIMIICLFLFLLHVAAQKDLKVFTCQRDEDCKVACATYGGDPWCFRNVCFCKHYNEGGTLHAELH	73	Sequence 228 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12159	MDKILKFVHIVILFVFLLLVLVAAEQHFVTLYKKKEKCALDVDCLELFPNSYKYLMKCVGGDCISLSKGFSHDEIKE	77	Sequence 229 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12160	MTKIVKFIYVMIIILSLFQLSKNAKVNCLDDADCLEVLCVFGSKAECVVNICICVPPRFGKFDEHFR	67	Sequence 230 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12161	HEAQISKSFYALIIFLSLILVVTSKDITCTVAGDCPNFFVCPPNNFVRCIRNLCKCRSLSYKQP	64	Sequence 231 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12162	MAKFVIVVCSVIIFLSSFLVAENSQPCNLSVTDTRDICPPGTTLQFVYKVCRCYPMKWRLDHVLT	65	Sequence 232 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12163	IFFLYLFIFATNINAICECEEDIDCPRTWCFGQFFVKCITNECICVHEDRLLPRIPWDPWIPMI	64	Sequence 233 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12164	MQKRKSMTEVLKLVYIMIIFLYIFLVVADTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS	66	Sequence 234 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12165	MAEIVKFVYLMIIFLSTFLVSTKILEKHKCVTDGVEILEKGKCFTDWECVRNSWLCPVDLVVRCIKETCKCIKILEPINVVPT	83	Sequence 235 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12166	MVETLRLFYIMILFVSLYLVVVDGVSKLAQSCSEDFECYIKNPHAPFGQLRCFEGYCQRLDKPT	64	Sequence 236 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12167	MAKLMKLFYVMIHFISLLLITRNVRAYDDCYNHAECTNKIKCVPPRIAQCVRFKCDCIRLNNGPKTPWSARPKRVHISPTRKNDF	85	Sequence 237 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12168	MQMKKMATILKFVYLIILLIYPLLVVTEESHYMKFSICKDDTDCPTLFCVLPNVPKCIGSKCHCKLMVN	69	Sequence 238 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12169	MQKDKSMVQIVKFVYVMIIVLSSFVVAINSDGYLECTTDYDCREEWLCPPDMEAKCFVSFALARFLSKGKCLCV	74	Sequence 239 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12170	MVAVTKLINVMLIFLTLFLGALSIFPEHNECRTSFDCRKYFCQLPLRPTCNYVEIFRHYYDTTCGCA	67	Sequence 240 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12171	MTAILKVAYIIMIICLFLLHDAASDDYLKYIYRCQNDGDCDQICATHGISKCVATMCFCNLNL	63	Sequence 241 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12172	MVEIHNFIYAMILLVFMFIVVVDSWSWGLTTECVTELDCYKKYRLPAEKKMKCIRGSCYRVRE	63	Sequence 242 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12173	MDKIHKFIYALIFFLALFLVVNARNGCIVDPRCPYQQCRRPLYCRRR	47	Sequence 243 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12174	MRYSLSVSILAIILEFIYIVVLFFSPCLLVTDAYNITCNSALDCASNRCILPGMPICVTNKCLCV	65	Sequence 244 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12175	MAGILKFFYIVIIYVSLFLFVVESERECVTDADCQKKLPFPHANHFICMNGLCALVFHD	59	Sequence 245 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12176	MAQFLIFVYTLIIFISLFLNAVQRPCVTVADCPPVKKPLKMWCIRQTCFYGFGKRPDL	58	Sequence 246 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12177	MVGILKLVYIVIIYVSFFLVVCKGETCVTVDDCQGKHHLPPGYHFICMNSRCVLIYYN	58	Sequence 247 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12178	MNIIFKCVYHMIVILLLLLVATEAGTGNIRQSCEFDVDCENKYCPPSHDGKCVWE	55	Sequence 248 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12179	IKIIKFVYAMTFLIFLFLFITDTAGECITFLDCLHLPCMPTETQLCVDKKCICMGLTIKSKNNYIT	66	Sequence 249 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12180	MAKIITIIQIFTIIMLFIFVIVTDASYPCKIHRDCTTITCSYPLVPRCLIQKCYCGFN	58	Sequence 250 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12181	LKLVYIAIIYVSFFLVVCEGEKCVTADDCQGKHHMPAGYHFICMNARCVLVYYN	54	Sequence 251 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12182	MKLFYVLIYFISLFLVINVQAFFDCENHDDCKNKIKYVLPRIAECRDYKCNCFPLNLSKTLWSASTKRVHKSLAQTNDFLH	81	Sequence 252 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12183	MTTILKFPYIMVICLLLLHVAAYEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGNQRFSVWVFGGSFLQHWSCHSSRS	77	Sequence 253 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12184	MDQISKSFYALMIFLSLILVVTSNDIKCTVAGDCPDFFRCPPNTFVRCISNICICRLVYLNTFLEVIIDKVFVF	74	Sequence 254 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12185	MDQISKSFYALMIFLSLILVVTSNDIKCTVAGDCPDFFRCPPNTFVRCISNICICRSLSH	60	Sequence 255 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12186	MAQISKSFYALIILLCLSLIVTGKDITCNVAGDCPEYFRCPPNTFVRCVSNICECRGLSHQQP	63	Sequence 256 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12187	MAQILISVHALSVFIFPFLVVIIRDKPAPIPCKFHADCPIMLSIVVECINNVCEFIYI	58	Sequence 257 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12188	MDEVFKFVYVMIIFPFLILDVATNAEKIRRCFNDAHCPPDMCTLGVIPKCSRFTICIC	58	Sequence 259 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12189	MAGILKIFYIAIIYVSLFLVVIEDERECVTDADCQKKYPGPYEHLLKCVSGYCVGVTGF	59	Sequence 260 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12190	MQRRKLNMVEILKFSHALIIFLFLSALVTNANIFFCSTDEDCTWNLCRQPWVQKCRLHMCSCEKN	65	Sequence 261 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12191	MVNILKFIYVIIFFILMFFVLIDVDGHVLVECIENRDCEKGMCKFPFIVRCLMDQCKCVRIHNLI	65	Sequence 262 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12192	LILFISLFLDVVKGHDQRECYTNYDCCVKYSCPYKHMVKCVGGYCLGFRNDYGKKNLY	58	Sequence 263 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12193	VSLFLAVVKSYDSKECYSDSDWHKKYSCPYTHMMKCVGGYC	41	Sequence 264 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12194	MAIIKFIYTMFLFILLFVVPTKVDGRITHDPSTRSTVSGGFGKCVRDADCVDEVCSPGCNKRCVGFECQCPL	72	Sequence 265 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12195	MALKFYSLFYIQLFIPFHLLNFLAYITAVYGCNDDTDCPPSCTTRGCPDSCAYPHVLRCIGKNCVCT	67	Sequence 266 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12196	MAEIFKFFYALIIFISLILSVANADPMYCFNDDDCRELKCSHPRVRKCRMFLCRCEEVDKEDEK	64	Sequence 267 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12197	MGDIIKVVFAMIIYLYMLTIVTNAVTICDSDQDCRRYRCDPPEYPRCLGILCKCVYVSG	59	Sequence 268 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12198	MAKLMMFFYVMIYFFVLVACQKRRRSTECRNDSDCEKMVKCVLPRIARCIKYRCQCRNFLESFE	64	Sequence 269 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12199	MVEVTKLVNVMLIFLTLFVVALSNDTEYTDCLQHSDCQAYACELPFKPDCLMVEYAPQFFRLACGCV	67	Sequence 270 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12200	MAENYKFVYVVIFFVSLFLDVVDGEKGTIVDIETTGQCADDYECYRLFSCPREVAFKCINGWCKCIL	67	Sequence 271 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12201	FDRRFICFDNSDCPQHLCHELIIPRCKIGVCVCLP	35	Sequence 272 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12202	MNNMVETCKYFYVVILFLFIFIMATDGVYLCEDDEDCHIMPCMVPEYAKCIRMICQCC	58	Sequence 273 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12203	MQRRKNMANNHMLIYAMIICLFPYLVVTFKTAITCDCNEDCLNFFTPLDNLKCIDNVCEVFM	62	Sequence 274 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12204	MTGIHKFFHMVIHFVFLFLVVYGSGIAEKECITDDDCNRKYPMHANRGLQCLNGECKSSRIIKSR	65	Sequence 275 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12205	MTPITKNIFDMIIFISPLIVTMSMRVLCGRDGRCPKFMCRTFL	43	Sequence 276 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12206	FVWLLIIFLSLFLFEITVGGRYTTPWCVRDIDCPKEKCKHPFKPRCLTHSCVCRLWGSQDVI	62	Sequence 277 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12207	IKFMYVIIIVLFVFLSVRKNTDAKNICIDDVHCQKYKCSPGLYPTCINGWCECK	54	Sequence 278 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12208	MKFVYVMILFLSLFIVSTNGYEKISCQNDFDCPESMCEFGMIRRCISYKCQCHEAY	56	Sequence 279 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12209	MDKVYKFVYVMIIFFSQIIVATNAQKIRRCFNDAHCPPDMCTPGVIPKCKFTICKC	56	Sequence 280 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12210	MGQIQKFISSLIIIISLVLVVTCNCIPMIHPLLYKKRVVPNCQTIVDCPDNMCTHPKEVYCIGYRCYCLK	70	Sequence 281 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12211	MDEILKFVYTLIIFFSLFFAANNVDANIMNCQSTFDCPRDMCSHIRDVICIFKKCKCAGGRYMPQVP	67	Sequence 282 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12212	MAQILYYFFAFLIFVSLFLVVTNQSIPDVLPCLFSNECPPDLCPIDLFPKCINLSCQCSAEFYNID	66	Sequence 283 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12213	DMIIFLSPLIVTMSMKVLCGRDGTCPRFMCGPGIIPKCVGRYCEC	45	Sequence 284 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12214	MVKIIKFVYFMTLFLSMLLVTTKEDGSVECIANIDCPQIFMLPFVMRCINFRCQIVNSEDT	61	Sequence 285 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12215	MAKIIKFVYVLAIFFSLFLVAKNVNGWTCVEDSDCPANICQPPMQRMCFYGECACVRSKFCT	62	Sequence 286 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12216	MTGVLKFVYTMVFFLSLFLIAIDIKVAAFLRCDFDLDCPPKMCYSHLYFVPMCVDNHCDCTQWKDIIPTIP	71	Sequence 287 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12217	TTFHPILVILFYSLFPFIPAPIRCNRVSDCPKIRCNIGFVLRCLYNQCKCVRITQLVDYVLK	62	Sequence 288 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12218	MAIIKFIYTMFLFIFLFVIPTKVDGRITHETLPLPVSKPIPILGGECISDADCKHPECDNCRGVCLNSRCICMARSGWTYTIPQN	85	Sequence 289 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12219	AIIYLSLFLFVFEDKRECDTNFDCQQKFSTQAEDLLWCIRGYCMSIPN	48	Sequence 290 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12220	MILCFSVFLFAKNIDALHCNNDNECPPSTWKPFVRCKMNRCIYSRVQPPWAC	52	Sequence 291 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12221	FSFLFLVVATLIEECVTDADCYKIYPEASFLHMFCIDGVCKTPIPL	46	Sequence 292 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12222	MAEILKFVFGIIIFLPIFLVAMDIVDKIDECESNVDCPKSYIINWDKNYVHKCINNRCEWIKIIRRR	67	Sequence 293 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12223	LYLVDLGCVTDADCKDKFPGNKYPIKCINGICKSVPN	37	Sequence 294 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12224	MTEIRKFFYMLIHVFFLFIVRKYGSECISDTDCNVLYPMYINRRLRCIQGICHTTTARRR	60	Sequence 295 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12225	MDETLKFVYILILFVSLCLVVADGVKNINRECTQTSDCYKKYPFIPWGKVRCVKGRCRLDM	61	Sequence 296 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12226	MAHKLVYAITLFIFLFLIANNIEDDIFCITDNDCPPNTLVQRYRCINGKCNLSFVSYG	58	Sequence 297 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12227	AIHCNDVNDCPPDISDPFVRCESNRCIYSRLEPPFGC	37	Sequence 298 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12228	MRKNMTKILMIGYALMIFIFLSIAVSITGNLARASRKKPVDVIPCIYDHDCPRKLYFLERCVGRVCKYL	69	Sequence 299 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12229	MTIIIKFVNVLIIFLSLFHVAKNDDNKLLLSFIEEGFLCFKDSDCPYNMCPSPLKEMCYFIKCVCGVYGPIRERRLYQSHNPMIQ	85	Sequence 300 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12230	ISLFLVVYCEKECANDIDCYKIFLGPPLIPMKCIDGECKRIT	42	Sequence 301 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12231	MAEIFKFVYSVILFVSLYLFVIYAEKECDTDADCRKKFAGANQHLLWCNNGYCECHTH	58	Sequence 302 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12232	MTETLKFFYAMILFLSLFLITTNVGGSYYGCETDADCPRSMNKDFYLKCVDKKCEWTAKI	60	Sequence 303 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12233	FRAIHECRAHSHCVARINCVLPRKPQCRNYACGCYDSNKYR	41	Sequence 304 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12234	MQRSRNMTTIFKFAYIMIICVFLLNIAAQEIENGIHPCKKNEDCNHMCVMPGLPWCHENNLCFCYENAYGNTR	73	Sequence 305 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12235	MIKQFSVCYIQMRRNMTTILKFPYIMVICLLLLHVAAYEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGYVCFCFENL	77	Sequence 306 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12236	GLFSFFIPTGWRCKKTDDCLKIEFCKFPKIARGTKPKFLFFEFGTGFCTWDD	52	Sequence 307 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12237	MAKVYMFVYALIIFVSPFLLATFRTRLPCEKDDDCPEAFLPPVMKCVNRFCQYEILE	57	Sequence 308 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12238	MQRRKKKAQVVMFVHDLIICIYLFIVITTRKTDIRCRFYYDCPRLEYHFCECIEDFCAYIRLN	63	Sequence 309 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12239	MANTHKLVSMILFIFLFLASNNVEGYVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	59	Sequence 310 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12240	MAGIIKFVHVLIIFLSLFHVVKNDDGSFCFKDSDCPDEMCPSPLKEMCYFLQCKCGVDTIA	61	Sequence 311 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12241	MQREKNMAKIFEFVYAMIIFILLFLVEKNVVAYLKFECKTDDDCQKSLLKTYVWKCVKNECYFFAKK	67	Sequence 312 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12242	MNHISKFVYALIIFLSIYLVVLDGLPISCKDHFECRRKINILRCIYRQEKPMCINSICTCVKLL	64	Sequence 313 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12243	MQMRKNMAQILFYVYALLILFTPFLVARIMVVNPNNPCVTDADCQRYRHKLATRMICNQGFCLMDFTHDPYAPSLP	76	Sequence 314 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12244	MQKRKNMAQIIFYVYALIILFSPFLAARLVFVNPEKPCVTDADCDRYRHESAIYSDMFCKDGYCFIDYHHDPYP	74	Sequence 315 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12245	MTAILKKFINAVFLFIVLFLATTNVEDFVGGSNDECVYPDVFQCINNICKCVSHHRT	57	Sequence 316 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12246	MFEIFKFVYVVVIFLSLYILSIEVGGALIECEIDLDCPKSYIKLWDRNYAHRCVNNICEWVKKPRIY	67	Sequence 317 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12247	MFEIFKFVYVVVIFLSLYILSTLIECEIDLDCPKSYIKLWDKNYAHRCVNNICEWVKKPRIY	62	Sequence 318 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12248	MQIGRKKKGETPKLVYVIILFLSIFLCTNSSFSQMINFSGCKRDKDCPQFRGVNIRCRSGFCTPIDS	67	Sequence 319 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12249	MQIGKNMVETPKLVYFIILFLSIFLCITVSNSSFSQIFNSACKTDKDCPKFGRVNVRCRKGNCVPI	66	Sequence 320 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12250	MTTSLKFVYVAILFLSLLLVVMGGIRKKECRQDSDCPSYFCEKLTIAKCIHSTCLCK	57	Sequence 321 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12251	MTTSLKFVYVAILFLSLLLVVMGGIRRFECRQDSDCPSYFCEKLTVPKCFWSKCYCK	57	Sequence 322 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12252	MATILMYVYITILFISILTVLTEGLYEPLYNFRRDPDCRRNIDCPSYLCVAPKVPRCIMFECHCKDIPSDH	71	Sequence 323 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12253	MQMRQNMATILNFVFVIILFISLLLVVTKGYREPFSSFTEGPTCKEDIDCPSISCVNPQVPKCIMFECHCKYIPTTLK	78	Sequence 324 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12254	MFHAQAENMAKVSNFVCIMILFLALFFITMNDAARFECREDSHCVTRIKCVLPRKPECRNYACGCYDSNKYR	72	Sequence 325 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12255	MVEILKNFYAMNLFIFLIILAVKIRGAHFPCVTDDDCPKPVNKLRVIKCIDHICQYARNLPDFASEISESTKMPCKGE	78	Sequence 326 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12256	MAEILKDFYAMNLFIFLIILPAKIRGETLSLTHPKCHHIMLPSLFITEVFQRVTDDGCPKPVNHLRVVKCIEHICEYGYNYRPDFASQIPESTKMPRKRE	100	Sequence 327 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12257	MAEIIKFVYIMILCVSLLLIEVAGEECVTDADCDKLYPDIRKPLMCSIGECYSLYKGKFSLSIISKTSFSLMVYNVVTLVICLRLAYISLLLKFL	95	Sequence 328 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12258	MAEILKFVYIVILFVSLLLIVVASERECVTDDDCEKLYPTNEYRMMCDSGYCMNLLNGKIIYLLCLKKKKFLIIISVLL	79	Sequence 329 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12259	MLRLYLVSYFLLKRTLLVSYFSYFSTYIIECKTDNDCPISQLKIYAWKCVKNGCHLFDVIPMMYE	65	Sequence 330 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12260	MQIGKNMVETPKLDYVIIFFFLYFFFRQMIILRLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI	96	Sequence 331 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12261	MAKIVNFVYSMIVFLFLFLVATKAARGYLCVTDSHCPPHMCPPGMEPRCVRRMCKCLPIGWRKYFVP	67	Sequence 332 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12262	MVETLRLFYIMILFVSLCLVVVDGESKLEQTCSEDFECYIKNPHVPFGHLRCFEGFCQQLNGPA	64	Sequence 333 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12263	MYKVVESIFIRYMHRKPNMTKFFKFVYTMFILISLFLVVTNANAHNCTDISDCSSNHCSYEGVSLCMNGQCICIYE	76	Sequence 334 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12264	MAKIMKFVYNMIPFLSIFIITLQVNVVVCEIDADCPQICMPPYEVRCVNHRCGWVNTDDSLFLTQEFTRSKQYIIS	76	Sequence 335 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12265	MTKIVVFIYVVILLLTIFHVSAKKKRYIECETHEDCSQVFMPPFVMRCVIHECKIFNGEHLRY	63	Sequence 336 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12266	MAKTLKFVYGLVLFLYLFLIEKGVDGKTFLMAEYIKCDTDADCPIVIHHSFYKCIDNLCKRFRRQKHLV	69	Sequence 337 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12267	MAQLIIFVYALMVFLSIFLVESYKTKTPCKSLNDCPKAIKPIFVKCLGNICQYSIGRI	58	Sequence 338 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12268	MANDLKFIYVIISFLSMFLVTKEVDGAFAGWIKCKVDEDCPNVFTYSYYKCVNELCEIFLREIPKKPYM	69	Sequence 339 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12269	MAKTLKFLCGLVLFVYLFFIKKDVAGNTFLMADNIECDTDAGCPKMVHHIFYKCIDNKCKQFRRS	65	Sequence 340 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12270	MAKIFKFIYGLVIFLYLFLIQKEVAGYIQCDFDADCPEMFRHIFYLCIDKLCRQFVTL	58	Sequence 341 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12271	MTQILLFVYFFIIFLSLSFVVTSYRTRIPCVSDYDCPKASYPLFIKCIYNFCEIWGSP	58	Sequence 342 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12272	MQRRTNMTQIVILFYVLIIFLILFPISCVSDDDCPKVPYPLYIKCEDNFCDIWASPY	57	Sequence 343 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12273	MAQILMFFYSLIIFFFLFLVETKRTNIPCFSDDDCPKTSPPLVLKCDDYFCRYFREKNLI	60	Sequence 344 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12274	MAKTLKFVYVVILFISIFLVLTVYDSKYFQIASPCVNDKDCPRFKNNNVRCRKGFCVNLCN	61	Sequence 345 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12275	MAKTLKFVYVVILFISIFLVLTVYDSKYFQIASPCVNDKDCPQFKNNNVRCRRGFCVNSGGATQKCLGCPSLK	73	Sequence 346 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12276	MAQFFMFVYILIIFLSSFLIEASTAATPCTSDKDCRLERYNVWCINGYCKYKFTPID	57	Sequence 347 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12277	MAQMLMFVYTLIIFLSLFLVITNSVRIPCVTVADCPPTILPVFYECIDKFCMLHIE	56	Sequence 348 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12278	MFLYALITFLFLFLVETSTTNTKTTIPCKFDNDCPEISYPLILMCIDDFCEYLLA	55	Sequence 349 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12279	MVETLKLVYVLIIFYSIFLGIIVCNSSTIMYYDVPCEKDKDCPAPPRFNIRCRKGYCVRI	60	Sequence 350 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12280	MTQILLFVHVLISFLSLLLIVTNSVEIPETPCESDAECPYYSPSLYARCIDGFCTLFLS	59	Sequence 351 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12281	MQRKKNMGQILIFVFALINFLSPILVEMTTTATIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	62	Sequence 352 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12282	MVELLKFVYVMILFLFLFFVTTEACGGKTHYSEIIECKNDADCPIGYKCIDEMCKYG	57	Sequence 353 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12283	MVETLKYVYVMFLFLSIFQLMVVYDSIYFRKPPPCITDKDCPQMKINNVRCRKGFCIQIHKFTP	64	Sequence 354 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12284	MQIGKNMVETLKFVYVILLFLSIFLFNKSPFSQIMFSDCKTDKDCPQFRRANIRCRKGQCVKL	63	Sequence 355 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12285	MAHILMFTYVLIIFLFSFRSMTFLTQCKFSCKTIFNCPALVYHQHASCLDGFCWYEEKFEDE	62	Sequence 356 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12286	MTKTMKFLYVLIIFISIFVVASVYDSIPYVNSGPCVTDKDCPKVSQYNIRCRKGQCARIRV	61	Sequence 357 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12287	MTTIVNFVCGMIIFLSEFMVATNFKRKQIPFYFFIREFYPCFIDGNCPRNMCKVYQIPKCVGGLCRCIPLRCGRWEK	77	Sequence 358 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12288	MPKIMEFVYVMIIFLSIFVVITNVNAHIECKNDFDCPKNMCLAPRVAWCVNNKCECVLTYGPKYSTMKEKLLQKEKI	77	Sequence 359 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12289	MNKILKFVYEMILFLSLFHLAREVPHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	64	Sequence 360 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12290	MQRGKHMVEILEFVYAMILFLPLFLVITEVDGVDIYCETDADCPQITDWFYVVKCVDHKCELTKKLRRLYEYQTQKSAETPYI	83	Sequence 361 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12291	MTQILKLVYIVILFCFHICFVAEAEQCVSDADCQIKFPGPRQHLLRCTQGNCVMLVGQGKNYFSIMSKTLFSLLVIIFLLL	81	Sequence 362 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12292	MPKSLKFVYTMILFIFLFLITKNVDALHDCEYDDDCPKSTSKRTYRCINKKCRSYFTRVEK	61	Sequence 363 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12293	MNKNMPQILMFVYTFIIFFSPFFVVTNGTTSCITDDDCPKAVSFLVFKCIDNICVRVEIL	60	Sequence 364 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12294	MAKILKFVYVPILYLSILLVLTIYDQVYFNYNPPCVSDKDCPSPKSPKSNIRCRQGYCVNLYS	63	Sequence 365 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12295	MAQLHKLIYALTIFLSLFIVGAVRIPRPLIDPLNCHIDIHCIYKECRRPFKPSCLNFKCDCGKE	64	Sequence 366 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12296	MRIGKKMVETLKLIYVIHLFLSIFLFTNSPFGQIIFRQCKTDKDCPKLGRANIRCREGYCVRI	63	Sequence 367 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12297	MAQIYMFVYVLIIFLSLFLVIINCTPIPCNTPADCPKRVCIYPLRAKCINFNCECDYVKK	60	Sequence 368 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12298	MTKTLKFILTMILLLSLFLVAESGDIPCESREQCPNTATRRYACLNKLCYCYDNNYPNGWNPFEP	65	Sequence 369 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12299	MFNTLTFAFVIILLVTLFLVPKNVDAFVKCETTDDCPKSDYIRQYECVNNWCRLARLHEFQPKKSTLTS	69	Sequence 370 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12300	MQRENNMAKTIKFVYTMILFLSLFIVAKEVHAYPGCETDAECPKIYELYPLIYKCENKFCILSQVLPYIV	70	Sequence 372 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12301	MKIGKNMAETLKFVYVILFISLFLMIIVSDSFNPLIRQYCVTDKDCPKFKKYNIRCRKGFCVQVNGG	67	Sequence 373 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12302	MTKIIKFVYALVLFLSLFIVSQAAQNDWMKCKTDDECPKVSNPPLYFKCIDRGCRIVIKMRF	62	Sequence 374 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12303	MATILKIVYAMILFISLFLVAMNVDAYVECETDADCQPNMCKWPFIVQCYKNVCICVHHTNPYL	64	Sequence 375 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12304	MVQILKFVCVRILFISLFLIATKFGVASDECQIDADCPKSGNLFYIYKCINHKCELVAAHLRFY	64	Sequence 376 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12305	MTNYIVIFFLALFLIVIDVSAILECIFDIDCPTKKCAPPLVAKCDMYECYCRCPPNN	57	Sequence 377 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12306	MAQIQKFVYTLIMFLSLFVMVTNGMVSTNAYIHRCIHQDDCPKYMCEISVLPECINGFCTCV	62	Sequence 378 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12307	MSQILKFFFATVLIFALFLSATNGQKFNECYEDTDCPIQMCGYPFNVDCVGNKCTCVYNP	60	Sequence 379 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12308	MQKKGKYMAKLVTFVYVMIYFLSLFLVTKGAYYECSNDSACQATTKCVLPRVPRCIKYKCLCGNSNGSGNRWSTRPNRIQKGSTESNYF	89	Sequence 380 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12309	MDKTLKFIYAMFSCLYLFMVTKEVYVIYIFFHFLILAKSICKVDDDCPQRFVMYPLMFMCIKNICRLVNE	70	Sequence 381 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12310	MAQLLKFVYAIIFLFSLCLAATKEKFHSCVNANDCPYDFCSPPKYAKCVYNSCYCEDQGRL	61	Sequence 382 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12311	MQKRENMTVIVKFVCVMIIFLSLCVFSMHIETVTTCIYDSDCPEDMCYPPKKSFCSTFEILSIERKVGVCECI	73	Sequence 383 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12312	MNTIPKFVYITILFISLLLVVTGAVRKPECRQNSDCPPYFCIKPTVPKCIKFKCLCK	57	Sequence 384 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12313	MAEILKFVCFMIIFLSSFIVSESLNGNRHGKDRCFKDSDCPKYMCPSSLVAKCIKKLCSCRKPGLQIQLNPK	72	Sequence 385 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12314	MAESFKFICVIIIFLCSFIAAKNIDEKCFRDDDCAKNMCPSYLVVKCVNGIYKCVRP	57	Sequence 386 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12315	MVEIQKLVYVLILFLSIFLEMIVSNCTFIGFQDNPCKTDNDCRKVRGVNLRCRNGHCVMILQ	62	Sequence 387 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12316	MAEIVKYVYVIIIFLSTILVATNIEGTMSCFHDADCVHKRCQLPQIPKCVGKKCRCRGQYQANPMG	66	Sequence 388 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12317	MAEFLHMTYVMIIFIFLFLSLIDAEVHRCIEYTDCPEDMCHLPLVVVCHDHICKCLRLP	59	Sequence 389 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12318	MAKIIKIVYVMIVFFFIFLSVTNSSAFSGCMNDSDCPDLFCLPPLDMKCHELVCKCR	57	Sequence 390 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12319	MKNMSAIIKFIYAMSLILFIANEHYRELICKTDDNCPRRGTNKYFIHKCIDYRCQWIPR	59	Sequence 391 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12320	MQRRKNMAQILFYVYALIILFSPSLVVPLKVIIPSSTCDSDYDCLRYEEALNVITCCNNGLCVMFCPDFD	70	Sequence 392 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12321	MTNIIKFVKVMIYFLSIFLISTYFKVKLSCFEDSDCPYDMCYAGFQPKCVNGWCDC	56	Sequence 393 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12322	MTNSIKFVYVMMYFLSIFLISTYFETKLNCIDDSDCPYDMCDPGLLPRCLNGWCDCSRFQPWPMDSMSSNLREFTLPN	78	Sequence 394 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12323	MSKNILFNCAIILFLSLFLVTYFERFGPCSSDSDCPSFLCDHDGVMKCFSNGCSCVDPSD	60	Sequence 395 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12324	MVKILKFIHIMIIFLIFIIVTNASNPCVSTRDCTTHTCNPPLVARCINLRCYCGYK	56	Sequence 396 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12325	MGGIIKIVYAFVIFISLILIVTSNVHSLLPCGTDDDCANDPCIHPEYPHCHTEQCHCV	58	Sequence 397 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12326	MQKKKNMAQMHLFVYIFIIILSLFIAVTNALIFCFEDINCPFDKCFPQLPKCINSFCECV	60	Sequence 399 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12327	MSMTIKFLYAMTLFLFLFHIEKSSALIDCKTVDDCPSSWTKIYKCIDNKCRYSVVKGLII	60	Sequence 400 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12328	MSKTIKFLYAITLFLFLFLIEKNNVLIDCKHVRDCPKGIWRSCRYKCIDNKCVFTYWPH	59	Sequence 401 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12329	MTHKLVYAIILFIFLFLVANNVEGYILCKTVNDCPPNTRNLRYRCIDGKCKSHRVLYEWDESHTQDITITPCIEE	75	Sequence 402 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12330	MTEILKFVCVMIIFLSSFIVSQNIDSGGNRRCFRDSDCPKNMCPSYLVVKCLRSNCKCVRPGLQVRLNPN	70	Sequence 403 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12331	MAEILKFICFMIIFLSSFIVSESLNGHGRNRCFRDSDCPKVMCPSYLVTKCFKKHCRCRKPGLQVQLNPK	70	Sequence 404 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12332	MSTIVNYVCSMMIICLFQFTVATNFERKQISFSFFMKEYWPCVTDDDCPSDLCKKVDQIPKCVGGLCKCFPIRFGQWER	79	Sequence 405 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12333	MAEIFKVFYTLIIFASLYYVVALVQNECVTDGDCRRLYPHLIPRYPMCNEGTCVCIFE	58	Sequence 406 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12334	MAQIFKFVYVMIIFIYLFLVLTNVDAGIRCHDVSECPKGLYCNVGSHMECVKHQCKCIKNFEPIDLA	67	Sequence 407 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12335	MAETFKFVYIVILLVSLCLVVVDGIRTYRECENASDCYSIYWRAPYGTMRCVKGHCKQIKDVKVMKFLYCV	71	Sequence 408 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12336	MTHISMFVYSLIIFLSIYLVVTDGIILCKDHFDCYENIRKLRCDFDTEKPFCISLNVCQCIKQ	63	Sequence 409 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12337	MAEFVKFVYVMIIFIFLCLVVENIDGFRCLRNLDCPDSMCSSAYTPRCRHRTCVCLNNDEIKIL	64	Sequence 410 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12338	MKMEENRAKTFKFVYGMVIFLYLYHVAKRVEAAIPCITDANCPCVFPLKPRCNFGYCICEEMIP	64	Sequence 411 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12339	MAEIVKFIYVMIIFLYLFLVSTNIEARQGCKIDYDCIKVVCKDGHAARCIMRRCECVEILNPIDLGST	68	Sequence 412 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12340	MAKIVKFVYVTIIFLYMFHISTNIEAGNYKCQTNYDCLRMWCPIGISPRCIKRRCKCIETLVQ	63	Sequence 413 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12341	MAGTLNFVYAMILFISLFLVAGGEEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVRLEPPYDMSISPKSVHK	75	Sequence 414 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12342	MVKIAKFLYVLIISLSLFLFAITVDGAYVTRFWCYRDLDCRKDMCKPPFNPRCHNHICICRLWGL	65	Sequence 415 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12343	MAKTIKFVNLLILFIFTFLVVADASATTRCVRNSDCRHHICMYPLVPRCKYPLCRCV	57	Sequence 416 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12344	MVKIIKYVNLLILFISIFLVVTDVSAHKRCRVDFDCRMRMCVYPTVSVCIDRLCRCRRPPNM	62	Sequence 417 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12345	MVKIIKYVNLLILFISIFLVVTDVSAQKRCKEDFDCRIRSCAYPLIPVCIDPFCRCRRASI	61	Sequence 418 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12346	MGKIIKFVNLSILFIFMFLVVVDVNAERTCKEDFDCRMRYCVYPTIPLCDVKHCRCRRPPNL	62	Sequence 419 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12347	MAKVLKLVNVMIIFLALVLVAMNVNADVINCTQDSDCQSIGCLSHLKPKCTMLGFFFNAFVGICECDQVM	70	Sequence 420 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12348	MAKILMFVYALIIFISLVITGRSTINVMCYYDHDCPFVLDHIAECKGGVCEYTAFFYE	58	Sequence 421 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12349	MQRKKLMAQIHLCVYALIIFLSPFLALTNDRIVYHGCYSDDQCPNECPAILMRCIHSLCVEFIKTDPLFI	70	Sequence 422 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12350	MQRMEHTTKIQFCVYVLIIFLSLFLVVTNGDKPRYTPRNAVKIAECVSYTDCQGGCPACYMRCIDGQCEPFIIKFI	76	Sequence 423 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12351	MQRMEHMTKIQFGVYVLIIFLSLFLVKVYECYNYIDCPVGCRACYMRCIDGQCIPFIKKLILFHLYVIVE	70	Sequence 424 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12352	MAQILMFIYDLIIFLSIFIIVTNGGLIPCVSDADCPEELALVMKCINKLCELVME	55	Sequence 425 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12353	MIKDVKFVYVMIIFLSLFLVAMSIDDSHCPHDICPFHLKPKCIFTKVVGQKFFSFSLDGKCGCM	64	Sequence 426 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12354	MAEILKFVYIIIIFLFITEIKGDKFVFDKNGADRCRSILDCPQDKCFPLLTLVCVNFACDCLHV	64	Sequence 427 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12355	MNKTLKFVYVLILFISLSIVSKSVAQYNIGCKTDDDCQKYYTKMFGMKCFKSWCITGILD	60	Sequence 428 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12356	MTKTLGIVYAIILFISLFLVLQNTEFEDYYYIECQRDFDCPQLNSEIFAFKCIEKLCKLEFIYQQAPFLLGQV	73	Sequence 429 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12357	MAHLKFVYVMILFLFLFLITKNIEAYKCNIDVDCPITPSPKFKWKCINKRCLYIRFDEIWTSDPRE	66	Sequence 430 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12358	MAKTLKFSYPMILFIFLFLVAYKIEALTKCETDANCPEISIFSPFFYKCINNGCVLIML	59	Sequence 431 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12359	MTKTLKFVYSIILFITLFLVAKNVDALKKCITFEDCPISKTRVYKCLHGECRYTIPYIPKVPKVK	65	Sequence 432 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12360	MSQILTFVYAMILFISIFLVAAEVDWIYHLCDTDTDCPEHWSKFFIYKCVNHVCDSISKVTTDSKEYKNFP	71	Sequence 433 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12361	MAKLLTFVYVMIYFLSLFLVTKGAHVECHNDSACEKTVKCMLPRIPRCIKYQCLCGYSDDPGNRWSTRPKRIQKGSTERKGFLY	84	Sequence 434 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12362	MDKTLKYMYTLISFISLFFIAKNDAVYIKCKTDADCPKSESTIFAMKCNNYRCIYDYIHKRNSYAT	66	Sequence 435 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12363	MPSFLKFVYAIILFVSLFLAATNVNATYDAYDECQTELDCPKNIDCVYPKSMKCIDKKCICVGARMIIPRVL	72	Sequence 436 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12364	MVAILKFIYSILLFIFLHLVSTNGYRNIKYCFIDTDCPRSMCHYPEIVRCVDQCKCVRIMP	61	Sequence 437 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12365	MTEILKLFYAMILFASLFLVAMEIGESFGCTEHRHCEIAMCKFPFIVRCSMNECNCERVHYLI	63	Sequence 438 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12366	MTIKTLKFVYVIILFFSLFLVAKNEPEPKFIECVTDADCLNSQSKMYALICEKNRCIYEFLKSMHYNLS	69	Sequence 439 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12367	MQNAKNMTEILKFVYVMFLFISMFIVTTEVGGECINDIDCPQTGNLFYVFICKNRICELINKYPQNL	67	Sequence 440 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12368	MVQLLKFVYAMILFISIVFLIRTQLSDIYEECETDDYCPKYRDLLYVFKCIDKRCELVEAHA	62	Sequence 441 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12369	MNKILKFVYEMILFLSLFHLAREVHDVAHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	67	Sequence 442 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12370	MVEIHKFVFAMIQFISLFLITIEVGRLRYGCETDADCPRYTHNNFSLKCINKKCEWSAKLH	61	Sequence 444 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12371	MAEIIKFVYVMILFLFLFLVAAEDIGGNCECIRDEDCFKQKRDEDCHKEYCMIFYVHKCENYKCVCAGMFN	71	Sequence 445 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12372	MTTILKFAYIMITCLFLLHIAAQEVLQYELFDCNEDRDCDNVICVAGGIPKCITPFCFCF	60	Sequence 446 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12373	MQRVKNMAETLKFVYVLILFISIFLVVIGCDSIYYPISRPCKTDKDCPNRKNYKGKCRKGFCMSSRLR	68	Sequence 447 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12374	MAETLKIVYIVILLVSLCLVVVDGISIYVRCASTNECYTTFKFAPLGSMRCVEGYCKHLKDFKVKTPLQIKEITPLLLHFP	81	Sequence 448 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12375	MAKTLKFVYVMILFTSLFLFAKNVVGYINCKTDDDCPKLESRMVVLKCTNSRCAAVILH	59	Sequence 449 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12376	MQMGESMAKIVKFVYFVIIFASPFVVANHEISGWITELPFGMCTSILDCPMDSCTHPQQPWCELHGVPILYHGSEIGLCICI	82	Sequence 450 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12377	MQRGESMGKIVKFVYFMIIFISPFVVANHAISGLLPKLPFGCCTSNLDCPRHMCTHPQQPWCIFYGNRIMYRGSRLGICKCS	82	Sequence 451 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12378	MQTGESMTKIIKFVYFMTIFISPFVVASLHEISGYVLGLPAGYCTSNHHCPVYNCTHPKQPWCKLVRLQLLFHGSLIGLCDCI	83	Sequence 452 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12379	MAEIVKFVYVMIIFLSLFLVSIHINALNECTQDYDCPIEMCPFPFQPKCIMLKNLSIFSNSGICSCT	67	Sequence 453 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12380	MGTIHKFLYAMILFIHITLVVSGNFFEFFHKCTQDSDCPSLLCRNKSELPKCIAGFMCRCPNV	63	Sequence 454 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12381	MADVLKFVYIVFLFVSQFCAEPDDNQKNCVSDSDCYKKFHLPRHFIMKCIKNRCTFV	57	Sequence 455 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12382	MIIFLFIFFVAMLVKVSHSHCVIDAHCPRNMCGFHFPPRCVEGDCVC	47	Sequence 456 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12383	MTKTFKFVIATILFLTLFFIVKNVDAQVKCKTVKDCPIRRNRKYYCLFGICKYDVM	56	Sequence 457 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12384	MSEIIKFVYAMFIFIFMFTVATETDALCDSNRDCRGYHCNWPKFPICVRMICECI	55	Sequence 458 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12385	MTIIIKFVYIMILLFFPFLVVSQIFPKWCLYDKDCPQNMCRPGRIPKCIFGHCNCVKQRS	60	Sequence 459 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12386	MIKFLKFVYGMIILISLFFAVRDVSAAPPVYCIEDEDCYDLCTSPLVEICTNYQCICLKRF	61	Sequence 460 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12387	MVELVKFVYVMITLLSIVVVAKNSQGNKENICFKDADCPQDICSYPFKPKCNIYGYCSC	59	Sequence 461 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12388	MAGNLKIVYALMILVSLILVVTSHSFLPCVTKDDCAYDECISPRKPTCYLETCHCL	56	Sequence 462 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12389	MAEIGKYIYVIIIFISLFFITMSVEGWRCKKTDDCIKIEFCKFPKIARCTKPKFLFLEFGTGFCTCDD	68	Sequence 463 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12390	AFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP	47	Sequence 464 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12391	AFETTEPMLTTYLILCVSEADCPKVVKPNYTMCAGGICWQSVQGSNQGP	49	Sequence 465 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12392	ALERTRTTMLTSYNIGCKSDADCPKAIEPHYTRCVDGHCWLYFGEGPKLHN	51	Sequence 466 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12393	WFKRTETGEIIWVVRCVTDTDCPKMGEPQYFKCLNGVCLEHIRELP	46	Sequence 467 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12394	ALERTETTMHNVQPSHFIPCFTAADCPMIDEPHYIECVTGFCWALMRNLH	50	Sequence 468 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12395	KKTDIPCDSRNDCPQQILPRYVLCVNGLCRIYFP	34	Sequence 469 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12396	AYERTEPIMHNGEPINLIPCVTVADCPRMDEPLHMTCLVGACWPCIRSLY	50	Sequence 470 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12397	VFKRTETGEIIWTLPCATDTDCPKMGEPMYFKCLNGFCLEHIRELHD	47	Sequence 471 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12398	QECKDDGDCPTNMCLPSLVSKCINFICECTHSMSTD	36	Sequence 472 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12399	RSFPSSFVSPKSYTSEIPCKATRDCPYELYYETKCVDSLCTYW	43	Sequence 473 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12400	KQTNIPCKSAEDCPKPIYPRYVLCSYGFCRIFFP	34	Sequence 474 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12401	AMFELTKSTIRCVTDADCPNVVKPLKPKCVDGFCEYT	37	Sequence 475 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12402	REPTKIPCVSDSDCHKVKKPLLLTCIDGICQYTLEATPFD	40	Sequence 476 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12403	RKGGPPGGRTYIPCISDDDCIVAQPPYVLLCVNNFCTYFKDDDLPQR	47	Sequence 477 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12404	AQIYITFFTIFSIFVFYTTFYHLTLTTFFSFHNAGYLPCSSDDDCPKEMKPVVVKCIHNFCEHFMVGEYEGP	72	Sequence 478 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12405	FFCGLAETKRTNIPCFSDDDCPKTCPPLVFEVR	33	Sequence 479 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12406	EKTHVRCITADDCPKVERPLKMKCIGNYCHYFLNNF	36	Sequence 480 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12407	YYPCNTDSDCPQNMCPPDMEPRCWTGYCSSCYIRWGK	37	Sequence 481 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12408	LTVPCENPTTCPEDFCTPPMITRCINFICLCDGPEYAEPEYDGPVEEYDHKGDFLSVKPKVINENMMMRERHMIKEIEV	79	Sequence 482 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12409	AFVPNSGPCTTDKDCKQVKGYIARCRKGYCMQSVKRTW	38	Sequence 483 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12410	RVCKSDKDCKDIIIYRYILKCRNGECVKIKI	31	Sequence 484 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12411	INKCSQDSHCPKDMCKKPSKPRCVVSPKLPLSSKSGVCTCV	41	Sequence 485 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12412	IRDKCFRPSDCPPSMYCDAGFQIGCVRKICTCLRILAPIDFVPT	44	Sequence 486 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12413	AYIIECQTDDDCPKSQLEMFAWKCVKNGCHLFGMYEDDDDP	41	Sequence 487 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12414	DDVVFQYVFDGCRIDADCPISGLQLLKWMCINNECEFNHVRPRYV	45	Sequence 488 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12415	LYIIECKTDADCPISKLNMYNWRCIKSSCHLYKVIQFMV	39	Sequence 489 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12416	KFTRCFRDSDCPKTLCHSPGKAKCMHHSICKCIFFGYNI	39	Sequence 490 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12417	YTDECSTDADCEYILCLFPIIKRCIHNHCKCVPMGSIEPMSTIPNGVHKFHIINN	55	Sequence 491 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12418	ELIKCTMDADCPTSLNRKWLCINNICRKMCVTNV	34	Sequence 492 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12419	AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR	36	Sequence 493 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12420	QIRCNDAFECRRSAICNFPNKWKCNDHKCECV	32	Sequence 494 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12421	FPDKIFIGDCKTDKDCKPKRGVNFRCRKGKCYPR	34	Sequence 495 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12422	AFVANTETCITDKDCPNGRNYIGRCRKGHCQQRLVR	36	Sequence 496 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12423	IHDQVYFNNNSPPCVTDKDCPRPQFRKSNVRCRNGHCVNLGN	42	Sequence 497 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12424	SFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI	35	Sequence 498 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12425	YFNDPRPCVSDKDCPRPKFQKSNVRCRKGYCVNLDG	36	Sequence 499 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12426	NNSPPCVTDKDCPRPQFRKSNVRCRNGYCVNLGN	34	Sequence 500 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12427	SNYSPTPFPCLTDKDCTRRKGFSVTCRKGFCVEFKHF	37	Sequence 501 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12428	TTPTPCRTDQDCPRKKKFSVTCRKGFCAEIRHVY	34	Sequence 502 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12429	VTSPWVLKQHCVTDKDCPQMGKIKIRCRNGECVQGF	36	Sequence 503 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12430	QIIFSECKTDKDCPKYQRANIRCRKGQCVRI	31	Sequence 504 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12431	TYLPTTRICITDKDCPSVKNYIGRCRKGYCQASKLR	36	Sequence 505 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12432	NSSFSHFFEGACKSDKDCPKLHRSNVRCRKGQCVQI	36	Sequence 506 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12433	AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR	36	Sequence 507 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12434	FIFLPCITDKDCQTLKKNKGKGRCRKGFCVDGLIG	35	Sequence 508 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12435	KTFDRACKTDKDCPKLRGVNVRCRKDQCVTV	31	Sequence 509 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12436	SFFPSSPVCKTDKDCPQLRGYTARCRKTQCLLIPRG	36	Sequence 510 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12437	HFHVSRPCMTDDDCAPEKYYNIRCRKGFCVQIRKY	35	Sequence 511 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12438	AYFPNSRPCKTDKNCAQVKNYISKCLKGLCVQEE	34	Sequence 512 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12439	AYLPLSRSCITDKDCSRVKNYNARCRKGYCQYLQY	35	Sequence 513 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12440	EEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR	41	Sequence 514 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12441	NPYIINIVCKTDKDCPKVQGANIKCRSGKCVQA	33	Sequence 515 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12442	KRIPCKDNNDCNNNWQLLACRFEREVPRCINSICKCMPM	39	Sequence 516 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12443	MLVTCEDHFDCRQNVQQVGCSFREIPQCINSICKCMKG	38	Sequence 517 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12444	VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR	43	Sequence 518 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12445	VFVSCNSHIHCRVNNHKIGCNIPEQYLLCVNLFCLWLDY	39	Sequence 519 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12446	RPVSCKDHYDCRRKVKIVGCIFPQEKPMCINSMCTCIREIVP	42	Sequence 520 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12447	GLFRCKVDIDCPQILCFDEQIAKCIARMCECDYE	34	Sequence 521 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12448	DFPCKTKDDCAQQIDYIAECIIGFCRYFTPFEHPF	35	Sequence 522 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12449	RNKTCNYSSECLFHNCPLGWVMKCFTYFCACSRL	34	Sequence 523 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12450	DFPCKTKVDCPQHKKYIAECIFGFCRHFKPLEHPF	35	Sequence 524 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12451	VKIPCVKDTDCPTLPCPLYSKCVDGFCKMLSI	32	Sequence 525 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12452	IPCKTKVDCPQQIYYVVECLDGFCDYWRD	29	Sequence 526 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12453	PRIKCNTEADCPQRFDNIVECLFGICHFYIK	31	Sequence 527 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12454	DLSPCLRSGDCSKDECPSHLVPKCIGLTCYCI	32	Sequence 528 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12455	DRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	34	Sequence 529 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12456	KQTNIPCENKRDCPQPLYPKFVTCFEGLCRMHYPLKKI	38	Sequence 530 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12457	IKIFTEHRCRTDADCPARELPEYLKCQGGMCRLLIKKD	38	Sequence 531 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12458	QITKLPCVTVDDCPKVEKPIPMVAKCFGKRFSRHCHYFYF	40	Sequence 532 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12459	SIKTKIACVTDNDCPRAIKPVVMWCINNYCHYYLYGYQ	38	Sequence 533 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12460	SIPCKTRTQCPEKMCRLPKFVWCIDGSCVCA	31	Sequence 534 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12461	AQFLCSDDSDCPRDLCVRNSLTLRCVNYICQCR	33	Sequence 535 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12462	EKLDIRCATVDDCPKVTKPVVMMCTGKFCHYFFVRKQIL	39	Sequence 536 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12463	ELEIRCVSDADCPLFPLPLHNRCIDDVCHLFTS	33	Sequence 537 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12464	DRIPCATDADGPPKILPIIHKCINNFCKLKLYN	33	Sequence 538 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12465	DRIPCVTNGDCPVMRLPLYMRCITYSCELFFDGPNLCAVERI	42	Sequence 539 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12466	SIHCVSVDDCPKVEKPITMKCINNYCKYFVDHKL	34	Sequence 540 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12467	NMVVLGCVSDDDCPKVPLPRFLKCIANLCCLVRKKDL	37	Sequence 541 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12468	AFVKCETDDDCPKYNGFRKYECVNNWCRLTGLH	33	Sequence 542 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12469	VLIDCKTVKDCPTSYTKIYRCKDNKCRFSFVIGL	34	Sequence 543 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12470	HFGCETDADCPRSTDKNFFLRCINKKCEWAAKRH	34	Sequence 544 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12471	DILCKVHEDCPQKSTHKYYCIDDECFLYYWEAP	33	Sequence 545 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12472	YIACQSEIDCPPNYSFLFAIRCIKQKCVTVGRYL	34	Sequence 546 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12473	FATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV	42	Sequence 547 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12474	FFVDIMCKVHEDCPQKSTHKYYCVDDKCFLYYWEGKP	37	Sequence 548 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12475	YVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	34	Sequence 549 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12476	DIVCITDNDCPPNTLVQGYRCIDGKCESVFLSYR	34	Sequence 550 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12477	IDIFVCQTDADCPKSELSMYTWKCIDNECNLFKVMQQMV	39	Sequence 551 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12478	AELGGPCRSDEECPQLSLRFFAIKCRENVCIYVDLDPYKPRAEKNQFLH	49	Sequence 552 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12479	SDDECKIDGDCPISWQKFHTYKCINQKCKWVLRFHEY	37	Sequence 553 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12480	KLTGCEVDGDCPKVFKLKVMILFIKCINNKCVRGLLSQTGTQCPDFFFLKRTLPRFYF	58	Sequence 554 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12481	QNLMKCNTDDECPKFDDKFPLSFKCINDGCRMVINDKYKHKTVQKLL	47	Sequence 555 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12482	YYYKCFKDSDCVKLLCRIPLRPKCMYRHICKCKVVLTQNNYVLT	44	Sequence 556 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12483	FQPCVTTADCMKTLKTDENIWYECINDFCIPFPIPKGRK	39	Sequence 557 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12484	ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD	33	Sequence 558 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12485	DDVKIKCVVAANCPDLMYPLVYKCLNGICVQFTLTFPFV	39	Sequence 559 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12486	NIHKIGCKTSEDCPYLGKCIEDFCQFKK	28	Sequence 560 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12487	AERIYRCLDHSHCPTFMCSPGLKPKCMNPKVCKCVPVQSRKYYALT	46	Sequence 561 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12488	IDPPHHITNHEIPCKYNHDCPTILDYISICPYHYCEFWRTY	41	Sequence 562 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12489	LYIGCETDRDYPPLANKTFYLKCIDKKCEWTVTDSLSTRSGRMQKLSI	48	Sequence 563 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12490	KKIYCENAASCPRLMYPLVYKCLDNKCVKFMMKSRFV	37	Sequence 564 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12491	IIRCFHDADCVHKICHPPQIRKCVSKICKCRLMITQKDYVLT	42	Sequence 565 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12492	KPFLTRPYPCNTGSDCPQNMCPPGYKPGCEDGYCNHCYKRW	41	Sequence 566 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12493	EPGGHRCSTDSFCPPNMCPPGMTPKCVRFRCKCVPIGWKNLSHVLA	46	Sequence 567 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12494	EQYCVDDADCQKLYPFHRQLSLKCIRAFCVKLVGQANDDLFPSTVHAADATGLGIDAK	58	Sequence 568 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12495	QCIYPACFKDHMCRQLKCSPGRTPKCVNYQCRCSPQALGSYHLLT	45	Sequence 569 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12496	ALIECQIDDDCPPIKFAKYLCINYKCRKICLGE	33	Sequence 570 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12497	EEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVKLEPPYDMSITPNSVHK	52	Sequence 571 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12498	KHDYHMFFQRIPCPKDKILDCNLLECWCK	29	Sequence 572 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12499	RIPCVSRNDCPKRPYPLFMKCIDNFCEIWKIGKE	34	Sequence 573 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12500	IYITFKKFIIDFIHNVYHPSITSNFSLFNNAGDIPNNSNRNSPKEDVFCNSNDDCPTILYYVSKCVYNFCEYW	73	Sequence 574 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12501	KTICIGDSDCRNERCMPGIKPVCSEGWCDCIGFIP	35	Sequence 575 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12502	YVWCETVEDCFKSQYFIFDCINNQCINVGKNPKEPRYPGIPRDQ	44	Sequence 576 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12503	REKVNCLDDADCLEVSCLNGSNAECVGNSCVCVFVFYRENFDEQFRR	47	Sequence 577 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12504	SVPCLTSFGCPRSTCYPPSTPNCILRICECI	31	Sequence 578 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12505	EEWNSHSWNSEFYLKKSCSSDFDCPRTMCIKLSLARCFNDFCHCY	45	Sequence 579 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12506	QTEPPGPLIPCEFDYDCPLIDCIRTSDSRCINGNCHCRE	39	Sequence 580 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12507	RIMVVNPNNPCVTDADCQRYRHKLATRMVCNIGFCLMDFTHDPYAPSLP	49	Sequence 581 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12508	QMINFRGCKRDKDCPQFRGVNIRCRSGFCTPIDS	34	Sequence 582 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12509	KRNYQCDPCFGHPDDMINFCPPGTAPKCFHGLIKCVPIMRGTNRMFA	47	Sequence 583 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12510	LFECNRDFVCGNDDECVYPYAVQCIHRYCKCLKSRN	36	Sequence 584 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12511	TRCNRDEDCPFICTGPQIPKCVSHICFCLSSGKEAY	36	Sequence 585 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12512	IPCNDDVDCPQTLCEQLIADFKYMIDFKSECVSRMCACTGSPV	43	Sequence 586 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12513	AVHKECKTDVDCRQIWFVTKCINHECQPIL	30	Sequence 587 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12514	HACTVNADCEQSMCDPFCVGGYHFTPICVIGWCVCVGNRVAPVL	44	Sequence 588 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12515	HIPCVHHDDCPKRPYPRFMKCVDNFCETWIIGWE	34	Sequence 589 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12516	NIPCNSDSDCPWKIYYTYRCNDGFCVYKSIDPSTIPQYMTDLIFPR	46	Sequence 590 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12517	RQTDIPCKSDDACPRVSSHHIECVKGFCTYWKLD	34	Sequence 591 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12518	EMTTTTIPCTFIDDCPKMPLVVKCIDNFCNYFEIK	35	Sequence 592 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12519	YHLCKTRFDCPRTYLLFFPRMWKCINRRCRYVYFFE	36	Sequence 593 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12520	GMRCNHVSDCPKDTFCWLDSHMQCIKHQCKCVRIFEPIDPA	41	Sequence 594 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12521	YIVCITDNDCPENTEVRQYECIEGRCRLSRVLNP	34	Sequence 595 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12522	GIRCRNVYDCPKATYCRAGSHRVQCIKHQCKCVRIFESIDPA	42	Sequence 596 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12523	CEDDSDCPQIFNFHPFICKCINNECEKVILQKGYMSMKPKILHKRYTRKNEFLH	54	Sequence 597 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12524	SDECVKVSDCSPTKYCLPGRRMICSKGKCKCLRNMFIPIPE	41	Sequence 598 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12525	YVVCRTVDDCPPDTRDLRYRCLNGKCKSYRLSYG	34	Sequence 599 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12526	MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK	35	Sequence 600 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12527	NIRCVSDDDCPKVIKPLVMKCIGNYCYFFMIYEGP	35	Sequence 601 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12528	LVIIDHHKPCVSDTDCAFYLDIPPTVKYCSDGLCAWYFPDNPLP	44	Sequence 602 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12529	PCISDDDCPEALSPQFPKCIHNVCVYFVEE	30	Sequence 605 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12530	SYIPISHPCTTVKDCPEVKNYKSRCLKGLCISGRLR	36	Sequence 606 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12531	AYIECEVDDDCPKPMKNSHPDTYYKCVKHRCQWAWK	36	Sequence 607 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12532	EADTSCHSFDDCPWVAHHYRECIEGLCAYRILY	33	Sequence 608 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12533	LETIECETDGDCPRSMIKMWNKNYRHKCIDGKCEWIKKLP	40	Sequence 609 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12534	IYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR	36	Sequence 610 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12535	YIPGIVNKPCKTDKDCPKKPPHNIRCRKGQCVEIL	35	Sequence 611 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12536	KIRCVTDDDCPKVEKPLHMYCGNHWCAYKLHFV	33	Sequence 612 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12537	IPCATSDDCLKNMCRPPLTPRCIEHNCKCK	30	Sequence 613 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12538	KEDDIECVTDADCYEKLPALQRAVMKCIQGFCKIHI	36	Sequence 615 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12539	NSIPCTTHAQCPGDMCELPQIVWCVVGFCECA	32	Sequence 616 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12540	YRSCKTDDDCPDYLCTSPKIGKCMDNDCYCI	31	Sequence 617 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12541	FPWKLYPCVTDKDCPRKNRHVVKCRKGYCVGVQII	35	Sequence 618 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12542	NMVICTQDFDCQTKICPFDLQPKCTILFEFLLSLCGCV	38	Sequence 619 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12543	LAGCITDADCVIKKCSSSCRIKCIDFRCLCPTGF	34	Sequence 620 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12544	SLPDAPPCLFTPECPPDMCPTDLTLKCINLSCQCTIEYDIDPDVVPS	47	Sequence 621 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12545	AILECREDSHCVTKIKCVLPRKPECRNNACTCYKGGFSFHH	41	Sequence 622 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12546	NRFLYRIGCDTSNDCPSYMCPPPLSPRCTKFYCKCI	36	Sequence 623 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12547	EQCVYDADCEKIYPLHRQHLFKCIKAFCVRSS	32	Sequence 624 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12548	DAPPCLFTPECPPDMCPTDLTLKCINLTCQCTSEYDID	38	Sequence 625 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12549	KDDCLVDADCVTLVCEFDERPQCVINTCRCRPLRFSGFYYEQLH	44	Sequence 626 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12550	FEECKEDADCHPVCSVPGCSNICTLPDVPTCIDNNCFCI	39	Sequence 627 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12551	LKIFCIDVADCPKDLYPLLYKCIYNKCIVFTRIPFPFDWI	40	Sequence 628 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12552	CNPCLVTCPDDLLNRCPPGMEPICEYGVIKCYPIGKETNRVLT	43	Sequence 629 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12553	IPDVLPCLFSNECPPDLCPTDLFAKCINLTCQCTAEYDLD	40	Sequence 630 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12554	YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT	41	Sequence 631 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12555	EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK	38	Sequence 632 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12556	NSAFSHFIPGCKTDKDCPKFYGSNVRCRKGKCVQLG	36	Sequence 633 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12557	SEFIFTKKLTSCDSSKDCRSFLCYSPKFPVCKRGICECI	39	Sequence 634 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12558	TFCHDDSHCVTKIKCVLPRTPQCRNEACGCYHSNKFR	37	Sequence 635 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12559	VKSLLLIKVRSFIPCQRSDDCPRNLCVDQIIPTCVWAKCKCKNYND	46	Sequence 636 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12560	NIISCTQDFDCQTKICPFHLKPKCIVLEILPHSLSGGICGCD	42	Sequence 637 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12561	EHIQCVIDDDCPKSLNKLLIIKCINHVCQYVGNLPDFASQIPKSTKMPYKGE	52	Sequence 638 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12562	IHIGCDKDRDCPKQMCHLNQTPKCLKNICKCV	32	Sequence 639 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12563	YNSDCQSYPCDLGESRNCTLNRCICVYNI	29	Sequence 640 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12564	ERECDTDADCQKKFPGSNQHLLWCNNGFCDCRTH	34	Sequence 641 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12565	TFIHFSIPCITDKDCSILQNYKARCRKGYCLRRKIR	36	Sequence 642 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12566	HQSIDDVIPCVLNTDCPRDMCPIHLFPKCINLLCRCSYWEDN	42	Sequence 643 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12567	KNIDGRVSYNSFIALPVCQTAADCPEGTRGRTYKCINNKCRYPKLLKPIQ	50	Sequence 644 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12568	IPCFGTKDKCPFNLYYKVECIDGFCYYPV	29	Sequence 645 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12569	ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR	42	Sequence 646 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12570	FNSKIVFTDCKTDKDCQNHRGFNFRCRKGNCVAKIR	36	Sequence 647 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12571	VIDINAFSFPCKTNSDCPSYLCHYPKNPECVERECICW	38	Sequence 648 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12572	SIPCETTADCPVAVPPEYYKCMYKVCVLIR	30	Sequence 649 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12573	IPCLSDDECPEMSHYSFKCNNKICEYDLGEMSDDDYYLEMSRE	43	Sequence 650 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP09788	LPFNLAKPELYIFVQ	15	Sequence 11 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09789	GRFLIRVTSSPLGPD	15	Sequence 12 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09790	TGSGLYLHQMVYLYQ	15	Sequence 13 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09791	FLIDSPLASIGPTSM	15	Sequence 14 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09792	FMIDSPLASIGPTSM	15	Sequence 15 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09793	FLSDPPAPPTSPGVV	15	Sequence 16 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09794	VLAWFSPLTLESSRL	15	Sequence 17 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09795	VIDLSGTRKSSSGTM	15	Sequence 18 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09796	VRKTTSHPPSYALLH	15	Sequence 19 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09797	TPPYRAALATPVLLL	15	Sequence 20 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09798	LSAPSPMFLPPVNPH	15	Sequence 21 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09799	HRPVKTPANAPTTMM	15	Sequence 22 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09800	CFNDPLDIVPPMLLL	15	Sequence 23 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09801	AHAPCSLFFPLSLRP	15	Sequence 24 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09802	KALYALHVPSMQVFA	15	Sequence 25 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09803	RPSRWPWQEPLPISI	15	Sequence 26 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09804	KVQIIPKDTLAPLPP	15	Sequence 27 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09805	RRRQRRKKR	9	Sequence 2 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09806	RKKRRQRRRGKKKKKKKKKKKKKKKKKKKKGRKKRRQRRR	40	Sequence 3 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09807	RRRQRRKKRGKKKKKKKKKKKKKKKKKKKKGRRRQRRKKR	40	Sequence 4 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09808	RKKRRQRRRGKKKKKKKKKKKKKKKGRKKRRQRRR	35	Sequence 5 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09809	SSRASHFQSHSSERQRHGSSQVWKHGSYGPAEYDYGHTGYGPSGGSRKSISNSHLSWSTDSTANKQLSRH	70	Sequence 2 from Patent US 20110015118	Homo sapiens	Antimicrobial	US 2011/0015118 A1	Patent Application	2011##1##20	DE102007059891A1, EP2217262A2, WO2009074133A2, WO2009074133A3	C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof.	The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.
DRAMP09810	SSRASHFQSHSSERQRHGSSQVWKHGSYGPAEYDYGHTGYGPSGGSRKSISNSHL	55	Sequence 3 from Patent US 20110015118	Homo sapiens	Antimicrobial	US 2011/0015118 A1	Patent Application	2011##1##20	DE102007059891A1, EP2217262A2, WO2009074133A2, WO2009074133A3	C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof.	The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.
DRAMP09811	KWKSFLKTFSKAKKKVLKTALKAISK	26	Sequence 63 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09812	KWKSFLKTFSKLKKKKLKTLLKLISK	26	Sequence 64 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09813	KWKSFLKTFSKLKKKKLKTLLKAISK	26	Sequence 65 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09814	KWKSFLKTFSKAKKKKLKTLLKAISK	26	Sequence 66 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09815	KLKSLLKTLSKAKKKLLKTALKALSK	26	Sequence 67 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09816	KLKSLLKTLSKAKKKKLKTLLKALSK	26	Sequence 68 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09817	SWSSFLSTFSKAKKKALKTLLSAISS	26	Sequence 69 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09818	SWSSFLKTFSKAKKKALKTLLSAISS	26	Sequence 70 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09819	SWSSFLKTFSKAKKKALKTLLKAISS	26	Sequence 71 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09820	SWKSFLKTFSKAKKKALKTLLKAISS	26	Sequence 72 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09821	SWKSFLKTFSKAKKKALKTLLKAISK	26	Sequence 73 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09822	KWKSFLKTFSKAKKKALKTLLKAISK	26	Sequence 74 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09823	KLKSLLKTLSKLKKKKLKTLLKALSK	26	Sequence 75 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09824	KLKSLLKTLSKLKKKKLKTLLKLLSK	26	Sequence 76 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09825	KXKSXLKTXSKXKKKXLKTXLKXXSK	26	Sequence 77 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09826	XWXSFLXTFSKXKKKXLKTLLXXXSX	26	Sequence 78 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09827	GIINTLQKYYXRVRGGRXXVLSALPKEEQIGKXSTRGRKXXRRXX	45	Sequence 2 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09828	GIINTLQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRR	43	Sequence 3 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09829	KYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	38	Sequence 4 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09830	YXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	36	Sequence 5 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09831	LQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	40	Sequence 6 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09832	RXAVLSXLPKEEQIGKXSTRGRKXXRRXX	29	Sequence 7 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09833	KEEQIGKXSTRGRKXXRRXX	20	Sequence 8 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09834	KXSTRGRKXXRRXX	14	Sequence 9 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09835	GIINTLQKYYWRVRGGRWAVLSWLPKEEQIGKWSTRGRKWWRRXX	45	Sequence 12 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09836	GIINTLQKYYFRVRGGRFAVLSFLPKEEQIGKFSTRGRKFFRRXX	45	Sequence 13 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09837	GIINTLQKYYYRVRGGRYAVLSYLPKEEQIGKYSTRGRKYYRRXX	45	Sequence 14 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09838	GIINTLQKYYSRVRGGRSAVLSSLPKEEQIGKSSTRGRKSSRRXX	45	Sequence 15 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09839	GIINTLQKYYARVRGGRAAVLSALPKEEQIGKASTRGRKAARRXX	45	Sequence 16 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09840	RGRKXXRRXX	10	Sequence 25 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09841	RGRKWWRRXX	10	Sequence 26 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09842	RGRKFFRRXX	10	Sequence 27 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09843	RGRKYYRRXX	10	Sequence 28 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09844	RGRKLLRRXX	10	Sequence 29 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09845	RGRKIIRRXX	10	Sequence 30 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09846	RGRKHHRRXX	10	Sequence 31 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09847	RGRKVVRRXX	10	Sequence 33 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09848	RGRKCCRRXX	10	Sequence 34 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09849	RGRKXXRR	8	Sequence 36 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09850	RGRKWWRR	8	Sequence 37 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09851	RGRKFFRR	8	Sequence 38 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09852	RGRKYYRR	8	Sequence 39 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09853	RGRKLLRR	8	Sequence 40 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09854	RGRKIIRR	8	Sequence 41 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09855	RGRKHHRR	8	Sequence 42 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09856	RGRKVVRR	8	Sequence 44 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09857	RGRKVVRRVV	10	Sequence 46 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09858	RGRKYYRRYY	10	Sequence 47 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09859	RGRKWWRRWW	10	Sequence 48 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09860	RVRKVVRR	8	Sequence 49 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09861	RRRKVVRR	8	Sequence 50 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09862	RDRKVVRR	8	Sequence 51 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09863	RGRKEERR	8	Sequence 52 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09864	RGRKKKRR	8	Sequence 53 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09865	RRRRRRRRRR	10	Sequence 54 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09866	VVVV	4	Sequence 55 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09867	YYYY	4	Sequence 56 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09868	RRVVKRGR	8	Sequence 57 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09869	RRVVKRGRK	9	Sequence 58 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09870	KKIRVRLSA	9	Sequence 1 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09871	RRIRVRLSA	9	Sequence 2 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09872	KRIRVRLSA	9	Sequence 3 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09873	RKIRVRLSA	9	Sequence 4 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09874	QKKIRVRLSA	10	Sequence 5 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09875	SDDPKESEGDLHCVCVKTTSLVRPRHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 1 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09876	SDDPKESEGDLHCVCVKTTSLVRPGHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 2 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09877	ALYKKFKKKLLKSLKRLG	18	Sequence 3 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09878	ARYKKFKKKLLKS	13	Sequence 4 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09879	KLYRKFKNKLLKLK	14	Sequence 5 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09880	ARYRKFKNKILKS	13	Sequence 6 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09881	ARYRKFRNKILRS	13	Sequence 7 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09882	KLYKKWKKKLLKLK	14	Sequence 8 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09883	ALYKKWKNKLLKS	13	Sequence 9 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09884	KLYKKWKNKLKRSLKRLG	18	Sequence 10 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09885	ALYKKLFKKLLKR	13	Sequence 11 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09886	GLYKRLFKKLLKS	13	Sequence 12 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09887	ALYKRLFKKLKKF	13	Sequence 13 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09888	ATKKNGRKLCLDLQAAL	17	Sequence 14 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09889	RFEKSKIK	8	Sequence 15 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09890	SAIHPSSILKLEVICIGVLQ	20	Sequence 16 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09891	YAERLCTCSIKAEV	14	Sequence 17 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09892	KFKHYFFWKYK	11	Sequence 18 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09893	KGYFYFLFKFK	11	Sequence 19 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09894	KWKWWWWWKWK	11	Sequence 20 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09895	PRIKKIVQKKLAG	13	Sequence 21 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09896	KWVREYINSLEMSKKGLAG	19	Sequence 22 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09897	EWVQKYVSDLELSAWKKILK	20	Sequence 23 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09898	SWVQEYVYDLEL	12	Sequence 24 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09899	ADSGEGDFLAEGGGVR	16	Sequence 25 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09900	ADSGEGDFLAEGGGVRKLIK	20	Sequence 26 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09901	EGVNDNEEGFFSA	13	Sequence 27 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09902	KFDKSKLKKTETQEKNPL	18	Sequence 28 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09903	ANLIATKKNGRKLCL	15	Sequence 29 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09904	IATKKNGRKLCLDLQAALYKKKIIKKLLES	30	Sequence 30 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09905	TNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	47	Sequence 31 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09906	NLIATKKNGRKLCLDLQAALYKKKIIKKLLES	32	Sequence 32 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09907	QAALYKKKIIKKLLES	16	Sequence 33 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09908	ALYKKFKKKLLKSLKRLGALYKKKL	25	Sequence 34 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09909	ALYKKFKKKLLKSLKRLGATKKNGRKLCLDLQAAL	35	Sequence 35 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09910	ATKKNGRKLCLDLQAALY	18	Sequence 36 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09911	CALYKKFKKKLLKSLKRLG	19	Sequence 37 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09912	ALYKKFKKKLLKCLKRLG	18	Sequence 38 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09913	ALYKKFKKKLLKSLKRLGC	19	Sequence 39 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09914	CALYKKFKKKLLKSLKRLGC	20	Sequence 40 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09915	ARYKKFKKKLLKSLKRLG	18	Sequence 41 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09916	ALYKKFKKKFLKSLKRLG	18	Sequence 42 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09917	ARYKKFKKKFLKSLKRLG	18	Sequence 43 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09918	GLRKLSKLLKKKFKKYLA	18	Sequence 44 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09919	LAAQLDLCLKRGNKKTA	17	Sequence 45 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09920	ALYKKFKKKLCLDLQAAL	18	Sequence 46 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09921	ATKKNGRKLCLKSLKRLG	18	Sequence 47 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09922	ATKKNGRKLCLDLQAALYKKK	21	Sequence 48 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09923	ATRRNGRRLCLDLQAALYRRR	21	Sequence 49 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09924	ATKKNGKKLCLDLQAALYKKK	21	Sequence 50 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09925	ATKKNGRKLCLELQAALYKKK	21	Sequence 51 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09926	ATEENGRELCLDLQAALYEEE	21	Sequence 52 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09927	ATKKNGRKLCLKLQAALYKKK	21	Sequence 53 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09928	ATKKNGEKLCLDLQAALYKKK	21	Sequence 54 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09929	ATKKNGGKLCLDLQAALYKKK	21	Sequence 55 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09930	ATKKNGRKLCLGLQAALYKKK	21	Sequence 56 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09931	ATKKNGRKLCLDLQAALFKKK	21	Sequence 57 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09932	ATKKNGRKLCLDLQAALWKKK	21	Sequence 58 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09933	KKKYLAAQLDLCLKRGNKKTA	21	Sequence 59 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09934	ATKKNGRKLCLDLQAALYKK	20	Sequence 60 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09935	ATRRNGRRLCLDLQAALYRR	20	Sequence 61 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09936	ATKKNGKKLCLDLQAALYKK	20	Sequence 62 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09937	ATKKNGRKLCLELQAALYKK	20	Sequence 63 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09938	ATEENGRELCLDLQAALYEE	20	Sequence 64 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09939	ATKKNGRKLCLKLQAALYKK	20	Sequence 65 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09940	ATKKNGEKLCLDLQAALYKK	20	Sequence 66 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09941	ATKKNGGKLCLDLQAALYKK	20	Sequence 67 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09942	ATKKNGRKLCLGLQAALYKK	20	Sequence 68 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09943	ATKKNGRKLCLDLQAALFKK	20	Sequence 69 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09944	ATKKNGRKLCLDLQAALWKK	20	Sequence 70 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09945	KKYLAAQLDLCLKRGNKKTA	20	Sequence 71 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09946	TKKNGRKLCLDLQAALYKKK	20	Sequence 72 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09947	TRRNGRRLCLDLQAALYRRR	20	Sequence 73 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09948	TKKNGKKLCLDLQAALYKKK	20	Sequence 74 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09949	TKKNGRKLCLELQAALYKKK	20	Sequence 75 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09950	TEENGRELCLDLQAALYEEE	20	Sequence 76 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09951	TKKNGRKLCLKLQAALYKKK	20	Sequence 77 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09952	TKKNGEKLCLDLQAALYKKK	20	Sequence 78 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09953	TKKNGGKLCLDLQAALYKKK	20	Sequence 79 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09954	TKKNGRKLCLGLQAALYKKK	20	Sequence 80 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09955	TKKNGRKLCLDLQAALFKKK	20	Sequence 81 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09956	TKKNGRKLCLDLQAALWKKK	20	Sequence 82 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09957	TKKNGRKLCLDLQAALYKK	19	Sequence 84 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09958	TRRNGRRLCLDLQAALYRR	19	Sequence 85 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09959	TKKNGKKLCLDLQAALYKK	19	Sequence 86 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09960	TKKNGRKLCLELQAALYKK	19	Sequence 87 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09961	TEENGRELCLDLQAALYEE	19	Sequence 88 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09962	TKKNGRKLCLKLQAALYKK	19	Sequence 89 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09963	TKKNGEKLCLDLQAALYKK	19	Sequence 90 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09964	TKKNGGKLCLDLQAALYKK	19	Sequence 91 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09965	TKKNGRKLCLGLQAALYKK	19	Sequence 92 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09966	TKKNGRKLCLDLQAALFKK	19	Sequence 93 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09967	TKKNGRKLCLDLQAALWKK	19	Sequence 94 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09968	KKYLAAQLDLCLKRGNKKT	19	Sequence 95 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09969	SDDPKESEGDLHCVCVKTTSLV	22	Sequence 96 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09970	SDDPKESEGDLHCVCVKTTSLVRPRHITNLELIKAGG	37	Sequence 97 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09971	SDDPKESEGDLHCVCVKTTSKV	22	Sequence 98 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09972	SDDPKESEGELRCVCVKTTSLV	22	Sequence 99 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09973	SDDPKESEGELRCVCVKTTSKV	22	Sequence 100 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09974	SDDPKESEGDLHCCVKTTSKV	21	Sequence 101 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09975	SDDPKESEGELRCCVKTTSLV	21	Sequence 102 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09976	SDDPKESEGELRCCVKTTSKV	21	Sequence 103 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09977	ALYKKFKKKLLKSLKRLGSDDPKESEGDLHCVCVKTTSLV	40	Sequence 104 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09978	ALYKRLFKKLKKFSDDPKESEGDLHCVCVKTTSLV	35	Sequence 105 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09979	ALTKKFKKKLLKSLKRLGSDDPKESEGELRCVCVKTTSKV	40	Sequence 106 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09980	EWVQKYVSNLELSAWKKILK	20	Sequence 107 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09981	SWVQEYVYNLEL	12	Sequence 108 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09982	ANSGEGNFLAEGGGVR	16	Sequence 109 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09983	ANSGEGNFLAEGGGVRKLIK	20	Sequence 110 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09984	KFNKSKLKKTETQEKNPL	18	Sequence 111 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09985	QRLRIRVAVIRA	12	Sequence 1 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09986	VQLRIRVAVIRA	12	Sequence 2 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09987	VRFRIRVAVIRA	12	Sequence 3 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09988	VRWRIRVAVIRA	12	Sequence 4 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09989	VRLWIRVAVIRA	12	Sequence 5 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09990	VRLRIRVWVIRA	12	Sequence 6 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09991	VRLRIRVAVRRA	12	Sequence 7 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09992	VRLRIRVAVIRK	12	Sequence 8 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09993	VQLRIRVRVIRK	12	Sequence 9 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09994	KRFRIRVAVRRA	12	Sequence 10 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09995	VRLRIRVRVIRK	12	Sequence 11 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09996	KQFRIRVRVIRK	12	Sequence 12 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09997	HQFRFRFRVRRK	12	Sequence 13 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09998	HQWRIRVAVRRH	12	Sequence 14 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09999	KRFRIRVRVIRK	12	Sequence 15 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10000	KRWRIRVRVIRK	12	Sequence 16 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10001	KIWVRWK	7	Sequence 17 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10002	IWVIWRR	7	Sequence 18 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10003	ALPWKWPWWPWRR	13	Sequence 19 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10004	IAPWKWPWWPWRR	13	Sequence 20 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10005	ILAWKWPWWPWRR	13	Sequence 21 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10006	ILPAKWPWWPWRR	13	Sequence 22 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10007	ILPWAWPWWPWRR	13	Sequence 23 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10008	ILPWKAPWWPWRR	13	Sequence 24 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10009	ILPWKWAWWPWRR	13	Sequence 25 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10010	ILPWKWPAWPWRR	13	Sequence 26 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10011	ILPWKWPWAPWRR	13	Sequence 27 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10012	ILPWKWPWWAWRR	13	Sequence 28 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10013	ILPWKWPWWPARR	13	Sequence 29 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10014	ILPWKWPWWPWAR	13	Sequence 30 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10015	ILPWKWPWWPWRA	13	Sequence 31 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10016	DLPWKWPWWPWRR	13	Sequence 32 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10017	IDPWKWPWWPWRR	13	Sequence 33 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10018	ILDWKWPWWPWRR	13	Sequence 34 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10019	ILPDKWPWWPWRR	13	Sequence 35 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10020	ILPWDWPWWPWRR	13	Sequence 36 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10021	ILPWKDPWWPWRR	13	Sequence 37 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10022	ILPWKWDWWPWRR	13	Sequence 38 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10023	ILPWKWPDWPWRR	13	Sequence 39 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10024	ILPWKWPWDPWRR	13	Sequence 40 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10025	ILPWKWPWWDWRR	13	Sequence 41 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10026	ILPWKWPWWPDRR	13	Sequence 42 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10027	ILPWKWPWWPWDR	13	Sequence 43 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10028	ILPWKWPWWPWRD	13	Sequence 44 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10029	ELPWKWPWWPWRR	13	Sequence 45 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10030	IEPWKWPWWPWRR	13	Sequence 46 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10031	ILEWKWPWWPWRR	13	Sequence 47 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10032	ILPEKWPWWPWRR	13	Sequence 48 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10033	ILPWEWPWWPWRR	13	Sequence 49 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10034	ILPWKEPWWPWRR	13	Sequence 50 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10035	ILPWKWEWWPWRR	13	Sequence 51 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10036	ILPWKWPEWPWRR	13	Sequence 52 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10037	ILPWKWPWEPWRR	13	Sequence 53 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10038	ILPWKWPWWEWRR	13	Sequence 54 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10039	ILPWKWPWWPERR	13	Sequence 55 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10040	ILPWKWPWWPWER	13	Sequence 56 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10041	ILPWKWPWWPWRE	13	Sequence 57 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10042	FLPWKWPWWPWRR	13	Sequence 58 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10043	IFPWKWPWWPWRR	13	Sequence 59 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10044	ILFWKWPWWPWRR	13	Sequence 60 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10045	ILPFKWPWWPWRR	13	Sequence 61 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10046	ILPWFWPWWPWRR	13	Sequence 62 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10047	ILPWKFPWWPWRR	13	Sequence 63 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10048	ILPWKWFWWPWRR	13	Sequence 64 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10049	ILPWKWPFWPWRR	13	Sequence 65 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10050	ILPWKWPWFPWRR	13	Sequence 66 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10051	ILPWKWPWWFWRR	13	Sequence 67 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10052	ILPWKWPWWPFRR	13	Sequence 68 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10053	ILPWKWPWWPWFR	13	Sequence 69 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10054	ILPWKWPWWPWRF	13	Sequence 70 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10055	GLPWKWPWWPWRR	13	Sequence 71 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10056	IGPWKWPWWPWRR	13	Sequence 72 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10057	ILGWKWPWWPWRR	13	Sequence 73 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10058	ILPGKWPWWPWRR	13	Sequence 74 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10059	ILPWGWPWWPWRR	13	Sequence 75 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10060	ILPWKGPWWPWRR	13	Sequence 76 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10061	ILPWKWGWWPWRR	13	Sequence 77 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10062	ILPWKWPGWPWRR	13	Sequence 78 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10063	ILPWKWPWGPWRR	13	Sequence 79 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10064	ILPWKWPWWGWRR	13	Sequence 80 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10065	ILPWKWPWWPGRR	13	Sequence 81 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10066	ILPWKWPWWPWGR	13	Sequence 82 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10067	ILPWKWPWWPWRG	13	Sequence 83 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10068	HLPWKWPWWPWRR	13	Sequence 84 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10069	IHPWKWPWWPWRR	13	Sequence 85 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10070	ILHWKWPWWPWRR	13	Sequence 86 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10071	ILPHKWPWWPWRR	13	Sequence 87 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10072	ILPWHWPWWPWRR	13	Sequence 88 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10073	ILPWKHPWWPWRR	13	Sequence 89 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10074	ILPWKWHWWPWRR	13	Sequence 90 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10075	ILPWKWPHWPWRR	13	Sequence 91 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10076	ILPWKWPWHPWRR	13	Sequence 92 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10077	ILPWKWPWWHWRR	13	Sequence 93 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10078	ILPWKWPWWPHRR	13	Sequence 94 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10079	ILPWKWPWWPWHR	13	Sequence 95 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10080	ILPWKWPWWPWRH	13	Sequence 96 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10081	IIPWKWPWWPWRR	13	Sequence 97 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10082	ILIWKWPWWPWRR	13	Sequence 98 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10083	ILPIKWPWWPWRR	13	Sequence 99 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10084	ILPWIWPWWPWRR	13	Sequence 100 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10085	ILPWKIPWWPWRR	13	Sequence 101 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10086	ILPWKWIWWPWRR	13	Sequence 102 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10087	ILPWKWPIWPWRR	13	Sequence 103 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10088	ILPWKWPWIPWRR	13	Sequence 104 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10089	ILPWKWPWWIWRR	13	Sequence 105 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10090	ILPWKWPWWPIRR	13	Sequence 106 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10091	ILPWKWPWWPWIR	13	Sequence 107 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10092	ILPWKWPWWPWRI	13	Sequence 108 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10093	KLPWKWPWWPWRR	13	Sequence 109 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10094	IKPWKWPWWPWRR	13	Sequence 110 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10095	ILKWKWPWWPWRR	13	Sequence 111 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10096	ILPKKWPWWPWRR	13	Sequence 112 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10097	ILPWKKPWWPWRR	13	Sequence 113 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10098	ILPWKWKWWPWRR	13	Sequence 114 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10099	ILPWKWPKWPWRR	13	Sequence 115 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10100	ILPWKWPWKPWRR	13	Sequence 116 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10101	ILPWKWPWWKWRR	13	Sequence 117 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10102	ILPWKWPWWPKRR	13	Sequence 118 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10103	ILPWKWPWWPWKR	13	Sequence 119 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10104	ILPWKWPWWPWRK	13	Sequence 120 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10105	LLPWKWPWWPWRR	13	Sequence 121 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10106	ILLWKWPWWPWRR	13	Sequence 122 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10107	ILPLKWPWWPWRR	13	Sequence 123 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10108	ILPWLWPWWPWRR	13	Sequence 124 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10109	ILPWKLPWWPWRR	13	Sequence 125 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10110	ILPWKWLWWPWRR	13	Sequence 126 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10111	ILPWKWPLWPWRR	13	Sequence 127 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10112	ILPWKWPWLPWRR	13	Sequence 128 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10113	ILPWKWPWWLWRR	13	Sequence 129 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10114	ILPWKWPWWPLRR	13	Sequence 130 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10115	ILPWKWPWWPWLR	13	Sequence 131 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10116	ILPWKWPWWPWRL	13	Sequence 132 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10117	MLPWKWPWWPWRR	13	Sequence 133 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10118	IMPWKWPWWPWRR	13	Sequence 134 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10119	ILMWKWPWWPWRR	13	Sequence 135 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10120	ILPMKWPWWPWRR	13	Sequence 136 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10121	ILPWMWPWWPWRR	13	Sequence 137 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10122	ILPWKMPWWPWRR	13	Sequence 138 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10123	ILPWKWMWWPWRR	13	Sequence 139 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10124	ILPWKWPMWPWRR	13	Sequence 140 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10125	ILPWKWPWMPWRR	13	Sequence 141 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10126	ILPWKWPWWMWRR	13	Sequence 142 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10127	ILPWKWPWWPMRR	13	Sequence 143 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10128	ILPWKWPWWPWMR	13	Sequence 144 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10129	ILPWKWPWWPWRM	13	Sequence 145 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10130	NLPWKWPWWPWRR	13	Sequence 146 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10131	INPWKWPWWPWRR	13	Sequence 147 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10132	ILNWKWPWWPWRR	13	Sequence 148 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10133	ILPNKWPWWPWRR	13	Sequence 149 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10134	ILPWNWPWWPWRR	13	Sequence 150 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10135	ILPWKNPWWPWRR	13	Sequence 151 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10136	ILPWKWNWWPWRR	13	Sequence 152 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10137	ILPWKWPNWPWRR	13	Sequence 153 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10138	ILPWKWPWNPWRR	13	Sequence 154 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10139	ILPWKWPWWNWRR	13	Sequence 155 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10140	ILPWKWPWWPNRR	13	Sequence 156 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10141	ILPWKWPWWPWNR	13	Sequence 157 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10142	ILPWKWPWWPWRN	13	Sequence 158 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10143	PLPWKWPWWPWRR	13	Sequence 159 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10144	IPPWKWPWWPWRR	13	Sequence 160 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10145	ILPPKWPWWPWRR	13	Sequence 161 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10146	ILPWPWPWWPWRR	13	Sequence 162 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10147	ILPWKPPWWPWRR	13	Sequence 163 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10148	ILPWKWPPWPWRR	13	Sequence 164 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10149	ILPWKWPWPPWRR	13	Sequence 165 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10150	ILPWKWPWWPPRR	13	Sequence 166 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10151	ILPWKWPWWPWPR	13	Sequence 167 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10152	ILPWKWPWWPWRP	13	Sequence 168 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10153	QLPWKWPWWPWRR	13	Sequence 169 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10154	IQPWKWPWWPWRR	13	Sequence 170 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10155	ILQWKWPWWPWRR	13	Sequence 171 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10156	ILPQKWPWWPWRR	13	Sequence 172 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10157	ILPWQWPWWPWRR	13	Sequence 173 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10158	ILPWKQPWWPWRR	13	Sequence 174 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10159	ILPWKWQWWPWRR	13	Sequence 175 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10160	ILPWKWPQWPWRR	13	Sequence 176 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10161	ILPWKWPWQPWRR	13	Sequence 177 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10162	ILPWKWPWWQWRR	13	Sequence 178 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10163	ILPWKWPWWPQRR	13	Sequence 179 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10164	ILPWKWPWWPWQR	13	Sequence 180 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10165	ILPWKWPWWPWRQ	13	Sequence 181 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10166	RLPWKWPWWPWRR	13	Sequence 182 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10167	IRPWKWPWWPWRR	13	Sequence 183 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10168	ILRWKWPWWPWRR	13	Sequence 184 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10169	ILPRKWPWWPWRR	13	Sequence 185 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10170	ILPWRWPWWPWRR	13	Sequence 186 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10171	ILPWKRPWWPWRR	13	Sequence 187 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10172	ILPWKWRWWPWRR	13	Sequence 188 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10173	ILPWKWPRWPWRR	13	Sequence 189 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10174	ILPWKWPWRPWRR	13	Sequence 190 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10175	ILPWKWPWWRWRR	13	Sequence 191 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10176	ILPWKWPWWPRRR	13	Sequence 192 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10177	SLPWKWPWWPWRR	13	Sequence 193 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10178	ISPWKWPWWPWRR	13	Sequence 194 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10179	ILSWKWPWWPWRR	13	Sequence 195 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10180	ILPSKWPWWPWRR	13	Sequence 196 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10181	ILPWSWPWWPWRR	13	Sequence 197 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10182	ILPWKSPWWPWRR	13	Sequence 198 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10183	ILPWKWSWWPWRR	13	Sequence 199 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10184	ILPWKWPSWPWRR	13	Sequence 200 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10185	ILPWKWPWSPWRR	13	Sequence 201 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10186	ILPWKWPWWSWRR	13	Sequence 202 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10187	ILPWKWPWWPSRR	13	Sequence 203 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10188	ILPWKWPWWPWSR	13	Sequence 204 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10189	ILPWKWPWWPWRS	13	Sequence 205 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10190	TLPWKWPWWPWRR	13	Sequence 206 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10191	ITPWKWPWWPWRR	13	Sequence 207 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10192	ILTWKWPWWPWRR	13	Sequence 208 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10193	ILPTKWPWWPWRR	13	Sequence 209 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10194	ILPWTWPWWPWRR	13	Sequence 210 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10195	ILPWKTPWWPWRR	13	Sequence 211 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10196	ILPWKWTWWPWRR	13	Sequence 212 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10197	ILPWKWPTWPWRR	13	Sequence 213 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10198	ILPWKWPWTPWRR	13	Sequence 214 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10199	ILPWKWPWWTWRR	13	Sequence 215 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10200	ILPWKWPWWPTRR	13	Sequence 216 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10201	ILPWKWPWWPWTR	13	Sequence 217 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10202	ILPWKWPWWPWRT	13	Sequence 218 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10203	VLPWKWPWWPWRR	13	Sequence 219 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10204	IVPWKWPWWPWRR	13	Sequence 220 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10205	ILVWKWPWWPWRR	13	Sequence 221 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10206	ILPVKWPWWPWRR	13	Sequence 222 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10207	ILPWVWPWWPWRR	13	Sequence 223 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10208	ILPWKVPWWPWRR	13	Sequence 224 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10209	ILPWKWVWWPWRR	13	Sequence 225 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10210	ILPWKWPVWPWRR	13	Sequence 226 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10211	ILPWKWPWVPWRR	13	Sequence 227 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10212	ILPWKWPWWVWRR	13	Sequence 228 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10213	ILPWKWPWWPVRR	13	Sequence 229 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10214	ILPWKWPWWPWVR	13	Sequence 230 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10215	ILPWKWPWWPWRV	13	Sequence 231 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10216	WLPWKWPWWPWRR	13	Sequence 232 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10217	IWPWKWPWWPWRR	13	Sequence 233 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10218	ILWWKWPWWPWRR	13	Sequence 234 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10219	ILPWWWPWWPWRR	13	Sequence 235 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10220	ILPWKWWWWPWRR	13	Sequence 236 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10221	ILPWKWPWWWWRR	13	Sequence 237 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10222	ILPWKWPWWPWWR	13	Sequence 238 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10223	ILPWKWPWWPWRW	13	Sequence 239 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10224	YLPWKWPWWPWRR	13	Sequence 240 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10225	IYPWKWPWWPWRR	13	Sequence 241 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10226	ILYWKWPWWPWRR	13	Sequence 242 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10227	ILPYKWPWWPWRR	13	Sequence 243 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10228	ILPWYWPWWPWRR	13	Sequence 244 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10229	ILPWKYPWWPWRR	13	Sequence 245 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10230	ILPWKWYWWPWRR	13	Sequence 246 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10231	ILPWKWPYWPWRR	13	Sequence 247 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10232	ILPWKWPWYPWRR	13	Sequence 248 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10233	ILPWKWPWWYWRR	13	Sequence 249 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10234	ILPWKWPWWPYRR	13	Sequence 250 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10235	ILPWKWPWWPWYR	13	Sequence 251 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10236	ILPWKWPWWPWRY	13	Sequence 252 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10237	ARLRIRVAVIRA	12	Sequence 253 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10238	DRLRIRVAVIRA	12	Sequence 254 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10239	ERLRIRVAVIRA	12	Sequence 255 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10240	FRLRIRVAVIRA	12	Sequence 256 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10241	GRLRIRVAVIRA	12	Sequence 257 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10242	HRLRIRVAVIRA	12	Sequence 258 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10243	IRLRIRVAVIRA	12	Sequence 259 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10244	KRLRIRVAVIRA	12	Sequence 260 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10245	LRLRIRVAVIRA	12	Sequence 261 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10246	MRLRIRVAVIRA	12	Sequence 262 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10247	NRLRIRVAVIRA	12	Sequence 263 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10248	PRLRIRVAVIRA	12	Sequence 264 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10249	RRLRIRVAVIRA	12	Sequence 266 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10250	SRLRIRVAVIRA	12	Sequence 267 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10251	TRLRIRVAVIRA	12	Sequence 268 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10252	WRLRIRVAVIRA	12	Sequence 269 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10253	YRLRIRVAVIRA	12	Sequence 270 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10254	VALRIRVAVIRA	12	Sequence 271 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10255	VDLRIRVAVIRA	12	Sequence 272 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10256	VELRIRVAVIRA	12	Sequence 273 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10257	VFLRIRVAVIRA	12	Sequence 274 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10258	VGLRIRVAVIRA	12	Sequence 275 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10259	VHLRIRVAVIRA	12	Sequence 276 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10260	VILRIRVAVIRA	12	Sequence 277 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10261	VKLRIRVAVIRA	12	Sequence 278 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10262	VLLRIRVAVIRA	12	Sequence 279 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10263	VMLRIRVAVIRA	12	Sequence 280 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10264	VNLRIRVAVIRA	12	Sequence 281 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10265	VPLRIRVAVIRA	12	Sequence 282 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10266	VSLRIRVAVIRA	12	Sequence 284 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10267	VTLRIRVAVIRA	12	Sequence 285 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10268	VVLRIRVAVIRA	12	Sequence 286 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10269	VWLRIRVAVIRA	12	Sequence 287 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10270	VYLRIRVAVIRA	12	Sequence 288 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10271	VRARIRVAVIRA	12	Sequence 289 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10272	VRDRIRVAVIRA	12	Sequence 290 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10273	VRERIRVAVIRA	12	Sequence 291 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10274	VRGRIRVAVIRA	12	Sequence 293 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10275	VRHRIRVAVIRA	12	Sequence 294 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10276	VRIRIRVAVIRA	12	Sequence 295 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10277	VRKRIRVAVIRA	12	Sequence 296 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10278	VRMRIRVAVIRA	12	Sequence 297 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10279	VRNRIRVAVIRA	12	Sequence 298 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10280	VRPRIRVAVIRA	12	Sequence 299 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10281	VRQRIRVAVIRA	12	Sequence 300 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10282	VRRRIRVAVIRA	12	Sequence 301 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10283	VRSRIRVAVIRA	12	Sequence 302 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10284	VRTRIRVAVIRA	12	Sequence 303 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10285	VRVRIRVAVIRA	12	Sequence 304 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10286	VRYRIRVAVIRA	12	Sequence 306 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10287	VRLAIRVAVIRA	12	Sequence 307 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10288	VRLDIRVAVIRA	12	Sequence 308 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10289	VRLEIRVAVIRA	12	Sequence 309 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10290	VRLFIRVAVIRA	12	Sequence 310 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10291	VRLGIRVAVIRA	12	Sequence 311 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10292	VRLHIRVAVIRA	12	Sequence 312 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10293	VRLIIRVAVIRA	12	Sequence 313 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10294	VRLKIRVAVIRA	12	Sequence 314 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10295	VRLLIRVAVIRA	12	Sequence 315 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10296	VRLMIRVAVIRA	12	Sequence 316 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10297	VRLNIRVAVIRA	12	Sequence 317 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10298	VRLPIRVAVIRA	12	Sequence 318 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10299	VRLQIRVAVIRA	12	Sequence 319 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10300	VRLSIRVAVIRA	12	Sequence 320 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10301	VRLTIRVAVIRA	12	Sequence 321 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10302	VRLVIRVAVIRA	12	Sequence 322 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10303	VRLYIRVAVIRA	12	Sequence 324 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10304	VRLRARVAVIRA	12	Sequence 325 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10305	VRLRDRVAVIRA	12	Sequence 326 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10306	VRLRERVAVIRA	12	Sequence 327 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10307	VRLRFRVAVIRA	12	Sequence 328 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10308	VRLRGRVAVIRA	12	Sequence 329 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10309	VRLRHRVAVIRA	12	Sequence 330 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10310	VRLRKRVAVIRA	12	Sequence 331 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10311	VRLRLRVAVIRA	12	Sequence 332 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10312	VRLRMRVAVIRA	12	Sequence 333 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10313	VRLRNRVAVIRA	12	Sequence 334 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10314	VRLRPRVAVIRA	12	Sequence 335 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10315	VRLRQRVAVIRA	12	Sequence 336 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10316	VRLRRRVAVIRA	12	Sequence 337 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10317	VRLRSRVAVIRA	12	Sequence 338 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10318	VRLRTRVAVIRA	12	Sequence 339 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10319	VRLRVRVAVIRA	12	Sequence 340 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10320	VRLRWRVAVIRA	12	Sequence 341 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10321	VRLRYRVAVIRA	12	Sequence 342 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10322	VRLRIAVAVIRA	12	Sequence 343 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10323	VRLRIDVAVIRA	12	Sequence 344 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10324	VRLRIEVAVIRA	12	Sequence 345 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10325	VRLRIFVAVIRA	12	Sequence 346 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10326	VRLRIGVAVIRA	12	Sequence 347 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10327	VRLRIHVAVIRA	12	Sequence 348 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10328	VRLRIIVAVIRA	12	Sequence 349 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10329	VRLRIKVAVIRA	12	Sequence 350 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10330	VRLRILVAVIRA	12	Sequence 351 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10331	VRLRIMVAVIRA	12	Sequence 352 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10332	VRLRINVAVIRA	12	Sequence 353 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10333	VRLRIPVAVIRA	12	Sequence 354 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10334	VRLRIQVAVIRA	12	Sequence 355 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10335	VRLRISVAVIRA	12	Sequence 356 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10336	VRLRITVAVIRA	12	Sequence 357 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10337	VRLRIVVAVIRA	12	Sequence 358 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10338	VRLRIWVAVIRA	12	Sequence 359 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10339	VRLRIYVAVIRA	12	Sequence 360 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10340	VRLRIRAAVIRA	12	Sequence 361 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10341	VRLRIRDAVIRA	12	Sequence 362 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10342	VRLRIREAVIRA	12	Sequence 363 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10343	VRLRIRFAVIRA	12	Sequence 364 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10344	VRLRIRGAVIRA	12	Sequence 365 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10345	VRLRIRHAVIRA	12	Sequence 366 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10346	VRLRIRIAVIRA	12	Sequence 367 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10347	VRLRIRKAVIRA	12	Sequence 368 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10348	VRLRIRLAVIRA	12	Sequence 369 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10349	VRLRIRMAVIRA	12	Sequence 370 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10350	VRLRIRNAVIRA	12	Sequence 371 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10351	VRLRIRPAVIRA	12	Sequence 372 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10352	VRLRIRQAVIRA	12	Sequence 373 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10353	VRLRIRRAVIRA	12	Sequence 374 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10354	VRLRIRSAVIRA	12	Sequence 375 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10355	VRLRIRTAVIRA	12	Sequence 376 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10356	VRLRIRWAVIRA	12	Sequence 377 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10357	VRLRIRYAVIRA	12	Sequence 378 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10358	VRLRIRVDVIRA	12	Sequence 379 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10359	VRLRIRVEVIRA	12	Sequence 380 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10360	VRLRIRVFVIRA	12	Sequence 381 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10361	VRLRIRVGVIRA	12	Sequence 382 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10362	VRLRIRVHVIRA	12	Sequence 383 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10363	VRLRIRVIVIRA	12	Sequence 384 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10364	VRLRIRVKVIRA	12	Sequence 385 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10365	VRLRIRVLVIRA	12	Sequence 386 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10366	VRLRIRVMVIRA	12	Sequence 387 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10367	VRLRIRVNVIRA	12	Sequence 388 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10368	VRLRIRVPVIRA	12	Sequence 389 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10369	VRLRIRVQVIRA	12	Sequence 390 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10370	VRLRIRVRVIRA	12	Sequence 391 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10371	VRLRIRVSVIRA	12	Sequence 392 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10372	VRLRIRVTVIRA	12	Sequence 393 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10373	VRLRIRVVVIRA	12	Sequence 394 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10374	VRLRIRVYVIRA	12	Sequence 396 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10375	VRLRIRVAAIRA	12	Sequence 397 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10376	VRLRIRVADIRA	12	Sequence 398 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10377	VRLRIRVAEIRA	12	Sequence 399 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10378	VRLRIRVAFIRA	12	Sequence 400 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10379	VRLRIRVAGIRA	12	Sequence 401 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10380	VRLRIRVAHIRA	12	Sequence 402 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10381	VRLRIRVAIIRA	12	Sequence 403 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10382	VRLRIRVAKIRA	12	Sequence 404 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10383	VRLRIRVANIRA	12	Sequence 407 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10384	VRLRIRVAPIRA	12	Sequence 408 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10385	VRLRIRVAQIRA	12	Sequence 409 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10386	VRLRIRVARIRA	12	Sequence 410 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10387	VRLRIRVASIRA	12	Sequence 411 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10388	VRLRIRVATIRA	12	Sequence 412 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10389	VRLRIRVAWIRA	12	Sequence 413 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10390	VRLRIRVAYIRA	12	Sequence 414 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10391	VRLRIRVAVARA	12	Sequence 415 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10392	VRLRIRVAVDRA	12	Sequence 416 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10393	VRLRIRVAVERA	12	Sequence 417 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10394	VRLRIRVAVFRA	12	Sequence 418 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10395	VRLRIRVAVGRA	12	Sequence 419 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10396	VRLRIRVAVHRA	12	Sequence 420 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10397	VRLRIRVAVKRA	12	Sequence 421 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10398	VRLRIRVAVLRA	12	Sequence 422 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10399	VRLRIRVAVMRA	12	Sequence 423 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10400	VRLRIRVAVNRA	12	Sequence 424 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10401	VRLRIRVAVPRA	12	Sequence 425 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10402	VRLRIRVAVQRA	12	Sequence 426 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10403	VRLRIRVAVSRA	12	Sequence 428 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10404	VRLRIRVAVTRA	12	Sequence 429 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10405	VRLRIRVAVVRA	12	Sequence 430 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10406	VRLRIRVAVWRA	12	Sequence 431 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10407	VRLRIRVAVYRA	12	Sequence 432 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10408	VRLRIRVAVIAA	12	Sequence 433 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10409	VRLRIRVAVIDA	12	Sequence 434 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10410	VRLRIRVAVIEA	12	Sequence 435 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10411	VRLRIRVAVIFA	12	Sequence 436 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10412	VRLRIRVAVIGA	12	Sequence 437 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10413	VRLRIRVAVIHA	12	Sequence 438 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10414	VRLRIRVAVIIA	12	Sequence 439 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10415	VRLRIRVAVIKA	12	Sequence 440 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10416	VRLRIRVAVILA	12	Sequence 441 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10417	VRLRIRVAVIMA	12	Sequence 442 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10418	VRLRIRVAVINA	12	Sequence 443 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10419	VRLRIRVAVIPA	12	Sequence 444 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10420	VRLRIRVAVIQA	12	Sequence 445 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10421	VRLRIRVAVISA	12	Sequence 446 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10422	VRLRIRVAVITA	12	Sequence 447 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10423	VRLRIRVAVIVA	12	Sequence 448 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10424	VRLRIRVAVIWA	12	Sequence 449 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10425	VRLRIRVAVIYA	12	Sequence 450 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10426	VRLRIRVAVIRD	12	Sequence 451 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10427	VRLRIRVAVIRE	12	Sequence 452 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10428	VRLRIRVAVIRF	12	Sequence 453 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10429	VRLRIRVAVIRG	12	Sequence 454 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10430	VRLRIRVAVIRH	12	Sequence 455 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10431	VRLRIRVAVIRI	12	Sequence 456 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10432	VRLRIRVAVIRL	12	Sequence 458 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10433	VRLRIRVAVIRM	12	Sequence 459 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10434	VRLRIRVAVIRN	12	Sequence 460 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10435	VRLRIRVAVIRP	12	Sequence 461 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10436	VRLRIRVAVIRQ	12	Sequence 462 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10437	VRLRIRVAVIRR	12	Sequence 463 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10438	VRLRIRVAVIRS	12	Sequence 464 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10439	VRLRIRVAVIRT	12	Sequence 465 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10440	VRLRIRVAVIRV	12	Sequence 466 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10441	VRLRIRVAVIRW	12	Sequence 467 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10442	VRLRIRVAVIRY	12	Sequence 468 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10443	RRRRVKWWR	9	Sequence 469 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10444	WLRKKQGRL	9	Sequence 470 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10445	KWVRVYLRW	9	Sequence 471 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10446	GKVMISIVR	9	Sequence 472 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10447	IKVVRWRWR	9	Sequence 473 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10448	RRRRRWVRR	9	Sequence 474 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10449	HMNRFRTVY	9	Sequence 475 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10450	VRKRGSWRM	9	Sequence 476 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10451	RIIRTYKRG	9	Sequence 477 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10452	WWRWRLRLI	9	Sequence 478 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10453	WLNRLYIRL	9	Sequence 479 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10454	IWRWTKWFW	9	Sequence 480 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10455	RFKGSWKYR	9	Sequence 481 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10456	VWVIRKKKW	9	Sequence 482 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10457	RGRRVWRLF	9	Sequence 483 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10458	WRWRKVKQW	9	Sequence 484 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10459	WWKYWRKVI	9	Sequence 485 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10460	WLVRIRKRI	9	Sequence 486 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10461	WWRWWQRRW	9	Sequence 487 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10462	RKKWWWKIR	9	Sequence 488 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10463	WVRKKIRRR	9	Sequence 489 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10464	RYRRRWYIR	9	Sequence 490 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10465	LYRWVWKVG	9	Sequence 491 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10466	VRRRWFKWL	9	Sequence 492 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10467	RRLWWWKWL	9	Sequence 493 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10468	WRFKWTRRG	9	Sequence 494 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10469	KWWRHRRMW	9	Sequence 495 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10470	RRKRWWWRT	9	Sequence 496 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10471	WRRKIVRVW	9	Sequence 497 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10472	KLRRGSLWR	9	Sequence 498 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10473	RVIWWWRRK	9	Sequence 499 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10474	TWRVWKVRW	9	Sequence 500 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10475	QRGIVIWRK	9	Sequence 501 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10476	GKWWKWGIW	9	Sequence 502 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10477	RVRRWWFVR	9	Sequence 503 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10478	FWRRRVKWR	9	Sequence 504 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10479	FRRYQNIVR	9	Sequence 505 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10480	RFWRWIFKW	9	Sequence 506 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10481	KRNVKRNWK	9	Sequence 507 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10482	WYSLIIFKR	9	Sequence 508 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10483	RKNRRIRVV	9	Sequence 509 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10484	FFRKRRWRI	9	Sequence 510 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10485	WKIRKVIKW	9	Sequence 511 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10486	IKWYWRKKK	9	Sequence 512 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10487	KRGWRKRWW	9	Sequence 513 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10488	RKWMGRRIR	9	Sequence 514 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10489	WKGKKRRVI	9	Sequence 515 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10490	KVIRYKVYI	9	Sequence 516 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10491	RRTRKWILR	9	Sequence 517 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10492	YNWNWLRRW	9	Sequence 518 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10493	KWKHWRWQW	9	Sequence 519 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10494	RKIVVKVRV	9	Sequence 520 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10495	QYLGWRFKW	9	Sequence 521 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10496	KIKTRKVKY	9	Sequence 522 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10497	VWIRWRRRW	9	Sequence 523 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10498	WGVRVRRLI	9	Sequence 524 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10499	WWKRVWKFI	9	Sequence 525 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10500	YWIYSRLRR	9	Sequence 526 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10501	RRYWKFKRR	9	Sequence 527 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10502	IVRRVIIRV	9	Sequence 528 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10503	ARRRGLKVW	9	Sequence 529 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10504	RRWVRRWWR	9	Sequence 530 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10505	WKWKWKWQS	9	Sequence 531 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10506	RWKVKQRRR	9	Sequence 532 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10507	YWTKFRLRI	9	Sequence 533 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10508	WVIKVRIRW	9	Sequence 534 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10509	ARVQVYKYR	9	Sequence 535 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10510	KWRWHWVYV	9	Sequence 536 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10511	KVKYKFRRW	9	Sequence 537 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10512	RFRKRKNRI	9	Sequence 538 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10513	MFRRRFIWK	9	Sequence 539 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10514	WRLRRFRLW	9	Sequence 540 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10515	WIQRIRIWV	9	Sequence 541 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10516	RRYHWRIYI	9	Sequence 542 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10517	SRFWRRWRK	9	Sequence 543 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10518	YRVWIIRRK	9	Sequence 544 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10519	WRVSWLIWR	9	Sequence 545 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10520	RFVKRKIVW	9	Sequence 546 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10521	RIYKIRWII	9	Sequence 547 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10522	RKFWHRGTI	9	Sequence 548 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10523	AWVVWRKRW	9	Sequence 549 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10524	WVWGKVRWG	9	Sequence 550 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10525	FGIRFRRMV	9	Sequence 551 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10526	FWIRKVFRI	9	Sequence 552 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10527	KRWKVRVVW	9	Sequence 553 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10528	KIRIWRIWV	9	Sequence 554 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10529	RGRWKRIKK	9	Sequence 555 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10530	RLWFLVLRR	9	Sequence 556 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10531	IIRVTRWTK	9	Sequence 557 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10532	AMWRWKWRK	9	Sequence 558 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10533	TRKYFGRFV	9	Sequence 559 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10534	ARRVKKKRR	9	Sequence 560 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10535	RWWKIWKRR	9	Sequence 561 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10536	RWRYKIQKW	9	Sequence 562 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10537	RVGIKIKMK	9	Sequence 563 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10538	WVLKLRYKW	9	Sequence 564 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10539	FRRKWIFKK	9	Sequence 565 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10540	WIQKLWRQR	9	Sequence 566 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10541	RIVRLHVRK	9	Sequence 567 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10542	VRIGWRRVK	9	Sequence 568 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10543	RRRIGIKRF	9	Sequence 569 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10544	RRRRKKVRI	9	Sequence 570 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10545	KLWRYKRWR	9	Sequence 571 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10546	RIRRFIKKW	9	Sequence 572 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10547	LWHKKKKIW	9	Sequence 573 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10548	LTRRFWLRR	9	Sequence 574 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10549	RRRYVIRRR	9	Sequence 575 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10550	WGWRWIWIK	9	Sequence 576 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10551	RWRWQRGRF	9	Sequence 577 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10552	RRKKWKVRI	9	Sequence 578 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10553	KMKLYKGSM	9	Sequence 579 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10554	GTIRWWRRR	9	Sequence 580 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10555	SLRRYIWRF	9	Sequence 581 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10556	GRYWKKWRR	9	Sequence 582 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10557	WIRQFRWKK	9	Sequence 583 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10558	AKVRRIKHW	9	Sequence 584 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10559	YSRRKTWWI	9	Sequence 585 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10560	RGRWWIRRQ	9	Sequence 586 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10561	WVFRWVWWR	9	Sequence 587 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10562	VYRVWWLKW	9	Sequence 588 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10563	WWVRRRVGW	9	Sequence 589 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10564	WFKIKRLYL	9	Sequence 590 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10565	WKMWKRGWT	9	Sequence 591 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10566	RWWRKSRRL	9	Sequence 592 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10567	FWRIRWWRW	9	Sequence 593 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10568	VWWFGKRTT	9	Sequence 594 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10569	VRIIWWIWR	9	Sequence 595 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10570	WWVRIWRWM	9	Sequence 596 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10571	RKWKKWFHR	9	Sequence 597 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10572	RKWKFWGYK	9	Sequence 598 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10573	FWYIWSKRV	9	Sequence 599 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10574	YWRQFRRKQ	9	Sequence 600 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10575	WWWKVKSRR	9	Sequence 601 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10576	WRLWIWWIR	9	Sequence 602 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10577	QFRVNRRKY	9	Sequence 603 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10578	RYRFWWVRR	9	Sequence 604 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10579	THIWLRRRR	9	Sequence 605 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10580	RRRFRKRRM	9	Sequence 606 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10581	LYTRVRRYS	9	Sequence 607 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10582	WSIRRLWWL	9	Sequence 608 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10583	YKIKRRRYG	9	Sequence 609 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10584	WKRIQFRRK	9	Sequence 610 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10585	HKKRRIWRK	9	Sequence 611 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10586	WRLIRWWIR	9	Sequence 612 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10587	LRKNWWWRR	9	Sequence 613 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10588	VKRIRIWML	9	Sequence 614 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10589	IRYRNWKWL	9	Sequence 615 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10590	GRILSRRWK	9	Sequence 616 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10591	KHWKIHVRW	9	Sequence 617 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10592	WIYWKVWRR	9	Sequence 618 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10593	KLWKVRNRR	9	Sequence 619 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10594	RRVYYYKWV	9	Sequence 620 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10595	WRWGVFRLR	9	Sequence 621 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10596	IWRVLKKRV	9	Sequence 622 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10597	AKKFWRNWI	9	Sequence 623 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10598	RQWRKVVKK	9	Sequence 624 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10599	GWKRWWVML	9	Sequence 625 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10600	KWRRTRRRK	9	Sequence 626 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10601	FRRMKRFLR	9	Sequence 627 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10602	RSWNWWWIR	9	Sequence 628 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10603	WRRRIWINR	9	Sequence 629 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10604	RWKWFYLKR	9	Sequence 630 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10605	RKRTIWRII	9	Sequence 631 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10606	RRRVWWRRR	9	Sequence 632 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10607	KWRFKWWKR	9	Sequence 633 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10608	KWIWGWRRW	9	Sequence 634 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10609	WIKRKWKMR	9	Sequence 635 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10610	MWKKVLRRV	9	Sequence 636 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10611	WRWRIFHWL	9	Sequence 637 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10612	KIQRWKGKR	9	Sequence 638 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10613	LWYKYWRWR	9	Sequence 639 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10614	YVRRIWKIT	9	Sequence 640 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10615	RWRQYRSRW	9	Sequence 641 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10616	VGRWKRRRW	9	Sequence 642 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10617	KSSRIYILF	9	Sequence 643 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10618	AKWWWYRKI	9	Sequence 644 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10619	FYWWRWFRV	9	Sequence 645 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10620	RTRWLRYRR	9	Sequence 646 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10621	WNIIWWIRR	9	Sequence 647 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10622	KRGFWWWRI	9	Sequence 648 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10623	RRRKKYIIR	9	Sequence 649 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10624	VWKVGWYYR	9	Sequence 650 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10625	LKFSTGRVR	9	Sequence 651 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10626	RRVWVRRKR	9	Sequence 652 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10627	RFWYMWKYV	9	Sequence 653 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10628	WYVRWMGRR	9	Sequence 654 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10629	WKRRMRRRK	9	Sequence 655 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10630	RVLRRVSWV	9	Sequence 656 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10631	RRLRKKWGW	9	Sequence 657 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10632	WYKKIRLII	9	Sequence 658 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10633	IYIIIWRTK	9	Sequence 659 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10634	TWRMRVKVS	9	Sequence 660 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10635	AWWKIRWRI	9	Sequence 661 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10636	RVRRYRWSW	9	Sequence 662 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10637	IWRIRRFRI	9	Sequence 663 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10638	KIRRKWWWF	9	Sequence 664 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10639	RRFWWIKIR	9	Sequence 665 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10640	WYWWRVRRV	9	Sequence 666 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10641	WYKLWRRKV	9	Sequence 667 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10642	WWFSWRWRV	9	Sequence 668 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10643	RFKTRRGWR	9	Sequence 669 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10644	WIWIVRRRV	9	Sequence 670 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10645	RRFKKWMYW	9	Sequence 671 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10646	RWYRVIRWK	9	Sequence 672 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10647	YRWMVRWVR	9	Sequence 673 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10648	KVRRYNRRR	9	Sequence 674 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10649	WFVWNRRVV	9	Sequence 675 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10650	RWKWRWRWY	9	Sequence 676 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10651	ARWRVRKWW	9	Sequence 677 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10652	KIKFWIIRR	9	Sequence 678 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10653	WYWRVRLQW	9	Sequence 679 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10654	YWWWKRRRR	9	Sequence 680 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10655	FIKRVRRRW	9	Sequence 681 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10656	VSVVFRRRY	9	Sequence 682 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10657	KFRVMVRVL	9	Sequence 683 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10658	WMYYKRRRR	9	Sequence 684 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10659	IWIWWRWRW	9	Sequence 685 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10660	WKKKKIIRV	9	Sequence 686 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10661	RRGWRRRRR	9	Sequence 687 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10662	WRWRKIWKW	9	Sequence 688 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10663	WWRWKRRII	9	Sequence 689 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10664	WKVRWKIRR	9	Sequence 690 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10665	RFWVRGRRS	9	Sequence 691 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10666	RRWVLWRRR	9	Sequence 692 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10667	KYIWKKRRY	9	Sequence 693 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10668	KWQWIRKIR	9	Sequence 694 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10669	YWIRRRWRL	9	Sequence 695 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10670	RVKWIKWLH	9	Sequence 696 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10671	YVRQWKKRR	9	Sequence 697 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10672	WKIVGVFRV	9	Sequence 698 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10673	VIKYVRMWW	9	Sequence 699 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10674	RRRRVWRVR	9	Sequence 700 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10675	RRRKIRVYR	9	Sequence 701 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10676	RRNRWRRIR	9	Sequence 702 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10677	IRKWIWRRV	9	Sequence 703 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10678	QRWRVRRRY	9	Sequence 704 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10679	WWMIIKIRN	9	Sequence 705 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10680	ARRRGRRVM	9	Sequence 706 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10681	RRWHWRKRK	9	Sequence 707 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10682	KRFLRKRRF	9	Sequence 708 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10683	RWKGWYLRT	9	Sequence 709 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10684	WSWRGRRKF	9	Sequence 710 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10685	KIIMKRRRW	9	Sequence 711 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10686	VWKRFLHWR	9	Sequence 712 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10687	RLKRRKKWR	9	Sequence 713 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10688	AVRKFRRVT	9	Sequence 714 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10689	IKQRFWWRT	9	Sequence 715 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10690	WKIVVWIIK	9	Sequence 716 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10691	LYRWIVWKR	9	Sequence 717 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10692	WWWRWRIRK	9	Sequence 718 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10693	RLWRKWQWN	9	Sequence 719 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10694	RVKLRWGWR	9	Sequence 720 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10695	AWRYKRRIF	9	Sequence 721 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10696	KRWQIRGIT	9	Sequence 722 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10697	KRWRWRWRW	9	Sequence 723 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10698	KRWVYKYRV	9	Sequence 724 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10699	VHWRWRFWK	9	Sequence 725 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10700	FVGKTKRKR	9	Sequence 726 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10701	RLRFGWFLF	9	Sequence 727 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10702	AKRWIWIQV	9	Sequence 728 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10703	RKYVRRWVY	9	Sequence 729 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10704	YRVYWWWWR	9	Sequence 730 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10705	KRRKKRRVR	9	Sequence 731 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10706	KKVRFTITW	9	Sequence 732 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10707	KLWYWKKVV	9	Sequence 733 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10708	WRWGLRWWQ	9	Sequence 734 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10709	AFFYRWWIR	9	Sequence 735 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10710	WYWRRRRLK	9	Sequence 736 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10711	YKFRWRIYI	9	Sequence 737 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10712	WLRKVWNWR	9	Sequence 738 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10713	RVRFKVYRV	9	Sequence 739 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10714	RWLSKIWKV	9	Sequence 740 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10715	RRRLGWRRG	9	Sequence 741 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10716	KKWGGGLVK	9	Sequence 742 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10717	YWWLWRKKR	9	Sequence 743 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10718	WIRLWVKWR	9	Sequence 744 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10719	GRRSTHWRI	9	Sequence 745 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10720	KKKLFINTW	9	Sequence 746 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10721	VYRRRRVKG	9	Sequence 747 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10722	KGWIIWKIV	9	Sequence 748 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10723	VFHRIRRIK	9	Sequence 749 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10724	RLRLWKSKR	9	Sequence 750 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10725	RRKVFKLRR	9	Sequence 751 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10726	VWLKVYWFK	9	Sequence 752 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10727	VRWGRRRWV	9	Sequence 753 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10728	RYNWVRRKK	9	Sequence 754 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10729	KIRWRKYHL	9	Sequence 755 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10730	VIWRWRKFY	9	Sequence 756 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10731	RRWWKWWWR	9	Sequence 757 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10732	WRVKGKRSK	9	Sequence 758 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10733	RWRTRRNIV	9	Sequence 759 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10734	WWFSIRLWR	9	Sequence 760 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10735	YTWYIKKKR	9	Sequence 761 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10736	VWRRKKYWR	9	Sequence 762 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10737	YLTRFVKYF	9	Sequence 763 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP12574	QNIDAGGNRKCFRDSDCPKFMCPSYLAVKCIGRLCRCGRPELQVELNPK	49	Sequence 651 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12575	LNGGGKDKCFRDSDCPKHMCPSSLVAKCINRLCRCRRPELQVQLNP	46	Sequence 652 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12576	KTQFLPNYYEFYHCYNHSDCQGSMCPTGSKPKCVDQVCECILIRM	45	Sequence 653 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12577	FQLFDNTDTATCITDADCPYDGKCIDGFCRFNVKNNNQV	39	Sequence 654 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12578	MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCV	31	Sequence 655 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12579	DDVKIKCVSAIDCMDLFNLLPIVYKCINNICVYEQSSQRLI	41	Sequence 656 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12580	EHNECETDADCPKHTTIFFVMKCIDHICRCMKTSI	35	Sequence 657 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12581	FKMFCRYDEDCPPRMCRLPQVPQCNEFICDCGMPVYKPYQNKYIKK	46	Sequence 658 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12582	WRCKTKYDCIKIRFCKFPTIARCTKPDFLFLEYDRGFCTCDD	42	Sequence 659 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12583	VIKCFQDSDCPKYMCMFPLKPKCVYILVFPPPWTAQCICD	40	Sequence 660 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12584	IKLIKCTVSDDCPMNFRCPPNTFVRCISDLCTCRSLLDEQS	41	Sequence 661 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12585	SFSEIIDSACKTDKDCPKLHKVNVRCRKGKCVAI	34	Sequence 662 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12586	GRECHANSHCVGKITCVLPQKPECWNYACVCYDSNKYR	38	Sequence 663 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12587	KECVTDVDCEKIYPGNKKPLICSTGYCYSLYEEPPRYHK	39	Sequence 664 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12588	LETQIVQKACVILLPNRSVCTNPYVNVYESSPKEIMCIHEHVCLPYLRAYTNYIPS	56	Sequence 665 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12589	KECVTDADCENLYYGNKWPLICSNIGYCLSSYEEPPHK	38	Sequence 666 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12590	FRDPCNFDFDCRNSNCTAPYVATCMYEHCYC	31	Sequence 667 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12591	IPICQTYMDCPSDMCTRPKHAYCVSYKCYCV	31	Sequence 668 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12592	KECVTDADCENLYPGNKKPMFCNNTGYCMSLYKEPSRYM	39	Sequence 669 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12593	LKCKTVHDCPKSQVVYKCVGNYCRAVKIRRWNLS	34	Sequence 670 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12594	YVVMCEKDSDCVDSFCVPPNVPKCRVVCKCLPK	33	Sequence 671 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12595	KSYGPCTTLQDCETHNWFEVCSCIDFECKCWSLL	34	Sequence 672 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12596	MEVGRRANVECESDKDCQEHWSEFFIIQCIDNICVPSERPL	41	Sequence 673 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12597	DRECDTDTECQKKFPGVNAHHLWCDNGNCVSYPK	34	Sequence 674 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12598	YKNRCFRDSDCPKEMCNHPKIPKCVNNAYCKCVVAMYFPPK	41	Sequence 675 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12599	GGNECVTDVDCEKLYPGNKKPLICNIGYCLSLYKEPPRYM	40	Sequence 676 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12600	ENICDGDYDCNPNEWWCPPNYVLKCINYQCSCIGFTPAIYALD	43	Sequence 677 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12601	EDFPFHKCEKDEDCLEICADDQMAMCILNVCFCY	34	Sequence 678 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12602	QEVLEKEIFPCQTDGECDHMCVTPGIPKCVANMCFCFDNL	40	Sequence 679 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12603	HRFLIYNNCKNDTECPNDCGPHEQAKCILYACYCVE	36	Sequence 680 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12604	VIFECSEDSHCVTKIKCVLPRKPECRNTQCTCYRGYKGSFTLHH	44	Sequence 681 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12605	KDGCKTNFDCLIKYPDHNEDILQCIGGHCLCLTN	34	Sequence 682 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12606	QHPFTPCETNADCKCRNHKRPDCLWHKCYCY	31	Sequence 683 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12607	KLWCDTDADCQEKFPGPSKYPIKCMKGICKCVIN	34	Sequence 684 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12608	WRPDCKENNDCPTFYCATWINTCIKFKCYCIRPWG	35	Sequence 685 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12609	KDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF	34	Sequence 686 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12610	YFIPDSGPCVTNKDCEQEIGYIVKCDTNTGFCVKILQRS	39	Sequence 687 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12611	DFDLHNDSYDYLYEFQECEVDNDCPQDPLPMKCINYICVVHNEEPSDNL	49	Sequence 688 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12612	NFEDISIECMFSIDCPQIKSNIFRFKCIEDRCKIEFIYQRKKYEI	45	Sequence 689 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12613	QKRWHGCKEDRDCDNICSVHAVTKCIGNMCRCLANVK	37	Sequence 690 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12614	QKDLKVFTCQRDEDCKVACATYGGDPWCFRNVCFCKHYNEGGTLHAELH	49	Sequence 691 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12615	EQHFVTLYKKKEKCALDVDCLELFPNSYKYLMKCVGGDCISLSKGFSHDEIKE	53	Sequence 692 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12616	AKVNCLDDADCLEVLCVFGSKAECVVNICICVPPRFGKFDEHFR	44	Sequence 693 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12617	KDITCTVAGDCPNFFVCPPNNFVRCIRNLCKCRSLSYKQP	40	Sequence 694 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12618	ENSQPCNLSVTDTRDICPPGTTLQFVYKVCRCYPMKWRLDHVLT	44	Sequence 695 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12619	ICECEEDIDCPRTWCFGQFFVKCITNECICVHEDRLLPRIPWDPWIPMI	49	Sequence 696 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12620	DTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS	38	Sequence 697 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12621	KILEKHKCVTDGVEILEKGKCFTDWECVRNSWLCPVDLVVRCIKETCKCIKILEPINVVPT	61	Sequence 698 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12622	VSKLAQSCSEDFECYIKNPHAPFGQLRCFEGYCQRLDKPT	40	Sequence 699 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12623	YDDCYNHTECTNKIKCVPPRIAQCFRFKCDCIRLNNGPKTPWSATPKRVHISPTRKNDF	59	Sequence 700 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12624	EESHYMKFSICKDDTDCPTLFCVLPNVPKCIGSKCHCKLMVN	42	Sequence 701 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12625	INSDGYLECTTDYDCREEWLCPPDMEAKCFVSFALARFLSKGKCLCV	47	Sequence 702 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12626	IFPEHNECRTSFDCRKYFCQLPLRPTCNYVEIFRHYYDTTCGCA	44	Sequence 703 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12627	DDYLKYIYRCQNDGDCDQICATHGISKCVATMCFCNLNL	39	Sequence 704 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12628	WSWGLTTECVTELDCYKKYRLPAEKKMKCIRGSCYRVRE	39	Sequence 705 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12629	RNGCIVDPRCPYQQCRRPLYCRRR	24	Sequence 706 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12630	YNITCNSALDCASNRCILPGMPICVTNKCLCV	32	Sequence 707 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12631	ERECVTDADCQKKLPFPHANHFICMNGLCALVFHD	35	Sequence 708 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12632	RPCVTVADCPPVKKPLKMWCIRQTCFYGFGKRPDL	35	Sequence 709 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12633	ETCVTVDDCQGKHHLPPGYHFICMNSRCVLIYYN	34	Sequence 710 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12634	GTGNIRQSCEFDVDCENKYCPPSHDGKCVWE	31	Sequence 711 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12635	GECITFLDCLHLPCMPTETQLCVDKKCICMGLTIKSKNNYIT	42	Sequence 712 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12636	SYPCKIHRDCTTITCSYPLVPRCLIQKCYCGFN	33	Sequence 713 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12637	EKCVTADDCQGKHHMPAGYHFICMNARCVLVYYN	34	Sequence 714 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12638	FFDCENHDDCKNKIKYVLPRIAECRDYKCNCFPLNLSKTLWSASTKRVHKSLAQTNDFLH	60	Sequence 715 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12639	NDIKCTVAGDCPDFFRCPPNTFVRCISNICICRLVYLNTFLEVIIDKVFVF	51	Sequence 716 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12640	NDIKCTVAGDCPDFFRCPPNTFVRCISNICICRSLSH	37	Sequence 717 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12641	KDITCNVAGDCPEYFRCPPNTFVRCVSNICECRGLSHQQP	40	Sequence 718 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12642	KPAPIPCKFHADCPIMLSIVVECINNVCEFIYI	33	Sequence 719 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12643	EKIRRCFNDAHCPPDMCTLGVIPKCSRFTICIC	33	Sequence 721 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12644	ERECVTDADCQKKYPGPYEHLLKCVSGYCVGVTGF	35	Sequence 722 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12645	NIFFCSTDEDCTWNLCRQPWVQKCRLHMCSCEKN	34	Sequence 723 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12646	HVLVECIENRDCEKGMCKFPFIVRCLMDQCKCVRIHNLI	39	Sequence 724 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12647	HDQRECYTNYDCCVKYSCPYKHMVKCVGGYCLGFRNDYGKKNLY	44	Sequence 725 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12648	YDSKECYSDSDWHKKYSCPYTHMMKCVGGYC	31	Sequence 726 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12649	RITHDPSTRSTVSGGFGKCVRDADCVDEVCSPGCNKRCVGFECQCPL	47	Sequence 727 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12650	CNDDTDCPPSCTTRGCPDSCAYPHVLRCIGKNCVCT	36	Sequence 728 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12651	DPMYCFNDDDCRELKCSHPRVRKCRMFLCRCEEVDKEDEK	40	Sequence 729 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12652	VTICDSDQDCRRYRCDPPEYPRCLGILCKCVYVSG	35	Sequence 730 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12653	QKRRRSTECRNDSDCEKMVKCVLPRIARCIKYRCQCRNFLESFE	44	Sequence 731 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12654	NDTEYTDCLQHSDCQAYACELPFKPDCLMVEYAPQFFRLACGCV	44	Sequence 732 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12655	EKGTIVDIETTGQCADDYECYRLFSCPREVAFKCINGWCKCIL	43	Sequence 733 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12656	VYLCEDDEDCHIMPCMVPEYAKCIRMICQCC	31	Sequence 735 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12657	FKTAITCDCNEDCLNFFTPLDNLKCIDNVCEVFM	34	Sequence 736 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12658	EKECITDDDCNRKYPMHANRGLQCLNGECKSSRIIKSR	38	Sequence 737 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12659	MRVLCGRDGRCPKFMCRTFL	20	Sequence 738 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12660	GRYTTPWCVRDIDCPKEKCKHPFKPRCLTHSCVCRLWGSQDVI	43	Sequence 739 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12661	KNICIDDVHCQKYKCSPGLYPTCINGWCECK	31	Sequence 740 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12662	YEKISCQNDFDCPESMCEFGMIRRCISYKCQCHEAY	36	Sequence 741 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12663	QKIRRCFNDAHCPPDMCTPGVIPKCKFTICKC	32	Sequence 742 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12664	IPMIHPLLYKKRVVPNCQTIVDCPDNMCTHPKEVYCIGYRCYCLK	45	Sequence 743 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12665	NIMNCQSTFDCPRDMCSHIRDVICIFKKCKCAGGRYMPQVP	41	Sequence 744 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12666	SIPDVLPCLFSNECPPDLCPIDLFPKCINLSCQCSAEFYNID	42	Sequence 745 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12667	KVLCGRDGTCPRFMCGPGIIPKCVGRYCEC	30	Sequence 746 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12668	KEDGSVECIANIDCPQIFMLPFVMRCINFRCQIVNSEDT	39	Sequence 747 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12669	WTCVEDSDCPANICQPPMQRMCFYGECACVRSKFCT	36	Sequence 748 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12670	VAAFLRCDFDLDCPPKMCYSHLYFVPMCVDNHCDCTQWKDIIPTIP	46	Sequence 749 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12671	PIRCNRVSDCPKIRCNIGFVLRCLYNQCKCVRITQLVDYVLK	42	Sequence 750 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12672	RITHETLPLPVSKPIPILGGECISDADCKHPECDNCRGVCLNSRCICMARSGWTYTIPQN	60	Sequence 751 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12673	KRECDTNFDCQQKFSTQAEDLLWCIRGYCMSIPN	34	Sequence 752 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12674	LHCNNDNECPPSTWKPFVRCKMNRCIYSRVQPPWAC	36	Sequence 753 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12675	LIEECVTDADCYKIYPEASFLHMFCIDGVCKTPIPL	36	Sequence 754 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12676	MDIVDKIDECESNVDCPKSYIINWDKNYVHKCINNRCEWIKIIRRR	46	Sequence 755 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12677	DLGCVTDADCKDKFPGNKYPIKCINGICKSVPN	33	Sequence 756 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12678	ECISDTDCNVLYPMYINRRLRCIQGICHTTTARRR	35	Sequence 757 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12679	VKNINRECTQTSDCYKKYPFIPWGKVRCVKGRCRLDM	37	Sequence 758 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12680	NNIEDDIFCITDNDCPPNTLVQRYRCINGKCNLSFVSYG	39	Sequence 759 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12681	VSITGNLARASRKKPVDVIPCIYDHDCPRKLYFLERCVGRVCKYL	45	Sequence 761 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12682	DDNKLLLSFIEEGFLCFKDSDCPYNMCPSPLKEMCYFIKCVCGVYGPIRERRLYQSHNPMIQ	62	Sequence 762 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12683	EKECANDIDCYKIFLGPPLIPMKCIDGECKRIT	33	Sequence 763 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12684	EKECDTDADCRKKFAGANQHLLWCNNGYCECHTH	34	Sequence 764 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12685	SYYGCETDADCPRSMNKDFYLKCVDKKCEWTAKI	34	Sequence 765 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12686	AIHECRAHSHCVARINCVLPRKPQCRNYACGCYDSNKYR	39	Sequence 766 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12687	QEIENGIHPCKKNEDCNHMCVMPGLPWCHENNLCFCYENAYGNTR	45	Sequence 767 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12688	YEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGYVCFCFENL	40	Sequence 768 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12689	WRCKKTDDCLKIEFCKFPKIARGTKPKFLFFEFGTGFCTWDD	42	Sequence 769 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12690	TFRTRLPCEKDDDCPEAFLPPVMKCVNRFCQYEILE	36	Sequence 770 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12691	DIRCRFYYDCPRLEYHFCECIEDFCAYIRLN	31	Sequence 771 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12692	DDGSFCFKDSDCPDEMCPSPLKEMCYFLQCKCGVDTI	37	Sequence 773 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12693	YLKFECKTDDDCQKSLLKTYVWKCVKNECYFFAKK	35	Sequence 774 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12694	LPISCKDHFECRRKINILRCIYRQEKPMCINSICTCVKLL	40	Sequence 775 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12695	RIMVVNPNNPCVTDADCQRYRHKLATRMICNQGFCLMDFTHDPYAPSLP	49	Sequence 776 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12696	ARLVFVNPEKPCVTDADCDRYRHESAIYSDMFCKDGYCFIDYHHDPYP	48	Sequence 777 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12697	NVEDFVGGSNDECVYPDVFQCINNICKCVSHHRT	34	Sequence 778 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12698	LIECEIDLDCPKSYIKLWDRNYAHRCVNNICEWVKKPRIY	40	Sequence 779 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12699	EIDLDCPKSYIKLWDKNYAHRCVNNICEWVKKPRIY	36	Sequence 780 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12700	QMINFSGCKRDKDCPQFRGVNIRCRSGFCTPIDS	34	Sequence 781 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12701	SFSQIFNSACKTDKDCPKFGRVNVRCRKGNCVPI	34	Sequence 782 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12702	GIRKKECRQDSDCPSYFCEKLTIAKCIHSTCLCK	34	Sequence 783 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12703	GIRRFECRQDSDCPSYFCEKLTVPKCFWSKCYCK	34	Sequence 784 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12704	LYEPLYNFRRDPDCRRNIDCPSYLCVAPKVPRCIMFECHCKDIPSDH	47	Sequence 785 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12705	YREPFSSFTEGPTCKEDIDCPSISCVNPQVPKCIMFECHCKYIPTTLK	48	Sequence 786 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12706	ARFECREDSHCVTRIKCVLPRKPECRNYACGCYDSNKYR	39	Sequence 787 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12707	AHFPCVTDDDCPKPVNKLRVIKCIDHICQYARNLPDFASEISESTKMPCKGE	52	Sequence 788 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12708	ETLSLTHPKCHHIMLPSLFITEVFQRVTDDGCPKPVNHLRVVKCIEHICEYGYNYRPDFASQIPESTKMPRKRE	74	Sequence 789 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12709	EECVTDADCDKLYPDIRKPLMCSIGECYSLYKGKFSLSIISKTSFSLMVYNVVTLVICLRLAYISLLLKFL	71	Sequence 790 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12710	ERECVTDDDCEKLYPTNEYRMMCDSGYCMNLLNGKIIYLLCLKKKKFLIIISVLL	55	Sequence 791 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12711	VSYFSYFSTYIIECKTDNDCPISQLKIYAWKCVKNGCHLFDVIPMMYE	48	Sequence 792 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12712	RLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI	64	Sequence 793 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12713	YLCVTDSHCPPHMCPPGMEPRCVRRMCKCLPIGWRKYFVP	40	Sequence 794 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12714	ESKLEQTCSEDFECYIKNPHVPFGHLRCFEGFCQQLNGPA	40	Sequence 795 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12715	HNCTDISDCSSNHCSYEGVSLCMNGQCICIYE	32	Sequence 796 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12716	EIDADCPQICMPPYEVRCVNHRCGWVNTDDSLFLTQEFTRSKQYIIS	47	Sequence 797 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12717	KKKRYIECETHEDCSQVFMPPFVMRCVIHECKIFNGEHLRY	41	Sequence 798 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12718	KTFLMAEYIKCDTDADCPIVIHHSFYKCIDNLCKRFRRQKHLV	43	Sequence 799 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12719	YKTKTPCKSLNDCPKAIKPIFVKCLGNICQYSIGRI	36	Sequence 800 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12720	AFAGWIKCKVDEDCPNVFTYSYYKCVNELCEIFLREIPKKPYM	43	Sequence 801 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12721	GNTFLMADNIECDTDAGCPKMVHHIFYKCIDNKCKQFRRS	40	Sequence 802 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12722	YIQCDFDADCPEMFRHIFYLCIDKLCRQFVTL	32	Sequence 803 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12723	YRTRIPCVSDYDCPKASYPLFIKCIYNFCEIWGSP	35	Sequence 804 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12724	DDDCPKVPYPLYIKCEDNFCDIWASPY	27	Sequence 805 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12725	KRTNIPCFSDDDCPKTSPPLVLKCDDYFCRYFREKNLI	38	Sequence 806 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12726	KYFQIASPCVNDKDCPRFKNNNVRCRKGFCVNLCN	35	Sequence 807 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12727	VYDSKYFQIASPCVNDKDCPQFKNNNVRCRRGFCVNSGGATQKCLGCPSLK	51	Sequence 808 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12728	ATPCTSDKDCRLERYNVWCINGYCKYKFTPID	32	Sequence 809 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12729	VRIPCVTVADCPPTILPVFYECIDKFCMLHIE	32	Sequence 810 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12730	KTTIPCKFDNDCPEISYPLILMCIDDFCEYLLA	33	Sequence 811 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12731	STIMYYDVPCEKDKDCPAPPRFNIRCRKGYCVRI	34	Sequence 812 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12732	VEIPETPCESDAECPYYSPSLYARCIDGFCTLFLS	35	Sequence 813 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12733	EMTTTATIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	36	Sequence 814 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12734	GKTHYSEIIECKNDADCPIGYKCIDEMCKYG	31	Sequence 815 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12735	IYFRKPPPCITDKDCPQMKINNVRCRKGFCIQIHKFTP	38	Sequence 816 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12736	QIMFSDCKTDKDCPQFRRANIRCRKGQCVKL	31	Sequence 817 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12737	FLTQCKFSCKTIFNCPALVYHQHASCLDGFCWYEEKFEDE	40	Sequence 818 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12738	VYDSIPYVNSGPCVTDKDCPKVSQYNIRCRKGQCARIRV	39	Sequence 819 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12739	TNFKRKQIPFYFFIREFYPCFIDGNCPRNMCKVYQIPKCVGGLCRCIPLRCGRWEK	56	Sequence 820 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12740	HIECKNDFDCPKNMCLAPRVAWCVNNKCECVLTYGPKYSTMKEKLLQKEKI	51	Sequence 821 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12741	VPHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	41	Sequence 822 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12742	VDIYCETDADCPQITDWFYVVKCVDHKCELTKKLRRLYEYQTQKSAETPYI	51	Sequence 823 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12743	EQCVSDADCQIKFPGPRQHLLRCTQGNCVMLVGQGKNYFSIMSKTLFSLLVIIFLLL	57	Sequence 824 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12744	LHDCEYDDDCPKSTSKRTYRCINKKCRSYFTRVEK	35	Sequence 825 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12745	TTSCITDDDCPKAVSFLVFKCIDNICVRVEIL	32	Sequence 826 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12746	NYNPPCVSDKDCPSPKSPKSNIRCRQGYCVNLYS	34	Sequence 827 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12747	VRIPRPLIDPLNCHIDIHCIYKECRRPFKPSCLNFKCDCGKE	42	Sequence 828 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12748	QIIFRQCKTDKDCPKLGRANIRCREGYCVRI	31	Sequence 829 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12749	TPIPCNTPADCPKRVCIYPLRAKCINFNCECDYVKK	36	Sequence 830 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12750	GDIPCESREQCPNTATRRYACLNKLCYCYDNNYPNGWNPFEP	42	Sequence 831 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12751	FVKCETTDDCPKSDYIRQYECVNNWCRLARLHEFQPKKSTLTS	43	Sequence 832 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12752	FTFSILCQVNSDCLGEICLPPKTHWCNKILLEIYISCHLVTMLEPNNLYLLPFLISWTRNNLYIILGLSLFSRTNSLVLSWR	82	Sequence 833 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12753	YPGCETDAECPKIYELYPLIYKCENKFCILSQVLPYIV	38	Sequence 834 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12754	FNPLIRQYCVTDKDCPKFKKYNIRCRKGFCVQVNGG	36	Sequence 835 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12755	AQNDWMKCKTDDECPKVSNPPLYFKCIDRGCRIVIKMRF	39	Sequence 836 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12756	YVECETDADCQPNMCKWPFIVQCYKNVCICVHHTNPYL	38	Sequence 837 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12757	DECQIDADCPKSGNLFYIYKCINHKCELVAAHLRFY	36	Sequence 838 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12758	ILECIFDIDCPTKKCAPPLVAKCDMYECYCRCPPNN	36	Sequence 839 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12759	MVSTNAYIHRCIHQDDCPKYMCEISVLPECINGFCTCV	38	Sequence 840 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12760	QKFNECYEDTDCPIQMCGYPFNVDCVGNKCTCVYNP	36	Sequence 841 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12761	AYYECSNDSACQATTKCVLPRVPRCIKYKCLCGNSNGSGNRWSTRPNRIQKGSTESNYF	59	Sequence 842 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12762	KSICKVDDDCPQRFVMYPLMFMCIKNICRLVNE	33	Sequence 843 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12763	ATKEKFHSCVNANDCPYDFCSPPKYAKCVYNSCYCEDQGRL	41	Sequence 844 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12764	MHIETVTTCIYDSDCPEDMCYPPKKSFCSTFEILSIERKVGVCECI	46	Sequence 845 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12765	VRKPECRQNSDCPPYFCIKPTVPKCIKFKCLCK	33	Sequence 846 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12766	LNGNRHGKDRCFKDSDCPKYMCPSSLVAKCIKKLCSCRKPGLQIQLNPK	49	Sequence 847 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12767	KNIDEKCFRDDDCAKNMCPSYLVVKCVNGIYKCVRP	36	Sequence 848 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12768	NCTFIGFQDNPCKTDNDCRKVRGVNLRCRNGHCVMILQ	38	Sequence 849 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12769	IEGTMSCFHDADCVHKRCQLPQIPKCVGKKCRCRGQYQANPMG	43	Sequence 850 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12770	EVHRCIEYTDCPEDMCHLPLVVVCHDHICKCLRLP	35	Sequence 851 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12771	SAFSGCMNDSDCPDLFCLPPLDMKCHELVCKCR	33	Sequence 852 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12772	HYRELICKTDDNCPRRGTNKYFIHKCIDYRCQWIPR	36	Sequence 853 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12773	LKVIIPSSTCDSDYDCLRYEEALNVITCCNNGLCVMFCPDFD	42	Sequence 854 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12774	FEDSDCPYDMCYAGFQPKCVNGWCDC	26	Sequence 855 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12775	IDDSDCPYDMCDPGLLPRCLNGWCDCSRFQPWPMDSMSSNLREFTLPN	48	Sequence 856 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12776	DSDCPSFLCDHDGVMKCFSNGCSCVDPSD	29	Sequence 857 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12777	SNPCVSTRDCTTHTCNPPLVARCINLRCYCGYK	33	Sequence 858 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12778	LLPCGTDDDCANDPCIPPEYPHCHMEQCHCV	31	Sequence 859 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12779	LYVCRSVSDCPENFCVPPLTIQCINYTCICDDPPYGEPEYDNNDDFVTLNREKAKIKNEEMMMRERDMMIEIETYSVADDLDPHL	85	Sequence 860 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12780	LIFCFEDINCPFDKCFPQLPKCINSFCECV	30	Sequence 861 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12781	LIDCKTVDDCPSSWTKIYKCIDNKCRYSVVKGLII	35	Sequence 862 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12782	KHVRDCPKGIWRSCRYKCIDNKCVFTYWPH	30	Sequence 863 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12783	YILCKTVNDCPPNTRNLRYRCIDGKCKSHRVLYEWDESHTQDITITPCIEE	51	Sequence 864 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12784	QNIDSGGNRRCFRDSDCPKNMCPSYLVVKCLRSNCKCVRPGLQVRLNPN	49	Sequence 865 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12785	LNGHGRNRCFRDSDCPKVMCPSYLVTKCFKKHCRCRKPGLQVQLNPK	47	Sequence 866 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12786	TNFERKQISFSFFMKEYWPCVTDDDCPSDLCKKVDQIPKCVGGLCKCFPIRFGQWER	57	Sequence 867 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12787	LVQNECVTDGDCRRLYPHLIPRYPMCNEGTCVCIFE	36	Sequence 868 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12788	GIRCHDVSECPKGLYCNVGSHMECVKHQCKCIKNFEPIDLA	41	Sequence 869 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12789	IRTYRECENASDCYSIYWRAPYGTMRCVKGHCKQIKDVKVMKFLYCV	47	Sequence 870 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12790	IILCKDHFDCYENIRKLRCDFDTEKPFCISLNVCQCIKQ	39	Sequence 871 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12791	FRCLRNLDCPDSMCSSAYTPRCRHRTCVCLNNDEIKIL	38	Sequence 872 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12792	AIPCITDANCPCVFPLKPRCNFGYCICEEMIP	32	Sequence 873 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12793	RQGCKIDYDCIKVVCKDGHAARCIMRRCECVEILNPIDLGST	42	Sequence 874 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12794	GNYKCQTNYDCLRMWCPIGISPRCIKRRCKCIETLVQ	37	Sequence 875 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12795	EEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVRLEPPYDMSISPKSVHK	52	Sequence 876 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12796	AYVTRFWCYRDLDCRKDMCKPPFNPRCHNHICICRLWGL	39	Sequence 877 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12797	TTRCVRNSDCRHHICMYPLVPRCKYPLCRCV	31	Sequence 878 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12798	HKRCRVDFDCRMRMCVYPTVSVCIDRLCRCRRPPNM	36	Sequence 879 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12799	QKRCKEDFDCRIRSCAYPLIPVCIDPFCRCRRASI	35	Sequence 880 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12800	ERTCKEDFDCRMRYCVYPTIPLCDVKHCRCRRPPNL	36	Sequence 881 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12801	DVINCTQDSDCQSIGCLSHLKPKCTMLGFFFNAFVGICECDQVM	44	Sequence 882 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12802	TINVMCYYDHDCPFVLDHIAECKGGVCEYTAFFYE	35	Sequence 883 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12803	NDRIVYHGCYSDDQCPNECPAILMRCIHSLCVEFIKTDPLFI	42	Sequence 884 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12804	DKPRYTPRNAVKIAECVSYTDCQGGCPACYMRCIDGQCEPFIIKFI	46	Sequence 885 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12805	YNYIDCPVGCRACYMRCIDGQCIPFIKKLILFHLYVIVE	39	Sequence 886 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12806	GLIPCVSDADCPEELALVMKCINKLCELVME	31	Sequence 887 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12807	IDDSHCPHDICPFHLKPKCIFTKVVGQKFFSFSLDGKCGCM	41	Sequence 888 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12808	DKFVFDKNGADRCRSILDCPQDKCFPLLTLVCVNFACDCLHV	42	Sequence 889 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12809	QYNIGCKTDDDCQKYYTKMFGMKCFKSWCITGILD	35	Sequence 890 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12810	EDYYYIECQRDFDCPQLNSEIFAFKCIEKLCKLEFIYQQAPFLLGQV	47	Sequence 891 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12811	YKCNIDVDCPITPSPKFKWKCINKRCLYIRFDEIWTSDPRE	41	Sequence 892 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12812	LTKCETDANCPEISIFSPFFYKCINNGCVLIML	33	Sequence 893 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12813	LKKCITFEDCPISKTRVYKCLHGECRYTIPYIPKVPKVK	39	Sequence 894 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12814	EVDWIYHLCDTDTDCPEHWSKFFIYKCVNHVCDSISKVTTDSKEYKNFP	49	Sequence 895 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12815	AHVECHNDSACEKTVKCMLPRIPRCIKYQCLCGYSDDPGNRWSTRPKRIQKGSTERKGFLY	61	Sequence 896 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12816	VYIKCKTDADCPKSESTIFAMKCNNYRCIYDYIHKRNSYAT	41	Sequence 897 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12817	TYDAYDECQTELDCPKNIDCVYPKSMKCIDKKCICVGARMIIPRVL	46	Sequence 898 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12818	NGYRNIKYCFIDTDCPRSMCHYPEIVRCVDQCKCVRIMP	39	Sequence 899 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12819	CTEHRHCEIAMCKFPFIVRCSMNECNCERVHYLI	34	Sequence 900 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12820	KNEPEPKFIECVTDADCLNSQSKMYALICEKNRCIYEFLKSMHYNLS	47	Sequence 901 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12821	ECINDIDCPQTGNLFYVFICKNRICELINKYPQN	34	Sequence 902 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12822	DIYEECETDDYCPKYRDLLYVFKCIDKRCELVEAHA	36	Sequence 903 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12823	VHDVAHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	44	Sequence 904 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12824	CETDADCPRYTHNNFSLKCINKKCEWSAKLH	31	Sequence 906 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12825	EDIGGNCECIRDEDCFKQKRDEDCHKEYCMIFYVHKCENYKCVCAGMFN	49	Sequence 907 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12826	QEVLQYELFDCNEDRDCDNVICVAGGIPKCITPFCFCF	38	Sequence 908 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12827	IYYPISRPCKTDKDCPNRKNYKGKCRKGFCMSSRLR	36	Sequence 909 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12828	ISIYVRCASTNECYTTFKFAPLGSMRCVEGYCKHLKDFKVKTPLQIKEITPLLLHFP	57	Sequence 910 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12829	YINCKTDDDCPKLESRMVVLKCTNSRCAAVILH	33	Sequence 911 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12830	NHEISGWITELPFGMCTSILDCPMDSCTHPQQPWCELHGVPILYHGSEIGLCICI	55	Sequence 912 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12831	NHAISGLLPKLPFGCCTSNLDCPRHMCTHPQQPWCIFYGNRIMYRGSRLGICKCS	55	Sequence 913 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12832	SLHEISGYVLGLPAGYCTSNHHCPVYNCTHPKQPWCKLVRLQLLFHGSLIGLCDCI	56	Sequence 914 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12833	LNECTQDYDCPIEMCPFPFQPKCIMLKNLSIFSNSGICSCT	41	Sequence 915 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12834	GNFFEFFHKCTQDSDCPSLLCRNKSELPKCIAGFMCRCPNV	41	Sequence 916 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12835	EPDDNQKNCVSDSDCYKKFHLPRHFIMKCIKNRCTFV	37	Sequence 917 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12836	HCVIDAHCPRNMCGFHFPPRCVEGDCVC	28	Sequence 918 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12837	QVKCKTVKDCPIRRNRKYYCLFGICKYDVM	30	Sequence 919 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12838	LCDSNRDCRGYHCNWPKFPICVRMICECI	29	Sequence 920 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12839	QIFPKWCLYDKDCPQNMCRPGRIPKCIFGHCNCVKQRS	38	Sequence 921 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12840	APPVYCIEDEDCYDLCTSPLVEICTNYQCICLKRF	35	Sequence 922 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12841	KNSQGNKENICFKDADCPQDICSYPFKPKCNIYGYCSC	38	Sequence 923 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12842	FLPCVTKDDCAYDECISPRKPTCYLETCHCL	31	Sequence 924 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12843	WRCKKTDDCIKIEFCKFPKIARCTKPKFLFLEFGTGFCTCD	41	Sequence 925 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12844	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	47	Sequence 2 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12845	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	48	Sequence 3 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12846	SSLLEKGLDGAKKAVGGLGKLGKDA	25	Sequence 4 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12847	SSLLEKGLDGAKKAVGGLGKLGK	23	Sequence 5 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12848	YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	90	Sequence 6 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12849	YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	91	Sequence 7 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12850	GDDPDEDAINNALNKVCSTG	20	Sequence 1 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12851	RRQRSICKQLLKKLRQQLSDALQNNDD	27	Sequence 2 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12852	VCSTGRRQRSICKQLLKKLRQQ	22	Sequence 3 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12853	AINNALNKVCSTGRRQRSICKQLLKKLRQQ	30	Sequence 4 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12854	AGPAYXVGYXGNXGXVT	17	Sequence 1 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12855	AGPAYXVGYXGNNGAVT	17	Sequence 2 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12856	AGXIXSGSVAV	11	Sequence 3 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12857	MRKIVAGKLQTGADFEGSKWGCVCSGSTAVANSHNAGPAYCVGYCGNNGVVTRNANANVAKTA	63	Sequence 4 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12858	MRKIVAGKLQTGADFEGSKGGCKCSGGAVVENSHNAGPAYCVGYCGNNGVVTRNANANLARTK	63	Sequence 5 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12859	MKLVETKTTKTGTNFEGNRAGCICNGTVAVANSHNAGPAYCVGYCGNSGVVTRNANANVAKTA	63	Sequence 6 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12860	AGVIXXGTXAV	11	Sequence 10 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12861	AGPAY	5	Sequence 11 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12862	AGXVXSGSTAV	11	Sequence 12 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12863	QSFEWIYKQIKKLWA	15	Sequence 1 from Patent US 20120308638	Synthetic constructn	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12864	MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA	51	Sequence 3 from Patent US 20120308638	Synthetic constructn	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12865	MAGFLKVVQILAKYGSKAVQWAWANKGKILDWINAGQAIDWVVEKIKQILGIK	53	Sequence 4 from Patent US 20120308638	Lactococcus lactis QU 14	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12866	MAGFLKVVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVSKIKQILGIK	53	Sequence 5 from Patent US 20120308638	Lactococcus lactis QU 5	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12867	MNMNFTKLFAIVLLAALVLLGQTEAGGLKKLGKKLEGAGKRVFKASEKALPVVVGIKAIGK	61	Sequence 1 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12868	GGLKKLGKKLEGAGKRVFKASEKALPVVVGIKAIGK	36	Sequence 2 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12869	MNMNFTKLFAIVLLAALVLLGQTEA	25	Sequence 3 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12870	GIGKFLHSAKKFGKAFVGEIMNSK	24	Sequence 1 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12871	IGKFLHAAKKFAKAFVAEIMNS	22	Sequence 2 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12872	GIGKFLHAAKKFAKAFVAEIMNS	23	Sequence 3 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12873	GIGKFLHSAKKFAKAFVAEIMNS	23	Sequence 4 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12874	IGKFLHSAKKFAKAFAFVAEIMNS	24	Sequence 5 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12875	FQWQRN	6	Sequence 1 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12876	FQWQR	5	Sequence 2 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12877	QWQR	4	Sequence 3 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12878	RRWQW	5	Sequence 5 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12879	RRWQ	4	Sequence 6 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12880	WQWR	4	Sequence 7 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12881	LRWQND	6	Sequence 9 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12882	LRWQN	5	Sequence 10 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12883	LRWQ	4	Sequence 11 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12884	FQWQRX	6	Sequence 13 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12885	RWQWR	5	Sequence 1 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12886	RRQWR	5	Sequence 2 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12887	KVSWR	5	Sequence 3 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12888	RNMRK	5	Sequence 4 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12889	RWQEK	5	Sequence 5 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12890	RRWQWR	6	Sequence 6 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12891	RRRQWR	6	Sequence 7 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12892	KTVSWR	6	Sequence 8 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12893	KRNMRK	6	Sequence 9 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12894	RWQEMK	6	Sequence 10 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12895	KTRRWQWRMKK	11	Sequence 11 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12896	KSRRRQWRMKK	11	Sequence 12 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12897	KTVSWQTYMKK	11	Sequence 13 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12898	KTFQWQRNMRK	11	Sequence 14 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12899	KTLRWQNEMRK	11	Sequence 15 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12900	RWQWX	5	Sequence 16 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12901	RRWQWX	6	Sequence 17 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12902	KTRRWQWRMKX	11	Sequence 18 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12903	IIGGR	5	Sequence 1 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12904	IVGGR	5	Sequence 2 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12905	HPQYNQR	7	Sequence 3 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12906	HPAYNPK	7	Sequence 5 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12907	HPAYNPR	7	Sequence 6 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12908	HPAYNQR	7	Sequence 7 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12909	HPQYAQR	7	Sequence 8 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12910	HPQYNQA	7	Sequence 9 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12911	HPQYNAR	7	Sequence 10 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12912	HAQYNQR	7	Sequence 11 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12913	HPQYNQ	6	Sequence 12 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12914	RHPQYNQR	8	Sequence 13 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12915	HPQYNQRTIQNDIMLLQLSR	20	Sequence 14 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12916	APQYNQR	7	Sequence 15 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12917	IIGGRESRPHSRPYMAYLQI	20	Sequence 16 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12918	QSPAGQSRCGGFLVREDFVL	20	Sequence 17 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12919	TAAHCWGSNINVTLGAHNIQ	20	Sequence 18 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12920	RRENTQQHITARRAIRHPQY	20	Sequence 19 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12921	RVRRNRNVNPVALPRAQEGL	20	Sequence 21 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12922	RPGTLCTVAGWGRVSMRRGT	20	Sequence 22 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12923	DTLREVQLRVQRDRQCLRIF	20	Sequence 23 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12924	GSYDPRRQICVGDRRERKAA	20	Sequence 24 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12925	FKGDSGGPLLCNNVAHGIVSY	21	Sequence 25 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12926	GKSSGVPPEVFTRFVSSFLPWIRTTMR	27	Sequence 26 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12927	IIGGH	5	Sequence 28 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12928	IIGGV	5	Sequence 29 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12929	HPQYNPQ	7	Sequence 30 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12930	HHQYNQR	7	Sequence 31 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12931	HPQANQR	7	Sequence 32 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12932	HPQKNTY	7	Sequence 33 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12933	HPQFNQR	7	Sequence 34 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12934	HPNYNQR	7	Sequence 35 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12935	HPEYNQR	7	Sequence 36 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12936	HPLYNQR	7	Sequence 37 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12937	RPGLTLCTVAGWG	13	Sequence 38 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12938	CTVAGWGRVSMRRGT	15	Sequence 39 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12939	WGRVSMRRGT	10	Sequence 40 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12940	KPGQTCSVAGWGQTAPLGKS	20	Sequence 42 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12941	KPQDVCYVAGWGRMAPMGKY	20	Sequence 43 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12942	EAQTRCQVAGWGSQSRSGGR	20	Sequence 44 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12943	GNGVQCLAMGWGLLGRNRGI	20	Sequence 45 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12944	PHGTQCLAMGWGRVGAHPPP	20	Sequence 46 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12945	AAGTTCVTTGWGLTRYTNAN	20	Sequence 47 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12946	GIGKFLHSAKKFKAFVGEIMN	21	Sequence 48 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12947	HPQYNPK	7	Sequence 49 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12948	HPQYNPR	7	Sequence 50 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12949	YPCYDPA	7	Sequence 51 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12950	HPAYNAK	7	Sequence 52 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12951	HPDYNQR	7	Sequence 53 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12952	YPCYDEY	7	Sequence 54 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12953	HPDYNPK	7	Sequence 55 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12954	HPDYNPD	7	Sequence 56 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12955	HPDYNAT	7	Sequence 57 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12956	HPAYDDK	7	Sequence 58 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12957	HPAFDRK	7	Sequence 59 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12958	DFASCHTNGGICLPNRCPGHMIQIGICFRPRVKCCRSW	38	Sequence 1 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12959	VRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	40	Sequence 2 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12960	EGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	42	Sequence 3 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12961	ERVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPCCRR	41	Sequence 4 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12962	EVVRNPQSCRWNMGVCIPISCPGNMRQIGTCFGPRVPCCR	40	Sequence 5 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12963	EGVRNHVTCRIYGGFCVPIRCPGRTRQIGTCFGRPVKCCRRW	42	Sequence 6 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12964	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPRIKCCR	40	Sequence 7 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12965	VRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	38	Sequence 8 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12966	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	40	Sequence 9 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12967	EGVRSYLSCWGNRGICLLNRCPGRMRQIGTCLAPRVKCCR	40	Sequence 10 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12968	GPLSCRRNGGVCIPIRCPGPMRQIGTCFGRPVKCCRSW	38	Sequence 11 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12969	YCXXNXGHCHPIRCPGXXRQIGTCHGZXHKCCR	33	Sequence 14 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12970	QIGTCFGRPVK	11	Sequence 17 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12971	NGGVCIPIR	9	Sequence 18 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12972	PVPMR	5	Sequence 19 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12973	PTHG	4	Sequence 20 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12974	SKMIEGVFAKGFKGASHLFKGIG	23	Sequence 9 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12975	SNMIEGVFAKGFKKASHLFKGIG	23	Sequence 10 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12976	XXMIEXVFAKXFKXAXXLFKGIG	23	Sequence 12 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12977	RPGGQIAIAIGESIRKKASNELKKATKSLWS	31	Sequence 13 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12978	KAIQTAQGVVAVAPGAKIIGDRINQGVKEIKKFLKWK	37	Sequence 14 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12979	LAKLAVKAIKGAIAGAKSAMG	21	Sequence 15 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12980	RNSLPKVAYATA	12	Sequence 16 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12981	RQIIVFMRKKNFVTKILKKQR	21	Sequence 17 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12982	AKSRWY	6	Sequence 18 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12983	IGEDVYTPGISGDSLR	16	Sequence 19 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12984	GIGKFLREAGKFGKAFVGEIMKP	23	Sequence 20 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12985	MGRIARGSKMSSLIVSLLVVLVSLNLASETTA	32	Sequence 21 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12986	MGKNGSLCCFSLLLLLLLAGLASGHQVL	28	Sequence 22 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12987	KKIEKAIKHIPKKIKAGPGVTIGIAHAKSQLW	32	Sequence 1 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12988	KLKKALRALARHWKAGPGVTIGIAHAKSQLW	31	Sequence 2 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12989	QRAVRRIYRAIRHIPRRIRIRALAGPGVTIGIAHAKSQLW	40	Sequence 3 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12990	QRAVKKIEKAIKHIPKKIKIRALAGPGVTIGIAHAKSQLW	40	Sequence 4 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12991	IQRVAQKLKKALRALARHWKRALAGPGVTIGIAHAKSQLW	40	Sequence 5 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12992	IRALQRAVRHPRAIRRIYRGWKKAIRAGPGVTIGIAHAKSQLW	43	Sequence 6 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12993	KLIRKLIRWLRRKIRALQRAVAGPGVTIGIAHAKSQLW	38	Sequence 7 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12994	QRAVGWLRRIGRRIERVGQHLRALAGPGVTIGIAHAKSQLW	41	Sequence 8 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12995	RRIYRAIRHIPRRIRGWLRRIGRRIERVGQH	31	Sequence 9 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12996	KKIEKAIKHIPKKIKLKKALRALARHWK	28	Sequence 10 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12997	GWLRRIGRRIERVGQHKLKKALRALARHWK	30	Sequence 11 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12998	KLKKALRALARHWKGWLRRIGRRIERVGQH	30	Sequence 12 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12999	AIAKFAKKALKSMLALMGEAVQT	23	Sequence 13 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13000	AIAIFKRIAKINFKALMGEAVQT	23	Sequence 14 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13001	AIANFERLMKKLIWALMGEAVQT	23	Sequence 15 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13002	KLKKALRALARHWK	14	Sequence 16 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13003	IQRVAQKLKKALRALARHWKRAL	23	Sequence 17 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13004	IRALQRAVRHPRAIRRIYRGWKKAIR	26	Sequence 18 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13005	KWKKALRALARHLK	14	Sequence 19 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13006	KLKKALRWLARHAK	14	Sequence 20 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13007	GAYRAIRHIPRRIR	14	Sequence 21 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13008	RRIYRAIRHIPRRIR	15	Sequence 22 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13009	IVGGRKARPRQFPFLASIQNQGRHF	25	Sequence 2 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13010	IVGGHEAXXPSDPYMDSLDM	20	Sequence 3 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13011	IHNFNINY	8	Sequence 4 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13012	TCRYLLVRSLQTFSQAWFTCRRCYRGNLVSIHNFNINYRI	40	Sequence 7 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13013	IVGGHEAQPHSRPYMASLEM	20	Sequence 8 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13014	IVGGRKARPHQFPFLASIQN	20	Sequence 9 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13015	IVGGHEAQPHSRPYMASLZM	20	Sequence 10 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13016	CYCRIPACIAGERRY	15	Sequence 11 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13017	VXSXRLVFXRRTGLR	15	Sequence 12 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13018	XPPQFTRAQWFAIQH	15	Sequence 13 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13019	IIGGRESRPHSRPYM	15	Sequence 14 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13020	TCRYLLVRSLQTFSQ	15	Sequence 16 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13021	IVGGRKARPRQFPFL	15	Sequence 17 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13022	IVGGHEAXXPSDPYM	15	Sequence 18 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13023	VNCETSCVQQPPCFP	15	Sequence 19 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13024	IVGGRRARPHAXPXM	15	Sequence 20 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13025	VNPGVVVRISQKGLD	15	Sequence 21 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13026	RVIEVVQGACRAIRHIPRRIRQGLERIL	28	Sequence 1 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13027	YHRLRDLLLIVTRIVELLGRR	21	Sequence 2 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13028	DLWETLRRGGRWILAIPRRIRQGLELTL	28	Sequence 3 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13029	FLIRQLIRLLTWLFSNCRTLLSRVY	25	Sequence 4 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13030	LLSRVYQILQPILQRLSATLQRIREVLR	28	Sequence 5 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13031	RIAGYGLRGLAVIIRICIRGLNLIFEIIR	29	Sequence 6 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13032	RVIEVVQGACRAIRHIPRRIR	21	Sequence 7 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13033	VVQGACRAIRHIPRRIR	17	Sequence 8 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13034	GACRAIRHIPRRIR	14	Sequence 9 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13035	RVIRVVQGACRAIRHIPRRIR	21	Sequence 10 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13036	RVIEVVRGACRAIRHIPRRIR	21	Sequence 11 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13037	RVIEVVQGICRAIRHIPRRIR	21	Sequence 12 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13038	RVISVVQGACRAIRRIPRRIR	21	Sequence 13 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13039	RVIRVVQGACRAIRHIPRRIRQGLERIL	28	Sequence 14 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13040	RVIEVVRGACRAIRHIPRRIRQGLERIL	28	Sequence 15 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13041	RVIEVVQGICRAIRHIPRRIRQGLERIL	28	Sequence 16 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13042	RVISVVQGACRAIRRIPRRIRQGLERIL	28	Sequence 17 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13043	RVIEVVQGACRAIRHIPRRIRQILERIL	28	Sequence 18 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13044	RVIEVVQGACRAIRHIPRRIRQGLRRIL	28	Sequence 19 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18752	RCLCGRGFC	9	Sequence 32 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18750	RCLCGLGVC	9	Sequence 30 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18751	RCLCGRGVC	9	Sequence 31 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18749	RCLCVRGIC	9	Sequence 29 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13048	RVIEVVQGACRAIRRIPRRIR	21	Sequence 23 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18747	RCLCRRGVC	9	Sequence 27 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18748	RCLCTRGIC	9	Sequence 28 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18746	RCICGRGFC	9	Sequence 26 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18744	RCICGLGIC	9	Sequence 24 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18745	RCICGRGVC	9	Sequence 25 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13052	RVIEVVQGACRAIRRIPRRIRQGLERIL	28	Sequence 27 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13053	VVRGACRAIRHIPRRIR	17	Sequence 28 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13054	VVQGICRAIRHIPRRIR	17	Sequence 29 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13055	VVQRACRAIRRIPRRIR	17	Sequence 30 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13056	VVRGACRAIRHIPRRIRGLERIL	23	Sequence 31 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13057	VVQGICRAIRHIPRRIRGLERIL	23	Sequence 32 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13058	VVQGACRAIRRIPRRIRGLERIL	23	Sequence 33 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13059	GACRAIRRIPRRIR	14	Sequence 34 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13060	GACRAIRRIPRRIRGLERIL	20	Sequence 35 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13061	VVQRACRAIRHIPRRIR	17	Sequence 36 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13062	RACRAIRHIPRRIR	14	Sequence 37 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13063	RVIRVVRGACRAIRHIPRRIR	21	Sequence 38 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18743	RCICVRGIC	9	Sequence 23 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13065	RRIRHIPRAIRVVQGAC	17	Sequence 40 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13066	RIRRPIHRIARCAGQVVEIVR	21	Sequence 41 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13067	LIRELGQRIRRPIHRIARCAGQVVEIVR	28	Sequence 42 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13068	LIRELGQRIRRPIHRIARCAGQVVRIVR	28	Sequence 43 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13069	LIRELGQRIRRPIHRIARCAGRVVEIVR	28	Sequence 44 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13070	LIRELGQRIRRPIHRIARCIGQVVEIVR	28	Sequence 45 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13071	LIRELGQRIRRPIRRIARCAGQVVEIVR	28	Sequence 46 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13072	LIRELGIRIRRPIHRIARCAGQVVEIVR	28	Sequence 47 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13073	LIRRLGQRIRRPIHRIARCAGQVVEIVR	28	Sequence 48 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18741	RCICRRGIC	9	Sequence 21 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18742	RCICTRGIC	9	Sequence 22 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13075	RIRRPIHRIARCAGQVVRIVR	21	Sequence 50 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13076	RIRRPIHRIARCAGRVVEIVR	21	Sequence 51 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13077	RIRRPIHRIARCIGQVVEIVR	21	Sequence 52 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13078	RIRRPIRRIARCAGQVVEIVR	21	Sequence 53 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13079	RIRRPIHRIIRCIGQVVRIVR	21	Sequence 54 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13080	RIRRPIRRIIRCIGQVVEIVR	21	Sequence 55 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13081	LIRELGQRIRRPIHRIARCAGQVV	24	Sequence 56 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13082	LIRELRQRIRRPIHRIARCARQVV	24	Sequence 57 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13083	LIRELGQRIRRPIHRIARCAGRVV	24	Sequence 58 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13084	LIRELGQRIRRPIHRIARCIGQVV	24	Sequence 59 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13085	LIRELGQRIRRPIRRIARCAGQVV	24	Sequence 60 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13086	LIRELGIRIRRPIHRIARCAGQVV	24	Sequence 61 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13087	LIRRLGQRIRRPIHRIARCAGQVV	24	Sequence 62 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13088	LIRELGQRIRRPIHRIARCAG	21	Sequence 63 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13089	LIRELGQRIRRPIHRIARCAR	21	Sequence 64 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13090	LIRELGQRIRRPIHRIARCAI	21	Sequence 65 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13091	LIRELGQRIRRPIHRIARCIG	21	Sequence 66 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13092	LIRELGQRIRRPIRRIARCAG	21	Sequence 67 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13093	LIRELGIRIRRPIHRIARCAG	21	Sequence 68 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13094	LIRRLGQRIRRPIHRIARCAG	21	Sequence 69 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13095	RAIRRAIRGAPRAIL	15	Sequence 70 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13096	RAIRRAIRGAPRAILRAIL	19	Sequence 71 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13097	KVIEVVQGACKAIKHIPKKIKQGLEKIL	28	Sequence 72 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13098	LWETLRRGGRWILAIPRRIR	20	Sequence 73 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13099	DLWETLRRIIRWILAIPRRIRQGLELTL	28	Sequence 74 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13100	DLWETLRRGGRWILAIPRRIRQGLELCL	28	Sequence 75 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13101	DLWETLRRGCRWILAIPRRIRQGLELTL	28	Sequence 76 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13102	DLWETLRRIIRWILAIPRRIRQGLELCL	28	Sequence 77 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13103	LWETLRRGGRWILAIPRRIRQGLELTL	27	Sequence 78 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13104	LWETLRRGGRWILAIPRRIRQGLELCL	27	Sequence 79 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13105	LWETLRRGCRWILAIPRRIRQGLELTL	27	Sequence 80 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13106	LWRTLRRGGRWILAIPRRIRQGLELTL	27	Sequence 81 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13107	LWETLRRGGRWILAIPRRIRQGLRLTL	27	Sequence 82 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13108	LWETLRRGGRWILAIPRRIRRGLELTL	27	Sequence 83 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13109	LWETLRRGGRWILAIPRRIRRQIELTL	27	Sequence 84 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13110	LWELLRRGGRWILAIPRRIRQGLELTL	27	Sequence 85 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13111	LWRLLRRGGRWILAIPRRIRQGLELTL	27	Sequence 86 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13112	DLWETLRRIIRWILAIPRRIR	21	Sequence 87 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13113	DLWETLRRGGRWILAIPRRIR	21	Sequence 88 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13114	DLWETLRRGCRWILAIPRRIR	21	Sequence 89 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18740	RCLCGRGIC	9	Sequence 20 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13116	LWETLRRIIRWILAIPRRIR	20	Sequence 91 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13117	LWETLRRGCRWILAIPRRIR	20	Sequence 92 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18738	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL	76	Sequence 17 from Patent US 20090264344	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18739	RCICGRGIC	9	Sequence 19 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18737	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL	76	Sequence 15 from Patent US 20090264344	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18736	MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD	97	Sequence 13 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13121	LWELLRRGGRWILAIPRRIR	20	Sequence 96 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13122	LWRLLRRGGRWILAIPRRIR	20	Sequence 97 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13123	LRRGGRWILAIPRRIR	16	Sequence 98 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13124	LWETLRRGGRWILAIPRAIL	20	Sequence 99 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13125	LRRGGRWILAIPRAIL	16	Sequence 100 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13126	LWETLRRGGRWILAIPREIL	20	Sequence 101 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13127	LRRGGRWILAIPREIL	16	Sequence 102 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13128	WILAIPRRIRGGRLWETL	18	Sequence 103 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13129	WETLPRRIRGGRLWILAI	18	Sequence 104 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13130	RIRRPIALIWRGGRRLTEWL	20	Sequence 105 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13131	DLWETLKKGGRWILAIPRRIKQGLELTL	28	Sequence 106 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13132	LWETLGRVGRWVLAIPRRIRQGLELAL	27	Sequence 107 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13133	YHRLRRLLLIVTRIVELLGRR	21	Sequence 108 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13134	YHRLRDLLRIVTRIVELLGRR	21	Sequence 109 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13135	YHRLRDLLLIVRRIVELLGRR	21	Sequence 110 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13136	YHRLRDLLLIVTRIVRLLGRR	21	Sequence 111 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13137	YHRLRDLLLIVTRIVCLLGRR	21	Sequence 112 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13138	YHRLRDLLLIVRRIVCLLGRR	21	Sequence 113 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13139	YHRLLRDLLIVTRIVELLGRR	21	Sequence 114 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13140	YHRLRRLLLIVTRIVELL	18	Sequence 115 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13141	YHRLRDLLRIVTRIVELL	18	Sequence 116 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13142	YHRLRDLLLIVRRIVELL	18	Sequence 117 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13143	YHRLRDLLLIVTRIVRLL	18	Sequence 118 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13144	YHRLRDLLLIVTRIVCLL	18	Sequence 119 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13145	YHRLRDLLLIVRRIVCLL	18	Sequence 120 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13146	YHRLLRDLLIVTRIVELL	18	Sequence 121 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13147	YHRLRDLLLIVTRIVELL	18	Sequence 122 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13148	RRGLLEVIRTVILPRRLLDRL	21	Sequence 123 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13149	YHRLRDLALIVTRIVELL	18	Sequence 124 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13150	RRGLLRVIRTVILALDIL	18	Sequence 125 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13151	RRGLLEVIRTVILLLDRLRHY	21	Sequence 126 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13152	RRGLLEVIRTVILALDRLRHY	21	Sequence 127 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13153	RRGLLEVIRTVILALDRL	18	Sequence 128 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13154	YHRLRDLLLIVCRIVELL	18	Sequence 129 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13155	YHRLRDLLLIVCRIVELLGRR	21	Sequence 130 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18734	RGCICRCIGRGCICRCIG	18	Sequence 10 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18735	AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL	59	Sequence 12 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13157	RRGLLEVIRCVILLLDRL	18	Sequence 132 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13158	RRGLLRVIRTVILLLDRL	18	Sequence 133 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13159	RRGLLEVIRTVILLLRRL	18	Sequence 134 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13160	RRGLLEVIRCVILLLDRLRHY	21	Sequence 135 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13161	RRGLLRVIRTVILLLDRLRHY	21	Sequence 136 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13162	RRGLLEVIRTVILLLRRLRHY	21	Sequence 137 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13163	YHKLKLLLIVTKIVELLGKK	20	Sequence 138 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13164	FLIRQLIRQLLTWQPILQYILQ	22	Sequence 139 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13165	FLIRQLIRLLTWLFSNCRTLLSEVY	25	Sequence 140 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13166	FLIRQLIRLLTWLFSNCRTLL	21	Sequence 141 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13167	LLTRCNSFLWTLLRILQRILF	21	Sequence 142 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13168	FLIRQLIRLLTWLFPNCRTLLSRVY	25	Sequence 143 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13169	YVRSLLTRCNSFLWTLLRILQRILF	25	Sequence 144 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13170	FLIKQLIKLLTWLFSNCKTLLSKVY	25	Sequence 145 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13171	RLVERIRQLTASRQLIPQLIQYV	23	Sequence 146 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13172	RLVRRIRQLTASRQLIPQLIQYV	23	Sequence 147 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13173	LLSRVYQILQPILQRLSATLQAIREVL	27	Sequence 148 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13174	LLSRVYQILQPILQRLCATLQRIREVLR	28	Sequence 149 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13175	RLVERIRQLTASLRQLIPQLIQYVRSLL	28	Sequence 150 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13176	LLSKVYQILQPILQKLSATLQKIKEVLK	28	Sequence 151 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13177	RLLTWLFSNCRTLLSRVYQILQPIL	25	Sequence 152 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13178	RLLTWLFSNRRTLLSRVYQILQEIL	25	Sequence 153 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13179	RLLTWLRRTLLSRVYQILQEIL	22	Sequence 154 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13180	RIAGYGLRGLAVIIRCIIRGLNLIFEIIR	29	Sequence 155 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13181	RIAGYGLRGLAVIIRIICRGLNLIFEIIR	29	Sequence 156 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13182	RIAGYGLRGLAVIPRRICIRGLNLIFEIIR	30	Sequence 157 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13183	RIIEFILNLGRICIRIIVALGRLGYGAIR	29	Sequence 158 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13184	KIAGYGLKGLAVIIKICIKGLNLIFEIIK	29	Sequence 159 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13185	RVIRVVQGACRAIRHIPRRIRQGLRRIL	28	Sequence 160 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13186	RVIEVVQGACRAIEHIPRRIEQGLERIL	28	Sequence 161 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13187	RVIEVVQGACRAIEHIPRRIRQGLERIL	28	Sequence 162 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13188	RVIEVVQGACRAIRHIPRRIEQGLERIL	28	Sequence 163 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13189	RVIEVVQGACRASRHIPRRIRQGLERIL	28	Sequence 164 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13190	RVIEVVQGACRAIRHIPRRSRQGLERIL	28	Sequence 165 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13191	FLIRQLIELLTWLFSNCRTLLSEVY	25	Sequence 166 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13192	LLSEVYQILQPILQELSATLQRIREVLR	28	Sequence 167 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13193	YHELRDLLLIVTRIVELLGRE	21	Sequence 168 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13194	RVIEVVQGAYRAIRHIPRRIRQGLERIL	28	Sequence 169 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13195	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNXLNRYR	37	Sequence 1 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13196	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNWLNRYR	37	Sequence 2 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13197	GXFKKAXRKVKNAGRRVLKGVGIHYGVGLI	30	Sequence 3 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13198	GFFKKAWRKVKHAGRRVLDTAKGVGRHYVNNWLNRYR	37	Sequence 4 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13199	LCNERPSQTWSGNCGNTAHCDKQCQDWEKASHGACHKRENHWKCFCYFNC	50	Sequence 2 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13200	ZKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 3 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13201	ZKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 4 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13202	ELCEKASKTWSGNCGNTGHCDNQCKSWEGAAHGACHVRNGKHMCFCYFNC	50	Sequence 5 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP15055	MERIYVIPLRKAKNVPRTIRAPKAVKIVREFLMKHMKADTVKLDESINEKLWERGIQKIPPRIKVKAVKDEDGVVEATLEE	81	Sequence 889 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15056	MKKAIHFQSQPVVFNCASCNSNFTIDSTAKQKDLAIDICGKCHPFYIGQLTKQTVHGRAEKLSQKFNAGKAFLENKTKKSNQAKVEKQTRHRSINEL	97	Sequence 890 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15057	MKANIHPAYAETTVVCGCGNTFQTRSTKPGGRIVVEVCSQCHPFYTGKQKILDSGGRVARFEKRYGKRKVGVDQVAAYPEQNNK	84	Sequence 891 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15058	MKKDFHFPSQSVSFKCASCSNSFTIESTLKQKEITIDICGKCHPFYIGELTKQTVHGRAEKLSGKFNAGKAFLENKTPKKAKGKTEEYTKHRSLNEL	97	Sequence 892 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15059	MKSDIHPAYEETTVVCGCGNTFQTRSTKPGGRIVVEVCSQCHPFYTGKQKILDSGGRVARFEKRYGKRKVGADKAVSTGK	80	Sequence 893 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15060	MPKADIHPTWYPDAKVTCNGEVIMTVGSTKPEINVEIWSGNHPFYTGTQKIIDTEGRVDRFMRKYGMKEKTTGDKQDKKKK	81	Sequence 895 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15061	AVPFRRTSKTRKRLRRTHFKLQVPGMVQCPNCGEWKLAHRVCKACGTYKGRDVVNK	56	Sequence 896 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15062	AVPFRRTSKMKKRLRRTHFKLNVPGMTECPSCGEMKLSHRVCKACGSYNGKDINVKSN	58	Sequence 897 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15063	MAKHPVPKKKTSKSKRDMRRSHHALTAPNLTECPQCHGKKLSHHICPNCGYYDGRQVLAV	60	Sequence 898 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15064	AVQQNKPTRSKRGMRRSHDALTAVTSLSVDKTSGEKHLRHHITADGYYRGRKVIAK	56	Sequence 903 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15065	AVQQNKKSRSRRDMRRSHDALTTAAVSVDKASGETHLRHHVTADGYYRGRKVINK	55	Sequence 904 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15066	MAVPDRRVSKTRAAKRRTHYSVKLAKPIKAKDGTWKLPHHINKFTKEY	48	Sequence 905 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15067	MAVPARHTSSAKKNRRRTHYKLTAPTVTFDETTGDYRHSHRVSLKGYYKGRKVRDDTK	58	Sequence 907 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15068	AVQQRRSSKHRRDKRRSHDALTLQTLSVCKKCGKKKLSHRVCSCGMYGELRVKKAH	56	Sequence 911 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15069	AVQQRRSSKHRRDKRRSHDALTAQALSVCQKCGKKKLFHRVCSCGMYGDLRVKKAY	56	Sequence 912 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15070	AVPKKKTSKAKRDQRRAHWRRQASSQAQKALSLGKSILSGRSTFLYPPAEEEGEEE	56	Sequence 913 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15071	AKHPVPKKKTSKARRDARRSHHALTPPILVPCPECKAMKPPHTVCPECGYYAGRKVLEV	59	Sequence 914 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15072	MKKKVTLACKNCGSRNYTTMKSSAALAERLEVKKYCNNCNSHTVHLETK	49	Sequence 916 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15073	MRVNITLACTECGERNYITSKNKRNNPERLELKKYCPRDRKVTLHRETK	49	Sequence 917 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15074	MRKKITLACKTCGNRNYTTMKSSASAAERLEVKKYCSTCNSHTAHLETK	49	Sequence 918 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15075	AKGIREKIKLVSSAGTGHFYTTTKNKRTKPEKLELKKFDPVVRQHVIYKEAKIK	54	Sequence 919 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15076	MAAKGAREKIRLVSTAETGHFYTTDKNKRNMPEKMEIKKFDPVVRKHVIYKEAKIK	56	Sequence 920 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15077	MKVKIGLKCSDCEDINYSTTKNAKTNTEKLELKKFCPRENKHTLHKEIKLKS	52	Sequence 921 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15078	MRVKITLICSSCGNKNYISSKNKATHPEKVETMKFCPKERIVTLHREG	48	Sequence 922 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15079	MRVNITLEHKESGERLYLTQKNKRNTPDKLELKKYSKKLRKHVIFKEVK	49	Sequence 923 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15080	MRSSTNKKATLVCVECLSRNYSVNKSGLTQKQRLEIKKFCTTCNAHTLHKETR	53	Sequence 924 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15081	MAVKRSTRLGCNECSEINYLTFKNVKKNPEKLALNKFCSRCRKVVLHKEVKRK	53	Sequence 925 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15082	MAVKRSTRLGCNDCREINYLTFKNVKKNPEKLALNKFCSRCRKVVVHKEVKRK	53	Sequence 926 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15083	MASSTDVRPKITLACEVCKHRNYITKKNRRNDPDRLELKKFCPNCGKHQAHRETR	55	Sequence 927 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15084	MAKKGKGARLVITLECTECRSNPDKRSNGVNRYTTMKNRRNTTARLELKKFCTHCNKHTIHKETK	65	Sequence 928 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15085	MRVKVALKCSQCGNKNYYTTRNKDKRAKLELRKYCPKCNAHTIHTETKA	49	Sequence 929 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15086	MASEVRIKLLLECTECKRRNYATEKNKRNTPNKLELRKYCPWCRKHTVHREVKI	54	Sequence 930 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15087	MKRTYQPNRRKRSKVHGFRARMSTKNGRKVLARRRRKGRKVLSA	44	Sequence 933 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15088	MKRTFQPNNRKRSKVHGFRSRMSSKNGRLVLARRRRKGRKVLSA	44	Sequence 934 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15089	MKRTYQPSRVKRNRKFGFRARMKTKGGRLILSRRRAKGRMKLTVSDEKKKY	51	Sequence 935 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15090	MKRTFQPSILKRNRSHGFRTRMATKNGRYILSRRRAKLRTRLTVSSK	47	Sequence 936 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15091	MKRTYQPSKQKRNRTHGFRARMATKNGRQVLNRRRAKGRKRLTV	44	Sequence 937 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15092	MKRTFQPSVLKRNRSHGFRARMATKNGRQVLARRRAKGRARLTVSK	46	Sequence 938 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15093	MKRTFQPSVLKRSRTHGFRARMATKNGRQVLARRRAKGRKSLSA	44	Sequence 939 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15094	MKRTYQPHNTPRKRTHGFLVRMKTKNGRKVINARRAKGRKKLSV	44	Sequence 940 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15095	MPAPRYRSRSYRRIYRRTPGGRIVIHYKRRKPGKPKCAICGAELHGVPRGRPVEIRKLPKSQRRPERPYGGYLCPRCLKRLMIQKARNL	89	Sequence 942 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15096	MPELRYRSRSYKRIFKKTPGGRTVTHYRRKKPSKHVCAGCGKPLHGVPRGRPYEIRKLSKSKKRPNRPYGGYYCSSCARKVFKKEARS	88	Sequence 943 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15097	MTKRTFQPNNRRRARKHGFRARMRTRAGRAILSARRGKNRAELSA	45	Sequence 944 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15098	MKRTWQPSKLKHARVHGFRARMATKNGRKVIKARRAKGRVRLSA	44	Sequence 945 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15099	MKRTYQPSKLKRAKTHGFMARMATAQGRKVLRQRRFKNRAQLTVSSER	48	Sequence 946 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15100	MRKGKRTFQPNNRRRARVHGFRLRMRTRAGRSIVSDRRRKGRRTLTA	47	Sequence 947 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15101	MKRTYQPSKLKRAKTHGFLARMATASGRKVLKLRRKKQRAQLTVSSER	48	Sequence 948 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15102	MAKGKRTFQPNNRRRALIHGFRARMRTRADRAIVAHRRSKGRRAPTA	47	Sequence 949 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15103	MTKGKRTFQPNNRRRARVHGFRLRMRTRAGRSIVSSRRRKGRRTLSA	47	Sequence 950 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15104	MKRTFQPSVLKRNRNHGFRARMATKNGRQVLARRRAKGRARLTVSSK	47	Sequence 952 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15105	MKRTFQPSTIKRARTHGFRARMATKNGRAVLSRRRAKGRKRLAI	44	Sequence 953 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15106	MSKRTFQPNNRRRAKTHGFRLRMRTRAGRAILANRRAKGRASLSA	45	Sequence 955 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15107	MSKRTFQPNNRRRAKTHGFRLRMRTRAGRAILATRRSKGRARLSA	45	Sequence 956 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15108	MPSPQQRSGSFRKVFVKLPSGKSTIHYERRKDNIARCGMCKKPLNGVKNNYTYKYSKTEKRPERVYGGYLCHKCLESLIKMTIRGIS	87	Sequence 957 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15109	MTQRTLGGTNRKQKRTSGFRARMRTHNGRKVIQARRSKGRHRLAV	45	Sequence 958 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15110	PKMKTHRGSAKRFKKTASGKLKRGHAYTSHLFANKTKKQKRHLRKATLVSPGDFKRIRQMLDNLK	65	Sequence 962 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15111	PKMKTHRGSAKRFKKTGSGKLKRSHAYTSHLFANKSQKQKRKLRKSAVVSAGDFKRIKQMLANIK	65	Sequence 963 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15112	MPKIKTLRSAAKRFKKTASGKFKRKQANLRHILTKKTTTKKRHLRPKILVSKGDISKVKSFLPYF	65	Sequence 964 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15113	PKIKTVRGAAKRFKKTGKGGFKHKHANLRHILTKKATKRKRHLRPKAMVSKGDLGLVIACLPYA	64	Sequence 966 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15114	PKIKTVRGAAKRFKKTASGGFKRKQSHLRHILTKKTTKRKRHLRHKSMVAKADQVLVVACLPYA	64	Sequence 967 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15115	MPKMKTNRGASKRFKVKKNLIKRGSAFKSHILTKKSPKRKANLNAPKHVHHTNAHSVMSLLCRA	64	Sequence 968 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15116	PKMKTKSALKKRIKITGTGKIMREQAYRSHLSQNKTTKQKRQARKSVQMHSSDVKRFKALI	61	Sequence 970 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15117	MKTKSAAVKRFKLTKSGQIKRKHAYTSHLAPHKSTKQKRHLRKQATVSNSELKRIGILI	59	Sequence 971 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15118	MKVKSAAKKRFKLTKSGQIKRKHAYTSHLAPHKTTKQKRHLRKQGTVSASDFKRIGNLI	59	Sequence 972 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15119	MPKMKTKSGAAKRFLKTANGIKHKHAFKSHILTKMSTKRKRQLRGSSLLHPSDVAKVERMLRLR	64	Sequence 973 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15120	MPKLKTRKAAAKRFRPTGSGKKIIRRKAFKNHLLEHKSSEQKHRRLSNLALVHEADEKNVRLMLPYM	67	Sequence 975 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15121	MKVRPSVKPICEKCKVIRRRGKVMVICENPKHKQRQG	37	Sequence 977 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15122	MKVRPSVKPICEKCKVIRRKGKVMVICENPKHKQKQG	37	Sequence 978 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15123	MAKSGIAAGVNKGRKTTAKEVAPKISYRKGASSQRTVFVRSIVKEVAGLAPYERRLIELIRNAGEKRAKKLAKKRLGTHKRALRKVEEMTQVIAESRRH	99	Sequence 980 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15124	MKVRASIKRICKDCKIIKRHGVNRVICINFKHKQRQG	37	Sequence 981 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15125	MKVRASVKKLCRNCKIVKRDGVIRVICSAEPKHKQRQG	38	Sequence 983 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15126	MKVRASVKKMCRNCKIVKREGVVRVLCSDPKHKQRQG	37	Sequence 984 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15127	MKVRPSVKKMCDNCKIIKRRGVIRVICATPKHKQRQG	37	Sequence 985 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15128	MKVRPSVKPICEYCKVIRRNGRVMVICPANPKHKQRQG	38	Sequence 986 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15129	MKVRASVKPICKDCKIIKRHRILRVICKTKKHKQRQG	37	Sequence 988 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15130	MKVRASVKPICKDCKIIKRHQIVRVICKTQKHKQRQG	37	Sequence 989 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15131	MKVNPSVKPICDKCRLIRRHGRVMVICSDPRHKQRQG	37	Sequence 990 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15132	MKVRASVRKICEKCRVIKRRGRVMVICANPKHKQRQG	37	Sequence 992 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15133	MKVRASVKKMCDKCRVIRRRGRVMVICSANPKHKQRQG	38	Sequence 993 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15134	MKVRASVKRICDKCKVIRRHGRVYVICENPKHKQRQG	37	Sequence 994 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15135	MKVRASVKKICRNCKVIKRNGVVRVICSEPKHKQRQG	37	Sequence 995 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15136	MGKGTASFGKRRNKSHTLCVRCGRRSFHIQKSRCSACAYPAARKRTYNWSVKAIRRKTTGTGRMRYLRNVPRRFKTCFREGTQATPRNKAAASSS	95	Sequence 996 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15137	MTKGTQAFGKKHVKSHTLCKRCGKSSFHIQKKRCASCGYQDAKKRTYNWGAKSIRRRTTGTGRTRHLRDVNARFRNGFRGTTPKPRAQPTN	91	Sequence 997 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15138	TGAGTPSQGKKNTTTHTKCRRCGEKSYHTKKKVCSSCGFGKSAKRRDYEWQSKAGE	56	Sequence 998 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15139	TKGTSSFGKRRNKTHTLCRRCGSKAYHLQKSTCGKCGYPAKRKRKYNWSAKAKRRNTTGTGRMRHLKIVYRRFRHGFREGTTPKPKRAAVAASSSS	96	Sequence 999 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15140	TKGTTSMGQRHGRTHILCRRCGRNSYHVQWERCAACAYPRASRRRYNWSVKAIKRRRTGTGRCRYLKVVNRRIANHFKTPKA	82	Sequence 1000 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15141	MSKGTPSMGKRNKGSYHIRCRRCGRRAYHVRKKRCAACGFPNKRMRKYSWQNKKVNGKRIK	61	Sequence 1001 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15142	MPKQIHEIKDFLLTARRKDARSVKIKRSKDIVKFKVRCSRYLYTLCVFDQEKADKLKQSLPPGLSVQDL	69	Sequence 1002 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15143	PRKIEEIKDFLLTARRKDAKSVKIKKNKDNVKFKVRCSRYLYTLVITDKEKAEKLKQSLPPGLAVKELK	69	Sequence 1003 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15144	MPKQIHEIKDFLLTARRKDARTVKIKKNKDMVKFKVRCSKYLYTLCVSDFEKADKLKQSLPPGLSVQDL	69	Sequence 1004 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15145	MPRQVTDIKLFLQLAHRGDATSARVKKNQNKAVKFKLRCSRYLYTLVVADAKKAEKLRQSLPPALTVTEVGKKA	74	Sequence 1005 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15146	MAREITDIKQFLELTRRADVKTATVKINKKLNKAGKPFRQTKFKVRGSSSLYTLVINDAGKAKKLIQSLPPTLKVNRL	78	Sequence 1006 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15147	MPSHKSFMIKKKLGKKMRQNRPIPHWIRLRTDNTIRYNAKHRHWRRTKLGF	51	Sequence 1007 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15148	MGKKTVGVKKRLAKAYKQNRRAPVWITVKTKRSVFGSPKRRHWRRSKLKV	50	Sequence 1008 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15149	MSALKKSFIKRKLAKKQKQNRPMPQWVRMKTGNTMKYNAKRRHWRRTKLKL	51	Sequence 1009 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15150	MAAHKSFRIKQKLAKKLKQNRSVPQWVRLATGNTIRYNAKRRHWRRTKLKL	51	Sequence 1010 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15151	GKKSKATKKRLAKLDNQNSRVPAWVMLKTDREVQRNHKRRHWRRNDTDE	49	Sequence 1011 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15152	SSHKTFRIKRFLAKKQKQNRPIPQWIRMKTGNKIRYNSKRRHWRRTKLGL	50	Sequence 1012 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15153	MPSHKTFRIKKKLAKKMRQNRPIPYWIRMRTDNTIRYNAKRRHWRRTKLGF	51	Sequence 1013 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15154	MMGSNKPLGKKVRLAKALKQNRRVPLFVIVKTRGRVRFHPKMRYWRRKKLKA	52	Sequence 1014 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15155	MSRNKHVARKLRMAKANRQNRRVPAWVMVKTNYRVRSHPKMRHWRRTKLKV	51	Sequence 1015 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15156	SKHKSLGKKLRLGKALKRNSPIPAWVIIKTQAEIRFNPLRRNWRRNNLKV	50	Sequence 1016 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15157	TVKTGIAIGLNKGKKVTSMTPAPKISYKKGAASNRTKFVRSLVREIAGLSPYERRLIDLIRNSGEKRARKVAKKRLGSFTRAKAKVEEMNNIIAASRRH	99	Sequence 1017 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15158	VIEPSLQVLARKYNCDKVVCRKCYARLHPRAVNCRKKKCGHSNHWRPKKKLK	52	Sequence 1027 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15159	IIEPSLMMLARKYNQDKMICRKCYARLHPRAVNCRKKKCGHSNQLRPKKKIK	52	Sequence 1028 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15160	IIEPSLMALARKYNQAKMICRKCYARLHPRAVNCRKKKCGHSNQLRPKKKIK	52	Sequence 1029 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15161	IIEPSLRQLAQKYNCDKQICRKCYARLPPRASNCRKKKCGHSSELRIKKKLK	52	Sequence 1030 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15162	IIEPSLQALARKYNQEKMICRKCYARLHPRAKNCRKKSCGHTNQLRPKKKLK	52	Sequence 1031 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15163	IIEPSLKALASKYNCEKQICRKCYARLPPRATNCRKRKCGHSSQIRPKKALKK	53	Sequence 1032 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15164	IEPSLVILARKYKCDKMICRKCYARLHPRAVNCRKKKCGHSNNLRPKKKLLK	52	Sequence 1033 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15165	IIEPSLRILAQKYNCDKMICRKCYARLHPRATNCRKKKCGHTNNLRPKKKLK	52	Sequence 1034 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15166	IIEPSLALLASKYNCEKKICRKCYARLPPRATNCRKKKCGHTSQLRPKKKPKN	53	Sequence 1035 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15167	IIEPSLRQLAQKYNCDKMICRKCYARLHPRAVNCRKKKCGHTNNLRPKKKVK	52	Sequence 1036 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15168	VMEPTLVALAKKYNWEKKVCRRCYARLPVRATNCRKKACGHCSNLRMKKKLR	52	Sequence 1037 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15169	MPFEEAMKRLFMKKICMRCNARNPWRATKCRKCGYKGLRPKAKEPRG	47	Sequence 1038 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15170	MARFEEAENRLFNIKICLKCNARNPPTAKTCRKCGYKGLRYKAKEPRG	48	Sequence 1039 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15171	IIEPSLMALARKYNQDKMICRKCYARLHPRAVNCRRKKCGHSNQLRPKKKIK	52	Sequence 1040 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15172	IIEPSLQALARKYNQDKMICRKCTARLHPRAVNCRKKKCGHSNQLRPKKKIKN	53	Sequence 1041 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15173	GMEPTIAALAKKYNCEKKVCRDCYARLPPKATNCRKRKCGHSNSLRLKKKPKE	53	Sequence 1042 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15174	IIEPSLKALASKFNCDKMICRKCYVRCPRRTPQRTCRVLTWIPQARLPPRATNCRKRKCGHTNHVRPKKKLK	72	Sequence 1043 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15175	VMEPTLEALAKKYNWEKKVCRRCYARLPVRATNCRKKGCGHCSNLRMKKKLR	52	Sequence 1044 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15176	VMEPTLEALAKKYNWEKKVCRRCYARLPVRASNCRKKACGHCSNLRMKKKLR	52	Sequence 1045 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15177	IIEPSLKALASKYNCDKSVCRKCYARLPPRATNCRKRKCGHTNQLRPKKKLK	52	Sequence 1046 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15178	MREKWKKKRSRRLRRKRRKMRARSK	25	Sequence 1047 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15179	MRAKWRKKRMRRLKRKRRKMRQRSK	25	Sequence 1048 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15180	MRWKWYKKRLRRLKRERKRARS	22	Sequence 1049 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15181	MRAKWKKKRMRRLKRKRRKMRQRSK	25	Sequence 1050 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15182	AKSKNHTAHNQTRKAHRNGIKKPKTYKYPSLKGVDPKFRRNHKHALHGTAKALAAAKK	58	Sequence 1052 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15183	VNVPKTKRAFCKGCKKHMMMKVTQYKTGKASLYAQGKRRYDRKQSGYGGQTKPVFHKKAKTTKKIVLRMQCQECKQTCMKGLKRCKHFEIGGDKKKGN	98	Sequence 1057 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15184	MQMPRRFNTYCPHCNEHQEHEVEKVRSGRQTGMKWIDRQRERNSGIGNDGKFSKVPGGDKPTKKTDLKYRCGECGKAHLREGWRAGRLEFQE	92	Sequence 1060 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15185	MKIPKKVRRYCPYCKKHTIHIVEKAKKGKPSELTWGQRQFRRVTAGYGGFPRPLPDRSKPVKKIDLRFKCTECGKMHTKANGCFRSGRFEFVEK	94	Sequence 1064 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15186	MKIPKERRTYCPNCRKHTVHEVLESKRRKASELKWGQRQFRRVTAGYRGYPRPLPSGNKPVKKLDLRLKCKECGKSHIKKKSFRAGRVEYVA	92	Sequence 1065 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15187	AAKKSFIIKQKLAKAKNQNRPLPQWFRLKTNNTIRYNAKRRHWRRTKLVC	50	Sequence 1070 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15188	AAQKSFRIKQKMAKAKKQNRPLPQWIRLRTNNTIRYNAKRRNWRRTKMNI	50	Sequence 1071 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15189	MAKIFRITGIMSKKGKDPLYFRKEYKALKPEDALEILYSEFGGRYKVKRSRIKILNIEEIKPEDVTDPVLKKLVTA	76	Sequence 1102 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15190	MKMKTKIFRVKGKFLMGDKLQPFTKELNAIREEEIYERLYSEFGSKHRVPRSKVKIEEIEEISPEEVQDPVVKALVQR	78	Sequence 1103 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15191	AEVKIFMVRGTAIFSASRFPTSQKFTKYVRALNEKQAIEYIYSQLGGKNKIKRYNIHIQEIKEVKEDEITDKTIRDLAKLDKIIM	85	Sequence 1104 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15192	AEVKIFMVRGTAIFSASRFPTSQKYVRALNEKQAIEYIYSQLGGKNKINDTTYTYKRSKKLRKMKSQTRQ	70	Sequence 1105 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15193	VFYKVTLSRSLIGVPHTTKSIVKSLGLGKRGSIVYKKVNPAIAGSLAKVKELVKVEVTEHELTPSQQRELRKSNPGFIVEKRTID	85	Sequence 1119 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15194	VKVKSKNSVIKLLSTAASGYSRYISIKKGAPLVTQVRYDPVVKRHVLFKEAKKRKVAERKPLDFLRTAK	69	Sequence 1122 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15195	MITKYFSKVIVRFNPFGKEAKVARLVLAAIPPTQRNMGTQIQSEIISDYNKVKPLVKVTYKDKKEMEVDPSNMNFQELANHFDRHSKQLDLKHMLEMH	98	Sequence 1123 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15196	MSKKSIIEREKKRKSLVKKYKNLRNFIKKEIKNELNFFEKIFLNFKLQKFPRDSSPCRLHNRCYLTGRPRGYYRFFGLSRHIFRDMAHYGLLPGVTKSSW	100	Sequence 1164 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15197	MAKKSMIERDRKRARLITKYAAKRKNLLVEIKTATSLEDKFNLHRKLQQLPRNSAPVRSHNRCTITGRPRGYFRDFGLSRHVLREYALQGFLPGVVKASW	100	Sequence 1165 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15198	MAKKSMIERDKKRENLMNKYLVKRQQLKTRLNETDSVEEKLLLNQELQKLPRNSAPSRVRIRCWLTGRPRGNYRDFGVSRHVLREMAHQGLLPGVTKSSW	100	Sequence 1166 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15199	MARKSLIQREKGRLKLENKYHFIRRSSKNEISKVPSLSDKWEIYGKLESPPRNSAPTRLRRRCFYTGRPRANYRDFGLCGHILREMVNACLLPGATRSSW	100	Sequence 1167 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15200	MSKKSLIARQRKRIILVLIHSHNRYVYRTNGKDEKSFEKKLRIYSFLQKLPRNSLRCRLRNRCYVTGRSRGYFRTFGLSRHILRDMAHYGLLPGVTKASW	100	Sequence 1168 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15201	MAKKSLIQREKKRQNLEKKYKILRNSLKKKITETSSLDEKWEFQKKLQSLPRNSAPTRLHRRCFLTGRPKANYRDFGLSRHLLREMAHACLLPGVTKSSW	100	Sequence 1170 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15202	MAKKSMIEREKKRIKLNNKYTPKRNTLLQAYRQTEDFQSRLDIHSKIQKLPRNSAKNRIRNRCWKTGRPRGFYRDFGVSRHVLREMAHSCLLPGVTKSSW	100	Sequence 1171 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15203	MAKKSLIAREKKRKKLEEKFYLIRRYPTKEMSKGGSLSESWEIQGKLEALPRNSAPTRLHRRCFLTGRPRANVRDFGLSGHILREMVHICLLPGATRSSW	100	Sequence 1173 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15204	MARKSLIQREKKRQALERKYHLIRQSLEEKSKVSSLDDKWEIHRKLQSSPRNSAPTRLHRRCSSTGRPRANYRDFGLSGHILREMAHACLLPGIKKSSW	99	Sequence 1174 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15205	MAKKNMIQREIKREKLEKKYYLKRLAIKEQLKKTTSFAEKIELRQKLQEMPRNSAPVRSRNRCWLTGRSRGYYRDFGLSRHVFREMSHECLLPGVTKSSW	100	Sequence 1175 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15206	MARKSLIQREKKRRNLEQKYHLIRRSSKQEIRKVTSLSDKWEIHGKLQSPPRNSAPARLHRRCFLTGRPRANIRDFGLSGHILREMVHTCLLPGATRSSW	100	Sequence 1176 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15207	MARKSLIQREKKRQKLEQKYHSIRRSSKKEISKVPSLSDKWEIYGKLQSPPRNSAPTRLHRRCFLTGRPRANYRDFGLSGHILREMVHACLLPGATRSSW	100	Sequence 1177 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15208	MKKKGGRKIFGFMVKEEKEENRGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRQRLLAYLAKKNRVRYKKLISQLDIREK	90	Sequence 1178 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15209	MSKNLFMDLSSISEKEKGSVEFQIFRLTNRVVKLTYHFKKHGKDYSSQRGLWKILGKRKRLLAYLFKTNFVSYENLIIQLGIRGLKKN	88	Sequence 1179 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15210	MKKKGGRKIFGFMVKEEKEENWGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRQRLLAYLAKKNRVRYKKLISQLDIRER	90	Sequence 1180 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15211	MINNLSISSSLIPDKQRGSVESQVFYLTNRVLRLTQHLQLHGRDYSSQRGLWKILSKRKQLLVYLSKRDKLRYDDLIGQLGIRGLKTR	88	Sequence 1181 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15212	MKKKGGRKIFGFMVKEEKEENRGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRRRLLAYLAKKNRVRYKKLIGQLNIREQ	90	Sequence 1182 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15213	MVKNSVISVISQEEKRGSVEFQVFNFTNKIRRLTSHLELHKKDYLSQRGLKKILGKRQRLLAYLSKKNRVRYKELINQLDIRETKTR	87	Sequence 1183 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15214	MLKIRLKRCGRKKQTSFKIVVMNNLDKRDGQAIEELGFMNPRTKEKYLNINKINHYLRLGAKPTKTVFDLLNKAKII	77	Sequence 1184 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15215	MVKLRLKRYGRKGQVTYRIVAMNNLSRRDGKAIEELGFYNPRTNESSLNIANIKRRIEQGAQPTNTVRYILAKANIL	77	Sequence 1185 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15216	MVKLRLKRCGRKQQAVYRIVAIDVRSRREGRDLRKVGFYDPIKNQTCLNVPAILYFLEKGAQPTRTVYDILRKAEFFKEKERTLS	85	Sequence 1186 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15217	MVKLRLKRCGRKQQAIYRIVAIDVRSRREGRDLRKVGFYDPIKNQTCLNVPAILYFLEKGAQPTRTVYDILRKAEFFKDKERTLS	85	Sequence 1187 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15218	MLKLRLKRSGRKKQPSYRLVVMENTTRRDGRPVEQVGYYNTITKESYFDVIKIKKWLNYGAKPTQTVLNLLKKAKIIDQ	79	Sequence 1188 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15219	MLKLRLKRCGRKQRFYDPIKNQTCLNVPAILYFLEKGAQPTRTVSDILRKAEFFKEKERTLS	62	Sequence 1189 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15220	MVKLRLKRYGRKQQPSYRIVAMDSRSKRDGKAIEELGFYNPITNETRIDIAKILKRLKQGAQTTRTVKNILNEAQIIAKENS	82	Sequence 1190 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15221	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGRDLRKVGFYDPITNQTYLNLPAILDFLKKGAQPTRTVHDISKKAGIFTELNLNKTKLN	88	Sequence 1191 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15222	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGKDLQKVGFYDPIKNQTYLNVPAILYFLEKGAQPTETVQDILKKAEVFKELRLNQPKFN	88	Sequence 1192 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15223	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGKDLRKVGFYDPIKNQTYLNVPAILYFLEKGAQPTGTVQDILKKAEVFKELRPNQS	85	Sequence 1193 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15224	MASKERVGVVIRNPQEKTVIVAVNNRVRHNKYSKIIIRTKKYQVHDHSHICKLGDEVKISEVKPISKTKRWIISEVLSSTVNPEKFGD	88	Sequence 1195 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15225	MPVKEKVGIVVSNKMQKTIVVKVESRYSHPIYSKTMTKTRKYLAHDEMGECNIGDQVLVQECRPLSKRKRWTLSKVLSKSSLVS	84	Sequence 1196 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15226	MPLKETTGKVVSDKMNKTIVVAVENRISHRKYAKTMTRTKKYKAHDENNECAVGDIVTIQETRPLSRTKCWTMVNILSKSFHN	83	Sequence 1197 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15227	MSVYRRRLSPLKPNQVIDYQDVELLRTFITDQGKILPRRVTGLTAKQQRAVTKAIKQARVLALLPFVNRES	71	Sequence 1199 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15228	MYKFKRSFRRRLSPIGSGNLIYYRNMSLISRFISEQGKILSRRVNRLTLKQQRLITIAIKQARILSLLPFINNEKQFERIESITRVKGFIKK	92	Sequence 1200 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15229	MKYPALIDYKNVNILRRFINFQGKIIPKRLNKPKLTYKQHRLLRKSVKQARYLGLLPFKTKDFF	64	Sequence 1201 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15230	MNKSKRSSRRRMPPIRSGEIIDYKNISLLRRFVSEQGKILSRRMNRLTSKQQRLLTIAIKRARVLALLPFLNNEN	75	Sequence 1202 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15231	MLAQKQKLSPISVNQKIDYKDIDLLKLFITEQGKILPRRATGVTVQQQRQIAKAIKRARVLSLLPFVASNSI	72	Sequence 1203 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15232	MKQTMDKPKQSFRRHFKPIRRRFKPIRRYLKPIRRHLSPIRSGDRIDYKNMSLISRFISEQGKILSGRVNRLTSKQQRLMTNAIKRARILSLLPFLYNEN	100	Sequence 1206 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15233	MAVYRKKISPIKPTEAVDYKDIDLLRKFITEQGKILPKRSTGLTSKQQKKLTKAIKQARILSLLPFLNKD	70	Sequence 1207 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15234	MARSLKKAPFVANHLLEKVERLNTQGDKKVIKTWSRSSTIVPLMIGHTIAVHNGREHIPVFITDQMVGHKLGEFAPTRTFRGHVKKDKKSKR	92	Sequence 1210 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15235	MARSLKKGPFIAHHLLKKVELLNTSGKTEVIKTWSRASTILPMMVGHTIAVHNGRQHLPVFITDQMVGHKLGEFAPTRTFKGHTKSDKKARR	92	Sequence 1211 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15236	MIHSPTLKKNLFVANHLRAKINKLNNKKKKEIIVTWSRASTIIPIMIGHMISIHNGKEHLPIYITDHMVGHKLGEFVPTLNFRGHAKSDNRSRR	94	Sequence 1212 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15237	MSRSLKKGPFVFYSLIKKVDQMNSNRFKSVILTWSRSCTIIPIMIGNTIGVYNGKEHIPVLVSDQMIGHKLGEFVQTRNYRGHKKHDKKTKTKR	94	Sequence 1213 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15238	TRKKTNPFVARHLLAKIEKVNMKEEKEIIVTWSRASSILPAMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYESTRKDTKSRR	92	Sequence 1214 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15239	TRSIKKGPFVADHLLKKIENLNLKKEKKIIITWSRASTIVPTMIGHTIAVHNGQEHLPIYITDRMVGHKLGEFAPTRTFRGHAKNDKKSRR	91	Sequence 1215 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15240	MPRSLKKGPFVAYHLLKKIDKMNASGKKDVITTWSRTSTILPTMVGHTIAVYNGRQHVPIFISDQLVGHKLGEFVSTRTFKSHIKTDKKTKR	92	Sequence 1216 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15241	TRKKTNPFVAHHLLAKIEKVNMKEEKETIVTWSRASSILPAMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYESARKDTKSRR	92	Sequence 1217 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15242	TRSRKKNPFVANHLLKKIKKLNTKGEKAIIKTWSRKSTIIPIMIGHTIAIHNGKEHLPVYITDRMVGHKLGEFSPTLNFGGFAKNDNKSRR	91	Sequence 1218 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15243	MARSLKKNPFVANHSLRKIKNLNIKEEKKIIVTWSRASVIVPAMIGHTIAVHNGREHLPIYVTDRMVDHKLGEFAPTLLFQGHARNDKKSRR	92	Sequence 1219 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15244	MSRSIHKGPFIDVSLLTRIEALNTSGKKEVIKTWSRASTIIPDMIGHTIAVYNGKQHFPVFVSDQMVGHKLGEFVPTRTFRTHVKGDRKARR	92	Sequence 1220 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15245	TRKKTNPFVAHHLLAKIEKVNMKEEKETIVTWSRASSILPTMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYENARKDTKSRR	92	Sequence 1221 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15246	TRSLKKNPFVANHLLRKINKLNTKAEKDIIITWSRASTIIPTMIGHTIAIHNGKEHLPIYITDRMVGHKLGEFSPTLNFRGHAKNDNRSRR	91	Sequence 1222 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15247	TRSLKKNPFVANHLLRKIEKLNKKAEKEIIVTWSRASTIIPTMIGHTIAIHNGREHLPIYITDRMVGHKLGEFAPTLNFRGHAKNDNKSRR	91	Sequence 1223 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15248	TRSLKKNPFVANHLLKKIDKLNTKAEKEIIVTWSRASTIIPTMIGHTIAIHNGKEHLPIYITDSMVGHKLGEFAPTLNFRGHAKSDNRSRR	91	Sequence 1224 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15249	MANTKSAIKRIKTIERNRIRNCAYKSVVKTFIKKYLKVLSDYTNAPNSNGVENIQTTLGIVYTKIDKAVKRGVYHSNKAARMKSKLALKYNVIKK	95	Sequence 1225 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15250	MANNASAEKRILINERNRLQNRFYKSSVRTLTKLYLKDLEVYKISRNPSDKEKAKNRLSLVYSLIDKGSKRNVFHKNTAARKKSKLASQLKIA	93	Sequence 1226 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15251	MAKNLSAIKRIKTSERNRLINRKYKSVVKTLTKRCLMNIENLENSNLNDVQLSISQVYSKIDKAIKKGAFHPNTGARKKARLARIFAYAQKQQN	94	Sequence 1227 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15252	MSATKKYEMMILLTEEFNDSELKTWAFNYAKALRKLSASEISVISRGKRDLSYYINNQKKGNFIQINFSSMPKYVDNFSKNLKFDSNVLRFLILNK	96	Sequence 1233 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15253	MQKARIKLSSTKHEELDSVCNQIKAIAEKTGVDMAGPIPLPTKSLKITTRKSTDGEGSSSFDRWTMRVHKRVIDIEADERTMKHIMKVKNS	91	Sequence 1276 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15254	MAKKSMIIKQKRTPKFKVRAYTRCERCGRPHSVYRKFKLCRICFRELAYKGQLPGIKKASW	61	Sequence 1381 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15255	AKKSMIAKQQRTPKFKVQEYTRCERCGRPHSVIRKFKLCRICFRELAYKGQIPGVKKASW	60	Sequence 1382 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15256	AKQSMKAREVKRVALADKYFAKRAELKAIISDVNASDEDRWNAVLKLQTLPRDSSPSRQRNRCRQTGRPHGFLRKFGLSRIKVREAAMRGEIPGLKKASW	100	Sequence 1386 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15257	AKQSMKARDVKRVKLAEKFYAKRVELKKIISDVNASDEDRWDAVLKLQTLPRDSSPSRQRNRCRQTGRPHGVLRKFGLSRIKVREAAMRGEIPGLKKASW	100	Sequence 1387 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15258	MAKKSMIAKAQRKPKFQVRAYTRCRICGRPHSVYRDFGLCRVCLRKMGSEGLIPGLRKASW	61	Sequence 1388 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15259	MAKKPWKKKYGYGIRPCQRCGHVGPGLIRKYGLNLCRQCFREIAHKLGFKKLD	53	Sequence 1392 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15260	MIVLPRKYGKASRKCSRCGDHSALVRRYGLMLCRQCFRELAPKIGFKKYN	50	Sequence 1393 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15261	MTKEPFKTKYGQGSKVCKRCGRKGPGIIRKYGLDLCRQCFRELAPKLGFKKYD	53	Sequence 1394 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15262	MAKKSLKVKQAKHPKFNVRNYTRCNHCGRPHAVLKKFGICRLCFRKFAYEGQIPGIKKAS	60	Sequence 1395 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15263	MAKKSLKVKQSRPNKFSVRDYTRCLRCGRARAVLSHFGVCRLCFRELAYAGAIPGVKKASW	61	Sequence 1396 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15264	MAKKALVNKAARKPKFTVRGYTRCSKCGRPRAVFRKFGLCRICLREMAHAGELPGVQKSSW	61	Sequence 1397 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15265	MAKKSLKVKQTRIPKFAVRAYTRCQRCGRARAVLSHFGVCRLCFRELAYAGAIPGVKKASW	61	Sequence 1398 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15266	MAKKAMVERDRKRKKLVEKYAAKREALKEQFAAATSQSERLELHRKLQQLPRNSAPNRVRNRCWVTGRPRGYYRDFGLCRNVLREMAHQGLLPGVVKSSW	100	Sequence 1403 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15267	MAKKSMIERDKRRSRLVAKYAAKREALKEEFRQAETLEDKLAVHQKLQDLPRNSAPNRRRNRCQVTGRPRSYYRDFGLCRNVLREWAHQGLLPGVTKSSW	100	Sequence 1404 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15268	ARKALIEKAKRTPKFKVRAYTRCVRCGRARSVYRFFGLCRICLRELAHKGQLPGVRKASW	60	Sequence 1405 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15269	ALTQERKREIIEQFKVHENDTGSPEVQIAILTEQINNLNEHLRVHKKDHHSRRGLLKMVGKRRRLLAYLRNKDVARYREIVEKLGLRR	88	Sequence 1408 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15270	AITQERKNQLINEFKTHESDTGSPEVQIAILTDSINNLNEHLRTHKKDHHSRRGLLKMVGKRRNLLTYLRNKDVTRYRELINKLGLRR	88	Sequence 1409 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15271	MALDSAKKAEIVAKFAKKPGDTGSTEVQVALLTARIAELTEHLKIYKNDFSSRLGLLKLVGQRKRLLSYLKRKDYNSYSKLITELNLRDK	90	Sequence 1410 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15272	SLSTEATAKIVSEFGRDANDTGSTEVQVALLTAQINHLQGHFAEHKKDHHSRRGLLRMVSQRRKLLDYLKRKDVARYTQLIERLGLRR	88	Sequence 1411 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15273	SLSTEKKAAIVAEFGRDAKDTGSSEVQIALLTAQINHLQTHFAEHKKDHHGRRGLLRMVSRRRKLLDYLKRTDLALYQSTIARLGLRR	88	Sequence 1412 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15274	MALNLEKKQEIIKAFATKENDTGSCEVQVALLNERIKLLTEHLKANPKDHSSRLGLLKLVAQRRNLLKYIKRTNHARYVVLIEKLGIKDR	90	Sequence 1413 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15275	MITKAKKAEIITRFGKSEKNTGDISVQIALLPEDIEKLKLHFEKNKKDKHSMRGFIAKVNKRKKLLNYLKEKNFASYKETIEALNIRK	88	Sequence 1416 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15276	MKIDKEQIIKAHQLHKNDVGSVQVQISILTDQIKKLTDHLLANKKDFISKRGLYTKVSKRKRLLKYLKERNIETYRDLIKNLNLRG	86	Sequence 1417 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15277	MISKARKQEIILKFGKNPKNTGNTSVQIALLTEDIERLKLHFLKNKKDKHSMRGFIAKVNKRKKLLNYLRINSFDTYKETIEALNIRK	88	Sequence 1418 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15278	MALTSEQKKEILSSYGLHATDTGSPEAQIALLTKRIADLTEHLKVHKHDHHSRRGLLLLVGRRRRLIKYLSLIDVQRYRSLIERLGLRR	89	Sequence 1419 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15279	MQIDKNGIIKSAQLHDKDVGSIQVQVSLLTSQIKQLTDHLLANKKDFISKRGLYAKVSKRKRLLKYLKHNDLEAYRNLVKTLNLRG	86	Sequence 1420 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15280	MALTAEQKKEILRSYGLHETDTGSPEAQIALLTKRIADLTEHLKVHKHDHHSRRGLLLLVGRRRRLIKYISQIDVERYRSLIERLGLRR	89	Sequence 1421 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15281	SLSTEAKAQIIAEFGRDANDSGSSEVQVALLTAQINHLQGHFSEHKKDHHSRRGLLRMVSQRRKLLDYLKRKNVTSYTALIGRLGLRR	88	Sequence 1423 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15282	MSLTQIRKQELMTEYQAHETDTGSADLQVAFLTERITQLTGHLKANPKDHASRRGLLKMIGRRKRLLSFINAREPERYQALIKRLGIRR	89	Sequence 1425 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15283	PITKEEKQKVIQEFARFPGDTGSTEVQVALLTLRINRLSEHLKVHKKDHHSHRGLLMMVGQRRRLLRYLQREDPERYRALIEKLGIRG	88	Sequence 1426 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15284	SLSVEAKAKIVADFGRDANDTGSSEVQVALLTAQINHLQGHFSEHKKDHHSRRGLLRMVSTRRKLLDYLKRKDVASYVSLIERLGLRR	88	Sequence 1430 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15285	AVKIRLKRMGAKKSPFYRIVVADSRSPRDGRFIETVGTYNPVAKPAEVKIDEELALKWLQTGAKPSDTVRNLFSSQGIMEKFHNAKQGK	89	Sequence 1432 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15286	MVTIRLARHGAKKRPFYQVVVADSRNARNGRFIERVGFFNPIASEKEEGTRLDLDRIAHWVGQGATISDRVAALIKEVNKAA	82	Sequence 1434 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15287	MVTIRLSRGGAKKRPFYQIVVADSRSPRDGRFIERVGFFNPIAQGNAERLRINLERVNHWVAQGASLSDRVASLVKEAQKAA	82	Sequence 1437 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15288	MTVIRLTRIGRKKKPFYRVVVTDSRKRRDGGWIESIGYYNPLSEPKDIKIDKERLNYWKGVGAKMSERVEKLSQKA	76	Sequence 1438 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15289	MRMGRVHYPLYRIVAVDSRVKRNGKYIALIGHLNPALKENKCKLDETVALDWLNKGAIPTDTVRSLFSESGLWKKFIESKNKKETSPKK	89	Sequence 1442 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15290	MRMGRVHYPTYRIVAVDSRVKRDGKYIALIGHLNPALKENKCKIDEAVALEWLNKGAKPTDTVRSLFSQTGLWKKFVESKKKPVAKSK	88	Sequence 1444 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15291	MVTIRLARHGAKKRPFYQVVVTDSRNARNGRFIERVGFFNPIASEKEEGTRLDLDRIAHWVGQGATISDRVAALIKEVKKAA	82	Sequence 1447 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15292	MIKLRLKRFGKKREVSYRIVAMHSTTRRDGRPLEELGFYNPRTDETRLDVPAIVKRLKEGAQPTDTVRSILTKAQVFEQLKA	82	Sequence 1448 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15293	TDKIRSVQGRVVSDKMEKSFVVAIERKVKHPLYGKFIRRTTKLHVHDENNEAKLGDLVEVRECRPISKTKSWTLVRVVEKAVIA	84	Sequence 1449 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15294	MTDVIRTLQGRVVSHKMEKSIVVAIERTVKHPIYGKFIKRTTKLHVHDENNECGIGDVVEIRECRPLSKTKSWTLVRVVDKAIL	84	Sequence 1450 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15295	SERNQRKVYVGRVVSDKMDKTITVLVETYKKHPLYGKRVKYSKKYKAHDEHNEAKVGDIVKIMETRPLSATKRFRLVEIVEKAVVL	86	Sequence 1451 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15296	SERNQRKVYQGRVVSDKMDKTITVVVETYKKHTLYGKRVKYSKKFKAHDENNQAKIGDIVKIMETRPLSATKRFRLVEVVEEAVII	86	Sequence 1452 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15297	MASDVRGRRKTKIGVVVSSKMEKTVVVRVERVYSHPQYAKVVRDSSKYYAHNELDVKEGDTVRIQETRPLSKTKRWRVVGRVN	83	Sequence 1454 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15298	TDKIRTLQGRVVSDKMEKSIVVAIERFVKHPIYGKFIKRTTKLHVHDENNECGIGDVVEIRECRPLSKTKSWTLVRVVEKAVL	83	Sequence 1458 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15299	TDKIRSVQGKVVSDKMEKSFVVAIERKVKHPLYGKFIRRTTKLHVHDENNEAKVGDTVEIRECRPLSKTKSWTLVRVVEKAVIA	84	Sequence 1459 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15300	MNTKEPHKRLVQGKVISKFAEKSAVILVERKVVHEKYRKIVKKFKKYTIHDENNQVKVGDFVSAIECRPLSKTKSFTLKEILVVGV	86	Sequence 1460 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15301	MQRNSRRVLIGKVVSDKMDKTITVLVETYKNHPIYKKRVKYSKKYKAHDENQVAQMGDKVEIMETRPLSKTKNFRLVRVIEKATL	85	Sequence 1466 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15302	MKRNQRKQLIGTVVSTKNAKTATVKVTSRFKHPLYHKSVIRHKKYHVHNFGELVANDGDRVQIIETRPLSALKRWRIVKIIERAK	85	Sequence 1467 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15303	MKRNQRKVLIGIVKSTKNAKTATVQVESRFKHPLYHKSVVRHKKYQAHNEGEVLAKDGDKVQIVETRPLSATKRFRIAKIIERAK	85	Sequence 1469 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15304	MERNSRKVLQGRVISDNLKKTITVLVETYKNHPLYKKRVKYSKKYLAHDEQNQAHIGDKVSIMETRPLSKTKHFRLIEVIEKAIG	85	Sequence 1472 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15305	MAVKERVGVVVSDKMDKTVVVAIEDRTAHPKYGKIVVRTKRYKAHDEDNRAKTGDRVRIQETRPLSRTKRWTVAEILESVGA	82	Sequence 1473 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15306	MAIKERVGIVVSNKMDKTVVVAVESRSPHPKYGKIVVKTKKFKAHDEENQCQEGDKVRIQETRPLSKTKRWQVINIMSHSS	81	Sequence 1474 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15307	AGRKGGRGKRRKVCYFTANNITHIDYKDVDLLKKFISERGKILPRRVTGTSAKYQRKLTVAIKRARQMALLPYVADE	77	Sequence 1478 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15308	AGGRRGGRAKRRKVCYFTSNGITHIDYKDVDLLKKFVSERGKILPRRVTGTNAKYQRKLTAAIKRARQMALLPYVSGE	78	Sequence 1479 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15309	MNRPVHNEHRRKRFAKKCPFVSAGWKTIDYKDVVTLKRFITERGKILPRRITGVSSRFQALLAQAVKRARHVGLLLS	77	Sequence 1481 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15310	ARYFRRRKFCRFTAEGVQEIDYKDIATLKNYITESGKIVPSRITGTRAKYQRQLARAIKRARYLSLLPYTDRHQ	74	Sequence 1483 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15311	ARYFRRRKFCRFTAENVVEIDYKDIATLKNYISESGKIVPSRITGTRAKYQRQLARAIKRARYLALLPYTDNHQ	74	Sequence 1485 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15312	MERKRYSKRYCKYTEAKISFIDYKDLDMLKHTLSERYKIMPRRLTGNSKKWQERVEVAIKRARHMALIPYIVDRKKVVDSPFKQH	85	Sequence 1486 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15313	MAKSSKRRPAPEKPVKTRKCVFCAKKDQAIDYKDTALLRTYISERGKIRARRVTGNCVQHQRDIALAVKNAREVALLPFTSSVR	84	Sequence 1490 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15314	MARQSFKRRKFCRFTAEKIQEVDYKQVDLLKDFISENGKIIPARITGTKAFYQRQLAVAVKRARFLALLPYTDQHK	76	Sequence 1491 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15315	MNYYRKRLSPLPPNQPIDYKDTELLRKFITERGKILPRRITGLTAKQQRDLTTAVKRSRLVALLPFVNKEI	71	Sequence 1492 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15316	GRSLKKGPFCDEHLMKKIEKLNETGQKQVIKTWSRRSTIFPQFVGHTIAVYDGRRHVPVYITEDMVGHKLGEFAPTATFRGHAGDDKKTKR	91	Sequence 1494 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15317	ARSLKKGPFVDGHLMTKIEKLNETDKKQVVKTWSRRSTIFPQFIGHTIAVYDGRKHVPVFISEDMVGHKLGEFAPTRTYKGHASDDKKTRR	91	Sequence 1495 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15318	MARSIKKGPFIEKSLYQKVLSSFGSEKRVVIKTYSRSSTIIPEMVSLTISVYNAKTFIPIYITEDLVGHKLGEFSPTRIFRGHAKSDKKGRK	92	Sequence 1496 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15319	PRSLKKGPFIDLHLLKKVEKAVESGDKKPLRTWSRRSTIFPNMIGLTIAVHNGRQHVPVFVTDEMVGHKLGEFAPTRTYRGHAADKKAKKK	91	Sequence 1498 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15320	PRSLKKGPFLDLHLLKKVEKAVESGDKKPIKTWSRRSMIIPSMIGLTIAVHNGRQHVPVYVSDEMIGHKLGEFAPTRTYRGHAADKKAKK	90	Sequence 1501 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15321	MSRSIKKGPFIDDHLMKKTLKAKEGKDNRPIKTWSRRSTILPEMIGFTYNVHNGRVFIPVYITENHVGYKLGEFAPTRTFKGHKGSVQKKIGK	93	Sequence 1502 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15322	MPRSLKKGPFVDEHLLKKVDVQNEKNTKQVIKTWSRRSTIIPDFIGHTFAVHDGRKHVPVFVTESMVGHKLGEFAPTRRFKGHIKDDRKSKRR	93	Sequence 1507 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15323	MARSLKKGPFVDENLFKKVTSAKDGEVIKTWSRRSTIFPEFIGKTFGVYNGKEFIPVYITEDMVGNKLGEFAPTRKFGGHGDDKGKKK	88	Sequence 1508 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15324	MSRSSKKGAFVDAHLLKKVIEMNKQAKKKPIKTWSRRSTIFPEFVGNTFSVHNGKTFINVYVTDDMVGHKLGEFSPTRNFKQHTANR	87	Sequence 1509 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15325	MPRSLKKGPFVDDHLLKKVDVQNEKNTKQVIKTWSRRSTIIPDFIGHTFAVHDGRKHVPVFVTEAMVGHKLGEFAPTRTFKGHIKDDRKAKRR	93	Sequence 1510 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15326	MSRSAKKGAFVDAHLLKKVIDMNKQEKKRPIKTWSRRSTIFPEFVGNTFAVHNGKTFINVYVTDDMVGHKLGEFSPTRNFKQHTANR	87	Sequence 1511 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15327	MARSLKKGPFVADHLLRKVEKLNAKGDKQVIKTWSRASTILPQMIGHTIAVHNGRQHVPVYVTEQMVGHKLGEFAPTRTFRGHTKDKKAGR	91	Sequence 1514 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15328	MGRSLKKGPFVAASLLRKIDKLNDKGDKQVVKTWSRASTILPQMVGHTIAVHNGRQHVPVFVSEQMVGHKLGEFAPTRTFRSHSKSDKKARK	92	Sequence 1515 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15329	MGRSRKKGPYVDRKLLEKIRKLNETGEKKVIKTWSRASMIIPKWVGHGIAVYNGMKHIPVYITENMIGHRLGEFAPTRRFGGHADKKAKKGELKK	95	Sequence 1516 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15330	PNIKSAIKRTKTNNERGVHNATIKSAMRTAIKQVEASVANNEADKAKTALTEAAKRIDKAVKTGLVHKNTAARYKSRLAKKVNGLSA	87	Sequence 1526 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15331	MRKNASALKRSRQNLKRKIRNVSVKSELKTIEKRCINMIKAGKKDEAIEFFKFVAKKLDTAARKRIIHKNKAARKKSRLNVLLLK	85	Sequence 1527 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15332	ANIKSAKKRAIQSEKARKHNASRRSMMRTFIKKVYAAIEAGDKAAAQKAFNEMQPIVDRQAAKGLIHKNKAARHKANLTAQINKLA	86	Sequence 1529 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15333	ANIKSAKKRAVQSEKRRQHNASQRSMMRTYIKKVYAQVAAGEKSAAEAAFVEMQKVVDRMASKGLIHANKAANHKSKLAAQIKKLA	86	Sequence 1530 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15334	MANHKSAEKRIRQTIKRTERNRFYKTKIKNIIKAVREAVAVNDVAKAQERLKIANKELHKFVSKGILKKNTASRKVSRLNASVKKIALA	89	Sequence 1531 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15335	MANIKSNEKRLRQDIKRNLNNKGQKTKLKTNVKKFNKEINLDNLSSVYSQADRLARKGIISLNRAKRLKSKNAVILHKSNTNSTAKKQ	88	Sequence 1533 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15336	MTNIKSQQKRNRTNERARLRNKSVKSSLRTAVRAFREAVHAGEKEKAAKLLVSTSRKLDKAASKGVIHKNQAANKKSALARTLNKL	86	Sequence 1534 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15337	MANIKSNEKRLRQNIKRNLNNKGQKTKLKTNVKNFHKEINLDNLGNVYSQADRLARKGIISTNRARRLKSRNVAVLNKTQVTAVEGK	87	Sequence 1535 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15338	MANTTSAKKATRKIARRSAVNKARRSRIRSFVRKVEEAIASGDQALAAAALKAAQPELMRPATKGVMHSNTASRKVSRLAQRVKSLSA	88	Sequence 1537 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15339	MANIKSALKRIEIAERNRLQNKSYKSAIKTLMKKTFQSVEAYASDPNPEKLDTINTSMAAAFSKIDKAVKCKVIHKNNAARKKARLAKALQSALPAA	97	Sequence 1538 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15340	MTQIVVGENEHIESALRRFKREVSKAGIFQDMRKHRHFETPIEKSKRKKLALHKQSKRRFRT	62	Sequence 1540 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15341	SKTIVRKNESIDDALRRFKRAVSKTGTLQEVRKREFYEKPSVRRKKKSEAARKRK	55	Sequence 1541 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15342	SKTVVRKNESLEDALRRFKRSVSKTGTLQEARKREFYEKPSVKRKKKSEAARKRKF	56	Sequence 1542 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15343	MTTILLKENEPFEVAIRRFRRAIEKNGLIAELRERQAYEKPTAVRKRKKAAAVKRLHKRLRSQMLPKKLH	70	Sequence 1543 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15344	MQNDAGQTVELYVPRKCSSSNRIIGPKDHASVQIDFVDVDPETGRMIPGKSTRYAICGAIRRMGESDDAILRLAQKDGLVPRDDVKSN	88	Sequence 1544 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15345	PVIKVRENEPFDVALRRFKRSCEKAGVLAEVRRREFYEKPTTERKRAKASAVKRHAKKLARENARRTRLY	70	Sequence 1545 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15346	PVIKVRENESFDVALRRFKRSCEKAGILAEVRAREFYEKPTTIRKRENATLAKRHAKRNARENARNTRLY	70	Sequence 1546 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15347	MPGIKVREGDAFDEAYRRFKKQTDRNLVVTECRARRFFESKTEKRKKQKISAKKKVLKRLYMLRRYESRL	70	Sequence 1547 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15348	MQNDAGEFVDLYVPRKCSASNRIIGAKDHASIQMNVAEVDKVTGRFNGQFKTYAICGAIRRMGESDDSILRLAKADGIVSKNF	83	Sequence 1548 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15349	MQNEEGKTVDLYVPRKCSATNRIITAKDHASVQINIGHLDANGLYDGHFTTFALSGFVRAQGDADSSLDRLWQKKKAEIKQ	81	Sequence 1549 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15350	MPGIRVKEGESIESALKRFKKATEKAGILSEIRKREHYEKPSVKRKKKALAAKKRAVKKARKSF	64	Sequence 1550 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15351	MQNEEGQMVDLYVPRKCSATNRIITAKDHASVQINIGHVDENGLYDGRFTTFALSGFIRAQGDADSALDRLWQKRKAEVKQQ	82	Sequence 1551 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15352	MQNDAGEFVDLYVPRKCSASNRIIAAKDHASIQMNVAEVDRSTGRFNGQFKTYGICGAIRRMGESDDSILRLAKADGIVSKNF	83	Sequence 1552 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15353	MTQVVVGQNEPIESALRRFKRQVAKAGIYTDFKKHQFFETPQEKHKRKEATRRRQRSRRR	60	Sequence 1553 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15354	MKSNRQARHILGLDHKISNQRKIVTEGDKSSVVNNPTGRKRPAEK	45	Sequence 1554 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15355	MVLSSDIDLLNPPAELEKTKHKRKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVMCGSCSSVLCTPTGWPRRLTEGCSFRRKSD	86	Sequence 1580 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15356	MPLIEVDLLNPTAASEAKAHKMKRLVPTPNSYFLEIKCPKCGATTTTFSHAHRQILCQKCGQPLGQPTGGKLKLTQQCKFRIKK	84	Sequence 1581 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15357	PLAKDLLHPSPSEEKRKCKLKRLVQHPNSYFMDVKCPGCFKISTVFSHAQTVVACVGCATVLCQPTGGKAKLTDGCSFRKKQN	83	Sequence 1582 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15358	MVLQNDIDLLNPPAELEKLKHKKKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVVCPGCQTVLCQPTGGKARLTEGSPSVARATKPVANWKSKPLLN	99	Sequence 1583 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15359	PLAKDLLHPSPEEEKRKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1584 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15360	MMELIPQPRTKFLRVQCPECNNEQIVFGSPATVVKCLTCGKVLVEPRGGKGKVKAKILEILG	62	Sequence 1585 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15361	PLARDLLHPSLEEEKKKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1586 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15362	PLAKDLLHPTPEEEKRKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1587 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15363	MDSQIKHAVVVKVMGRTGSRGQVTQVRVKFTDSDRFIMRNVKGPVREGDVLTLLESEREARRLR	64	Sequence 1588 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15364	MDTSRVQPIKLARVTKVLGRTGSQGQCTQVRVEFMDDTSRSIIRNVKGPVREGDVLTLLESEREARRLR	69	Sequence 1589 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15365	MDTQVKLAVVVKVMGRTGSRGQVTQVRVKFLDDQNRLIMRNVKGPVCEGDILTLLESEREARRLR	65	Sequence 1590 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15366	MMRMEDEFVYKEAVAAEVIEVIGRTGVTGGIIQVRCKILGGKDTGRVLVRNVKGPVKVGDIIMLRETEREARPLDRRR	78	Sequence 1591 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15367	MDSSKVPVKLAKVIKVLGRTGSRGGVTQVRVEFMDDTSRSIIRNVKGPVREDDILVLLESEREARRLR	68	Sequence 1592 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15368	GHQQLYWSHPRKFGQGSRSCRVCSNRHGLIRKYGLNMCRQCFRQYAKDIGFIKLD	55	Sequence 1594 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15369	KVHGSLARAGKVRGRHQKVAKQDKKKKPRGRAHKRLQHNRRFVTAVVGFGKKRGPNSSEK	60	Sequence 1595 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15370	KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS	59	Sequence 1596 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15371	AKVHGSLARAGKVKSQTPKVEKTEKPKKPKGRAYKRLLYTRRFVNVTLVNGKRRMNPGPSVQ	62	Sequence 1597 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15372	MDTKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTTRTIVRNVKGPVREGDILVLMESEREARRLR	67	Sequence 1599 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15373	MDSKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTTRTIVRNVKGPVREGDILVLMESEREARRLR	67	Sequence 1600 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15374	MDSKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTSRTIVRNVKGPVRENDILVLMESEREARRLR	67	Sequence 1601 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15375	GKKRKKKVYTTPKKIKHKHKKVKLAVLSYYKVDAEGKVTKLRRECSNPTCGAGVFLANHKDRLYCGKCHSVYKVNA	76	Sequence 1602 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15376	MRPYEIMVILDPTLDERTVAPSLETFLNVVRKDGGKVEKVDIWGKRRLAYEIAKHAEGIYVVIDVKAAPATVSELDRQLSLNESVLRTKVMRTDKH	96	Sequence 1618 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15377	GKGDRRTRRGKIWRGTYGKYRPRKKK	26	Sequence 1680 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15378	MRVLFLYGLCVRFLYFCLVLYFSPRLPSSGNRRCLYAICYMFNILWFFCVFCCVCFLNHLLFIVEGGGFIDLPGVKYFSRFFLNA	85	Sequence 1703 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15379	MLFYCVLLYGLCLRFLLFSFRYFMCPRLPSSGNRMIGCLLLLLFYSFWLLRCFFIFFLVSCFIYVVEGGGFIDLPSLRYFTRLFYFV	87	Sequence 1716 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15380	MKYLLIKNKKLYKLFFKFELKRLQYKSVMLNTRLPNYIRQKAFMYINKLDKNTSYVAIKQRCFLSNNGRSVLNHFKLSRIKLRLLISNNYVNGVKKFNK	99	Sequence 1725 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15381	MSEKQNSRDHKRRLLAAKFELRRKLYKAFCKDPDLPSDMRDKHRYKLSKLPRNSSFARVRNRCISTGRPRSVSEFFRIYRIVFRGLASRGSLMGIKKSSW	100	Sequence 1726 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15382	MSNQIIRDHKRRLLVAKYELKRMHYKAICQDRNLPNKIRYEYFFKLSKLPRNSSKTRVRNRCIFTGRPRSVYKLFRISRIVFRELASKGSLIGINKSCW	99	Sequence 1728 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15383	MEKRNIRDHKRRLLATKYELRRKLYKAFCNDPALPSDMRDKHRYKLSKLPRNSSFARVRNRCISTGRPRSVYEFFRISRIVFRGLASRGPLMGIKKSSW	99	Sequence 1729 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15384	MFNSIKRDLKRRKLYKKYESKRLLYKALISDCNLNQDLRFILTQKLNKLPRNSSQVRVKNRCILTGRGHSVYKFCRISRIKFRDLANQGLIQGCVKSSW	99	Sequence 1731 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15385	MSEKRNIRDHKRRLLAAKYELRRKLYKAFCKDSDLPSDMRDKLRYKLSKLPRNSSFARVRNRCISTGRPRSVYELFRISRIVFRSLASRGPLMGIKKSSW	100	Sequence 1732 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15386	MRSVWKGCFYKNNNNGLSKSSTVINTMLKKKFTLHDGKSYKSILIDRSMVGLKIGEFVFTRKMGVLHKKKVLKKKGKK	78	Sequence 1734 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15387	MTRSIWKGPFVDTCLFKQKKIRWRIWSRRSCILPQFVGCYAQIYNGKGFVGLKITEEMVGHKFGEFASTRKTSSLGKRALPSKTKIKPIKKVR	93	Sequence 1735 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15388	MPRRSIWKGSFVDAFLLRMKKKRDLLFNRKIWSRRSSILPEFVDCFVRIYNGKTFVRCKITEGKVGHKFGEFAFTRKRRPSRTNIGPGRKRGKK	94	Sequence 1736 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15389	MSRAIWKGPFIDPFFFRKNGSSNSNNKIYSRRSVVSPKFIGREVEIYNGHKWITIKIKEDMIGHKFGEFAFTRKATIHKKKTK	83	Sequence 1737 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15390	MARSLSKPPFCEVKLATNNSVTKIWSRRSAILPQFVGKTVSIHNGRIFIPCKISPEMIGHKFGEFAVTRKKPIHKKKK	78	Sequence 1738 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15391	MFMSYDKVSQAKSIIIGTKQTVKALKRGSVKEVVVAKDADPILTSSVVSLAEDQGISVSMVESMKKLGKACGIEVGAAAVAIIL	84	Sequence 1741 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15392	MKPNIHPEYRTVVFHDTSVDEYFKIGSTIKTDREIELDGVTYPYVTIDVSSKSHPFYTGKLRTVASEGNVARFTQRFGRFVSTKKGA	87	Sequence 1744 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15393	MSGMEWFPLLGLANRARKVVSGEDLVIKEIRNARAKLVLLTEDASSNTAKKVTDKCNYYKVPYKKVESRAVLGRSIGKEARVVVAVTDQGFANKLISLLD	100	Sequence 1745 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15394	MQPAARLLSRSVWKGPNIVPLPIREAMTKGTPIRTNARAATILPQFVGLKFQIHNGKEYVPIEISEDMVGHKLGEFAPTRKRFSYTQTKNK	91	Sequence 1749 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15395	RTCENLADKYRGPCFSGCDTHCTTKENAVSGRCRDDFRCWCTKRC	45	Sequence 2 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15396	RTCENLARKYRGPCFSGCDTHCTTKENAVSGRCRDDFRCWCTKRC	45	Sequence 4 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15397	KICRRRSAGFKGPCMSNKNCAQVCQQEGWGGGNCDGPFRRCKCIRQC	47	Sequence 5 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15398	EMSWIXSVLWFADFPKGESLXVLTNRKRTSLSXKGKDDFIQEPIPEAAIXEIWRRLEAPXARLGKIILTPFGGKXSEMAEYVXPFP	86	Sequence 39 from Patent WO 1998013478	Arabidopsis thaliana	Antimicrobial, Antifungal	WO 1998/013478 A2	Patent Application	1998##4##2	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, US20020168735, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterised in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using 
DRAMP15399	SWKVRLVQVXTTVTVFVVGRNVDQGAADVVARWQDVAPSLPPELTIRVIVRGQRATFQSLYLGSCADLVPTMSSMFPELGMTI	83	Sequence 49 from Patent WO 1998013478	Oryza sativa Japonica Gro	Antimicrobial, Antifungal	WO 1998/013478 A2	Patent Application	1998##4##2	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, US20020168735, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterised in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using 
DRAMP15400	DSHAKRHHGYKRKFHEKHHSHRGY	24	Sequence 1 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15401	KRKFHEKHHSHRGY	14	Sequence 2 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15402	KRLFKELKFSLRKY	14	Sequence 3 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15403	KRLFKELLFSLRKY	14	Sequence 4 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15404	XXLFXELXXSLXXY	14	Sequence 7 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15405	XXLFXELLXSLXXY	14	Sequence 8 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15406	KRLFKKLKFSLRKY	14	Sequence 9 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15407	KRLFKKLLFSLRKY	14	Sequence 10 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15408	LLLFLLKKRKKRKY	14	Sequence 11 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15409	KRKFHEKHHSHRGYCCYGRHSHHKEHFKRK	30	Sequence 14 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15410	YGRHSHHKEHFKRKCCKRKFHEKHHSHRGY	30	Sequence 15 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15411	KRKFHEKHHSHRGYKRKFHEKHHSHRGYK	29	Sequence 16 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15412	KRLFKELKFSLRKYKRLFKELKFSLRKYK	29	Sequence 17 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15413	KRLFKKLKFSLRKYKRLFKKLKFSLRKYK	29	Sequence 18 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15414	KRLFKKLLFSLRKYKRLFKKLLFSLRKYK	29	Sequence 19 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15415	LLLFLLKKRKKRKYLLLFLLKKRKKRKYK	29	Sequence 20 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15416	GICRCICGRGICRCICGR	18	Sequence 1 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18733	GICICICGRGICYCICGR	18	Sequence 9 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP15418	GICRCYCGRGICRCICGR	18	Sequence 3 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15419	GICRCICGRGICRCYCGR	18	Sequence 4 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15420	GYCRCICGRGICRCICGR	18	Sequence 5 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15421	GICRCICGRGYCRCICGR	18	Sequence 6 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15422	GICYCICGRGICRCICGR	18	Sequence 7 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15423	GICICICGYGICRCICGR	18	Sequence 8 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15424	GICICICGRGICYCICGR	18	Sequence 9 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15425	RGCICRCIGRGCICRCIG	18	Sequence 10 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15426	AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL	59	Sequence 12 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15427	MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD	97	Sequence 13 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15428	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL	76	Sequence 15 from Patent US 20030144184	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15429	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL	76	Sequence 17 from Patent US 20030144184	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15430	RCICGRGIC	9	Sequence 19 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15431	RCLCGRGIC	9	Sequence 20 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15432	RCICRRGIC	9	Sequence 21 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15433	RCICTRGIC	9	Sequence 22 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15434	RCICVRGIC	9	Sequence 23 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15435	RCICGLGIC	9	Sequence 24 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15436	RCICGRGVC	9	Sequence 25 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15437	RCICGRGFC	9	Sequence 26 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15438	RCLCRRGVC	9	Sequence 27 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15439	RCLCTRGIC	9	Sequence 28 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15440	RCLCVRGIC	9	Sequence 29 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15441	RCLCGLGVC	9	Sequence 30 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15442	RCLCGRGVC	9	Sequence 31 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15443	RCLCGRGFC	9	Sequence 32 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15444	RCICRRGVC	9	Sequence 33 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15445	RCICRRGFC	9	Sequence 34 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15446	RCICTRGVC	9	Sequence 35 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15447	RCICTRGFC	9	Sequence 36 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15448	RCICTLGIC	9	Sequence 37 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15449	RCICVLGFC	9	Sequence 38 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15450	RCICRLGIC	9	Sequence 39 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15451	RCICVRGVC	9	Sequence 40 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15452	RCICGLGFC	9	Sequence 42 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15453	RCICGLGVC	9	Sequence 43 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15454	RCLCRLGIC	9	Sequence 44 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15455	RCLCRRGFC	9	Sequence 46 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15456	RCLCTLGIC	9	Sequence 47 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15457	RCLCTRGVC	9	Sequence 48 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15458	RCLCTRGFC	9	Sequence 49 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15459	RCLCVLGIC	9	Sequence 50 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15460	RCLCVRGVC	9	Sequence 51 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15461	RCICRLGVC	9	Sequence 53 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15462	RCICRLGFC	9	Sequence 54 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15463	RCICTLGVC	9	Sequence 55 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15464	RCICTLGFC	9	Sequence 56 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15465	RCICVLGVC	9	Sequence 57 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15466	RCLCGLGIC	9	Sequence 60 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15467	RCLCTLGVC	9	Sequence 61 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15468	RCLCVLGVC	9	Sequence 63 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15469	RCICGRRIC	9	Sequence 74 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15470	RCLCGRRIC	9	Sequence 75 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15471	RCICRRRIC	9	Sequence 76 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15472	RCICTRRIC	9	Sequence 77 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15473	RCICVRRIC	9	Sequence 78 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15474	RCICGLRIC	9	Sequence 79 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15475	RCICGRRVC	9	Sequence 80 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15476	RCICGRRFC	9	Sequence 81 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15477	RCLCRRRVC	9	Sequence 82 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15478	RCLCTRRIC	9	Sequence 83 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15479	RCLCVRRIC	9	Sequence 84 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15480	RCLCGLRVC	9	Sequence 85 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15481	RCLCGRRVC	9	Sequence 86 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15482	RCLCGRRFC	9	Sequence 87 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15483	RCICRRRVC	9	Sequence 88 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15484	RCICRRRFC	9	Sequence 89 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15485	RCICTRRVC	9	Sequence 90 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15486	RCICTRRFC	9	Sequence 91 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15487	RCICTLRIC	9	Sequence 92 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15488	RCICVLRFC	9	Sequence 93 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15489	RCICRLRIC	9	Sequence 94 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15490	RCICVRRVC	9	Sequence 95 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15491	RCICGLRFC	9	Sequence 97 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15492	RCICGLRVC	9	Sequence 98 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15493	RCLCRLRIC	9	Sequence 99 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15494	RCLCRRRFC	9	Sequence 101 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15495	RCLCTLRIC	9	Sequence 102 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15496	RCLCTRRFC	9	Sequence 104 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15497	RCLCVLRIC	9	Sequence 105 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15498	RCLCVRRVC	9	Sequence 106 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15499	RCICRLRVC	9	Sequence 108 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15500	RCICRLRFC	9	Sequence 109 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15501	RCICTLRVC	9	Sequence 110 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15502	RCICTLRFC	9	Sequence 111 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15503	RCICVLRVC	9	Sequence 112 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15504	RCLCGLRIC	9	Sequence 115 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15505	RCLCTLRVC	9	Sequence 116 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15506	RCLCVLRVC	9	Sequence 118 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18732	GICICICGYGICRCICGR	18	Sequence 8 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18731	GICYCICGRGICRCICGR	18	Sequence 7 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18730	GICRCICGRGYCRCICGR	18	Sequence 6 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18729	GYCRCICGRGICRCICGR	18	Sequence 5 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18728	GICRCICGRGICRCYCGR	18	Sequence 4 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18727	GICRCYCGRGICRCICGR	18	Sequence 3 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18726	GICRCICGKGICRCICGR	18	Sequence 2 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18857	KWKSFIKNLEKVLKKGPILANLVSIV	26	Sequence 6 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOHand NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH. Also provided are methods for inhibiti2936, utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18725	GICRCICGRGICRCICGR	18	Sequence 1 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP15613	GICRCICGKGICRCYCGR	18	Sequence 126 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15614	GICKCICGKGICKCICGR	18	Sequence 127 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15615	GICRCICGKRICRCICGR	18	Sequence 128 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15616	GICRCICGKKICRCICGR	18	Sequence 129 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15617	GICRCICGRKICRCICGR	18	Sequence 130 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15618	GICRCICGRRICKCICGR	18	Sequence 131 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15619	GICKCICGRRICRCICGR	18	Sequence 132 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15620	GICRCICGRRICRCICGK	18	Sequence 133 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15621	GVCRCICGRGVCRCICRR	18	Sequence 134 from Patent US 20090264344	Orangutan	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15622	GVCRCICGRGVCRCICGR	18	Sequence 135 from Patent US 20090264344	Orangutan	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15623	RXICGXXIC	9	Sequence 136 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15624	GICYCICGKGICRCICGR	18	Sequence 137 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15625	GICRCICGRYICRCICGR	18	Sequence 138 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15626	RYICRCICGRGICRCICG	18	Sequence 139 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15627	GICRCICGRRICRCICGR	18	Sequence 140 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15628	CVHAYRS	7	Sequence 1 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15629	CVHAYRA	7	Sequence 2 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15630	CVHAFRS	7	Sequence 3 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15631	CVHAFRA	7	Sequence 4 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15632	CVHSYRS	7	Sequence 5 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15633	CVHSYRA	7	Sequence 6 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15634	CVHSFRS	7	Sequence 7 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15635	CVHSFRA	7	Sequence 8 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15636	CVHTYRS	7	Sequence 9 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15637	CVHTYRA	7	Sequence 10 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15638	CVHTFRS	7	Sequence 11 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15639	CVHTFRA	7	Sequence 12 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15640	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQLLGI	59	Sequence 1 from Patent US 20040091855	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15641	NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	38	Sequence 2 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15642	GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	43	Sequence 3 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15643	GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI	54	Sequence 4 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15644	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL	36	Sequence 5 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15645	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL	38	Sequence 6 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15646	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	40	Sequence 7 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15647	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI	50	Sequence 8 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15648	ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ	36	Sequence 9 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15649	RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL	36	Sequence 10 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15650	SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	36	Sequence 11 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15651	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	35	Sequence 12 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15652	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	36	Sequence 13 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15653	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	34	Sequence 14 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15654	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	35	Sequence 15 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15655	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW	36	Sequence 16 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15656	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG	37	Sequence 17 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15657	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI	38	Sequence 18 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15658	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR	44	Sequence 19 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15659	LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG	36	Sequence 20 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15660	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	42	Sequence 21 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15661	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY	47	Sequence 22 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15662	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK	49	Sequence 23 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15663	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	51	Sequence 24 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15664	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	36	Sequence 25 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15665	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	45	Sequence 26 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15666	QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 27 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15667	RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	34	Sequence 28 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15668	QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ	41	Sequence 29 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15669	QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ	41	Sequence 30 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15670	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK	49	Sequence 31 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15671	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK	49	Sequence 32 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15672	WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL	36	Sequence 33 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15673	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ	51	Sequence 34 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15674	QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK	49	Sequence 35 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15675	QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK	49	Sequence 36 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15676	QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK	49	Sequence 37 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15677	QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ	51	Sequence 38 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15678	QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ	51	Sequence 39 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15679	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ	51	Sequence 40 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15680	QARQLVSGLVQQQNNILRALEATQHLVQLLVWGVKQLQARVLALERYIK	49	Sequence 41 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15681	QIRQLLSGIVQQQNNLLRAIEAIQHLLQLIVWGIKQLQARILAVERYLK	49	Sequence 42 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15682	QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ	41	Sequence 43 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15683	QQQNNLLRAIEAQQHLLQLTVWGIAQLQARILAVERYLKDQ	41	Sequence 44 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15684	QQQNNLLRAIEAQQHLLQLTVWGIKQLAARILAVERYLKDQ	41	Sequence 45 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15685	QQQNNLLRAIEAQQHALQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 46 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15686	QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ	51	Sequence 47 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15687	QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ	41	Sequence 48 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15688	LEQVLQSVLLQLQI	14	Sequence 1 from Patent US 20040102605	Pseudomonas sp.	Antimicrobial, Antiviral	US 2004/0102605 A1	Patent Application	2004##5##27	EP1369426A1, EP1369426A4, EP1369426B1, EP2116552A2, EP2116552A3, US7268209, WO2002062831A1	Novel peptides, derivatives thereof, process for producing the same, novel strain producing the same, and antiviral agent comprising the same	Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.
DRAMP15689	LEQVLQSVVLQLQL	14	Sequence 4 from Patent US 20040102605	Pseudomonas sp.	Antimicrobial, Antiviral	US 2004/0102605 A1	Patent Application	2004##5##27	EP1369426A1, EP1369426A4, EP1369426B1, EP2116552A2, EP2116552A3, US7268209, WO2002062831A1	Novel peptides, derivatives thereof, process for producing the same, novel strain producing the same, and antiviral agent comprising the same	Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.
DRAMP15690	RRKKAAVALLPAVLLALLAP	20	Sequence 1 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15691	RRKKAAVALLAVLLALLAPP	20	Sequence 3 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15692	RRKKPAVLLALLA	13	Sequence 4 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15693	KLALKLALKALKAALKLA	18	Sequence 5 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15694	RQIKIWFPNRRMKWKKPGYAGAVVNDL	27	Sequence 7 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15695	RQIKIWFPNRRMKWKK	16	Sequence 8 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15696	RQIKIFFPNRRMKFKK	16	Sequence 9 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15697	YGRKKRRQRRRPGYAGAVVNDL	22	Sequence 10 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15698	YGRKKRRQRRRPGDVYANGLVA	22	Sequence 11 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15699	GWTLNSAGYLLGKINLKALAALAKKIL	27	Sequence 12 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15700	DPKGDPKGVTVTVTVTVTGKGDPKPD	26	Sequence 13 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15701	RRKK	4	Sequence 16 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15702	RRKKLAALPLVLAAPLAVLA	20	Sequence 17 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15703	RRKKAAVALLP	11	Sequence 18 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15704	RRKKAVAVAVPAVLLALLAP	20	Sequence 19 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15705	RRKKPAVLLA	10	Sequence 20 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15706	RRKKPAVLLALLALLA	16	Sequence 22 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15707	RRKKALLPAVLLALLAP	17	Sequence 23 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15708	RRKKPAVLLALLAP	14	Sequence 24 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15709	RRKKLLALLAP	11	Sequence 25 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15710	RRKKLLAP	8	Sequence 26 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15711	RRKKAAVALLPAVLLAL	17	Sequence 27 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15712	RRKKAAVAVVPAVL	14	Sequence 28 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15713	RRKKAAVAVVP	11	Sequence 29 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15714	RRKKAAVA	8	Sequence 30 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15715	PGYAGAVVNDL	11	Sequence 31 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15716	PGDVYANGLVA	11	Sequence 32 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15717	HGVSGWGQHGTHG	13	Sequence 1 from Patent US 20070293424	Synthetic construct	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15718	HGGGWGQPHGGG	12	Sequence 2 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15719	GGGGWGQGGTHG	12	Sequence 3 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15720	GGGWGQPHVGG	11	Sequence 4 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15721	VGGWGQPHGGG	11	Sequence 5 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15722	GGGWGQPHGGG	11	Sequence 8 from Patent US 20070293424	Bos taurus	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15723	QGGGGWGQPHGGGWG	15	Sequence 9 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15724	HGGGWGQPHGGGWG	14	Sequence 10 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15725	HGGGWGQGGGTHS	13	Sequence 11 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15726	HGVSGHGQHGVHG	13	Sequence 12 from Patent US 20070293424	Calliphora vicina	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15727	SWLRDVWDWICTVL	14	Sequence 2 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15728	SWLRDVWDWVCTIL	14	Sequence 3 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15729	SWLRDIWEWVLSIL	14	Sequence 4 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15730	SWLRIIWDWVCSWC	14	Sequence 5 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15731	SWLRTIWDWVCSVC	14	Sequence 6 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15732	SWLHDIWDWVCIVC	14	Sequence 7 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15733	SWLWDVWDWVLHVL	14	Sequence 8 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15734	SWLYDIVNWVCTVC	14	Sequence 9 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15735	SWLRDIWDWVCTVC	14	Sequence 10 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15736	SWLRDIWDWICEVL	14	Sequence 11 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15737	LRDIWDWICEVLSDFKTWLKA	21	Sequence 12 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15738	WLRDVWDWICTVLTDFKTWLQSKL	24	Sequence 13 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15739	WLRDVWDWVCTILTDFKNWLTSKL	24	Sequence 14 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15740	WLRDIWEWVLSILTDFKNWLSAKL	24	Sequence 15 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15741	WLRIIWDWVCSVVSDFKTWLSAKI	24	Sequence 16 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15742	WLRTIWDWVCSVLADFKAWLSAKI	24	Sequence 17 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15743	WLHDIWDWVCIVLSDFKTWLSAKI	24	Sequence 18 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15744	WLWDVWDWVLHVLSDFKTCLKAKF	24	Sequence 19 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15745	WLYDIVNWVCTVLADFKLWLGAKI	24	Sequence 20 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15746	WLRDIWDWVCTVLSDFRVWLKSKL	24	Sequence 21 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15747	SWLRDVWDWICTVLTDFKTWLQSKL	25	Sequence 22 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15748	SWLRDVWDWVCTILTDFKNWLTSKL	25	Sequence 23 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15749	SWLRDIWEWVLSILTDFKNWLSAKL	25	Sequence 24 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15750	SWLRIIWDWVCSWSDFKTWLSAKI	24	Sequence 25 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15751	SWLRTIWDWVCSVLADFKAWLSAKI	25	Sequence 26 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15752	SWLHDIWDWVCIVLSDFKTWLSAKI	25	Sequence 27 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15753	SWLWDVWDWVLHVLSDFKTCLKAKF	25	Sequence 28 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15754	SWLYDIVNWVCTVLADFKLWLGAKI	25	Sequence 29 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15755	SWLRDIWDWVCTVLSDFRVWLKSKL	25	Sequence 30 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15756	SGSLRDIWDWICEVLSDFKTWLKA	24	Sequence 31 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15757	SGSWLRDVWDWICTVLTDFKTWLQSKL	27	Sequence 32 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15758	SGSWLRDVWDWVCTILTDFKNWLTSKL	27	Sequence 33 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15759	SGSWLRDIWEWVLSILTDFKNWLSAKL	27	Sequence 34 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15760	SGSWLRIIWDWVCSWSDFKTWLSAKI	26	Sequence 35 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15761	SGSWLRTIWDWVCSVLADFKAWLSAKI	27	Sequence 36 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15762	SGSWLHDIWDWVCIVLSDFKTWLSAKI	27	Sequence 37 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15763	SGSWLWDVWDWVLHVLSDFKTCLKAKF	27	Sequence 38 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15764	SGSWLYDIVNWVCTVLADFKLWLGAKI	27	Sequence 39 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15765	SGSWLRDIWDWVCTVLSDFRVWLKSKL	27	Sequence 40 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15766	GSWLRDVWDWICTVLTDFKTWLQSKL	26	Sequence 41 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15767	GSWLRDVWDWVCTILTDFKNWLTSKL	26	Sequence 42 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15768	GSWLRDIWEWVLSILTDFKNWLSAKL	26	Sequence 43 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15769	GSWLRIIWDWVCSWSDFKTWLSAKI	25	Sequence 44 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15770	GSWLRTIWDWVCSVLADFKAWLSAKI	26	Sequence 45 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15771	GSWLHDIWDWVCIVLSDFKTWLSAKI	26	Sequence 46 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15772	GSWLWDVWDWVLHVLSDFKTCLKAKF	26	Sequence 47 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15773	GSWLYDIVNWVCTVLADFKLWLGAKI	26	Sequence 48 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP13964	NLCEKASKTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 225 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13965	NLCERASKTWSGNCGNTKHCDTQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 226 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13966	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 227 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13967	NLCEKASKTWSGNCGNTKHCDTQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 229 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13968	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 230 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13969	NLCERASKTWSGNCGNTKHCDNQCKSWEGAQHGACHVRNGKHKCFCYFNC	50	Sequence 231 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13970	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 232 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13971	NLCERASKTWTGNCGNTKHCDTQCRSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 233 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13972	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 234 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13973	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 235 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13974	NLCERASKTWSGNCGNTKHCDNQCISWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 236 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13975	NLCERASKTWTGNCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 238 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13976	NLCERASKTWAGNCGNTKHCDNQCRSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 239 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13977	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 240 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13978	NLCEKASKTWSGNCGNTNHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 241 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13979	NLCERASKTWSGNCGSTKHCDNQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 242 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13980	NLCERASKTWSGNCGNTKHCDNQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 244 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13981	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 245 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13982	NLCERASKTWTGNCGNTKHCDTQCRSWEGAAHGACHVRGGKHKCFCYFNC	50	Sequence 246 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13983	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 247 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13984	NLCERASKTWSGNCGNTKHCDNQCRSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 248 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13985	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 249 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13986	NLCERASKTWSSNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 250 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13987	NLCERASKTWSGNCGNTKHCDTQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 251 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13988	NLCERASKTWSGDCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 252 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13989	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRGGKWKCFCYFNC	50	Sequence 253 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13990	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 254 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13991	NLCERASKTWSGNCGNTKHCDNQCKNWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 255 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13992	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 256 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13993	NLCEKASKTWSGNCGNTKHCDTQCKNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 257 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13994	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 258 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13995	NLCERASKTWSGNCGNTKHCDNQCRNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 259 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13996	NLCERASKTWTGNCGNTKHCDTQCRNWEGARHGACHVRNGKWKCFCYFNC	50	Sequence 260 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13997	NLCERASKTWSGNCGNTKHCDNQCRSWEGAAHGACHVRNGKWKCFCYFNC	50	Sequence 261 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13998	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 262 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13999	NLCERASKTWTGNCGNTKHCDNQCRSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 263 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14000	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 264 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14001	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 265 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14002	NLCERASKTWTGNCGNTKHCDNQCKNWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 266 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14003	NLCERASKTWTGNCGNTKHCDNQCRSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 267 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14004	NLCERASKTWTGNCGNTKHCDNQCKNWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 268 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14005	NLCEKASKTWSGNCGNTKHCDNQCRNWEGAEHGACHVRNGKHKCFCYFNC	50	Sequence 269 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14006	NLCERASKTWSGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 270 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14007	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 271 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14008	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 272 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14009	NLCERASRTWSGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 273 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14010	NLCERASKTWSGNCGITKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 274 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14011	NLCERASKTWSGNCSNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 275 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14012	NLCERASKTWSGNCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 276 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14013	NLCEKASKTWSGNCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 277 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14014	NLCERASKTWSGNCGNTKHCDNQCKGWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 278 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14015	DGVKLCERPSQTWTGNCGNTKHCDKQCKSWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 280 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14016	DGVKLCEKPSQTWTGHCGNTKHCDTQCRSWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 281 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14017	DGVKLCERASKTWTGNCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 282 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14018	DGVKLCEKASKTWSGNCGNTKHCDKQCRSWEKAKHGACHVRNGKHKCFCYFNC	53	Sequence 283 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14019	NLCERASKTWSGHCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 284 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14020	DGVKLCERPSKTWSGNCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 285 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14021	DGVKLCEKPSKTWSGHCGNTKHCDKQCKNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 286 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14022	NLCEKASQTWTGHCGNTKHCDKQCKSWEGAAHGACHVRSGKWKCFCYFNC	50	Sequence 287 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14023	DGVKLCERPSQTWSGNCGNTKHCDKQCRNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 288 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14024	DGVKLCEKPSKTWTGHCGNTKHCDNQCKNWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 289 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14025	DGVKLCEKPSKTWTGHCGNTKHCDKQCKNWEKAAHGACHVRNGKWKCFCYFNC	53	Sequence 290 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14026	DGVKLCERASQTWSGHCGNTKHCDKQCKNWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 291 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14027	DGVKLCERASQTWTGHCGNTKHCDKQCKSWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 292 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14028	DGVKLCERASQTWSGHCGNTKHCDKQCRNWEGAAHGACHVRNGKWKCFCYFNC	53	Sequence 293 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14029	DGVKLCEKASQTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 294 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14030	DGVKLCERASQTWTGHCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 295 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14031	DGVKLCEKPSQTWTGHCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 296 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14032	DGVKLCERASQTWTGHCGNTKHCDKQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 297 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14033	NLCERASHTWSGHCGNTKHCDKQCRSWEGAAHGACHVRNGKRKCFCYFNC	50	Sequence 298 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14034	DGVKLCEKPSKTWSGHCGNTKHCDNQCRNWEKAAHGACHVRNGKWKCFCYFNC	53	Sequence 299 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14035	QKLCEKASQTWTGHCGNTKHCDNQCRNWEKAAHGACHVRNGKWKCFCYFNC	51	Sequence 300 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14036	DGVKLCERASQTWTGHCGNTKHCDTQCRSWEGAAHGACHKRNGKWKCFCYFNC	53	Sequence 301 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14037	DGVKLCERASKTWSGHCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	53	Sequence 302 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14038	DGVKLCERASKTWSGHCGNTKHCDKQCKNWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 303 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14039	DGVKLCEKPSQTWSHCGNTKHCDNQCKNWEGAAHGACHKRSGKWKCFCYFNC	52	Sequence 304 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14040	DGVKLCERASQTWTGHCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 305 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14041	DGVKLCEKASQTWSGHCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 306 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14042	DGVKLCEKPSKTWSGHCGNTKHCDTQCRNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 307 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14043	DGVKLCEKASQTWSGHCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 308 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14044	DGVKLCEKPSQTWTGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 309 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14045	DGVKLCERASQTWTGHCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 310 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14046	DGVKLCERASKTWTGNCGNTKHCDKQCKNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 312 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14047	DGVKLCERASKTWSGHCGNTKHCDNQCRSWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 313 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14048	DGVKLCERPSQTWTGNCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 314 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14049	NLCERPSKTWTGHCGNTKHCDKQCKSWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 315 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14050	DGVKLCEKPSQTWSGNCGNTKHCDKQCKSWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 316 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14051	DGVKLCEKASQTWTGHCGNTKHCDKQCKSWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 317 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14052	QKLCERASKTWTGHCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	51	Sequence 318 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14053	DGVKLCERPSQTWTGNCGNTKHCDKQCRNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 319 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14054	DGVKLCEKASQTWTGNCGNTKHCDNQCKNWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 320 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14055	QKLCERPSQTWTGHCGNTKHCDTQCKSWEGAKHGACHKRNGKWKCFCYFNC	51	Sequence 321 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14056	DGVKLCEKPSQTWTGNCGNTKHCDKQCRNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 322 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14057	DGVKLCEKPSKTWSGNCGNTKHCDNQCRSWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 323 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14058	DGVKLCERPSKTWSGNCGNTKHCDKQCRSWEGAKHGACHVRSGKHKCFCYFNC	53	Sequence 324 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14059	DGVKLCERASQTWSGHCGNTKHCDNQCKSWEKAKHGACHVRSGKHKCFCYFNC	53	Sequence 325 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14060	QKLCEKASKTWTGNCGNTKHCDKQCRSWEKAKHGACHVRNGKWKCFCYFNC	51	Sequence 326 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14061	DGVKLCEKASKTWSGNCGNTKHCDKQCRSWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 327 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14062	DGVKLCEKASKTWTGHCGNTKHCDKQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 328 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14063	DGVKLCEKASKTWSGNCGNTKHCDKQCKNWEGAAHGACHKRNGKWKCFCYFNC	53	Sequence 329 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14064	DGVKLCEKASQTWTGHCGNTKHCDKQCKSWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 330 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14065	DGVKLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	53	Sequence 331 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14066	DGVKLCERPSKTWTGHCGNTKHCDKQCRNWEGAAHGACHVRNGKHKCFCYFNC	53	Sequence 332 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14067	DGVKLCERPSKTWSGNCGNTKHCDNQCRNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 333 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14068	DGVKLCERASQTWTGHCGNTKHCDNQCRSWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 334 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14069	DGVKLCERPSQTWTGHCGNTKHCDKQCRNWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 335 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14070	DGVKLCERPSQTWSGHCGNTKHCDKQCRNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 336 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14071	QKLCERPSQTWTGHCGNTKHCDKQCKNWEGAKHGACHVRNGKWKCFCYFNC	51	Sequence 337 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14072	DGVKLCERASKTWSGHCGNTKHCDKQCKNWEKAAHGACHVRNGKWKCFCYFSC	53	Sequence 338 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14073	DGVKLCERPSKTWSGHCGNTKHCDKQCRSWEGAAHGACHVRNGKWKCFCYFNC	53	Sequence 339 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14074	QKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYFPC	51	Sequence 341 from Patent US 7785828	Arabidopasis thaiana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14075	QKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYVPC	51	Sequence 342 from Patent US 7785828	Arabidopasis thaiana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14076	QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 343 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14077	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 344 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14078	QKLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	51	Sequence 345 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14079	QKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 346 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14080	ELCEKASKTWSGNCGNTKHCDDQCKSWEGAAHGACHVRNGKHMCFCYFNCN	51	Sequence 349 from Patent US 7785828	Cnicus benedictus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14081	ELCEKASKTWSGNCGNTKHCDNKCKSWEGAAHGACHVRSGKHMCFCYFNC	50	Sequence 350 from Patent US 7785828	Cnicus benedictus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14082	QKLCERPSRTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 354 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14083	QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 355 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14084	QKLCERPSRTWSGVCGNNNACKNQCINLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 356 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14085	QKLCMRPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 357 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14086	QKLCERPSGTWSGVCMNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 358 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14087	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 359 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14088	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 361 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14089	QKLCMRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 362 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14090	QKLCQRPSGTWSGVCMNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 363 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14091	KLCERSSRTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 364 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14092	KLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYRFPAHKCICYFPC	50	Sequence 365 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14093	KLCERSSRTWSGVCGNNNACKNQCIRLEGAQHGSCNYRFPAHKCICYFPC	50	Sequence 366 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14094	KLCMRSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 367 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14095	KLCERSSGTWSGVCMNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 368 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14096	QKLCERSSRTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 369 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14097	QKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYRFPYHRCICYFPC	51	Sequence 370 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14098	QKLCERSSRTWSGVCGNNNACKNQCINLEGARHGSCNYRFPYHRCICYFPC	51	Sequence 371 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14099	QKLCMRSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 372 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14100	QKLCERSSGTWSGVCMNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 373 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14101	MAKVASIVALLFPALVIFAAFEAPTMVEAQKLCERPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	80	Sequence 374 from Patent US 7785828	Brassica oleracea	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14102	MAKSAAIITFLFAALVLFAAFEAPIMVEAQKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYFPC	80	Sequence 375 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14103	MAKFVSIITLFFAALVLFAAFEAPTMVKAQKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYVFPYHRCICYFPC	80	Sequence 376 from Patent US 7785828	Brassica rapa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14104	MAKFASIIALLFAALVLFSAFEAPSMVEAQKLCEKSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	80	Sequence 377 from Patent US 7785828	Wasabia japonica	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14105	MAKFASIITLLFAALVVFAAFEAPTMVEAKLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	79	Sequence 378 from Patent US 7785828	Brassica napus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14106	QKLCQRPSGTWSGVCGNNNACRNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 379 from Patent US 7785828	Sinapis alba	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14107	MAKSATIVTLFFAALVFFAALEAPMVVEAQKLCERPSGTWSGVCGNSNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	80	Sequence 380 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14108	MAKFASIITLIFAALVLFAAFDAPAMVEAQKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYVPC	80	Sequence 381 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14109	QKLCEKPSGTWSGVCGNSNACKNQCINLERARHGSCNYVFPAHKCICYFPC	51	Sequence 383 from Patent US 7785828	Descurainia sophia	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14110	ELCEKASKTWSGKCGNTRHCDDQCKSWEGAAHGACHVRGGKHMCFCYFNC	50	Sequence 384 from Patent US 7785828	Helianthus annuus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14111	ELCEKPSKTWSGNCGNTGHCDGQCKSWEGGAHGACHVRGGKHMCFCYFNC	50	Sequence 387 from Patent US 7785828	Lactuca sativa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14112	ELCEKXXKKWSGNCXNTGHCDGQCKSWEGGAHGACHVRGGKHMCFCYFNC	50	Sequence 388 from Patent US 7785828	Lactuca sativa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14113	VFRLKKWIQK	10	Sequence 2 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14114	THVFRLKKWIQKVIDQFGE	19	Sequence 3 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14115	NHVFRLKKWIQKVIDQFGE	19	Sequence 4 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14116	SHVFRLKKWIQKVIDQFGE	19	Sequence 5 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14117	THVFRLKKWIKKVIKQFGE	19	Sequence 6 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14118	VFRLKKWIQKVIDQFG	16	Sequence 7 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14119	VFRLKKWIRKVTRQFG	16	Sequence 8 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14120	LFRLKKWIRKVTRLFG	16	Sequence 9 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14121	LFRLKKWLRKVTKQFG	16	Sequence 10 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14122	LTRLKKWIRKVTKQFGE	17	Sequence 11 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14123	LTRLKKWLRKVTDQFGE	17	Sequence 12 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14124	LFRLKKWIRKVTRQFGR	17	Sequence 13 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14125	LFRLKKWIRKVTKQFGR	17	Sequence 14 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14126	LFRLKKWIRKVIRQFGE	17	Sequence 15 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14127	LFRLKKWIRKVTRQFGE	17	Sequence 16 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14128	LFRLKKWLRKVTDQFGR	17	Sequence 17 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14129	LFRLKKWIRKVTDQFGR	17	Sequence 18 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14130	LFRLKKWIRKVIKQFGE	17	Sequence 19 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14131	LFRLKKWLRKVIKQFGE	17	Sequence 20 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14132	VFRLKKWIRKVTRQFGE	17	Sequence 21 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14133	LFRLKKWIRKVTKQFGE	17	Sequence 22 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14134	VFRLKKWLRKVTRQFGE	17	Sequence 23 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14135	LFRLKKWLRKVTKQFGE	17	Sequence 24 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14136	LFRLKKWIKKVTRQFGE	17	Sequence 25 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14137	VFRLKKWIRKVTKQFGE	17	Sequence 26 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14138	VFRLKKWLRKVTKQFGE	17	Sequence 27 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14139	LFRLKKWIKKVTKQFGE	17	Sequence 28 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14140	LFRLKKWLKKVTKQFGE	17	Sequence 29 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14141	LFRLKKWLQKVTRQFGE	17	Sequence 30 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14142	LFRLKKWIQKVTRQFGE	17	Sequence 31 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14143	LFRLKKWIRKVTRLFGE	17	Sequence 32 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14144	LFRLKKWLRKVTDQFGE	17	Sequence 33 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14145	LFRLKKWLQKVTKQFGE	17	Sequence 34 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14146	LFRLKKWLRKVTKLFGE	17	Sequence 35 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14147	LFRLKKWLKKVTDQFGE	17	Sequence 36 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14148	VFRLKKWLRKVTDQFGE	17	Sequence 37 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14149	VKRLKKWIQKVIDQFGE	17	Sequence 39 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14150	VFRLKKWIQKVIKQFGE	17	Sequence 40 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14151	VFRLKKWIQKVIDQFGK	17	Sequence 41 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14152	VKRLKKWIQKVIKQFGK	17	Sequence 42 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14153	VKRLKKWIQKVIKLFGK	17	Sequence 43 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14154	VKRLKKWIKKVIKLFGK	17	Sequence 44 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14155	VRRLKKWIQKVIRQFGR	17	Sequence 45 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14156	VRRLKKWIQKVIRLFGR	17	Sequence 46 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14157	VKRLKKWIKKVIKIFGK	17	Sequence 47 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14158	VRRLKKWIQKVIRIFGR	17	Sequence 48 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14159	VSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE	35	Sequence 49 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14160	GKYGIYTKVSRYVNWIKEKTKLT	23	Sequence 50 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14161	GKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK	42	Sequence 51 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14162	ERPGVYTNVVEYVDWILEKTQAV	23	Sequence 52 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14163	GHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP	35	Sequence 53 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14164	NKPGVYTDVAYYLAWIREHTVS	22	Sequence 54 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14165	GKYGFYTHVFRLKKWIQKVIDQFGE	25	Sequence 55 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14166	EQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA	33	Sequence 56 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14167	HNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP	32	Sequence 57 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14168	CQKRYRGHKITHKMIC	16	Sequence 58 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14169	NWRENLDRDIALMKLKKP	18	Sequence 60 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14170	EQPGVYTKVAEYMDWILEKTQSSDG	25	Sequence 65 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14171	HVFRLKKWIQKVIDQFGE	18	Sequence 66 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14172	NVVEYVDWILEKTQAV	16	Sequence 67 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14173	KVAEYMDWILEKTQSSDG	18	Sequence 68 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14174	KVSRYVNWIKEKTKLT	16	Sequence 69 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14175	CKDSTRIRITDNMFC	15	Sequence 70 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14176	NRPGIFVRVAYYAKWIHKIILTYKV	25	Sequence 71 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14177	RVAYYAKWIHKIILTYKV	18	Sequence 72 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14178	MALLNKLLCFALVFMIFGEFVTPDCYEDWSRCTPGTSFLTGILWKDCHSRCKELGHRGGRCVDSPSKHCPGVLKNNKQCHCY	82	Sequence 2 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14179	MFSKYERQKDKRSYGERFSMFTGPQFISPPERIKPNKILQWDGEGMPIYATSGAAAE	57	Sequence 4 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14180	MELKSGLSILLCFGICIAVINAGCFEDWSRCSPSTSRGTGVLWRDCDSYCKVCFKADRGECFDSPSLNCPQRLPNNKQCRCINARTAKDNRNPTCWA	97	Sequence 6 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14181	CFEDWSRCSPSTASATGVLWRSCDSYCKVCFKADRGECYDSPSLNCPHRLPNNKQCRCINARTAKDNRNPTCWA	74	Sequence 8 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14182	MDKKAANGGKEKGPLEACWDEWSRCTGWSSAGTGVLWKSCDDQCKKLGKSGGECVLTPSTCPFTRTDKAYQCQCKK	76	Sequence 10 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14183	MSLCISDYLYLTLTFSKYERQKDKRPYSERKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA	76	Sequence 12 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14184	MYSKYERQKDKRPYSERKDQYTGPQFLYPPDRIPPSKAIKWNEEGLPMYEVLPDGAGAKTAVEAAAE	67	Sequence 14 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14185	GCYEDWSRCTPSTSWLTGILWKSCTNRCKEQGHRGGNCRDSPSPCPGLQNNKQCYCF	57	Sequence 15 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14186	NVIGRCWDTWSRCSTWSRWFTGRVWLTRDGKCRELGKRGGNCVMTPSTCPLSSEAFQCQCYT	62	Sequence 16 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14187	DCYEDWSRCTPGTSFLTGILWKDCHSRCKELGHRGGRCVDSPSKHCPGVLKNNKQCHCY	59	Sequence 28 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14188	GCFEDWSRCSPSTSRGTGVLWRDCDSYCKVCFKADRGECFDSPSLNCPQRLPNNKQCRCINARTAKDNRNPTCWA	75	Sequence 37 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14189	GCFEDWSRCSPSTASATGVLWRSCDSYCKVCFKADRGECYDSPSLNCPHRLPNNKQCRCINARTAKDNRNPTCWA	75	Sequence 38 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14190	ASIIKTTIKVSKAVCKTLTCICTGSCSNCK	30	Sequence 1 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14191	ASIIKTTIKVSKAVCKTLTCICTGCCSNSK	30	Sequence 2 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14192	ASIIKTTIKVCKAVSKTLTCICTGSCSNCK	30	Sequence 3 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14193	ASIIKTTIKVCKAVSKTLTCICTGCCSNSK	30	Sequence 4 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14194	AXIIKXXIKVAKAVAKXLXAIAXGAAXNAK	30	Sequence 5 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14195	XXXXXXXXXVAXAVAXXXXAXAXGAAANAX	30	Sequence 6 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14196	XXLLKXXLKVAKAVAKXLXALAXGAAANAK	30	Sequence 7 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14197	XXXXKXXXKVAKAVAKXXXAXAXGAAXNAX	30	Sequence 8 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14198	XXIIKXXIKVAKAVAKXIXAIAXGAAANAK	30	Sequence 9 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14199	XTXXTXXLLX	10	Sequence 10 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14200	IXAIXLAXPGAKXGALMGANMKXAXAHASIHVXK	34	Sequence 11 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14201	IAAKFIAXPGAAKXGAFNAYA	21	Sequence 12 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14202	AGPAIRAAVKQAQKXLKAXRLFXVAAKGKNGAK	33	Sequence 13 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14203	MKAFSVAVVLVIACMFILESTAVPFSE	27	Sequence 282 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14204	EPFRFKRQIHLSLCGLCCNCCHNIGCGFCCKF	32	Sequence 283 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14205	VRTEEVGSFDSPVGEHQQPGGESMHLP	27	Sequence 284 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14206	MHFRFKRQSHLSLCRWCCNCCHNKGCGFCCKF	32	Sequence 285 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14207	MKTVLAFLFLTFIAFTYAESYEDVKEEIKNEVEKEIFEDLEEESDALDSSVREFNDAKPWRFRRAIRRVRWRKVAPYIPFVVKTVGKK	88	Sequence 2 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14208	MKTVLAFLFLTFIAFTHAESYEDVKEEIKNEVEREIFEDLEEESDVLESNVRELNDAKPWRFRRAIRRVRWRKVAPYIPFVVRTVGKK	88	Sequence 5 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14209	MKTVLAFLFLTFIAFTYAESYEDVKEEIKNEVEREIFEDLEEESDVLDSNVREFNDAKPWRFRRAIRRVRWRKVAPYIPFVVRTVGKK	88	Sequence 7 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14212	KLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 10 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14214	QKLCERPSGTWSGVCGNNNACKNQCIN	27	Sequence 12 from Patent US 20020152498	Brassica rapa	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14215	QKLCERPSGTXSGVCGNNNACKNQCIR	27	Sequence 13 from Patent US 20020152498	Brassica rapa	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14216	QKLCERPSGTWSGVCGNNNACKNQCINLEK	30	Sequence 14 from Patent US 20020152498	Brassica napus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14217	QKLCERPSGTWSGVCGNNNACKN	23	Sequence 15 from Patent US 20020152498	Brassica napus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14218	QKLCERPSGTWSGVCGNNNACKNQC	25	Sequence 16 from Patent US 20020152498	Sinapis alba	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14219	QKLCQRPSGTWSGVCGNNNACRNQCI	26	Sequence 17 from Patent US 20020152498	Sinapis alba	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14220	QKLCERPSGTWSGVCGNSNACKNQCIN	27	Sequence 18 from Patent US 20020152498	Arabidopsis thaliana	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14221	RVCMKGSAGFKGLCMRDQNCAQVCLQEGWGGGNCDGVMRQCKCIRQC	47	Sequence 21 from Patent US 20020152498	Sorghum bicolor	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14223	QKLCQRPSGGWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 23 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14224	QKLCQRPSGTSSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 24 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14226	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKWRHGSCNYVFPAHKCICYFPC	51	Sequence 26 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14227	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNGVFPAHKCICYFPC	51	Sequence 27 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14228	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVMPAHKCICYFPC	51	Sequence 28 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14229	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHQCICYFPC	51	Sequence 29 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14230	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPPAHKCICIFPC	51	Sequence 30 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14231	QKLCQRPSGAWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 31 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14232	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARAGSCNYVFPAHKCICYFPC	51	Sequence 32 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14233	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNAVFPAHKCICYFPC	51	Sequence 33 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14234	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVAPAHKCICYFPC	51	Sequence 34 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14235	QKLCQRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	50	Sequence 35 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14236	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPAHKCICYFPC	50	Sequence 36 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14237	QKLCQRRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 37 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14239	QKLCQRPSGTWRGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 39 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14240	QKLCQRPSGTWSGVCGNNNACKNQCRRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 40 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14241	QKLCQRPSGTWSGVCGNNNACKNQCIRREKARHGSCNYVFPAHKCICYFPC	51	Sequence 41 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14242	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCRYVFPAHKCICYFPC	51	Sequence 42 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14243	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 43 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14244	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPRHKCICYFPC	51	Sequence 44 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14245	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCRCYFPC	51	Sequence 45 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14246	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYRPC	51	Sequence 46 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14263	XKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 77 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14264	SINVDIEQETAWVQAGATLGEVYYR	25	Sequence 1 from Patent US 20020168735	Helianthus annuus	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14265	DPSFPITGEVYTPGXSSFPTVLQNY	25	Sequence 2 from Patent US 20020168735	Helianthus annuus	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14266	TSTSIIDRFTQXLNNRADPXX	21	Sequence 49 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14267	XIXVXIEDETAXVQAGATLGEVYX	24	Sequence 50 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14268	ADPSFPLSGQLYYP	14	Sequence 51 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14269	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 1 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14270	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 2 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14271	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 3 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14272	DKLIGTCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 4 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14273	DKLIGSCVWGAVNYTTDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 5 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14274	DKLIGSCVWGAVNYTRDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 6 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14275	DKLIGSCVWGAVNYTSDCRGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 7 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14276	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFINVNCWCET	44	Sequence 8 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14277	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 10 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14278	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNINCWCET	44	Sequence 11 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14279	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCER	44	Sequence 12 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14280	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 13 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14281	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 14 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14282	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 15 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14283	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFINVNCWCQT	44	Sequence 16 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14284	NKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 17 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14285	DKLIGSCVWGAVNYTRNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 18 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14286	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 19 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14287	DKLIGSCVWGAVNYTSRCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 20 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14288	DKLIGSCVWGAVNYTSNCRAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 21 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14289	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCET	44	Sequence 22 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14290	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANINCWCET	44	Sequence 23 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14291	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNINCWCET	44	Sequence 24 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14292	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 25 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14293	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 26 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14294	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCER	44	Sequence 27 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14295	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 28 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14296	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCQT	44	Sequence 29 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14297	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCER	44	Sequence 30 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14298	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCER	44	Sequence 31 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14299	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 32 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14300	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 33 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14301	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 34 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14302	DKLIGSCVWGAVRYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 37 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14303	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANINCWCET	44	Sequence 41 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14304	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANLNCWCQT	44	Sequence 47 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14305	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANINCWCQT	44	Sequence 48 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14306	RRKCEANCNSTYNVA	15	Sequence 70 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14307	SFINVNCWCET	11	Sequence 74 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14308	SFLNVNCWCET	11	Sequence 77 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14309	SFANVNCWCQT	11	Sequence 80 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14310	SFANVNCWCER	11	Sequence 86 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14311	SFLNVNCWCQT	11	Sequence 89 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14312	SFLNVNCWCER	11	Sequence 92 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14313	SLDKRNKLIG	10	Sequence 96 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14314	CKNQCIRLEKARHGS	15	Sequence 1 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14315	CIRLEKARHGSCNYV	15	Sequence 2 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14316	EKARHGSCNYVFPAH	15	Sequence 3 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14317	HGSCNYVFPAHKCIC	15	Sequence 4 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14318	CNYVFPAHKC	10	Sequence 5 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14319	FPAHKC	6	Sequence 6 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14320	AHKCIC	6	Sequence 7 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14321	HKCICY	6	Sequence 8 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14322	QCIRLEKAR	9	Sequence 9 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14323	CIRLEKARH	9	Sequence 10 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14324	RHGSCNYVF	9	Sequence 11 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14325	CNYVFPAHK	9	Sequence 12 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14326	FPAHKCICY	9	Sequence 13 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14327	PAHKCICYF	9	Sequence 14 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14328	AHKCICYFP	9	Sequence 15 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14329	HKCICYFPC	9	Sequence 16 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14330	CIRLEKARHGSC	12	Sequence 17 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14331	EKARHGSCNYVF	12	Sequence 18 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14332	KARHGSCNYVFP	12	Sequence 19 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14333	RHGSCNYVFPAH	12	Sequence 20 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14334	HGSCNYVFPAHK	12	Sequence 21 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14335	ARHGSCNYVFPAHKCICYF	19	Sequence 22 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14336	ASHGACHKRENHWKCFCYF	19	Sequence 23 from Patent US 20030226169	Aesculus hippocastanum	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14337	AAHGACHVRNGKHMCFCYF	19	Sequence 24 from Patent US 20030226169	Dahlia merckii	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14338	ARHGSXNYVFPAHKXIXYF	19	Sequence 26 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14339	ASHGAXHKRENHWKXFXYF	19	Sequence 27 from Patent US 20030226169	Aesculus hippocastanum	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14340	KARHGSXNYVFPAHKXIXYF	20	Sequence 29 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14341	AAHGAXHVRNGKHMXFXYF	19	Sequence 30 from Patent US 20030226169	Dahlia merckii	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14342	RHGSXNYVFPAHKXIXYF	18	Sequence 31 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14343	QKLCQRPSGTWSGVC	15	Sequence 46 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14344	QRPSGTWSGVCGNNN	15	Sequence 47 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14345	GTWSGVCGNNNACKN	15	Sequence 48 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14346	GVCGNNNACKNQCIR	15	Sequence 49 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14347	NNNACKNQCIRLEKA	15	Sequence 50 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14348	NYVFPAHKCICYFPC	15	Sequence 55 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14349	DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC	54	Sequence 56 from Patent US 20030226169	Huechera sanguinea	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14352	IRLEKARHGSXNY	13	Sequence 59 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14353	RLEKARHGSXNYV	13	Sequence 60 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14354	LEKARHGSXNYVF	13	Sequence 61 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14355	EKARHGSXNYVFP	13	Sequence 62 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14356	KARHGSXNYVFPA	13	Sequence 63 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14357	ARHGSXNYVFPAH	13	Sequence 64 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14358	RHGSXNYVFPAHK	13	Sequence 65 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14359	HGSXNYVFPAHKX	13	Sequence 66 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14360	GSXNYVFPAHKXI	13	Sequence 67 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14361	SXNYVFPAHKXIX	13	Sequence 68 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14362	XNYVFPAHKXIXY	13	Sequence 69 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14363	NYVFPAHKXIXYF	13	Sequence 70 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14364	IRLEKARHGSXNYV	14	Sequence 71 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14365	RLEKARHGSXNYVF	14	Sequence 72 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14366	LEKARHGSXNYVFP	14	Sequence 73 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14367	EKARHGSXNYVFPA	14	Sequence 74 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14368	KARHGSXNYVFPAH	14	Sequence 75 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14369	ARHGSXNYVFPAHK	14	Sequence 76 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14370	RHGSXNYVFPAHKX	14	Sequence 77 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14371	HGSXNYVFPAHKXI	14	Sequence 78 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14372	GSXNYVFPAHKXIX	14	Sequence 79 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14373	SXNYVFPAHKXIXY	14	Sequence 80 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14374	XNYVFPAHKXIXYF	14	Sequence 81 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14375	IRLEKARHGSXNYVF	15	Sequence 82 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14376	RLEKARHGSXNYVFP	15	Sequence 83 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14377	LEKARHGSXNYVFPA	15	Sequence 84 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14378	EKARHGSXNYVFPAH	15	Sequence 85 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14379	KARHGSXNYVFPAHK	15	Sequence 86 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14380	ARHGSXNYVFPAHKX	15	Sequence 87 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14381	RHGSXNYVFPAHKXI	15	Sequence 88 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14382	HGSXNYVFPAHKXIX	15	Sequence 89 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14383	GSXNYVFPAHKXIXY	15	Sequence 90 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14384	SXNYVFPAHKXIXYF	15	Sequence 91 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14385	IRLEKARHGSXNYVFP	16	Sequence 92 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14386	RLEKARHGSXNYVFPA	16	Sequence 93 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14387	LEKARHGSXNYVFPAH	16	Sequence 94 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14388	EKARHGSXNYVFPAHK	16	Sequence 95 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14389	KARHGSXNYVFPAHKX	16	Sequence 96 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14390	ARHGSXNYVFPAHKXI	16	Sequence 97 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14391	RHGSXNYVFPAHKXIX	16	Sequence 98 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14392	HGSXNYVFPAHKXIXY	16	Sequence 99 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14393	GSXNYVFPAHKXIXYF	16	Sequence 100 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14394	IRLEKARHGSXNYVFPA	17	Sequence 101 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14395	RLEKARHGSXNYVFPAH	17	Sequence 102 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14396	LEKARHGSXNYVFPAHK	17	Sequence 103 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14397	EKARHGSXNYVFPAHKX	17	Sequence 104 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14398	KARHGSXNYVFPAHKXI	17	Sequence 105 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14399	ARHGSXNYVFPAHKXIX	17	Sequence 106 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14400	RHGSXNYVFPAHKXIXY	17	Sequence 107 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14401	HGSXNYVFPAHKXIXYF	17	Sequence 108 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14402	IRLEKARHGSXNYVFPAH	18	Sequence 109 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14403	RLEKARHGSXNYVFPAHK	18	Sequence 110 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14404	LEKARHGSXNYVFPAHKX	18	Sequence 111 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14405	EKARHGSXNYVFPAHKXI	18	Sequence 112 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14406	KARHGSXNYVFPAHKXIX	18	Sequence 113 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14407	ARHGSXNYVFPAHKXIXY	18	Sequence 114 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14408	IRLEKARHGSXNYVFPAHK	19	Sequence 116 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14409	RLEKARHGSXNYVFPAHKX	19	Sequence 117 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14410	LEKARHGSXNYVFPAHKXI	19	Sequence 118 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14411	EKARHGSXNYVFPAHKXIX	19	Sequence 119 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14412	KARHGSXNYVFPAHKXIXY	19	Sequence 120 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14413	IRLEKARHGSXNYVFPAHKX	20	Sequence 122 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14414	RLEKARHGSXNYVFPAHKXI	20	Sequence 123 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14415	LEKARHGSXNYVFPAHKXIX	20	Sequence 124 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14416	EKARHGSXNYVFPAHKXIXY	20	Sequence 125 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14417	CICYFP	6	Sequence 129 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14418	ICYFPC	6	Sequence 130 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14419	VFPAHKCICYFP	12	Sequence 131 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14420	FPAHKCICYFPC	12	Sequence 132 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14421	QKLCQR	6	Sequence 133 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14422	KLCQRP	6	Sequence 134 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14423	LCQRPS	6	Sequence 135 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14424	QKLCQRPSG	9	Sequence 136 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14425	KLCQRPSGT	9	Sequence 137 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14426	LCQRPSGTW	9	Sequence 138 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14427	QKLCQRPSGTWS	12	Sequence 139 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14428	KLCQRPSGTWSG	12	Sequence 140 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14429	LCQRPSGTWSGV	12	Sequence 141 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14430	KARHGSCNYVFPAHKCICYF	20	Sequence 29 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14431	RHGSCNYVFPAHKCICYF	18	Sequence 31 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14432	IRLEKARHGSCNY	13	Sequence 59 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14433	RLEKARHGSCNYV	13	Sequence 60 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14434	LEKARHGSCNYVF	13	Sequence 61 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14435	EKARHGSCNYVFP	13	Sequence 62 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14436	KARHGSCNYVFPA	13	Sequence 63 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14437	ARHGSCNYVFPAH	13	Sequence 64 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14438	RHGSCNYVFPAHK	13	Sequence 65 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14439	HGSCNYVFPAHKC	13	Sequence 66 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14440	GSCNYVFPAHKCI	13	Sequence 67 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14441	SCNYVFPAHKCIC	13	Sequence 68 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14442	CNYVFPAHKCICY	13	Sequence 69 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14443	NYVFPAHKCICYF	13	Sequence 70 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14444	IRLEKARHGSCNYV	14	Sequence 71 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14445	RLEKARHGSCNYVF	14	Sequence 72 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14446	LEKARHGSCNYVFP	14	Sequence 73 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14447	EKARHGSCNYVFPA	14	Sequence 74 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14448	KARHGSCNYVFPAH	14	Sequence 75 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14449	ARHGSCNYVFPAHK	14	Sequence 76 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14450	RHGSCNYVFPAHKC	14	Sequence 77 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14451	HGSCNYVFPAHKCI	14	Sequence 78 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14452	GSCNYVFPAHKCIC	14	Sequence 79 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14453	SCNYVFPAHKCICY	14	Sequence 80 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14454	CNYVFPAHKCICYF	14	Sequence 81 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14455	IRLEKARHGSCNYVF	15	Sequence 82 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14456	RLEKARHGSCNYVFP	15	Sequence 83 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14457	LEKARHGSCNYVFPA	15	Sequence 84 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14458	KARHGSCNYVFPAHK	15	Sequence 86 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14459	ARHGSCNYVFPAHKC	15	Sequence 87 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14460	RHGSCNYVFPAHKCI	15	Sequence 88 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14461	GSCNYVFPAHKCICY	15	Sequence 90 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14462	SCNYVFPAHKCICYF	15	Sequence 91 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14463	IRLEKARHGSCNYVFP	16	Sequence 92 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14464	RLEKARHGSCNYVFPA	16	Sequence 93 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14465	LEKARHGSCNYVFPAH	16	Sequence 94 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14466	EKARHGSCNYVFPAHK	16	Sequence 95 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14467	KARHGSCNYVFPAHKC	16	Sequence 96 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14468	ARHGSCNYVFPAHKCI	16	Sequence 97 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14469	RHGSCNYVFPAHKCIC	16	Sequence 98 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14470	HGSCNYVFPAHKCICY	16	Sequence 99 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14471	GSCNYVFPAHKCICYF	16	Sequence 100 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14472	IRLEKARHGSCNYVFPA	17	Sequence 101 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14473	RLEKARHGSCNYVFPAH	17	Sequence 102 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14474	LEKARHGSCNYVFPAHK	17	Sequence 103 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14475	EKARHGSCNYVFPAHKC	17	Sequence 104 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14476	KARHGSCNYVFPAHKCI	17	Sequence 105 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14477	ARHGSCNYVFPAHKCIC	17	Sequence 106 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14478	RHGSCNYVFPAHKCICY	17	Sequence 107 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14479	HGSCNYVFPAHKCICYF	17	Sequence 108 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14480	IRLEKARHGSCNYVFPAH	18	Sequence 109 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14481	RLEKARHGSCNYVFPAHK	18	Sequence 110 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14482	LEKARHGSCNYVFPAHKC	18	Sequence 111 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14483	EKARHGSCNYVFPAHKCI	18	Sequence 112 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14484	KARHGSCNYVFPAHKCIC	18	Sequence 113 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14485	ARHGSCNYVFPAHKCICY	18	Sequence 114 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14486	IRLEKARHGSCNYVFPAHK	19	Sequence 116 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14487	RLEKARHGSCNYVFPAHKC	19	Sequence 117 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14488	LEKARHGSCNYVFPAHKCI	19	Sequence 118 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14489	EKARHGSCNYVFPAHKCIC	19	Sequence 119 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14490	KARHGSCNYVFPAHKCICY	19	Sequence 120 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14491	IRLEKARHGSCNYVFPAHKC	20	Sequence 122 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14492	RLEKARHGSCNYVFPAHKCI	20	Sequence 123 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14493	LEKARHGSCNYVFPAHKCIC	20	Sequence 124 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14494	EKARHGSCNYVFPAHKCICY	20	Sequence 125 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14495	VKRGLKL	7	Sequence 1 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14496	KHLKKHLKKHLK	12	Sequence 2 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14497	GKRKKKGKLGKKRDP	15	Sequence 3 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14498	KLAKLAKKLAKLAK	14	Sequence 4 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14499	VKRGLKLKLAKLAKKLAKLAK	21	Sequence 6 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14500	KLAKLAKKLAKLAKKHLKKHLKKHLK	26	Sequence 8 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14501	KLAKLAKKLAKLAKGKRKKKGKLGKKRDP	29	Sequence 10 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14502	KLAKLAK	7	Sequence 11 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14511	NQGRHFTGGALIHARFVMTAASCFQ	25	Sequence 9 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14512	NQGRHFCGGALIHARFVMTAASTFQ	25	Sequence 10 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14513	NQGRHFTGGALIHARFVMTAASTFQ	25	Sequence 11 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14514	RHFTGGALIHARFVMTAASC	20	Sequence 12 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14515	RHFCGGALIHARFVMTAAST	20	Sequence 13 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14516	RHFTGGALIHARFVMTAAST	20	Sequence 14 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14517	GTRCQVAGWGSQRSGGRLSRFPRFVNV	27	Sequence 16 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14518	MKFTGIFFIIMAIIALFIGSNEAAPKVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	64	Sequence 1 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14519	MNFTGIFFMIMAIIALFIGSNEAAPKVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	64	Sequence 2 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14520	MRLSIILVVVMMVMAMFVSSGDAAPGKIPVKAIKKGGQIIGKALRGINIASTAHDIISQFKPKKKKNH	68	Sequence 3 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14521	KVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	39	Sequence 4 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14522	GGQIIGKALRGINIASTAHDIISQFKPKKKKNH	33	Sequence 5 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14523	MKLTKVFVILIVVVALLVPSEAAPGKIPVKAIKKAGAAIGKGLRAINIASTAHDVYSFFKPKHKKKH	67	Sequence 14 from Patent US 20080032924	Spodoptera litura	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14524	MKLTSLFIFVIVALSLLFSSTDAAPGKIPVKAIKQAGKVIGKGLRAINIAGTTHDVVSFFRPKKKKH	67	Sequence 15 from Patent US 20080032924	Manduca sexta	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14525	MNILKFFFVFIVAMSLVSCSTAAPAKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH	66	Sequence 16 from Patent US 20080032924	Bombyx mori	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14526	GKIPIGAIKKAGKAIGKGLRAVNIASTAHDVYTFFKPKKRH	41	Sequence 17 from Patent US 20080032924	Heliothis virescens	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14527	MYFLKYFIVVLVALSLMICSGQADPKIPVKSLKKGGKVIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 18 from Patent US 20080032924	Bombyx mori	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14528	KVNVNAIKKGGKAIGKGFKVISAASTAHDVYE	32	Sequence 19 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14529	GGQIIGKALRGINIASTAHDIISQFKPK	28	Sequence 20 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14530	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYS	32	Sequence 30 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14531	MKLTGLFFMIMAMLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRH	63	Sequence 47 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14532	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRH	38	Sequence 48 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14533	MKLTGLFLMIMAVLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVLGAAGTAHEVYNHVRNRQ	63	Sequence 52 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14534	KVPIGAIKKGGKIIKKGLGVLGAAGTAHEVYNHVRNRQ	38	Sequence 53 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14535	MKLTKVFVIVIVVVALLVPSEAAPGKIPVKAIKKAGTAIGKGLRAINIASTAHDVYSFFKPKHKKKH	67	Sequence 57 from Patent US 20080032924	Spodoptera exigua	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14536	AMSLVSCSTAAPAKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH	54	Sequence 58 from Patent US 20080032924	Hyblaea puera	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14537	GKIPINAIRKGAKAVGHGLRALNIASTAHDIASAFHRKRKH	41	Sequence 59 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14538	RKIPVEAIKKGASRAWRALDLASTAYDIASIFNRKRE	37	Sequence 60 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14539	GKIPVEALKKGAKVAGRAWRALDLASTAYDIAHLFDRKRN	40	Sequence 61 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14540	MQFTKIAIFLFAAMGAVANPIAAESGDLDVRDVQLSKYGGECSLQHNTCTYLKGGKNQVVHCGSAANQKCKSDRHHCEYDEHHKTVNCQTPV	92	Sequence 2 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14541	LSKYGGECSLQHNTCTYLKGGKNQVVHCGSAANQKCKSDRHHCEYDEHHKTVNCQTPV	58	Sequence 3 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14542	LSKYGGECSLQHNTC	15	Sequence 5 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14543	MVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	52	Sequence 1 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14544	ARSVPLVSTISXFLLHLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	75	Sequence 2 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14545	TCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRXRCFCTTHC	46	Sequence 3 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14546	PSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	54	Sequence 4 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14547	MARSVFLVSTIFVFLLVLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 5 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14548	SDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	32	Sequence 6 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14549	MARSVSLVFTIFVFLLLVVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 7 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14550	RFSGGHCRGFRRRCFCTTHC	20	Sequence 8 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14551	STIFVFLLFLVATGPSVVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	68	Sequence 9 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14552	NCASVCQTERFSGGHCRGFRRRCFCTTHC	29	Sequence 10 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14553	MVAEARTCESQSHKFKGPCANDHNCASVCQTERFSGGHCRGFRRRCFCTTHW	52	Sequence 11 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14554	MGSFSSFGFTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 12 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14555	SHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	41	Sequence 13 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14556	VFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	64	Sequence 15 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14557	LVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	70	Sequence 16 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14558	TSLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	72	Sequence 17 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14559	GTSLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	73	Sequence 18 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14560	HQVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	71	Sequence 20 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14561	IFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	66	Sequence 21 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14562	SMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	53	Sequence 23 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14563	VPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	72	Sequence 25 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14564	GSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	74	Sequence 26 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14565	MARSVPLVSTIFVFLLLLVATG	22	Sequence 27 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14566	GPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	55	Sequence 28 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14567	ATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	57	Sequence 30 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14568	SVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	73	Sequence 32 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14569	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFFGGHCRGFRRRCFCTTHC	76	Sequence 33 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14570	FVCQTERFFGGHXRGFRXXCFCTTHC	26	Sequence 34 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14571	ARGDHNCASVCQTERFSGGH	20	Sequence 35 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14572	CRGFRRRCFCTTHC	14	Sequence 36 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14573	QTERFFGGHCRGFRRXCFCTTHC	23	Sequence 38 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14574	ATGPSMVAXARTCESQSHKFKGPXXSDHNXXXVCQTERFFGGHCRGFRRXCFCTTHC	57	Sequence 39 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14575	GFRRRCFCTTHC	12	Sequence 40 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14576	LVAXGPSMVAEARTCESQSXKFKGPCXSDXNCAXVCQTERFFGGHXRGFRRRCFCTTHC	59	Sequence 41 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14577	IPHEGGFRRRCFCTTHC	17	Sequence 42 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14578	SARGARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTL	59	Sequence 43 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14579	VFLLLLVATGPSMVAEARTCESQSHKFKGPCASD	34	Sequence 44 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14580	FVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQ	43	Sequence 45 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14581	ARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	75	Sequence 46 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14582	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 47 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14583	MARSVPLVSTIFVFLLLLVATGPSMVGEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 56 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14584	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRXCFCTTHC	76	Sequence 57 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14585	RTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	47	Sequence 71 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14586	RTCESQSHKFKGPCASDHNCASVCQTERFFGGHCRGFRRRCFCTTHC	47	Sequence 105 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14587	MARSVPLVSTIFVFFLLIVATEMGPSMVAARTCETPSNSFKGACFSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	77	Sequence 113 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14588	RTCETPSNSFKGACFSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	47	Sequence 114 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14589	MARSVPLVSTIFVFFLLLVATEMGPIMVAEARTCETPSNNFKGLCVSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	78	Sequence 115 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14590	RTCETPSNNFKGLCVSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	47	Sequence 116 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14591	MARSVPLVSTIFVFLLLLVATGPSMVAEA	29	Sequence 117 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14592	MARSVPLVSTIFVFFLLIVATEMGPSMVAA	30	Sequence 119 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14593	MARSVPLVSTIFVFFLLLVATEMGPIMVAEA	31	Sequence 120 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14594	MARSVFLVSTIFVFLLVLVATGPSMVAEA	29	Sequence 121 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14595	MARSVSLVFTIFVFLLLVVATGPSMVAEA	29	Sequence 122 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14596	MARSVPLVSTIFVFLLLLVATGPSMVGEA	29	Sequence 123 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14597	RTCESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHC	47	Sequence 125 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14598	RTSESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHS	47	Sequence 135 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14599	RTCESQSHKFKGPSASDHNCASVCQTERFSGGRSRGFRRRCFCTTHC	47	Sequence 136 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14600	RTCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGFRRRSFCTTHC	47	Sequence 137 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14601	RTCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGFRRRCFSTTHC	47	Sequence 138 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14602	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHC	76	Sequence 151 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14603	RTCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGF	37	Sequence 152 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14604	SHKFKGPCASDHNSASVCQTERFSGGRCRGFRRRSF	36	Sequence 153 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14605	TCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGFR	37	Sequence 154 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14606	RTCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGF	37	Sequence 155 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14607	TCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGFR	37	Sequence 156 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14608	ACMSHTWGERNL	12	Sequence 21 from Patent US 20100015663	Synthetic construct	Antimicrobial, Antifungal	US 2010/0015663 A1	Patent Application	2010##1##21	EP2132319A1, EP2132319B1, US20120196324, WO2008101847A1	Method for producing an antifungal peptide in a filamentous fungal host cell.	The present invention provides a method for producing an antifungal peptide in a filamentous fungal host cell by expressing the antifungal peptide in a host cell which is deficient or partially deficient in the expression of an endogenous glucosyl-ceramide synthase (gcs) gene.
DRAMP14609	HGWGEDANLAMNPS	14	Sequence 22 from Patent US 20100015663	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0015663 A1	Patent Application	2010##1##21	EP2132319A1, EP2132319B1, US20120196324, WO2008101847A1	Method for producing an antifungal peptide in a filamentous fungal host cell.	The present invention provides a method for producing an antifungal peptide in a filamentous fungal host cell by expressing the antifungal peptide in a host cell which is deficient or partially deficient in the expression of an endogenous glucosyl-ceramide synthase (gcs) gene.
DRAMP14610	GSVIKKRRKRMSKKKHRKMLRRTRVQRRKLGK	32	Sequence 1 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14611	NYRLVNAIFSKIFKKKFIKF	20	Sequence 2 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14612	YIQFHLNQQPRPKVKKIKIFL	21	Sequence 3 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14613	GSVIKKRRKRMAKKKHRKLLKKTRIQRRRAGK	32	Sequence 4 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14614	MRFGSLALVAYDSAIKHSWPRPSSVRRLRM	30	Sequence 5 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14615	FESKILNASKELDKEKKVNTALSFNSHQDFAKAYQNGKI	39	Sequence 6 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14616	KGKSLMPLLKQINQWGKLYL	20	Sequence 7 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14617	WSRVPGHSDTGWKVWHRW	18	Sequence 8 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14618	MGIIAGIIKFIKGLIEKFTGK	21	Sequence 9 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14619	ILNKKPKLPLWKLGKNYFRRFYVLPTFLA	29	Sequence 10 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14620	RESKLIAMADMIRRRI	16	Sequence 11 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14621	LDPLEPRIAPPGDRSHQGAPACHRDPLRGRSARDAER	37	Sequence 12 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14622	MPVSKKRYMLSSAYATALGICYGQVATDEKESEITAIPDLLDYLSVEEYLL	51	Sequence 13 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14623	LSLATFAKIFMTRSNWSLKRFNRL	24	Sequence 14 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14624	MIRIRSPTKKKLNRNSISDWKSNTSGRFFY	30	Sequence 15 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14625	MKRRRCNWCGKLFYLEEKSKEAYCCKECRKKAKKVKK	37	Sequence 16 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14626	VLPFPAIPLSRRRACVAAPRPRSRQRAS	28	Sequence 17 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14627	KNKKQTDILEKVKEILDKKKKTKSVGQKLY	30	Sequence 18 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14628	SLQSQLGPCLHDQRH	15	Sequence 19 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14629	WKRLWPARILAGHSRRRMRWMVVWRYFAAT	30	Sequence 20 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14630	KFQGEFTNIGQSYIVSASHMSTSLNTGK	28	Sequence 21 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14631	TKKIELKRFVDAFVKKSYENYILERELKKLIKAINEELPTK	41	Sequence 22 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14632	KFSDQIDKGQDALKDKLGDL	20	Sequence 23 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14633	LSEMERRRLRKRA	13	Sequence 24 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14634	RRGCTERLRRMARRNAWDLYAEHFY	25	Sequence 25 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14635	SKFKVLRKIIIKEYKGELMLSIQKQR	26	Sequence 26 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14636	FELVDWLETNLGKILKSKSA	20	Sequence 27 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14637	LVLRICTDLFTFIKWTIKQRKS	22	Sequence 28 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14638	VYSFLYVLVIVRKLLSMKKRIERL	24	Sequence 29 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14639	GIVLIGLKLIPLLANVLR	18	Sequence 30 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14640	VMQSLYVKPPLILVTKLAQQN	21	Sequence 31 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14641	SFMPEIQKNTIPTQMK	16	Sequence 32 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14642	LGLTAGVAYAAQPTNQPTNQPTNQPTNQPTNQPTNQPRW	39	Sequence 33 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14643	CGKLLEQKNFFLKTR	15	Sequence 34 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14644	ASKQASKQASKQASKQASKQASRSLKNHLL	30	Sequence 35 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14645	PDAPRTCYHKPILAALSRIVVTDR	24	Sequence 36 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14646	NYAVVSHT	8	Sequence 37 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14647	ILVLLALQVELDSKFQY	17	Sequence 38 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14648	YVNYNQSFNSGW	12	Sequence 39 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14649	FQKPFTGEEVEDFQDDDEIPTII	23	Sequence 40 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14650	GGGG	4	Sequence 41 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14651	GGGGG	5	Sequence 42 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14652	GGSGGS	6	Sequence 43 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14653	PSPSP	5	Sequence 44 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14654	ASASA	5	Sequence 45 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14655	KKKK	4	Sequence 47 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14656	RRRR	4	Sequence 48 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14657	GGGGS	5	Sequence 49 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14658	GGGGSGGGGS	10	Sequence 50 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14659	GGGGSGGGGSGGGGS	15	Sequence 51 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14660	GGGGSGGGGSGGGGSGGGGS	20	Sequence 52 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14661	GGGGSGGGGSGGGGSGGGGSGGGGS	25	Sequence 53 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14662	GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS	30	Sequence 54 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14663	TFFRLFNRSFTQALGK	16	Sequence 55 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14664	TFFRLFNR	8	Sequence 56 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14665	NIFEYFLE	8	Sequence 57 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14666	KFINGVLSQFVLERK	15	Sequence 58 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14667	YSKTLHFAD	9	Sequence 59 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14668	GKAKPYQVRQVLRAVDKLETRRKKGGR	27	Sequence 60 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14669	SKRGRKRKDRRKKKANHGKRPNS	23	Sequence 61 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14670	HSSHL	5	Sequence 62 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14671	DLRKAK	6	Sequence 63 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14672	LVRLA	5	Sequence 64 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14673	EVYSSPTNNVAITVQNN	17	Sequence 65 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14674	SKFELVNYASGCSCGADCKCASETECKCASKK	32	Sequence 66 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14675	GVGIGFIMMGVVGYAVKLVHIPIRYLIV	28	Sequence 67 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14676	HARAAVGVAELPRGAAVEVELIAAVRP	27	Sequence 68 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14677	VVRRFQGM	8	Sequence 69 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14678	NILFGIIGFVVAMTAAVIVTAISIAK	26	Sequence 70 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14679	MPKARPVNHNKKKSKITIKSNFTLFYMFNP	30	Sequence 71 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14680	MIHLTKQNTMEALHFIKQFYDMFFILNFNV	30	Sequence 72 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14681	RFFNFEIKKSTKVDYVFAHVDLSDV	25	Sequence 73 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14682	EILNNNQVIKELTMKYKTQFESNLGGWTARARR	33	Sequence 74 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14683	VYRHLRFIDGKLVEIRLERK	20	Sequence 76 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14684	KLRSASKKSLQEKSCGIMPEKPAG	24	Sequence 77 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14685	FRSPCINNNSLQPPGVYPAR	20	Sequence 78 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14686	YVEEAVRAALKKEARISTEDTPVNLPSFDC	30	Sequence 79 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14687	MTCHQAPTTTHQSNMA	16	Sequence 80 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14688	MVILVFSLIFIFTDNYLVYQSKSIKEDVMI	30	Sequence 81 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14689	KKIIPLITLFVVTLVG	16	Sequence 82 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14690	DKSTQDKDIKQAKLLAQELGL	21	Sequence 83 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14691	ISLIIFIMLFVVALFKCITNYKHQS	25	Sequence 84 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14692	GMPQIPRLRI	10	Sequence 85 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14693	IDMR	4	Sequence 86 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14694	DSFDSLSPFRERGGEREDGCDAMPLP	26	Sequence 87 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14695	NDDAQ	5	Sequence 88 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14696	ALALLKQDLLNFEGRGRIITSTYLQFNEGCVP	32	Sequence 89 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14697	FSLNFSKQKYVTVN	14	Sequence 90 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14698	ALAGLAGLISGK	12	Sequence 91 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14699	DVILRVEAQ	9	Sequence 92 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14700	GLAAIATVFALY	12	Sequence 93 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14701	PMNAAEPE	8	Sequence 94 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14702	PPSSFLV	7	Sequence 95 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14703	LIIYFSKTGNTARATRQI	18	Sequence 96 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14704	SKKYNHILNQENR	13	Sequence 97 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14705	NNAIVYIS	8	Sequence 98 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14706	PALVDLSNKEAVWAVLDDHS	20	Sequence 99 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14707	GGTKEIVYQRG	11	Sequence 100 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14708	NRQAQGERAHGEQQG	15	Sequence 101 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14709	AIEGVIKKGACFKLLRHEMF	20	Sequence 102 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14710	RLARGRPTNLCGRRG	15	Sequence 104 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14711	RLTSNQFLTRITPFVFAQH	19	Sequence 105 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14712	KVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	38	Sequence 1 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14713	MKLTGLFLMIMAVIALFIDVGQADPKVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	63	Sequence 2 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14714	MKLTGLFLMIMAVVALFISVGQADPKVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	63	Sequence 4 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14715	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRQ	38	Sequence 5 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14716	MKLTGLFLMIMAVLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRQ	63	Sequence 6 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14717	KGIGSALKKGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	38	Sequence 7 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14718	MKFFNLVLMVFAVVALMLNGTNAEPKGIGSALKKGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	63	Sequence 8 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14719	KGIGSALKRGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	38	Sequence 9 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14720	MKFFNLVLMVFAVLALMLNGTNAEPKGIGSALKRGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	63	Sequence 10 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14721	KGIGSALKKGGKIIKGGLGALGAIGTGQQVYE	32	Sequence 24 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14722	AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLEPKKRKH	42	Sequence 32 from Patent US 20100204098	Antheraea pernyi	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14723	MKVFSFFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTAIGVGAAGHEVYQDSKNSG	65	Sequence 44 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14724	MKVFSLFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTAIGVGAAGHEVYQDSKNSG	65	Sequence 45 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14725	MKVFSIFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTVIGVGAAGHEVYQESKNSG	65	Sequence 46 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14726	MKVFSIFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTVIGVGAAGHDAYQQSQNSG	65	Sequence 47 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14727	MKVFSLFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKIIKHGLTVIGVGAAGHDAYQQSQNSG	65	Sequence 48 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14728	MKLFNFFIVFFALMALMLGGTNAAPKGAGKAIRKGGKIIKHGLTAIGIIGTGHEVYREAKNQG	63	Sequence 49 from Patent US 20100204098	Lonomia obliqua	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14729	MYFLKYFIVVLVALSLMICSGQADPKIPVKSLKKGGKIIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 51 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14730	MDFLKYFIVVLVALSLMVCSGQADPKIPVKSLKKGGKIIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 52 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14731	KWKLFKKIPKFLHLAKKF	18	Sequence 3 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14732	RWKLFKKIPKFLHLAKKF	18	Sequence 4 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14733	FKKLFKKIPKFLHAAKKF	18	Sequence 5 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14734	KWKLLKKIPKFKKLALKF	18	Sequence 6 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14735	KWKLFKKIPKFLHAAKKF	18	Sequence 7 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14736	KWKKFLKIPKFLHAAKKF	18	Sequence 8 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14737	KWKKLLKIPKFLHAAKKF	18	Sequence 9 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14738	KWKKLPKKLLKLL	13	Sequence 10 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14739	FKKALHLFKPIKKFLKWK	18	Sequence 11 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14740	KFLHLAKKFPKWKLFKKI	18	Sequence 12 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14741	LKYTGTCTRANNQCKYKGQNDRDTFVKCPTFANKKCTRDGAPCSFDSYSRAVTCD	55	Sequence 2 from Patent US 20120102595	Penicillium simplicissimu	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14742	LKYTGTCTRKNNQCKYRGQNNRDTFVKCPTFANKRCTRDGAPCSFDSYSRAVTCD	55	Sequence 4 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14743	LKYTGTCRRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGAKCSFDSYSRAVTCD	55	Sequence 6 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14744	LKYTGTCRRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGEKCSFDSYSRAVTCD	55	Sequence 8 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14745	LSKFGGECSLKHNTCTYLKGGKNHVVNCGSAANKKCKSDRHHCEYDEHHKRVDCQTPV	58	Sequence 10 from Patent US 20120102595	Monascus ruber	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14746	LSKYGGECSLKHNTCTYRKGGKNQVVNCGTAANKKCKTDRHHCEYDEYHKRVDCQTPV	58	Sequence 12 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14747	LSKYGGECSRKHNTCTYKKGGKNQIVNCPTAANKRCKTDRHHCEYDEYHRRVDCQTPV	58	Sequence 14 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14748	LSKYGGECSRAHNTCTYRKGGKNQVVNCPSAANKKCKSDRHHCEYDEYHKRVDCQTPV	58	Sequence 16 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14749	LSKYGGECSREHNTCTYKKGGKNQVVACGKAANKKCKTDRHHCEYDSYHKKVDCQTPV	58	Sequence 18 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14750	LSKYGGECSREHNTCTYLKGGKNQVVACGSAANKKCKRDRHHCEYDDYHKTVDCQTPV	58	Sequence 20 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14751	LSKYGGECSRAHNTCTYRKGGKNQVVKCGTAANKKCKSDRHHCEYDDYHKRVDCQTPV	58	Sequence 22 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14752	LSKYGGECSKEHNTCKYLKGGKNQVVACPKAANKKCKTDRHHCEYDEYHKTVDCQTPV	58	Sequence 24 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14753	LKYTGTCTRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGAPCSFDSYSRAVTCD	55	Sequence 25 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14754	LSKYGGECSRXHNTCTYRKGGKNQVVNCGSAANKKCKSDRHHCEYDEYHKRVDCQTPV	58	Sequence 26 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14755	MANKHLSLSLFLVLLGLSASLASG	24	Sequence 28 from Patent US 20120102595	Hordeum vulgare	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14756	KDEL	4	Sequence 29 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14757	SEKDEL	6	Sequence 30 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14758	HDEL	4	Sequence 31 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14759	HDEF	4	Sequence 32 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14760	KAHWLRLKALAKRK	14	Sequence 1 from Patent US 5464944	Synthetic construct	Antimicrobial, Antifungal	US 5464944 A	Granted Patent	1995##11##7	CA2165986A1, EP0705343A1, WO1995000653A1	Synthetic antifungal peptides.	Two synthetic polypeptides provide cell-expressible antifungal activity.
DRAMP14761	KHRKKRKAWLLALA	14	Sequence 2 from Patent US 5464944	Synthetic construct	Antimicrobial, Antifungal	US 5464944 A	Granted Patent	1995##11##7	CA2165986A1, EP0705343A1, WO1995000653A1	Synthetic antifungal peptides.	Two synthetic polypeptides provide cell-expressible antifungal activity.
DRAMP14762	AVFTVVNQCPFTVWAASVPVGGGRQLNRGE	30	Sequence 1 from Patent US 5521153	Synthetic construct	Antimicrobial, Antifungal	US 5521153 A	Granted Patent	1996##5##28	EP0738324A1, US5559034, US5703044, US5981844, WO1995018859A1	Synergistic antifungal protein and compositions containing same.	Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.
DRAMP14763	AVFTVVNRCPYTVWAASVPVGG	22	Sequence 2 from Patent US 5521153	Synthetic construct	Antimicrobial, Antifungal	US 5521153 A	Granted Patent	1996##5##28	EP0738324A1, US5559034, US5703044, US5981844, WO1995018859A1	Synergistic antifungal protein and compositions containing same.	Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.
DRAMP14764	WTAFXGPVGPXGRDS	15	Sequence 1 from Patent US 5994625	Synthetic construct	Antimicrobial, Antifungal	US 5994625 A	Granted Patent	1999##11##30	CA2145984A1, WO1994008009A1	Antifungal chitin binding proteins and DNA coding therefor.	Chimeric genes encoding antifungal chitin binding proteins (antifungal CBPs) with very low chitinase activity (10% or less than that of the class-I chitinases from tobacco). Also substantially pure DNA sequences encoding antifungal CBP are provided for the obtention of transgenic plants producing antifungal CBP. Plants expressing an antifungal CBP gene, optionally in combination with a plant expressible glucanase gene, show reduced susceptibility to fungi.
DRAMP14765	EYXSPSQGXQSQXSGGGGXGGGGGGGGAQN	30	Sequence 2 from Patent US 5994625	Synthetic construct	Antimicrobial, Antifungal	US 5994625 A	Granted Patent	1999##11##30	CA2145984A1, WO1994008009A1	Antifungal chitin binding proteins and DNA coding therefor.	Chimeric genes encoding antifungal chitin binding proteins (antifungal CBPs) with very low chitinase activity (10% or less than that of the class-I chitinases from tobacco). Also substantially pure DNA sequences encoding antifungal CBP are provided for the obtention of transgenic plants producing antifungal CBP. Plants expressing an antifungal CBP gene, optionally in combination with a plant expressible glucanase gene, show reduced susceptibility to fungi.
DRAMP14766	RSVCRQIKICRRRGGCYYLCTNRPY	25	Sequence 1 from Patent US 6127336	Synthetic construct	Antimicrobial, Antifungal	US 6127336 A	Granted Patent	2000##10##3	CA2245518A1, CN1216047A, EP0882063A2, US6331522, WO1997030082A2, WO1997030082A3	Antibacterial and antifungal peptide.	The present invention provides a peptide with antibacterial and antifungal properties, and compositions containing the peptide. Methods of making and using the antibacterial and antifungal peptide are also provided.
DRAMP14767	RSVXRQIKIXRRRGGXYYKXTNRPT	25	Sequence 2 from Patent US 6127336	Synthetic construct	Antimicrobial, Antifungal	US 6127336 A	Granted Patent	2000##10##3	CA2245518A1, CN1216047A, EP0882063A2, US6331522, WO1997030082A2, WO1997030082A3	Antibacterial and antifungal peptide.	The present invention provides a peptide with antibacterial and antifungal properties, and compositions containing the peptide. Methods of making and using the antibacterial and antifungal peptide are also provided.
DRAMP14768	EDPYRFFERNVTYGTIYPLGVPQQXILINGQF	32	Sequence 1 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14769	EKGVYGTTXPXPPGKRFTYILQMKDQIXSXXY	32	Sequence 2 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14770	TXLSASGPRPNXQGXYXYGX	20	Sequence 15 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14771	IPVPFPDPADDYTLLIGDWYK	21	Sequence 16 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14772	EDPYRFFE	8	Sequence 17 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14773	MARSIYFMAFLVLATLFVAYGVQGKEICCKELTKPVKCSSDPLCQKLCMEKEKYEDGHCFTILSKCLCMKRCNAKTLATELLA	83	Sequence 2 from Patent US 6300489	Synthetic construct	Antimicrobial, Antifungal	US 6300489 B1	Granted Patent	2001##10##9	EP1101771A1	Small and cysteine rich antifungal defensin and thionine-like protein genes highly expressed in the incompatible interaction.	The present invention related to two cDNA clones, designated to PepDef (pepper defensin protein gene) and PepThi (pepper thionin-like protein gene) and individual component; thereof including its coding region and its gene product; modification thereto; application of said gene, coding region and modification thereto; DNA construct, vectors and transformed plants each comprising the gene or part thereof.
DRAMP14774	MAGFSKVVATIFLMMKVFATDMMAEAKICEALSGNFKGLCLSSRDCGNVCRREGFTDGSCIGFRLQCFCTKPCA	74	Sequence 4 from Patent US 6300489	Synthetic construct	Antimicrobial, Antifungal	US 6300489 B1	Granted Patent	2001##10##9	EP1101771A1	Small and cysteine rich antifungal defensin and thionine-like protein genes highly expressed in the incompatible interaction.	The present invention related to two cDNA clones, designated to PepDef (pepper defensin protein gene) and PepThi (pepper thionin-like protein gene) and individual component; thereof including its coding region and its gene product; modification thereto; application of said gene, coding region and modification thereto; DNA construct, vectors and transformed plants each comprising the gene or part thereof.
DRAMP14775	DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN	32	Sequence 1 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14776	DSHAKRHHGYKRKFHEKHHSHRG	23	Sequence 2 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14777	AKRHHGYKR	9	Sequence 3 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14778	AKRFHGYKRKFH	12	Sequence 4 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14779	AKRHFGYKRKFH	12	Sequence 5 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14780	AKRHHGYKRKFF	12	Sequence 6 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14781	AKRFFGYKRKFH	12	Sequence 7 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14782	AKRFFGYKRKFF	12	Sequence 8 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14783	AKRHHKYKRKFH	12	Sequence 9 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14784	AKRHHGYHRKFH	12	Sequence 10 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14785	AKRHHKYHRKFH	12	Sequence 11 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14786	AKRHHGYFRKFH	12	Sequence 12 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14787	AKRYYGYKRKFY	12	Sequence 13 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14788	VKVGLATKAERASRQQRKQRKNRQKTLRGTAKVKGAKAKK	40	Sequence 1 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14789	VKVGLATKAERASRQQRKQRKNRQKTLMGTAKVKGAKAKK	40	Sequence 19 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14790	VKVGLATKAERASRQQRKQRKNRQKTRRGTAKVKGAKAKK	40	Sequence 20 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14791	VKVGLATKAERASRQQRKQRKNRQKTLRGTAQVKGAKAKK	40	Sequence 21 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14792	VKVGLATKAERASRQQRKQRKNRQKTLRGTRKVKGAKAKK	40	Sequence 22 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14793	VKVGLATKAERASRQQRKQRKNRQKTLMGTAQVKGAKAKK	40	Sequence 23 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14794	VKVGLATKAERASRQQRKQRKNRQKTRRGTRKVKGAKAKK	40	Sequence 24 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14795	MAVPKKRTSISKKRIRKKIWKRKGYWTSLKAFSLGKSLSTGNSKSFFVQQNK	52	Sequence 31 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14796	MKIRASIRRISGKSRPIRRRKRVMIISSNPRHKQKQG	37	Sequence 32 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14797	MNSHRLPGKGRRMGPIMGHTMHYRRMIITLQSSYSIPPLRKKRT	44	Sequence 33 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14798	MAAQKSFRIKQKMAKAKKQNRPLPQWIRLRTNNTIRYNAKRRNWRRTKMN	50	Sequence 34 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14799	MRAKWRKKRTRRLKRKRRKVRARSK	25	Sequence 35 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14800	MPLTKDLLHPSPEEKRKHKKKRLVQSPNSYFMDVKCPRCYKITTVFSHAQTVVLCVGCSTVLCQPIGGKARLTEGCSFRRKQH	83	Sequence 38 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14801	MGKYKPPAERRFGKGVQLCKRCGSRDSVMQKYGLYLCRQCFREVAYPMGFRKTR	54	Sequence 41 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14802	MPGKYGVRYGASLRRDVRKIEVQQHSRYQCPFCGRLTVKRTAAGIWKCSGKGCSKTLAGGAWTVTTAAATSARSTIRRLREMVEV	85	Sequence 42 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14803	MGKVHGSLARAGKVKSQTPKVEKQEKPKQPKGRAYKRLLYVRRFVNVTNMVGGKRRMNPSS	61	Sequence 44 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14804	MGSYSIYNAHPRNYGNGSRTCRKCGARKGLIRKYGLDLCRRCLREKAVEIGFQKLD	56	Sequence 46 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14805	MAHKKGSGSSKNGRDSNAKYLGIKKFGKQIVTPGQIIVRQRGTKIKPGLNVGLGRDYTIFSMIAGRVNYSTQKNKKIVSVDPSYGKIQAIEIRKASHFAT	100	Sequence 48 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14806	MTRSIWKGPHVDSSLLSKLNKIRKTDSKKKINTWSRRSVILPQFIGLSFNIYNGNKWVSVTVTEDMIGHKLGEFSLTRKAVKHKKK	86	Sequence 58 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14807	MISHFSIKDKKRRFLYLKYEWKRLQLKAIAENMLLPMDIRFKARLEINELPKDSSKVRIRNRCIITGRPRGVHKYWRLSRIKIRELMAQNKIPGLRKSSW	100	Sequence 60 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14808	MATKKSGGSSRNGRDSKGRRLGVKLFGGEYATIGSIIVRQRGTKILPYKNVGLGRDHTIFALKEGIVSYYKDKTKTYVSIV	81	Sequence 65 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14809	MKRTFQPSTLVKKRKHGFLNRNKTKNGKALLKRRFLKGRKVI	42	Sequence 66 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14810	MKKGIHPLKRSLDVIMTNGSFVKTIIVSSYIKKNLKLDIDTNKHPCWNPHKKVFVLDSSNLLQKFKSKYQI	71	Sequence 67 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14811	MGNIRTSFVKRIAKEMIETHPGKFTDDFDTNKKLVEEFSTVSTKHLRNKIAGYITRIISQQK	62	Sequence 78 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14812	MIGVIFYNTKGNFLRVKCLDCGNQQVVFDRAASYVQCIICGKTLVEPTGGKSKIKAQILEVLD	63	Sequence 79 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14813	MKFEVRGAFKTLEGWQKFTKVVEANNERYALEKVYSLIGSNHKVKRNLIKIEEVKQA	57	Sequence 84 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14814	MKKERTKVFGRGANECRRCGRRRGLIRMYGLYLCRQCFREVASELGFKKYW	51	Sequence 87 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14815	MAKGAESIYRYYEIKGEKVVRKKKFCPRCGEGVFLAEHKDRLSCGKCGYTEFKKK	55	Sequence 89 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14816	MGTVKPAYIKVIARELLKKYPEVFTGNFDENKRLVAELTNIQSKTVRNRVAGYITRRVNRGLVNV	65	Sequence 91 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14817	MADEEDIQPAEVVELVGRTGMHGEVTQVKVRVLAGENKGRVITRNVFGPVKVGDIIMIKETAREARKLAVR	71	Sequence 93 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14818	MTKGTQSFGMRHNKSHTICRRCGKRSFHIQKSTCACCGYPAAKTRSYNWGAKAKRRRTTGTGRMSYLKKVHRSFKNGFRAGKPTSAATA	89	Sequence 98 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14819	MFFVRSYCLYGFCVRFCFVFLCIYVSPRLPSSGNRRVYVVCFNLYSFVIYCFLFGCCVICYSQSFYFLCEGGGFVDLPCIKLYVRVPIA	89	Sequence 101 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14820	MASVCEICAKGELSGNNVSHSHLKTRRTWKPNIQRVRAVVEGEVKRVNVCTRCLRSGKVQRAL	63	Sequence 104 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14821	MYKDRDTNQRDSRFENQQDGFKKNSNFRFFKRKSCKFCDSGKHPDYKDFDFLKKFITEQGKILPKRITGTSAKHQRRLALEIKRARYMALLPFVKK	96	Sequence 105 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14822	MPAVKVKENEPFDVALRRFKRSCEKAGVLAEVRSREFYEKPTAERKRKAAAAVKRHAKKVQREQRRAVRLY	71	Sequence 108 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14823	MSRSSKKGAFVEASLYKKVLDMNAQQKKKIIKTWSRRSTIFPDFVGHTFAVHNGKKFINVYVTEDMIGHKLGEFSPTRTFKGHSSNR	87	Sequence 110 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14824	MRNSRKVLMGVVVSDKMQKTATVKVESKNRHPFYHKLVISHKKYHVHNEEGENAAKVGDKVLIMETRPLSATKRWRIAKIIERAK	85	Sequence 111 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14825	MAKTSLKIKQARHAKFKVRAYTRCKRCGRPHAVYRKFGICRLCFRHLAYNGSLPGVKKSSW	61	Sequence 112 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14826	MAKSTKRRPAPEKPAKARKCVFCAKKNQQIDYKDTTLLRTYISERGKIRARRVTGNCVQHQRDIAIAVKNAREVALLPFTSSAR	84	Sequence 113 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14827	MTKGTQAFGKKHVKSHTLCKRCGKSSFHIQKKRCASCGYPDAKKRTYNWGAKSIRRRTTGTGRTRHLRDVNARFRNGFREGTTPKPRAQPTN	92	Sequence 132 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14828	MVLQNDIDLLNPPAELEKRKHKLKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVMCGNCQTLLCTPTGGKAKLTEGCSFRKK	84	Sequence 136 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14829	MAERRRTNHRVSRFNYWLRIHASVQINVGHLDESGVYNGHFSTFALCGFTRAQEMLTVELTACGRKKKLNLSIDDMITSCCVLLTDLCVSSTFP	94	Sequence 141 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14830	MVVRAPKKKVCMYCEQKREPDYKNYEELRNFLTERGRIKDRKQTGLCAKHQRRLAVQIKRARQLGLLPYVVY	72	Sequence 146 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14831	MKVRSSVKKRCAKCKIIRRKGRVMVICEIPSHKQKTGVTEVRNGENSGR	49	Sequence 150 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14832	MADSEICGKRPVVGRRVTLSGERNRRIFKPNVHKMRVMLPDGTVKRMYVCTKCLKAGKVMKAPRIPKEG	69	Sequence 151 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14833	MVTEGLKPHISIKKKKRKSGFLARMRTKSGRKIIARRRRKGRKRLAP	47	Sequence 153 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14834	MVLPKDVKWDLIRQFQRHEQDTGSPEVQIAILTERINRLTEHMKKHKKDIHSRRGLIAMVNKRRKLLEYLRETDYAKYLEVVQKLNLKVK	90	Sequence 154 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14835	MAKVKMKTNRSAAKRFKVTAKGKIKRWKSGGAHYNTKKSSKRKRHLRKHTYVKDNMLKHVKALLKEF	67	Sequence 156 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14836	MVTVIVQEGEPIEKVLKRFKARVEQEQILTELKRREYYEPPSERKKKRERNRRKKILKALKKQQQLI	67	Sequence 157 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14837	MAVPKAKTSKWRRNQRRAQNFFNKFRRSLPSLSVCSNCGERIIPHRVCPYCGHYKGKEVIETE	63	Sequence 159 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14838	MYAVIKTGGKQYKVEKGMKLKVEKLPYEVGQTVEFEALMLRKDDGSIEFNKGKVIAEVKAHGRGKKLIVFKYRPKKNYKRWKGHRQPYTEIEIKDILP	98	Sequence 160 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14839	MPRKAKVAKDLMYYPKWKSRKKNRCPICGRPRAFIRYFNMCRICFREHALRGDLPGVRKASW	62	Sequence 165 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14840	MASKASGGSTRNGRDSISKRLGVKRYDGQFVKAGNIIVRQRGTRIYPGKNVGMGSDYTLFALKDGYVYFETRRKKKFVSVLSPEEWEKVMAQKNGKVH	98	Sequence 168 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14841	MATKPFFRRRKVCPFSGDNAPKIDYKDVRLLQRYISERGKIVPARITAVSAKKQRELAQAIKRARFLALLPYAVK	75	Sequence 176 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14842	MPKMKNNKGAAKRFKKTAGGIKYKHATKRHILTKRTTKNKRQLRPNAILPKCELAAVARMLPYA	64	Sequence 177 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14843	MAEKRKYSRKYCKYTEAKVEFIDYKDTAMLKHALSERFKIMPRRLTGTSKKYQEMVEVAIKRARHVALIPYIVDRKEVINNPFEGL	86	Sequence 179 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14844	MEVKVFRVSGYFEKDGRKFKFTKEYRALKEEHVKELVYSDIGSRHKVKRRKIFIKEIREIKPEEAEDIVVRRLSLEL	77	Sequence 185 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14845	MVQKPHSFRRKTRKKLRKHPRRRGLPPLTRFLQEFEVGQKVHIVIEPSYHKGMPDPRFHGRTGTVVGKRGDAYIVEVPDGNKVKTLFIHPVHLRPQK	97	Sequence 186 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14846	MARFPEAEARIFKKYICLRCGATNPWGAEKCRKCGYKRLRPKAREPRGGGR	51	Sequence 187 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14847	MAEDEGYPAEVIEIIGRTGTTGDVTQVKVRILEGRDKGRVIRRNVRGPVRVGDILILRETEREAREIKSRR	71	Sequence 188 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14848	MAKADYNKRKPRKFGKGARRCIRCGQYGPIIRIHGLMLCRHCFREVAPKLGFRKYE	56	Sequence 190 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14849	MSIEEIDAKIRELRLQLAKERGMLTMGTSLENPMVIRNLRRDIARLLTIKKEKLREMGKK	60	Sequence 191 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14850	MDPYKVIIRPVVTEKAISLIEKENKLTFIVDRRATKTDIKKAIEEIFNVKVEKVNTLITPKGEKKAYVKLKPEYSASEIAARLGLF	86	Sequence 192 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14851	MAPKKKWSKGKVKDKAQHATVFDKSIIDRINKEVPAFKFISVSVLVDRMKINGSLARIAIRDLAERGVIQKVDQHSKQAIYTRAAASA	88	Sequence 193 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14852	MAKKNKARLLVKLLSTAGTGFFYVRSRPKAAPKLAFIKYDPKIHKRVLFEESKMK	55	Sequence 194 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14853	MTKGTQSFGMRHNKSHTICRRCGKRSFHIQKSTCACCGYPAAKTRSYNWGAKAKRRRTTGTGRMSYLKKVHRSFKNGFRSGKPAAAVAASA	91	Sequence 195 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14854	MFLSAVFFAKSKSKNILVRMVSEAGTGFCFNTKRNRLREKLTLLHYDPVVKQRVLFVEKKKIRSL	65	Sequence 198 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14855	MLKKKIIKYNIFGNVLSDGSFHFCLLTNSYLKESLNYKSVDILNHPVWTGKRQKEQTEISLFIGRLTSK	69	Sequence 207 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14856	MIVINLAGKVHGSLARAGKVRGQTPKVAKQDKKKKPRGRAHKRLQHNRRFVTAVVGFGKKRGPNSSEK	68	Sequence 214 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14857	MKDPRDIIKRPIITENTMNLIGQKKYTFEVDVKANKTEVKDAVEKIFGVKVAKVNIMNYKGKFKRVGRYSGYTNRRRKAIVTLTPDSKEIELFEV	95	Sequence 218 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14858	MQHMHRIIGQMIRTRGLKNVRCMAVEGKHNGRKNGARA	38	Sequence 219 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14859	MSKKCALTGRKPRRGYSYAIRGISKKKKGIGLKVTGRTKRRFFPNMMTKRLWSTEENRFLKLKISAAALRLVDKLGLDQVVARAKSKGF	89	Sequence 223 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14860	MASKNREIIKLKSTESSEMYWTVKNKRKTSGRLELKKYDRKLRKHVIFKEAK	52	Sequence 226 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14861	MPSVKVRVGEPIDRALRILKKKIDKEGILKTSKSHRFYDKPSVKKRAKSKAAAKYRGR	58	Sequence 228 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14862	MAHKKGQGASRNGRDSESKRLGLKVGAGQRVSTGSILVRQRGTKWHPAVNVGRGKDDTLFALVDGIVVMKKTDRTYVSVIPQA	83	Sequence 229 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14863	MGAKKNLLAELREKSSEELDEFIRDNKKALFALRAEAALQNKVVKTHQFSLYKKSIARALTIKQEKKDRVHG	72	Sequence 242 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14864	MSRSLRKGPFVDHHLLKKVRDMNALEKKTPIKTWSRRSMITPEMIGHTFEVHNGRKFLTVFVSETMVGHKLGEFSPTRMFKSHPVKKG	88	Sequence 245 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14865	MAPRKPSKKVGPQKRPSAEKRVITSKKKQLRNQSFKSKVRTILKKFELAVQSGDVESISAGLRSVYSIADKAVKRGIFKKGKADRVKSRTSERACPAA	98	Sequence 247 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14866	MKRTYQPSKRKRRNSVGFRARMATKSGRNLLNRRRRHGRHSLIDL	45	Sequence 248 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14867	MRVSSSIKADPSKGDKLVRRKGRLYVINKKDPNRKQRQAGPARKK	45	Sequence 249 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14868	MNRPVHNEHRRKRFAKKCPFVSAGWKTIDYKDVTTLKRFITERGKILPRRITGVSSRFQALLAQAVKRARHVGLLPFVGED	81	Sequence 252 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14869	MAVPRNRHSNARKNIRRSHHAKKACSAAVCSNCKQAFIPHTVCASCGFYKGKAVITVEK	59	Sequence 253 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14870	MPKMKSNKSVAARFKLTGSGQLKRTRPGKRHKLSKRSSQQKRNLSKQPLVDQGQVGMYKRMMLV	64	Sequence 254 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14871	MTKRTLRGSVRKKKRTSGFRARMETPTGRRVIKARRSRGRVRLTTV	46	Sequence 258 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14872	MSLDAAVKKQIITEFGTKEGDTGSPEVQVALLSRRISDLTEHLKTHKHDHHSRRGLLILVGQRRRLLQYLAKKDIQRFRALVERLGIRRGAAGAR	95	Sequence 259 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14873	MKVKPSVKKICDKCRVIRRHGRVMVICDNPRHKQRQG	37	Sequence 260 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14874	MALSVEEKAQIVAEYQQTAGDTGSPEVQVALLTANINKLQGHLKPTTKTTTPVRGLIRMVNHRRKLLDYLKGKDTTRYSALIGRLGLRR	89	Sequence 266 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14875	MPKNKSHSGASKRFKITGSGKVLRERAGKRHLLEHKSSRVTRRLTGNAEMAPGDAAKIKKLLGK	64	Sequence 268 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14876	MFFPLSTMGFQNLWFSHPRKFGPGSRSCRVCAGHHGLIRKYGLDLCRRCFREQARDIGFKKQPASTSATASSNLVIVNFMSSINKLLA	88	Sequence 270 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14877	MPRRSIWKGSFVDAFLFRIKKNRESLMSRKIWSRRSSISPEFVDCSVLIYNGKTPVRCKITEGKVGHKFGEFAFTRRRRPYQTNRGKGRKGKK	93	Sequence 271 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14878	MQNEEGKTVDLYVPRKCSATNRIITAKDHASVQINIGHLDANGLYDGHFTTFALSGFVRAQGDADSSLDRLRQKKKADIKQ	81	Sequence 273 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14879	MPKQIHEIKGLPPDGEEEGREVGADQEDQGRRQVQGALLQVPLHPLRLRRRQGQQAQAVAPPRFDCPGGLSIKARPCCL	79	Sequence 274 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14880	MVRSRWKGIYVAKELQNYNTVTNPTIVTTERSSVIVPYYLTKTIYVYNGRKYVGVKITEKSLGRKLGEYVLTKKVEKYKASGKSKKK	87	Sequence 286 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14881	MKKRSSIKKICNKCKLIKRFKKLHIICINKKHKQTQ	36	Sequence 287 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14882	MYIIFFIRGFYLYGLCLRLFIFLCVYYISPRLPSSGNRRLCCSIFWLSNIIFYVSVFFCCIYFVVFSQQLFIVEGGGFIDLPGIKYYSRFFY	92	Sequence 288 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14883	MPAGSSERARTRDLFARPFRKKGYIPLSTYLRTFKVGRLRRCQGNGAIHKGSLISSTMVVLVASGISLTCVV	72	Sequence 294 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14884	MYNYYNPASLITHGFGVHRFIFRRISNKAIEFIQV	35	Sequence 296 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14885	MGMRGGLTRLIEELSCPSQHARYAEGRCALRPPDRYWNRNGKFISARATGSISSTSKTCRCSRA	64	Sequence 297 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14886	MVQNNDVDGAFGLLNRLMDSEGMLKIIRRTQFYQKPYMQRKTLSMEASTAIFNEDMNRKMKFLVRKNRPDKHPGQVTS	78	Sequence 303 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14887	MPAIEVGRVCIKTAGREAGKVCVIVDILDKNFVIVDGLVKRRRCNIKHLEPTEKKVDIPKGASTEEVKLALDAAGLLKEE	80	Sequence 312 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14888	MMGRIRQTLIKRTAMELIKKYRDLFTTDFETNKRVLEEVAQISTKRLRNRIAGYITHKMRQLQ	63	Sequence 320 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14889	MPEWRTCSFCGYEIEPGKGKMVVEKDGTVLYFCSSKCEKSYRMGRNPRKLKWTKVYQDMKAELKKAQESQ	70	Sequence 332 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14890	MVLVQDLLHPTAASEARKHKLKTLVQGPRSYFLDVKCPGCLNITTVFSHAQTAVTCESCSTILCTPTGGKAKLSEGTSFRRK	82	Sequence 335 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14891	MVLVQDLLHPTAASEARKHKLKTLVQGPRSYFLDVKCPGCLNITTVFSHAQTAVTCESCSTVLCTPTGGKAKLSEGTSFRRK	82	Sequence 336 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14892	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKIDGSGKVQRLRKECPNATCGAGTFMASHFDRHYCGKCGLTYVYQKEGVEA	81	Sequence 337 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14893	AKKRKKKTYTKPKKIKHKKKKVKLAVLQFYKVDDTGKVIRLRKECPNAECGAGTFMANHKDRHYCGKCGLTYVYQKGE	78	Sequence 338 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14894	AKKRKKKVYTTPKKNKRKPKKVKLAVLKYYKVDENGKITRLRKECQQPSCGGGVFMAQHANRHYCGRCHDTLVVDTATAAATSGEKGGKKGKK	93	Sequence 339 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14895	AKKRKKKVYTTPKKNKRKPKKVKLAVLKYYKIDENGKITRLRKECQQPSCGGGVFMAQHANRHYCGRCHDTLVVDTATAAATSGEKGGKKGKK	93	Sequence 340 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14896	GGKKKKKKTYATPKVLKRKLRKVKLAVLKYYKFDENGKIKRVLRECPAETCGAGVFMAQHANRQYCGKCHSTLVKKSK	78	Sequence 341 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14897	AKKRKKKNYSTPKKIKHKRKKVKLAVLKYYKVDENGKIHRLRRECPGENCGAGVFMAAHEDRHYCGKCNLTFVFSKPEEK	80	Sequence 342 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14898	AKKRKKKTYTKPKKQKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNADCGAGTFMANHFDRHYCGKCGLTYVYNQKA	79	Sequence 343 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14899	AKKRKKKSYTTPKKNKHKRKKVKLAVLKYYKVDENGKISRLRRECPSDECGAGVFMASHFDRHYCGKCCLTYCFNKPEDK	80	Sequence 344 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14900	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDSGKVQRLRKECPNTECGAGTFMANHFDRHYCGKCGKTYVYQKADA	79	Sequence 345 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14901	AKKRKKKTYTKPKKIKHKKKKVKLAVLQFYKVDDTGKVQRLRKECPNAECGAGTFMANHFDRHYCGKCGLTYVYNKAGGD	80	Sequence 346 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14902	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNTECGAGVFMANHFDRHYCGKCGLTYVYNQKA	79	Sequence 347 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14903	AKKRKKKNYSTPKKIKHKKKKVKLAVLRFYKVDENGKIHRLRRECTGEQCGAGVFMAVMEDRHYCGKCHSTMVFKDDDK	79	Sequence 348 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14904	MTKGKKTAKYKYYKIEGDKVIRLKKTCPRCGPGVFMAEHLNRYACGKCGYMEWKQPQKKE	60	Sequence 349 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14905	MKKFELYEVKDGKLVRKNPFCVRCSNGVFMADHGDRYACGKCGYTEWKNRE	51	Sequence 350 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14906	GKKRKKKVYTTPKKIKHKRKKTKLAVLKYYKVDSDGKIDRLRRECPNETCGAGVFMAAMQDRQYCGRCHLTYVFEKSS	78	Sequence 351 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14907	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNHDCGAGTFMANHFDRHYCRKCRLTYVYNQKA	79	Sequence 352 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14908	AKKRKKKSYTTPKKNKHKRKKVKLAVLKYYKVDENGKISRLRRECPSDECGAGVFMGSHFDRHYCGKCCLTYCFNKPEDK	80	Sequence 353 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14909	AHENVWFSHPRRYGKGSRQCRVCSSHTGLIRKYGLNICRQCFREKANDIGFNKFR	55	Sequence 355 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14910	AHENVWFSHPRRFGKGSRQCRVCSSHTGLVRKYDLNICRQCFREKANDIGFHKYR	55	Sequence 356 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14911	MSIKGVVLSYRRSKENQHNNVMIIKPLDVNSREEASKLIGRLVLWKSPSGKILKGKIVRVHGTKGAVRARFEKGLPGQALGDYVEIV	87	Sequence 359 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14912	AKRTKKVGIVGKYGTRYGASIRKQIKKMEVSQHSKYFCEFCGKYGVKRKAVGIWGCKDCGKVKAGGAYTMNTASAVTVRSHTIRRLREQIEG	92	Sequence 364 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14913	AKRTKKVGIVGKYGTRYGASLRKMVKKIEISQHAKYTCSFCGKTKMKRKAVGIWHCGSCMKTVAGGAWTYNTTSAVTVKSAIRRLKELKDQ	91	Sequence 365 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14914	AKRTKKVGIVGKYGTRYGASLRKMVKKIEISQHAKYTCSFCGKTKMKRRAVGIWHCGSCMKTVAGGAWTYNTTSAVTVKSAIRRLKELKDQ	91	Sequence 366 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14915	MFSHTKKVGPTGRFGPRYGLKIRVRVRDVEIKAKKKYKCPVCGFPKLKRASTSIWVCGKCGAKIAGGAYTPETGAGKAVMKAIRRIVERKEE	92	Sequence 367 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14916	MARTKKVGITGRFGPRYGRKAKRAVKKIEEEMKRKHVCPSCDRPGVKRESRGIWKCRKCGAVFTGGAYLPVTPMGKTAARNIKRIVGGK	89	Sequence 368 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14917	AKRTKKVGITGKYGVRYGSSLRRQVKKLEIQQHARYDCSFCGKKTVKRGAAGIWTCSCCKKTVAGGAYTVSTAAAATVRSTIRRLREMVEA	91	Sequence 369 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14918	GKGTPSFGKRHNKSHTLCNRCGRRSFHVQKKTCSSCGYPAAKTRSYNWGAKAKRRHTTGTGRMRYLKHVSRRFKNGFQTGSASKASA	87	Sequence 373 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14919	GKGTPSFGKRHNKSHTLCNRCGRRSFHVQKKTCSSCGYPSAKTRSHNWAAKAKRRHTTGTGRMRYLKHVSRRFKNGFQTGSAKATSA	87	Sequence 374 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14920	MIQPQTRLNVADNSGARELMCIRIIGASNRRYAHIGDIIVARRNPKGTRVFGAIAHELRELSFTKIVSLAPEVL	74	Sequence 387 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14921	MDGIKYAVFTDKSIRLLGKNQYTFNVESGSTRTEIKHWVELFFGVMVIAMNSHRLPGKVKRMGPILGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 448 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14922	MLNFVRIFLPFLKYQVFTDKTNDLLKYNIYVFDVDKKLNKLQIKNIIEYIFNIKIYSINTYIKNNKYCCFNKIKGLKTNYKRAFIRLKSVNIIPYFSC	98	Sequence 449 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14923	MMLDLVKYPVIRTEKTTRLVENNQLSFDVDVRITKPQIRKIIEEFFNVKVLAVNTHRPPRKTNRLGSKPSYKRVIVTVDSDVTLLK	86	Sequence 450 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14924	MFYFISRKFYDQFKYGILTDKTNKLLKNNVYTFDVDIQMSKRQFKDLIETAFSVKITSVNSYVKSSKYYRSNNFEGMKKYYKRMFIKLNDLETIPFFSCL	100	Sequence 451 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14925	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRMGPILGHTMHYRRMIITLQPGYSIPLLDRETN	93	Sequence 452 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14926	MNQVKYPVLTEKTIRLLEKNQYSFDVNIDSNKTQIKKWIELFFNVKVISVNSHRLPKKKKKIGTTTGYTVRYKRMIIKLQSGYSIPLFSNK	91	Sequence 453 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14927	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRMGPILGHTMHYRRMIITLQPGYSIPLLDREKN	93	Sequence 455 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14928	MDEVKYPVLTEKSIRLLERNQYTFNVDSQSNKTKIKNWIENFFDVKVIAMNSYRLPEKGGKRVSMIGHPIRCKRVIITLRTGDSIPLFSEQ	91	Sequence 456 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14929	MDGIKYAVFTDKSIRLLGKNQYTFNVESGSTRTEIKHWVELFFGVKVIAMNSHRLPGKVKRMGPILGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 458 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14930	MDGIKYAVFTDKSIQLLGKKQYTSNVESRSTRTEIKHWVELWNSYEMNSHRLPGKGRRMGPIMGHTMHYRRMIITLQSSYSIPPLRKKRT	90	Sequence 459 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14931	MDGIKYAVFTDKSIRLLGKNQYTSNVESGSTRTEIKHWVELFFGVKVIAMNSHRLPGKSRRMGPIMGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 460 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14932	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRIGPILGHTMHYRRMIITLQPGYSIPLLDREKN	93	Sequence 461 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14933	MRKQQKIHVKIGDNVKIITGFDKNKIGKVSKIDRNTGKIIVKGINFKFKHIKPNAENEVGEIKQFEAPIHHSNVKLN	77	Sequence 462 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14934	MKSSLIKNTVNKKVKFKKGDLVQILSGSDKKKTGEIIAIIHKTSKVIVKGINLKVEASKDLSKKVETGEITKFEAPIHSSNVMLFSQKNNISSRF	95	Sequence 463 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14935	MAHKKGAGSTKNGRDSNAKRLGVKRFGGQRVKAGNILVRQRGMKFTPGLNVGCGKDFTLYALTDGIVNFDYKNAQQKRINIIG	83	Sequence 465 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14936	MAHKKGAGSTKNGRDSNSKRLGVKVYGDQPVKKGGIIIRQRGLTFKPGINVAVGRDYTLFALQEGDVKFETIADRKFVSVIK	82	Sequence 466 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14937	MAHKKGSGSTRNGRDSNSKRLGVKKYGGEQVTAGNILIRQRGTKVKPGQNVGKGKDDTLFALIDGFVLFEKSNQKQKTISVYSSKN	86	Sequence 467 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14938	MARQCELTGKKANNGYTVSHSHRRTKCLQKANLQTKRIWSPTLKRWLKLQVSTKVIKDLKRKSIDALLKI	70	Sequence 469 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14939	MSKKCQLTGKVANNGYAVSHSHKRTKKLQNVNLQYKKVWSTEQNKWIKMLISTKAIKTLTKAL	63	Sequence 470 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14940	MSTVQFNEMIALPNSEISQAIIQTEKELFQLQFKKATRQPFKPHEIKKAKRRLAQLKTILTSRLDALEKKRGNTVMKLIKKQNYMTGNF	89	Sequence 472 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14941	MTLPKILDVIQMDDSSLSEEIIAIKRQLFDLRLKRATRQDFKPHLFKHSKHRLAQLLTVEKSRAQSN	67	Sequence 473 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14942	MAKVDIHPIWYPDAKVYCDGQLIMTIGSTKPELHVDIWSGNHPFFTGSQRIIDTEGRVERFMRKYKMEKD	70	Sequence 474 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14943	AVPKKKMSHSKSNSRKSNWKRKVIKKINFAVTLGKSLSFGKLSKFYLDD	49	Sequence 475 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14944	AVPKKRTSISKKRIRKKIWKRKGYWTSLKAFSLGKSLSTGNSKSFFVQQNK	51	Sequence 476 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14945	AVPKKRKSKMKTRLRKAQWKSEASREAAKALSKAKTVIKSLLAANSANLESNSENSN	57	Sequence 477 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14946	AVPKKRTSKSKKKSRRSHWINKAKTRIRNFLNLAKSISNKKATSFAYSTIKN	52	Sequence 478 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14947	AVPKKKMSKSRRNSRKSNWKKKVLKKVLFALSLGKSFEANTNVNFSFGDKLPQ	53	Sequence 479 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14948	AVPKKRTSMSKKRIRKNLWKKKTYFSIVQSYSLAKSRSFSRGNEHPKPKGFSGQQANK	58	Sequence 480 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14949	AVPKKRTSKSKTRIRKAIWKNKANKSALRAFSLAKSILTNRSKSFYYTINDKLLNSSKSISTSKLDES	68	Sequence 481 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14950	AVPKKRTSKAKKNARKSVWKKKADKAAKKSLSLAKSVLQGKTTSFVYSLYIDELFSI	57	Sequence 482 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14951	AVPKKRTSMSKKRIRKNLWKKKTYFSIVQSYSLAKSRSFSGVSEHPKPKGFSRQQTNNRVLG	62	Sequence 483 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14952	AVPKKRTSRSKKKIRKNVRKGKAYRAAIKAFSLAKSISTGHSKSFYCIVNDDSSGSSESKLTAIDLDDP	69	Sequence 484 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14953	MAVPKKRTSKAKKNARKANWKNQAKTEAQKALSLAKSVLTGKSNGFVYNTLEVADAIVE	59	Sequence 485 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14954	AVPKKRTSTSKKRIRKNIWKRKGYSIALKAFSLAKSLSTGNSKSFFVRQTKINK	54	Sequence 486 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14955	MPVPKKRTSISKKKIRKNFWKKKGYKAALKAFSLADSILTGTSKVIVL	48	Sequence 487 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14956	MARAKGVRILVTLECTECRSNGERLGGGVSRYATKKNRRNTPNRLELNKFCPYCKKHVLHREIK	64	Sequence 488 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14957	MAKSKDARVAVILECTSCIRNSVNKVLTGISRYITQKNRRNTPNRLELRKFCPYCYKHMIHGEIKK	66	Sequence 489 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14958	AKGKDVRIRVILECISCVRKGTNKESTGISRYSTQKNRHNTPGQLELRKFCRYCRKHTTHNEIKK	65	Sequence 490 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14959	AKSKDIRVTINLECINCAQNDEKRKKGISRYTTQKNRRNTPIRLELKKFCCYCNKHTIHKEIKK	64	Sequence 491 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14960	MGKAKGIRILITLECTECRSNTNKRSNGVSRYTTQKNRRNNPERIELKKYCPHCNKSTIHKEIK	64	Sequence 492 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14961	AKGKDVRIRVILQCVSCVRKGANEESAGISRYSTQKNRHNTPGQLELRKFCRYCRKHTIHAEIKK	65	Sequence 493 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14962	AKSGDIRVTITLECTSCTQDSVYKRFPGISRYTTRKNRRNTPIRLESNKFCPYCYKHTIHGEIKKRD	67	Sequence 494 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14963	MAKSKGARIVITLECSNKSVDISQKRKAGVFRYTTTKNRRNTPGRIELKKFCPNCNSHCVFKEIK	65	Sequence 495 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14964	AKGKDVRVTVILECTSCVRNSVDKVSRGISRYITQKNRHNTPNRLELKKFCPYCYKHTIHGEIKK	65	Sequence 496 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14965	MIQRTLTGTNRKKTKRSGFRSRMLQTEEEKLLILDVMKKRYYLVK	45	Sequence 497 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14966	MSKRTLEGSHRKKVRKSGFLSRSQSPTGRRILKARRKKGRKMLVKY	46	Sequence 498 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14967	MTKRTLSNKTRYSILKLSGFRARMSTAQGRKTLKARRKKGRKQLAVRR	48	Sequence 499 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14968	MTKRTLEGTKRKSIRKSGFRARMATKLGRKVLNKRRQKGENS	42	Sequence 500 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14969	MTKGTLQGSKRKKIRISGFRARMKTPSGRSILNERRRKGRKKIMAS	46	Sequence 501 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14970	MYKLKTRKAAAKRYKAVGNKKISRRKAFRSHLLQKKSTNRKRQLSQVVIASPGDTKKIYLMLPYL	65	Sequence 502 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14971	MPKLKTRKAALKRYKKTATGKFLRRHAYKGHLLMKKSKTQKRKLSQIICVSNNDSKPIKLMLPY	64	Sequence 503 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14972	MPKLKTSKAIAKRFKVSSSGKILRHKASKSHLLQKKSSKHRRHLSSTCQVDSRDAKNISINLPYL	65	Sequence 504 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14973	MKVYSSVRKICKSCGLIRRHGKLFVRCINSKHNQRQN	37	Sequence 506 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14974	MKVRPSVKKMCDKCRLIKRKGTLRVICQNPKHKQRQG	37	Sequence 507 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14975	MKVRASVRKMCEKCRTIRRKGRVMVICSNSKHKQRQG	37	Sequence 508 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14976	MKIRASIRKICEKCRLICRRRRIIVICSNPRHKQRQG	37	Sequence 509 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14977	MKIRSSVKKICNKCYLIRRKNNLLVVCINNKHKQRQG	37	Sequence 510 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14978	MKIRASVRKICENCRLIRRRRRIMVVCSNPKHKQRQG	37	Sequence 511 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14979	MKVRPSVKKMCDKCRVIKRKGKIMVICPNAKHKQRQG	37	Sequence 512 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14980	MKIRASVRKICTKCRLIRRRGRIRVICSNPKHKQRQG	37	Sequence 513 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14981	MKVAASVRKICEKCRLIRRRGRLLVICSNPKHKQRQG	37	Sequence 514 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14982	MKIRASIRRICGKCRPIRRRKRVMIICSNPRHKQKQG	37	Sequence 515 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14983	MKVRPSVRKMCEKCRIIRRHRKVMVICNNPKHKQRQG	37	Sequence 516 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14984	MKIRASVRPICEKCRLIRRRGRIIVICSNPKHKQRQG	37	Sequence 517 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14985	MKIRASVRKICEKCRLIRRRGRIIVICSNPRHKQRQG	37	Sequence 518 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14986	PSSNGPLEGTRGKLKNKPRDRGTSPPQRAVEEFDDGEKVHLKIDPSVPNGRFHPRFDGQTGTVEGKQGDAYKVDIVDGGKEKTIIVTAAHLRRQE	95	Sequence 703 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14987	MVQMSEGFRRKTRKKLSKHPRERGLYPITRALREFKEGEYVHIVIDPSVHKGMPHPRFHGRTGIVVGKQGRAFIVKVRDGGKYKQIIAYPQHLRPATA	98	Sequence 706 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14988	MRRSRGFRSKTRHKLQKVKRPGRSNPITRKIQSFNEGDLVHIIIDPSIHRGQPHPRFHGKTGRVVGMMGKSYVVALKDGNKDKQLVVRPEHLQMQE	96	Sequence 707 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14989	MHAIVVCGAKQYLVHENESIFVEKLAGKVGQEIQLDKVLMLDEKIGKPYLEKAKVVCVIEKHGLKSKIKLIKHISQKHHLKRYGHRQPYTKLKVVRFIHD	100	Sequence 709 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14990	MHAIVVCGSKQYLVHENDTFFVEKLEAPVGKEIQLDKVLMLDEKIGAPYLEKARVVCVVEKHGLQRKVNVIKHISQKHHLKKYGHRQPYTKLKVVRFVHD	100	Sequence 710 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14991	MSQERLLKVLKAPHISEKATNNAEKSNTIVFKVALDANKVEITNAVEQLFEVKVDSVRTVVVKGKTKRRGAKIGRRSDWKKAYVTLQEGQSLDFVEGAAE	100	Sequence 738 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14992	MKDPRDIIKRPIITENTMNLIGQKKYTFEVDVKANKTEVKDAVEKIFGVKVEKVNIMNYKGKFKRVGRYSGYTNRRKKAIVTLTPDSKEIELFEV	95	Sequence 739 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14993	MKDPRDVLKRPVITERSADLMTEEKYTFEVDVRANKTEAKDAVESIFGVKVDKVNIMNYKGKSKRVGRYTGMTSRRRKAIVKLTADSKEIEIFEA	95	Sequence 740 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14994	MIREERLLKVLRAPHVSEKASTAMEKSNTIVLKVAKDATKAEIKAAVQKLFEVEVEVVNTLVVKGKVKRHGQRIGRRSDWKKAYVTLKEGQNLDFVGGAE	100	Sequence 745 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14995	MSQERLLSVLRAPHISEKATNNAEKSNTVVLKVALDANKAEIAAAVAQLFEVKVDSVRTVVVKGKTKRRGNKMGRRSDWKKAYVTLAEGQNLDFVDSAE	99	Sequence 746 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14996	MADIMDIKSILYTEKSLGLQEKGVLVVQTAQNVTKNQLKEVFKTYFGFEPLKINSLKQEGKVKRFRGKLGQRKSFKKFYVKVPEGASIAALGA	93	Sequence 747 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14997	MDAFDVIKAPVVTEKTVRMIEEENKLVFYVDRRATKQDIKRAMKELFDVEVEKVNTLITPKGEKKAYVKLKEGYDASKIAASLGIY	86	Sequence 749 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14998	MATLADPRDIILAPVISEKSYGLLDDNVYTFLVRPDSNKTQIKIAVEKIFGVKVASVNTANRQGKRKRTRTGYGKRKSTKRAIVTLAPGSRPIDLFGAPA	100	Sequence 750 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14999	MHITEVLKKPVLTEKSFAGHKDNVYTFLVDKKANKVQIKKTFEEIFEVKVESVRTINYDAKEKRLGKYVGKKPSYKKAIITLKEGQKLDVLSDL	94	Sequence 751 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15000	MATIADSRDIILAPVISEKSYGLLDDNVYTFVVHPDSNKTQIKIAIEKIFSVKVASVNTSNRKGKCKRTRTGFGRRKNTKRAIVTLAPGSKSIDLFGTPA	100	Sequence 753 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15001	MAEANIRALADIIRRPIITEKATRLLENNQYTFEVDPRASKPEIKAAIEALFQVKVVGLSTQLPPRKARRVGRFAGHRAQVKRAVARLADGDSITLFPEV	100	Sequence 754 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15002	MKQEKLSLHDVLIRPIITEKALILREQRKYVFEVNPLANKNLVKEAVEKLFNVKVEKVNILNMKPKPKRRGIFEGKTRSWKKAVVTLKEGYTIKELEGEH	100	Sequence 756 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15003	MIREERLLKVLRAPHVSEKASAAMEKNNTIVLKVAKDATKAEIKAAVQKLFEVEVEDVNTLLVKGKSKRHGQRVGRRSDWKKAYVTLKEGQNLDFIGGAE	100	Sequence 759 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15004	MIREERLLKVLRSPHVSEKASAAMEKNNTIVLKVAKDATKAEIKAAVQKLFEVEVEDVNTLLVKGKSKRHGQRVGRRSDWKKAYVTLKEGQNLDFIGGAE	100	Sequence 760 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15005	MKSEIKKNDIVKVIAGDDKGKVAKVLAVLPKTSQVVVEGCKVVKKAIKPTDDNPKGGFIHKEKPMHISNVKKA	73	Sequence 767 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15006	MFTINAEVRKEQGKGASRRLRAANKFPAIIYGGKEAPLAIELDHDKVMNMQAKAEFYSEVLTIVVDGKEIKVKAQDVQRHPYKPKLQHIDFVRA	94	Sequence 783 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15007	MAFKFNAEVRTAQGKGASRRLRHNGQIPAIVYGGSEEPVSIILNHDELNNAQAHESFYSEVITLVVEGKEVAVKVQAMQRHPFKPKLVHIDFKRA	95	Sequence 784 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15008	ASKKGVGSTKDGRDSIAKRLGAKRADGQFVTGGSILYRQRGTKVHPGLNVGRGGDDTLYAKIDGIVRFERLGRDRKRVSVYPVSQEA	87	Sequence 794 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15009	MLRLDLQFFASKKGVGSTKNGRDSEAKRLGAKRADGQFVTGGSILYRQRGTKIYPGENVGRGGDDTLFAKIDGTVKFERFGRDRKKVSVYPVAQ	94	Sequence 795 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15010	AHKKAGGSTRNGRDSEAKRLGVKRFGGESVLAGSIIVRQRGTKFHAGANVGCGRDHTLFAKADGKVKFEVKGPKNRKFISIEAE	84	Sequence 797 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15011	ATKKAGGSTRNGRDSEAKRLGVKRFGGESVLAGSIIVRQRGTKFHAGNNVGMGRDHTLFATADGKVKFEVKGEKSRKYVVIVTE	84	Sequence 798 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15012	MAHKKGQGSTQNNRDSAGRRLGVKKFGSEFVRAGNIIVRQRGTKMHPGNNVGMGKDHTLYALIDGVVKFEHKDRNRKKVSVVSQNFGE	88	Sequence 799 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15013	MAHKKGASSTRNGRDSNAQRLGVKRFGGQAVNAGEILVRQRGTHFHPGTGVGRGGDDTLFALAAGAVQFGTHRGRKVVNIVPLAV	85	Sequence 806 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15014	MAHKKGTGSTRNGRDSNAQRLGVKRYGGQTVTAGSIIVRQRGTQVHPGNNVGRGKDDTLFALIDGVVKFEHKTRSRRKVSVYPATAE	87	Sequence 807 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15015	AKCFITGKKKSFGNTRSHAMNASRRDWKANLQKVRILVDGKPKRVWVSARALKSGKVKRV	60	Sequence 809 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15016	MARKCVITGKKTTAGNNRSHAMNASKRTWGANLQKVRILVNGKPKKVYVSARALKSGKVERV	62	Sequence 810 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15017	SRVCQVTGKRPVTGNNRSHALNATKRRFLPNLHSHRFWVESEKRFVTLRVSAKGMRVIDKKGIDTVLAELRARGEKY	77	Sequence 811 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15018	SRVCQVTGKRPAVGNNRSHAMNATRRRFLPNLHTHRFWVESENRFVTLRLTAKGMRIIDKKGIDAVLAEIRARGEKI	77	Sequence 812 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15019	MAKRCALTFKGPMIGNHVSHANNKNKRRLLPNLRSIKIQLDDGTTKRIKVAASTLRTMRKGA	62	Sequence 813 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15020	MAKKDQLTLRGPLYGNNRSHSKTITRRKWNVNLQSCKIKDTNGKVTRILVSTKTIRTLKKQNRF	64	Sequence 816 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15021	MAKKDQLTLRGPLYGNNRSHSKTITRRKWNVNLQPCKVKTADGKTTRILVSTRTLRTLKKHNRLS	65	Sequence 817 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15022	MSARCQITGRTVGFGKAVSHSHRRTRRRWPPNIQLKAYYLPSEDRRIKVRVSAQGIKVIDRDGHRGRRRAARAGSAPAHFARQAGSSLRTAAIL	94	Sequence 818 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15023	MARRCQLTGKKANNGFAVSHSHRRTKKLQQANLQWKRVWWPEGNRFVRLRLSTTAIKTLESKGINAMAKEAGINLNKF	78	Sequence 820 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15024	MKAQELRTKSVEELNAELVNLLGEQFKLRMQAATGQLQQTHQLKQVRRSIAQIKTVLTEKAGE	63	Sequence 821 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15025	MKAQELREKGVEELNTELLNLLREQFNLRMQGASGQLQQTHLLKQVRRNVARVKTLLTEKAGV	63	Sequence 822 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15026	MKAKEIRELTTAEIEQKIKALKEELFNLRFQLATGQLENTARIRQVRKDIARMKTIIRERELAANK	66	Sequence 823 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15027	MKANEIRDLTTAEIEQKVKSLKEELFNLRFQLATGQLENTARIREVRKAIARMKTVIREREIAANK	66	Sequence 824 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15028	MGAKKNLLAELREKSSEELDEFIRDNKKALFALRAEAALQNKVVKTHQFSLYKKSIARALIIKQEKKGRVHG	72	Sequence 825 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15029	MAKSKNHTNHNQNKKAHRNGIKRPLRKRHESTLGMDVKFLINQRYARKGNLSREESVKRYNERIASQKGKPKPVTL	76	Sequence 826 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15030	MKAKELREKSVEELNTELLNLLREQFNLRMQAASGQLQQSHLLKQVRRDVARVKTLLNEKAGA	63	Sequence 827 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15031	MKAQDLRTKSVEELNAELVNLLGEQFKLRMQTATGQLQQTHQAKQVRRDIARVKTVLTEKAGE	63	Sequence 828 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15032	MKYTELKDKSIKELEELLHAKKAELFELRVKLKAMQLSNPNEIKKARRNIARINTAINAHYSSSVE	66	Sequence 829 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15033	MAILRADELRGMSMEELKEKLVELKRELLKERASKAVAGAPSNPGRMREIRRTIARILTIMNEKKRMTSQ	70	Sequence 830 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15034	MAILRSEEIREMDGEELQKKLDELKAEYARYISKSAAAGIHENPGKMREIRRTIARVLTIMNEK	64	Sequence 831 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15035	MAVGVSPGELRELTDEELAERLRESKEELFNLRFQMATGQLNNNRRLRTVRQEIARIYTVSARTRTGSGGDWARW	75	Sequence 833 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15036	MALPKIEDVRNLSDADLAEKIAEAKRELFDLRFQRATRQLEKPHLFKHTKHRLAQLLTVERERQ	64	Sequence 837 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15037	MALPNIADARKLGDEELATEILATKQRLFQLRFQQATRRPENPHEFKHARHRLAQLLTVERERQLENSPSEEA	73	Sequence 838 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15038	MKASELRNYTDEELKNLLEEKKRQLMELRFQLAMGQLKNTSLIKLTKRDIARIKTILRERELGIRR	66	Sequence 839 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15039	MAKTIKVTQVRSSIGRLPKHKATLLGLGLRRIGHTVEREDTPALRGMINLVSYMVKVEE	59	Sequence 862 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15040	AKKLAITLTRSVIGRPEDQRITVRTLGLRKMHQTVVHNDNPAIRGMINKVAHLVKVKEIEEE	62	Sequence 863 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15041	AKLEITLKRSVIGRPEDQRVTVRTLGLKKTNQTVVHEDNAAIRGMINKVSHLVSVKEQ	58	Sequence 864 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15042	AKTIKITQTRSAIGRLPKHKATLLGLGLRRIGHTVEREDTPAIRGMINAVSFMVKVEE	58	Sequence 866 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15043	AKTIKVTQVRSSIARLPKHKATLRGLGLRHIHHTVELIDTPAVRGMINQVSYMVKVEE	58	Sequence 867 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15044	MFESTRKNIQPSDATLVITQTRGVTGSKQNHRDTLRSLGLKRIGHQVTRKADAVTVGMVNTVPHLVSVEEVNNG	74	Sequence 874 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15045	MASLKITQVRSTIGVRWKQRESLRTLGLRRIRHSVIREDNLQTRGLIAVVRHLVEVEPATGGSTPVGGGRD	71	Sequence 875 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15046	MAKLQITLTRSVIGRPETQRKTVEALGLKKTNSSVVVEDNPAIRGQINKVKHLVTVEEK	59	Sequence 877 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15047	MAQLKITQVKSYIGSKQNHRDTLRSLGLKGINTQVVKEDRPEFRGMVHTVRHLVTVEEVD	60	Sequence 878 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15048	MPRLKVKLVKSPIGYPKDQKAALKALGLRRLQQERVLEDTPAIRGNVEKVAHLVRVEVVE	60	Sequence 879 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15049	MKAGIHPNFKKATVKCACGNEFETGSVKEEVRVEICSECHPFYTGRQKFASADGRVDRFNKKYGLK	66	Sequence 881 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15050	MKKDIHPKYEEITASCSCGNVMKIRSTVGHDLNLDVCSKCHPFFTGKQRDVATGGRVDRFNKRFNIPGSK	70	Sequence 883 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15051	MKQGIHPEYKEITATCSCGNVIKTRSTVEKNLNLDVCGNCHPFYTGKQRVVDTGGRVERFNKRFNIPSTK	70	Sequence 884 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15052	MKQGIHPEYKEITATCSCGNVIKTRSTLGKDINLDVCGNCHPFYTGKQRVVDTGGRVERFNSRFKIPSTK	70	Sequence 885 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15053	MKKGIHPEYIPCKVTCVTSGKEIEVLSTKPEMRIDISSFCHPFYTGSDKIADTAGRVEKFKQRYNLK	67	Sequence 886 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15054	MEVLMMEERIYTIPLRDVINKSVRTKRAPRAIKKIKQFLKRHMKAEIVKIDNELNEKIWERGIQKPPARVRVKAVKEGNVVIATLAE	87	Sequence 888 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15774	GSWLRDIWDWVCTVLSDFRVWLKSKL	26	Sequence 49 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15775	SWLRDVWDWICTVLT	15	Sequence 50 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15776	SWLRDVWDWVCTILT	15	Sequence 51 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15777	SWLRDIWEWVLSILT	15	Sequence 52 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15778	SWLRIIWDWVCSWSD	15	Sequence 53 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15779	SWLRTIWDWVCSVLA	15	Sequence 54 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15780	SWLHDIWDWVCIVLS	15	Sequence 55 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15781	SWLWDVWDWVLHVLS	15	Sequence 56 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15782	SWLYDIVNWVCTVLA	15	Sequence 57 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15783	SWLRDIWDWVCTVLS	15	Sequence 58 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15784	SWLRDVWDWICTVLTD	16	Sequence 59 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15785	SWLRDVWDWVCTILTD	16	Sequence 60 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15786	SWLRDIWEWVLSILTD	16	Sequence 61 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15787	SWLRIIWDWVCSWSDF	16	Sequence 62 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15788	SWLRTIWDWVCSVLAD	16	Sequence 63 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15789	SWLHDIWDWVCIVLSD	16	Sequence 64 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15790	SWLWDVWDWVLHVLSD	16	Sequence 65 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15791	SWLYDIVNWVCTVLAD	16	Sequence 66 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15792	SWLRDIWDWVCTVLSD	16	Sequence 67 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15793	SWLRDVWDWICTVLTDF	17	Sequence 68 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15794	SWLRDVWDWVCTILTDF	17	Sequence 69 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15795	SWLRDIWEWVLSILTDF	17	Sequence 70 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15796	SWLRIIWDWVCSWSDFK	17	Sequence 71 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15797	SWLRTIWDWVCSVLADF	17	Sequence 72 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15798	SWLHDIWDWVCIVLSDF	17	Sequence 73 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15799	SWLWDVWDWVLHVLSDF	17	Sequence 74 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15800	SWLYDIVNWVCTVLADF	17	Sequence 75 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15801	SWLRDIWDWVCTVLSDF	17	Sequence 76 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15802	SGSWLRDVWDWICTVLTDFKTWLQSKLDYK	30	Sequence 77 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15803	QDVLKEVKAAASKVKANLLSVEE	23	Sequence 79 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15804	DVRCHARKAVAHINSVWKD	19	Sequence 80 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15805	IEQGMMLAEQFKQKALGLLQTASRHAEV	28	Sequence 81 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15806	LRDVWDWICTVLTDFKT	17	Sequence 83 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15807	LRDVWDWICT	10	Sequence 84 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15808	DVWDWICTVLTD	12	Sequence 85 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15809	SWLRDVWDWIC	11	Sequence 86 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15810	LCLAGRGLQEAEGLLLELLSEHHPLLDV	28	Sequence 87 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15811	ELGFQPGLKVAQHLAYPVPDVP	22	Sequence 88 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15812	SGSWLRDVWDWICTVLTDFKTWLQSKLDYKD	31	Sequence 89 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15813	SGSWLRDDWDWECTVLTDDKTWLQSKLDYKD	31	Sequence 90 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15814	SGSWLRDDWDWECTVLTDDKTWLQSKL	27	Sequence 91 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15815	RLLLRLLLGY	10	Sequence 3 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15816	RVLLRLLLGY	10	Sequence 4 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15817	RILLRLLLGY	10	Sequence 5 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15818	RLVLRLLLGY	10	Sequence 6 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15819	RLILRLLLGY	10	Sequence 7 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15820	RLLVRLLLGY	10	Sequence 8 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15821	RLLIRLLLGY	10	Sequence 9 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15822	RLLLRVLLGY	10	Sequence 10 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15823	RLLLRILLGY	10	Sequence 11 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15824	RLLLRLVLGY	10	Sequence 12 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15825	RLLLRLILGY	10	Sequence 13 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15826	RLLLRLLVGY	10	Sequence 14 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15827	RLLLRLLIGY	10	Sequence 15 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15828	RWLLRLLLGY	10	Sequence 16 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15829	RLWLRLLLGY	10	Sequence 17 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15830	RLLWRLLLGY	10	Sequence 18 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15831	RLLLRWLLGY	10	Sequence 19 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15832	RLLLRLWLGY	10	Sequence 20 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15833	RLLLRLLWGY	10	Sequence 21 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15834	RYLLRLLLGY	10	Sequence 22 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15835	RLYLRLLLGY	10	Sequence 23 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15836	RLLYRLLLGY	10	Sequence 24 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15837	RLLLRYLLGY	10	Sequence 25 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15838	RLLLRLYLGY	10	Sequence 26 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15839	RLLLRLLYGY	10	Sequence 27 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15840	KYKETDLLILFKDDYFAKKNEERK	24	Sequence 1 from Patent US 20090233868	Homo sapiens	Antimicrobial, Antiviral	US 2009/0233868 A1	Patent Application	2009##9##17	CA2606668A1, EP1877431A1, US20110091966, WO2006117805A1	Small antiviral peptides against hepatitis C virus.	Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.
DRAMP15841	KYKETDL	7	Sequence 2 from Patent US 20090233868	Homo sapiens	Antimicrobial, Antiviral	US 2009/0233868 A1	Patent Application	2009##9##17	CA2606668A1, EP1877431A1, US20110091966, WO2006117805A1	Small antiviral peptides against hepatitis C virus.	Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.
DRAMP15842	RQARRNRRRRWR	12	Sequence 1 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15843	RKKRRQRRR	9	Sequence 2 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15844	PKKKRKV	7	Sequence 3 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15845	RKKKRKV	7	Sequence 4 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15846	YGRKKRRQRRR	11	Sequence 5 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15847	LPPLERLTLD	10	Sequence 6 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15848	LALKLAGLDI	10	Sequence 7 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15849	LPPDLRLTLD	10	Sequence 8 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15850	LSAQLYSSLSLD	12	Sequence 9 from Patent US 20090258815	Human T-cell lymphotropic	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15851	RQARRNRRRRWRLPPLERLTLD	22	Sequence 10 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15852	LPPLERLTLDRQARRNRRRRWR	22	Sequence 11 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15853	YGRKKRRQRRRLPPLERLTLD	21	Sequence 12 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15854	RKKKRKVLALKAGLDI	16	Sequence 13 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15855	RRMKWKK	7	Sequence 14 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15856	RVHPYQR	7	Sequence 15 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15857	KRPACTLKPECVQQLLVCSQEAKK	24	Sequence 16 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15858	GKKRSKA	7	Sequence 18 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15859	KAKRQR	6	Sequence 19 from Patent US 20090258815	avian reticuloendothelios	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15860	RGRRRRQR	8	Sequence 20 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15861	RKRRR	5	Sequence 21 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15862	PPVKRERTS	9	Sequence 22 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15863	PYLNKRKGKP	10	Sequence 23 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15864	CYGSKNTGAKKRKIDDA	17	Sequence 24 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15865	KKKKRKREK	9	Sequence 25 from Patent US 20090258815	Drosophila sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15866	KKKRRSREK	9	Sequence 26 from Patent US 20090258815	Drosophila sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15867	KVTKRKHDNEGSGSKRPK	18	Sequence 27 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15868	KKKKKEEEGEGKKK	14	Sequence 28 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15869	PRPRKIPR	8	Sequence 29 from Patent US 20090258815	Borna disease virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15870	PPRIYPQLPSAPT	13	Sequence 30 from Patent US 20090258815	Borna disease virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15871	KDCVINKHHRNRCQYCRLQR	20	Sequence 31 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15872	APKRKSGVSKC	11	Sequence 32 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15873	MPKTRRRPRRSQRKRPPT	18	Sequence 35 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15874	KRPMNAFIVWSRDQRRK	17	Sequence 36 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15875	RPRRK	5	Sequence 37 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15876	KRPMNAFIVWAQAARRK	17	Sequence 38 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15877	PRRRK	5	Sequence 39 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15878	RKRR	4	Sequence 40 from Patent US 20090258815	Arabidopsis sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15879	PPRKKRTVV	9	Sequence 41 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15880	YKRPCKRSFIRFI	13	Sequence 42 from Patent US 20090258815	epstein-barr virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15881	LKDVRKRKLGPGH	13	Sequence 43 from Patent US 20090258815	epstein-barr virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15882	KRPRP	5	Sequence 44 from Patent US 20090258815	adenovirus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15883	RKRKK	5	Sequence 45 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15884	RRSMKRK	7	Sequence 46 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15885	PAKRARRGYK	10	Sequence 47 from Patent US 20090258815	canine parvovirus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15886	RKCLQAGMNLEARKTKK	17	Sequence 48 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15887	RRERNKMAAAKCRNRRR	17	Sequence 49 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15888	KRMRNRIAASKCRKRKL	17	Sequence 50 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15889	KKSKKGRQEALERLKKA	17	Sequence 51 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15890	RKEWLTNFMEDRRQRKL	17	Sequence 52 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15891	KKQTTLAFKPIKKGKKR	17	Sequence 53 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15892	RKRKKMPASQRSKRRKT	17	Sequence 54 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15893	RAIKRRPGLDFDDDGEGNSKFLR	23	Sequence 55 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15894	RIRKKLR	7	Sequence 56 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15895	KRAAEDDEDDDVDTKKQK	18	Sequence 57 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15896	GRKRKKRT	8	Sequence 58 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15897	REKKEKEQKEKCA	13	Sequence 59 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15898	LEKKVKKKFDWCA	13	Sequence 60 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15899	RKRRTKK	7	Sequence 61 from Patent US 20090258815	Arabidopsis sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15900	SDKKVRSRLIECA	13	Sequence 62 from Patent US 20090258815	Thermoplasma acidophilum	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15901	LKRKLQR	7	Sequence 63 from Patent US 20090258815	avian neuroretina	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15902	RRKGKEK	7	Sequence 64 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15903	CKRKTTNADRRKA	13	Sequence 65 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15904	VNEAFETLKRC	11	Sequence 66 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15905	MPTEERVRKRKESNRESARRSRYRKAAHLK	30	Sequence 67 from Patent US 20090258815	Zea mays	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15906	KVNSRKRRKEVPGPNGATEED	21	Sequence 68 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15907	PRRGPR	6	Sequence 69 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15908	PRGRRQPIPKARQP	14	Sequence 70 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15909	KRSAEGGNPPKPLKKLR	17	Sequence 71 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15910	EYLSRKGKLEL	11	Sequence 72 from Patent US 20090258815	Agrobacterium tumefaciens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15911	PKRPRDRHDGELGGRKRARG	20	Sequence 73 from Patent US 20090258815	Agrobacterium tumefaciens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15912	KRPAATKKAGQAKKKK	16	Sequence 74 from Patent US 20090258815	Xenopus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15913	KRKKEMANKSAPEAKKKK	18	Sequence 75 from Patent US 20090258815	Gallus gallus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15914	YNNQSSNFGPMKGGN	15	Sequence 76 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15915	PAAKRVKLD	9	Sequence 77 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15916	KRPAEDMEEEQAFKRSR	17	Sequence 78 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15917	MNKIPIKDLLNPG	13	Sequence 79 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15918	PKKARED	7	Sequence 80 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15919	VSRKRPR	7	Sequence 81 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15920	APTKRKGS	8	Sequence 82 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15921	PNKKKRK	7	Sequence 83 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15922	EEDGPQKKKRRL	12	Sequence 84 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15923	PLLKKIKQ	8	Sequence 85 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15924	PPQKKIKS	8	Sequence 86 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15925	PQPKKKP	7	Sequence 87 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15926	SKRVAKRKL	9	Sequence 88 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15927	IKYFKKFPKD	10	Sequence 89 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15928	KTRKHRG	7	Sequence 90 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15929	KHRKHPG	7	Sequence 91 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15930	PQSRKKLR	8	Sequence 92 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15931	KKEKKKSKK	9	Sequence 93 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15932	KRKKRRHR	8	Sequence 94 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15933	AQEVKNWMTETLLVA	15	Sequence 3 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15934	AQEVKXWMTXTLLVA	15	Sequence 4 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15935	AQAVKXWMTXTLLVA	15	Sequence 5 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15936	AQEVKXWMTXTLLVAKKK	18	Sequence 6 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15937	AQKVEXWMTXTLLVA	15	Sequence 7 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15938	AQAVKXWMTXTLLVENA	17	Sequence 8 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15939	AQAVKXWMTXTLLKANAE	18	Sequence 9 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15940	EQLVWXKMTXALAVT	15	Sequence 10 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15941	AQAVKNWMTXTLLXA	15	Sequence 12 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15942	AQAWKXWATXTLLVAE	16	Sequence 13 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15943	AQAVKXWMEXTLKVAE	16	Sequence 14 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15944	AQAVKXWMTETLXVA	15	Sequence 15 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15945	AQAWKXWATETLXVAN	16	Sequence 16 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15946	IAQAKVEXWMTXTLLVAN	18	Sequence 17 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15947	AQAVKNWMTETLLVA	15	Sequence 19 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15948	SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE	36	Sequence 1 from Patent US 20100021427	Homo sapiens	Antimicrobial, Antiviral	US 2010/0021427 A1	Patent Application	2010##1##28	Unknown	Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV.	The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.
DRAMP15949	RRKKAAVALLPAVLLALLA	19	Sequence 2 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15950	RRKKAAVALLPAVLLALL	18	Sequence 3 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15951	RRKKAAVALLPAVLLA	16	Sequence 5 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15952	RRKKAAVALLPAVLL	15	Sequence 6 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15953	RRKKAAVALLPAVL	14	Sequence 7 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15954	RRKKAAVALLPAV	13	Sequence 8 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15955	RRKKAAVALLPA	12	Sequence 9 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15956	RRKKAAVALL	10	Sequence 11 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15957	RRKKAAVAL	9	Sequence 12 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15958	RRKKAAV	7	Sequence 14 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15959	RRKKAA	6	Sequence 15 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15960	RRKKA	5	Sequence 16 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15961	RRKKAVALLPAVLLALLAP	19	Sequence 18 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15962	RRKKVALLPAVLLALLAP	18	Sequence 19 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15963	RRKKLLPAVLLALLAP	16	Sequence 21 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15964	RRKKLPAVLLALLAP	15	Sequence 22 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15965	RRKKVLLALLAP	12	Sequence 23 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15966	RRKKALLAP	9	Sequence 25 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15967	RRKKLAP	7	Sequence 27 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15968	RRKKAP	6	Sequence 28 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15969	RRKKP	5	Sequence 29 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15970	RRKKAALLVLAALAVLA	17	Sequence 30 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15971	RRKKAAVALLAVLLALLA	18	Sequence 43 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15972	RRKKLLAVLLALLA	14	Sequence 44 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15973	RRKKLAVLLALLA	13	Sequence 45 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15974	RRKKAAAAAAAAA	13	Sequence 49 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15975	RKKLAVLLALLA	12	Sequence 50 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15976	RKAVLLALLA	10	Sequence 51 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15977	KLAVLLALLA	10	Sequence 52 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15978	KKLAVLLALLA	11	Sequence 53 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15979	EEDDLAVLLALLA	13	Sequence 54 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15980	RRKKLAVAAALLA	13	Sequence 55 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15981	RRKKLAVLLAAAA	13	Sequence 56 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15982	EEDD	4	Sequence 61 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15983	ITFEDLLDYYGP	12	Sequence 1 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15984	ITFXDLLXYYGP	12	Sequence 6 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15985	ITFXDLLXYYGPKKK	15	Sequence 7 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15986	WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	64	Sequence 1 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15987	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 2 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15988	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	36	Sequence 3 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15989	TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL	38	Sequence 5 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15990	TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL	38	Sequence 6 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15991	TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL	38	Sequence 7 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15992	TTWEAWDRAIAEYAARIEALLRAAQEQQEKNEAALREL	38	Sequence 8 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15993	TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL	38	Sequence 9 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15994	TTWEAWDRAIAEYAARIEALLRAAQEQQEKLEAALREL	38	Sequence 10 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15995	TTWEAWDRAIAEYAARIEALIRALQEQQEKLEAALREL	38	Sequence 11 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15996	TTWEAWDRAIAEYAARIEALIRAIQEQQEKLEAALREL	38	Sequence 12 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15997	TTWEAWDRAIAEYAARIEALIRALQEQQEKIEAALREL	38	Sequence 13 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15998	TTWEAWDRAIAEYAARIEALLRAIQEQQEKNEAALREL	38	Sequence 14 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15999	TTWEAWDRAIAEYAARIEALLRAAQEQQEKIEAALREL	38	Sequence 15 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16000	TTWEAWDRAIAE	12	Sequence 17 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16001	YAARIEALLRALQE	14	Sequence 18 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16002	QQEKNEAALRE	11	Sequence 19 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16003	QQEKNEAALREL	12	Sequence 20 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16004	TTWEAWDRAIA	11	Sequence 21 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16005	EYAARIEALLRALQE	15	Sequence 22 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16006	TTWEAWDRAI	10	Sequence 23 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16007	AEYAARIEALLRALQE	16	Sequence 24 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16008	TTWEAWDRA	9	Sequence 25 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16009	IAEYAARIEALLRALQE	17	Sequence 26 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16010	TTWEAWDR	8	Sequence 27 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16011	AIAEYAARIEALLRALQE	18	Sequence 28 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16012	TTWEAWDRAIAEYAARIEAL	20	Sequence 29 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16013	LRALQEQQEKNEAALRE	17	Sequence 30 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16014	LRALQEQQEKNEAALREL	18	Sequence 31 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16015	TTWEAWDRAIAEYAARIE	18	Sequence 32 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16016	ALLRALQEQQEKNEAALRE	19	Sequence 33 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16017	ALLRALQEQQEKNEAALREL	20	Sequence 34 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16018	YAARIEALLRALQEQQEKNEAALREL	26	Sequence 35 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16019	EYAARIEALLRALQEQQEKNEAALREL	27	Sequence 36 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16020	AEYAARIEALLRALQEQQEKNEAALREL	28	Sequence 37 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16021	IAEYAARIEALLRALQEQQEKNEAALREL	29	Sequence 38 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16022	AIAEYAARIEALLRALQEQQEKNEAALREL	30	Sequence 39 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16023	TTWEAWDRAIAEYAARIEALLRALQE	26	Sequence 40 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16024	YAARIEALLRAAQE	14	Sequence 41 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16025	QQEKLEAALRE	11	Sequence 42 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16026	QQEKLEAALREL	12	Sequence 43 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16027	EYAARIEALLRAAQE	15	Sequence 44 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16028	AEYAARIEALLRAAQE	16	Sequence 45 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16029	IAEYAARIEALLRAAQE	17	Sequence 46 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16030	AIAEYAARIEALLRAAQE	18	Sequence 47 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16031	LRAAQEQQEKLEAALRE	17	Sequence 48 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16032	LRAALQEQQEKLEAALREL	19	Sequence 49 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16033	ALLRAAQEQQEKLEAALRE	19	Sequence 50 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16034	ALLRAAQEQQEKLEAALREL	20	Sequence 51 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16035	YAARIEALLRAAQEQQEKLEAALREL	26	Sequence 52 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16036	EYAARIEALLRAAQEQQEKLEAALREL	27	Sequence 53 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16037	AEYAARIEALLRAAQEQQEKLEAALREL	28	Sequence 54 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16038	IAEYAARIEALLRAAQEQQEKLEAALREL	29	Sequence 55 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16039	AIAEYAARIEALLRAAQEQQEKLEAALREL	30	Sequence 56 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16040	TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRE	37	Sequence 57 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16041	AARIEALLRALQEQQEKNEAALRE	24	Sequence 58 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16042	RIEALLRALQEQQEKNEAALRE	22	Sequence 59 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16043	QEQQEKNEAALREL	14	Sequence 60 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16044	LQEQQEKNEAALREL	15	Sequence 61 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16045	EQQEKNEAALREL	13	Sequence 62 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16046	TTWEAWDRAIAEYAARIEALLRALQ	25	Sequence 63 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16047	TTWEAWDRAIAEYAARIEALLRAL	24	Sequence 64 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16048	TTWEAWDRAIAEYAARIEALLR	22	Sequence 65 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16049	TTWEAWDRAIAEYAARIEALL	21	Sequence 66 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16050	TTWEAWDRAIAEYAARIEA	19	Sequence 67 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16051	TTWEAWDRAIAEYAARI	17	Sequence 68 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16052	TTWEAWDRAIAEYAAR	16	Sequence 69 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16053	TTWEAWDRAIAEYAA	15	Sequence 70 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16054	TTWEAWDRAIAEYA	14	Sequence 71 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16055	TTWEAWDRAIAEY	13	Sequence 72 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16056	EL	2	Sequence 73 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16057	AARIEALLRALQE	13	Sequence 74 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16058	ARIEALLRALQE	12	Sequence 75 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16059	RIEALLRALQE	11	Sequence 76 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16060	EALLRALQE	9	Sequence 77 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16061	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF	39	Sequence 78 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16062	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT	39	Sequence 79 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16063	YQEWERKVDFLEENITALLEEAQIQQEKNMYELQKL	36	Sequence 80 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16064	CNDFRSKTC	9	Sequence 1 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16065	NDFRSKT	7	Sequence 2 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16066	QHSTKWF	7	Sequence 3 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16067	LPYAAKH	7	Sequence 4 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16068	ILGDKVG	7	Sequence 5 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16069	LPYGSKH	7	Sequence 6 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16070	ILGYKVG	7	Sequence 7 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16071	HPQFLSL	7	Sequence 8 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16072	GLYNHPQ	7	Sequence 9 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16073	CSWGEYDMC	9	Sequence 10 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16074	ITEXDLLXYYGKKK	14	Sequence 7 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16075	ISFXELLDYYXESGS	15	Sequence 8 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16076	ITFEDLLXYYGXKK	14	Sequence 9 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16077	AQAVKXWMTXTLLVAKKK	18	Sequence 10 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16078	ISFXELLXYYGR	12	Sequence 11 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16079	ITFXDILXYYGEK	13	Sequence 12 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16080	ISFXELLXYYGEK	13	Sequence 13 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16081	ITFXDWLXYYGR	12	Sequence 14 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16082	ISFXEWLQYYXR	12	Sequence 15 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16083	ISFXELLXYYGRSGS	15	Sequence 16 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16084	ISFXELLXYYGESGS	15	Sequence 17 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16085	ISFXEILXYYGESGS	15	Sequence 18 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16086	ISFDELLDYYGESGS	15	Sequence 19 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16087	IXFEXXLXYY	10	Sequence 21 from Patent US 20120165249	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16088	XPXEXXXTVTTQNXAXQTMS	20	Sequence 1 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16089	PAEPYTTVTTQNTASQTMS	19	Sequence 2 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16090	RRRRRRRRPAEPYTTVTTQNTASQTMS	27	Sequence 3 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16091	SLVSSDESSSGSSHSSGEHS	20	Sequence 4 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16092	RRRRRRRRSLVSSDESSSGSSHSSGEHS	28	Sequence 5 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16093	RRRRRRRRHPAEPGSTVTTQNTASQTMS	28	Sequence 6 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16094	RRRRRRRRHPTESGSTVTTQNSAAQTMS	28	Sequence 8 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16095	YTTTVTTQNTASQT	14	Sequence 13 from Patent US 20120289459	African swine fever virus	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16096	XAXQT	5	Sequence 14 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16097	FAGIAIGIAALGVATAAQVT	20	Sequence 1 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16098	FAGIAIGIAALGVATAAQVTAAV	23	Sequence 2 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16099	VNINILQQIGYIKQQVRQLSYYS	23	Sequence 3 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16100	ECRSTSYAGAVVNDL	15	Sequence 1 from Patent US 4795740	Synthetic construct	Antimicrobial, Antiviral	US 4795740 A	Granted Patent	1989##1##3	Unknown	Antiviral peptides and means for treating herpes infections.	Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 -B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylacetyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the four amino acid residues immediately preceding R.sup.11 may optionally be deleted, R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.
DRAMP16101	STSYAGAVVNDL	12	Sequence 2 from Patent US 4795740	Synthetic construct	Antimicrobial, Antiviral	US 4795740 A	Granted Patent	1989##1##3	Unknown	Antiviral peptides and means for treating herpes infections.	Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 -B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylacetyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the four amino acid residues immediately preceding R.sup.11 may optionally be deleted, R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.
DRAMP16102	RRWWCRX	7	Sequence 1 from Patent US 5441936	Synthetic construct	Antimicrobial, Antiviral	US 5441936 A	Granted Patent	1995##8##15	WO1995015766A1	Antiviral peptides.	The present invention provides antiviral peptides having the general structure, Arg-Arg-Trp-Trp-Cys-Arg-X, where X is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be (D)- or (L)-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides a pharmaceutical composition comprising an antiviral peptide and methods of using an antiviral peptide in vitro or in vivo to reduce or inhibit a herpes simplex virus infection.
DRAMP16103	TKPKTKPK	8	Sequence 1 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16104	TKPKTKPR	8	Sequence 2 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16105	AKTKPRQQ	8	Sequence 3 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16106	ASTTTNYT	8	Sequence 4 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16108	DWLKAFYDKVAEKLKEAF	18	Sequence 6 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16109	KWLDAFYKDVAKELEKAF	18	Sequence 7 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16110	IKILGNQGSTLTKGPYSK	18	Sequence 8 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16111	LKIEDSDTYICEVEDQKEE	19	Sequence 9 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16112	TYICEVEDQKEE	12	Sequence 10 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16113	XPXLX	5	Sequence 11 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16114	CATCEQIADSQHRSHRQMV	19	Sequence 1 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16115	CATCEQIADSQHRSHRQM	18	Sequence 3 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16116	CATCEQIADSQHRSHRQ	17	Sequence 4 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16117	CATCEQIADSQHRSHR	16	Sequence 5 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16118	CATCEQIADSQHRSH	15	Sequence 6 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16119	CATCQIADSQHRSHRQMV	18	Sequence 7 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16120	CATCIADSQHRSHRQMV	17	Sequence 8 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16121	CATCADSQHRSHRQMV	16	Sequence 9 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16122	CTCEQIADSQHRSHRQMV	18	Sequence 10 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16123	CACEQIADSQHRSHRQMV	18	Sequence 11 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16124	CATCEQIADSQHRHRQMV	18	Sequence 12 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16125	CAACEQIADSQHRSHRQMV	19	Sequence 16 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16126	CATCAQIADSQHRSHRQMV	19	Sequence 17 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16127	CATCEAIADSQHRSHRQMV	19	Sequence 18 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16128	CATCEQAADSQHRSHRQMV	19	Sequence 19 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16129	CATCEQIAASQHRSHRQMV	19	Sequence 20 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16130	CATCEQIADAQHRSHRQMV	19	Sequence 21 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16131	CATCEQIADSAHRSHRQMV	19	Sequence 22 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16132	CATCEQIADSQHASHRQMV	19	Sequence 23 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16133	CATCEQIADSQHRAHRQMV	19	Sequence 24 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16134	CATCEQIADSQHRSHAQMV	19	Sequence 25 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16135	CATCEQIADSQHRSHRAMV	19	Sequence 26 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16136	CATCEQIADSQHRSHRQAV	19	Sequence 27 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16137	CATCEQIADSQHRSHRQMA	19	Sequence 28 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16138	CATCEQIADSQHKSHRQMV	19	Sequence 29 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16139	CATCEQIADSQHRSHKQMV	19	Sequence 30 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16140	CATCEQIADSQHKSHKQMV	19	Sequence 31 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16141	CASCEQIADSQHRSHRQMV	19	Sequence 32 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16142	CATCDQIADSQHRSHRQMV	19	Sequence 33 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16143	CATCENIADSQHRSHRQMV	19	Sequence 34 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16144	CATCEQLADSQHRSHRQMV	19	Sequence 35 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16145	CATCEQVADSQHRSHRQMV	19	Sequence 36 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16146	CATCEQIAESQHRSHRQMV	19	Sequence 37 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16147	CATCEQIADTQHRSHRQMV	19	Sequence 38 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16148	CATCEQIADSNHRSHRQMV	19	Sequence 39 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16149	CATCEQIADSQHRTHRQMV	19	Sequence 40 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16150	CATCEQIADSQHRSHRNMV	19	Sequence 41 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16151	CATCEQIADSQHRSHRQML	19	Sequence 42 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16152	CATCEQIADSQHRSHRQMI	19	Sequence 43 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16153	CXTCEQIADSQHRSHRQMV	19	Sequence 44 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16154	CATCEQIADSQHXSHRQMV	19	Sequence 45 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16155	CATCEQIADSQHRSHXQMV	19	Sequence 46 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16156	CXTCEQIADSQHXSHRQMV	19	Sequence 47 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16157	CXTCEQIADSQHXSHXQMV	19	Sequence 48 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16158	LTVPSERGLQRRR	13	Sequence 54 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16159	ALNGNGDPNNMDKAVKLY	18	Sequence 55 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16160	KREITFHGAKEISLS	15	Sequence 56 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16161	EQIADSQHRSHRQMV	15	Sequence 57 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16162	GTHPSSSAGLKNDLLEN	17	Sequence 58 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16163	APGDEPAPPY	10	Sequence 3 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16164	APGDEPAPP	9	Sequence 4 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16165	AAPGDEPAPP	10	Sequence 5 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16166	AAAPGDEPAPP	11	Sequence 6 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16167	AGATAEETAY	10	Sequence 7 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16168	AGATAEETAA	10	Sequence 8 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16169	GATAEETA	8	Sequence 9 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16170	AGATAEETA	9	Sequence 10 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16171	EETRRMLHRAFDTLA	15	Sequence 11 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16172	SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS	36	Sequence 2 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16173	YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 3 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16174	YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF	36	Sequence 4 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16175	YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF	36	Sequence 5 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16176	LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF	36	Sequence 6 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16177	LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	36	Sequence 7 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16178	CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 8 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16179	LQARILAVERYLKDQQQ	17	Sequence 9 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16180	QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ	38	Sequence 10 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16181	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	48	Sequence 16 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16182	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	37	Sequence 17 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16183	ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS	35	Sequence 18 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16184	ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR	34	Sequence 19 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16185	VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS	33	Sequence 20 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16186	AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV	33	Sequence 21 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16187	VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL	33	Sequence 22 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16188	SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT	33	Sequence 23 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16189	KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS	33	Sequence 24 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16190	LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD	33	Sequence 25 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16191	GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK	33	Sequence 26 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16192	EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN	33	Sequence 27 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16193	VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY	33	Sequence 28 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16194	NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI	33	Sequence 29 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16195	KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID	33	Sequence 30 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16196	IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK	33	Sequence 31 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16197	ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ	33	Sequence 32 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16198	TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN	35	Sequence 33 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16199	LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ	35	Sequence 34 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16200	NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK	35	Sequence 35 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16201	NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL	35	Sequence 36 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16202	SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD	35	Sequence 37 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16203	VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS	35	Sequence 38 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16204	ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI	35	Sequence 39 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16205	LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG	35	Sequence 40 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16206	DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN	35	Sequence 41 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16207	PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW	35	Sequence 42 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16208	IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH	35	Sequence 43 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16209	DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ	35	Sequence 44 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16210	ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS	35	Sequence 45 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16211	SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS	35	Sequence 46 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16212	IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST	35	Sequence 47 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16213	ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT	35	Sequence 48 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16214	TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS	35	Sequence 49 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16215	AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI	35	Sequence 50 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16216	LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL	35	Sequence 51 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16217	VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI	35	Sequence 52 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16218	EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV	35	Sequence 53 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16219	AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA	35	Sequence 54 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16220	KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI	35	Sequence 55 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16221	QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK	35	Sequence 56 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16222	ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS	35	Sequence 57 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16223	RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV	35	Sequence 58 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16224	SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ	35	Sequence 59 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16225	KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN	35	Sequence 60 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16226	LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK	35	Sequence 61 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16227	AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV	35	Sequence 62 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16228	WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK	35	Sequence 63 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16229	QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL	35	Sequence 64 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16230	EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN	35	Sequence 65 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16231	WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS	35	Sequence 66 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16232	ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW	35	Sequence 67 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16233	RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD	35	Sequence 68 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16234	KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV	35	Sequence 69 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16235	VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF	35	Sequence 70 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16236	DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG	35	Sequence 71 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16237	FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN	35	Sequence 72 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16238	LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL	34	Sequence 73 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16239	HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE	34	Sequence 74 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16240	RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES	34	Sequence 75 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16241	IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS	34	Sequence 76 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16242	DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD	34	Sequence 77 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16243	LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ	34	Sequence 78 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16244	GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI	34	Sequence 79 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16245	PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL	34	Sequence 80 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16246	PISLERLDVGTNLGNAIAKLEAKELLESSDQILR	34	Sequence 81 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16247	SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM	34	Sequence 82 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16248	LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK	34	Sequence 83 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16249	MKQLEDKVEELLSKNYHLENEVARLKKL	28	Sequence 84 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16250	TDTLQAETDQLEDEKSALQTEIANLLKE	28	Sequence 85 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16251	IARLEEKVKTLKAQNSELASTANMLREQ	28	Sequence 86 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16252	EQKLISEEDLLEKRREQLKHKLEQLRNS	28	Sequence 87 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16253	IEKTNEKFHQIEKEFSEVEGRIQDLEKY	28	Sequence 88 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16254	YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST	46	Sequence 97 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16255	ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL	54	Sequence 98 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16256	GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT	53	Sequence 99 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16257	GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP	70	Sequence 100 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16258	YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT	56	Sequence 101 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16259	PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED	35	Sequence 118 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16260	TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF	47	Sequence 120 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16261	IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	42	Sequence 121 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16262	VSKGYSALRTGWYTSVITIELSNIKEN	27	Sequence 122 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16263	AFIRKSDELLHNV	13	Sequence 123 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16264	YTSVITIELSNIKENKXNGTDAKVKLIKQELDKYK	35	Sequence 124 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16265	TSVITIELSNIKENKXNGTDAKVKLIKQELDKYKN	35	Sequence 125 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16266	SVITIELSNIKENKXNGTDAKVKLIKQELDKYKNA	35	Sequence 126 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16267	SNIKENKXNGTDAKVKLIKQELDKYKNAVTELQLL	35	Sequence 127 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16268	KENKXNGTDAKVKLIKQELDKYKNAVTELQLLMQS	35	Sequence 128 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16269	AVSKGYLSALRTGWYTSVITIELSNIKENKXNGTDA	36	Sequence 129 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16270	VVSLSNGVSVLTSKVLDLKNYIDKQLL	27	Sequence 130 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16271	LLSTNKAVVSLSNGVSVLTSKVLDLKNY	28	Sequence 131 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16272	VLHLEGEVNKIKSALLSTNKAVVSLSNG	28	Sequence 132 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16273	ASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGV	37	Sequence 134 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16274	VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSK	35	Sequence 135 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16275	NDQKKLMSNNVQIVRQQSYSIMSIIKEE	28	Sequence 136 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16276	SISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVS	36	Sequence 137 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16277	PIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR	35	Sequence 138 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16278	RMKQLEDKVEELLSKLAFIRKSDELLHNV	29	Sequence 139 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16279	AFIRKSDELLHNVNAGKST	19	Sequence 140 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16280	FDASISQVNEKINQSLAFI	19	Sequence 141 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16281	SLAFIRKSDELLHNVNAGKST	21	Sequence 142 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16282	FDASISQVNEKINQSLAFIRKSDELLHNVNAGK	33	Sequence 143 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16283	ASISQVNEKINQSLAFIRKSDELLHNVNAGKST	33	Sequence 144 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16284	FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST	35	Sequence 145 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16285	ATSAQITAAVALVEAKQARSDIEKLKEA	28	Sequence 146 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16286	AAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSS	35	Sequence 147 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16287	IRDTNKAVQSVQSSIGNLIVAIKSVQDY	28	Sequence 149 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16288	AVQSVQSSIGNLIVAIKSVQDYVNKEIV	28	Sequence 150 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16289	LKEAIRDTNKAVQSVQSSIGNLIVAIKS	28	Sequence 151 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16290	EWIRRSNQKLDSI	13	Sequence 152 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16291	IDISIELNKAKSDLEESKEWIKKSNQKLDSIGNWH	35	Sequence 153 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16292	RMKQLEDKVEELLSKLEWIRRSNQKLDSI	29	Sequence 154 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16293	DQQIKQYKRLLDRLIIPLYDGLRQKDVIVSNQESN	35	Sequence 155 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16294	YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI	36	Sequence 156 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16295	TSITLQVRLPLLTRLLNTQIYRVDSISYNIQNREWY	36	Sequence 157 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16296	NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEEQNQQEKNEQELLELDKWASLWNWF	57	Sequence 158 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16297	WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE	35	Sequence 159 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16298	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI	49	Sequence 160 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16299	EAAAREAAAREAAARLELDKWASLWNWF	28	Sequence 161 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16300	RMKQLEDKVEELLSKLELDKWASLWNWF	28	Sequence 162 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16301	FWNWLSAWKDLELKSLLEEVKDELQKMR	28	Sequence 163 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16302	RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF	35	Sequence 164 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16303	FWNWLSAWKDLELYPGSLELDKWASLWNWF	30	Sequence 165 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16304	CLELDKWASLWNWFC	15	Sequence 166 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16305	CLELDKWASLANWFC	15	Sequence 167 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16306	CLELDKWASLWNFFC	15	Sequence 168 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16307	LELDKWASLANAF	13	Sequence 169 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16308	LELDKWASLFNFF	13	Sequence 170 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16309	LELDKWASLWNAF	13	Sequence 171 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16310	LELDKWASLWNWA	13	Sequence 172 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16311	LELDKWASAWNWF	13	Sequence 173 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16312	LELDKAASLWNWF	13	Sequence 174 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16313	LKLDKWASLWNWF	13	Sequence 175 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16314	LELKKWASLWNWF	13	Sequence 176 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16315	CGGYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	39	Sequence 177 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16316	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF	36	Sequence 178 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16317	YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF	36	Sequence 179 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16318	YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF	36	Sequence 180 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16319	YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF	36	Sequence 181 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16320	YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF	36	Sequence 182 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16321	YTSLIQSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 183 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16322	YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF	36	Sequence 184 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16323	YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF	36	Sequence 185 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16324	YTSLIHSLIEQSQNQQEKNEQELLELDKWASLWNWF	36	Sequence 186 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16325	YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 187 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16326	YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF	36	Sequence 188 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16327	YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA	36	Sequence 189 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16328	YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF	36	Sequence 191 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16329	YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF	36	Sequence 192 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16330	YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF	36	Sequence 193 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16331	YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF	36	Sequence 194 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16332	YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF	36	Sequence 195 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16333	YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF	36	Sequence 196 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16334	YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF	36	Sequence 197 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16335	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF	36	Sequence 198 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16336	LLDNFESTWEQSKELWEQQEISIQNLHKSALQEYWN	36	Sequence 199 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16337	LSNLLQISNNSDEWLEALEIEHEKWKLTQWQSYEQF	36	Sequence 200 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16338	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWG	63	Sequence 201 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16339	SELEIKRYKNRVASRKCRAKFQLLQHYREVAAAKSSENDRLRLLL	45	Sequence 202 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16340	ASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS	45	Sequence 203 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16341	LLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSI	35	Sequence 204 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16342	LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHED	45	Sequence 205 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16343	SSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDL	35	Sequence 206 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16344	SENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF	37	Sequence 207 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16345	PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP	46	Sequence 208 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16346	PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTSTGPCRTCMTT	57	Sequence 209 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16347	VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV	35	Sequence 210 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16348	DEFDASISQVNEKINQSLAFIRKSDELL	28	Sequence 211 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16349	IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK	35	Sequence 212 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16350	INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS	35	Sequence 213 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16351	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE	35	Sequence 214 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16352	YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL	35	Sequence 215 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16353	DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	35	Sequence 216 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16354	PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH	35	Sequence 217 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16355	LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN	35	Sequence 218 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16356	VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV	35	Sequence 219 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16357	FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN	35	Sequence 220 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16358	PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA	35	Sequence 221 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16359	SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG	35	Sequence 222 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16360	DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK	35	Sequence 223 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16361	EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS	35	Sequence 224 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16362	DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT	35	Sequence 226 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16363	FDASISQVNEKINQSLAFIRKSDELLHNVNA	31	Sequence 227 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16364	FDASISQVNEKINQSLAFIRKSDELLHNV	29	Sequence 228 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16365	FDASISQVNEKINQSLAFIRKSDELLH	27	Sequence 229 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16366	FDASISQVNEKINQSLAFIRKSDEL	25	Sequence 230 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16367	ISQVNEKINQSLAFIRKSDELLHNVNAGKST	31	Sequence 231 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16368	QVNEKINQSLAFIRKSDELLHNVNAGKST	29	Sequence 232 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16369	GRKKRRQRRRPLAALPLVLAAPLAVLA	27	Sequence 30 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16370	YGRKKRRQRRRPLAALPLVLAAPLAVLA	28	Sequence 31 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16371	LAALPLVLAAPLAVLAPGRKKRRQRRRC	28	Sequence 32 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16372	LVLAAPLAVLAPGRKKRRQRRRC	23	Sequence 33 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16373	LAVLAPGRKKRRQRRRC	17	Sequence 34 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16374	GRKKRRQRRRC	11	Sequence 35 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16375	GRKKRRQRRR	10	Sequence 36 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16376	GRXXRRQRRRC	11	Sequence 40 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16377	GRKKRRQXXRC	11	Sequence 41 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16378	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI	60	Sequence 1 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16379	NNLLRAIEAQQHLLQLTVWGIKQLQARILAV	31	Sequence 34 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16380	NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC	41	Sequence 35 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16381	CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC	44	Sequence 36 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16382	LSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV	39	Sequence 37 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16383	YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF	36	Sequence 40 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16384	WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKL	36	Sequence 42 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16385	DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	42	Sequence 43 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16386	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	48	Sequence 44 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16387	NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK	42	Sequence 45 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16388	WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF	46	Sequence 46 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16389	NNMTWQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF	50	Sequence 47 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16390	WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF	36	Sequence 48 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16391	WQEWDREISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF	46	Sequence 49 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16392	WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLEWEW	40	Sequence 50 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16393	WQEWDREITALLEQAQIQQEKNEYELQKLDKWASLWNWF	39	Sequence 51 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16394	WQEWDREITALLEQAQIQQEKNEYELQKLDEWASLWEWF	39	Sequence 52 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16395	WQEWDREITALLEQAQIQQEKNEYELQKLDEWEWF	35	Sequence 53 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16396	WQEWEREITALLEQAQIQQEKIEYELQKLIEWEWF	35	Sequence 54 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16397	WQEWEREITALLEQAQIQQEKNEYELQKLIEWEWF	35	Sequence 55 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16398	WQEWEREITALLEQAQIQQEKIEYELQKLDEWEWF	35	Sequence 56 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16399	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF	39	Sequence 57 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16400	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF	39	Sequence 58 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16401	WQEWEQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF	39	Sequence 59 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16402	WQEWEQKITALLEQAQIQQEKIEYELQKLIEWEWF	35	Sequence 60 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16403	NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLI	36	Sequence 75 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16404	NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN	36	Sequence 76 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16405	KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ	36	Sequence 77 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16406	SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ	36	Sequence 78 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16407	LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE	36	Sequence 79 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16408	EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK	36	Sequence 80 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16409	QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN	36	Sequence 81 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16410	IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE	36	Sequence 82 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16411	WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ	36	Sequence 83 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16412	NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE	36	Sequence 84 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16413	NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL	36	Sequence 85 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16414	TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE	36	Sequence 87 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16415	MEWDREINNYTSLIHSLIEESQNQQEKNEQELLED	35	Sequence 89 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16416	EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK	36	Sequence 90 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16417	WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW	36	Sequence 91 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16418	NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW	36	Sequence 92 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16419	TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN	36	Sequence 93 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16420	SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI	36	Sequence 94 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16421	LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT	36	Sequence 95 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16422	KSLEQIWNNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE	43	Sequence 96 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16423	NNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE	36	Sequence 97 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16424	EWEREIDNYTSLIYSLIEESQNQQEKNEQE	30	Sequence 98 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16425	SLEQIWNNMTWMEWEREIDNYTSLIYSLI	29	Sequence 99 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16426	LTWQEWDREINNYTSLIYSLIEESQNQQEENEQELL	36	Sequence 114 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16427	SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELL	44	Sequence 1 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16428	WEEWDREINNYTKLIHELIEESQNQQEKNEQELL	34	Sequence 2 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16429	WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	34	Sequence 5 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16430	WQEWERKVDFLEENITALLEEAQIQQEKNMYELQ	34	Sequence 6 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16431	WEEWDREINNYTKLIHELIEESQNQQEENEQELL	34	Sequence 7 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16432	SLEQIWNNMTWEEWDREINNYTXLIHELIEESQNQQEKNEQELL	44	Sequence 8 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16433	SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELLX	45	Sequence 9 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16434	WEEWDREINNYTXLIHELIEESQNQQEKNEWELL	34	Sequence 10 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16435	WEEWDREINNYTELIHELIEESQNQQEKNEQELLX	35	Sequence 11 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16436	WQEWEQKITALLXQAQIQQEKNEYELQKLDKWASLWEWF	39	Sequence 12 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16437	WQEWEQKITALIEQAQIQQEKNEYELQKLDKWASLWEWFX	40	Sequence 13 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16438	WEEWDREINNYTXLIHELIEESQNQQEENEQELL	34	Sequence 14 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16439	WEEWDREINNYTKLIHELIEESQNQQEENEQELLX	35	Sequence 15 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16440	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 2 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16441	YTSVITIELSNIKENKCNGDAKVKLIKQELDKYK	34	Sequence 14 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16442	TSVITIELSNIKENKCNGDAKVKLIKQELDKYKN	34	Sequence 15 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16443	VITIELSNIKENKCNGDAKVKLIKQELDKYKNAV	34	Sequence 16 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16444	VITIELSNIKENKMNGDAKVKLIKQELDKYKNAV	34	Sequence 17 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16445	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW	35	Sequence 87 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16446	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN	34	Sequence 88 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16447	YTSLIHSLIEESQNQQEKNEQELLELDKWASLW	33	Sequence 89 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16448	YTSLIHSLIEESQNQQEKNEQELLELDKWASL	32	Sequence 90 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16449	YTSLIHSLIEESQNQQEKNEQELLELDKWAS	31	Sequence 91 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16450	YTSLIHSLIEESQNQQEKNEQELLELDKWA	30	Sequence 92 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16451	YTSLIHSLIEESQNQQEKNEQELLELDKW	29	Sequence 93 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16452	YTSLIHSLIEESQNQQEKNEQELLELDK	28	Sequence 94 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16453	YTSLIHSLIEESQNQQEKNEQELLELD	27	Sequence 95 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16454	YTSLIHSLIEESQNQQEKNEQELLEL	26	Sequence 96 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16455	YTSLIHSLIEESQNQQEKNEQELLE	25	Sequence 97 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16456	YTSLIHSLIEESQNQQEKNEQELL	24	Sequence 98 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16457	YTSLIHSLIEESQNQQEKNEQEL	23	Sequence 99 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16458	YTSLIHSLIEESQNQQEKNEQE	22	Sequence 100 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16459	YTSLIHSLIEESQNQQEKNEQ	21	Sequence 101 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16460	YTSLIHSLIEESQNQQEKNE	20	Sequence 102 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16461	YTSLIHSLIEESQNQQEKN	19	Sequence 103 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16462	YTSLIHSLIEESQNQQEK	18	Sequence 104 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16463	YTSLIHSLIEESQNQQE	17	Sequence 105 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16464	YTSLIHSLIEESQNQQ	16	Sequence 106 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16465	YTSLIHSLIEESQNQ	15	Sequence 107 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16466	YTSLIHSLIEESQN	14	Sequence 108 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16467	YTSLIHSLIEESQ	13	Sequence 109 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16468	YTSLIHSLIEES	12	Sequence 110 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16469	YTSLIHSLIEE	11	Sequence 111 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16470	YTSLIHSLIE	10	Sequence 112 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16471	YTSLIHSLI	9	Sequence 113 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16472	YTSLIHSL	8	Sequence 114 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16473	YTSLIHS	7	Sequence 115 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16474	YTSLIH	6	Sequence 116 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16475	TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	35	Sequence 117 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16476	SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	34	Sequence 118 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16477	LIHSLIEESQNQQEKNEQELLELDKWASLWNWF	33	Sequence 119 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16478	IHSLIEESQNQQEKNEQELLELDKWASLWNWF	32	Sequence 120 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16479	HSLIEESQNQQEKNEQELLELDKWASLWNWF	31	Sequence 121 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16480	SLIEESQNQQEKNEQELLELDKWASLWNWF	30	Sequence 122 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16481	LIEESQNQQEKNEQELLELDKWASLWNWF	29	Sequence 123 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16482	IEESQNQQEKNEQELLELDKWASLWNWF	28	Sequence 124 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16483	EESQNQQEKNEQELLELDKWASLWNWF	27	Sequence 125 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16484	ESQNQQEKNEQELLELDKWASLWNWF	26	Sequence 126 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16485	SQNQQEKNEQELLELDKWASLWNWF	25	Sequence 127 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16486	QNQQEKNEQELLELDKWASLWNWF	24	Sequence 128 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16487	NQQEKNEQELLELDKWASLWNWF	23	Sequence 129 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16488	QQEKNEQELLELDKWASLWNWF	22	Sequence 130 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16489	QEKNEQELLELDKWASLWNWF	21	Sequence 131 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16490	EKNEQELLELDKWASLWNWF	20	Sequence 132 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16491	KNEQELLELDKWASLWNWF	19	Sequence 133 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16492	NEQELLELDKWASLWNWF	18	Sequence 134 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16493	EQELLELDKWASLWNWF	17	Sequence 135 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16494	QELLELDKWASLWNWF	16	Sequence 136 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16495	ELLELDKWASLWNWF	15	Sequence 137 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16496	LLELDKWASLWNWF	14	Sequence 138 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16497	LELDKWASLWNWF	13	Sequence 139 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16498	ELDKWASLWNWF	12	Sequence 140 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16499	LDKWASLWNWF	11	Sequence 141 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16500	DKWASLWNWF	10	Sequence 142 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16501	KWASLWNWF	9	Sequence 143 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16502	WASLWNWF	8	Sequence 144 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16503	ASLWNWF	7	Sequence 145 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16504	SLWNWF	6	Sequence 146 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16505	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKD	37	Sequence 147 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16506	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLK	36	Sequence 148 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16507	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYL	35	Sequence 149 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16508	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERY	34	Sequence 150 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16509	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVER	33	Sequence 151 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16510	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVE	32	Sequence 152 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16511	NNLLRAIEAQQHLLQLTVWQIKQLQARILAV	31	Sequence 153 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16512	NNLLRAIEAQQHLLQLTVWQIKQLQARILA	30	Sequence 154 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16513	NNLLRAIEAQQHLLQLTVWQIKQLQARIL	29	Sequence 155 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16514	NNLLRAIEAQQHLLQLTVWQIKQLQARI	28	Sequence 156 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16515	NNLLRAIEAQQHLLQLTVWQIKQLQAR	27	Sequence 157 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16516	NNLLRAIEAQQHLLQLTVWQIKQLQA	26	Sequence 158 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16517	NNLLRAIEAQQHLLQLTVWQIKQLQ	25	Sequence 159 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16518	NNLLRAIEAQQHLLQLTVWQIKQL	24	Sequence 160 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16519	NNLLRAIEAQQHLLQLTVWQIKQ	23	Sequence 161 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16520	NNLLRAIEAQQHLLQLTVWQIK	22	Sequence 162 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16521	NNLLRAIEAQQHLLQLTVWQI	21	Sequence 163 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16522	NNLLRAIEAQQHLLQLTVWQ	20	Sequence 164 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16523	NNLLRAIEAQQHLLQLTVW	19	Sequence 165 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16524	NNLLRAIEAQQHLLQLTV	18	Sequence 166 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16525	NNLLRAIEAQQHLLQLT	17	Sequence 167 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16526	NNLLRAIEAQQHLLQL	16	Sequence 168 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16527	NNLLRAIEAQQHLLQ	15	Sequence 169 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16528	NNLLRAIEAQQHLL	14	Sequence 170 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16529	NNLLRAIEAQQHL	13	Sequence 171 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16530	NNLLRAIEAQQH	12	Sequence 172 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16531	NNLLRAIEAQQ	11	Sequence 173 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16532	NNLLRAIEAQ	10	Sequence 174 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16533	NNLLRAIEA	9	Sequence 175 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16534	NNLLRAIE	8	Sequence 176 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16535	NNLLRAI	7	Sequence 177 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16536	NNLLRA	6	Sequence 178 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16537	NLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	37	Sequence 179 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16538	LLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	36	Sequence 180 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16539	LRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	35	Sequence 181 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16540	RAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	34	Sequence 182 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16541	AIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	33	Sequence 183 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16542	IEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	32	Sequence 184 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16543	EAQQHLLQLTVWQIKQLQARILAVERYLKDQ	31	Sequence 185 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16544	AQQHLLQLTVWQIKQLQARILAVERYLKDQ	30	Sequence 186 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16545	QQHLLQLTVWQIKQLQARILAVERYLKDQ	29	Sequence 187 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16546	QHLLQLTVWQIKQLQARILAVERYLKDQ	28	Sequence 188 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16547	HLLQLTVWQIKQLQARILAVERYLKDQ	27	Sequence 189 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16548	LLQLTVWQIKQLQARILAVERYLKDQ	26	Sequence 190 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16549	LQLTVWQIKQLQARILAVERYLKDQ	25	Sequence 191 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16550	QLTVWQIKQLQARILAVERYLKDQ	24	Sequence 192 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16551	LTVWQIKQLQARILAVERYLKDQ	23	Sequence 193 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16552	TVWQIKQLQARILAVERYLKDQ	22	Sequence 194 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16553	VWQIKQLQARILAVERYLKDQ	21	Sequence 195 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16554	WQIKQLQARILAVERYLKDQ	20	Sequence 196 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16555	QIKQLQARILAVERYLKDQ	19	Sequence 197 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16556	IKQLQARILAVERYLKDQ	18	Sequence 198 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16557	KQLQARILAVERYLKDQ	17	Sequence 199 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16558	QLQARILAVERYLKDQ	16	Sequence 200 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16559	LQARILAVERYLKDQ	15	Sequence 201 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16560	QARILAVERYLKDQ	14	Sequence 202 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16561	ARILAVERYLKDQ	13	Sequence 203 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16562	RILAVERYLKDQ	12	Sequence 204 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16563	ILAVERYLKDQ	11	Sequence 205 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16564	LAVERYLKDQ	10	Sequence 206 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16565	AVERYLKDQ	9	Sequence 207 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16566	VERYLKDQ	8	Sequence 208 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16567	ERYLKDQ	7	Sequence 209 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16568	RYLKDQ	6	Sequence 210 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16569	LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW	35	Sequence 211 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16570	LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTN	34	Sequence 212 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16571	LEANISQSLEQAQIQQEKNMYELQKLNSWDVFT	33	Sequence 213 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16572	LEANISQSLEQAQIQQEKNMYELQKLNSWDVF	32	Sequence 214 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16573	LEANISQSLEQAQIQQEKNMYELQKLNSWDV	31	Sequence 215 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16574	LEANISQSLEQAQIQQEKNMYELQKLNSWD	30	Sequence 216 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP17299	GLFRALLRLLRSLWRLLLRA	20	Sequence 20 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17300	CPGPEGAGCLLIILRRRIRKQAHAHSK	27	Sequence 21 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17301	CREKALLIILRRRIRKQAHAHSK	23	Sequence 22 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17302	AREKA	5	Sequence 23 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17303	CAEKA	5	Sequence 24 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17304	CRAKA	5	Sequence 25 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17305	CREAA	5	Sequence 26 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17306	LALLALTSAV	10	Sequence 3 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17307	ALLALTSAV	9	Sequence 4 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17308	ALLALTSAVA	10	Sequence 5 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17309	LLALTSAVA	9	Sequence 6 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17310	NAQCQETIRV	10	Sequence 7 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17311	AQCQETIRV	9	Sequence 8 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17312	MQHRGFLLLTLLALL	15	Sequence 9 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17313	RGFLLLTLLALLALT	15	Sequence 10 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17314	LTLLALLALTSAV	13	Sequence 11 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17315	LTLLALLALTSAVA	14	Sequence 12 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17316	LTLLALLALTSAVAK	15	Sequence 13 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17317	LLALTSAVAKKKDKV	15	Sequence 14 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17318	ARYNAQCQETIRVTK	15	Sequence 15 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17319	KXVAAWTLKAA	11	Sequence 16 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17320	AQTQRIRCRV	10	Sequence 17 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17321	TSAVAKKKDKVKKGG	15	Sequence 18 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17322	KDKVKKGGPGSECAE	15	Sequence 19 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17323	AEWAWGPCTPSSKDC	15	Sequence 20 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17324	CGVGFREGTCGAQ	13	Sequence 21 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17325	QTQRIRCRVPCNWKK	15	Sequence 22 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17326	CRVPCNWKKEFGADC	15	Sequence 23 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17327	CNWKKEFGADCKYKF	15	Sequence 24 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17328	KEFGADCKYKFENWG	15	Sequence 25 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17329	CKYKFENWGACDGGT	15	Sequence 26 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17330	ENWGACDGGTGTKVR	15	Sequence 27 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17331	GTKVRQGTLKKARYN	15	Sequence 28 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17332	GTLKKARYNAQCQET	15	Sequence 29 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17333	ETIRVTKPCTPKTKA	15	Sequence 30 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17334	PKYVKQNTLKLAT	13	Sequence 31 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17335	EAEQLRAYLDGTGVE	15	Sequence 32 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17336	AKTIAYDEEARRGLE	15	Sequence 33 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17337	TERVRLVTRHIYNREE	16	Sequence 34 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17338	AAYAAAKAAALAA	13	Sequence 35 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17339	ESWGAVWRIDTPDKLTGPFT	20	Sequence 36 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17340	EKKYFAATQFEPLAARL	17	Sequence 37 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17341	AGDLLAIETDKATI	14	Sequence 38 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17342	LTLGEFLKL	9	Sequence 39 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17343	ELTLGEFLKL	10	Sequence 40 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17344	AYACNTSTL	9	Sequence 41 from Patent US 20110159022	Synthetic construct	Anticancer	US 2011/0159022 A1	Patent Application	2011##6##30	CA2728459A1, CN102123731A, EP2296697A1, WO2009153463A1	Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.	A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
DRAMP17345	KLLLKLLKKLLKLLKKK	17	Sequence 1 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17346	YHWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK	32	Sequence 2 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17348	MQLPLAT	7	Sequence 5 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17349	YHWYGYTPQNVI	12	Sequence 7 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17350	YRWYGYTPQNVI	12	Sequence 9 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17351	YKWYGYTPQNVI	12	Sequence 10 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17352	FLKLLKKLAAKLF	13	Sequence 11 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17353	RLLRRLLRRLLRRLLRRLLR	20	Sequence 12 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17354	RLLRRLLRRLLRK	13	Sequence 13 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17355	YRWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK	32	Sequence 14 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17356	YCDGFYACYMDVGGGKLLLKLLKKLLKLLKKK	32	Sequence 15 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17357	WHSDMEWWYLLGGGGKLLLKLLKKLLKLLKKK	32	Sequence 16 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17358	THRPPMWSPVWPGGGKLLLKLLKKLLKLLKKK	32	Sequence 17 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17359	KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK	33	Sequence 18 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17360	KDLLLHLKKLFREGQFNGGGKLLLKLLKKLLKLLKKK	37	Sequence 19 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17361	NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKLLKKK	35	Sequence 20 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17362	YHWYGYTPQNVIGGGGGRLLRRLLRRLLRK	30	Sequence 21 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17363	CGRRAGGSC	9	Sequence 22 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17364	RQIKIQFQNRRMKWKKKAYARIGNSYFK	28	Sequence 25 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17365	KQLIRFLKRLDRN	13	Sequence 26 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17366	KDLLLHLKKLFREGQFN	17	Sequence 28 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17367	NYQWVPYQGRVPYPR	15	Sequence 29 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17368	YCDGFYACYMDV	12	Sequence 30 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17369	WHSDMEWWYLLG	12	Sequence 31 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17370	VEPNCDIHVMWEWECFERL	19	Sequence 32 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17371	GGNECDAIRMWEWECFERL	19	Sequence 33 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17372	THRPPMWSPVWP	12	Sequence 34 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17373	CQKHHNYLC	9	Sequence 35 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17374	ATWLPPR	7	Sequence 36 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17375	EWLS	4	Sequence 37 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17376	SNEW	4	Sequence 38 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17377	WDLAWMFRLPVG	12	Sequence 39 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17378	CTVALPGGYVRVC	13	Sequence 40 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17379	LKLLKKLLKKLLKLL	15	Sequence 41 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17380	YHWYGYTPQNVIGGGLKLLKKLLKKLLKLL	30	Sequence 42 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17381	LLKLLKKLLKKLLKL	15	Sequence 45 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17382	NYQWVPYQGRVPYPRGGLLKLLKKLLKKLLKL	32	Sequence 46 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17383	GRVPYPRGGLLKLLKKLLKKLLKL	24	Sequence 47 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17384	ATWLPPRGGGKLLLKLLKKLLKLLKKK	27	Sequence 51 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17385	LLGPYELWELSH	12	Sequence 52 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17386	ALVRYKDPLFVWGFL	15	Sequence 53 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17387	KCCYSL	6	Sequence 54 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17388	WTGWCLNPEESTWGFCTGSF	20	Sequence 55 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17389	DTDMCWWWSREFGWECAGAG	20	Sequence 56 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17390	MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE	86	Sequence 57 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17391	RQIKIQFQNRRMKWKK	16	Sequence 58 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17392	KAYARIGNSYFK	12	Sequence 59 from Patent US 20110319336	Synthetic construct	Anticancer	US 2011/0319336 A1	Patent Application	2011##12##29	CN102238965A, EP2370107A2, WO2010064207A2, WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP17393	LFGRAP	6	Sequence 2 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17394	KAMQDAEVSKSDIGEVI	17	Sequence 3 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17395	KAMQDAEVSKSDIGEVIC	18	Sequence 4 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17396	QDLFGRAPSKAVNPDEA	17	Sequence 5 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17397	CQDLFGRAPSKAVNPDEA	18	Sequence 6 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17398	KAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAV	50	Sequence 7 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17399	EVILVG	6	Sequence 8 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17400	DLFGR	5	Sequence 9 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17401	EVILVGGMT	9	Sequence 10 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17402	DLFGRAP	7	Sequence 11 from Patent US 20120302729	Synthetic construct	Anticancer	US 2012/0302729 A1	Patent Application	2012##11##29	EP2511371A1, EP2511371A4	Anticancer anti-mortalin peptide antibody.	The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and â€
DRAMP17403	TAWYANFEKLLR	12	Sequence 1 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17404	WYANFEKLLR	10	Sequence 2 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17405	TAXYANFEKLLR	12	Sequence 3 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17406	XYANFEKLLR	10	Sequence 5 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17407	TAWYANXEKLLR	12	Sequence 7 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17408	WYANXEKLLR	10	Sequence 9 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17409	TAWYANFEKLXR	12	Sequence 11 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17410	WYANFEKLXR	10	Sequence 12 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17411	TAXYANXEKLLR	12	Sequence 13 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17412	XYANXEKLLR	10	Sequence 19 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17413	TAWYANXEKLXR	12	Sequence 23 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17414	WYANXEKLXR	10	Sequence 25 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17415	TAXYANXEKLXR	12	Sequence 27 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17416	XYANXEKLXR	10	Sequence 31 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17417	TNWYANLEKLLR	12	Sequence 35 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17418	WYANLEKLLR	10	Sequence 36 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17419	TNXYANLEKLLR	12	Sequence 37 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17420	XYANLEKLLR	10	Sequence 38 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17421	TNWYANXEKLLR	12	Sequence 39 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17422	TNWYANLEKLXR	12	Sequence 41 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17423	WYANLEKLXR	10	Sequence 42 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17424	TNXYANXEKLLR	12	Sequence 43 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17425	TNWYANXEKLXR	12	Sequence 45 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17426	TNXYANXEKLXR	12	Sequence 47 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17427	DWWPLAFEALLR	12	Sequence 49 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17428	WPLAFEALLR	10	Sequence 50 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17429	DWXPLAFEALLR	12	Sequence 51 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17430	XPLAFEALLR	10	Sequence 52 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17431	DWWPLAXEALLR	12	Sequence 53 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17432	WPLAXEALLR	10	Sequence 54 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17433	DWWPLAFEALXR	12	Sequence 55 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17434	WPLAFEALXR	10	Sequence 56 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17435	DWXPLAXEALLR	12	Sequence 57 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17436	XPLAXEALLR	10	Sequence 58 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17437	DWWPLAXEALXR	12	Sequence 59 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17438	WPLAXEALXR	10	Sequence 60 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17439	DWXPLAXEALXR	12	Sequence 61 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17440	XPLAXEALXR	10	Sequence 62 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17441	TSFAEYWNLLSP	12	Sequence 63 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17442	WYANFEKLLA	10	Sequence 64 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17443	TAWYANFEKLLA	12	Sequence 65 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17444	WYANFEALLR	10	Sequence 66 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17445	TAWYANFEALLR	12	Sequence 67 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17446	WYANFAKLLA	10	Sequence 68 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17447	TAWYANFAKLLA	12	Sequence 69 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17448	WYXNFEKLLX	10	Sequence 70 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17449	TAWYXNFEKLLX	12	Sequence 71 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17450	WYXNFEXLLR	10	Sequence 72 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17451	TAWYXNFEXLLR	12	Sequence 73 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17452	DWWPXAFEXLLR	12	Sequence 74 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17453	DWWPXAFEALLX	12	Sequence 75 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17454	DWWPLXFEXLLR	12	Sequence 76 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17455	DWWPLXFEALLX	12	Sequence 77 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17456	DWWPLAFXALLX	12	Sequence 78 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17457	DWWPLAFEXLLX	12	Sequence 79 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17458	TAWYAXFEXLLR	12	Sequence 84 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17459	WYAXFEXLLR	10	Sequence 85 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17460	TAWYAXFEKLLX	12	Sequence 86 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17461	WYAXFEKLLX	10	Sequence 87 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17462	TAWYANFXKLLX	12	Sequence 88 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17463	WYANFXKLLX	10	Sequence 89 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17464	TAWYANFEXLLX	12	Sequence 90 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17465	WYANFEXLLX	10	Sequence 91 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17466	DWXPLAFEALXR	12	Sequence 92 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17467	XPLAFEALXR	10	Sequence 93 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17468	DXWPLAFEALLR	12	Sequence 94 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17469	DXWPLAXEALLR	12	Sequence 95 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17470	DXWPLAFEALXR	12	Sequence 96 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17471	DXWPLAXEALXR	12	Sequence 97 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17472	DXXPLAFEALLR	12	Sequence 98 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17473	DXXPLAXEALLR	12	Sequence 99 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17474	DXXPLAFEALXR	12	Sequence 100 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17475	DXXPLAXEALXR	12	Sequence 101 from Patent US 20120328692	Synthetic construct	Anticancer	US 2012/0328692 A1	Patent Application	2012##12##27	Unknown	Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.	The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists.
DRAMP17476	SASRALSDKPLAHVVANPQVEGQLQWL	27	Sequence 1 from Patent US 4529594	Synthetic construct	Antitumor	US 4529594 A	Granted Patent	1985##7##16	DE3462506D1, EP0132125A2, EP0132125A3, EP0132125B1, EP0132125B2	Protein having antitumor activity.	A protein having a polypeptide subunit containing an N-terminal amino acid sequence of Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu. The protein of the present invention is obtained in substantially pure form at high activity recovery, and is excellent in inducing necrosis of tumors with no toxicity upon the normal tissues of the living body. The protein of the present invention is thermally stable and, therefore, when preparation of pharmaceutical compositions is conducted, the protein of the present invention can be stably formulated into compositions.
DRAMP17477	XVXPPVF	7	Sequence 1 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17478	XVXPX	5	Sequence 2 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17479	XVXPPVX	7	Sequence 3 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17480	XVXPPVH	7	Sequence 4 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17481	XXXPPVW	7	Sequence 5 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17482	XVXPPXF	7	Sequence 6 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17483	XVXPPIF	7	Sequence 7 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17484	XVXPXVF	7	Sequence 8 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17485	XVXXPVF	7	Sequence 9 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17486	XXPPVF	6	Sequence 11 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17487	XIXPPVF	7	Sequence 12 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17488	XXXPPVF	7	Sequence 13 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17489	XLXPPVF	7	Sequence 14 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17490	XVXPPFF	7	Sequence 15 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17491	XVXPPV	6	Sequence 16 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17492	XVXPPX	6	Sequence 17 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17493	XXXPPV	6	Sequence 19 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17494	XVXXPV	6	Sequence 20 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17495	XVXPXV	6	Sequence 21 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17496	XVXX	4	Sequence 22 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17497	XXXPP	5	Sequence 23 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17498	XXPP	4	Sequence 24 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17499	XVXP	4	Sequence 25 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17500	XXXPX	5	Sequence 26 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17501	XXPPV	5	Sequence 27 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17502	XVPPVF	6	Sequence 28 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17503	XVPP	4	Sequence 29 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17504	XXPX	4	Sequence 30 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17505	XVXPXF	6	Sequence 31 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17506	XXPPX	5	Sequence 32 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17507	XXPXF	5	Sequence 33 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17508	XVXPPXX	7	Sequence 35 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17509	XVXPPLF	7	Sequence 36 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17510	XVXPPVA	7	Sequence 38 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17511	XIXPX	5	Sequence 43 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17512	XVXPXLF	7	Sequence 45 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17513	XVXPXX	6	Sequence 46 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17514	XLXPPX	6	Sequence 47 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17515	XKXPPVF	7	Sequence 49 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17516	XKXPPV	6	Sequence 50 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17517	XKXPP	5	Sequence 51 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17518	XKXPX	5	Sequence 52 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17519	XVXPPVK	7	Sequence 55 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17520	XVXPPVY	7	Sequence 57 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17521	XVXPPI	6	Sequence 58 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17522	XVXPPL	6	Sequence 59 from Patent US 5831002	Synthetic construct	Antitumor	US 5831002 A	Granted Patent	1998##11##3	CA2219818A1, CA2219818C, CA2219819A1, CA2219819C, CN1182153C, CN1182154C, CN1187198A, CN1187199A, DE69623472D1, DE69623472T2, DE69623992D1, DE69623992	Antitumor peptides.	Novel compounds of the formula EQU R.sup.1 R.sup.2 N--CHX-CO-A-B-D-(E).sub.s -(F).sub.t -(G).sub.U -KI in which R.sup.1, R.sup.2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
DRAMP17523	MKVLLLFAVFFCLVQRNSGDIPPGIRNTVCFMQRGHCRLFMCRSGERKGDICSDPWNRCCVSSSIKNR	68	Sequence 2 from Patent US 20040058371	Homo sapiens	Antimicrobial, Antibacterial	US 2004/0058371 A1	Patent Application	2004##3##25	CN1206241C, CN1367180A, DE60239390D1, EP1364963A1, EP1364963A4, EP1364963B1, US6887981, WO2002068463A1	Novel natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof.	The invention provides a novel Bin1b protein, and its encoding polynucleotide. Bin1b protein is a natural antimicrobial peptide and associates to sperm maturation. The invention also discloses the preparation and uses of Bin1b protein and nucleic acid. Bin1b protein is useful to treat various diseases, e.g, urogenital infection. The invention also provides a pharmaceutical composition containing Bin1b protein.
DRAMP17524	GIRNTVCFMQRGHCRLFMCRSGERKGDICSDPWNRCCVSSSIKNR	45	Sequence 3 from Patent US 20040058371	Homo sapiens	Antimicrobial, Antibacterial	US 2004/0058371 A1	Patent Application	2004##3##25	CN1206241C, CN1367180A, DE60239390D1, EP1364963A1, EP1364963A4, EP1364963B1, US6887981, WO2002068463A1	Novel natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof.	The invention provides a novel Bin1b protein, and its encoding polynucleotide. Bin1b protein is a natural antimicrobial peptide and associates to sperm maturation. The invention also discloses the preparation and uses of Bin1b protein and nucleic acid. Bin1b protein is useful to treat various diseases, e.g, urogenital infection. The invention also provides a pharmaceutical composition containing Bin1b protein.
DRAMP17525	XLRKXFRKXXKXIXKLXR	18	Sequence 2 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17526	GLRKKFRKTRKRIQKLGR	18	Sequence 3 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17527	GLRKLFRKLLKLIQKLLR	18	Sequence 4 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17528	KLRKLFRKLLKLIRKLLR	18	Sequence 5 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17529	GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI	43	Sequence 6 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17530	LGRKIGKTGRKVWKAWRE	18	Sequence 7 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17531	TRKRIQKLGRKIGKTGR	17	Sequence 8 from Patent US 20060009374	Synthetic construct	Antimicrobial, Antibacterial	US 2006/0009374 A1	Patent Application	2006##1##12	CA2499783A1, CA2499783C, DE602005012757D1, EP1614691A1, EP1614691B1, US7452856, US8242082, US20090149632	Antibacterial peptide.	The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient. The present invention also p
DRAMP17532	QEKIRVRLSA	10	Sequence 1 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17533	QAKIRVRLSA	10	Sequence 2 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17534	KIRVRLSA	8	Sequence 3 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17536	AKKIRVRLSA	10	Sequence 5 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17537	QKAIRVRLSA	10	Sequence 6 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17538	QKKARVRLSA	10	Sequence 7 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17539	QKKIAVRLSA	10	Sequence 8 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17540	QKKIRARLSA	10	Sequence 9 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17541	QKKIRVALSA	10	Sequence 10 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17542	QKKIRVRASA	10	Sequence 11 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17543	QKKIRVRLAA	10	Sequence 12 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17544	QRKIRVRLSA	10	Sequence 13 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17545	QKRIRVRLSA	10	Sequence 14 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17546	QRRIRVRLSA	10	Sequence 15 from Patent US 20090053151	Synthetic construct	Antimicrobial, Antibacterial	US 2009/0053151 A1	Patent Application	2009##2##26	CA2570396A1, DE602005018374D1, EP1789436A1, EP1789436B1, US8268961, WO2006006195A1, WO2006006195A9, WO2006006195B1	Antibacterial peptides and analogues thereof.	Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic agents and coadjutants against infections caused by strains that are resistant to common antibiotics.
DRAMP17547	KKKKK	5	Sequence 1 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17548	KKKKKKK	7	Sequence 2 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17549	KKKKKKKKK	9	Sequence 3 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17550	KKKKKKKKKKKKKKK	15	Sequence 4 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17551	RVRVR	5	Sequence 5 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17552	RRVVR	5	Sequence 6 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17553	RRVRR	5	Sequence 7 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17554	RRVRVR	6	Sequence 8 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17555	RRVVRR	6	Sequence 9 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17556	RRRVRRR	7	Sequence 10 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17557	RRVRVRR	7	Sequence 11 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17558	RRRVVRRR	8	Sequence 12 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17559	RRVRRVRR	8	Sequence 13 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17560	RRRRVVRRRR	10	Sequence 14 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17561	RRVVRRVVRR	10	Sequence 15 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17562	RWRWR	5	Sequence 16 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17563	RRWWR	5	Sequence 17 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17564	RRWRR	5	Sequence 18 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17565	RRWRWR	6	Sequence 19 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17566	RRWWRR	6	Sequence 20 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17567	RRRWRRR	7	Sequence 21 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17568	RRWRWRR	7	Sequence 22 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17569	RRRWWRRR	8	Sequence 23 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17570	RRWRRWRR	8	Sequence 24 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17571	GKKEKPEKKVKK	12	Sequence 25 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17572	KLTKPKPQAESKKKKK	16	Sequence 26 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17573	KKKKKEGKKQEKMLD	15	Sequence 27 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17574	KKKDKVKK	8	Sequence 28 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17575	KVRQGTLKKAR	11	Sequence 29 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17576	PKTKAKAKAKKGKGKD	16	Sequence 30 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17577	RRRRRRRRR	9	Sequence 31 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17578	RRRRRRRRRRR	11	Sequence 32 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17579	RRRRRRRRRRRRR	13	Sequence 33 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17580	RRRRRRRRRRRRRRR	15	Sequence 34 from Patent US 20100137222	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2010/0137222 A1	Patent Application	2010##6##3	CA2706738A1, CN101641370A, EP2125872A1, WO2008093059A1	Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents.	The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.
DRAMP17581	XRPDKPRPYLPRPRPPRPVR	20	Sequence 1 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17582	XRPDKPRPYLPRPRPPRPV	19	Sequence 2 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17584	RPYLPRPRPPRPVR	14	Sequence 4 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17585	DKGSYLPRPTPPRPIYNR	18	Sequence 5 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17586	XXPXXPRPYLPXPRPPRPXX	20	Sequence 6 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17587	XRPDKPRPYLPRPRPPRPVRX	21	Sequence 7 from Patent US 20100323951	Synthetic construct	Antimicrobial, Antibacterial	US 2010/0323951 A1	Patent Application	2010##12##23	WO2009108347A2, WO2009108347A3	Antibacterial peptides active in systemic infections.	Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.
DRAMP17588	NPSRQERR	8	Sequence 1 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17589	PDENK	5	Sequence 2 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17590	YTRGLPM	7	Sequence 3 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17591	VHTAPK	6	Sequence 4 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17592	LSQKSVK	7	Sequence 5 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17593	MLNERVK	7	Sequence 6 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17594	GKLSNK	6	Sequence 7 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17595	NPSRQQRR	8	Sequence 8 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17596	NPSRQEFF	8	Sequence 9 from Patent US 20110105385	Synthetic construct	Antimicrobial, Antibacterial	US 2011/0105385 A1	Patent Application	2011##5##5	Unknown	Antibacterial lactobacillus GG peptides and methods of use.	The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
DRAMP17597	WTSFFHNIVGYDEPLSKEVLTAYHLKEITDLNELPEHHKKVFETLSAIEYSTVEQALKTFKTNYVEGI	68	Sequence 8 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17598	MEFLKYPSLVNHYAIGKSKRLVNRFDNILWYASEKIHGANASYALSATGEEYFAKRSGIISKDDKQFSMLPECVTSDIREGTKKAFRILS	90	Sequence 9 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17599	MALTMFEKESLQKENARLKRELATLKASQKLGGGLNEKELQKALNSCQRIFKTLNRGKRSLVLSKSAMVASVEYSGSGRSKNL	83	Sequence 13 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17600	VVAQKTYKDCSKTAIREAEKSAWEIMSLENDFRNIHHFLKHGTMKAEDKDNA	52	Sequence 14 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17601	MLNIIVTVISTAAVFKGARNGE	22	Sequence 15 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17602	MVNKKLSDRLTKSIKFSRKKAKKRFIIARVTEEQAYTLRLLKAISKEDEAVCKATNKALLEYGYEEAGGHSYEKAREKFSSLPDVKKWHTNRRTRKR	97	Sequence 16 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17603	MTKNHYKLYVDMKEGTHDYVSATVYSMFDEKVLWLPDIKKPENVADYTDEWKNGLYSYYEKLAISELNDYNATFSHL	77	Sequence 17 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17604	LFFETYYDFQEFLGNYFYGQGYYAFKHDNKEYTISLDISATSEYVRIYISDENNEELQQSYEQETFMDLDREGVEAYLKDEGIEFTDLKHAL	92	Sequence 19 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17605	MENNKAYERLLKEVELLQNDLMDIEDYSEEVYQAFQKVIDELEYIQAS	48	Sequence 20 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17606	MTKQFKNIIATLTILVIALAAASGIATIKAVENANDKAILAERVEALEKTFR	52	Sequence 21 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17607	MIKLSLPNVWKLWKKLSDKQEYDIAVKSNVIGAYLINHEEEAQKEYTEAYKAHKPTLLKKLP	62	Sequence 22 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17608	VRGFSEGYLKGVSGRNLKANLERQVESFVVDLFFIKGNEKPLRNAVAAGLWERWLERLSDSFQID	65	Sequence 23 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17609	MVPNPSYNLINACVNTPLERGKASRAADKRRPLYLWNLFLKGSKEEPSGKVALKLSDVY	59	Sequence 24 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17610	LTWPLFLWYTIRNDKKGVLKAMLERIKGMLRKIRLANGLATA	42	Sequence 25 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17611	MVAGIQKISLSKGKPVKGVNIKTGEEITFQTVSEVISYGFDKSHVASCARGESKTHKGFIWKYV	64	Sequence 26 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17612	MNWKAFRLVSLYYLLALVIAFGLIVVITLVFGASVTIAIGRILGNLIILKVIWDMLHKEYEEAKEDLEK	69	Sequence 28 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17613	LSEKLTKRIILAAVIIAYLITVGIIFGILWLVSLITGWEQLFFYLGVLFLIDLLWETTKYAFIRYNKDKHKTLEEL	76	Sequence 29 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17614	VLKNKVYAGHVWSYTGREFEKGSPLASKKPIKKVFGG	37	Sequence 32 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17615	MLIEEDLGGFLVKLIKEVKSVDVETGLETVYRSAYAASKDLGKYSTSVRNACAKK	55	Sequence 33 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17616	MKLIDATVVLNYIEKTKNELNTTSPANNSKFGKGWDAGFIRGIESIKGLVKDIIIEDEIPLANPSDMIPKK	71	Sequence 34 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17617	MGMNRIKVYTKDACAACKMTKRVLTEAGVSFDEVFVDVRNDTETVEMLRLVGFRSFPVVMLDEDFDTAISGFHPPRLKVFIETVKEEA	88	Sequence 36 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17618	VLYGKKEDLNEEIYSLEREIEDLEGQVYDLENELGSSEETVEELTEEVDTLSERVEELEEIIESMEEWE	69	Sequence 37 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17619	MSKLPFEKELKEACSKPTLTQRETALIELVGKLQNALVDSNWDKLIAEQELEYAEERLTSVVWEKRRLERGDL	73	Sequence 38 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17620	MQEITVEEFKQEEIGEF	17	Sequence 39 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17621	MEGIELDNYYNFLEIGYLEGDQANVETTVYNLTGMLSAKVSDVTESEFEAAVEEVTEAIDNLTNSLEVLSELFTEAKQYLAKEDKKWEDNV	91	Sequence 40 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17622	MLKLLTEERRRQTESYLADEASDRKNKEFSQKQMWAVATALVTGVGSALVTIVKLIMS	58	Sequence 43 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17623	MDVVISIAVVLGGVTTGLVNLVKSMDVVSPKYLPLVSLAIGMVFGLAMSPLLGITLYVGAISGLVAGLSAMGFYELTKTPAE	82	Sequence 44 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17624	MAHEVTKIADLINPEVIGAFLHQKMLDNLVLAPFAEIDRTLQGRPGDTLTLPQWNFIGLAEDLAEGEELQSVKLTAEDRKATVKKGC	87	Sequence 51 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17625	MVLCSDLGIPSSDFWTSTPYEFNGMLRGAYQRQSREASLFLSLVQSKKPVKLEKYQGFELVNETNKPKTTRDMAETMDELDRAAFKEEELSNLFDYFD	98	Sequence 60 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17626	LRVWIEDKVGLLTGYSTEPLEGYKCVNIDPSESLEMLGGMLDFHNYYYDGEKVYRDTNNDFQKFLEEEANKPPEPSKEEMEERLAKLEALLADLL	95	Sequence 67 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17627	LDVPHVYLRDTKDCSKITIGNLPTEPFEVTVSAYREPSDITVGMIPVSFIEGDFDKYYEDFASDITKRLKDMAKLKEDSHKQAVDSINKEKVAEVVMFFE	100	Sequence 69 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17628	MCYDGFIKDLRRGFIMEVWKPVVGFESHYEVSSLGRIRSLDREVYSEKRLIYEIS	55	Sequence 72 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17629	MLKEAVSESLWNAAYEILHTTMATADKVIALVTVYNASNLEESTYAYEAIQDSVNKAICGGAVEDVKWKQFVGSLDSDYKEFFEKV	86	Sequence 75 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17630	MDYSKFKIGDTVMYQGQLCGAGTVINGNTYTVVQLTSKPRYAFIIDEHGNKKLIQMGFNFAKIKEA	66	Sequence 76 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17631	MNVESRNSEKAWNRAIVKAEQEAAKKKMERLAKMRAKSKRK	41	Sequence 79 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17632	MKDTVTISKSEYERLLKAEAFLEALEEAGVDNWEGYAMAFF	41	Sequence 80 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17633	MILRIGFFWRSNSESLHCKSIEYIDMFQCGEEGYYKVVFKINEYTYEEHLPDSAYTAITLINKEEE	66	Sequence 81 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17634	MNLGQLLDTVEYGTRVRLVYYKSTYNSDEYITTFVMSDTLEYTKAYELVEPHIEKRSNYNLCYSRWKIMC	70	Sequence 82 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17635	VETMYTVIYKNAVESEPALEGGSFLTDAPKTDGLKLMTFGTRVF	44	Sequence 83 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17636	VWNQWTLYWTDRETGEEGNFKIPRPNALFIGMPIDIDEYRYTVTAVSTPTKEVWTERIPFDFGTKPPWEHNN	72	Sequence 84 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17637	VAEFLGRTPESVKAKYYELRKQGLLEYPSSINKKWTEEERQYVLDNYGKISNKEMARKLGVKTSQLIQLKWYHTHKK	77	Sequence 86 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17638	MSLLEDAAYVLAFDSCDSRFAVEVVKGRSGNEGKQVEGIFLPVIGYVEESSDEAVTDVFEGIEF	64	Sequence 90 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17639	FEIKKPTKFKSNINLNLKSENVKAGTEFRKASRIGGSYNVRSNIPLTLIDEIYKRIEEEL	60	Sequence 92 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17640	MSFYLSQMNNLKEKIRYEKTSVKLIRESIERIGKPTGEYSLGYTDALKMELLIHQKMLEDAQKELLDLEKERNK	74	Sequence 93 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17641	MTATKELWKPLVFKGIHSDIYEVSSEGLVKKQVD	34	Sequence 94 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17642	MANLLISEKSYYEKLVEAETANEFRMVLIRLINRVVMKVKVPLEVRELFL	50	Sequence 100 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17643	MRQFKKRMYEGKKQRIAEAKKGEWA	25	Sequence 103 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17644	MKQYIKIGAAILILLIGVAVWLIEFILPFVLLKWAL	36	Sequence 104 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17645	MGLLERITYSLFIALVVVLAVGAFFVGVYWLAVWTSGLGGLGTFVAVGIVMFVFTALAVFLGFD	64	Sequence 105 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17646	MANYYVLKRLDDGSGKLHQVKCYKSLDKAIKYAKEMSTFKKTYQVAGQFDMNRLANTGRLI	61	Sequence 108 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17647	MNSLYEQFKEGTLKEGQRFSVTGTIVLIDAEDPALPLKVDIDGEGIKWLKEGAIKYMEPAAEKLYEVSIGGRLLSYYGSDYEEGKWTCFFVEK	93	Sequence 112 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17648	MKKGNGHAFLWRSREEPKDIFVQAFPMSFLEKHFPEVVEIAKESNKEEGGNAL	53	Sequence 113 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17649	MEIKVEQPKEILLEVGWRYTSDWIVNSTTVSVEDNVYAYENACYKVLEELCESIDAKYIDICFVREATENA	71	Sequence 115 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17650	MLREIWDLNYTFKTRGKLMEKLIDRGVGLDGEFLKYLVD	39	Sequence 117 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17651	MNYEEFKKEIESIDYLSVENRYDRVLVYSSLGDYPLVAVSILETGFVDYNWRGHVRARDIPVLTEAVEKFAETPYEERFPKKLLPTYWRKLC	92	Sequence 118 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17652	MRSVFQKNYYLLIGENYVSGITFTYPWLSADCEPEEPIEVTFNEAFPHLFTNRNKEQASKMLDAAKIKHTWEVV	74	Sequence 119 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17653	VLLTELALIFWEEGSVHEVIKRNGTLIIDDDDTLGRGIRNSDDILSYLNLEYPVKNGSSGGRHHEKHWGTHN	72	Sequence 120 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17654	MEVVEEGIMKSTGERITRDNIKEGMKVVCVKSIYESQGYFTVGKEYEVVMGNCGYLGIKDNGRDGFIWDCAIFNEDKFVFEILEEPSEKSFFKSFRK	97	Sequence 121 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17655	MAVMDLSGIVQSLMKTSLSSRFWKSLQKKASLKALESKIRELNNHQQELFQKRDRINKQAIQLGSKARRLEEAKALIEKYI	81	Sequence 122 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17656	LWKALKKELSEQLSEDLTPADITVLNIIPMDKKQSSLITGI	41	Sequence 123 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17657	MEDLFKFACTLVLMTVLISGYVAIQLVIIAVAGTFLPTWAFVIVLGWLVYTNYRVLLKGGEY	62	Sequence 125 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17658	VNTVYQDTQDIYLKAFWICIDRARNRAGVTWTYLQGGDTPRAINGTANPSIKKDFAAYGQA	61	Sequence 126 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17659	MNILNGSEMSRLIYMVECQLADVKCNLAFYQQDSISGSPGIIESLTEDLTELTRIKARLEVMLEQFEKLV	70	Sequence 127 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17660	MDLTAEELTFLACLVENNNEEVQDSINIYKSFDKDAAAKVLEKQLLESIRLASRLREESKKSMLIGGLSIC	71	Sequence 128 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17661	MLIKKEKKAYLFTIYGLHSYPSVIGVDSYSDSVAMERFYKIWRKHYPKHYKTHKEFTVKKFDI	63	Sequence 129 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17662	MIPEGTYLKDSSGLNHYFIEGHIVGVRTGVRGYQTVVWDKELDKNV	46	Sequence 130 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17663	MKKRLEELTPDELQQYA	17	Sequence 131 from Patent US 20120052048	Phage F168/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17664	MNNLTAQDLLDELLELKDQGHALEDYIVVGEPINPYDHYLEFDGWHLDSNTNMIILKG	58	Sequence 133 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17665	MNVLKQYIKEVHSVTPYTEDWTKHDKGFLMVDLTVNCYGSLSRREHLFYVDEWEEAKKKGYYMA	64	Sequence 134 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17666	MKPDYSSIIGKRFIPKKRYPRILMKEVYPTRVFYDFPRVLPWEKAPDIPLRVKFVEFTFIHEGRVEKERYTYYSFFTHFERSG	83	Sequence 138 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17667	MKLVTCPECGGNILEGAPNEYGFECDTCPYPYKEEDLI	38	Sequence 141 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17668	MTKLSSAWLVKFEYRAVKMRAFTSYDKAVTYYNEMVQNIDEQIEESYYETKTTYTDDHKPLLTQFIYWNEDRTFRNILGFVSIKEIELEEN	91	Sequence 144 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17669	MIRKQLLFELEVEVDEPMVGRNGYRTVMQTTRLYAYSLDDAYHAFRENHRYIIKSIKEVEEEINDEIKLSMVSEI	75	Sequence 145 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17670	MRIRKHANKIIGWLFIFLAVLTIVKVIVLGKPLDGFDIVLYVLLQLLYGMEKLSNDE	57	Sequence 146 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17671	MVLTMNKPVRATSEQVVYREEYANGWAVEVIHSLKGFGHIYVENKPYSVAIMKPAENFADYSTVGTAEEVLKLIEEVVEYEEDM	84	Sequence 148 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17672	MTIIDYGSKPLNNCSKNELLDIIQSQLENEVKLIKLIERTTKEVEEEKEVPHYKNYISPEKRSYLEGMERVENIVRNFYGFNNE	84	Sequence 149 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17673	MELMIEGVSRGEFSKQFIKVSQTTEATVDIAVINRTVEVFRPDCVHEQTVTLTKENLDLLVTAIGYTKERMSNHG	75	Sequence 153 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17674	MSKELISCGACNEVFSEMDEVVRLTDDSMYHKDCVTLYSTGYCAFLDDEYLGDTENGEGEPACFFLEEGEYIEEEE	76	Sequence 155 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17675	MANKVSLENLLAMAVTAKEHEMSRHANKMRQLEKTEANIKKRIKELSKEG	50	Sequence 157 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17676	MTKVTVYSKDMCGQCLFLKNMLNGKNIPFDEKNISHDEQALAYLKEKGVSSLPYVEADDGFSFNGVRPDLVKKLEKELGV	80	Sequence 161 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17677	LATRNKIGTYTNDEGNVVVQMAGSKAELLELLSFLNAKYLLEVTDTPEEYQKVFNRLQVETGKNYSVLLLDKVTNKSQESEDFLGDKV	88	Sequence 162 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17678	MEEKVPKPKVLKRVREARGESLRELANMIGVHWSSISYWENGIKEPRVKNRVKLAKLYNIPVEILFEEDNGQELPL	76	Sequence 164 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17679	MKKFYGIISTTTTRTEEYEKKLKNGKTEIRTREVTVPKEITVQSSQPDRLGARKELEAFARKCNGKVTYIGAFA	74	Sequence 165 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17680	MILQILGERKYDCKDSTEEPIVKPFIELIDGVQFLLEQENAFSLLNSKHEEITRVPNSPYEYRTEKEGYKTFVNSVYVLNDEGKTLRRLFERGL	94	Sequence 166 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17681	MYETALVCVLLLQMFVYLMSYYVTRALQYKKLQAELSPLASYKFTFVLYGISIGSLYLFFNGYYIPIVYTVGAIIGILVCLWFTSD	86	Sequence 176 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17682	MDNSKRIIKKIIFITISALVMVTLSKLFSKYVIVEQNAPFQALIGGASCALLSSILFDWYTNKKKKENVENQLKEAISDLQKIKAIIKR	89	Sequence 177 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17683	VSITNKDIKDKRRYIFSQSSKTTTIKRGDKRISSATRICAVCGRPLSKLVLRTGVPTVVVDHISCKISDIVRLNVCEDIRSCYAYSSKKGES	92	Sequence 178 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17684	MLKSEILINKTVTTAFGEVTFDHNGETTDLTVEQQEHLGTKVPYIQYIPDAPKAKEKEATAEKADEAPKKAKKAPAKKTTKSKKEED	87	Sequence 191 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17685	VAKETEKVVKKEVKKEQPKKPKGYVHVDTFLDYAKVLYGLNKYQVAGFRALMAGREYQHEDADFVPFLEKYIGKEVK	77	Sequence 196 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17686	VKYPYLVELYAKHVIRDSGYIENVPPVIYEDVVKRVEEIKREENLTID	48	Sequence 199 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17687	MYPYLSMLYASYVIKDPENYPLEKVPALIREDVEKIVEEMAKKNEKQG	48	Sequence 207 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17688	LPETHRQTSSGALIFKPTIAEQEHKNAMESIKQERTELEKELANVKAIKDELSKELADIKQLKDELSK	68	Sequence 216 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17689	MLIPEFKPPLLYVMGSFSVMLEKHQCSVTFYLREPYLGTSYDKIVKLIKMTYPNYSLTYVGMADNKYKFTLKNKED	76	Sequence 226 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17690	MAKTYQEALATVQSYLESDSVMKETSSISVSFSANWTGEREDYVIDTLTYDIDLRVFSLETAHVVAIGKKLPQDSNEHAELLKRLKKEFKQASKKLRED	99	Sequence 231 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17691	VEQNNTGKYAPFIRLIVMGISFVATGLTTIFGWEPLPFTDEQMNQGLMLVLSVGLAIYNWYKNNAVTSYGKAKEEAGKEVVGTRQDFKNRD	91	Sequence 241 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17692	MNDNKEKCVKQEIRDTYKGYDILLDEENGFFYVSVLDPDGKEIISGFVEADKPIEEYYKELLGKCDQDISFKDLLGFLNGRRDTERTDIRFLKRDSGV	98	Sequence 244 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17693	LILFIFSIITMLSMFLLYLFGMASVALIELGLLMGSQNDITKGAHSLLFTGVTLTVVTEITKQCLLLF	68	Sequence 257 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17694	MSYTKRALEARGYDFDTMSMLEKMNALLELLEEPEFQEQMRKEYEEFSKECATNGE	56	Sequence 259 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17695	MENEKLESYFMKEIAPILDEIEMSEELIKGMENNNPSDMITVSFSKEEVDILLAMLDLELPRLDSGSELFSPNLVREAKLQLIKNKLTSK	90	Sequence 260 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17696	MNEQKKVYAKLTEDEAVFACELGDKIKQIRESQELSRLELAKRAKVDHSTLILIEQGKRLPTLRIMMKLSKALHRELAISFTD	83	Sequence 261 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17697	MRGSLDYYNYLYQTIENRPTEELDVLYDGLYKKAGDLFAIDNFQGVKEGRLILKILKAIREEINSRIDEEIDLYLYNIYDSISDEDKRVNWLYEV	95	Sequence 262 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17698	MSQVSKHGEKRVRERVGVNKSSVDRQFELALERGYRQKELTGRLKKWVVSRVFNSKYPQTCILYNGKCFIVSSEGTLVTVLNIPSNLLKDFAKLSKKRGK	100	Sequence 265 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17699	MDIMDIEFLEEHKQLVKEHVEQELKLMHPLKKLQVMTDWLGDTEDKLSQGDLDYFNDLTETELIEAMDASEIVESYSDVLLDFIDYYNIDLTGLEEQLGV	100	Sequence 266 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17700	MDKAEKVDNIVRQVTGAIIKTTAKVAFIVFVLTFAGILVGYYSYSFLTNAGWFALPMILSVDLLYVAVLLGGLAFIFAEVYKVVLEVKKIVKRGGQL	97	Sequence 267 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17701	MSNKTLEQRVIDANKEINDKLNESSIIRKQIEELEEQEAILLSDVEDLLDYLENIGVDL	59	Sequence 268 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17702	MSKDEKLVEWFVVALMVIVWLLITFSILYTIVSLPFMVHEGDWLGIVRNVLLDIVVLVIGVVATWLQLRFKKGMEE	76	Sequence 271 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17703	MNFHGKVFHDKVFDILSRDYPDWQRYQTEKRPHPNELRKDFAIDSTDSRYEEYVMGEFNVETASGDVKVYAVGIRRVVHKRAEEE	85	Sequence 273 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17704	LNKKETLLNTTVTFLGGTSQSSRPKGKQTLCEMQKSDGSVEFIFDGTVFYVHSMVVVYMANKKHSMQATVSAIDGNYKYAGITFKLKVDYKENTLLLEEI	100	Sequence 276 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17705	MYFVIVVNGQHRTLLKVTGKEWEMSPHTEEAVIEVALDTCYTYIENQEAQKN	52	Sequence 278 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17706	MIGDFILWFKQAWKETFCIHDYTVKGVYKTLDNHGYLKCKKCGRIK	46	Sequence 279 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17707	MNKYKFTYADIKNLSEEEKEKELKNRCGVLAVECLSTKQLQKKKPRFMVFLNTVIFDSTAETGGQYATATVKTEPIGDGRFRVCDGWGQLSNGIIELLK	99	Sequence 284 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17708	MFKRLEEYRKNLSNEELKIFNNTMKLLNDNKTDFQERTKNFDKELQYTELENEKEKILIVLDTIRVSNENYKNVISENLYHSIKEMTIIFELLYNL	96	Sequence 285 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17709	MMNGLKRLMKAKRYKKEVKEIITMQKKAINELETLNKNLKLINQNY	46	Sequence 287 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17710	MTKEELKSYLENYNKPFSTSMDNVFSLFINDVRAVADDFRKGEAFIYTCAELIEEQAETLEKSDLEELEEKSGESLVIQDINGYLYFV	88	Sequence 288 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17711	MIIAENELYLVKNPLNEWDMNYHLIEKETGKDFLIDIGDVADNEEEREKYELGLLFSDLKNLIVDLLIEYSWKTI	75	Sequence 289 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17712	MTEQQFKKEHLLEPTEWRSGGYLDTSLIDQSQSYYIESRPRVYGGCYVYQYVTMKDGTVYELYSMTASTRGIVAHNCHARNVLQRDVKQYRDSAIHY	97	Sequence 290 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17713	MKLSDIILVGLLVSIVLLWGYLSIMICLQVFRALGGWDIRTLTVCSGLLFAYVFGLKGIWEQGTGKSK	68	Sequence 291 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17714	MKLNVIHLLFCLFQEQESYSILSYESIDEFYSRLGYDLESEWLLRDLGINGTSGLAELLTDYNNLLENEITKAVFSDKWL	80	Sequence 292 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17715	MNELECIYDSRKSFYGKANLVEEENGISLYSYDTKVATIYTNGLAKVFGTYSQTTLRHIKEFFKQNGLKADTKKQIEKDYL	81	Sequence 293 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17716	MLKITKEITLGEFEAWEGGKDRLETIKELDILDEAQQEIELMIEGAEEVTEMTINDILWFEMDEFIAQFEEEEEEE	76	Sequence 294 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17717	MTTEEKALNIAENKGITDYKVKGNVLSYYTSYPMEKCTYLVTIDIETLEEERKELKKYYKKGLQNACL	68	Sequence 295 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17718	VAVTINNRIKKLQYERIRKLEKRKRGEPPEFIFNGNYSLEEIELFLHFRKKSEGKK	56	Sequence 296 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17719	MTKTELQYKKAIGVAIFATSEEDKKQLGNVAPFSIYEILEIDLNKNRVYYALNCGERHAVCFTKLRKEEETGDNFILINKQPFFLKDIHKGLTWSKSL	98	Sequence 297 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17720	MKIGKKEELEANNIFNRADELLGAVTMEELERDNGGSIFYADGSPDTVLWHMKKEFSLKPFHCYYFDGWYIALINI	76	Sequence 298 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17721	MKLTEKELNTILRDDETGNGGTAFLGETLADFLEESGIDFTNLTILEVNELLENNGIRPIEVVPC	65	Sequence 301 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17722	MLKNIKKSDKLTRKDIQGFWGDEAKTLEEWYKSISKESDTDKMINTLKEYANNNEFHFVKGEQGQ	65	Sequence 302 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17723	MEQLKGLTIRELIKKLEEVPEENKDLPIYTFENENSLPIKGISLYDENGKHSQENPLSFDVIR	63	Sequence 304 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17724	MKLKEFIKLAESKGATLEAYNELGGYELTRGDIVDQNPVLIAYMQGTHSVEISNEELENKELTELAFVYKNASFIYPNEKELLSGLGL	88	Sequence 306 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17725	MLEVGKFVRGNNGARTWVGQIVGIDRLAGEYRVRDVVTGIYFYVSCSAVYECARP	55	Sequence 307 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17726	VDTVTDIIDVLGIIKQDIEYKGERIKELEGQGKQEQAELLEAEVKGMREVVQDIEQAL	58	Sequence 308 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17727	MNNNKLDELLEEEYSTLDELLDSKEFKKQMNNLNHVPQMQPQSHNSNTLADTGRYPEK	58	Sequence 309 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17728	MTIEQINAEVKQQEMLGNKLEVIQLGNDIYMYINGEPYKTIELI	44	Sequence 310 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17729	MTIEQVKDYGKAYGKELSTKEVKEFFEKHNDMPSLMDLAKFCGAMNEDGTKN	52	Sequence 311 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17730	MTPELAEMNLTKNDSPFSFINESGVFIEPIKNPFSCEGTYLQACKDVAGELETNKEVGNEIDNYLKMQNWLNKLAYEYI	79	Sequence 312 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17731	MKSIIIKQIKDGYKGILERRNNGWADEELNSYTTGVSNTLFELINDLQDNGVISEEEAEEIEEVFSNTIDILNF	74	Sequence 313 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17732	MSRKYRGFDTAFTKDGVCVYVIKDDKEKGTALVRDTRGGDEYTVSNEGMIYTKDMESIDVYMPW	64	Sequence 315 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17733	MEINKAYERLLKEVELLQNDLMDIEDYSEEVYQAFQKVIDELEYVIEEG	49	Sequence 316 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17734	MLNSRGEPLLPINTQVRLNNFTFECNGRGRSPMGRVIGYDNSVCKEFTDYYIVESGDLQGYAHYTNVTEVVLGGT	75	Sequence 317 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17735	MLNIFYNVWGGFISHPVLITLSIVGIYVLGYALVKFIVGIVVLSNSLNTKWVIASAIFTTVLSIVFTIYSFLVEIYVVLVVISGLVVLLT	90	Sequence 318 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17736	MKYLIYATLVVYGLITLLTSYILTYGVYWQLTNELSNPMPWFVIVLCGGIVLVLITAFIILVVNVIQLNKIENQEVNIAIIKEENDG	87	Sequence 321 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17737	MKLKDLIKLMKPGVDVLVTYPTAGATITVRTKIGSNNEVLEPYLDYEIANVSKTNHYIAIDII	63	Sequence 323 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17738	MKVEQGELAITLPQNPEENATATIYFSVDDYGDIAITTTGEEGYTQFDFNFTEEQWAVIVDTISVQLRAQKLSS	74	Sequence 324 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17739	MEKPYVAVRSIHTGRVEYCTEDWLFCGSERNAMPCKEIRYVDMLHCGMESYYEVTFKANQYTYTEELPVYAFTGIKMIEKEES	83	Sequence 325 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17740	MGHLPDDVGSWATHCINLVCDGELLEDKKSQTYTCEDCGEVVTLDELNEHLEKEAESYLKFFGYK	65	Sequence 327 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17741	MSYEITYDSNTSVNIQEKIIAVNNSALYKVCVEKKASRVNEKTEVKYTLEVSSAESQESTKLELPHEVMLRLSELIENSLEF	82	Sequence 329 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17742	MRKINVYIETTWAGIGEIETVEVPDNATNEEIDEVARDVFSSYCSFGWGDVEDEEE	56	Sequence 333 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17743	MIECLMCQVPLEETCGDFYLDEMLCGLCAMHLLLDGIEQSLMMEIYVSELLLEEEENML	59	Sequence 338 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17744	LNKQRENHKEKIKEHTEIIGHIEEKIENILYIPEEEEYNRDLPF	44	Sequence 343 from Patent US 20120052048	Phage F170/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17745	GILLVDSQQALECCALSSQWGSGNNGIHHQA	31	Sequence 344 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17746	MDKGEVADLTAWLEKVKEIQERYPLPEEPK	30	Sequence 346 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17747	MAEVITTVLEMPNTVIATAVGDKIMEADAYRHYLESINVDPRFVLEEYIAMVAEKDQEVWKHV	63	Sequence 350 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17748	MNYYLLYLALGAAWFFVAIGHIFRVPSKQTVERIITPPILISLSFFSTFMFYVFLWPLALLIDIWRRMIKKSTT	74	Sequence 352 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17749	MSLDGQTVAVHIVMFTNYFGYVPGKKQIDHLCGQRLCCNPAHLEMVTHLTNQKRRAKRAKSKE	63	Sequence 355 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17750	MIKHFGGIEEAEAAIASGKAVYGKPTVPKGYILGTDIKGMYVLHKE	46	Sequence 357 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17751	MSKLQDLPVLIDRPGNYVTRDGSRVVIFTVTERPEGYSMLTFDARGSYTRVNNTAKPECWHVSGRLHAFREHRKT	75	Sequence 365 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17752	MQFSDLSPVEQKLYPTHSSLKEALEEARHLLPGGSHHDFMRAMMGYHNTFLLFVGEWTPSE	61	Sequence 367 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17753	MSGDAIAMIVAYFATAIVAAGLFDFVLYDDYDDKADRSVTLGILWPIALPIVFGLTVTKIIKTAWKGFKDLCKYGIK	77	Sequence 368 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17754	MRKSYLKFLDTMAWIVAVLVFVVVAVASLTVYNGLVALFVMLGAAVGIGMTFGFWFLGYGIYEELQKLNARVRA	74	Sequence 373 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17755	MNVAAWLHNGEWHLFTDEMNRVVSDQAYYQAGLKGPDKRDLVLLRMTAKRRNTAYWFHFRKDNPFNKYMPVAYTEEIPKELQALLTIYGL	90	Sequence 375 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17756	MELVVWKDGDNWRVFADDAVPALDGTVDRVAEGLATLYRKEKEPVVFTRRKTAFYDGQYWLMWKYYPTYGRAYGKEASDEMIKEPSAIALLAGY	94	Sequence 376 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17757	VSHYAFYKEDDTWKFVKYGGLLELVQAASMMAYSPKEAAACTCYKLNGVRWWWMGMTDKDAIEDVNLLPADLRAMLVIWSLDQLLE	86	Sequence 377 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17758	MTRTYLKRVVIRDDNGMFVSDGDTLIDALREVKLKNLLKQLTVIDQDDGHRWMFQYSHVNNHIVLTKQSPDCCDGIIRMGDLL	83	Sequence 381 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17759	MPTDLKTPTGGTVTGRLVVDRDYLNKLLEVRKYSDRKIDMVYIDMTALEERVMAHMLDQIPKPVKKSKRRPKWEMPVRNHETNHLGKGPRNKFGGFN	97	Sequence 383 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17760	MALKKSNARTNTAAQSDDTRAASFINISIGTRGGDPVRLGNGIPLRLSEAVEAQLHEYLAEAKDDKDLAKRIENLRSRLILSFRVVRDKSELQLDL	96	Sequence 384 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17761	MIVLITRKATSILDRGYRECLDAESVARELHAIGMSAVTEEDVLNHWADWDNDLSDEPRWV	61	Sequence 385 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17762	VTDVEILNLLCLYIASSVAVLNGYMKWSSNNYTMQQTWMGLVIDILVMHVLTFSGMFALIGAVCIFFNLVGLL	73	Sequence 386 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17763	VIILIMFLLFAVGLSMLVIGLHRQWVINEMLRFPLSISRRHDLEMRRIHAWVMAVCGLGLLFAGCGPLFIFLAGGLL	77	Sequence 387 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17764	MTIVQLLAVIAVLLLVVPTVLSFLRMLVWAAETWVRCETGRGNRGTAAVATVLYGVATWVCAYLFFVVGAYL	72	Sequence 388 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17765	MLTIACIVLIVFCGYLFLVKCLASLTCFGALFVLPGAEKVAAVVGLVWNVFWAAVWVTAINFLFHVA	67	Sequence 389 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17766	MSTNLNLTGRLFDIKIIPTNGKLTGFRVRMTLFNMDCPNTVLTHVVMCGDEYTAKSLKTAILQRRRLNLKHWHWTEVNKDLPGACTNRLKTKPFTLEI	98	Sequence 390 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17767	MMYKYARIKRVRNITVYDIACQCWARDFQYDQCLFLLIQHGFSPIQSLEEFQRVWNMLDQAFADFCNERGCPADPIGFADVRI	83	Sequence 392 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17768	MNTLYHKMQEHVCFVGFTRDGVNYQTNRVRTFGEARHFITFNCSPSDKDIRIFYRIPHEGAEDVEVVIARLDLTETKENN	80	Sequence 393 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17769	MSNPHSVFRVNKCFVRMVTNGELITSPTIHNLEEMRDYNRNNCKPTDTGIRLSYMSETEGCEVVLARFDHNGKVLV	76	Sequence 394 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17770	MDQNIYTLLYTNECLHSIEHEFEAVSDEVARIKATAMCRGQEGLWSGIYLTDPQGEAITFDPF	63	Sequence 395 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17771	MFKALNQFFAMLESMFRAVTNLTKAAENVTEWAEEESAHFNNKARLQREQAIALLNIENAQELQEKGLTEAVESVRKERTKAKA	84	Sequence 396 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17772	MVVVTQDQSTAQPKASLDLEVQTDDWVEVELNKVG	35	Sequence 397 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17773	MKADWVSNLIFALVWSLYVPKPASEEHLWLFHLLHFLFALLLWTAIDVTRYSPEWKEKPVFAFFIFAPMVPMNLYGAMMLLELLWN	86	Sequence 400 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17774	MDISYAHVQMKLKNGKTTSHKVEIPYSLSEVQDDFYSTVAQILNLVRRGTGISVLNVTHSRVLFTAGPNQ	70	Sequence 401 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17775	MQNAQSEKVQQESANSLLTHLKSPEKTELKIDVSDRAADAIDIMRQNAEALARLQQEMIAGKQLSAKDVAERSMDFGEVIEGELA	85	Sequence 404 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17776	MQLIKEYEHAQPLKFKGWQVSEDHEQNVQALQEMLGSFPFITAAFGDNADGERVYSLSNFNEGATLDVKAGEWIFVNEEGSIEGWSAEVGAVRFKEIQA	99	Sequence 407 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17777	MGVLKGLFGAGALAGAVIGILFIGFVFSWIFRILGVVVALFIVLLILCWVGWEWLKYCFSRKKEGEQ	67	Sequence 419 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17778	MGDLSKACMLKNMHVTRVLHLIEMRNKLTNTLRDNATDDGMATLEMFDAALKQETDRFLRALRAVGNENINEIKKAAE	78	Sequence 421 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17779	MAKFLLVGCKGWSALVWTPLRGGGCTRCNGPEHSLMPTGSIDIRKPAGGSWLGLQRHQLREVVNGPLDLGGQGGLGSGIQGPMRW	85	Sequence 422 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17780	MAVNTKKSPPTRNHYENFRKGMKVVTYQRTKGNTLFTVDCDPVEVADLHAC	51	Sequence 423 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17781	MSYGFRFYDANGNVTVDSTNKSFRSVYRQQVFPVLGGTTNLPPGFDASKGDIFFFTWFQLAPNPWPQFVDFGFVNNQIQWYDTYSTSYGKAYLNVVSFR	99	Sequence 436 from Patent US 20120052048	Phage F770/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17782	LNPSNLPDGDGNGGGVYEFGLTKSSRTSLTISNDVYFDLGSQRGSGANANRGTINKIIGVRK	62	Sequence 440 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17783	MLKLISPTFEDIKTWYQLKEYSKEDIAWYVDMEVIDK	37	Sequence 442 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17784	MFGFTKRHEQDWRLTRLEENDKTMFEKFDRIEDSLRTQEKNL	42	Sequence 443 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17785	MDAKVITRYIVLILALVNQFLANKGISPIPVDEESVSSIILTVVALYTTYKDNPTSQEGKWANQKIKEI	69	Sequence 444 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17786	KAESKYRKATGQAPIKEVMTPTNMNDTNDLG	31	Sequence 445 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17787	MLTEGSYSQQKKGNPLCNNQIAGVLKKTTKALNMNKKVTTHTFRHTHITLLVEMNVSLKAIMKRVGHVDEKNNHSHIYSCN	81	Sequence 450 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17788	MWIEKFKNKNNETKYRYYEKYKDPYTDKWKRVSVVLNKNTKQSQKRSNVSFRRKNKRKN	59	Sequence 452 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17789	MTQFLGALLLTGVLGYIPYKYLTMIGLVSEKKQGYQYSCIIDFFLLKHV	49	Sequence 453 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17790	LNGGENFMVDKNKKQETTRSNPLNKSFEKSGASEKLKSTLSEKAKKKRLVFIH	53	Sequence 455 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17791	MPEQLSVRKWRLVRDLKQQEVADILGVNAKTVGHWEKDDTNLSNVTVYALAKLYDIEVDQIKV	63	Sequence 460 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17792	MNEEKLKMILLLLEDIPRDEWNRLVNEVNNQYSYQADKVGLASDNCQQIANNYKHYGF	58	Sequence 461 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17793	VISIHKRLLTQYLDKEIVTSLDLHLINGEVIKVQEHIKDAESKTLHIIHPKDRVVSLDHVLYFDINVKGEKNNDSPYPS	79	Sequence 462 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17794	VKKLYATPTQIHQLFGVCRSTVYNWLKYYRKDNLGVENLYIDYSPTGTLINISKLEEYLIRKHKKMVLGGY	71	Sequence 463 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17795	MSDTYKSYLIAVLCFTVLAIVLMPLLYFTTAWSIAGFASIATFIYYKEYFYEE	53	Sequence 464 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17796	MAENIKTEQHYYTKDFSGYRNEEDNFVANQELTVTITLNEYRKLIEIKAVKDKEEDTYRGKYFEEERKKRKIGKRKYKTKKQNL	84	Sequence 465 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17797	MYYKIGEIKNKIISFNGFEFKVSAMKRHDGISIQIKDMNNVPFKSFHVIDLSELYIAMDAIHDVVNEWIEENTDEQDKLMNLVMKW	86	Sequence 466 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17798	MAILEDIFEELKLLNNNLRVLNTELSTVDSSIVQEKVKEAPMPKEETAQLESIEEVKETSADLTKDYVLSVGKEFLKKSRYF	82	Sequence 467 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17799	MKRLQNFYINCLISKKWADEVEQYALNQAKENDKNYPGWKLVEGRSRRMITDTKAMLEKLVEAGYKPEDITETKLLSITNLEKLIGKKSIF	91	Sequence 469 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17800	LVKKAFSKITEGFIEKPQGKLTLATESDKRPAIKQSAEDDFDKL	44	Sequence 470 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17801	MILTNYKNLKGRYINMKAKVLNKTKVITGKVRASYAHIF	39	Sequence 471 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17802	MNIDIETYSSNDISKCGAYKYTEAEDFEILIIAYSIDGGAISAIDMTKVDNEPFHADFETFKIALFDPAVKKVCIQC	77	Sequence 473 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17803	MPPEEWICTMVNSMRIGLPASLDKVGEVLRLQNQKDKAGKNLIRYFSIPCKPTKVNGGRTRNLPEHDLEKMATIYRLLYSRCRSRNDDCS	90	Sequence 474 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17804	MQHQAYINASVDIRIPTEVESVNYNQIDKEKENLADYLFNNPGELLKYNVINIKVLDLEVE	61	Sequence 478 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17805	MMARRKVIRVRIKGKLMTLREVSEKYHISPELLRYRYKHKMRGDELLCGRKDSKSKDEVEYMKSQIKDEEKEREKIRKKSDFEPIPTKCESGI	93	Sequence 479 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17806	MKKKREKKSEKKAILNLYQRNVRAEYEEERKRRLRPWLYDGTPQKHSRDPYWFDVTYNQMFKKWSEA	67	Sequence 480 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17807	MSIISNRKVDMNETQDNVKQPAHYTYGDIEIIDFIEQVTAQYPPQLAFAIGNAIKYLSRAPLKNGHEDLAKAKFYVDRVFDLWEG	85	Sequence 481 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17808	MATQKQVDYVMSLQEQLELEDCEKYTDEQVKAMSHKEVSNVIENYKTSIRNEELYYECMSFGLPNC	66	Sequence 482 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17809	VAHTHVVNGTYYFHGHIVPGWQSVKKTFDTAEELEIYIKQHGLEYEEQKQLTLF	54	Sequence 483 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17810	MNNREQIEQSIISASAYNGNDTEGLLKEIEDVYKKAQAFDEILEGLPNAMQDALKEDIGLDEAVGIMTGQVVYKYEEEQENEEI	84	Sequence 484 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17811	MKKFNVQITYTGMIEETIEAESLEEAEFEADVIARLEAPFDCDEYEINVEEEQEND	56	Sequence 485 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17812	VRERTKIIYRGWNKEIFILQGKNMNVIGLRQIFDELKRSYEGYKIVVIPIEVDFEIK	57	Sequence 487 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17813	VTQYLVTTFKDSTGLPHEHITVARDNQTFTVVEAESKEEAKEKYEARNVPVDGATNLNDIKSNIGIFHVEKVEPNEGMVDINIETMKPFEEADDD	95	Sequence 488 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17814	MINIPKMKFPKKYTEIISKKYKNKTPEEKAKIENDFIKDINDKDSEFYSPMMANMNEHELRAMLRMMPSLIDTGDDNDD	79	Sequence 489 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17815	MIKQILRLLFLLAMYELGKYVTEQVYIMMTANDDVEAPSDFAKIRAEVSW	50	Sequence 491 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17816	MKESTLEKYLVKEITKLNGLCLKWVAPGTRGVPDRIIIMPEGKTFFVEMKQEKGKLHPLQKICA	64	Sequence 495 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17817	VHRQFENRDHTVYVLWNKEQVNTFIRMVGGTFGD	34	Sequence 496 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17818	MLVIAPKQVAKDTWVDEVDKWNHLNHLKVSLILGTPKERNDALNTEADIYVTNKENTKWLCDQYKKRMAI	70	Sequence 497 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17819	LYIETYEFYCRLRDELKNSDLMIEHTNKAGASNIIKNPLSIELTKTVQTLNNLLKSMGLTAAQRKKIVQEEGGFGDY	77	Sequence 501 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17820	MKQARILFDESKAMIKASPKLDKNFRTLRDEIHYDATISKIMPQASDSDKLDGLNTHMGIF	61	Sequence 503 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17821	LISVIKNSRAARLQPLLIYITTAGYQLDGPLVDMVEAGRDTLDQIIEDERTFLLFSIFG	59	Sequence 504 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17822	LDDDDDINDSSNWIKANPNLGVSINLDEMKEEWEKAKRTPAERGDFITKRFNIFANNDEMSFIDYPTLQKK	71	Sequence 505 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17823	LSPALKDLKEMFLDGKIIFNNNPLMKWYINNVQLKLDRNGNWLPSKQSRYRKIDGFAAFLNTYTDIMNKVVSDSGEGNIEFISIKDIMR	89	Sequence 507 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17824	MLKYGSNVGKEKKAASVRRFQTVL	24	Sequence 509 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17825	MSMKAKYFQMKRKSKSKGEIFIYGDIVSDKWFESDVTATDFKNKLDELGDISEIDVHINSSGGSVFEGHAIYNMLKNASCKN	82	Sequence 511 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17826	MSLEEIKLWLRIDYNFENDLIEGLIQSAKSELLLSGVPDYDKDDLEYPLFLYSD	54	Sequence 514 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17827	MKRKKMKLYSCFCKIYNPSMKDREILKATESKSGLTIIMRSSKIEYLPQTNHLVKIDRGLYSDKLFNIKEIRIDTPDIGYNTVVLSEK	88	Sequence 515 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17828	MSVEIKGIPEVLKKLESVYGKQSMQAKSDRALNEASEFFYKGFKERIREF	50	Sequence 516 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17829	MKHLNFFIKALKKEFESFKDTGASIEEMTKSKPYTKVGSQERAVLIEWVGPMNRKNIIHLNEHGYTRDGKKIYTKRFWSYCKNISC	86	Sequence 517 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17830	MNRKVDVDGTSQGIVYGYHEGKEGETEFFKKSIRWIHGQ	39	Sequence 520 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17831	VKIIQRILQVRYPANPQNVEVAVNSKSATVSAE	33	Sequence 521 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17832	MEQYGWTLTEVRKQPYVKLLEILNEENKEETEEKTK	36	Sequence 524 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17833	MNEKVEGMTLELKLDHLGVQEGMKGLKRQLGVVNSEMKANLSAFDKSEKINGKNIRRELRG	61	Sequence 525 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17834	MIGLKFKKKMYSQVEDELKQVNANYQKAKSSVKDVEKAYLKLVEANKKRKISS	53	Sequence 526 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17835	LRDAEQKLKNSNQATTAQLKRASDAVQKQSAKHKALVEQYKQEGNQVQKTKSAK	54	Sequence 527 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17836	LRIKFFKTAYDRVEWFRNGINGLGETIKFFGGKIIGGAVRKLGEFKKLSWKYRQKLQRKVFKRYERWL	68	Sequence 530 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17837	MKDGYKSLSDDDLLKVGVNKFKGFMQTMGTASKKSV	36	Sequence 531 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17838	VLGKGVSKETEKALEKYVHYSEENSRIMEKVRLNSGQISEDKAKKTFEN	49	Sequence 532 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17839	MTCELKKEQELNQKIKELKEKSFE	24	Sequence 533 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17840	MALKVGGLTLEKTKRKKSDKYAKEQEETARRNRENIKKWFGNAWDGVKSKTGEAFSKMGRNANHFGGEMKKNVERNQRDSKQIKFRLELSQKFCRIPH	98	Sequence 535 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17841	MVEAAGDKIKDGASWLGDKIGDVWDYVQHPGKLVNKVMSGLNINFGGGANATVKIAKGAYSLLKKEISRQSKIVV	75	Sequence 537 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17842	MLSDKGNKLTDALIQTVSSQDNNLGSNDAIRGLEKILSKQSGHRANANNYMGGLTN	56	Sequence 539 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17843	MQSFVKIIDGYKEEVITDFNQLIFLDARAESPNTNDNSVTINGVDGILPGAISFAPFFISIKVWL	65	Sequence 540 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17844	LILDGKQIKQISCFAKSVQSETIDLIKNIDKGKHVLEMIFLGEDPKNRIDISSNKKS	57	Sequence 544 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17845	MLELKKSTVLNLIADNSGRNQYKAIVDYVADSAKQFGIRYANTQTNEDIETQDKLLEFAKKANK	64	Sequence 545 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17846	MATEEVKIKALLENDKQYFPATHWKAINGIPYAGSSDIDGLPQDGIISVDDKNKLDKLKIGEAGIIQNSIVQKSPNGKLWKITVDDSGKLGTVLFY	96	Sequence 547 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17847	VGGHGTHNGYRYIDDELWIYSFILNGNNENTLVRFKYTPNVEISYGKYGMQDVFTGHPEKPYITPVINEKRK	72	Sequence 549 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17848	MSDINIVGMSFYLTTDDTKRFTDFPTERKGVAGWNLYVEASNTGGFVHRLVRNSVTASAEILLKNYDSKTSSGPWTLHEGRIIS	84	Sequence 552 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17849	MSNLEKSVAINLENTAHYENISNLDITFRTGESDSSVLLFNIIKNNQPLLLSEENIKARIAIRGKGV	67	Sequence 553 from Patent US 20120052048	Phage F197/08	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17850	MKAKNSDFKGGDKMDLNKINVFFNFLVANLVSILFLLGLFVVNVSMYKAFGQNIGLLCIGITLIVISLILNHESNQERS	79	Sequence 556 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17851	MAMYEVKKSYTDLEKGQYLKSGKRVEMTVKRAEYVNKKLKEHGVILERVKEE	52	Sequence 560 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17852	MNDSNQGLQANPQYTIHYLSQEITRLTQENAMLKAYIQEQNEKSKSAEEE	50	Sequence 570 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17853	MANEIIKKTERFILVQIDKEGTERVLYQDFVGSFTTSDSASYAQDFKSEENAKKIAETLNLLYQLTVNQNGVKVVKEVVDRTDLSSDKSVDSEIM	95	Sequence 571 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17854	MLALLKSLERRCLMITISTMLQFGLFLIALIGLVIKLIELSNKK	44	Sequence 573 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17855	MINWKIRMKQKSFWVAILSAIFLFAQNIAKAIGYDIQVYTEQLTDGLNAILGFLVLTGVIQDPTTKGIGDSHQALEYEEPRRKY	84	Sequence 574 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17856	VRDGYSTNSRITGVLPNNATIKYDGAYCINGYRWITYIANSGQRRYIATGEVDKAGNRISSFGNFSAV	68	Sequence 577 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17857	LNGGENFMADKNKKQEATRSNPINKSFEKPGASENLKSTLSEKAKKKD	48	Sequence 579 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17858	MKITNCKIKRETIVYEVLTSGNQPFTYELPKDLSSHNARKYLEFISQKIDGDKLTKEDSL	60	Sequence 580 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17859	MKTLKELRTDYGLTQKELGDLFKVSSRTIQNMEKDSTNIKDSLLSKYMSAFNVKYDDIFLGNEYENFVFTNDKKKSIILAFKEKQTS	87	Sequence 584 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17860	MNIQVATKLAMEKGISIRRENQDVYGILPTNLQRYQCLVVSRHYKKKRQTAAGRWQPSADDLIADDWILDY	71	Sequence 585 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17861	MQAQNKKVIYYYYDEAGNRRPVNIQYNDGYDLMIDPRFIEMTLERHPHLKNNFYGLIDGKEFKLD	65	Sequence 588 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17862	MLQKFRIAKEKNKLKLKLLKHASYCLERSNNPELLRAVAELLKKVN	46	Sequence 589 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17863	MSNIYKSYLLAVLCFTVLAIVLMPLLYFTTAWSIAGFASIATFIFYKEYFYEE	53	Sequence 592 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17864	MKKLLLAPTSNSDKRLTKLI	20	Sequence 593 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17865	MYYKTGDVCQKIINVDGFDFRLRVKKRAYSVEIVVLDHEGNSIDGILVSDENDLYTALDILKQSIYEWIENNTDEQDKLMNLVMKW	86	Sequence 595 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17866	MRDTERNILNIFKTLFDEYTLSNQRALLEIERNHHGYLSINFLHYHDSYKTNNKLVQIHEINPDSHERIKNLIIEVLRGHRKIKKGA	87	Sequence 596 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17867	MDAFDKYYLFDHDGNKMFSVTPHFKDGRHLVVGLKHTKFNGRRWYLDDYELKTLIDNEQMELGHQTSLFEYI	72	Sequence 602 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17868	MTDNARKEYLNQFFGFKRYLYQDNERVAHIHVVNGTYYFHGHIVPGWQSVKKTFDTAEELEIYIKQHGLEYEEQKQLTLF	80	Sequence 605 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17869	MEMMNAEKHMQMMQMLQNCVIDKYVSHDEYEELIAIDKHGNKMFIKFYPNTEDDTNE	57	Sequence 606 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17870	MNNREQIEQSVISASAYNGNDTEGLLKEIEDVYKKAQAFDEILEGMTNAIQHSVKEGVELDEAVGIMAGQVVYKYEEEQENEH	83	Sequence 607 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17871	MSISVGDKVFNPETNSTLEIVQLVGDIRDTHYKLSDGSIISLIDFVVKPIHLIKEEQEND	60	Sequence 608 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17872	VTQYLVTTFKDSTGRKHTHITKAKSNQRFTVVEAESKEEAKEKYEKQVKRDAVIKVGQLFENIRECGK	68	Sequence 610 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17873	MIKQILRLLFLLAMYELGKYVTEQVYIMMTANDDVEAPSDYVFRAEVSE	49	Sequence 612 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17874	MWITMTIVFAILLLVCISINSDRAREIQALRYMNDYLLDEVVKTKGYNGLKEYRIELKRMNNDIKK	66	Sequence 613 from Patent US 20120052048	Phage F86/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17875	MVKFKVVREFKDIEHNQHKYKVGELYPAEGYNNPRVELLTNQIKNKYDKVYIVPLDKLTKQELLELCESLQKKASSSMVKSEIIDLLNGEDNDD	94	Sequence 622 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17876	MTIDDLLVKFKSLEKIDHNSEDEYLKQLLKMSYERIKNQCGVFELENLIGQELILIRARYAYQDLLEHFNDNYRPEIIDFSLSLMEVSEDEESV	94	Sequence 623 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17877	LKYTTDQTNIVSINSDGQVTAEAQGIATVKATVGNMSDTITINVEA	46	Sequence 629 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17878	MLKNMDTLMMDLIENGKDANEVLKMPFHYVLSIYQNKNNDISEEKAEALIDAF	53	Sequence 631 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17879	MQDNKQGLQANPEYTIHYLSQEIMRLTQENAMLKAYIQENKENQQCAEEE	50	Sequence 636 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17880	MAKEIINNTERFILVQIDKEGTERVVYQDFTGSFTTSEMVNHAQDFKSEENAKKIAETLNLLYQLTNKKQRVK	73	Sequence 637 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17881	LGWFKKHEHEWRIRRLEENDKTMLSTLNEIKLGQKTQEQVNIKLDKTLDAIQKEREIDEKNKKENDKNIRDMKMWVLGLVGTIFGSLIIALLRMLMGI	98	Sequence 638 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17882	MVALLKSLERRRLMITISTMLQFGLFLIALIGLVIKLIELSNKK	44	Sequence 639 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17884	VPAGYTLDKNNVPYKKETGYYTVANVKGNNVRDGYSTNSRITGVLPNNATIKYDGAYCINGYRWITYIANNGQRCYIATGEVDKAGNRISSFGNFSAL	98	Sequence 643 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17885	MKITNCKIKKETIVYEVLTSGNQPFTYELPKDLSSHNARKYLEFISQKIDGDKLTKEDSL	60	Sequence 647 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17886	MSTYKEIEHLHINTGGKELTQEQIEEAKAFIDSQEFKDMIREAKESHQRVMESKITDRTKL	61	Sequence 648 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17887	MDFKEVDINIEEWEMVEIPFYTEEELTYRLNNGLPITKSELEEQESKK	48	Sequence 649 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17888	MIYNFDYSLLYERMAEYRYSQSSLANAIPISRTSINHKLQGKNLFTQWEIKRICELLEIPPTKVGRYFFEQNVQKPVQMS	80	Sequence 652 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17889	MEQITLTKEELKEIIAKEVREAINGKKPISSGSNFQQSKNQP	42	Sequence 653 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17890	MLQKFRIAKEKNKLKLKLLKHASYCLERNNNPELLRAVAELLKKVS	46	Sequence 655 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17891	MKLLVTLKDGSKKHVSDLKKIVFPGYEGIETVTKEEIETFFLDPTKTYVFVGSQTLSVEAGQILTVEFS	69	Sequence 656 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17892	MEQITLTKEECVEQCINKDLKLLDYRVQQILEGVLSESTTYGDARNKLETLKIIAESHFKTEHASVIYKLALKKLDKKINATPIKE	86	Sequence 658 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17893	MFKILNDIKTSLKNHPWGWKEHLPYLLMLTLSLVALIFGVLSAIL	45	Sequence 659 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17894	MSKTYKSYLLAVLCFTVLAIVLMPFLYFTTAWSIAGFASIATFIFYKEYFYEE	53	Sequence 661 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17895	MYYKIGDVCQKVINVDGFDFKLAVKKQDYSILVNVLDLEDRFIDSINITDENDLYTALDILNQSIYEWIEENTDERDRLINLVMRW	86	Sequence 662 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17896	MVGISMRDTERNILNIFKTLFDEYTLSNQRALLEIERNHHGYLSINFLHYHDSYKTNNKLVQIHEINPDSHERIKNLIIEVLRGHRKIKKGA	92	Sequence 663 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17898	MTDNARKEYLNQFFGSKRYLYQDNERVAHIHVANGNYYFHGHIVPGWQGVKKTFDTAEELEIYIKQHGLEYEKQKQLTLF	80	Sequence 672 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17899	MQDALKEDIGLDEAVGIMTGQVVYKYEEAQENE	33	Sequence 673 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17900	VSDMLEIFLIGFGVYLFYRIAIIFLKSKKTIHTNIYEMLMLATIFMISTFAYKHQKTHILIAFLVMFFMSKLKQVQGSYEE	81	Sequence 675 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17901	MTQYLVTTFKDSTGRKHTHITKAKSNQRFTVVEAESKEEAKEKYEKQVKRDAVIKVGQLFENIRECGK	68	Sequence 676 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17904	MMTKDERIRFYKSKEWQTTRKRVLERDNYECQQCKRDGKLTTYDKSKRKSLDVDHILSLEHHPEFAHDLNNLETLCIKCHNKKEKRFIKKENKWKDEKW	99	Sequence 681 from Patent US 20120052048	Phage F87s/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17905	MYLKDTRIEIVGVNKKDPLQYAEAIDKLVSSGSFTRNEVRIMLGEEPSDNPELDEYLVTKNYEKANENGSTLKGGDEDESGD	82	Sequence 686 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17906	MVKFKVVRAFKDIEHNQHKYKVGELYPAEGYNNPRVELLTNQIKNKYDKVYIVPLDKLTKQELLELCESLQKKDV	75	Sequence 690 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17907	MVKTMTIDDLLVKFKSLEKIDHNSEDEYLKQLLKMSYERIKNQCGVFELENLIGQELILIRARYAYQDLLEHFNDNYRPEIIDFSLSLMEVSEDEESV	98	Sequence 691 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17908	MAIKHASAPKAYFNITGLGFAKLTKEGAELKYSDITKTRGLQKIGVETGGELKTAYADGGPIESGNTDGEGKISLQMHAFPKEIRKIVF	89	Sequence 695 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17909	MFTNPKIDGETAEKDWDFSSEEVEGEALFPLVDNKKSVRKYIFDSANMTNHDGDGEKGEEAFLKKILGEEYTGNVTEGNEETL	83	Sequence 696 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17911	MLKNMDTLMMDLIENGKDANEVLKMPFHYVLSIYQNKNNDIS	42	Sequence 699 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17912	LSNVNGFDDPSLLLKMIEQQQQQIALLLKIAQSNDVIADKDYQPIIDEYAFDKKVNASIEKRERQESTKVKFRKGGIAIQ	80	Sequence 702 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17915	MLSTLNEIKLGQKTQEQVNIKLDKTLDAIQKEREIDEKNKKENDKNIRDMKMWVLGLVGTIFGSLIIALLRMLMGI	76	Sequence 709 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17917	LSAIFLFAQNIAKAIGYDIQVYTEQLTDGLNAILGFLVLTGVIQDPTTKGIGDSHQALEYEEPRRKY	67	Sequence 711 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17918	VPAGYTLDKNNVPYKKETGYYTVANVKGNNVRDGYSTNSRITGVLPNNATIKYDGAYCINGYRWITYIANSGQRRYIATGEVDKAGNRISSFGKFSAV	98	Sequence 714 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17919	LVNKINKFNQYVARFIPYIATKIPIKKNIAPMIKQKSDAELLKNEVFRVRK	51	Sequence 717 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17920	MKITNCKIKRETIVYEVLTSGNQPFTYELPKDLSSHNARKYLEFISQKIRWR	52	Sequence 720 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17924	MEQITLTKEELKEIIAKEVRNAIKGEKPISSGAISVK	37	Sequence 726 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17927	MIDQRFIEMTLERHPHLKNNFYGLIDGKEFKLD	33	Sequence 730 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17928	MSKTYKSYLVAVLCFTVLAIVLMPFLYFTTAWSIAGFASIATFIFYKEYFYEE	53	Sequence 733 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17929	MTKNYKDMTQEEIKDLLSEKTAELYELAKEIKGESKFDILLFSSIGVIDGDYLAGSSSVIGHTFDLAYLLDSTKSYKDIVNVLQMCKSQKILGIDDDKED	100	Sequence 734 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17930	MYYKTGDVCRKIFNVDGFDFQLRVKKRAYSVEIVVLDHEGNSIDGLLVSDENDLYTALDILKQSIYEWIENNTDEQDRLINLVMKW	86	Sequence 735 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17932	MDAFDKYYLFDHDGNKMFSVTPHFKDGRHLVVGIKETKFNGRRWYLDDYELNTLIDNEQMELGHQTSLFEYI	72	Sequence 742 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17933	MSVISNRKVDMNEIQDNVKQPAHYTYGDIEIIDFIEQVTAQYPPQLAFAIGNAIKYLSRAPLKNGHEDLAKAKFYVQRAFDLWEQ	85	Sequence 745 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17934	VPGWQSVKKTFDTAEELEIYIKQHGLEYEEQKQLTLF	37	Sequence 746 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17935	MEMMNNREQIEQSVISASAYNGNDTEGLLKEIEDVYKKARAFDEILDGMTNAIQHSVKEGIELDEAVGIMAGQVIYKYEEEQGK	84	Sequence 747 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17936	MKLLYLNYIQFIFVHVMHTLTEQFVKGIDNSIVQVLIMPFLYANTYYTIDQLIDAYKKKMKRNHERQDGTADAGKGYV	78	Sequence 749 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17937	VSDMLEIFLIGFGVYLFYRIAIIFLKSKKTIHTNIYEMLMLATIFMISTIAYKHQKTHILIAFLVMFFMSKLKQVQGSYEE	81	Sequence 750 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17938	MTQYLVTTFKDSTGQPHEHFTTARDNQTFTVVEAESKEEAERKYEAQVKRGAVIKLGQLFENIRECGK	68	Sequence 751 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17940	MWITMTIVFAILLLVCISINSDHAREIQALRYMNDYLLDEVVKTKGYNGLEEYRIELKRINNDIKK	66	Sequence 753 from Patent US 20120052048	Phage F91a/06	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17941	GFDVTIEPIAQDKYFLVDSKQIREYRG	27	Sequence 761 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17942	VSKIKMNEYRGKPPYSMDDLAEDPQLERRYIQRERRNHVKERDLDRRNKRQAKRNGY	57	Sequence 763 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17943	MAIIRIPIRTEAEANQFISIVKSQGLALPDLDVVHRLGLATARVGSDACVWTGIEQYIGTRHDFPHSDETVTVNQLYKRLQER	83	Sequence 767 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17944	MQVGSKVVCVYAGDSTLIETHGTYEVLGFSSYDGPNSHVEIGLDGRLLGSYSPKRFMTVEEVTKQTQENLND	72	Sequence 777 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17945	MIIDGTKLRCINDKGQRIVKEGSLYTAWVRDGIGIDGRIFIKEHKRFALLITRFEVVE	58	Sequence 779 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17946	MLLLIITILVVVLAVVIYKSEKETVRECFGILVEGVTLAKAKSDILKVAKVWFYTLKLTGELILVPFLTIALILFIIAGATYRAIIK	87	Sequence 782 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17947	MSVDKIPNFTEDQIYWLDSIFPENTQLTTNPNEVYVKLGQRQVIQRIKQDTARKRNAYNRANGG	64	Sequence 783 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17948	MPQLCEAIISPALTGQALEVGDRAFEQGNTPAANDRVATLEGQVQALLALLQGQQAAGAPVAPVEVVAEEVKAPAKKATAEK	82	Sequence 788 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17949	MSPEEIRRRLDTITERIANAVMIVNLIKEKSK	32	Sequence 800 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17950	MSTKREVVVQAVDNAVSVAKAVNANAEYKHKDKVTKGLELAGNVLQLLKLFK	52	Sequence 801 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17951	MDGFESTVKVGVKHTQYEELRDLKQRGETFDDVIRRLLDAHKSLKSIGLLD	51	Sequence 802 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17952	LYSSLSSIYSITLIVISIYIYIVISYCSLFMFFILYSYTCSIQ	43	Sequence 803 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17953	MKTLTHHIAVQCTCGATGQTGDFLVDIEHFKLTGELIALDGMVFRSLTALYAYANTYGLPTKRLNTPIVYQS	72	Sequence 804 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17954	MKVKVRNKFAAATSINYKGHYVVRNGNGTLTLGAEHITEEQAAVLNLQEFSKVREWLGPSYSVEIIV	67	Sequence 806 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17955	MFKEYNYCGQCRVNYINCHCPTHYPERNKDDHHL	34	Sequence 809 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17956	MKKLGLIVVYTAAYAAISLVQWLQDDK	27	Sequence 810 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17957	VKHVHVVEVIMWILIMSIVVGSYRGVSATTQEFTSKERCMVAAQMALDKKMGGGDNSNRLTAICVPK	67	Sequence 814 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17958	VSAPNNIFHKGMRVIVTKADRDDVRLGLHGDTIATVVGVH	40	Sequence 816 from Patent US 20120052048	Phage F1245/05	Antimicrobial, Antibacterial	US 2012/0052048 A1	Patent Application	2012##3##1	CA2751641A1, CN102348460A, EP2393502A2, WO2010090542A2, WO2010090542A3	Antibacterial phage, phage peptides and methods of use thereof.	The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
DRAMP17959	PRPPHPRX	8	Sequence 1 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17960	XPXXXP	6	Sequence 2 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17961	RPTYVP	6	Sequence 3 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17962	RPQQVP	6	Sequence 4 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17963	RPRPAP	6	Sequence 5 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17964	KPRPAP	6	Sequence 6 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17965	NRPTYVPPPRPPHPRL	16	Sequence 7 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17966	NRPTYVPAPRPPHPRL	16	Sequence 8 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17967	GKPRPQQVPPRPPHPRL	17	Sequence 9 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17968	RPQQVPPRPPHPRL	14	Sequence 10 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17969	SNKPRPQQVPPRPPHPRL	18	Sequence 11 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17970	NKPRPQQVPPRPPHPRL	17	Sequence 12 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17971	GKPNRPRPAPIQPRPPHPRL	20	Sequence 13 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17972	NRPRPAPIQPRPPHPRL	17	Sequence 14 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17973	GKPNKPRPAPIKPRPPHPRL	20	Sequence 15 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17974	NKPRPAPIKPRPPHPRL	17	Sequence 16 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17975	GKPSKPRPAPIKPRPPHPRL	20	Sequence 17 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17976	SKPRPAPIKPRPPHPRL	17	Sequence 18 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17977	PRXPHPRX	8	Sequence 19 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17978	SQPRPQP	7	Sequence 20 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17979	QVPIRPSQPRPQP	13	Sequence 21 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17980	SRPSPQVPIRPSQPRPQP	18	Sequence 22 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17982	GNNRPVYIPQPRPPHPRL	18	Sequence 24 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17983	GNNRPIYIPQPRPPHPRI	18	Sequence 25 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17984	GNNRPVYISQPRPPHPRI	18	Sequence 26 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17985	ANRPVYIPPPRPPHPRL	17	Sequence 27 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17986	NRPVYIPPPRPPHPRL	16	Sequence 28 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17988	GKPRPYSPRPTSHPRPIRV	19	Sequence 30 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17989	PRPPHPRL	8	Sequence 31 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17991	SRPSPQVPIRPSQPRPQPGKPRPQQVPPRPPHPRL	35	Sequence 33 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17992	FKPRPQQVPPRPPHPRL	17	Sequence 34 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17993	SRPSPQVPIRPSQPRPQPFKPRPQQVPPRPPHPRL	35	Sequence 35 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17994	GKPRPQQVPPRTPHPRL	17	Sequence 36 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17995	SRPSPQVPIRPSQPRPQPGKPRPQQVPPRTPHPRK	35	Sequence 37 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17996	FKPRPQQVPPRTPHPRL	17	Sequence 38 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17997	SRPSPQVPIRPSQPRPQPFKPRPQQVPPRTPHPRL	35	Sequence 39 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17998	QVPIRPSQPRPQPFKPRPQQVPPRTPHPRL	30	Sequence 40 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP17999	SQPRPQPFKPRPQQVPPRTPHPRL	24	Sequence 41 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP18000	SNKP	4	Sequence 42 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP18001	GKPX	4	Sequence 43 from Patent US 5466671	Synthetic construct	Antimicrobial, Antibacterial	US 5466671 A	Granted Patent	1995##11##14	CA2183665A1, WO1995023513A1	Apidaecin-type peptide antibiotics with improved activities and/or different antibacterial spectrum.	This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.
DRAMP18002	AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH	42	Sequence 1 from Patent US 5646014	Synthetic construct	Antimicrobial, Antibacterial	US 5646014 A	Granted Patent	1997##7##8	DE19532001A1	Peptide, antibacterial agent, peptide gene, recombinant DNA and method for preparing the peptide.	The present invention relates to a peptide represented by the amino acid sequence of SEQ ID NO: 1, an antibacterial agent comprising the peptide as an active ingredient, a peptide gene encoding the peptide, a recombinant DNA comprising the peptide gene and a method for producing a peptide. The peptide of the present invention exhibits an effective antibacterial activity against various Gram-negative and -positive bacteria including Staphylococcus aureus and Bacillus cereus which are pathogenic bacteria causing food poisoning. Therefore, this peptide is useful as a food preservative and an antibacterial agent for medical use.
DRAMP18003	AKIPIKAIKTVGKAVGKGLRAINIASTANDVFN	33	Sequence 2 from Patent US 5646014	Synthetic construct	Antimicrobial, Antibacterial	US 5646014 A	Granted Patent	1997##7##8	DE19532001A1	Peptide, antibacterial agent, peptide gene, recombinant DNA and method for preparing the peptide.	The present invention relates to a peptide represented by the amino acid sequence of SEQ ID NO: 1, an antibacterial agent comprising the peptide as an active ingredient, a peptide gene encoding the peptide, a recombinant DNA comprising the peptide gene and a method for producing a peptide. The peptide of the present invention exhibits an effective antibacterial activity against various Gram-negative and -positive bacteria including Staphylococcus aureus and Bacillus cereus which are pathogenic bacteria causing food poisoning. Therefore, this peptide is useful as a food preservative and an antibacterial agent for medical use.
DRAMP18004	AKIPIKAIKTVGKAVGKGLRAINIASTAN	29	Sequence 3 from Patent US 5646014	Synthetic construct	Antimicrobial, Antibacterial	US 5646014 A	Granted Patent	1997##7##8	DE19532001A1	Peptide, antibacterial agent, peptide gene, recombinant DNA and method for preparing the peptide.	The present invention relates to a peptide represented by the amino acid sequence of SEQ ID NO: 1, an antibacterial agent comprising the peptide as an active ingredient, a peptide gene encoding the peptide, a recombinant DNA comprising the peptide gene and a method for producing a peptide. The peptide of the present invention exhibits an effective antibacterial activity against various Gram-negative and -positive bacteria including Staphylococcus aureus and Bacillus cereus which are pathogenic bacteria causing food poisoning. Therefore, this peptide is useful as a food preservative and an antibacterial agent for medical use.
DRAMP18005	DVFNFLKPKKRKH	13	Sequence 4 from Patent US 5646014	Synthetic construct	Antimicrobial, Antibacterial	US 5646014 A	Granted Patent	1997##7##8	DE19532001A1	Peptide, antibacterial agent, peptide gene, recombinant DNA and method for preparing the peptide.	The present invention relates to a peptide represented by the amino acid sequence of SEQ ID NO: 1, an antibacterial agent comprising the peptide as an active ingredient, a peptide gene encoding the peptide, a recombinant DNA comprising the peptide gene and a method for producing a peptide. The peptide of the present invention exhibits an effective antibacterial activity against various Gram-negative and -positive bacteria including Staphylococcus aureus and Bacillus cereus which are pathogenic bacteria causing food poisoning. Therefore, this peptide is useful as a food preservative and an antibacterial agent for medical use.
DRAMP18006	GIGKFLKKAKKGIGAVLKVLTTGL	24	Sequence 1 from Patent US 5714467	Synthetic construct	Antimicrobial, Antibacterial	US 5714467 A	Granted Patent	1998##2##3	Unknown	Antibacterial and antimalarial hybrid peptides.	The invention relates to antibacterial and antimalarial peptides which are hybrids peptides which a of naturally occurring peptides such as cecropins, attacins, magainins, sarcotoxin, sapecin, bactenecins, alamethidicins, defensins and PGLa, and toxins such as streptolysins, melittin, barbatolysin, paradaxins and delta hemolysin. The hybrid peptides of the present invention are easily synthesized and have reduced toxicity. Also included in the invention are pharmaceutical compositions containing such hybrid peptides, and methods of treating patients infected with an organism against which these peptides are active.
DRAMP18008	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	35	Sequence 3 from Patent US 5714467	Synthetic construct	Antimicrobial, Antibacterial	US 5714467 A	Granted Patent	1998##2##3	Unknown	Antibacterial and antimalarial hybrid peptides.	The invention relates to antibacterial and antimalarial peptides which are hybrids peptides which a of naturally occurring peptides such as cecropins, attacins, magainins, sarcotoxin, sapecin, bactenecins, alamethidicins, defensins and PGLa, and toxins such as streptolysins, melittin, barbatolysin, paradaxins and delta hemolysin. The hybrid peptides of the present invention are easily synthesized and have reduced toxicity. Also included in the invention are pharmaceutical compositions containing such hybrid peptides, and methods of treating patients infected with an organism against which these peptides are active.
DRAMP18009	WNPFKELEKVGQRVRDAVISAGPAVATVAQATALAK	36	Sequence 4 from Patent US 5714467	Synthetic construct	Antimicrobial, Antibacterial	US 5714467 A	Granted Patent	1998##2##3	Unknown	Antibacterial and antimalarial hybrid peptides.	The invention relates to antibacterial and antimalarial peptides which are hybrids peptides which a of naturally occurring peptides such as cecropins, attacins, magainins, sarcotoxin, sapecin, bactenecins, alamethidicins, defensins and PGLa, and toxins such as streptolysins, melittin, barbatolysin, paradaxins and delta hemolysin. The hybrid peptides of the present invention are easily synthesized and have reduced toxicity. Also included in the invention are pharmaceutical compositions containing such hybrid peptides, and methods of treating patients infected with an organism against which these peptides are active.
DRAMP18010	GIGAVLKVLTTGLPALISWIKRKRQQ	26	Sequence 5 from Patent US 5714467	Synthetic construct	Antimicrobial, Antibacterial	US 5714467 A	Granted Patent	1998##2##3	Unknown	Antibacterial and antimalarial hybrid peptides.	The invention relates to antibacterial and antimalarial peptides which are hybrids peptides which a of naturally occurring peptides such as cecropins, attacins, magainins, sarcotoxin, sapecin, bactenecins, alamethidicins, defensins and PGLa, and toxins such as streptolysins, melittin, barbatolysin, paradaxins and delta hemolysin. The hybrid peptides of the present invention are easily synthesized and have reduced toxicity. Also included in the invention are pharmaceutical compositions containing such hybrid peptides, and methods of treating patients infected with an organism against which these peptides are active.
DRAMP18011	LTCDLLSFEAKGFAA	15	Sequence 1 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18012	ALRLAIRKR	9	Sequence 3 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18013	ALLLAIRKR	9	Sequence 4 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18014	AWLLAIRKR	9	Sequence 5 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18015	ALYLAIRKR	9	Sequence 6 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18016	ALWLAIRKR	9	Sequence 7 from Patent US 6476189	Synthetic construct	Antimicrobial, Antibacterial	US 6476189 B1	Granted Patent	2002##11##5	Unknown	Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.	An object of the present invention is to provide antibacterial peptides of high safety, improved antibacterial activity, wide antibacterial spectrum and lower molecular weight, and antibacterial agents containing such peptides as an effective ingredient, whose effects on in vivo immune system is decreased because of lower molecular weight thereof when they are given. To achieve this object, there are provided antibacterial peptides represented by the following formula: X-Ala-Ile-Arg-Lys-Arg-NH 2   ( 1 ) wherein X is a peptide in which one or more than two amino acid residues are linked by peptide linkage, and Arg-NH 2 means that a carboxyl group of Arg is amidated.
DRAMP18017	GSSKSPSKKKKKKPGDC	17	Sequence 1 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18018	GSSKSPSKDKDKDPGDC	17	Sequence 2 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18019	GIGAVLKVLTTGLPALISWIKRKRQQC	27	Sequence 3 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18020	DGPKKKKKKSPSKSSG	16	Sequence 4 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18021	GSSKSPSKKKKKKPGD	16	Sequence 5 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18022	SPSNETPKKKKKRFSFKKSG	20	Sequence 6 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18023	DGPKKKKKKSPSKSSK	16	Sequence 7 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18024	SKDGKKKKKKSKTK	14	Sequence 8 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18025	GIGKFLHSAGKFGKAFVGEIMK	22	Sequence 9 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18027	VGALAVVVWLWLWLW	15	Sequence 11 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18028	GLLSVLGSVAKHVLPHVVPVIAEHL	25	Sequence 12 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18029	FLGGLIKIVPAMICAVTKKC	20	Sequence 13 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18030	GLFGVLAKVAAHVVPAIAEHF	21	Sequence 14 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18031	VKLKVYPLKVKLYP	14	Sequence 15 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18033	XTXXXFXXXT	10	Sequence 17 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18035	KWKLFKKIGIGAVLKVLTTGLPALTLTK	28	Sequence 19 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18869	KKWWRRVLSGLKTAGPAIQSVLNK	24	Sequence 18 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO19). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18868	KKWWRRALQALKNGPALSNV	20	Sequence 17 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO18). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18866	KKWWRRVLSGLKTGPALSNV	20	Sequence 15 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO16). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18867	KKWWRRVLKGLSSGPALSNV	20	Sequence 16 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO17). Also provided are methods for inhibiti
DRAMP18865	KWKKFIKELQKVLKPGGLLSNIVTSL	26	Sequence 14 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO15). Also provided are methods for inhibiti
DRAMP18041	RLSRIVVIRVSR	12	Sequence 25 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18042	PFXXVPFXXV	10	Sequence 26 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18043	XVKLKVXXLKVKLY	14	Sequence 27 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18863	KWKSFIKKLTSVLKKVVTTAKPLISS	26	Sequence 12 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO13). Also provided are methods for inhibiti
DRAMP18864	KKKSFIKLLTSAKVSVLTTAKPLISS	26	Sequence 13 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO14). Also provided are methods for inhibiti
DRAMP18862	KWKLFKKKGTGAVLTVLTTGLPALIS	26	Sequence 11 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO12). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18046	GIGAXLKXLTTGLPALXSWIXRKRQQ	26	Sequence 30 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18860	KWKSFIKKLTSVLKKVVTTALPALIS	26	Sequence 9 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO10). Also provided are methods for inhibiti
DRAMP18861	KWKSFIKNLTKVLKKVVTTALPALIS	26	Sequence 10 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO11). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject..
DRAMP18048	GIGKFLHSAKKFGKAFVAEIMNS	23	Sequence 32 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18049	GIAKFLHSAKKFGKAFVAEIMNS	23	Sequence 33 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18050	AAGKFLHSAKKFGKAFVGDIMNS	23	Sequence 34 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18051	GGKFLHSAKKFGKAFVGEIMNS	22	Sequence 35 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18052	GGKFIHSAKKFGKAFVGEIMNS	22	Sequence 36 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18053	GIGKFIHSAKKFGKAFVGEIMNSK	24	Sequence 37 from Patent US 7078380	Synthetic construct	Antimicrobial, Antibacterial	US 7078380 B2	Granted Patent	2006##7##18	CA2426012A1, EP1334117A1, EP1334117B1, US20040106544, WO2002036612A1	Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements.	The invention concerns agents with anti-bacterial activity and methods and intermediates for their production. The present invention further concerns the use of such agents for the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure: V-L-W-X; wherein V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a linking group; W is a peptidic membrane-associating element such as an element based on naturally-occurring animal or bacterial peptide antibiotics; and X is hydrogen or a membrane-insertive element.
DRAMP18859	KWKKFIKELQKVLAPGGLLSNIVTSL	26	Sequence 8 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,9). Also provided are methods for inhibiti
DRAMP18055	TRKKLFHIFHATIRSR	16	Sequence 1 from Patent US 8227423	Synthetic construct	Antimicrobial, Antibacterial	US 8227423 B2	Granted Patent	2012##7##24	US20080249023, WO2006034134A2, WO2006034134A3	Antibacterial peptide with activity against B. anthracis.	Disclosed is a therapeutic peptide useful in the treatment or prevention of infection caused by Gram-positive bacteria such as Bacillus anthracis.
DRAMP18056	RFARKGALRQKNV	13	Sequence 2 from Patent US 8227423	Synthetic construct	Antimicrobial, Antibacterial	US 8227423 B2	Granted Patent	2012##7##24	US20080249023, WO2006034134A2, WO2006034134A3	Antibacterial peptide with activity against B. anthracis.	Disclosed is a therapeutic peptide useful in the treatment or prevention of infection caused by Gram-positive bacteria such as Bacillus anthracis.
DRAMP05511	RLLRNWPIGRLLRRLLRRLLR	21	Sequence 20 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05512	KLLKNWPIGKLLKKLLKKLLK	21	Sequence 21 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05513	RVLRNWPIGRVLRRVLRRVLR	21	Sequence 22 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05514	KVLKNWPIGKVLKKVLKKVLK	21	Sequence 23 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05515	RLVRNWPIGRLVRRLVRRLVR	21	Sequence 24 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05516	KLVKNWPIGKLVKKLVKKLVK	21	Sequence 25 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05517	RVVKNWPIGRVVKRVVKRVVK	21	Sequence 26 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05518	KVVRNWPIGKVVRKVVRKVVR	21	Sequence 27 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05519	RLLKNWPIGRLLKRLLKRLLK	21	Sequence 28 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05520	KLLRNWPIGKLLRKLLRKLLR	21	Sequence 29 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05521	RVLKNWPIGRVLKRVLKRVLK	21	Sequence 30 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05522	KVLRNWPIGKVLRKVLRKVLR	21	Sequence 31 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05523	RLVKNWPIGRLVKRLVKRLVK	21	Sequence 32 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05524	KLVRNWPIGKLVRKLVRKLVR	21	Sequence 33 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05525	KLVRNFPVGKLVRKLVRKLVR	21	Sequence 34 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05526	RVVRRVVRRVVRQWPIGRVVR	21	Sequence 35 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05527	KVVKKVVKKVVKQWPIGKVVK	21	Sequence 36 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05528	RLLRRLLRRLLRQWPIGRLLR	21	Sequence 37 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05529	KLLKKLLKKLLKQWPIGKLLK	21	Sequence 38 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05530	RVLRRVLRRVLRQWPIGRVLR	21	Sequence 39 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05531	KVLKKVLKKVLKQWPIGKVLK	21	Sequence 40 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05532	RLVRRLVRRLVRQWPIGRLVR	21	Sequence 41 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05533	KLVKKLVKKLVKQWPIGKLVK	21	Sequence 42 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05534	RVVKRVVKRVVKQWPIGRVVK	21	Sequence 43 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05535	KVVRKVVRKVVRQWPIGKVVR	21	Sequence 44 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05536	RLLKRLLKRLLKQWPIGRLLK	21	Sequence 45 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05537	KLLRKLLRKLLRQWPIGKLLR	21	Sequence 46 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05538	RVLKRVLKRVLKQWPIGRVLK	21	Sequence 47 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05539	KVLRKVLRKVLRQWPIGKVLR	21	Sequence 48 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05540	RLVKRLVKRLVKQWPIGRLVK	21	Sequence 49 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05541	KLVRKLVRKLVRQWPIGKLVR	21	Sequence 50 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05542	KLVRKLVRKLVRQFPVGKLVR	21	Sequence 51 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05543	RVVRRVVRRVVRNWPIGRVVR	21	Sequence 52 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05544	KVVKKVVKKVVKNWPIGKVVK	21	Sequence 53 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05545	RLLRRLLRRLLRNWPIGRLLR	21	Sequence 54 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05546	KLLKKLLKKLLKNWPIGKLLK	21	Sequence 55 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05547	RVLRRVLRRVLRNWPIGRVLR	21	Sequence 56 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05548	KVLKKVLKKVLKNWPIGKVLK	21	Sequence 57 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05549	RLVRRLVRRLVRNWPIGRLVR	21	Sequence 58 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05550	KLVKKLVKKLVKNWPIGKLVK	21	Sequence 59 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05551	RVVKRVVKRVVKNWPIGRVVK	21	Sequence 60 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05552	KVVRKVVRKVVRNWPIGKVVR	21	Sequence 61 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05553	RLLKRLLKRLLKNWPIGRLLK	21	Sequence 62 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05554	KLLRKLLRKLLRNWPIGKLLR	21	Sequence 63 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05555	RVLKRVLKRVLKNWPIGRVLK	21	Sequence 64 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05556	KVLRKVLRKVLRNWPIGKVLR	21	Sequence 65 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05557	RLVKRLVKRLVKNWPIGRLVK	21	Sequence 66 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05558	KLVRKLVRKLVRNWPIGKLVR	21	Sequence 67 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05559	KLVRKLVRKLVRNFPVGKLVR	21	Sequence 68 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05560	SFGLCRLRRGFCAHGRCRFPSIPIGRCSRFVQCCRRVW	38	Sequence 1 from Patent US 7384911	Aptenodytes patagonicus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05561	SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW	38	Sequence 2 from Patent US 7384911	Aptenodytes patagonicus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05562	GTATQCRIRGGFCRVGSCRFPHIAIGKCATFISCCGRAY	39	Sequence 3 from Patent US 7384911	Gallus gallus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05563	GTPIQCRIRGGFCRFGSCRFPHIAIAKCATFIPCCGSIW	39	Sequence 4 from Patent US 7384911	Meleagris gallopavo	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05564	DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	36	Sequence 5 from Patent US 7384911	Homo sapiens	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP18856	KWKSFIKNLEKVLKPGGLLSNIVTSL	26	Sequence 5 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,6). Also provided are methods for inhibiti
DRAMP18858	KWKEFIKKLTTAVKKVLTTGLPALIS	26	Sequence 7 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,8). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP05566	LQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	40	Sequence 7 from Patent US 7384911	Homo sapiens	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05567	ELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP	48	Sequence 8 from Patent US 7384911	Homo sapiens	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05568	DHYNCVRSGGQCLYSACPIYTRIQGTCYHGKAKCCK	36	Sequence 9 from Patent US 7384911	Macaca mulatta	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05569	GIGDPVTCLKNGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	41	Sequence 10 from Patent US 7384911	Macaca mulatta	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05570	DHYNCVSSGGQCLYSACPIFTKIQGTCYGGKAKCCK	36	Sequence 11 from Patent US 7384911	Pan troglodytes	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05571	GIINTLQKYYCRVRGGRCAVLTCLPKEEQIGKCSTRGRKCCR	42	Sequence 12 from Patent US 7384911	Pan troglodytes	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05572	GVGNPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK	41	Sequence 13 from Patent US 7384911	Bos taurus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05573	GVRNSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK	41	Sequence 14 from Patent US 7384911	Bos taurus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05574	GISNPLSCRLNRGICVPIRCPGNLRQIGTCFTPSVKCCRWR	41	Sequence 15 from Patent US 7384911	Bos taurus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05575	QYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	36	Sequence 16 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05576	AVGSLKSIGYEAELDHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYMK	51	Sequence 17 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05577	KKINNPVSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKRK	41	Sequence 18 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05578	QIINNPITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCKIR	41	Sequence 19 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05579	QLINSPVTCMSYGGSCQRSCNGGFRLGGHCGHPKIRCCRRK	41	Sequence 20 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05580	QDINSKRACYREGGECLQRCIGLFHKIGTCNFRFKCCKFQIPEKKTKIL	49	Sequence 21 from Patent US 7384911	Mus musculus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05581	SRRSCHRNKGVCALTRCPRNMRQIGTCFGPPVKCCRKK	38	Sequence 22 from Patent US 7384911	Capra hircus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05582	QGIINHRSCYRNKGVCAPARCPRNMRQIGTCHGPPVKCCRKK	42	Sequence 23 from Patent US 7384911	Capra hircus	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05583	QGVRNRLSCHRNKGVCVPSRCPRHMRQIGTCRGPPVKCCRKK	42	Sequence 24 from Patent US 7384911	Ovis aries	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05584	HGVTDSLSCRWKKGICVLTRCPGTMRQIGTCGGPPVKCCRLK	42	Sequence 25 from Patent US 7384911	Ovis orientalis aries	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05585	NIGNSVSCLRNKGVCMPGKCAPKMKQIGTCGMPQVKCCKRK	41	Sequence 26 from Patent US 7384911	Sus scrofa	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05586	SFGLXRLRRGFXAXGRXRFPSIPIGRXSRFVQXXRRVW	38	Sequence 27 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05587	SFGL	4	Sequence 28 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05588	RLRRGF	6	Sequence 29 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05589	RFPSIPIGR	9	Sequence 30 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05590	SRFVQ	5	Sequence 31 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05591	RRVW	4	Sequence 32 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05592	AXGR	4	Sequence 33 from Patent US 7384911	Synthetic construct	Antimicrobial	US 7384911 B2	Granted Patent	2008##6##10	CA2492053A1, DE60330454D1, EP1517916A2, EP1517916B1, US20050245437, WO2004003006A2, WO2004003006A3	Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs.	An isolated peptide including an amino acid sequence of formula (II): Xaa-Ca1-Xab-Ca2-Xac-Ca3-Xad-Ca4-Xae-Ca5-Ca6-Xaf (II). wherein Xaa is Ser-Phe-Gly-Leu, Xab is Arg-Leu-Arg-Arg-Gly-Phe, Xac is Ala-Xac2-Gly-Arg, Xad is Arg-Phe-Pro-Ser-Ile-Pro-Ile-Gly-Arg, Xae is Ser-Arg-Phe-Val-Gln, and Xaf is Arg-Arg-Val-Trp, Xac2 is histidine or arginine, Ca1, Ca2, Ca3, Ca4, Ca5 and Ca6 are sulfur containing amino acids, wherein each of Ca1-Ca5, Ca2-Ca4 and Ca3-Ca6 are linked together by a sulfur bridge, and wherein the amino acid sequence has antimicrobial activity.
DRAMP05593	HEAEPEAEPIM	11	Sequence 27 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05594	EAEPEAEP	8	Sequence 28 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05595	EAKPEAEP	8	Sequence 29 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05596	EAEPKAEP	8	Sequence 30 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05597	EAESEAEP	8	Sequence 31 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05598	EAELEAEP	8	Sequence 32 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05599	EPEAEP	6	Sequence 33 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05600	EAEP	4	Sequence 34 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05601	YVPLPNVPQPGRRPFPTFPGQGPFNPKIKWPQGY	34	Sequence 37 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05602	VFIDILDKVENAIHNAAQVGIGFAKPFEKLINPK	34	Sequence 38 from Patent US 20050260715	Drosophila melanogaster	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP18855	KWKKFIKNLTKGGSKILTTGLPALIS	26	Sequence 4 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,5). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP05604	GNNRPIYIPQPRPPHPRL	18	Sequence 41 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05605	RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLRFP	42	Sequence 43 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05606	RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRP	59	Sequence 44 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05607	WNPFKELERAGQRVRDAVISAAPAVATVGQAAAIARG	37	Sequence 45 from Patent US 20050260715	Manduca sexta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05608	WNPFKELERAGQRVRDAIISAGPAVATVGQAAAIARG	37	Sequence 46 from Patent US 20050260715	Manduca sexta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05609	WNPFKELERAGQRVRDAIISAAPAVATVGQAAAIARG	37	Sequence 47 from Patent US 20050260715	Manduca sexta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05610	WNPFKELERAGQRVRDAVISAAAVATVGQAAAIARGG	37	Sequence 48 from Patent US 20050260715	Manduca sexta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05611	GIGALSAKGALKGLAKGLAZHFAN	24	Sequence 49 from Patent US 20050260715	Bombina variegata	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05612	GIGASILSAGKSALKGLAKGLAEHFAN	27	Sequence 50 from Patent US 20050260715	Bombina orientalis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05613	GIGSAILSAGKSALKGLAKGLAEHFAN	27	Sequence 51 from Patent US 20050260715	Bombina orientalis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05614	IKITTMLAKLGKVLAHV	17	Sequence 52 from Patent US 20050260715	Megabombus pennsylvanicus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05615	SKITDILAKLGKVLAHV	17	Sequence 53 from Patent US 20050260715	Megabombus pennsylvanicus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05616	RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA	58	Sequence 54 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05617	FLPLLAGLAANFLPKIFCKITRKC	24	Sequence 55 from Patent US 20050260715	Rana esculenta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05618	GIMDTLKNLAKTAGKGALQSLLNKASCKLSGQC	33	Sequence 56 from Patent US 20050260715	Rana esculenta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP18854	KWKSFIKNLTKGGSKILTTGLPALIS	26	Sequence 3 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,4). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject..
DRAMP05620	GWLKKLGKRIERIGQHTRDATIQGLGIAQQAANVAATARG	40	Sequence 59 from Patent US 20050260715	Drosophila melanogaster	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP18852	KWKSFIKKLTTAVKKVLTTGLPALIS	26	Sequence 1 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2 	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18853	KWKSFIKKLTSAAKKVVTTAKPLISS	26	Sequence 2 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2 	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO,1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO,3). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP05622	SWLSKTAKKLENSAKKRISEGIAIAIQGGPR	31	Sequence 61 from Patent US 20050260715	Sus scrofa	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05623	ZFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS	37	Sequence 62 from Patent US 20050260715	Leiurus quin-questriatus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05624	FLPLILRKIVTAL	13	Sequence 63 from Patent US 20050260715	Vespa crabo	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05625	LRDLVCYCRSRGCKGRERMNGTCRKGHLLYTLCCR	35	Sequence 64 from Patent US 20050260715	Mus musculus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05626	LRDLVCYCRTRGCKRRERMNGTCRKGHLMYTLCCR	35	Sequence 65 from Patent US 20050260715	Oryctolagus cuniculus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05627	VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR	33	Sequence 67 from Patent US 20050260715	Oryctolagus cuniculus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05628	RRCICTTRTCRFPYRRLGTCIFQNRVYTFCC	31	Sequence 68 from Patent US 20050260715	Cavia cutteri	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05629	RRCICTTRTCRFPYRRLGTCLFQNRVYTFCC	31	Sequence 69 from Patent US 20050260715	Cavia cutteri	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05630	VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR	32	Sequence 74 from Patent US 20050260715	Rattus norvegicus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05631	VTCYCRSTRCGFRERLSGACGYRGRIYRLCCR	32	Sequence 75 from Patent US 20050260715	Rattus norvegicus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05634	NPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK	38	Sequence 78 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05635	ATCDLLSGTGINHSACAAHCLLRGNRGGYCNGKAVCVCRN	40	Sequence 79 from Patent US 20050260715	Sacrophaga peregrina	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05636	GFGCPLDQMQCHRHCQTITGRSGGYCSGPLKLTCTCYR	38	Sequence 80 from Patent US 20050260715	Aeschna cyanea	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05637	GFGCPLNQGACHRHCRSIRRRGGYCAGFFKQTCTCYRN	38	Sequence 81 from Patent US 20050260715	Leiurus quinquestriatus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05638	ALWKTMLKKLGTMALHAGKAALGAADTISQTQ	32	Sequence 82 from Patent US 20050260715	Phyllomedusa sauvagii	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05640	GIFSKLGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC	46	Sequence 84 from Patent US 20050260715	Rana esculenta	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05641	FKCRRWQWRMKKLGAPSITCVRRAF	25	Sequence 86 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05642	ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK	34	Sequence 87 from Patent US 20050260715	Lactococcus lactis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05643	TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK	34	Sequence 88 from Patent US 20050260715	Staphylococcus epidermidi	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05644	MSKFDDFDLDVVKVSKQDSKITPQWKSESLCTPGCVTGALQTCFLQTLTCNCKISK	56	Sequence 89 from Patent US 20050260715	Bacillus subtilis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05645	KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW	37	Sequence 90 from Patent US 20050260715	Leuconostoc gelidum	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05646	GMASKAGAIAGKIAKVALKAL	21	Sequence 93 from Patent US 20050260715	Xenopus laevis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05647	GVLSNVIGYLKKLGTGALNAVLKQ	24	Sequence 94 from Patent US 20050260715	Xenopus laevis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05648	GWASKIGQTLGKIAKVGLKELIQPK	25	Sequence 95 from Patent US 20050260715	Xenopus laevis	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05649	INLKALAALAKKIL	14	Sequence 96 from Patent US 20050260715	Vespula lewisii	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05651	ATCDLLSGTGINHSACAAHCLLRGNRGGYCNGKGVCVCRN	40	Sequence 98 from Patent US 20050260715	Phormia terronovae	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05652	ATCDLLSGTGINHSACAAHCLLRGNRGGYCNRKGVCVRN	39	Sequence 99 from Patent US 20050260715	Phormia terronovae	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05653	RRWCFRVCYKGFCYRKCR	18	Sequence 101 from Patent US 20050260715	Limulus polyphemus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05655	RGGRLCYCRRRFCICV	16	Sequence 103 from Patent US 20050260715	Sus scrofa	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05657	VTCDLLSFKGQVNDSACAANCLSLGKAGGHCEKGVCICRKTSFKDLWDKYF	51	Sequence 105 from Patent US 20050260715	Apis mellifera	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05658	GWLKKIGKKIERVGQHTRDATIQGLGIAQQAANVAATAR	39	Sequence 106 from Patent US 20050260715	Sacrophaga peregrina	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05659	GWLKKIGKKIERVGQHTRDATIQVIGVAQQAANVAATAR	39	Sequence 107 from Patent US 20050260715	Sacrophaga peregrina	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05660	SDEKASPDKHHRFSLSRYAKLANRLANPKLLETFLSKWIGDRGNRSV	47	Sequence 108 from Patent US 20050260715	Bos taurus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05661	RWCFRVCYRGICYRKCR	17	Sequence 110 from Patent US 20050260715	Tachypleus tridentatus	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05662	KSCCKDTLARNCYNTCRFAGGSRPVCAGACRCKIISGPKCPSDYPK	46	Sequence 111 from Patent US 20050260715	Hordeum vulgare	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05663	GGKPDLRPCIIPPCHYIPRPKPR	23	Sequence 112 from Patent US 20050260715	Trimeresurus wagleri	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05664	VKDGYIVDDVNCTYFCGRNAYCNEECTKLKGESGYCQWASPYGNACYCKLPDHVRTKGPGRCH	63	Sequence 113 from Patent US 20050260715	Androctonus australis hec	Antimicrobial	US 2005/0260715 A1	Patent Application	2005##11##24	US6946261	Efficient methods for producing antimicrobial cationic peptides in host cells.	Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
DRAMP05665	CVSLQGTCRRDICKLIEDEIGACRRRWKCCRL	32	Sequence 17 from Patent US 20050277176	Mus musculus	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05666	KQCISLKGICKDLACTSSDDTIGVCNDVKKCCRK	34	Sequence 19 from Patent US 20050277176	Mus musculus	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05667	QRCWNLYGKCRYRCSKKERVYVYCINNKMCCVK	33	Sequence 51 from Patent US 20050277176	Homo sapiens	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05668	QKCWNLHGKCRHRCSRKESVYVYCTNGKMCCVK	33	Sequence 52 from Patent US 20050277176	Mus musculus	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05669	ERCWKSFGVCREECAKKESFYIFCWNGKLCCVK	33	Sequence 53 from Patent US 20050277176	Mus musculus	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05670	ETCWNFRGSCRDECLKNERVYVFCVSGKLCCLK	33	Sequence 54 from Patent US 20050277176	Mus musculus	Antimicrobial	US 2005/0277176 A1	Patent Application	2005##12##15	US20030176652, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP05671	VTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	36	Sequence 12 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05672	CVLNVCSTSLKQIGTYGHDRIKCCKK	26	Sequence 13 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05673	YYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	37	Sequence 14 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05674	RICGYGTARCRKKCRSQEYRIGRCPNTYACCLRK	34	Sequence 15 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05675	ESCKLGRGKCRKECLENEKPDGNCRLNFLCCRQI	34	Sequence 16 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05676	EKCNKLKGTCKNNCGKNEELIALCQKSLKCCRTIQPC	37	Sequence 17 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05677	TNCCEAECLTFEVKIGGCRAELAPFCCKNRKKH	33	Sequence 18 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05678	EICERPNGSCRDFCLETEIHVGRCLNSRPCCLPLGHQ	37	Sequence 19 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05679	GHCLNLSGVCRRDVCKVVEDQIGACRRRMKCCRAWWIL	38	Sequence 20 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05680	TICRMQQGICRLEFCHSGEKKRDICSDPWNRCCVSNTDE	39	Sequence 22 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05681	DECPSEYYHCRLKCNADEHAIRYCADFSICCKLKI	35	Sequence 23 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05682	NSKRACYREGGECLQRCIGLFHKIGTCNFRFKCCKFQ	37	Sequence 26 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05683	NEPVSCIRNGGICQYRCIGLRHKIGTCGSPFKCCK	35	Sequence 27 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05684	EFELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP	50	Sequence 29 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05685	DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	37	Sequence 30 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05686	AELDHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYMK	40	Sequence 31 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05687	INNPVSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKRK	39	Sequence 32 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05688	INNPITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCKIR	39	Sequence 33 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05689	GNPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK	39	Sequence 34 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05690	NHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	38	Sequence 36 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05691	GPLSCGRNGGVCIPIRCPVPMRQIGTCFGRPVKCCRSW	38	Sequence 37 from Patent US 20060034820	Homo sapiens	Antimicrobial	US 2006/0034820 A1	Patent Application	2006##2##16	US7338936, US20070207963, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP05692	RKSYKCLHKRCR	12	Sequence 1 from Patent US 20060069022	Homo sapiens	Antimicrobial	US 2006/0069022 A1	Patent Application	2006##3##30	US7271239	D-isomers of antimicrobial peptide	This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents.
DRAMP05693	AKRHHGYKRKFH	12	Sequence 2 from Patent US 20060069022	Homo sapiens	Antimicrobial	US 2006/0069022 A1	Patent Application	2006##3##30	US7271239	D-isomers of antimicrobial peptide	This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents.
DRAMP05694	LAHQKPFIRKSYKCLHKRCR	20	Sequence 4 from Patent US 20060069022	Homo sapiens	Antimicrobial	US 2006/0069022 A1	Patent Application	2006##3##30	US7271239	D-isomers of antimicrobial peptide	This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents.
DRAMP05695	EELLKAVRLIKLLYQ	15	Sequence 1 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05696	EDLLKAVRLIKFLYQ	15	Sequence 2 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05697	EELIRTVRLIKLLYQ	15	Sequence 3 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05698	RRAAQAVRLIKLLYQ	15	Sequence 4 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05699	EELLQTVRFIKFLYQ	15	Sequence 5 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05700	RELLTAVRIIKILYQ	15	Sequence 6 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05701	EDLLRTVRLIKVLYQ	15	Sequence 7 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05702	ENLLKAIRLIKFLYQ	15	Sequence 8 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05703	QQLLQAIQIIKILYQ	15	Sequence 9 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05704	EELLKTVRLIKLLYQ	15	Sequence 10 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05705	EELLKTVRLIKFLYQ	15	Sequence 11 from Patent US 20060089488	Human immunodeficiency vi	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05706	VRLIKLLYQ	9	Sequence 12 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05707	VRLIKFLYQ	9	Sequence 13 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05708	VRFIKFLYQ	9	Sequence 14 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05709	VRIIKILYQ	9	Sequence 15 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05710	IRLIKFLYQ	9	Sequence 16 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05711	RLIKLLYQ	8	Sequence 17 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05712	RLIKLLYQRLIKLLYQ	16	Sequence 18 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05713	KTKEGVKT	8	Sequence 26 from Patent US 20060089488	Synthetic construct	Antimicrobial	US 2006/0089488 A1	Patent Application	2006##4##27	US7615534	Antimicrobial peptides and use thereof.	Artificially synthesized antimicrobial peptide that does not occur naturally is provided by the present invention. The antimicrobial peptide includes one unit, two units or more units of amino acid sequence composed of the following 8 amino acid residues: (R or Q)-(L or F or I)-I-K-(L or F or I or V)-L-Y-Q; and/or, modified sequence composed of said sequence with partial modification.
DRAMP05714	FFKKAAHVGKH	11	Sequence 1 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05715	HVGKAALTHYL	11	Sequence 3 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05716	MKFTATF	7	Sequence 7 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05717	KRAVDE	6	Sequence 9 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05718	KGRWLER	7	Sequence 11 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05719	YQEGEE	6	Sequence 13 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05720	RKRKWLR	7	Sequence 15 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05721	KAAHVG	6	Sequence 17 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05722	FLGALIK	7	Sequence 20 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05723	YDEQQE	6	Sequence 22 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05724	HGRHAA	6	Sequence 24 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05725	GFLFHG	6	Sequence 27 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05726	SFDDNP	6	Sequence 29 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05727	RSTEDI	6	Sequence 31 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05728	DDDDSP	6	Sequence 33 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05729	WMENPT	6	Sequence 35 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05730	GMMPNN	6	Sequence 38 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05731	WMMPNN	6	Sequence 41 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05732	AALVVD	6	Sequence 44 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05733	VLLTEAP	7	Sequence 46 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05734	VFPSIV	6	Sequence 48 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05735	HTFYNEL	7	Sequence 50 from Patent US 20060093596	Salmo salar	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05736	MHLPEP	6	Sequence 52 from Patent US 20060093596	Salmo salar	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05737	MNLPMH	6	Sequence 55 from Patent US 20060093596	Salmo salar	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05738	IVGRPRHQ	8	Sequence 58 from Patent US 20060093596	Salmo salar	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05739	GYALPHAI	8	Sequence 60 from Patent US 20060093596	Salmo salar	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05740	GKGRWLERIGKAGGIIIGGALDHL	24	Sequence 62 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05741	WLRRIGKGVKIIGGAALDHL	20	Sequence 63 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05742	GRRKRKWLRRIGKGVKIIGGAALDHL	26	Sequence 64 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05743	FLGALIKGAIHGGRFIHGMIQNHH	24	Sequence 66 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05744	GWGSIFKHGRHAAKHIGHAAVNHYL	25	Sequence 67 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05745	RWGKWFKKATHVGKHVGKAALTAYL	25	Sequence 68 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05746	RSTEDIIKSISGGGFLNAMNA	21	Sequence 69 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05747	FFRLLFHGVHHGGGYLNAA	19	Sequence 70 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05748	FFRLLFHGVHHVGKIKPRA	19	Sequence 71 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05749	GWKSVFRKAKKVGKTVGGLALDHYL	25	Sequence 72 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05750	GWKKWFNRAKKVGKTVGGLAVDHYL	25	Sequence 73 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05751	GWRTLLKKAEVKTVGKLALKHYL	23	Sequence 74 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05752	AGWGSIFKHIFKAGKFIHGAIQAHND	26	Sequence 75 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05753	GFWGKLFKLGLHGIGLLHLHL	21	Sequence 76 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05754	GWKKWLRKGAKHLGQAAIK	19	Sequence 77 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05755	GWKKWLRKGAKHLGQAAIKGLAS	23	Sequence 78 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05756	GWKKWFTKGERLSQRHFA	18	Sequence 79 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05757	FLGLLFHGVHHVGKWIHGLIHGHH	24	Sequence 80 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05758	GFLGILFHGVHHGRKKALHMNSERRS	26	Sequence 81 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05759	MKTFSVAVAVVVVLACMFILESTAVPFSEVRTEEVESIDSPVGEHQQPGGTSMNLPMHFRFKRQSHLSLCRWCCNCCHNKGCGFCCKF	88	Sequence 174 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05760	MKAFSVAVVLVIACMFILESTAVPFSEVRTEEVGSFDSPVGEHQQPGGESMHLPEPFRFKRQIHLSLCGLCCNCCHNIGCGFCCKF	86	Sequence 176 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05761	RTEEVESIDSPVGEHQQPGGTSMNLPMHFRFKRQSHLSLCRWCCNCCHNKGCGFCCKF	58	Sequence 177 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05762	MKTFSVAVVPVIACMFILESTAVPFSEVRTEEVGSFDSPVGEHQQPGGTSMNLPMHFRFKRQSHLSLCRWCFNCCHNKGCGFCCKF	86	Sequence 178 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05763	MKQFSVAVVLVMACMFIVESTAVPFSEVRTEEVGSLDSPVGEHQQPGGESMHLPEPFRFKRQIHLSLCGLCCNCCHNIGCGFCCKF	86	Sequence 179 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05764	MKAFSIAVAVTLVLAFVCIQCSSAVPFQGVQELEEAGGNDTPVAEHQVMSMESWMENPTRQKRHISHISLCRWCCNCCKANKGCGFCCKF	90	Sequence 180 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05765	MKTFSVAVAVTLVLAFVCIQDSSAVPFQGVQELEEAGGNDTPVAAHQMMSMESWMESPVRQKRHISHISMCRWCCNCCKAKGCGPCCKF	89	Sequence 181 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05766	MKTFSVAVTVAVVLVFICIQQSSGTFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRAFKCKFCCGCCRAGVCGLCCKF	84	Sequence 182 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05767	MKTFSVAVTVAVVLVFICIQQSSASFPEAQELEEAVSNDNAAAEHQETPVDSWMMPYNRQKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 183 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05768	MKTFSVAVTVAVVLVFICIQQSSASFPEAQELEEAVSNDNAAAEHQETPVDSWMMPNNRQKRGFKCKFCCGCCRAGVCGLCCKF	84	Sequence 184 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05769	MKTFSVAVTVAVVLVFICIQQSSATFPEMPYNRQKRGFKCKFCCGCCGAGVCGMCCKF	58	Sequence 185 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05770	MKTFSVAVTVAVVLVFICIQQSSASFPEAQELEEAVSNDNAAAEHQETPVDSRIPYNRQKRSFKCKFCCGCCRAGVCGLCCKF	83	Sequence 186 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05771	MKTCSVAVTVAVVLVFICIQQSSASFPEVQELEEAVSNDNAAAEHQETPVDSWMMPNNRQKRGFKCKFCCGCCRAGVCGLCCKF	84	Sequence 187 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05772	MKTISVAVTVAVVLVFICIQQSSASFPEAQELEEAVSNDNAAAEHQETPVDSGMIPYNRQKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 188 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05773	MKTFSGAVTVAVVLVFICIQQSSASFPEVQELEEAVSNDNAAAEHQETPVDSWMMPNNRQKRGFKCKFCCGCCRAGVCGLCCKF	84	Sequence 189 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05774	MKTSVVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAAHQETSVDSWMMPYNRPKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 190 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05775	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRPKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 191 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05776	MKTFVVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 192 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05777	MKTSVVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAAHQETSVDSWMMPYNRQKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 193 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05778	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDLWMMPYNRQKRGFKCKFCCGCCSPGVCGLCCRF	84	Sequence 194 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05779	MKTFSVAVAVAVVLIFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSLDSWMMPYNRQKRGFKCKFCCGCCRAGVCGLCCKF	84	Sequence 195 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05780	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSLDSWMMPYNRHKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 196 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05781	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELGEAVSNDNAAAEHQETSVDSWMMPYNRPKRSFKCKFCCGCCRAGVCGLCCKF	84	Sequence 197 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05782	MKTFSVAVTVAVVLIFICIQQSSATSPEVQGLEEAVSNDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCCRPGVCGLCCRS	84	Sequence 198 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05783	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDLWMMPYNRQKRGFKCKFCCGCCRPGVCGLCCRF	84	Sequence 199 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05784	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCCSPGVCGLCCKF	84	Sequence 201 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05785	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCCRPGVCGLCCKF	84	Sequence 202 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05786	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCCRPGVCGLCCRF	84	Sequence 204 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05787	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSSDNAAAEHQETSVDSWMMPYNRQKRSFKCKFCCGCCRRGVCGLCCKF	84	Sequence 205 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05788	MKTISVAVTVAVVLLFICTQQSSATFPEVQELEEAVSSDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCRCGALCGLCCKF	84	Sequence 206 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05789	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEPVSSDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCRCGALCGLCCKF	84	Sequence 207 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05790	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSSDNAAAEHQETSVDSWMMPYNRQKRGFKCKFCCGCRCGALCGLCCKF	84	Sequence 208 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05791	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETPVDSGMMPNNRQKRSADCWPCCNQNGCGTCCKV	81	Sequence 209 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05792	MKTFSVAVTVAVVLVFICIQQSSATFPEVQELEEAVSNDNAAAEHQETSVDSWMMPYNRQKRSAECSFCCNESGCGICCKF	81	Sequence 210 from Patent US 20060093596	Synthetic constructn	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05793	MPNNRQKRGSNCKPCCNHNGCGTCCEV	27	Sequence 243 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05794	MKFTATFLMLFIFVLMVEPGECGWKSVFRKAKKVGKTVGGLALDHYLGEQQELDKRAVDEDPSIVFD	67	Sequence 244 from Patent US 20060093596	Hippoglossoides platessoi	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05795	MKFTATFLMLFIFVLMVEPGECGWKKWFNRAKKVGKTVGGLAVDHYLGKQPELDKRAVDEDPSIVFD	67	Sequence 245 from Patent US 20060093596	Hippoglossoides platessoi	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05796	MKFTANFLMLFIFVLMFEPGECGWRTLLKKAEVKTVGKLALKHYLGKQPELDKRAIDDDPSIIVFD	66	Sequence 246 from Patent US 20060093596	Hippoglossoides platessoi	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05797	MKFTATFLMIAIFVLMVEPGECGWGSFFKKAAHVGKHVGKAALTHYLGDKQELNKRAVDEDPNVIVFE	68	Sequence 247 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05798	MKFTATFLMMCIFVLMVEPGECRWGKWFKKATHVGKHVGKAALTAYLGDKQELDKR	56	Sequence 248 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05799	MKFTATFLMMFIFVLMVEPGECGWGSIFKHGRHAAKHIGHAAVNHYLGEQQDLDKRAVDEDPNVIVFE	68	Sequence 249 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05800	MKFTATFLMMFMVVLMAEPGEAGWGSIFKHIFKAGKFIHGAIQAHNDGEEQDLDKR	56	Sequence 250 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05801	MKFTATFLVLFMVVLMAGSGECGWKKWFTKGAKHLGQAAINGLASCEEQQELDKRSEDDEPSAIVFE	67	Sequence 251 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05802	MKFTATFLVLFMVVLMAGSGECGWKKWLRKGAKHLGQAAIKGLASCEEQQELDKRSMDDEPSAIVFD	67	Sequence 252 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05803	MKFTATFLVLFMVVLMAGSGECGWKKWFTKGERLSQRHFADVEQQELDKRSVDDEPSSIAFD	62	Sequence 255 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05804	MKFTATFLVLFMVVLMAEPGEGYWRFRNHRGERLSQRHFADVEQQELDKRSVDDEPSSIAFD	62	Sequence 256 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05805	MKFTATFLVLVIVMFEPGECFGMLFHRVHHAGRLIHRFIKRHGDVEQQELDKRSVDDEPSSIAFA	65	Sequence 257 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05806	MKFTATFLVLFMVVLMAEPGDCIFGLIATAVHNAGRLIHRLLGFHHGPPGFWHGDVEQQELDKRSVDEEPSAIVFE	76	Sequence 258 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05807	MKFTATFLVLFMVVLMAEPGDCIFGLIATAVHNVGRLVHRLLGFHHGPPGFWHGDVEQQELDKRSVDEEPSAIVFE	76	Sequence 259 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05808	MKFTATFLVLSLVVLMAEPGECFLGALIKGAIHGGRFIHGMIQNHHGYDEQQELDKRSVDDNPGAIVFD	69	Sequence 260 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05809	MKLAAAFLVLFLVVLMAEPGESFLGFLFHGIRHGIKAIHGMIHGNSLDEMQELDKRSFDDNPNAIVFD	68	Sequence 261 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05810	MKLAAAFLVLFLVVLMAEPGEGFLGFLFHGIHHGIRAIHHLIHGQRYDEQQELDKRSVDDNPGAIVFD	68	Sequence 262 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05811	MKFTATFLVLFMVVLMAEPGECFLGLLFHGVHHVGKLIHGLIHGGYDEQQELDKR	55	Sequence 263 from Patent US 20060093596	Hippoglossus hippoglossus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05812	MKFTATFLVLFMVVLMAEPGECFLGLLFHGVHHVGKWIHGLIHGHHGYDEQQELDKR	57	Sequence 264 from Patent US 20060093596	Hippoglossus hippoglossus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05813	MKFTATFLVLFMVVLMAEPGEGFLGILFHGVHHGRKKALHMNSERRSYDERQQQQQELDKR	61	Sequence 265 from Patent US 20060093596	Hippoglossus hippoglossus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05814	MKFTATFLVLFMVVLMAEPGEGLGNWMGPHISGEKKALHMNSERRSYDERQQQQQELDKR	60	Sequence 266 from Patent US 20060093596	Hippoglossus hippoglossus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05815	MKLTATFLVLFMVVLMAEPGEGFWGKLFKLGLHGIGLLHLHLG	43	Sequence 267 from Patent US 20060093596	Glyptocephalus cynoglossu	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05816	MKFATAFLMLSMVVLMAEPGECRSTEDIIKSISGGGFLNAMNAGYNEQQELNKRSDDDDSPSLIVFD	67	Sequence 268 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05817	MKFTATFLLLFIFVLMVDLGEGRRKRKWLRRIGKGVKIIGGAALDHLGQGQVQGQDYDYQEGQELNKR	68	Sequence 269 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05818	MKFTATLLLLFIFVLMVDLGEGRRKKKGSKRKGSKGKGSKGKGRWLDRIGKAGGIIIGGALDHLGQGQVQGPDYDYQEGEELNKRSDDDDSPSLIFFD	98	Sequence 270 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05819	MKFTATFLLLFIFVLMVDLGEGRRKKKGSKRKGSKGKGSKGKGRWLERIGKAGGIIIGGALDHLGQGQVQGPDYDYQEGEELNKR	85	Sequence 271 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05820	MKFTATFLMIAIFVLMVEPGECGWGSFFKKAAHVGKHVGKAALTHYLGDKQELNKRAVDE	60	Sequence 274 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05821	MKFTATFLMMFIFVLMVEPGECGWGSIFKHGRHAAKHIGHAAVNHYLGEQQDLDKRAVDE	60	Sequence 275 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05822	MKFTATFLVLSLVVLMAEPGECFLGALIKGAIHGGRFIHGMIQNHHGYDEQQELNKRAVDE	61	Sequence 276 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05823	MKFTATFLLLFIFVLMVDLGEGRRKRKWLRRIGKGVKIIGGAALDHLGQGQVQGQDYDYQEGQELNKRAVDE	72	Sequence 277 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05824	MKFTATFLLLFIFVLMVDLGEGRRKKKGSKRKGSKGKGSKGKGRWLERIGKAGGIIIGGALDHLGQGQVQGPDYDYQEGEELNKRAVDE	89	Sequence 278 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05825	MWKDVLKKIGTVALHAGKAALGAV	24	Sequence 279 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05826	SIGSAFKKALPVAKKIGKAALPIAK	25	Sequence 280 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05827	MKTFSAAVTVAVVLVFICIQQSSATSPEVQELEEAVSSDNAAAEHQEQSADSWMMPQNRQKRDVKCGFCCKDGGCGVCCNF	81	Sequence 286 from Patent US 20060093596	Paralichthys olivaceus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05828	MKTCGFAAAVAVLLTFICIQEGCAVSVAEEQVLKDPMGNGDPQEVPAESSGRQWMMPFHFRQRRGSGPMPCRQCCHCCPENGRVYV	86	Sequence 294 from Patent US 20060093596	Hippoglossus hippoglossus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05829	MKTFSVAVAVAVVLAFICLQESSAVPVTEVQELEEPMSNEYQEMPVESWKMPYNNRHKRHSSPGGCRFCCNCCPNMSGCGVCCRF	85	Sequence 295 from Patent US 20060093596	Morone saxatilis	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05830	MKAFSIAVAVTLVLAFICILQSSAIPVNGVKELEEAASNDTPVAARHEMSMQPWMLPNHIREKRQSHISMCTMCCNCCKNYKGCGFCCRF	90	Sequence 296 from Patent US 20060093596	Oryzias latipes	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05831	MKAFSIAVAVTLVLAFVCIQDSSAIPFQGVQELEEAGGNDTPVAAHQMMSMESWMESPVRQKRHISHISMCRWCCNCCKAKGCGXCCKF	89	Sequence 298 from Patent US 20060093596	Paralichthys olivaceus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05832	LQVLTEEVGSIDSPVGEHQQPGGESMRLPEHFRFKRXSHLSLCRWCCNCCHNKGXGFCCKF	61	Sequence 302 from Patent US 20060093596	Oncorhynchus mykiss	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05833	MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT	84	Sequence 304 from Patent US 20060093596	Homo sapiens	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05834	MKFTATFLXXXLLFIFXVLMXVEDPLGECG	30	Sequence 305 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05835	YXXXEXXXQELXKRXVDX	18	Sequence 306 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05836	MKTFSVAV	8	Sequence 308 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05837	MKTFSVAVTVAVVLXFICIQQSSA	24	Sequence 309 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05838	MKTFSVAVAVXXVLAFXXXXXXSXAVPFXXV	31	Sequence 310 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05839	PEVQXLEEAXSXDNAAAEHQE	21	Sequence 311 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05840	PFXXVXXXEEVXXXDXPVXXHQ	22	Sequence 312 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05841	GWXXXFXK	8	Sequence 315 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05842	FKCKFCCGCCXXGVCGXCC	19	Sequence 317 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05843	CXXCCNCCXXKGCGFCCKF	19	Sequence 318 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05844	FKCKFCCGCRCGXXCGLCCKF	21	Sequence 319 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05845	XXXCXXCCNXXGCGXCCKX	19	Sequence 320 from Patent US 20060093596	Synthetic construct	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05846	GCGFCC	6	Sequence 322 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05847	GRRKRK	6	Sequence 323 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05848	MKFTATFLMMAIFVLMVEPGECGWGSFFKKAAHVGKHVGKAALTHYLGDKQELNKRAVDEDPNVIVFE	68	Sequence 329 from Patent US 20060093596	Pleuronectes americanus	Antimicrobial	US 2006/0093596 A1	Patent Application	2006##5##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2, WO2004018706A3	Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP05849	KVQIINKK	8	Sequence 1 from Patent US 20060122122	Rattus norvegicus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05850	SVQIVYKP	8	Sequence 2 from Patent US 20060122122	Rattus norvegicus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05851	QVEVKSEK	8	Sequence 3 from Patent US 20060122122	Rattus norvegicus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05852	KKVAVVRT	8	Sequence 4 from Patent US 20060122122	Rattus norvegicus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05853	KKVAIIRT	8	Sequence 5 from Patent US 20060122122	Mus musculus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05854	KKPTSAK	7	Sequence 6 from Patent US 20060122122	Homo sapiens	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05862	LMWWML	6	Sequence 14 from Patent US 20060122122	Homo sapiens	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05863	LMWWLL	6	Sequence 15 from Patent US 20060122122	Drosophila melanogaster	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05864	CLFWLL	6	Sequence 16 from Patent US 20060122122	Arabidopsis thaliana	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05865	LIWYLL	6	Sequence 17 from Patent US 20060122122	Saccharomyces cerevisiae	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05866	VVYWLL	6	Sequence 18 from Patent US 20060122122	Haloarcula marismortui	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05867	LYLGAV	6	Sequence 19 from Patent US 20060122122	Escherichia coli	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05868	LITSKM	6	Sequence 20 from Patent US 20060122122	Pediococcus acidilactici	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05869	FFYMVI	6	Sequence 21 from Patent US 20060122122	Acanthamoeba castellanii	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05870	LLTAKM	6	Sequence 22 from Patent US 20060122122	Staphylococcus aureus	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05871	KKVAVVR	7	Sequence 23 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05872	LKRKLQRVQIVYK	13	Sequence 25 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05873	LKRKLQRVQIINK	13	Sequence 26 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05874	KKVAVVRKKVAVVR	14	Sequence 27 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05875	KVQIINKKKVQIINKK	16	Sequence 28 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05876	RKKKRKVKKVAVVR	14	Sequence 29 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05877	KKVAVVRTKKVAVVRT	16	Sequence 30 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05878	RKKKRKVKVQIINKK	15	Sequence 31 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05879	RKKKRKVKKVAVVRT	15	Sequence 32 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05880	KVQIINKKLDVSNLMWWLL	19	Sequence 33 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05881	KVQIINKKLMWWLL	14	Sequence 34 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05882	PPRKKRTVVKVQIINKK	17	Sequence 35 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05883	VQIVYKVQIVYK	12	Sequence 36 from Patent US 20060122122	Synthetic construct	Antimicrobial	US 2006/0122122 A1	Patent Application	2006##6##8	US7964556	Antimicrobial peptides and use thereof.	Antimicrobial agent including an artificially synthesized antimicrobial peptide that does not occur naturally is provided by present invention. The peptide included in the antimicrobial agent includes 1 unit, 2 units or more units of sequence(s) or sequence(s) with partial modification, the sequence(s) composed of at least 6 contiguous amino acid residues selected from any one of amino acid sequences: (a) KVQIINKK; (b) SVQIVYKP; (c) QVEVKSEK; (d) KKVAVVRT; (e) KKVAIIRT; (f) KKPTSAK, and the total number of amino acid residues included in 1 unit, 2 units or more units of sequence(s) is 30% or more of the total number of amino acid residues constituting the peptide chain.
DRAMP05885	KXRRXI	6	Sequence 1 from Patent US 20060128614	Synthetic construct	Antimicrobial	US 2006/0128614 A1	Patent Application	2006##6##15	US7964556	Antimicrobial peptides with reduced hemolysis and methods of their use.	The present invention provides novel cyclic and linear short peptides containing one of the following amino acid residue sequences: Xa1-Naa-Xa1-Xa1-Naa-Xa2 or Xa1-Naa-Xa2-Xa1-Naa-Xa1 wherein: Xa1 represents lysine, arginine, or histidine; Naa represents an unnatural hydrophobic aromatic amino acid moiety selected from the group consisting of (naphtha-1-yl)alanine (1-Nal), (naphtha-2-yl)alanine (2-Nal), (benzothien-3-yl)alanine (Bal), diphenylalanine (Dip), (4,4'-biphen-yl)alanine (Bip), (anthracen-9-yl)alanine (Ath), and (2,5,7-tri-tert-butyl-indol-3-yl)alanine (Tht); and Xa2 represents valine, leucine, or isoleucine. The novel peptides exhibit broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi by effecting modification of the primary peptide structure. Further, the peptides exhibit improved serum compatibility and reduced hemolysis.
DRAMP05886	KXRRXV	6	Sequence 2 from Patent US 20060128614	Synthetic construct	Antimicrobial	US 2006/0128614 A1	Patent Application	2006##6##15	US7964556	Antimicrobial peptides with reduced hemolysis and methods of their use.	The present invention provides novel cyclic and linear short peptides containing one of the following amino acid residue sequences: Xa1-Naa-Xa1-Xa1-Naa-Xa2 or Xa1-Naa-Xa2-Xa1-Naa-Xa1 wherein: Xa1 represents lysine, arginine, or histidine; Naa represents an unnatural hydrophobic aromatic amino acid moiety selected from the group consisting of (naphtha-1-yl)alanine (1-Nal), (naphtha-2-yl)alanine (2-Nal), (benzothien-3-yl)alanine (Bal), diphenylalanine (Dip), (4,4'-biphen-yl)alanine (Bip), (anthracen-9-yl)alanine (Ath), and (2,5,7-tri-tert-butyl-indol-3-yl)alanine (Tht); and Xa2 represents valine, leucine, or isoleucine. The novel peptides exhibit broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi by effecting modification of the primary peptide structure. Further, the peptides exhibit improved serum compatibility and reduced hemolysis.
DRAMP05887	KXIKXR	6	Sequence 3 from Patent US 20060128614	Synthetic construct	Antimicrobial	US 2006/0128614 A1	Patent Application	2006##6##15	US7964556	Antimicrobial peptides with reduced hemolysis and methods of their use.	The present invention provides novel cyclic and linear short peptides containing one of the following amino acid residue sequences: Xa1-Naa-Xa1-Xa1-Naa-Xa2 or Xa1-Naa-Xa2-Xa1-Naa-Xa1 wherein: Xa1 represents lysine, arginine, or histidine; Naa represents an unnatural hydrophobic aromatic amino acid moiety selected from the group consisting of (naphtha-1-yl)alanine (1-Nal), (naphtha-2-yl)alanine (2-Nal), (benzothien-3-yl)alanine (Bal), diphenylalanine (Dip), (4,4'-biphen-yl)alanine (Bip), (anthracen-9-yl)alanine (Ath), and (2,5,7-tri-tert-butyl-indol-3-yl)alanine (Tht); and Xa2 represents valine, leucine, or isoleucine. The novel peptides exhibit broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi by effecting modification of the primary peptide structure. Further, the peptides exhibit improved serum compatibility and reduced hemolysis.
DRAMP05888	KXRRXVRXI	9	Sequence 4 from Patent US 20060128614	Synthetic construct	Antimicrobial	US 2006/0128614 A1	Patent Application	2006##6##15	US7964556	Antimicrobial peptides with reduced hemolysis and methods of their use.	The present invention provides novel cyclic and linear short peptides containing one of the following amino acid residue sequences: Xa1-Naa-Xa1-Xa1-Naa-Xa2 or Xa1-Naa-Xa2-Xa1-Naa-Xa1 wherein: Xa1 represents lysine, arginine, or histidine; Naa represents an unnatural hydrophobic aromatic amino acid moiety selected from the group consisting of (naphtha-1-yl)alanine (1-Nal), (naphtha-2-yl)alanine (2-Nal), (benzothien-3-yl)alanine (Bal), diphenylalanine (Dip), (4,4'-biphen-yl)alanine (Bip), (anthracen-9-yl)alanine (Ath), and (2,5,7-tri-tert-butyl-indol-3-yl)alanine (Tht); and Xa2 represents valine, leucine, or isoleucine. The novel peptides exhibit broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi by effecting modification of the primary peptide structure. Further, the peptides exhibit improved serum compatibility and reduced hemolysis.
DRAMP05889	IXRVXRRXK	9	Sequence 5 from Patent US 20060128614	Synthetic construct	Antimicrobial	US 2006/0128614 A1	Patent Application	2006##6##15	US7964556	Antimicrobial peptides with reduced hemolysis and methods of their use.	The present invention provides novel cyclic and linear short peptides containing one of the following amino acid residue sequences: Xa1-Naa-Xa1-Xa1-Naa-Xa2 or Xa1-Naa-Xa2-Xa1-Naa-Xa1 wherein: Xa1 represents lysine, arginine, or histidine; Naa represents an unnatural hydrophobic aromatic amino acid moiety selected from the group consisting of (naphtha-1-yl)alanine (1-Nal), (naphtha-2-yl)alanine (2-Nal), (benzothien-3-yl)alanine (Bal), diphenylalanine (Dip), (4,4'-biphen-yl)alanine (Bip), (anthracen-9-yl)alanine (Ath), and (2,5,7-tri-tert-butyl-indol-3-yl)alanine (Tht); and Xa2 represents valine, leucine, or isoleucine. The novel peptides exhibit broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi by effecting modification of the primary peptide structure. Further, the peptides exhibit improved serum compatibility and reduced hemolysis.
DRAMP05890	MNKFKDLNELELSNIAGGSNNIFWTRVGVGWAAEARCMIKPSLGNWTTKAVSCGAKGLYAAVRG	64	Sequence 74 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05891	MKQIIITENKVILSKILGGSSSIDDIGLNDTEHMLPLYSKKGSNHKRDVYLENPRYQTHFKFM	63	Sequence 76 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05892	MEKLMVLNEEKLSYVIGGGNPKVAHCASQIGRSTAWGAVSGAATGTAVGQAVGALGGALFGGSMGVIKGSAACVSYLTRHRHH	83	Sequence 84 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05893	MKKKVVKKTVLKEKELTKVVGGKKAPISGYVGRGLWENLSNIFKHHK	47	Sequence 86 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05894	LAVFLHGVQIGGSRIKQDARSVRKYDRIGIFFYSFKSA	38	Sequence 88 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05895	VMKMKLRQEQLNRKELSQVIGGRRDMILVALPHAVGPDGMPGSGRGGGAQMRAIGSIPPWRPNWWK	66	Sequence 90 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05896	VKNMQEWKKTTLSDNELIDVIGGSAKSYIRRLGPDGGYGGRESKLIAMADMIRRRI	56	Sequence 92 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05897	MKKLKVMNNGELEKVIGGSLYEMKNSVPRLLGPDGMEGSMGGSTGGIQSFRHFPGFGR	58	Sequence 96 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05898	MLYLLYIFLGLLIILGVNLLVTAFWALHDMYVHKDEEACDLNTFKKYFVKNNNIPTKMSDIFN	63	Sequence 108 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05899	MNKKNSQNNFSILGLIISLIIAWVITFFAMWASRGFSRDFFIMPRFAFVLVLSIAGAIIIGPAIYGFLYIGRKKD	75	Sequence 110 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05900	MAELNDSLTFKHGAKISNRFVQPPMLTNSGIDGEASEDTINYWRHHSKSGGMLITEC	57	Sequence 132 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05901	MKRTTKLGVSALLVSLFALFVGKKLDDEVNKDDASDDRGVGPLD	44	Sequence 136 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05902	MAKEIIYNLADTVQMKKPHACQTNDWEILRMGADIKLKCLGCGRMVMMPRSEFNRKVKKVLTKANDPVNLKKEHYVPKDRIVRPNFG	87	Sequence 156 from Patent US 20060134745	Lactobacillus acidophilus	Antimicrobial	US 2006/0134745 A1	Patent Application	2006##6##22	US7550576, US7754868, US20080233615, US20100279349	Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor.	Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.
DRAMP05903	WLNALLHHGLNCAKGVLA	18	Sequence 1 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05904	WLNALLHHGLNCAKG	15	Sequence 2 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05905	WLNALLHHGLNCAKGVL	17	Sequence 3 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05906	WLNALLHHGLNCAKGV	16	Sequence 4 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05907	WLNALLHHGLNCAK	14	Sequence 5 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05908	WLNALLHHGLNCA	13	Sequence 6 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05909	WLNALLHHGLNC	12	Sequence 7 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05910	WLNALLKKGLNCAKGVLA	18	Sequence 8 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05911	KWLNALLHHGLNCAKGVLA	19	Sequence 9 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05912	KWLNALLKKGLNCAKGVLA	19	Sequence 10 from Patent US 7504380	Halocynthia aurantium	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05913	ALLHHGLNCAKGVLA	15	Sequence 15 from Patent US 7504380	Synthetic construct	Antimicrobial	US 7504380 B2	Granted Patent	2009##3##17	US20060135748, WO2004048407A1	Antimicrobial peptide isolated from halocynthia aurantium.	The present invention relates to an antimicrobial peptide isolated from Halocynthia aurantium, more particularly, to an antimicrobial peptide isolated from the body fluid of Halocynthia aurantium and an antimicrobial agent comprising the same as an active ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a natural antimicrobial agent.
DRAMP05914	LKALKALKALKALKR	15	Sequence 1 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05915	LKVLKVLKVLKVLKV	15	Sequence 2 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05916	LKVLKVLKVLKVLKVLKV	18	Sequence 3 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05917	FKAFKAFKAFKAFKA	15	Sequence 4 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05918	LLARLLLARLLLARL	15	Sequence 7 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05919	LARLLARLLARL	12	Sequence 8 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05920	LARLLARLLARLLARL	16	Sequence 9 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05921	ARLARLARL	9	Sequence 10 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05922	ARLARLARLARL	12	Sequence 11 from Patent US 20060166883	Synthetic construct	Antimicrobial	US 2006/0166883 A1	Patent Application	2006##7##27	US7563764	Novel antimicrobial peptides based on tripeptide repeats.	The invention described herein relates to compositions of novel antimicrobial peptides that comprise hydrophobic and cationic residues, based on monomeric tri-peptide units. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates, medical devices, protective garments and barrier materials comprising the peptides of the present invention.
DRAMP05923	MWWLVGLTPVELIHLX	16	Sequence 1 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05924	MWWLVGLTPVELIHLXA	17	Sequence 2 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05925	MWWLVGLTPVELIHLXAF	18	Sequence 3 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05926	MWWLVGLTPVELIHLXAFR	19	Sequence 4 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05927	MWWLVGLTPVELIHLXAFRE	20	Sequence 5 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05928	MWWLVGLTPVELIHLXAFRER	21	Sequence 6 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05929	MWWLVGLTPVELIHLXAFRERL	22	Sequence 7 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05930	MWWLVGLTPVELIHLXAFRERLX	23	Sequence 8 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05931	MWWLVGLTPVELIHLXAFRERLXH	24	Sequence 9 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05932	MWWLVGLTPVELIHLXAFRERLXHL	25	Sequence 10 from Patent US 20060168682	Arabidopsis thaliana	Antimicrobial	US 2006/0168682 A1	Patent Application	2006##7##27	CA2491607A1, DE60332535D1, EP1525217A1, EP1525217B1, US7465783, WO2004005329A1	Plant peptide with antimicrobial activity.	The invention concerns novel peptides, in particular plant peptides, having an antimicrobial activity and a cytotoxic activity, in particular for plant cells. The invention also concerns polynucleotides coding for said peptides, vectors comprising said polynucleotides, micro-organisms and cells transformed with said vectors, transgenic organisms whereof all of part of the cells contain and/or express said vectors, uses of said peptides and said polynucleotides, in particular as plant-specific antimicrobial agents. The invention further concerns an antimicrobial and/or cytotoxic method for treating plants.
DRAMP05933	GFWKKVGSAAWGGVKAAAKGAAVGGLNALAKHIQ	34	Sequence 1 from Patent US 20060205640	Halocynthia papillosa	Antimicrobial	US 2006/0205640 A1	Patent Application	2006##9##14	DE602004006390D1, DE602004006390T2, EP1601769A1, EP1601769B1, US7531509, WO2004081214A1	Papillosin antimicrobial peptide, a gene coding said peptide, a vector, a transformed organism and a compound containing said organism.	A antimicrobial peptide isolated from an extract from a marine invertebrate, whose amino acid sequence is as follows: GFWKKVGSAAWGGVKAAAKGAAVGGLNALAKHIQ (SEQ ID No. 1), its derivatives, its fragments and a polypeptide, as well as transformed host organisms capable of producing the peptide such as microorganisms, animal cells, digital cells and plants, and an anti-microbial composition containing the peptide.
DRAMP05934	YIVYKIRSARKRSKALK	17	Sequence 1 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05935	YIVYKIRSADKRRKALK	17	Sequence 2 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05936	YIVYKRRSARKRSKALK	17	Sequence 3 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05937	YIVYKRRSADKRRKALK	17	Sequence 4 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05938	YIVYKIRSARKRRKALK	17	Sequence 5 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05939	YIRYKIRSARKRRKALK	17	Sequence 6 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05940	YIVYKRRSARKRRKALK	17	Sequence 7 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05941	YIRYKRRSADKRRKALK	17	Sequence 8 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05942	YIRYKRRSARKRRKALK	17	Sequence 10 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05943	YIVYKIRSAPKRSKALK	17	Sequence 11 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05944	YIVWKIRSADKRSKALK	17	Sequence 12 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05945	YIVYKIRWADKRSKALK	17	Sequence 13 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05946	YIVYKIRSAWKRSKALK	17	Sequence 14 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05947	YIVYKIRSADKRWKALK	17	Sequence 15 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05948	YIVYKIRSAWKRRKALK	17	Sequence 16 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05949	YIVYKIRSAWKRWKALK	17	Sequence 17 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05950	YIVYKIRSARKRWKALK	17	Sequence 18 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05951	YIVYKIRWAWKRSKALK	17	Sequence 19 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05952	YIVYKIRWAWKRRKALK	17	Sequence 20 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05953	YIVYKIRWARKRSKALK	17	Sequence 21 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05954	YIVYKIRWARKRRKALK	17	Sequence 22 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05955	YIVYKIRWARKRWKALK	17	Sequence 23 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05956	YIVYKIRRARKRRKALK	17	Sequence 24 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05957	YIVYKIRRAWKRSKALK	17	Sequence 25 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05958	YIVYKIRRAWKRRKALK	17	Sequence 26 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05959	YIVYKIRRAWKRWKALK	17	Sequence 27 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05960	YIVYKIRSAKKRKKALK	17	Sequence 28 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05961	YIVYKIRSAKKRWKALK	17	Sequence 29 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05962	YIVYKIRSAWKRKKALK	17	Sequence 30 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05963	YIVYKIRWAKKRKKALK	17	Sequence 31 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05964	YIVYKIRWAKKRWKALK	17	Sequence 32 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05965	YIVYKIRWAWKRKKALK	17	Sequence 33 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05966	YIVYKIRSAWKRWKAL	16	Sequence 34 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05967	YIVYKIRSARKRWKAL	16	Sequence 35 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05968	YIVYKIRSAWKRRK	14	Sequence 36 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05969	YIVYKIRSAWKRWK	14	Sequence 37 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05970	YIVYKIRSARKRWK	14	Sequence 38 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05971	YIVYKIRWARKRRKAL	16	Sequence 39 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05972	YIVYKIRWARKRRK	14	Sequence 40 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05973	YIVWKIRSARKRRKALK	17	Sequence 41 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05974	YIVWKIRSAWKRSKALK	17	Sequence 42 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05975	YIVRKIRSAWKRWKALK	17	Sequence 43 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05976	YIVRKIRSAWKRRKALK	17	Sequence 44 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05977	YIVWKIRSARKRWKALK	17	Sequence 45 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05978	YIVWKIRSAWKRWKALK	17	Sequence 46 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05979	YIVRKIRSARKRRKALK	17	Sequence 47 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05980	KYIVYKIRSARKRRKALK	18	Sequence 48 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05981	KYIVYKIRSAWKRSKALK	18	Sequence 49 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05982	KYIVYKIRSAWKRRKALK	18	Sequence 50 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05983	KYIVYKIRWARKRRKALK	18	Sequence 51 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05984	YIVYKIRFAFKRSKAL	16	Sequence 52 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05985	YIVYKIRFAFKRRKAL	16	Sequence 53 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05986	YIVYKIRWAWKRSKAL	16	Sequence 54 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05987	YIVYKIRWTWKRSKAL	16	Sequence 55 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05988	KLAKRRKWAWRIKYVIY	17	Sequence 56 from Patent US 20060252915	Synthetic construct	Antimicrobial	US 2006/0252915 A1	Patent Application	2006##11##9	DE50213300D1, EP1453855A1, EP1453855B1, US7449545, US20090149391, WO2003048201A1	Antimicrobial bolisin peptides.	The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.
DRAMP05989	QCRRLCYKQRCVTYCRGR	18	Sequence 3 from Patent US 20060276380	Synthetic construct	Antimicrobial	US 2006/0276380 A1	Patent Application	2006##12##7	US7723468, US20030186854, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, compositions, and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting similar antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a hairpin structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cysteine forming two disulphide bridges, configurable as a cyclic chain with open or closed ends.
DRAMP05990	XCRRLDYKQRXVTYCRGX	18	Sequence 4 from Patent US 20060276380	Synthetic construct	Antimicrobial	US 2006/0276380 A1	Patent Application	2006##12##7	US7723468, US20030186854, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, compositions, and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting similar antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a hairpin structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cysteine forming two disulphide bridges, configurable as a cyclic chain with open or closed ends.
DRAMP05991	XERRLCYKQRCVTYKRGX	18	Sequence 5 from Patent US 20060276380	Synthetic construct	Antimicrobial	US 2006/0276380 A1	Patent Application	2006##12##7	US7723468, US20030186854, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, compositions, and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting similar antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a hairpin structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cysteine forming two disulphide bridges, configurable as a cyclic chain with open or closed ends.
DRAMP05992	XDRRLCYKQRCVTYXRGX	18	Sequence 6 from Patent US 20060276380	Synthetic construct	Antimicrobial	US 2006/0276380 A1	Patent Application	2006##12##7	US7723468, US20030186854, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, compositions, and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting similar antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a hairpin structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cysteine forming two disulphide bridges, configurable as a cyclic chain with open or closed ends.
DRAMP05993	QRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVIQGLV	39	Sequence 2 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05994	QRSVSNAATRVCRT	14	Sequence 3 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05995	GRSRW	5	Sequence 4 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05996	GQSQW	5	Sequence 5 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05997	RDVCRNFMRR	10	Sequence 6 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05998	QSRVIQGLV	9	Sequence 7 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP05999	QRSVSNAATRVCRTGRSRWRDVCRNFMRR	29	Sequence 8 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06000	QRSVSNAATRVSRTGRSRWRDVSRNFMRR	29	Sequence 9 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06001	QRSVSNPPTRVSRPPRSRWRDVSRPPMRR	29	Sequence 10 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06002	QRSVSRAATRVSRTGRSRWRDVSRNFMRR	29	Sequence 11 from Patent US 7745390	Homo sapiens	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06003	QRSVSNAATRVSRTGRSRWRDVSRRFMRR	29	Sequence 12 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06004	QRSVSRAATRVSRTGRSNWRDVGRRFMRR	29	Sequence 13 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06005	QRSVSRAATRVSRTGRSRWRDVSRRFMRR	29	Sequence 14 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06006	QRAVARAATRVARTGRARWRDVARNFMRR	29	Sequence 15 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06007	QRAVANAATRVARTGRARWRDVARRFMRR	29	Sequence 16 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06008	QRAVARAATRVARTGRARWRDVARRFMRR	29	Sequence 17 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06009	QRSVSRPPTRVSRTGRSRWRDVSRRFMRR	29	Sequence 18 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06010	QRSVSRAATRVSRTGRSRWRRVSRRFMRR	29	Sequence 19 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06011	QRAVARAATRVARTGRARWRRVARRFMRR	29	Sequence 20 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06012	WRDVSRNFMRRGRSRGWRDVSRNFMRR	27	Sequence 21 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06013	RDVSRRFMRRGSRDVSRRFMRR	22	Sequence 22 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06014	RDVSRRFMRRGSRDVSRRFMRRGSRDVSRRFMRR	34	Sequence 23 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06015	RDVSRRFMRRGRDVSRRFMRR	21	Sequence 24 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06016	RDVSRRFMRRRDVSRRFMRR	20	Sequence 25 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06017	RRVSRRFMRR	10	Sequence 26 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06018	RRVVRRFMRR	10	Sequence 27 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06019	RRVXRRFMRR	10	Sequence 28 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06020	RRVVRRLLRR	10	Sequence 29 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06021	RRLLRRLLRR	10	Sequence 30 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06022	RRLLRRLLRRGSRRLLRRLLRR	22	Sequence 31 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06023	RRVSRRFMRRGSRRVSRRFMRR	22	Sequence 32 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06024	KKVSKKFMKK	10	Sequence 33 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06025	KKVSKKFMKKGSKKVSKKFMKK	22	Sequence 34 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06026	KKVSKKFMKKGSKKVSKKFMKKGSKKVSKKFMKK	34	Sequence 35 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06027	RRVSRRFMRRGSRRVSRRFMRRGSRRVSRRFMRR	34	Sequence 36 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06028	RRDSRRFMRR	10	Sequence 37 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06029	CRRVSRRFMRRC	12	Sequence 38 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06030	RRVSRRFMRRD	11	Sequence 39 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06031	CKKVSKKFMKKGSKKVSKKFMKKC	24	Sequence 40 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06032	KKVSKKFMKKGSKKVSKKFMKKD	23	Sequence 41 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06033	RRMFRRSVRRCCRRVSRRFMRR	22	Sequence 42 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06034	RRPSRRFPRR	10	Sequence 43 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06035	RRVSRRFMRRSGSGSGSGQQMVQQSGQQFS	30	Sequence 44 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06036	RRVSRRFMRRSRWARKGSGQMVQQSSQQFQ	30	Sequence 45 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06037	VHKRRVSRRFMRRLGH	16	Sequence 46 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06038	FDTPRRVSRRFMRRLGH	17	Sequence 47 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06040	RDVCRNFMRRYQSRVIQGLV	20	Sequence 49 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06041	RDVSRNFMRRYQSRVIQGLV	20	Sequence 50 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06042	RDVSRRFMRRYQSRVIQGLV	20	Sequence 51 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06043	RDVSRRFMRRQSRVIQGLV	19	Sequence 52 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06044	RDVARRFMRRQSRVISRLV	19	Sequence 53 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06045	SDVARRFMRRQSRVIRRLV	19	Sequence 54 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06046	SDVAKKFMKKQSKVIKKLV	19	Sequence 55 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06047	RDVARRFMRRYQARVIQGLV	20	Sequence 56 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06048	RRVSRRFMRRYQSRVIQGLV	20	Sequence 57 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06049	RRVSRRFMRRYRSRVIRGLV	20	Sequence 58 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06050	RRVSRRFMRRYRSRRIRRLV	20	Sequence 59 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06051	KKVSKKFMKKYQSKVIQGLV	20	Sequence 60 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06052	RRVSRRFMRRYQSRVPQGLV	20	Sequence 61 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06053	QRRSSRFMRRYQRVVPRGLV	20	Sequence 62 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06054	RRVSRRFMRRYRSRRPRRLV	20	Sequence 63 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06055	RRVSRRPMRRYRSRRPRRLV	20	Sequence 64 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06056	RRVSRPPPRRYRSRRPRRLV	20	Sequence 65 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06057	RRVSRPPMRRYRSRRPRRLV	20	Sequence 66 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06058	QRSVSNAATRVCRTGRSRW	19	Sequence 67 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06059	QRSVSNAATRVSRTGRSRW	19	Sequence 68 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06060	QRSVSRAATRVSRTGRSRW	19	Sequence 69 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06061	QRSVSRPPTRVSRPPRSRW	19	Sequence 70 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06062	QRAVARAATRVARTGRARW	19	Sequence 71 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06063	QRSVSRAPTRVSRTGRSRW	19	Sequence 72 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06064	QKSVSKAATKVSKTGKSKW	19	Sequence 73 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06065	QRSVSRPPTRVSRTGRSRW	19	Sequence 74 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06066	QRSVSRPPTRVSRTGRARW	19	Sequence 75 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06067	QRSVSRAATRVCRTGRSNW	19	Sequence 76 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06068	GRSRWRDVCRNFMRR	15	Sequence 77 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06069	GRSRWRDVSRNFMRR	15	Sequence 78 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06070	GRSGWRDVSRNFRRG	15	Sequence 79 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06071	GRSLWRDVSRNFMRR	15	Sequence 80 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06072	GRSRWRDVSRRFMRR	15	Sequence 81 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06073	GRARWRDVARRFMRR	15	Sequence 82 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06074	GRSRWRRVSRRFMRR	15	Sequence 83 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06075	GSRRWRDVSRRFMRR	15	Sequence 84 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06076	GRSRWRDVSRNFMRRYQSRVIQGLV	25	Sequence 85 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06077	QRSVSNAATRVSRTGRSRWRDVSRNFMRRYQSRVIQGLV	39	Sequence 86 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06078	RRSVRRFMRRD	11	Sequence 87 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06080	RRSVRRFMRR	10	Sequence 89 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06083	RRVSRR	6	Sequence 92 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and may further be modified by the addition of altered residues and alterations in normal peptide secondary and tertiary structure, including modifications in quaternary (multimeric) structure.
DRAMP06084	RRRRRRRVSRRFMRR	15	Sequence 93 from Patent US 7745390	Synthetic construct	Antimicrobial	US 7745390 B2	Granted Patent	2010##6##29	US20060287232, WO2006127715A1	Antimicrobial peptides.	unknow
DRAMP06085	RKKKRKVLMWWMLR	14	Sequence 10 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06086	RKKKRKVLMWWML	13	Sequence 11 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06087	RIRKKLRLMWWML	13	Sequence 12 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06088	LMWWMLRIRKKLR	13	Sequence 13 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06089	LMWWMLRKKKRKV	13	Sequence 14 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06090	RKKKRKVLMWWMLAR	15	Sequence 15 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06091	RIRKKLRLMWWMLAR	15	Sequence 16 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06092	RKKKRKVVVYWLLR	14	Sequence 18 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06093	RKKKRKVLLTAKMR	14	Sequence 19 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06094	RKKKRKVFFYMVIR	14	Sequence 20 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06095	RKKKRKVLYLGAVR	14	Sequence 21 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06096	RKRKRKRLMWWML	13	Sequence 22 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06097	RIRKKLRLMWWMLR	14	Sequence 23 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06098	LKRKLQRLMWWML	13	Sequence 24 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06099	RKRRLMWWMLKKLR	14	Sequence 26 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06100	LKRKLQRLMWWMLR	14	Sequence 27 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06101	RKKRRQRRRLMWWML	15	Sequence 28 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06102	LMWWMLRIRKKLRVGR	16	Sequence 29 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06103	RKKKRKVLMWWMLKPV	16	Sequence 30 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06104	RGDLMWWMLAR	11	Sequence 31 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06105	TGTG	4	Sequence 32 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06106	RAVTLYLGAVAA	12	Sequence 34 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06107	RLLTAKMLMWWMLR	14	Sequence 35 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06108	RIRKKLRYIGSR	12	Sequence 36 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06109	RKKKRKVYIGSR	12	Sequence 37 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06110	LKRKLQRVVYWLL	13	Sequence 38 from Patent US 20070032431	Synthetic construct	Antimicrobial	US 2007/0032431 A1	Patent Application	2007##2##8	EP1688486A1, EP1688486A4, US7674771, WO2005049819A1	Antimicrobial peptides and utilization of the same.	Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of amino acid residue(s) conservatively replaced, and an amino acid sequence that can express antimicrobial activity against at least one kind of bacteria or fungi. It is desirable that the total number of amino acid residues is 100 or less.
DRAMP06111	KRIVQRIKDVF	11	Sequence 2 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06112	RKSKEKIG	8	Sequence 3 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06113	KSKEKIGK	8	Sequence 4 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06115	KRIVQRIKDFLRNLVP	16	Sequence 13 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06116	KRIVQRIKDFLRNLVPR	17	Sequence 14 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06117	KRIVQRIKDFLRNLVPRT	18	Sequence 15 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06118	KRIVQRIKDFLRNLVPRTE	19	Sequence 16 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06119	KRIVQRIKDFLRNLVPRTES	20	Sequence 17 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06120	KSKEKIGKEFKRIVQRIKDFLRNLVP	26	Sequence 18 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06121	KSKEKIGKEFKRIVQRIKDFLRNLVPR	27	Sequence 19 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06122	KSKEKIGKEFKRIVQRIKDFLRNLVPRT	28	Sequence 20 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06123	KSKEKIGKEFKRIVQRIKDFLRNLVPRTE	29	Sequence 21 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06124	KSKEKIGKEFKRIVQRIKDFLRNLVPRTES	30	Sequence 22 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06125	RKSKEKIGKEFKRIVQRIKDFLRNLVP	27	Sequence 23 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06126	RKSKEKIGKEFKRIVQRIKDFLRNLVPR	28	Sequence 24 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06127	RKSKEKIGKEFKRIVQRIKDFLRNLVPRT	29	Sequence 25 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06128	RKSKEKIGKEFKRIVQRIKDFLRNLVPRTE	30	Sequence 26 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06129	RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	31	Sequence 27 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06130	LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	36	Sequence 28 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06131	GGGGGGSMFGGAKKRSGGGGGG	22	Sequence 29 from Patent US 20070037744	Synthetic constructn	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06132	SSLLEKGLDGA	11	Sequence 30 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06133	SSLLE	5	Sequence 31 from Patent US 20070037744	Homo sapiens	Antimicrobial	US 2007/0037744 A1	Patent Application	2007##2##15	CN1878789A, US7718618, WO2005040192A2, WO2005040192A3, WO2005040201A1	Human cathelicidin antimicrobial peptides.	Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
DRAMP06135	PQRCPSLRQAVQLTHQQQRQV	21	Sequence 1 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06136	RCGQQLRNISPPQRCPSLRQAVQLTHQQQGQ	31	Sequence 2 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06137	PQRCPSLRQAVQLTHQQQGQV	21	Sequence 3 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06138	PQRCPSLRQAVQLTHQ	16	Sequence 4 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06139	QGPGRQPDFQRCGQQLRNISPP	22	Sequence 5 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06140	QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVASNIPST	60	Sequence 6 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06141	GQVGPQQVRQMYRVASNIPST	21	Sequence 7 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06142	PQRCPSLRQAV	11	Sequence 8 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06143	SLRQAVQLTHQ	11	Sequence 9 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06144	AVQLTHQQQGQV	12	Sequence 10 from Patent US 20070099838	Escherichia coli	Antimicrobial	US 2007/0099838 A1	Patent Application	2007##5##3	DE602004003508D1, EP1660525A1, EP1660525B1, WO2005019253A1	Plant-derived peptides harboring water-cleaning and antimicrobial activities.	Protein family derived from the protein defined by the amino acid sequence of QGPGRQPDFQRCGQQLRNISPPQRCPSLRQAVQLTHQQQGQVGPQQVRQMYRVAS NIPST (SEQ ID NO:6) is described.
DRAMP06145	KCRRWQWRMKKLGAPSITCV	20	Sequence 1 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06146	KCFQWQRNMRKVRGPPVSCI	20	Sequence 3 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP18830	RCLCVLRIC	9	Sequence 119 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18828	RCLCTLRIC	9	Sequence 117 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18829	RCLCVLRVC	9	Sequence 118 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18826	RCLCGLRIC	9	Sequence 115 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18827	RCLCTLRVC	9	Sequence 116 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18825	RCLCGLRVC	9	Sequence 114 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18823	RCICVLRVC	9	Sequence 112 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18824	RCICVLRFC	9	Sequence 113 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18822	RCICTLRFC	9	Sequence 111 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18820	RCICRLRFC	9	Sequence 109 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18821	RCICTLRVC	9	Sequence 110 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18819	RCICRLRVC	9	Sequence 108 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18817	RCLCVRRVC	9	Sequence 106 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18818	RCICGRRIC	9	Sequence 107 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18814	RCLCGRRVC	9	Sequence 103 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18815	RCLCTRRFC	9	Sequence 104 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18816	RCLCVLRIC	9	Sequence 105 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06165	WQR	3	Sequence 23 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP18812	RCLCRRRFC	9	Sequence 101 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18813	RCLCTLRIC	9	Sequence 102 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18811	RCLCRRRVC	9	Sequence 100 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18809	RCICGLRVC	9	Sequence 98 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18810	RCLCRLRIC	9	Sequence 99 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06169	QWR	3	Sequence 27 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP18808	RCICGLRFC	9	Sequence 97 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18806	RCICVRRVC	9	Sequence 95 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18807	RCICGRRFC	9	Sequence 96 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18805	RCICRLRIC	9	Sequence 94 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06173	RWQ	3	Sequence 31 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06174	KXXXXQXXMRK	11	Sequence 34 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06175	KNVRWCTISQPEWFKCRRWQWRMKKLGAPSITCVRRAF	38	Sequence 42 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06176	TISQPEWFKCRRWQWRMKKLGAPSITCVRRAF	32	Sequence 43 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06177	VSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCI	36	Sequence 44 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06178	KXXXK	5	Sequence 45 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06179	GRRRRSVQWCA	11	Sequence 46 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06180	APRKNVRWCTISQPEWFKCRRWQWRMKKLGAPSITCVRRAFALECIRAIA	50	Sequence 47 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06181	PEWFKCRRWQWRMKKLGA	18	Sequence 48 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06182	FKCRRWQWRMKKLGA	15	Sequence 49 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06183	KCRRWQWRMKKLGA	14	Sequence 50 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06184	CRRWQWRMKKLGA	13	Sequence 51 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06185	RRWQWRMKKLGA	12	Sequence 52 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06186	KKCRRWQWRMKKLGA	15	Sequence 53 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06187	FKCFRWQWRMKKLGA	15	Sequence 54 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06188	KKCFRWQWRMKKLGA	15	Sequence 55 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06189	FKCRRWQWRMKKLG	14	Sequence 56 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06190	CRRWQWRMKKLGAPSITCV	19	Sequence 57 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06191	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP	39	Sequence 65 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06192	PEPT	4	Sequence 79 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06193	EPTP	4	Sequence 80 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06194	PTEP	4	Sequence 81 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06195	TPEP	4	Sequence 82 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06196	IEGR	4	Sequence 83 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06197	QSHVQSAP	8	Sequence 84 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06198	QSAP	4	Sequence 85 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06199	XDDDKX	6	Sequence 86 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06200	XKRX	4	Sequence 87 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06201	PXGPXX	6	Sequence 89 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06202	XGVRGPRX	8	Sequence 90 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06203	SNGX	4	Sequence 91 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06204	DDEEE	5	Sequence 92 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06205	DDDEE	5	Sequence 93 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06206	DDDDE	5	Sequence 94 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06207	EEDDE	5	Sequence 95 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06208	DDEED	5	Sequence 96 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06209	EDEDE	5	Sequence 97 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06210	DDDEEE	6	Sequence 98 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06211	DEDEDE	6	Sequence 99 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06212	EEDDEE	6	Sequence 100 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06213	DDDDDP	6	Sequence 101 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06214	EEEEEDP	7	Sequence 102 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06215	DDDE	4	Sequence 103 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06216	DEDEDEDP	8	Sequence 104 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06217	DDDGGEEEGGDDDP	14	Sequence 105 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06218	DDDGGDDDPPDDDE	14	Sequence 106 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06219	DDDDEGGGGGGGGERRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP	53	Sequence 117 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06220	DDDDEGGGGGGGGGGGGERRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP	57	Sequence 118 from Patent US 20070104764	Synthetic construct	Antimicrobial	US 2007/0104764 A1	Patent Application	2007##5##10	CA2536782A1, CN1845989A, CN1845989B, EP1680503A1, EP1680503B1, US7935501, WO2005024002A1	Recombinant production of antimicrobial peptides.	The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.
DRAMP06221	MKKTAIAIAVALAGFATVAQA	21	Sequence 2 from Patent US 20070122425	Escherichia coli	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06222	MKKLLFAIPLVVPFYSHS	18	Sequence 3 from Patent US 20070122425	Bacteriophage fd	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06223	MKKTAIAIAVALAGFATVAQADPKGLKKLLKGLKKLLKL	39	Sequence 4 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06224	MKKLLFAIPLVVPFYSHSDPKGLKKLLKGLKKLLKL	36	Sequence 5 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06225	MKKTAIAIAVALAGFATVAQAKGLKKLLKGLKKLLKLHHHHHH	43	Sequence 6 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06226	MKKLLFAIPLVVPFYSHSKGLKKLLKGLKKLLKLHHHHHH	40	Sequence 7 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06227	MKKTAIAIAVALAGFATVAQAD	22	Sequence 15 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06228	PKGLKKLLKGLKKLLKL	17	Sequence 16 from Patent US 20070122425	Synthetic construct	Antimicrobial	US 2007/0122425 A1	Patent Application	2007##5##31	US7579005	Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic	A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.
DRAMP06229	HKHGHGHGKHKNKGKKNGKH	20	Sequence 1 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06230	GGHVLDHKHGHGHGHKNKG	19	Sequence 2 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06231	KHNLGHGHKHERDQGHGHQR	20	Sequence 3 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06232	GHHPHGHHPHGHHPHGHHPH	20	Sequence 4 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06233	LRKCCEDGMRENPMRFSCQRRTRFIS	26	Sequence 5 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06234	LGEACKKVFLDCCNYITELRRQHARAS	27	Sequence 6 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06235	CNYITELRRQHARASHLGLAR	21	Sequence 7 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06236	SRNLSEIKLLISQARK	16	Sequence 8 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06237	SRNLSEIKLLISQARKQAASIKVAVSADR	29	Sequence 9 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06238	KDFLSIELFRGRVKV	15	Sequence 10 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06239	SAVRKKLSVELSIRT	15	Sequence 11 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06240	LGTRLRAQSRQRSRPGRWHKVSVRW	25	Sequence 12 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06241	PPPPLTSASKAIQVFLLGGSRKRVL	25	Sequence 13 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06242	RLRAQSRQRSRPGRWHKVSVRW	22	Sequence 14 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06243	PGRWHKVSVRW	11	Sequence 15 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06244	RIQNLLKITNLRIKFVKL	18	Sequence 16 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06245	QPPRARITGYIIKYEKPG	18	Sequence 17 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06246	YIGLKDRKRPSELRRIASQVKYA	23	Sequence 18 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06247	SEKTLRKWLKMFKKRQLELY	20	Sequence 19 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06248	ARKKAAKAARKKAAKAARKKAAKA	24	Sequence 20 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06249	AKKARAAKKARAAKKARAAKKARA	24	Sequence 21 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06250	AKKQRFRHRNRKGYR	15	Sequence 22 from Patent US 20070185019	Synthetic construct	Antimicrobial	US 2007/0185019 A1	Patent Application	2007##8##9	CA2523998A1, CN1791612A, CN100362017C, CN101161284A, CN101161284B, EP1625155A1, EP1625155B1, US20090074864, WO2005061535A1	Novel antimicrobial peptides with heparin binding activity.	The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.
DRAMP06251	MRTSYLLLFTLCLLLSEMASGGNFLTGLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	68	Sequence 39 from Patent US 20070207963	Homo sapiens	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP18804	RCICVLRFC	9	Sequence 93 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06253	MKTHYFLLVMICFLFSQMEPGVGILTSLGRRTDQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	69	Sequence 43 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06254	MRTLCSLLLICCLLFSYTTPAVGSLKSIGYEAELDHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYMK	71	Sequence 44 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06255	MRIHYLLFAFLLVLLSPPAAFSKKINNPVSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKRK	63	Sequence 45 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06256	MRIHYLLFTFLLVLLSPLAAFTQIINNPITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCKIR	63	Sequence 46 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06257	MKIHYLLFAFLLVLLSPLAGVFSKTINNPVSCCMIGGICRYLCKGNILQNGSCGVTSLNCCKRK	64	Sequence 47 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06258	MKIHYLLFAFILVMLSPLAAFSQLINSPVTCMSYGGSCQRSCNGGFRLGGHCGHPKIRCCRRK	63	Sequence 48 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06259	MRIHYVLFAFLLVLLSPFAAFSQDINSKRACYREGGECLQRCIGLFHKIGTCNFRFKCCKFQIPEKKTKIL	71	Sequence 49 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06260	MRIHYLLFTFLLVLLSPLAAFSQKINEPVSCIRNGGICQYRCIGLRHKIGTCGSPFKCCK	60	Sequence 50 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06261	MRTLCSLLLICCLLFSYTTPAANSIIGVSEMERCHKKGGYCYFYCFSSHKKIGSCFPEWPRCCKNIK	67	Sequence 51 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06262	MRTLCSLLLICCLLFSYTTPAVGDLKHLILKAQLARCYKFGGFCYNSMCPPHTKFIGNCHPDHLHCCINMKELEGST	77	Sequence 52 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06263	MRIFSLIVAGLVLLIQLYPAWGTLYRRFLCKKMNGQCEAECFTFEQKIGTCQANFLCCRKRKEH	64	Sequence 53 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06264	MPQTFFVFCFLFFVFLQLFPGTGEIAVCETCRLGRGKCRRACIESEKIVGWCKLNFFCCRERI	63	Sequence 54 from Patent US 20070207963	Mus musculus	Antimicrobial	US 2007/0207963 A1	Patent Application	2007##9##6	US7338936, US20060034820, US20090023893	Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.	The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
DRAMP06265	SWLSKTAKKLENSAKKRISEGIAIAIQGGPRC	32	Sequence 1 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06266	GVLSNVIGYLKKLGTGALNAVLKQC	25	Sequence 2 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06267	SIGSALKKALPVAKKIGKIALPIAKAALPC	30	Sequence 3 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06268	GGLKKLGKKLEGVGKRVFKASEKALPVAVGIKALGC	36	Sequence 4 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06269	GFASFLGAALKAALIGANMLGGTPQQC	27	Sequence 5 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06270	SWLSSKTAKKLENSAKKRISEGIAIAIQGGPRC	33	Sequence 6 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06271	RGLRRLGRKIAHGVKKYGPTVLRIIRIAGC	30	Sequence 7 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06272	GWGSFFKKAAHVGKHVGKAALHTYLC	26	Sequence 8 from Patent US 20070231833	Synthetic construct	Antimicrobial	US 2007/0231833 A1	Patent Application	2007##10##4	Unknown	Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest.	Labeled antimicrobial peptides and method of using the same to detect a microorganism of interest. In one embodiment, the method involves adding immuno-capture beads to a sample, the immuno-capture beads including capture antibodies coupled to a paramagnetic bead, the capture antibodies being specific for the type of microorganism of interest. After mixing, the target microorganism binds to the capture antibodies. Next, the beads are collected by positioning a magnet close to the sample, and the unbound material is removed from the sample. Then, a solution containing fluorescently-labeled antimicrobial peptide is added to the sample, the labeled peptide binding in great numbers to the immuno-captured microorganism. After removing unbound peptide, the beads are suspended in solution and a magnetic probe is used to collect the beads in a small volume. With the beads thus drawn together, the solution is excited with a laser. Such excitation causes the label to fluoresce, which fluorescence is then de
DRAMP06273	CGGGGGGCGGGGCGGGGGGGGGCGGGGGGCC	31	Sequence 1 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06274	CLLLLLLCLLLLCLLLLLLLLLCLLLLLLCC	31	Sequence 2 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06275	CLGLGLGCGLGLCLGLGLGLGLCGLGLGLCC	31	Sequence 3 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06276	CRKRKRRCRKRKCKRKRKRKRKCRKRKRKCC	31	Sequence 4 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP18803	RCICTLRIC	9	Sequence 92 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06278	RRRRRRR	7	Sequence 6 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06279	GGGGGGGCGGGGGGCGGGGCGGGGGGGGGCGGGGGGCCGG	40	Sequence 7 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06280	LLLLLLLCLLLLLLCLLLLCLLLLLLLLLCLLLLLLCCLL	40	Sequence 8 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06281	GLGLGLGCLGLGLGCGLGLCLGLGLGLGLCGLGLGLCCLG	40	Sequence 9 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06282	KRKRKRKCRKRKRRCRKRKCKRKRKRKRKCRKRKRKCCRRKK	42	Sequence 10 from Patent US 20070244044	Synthetic construct	Antimicrobial	US 2007/0244044 A1	Patent Application	2007##10##18	CA2575058A1, CN101031583A, DE602005023315D1, EP1778720A2, EP1778720B1, EP1927597A1, EP2096118A1, US7847059, US8088888, US8350003, US20110021415, US201	Antimicrobial Peptides.	The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, for use as a medicaments.
DRAMP06283	QEAGLKK	7	Sequence 1 from Patent US 20070254006	Synthetic construct	Antimicrobial	US 2007/0254006 A1	Patent Application	2007##11##1	CA2655168A1, EP1991245A2, WO2007095393A2, WO2007095393A3, WO2007095393A9	Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides.	Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin/avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and/or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxic
DRAMP06284	KWKLFKKIGAVLKVL	15	Sequence 2 from Patent US 20070254006	Synthetic construct	Antimicrobial	US 2007/0254006 A1	Patent Application	2007##11##1	CA2655168A1, EP1991245A2, WO2007095393A2, WO2007095393A3, WO2007095393A9	Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides.	Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin/avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and/or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxic
DRAMP06285	FLGVVFKLASKVFPAVFGKV	20	Sequence 3 from Patent US 20070254006	Synthetic construct	Antimicrobial	US 2007/0254006 A1	Patent Application	2007##11##1	CA2655168A1, EP1991245A2, WO2007095393A2, WO2007095393A3, WO2007095393A9	Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides.	Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin/avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and/or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxic
DRAMP06286	FLFRVASKVFPALIGKFKKK	20	Sequence 4 from Patent US 20070254006	Synthetic construct	Antimicrobial	US 2007/0254006 A1	Patent Application	2007##11##1	CA2655168A1, EP1991245A2, WO2007095393A2, WO2007095393A3, WO2007095393A9	Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides.	Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin/avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and/or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxic
DRAMP06287	GLLSKLKKAAKKALKHVL	18	Sequence 2 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06288	GLFTKLRKATKRILEHVL	18	Sequence 3 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06289	GLLKTIRKKIKRVLKHVR	18	Sequence 4 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06290	GLWRKLKKALKRAVQGVR	18	Sequence 5 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06291	GMLSKLGITIKIAVKHIR	18	Sequence 6 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06292	GWFSKLKKTAKKLLQRVL	18	Sequence 7 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06293	GMLRKLKRKVKRTLQHVL	18	Sequence 8 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06294	GLFSIIMRAVKKVWQRVR	18	Sequence 9 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06295	GLLRKLGKKIKRVVKHVG	18	Sequence 10 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06296	GWFNKLKTKIKKTLKHVL	18	Sequence 11 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06297	GLLEKLRKALKRILQHVL	18	Sequence 12 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06298	GLWRKLRRKAKKVLQHIL	18	Sequence 13 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06299	GLLSRLRRATKIILKGIR	18	Sequence 14 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06300	GLWNMLKKKLKKIAQGIR	18	Sequence 15 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06301	GLLSKIMKAVKRTLKHIL	18	Sequence 16 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06302	GMLIKLEMEAKKVVKNVL	18	Sequence 17 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06303	GLLNKIKKTIKRAVQHVL	18	Sequence 18 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06304	GLLSKLKKTVKRVVKHVR	18	Sequence 19 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06305	GLLSKIRKKLKRVLQSIR	18	Sequence 20 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06306	GLVTLLKKAMKNALEDVL	18	Sequence 21 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06307	GLLRKIKMKAKKVLKNIL	18	Sequence 22 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06308	GLFRKLRKKVKKVLKHVL	18	Sequence 23 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06309	GLLSILKRKSKRILKHIL	18	Sequence 24 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06310	GILNIIGRAVKTVLESIR	18	Sequence 25 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06311	GLLSMLGKAVKRAVQHVL	18	Sequence 26 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06312	GILNKLRKKLKRVLQRIL	18	Sequence 27 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06313	GLLSKLGKAVKNILEDVV	18	Sequence 28 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06314	GLWSSIKKEAKHALKHIL	18	Sequence 29 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06315	GLLSKLKRKIKKAVKHIL	18	Sequence 30 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06316	GLFRKLKKTIKRVLKHVP	18	Sequence 31 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06317	GLFSLLRKTIKKVLQHIR	18	Sequence 32 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06318	GLLNKLKRALKKVVKHVR	18	Sequence 33 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06319	GWLRKIGKAVKKVVKRVL	18	Sequence 34 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06320	GLLGKLKRKIKKALEGIR	18	Sequence 35 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06321	GWLKILEKAAKITVKNVL	18	Sequence 36 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06322	GLLRILKKKAKKALQHIL	18	Sequence 37 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06323	GLLGKIRKEGRMFWRVFRRWL	21	Sequence 38 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06324	GLLRKLRKEVKKVLSIFFRWL	21	Sequence 39 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06325	GLLNKLKKNVKNIVQHILRWL	21	Sequence 40 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06326	GLFSILKREIKRTFSMFYRWL	21	Sequence 41 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06327	GLLGKLKKELKNVLEHIYRWL	21	Sequence 42 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06328	GILSKLKKAIKRILQDVLRWL	21	Sequence 43 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06329	GMLKKLKKKTKRAFSVFCRWL	21	Sequence 44 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06330	GILSMLERRWSMYCSIFCRWL	21	Sequence 45 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06331	GILSKLKKKAKNAVKMFCRWL	21	Sequence 46 from Patent US 20070259087	Synthetic construct	Antimicrobial	US 2007/0259087 A1	Patent Application	2007##11##8	CA2529061A1, DE602004018794D1, EP1664095A2, EP1664095B1, WO2004108757A2, WO2004108757A3	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP06333	YDPEAASAPGSGNPCHEASAAQKENAGEDP	30	Sequence 4 from Patent US 20080020976	Synthetic construct	Antimicrobial	US 2008/0020976 A1	Patent Application	2008##1##24	DE10129983A1, DE50206480D1, EP1397384A2, EP1397384B1, US7348409, WO2002100895A2, WO2002100895A3	Antimicrobially active peptide.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP06334	DPYAEAASGPNPGSKSHESAQAENCGADPE	30	Sequence 5 from Patent US 20080020976	Synthetic construct	Antimicrobial	US 2008/0020976 A1	Patent Application	2008##1##24	DE10129983A1, DE50206480D1, EP1397384A2, EP1397384B1, US7348409, WO2002100895A2, WO2002100895A3	Antimicrobially active peptide.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP06335	AYLDEELQTELYEILHQILQTMGVLSLQGSMLSVGDKVSTNGQSVNFDTIKEMCTFRAGGNIAVPRTPEENEAIASIAKKYNNYVYLGMIEDQ	93	Sequence 3 from Patent US 20080020983	Rat	Antimicrobial	US 2008/0020983 A1	Patent Application	2008##1##24	US7273847, US20040037781, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	One embodiment of the present invention is directed toward methods for inhibiting the oxidation of lipids, proteins, and other compounds. Another embodiment is directed toward methods for treating conditions associated with microbial contamination, colonization, and/or infection.
DRAMP18802	RCICTRRFC	9	Sequence 91 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06337	SVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLAR	77	Sequence 2 from Patent US 20080069849	Human	Antimicrobial	US 2008/0069849 A1	Patent Application	2008##3##20	CA2588145A1, CN101068563A, CN101068563B, EP1817046A1, EP1817046A4, WO2006054947A1	Novel Antimicrobial Peptides.	The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus, parasites as well as yeast.
DRAMP06338	LLGDFFRKSKEK	12	Sequence 2 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06339	IGKEFKRIVQRIKDFLRNLVPRTES	25	Sequence 3 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06340	FKRIVQRIKDFLRNLV	16	Sequence 4 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06341	FKRIVQRIKDFLR	13	Sequence 5 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06342	LLGDFKRIVQRIKDF	15	Sequence 6 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06343	GLFDIIKKIAESF	13	Sequence 8 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06344	GLFDKLKSLVSDDKK	15	Sequence 9 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06345	FKRIVQRIKDFLRXXXXXXXX	21	Sequence 10 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06346	NLV	3	Sequence 11 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06347	RLFDKIRQVIRKF	13	Sequence 12 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06348	GLFDIIKKIAESX	13	Sequence 14 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06349	GLFDIIKKIAESW	13	Sequence 15 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06350	GGXGG	5	Sequence 17 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06351	VLN	3	Sequence 19 from Patent US 20080125359	Synthetic construct	Antimicrobial	US 2008/0125359 A1	Patent Application	2008##5##29	US7465784, US7985836, US20090156499, US20110251120	Antimicrobial peptides and methods of identifying the same.	Antimicrobial peptides and methods of identifying the same are provided.
DRAMP06352	SGSLSTFFRLFNRSFTQALGK	21	Sequence 1 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18801	RCICTRRVC	9	Sequence 90 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06354	KNLRIIRKGIHIIKKY	16	Sequence 3 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06355	TFFRLFNRSFTQALGKGGGKNLRIIRKGIHIIKKY	35	Sequence 4 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18800	RCICRRRFC	9	Sequence 89 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06357	TFFRLFNRGGGKNLRIIRKGIHIIKKY	27	Sequence 6 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06358	FKKFWKWFRRF	11	Sequence 7 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06359	TRRRLFNRSFTQALGKSGGGFKKFWKWFRRF	31	Sequence 8 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06360	TFFRLFNRSGGGFKKFWKWFRRF	23	Sequence 9 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18799	RCICRRRVC	9	Sequence 88 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06362	KLFKFLRKHLL	11	Sequence 11 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06363	NIFEYFLEGGGKNLRIIRKGIHIIKKY	27	Sequence 12 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06364	NIFEYFLEGGGKLFKFLRKHLL	22	Sequence 13 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06365	TFFRLFNRSFTQALGKGGGKLFKFLRKHLL	30	Sequence 14 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06366	TFFRLFNRGGGKLFKFLRKHLL	22	Sequence 15 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06367	NIFEYFLEGGGFKKFWKWFRRF	22	Sequence 16 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06368	GGG	3	Sequence 17 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06369	AAA	3	Sequence 18 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06370	SAT	3	Sequence 19 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06371	ASA	3	Sequence 20 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06372	SGG	3	Sequence 21 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06373	PYP	3	Sequence 22 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06374	SGS	3	Sequence 23 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06375	GGS	3	Sequence 24 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06376	SPS	3	Sequence 25 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06377	PSGSP	5	Sequence 26 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18798	RCLCGRRFC	9	Sequence 87 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18797	RCLCGRRVC	9	Sequence 86 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06380	EMRLSKFFRDFILQRKK	17	Sequence 29 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06381	EMRISRIILDFLFLRKK	17	Sequence 30 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06382	KKHRKHRKHRKH	12	Sequence 31 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06383	KKHRKHRKHRKHGGSGGSKNLRRIIRKGIHIIKKYG	36	Sequence 36 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06384	RLFNRSFTQALGK	13	Sequence 37 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06385	TFFNRSFTQALGK	13	Sequence 38 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06386	TFFRLFTQALGK	12	Sequence 39 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06387	TFFRLFNRSALGK	13	Sequence 40 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06388	TFFRLFNRSFTQK	13	Sequence 41 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06389	TFFRLFNRS	9	Sequence 42 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06390	RLFNRSFTQA	10	Sequence 43 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06391	RSFTQALGK	9	Sequence 44 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06392	TFF	3	Sequence 45 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06393	TFFR	4	Sequence 46 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06394	TFFRL	5	Sequence 47 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06395	TGGRLGNRSGTQALGK	16	Sequence 48 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06396	TFFNLFNNSFTQALGK	16	Sequence 49 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06397	AAAALFNRSFTQALGK	16	Sequence 50 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06398	TFFRAAAASFTQALGK	16	Sequence 51 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06399	TFFRLFNRAAAAALGK	16	Sequence 52 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06400	TFFRLFNRSFTQAAAA	16	Sequence 53 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06401	VFIDILDKMENAIHKAAQAGIGIAKPIEKMILPK	34	Sequence 54 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06402	GNRPVYIPPPRPPHPRL	17	Sequence 55 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06403	TRSSRAGLQFPVGRVHRLLRK	21	Sequence 58 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06404	VFQFLGKIIHHVGNFVHGFSHVF	23	Sequence 60 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06405	RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI	35	Sequence 61 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06406	RICRIIFLRVCR	12	Sequence 62 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06407	SLFSLIKAGAKFLGKNLLKQGACYAACKASKQC	33	Sequence 65 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06408	DSHEERHHGRHGHHKYGRKFHEKHHSHRGYRSNYLYDN	38	Sequence 66 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06409	LGGLIKIVPAMICAVTKKC	19	Sequence 71 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06410	ILGPVLGLVSDTLDDVLGIL	20	Sequence 73 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06411	DDDDDD	6	Sequence 74 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18796	RCLCGLRVC	9	Sequence 85 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18795	RCLCVRRIC	9	Sequence 84 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06414	GLWSKIKTAGKSVAKAAAKAAVKAVTNAV	29	Sequence 78 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06415	AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA	42	Sequence 79 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06416	GIGALSAKGALKGLAKGLAEHFAN	24	Sequence 80 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06417	GWGSFFKKAAHVGKHVGKAALHTYL	25	Sequence 81 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06418	RGLRRLGRKIAHGVKKYGPTVLRIIRIAG	29	Sequence 82 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06419	RIIDLLWRVRRPQKPKFVTVWVR	23	Sequence 83 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06420	FLPIIGKLLSGLL	13	Sequence 84 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06421	VDKGSYLPRPTPPRPIYNRN	20	Sequence 87 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06422	KLLKLLLKLLKLLLKLLLKLLK	22	Sequence 88 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06423	KLALKLALKAWKAALKLA	18	Sequence 89 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP18794	RCLCTRRIC	9	Sequence 83 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP06425	KLWKKWAKKWLKLWKAW	17	Sequence 91 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06426	YKLLKLLLPKLKGLLFKL	18	Sequence 93 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06427	KKVVFKFKFK	10	Sequence 94 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06428	GWRLIKKILRVFKGL	15	Sequence 95 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06429	GILSKLGKALKKAAKHAAKA	20	Sequence 96 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06430	GLLRRLRDFLKKIGEKFKKIGY	22	Sequence 97 from Patent US 20080170991	Synthetic construct	Antimicrobial	US 2008/0170991 A1	Patent Application	2008##7##17	CA2661634A1, CN101511382A, EP2061488A2, EP2061488A4, US7846895, US20110207657, WO2008030988A2, WO2008030988A3	Selectively targeted antimicrobial peptides and the use thereof.	The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
DRAMP06431	RRIARVIVAVLR	12	Sequence 2 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06432	ARRLIVRVRVIA	12	Sequence 3 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06433	IRARIAVRRVVL	12	Sequence 4 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06434	IVRVAVALRRIR	12	Sequence 5 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06435	VRIRARRVILVA	12	Sequence 6 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06436	RRLVAIVAVRRI	12	Sequence 7 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06437	VLIRIRRVARAV	12	Sequence 8 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06438	IIRAALRRVRVV	12	Sequence 9 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06439	AAVRRRVRLVII	12	Sequence 10 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06440	AVRVRRRAILVI	12	Sequence 11 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06441	IAARRLIRVVRV	12	Sequence 12 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06442	VARIVVRLIRAR	12	Sequence 13 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06443	RAVAVIIRLRRV	12	Sequence 14 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06444	AVRAIRVLRVIR	12	Sequence 15 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06445	RARIVRVRVILA	12	Sequence 16 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06446	VILARRRVRIAV	12	Sequence 17 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06447	RRVAIVVIARLR	12	Sequence 18 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06448	ILVARVIRRRVA	12	Sequence 19 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06449	RRAAVVLIVIRR	12	Sequence 20 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06450	ARIARRVRILVV	12	Sequence 21 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06451	ILRRVRVRAVAI	12	Sequence 22 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06452	RRRAIVRVVAIL	12	Sequence 23 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06453	RAIIRRVLVRVA	12	Sequence 24 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06454	ARAILIRVVRRV	12	Sequence 25 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06455	IARRIVAVRLRV	12	Sequence 26 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06456	RVLIARVVRAIR	12	Sequence 27 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06457	VIVRLAARRVRI	12	Sequence 28 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06458	IILAVRAVRRVR	12	Sequence 29 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06459	IVVRRRRAALVI	12	Sequence 30 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06460	LAIVRRARVRIV	12	Sequence 31 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06461	ARRARIRILVVV	12	Sequence 32 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06462	IRVRRLVAAVIR	12	Sequence 33 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06463	VRLRIRVAVIRA	12	Sequence 34 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06464	RVLRVVRAAIRI	12	Sequence 35 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06465	RARRVRVLIAIV	12	Sequence 36 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06466	RAIRVRRIVLAV	12	Sequence 37 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06467	VVIRAAIRRVRL	12	Sequence 38 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06468	RIVLRRAAVIRV	12	Sequence 39 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06469	VLARVVARRIRI	12	Sequence 40 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06470	RLRVAIVAIVRR	12	Sequence 41 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06471	ILVIVRRRARAV	12	Sequence 42 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06472	RVLIVIRARRVA	12	Sequence 43 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06473	VIRRRRILAAVV	12	Sequence 44 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06474	VIALRIAVRRVR	12	Sequence 45 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06475	RRRVIVAVLARI	12	Sequence 46 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06476	RVLIAARVIRRV	12	Sequence 47 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06477	VVRALRRIIARV	12	Sequence 48 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06478	VIALVRARVRRI	12	Sequence 49 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06479	RRVIAIAVRRLV	12	Sequence 50 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06480	RLARIVVIRVA	11	Sequence 51 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06481	LARIVVIRVAR	11	Sequence 52 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06482	RLARIVVIRV	10	Sequence 53 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06483	LARIVVIRVA	10	Sequence 54 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06484	ARIVVIRVAR	10	Sequence 55 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06485	RLARIVVIR	9	Sequence 56 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06486	LARIVVIRV	9	Sequence 57 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06487	ARIVVIRVA	9	Sequence 58 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06488	RIVVIRVAR	9	Sequence 59 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06489	RLARIVVI	8	Sequence 60 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06490	LARIVVIR	8	Sequence 61 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06491	ARIVVIRV	8	Sequence 62 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06492	RIVVIRVA	8	Sequence 63 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06493	IVVIRVAR	8	Sequence 64 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06494	RLARIVV	7	Sequence 65 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06495	LARIVVI	7	Sequence 66 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06496	ARIVVIR	7	Sequence 67 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06497	RIVVIRV	7	Sequence 68 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06498	IVVIRVA	7	Sequence 69 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06499	VVIRVAR	7	Sequence 70 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06500	RLARIV	6	Sequence 71 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06501	LARIVV	6	Sequence 72 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06502	ARIVVI	6	Sequence 73 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06503	RIVVIR	6	Sequence 74 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06504	IVVIRV	6	Sequence 75 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06505	VVIRVA	6	Sequence 76 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06506	VIRVAR	6	Sequence 77 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06507	RLARI	5	Sequence 85 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06508	LARIV	5	Sequence 86 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06509	ARIVV	5	Sequence 87 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06510	RIVVI	5	Sequence 88 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06511	IVVIR	5	Sequence 89 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06512	VVIRV	5	Sequence 90 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06513	VIRVA	5	Sequence 91 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06514	IRVAR	5	Sequence 92 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06515	ALARIVVIRVAR	12	Sequence 93 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06516	CLARIVVIRVAR	12	Sequence 94 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06517	DLARIVVIRVAR	12	Sequence 95 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06518	ELARIVVIRVAR	12	Sequence 96 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06519	FLARIVVIRVAR	12	Sequence 97 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06520	GLARIVVIRVAR	12	Sequence 98 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06521	HLARIVVIRVAR	12	Sequence 99 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06522	ILARIVVIRVAR	12	Sequence 100 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06523	KLARIVVIRVAR	12	Sequence 101 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06524	LLARIVVIRVAR	12	Sequence 102 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06525	MLARIVVIRVAR	12	Sequence 103 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06526	NLARIVVIRVAR	12	Sequence 104 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06527	PLARIVVIRVAR	12	Sequence 105 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06528	QLARIVVIRVAR	12	Sequence 106 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06529	SLARIVVIRVAR	12	Sequence 107 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06530	TLARIVVIRVAR	12	Sequence 108 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06531	VLARIVVIRVAR	12	Sequence 109 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06532	WLARIVVIRVAR	12	Sequence 110 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06533	YLARIVVIRVAR	12	Sequence 111 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06534	RAARIVVIRVAR	12	Sequence 112 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06535	RCARIVVIRVAR	12	Sequence 113 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06536	RDARIVVIRVAR	12	Sequence 114 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06537	REARIVVIRVAR	12	Sequence 115 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06538	RFARIVVIRVAR	12	Sequence 116 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06539	RGARIVVIRVAR	12	Sequence 117 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06540	RHARIVVIRVAR	12	Sequence 118 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06541	RIARIVVIRVAR	12	Sequence 119 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06542	RKARIVVIRVAR	12	Sequence 120 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06543	RMARIVVIRVAR	12	Sequence 121 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06544	RNARIVVIRVAR	12	Sequence 122 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06545	RPARIVVIRVAR	12	Sequence 123 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06546	RQARIVVIRVAR	12	Sequence 124 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06547	RRARIVVIRVAR	12	Sequence 125 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06548	RSARIVVIRVAR	12	Sequence 126 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06549	RTARIVVIRVAR	12	Sequence 127 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06550	RVARIVVIRVAR	12	Sequence 128 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06551	RWARIVVIRVAR	12	Sequence 129 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06552	RYARIVVIRVAR	12	Sequence 130 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06553	RLCRIVVIRVAR	12	Sequence 131 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06554	RLDRIVVIRVAR	12	Sequence 132 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06555	RLERIVVIRVAR	12	Sequence 133 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06556	RLFRIVVIRVAR	12	Sequence 134 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06557	RLGRIVVIRVAR	12	Sequence 135 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06558	RLHRIVVIRVAR	12	Sequence 136 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06559	RLIRIVVIRVAR	12	Sequence 137 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06560	RLKRIVVIRVAR	12	Sequence 138 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06561	RLLRIVVIRVAR	12	Sequence 139 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06562	RLMRIVVIRVAR	12	Sequence 140 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06563	RLNRIVVIRVAR	12	Sequence 141 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06564	RLPRIVVIRVAR	12	Sequence 142 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06565	RLQRIVVIRVAR	12	Sequence 143 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06566	RLRRIVVIRVAR	12	Sequence 144 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06567	RLSRIVVIRVAR	12	Sequence 145 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06568	RLTRIVVIRVAR	12	Sequence 146 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06569	RLVRIVVIRVAR	12	Sequence 147 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06570	RLWRIVVIRVAR	12	Sequence 148 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06571	RLYRIVVIRVAR	12	Sequence 149 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06572	RLAAIVVIRVAR	12	Sequence 150 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06573	RLACIVVIRVAR	12	Sequence 151 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06574	RLADIVVIRVAR	12	Sequence 152 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06575	RLAEIVVIRVAR	12	Sequence 153 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06576	RLAFIVVIRVAR	12	Sequence 154 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06577	RLAGIVVIRVAR	12	Sequence 155 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06578	RLAHIVVIRVAR	12	Sequence 156 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06579	RLAIIVVIRVAR	12	Sequence 157 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06580	RLAKIVVIRVAR	12	Sequence 158 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06581	RLALIVVIRVAR	12	Sequence 159 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06582	RLAMIVVIRVAR	12	Sequence 160 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06583	RLANIVVIRVAR	12	Sequence 161 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06584	RLAPIVVIRVAR	12	Sequence 162 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06585	RLAQIVVIRVAR	12	Sequence 163 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06586	RLASIVVIRVAR	12	Sequence 164 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06587	RLATIVVIRVAR	12	Sequence 165 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06588	RLAVIVVIRVAR	12	Sequence 166 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06589	RLAWIVVIRVAR	12	Sequence 167 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06590	RLAYIVVIRVAR	12	Sequence 168 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06591	RLARAVVIRVAR	12	Sequence 169 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06592	RLARCVVIRVAR	12	Sequence 170 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06593	RLARDVVIRVAR	12	Sequence 171 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06594	RLAREVVIRVAR	12	Sequence 172 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06595	RLARFVVIRVAR	12	Sequence 173 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06596	RLARGVVIRVAR	12	Sequence 174 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06597	RLARHVVIRVAR	12	Sequence 175 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06598	RLARKVVIRVAR	12	Sequence 176 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06599	RLARLVVIRVAR	12	Sequence 177 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06600	RLARMVVIRVAR	12	Sequence 178 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06601	RLARNVVIRVAR	12	Sequence 179 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06602	RLARPVVIRVAR	12	Sequence 180 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06603	RLARQVVIRVAR	12	Sequence 181 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06604	RLARRVVIRVAR	12	Sequence 182 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06605	RLARSVVIRVAR	12	Sequence 183 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06606	RLARTVVIRVAR	12	Sequence 184 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06607	RLARVVVIRVAR	12	Sequence 185 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06608	RLARWVVIRVAR	12	Sequence 186 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06609	RLARYVVIRVAR	12	Sequence 187 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06610	RLARIAVIRVAR	12	Sequence 188 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06611	RLARICVIRVAR	12	Sequence 189 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06612	RLARIDVIRVAR	12	Sequence 190 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06613	RLARIEVIRVAR	12	Sequence 191 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06614	RLARIFVIRVAR	12	Sequence 192 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06615	RLARIGVIRVAR	12	Sequence 193 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06616	RLARIHVIRVAR	12	Sequence 194 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06617	RLARIIVIRVAR	12	Sequence 195 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06618	RLARIKVIRVAR	12	Sequence 196 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06619	RLARILVIRVAR	12	Sequence 197 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06620	RLARIMVIRVAR	12	Sequence 198 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06621	RLARINVIRVAR	12	Sequence 199 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06622	RLARIPVIRVAR	12	Sequence 200 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06623	RLARIQVIRVAR	12	Sequence 201 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06624	RLARIRVIRVAR	12	Sequence 202 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06625	RLARISVIRVAR	12	Sequence 203 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06626	RLARITVIRVAR	12	Sequence 204 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06627	RLARIWVIRVAR	12	Sequence 205 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06628	RLARIYVIRVAR	12	Sequence 206 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06629	RLARIVAIRVAR	12	Sequence 207 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06630	RLARIVCIRVAR	12	Sequence 208 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06631	RLARIVDIRVAR	12	Sequence 209 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06632	RLARIVEIRVAR	12	Sequence 210 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06633	RLARIVFIRVAR	12	Sequence 211 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06634	RLARIVGIRVAR	12	Sequence 212 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06635	RLARIVHIRVAR	12	Sequence 213 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06636	RLARIVIIRVAR	12	Sequence 214 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06637	RLARIVKIRVAR	12	Sequence 215 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06638	RLARIVLIRVAR	12	Sequence 216 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06639	RLARIVMIRVAR	12	Sequence 217 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06640	RLARIVNIRVAR	12	Sequence 218 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06641	RLARIVPIRVAR	12	Sequence 219 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06642	RLARIVQIRVAR	12	Sequence 220 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06643	RLARIVRIRVAR	12	Sequence 221 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06644	RLARIVSIRVAR	12	Sequence 222 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06645	RLARIVTIRVAR	12	Sequence 223 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06646	RLARIVWIRVAR	12	Sequence 224 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06647	RLARIVYIRVAR	12	Sequence 225 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06648	RLARIVVARVAR	12	Sequence 226 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06649	RLARIVVCRVAR	12	Sequence 227 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06650	RLARIVVDRVAR	12	Sequence 228 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06651	RLARIVVERVAR	12	Sequence 229 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06652	RLARIVVFRVAR	12	Sequence 230 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06653	RLARIVVGRVAR	12	Sequence 231 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06654	RLARIVVHRVAR	12	Sequence 232 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06655	RLARIVVKRVAR	12	Sequence 233 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06656	RLARIVVLRVAR	12	Sequence 234 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06657	RLARIVVMRVAR	12	Sequence 235 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06658	RLARIVVNRVAR	12	Sequence 236 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06659	RLARIVVPRVAR	12	Sequence 237 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06660	RLARIVVQRVAR	12	Sequence 238 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06661	RLARIVVRRVAR	12	Sequence 239 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06662	RLARIVVSRVAR	12	Sequence 240 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06663	RLARIVVTRVAR	12	Sequence 241 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06664	RLARIVVVRVAR	12	Sequence 242 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06665	RLARIVVWRVAR	12	Sequence 243 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06666	RLARIVVYRVAR	12	Sequence 244 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06667	RLARIVVIAVAR	12	Sequence 245 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06668	RLARIVVICVAR	12	Sequence 246 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06669	RLARIVVIDVAR	12	Sequence 247 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06670	RLARIVVIEVAR	12	Sequence 248 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06671	RLARIVVIFVAR	12	Sequence 249 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06672	RLARIVVIGVAR	12	Sequence 250 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06673	RLARIVVIHVAR	12	Sequence 251 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06674	RLARIVVIIVAR	12	Sequence 252 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06675	RLARIVVIKVAR	12	Sequence 253 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06676	RLARIVVILVAR	12	Sequence 254 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06677	RLARIVVIMVAR	12	Sequence 255 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06678	RLARIVVINVAR	12	Sequence 256 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06679	RLARIVVIPVAR	12	Sequence 257 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06680	RLARIVVIQVAR	12	Sequence 258 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06681	RLARIVVISVAR	12	Sequence 259 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06682	RLARIVVITVAR	12	Sequence 260 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06683	RLARIVVIVVAR	12	Sequence 261 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06684	RLARIVVIWVAR	12	Sequence 262 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06685	RLARIVVIYVAR	12	Sequence 263 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06686	RLARIVVIRAAR	12	Sequence 264 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06687	RLARIVVIRCAR	12	Sequence 265 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06688	RLARIVVIRDAR	12	Sequence 266 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06689	RLARIVVIREAR	12	Sequence 267 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06690	RLARIVVIRFAR	12	Sequence 268 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06691	RLARIVVIRGAR	12	Sequence 269 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06692	RLARIVVIRHAR	12	Sequence 270 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06693	RLARIVVIRIAR	12	Sequence 271 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06694	RLARIVVIRKAR	12	Sequence 272 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06695	RLARIVVIRLAR	12	Sequence 273 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06696	RLARIVVIRMAR	12	Sequence 274 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06697	RLARIVVIRNAR	12	Sequence 275 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06698	RLARIVVIRPAR	12	Sequence 276 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06699	RLARIVVIRQAR	12	Sequence 277 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06700	RLARIVVIRRAR	12	Sequence 278 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06701	RLARIVVIRSAR	12	Sequence 279 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06702	RLARIVVIRTAR	12	Sequence 280 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06703	RLARIVVIRWAR	12	Sequence 281 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06704	RLARIVVIRYAR	12	Sequence 282 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06705	RLARIVVIRVCR	12	Sequence 283 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06706	RLARIVVIRVDR	12	Sequence 284 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06707	RLARIVVIRVER	12	Sequence 285 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06708	RLARIVVIRVFR	12	Sequence 286 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06709	RLARIVVIRVGR	12	Sequence 287 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06710	RLARIVVIRVHR	12	Sequence 288 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06711	RLARIVVIRVIR	12	Sequence 289 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06712	RLARIVVIRVKR	12	Sequence 290 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06713	RLARIVVIRVLR	12	Sequence 291 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06714	RLARIVVIRVMR	12	Sequence 292 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06715	RLARIVVIRVNR	12	Sequence 293 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06716	RLARIVVIRVPR	12	Sequence 294 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06717	RLARIVVIRVQR	12	Sequence 295 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06718	RLARIVVIRVRR	12	Sequence 296 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06719	RLARIVVIRVSR	12	Sequence 297 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06720	RLARIVVIRVTR	12	Sequence 298 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06721	RLARIVVIRVVR	12	Sequence 299 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06722	RLARIVVIRVWR	12	Sequence 300 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06723	RLARIVVIRVYR	12	Sequence 301 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06724	RLARIVVIRVAA	12	Sequence 302 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06725	RLARIVVIRVAC	12	Sequence 303 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06726	RLARIVVIRVAD	12	Sequence 304 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06727	RLARIVVIRVAE	12	Sequence 305 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06728	RLARIVVIRVAF	12	Sequence 306 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06729	RLARIVVIRVAG	12	Sequence 307 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06730	RLARIVVIRVAH	12	Sequence 308 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06731	RLARIVVIRVAI	12	Sequence 309 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06732	RLARIVVIRVAK	12	Sequence 310 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06733	RLARIVVIRVAL	12	Sequence 311 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06734	RLARIVVIRVAM	12	Sequence 312 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06735	RLARIVVIRVAN	12	Sequence 313 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06736	RLARIVVIRVAP	12	Sequence 314 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06737	RLARIVVIRVAQ	12	Sequence 315 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06738	RLARIVVIRVAS	12	Sequence 316 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06739	RLARIVVIRVAT	12	Sequence 317 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06740	RLARIVVIRVAV	12	Sequence 318 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06741	RLARIVVIRVAW	12	Sequence 319 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06742	RLARIVVIRVAY	12	Sequence 320 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06743	GATPEDLNQKLS	12	Sequence 321 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06744	RRWRIVVIRVRR	12	Sequence 322 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06745	RRWKIVVIRWRR	12	Sequence 323 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06746	RWWKIWVIRWWR	12	Sequence 324 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06747	RLRRIVVIRVRR	12	Sequence 325 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06748	KIWVIRWR	8	Sequence 326 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06749	RIWVIRWR	8	Sequence 327 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06750	RIWVIWRR	8	Sequence 328 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06751	RRWVIWRR	8	Sequence 329 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06752	PNGKIIWRM	9	Sequence 330 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06753	RRLYMKFKN	9	Sequence 331 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06754	SRNGGASIR	9	Sequence 332 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06755	KWKSIRGHG	9	Sequence 333 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06756	VRRRWIRFW	9	Sequence 334 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06757	RIKIWGGGP	9	Sequence 335 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06758	VKPTRAWRV	9	Sequence 336 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06759	RTKQTTKVR	9	Sequence 337 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06760	KWYRWNNAR	9	Sequence 338 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06761	HYKPNYWKW	9	Sequence 339 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06762	KWSLKHWVV	9	Sequence 340 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06763	VWVIRGLGK	9	Sequence 341 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06764	GQRVYVRMW	9	Sequence 342 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06765	RYWMRTRPW	9	Sequence 343 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06766	RGTMLRMFQ	9	Sequence 344 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06767	RVGRRHTGK	9	Sequence 345 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06768	VDKYRVRFR	9	Sequence 346 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06769	WSMPLWKRY	9	Sequence 347 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06770	RSIMTQRWW	9	Sequence 348 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06771	RWKPTHHLW	9	Sequence 349 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06772	WQWKVRIWR	9	Sequence 350 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06773	FKGYHWYRR	9	Sequence 351 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06774	KKKIIMMMR	9	Sequence 352 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06775	KRNMGHWMH	9	Sequence 353 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06776	KWSKGVVTN	9	Sequence 354 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06777	WGQTHKSRM	9	Sequence 355 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06778	KHRKWWKRQ	9	Sequence 356 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06779	FYVIWKKGQ	9	Sequence 357 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06780	IQIKYIYKS	9	Sequence 358 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06781	KRNWVGVRG	9	Sequence 359 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06782	YRPWNKGWN	9	Sequence 360 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06783	VKPVRVWKF	9	Sequence 361 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06784	HPQHFRRWR	9	Sequence 362 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06785	KRPHMHHWM	9	Sequence 363 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06786	RKLWRWKRT	9	Sequence 364 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06787	YHQHKGWIR	9	Sequence 365 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06788	PVKRKQRRM	9	Sequence 366 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06789	SRTMQNAMR	9	Sequence 367 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06790	VYKRLQRGL	9	Sequence 368 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06791	TRSVVRKKL	9	Sequence 369 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06792	RAGFVMRMR	9	Sequence 370 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06793	RRYYWKKGV	9	Sequence 371 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06794	WKGRWYKTT	9	Sequence 372 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06795	RWIRVAMRD	9	Sequence 373 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06796	RPRWWAGFY	9	Sequence 374 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06797	WIKWGYRTG	9	Sequence 375 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06798	RNVFQRMAG	9	Sequence 376 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06799	AGRKRVWHK	9	Sequence 377 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06800	MQWGATKIR	9	Sequence 378 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06801	LIMGWQRKP	9	Sequence 379 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06802	ARSWRNPWF	9	Sequence 380 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06803	KVPRPGVMI	9	Sequence 381 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06804	MMWRRIGIK	9	Sequence 382 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06805	VVRKHSLIK	9	Sequence 383 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06806	VWWRGFNRM	9	Sequence 384 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06807	QQRRWWSYV	9	Sequence 385 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06808	RSAQKRGYI	9	Sequence 386 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06809	TRVTRKVTW	9	Sequence 387 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06810	IWSWRWWRM	9	Sequence 388 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06811	KLTRVYRKY	9	Sequence 389 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06812	IKMWRALIR	9	Sequence 390 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06813	RWGKWSWRK	9	Sequence 391 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06814	WKAVRWKKV	9	Sequence 392 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06815	RRIKPVWAW	9	Sequence 393 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06816	SVWMKGRYA	9	Sequence 394 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06817	VSIMARMKW	9	Sequence 395 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06818	RWVGIRVRI	9	Sequence 396 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06819	RIQHKKNGY	9	Sequence 397 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06820	NMGMRWRAK	9	Sequence 398 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06821	RNIQPTRMH	9	Sequence 399 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06822	AKLVSRYKR	9	Sequence 400 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06823	TRRQRHKPQ	9	Sequence 401 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06824	SWMINRYRR	9	Sequence 402 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06825	WYRVIHHYK	9	Sequence 403 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06826	FTMNIRNRM	9	Sequence 404 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06827	WHMSWHKRK	9	Sequence 405 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06828	RLFNSKKYK	9	Sequence 406 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06829	WKQIVVGKY	9	Sequence 407 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06830	KMKEGAKGF	9	Sequence 408 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06831	VWGIRKNSS	9	Sequence 409 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06832	RGIAVIKMV	9	Sequence 410 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06833	YVIIGRGRR	9	Sequence 411 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06834	RVKKLRIQP	9	Sequence 412 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06835	KQWSGIKNT	9	Sequence 413 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06836	KRRWMWVKR	9	Sequence 414 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06837	PHKWNFSKY	9	Sequence 415 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06838	FGRWPKLFR	9	Sequence 416 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06839	KVYRRHAGY	9	Sequence 417 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06840	TYWRRTGPY	9	Sequence 418 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06841	KRSKPKYKA	9	Sequence 419 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06842	MIRRWKKQW	9	Sequence 420 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06843	HQRSRLWHK	9	Sequence 421 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06844	WNIFVKGWR	9	Sequence 422 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06845	PKTRKKGLY	9	Sequence 423 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06846	RSNKGHWYV	9	Sequence 424 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06847	MRIWRHWRK	9	Sequence 425 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06848	IRGRWKKLR	9	Sequence 426 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06849	VKKVRKGIV	9	Sequence 427 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06850	MGFFRRRPN	9	Sequence 428 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06851	MMKGFMGRW	9	Sequence 429 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06852	GRRRLVWTR	9	Sequence 430 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06853	VAKRTKAYW	9	Sequence 431 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06854	KYKQRVQHI	9	Sequence 432 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06855	KKRTYKYPF	9	Sequence 433 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06856	FRWKWVKHI	9	Sequence 434 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06857	KWRWRVKKR	9	Sequence 435 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06858	IIIWGLRRA	9	Sequence 436 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06859	NIARRKGFR	9	Sequence 437 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06860	SHMHLRKVR	9	Sequence 438 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06861	RIGAGNKQG	9	Sequence 439 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06862	GGHLRWKNA	9	Sequence 440 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06863	RINKVVPRV	9	Sequence 441 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06864	WSPRKKQKI	9	Sequence 442 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06865	VYSRYMKGG	9	Sequence 443 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06866	GKMWRNNYL	9	Sequence 444 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06867	KRHWHNSIW	9	Sequence 445 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06868	PWTTKNFWR	9	Sequence 446 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06869	FPNAVHRRR	9	Sequence 447 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06870	PFRAGNTKR	9	Sequence 448 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06871	WGRISKRMR	9	Sequence 449 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06872	GWRKVRVVV	9	Sequence 450 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06873	WGKIVGKGR	9	Sequence 451 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06874	MWPGARGAR	9	Sequence 452 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06875	IAGRNIWPR	9	Sequence 453 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06876	VRTMVKVPM	9	Sequence 454 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06877	HKRGWRKGA	9	Sequence 455 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06878	SGRWHSKFW	9	Sequence 456 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06879	ITWTKIKKF	9	Sequence 457 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06880	KRSLMKMWP	9	Sequence 458 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06881	VWSRYNKPR	9	Sequence 459 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06882	PHVKKGGVA	9	Sequence 460 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06883	AYGGTKMRV	9	Sequence 461 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06884	HPVKWRRKK	9	Sequence 462 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06885	RWVRFVMGI	9	Sequence 463 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06886	SIVQKGWFR	9	Sequence 464 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06887	NSKTHGFRY	9	Sequence 465 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06888	RVVRSARGI	9	Sequence 466 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06889	LGKNKATKT	9	Sequence 467 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06890	KGFPKSMSG	9	Sequence 468 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06891	GKKFWNFWG	9	Sequence 469 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06892	MKMKPRKVS	9	Sequence 470 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06893	RNVRNNNTR	9	Sequence 471 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06894	WRGKPKGLF	9	Sequence 472 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06895	KIRNRKIKW	9	Sequence 473 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06896	RRRRARGHW	9	Sequence 474 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06897	GNMFQWRKG	9	Sequence 475 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06898	VRISIMRWW	9	Sequence 476 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06899	RVRHGFKWW	9	Sequence 477 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06900	WKWKWSKWI	9	Sequence 478 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06901	GKNVMMGRI	9	Sequence 479 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06902	YWKVKTKHH	9	Sequence 480 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06903	IKQWMRRKN	9	Sequence 481 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06904	HKKNPWNGK	9	Sequence 482 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06905	KRSRIRIGV	9	Sequence 483 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06906	QGKWQRPRM	9	Sequence 484 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06907	QRSTQRSWW	9	Sequence 485 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06908	NRSMRRKPR	9	Sequence 486 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06909	HWKRISWGR	9	Sequence 487 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06910	RRRWFRTRG	9	Sequence 488 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06911	VKSPKWWIG	9	Sequence 489 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06912	RIWVWRHKY	9	Sequence 490 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06913	WVRPRGFWS	9	Sequence 491 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06914	LRSRGSGVH	9	Sequence 492 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06915	FHRWWYFFK	9	Sequence 493 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06916	RGVFKAMST	9	Sequence 494 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06917	WRGGWTHRR	9	Sequence 495 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06918	SRMKFWVIK	9	Sequence 496 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06919	YMTNRKVSG	9	Sequence 497 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06920	WQIGKIWRT	9	Sequence 498 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06921	RQVKYINHY	9	Sequence 499 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06922	FMWRVIKMI	9	Sequence 500 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06923	FDRAGRKLI	9	Sequence 501 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06924	VKRVKWWWS	9	Sequence 502 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06925	RVVFRSQPF	9	Sequence 503 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06926	RVKVWSKKF	9	Sequence 504 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06927	NAMWKYVWR	9	Sequence 505 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06928	RTQQSRPSV	9	Sequence 506 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06929	VRYIGAIYR	9	Sequence 507 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06930	SIRKWIFWI	9	Sequence 508 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06931	NKIVTLPKL	9	Sequence 509 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06932	IMARVFPRW	9	Sequence 510 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06933	TIRKKWKGS	9	Sequence 511 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06934	RRIEKSLRW	9	Sequence 512 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06935	RWKSRGRTL	9	Sequence 513 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06936	EGNIRKRVY	9	Sequence 514 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06937	ILKSFQRGH	9	Sequence 515 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06938	GINFKHKRF	9	Sequence 516 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06939	KNMRLSNWQ	9	Sequence 517 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06940	GRNFKVPVR	9	Sequence 518 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06941	IKKKFKWNT	9	Sequence 519 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06942	DRRRVQKGL	9	Sequence 520 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06943	GQRGRPWAT	9	Sequence 521 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06944	HRKNKKHYM	9	Sequence 522 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06945	INPGTAGKK	9	Sequence 523 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06946	KFIVVKRVV	9	Sequence 524 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06947	RHKTWYPGK	9	Sequence 525 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06948	RPLRKKVKL	9	Sequence 526 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06949	SKRWILVRR	9	Sequence 527 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06950	TKRWQTKFM	9	Sequence 528 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06951	WPKTRTVAK	9	Sequence 529 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06952	FKPVRIVFS	9	Sequence 530 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06953	MRVITVRIL	9	Sequence 531 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06954	RHWQQKVRS	9	Sequence 532 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06955	NQAKKKVGA	9	Sequence 533 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06956	MKYQGKGMQ	9	Sequence 534 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06957	RGWPRNWPT	9	Sequence 535 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06958	LKISGYVKH	9	Sequence 536 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06959	RWKLFKVWW	9	Sequence 537 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06960	RRANFFFSV	9	Sequence 538 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06961	RYNWYGQLR	9	Sequence 539 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06962	RGFWMKRWW	9	Sequence 540 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06963	GGGRRSQWK	9	Sequence 541 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06964	WYGFKRKIV	9	Sequence 542 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06965	WSAIRKKGK	9	Sequence 543 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06966	HRQPWRGRI	9	Sequence 544 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06967	KNMVTKWNK	9	Sequence 545 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06968	HIRGRFWRW	9	Sequence 546 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06969	IIPPKWYRS	9	Sequence 547 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06970	IPRQWWTFK	9	Sequence 548 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06971	WSNIIRKFM	9	Sequence 549 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06972	RVTYRRNVT	9	Sequence 550 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06973	KWWRIRGWI	9	Sequence 551 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06974	VEKHIRQRV	9	Sequence 552 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06975	RISSVPRMP	9	Sequence 553 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06976	ANNPLRVRL	9	Sequence 554 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06977	QRWIRIKPW	9	Sequence 555 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06978	RGWPRQIYY	9	Sequence 556 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06979	VKLGLGYQR	9	Sequence 557 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06980	VHQLKKRHW	9	Sequence 558 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06981	RWWQVRMYI	9	Sequence 559 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06982	IVLRNIKFI	9	Sequence 560 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06983	VRTRHWSPS	9	Sequence 561 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06984	WFRWHNRLV	9	Sequence 562 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06985	NRLWRYGRL	9	Sequence 563 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06986	HPWNRYKWG	9	Sequence 564 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06987	QVRVRRRII	9	Sequence 565 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06988	VRRRPSMFM	9	Sequence 566 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06989	RKYQIGRHI	9	Sequence 567 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06990	AKRRSRMKR	9	Sequence 568 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06991	KLWWMIRRW	9	Sequence 569 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06992	HNLHDIKRK	9	Sequence 570 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06993	RGVGVTFKL	9	Sequence 571 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06994	VPKLHYVVR	9	Sequence 572 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06995	VHWRGAKVT	9	Sequence 573 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06996	NGRWRFWSG	9	Sequence 574 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06997	KPVHWKKLQ	9	Sequence 575 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06998	KRNRGGWKV	9	Sequence 576 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP06999	TRNKTGYWW	9	Sequence 577 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07000	YQQRLRHIY	9	Sequence 578 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07001	GVVVWRRRV	9	Sequence 579 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07002	IMTRWKMHT	9	Sequence 580 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07003	TVHKRAAYP	9	Sequence 581 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07004	VKHKRGFYR	9	Sequence 582 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07005	RWTISFKRS	9	Sequence 583 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07006	GRMRHKRFT	9	Sequence 584 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07007	HSKSVLWIK	9	Sequence 585 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07008	KQMGRRISG	9	Sequence 586 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07009	RRMHSKIKG	9	Sequence 587 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07010	RINPKIYRS	9	Sequence 588 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07011	TIKRYIWIK	9	Sequence 589 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07012	WLIRPGAKL	9	Sequence 590 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07013	NTFRRAWRM	9	Sequence 591 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07014	KTRARWKNK	9	Sequence 592 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07015	HRPKIGFAG	9	Sequence 593 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07016	MSHKMRQKR	9	Sequence 594 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07017	FRGRWPLAR	9	Sequence 595 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07018	VIKQVGPHK	9	Sequence 596 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07019	AGFKRMWRV	9	Sequence 597 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07020	YRAVNKNPI	9	Sequence 598 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07021	AIWIPSKWR	9	Sequence 599 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07022	KNGAWWVLR	9	Sequence 600 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07023	MKMKRRMGV	9	Sequence 601 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07024	RTIKRWWWW	9	Sequence 602 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07025	AWYKKKRWW	9	Sequence 603 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07026	PRVLSRLIK	9	Sequence 604 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07027	WMFPKATRV	9	Sequence 605 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07028	MQVSKVKQI	9	Sequence 606 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07029	SWKRINQIN	9	Sequence 607 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07030	NRWRLINAQ	9	Sequence 608 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07031	RPSWHKWHH	9	Sequence 609 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07032	RVPINKWHR	9	Sequence 610 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07033	ILKIVRIKR	9	Sequence 611 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07034	DVWWKRLPR	9	Sequence 612 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07035	WIYWKVRGG	9	Sequence 613 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07036	HHRPPFRFQ	9	Sequence 614 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07037	MQRNFRRSI	9	Sequence 615 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07038	LMVRVLKNR	9	Sequence 616 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07039	HKWTQKYKA	9	Sequence 617 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07040	LWRRKWRTG	9	Sequence 618 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07041	KYVRRWKSG	9	Sequence 619 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07042	VAGWWSRRM	9	Sequence 620 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07043	IRQRWIWWY	9	Sequence 621 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07044	FRVRRWVRM	9	Sequence 622 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07045	FVMFLRQFK	9	Sequence 623 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07046	RNFVPRMIG	9	Sequence 624 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07047	RPTRQKNMN	9	Sequence 625 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07048	RRYIKWHIV	9	Sequence 626 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07049	WGKMNVRIH	9	Sequence 627 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07050	KITFRRYNP	9	Sequence 628 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07051	QAQQWWFKR	9	Sequence 629 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07052	IKSMFWRGP	9	Sequence 630 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07053	QPMRGIRMT	9	Sequence 631 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07054	HMILIRLFR	9	Sequence 632 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07055	SMNAPRVKR	9	Sequence 633 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07056	WKSKLSVNK	9	Sequence 634 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07057	ISNMRVSAK	9	Sequence 635 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07058	VRMGWWAHR	9	Sequence 636 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07059	RWPRVSWQA	9	Sequence 637 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07060	LSRTGVTRG	9	Sequence 638 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07061	RQLKPQNWS	9	Sequence 639 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07062	LHVRHKQHM	9	Sequence 640 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07063	QFRKIKAVS	9	Sequence 641 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07064	HWFNGNKKK	9	Sequence 642 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07065	RRVKIVRKI	9	Sequence 643 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07066	SMGKRTWMR	9	Sequence 644 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07067	KYSWVKKNI	9	Sequence 645 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07068	FPIRFKIWI	9	Sequence 646 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07069	KFFTYSRFR	9	Sequence 647 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07070	LGRKRMGHW	9	Sequence 648 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07071	NWRKLYRRK	9	Sequence 649 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07072	RGKIVVATL	9	Sequence 650 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07073	GWRRPGHNK	9	Sequence 651 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07074	IIAGTGLKR	9	Sequence 652 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07075	RRMKRRSIM	9	Sequence 653 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07076	KVFGRRYRK	9	Sequence 654 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07077	LQMFWYLRR	9	Sequence 655 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07078	RAYHKMRKK	9	Sequence 656 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07079	NPARWRPRV	9	Sequence 657 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07080	YVGKDRRKP	9	Sequence 658 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07081	LRWWTNTRW	9	Sequence 659 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07082	MYKQMMRVG	9	Sequence 660 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07083	PRRPWMRHR	9	Sequence 661 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07084	LNKFVKQRR	9	Sequence 662 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07085	ITINSRKWT	9	Sequence 663 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07086	RQFGMRKWT	9	Sequence 664 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07087	RIAVRHWHM	9	Sequence 665 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07088	HAVSQHRGK	9	Sequence 666 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07089	KSMYFRRSM	9	Sequence 667 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07090	VGTIRLGRG	9	Sequence 668 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07091	MRVGMRTKF	9	Sequence 669 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07092	LRRIWRMWS	9	Sequence 670 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07093	RFHRRAMFR	9	Sequence 671 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07094	MRPRHYIKN	9	Sequence 672 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07095	MRKRMKVYS	9	Sequence 673 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07096	MKHRHFGII	9	Sequence 674 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07097	VRGKVYAWW	9	Sequence 675 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07098	KIRLIRGKI	9	Sequence 676 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07099	KWINGPRKA	9	Sequence 677 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07100	GKNRITYSK	9	Sequence 678 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07101	GRAKRQHVI	9	Sequence 679 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07102	GIRFTRWLK	9	Sequence 680 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07103	AKMAWYKNP	9	Sequence 681 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07104	TRAKYIILR	9	Sequence 682 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07105	RSIVRWFGR	9	Sequence 683 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07106	RSEYKQIYR	9	Sequence 684 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07107	KRRMRWIIM	9	Sequence 685 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07108	YTKRWPVFR	9	Sequence 686 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07109	PYVSRWYKK	9	Sequence 687 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07110	RRFIKWGHV	9	Sequence 688 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07111	YVHKRKSMW	9	Sequence 689 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07112	QIGYIYRVR	9	Sequence 690 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07113	ARHWKMLWY	9	Sequence 691 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07114	VAVKKKRIS	9	Sequence 692 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07115	RKYGRSVPH	9	Sequence 693 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07116	TTGRGKIKR	9	Sequence 694 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07117	VWTIHTKMK	9	Sequence 695 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07118	RRWQEKGWR	9	Sequence 696 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07119	RQSGTFFKW	9	Sequence 697 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07120	WRITRGGII	9	Sequence 698 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07121	VAGRYKMQA	9	Sequence 699 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07122	KRGTHMRNV	9	Sequence 700 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07123	IGYHKIPMR	9	Sequence 701 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07124	YRFWGKKGF	9	Sequence 702 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07125	HYKRRGSRW	9	Sequence 703 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07126	GAKGGQIVR	9	Sequence 704 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07127	MIIIRSRRV	9	Sequence 705 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07128	NLGAWYKWK	9	Sequence 706 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07129	GPRVRKIWS	9	Sequence 707 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07130	RGISTYHKR	9	Sequence 708 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07131	IRAIKKVRK	9	Sequence 709 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07132	FGYRIKKRN	9	Sequence 710 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07133	PKNYMKIFP	9	Sequence 711 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07134	QAAQKKKRS	9	Sequence 712 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07135	MFGIPRHMR	9	Sequence 713 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07136	HAGVGIRHR	9	Sequence 714 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07137	LKWQAKSWI	9	Sequence 715 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07138	RYRRKRRWA	9	Sequence 716 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07139	LRGLVLKSG	9	Sequence 717 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07140	RRRKIHGPW	9	Sequence 718 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07141	RTARGGKFK	9	Sequence 719 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07142	MGNKIVWKN	9	Sequence 720 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07143	WRITIIKIT	9	Sequence 721 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07144	FRWRVSGRW	9	Sequence 722 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07145	TRVIPRMYY	9	Sequence 723 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07146	KKQARKYIK	9	Sequence 724 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07147	WIYIARSVK	9	Sequence 725 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07148	RVFTLARHV	9	Sequence 726 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07149	NYIVYRRVF	9	Sequence 727 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07150	NRFSKKHWK	9	Sequence 728 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07151	NSRGWQRRW	9	Sequence 729 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07152	TSSGNRKVT	9	Sequence 730 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07153	WIKAGWRSW	9	Sequence 731 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07154	TWIRLSRRV	9	Sequence 732 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07155	IRKWWVRNV	9	Sequence 733 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07156	YKKPPWQFK	9	Sequence 734 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07157	QQSILRKNN	9	Sequence 735 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07158	GHKFWKINR	9	Sequence 736 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07159	RVRWYRIFY	9	Sequence 737 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07160	WWRVVYKGV	9	Sequence 738 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07161	SKGIIAKWW	9	Sequence 739 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07162	QIKKQFVKQ	9	Sequence 740 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07163	KGTVNFYRQ	9	Sequence 741 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07164	LMMRHYWIR	9	Sequence 742 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07165	WWNRRKVDQ	9	Sequence 743 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07166	RYRIRKKRG	9	Sequence 744 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07167	KRQMHIHSR	9	Sequence 745 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07168	HKSMLRIWG	9	Sequence 746 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07169	WKILIIFGR	9	Sequence 747 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07170	KKVSLHREA	9	Sequence 748 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07171	PLSRVRNRW	9	Sequence 749 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07172	GWSHRVKGI	9	Sequence 750 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07173	RTIRRNWIE	9	Sequence 751 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07174	ITMPSKRRV	9	Sequence 752 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07175	KRKPPVHQK	9	Sequence 753 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07176	IWPKHRSKW	9	Sequence 754 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07177	QKAFWMWWR	9	Sequence 755 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07178	WRQHWGRHR	9	Sequence 756 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07179	VMGKARFWR	9	Sequence 757 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07180	WIVVKKQNR	9	Sequence 758 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07181	PRYQGWWRV	9	Sequence 759 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07182	KMRRPNIWL	9	Sequence 760 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07183	GGKRVFVRS	9	Sequence 761 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07184	GRGHPKYVT	9	Sequence 762 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07185	KAARNWKVW	9	Sequence 763 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07186	KKMSWGHTR	9	Sequence 764 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07187	KKTYWYNRA	9	Sequence 765 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07188	KNRRRRFWF	9	Sequence 766 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07189	RRRQKRGVW	9	Sequence 767 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07190	GRRNHQRAK	9	Sequence 768 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07191	QKMGHRWRI	9	Sequence 769 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07192	PKWKIQKGH	9	Sequence 770 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07193	AMRRFMRRP	9	Sequence 771 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07194	GKGMGRRAW	9	Sequence 772 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07195	HKRRKAKIM	9	Sequence 773 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07196	IMMNHRKWQ	9	Sequence 774 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07197	RWMRMKWVT	9	Sequence 775 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07198	RWGYRYNFI	9	Sequence 776 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07199	MWKKNNWNL	9	Sequence 777 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07200	WKRVGRKRL	9	Sequence 778 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07201	WLHGVKKMW	9	Sequence 779 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07202	EYWNWKRKV	9	Sequence 780 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07203	TKVTRGWPW	9	Sequence 781 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07204	QRWIQNTRW	9	Sequence 782 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07205	GKYIFKWWQ	9	Sequence 783 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07206	IVWKLRFQP	9	Sequence 784 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07207	WWAVNRNRK	9	Sequence 785 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07208	SIRMTKGKM	9	Sequence 786 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07209	NIKWGFFGK	9	Sequence 787 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07210	WMRQWRHWY	9	Sequence 788 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07211	PKVKRIWPK	9	Sequence 789 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07212	RRRKIAHKM	9	Sequence 790 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07213	RKYIKYVWN	9	Sequence 791 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07214	QPKRYVQTP	9	Sequence 792 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07215	LVGNPKWGR	9	Sequence 793 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07216	YKRAYSPIS	9	Sequence 794 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07217	KHKWGTFRF	9	Sequence 795 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07218	KIFLKYKGW	9	Sequence 796 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07219	RNVRHHWFR	9	Sequence 797 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07220	VIAVKRHLG	9	Sequence 798 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07221	RWKVGILRR	9	Sequence 799 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07222	WIQGIKMVR	9	Sequence 800 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07223	GWFKVTYKK	9	Sequence 801 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07224	YVMTKWRYV	9	Sequence 802 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07225	PRIFWKHIN	9	Sequence 803 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07226	VSPRWIWLK	9	Sequence 804 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07227	WVAIPGRSR	9	Sequence 805 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07228	NGFRKWWSR	9	Sequence 806 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07229	QFYIMKRYY	9	Sequence 807 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07230	ARHGRKTKK	9	Sequence 808 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07231	KRGRAKHIK	9	Sequence 809 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07232	NLWKIKTPI	9	Sequence 810 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07233	VPKGWKFLS	9	Sequence 811 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07234	RFMKEWFAK	9	Sequence 812 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07235	MGARKWIWW	9	Sequence 813 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07236	GLNHRRRPI	9	Sequence 814 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07237	VLMRKRIWH	9	Sequence 815 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07238	PGPYKKRQF	9	Sequence 816 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07239	WKYLYKPNP	9	Sequence 817 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07240	RKMRWWIRR	9	Sequence 818 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07241	AWRNSFRRG	9	Sequence 819 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07242	WKVGIIRAG	9	Sequence 820 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07243	WGRKTHYWH	9	Sequence 821 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07244	RIQHRYFLM	9	Sequence 822 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07245	FSWKVRIGV	9	Sequence 823 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07246	MPTKYGRHR	9	Sequence 824 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07247	RSPWRHRQF	9	Sequence 825 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07248	KRIWHIWRW	9	Sequence 826 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07249	KVVWLHRWQ	9	Sequence 827 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07250	IYRRKMIFQ	9	Sequence 828 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07251	HRYQYWKLT	9	Sequence 829 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07252	AYKYFSQKR	9	Sequence 830 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07253	KLVHKVTMT	9	Sequence 831 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07254	VRNRRFIWR	9	Sequence 832 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07255	RVLLVARPN	9	Sequence 833 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07256	YKKHLRWGL	9	Sequence 834 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07257	RKVYSARPG	9	Sequence 835 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07258	QVMRWVQKL	9	Sequence 836 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07259	IKILVLRVI	9	Sequence 837 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07260	WHKRYFRSP	9	Sequence 838 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07261	KMGNAKWRH	9	Sequence 839 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07262	FGHHRFRLA	9	Sequence 840 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07263	GHPSKIVRR	9	Sequence 841 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07264	WRVWVRVKR	9	Sequence 842 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07265	RSMTLWRKH	9	Sequence 843 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07266	IRLYITRWL	9	Sequence 844 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07267	IVKMRRRHA	9	Sequence 845 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07268	FWRRQRWKQ	9	Sequence 846 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07269	QQMYSRQRK	9	Sequence 847 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07270	KPMKTWAKG	9	Sequence 848 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07271	KYFVTKWGT	9	Sequence 849 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07272	IRRKGTKRR	9	Sequence 850 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07273	GMRHFKWGI	9	Sequence 851 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07274	KKQVAIVRT	9	Sequence 852 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07275	NGFKYVRSM	9	Sequence 853 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07276	LWVGRLVYK	9	Sequence 854 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07277	RWVNKITWI	9	Sequence 855 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07278	AARIFRRYS	9	Sequence 856 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07279	SQRWPTRGR	9	Sequence 857 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07280	IRAKRWRQI	9	Sequence 858 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07281	VKKPGWRLY	9	Sequence 859 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07282	KRKTKLNPA	9	Sequence 860 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07283	HVKGWTKFR	9	Sequence 861 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07284	RPPVFHKHN	9	Sequence 862 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07285	NVMTMRLKK	9	Sequence 863 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07286	QWIKIRFSR	9	Sequence 864 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07287	WYRRWSNVR	9	Sequence 865 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07288	VFARRIWGI	9	Sequence 866 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07289	HFTRPKFWR	9	Sequence 867 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07290	WVQVKMASK	9	Sequence 868 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07291	SWRSVKKVN	9	Sequence 869 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07292	WYYVRYRWW	9	Sequence 870 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07293	MHDRKWAVR	9	Sequence 871 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07294	GGKGGRYRG	9	Sequence 872 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07295	YVTYKTWRS	9	Sequence 873 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07296	QRRNNQRVV	9	Sequence 874 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07297	WRWVFMIVR	9	Sequence 875 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07298	FYSMTYIRK	9	Sequence 876 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07299	HPKKMAVVR	9	Sequence 877 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07300	YRLTRYKGA	9	Sequence 878 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07301	VKARFRIQW	9	Sequence 879 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07302	IRRAKLRGR	9	Sequence 880 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07303	KGINIKWKP	9	Sequence 881 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07304	LWKYLRHGV	9	Sequence 882 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07305	THAMWKGKN	9	Sequence 883 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07306	IKKIHYRNK	9	Sequence 884 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07307	RIMGWVHIK	9	Sequence 885 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07308	KIRHIWIVG	9	Sequence 886 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07309	PRQLFWPRW	9	Sequence 887 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07310	SHARWMKIH	9	Sequence 888 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07311	KISKKIKVV	9	Sequence 889 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07312	HGKVVGQRI	9	Sequence 890 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07313	RQVIWRWIT	9	Sequence 891 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07314	TKIRARRVL	9	Sequence 892 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07315	YRRVRQRDY	9	Sequence 893 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07316	YKRKMWYIW	9	Sequence 894 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07317	WKYGGPRQR	9	Sequence 895 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07318	ATWPHGKKV	9	Sequence 896 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07319	RGGKHRKKA	9	Sequence 897 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07320	WKRWIRVMQ	9	Sequence 898 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07321	WIIKEVRKP	9	Sequence 899 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07322	YRQIMRWVQ	9	Sequence 900 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07323	FKRRGGWLR	9	Sequence 901 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07324	IVWNNSRVR	9	Sequence 902 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07325	RRGGYVMYV	9	Sequence 903 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07326	TSVKMFWRA	9	Sequence 904 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07327	KHIWWKLHM	9	Sequence 905 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07328	RLWGIIRKT	9	Sequence 906 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07329	MVRPNRIRR	9	Sequence 907 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07330	WPRAKNPSA	9	Sequence 908 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07331	RRWLRAIIY	9	Sequence 909 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07332	IGNRRNTGI	9	Sequence 910 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07333	YIRSLIGKP	9	Sequence 911 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07334	TGGWNIRMR	9	Sequence 912 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07335	VVAVNKERK	9	Sequence 913 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07336	NAHNKRYYR	9	Sequence 914 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07337	WWRIAFKLT	9	Sequence 915 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07338	NGQRKYIYI	9	Sequence 916 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07339	RGWGWRRLY	9	Sequence 917 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07340	RIAFPMKGG	9	Sequence 918 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07341	RAKNVLGTY	9	Sequence 919 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07342	NRRIKGQWV	9	Sequence 920 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07343	RTSWMNRIW	9	Sequence 921 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07344	TWIKQLINK	9	Sequence 922 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07345	QKRKPRWPW	9	Sequence 923 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07346	SKLLVRMWK	9	Sequence 924 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07347	YKQGWWKWL	9	Sequence 925 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07348	TWAPRHKSQ	9	Sequence 926 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07349	KWVRTGYQW	9	Sequence 927 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07350	QARRKQVWI	9	Sequence 928 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07351	WKIGRIKMR	9	Sequence 929 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07352	FIIRGRWAN	9	Sequence 930 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07353	MLRKMGAPQ	9	Sequence 931 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07354	KRRPVKSYK	9	Sequence 932 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07355	IYWVNFRLR	9	Sequence 933 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07356	MRIRKWQLS	9	Sequence 934 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07357	WGRKQKQWS	9	Sequence 935 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07358	RNWWTGHWR	9	Sequence 936 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07359	VGRQQRYMK	9	Sequence 937 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07360	GRKRNVEGR	9	Sequence 938 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07361	ALGRIRGKR	9	Sequence 939 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07362	MNKWINKLM	9	Sequence 940 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07363	PKRWWGIRN	9	Sequence 941 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07364	RHYRYTGII	9	Sequence 942 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07365	PVRRWGWTL	9	Sequence 943 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07366	RIVSGWGWR	9	Sequence 944 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07367	RIKLLTIWK	9	Sequence 945 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07368	KWVKNWRYR	9	Sequence 946 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07369	YQKGVRVIT	9	Sequence 947 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07370	VRGGAKGGS	9	Sequence 948 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07371	AIWGRIRKR	9	Sequence 949 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07372	RIWKTATFG	9	Sequence 950 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07373	HISRGARHK	9	Sequence 951 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07374	YVTRKMIHQ	9	Sequence 952 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07375	LMIRVGWRW	9	Sequence 953 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07376	WSQYMFKRW	9	Sequence 954 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07377	RNIITYRFQ	9	Sequence 955 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07378	KWRWAKGRQ	9	Sequence 956 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07379	PGRTKIHRG	9	Sequence 957 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07380	MNVYARLRH	9	Sequence 958 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07381	WFNYKRHVL	9	Sequence 959 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07382	RQMRSIRGR	9	Sequence 960 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07383	RGFRKIYKR	9	Sequence 961 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07384	YSGPIRQAR	9	Sequence 962 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07385	IVATVWRKN	9	Sequence 963 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07386	WGKRYPKYW	9	Sequence 964 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07387	ITWPRGGGK	9	Sequence 965 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07388	WKFKKIGMQ	9	Sequence 966 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07389	RQGRIWWVR	9	Sequence 967 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07390	YMKAFVSRW	9	Sequence 968 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07391	MHAKVRIGL	9	Sequence 969 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07392	YHVRSKWGW	9	Sequence 970 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07393	ITAAKIKQK	9	Sequence 971 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07394	LNYSRIHTR	9	Sequence 972 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07395	WVQKRKKGR	9	Sequence 973 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07396	WQAIRRIVG	9	Sequence 974 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07397	RRLITWLVP	9	Sequence 975 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07398	KVKRQNKKR	9	Sequence 976 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07399	WSKTHIRRN	9	Sequence 977 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07400	LQVKWWVKF	9	Sequence 978 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07401	RKDNKKVVV	9	Sequence 979 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07402	VRPWRGRIL	9	Sequence 980 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07403	KWRAAQWVL	9	Sequence 981 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07404	IKAGRGMVR	9	Sequence 982 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07405	KIRLKVWRA	9	Sequence 983 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07406	HWWLRPIVR	9	Sequence 984 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07407	GMYNKRFKR	9	Sequence 985 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07408	RLQIWTRGW	9	Sequence 986 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07409	KTGLKSKVR	9	Sequence 987 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07410	RKQQVWRIQ	9	Sequence 988 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07411	LGKRGKHRW	9	Sequence 989 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07412	GLRHGNYRW	9	Sequence 990 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07413	RVRRMTRWM	9	Sequence 991 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07414	KLARWTRGG	9	Sequence 992 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07415	VVRKRYVRI	9	Sequence 993 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07416	VHRYMPFGR	9	Sequence 994 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07417	KITHTFRPR	9	Sequence 995 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07418	ARRPAQWIQ	9	Sequence 996 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07419	RVSSGKLTH	9	Sequence 997 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07420	RWRTGPSIP	9	Sequence 998 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07421	LRLRRYKKW	9	Sequence 999 from Patent US 20080207522	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07422	AKMTWIFRP	9	Sequence 1000 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07423	ARWKRMWML	9	Sequence 1001 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07424	GRRVAVHRR	9	Sequence 1002 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07425	RRWWFPFYA	9	Sequence 1003 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07426	KHHKGVWWA	9	Sequence 1004 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07427	LLYWKRGIY	9	Sequence 1005 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07428	PVNYRKKRP	9	Sequence 1006 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07429	LRGGTGIFR	9	Sequence 1007 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07430	HHGRFRHWW	9	Sequence 1008 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07431	TNRHQQKRW	9	Sequence 1009 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07432	VQQLTKWSK	9	Sequence 1010 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07433	RRRPGQKKW	9	Sequence 1011 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07434	RPGSWRWRV	9	Sequence 1012 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07435	PRLWNRRQR	9	Sequence 1013 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07436	RWIVWSRGK	9	Sequence 1014 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07437	SPHLGWKRS	9	Sequence 1015 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07438	NRRWQWRMI	9	Sequence 1016 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07439	WPRRGYMVA	9	Sequence 1017 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07440	RWWLWQPWR	9	Sequence 1018 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07441	WRGILYRSH	9	Sequence 1019 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07442	IGWQRNRKY	9	Sequence 1020 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07443	WIHKFRRKS	9	Sequence 1021 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07444	GKALHKNKI	9	Sequence 1022 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07445	KTKKKGVRK	9	Sequence 1023 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07446	WFIKWRLWA	9	Sequence 1024 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07447	GRKVYRVKV	9	Sequence 1025 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07448	NAKWHTWYR	9	Sequence 1026 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07449	TRGKIQISM	9	Sequence 1027 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07450	MTVIKRNLF	9	Sequence 1028 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07451	KRMALNQRH	9	Sequence 1029 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07452	RWVFNGSKV	9	Sequence 1030 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07453	RQGRLMGMA	9	Sequence 1031 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07454	IIYRRTPVG	9	Sequence 1032 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07455	LRRWKIMTT	9	Sequence 1033 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07456	YKKGNNWTA	9	Sequence 1034 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07457	TRWRWKRVS	9	Sequence 1035 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07458	RRAAPTGRG	9	Sequence 1036 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07459	YIKRWYGIW	9	Sequence 1037 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07460	PWGHIKKRK	9	Sequence 1038 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07461	TVGFPTQKR	9	Sequence 1039 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07462	KWVKGGWQV	9	Sequence 1040 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07463	AFRIRKNID	9	Sequence 1041 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07464	VWRKKMVLV	9	Sequence 1042 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07465	FGYIKRGGP	9	Sequence 1043 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07466	KLRMVKWQG	9	Sequence 1044 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07467	KKWAAWQPR	9	Sequence 1045 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07468	RKSLKQKHW	9	Sequence 1046 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07469	HKRKQWQRG	9	Sequence 1047 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07470	RAKIPKRIM	9	Sequence 1048 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07471	VKQHHKNWR	9	Sequence 1049 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07472	RRWIPQKRR	9	Sequence 1050 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07473	AKRNFWKRW	9	Sequence 1051 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07474	LKWMWNVKR	9	Sequence 1052 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07475	KAGQWFGRM	9	Sequence 1053 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07476	VKWANIIWK	9	Sequence 1054 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07477	WWKKGLLAT	9	Sequence 1055 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07478	STLSYRRKF	9	Sequence 1056 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07479	RKSWWGVGR	9	Sequence 1057 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07480	RRIPRIQWV	9	Sequence 1058 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07481	WVARNRRWV	9	Sequence 1059 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07482	FGHPFLRKV	9	Sequence 1060 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07483	LLPQPRIFR	9	Sequence 1061 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07484	MVITRYRRW	9	Sequence 1062 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07485	GVKPKMLKL	9	Sequence 1063 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07486	LKTKHWLNW	9	Sequence 1064 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07487	FGHKFLMFR	9	Sequence 1065 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07488	RLVWRQWLR	9	Sequence 1066 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07489	QIRILKTRY	9	Sequence 1067 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07490	VRHTPKRVR	9	Sequence 1068 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07491	AGRSKRHPI	9	Sequence 1069 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07492	HSRILRKNK	9	Sequence 1070 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07493	KIQKYVANW	9	Sequence 1071 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07494	WAHGIKYFK	9	Sequence 1072 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07495	RSGHGRSYQ	9	Sequence 1073 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07496	IFMSWKSRW	9	Sequence 1074 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07497	HYSRKMAWR	9	Sequence 1075 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07498	KRWIVKWVK	9	Sequence 1076 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07499	WRNWPYKGK	9	Sequence 1077 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07500	RPYKPGWGK	9	Sequence 1078 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07501	WWAGPRLRI	9	Sequence 1079 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07502	TFQIKKPTW	9	Sequence 1080 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07503	GFAFKRTLR	9	Sequence 1081 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07504	QPNGRRYMA	9	Sequence 1082 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07505	HRNHWMNKW	9	Sequence 1083 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07506	NKRRVLIFI	9	Sequence 1084 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07507	WWAMKWIRV	9	Sequence 1085 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07508	GAKKFQWFQ	9	Sequence 1086 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07509	VAKTPTRNW	9	Sequence 1087 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07510	RMRHLRKVR	9	Sequence 1088 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07511	YGQRNMWRV	9	Sequence 1089 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07512	IMVMLKTVK	9	Sequence 1090 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07513	RLRRGISTK	9	Sequence 1091 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07514	HRVWVKWPY	9	Sequence 1092 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07515	MYIRGGNRF	9	Sequence 1093 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07516	RIRWTGYGI	9	Sequence 1094 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07517	PRRRTVRSM	9	Sequence 1095 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07518	RIYYMGFRT	9	Sequence 1096 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07519	YPPKFHKIK	9	Sequence 1097 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07520	YWRGWRHGL	9	Sequence 1098 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07521	RIKFFFNMW	9	Sequence 1099 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07522	IRVLIIMRR	9	Sequence 1100 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07523	HRRMVRLGV	9	Sequence 1101 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07524	FRRYIMNWW	9	Sequence 1102 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07525	HRHNRAPGS	9	Sequence 1103 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07526	GHKHFQKGQ	9	Sequence 1104 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07527	WNTPKFMLR	9	Sequence 1105 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07528	FMVWWKRPI	9	Sequence 1106 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07529	VKIKKRHQN	9	Sequence 1107 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07530	IVSTKRNNP	9	Sequence 1108 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07531	RMKTWKNWM	9	Sequence 1109 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07532	RRNWIRGIK	9	Sequence 1110 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07533	VWAKWWYAR	9	Sequence 1111 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07534	TSKKTKQVR	9	Sequence 1112 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07535	LIRALIFKW	9	Sequence 1113 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07536	SLWQTKVYK	9	Sequence 1114 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07537	NRVHRRVYW	9	Sequence 1115 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07538	HLRIRIYQL	9	Sequence 1116 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07539	PKKVRVNAH	9	Sequence 1117 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07540	NRWRYWFAA	9	Sequence 1118 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07541	WGQKRSRAF	9	Sequence 1119 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07542	RLWPTWRTW	9	Sequence 1120 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07543	IVGKKKMRM	9	Sequence 1121 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07544	PWKVVIVRW	9	Sequence 1122 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07545	WNFIGVIKR	9	Sequence 1123 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07546	RFVPRVTYT	9	Sequence 1124 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07547	RWGRHKRPQ	9	Sequence 1125 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07548	WRRVPRKWE	9	Sequence 1126 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07549	HGVRGFKHW	9	Sequence 1127 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07550	KNKRSQLVW	9	Sequence 1128 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07551	RIIPKYWWR	9	Sequence 1129 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07552	ILRLKFTYT	9	Sequence 1130 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07553	GVRPQIRRQ	9	Sequence 1131 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07554	QIHNRIRSF	9	Sequence 1132 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07555	RSAIRFGTG	9	Sequence 1133 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07556	RGRHNFVSI	9	Sequence 1134 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07557	AWRVMIYRF	9	Sequence 1135 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07558	KKNNGLWKH	9	Sequence 1136 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07559	RMQMRWKRK	9	Sequence 1137 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07560	VKTGRKWNN	9	Sequence 1138 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07561	PLFGSRRIK	9	Sequence 1139 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07562	RKWYIVQKK	9	Sequence 1140 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07563	PIGFSRGMK	9	Sequence 1141 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07564	KAKVKTIWA	9	Sequence 1142 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07565	HKWRPVNRM	9	Sequence 1143 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07566	RHRVWVRRR	9	Sequence 1144 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07567	RPRTWAIRR	9	Sequence 1145 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07568	KFRYLKLAL	9	Sequence 1146 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07569	ASKMNPLYR	9	Sequence 1147 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07570	RLHVGRVKH	9	Sequence 1148 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07571	VVALQRRLW	9	Sequence 1149 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07572	LPRKWATGA	9	Sequence 1150 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07573	VWIHKVKGF	9	Sequence 1151 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07574	WVAWRWTRS	9	Sequence 1152 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07575	HNRKTFNGG	9	Sequence 1153 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07576	KGWLRANPR	9	Sequence 1154 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07577	SLNRKFHGK	9	Sequence 1155 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07578	IRGWWLKQG	9	Sequence 1156 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07579	KRRIRPRVR	9	Sequence 1157 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07580	FWPRYGTKF	9	Sequence 1158 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07581	IRTLRVFRT	9	Sequence 1159 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07582	WRNTWIRWN	9	Sequence 1160 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07583	RRRKYHTRD	9	Sequence 1161 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07584	ERPAFRMWR	9	Sequence 1162 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07585	LIVIRSKGR	9	Sequence 1163 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07586	WVTVYWKRF	9	Sequence 1164 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07587	FGSANYRQK	9	Sequence 1165 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07588	QTKYWQVAK	9	Sequence 1166 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07589	MVVMVVWRR	9	Sequence 1167 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07590	KWQTGKRTS	9	Sequence 1168 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07591	KWYRWRNHR	9	Sequence 1169 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07592	KTHWWRGRI	9	Sequence 1170 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07593	PSARRGWIY	9	Sequence 1171 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07594	KRAFKIRHI	9	Sequence 1172 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07595	GWYNPTRKI	9	Sequence 1173 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07596	VRNISFVRL	9	Sequence 1174 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07597	RRGTKKERS	9	Sequence 1175 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07598	ARRWKFIKT	9	Sequence 1176 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07599	GPGRAGVRN	9	Sequence 1177 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07600	PQIWGIKRK	9	Sequence 1178 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07601	KKVWHWFTG	9	Sequence 1179 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07602	RMRRRGKKW	9	Sequence 1180 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07603	RIERVNRKP	9	Sequence 1181 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07604	RTQYRYAHG	9	Sequence 1182 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07605	NKPRMPWYV	9	Sequence 1183 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07606	PHAYRVRFK	9	Sequence 1184 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07607	KNVRQAKIW	9	Sequence 1185 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07608	IWRGRVRAI	9	Sequence 1186 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07609	IWYLRIYKW	9	Sequence 1187 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07610	WRVRAGRWP	9	Sequence 1188 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07611	HMKRWHRWG	9	Sequence 1189 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07612	KGIYVWRRP	9	Sequence 1190 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07613	QKQIGTRTH	9	Sequence 1191 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07614	GMKVWRNLA	9	Sequence 1192 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07615	RIAMWKVFR	9	Sequence 1193 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07616	RKAGAIGAG	9	Sequence 1194 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07617	YSWRKKFQP	9	Sequence 1195 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07618	IRRIGGVGN	9	Sequence 1196 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07619	KRPWYNRKI	9	Sequence 1197 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07620	AHYNGYKRY	9	Sequence 1198 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07621	AWGRYTKVA	9	Sequence 1199 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07622	KRADAHRPI	9	Sequence 1200 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07623	ASRSKWNVI	9	Sequence 1201 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07624	RRGIPIKSR	9	Sequence 1202 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07625	MKLVNSRHL	9	Sequence 1203 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07626	HRIHRVTVF	9	Sequence 1204 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07627	IRYIMNHGK	9	Sequence 1205 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07628	RKRRRQGFI	9	Sequence 1206 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07629	IKIRFAAQW	9	Sequence 1207 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07630	WGKMRMRVW	9	Sequence 1208 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07631	YRKINGGWY	9	Sequence 1209 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07632	WQAQKMWWR	9	Sequence 1210 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07633	RVHPFQKRL	9	Sequence 1211 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07634	TRIYGVWAR	9	Sequence 1212 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07635	RHRRKVKLI	9	Sequence 1213 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07636	KWRWVGIFM	9	Sequence 1214 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07637	WPKRFWNVW	9	Sequence 1215 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07638	NIIQKKMMG	9	Sequence 1216 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07639	KKWNRRRVK	9	Sequence 1217 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07640	WWKGGYIMK	9	Sequence 1218 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07641	NKIMAKRNW	9	Sequence 1219 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07642	KFSRGGMWW	9	Sequence 1220 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07643	GSHGWRRPP	9	Sequence 1221 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07644	LRNIKIPRS	9	Sequence 1222 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07645	KYFKARNSW	9	Sequence 1223 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07646	FWRMRQWKG	9	Sequence 1224 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07647	KLWDKRWMP	9	Sequence 1225 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07648	KSYWWTRWT	9	Sequence 1226 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07649	QRIRVVPYA	9	Sequence 1227 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07650	RQRVRGRKW	9	Sequence 1228 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07651	VPTRGRTQN	9	Sequence 1229 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07652	VRVRVSRWW	9	Sequence 1230 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07653	KQGNNRRYN	9	Sequence 1231 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07654	SYHRRARPK	9	Sequence 1232 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07655	WPYKHKRRI	9	Sequence 1233 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07656	WKKHLLKIM	9	Sequence 1234 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07657	ISGKRGSRR	9	Sequence 1235 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07658	KVGRKQWWI	9	Sequence 1236 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07659	RRAFRLQGK	9	Sequence 1237 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07660	GISKGIIRI	9	Sequence 1238 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07661	WWKNKHHWK	9	Sequence 1239 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07662	RVIHRWHRG	9	Sequence 1240 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07663	WRYWLVRNG	9	Sequence 1241 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07664	KRVWISIQI	9	Sequence 1242 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07665	GRWKVMNRT	9	Sequence 1243 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07666	IAWRVIVKW	9	Sequence 1244 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07667	NVWFVKRQQ	9	Sequence 1245 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07668	PRISRRRPW	9	Sequence 1246 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07669	TYWRRRPAV	9	Sequence 1247 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07670	IKRSHIITN	9	Sequence 1248 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07671	LKWWVGRAG	9	Sequence 1249 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07672	NSHGGRTRV	9	Sequence 1250 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07673	MRYAIWRTI	9	Sequence 1251 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07674	QIKRTWRRT	9	Sequence 1252 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07675	KMYIWKRKI	9	Sequence 1253 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07676	IFKMRTWTM	9	Sequence 1254 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07677	RAVWVRRMG	9	Sequence 1255 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07678	YWRQKINAW	9	Sequence 1256 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07679	GKYKWWRIR	9	Sequence 1257 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07680	MQRGFRKRK	9	Sequence 1258 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07681	WRRHWLPQN	9	Sequence 1259 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07682	WHIRRWKFI	9	Sequence 1260 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07683	WGSWRMRKH	9	Sequence 1261 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07684	KGWTNYNGR	9	Sequence 1262 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07685	VFIGKRTKS	9	Sequence 1263 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07686	GKPIGRKTY	9	Sequence 1264 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07687	RIRKWWSNH	9	Sequence 1265 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07688	RWIHTMWRG	9	Sequence 1266 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07689	WARKISNSW	9	Sequence 1267 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07690	WSRKRVWKF	9	Sequence 1268 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07691	WAWKLWIIK	9	Sequence 1269 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07692	GWAIGRGRI	9	Sequence 1270 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07693	YKIWHPKKV	9	Sequence 1271 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07694	SGKGMRIHT	9	Sequence 1272 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07695	WKQHNVKLG	9	Sequence 1273 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07696	HYRVAYWPR	9	Sequence 1274 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07697	RMTMHISIK	9	Sequence 1275 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07698	KRMYKQAGI	9	Sequence 1276 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07699	WIKIHRGLS	9	Sequence 1277 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07700	PWIAHRRPR	9	Sequence 1278 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07701	QWKVIFRVW	9	Sequence 1279 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07702	RYIRRIVHG	9	Sequence 1280 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07703	MAYKFLIKN	9	Sequence 1281 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07704	PGSRYTRNW	9	Sequence 1282 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07705	QWKGTYIRP	9	Sequence 1283 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07706	KVWRKFQYF	9	Sequence 1284 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07707	IIFRKHRIL	9	Sequence 1285 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07708	WSGIWRRWF	9	Sequence 1286 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07709	RKWLKVTMR	9	Sequence 1287 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07710	VRQQWIIRW	9	Sequence 1288 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07711	YYQQGRLRY	9	Sequence 1289 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07712	LGTTFKRGT	9	Sequence 1290 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07713	AKRVTRGMS	9	Sequence 1291 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07714	VGRKGGWWL	9	Sequence 1292 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07715	YRMQVKWVR	9	Sequence 1293 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07716	RPGRWGRVW	9	Sequence 1294 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07717	IGGITVVKR	9	Sequence 1295 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07718	KSVMVVKGR	9	Sequence 1296 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07719	QYIRRAQMF	9	Sequence 1297 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07720	IKHWKWWAV	9	Sequence 1298 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07721	KHPFSKQSR	9	Sequence 1299 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07722	AISGKKRFW	9	Sequence 1300 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07723	RLRVRIWIL	9	Sequence 1301 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07724	KPQTRNWWV	9	Sequence 1302 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07725	WTKRWTQVN	9	Sequence 1303 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07726	RWRSVQILV	9	Sequence 1304 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07727	RHRWGWISK	9	Sequence 1305 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07728	GPGLGIVRR	9	Sequence 1306 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07729	GARHRILYW	9	Sequence 1307 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07730	VWLKGKHNN	9	Sequence 1308 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07731	YWVLRNMKN	9	Sequence 1309 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07732	YIVRRTLGV	9	Sequence 1310 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07733	RGKGIWMWN	9	Sequence 1311 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07734	IKNWPQIKT	9	Sequence 1312 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07735	NGAFKRTQK	9	Sequence 1313 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07736	KMWRWHGRW	9	Sequence 1314 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07737	KVWHINAIR	9	Sequence 1315 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07738	WWLQPKQWK	9	Sequence 1316 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07739	IKARGNRMS	9	Sequence 1317 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07740	KGTRMTAGW	9	Sequence 1318 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07741	GSHRIKVKW	9	Sequence 1319 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07742	TWRIDRIRR	9	Sequence 1320 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07743	AKVHYWVKI	9	Sequence 1321 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07744	RTWIMITKV	9	Sequence 1322 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07745	GGKMPKIRG	9	Sequence 1323 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07746	KIGRKWVYG	9	Sequence 1324 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07747	KVKAMVGKM	9	Sequence 1325 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07748	SWRSVHSRK	9	Sequence 1326 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07749	VSRNSVVKK	9	Sequence 1327 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07750	ARWWGIRRR	9	Sequence 1328 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07751	SHRFRKHKR	9	Sequence 1329 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07752	ARWRIVVIRVRR	12	Sequence 1330 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07753	CRWRIVVIRVRR	12	Sequence 1331 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07754	DRWRIVVIRVRR	12	Sequence 1332 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07755	ERWRIVVIRVRR	12	Sequence 1333 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07756	FRWRIVVIRVRR	12	Sequence 1334 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07757	GRWRIVVIRVRR	12	Sequence 1335 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07758	HRWRIVVIRVRR	12	Sequence 1336 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07759	IRWRIVVIRVRR	12	Sequence 1337 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07760	KRWRIVVIRVRR	12	Sequence 1338 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07761	LRWRIVVIRVRR	12	Sequence 1339 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07762	MRWRIVVIRVRR	12	Sequence 1340 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07763	NRWRIVVIRVRR	12	Sequence 1341 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07764	PRWRIVVIRVRR	12	Sequence 1342 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07765	QRWRIVVIRVRR	12	Sequence 1343 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07766	SRWRIVVIRVRR	12	Sequence 1344 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07767	TRWRIVVIRVRR	12	Sequence 1345 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07768	VRWRIVVIRVRR	12	Sequence 1346 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07769	WRWRIVVIRVRR	12	Sequence 1347 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07770	YRWRIVVIRVRR	12	Sequence 1348 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07771	RAWRIVVIRVRR	12	Sequence 1349 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07772	RCWRIVVIRVRR	12	Sequence 1350 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07773	RDWRIVVIRVRR	12	Sequence 1351 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07774	REWRIVVIRVRR	12	Sequence 1352 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07775	RFWRIVVIRVRR	12	Sequence 1353 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07776	RGWRIVVIRVRR	12	Sequence 1354 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07777	RHWRIVVIRVRR	12	Sequence 1355 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07778	RIWRIVVIRVRR	12	Sequence 1356 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07779	RKWRIVVIRVRR	12	Sequence 1357 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07780	RLWRIVVIRVRR	12	Sequence 1358 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07781	RMWRIVVIRVRR	12	Sequence 1359 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07782	RNWRIVVIRVRR	12	Sequence 1360 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07783	RPWRIVVIRVRR	12	Sequence 1361 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07784	RQWRIVVIRVRR	12	Sequence 1362 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07785	RSWRIVVIRVRR	12	Sequence 1363 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07786	RTWRIVVIRVRR	12	Sequence 1364 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07787	RVWRIVVIRVRR	12	Sequence 1365 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07788	RWWRIVVIRVRR	12	Sequence 1366 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07789	RYWRIVVIRVRR	12	Sequence 1367 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07790	RRARIVVIRVRR	12	Sequence 1368 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07791	RRCRIVVIRVRR	12	Sequence 1369 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07792	RRDRIVVIRVRR	12	Sequence 1370 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07793	RRERIVVIRVRR	12	Sequence 1371 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07794	RRFRIVVIRVRR	12	Sequence 1372 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07795	RRGRIVVIRVRR	12	Sequence 1373 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07796	RRHRIVVIRVRR	12	Sequence 1374 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07797	RRIRIVVIRVRR	12	Sequence 1375 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07798	RRKRIVVIRVRR	12	Sequence 1376 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07799	RRLRIVVIRVRR	12	Sequence 1377 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07800	RRMRIVVIRVRR	12	Sequence 1378 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07801	RRNRIVVIRVRR	12	Sequence 1379 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07802	RRPRIVVIRVRR	12	Sequence 1380 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07803	RRQRIVVIRVRR	12	Sequence 1381 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07804	RRRRIVVIRVRR	12	Sequence 1382 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07805	RRSRIVVIRVRR	12	Sequence 1383 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07806	RRTRIVVIRVRR	12	Sequence 1384 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07807	RRVRIVVIRVRR	12	Sequence 1385 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07808	RRYRIVVIRVRR	12	Sequence 1386 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07809	RRWAIVVIRVRR	12	Sequence 1387 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07810	RRWCIVVIRVRR	12	Sequence 1388 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07811	RRWDIVVIRVRR	12	Sequence 1389 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07812	RRWEIVVIRVRR	12	Sequence 1390 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07813	RRWFIVVIRVRR	12	Sequence 1391 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07814	RRWGIVVIRVRR	12	Sequence 1392 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07815	RRWHIVVIRVRR	12	Sequence 1393 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07816	RRWIIVVIRVRR	12	Sequence 1394 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07817	RRWKIVVIRVRR	12	Sequence 1395 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07818	RRWLIVVIRVRR	12	Sequence 1396 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07819	RRWMIVVIRVRR	12	Sequence 1397 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07820	RRWNIVVIRVRR	12	Sequence 1398 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07821	RRWPIVVIRVRR	12	Sequence 1399 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07822	RRWQIVVIRVRR	12	Sequence 1400 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07823	RRWSIVVIRVRR	12	Sequence 1401 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07824	RRWTIVVIRVRR	12	Sequence 1402 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07825	RRWVIVVIRVRR	12	Sequence 1403 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07826	RRWWIVVIRVRR	12	Sequence 1404 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07827	RRWYIVVIRVRR	12	Sequence 1405 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07828	RRWRAVVIRVRR	12	Sequence 1406 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07829	RRWRCVVIRVRR	12	Sequence 1407 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07830	RRWRDVVIRVRR	12	Sequence 1408 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07831	RRWREVVIRVRR	12	Sequence 1409 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07832	RRWRFVVIRVRR	12	Sequence 1410 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07833	RRWRGVVIRVRR	12	Sequence 1411 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07834	RRWRHVVIRVRR	12	Sequence 1412 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07835	RRWRKVVIRVRR	12	Sequence 1413 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07836	RRWRLVVIRVRR	12	Sequence 1414 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07837	RRWRMVVIRVRR	12	Sequence 1415 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07838	RRWRNVVIRVRR	12	Sequence 1416 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07839	RRWRPVVIRVRR	12	Sequence 1417 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07840	RRWRQVVIRVRR	12	Sequence 1418 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07841	RRWRRVVIRVRR	12	Sequence 1419 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07842	RRWRSVVIRVRR	12	Sequence 1420 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07843	RRWRTVVIRVRR	12	Sequence 1421 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07844	RRWRVVVIRVRR	12	Sequence 1422 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07845	RRWRWVVIRVRR	12	Sequence 1423 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07846	RRWRYVVIRVRR	12	Sequence 1424 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07847	RRWRIAVIRVRR	12	Sequence 1425 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07848	RRWRICVIRVRR	12	Sequence 1426 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07849	RRWRIDVIRVRR	12	Sequence 1427 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07850	RRWRIEVIRVRR	12	Sequence 1428 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07851	RRWRIFVIRVRR	12	Sequence 1429 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07852	RRWRIGVIRVRR	12	Sequence 1430 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07853	RRWRIHVIRVRR	12	Sequence 1431 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07854	RRWRIIVIRVRR	12	Sequence 1432 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07855	RRWRIKVIRVRR	12	Sequence 1433 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07856	RRWRILVIRVRR	12	Sequence 1434 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07857	RRWRIMVIRVRR	12	Sequence 1435 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07858	RRWRINVIRVRR	12	Sequence 1436 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07859	RRWRIPVIRVRR	12	Sequence 1437 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07860	RRWRIQVIRVRR	12	Sequence 1438 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07861	RRWRIRVIRVRR	12	Sequence 1439 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07862	RRWRISVIRVRR	12	Sequence 1440 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07863	RRWRITVIRVRR	12	Sequence 1441 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07864	RRWRIWVIRVRR	12	Sequence 1442 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07865	RRWRIYVIRVRR	12	Sequence 1443 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07866	RRWRIVAIRVRR	12	Sequence 1444 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07867	RRWRIVCIRVRR	12	Sequence 1445 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07868	RRWRIVDIRVRR	12	Sequence 1446 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07869	RRWRIVEIRVRR	12	Sequence 1447 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07870	RRWRIVFIRVRR	12	Sequence 1448 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07871	RRWRIVGIRVRR	12	Sequence 1449 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07872	RRWRIVHIRVRR	12	Sequence 1450 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07873	RRWRIVIIRVRR	12	Sequence 1451 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07874	RRWRIVKIRVRR	12	Sequence 1452 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07875	RRWRIVLIRVRR	12	Sequence 1453 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07876	RRWRIVMIRVRR	12	Sequence 1454 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07877	RRWRIVNIRVRR	12	Sequence 1455 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07878	RRWRIVPIRVRR	12	Sequence 1456 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07879	RRWRIVQIRVRR	12	Sequence 1457 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07880	RRWRIVRIRVRR	12	Sequence 1458 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07881	RRWRIVSIRVRR	12	Sequence 1459 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07882	RRWRIVTIRVRR	12	Sequence 1460 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07883	RRWRIVWIRVRR	12	Sequence 1461 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07884	RRWRIVYIRVRR	12	Sequence 1462 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07885	RRWRIVVARVRR	12	Sequence 1463 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07886	RRWRIVVCRVRR	12	Sequence 1464 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07887	RRWRIVVDRVRR	12	Sequence 1465 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07888	RRWRIVVERVRR	12	Sequence 1466 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07889	RRWRIVVFRVRR	12	Sequence 1467 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07890	RRWRIVVGRVRR	12	Sequence 1468 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07891	RRWRIVVHRVRR	12	Sequence 1469 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07892	RRWRIVVKRVRR	12	Sequence 1470 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07893	RRWRIVVLRVRR	12	Sequence 1471 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07894	RRWRIVVMRVRR	12	Sequence 1472 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07895	RRWRIVVNRVRR	12	Sequence 1473 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07896	RRWRIVVPRVRR	12	Sequence 1474 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07897	RRWRIVVQRVRR	12	Sequence 1475 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07898	RRWRIVVRRVRR	12	Sequence 1476 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07899	RRWRIVVSRVRR	12	Sequence 1477 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07900	RRWRIVVTRVRR	12	Sequence 1478 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07901	RRWRIVVVRVRR	12	Sequence 1479 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07902	RRWRIVVWRVRR	12	Sequence 1480 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07903	RRWRIVVYRVRR	12	Sequence 1481 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07904	RRWRIVVIAVRR	12	Sequence 1482 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07905	RRWRIVVICVRR	12	Sequence 1483 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07906	RRWRIVVIDVRR	12	Sequence 1484 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07907	RRWRIVVIEVRR	12	Sequence 1485 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07908	RRWRIVVIFVRR	12	Sequence 1486 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07909	RRWRIVVIGVRR	12	Sequence 1487 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07910	RRWRIVVIHVRR	12	Sequence 1488 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07911	RRWRIVVIIVRR	12	Sequence 1489 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07912	RRWRIVVIKVRR	12	Sequence 1490 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07913	RRWRIVVILVRR	12	Sequence 1491 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07914	RRWRIVVIMVRR	12	Sequence 1492 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07915	RRWRIVVINVRR	12	Sequence 1493 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07916	RRWRIVVIPVRR	12	Sequence 1494 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07917	RRWRIVVIQVRR	12	Sequence 1495 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07918	RRWRIVVISVRR	12	Sequence 1496 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07919	RRWRIVVITVRR	12	Sequence 1497 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07920	RRWRIVVIVVRR	12	Sequence 1498 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07921	RRWRIVVIWVRR	12	Sequence 1499 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07922	RRWRIVVIYVRR	12	Sequence 1500 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07923	RRWRIVVIRARR	12	Sequence 1501 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07924	RRWRIVVIRCRR	12	Sequence 1502 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07925	RRWRIVVIRDRR	12	Sequence 1503 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07926	RRWRIVVIRERR	12	Sequence 1504 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07927	RRWRIVVIRFRR	12	Sequence 1505 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07928	RRWRIVVIRGRR	12	Sequence 1506 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07929	RRWRIVVIRHRR	12	Sequence 1507 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07930	RRWRIVVIRIRR	12	Sequence 1508 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07931	RRWRIVVIRKRR	12	Sequence 1509 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07932	RRWRIVVIRLRR	12	Sequence 1510 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07933	RRWRIVVIRMRR	12	Sequence 1511 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07934	RRWRIVVIRNRR	12	Sequence 1512 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07935	RRWRIVVIRPRR	12	Sequence 1513 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07936	RRWRIVVIRQRR	12	Sequence 1514 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07937	RRWRIVVIRRRR	12	Sequence 1515 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07938	RRWRIVVIRSRR	12	Sequence 1516 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07939	RRWRIVVIRTRR	12	Sequence 1517 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07940	RRWRIVVIRWRR	12	Sequence 1518 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07941	RRWRIVVIRYRR	12	Sequence 1519 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07942	RRWRIVVIRVAR	12	Sequence 1520 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07943	RRWRIVVIRVCR	12	Sequence 1521 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07944	RRWRIVVIRVDR	12	Sequence 1522 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07945	RRWRIVVIRVER	12	Sequence 1523 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07946	RRWRIVVIRVFR	12	Sequence 1524 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07947	RRWRIVVIRVGR	12	Sequence 1525 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07948	RRWRIVVIRVHR	12	Sequence 1526 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07949	RRWRIVVIRVIR	12	Sequence 1527 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07950	RRWRIVVIRVKR	12	Sequence 1528 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07951	RRWRIVVIRVLR	12	Sequence 1529 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07952	RRWRIVVIRVMR	12	Sequence 1530 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07953	RRWRIVVIRVNR	12	Sequence 1531 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07954	RRWRIVVIRVPR	12	Sequence 1532 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07955	RRWRIVVIRVQR	12	Sequence 1533 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07956	RRWRIVVIRVSR	12	Sequence 1534 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07957	RRWRIVVIRVTR	12	Sequence 1535 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07958	RRWRIVVIRVVR	12	Sequence 1536 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07959	RRWRIVVIRVWR	12	Sequence 1537 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07960	RRWRIVVIRVYR	12	Sequence 1538 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07961	RRWRIVVIRVRA	12	Sequence 1539 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07962	RRWRIVVIRVRC	12	Sequence 1540 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07963	RRWRIVVIRVRD	12	Sequence 1541 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07964	RRWRIVVIRVRE	12	Sequence 1542 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07965	RRWRIVVIRVRF	12	Sequence 1543 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07966	RRWRIVVIRVRG	12	Sequence 1544 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07967	RRWRIVVIRVRH	12	Sequence 1545 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07968	RRWRIVVIRVRI	12	Sequence 1546 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07969	RRWRIVVIRVRK	12	Sequence 1547 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07970	RRWRIVVIRVRL	12	Sequence 1548 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07971	RRWRIVVIRVRM	12	Sequence 1549 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07972	RRWRIVVIRVRN	12	Sequence 1550 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07973	RRWRIVVIRVRP	12	Sequence 1551 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07974	RRWRIVVIRVRQ	12	Sequence 1552 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07975	RRWRIVVIRVRS	12	Sequence 1553 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07976	RRWRIVVIRVRT	12	Sequence 1554 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07977	RRWRIVVIRVRV	12	Sequence 1555 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07978	RRWRIVVIRVRW	12	Sequence 1556 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07979	RRWRIVVIRVRY	12	Sequence 1557 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07980	AWWKIWVIRWWR	12	Sequence 1558 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07981	CWWKIWVIRWWR	12	Sequence 1559 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07982	DWWKIWVIRWWR	12	Sequence 1560 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07983	EWWKIWVIRWWR	12	Sequence 1561 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07984	FWWKIWVIRWWR	12	Sequence 1562 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07985	GWWKIWVIRWWR	12	Sequence 1563 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07986	HWWKIWVIRWWR	12	Sequence 1564 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07987	IWWKIWVIRWWR	12	Sequence 1565 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07988	KWWKIWVIRWWR	12	Sequence 1566 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07989	LWWKIWVIRWWR	12	Sequence 1567 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07990	MWWKIWVIRWWR	12	Sequence 1568 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07991	NWWKIWVIRWWR	12	Sequence 1569 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07992	PWWKIWVIRWWR	12	Sequence 1570 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07993	QWWKIWVIRWWR	12	Sequence 1571 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07994	SWWKIWVIRWWR	12	Sequence 1572 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07995	TWWKIWVIRWWR	12	Sequence 1573 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07996	VWWKIWVIRWWR	12	Sequence 1574 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07997	WWWKIWVIRWWR	12	Sequence 1575 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07998	YWWKIWVIRWWR	12	Sequence 1576 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP07999	RAWKIWVIRWWR	12	Sequence 1577 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08000	RCWKIWVIRWWR	12	Sequence 1578 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08001	RDWKIWVIRWWR	12	Sequence 1579 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08002	REWKIWVIRWWR	12	Sequence 1580 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08003	RFWKIWVIRWWR	12	Sequence 1581 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08004	RGWKIWVIRWWR	12	Sequence 1582 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08005	RHWKIWVIRWWR	12	Sequence 1583 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08006	RIWKIWVIRWWR	12	Sequence 1584 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08007	RKWKIWVIRWWR	12	Sequence 1585 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08008	RLWKIWVIRWWR	12	Sequence 1586 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08009	RMWKIWVIRWWR	12	Sequence 1587 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08010	RNWKIWVIRWWR	12	Sequence 1588 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08011	RPWKIWVIRWWR	12	Sequence 1589 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08012	RQWKIWVIRWWR	12	Sequence 1590 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08013	RRWKIWVIRWWR	12	Sequence 1591 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08014	RSWKIWVIRWWR	12	Sequence 1592 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08015	RTWKIWVIRWWR	12	Sequence 1593 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08016	RVWKIWVIRWWR	12	Sequence 1594 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08017	RYWKIWVIRWWR	12	Sequence 1595 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08018	RWAKIWVIRWWR	12	Sequence 1596 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08019	RWCKIWVIRWWR	12	Sequence 1597 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08020	RWDKIWVIRWWR	12	Sequence 1598 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08021	RWEKIWVIRWWR	12	Sequence 1599 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08022	RWFKIWVIRWWR	12	Sequence 1600 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08023	RWGKIWVIRWWR	12	Sequence 1601 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08024	RWHKIWVIRWWR	12	Sequence 1602 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08025	RWIKIWVIRWWR	12	Sequence 1603 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08026	RWKKIWVIRWWR	12	Sequence 1604 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08027	RWLKIWVIRWWR	12	Sequence 1605 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08028	RWMKIWVIRWWR	12	Sequence 1606 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08029	RWNKIWVIRWWR	12	Sequence 1607 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08030	RWPKIWVIRWWR	12	Sequence 1608 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08031	RWQKIWVIRWWR	12	Sequence 1609 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08032	RWRKIWVIRWWR	12	Sequence 1610 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08033	RWSKIWVIRWWR	12	Sequence 1611 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08034	RWTKIWVIRWWR	12	Sequence 1612 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08035	RWVKIWVIRWWR	12	Sequence 1613 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08036	RWYKIWVIRWWR	12	Sequence 1614 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08037	RWWAIWVIRWWR	12	Sequence 1615 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08038	RWWCIWVIRWWR	12	Sequence 1616 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08039	RWWDIWVIRWWR	12	Sequence 1617 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08040	RWWEIWVIRWWR	12	Sequence 1618 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08041	RWWFIWVIRWWR	12	Sequence 1619 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08042	RWWGIWVIRWWR	12	Sequence 1620 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08043	RWWHIWVIRWWR	12	Sequence 1621 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08044	RWWIIWVIRWWR	12	Sequence 1622 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08045	RWWLIWVIRWWR	12	Sequence 1623 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08046	RWWMIWVIRWWR	12	Sequence 1624 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08047	RWWNIWVIRWWR	12	Sequence 1625 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08048	RWWPIWVIRWWR	12	Sequence 1626 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08049	RWWQIWVIRWWR	12	Sequence 1627 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08050	RWWRIWVIRWWR	12	Sequence 1628 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08051	RWWSIWVIRWWR	12	Sequence 1629 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08052	RWWTIWVIRWWR	12	Sequence 1630 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08053	RWWVIWVIRWWR	12	Sequence 1631 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08054	RWWWIWVIRWWR	12	Sequence 1632 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08055	RWWYIWVIRWWR	12	Sequence 1633 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08056	RWWKAWVIRWWR	12	Sequence 1634 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08057	RWWKCWVIRWWR	12	Sequence 1635 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08058	RWWKDWVIRWWR	12	Sequence 1636 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08059	RWWKEWVIRWWR	12	Sequence 1637 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08060	RWWKFWVIRWWR	12	Sequence 1638 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08061	RWWKGWVIRWWR	12	Sequence 1639 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08062	RWWKHWVIRWWR	12	Sequence 1640 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08063	RWWKKWVIRWWR	12	Sequence 1641 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08064	RWWKLWVIRWWR	12	Sequence 1642 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08065	RWWKMWVIRWWR	12	Sequence 1643 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08066	RWWKNWVIRWWR	12	Sequence 1644 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08067	RWWKPWVIRWWR	12	Sequence 1645 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08068	RWWKQWVIRWWR	12	Sequence 1646 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08069	RWWKRWVIRWWR	12	Sequence 1647 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08070	RWWKSWVIRWWR	12	Sequence 1648 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08071	RWWKTWVIRWWR	12	Sequence 1649 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08072	RWWKVWVIRWWR	12	Sequence 1650 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08073	RWWKWWVIRWWR	12	Sequence 1651 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08074	RWWKYWVIRWWR	12	Sequence 1652 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08075	RWWKIAVIRWWR	12	Sequence 1653 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08076	RWWKICVIRWWR	12	Sequence 1654 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08077	RWWKIDVIRWWR	12	Sequence 1655 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08078	RWWKIEVIRWWR	12	Sequence 1656 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08079	RWWKIFVIRWWR	12	Sequence 1657 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08080	RWWKIGVIRWWR	12	Sequence 1658 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08081	RWWKIHVIRWWR	12	Sequence 1659 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08082	RWWKIIVIRWWR	12	Sequence 1660 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08083	RWWKIKVIRWWR	12	Sequence 1661 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08084	RWWKILVIRWWR	12	Sequence 1662 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08085	RWWKIMVIRWWR	12	Sequence 1663 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08086	RWWKINVIRWWR	12	Sequence 1664 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08087	RWWKIPVIRWWR	12	Sequence 1665 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08088	RWWKIQVIRWWR	12	Sequence 1666 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08089	RWWKIRVIRWWR	12	Sequence 1667 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08090	RWWKISVIRWWR	12	Sequence 1668 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08091	RWWKITVIRWWR	12	Sequence 1669 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08092	RWWKIVVIRWWR	12	Sequence 1670 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08093	RWWKIYVIRWWR	12	Sequence 1671 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08094	RWWKIWAIRWWR	12	Sequence 1672 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08095	RWWKIWCIRWWR	12	Sequence 1673 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08096	RWWKIWDIRWWR	12	Sequence 1674 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08097	RWWKIWEIRWWR	12	Sequence 1675 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08098	RWWKIWFIRWWR	12	Sequence 1676 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08099	RWWKIWGIRWWR	12	Sequence 1677 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08100	RWWKIWHIRWWR	12	Sequence 1678 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08101	RWWKIWIIRWWR	12	Sequence 1679 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08102	RWWKIWKIRWWR	12	Sequence 1680 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08103	RWWKIWLIRWWR	12	Sequence 1681 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08104	RWWKIWMIRWWR	12	Sequence 1682 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08105	RWWKIWNIRWWR	12	Sequence 1683 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08106	RWWKIWPIRWWR	12	Sequence 1684 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08107	RWWKIWQIRWWR	12	Sequence 1685 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08108	RWWKIWRIRWWR	12	Sequence 1686 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08109	RWWKIWSIRWWR	12	Sequence 1687 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08110	RWWKIWTIRWWR	12	Sequence 1688 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08111	RWWKIWWIRWWR	12	Sequence 1689 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08112	RWWKIWYIRWWR	12	Sequence 1690 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08113	RWWKIWVARWWR	12	Sequence 1691 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08114	RWWKIWVCRWWR	12	Sequence 1692 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08115	RWWKIWVDRWWR	12	Sequence 1693 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08116	RWWKIWVERWWR	12	Sequence 1694 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08117	RWWKIWVFRWWR	12	Sequence 1695 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08118	RWWKIWVGRWWR	12	Sequence 1696 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08119	RWWKIWVHRWWR	12	Sequence 1697 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08120	RWWKIWVKRWWR	12	Sequence 1698 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08121	RWWKIWVLRWWR	12	Sequence 1699 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08122	RWWKIWVMRWWR	12	Sequence 1700 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08123	RWWKIWVNRWWR	12	Sequence 1701 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08124	RWWKIWVPRWWR	12	Sequence 1702 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08125	RWWKIWVQRWWR	12	Sequence 1703 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08126	RWWKIWVRRWWR	12	Sequence 1704 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08127	RWWKIWVSRWWR	12	Sequence 1705 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08128	RWWKIWVTRWWR	12	Sequence 1706 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08129	RWWKIWVVRWWR	12	Sequence 1707 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08130	RWWKIWVWRWWR	12	Sequence 1708 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08131	RWWKIWVYRWWR	12	Sequence 1709 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08132	RWWKIWVIAWWR	12	Sequence 1710 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08133	RWWKIWVICWWR	12	Sequence 1711 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08134	RWWKIWVIDWWR	12	Sequence 1712 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08135	RWWKIWVIEWWR	12	Sequence 1713 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08136	RWWKIWVIFWWR	12	Sequence 1714 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08137	RWWKIWVIGWWR	12	Sequence 1715 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08138	RWWKIWVIHWWR	12	Sequence 1716 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08139	RWWKIWVIIWWR	12	Sequence 1717 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08140	RWWKIWVIKWWR	12	Sequence 1718 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08141	RWWKIWVILWWR	12	Sequence 1719 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08142	RWWKIWVIMWWR	12	Sequence 1720 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08143	RWWKIWVINWWR	12	Sequence 1721 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08144	RWWKIWVIPWWR	12	Sequence 1722 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08145	RWWKIWVIQWWR	12	Sequence 1723 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08146	RWWKIWVISWWR	12	Sequence 1724 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08147	RWWKIWVITWWR	12	Sequence 1725 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08148	RWWKIWVIVWWR	12	Sequence 1726 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08149	RWWKIWVIWWWR	12	Sequence 1727 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08150	RWWKIWVIYWWR	12	Sequence 1728 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08151	RWWKIWVIRAWR	12	Sequence 1729 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08152	RWWKIWVIRCWR	12	Sequence 1730 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08153	RWWKIWVIRDWR	12	Sequence 1731 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08154	RWWKIWVIREWR	12	Sequence 1732 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08155	RWWKIWVIRFWR	12	Sequence 1733 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08156	RWWKIWVIRGWR	12	Sequence 1734 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08157	RWWKIWVIRHWR	12	Sequence 1735 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08158	RWWKIWVIRIWR	12	Sequence 1736 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08159	RWWKIWVIRKWR	12	Sequence 1737 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08160	RWWKIWVIRLWR	12	Sequence 1738 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08161	RWWKIWVIRMWR	12	Sequence 1739 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08162	RWWKIWVIRNWR	12	Sequence 1740 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08163	RWWKIWVIRPWR	12	Sequence 1741 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08164	RWWKIWVIRQWR	12	Sequence 1742 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08165	RWWKIWVIRRWR	12	Sequence 1743 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08166	RWWKIWVIRSWR	12	Sequence 1744 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08167	RWWKIWVIRTWR	12	Sequence 1745 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08168	RWWKIWVIRVWR	12	Sequence 1746 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08169	RWWKIWVIRYWR	12	Sequence 1747 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08170	RWWKIWVIRWAR	12	Sequence 1748 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08171	RWWKIWVIRWCR	12	Sequence 1749 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08172	RWWKIWVIRWDR	12	Sequence 1750 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08173	RWWKIWVIRWER	12	Sequence 1751 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08174	RWWKIWVIRWFR	12	Sequence 1752 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08175	RWWKIWVIRWGR	12	Sequence 1753 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08176	RWWKIWVIRWHR	12	Sequence 1754 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08177	RWWKIWVIRWIR	12	Sequence 1755 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08178	RWWKIWVIRWKR	12	Sequence 1756 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08179	RWWKIWVIRWLR	12	Sequence 1757 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08180	RWWKIWVIRWMR	12	Sequence 1758 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08181	RWWKIWVIRWNR	12	Sequence 1759 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08182	RWWKIWVIRWPR	12	Sequence 1760 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08183	RWWKIWVIRWQR	12	Sequence 1761 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08184	RWWKIWVIRWRR	12	Sequence 1762 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08185	RWWKIWVIRWSR	12	Sequence 1763 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08186	RWWKIWVIRWTR	12	Sequence 1764 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08187	RWWKIWVIRWVR	12	Sequence 1765 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08188	RWWKIWVIRWYR	12	Sequence 1766 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08189	RWWKIWVIRWWA	12	Sequence 1767 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08190	RWWKIWVIRWWC	12	Sequence 1768 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP09045	SSLLEKGLDGAKKAVGGLGKLGKDAV	26	Sequence 36 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09046	SSLLEKGLDGAKKAVGGLGKLGKDAVE	27	Sequence 37 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09047	SSLLEKGLDGAKKAVGGLGKLGKDAVED	28	Sequence 38 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09048	SSLLEKGLDGAKKAVGGLGKLGKDAVEDL	29	Sequence 39 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09049	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLE	30	Sequence 40 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09050	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLES	31	Sequence 41 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09051	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESV	32	Sequence 42 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09052	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVG	33	Sequence 43 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09053	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGK	34	Sequence 44 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09054	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKG	35	Sequence 45 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09055	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGA	36	Sequence 46 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09056	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAV	37	Sequence 47 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09057	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVH	38	Sequence 48 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09058	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHD	39	Sequence 49 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09059	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDV	40	Sequence 50 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09060	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVK	41	Sequence 51 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09061	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKD	42	Sequence 52 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09062	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDV	43	Sequence 53 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09063	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVL	44	Sequence 54 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09064	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLD	45	Sequence 55 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09065	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDS	46	Sequence 56 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09066	SLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	47	Sequence 57 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09067	LLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	46	Sequence 58 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09068	LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	45	Sequence 59 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09069	EKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	44	Sequence 60 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09070	KGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	43	Sequence 61 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09071	GLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	42	Sequence 62 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09072	LDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	41	Sequence 63 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09073	DGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	40	Sequence 64 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09074	GAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	39	Sequence 65 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09075	AKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	38	Sequence 66 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09076	KKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	37	Sequence 67 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09077	KAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	36	Sequence 68 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09078	AVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	35	Sequence 69 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09079	VGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	34	Sequence 70 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09080	GGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	33	Sequence 71 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09081	GLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	32	Sequence 72 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09082	LGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	31	Sequence 73 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09083	GKLGKDAVEDLESVGKGAVHDVKDVLDSVL	30	Sequence 74 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09084	KLGKDAVEDLESVGKGAVHDVKDVLDSVL	29	Sequence 75 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09085	LGKDAVEDLESVGKGAVHDVKDVLDSVL	28	Sequence 76 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09086	GKDAVEDLESVGKGAVHDVKDVLDSVL	27	Sequence 77 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09087	KDAVEDLESVGKGAVHDVKDVLDSVL	26	Sequence 78 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09088	DAVEDLESVGKGAVHDVKDVLDSVL	25	Sequence 79 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09089	AVEDLESVGKGAVHDVKDVLDSVL	24	Sequence 80 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09090	VEDLESVGKGAVHDVKDVLDSVL	23	Sequence 81 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09091	EDLESVGKGAVHDVKDVLDSVL	22	Sequence 82 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09092	DLESVGKGAVHDVKDVLDSVL	21	Sequence 83 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09093	LESVGKGAVHDVKDVLDSVL	20	Sequence 84 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09094	ESVGKGAVHDVKDVLDSVL	19	Sequence 85 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09095	SVGKGAVHDVKDVLDSVL	18	Sequence 86 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09096	VGKGAVHDVKDVLDSVL	17	Sequence 87 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09097	GKGAVHDVKDVLDSVL	16	Sequence 88 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09098	KGAVHDVKDVLDSVL	15	Sequence 89 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09099	GAVHDVKDVLDSVL	14	Sequence 90 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09100	AVHDVKDVLDSVL	13	Sequence 91 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09101	VHDVKDVLDSVL	12	Sequence 92 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09102	HDVKDVLDSVL	11	Sequence 93 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09103	DVKDVLDSVL	10	Sequence 94 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09104	SLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	46	Sequence 95 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09105	LLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	45	Sequence 96 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09106	LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	44	Sequence 97 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09107	EKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	43	Sequence 98 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09108	KGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	42	Sequence 99 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09109	GLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	41	Sequence 100 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09110	LDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	40	Sequence 101 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09111	DGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	39	Sequence 102 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09112	GAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	38	Sequence 103 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09113	AKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	37	Sequence 104 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09114	KKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	36	Sequence 105 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09115	KAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	35	Sequence 106 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09116	AVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	34	Sequence 107 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09117	VGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	33	Sequence 108 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09118	GGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	32	Sequence 109 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09119	GLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	31	Sequence 110 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09120	LGKLGKDAVEDLESVGKGAVHDVKDVLDSV	30	Sequence 111 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09121	GKLGKDAVEDLESVGKGAVHDVKDVLDSV	29	Sequence 112 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09122	KLGKDAVEDLESVGKGAVHDVKDVLDSV	28	Sequence 113 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09123	LGKDAVEDLESVGKGAVHDVKDVLDSV	27	Sequence 114 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09124	GKDAVEDLESVGKGAVHDVKDVLDSV	26	Sequence 115 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09125	KDAVEDLESVGKGAVHDVKDVLDSV	25	Sequence 116 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09126	DAVEDLESVGKGAVHDVKDVLDSV	24	Sequence 117 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09127	AVEDLESVGKGAVHDVKDVLDSV	23	Sequence 118 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09128	VEDLESVGKGAVHDVKDVLDSV	22	Sequence 119 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09129	EDLESVGKGAVHDVKDVLDSV	21	Sequence 120 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09130	DLESVGKGAVHDVKDVLDSV	20	Sequence 121 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09131	LESVGKGAVHDVKDVLDSV	19	Sequence 122 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09132	ESVGKGAVHDVKDVLDSV	18	Sequence 123 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09133	SVGKGAVHDVKDVLDSV	17	Sequence 124 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09134	VGKGAVHDVKDVLDSV	16	Sequence 125 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09135	GKGAVHDVKDVLDSV	15	Sequence 126 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09136	KGAVHDVKDVLDSV	14	Sequence 127 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09137	GAVHDVKDVLDSV	13	Sequence 128 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09138	AVHDVKDVLDSV	12	Sequence 129 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09139	VHDVKDVLDSV	11	Sequence 130 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09140	HDVKDVLDSV	10	Sequence 131 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09141	SLLEKGLDGAKKAVGGLGKLGK	22	Sequence 132 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09142	LLEKGLDGAKKAVGGLGKLGK	21	Sequence 133 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09143	LEKGLDGAKKAVGGLGKLGK	20	Sequence 134 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09144	EKGLDGAKKAVGGLGKLGK	19	Sequence 135 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09145	KGLDGAKKAVGGLGKLGK	18	Sequence 136 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09146	GLDGAKKAVGGLGKLGK	17	Sequence 137 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09147	LDGAKKAVGGLGKLGK	16	Sequence 138 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09148	DGAKKAVGGLGKLGK	15	Sequence 139 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09149	GAKKAVGGLGKLGK	14	Sequence 140 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09150	AKKAVGGLGKLGK	13	Sequence 141 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09151	KKAVGGLGKLGK	12	Sequence 142 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09152	KAVGGLGKLGK	11	Sequence 143 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09153	AVGGLGKLGK	10	Sequence 144 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP18793	RCLCRRRVC	9	Sequence 82 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP09155	SLLEKGLDGAKKAVGGLGKLGKDA	24	Sequence 146 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09156	LLEKGLDGAKKAVGGLGKLGKDA	23	Sequence 147 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09157	LEKGLDGAKKAVGGLGKLGKDA	22	Sequence 148 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09158	EKGLDGAKKAVGGLGKLGKDA	21	Sequence 149 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09159	IKHQHPQE	8	Sequence 1 from Patent US 20090214498	Lactobacillus acidophilus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09160	SDIPNPIGSENSEK	14	Sequence 2 from Patent US 20090214498	Lactobacillus acidophilus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09161	VLNENLLR	8	Sequence 3 from Patent US 20090214498	Lactobacillus acidophilus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09162	KTKLTEEEKNRLNFLKKISQRYQKFALPQYLKTVYQHQK	39	Sequence 4 from Patent US 20090214498	Bos taurus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09163	KKTKLTEEEKNRLNFL	16	Sequence 5 from Patent US 20090214498	Bos taurus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09164	QKFALPQYLKTVYQHQKAMKQ	21	Sequence 6 from Patent US 20090214498	Bos taurus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09165	RPKHPIKHQGLPQEVLNENLLRF	23	Sequence 7 from Patent US 20090214498	Bos taurus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09166	RPKHPIKHQ	9	Sequence 8 from Patent US 20090214498	Bos taurus	Antimicrobial	US 2009/0214498 A1	Patent Application	2009##8##27	EP1951745A2, WO2007057872A2, WO2007057872A3	Antimicrobial peptides and bacterial strains that produce them.	The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th Nov. 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
DRAMP09167	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	38	Sequence 4 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09168	LKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	37	Sequence 6 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09169	KELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	36	Sequence 8 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09170	ELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	35	Sequence 10 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09171	LITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	34	Sequence 12 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09172	ITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	33	Sequence 14 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09173	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQP	33	Sequence 16 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09174	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPR	34	Sequence 18 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09175	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPRE	35	Sequence 20 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09176	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREE	36	Sequence 22 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09177	RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEK	37	Sequence 24 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09178	DRLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	39	Sequence 26 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09179	IDRLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	40	Sequence 28 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09180	KIDRLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	41	Sequence 30 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09181	KKIDRLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS	42	Sequence 32 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09182	METQKDSPSLGRWSLLLLLLGLVITPAASRALSYREAVLRAVNGFNQRSSEENLYRLLQLNSQPKG	66	Sequence 43 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09183	DEDPNIPKPVSFTVKETVCPKTTQQPLEQCGFKDNG	36	Sequence 44 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09184	LVKQCEGTVILDEDTGYFDLNCDS	24	Sequence 45 from Patent US 7985832	Canis familiaris	Antimicrobial	US 7985832 B2	Granted Patent	2011##7##26	CA2632782A1, CN101351474A, EP1966235A2, EP1966235A4, US20090221483, WO2007076162A2, WO2007076162A3	Antimicrobial Cathelicidin Peptides.	The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In addition, the invention also provides compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial polypeptide.
DRAMP09185	FWQRIRKVR	9	Sequence 1 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09186	FWQRRIRKVRR	11	Sequence 2 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09187	FWQRKIRKVRK	11	Sequence 3 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09188	FWQRNIRIRR	10	Sequence 4 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09189	FWQRNIRKVR	10	Sequence 5 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09190	FWQRNIRVR	9	Sequence 6 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09191	FWQRNIRKVRR	11	Sequence 7 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09192	FWQRNIRKVKK	11	Sequence 8 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09193	FWQRNIRKVRRR	12	Sequence 9 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09194	FWQRNIRKVKKK	12	Sequence 10 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09195	FWQRNIRKVRRRR	13	Sequence 11 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09196	FWQRNIRKVRRRI	13	Sequence 12 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09197	FWQRNIRKVKKKK	13	Sequence 13 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09198	FWQRNIRKVKKKI	13	Sequence 14 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09199	FWQRNIRKIR	10	Sequence 15 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09200	FWQRNIRKLR	10	Sequence 16 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09201	FWQRNIRKWR	10	Sequence 17 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09202	FWQRNWRKVR	10	Sequence 18 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09203	FWQRNFRKVR	10	Sequence 19 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09204	FWQRNYRKVR	10	Sequence 20 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09205	FWQRNIRKVS	10	Sequence 21 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09206	FWQRRIRIRR	10	Sequence 22 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09207	FWQRPIRKVR	10	Sequence 23 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09208	FWQRRIRKWR	10	Sequence 24 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09209	FWQRRIRRWRR	11	Sequence 25 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09210	FWPRNIRKVR	10	Sequence 26 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09211	FWARNIRKVR	10	Sequence 27 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09212	FWIRNIRKVR	10	Sequence 28 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09213	FWLRNIRKVR	10	Sequence 29 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09214	FWVRNIRKVR	10	Sequence 30 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09215	FWQRNIFKVR	10	Sequence 31 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09216	FWQRNIYKVR	10	Sequence 32 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09217	FAWQRNIRKVR	11	Sequence 33 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09218	FIWQRNIRKVR	11	Sequence 34 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09219	FLWQRNIRKVR	11	Sequence 35 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09220	FVWQRNIRKVR	11	Sequence 36 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09221	FWRIRKWR	8	Sequence 37 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09222	FWRIRKVR	8	Sequence 38 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09223	FWRWRR	6	Sequence 39 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09224	FWRRWRR	7	Sequence 40 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09225	FWRRWIRR	8	Sequence 41 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09226	FWRGWRIRR	9	Sequence 42 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09227	FWRRFWRR	8	Sequence 43 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09228	FWRWRWR	7	Sequence 44 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09229	FWRIWRWR	8	Sequence 45 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09230	FWRIWRIWR	9	Sequence 46 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09231	FWRNIRKWR	9	Sequence 47 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09232	FWRRRIRIRR	10	Sequence 48 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09233	FIWRWRWR	8	Sequence 49 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09234	PFWRWRIWR	9	Sequence 50 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09235	PFWRIRIRR	9	Sequence 51 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09236	PFWRQRIRR	9	Sequence 52 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09237	PFWRARIRR	9	Sequence 53 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09238	PFWRKRIRR	9	Sequence 54 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09239	PFWRKRLRR	9	Sequence 55 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09240	PFWRKRWRR	9	Sequence 56 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09241	PFWRRRIRR	9	Sequence 57 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09242	PFWRRRWRR	9	Sequence 58 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09243	PFWRIRIRRD	10	Sequence 59 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09244	PFFWRIRIRR	10	Sequence 60 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09245	PWRIRIRR	8	Sequence 61 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09246	RFWQRNIRKVRR	12	Sequence 62 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09247	RFWQRNIRKYR	11	Sequence 63 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09248	PFWQRNIRKWR	11	Sequence 64 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09249	RFRWQRNIRKYRR	13	Sequence 65 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09250	RWKRINRQWF	10	Sequence 66 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09251	KRFCFKK	7	Sequence 67 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09252	KRFSFKKC	8	Sequence 68 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09253	KRWSWKK	7	Sequence 69 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09254	FRFSFKK	7	Sequence 70 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09255	RRFWFRR	7	Sequence 71 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09256	FWRNIRIRR	9	Sequence 72 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09257	FWQRIRIRR	9	Sequence 73 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09258	FWRWRIWR	8	Sequence 74 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09259	FWRIRIRR	8	Sequence 75 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09260	FWRNIRIWRR	10	Sequence 76 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP18792	RCICGRRFC	9	Sequence 81 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP09262	RFWQRNIRIRR	11	Sequence 78 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09263	RWQRNIRIRR	10	Sequence 79 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09264	RRIRINRQWF	10	Sequence 80 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09265	PFWRRQIRR	9	Sequence 81 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09266	PFWRKKLKR	9	Sequence 82 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09267	PWRRIRR	7	Sequence 83 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09268	PWRRKIRR	8	Sequence 84 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09269	PFWRRRIRIRR	11	Sequence 85 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09270	RRWFWRR	7	Sequence 86 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09271	FQWQRNIRKVR	11	Sequence 87 from Patent US 7960339	Synthetic construct	Antimicrobial	US 7960339 B2	Granted Patent	2011##6##14	CA2657543A1, CN101528248A, EP2046363A1, EP2078529A1, US20090233870, WO2008006125A1	Antimicrobial peptides.	The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.
DRAMP09272	MSQVVGGKYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS	50	Sequence 12 from Patent US 7951385	ENTEROCOCCUS MUNDTII ST4S	Antimicrobial, Antibacterial	US 7951385 B2	Granted Patent	2011##5##31	CN101454440A, US20090297482	Probiotic strain and antimicrobial peptide derived therefrom.	The invention relates to a strain of Enterococcus mundtii having probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. The invention also provides an isolated nucleotide sequence which codes for the antimicrobial peptide (peptide ST4SA). Another aspect of the invention relates to a process for the production of a peptide of the invention which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 100 ℃. and 45 ℃., until a recoverable quantity of said peptide is produced, and recovering said peptide. The isolated peptide of the invention may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
DRAMP09273	MSNLKWFSGGDDRRKKAEVIITELLDDLEIDLGNESLRKVLGSYLEKLKNEGTSVPLVLSRMNIEISNAIKKDGVSLNENQSKKLKELISISNIRYGY	98	Sequence 16 from Patent US 7951385	ENTEROCOCCUS MUNDTII ST4S	Antimicrobial, Antibacterial	US 7951385 B2	Granted Patent	2011##5##31	CN101454440A, US20090297482	Probiotic strain and antimicrobial peptide derived therefrom.	The invention relates to a strain of Enterococcus mundtii having probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. The invention also provides an isolated nucleotide sequence which codes for the antimicrobial peptide (peptide ST4SA). Another aspect of the invention relates to a process for the production of a peptide of the invention which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 100 ℃. and 45 ℃., until a recoverable quantity of said peptide is produced, and recovering said peptide. The isolated peptide of the invention may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
DRAMP09274	KYYGNGVSCNKKGCSVDWGKAIGIIGNNS	29	Sequence 17 from Patent US 7951385	ENTEROCOCCUS MUNDTII ST4S	Antimicrobial, Antibacterial	US 7951385 B2	Granted Patent	2011##5##31	CN101454440A, US20090297482	Probiotic strain and antimicrobial peptide derived therefrom.	The invention relates to a strain of Enterococcus mundtii having probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. The invention also provides an isolated nucleotide sequence which codes for the antimicrobial peptide (peptide ST4SA). Another aspect of the invention relates to a process for the production of a peptide of the invention which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 100 ℃. and 45 ℃., until a recoverable quantity of said peptide is produced, and recovering said peptide. The isolated peptide of the invention may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
DRAMP09275	KAIGLLGNNSAANLATGGAAGWKS	24	Sequence 18 from Patent US 7951385	ENTEROCOCCUS MUNDTII ST4S	Antimicrobial, Antibacterial	US 7951385 B2	Granted Patent	2011##5##31	CN101454440A, US20090297482	Probiotic strain and antimicrobial peptide derived therefrom.	The invention relates to a strain of Enterococcus mundtii having probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. The invention also provides an isolated nucleotide sequence which codes for the antimicrobial peptide (peptide ST4SA). Another aspect of the invention relates to a process for the production of a peptide of the invention which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 100 ℃. and 45 ℃., until a recoverable quantity of said peptide is produced, and recovering said peptide. The isolated peptide of the invention may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
DRAMP09276	KRGFGKKLRKRLKKFRNSIKKRLKNFNVVIPIPLPG	36	Sequence 1 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09277	KRGFGKKLRKRLKKFRNSIKKRLKNFNVVIPIPLP	35	Sequence 2 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09278	KRGFGKKLRKRLKKFRNSIKKRLKNFN	27	Sequence 3 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09279	KRGFGKKLRKRLKKFRNSIKKRL	23	Sequence 4 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09280	GFGKKLRKRLKKFRNSIKKRLKNFN	25	Sequence 5 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09281	KLRKRLKKFRNSIKKRLKNFN	21	Sequence 6 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09282	RLKKFRNSIKKRLKNFN	17	Sequence 7 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09283	GPLPIPIVVNFNKLRKKISNRFKKLRKRLKKGFGRK	36	Sequence 12 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09284	PLPIPIVVNFNKLRKKISNRFKKLRKRLKKGFGRK	35	Sequence 13 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09285	KRGLWESLKRKATKLGDDIRNTLRNFKIKFPVPRQG	36	Sequence 18 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09286	KRGLWESLKRKATKLGDDIRNTLRNFKIKFPVPRQ	35	Sequence 19 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09287	GQRPVPFKIKFNRLTNRIDDGLKTAKRKLSEWLGRK	36	Sequence 24 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09288	QRPVPFKIKFNRLTNRIDDGLKTAKRKLSEWLGRK	35	Sequence 25 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09289	TPELFRSRSPPGRKKGSKRHKPGSYSVIALGKPGVKKSPYMEAL	44	Sequence 30 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09290	RKKGSKRHKPGSYSVIALGKPGVKKSPYMEAL	32	Sequence 31 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09291	PGSYSVIALGKPGVKKSPYMEAL	23	Sequence 32 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09292	SVIALGKPGVKKSPYMEAL	19	Sequence 33 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09293	ALGKPGVKKSPYMEAL	16	Sequence 34 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09294	SVIALGKPGVKKSPYMEA	18	Sequence 35 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09295	LAEMYPSKKVGPKGLAIVSYSGPKHRKSGKKR	32	Sequence 38 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09296	YPYDVPDYA	9	Sequence 41 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09297	GKPIPNPLLGLDST	14	Sequence 42 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09298	HHHHHH	6	Sequence 43 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09299	FQKLISEEDL	10	Sequence 44 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09300	DYKDDDDKC	9	Sequence 45 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09301	PEAVPTADKQIPNRA	15	Sequence 47 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09302	PLSSLSQTSTAHFEVHRGNALQIYSSPNQGPHEQTLKRNLKPTTELLLDQTDLKQSSNEQGIAAIILTP	69	Sequence 48 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09303	DSTSACPEAVPTADKQIPNRA	21	Sequence 50 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09304	EHRKVLASVAIISTQAPLSSLSQTSTAHFEVHRGNALQIYSSPNQGPHEQTLKRNLKPTTELLLDQTDLKQSSNEQGIAAIILTP	85	Sequence 51 from Patent US 20090312248	Synthetic construct	Antimicrobial	US 2009/0312248 A1	Patent Application	2009##12##17	CA2641064A1, EP2004674A1, EP2004674A4, EP2004674B1, US8383125, WO2007106951A1	Antimicrobial protein.	The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are particularly useful for broad spectrum applications, especially for the treatment of bacterial infections.
DRAMP09305	GKRKKKGKGLGKKRDPCLRKYK	22	Sequence 1 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09306	PKRKKKGGKNGKNRRNRKKKN	21	Sequence 2 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09307	GRPRESGKKRKRKRKLKPT	19	Sequence 3 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09308	QRAKTPQTRVTIRTVRVRRPP	21	Sequence 4 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09309	RVRRPPKGKHRKFKHTHDKTA	21	Sequence 5 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09310	LRPVQVRKIEIVRKKPIFKKATVT	24	Sequence 6 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09311	LKKNGSCKRGPRTHYGQKAIL	21	Sequence 7 from Patent US 20090312265	Human growth factor	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09312	LKRTGQYKLGSKTGPGQKAIL	21	Sequence 8 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09313	LNQKGIPVRGKKTKKEQKTAH	21	Sequence 9 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09314	LNGKGAPRRGQKTRRKNTSAH	21	Sequence 10 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09315	LKIKTKKVNTADQCANRCTRNKGL	24	Sequence 11 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09316	KRKKKGKGLGKKRDPCLRKY	20	Sequence 12 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09317	KRKRKGKGLGKKKDPCLRKF	20	Sequence 13 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09318	KRKKKGKGLGKKRLPCLRKY	20	Sequence 14 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09319	KRKKKGKGWGKKRDPCLRKY	20	Sequence 15 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09320	KRKKKGKGWGKKRLPCLRKY	20	Sequence 16 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09321	KRKKKGKGWGKKRWPCLRKY	20	Sequence 17 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09322	KRKKKGKGLGKKRWPCLRKY	20	Sequence 18 from Patent US 20090312265	Synthetic construct	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09323	KRKKKGKGLG	10	Sequence 20 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09324	KRKKKGKGLGKKRDP	15	Sequence 21 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09325	EHGKRKKKGKGLGKKRDPCLRKYKD	25	Sequence 22 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09326	KEEHGKRKKKGKGLGKKRDPCLRKYKDFCI	30	Sequence 23 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09327	KPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYK	35	Sequence 24 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09328	ALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGEC	40	Sequence 25 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09329	RVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGECK	50	Sequence 26 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09330	DKPKRKKKGGKNGKNRRNRKKKNPCNAEFQ	30	Sequence 27 from Patent US 20090312265	Homo sapiens	Antimicrobial	US 2009/0312265 A1	Patent Application	2009##12##17	CA2637216A1, EP1987055A1, WO2007091958A1, WO2007091958A8	Novel antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP09331	SIPENNIMRTIIEFLSFLHLKEAGAL	26	Sequence 1 from Patent US 20090317395	Homo sapiens	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09332	ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGAL	41	Sequence 2 from Patent US 20090317395	Homo sapiens	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09333	ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGALDRLLDLPAAASSEDIERS	59	Sequence 3 from Patent US 20090317395	Homo sapiens	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09334	ELQPQDDVKPGSFDRSMPENNIMRTIIEFLSFLHLKEAGAFDRLPDLPAGASSEDMERS	59	Sequence 4 from Patent US 20090317395	Macaca mulatta	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09335	ELEPEDEARPGSFDRPLAENNVVRTIIEFLTFLHLKDAGALERLPSLPTAESAEDAERS	59	Sequence 5 from Patent US 20090317395	Bos taurus	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09336	EERRPGSVDVPLPESNIVRTIMEFLSFLHLKEAGALDSLPGIPLATSSEDLEKS	54	Sequence 6 from Patent US 20090317395	Mus musculus	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09337	ELEPEDEARPGGFDRLQSEDKAIRTIMEFLAFLHLKEAGALGRLPGLPSAASSEDAGQS	59	Sequence 7 from Patent US 20090317395	Sus scrofa	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09338	ELPPEDEGRSGGFAGPLSLSENAAVRMLIEFLTFLRLKEAGALPDLPDLPSAVSAEDMEQ	60	Sequence 8 from Patent US 20090317395	Canis familiaris	Antimicrobial	US 2009/0317395 A1	Patent Application	2009##12##24	EP2046825A1, WO2008006467A1	Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP).	The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.
DRAMP09339	KKLFKKILKKL	11	Sequence 1 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09340	YKLFKKILKKL	11	Sequence 2 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09341	LKLFKKILKKL	11	Sequence 3 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09342	FKLFKKILKKL	11	Sequence 4 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09343	WKLFKKILKKL	11	Sequence 5 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09344	KKLFKKILKYL	11	Sequence 6 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09345	YKLFKKILKYL	11	Sequence 7 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09346	LKLFKKILKYL	11	Sequence 8 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09347	FKLFKKILKYL	11	Sequence 9 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09348	WKLFKKILKYL	11	Sequence 10 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09349	KKLFKKILKVL	11	Sequence 11 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09350	YKLFKKILKVL	11	Sequence 12 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09351	LKLFKKILKVL	11	Sequence 13 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09352	FKLFKKILKVL	11	Sequence 14 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09353	WKLFKKILKVL	11	Sequence 15 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09354	KKLFKKILKFL	11	Sequence 16 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09355	YKLFKKILKFL	11	Sequence 17 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09356	LKLFKKILKFL	11	Sequence 18 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09357	FKLFKKILKFL	11	Sequence 19 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09358	WKLFKKILKFL	11	Sequence 20 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09359	KKLFKKILKWL	11	Sequence 21 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09360	YKLFKKILKWL	11	Sequence 22 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09361	LKLFKKILKWL	11	Sequence 23 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09362	FKLFKKILKWL	11	Sequence 24 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09363	WKLFKKILKWL	11	Sequence 25 from Patent US 8026219	Synthetic construct	Antimicrobial	US 8026219 B2	Granted Patent	2011##9##27	CA2650903A1, CN101466731A, EP2017285A1, EP2017285A4, US20100016167, WO2007125142A1, WO2007125142A8	Antimicrobial linear peptides.	The present invention relates to novel linear peptides with antimicrobial activity. Said peptides are made up of 11 amino acids, and they have the amino group of the amino acid constituting the N-terminal end in a non-derived form or functionalized with an acetyl group, p-toluene sulphonyl, benzyl or benzoyl. The amino acid constituting the C-terminal end of said peptides is in carboxamide form. The invention describes the synthesis and use of said peptides as antimicrobial agents to combat pathogenic bacteria for plants. The invention also relates to compositions containing said peptides and an auxiliary agent, and to a method for preventing and treating infections and diseases of plants caused by pathogenic bacteria.
DRAMP09364	MALEHMKWKLFKKIGIGAVLKVLTTGLPALKLTL	34	Sequence 1 from Patent US 20100024068	Synthetic construct	Antimicrobial	US 2010/0024068 A1	Patent Application	2010##1##28	WO2006138276A2, WO2006138276A3	Antimicrobial Peptides and Uses Thereof.	The subject invention pertains to methods and materials for enhancing microbial resistance in plants. Specifically exemplified herein are grapevines transformed with polynucleotides that express a peptide which confers antimicrobial resistance.
DRAMP09365	MAKWKLFKKIGIGAVLKVLTTGLPALKLTK	30	Sequence 2 from Patent US 20100024068	Synthetic construct	Antimicrobial	US 2010/0024068 A1	Patent Application	2010##1##28	WO2006138276A2, WO2006138276A3	Antimicrobial Peptides and Uses Thereof.	The subject invention pertains to methods and materials for enhancing microbial resistance in plants. Specifically exemplified herein are grapevines transformed with polynucleotides that express a peptide which confers antimicrobial resistance.
DRAMP09366	GIINTLQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRKK	45	Sequence 2 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09367	KYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRKK	38	Sequence 3 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09368	YXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRKK	36	Sequence 4 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09369	LQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRKK	40	Sequence 5 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09370	RXAVLSXLPKEEQIGKXSTRGRKXXRRKK	29	Sequence 6 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09371	KEEQIGKXSTRGRKXXRRKK	20	Sequence 7 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09372	KXSTRGRKXXRRKK	14	Sequence 8 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09373	RGRKXXRRKK	10	Sequence 9 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09374	RGRKXXRRK	9	Sequence 10 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09375	KYYXRVRGGRXAVLSXLPK	19	Sequence 11 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09376	GIINTLQKYYXRVRGGR	17	Sequence 12 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09377	GIINTLQKYYWRVRGGRWAVLSWLPKEEQIGKWSTRGRKWWRRKK	45	Sequence 13 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09378	GIINTLQKYYFRVRGGRFAVLSFLPKEEQIGKFSTRGRKFFRRKK	45	Sequence 14 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09379	GIINTLQKYYYRVRGGRYAVLSYLPKEEQIGKYSTRGRKYYRRKK	45	Sequence 15 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09380	GIINTLQKYYSRVRGGRSAVLSSLPKEEQIGKSSTRGRKSSRRKK	45	Sequence 16 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09381	GIINTLQKYYARVRGGRAAVLSALPKEEQIGKASTRGRKAARRKK	45	Sequence 17 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09382	GIINTLQKYYXRVRGGRCAVLSCLPKEEQIGKCSTRGRKXCRRKK	45	Sequence 26 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09383	GIINTLQKYYXRVRGGRCAVLSCLPKEEQIGKCSTRGRKCXRRKK	45	Sequence 27 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09384	KYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	38	Sequence 29 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09385	YCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	36	Sequence 30 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09386	KEEQIGKSSTRGRKSSRRKK	20	Sequence 31 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09387	KSSTRGRKSSRRKK	14	Sequence 32 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09388	RGRKSSRRKK	10	Sequence 33 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09389	RGRKSSRRK	9	Sequence 34 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09390	KYYSRVRGGRSAVLSSLPK	19	Sequence 35 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09391	GIINTLQKYYSRVRGGR	17	Sequence 36 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09392	RGRKCCRRKK	10	Sequence 37 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09393	RGRKWWRRKK	10	Sequence 38 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09394	RGRKFFRRKK	10	Sequence 39 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09395	RGRKYYRRKK	10	Sequence 40 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09396	RGRKLLRRKK	10	Sequence 41 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09397	RGRKIIRRKK	10	Sequence 42 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09398	RGRKVVRRKK	10	Sequence 43 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09399	RGRKHHRRKK	10	Sequence 44 from Patent US 20100048469	Synthetic construct	Antimicrobial	US 2010/0048469 A1	Patent Application	2010##2##25	EP2010561A1, EP2010561A4, EP2277899A2, EP2277899A3, WO2007126392A1, WO2007126392A8	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In parti	There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.
DRAMP09400	KWKSFLKTFKSLKKTKLHTLLKLISS	26	Sequence 56 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09401	KWKSFLKTFKSLKKTKLHTLLKVISS	26	Sequence 57 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09402	KWKSFLKTFKSVKKTKLHTLLKLISS	26	Sequence 58 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09403	KWKSFLKTFKSVKKTKLHTLLKVISS	26	Sequence 59 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09404	KWKSFLKTFKSLKKTKLHTLLKAISS	26	Sequence 60 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09405	KWKSFLKTFKSAKKTKLHTLLKLISS	26	Sequence 61 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09406	KWKSFLKTFKSXXKTXLHTXLKXISS	26	Sequence 62 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09407	XGAKGAGVGL	10	Sequence 63 from Patent US 20100099614	Synthetic construct	Antimicrobial	US 2010/0099614 A1	Patent Application	2010##4##22	CA2739842A1, EP2346521A1, EP2346521A4, WO2010042534A1	Antimicrobial Peptides and Methods of Use.	Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.
DRAMP09408	FLGWLFKWAKK	11	Sequence 1 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09409	FLKWLFKWAKK	11	Sequence 2 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09410	FLGWLFKWAWK	11	Sequence 3 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09411	FLWWLFKWAWK	11	Sequence 4 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09412	FLGWLFKWASKVL	13	Sequence 5 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09413	FLXWLFKWAXK	11	Sequence 6 from Patent US 8076284	Synthetic construct	Antimicrobial, Anticancer	US 8076284 B2	Granted Patent	2011##12##13	CN101443352A, EP2016094A1, EP2016094A4, US20100105626, WO2007133033A1	Analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5.	Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.
DRAMP09414	MAKWKLFKKIGIGFKKAAHVGKAALTK	27	Sequence 2 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09415	KWKLFKKIGIGAVLKVTTGLPALKTLK	27	Sequence 4 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09416	MALEHM	6	Sequence 5 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09417	MALEHMKWKLFKKIGIGAVLKVLTTGLPALKTLK	34	Sequence 6 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09418	AKWKLFKKIGIGFKKAAHVGKAALTK	26	Sequence 8 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09419	KWKLFKKIGIGFKKAAHVGKAALTK	25	Sequence 9 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09420	WKLFKKIGIGFKKAAHVGKAALTK	24	Sequence 10 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09421	KLFKKIGIGFKKAAHVGKAALTK	23	Sequence 11 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09422	LFKKIGIGFKKAAHVGKAALTK	22	Sequence 12 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09423	MAKWKLFKKIGIGFKKAAHVGKAALT	26	Sequence 13 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09424	MAKWKLFKKIGIGFKKAAHVGKAAL	25	Sequence 14 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09425	MAKWKLFKKIGIGFKKAAHVGKAA	24	Sequence 15 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09426	MAKWKLFKKIGIGFKKAAHVGKA	23	Sequence 16 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09427	MAKWKLFKKIGIGFKKAAHVGK	22	Sequence 17 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09428	AKWKLFKKIGIGFKKAAHVGKAALT	25	Sequence 18 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09429	KWKLFKKIGIGFKKAAHVGKAAL	23	Sequence 19 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09430	WKLFKKIGIGFKKAAHVGKAA	21	Sequence 20 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09431	KLFKKIGIGFKKAAHVGKA	19	Sequence 21 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09432	LFKKIGIGFKKAAHVGK	17	Sequence 22 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09433	FKKIGIGFKKAAHVG	15	Sequence 23 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09434	XMAKWKLFKKIGIGFKKAAHVGKAALTK	28	Sequence 24 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09435	XXMAKWKLFKKIGIGFKKAAHVGKAALTK	29	Sequence 25 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09436	XXXMAKWKLFKKIGIGFKKAAHVGKAALTK	30	Sequence 26 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09437	XXXXMAKWKLFKKIGIGFKKAAHVGKAALTK	31	Sequence 27 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09438	XXXXXMAKWKLFKKIGIGFKKAAHVGKAALTK	32	Sequence 28 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09439	MAKWKLFKKIGIGFKKAAHVGKAALTKX	28	Sequence 29 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09440	MAKWKLFKKIGIGFKKAAHVGKAALTKXX	29	Sequence 30 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09441	MAKWKLFKKIGIGFKKAAHVGKAALTKXXX	30	Sequence 31 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09442	MAKWKLFKKIGIGFKKAAHVGKAALTKXXXX	31	Sequence 32 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09443	XMAKWKLFKKIGIGFKKAAHVGKAALTKX	29	Sequence 34 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09444	XXMAKWKLFKKIGIGFKKAAHVGKAALTKXX	31	Sequence 35 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09445	XXXMAKWKLFKKIGIGFKKAAHVGKAALTKXXX	33	Sequence 36 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09446	XXXXMAKWKLFKKIGIGFKKAAHVGKAALTKXXXX	35	Sequence 37 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09447	XXXXXMAKWKLFKKIGIGFKKAAHVGKAALTKXXXXX	37	Sequence 38 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09448	XKWKLFKKIGIGFKKAAHVGKAAL	24	Sequence 39 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09449	XXKWKLFKKIGIGFKKAAHVGKAAL	25	Sequence 40 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09450	XXXKWKLFKKIGIGFKKAAHVGKAAL	26	Sequence 41 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09451	XXXXKWKLFKKIGIGFKKAAHVGKAAL	27	Sequence 42 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09452	XXXXXKWKLFKKIGIGFKKAAHVGKAAL	28	Sequence 43 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09453	KWKLFKKIGIGFKKAAHVGKAALX	24	Sequence 44 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09454	KWKLFKKIGIGFKKAAHVGKAALXX	25	Sequence 45 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09455	KWKLFKKIGIGFKKAAHVGKAALXXX	26	Sequence 46 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09456	KWKLFKKIGIGFKKAAHVGKAALXXXXX	28	Sequence 48 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09457	XKWKLFKKIGIGFKKAAHVGKAALX	25	Sequence 49 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09458	XXKWKLFKKIGIGFKKAAHVGKAALXX	27	Sequence 50 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09459	XXXKWKLFKKIGIGFKKAAHVGKAALXXX	29	Sequence 51 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09460	XXXXKWKLFKKIGIGFKKAAHVGKAALXXXX	31	Sequence 52 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP09461	XXXXXKWKLFKKIGIGFKKAAHVGKAALXXXXX	33	Sequence 53 from Patent US 20100138957	Synthetic construct	Antimicrobial	US 2010/0138957 A1	Patent Application	2010##6##3	WO2008094684A1	Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides.	The present invention concerns the development and utilization of hybrid lytic peptides derived from non-venomous molecular sources to confer a high level of sustainable resistance to phytopathogens in transgenic plants. In an exemplified embodiment, a composition of the invention comprises a cecropin-pleurocidin hybrid peptide of 27 amino acids. The peptide was designed based on optimization of critical molecular and physiochemical parameters. Peptides of the invention offer significantly enhanced antimicrobial activity and molecular properties associated with low cytotoxicity. Transgenic plants of grapevine (Vitis vinifera) that express a peptide of the invention show antimicrobial activity against xylem-limited phytopathogenic bacterium Xylella fastidiasa at a level significantly higher than that from other existing lytic peptides. Thus, the hybrid peptides of the invention can be utilized as an antimicrobial agent for agricultural use.
DRAMP18791	RCICGRRVC	9	Sequence 80 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP09464	DLWETLRRGGRWILAIPRRIREGLELTL	28	Sequence 3 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP18790	RCICGLRIC	9	Sequence 79 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18789	RCICVRRIC	9	Sequence 78 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18788	RCICTRRIC	9	Sequence 77 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18787	RCICRRRIC	9	Sequence 76 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18785	RCICGRRIC	9	Sequence 74 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18784	RCLCVLGIC	9	Sequence 64 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18783	RCLCVLGVC	9	Sequence 63 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP09474	RVIAVVQGACRAIRRIPRRIR	21	Sequence 13 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP18782	RCLCTLGIC	9	Sequence 62 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18781	RCLCTLGVC	9	Sequence 61 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18780	RCLCGLGIC	9	Sequence 60 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18779	RCLCGLGVC	9	Sequence 59 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18778	RCICVLGFC	9	Sequence 58 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP09481	RVIEVVQGACRRIRRIPRRIR	21	Sequence 23 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP18777	RCICVLGVC	9	Sequence 57 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18776	RCICTLGFC	9	Sequence 56 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18775	RCICTLGVC	9	Sequence 55 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18774	RCICRLGFC	9	Sequence 54 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18773	RCICRLGVC	9	Sequence 53 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18772	RCICGRGIC	9	Sequence 52 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18771	RCLCVRGVC	9	Sequence 51 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18770	RCLCVLGIC	9	Sequence 50 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18769	RCLCTRGFC	9	Sequence 49 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18768	RCLCTRGVC	9	Sequence 48 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18767	RCLCTLGIC	9	Sequence 47 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18766	RCLCRRGFC	9	Sequence 46 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18765	RCLCRRGVC	9	Sequence 45 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18764	RCLCRLGIC	9	Sequence 44 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18763	RCICGLGVC	9	Sequence 43 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18762	RCICGLGFC	9	Sequence 42 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18761	RCICGRGFC	9	Sequence 41 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18760	RCICVRGVC	9	Sequence 40 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18759	RCICRLGIC	9	Sequence 39 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18758	RCICVLGFC	9	Sequence 38 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18757	RCICTLGIC	9	Sequence 37 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18756	RCICTRGFC	9	Sequence 36 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18755	RCICTRGVC	9	Sequence 35 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18786	RCLCGRRIC	9	Sequence 75 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP09547	LWETLRRGGRWILAIPRRIL	20	Sequence 99 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP09559	YHRLRDLLLIIVTRIVRLLGRR	22	Sequence 111 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP09562	YHRRLRDLLIVTRIVELLGRR	21	Sequence 114 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP09592	FLIKQLIKLLTWLFSNCLTLLSKVY	25	Sequence 145 from Patent US 20100150985	Synthetic construct	Antimicrobial	US 2010/0150985 A1	Patent Application	2010##6##17	Unknown	Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making 	Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject.
DRAMP09617	KHNLGHGHKHERDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGWK	83	Sequence 1 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09618	FFFHKHGHGHGKHKNKGKKN	20	Sequence 2 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09619	WWWHKHGHGHGKHKNKGKKN	20	Sequence 3 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09620	HKHGHGHGKHKNKGKKNWWW	20	Sequence 4 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09621	HKHGHGHGKHKNKGKKNFFF	20	Sequence 5 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09622	FFFGKHKNKGKKNGKHNGWK	20	Sequence 6 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09623	WWWGKHKNKGKKNGKHNGWK	20	Sequence 7 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09624	GKHKNKGKKNGKHNGWKWWW	20	Sequence 8 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09625	GKHKNKGKKNGKHNGWKFFF	20	Sequence 9 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09626	HKHGHGHGKHKNKGKKN	17	Sequence 10 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09628	GKHKNKGKKNGKHNGWK	17	Sequence 12 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09630	LHKHGHGHGKHKNKGKKN	18	Sequence 14 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09631	LLHKHGHGHGKHKNKGKKN	19	Sequence 15 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09632	LLLHKHGHGHGKHKNKGKKN	20	Sequence 16 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09633	HKHGHGHGKHKNKGKKNL	18	Sequence 17 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09634	HKHGHGHGKHKNKGKKNLL	19	Sequence 18 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09635	HKHGHGHGKHKNKGKKNLLL	20	Sequence 19 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09636	HKHGHGHGLKHKNKGKKN	18	Sequence 20 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09637	HKHGHGHGLLKHKNKGKKN	19	Sequence 21 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09638	HKHGHGHGLLLKHKNKGKKN	20	Sequence 22 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09639	AAAHKHGHGHGKHKNKGKKN	20	Sequence 23 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09640	IIIHKHGHGHGKHKNKGKKN	20	Sequence 24 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09641	VVVHKHGHGHGKHKNKGKKN	20	Sequence 25 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09642	PPPHKHGHGHGKHKNKGKKN	20	Sequence 26 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09643	YYYHKHGHGHGKHKNKGKKN	20	Sequence 27 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09644	FHKHGHGHGKHKNKGKKN	18	Sequence 28 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09645	FFHKHGHGHGKHKNKGKKN	19	Sequence 29 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09647	WHKHGHGHGKHKNKGKKN	18	Sequence 31 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09648	WWHKHGHGHGKHKNKGKKN	19	Sequence 32 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09655	LLLNKKGKNKHKGHGHGHKH	20	Sequence 39 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09656	NKKGKNKHKGHGHGHKHLLL	20	Sequence 40 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09657	WWWWHKHGHGHGKHKNKGKK	20	Sequence 41 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09658	FFFFHKHGHGHGKHKNKGKK	20	Sequence 42 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09659	LLLLHKHGHGHGKHKNKGKK	20	Sequence 43 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09660	IIIIHKHGHGHGKHKNKGKK	20	Sequence 44 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09663	HKHGHGHLKHKNKGKKNGKH	20	Sequence 47 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09664	HKHGHLHLKHKNKGKKNGKH	20	Sequence 48 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09665	HKHLHLHLKHKNKGKKNGKH	20	Sequence 49 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09666	HKHLHGHLKHKNKLKKNGKH	20	Sequence 50 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09667	HKHGHLHLKHKNKLKKNGKH	20	Sequence 51 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09668	HKHGHGHLKHKNKLKKNGKH	20	Sequence 52 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09669	HKHGHGHGKHKNKLKKNGKH	20	Sequence 53 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09671	LGKHKNKGKKNGKHNGWK	18	Sequence 55 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09672	LLGKHKNKGKKNGKHNGWK	19	Sequence 56 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09673	LLLGKHKNKGKKNGKHNGWK	20	Sequence 57 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09674	GKHKNKGKKNGKHNGWKL	18	Sequence 58 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09675	GKHKNKGKKNGKHNGWKLL	19	Sequence 59 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09676	GKHKNKGKKNGKHNGWKLLL	20	Sequence 60 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09677	GKHKNKGKKLNGKHNGWK	18	Sequence 61 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09678	GKHKNKGKKLLNGKHNGWK	19	Sequence 62 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09679	GKHKNKGKKLLLNGKHNGWK	20	Sequence 63 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09680	AAAGKHKNKGKKNGKHNGWK	20	Sequence 64 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09681	IIIGKHKNKGKKNGKHNGWK	20	Sequence 65 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09692	KNKGKKNGKH	10	Sequence 76 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09693	KNKGKKNGKHWWW	13	Sequence 77 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09694	KNKGKKNGKWWW	12	Sequence 78 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09695	KNKGKKNGWWW	11	Sequence 79 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09696	KNKGKKNWWW	10	Sequence 80 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09697	KNKGKKWWW	9	Sequence 81 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09698	KNKGKWWW	8	Sequence 82 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09699	KNKGWWW	7	Sequence 83 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09700	KNKWWW	6	Sequence 84 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09701	KNWWW	5	Sequence 85 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09702	KWWW	4	Sequence 86 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09703	WWW	3	Sequence 87 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09704	KNKGKKNGKHWWWWW	15	Sequence 88 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09705	KNKGKKNGKWWWWW	14	Sequence 89 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09706	KNKGKKNGWWWWW	13	Sequence 90 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09707	KNKGKKNWWWWW	12	Sequence 91 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09708	KNKGKKWWWWW	11	Sequence 92 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09709	KNKGKWWWWW	10	Sequence 93 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09710	KNKGWWWWW	9	Sequence 94 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09711	KNKWWWWW	8	Sequence 95 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09712	KNWWWWW	7	Sequence 96 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09713	KWWWWW	6	Sequence 97 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09715	NKGKKNGKHWWW	12	Sequence 99 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09716	KGKKNGKHWWW	11	Sequence 100 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09717	GKKNGKHWWW	10	Sequence 101 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09718	KKNGKHWWW	9	Sequence 102 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09719	KNGKHWWW	8	Sequence 103 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09720	NGKHWWW	7	Sequence 104 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09721	GKHWWW	6	Sequence 105 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09722	KHWWW	5	Sequence 106 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09723	HWWW	4	Sequence 107 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09724	WWWKNKGKKNGKH	13	Sequence 108 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09725	WWWKNKGKKNGK	12	Sequence 109 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09726	WWWKNKGKKNG	11	Sequence 110 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09727	WWWKNKGKKN	10	Sequence 111 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09728	WWWKNKGKK	9	Sequence 112 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09729	WWWKNKGK	8	Sequence 113 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09730	WWWKNKG	7	Sequence 114 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09731	WWWKNK	6	Sequence 115 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09732	WWWKN	5	Sequence 116 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09733	WWWK	4	Sequence 117 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09734	SNSGSSNGSH	10	Sequence 118 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09735	SNSGSSNGSHWWW	13	Sequence 119 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09736	WWWSNSGSSNGSH	13	Sequence 120 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09737	KKKKKKKKKK	10	Sequence 121 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09738	KKKKKKKKKKWWW	13	Sequence 122 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09739	KKKKKKKKKWWW	12	Sequence 123 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09740	KKKKKKKKWWW	11	Sequence 124 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09741	KKKKKKKWWW	10	Sequence 125 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09742	KKKKKKWWW	9	Sequence 126 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09743	KKKKKWWW	8	Sequence 127 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09744	KKKKWWW	7	Sequence 128 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09745	KKKWWW	6	Sequence 129 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09746	KKWWW	5	Sequence 130 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09748	SSSSSSSSSS	10	Sequence 132 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09749	SSSSSSSSSSWWW	13	Sequence 133 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09750	DDDDDDDDDD	10	Sequence 134 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09751	DDDDDDDDDDWWW	13	Sequence 135 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09752	KNKGKKNGKHGSGSPWWW	18	Sequence 136 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09753	CNYITELRRQHARASHLGLA	20	Sequence 137 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09754	CNYITELRRQHARASHLGLAWWW	23	Sequence 138 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09755	CKYILLLRRQHARAWRRGLR	20	Sequence 139 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09756	CKYILLLRRQHARAWRRGLRWWW	23	Sequence 140 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09758	GKRKKKGKGLGKKRDPCLRKYKWWW	25	Sequence 142 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09760	PKRKKKGGKNGKNRRNRKKKNWWW	24	Sequence 144 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09761	VFRLKKWIQKVIDQFGE	17	Sequence 145 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09762	VFRLKKWIQKVIDQFGEWWW	20	Sequence 146 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09764	SEKTLRKWLKMFKKRQLELYWWW	23	Sequence 148 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09765	QPTRRPRPGTGPGRRPRPRPRP	22	Sequence 149 from Patent US 8227406	Homo sapiens	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09766	QPTRRPRPGTGPGRRPRPRPRPWWW	25	Sequence 150 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09767	LLGDFFRKSKEKIKEFKRIVQRIKDFLRNLVPRTES	36	Sequence 151 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09768	LLGDFFRKSKEKIKEFKRIVQRIKDFLRNLVPRTESWWW	39	Sequence 152 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09770	ILRWPWWPWRRKWWW	15	Sequence 154 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09771	WWYYII	6	Sequence 160 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09772	WYIV	4	Sequence 161 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09773	YYVVFF	6	Sequence 162 from Patent US 8227406	Synthetic construct	Antimicrobial	US 8227406 B2	Granted Patent	2012##7##24	CA2651990A1, EP2021364A1, EP2021364A4, US20100159006, WO2007133153A1, WO2007133153A8	Antimicrobial peptides.	The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.
DRAMP09774	CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNEEVE	92	Sequence 2 from Patent US 8003348	Synthetic construct	Antimicrobial	US 8003348 B2	Granted Patent	2011##8##23	US20100184949	Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a tr	The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment. Therefore, it is possible to achieve easy mass pro
DRAMP09775	CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLEEVE	63	Sequence 3 from Patent US 8003348	Synthetic construct	Antimicrobial	US 8003348 B2	Granted Patent	2011##8##23	US20100184949	Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a tr	The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment. Therefore, it is possible to achieve easy mass pro
DRAMP09776	RAGLQFPVGRLLRRLLRRLLR	21	Sequence 6 from Patent US 8003348	Synthetic construct	Antimicrobial	US 8003348 B2	Granted Patent	2011##8##23	US20100184949	Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a tr	The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment. Therefore, it is possible to achieve easy mass pro
DRAMP09777	EEVE	4	Sequence 20 from Patent US 8003348	Synthetic construct	Antimicrobial	US 8003348 B2	Granted Patent	2011##8##23	US20100184949	Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a tr	The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment. Therefore, it is possible to achieve easy mass pro
DRAMP09778	EGVLGAALSAFSFDS	15	Sequence 1 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09779	QAQPCPNQPDGSVYA	15	Sequence 2 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09780	STALPLWSNYSYDSA	15	Sequence 3 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09781	RTFGAKPPNIPFPRR	15	Sequence 4 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09782	KAIAFQSSPGSPVLL	15	Sequence 5 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09783	TCNLSDYTLPRARVL	15	Sequence 6 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09784	NFLCPSPYPKVQPGL	15	Sequence 7 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09785	VPESIHKASLVCYRF	15	Sequence 8 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09786	SRPIARFYTWSQNTT	15	Sequence 9 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09787	FSPFRISELVYTLHP	15	Sequence 10 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP13203	ELCEKASKTWSGNCGNTKHCDDQCKSWEGAAHGACHVRNGKHMCFCYFNC	50	Sequence 6 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13204	NLCERASLTWTGNCGNTGHCDTQCRNWESAKHGACHKRGNWKCFCYFDC	49	Sequence 7 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13205	KTCENLSGTFKGPCIPDGNCNKHCKNNEHLLSGRCRDDFXCWCTRNC	47	Sequence 8 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13206	KTCENLVDTYRGPCFTTGSCDDHCKNKEHLLSGRCRDDVRCWCTRNC	47	Sequence 9 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13207	NTCENLAGSYKGVCFGGCDRHCRTQEGAISGRCRDDFRCWCTKNC	45	Sequence 10 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13208	RVCMGKSAGFKGLCMRDQNCAQVCLQEGWGGGNCDGVMRQCKCIRQCW	48	Sequence 11 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13210	RHCESLSHRFKGPCTRDSNCASVCETERFSGGNCHGFRRRCFCTKPC	47	Sequence 13 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13211	QNICPRVNRIVTPCVAYGLGRAPIAPCCRALNDLRFVNTRNLRRAACRCLVGVVNRNPGLRRNPRFQNIPRDCRNTFVRPFWWRPRIQCGRIN	93	Sequence 1 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13212	ALSCGTVNSLNAACIGYLTQNAPLARGCCTGVTNLNNMATTP	42	Sequence 2 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13213	GITCGMVSSKLAPCIGILKGGPLGGGCCGGIKALNAAAATTPDRKTACNCLKSAANAIKGINYGKAAGLPGMCGVHIPYAISPSTNCNAVH	91	Sequence 3 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13214	VLTCGQVTGALAPCLGYLRSQVNVPVPLTCCNVVRGLNNAARTTLDRKTACGCLKQTANAVTGLNLNAAAGLPARCGVNIPYKISPTTDCNRVV	94	Sequence 4 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13215	ALSCGQVQSGLAPCLPYLQGRGPLGSCCGGVKGLLGAAKSLSDRKTACICLKSAANAIKGIDMGKAAGLPGACGVNIPYKISPSTDCSKVQ	91	Sequence 5 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13216	ALTCGQVTAGLAPCLPYLQGRGPLGGCCGGVKNLLGSAKTTADRKTACTCLKSAANAIKGIDLNKAAGIPSVCKVNIPYKISPSTDCSTVQ	91	Sequence 6 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13217	VDCGQVNSSLASCIPFLTGGVASPSASCCAGVQNLKTLAPTSADRRAACECIKAAAARFPTIKQDAASSLPKKCGVDINIPISKTTNCQAIN	92	Sequence 7 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13218	VNCGQVNKALSSCVPFLTGFDTTPSLTCCAGVMLLKRLAPTVKDKRIACECVKTAAARYPNIREDAASSLPYKCGVVINVPISKTTNCHEIN	92	Sequence 8 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13219	AVPCSTVDMKAAACVGFATGKDSKPSQACCTGLQQLAQTVKTVDDKKAICRCLKASSKSLGIKDQFLSKIPAACNIKVGFPVSTNTNCETIH	92	Sequence 9 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13220	ALNCGQVDSKMKPCLTYVQGGPGGPSGLCCNGVRDLHNQAQSSGDRQTVCNCLKGIARGIHNLNLNNAASIPSKCNVNVPYTISPDIDCSRIY	93	Sequence 10 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13221	AITCGQVSSALGPCAAYAKGSSTSPSAGCCSGVKRLAGLARSTADKQATCRCLKSVAGAYNAGRAAGIPSRCGVSVPYTISASVDCSKIH	90	Sequence 11 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13222	AISCGQVSSALSPCISYARGNGAKPPAACCSGYKRLAGAAQSTADKQATCRCIKSAAGGLNAGKAAGIPSMCGVSVPYAISASVDCSKIR	90	Sequence 12 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13223	IDCGHVDSLVRPCLSYVQGGPGPSGQCCDGVKNLHNQARSQSDRQSACNCLKGIARGIHNLNEDNARSIPPKCGVNLPYTISLNIDCSRV	90	Sequence 13 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13224	AISCGQVASAIAPCISYARGQGSGPSAGCCSGVRSLNNAARTTADRRAACNCLKNAAAGVSGLNAGNAASIPSKCGVSIPYTISTSTDCSRVN	93	Sequence 14 from Patent US 5773694	Synthetic construct	Antimicrobial	US 5773694 A	Granted Patent	1998##6##30	CA2166309A1, EP0712413A1, WO1995004754A1	Antimicrobial proteins from Allium.	Antimicrobial proteins capable of isolation from seeds of Allium show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.
DRAMP13226	RRRPRPPYLPRPRPPPFFPPRLPPRI	26	Sequence 2 from Patent US 5830993	Synthetic construct	Antimicrobial	US 5830993 A	Granted Patent	1998##11##3	WO1996032129A1	Synthetic antimicrobial peptide.	New antimicrobial truncated peptides are disclosed which are based upon a known peptide, PR-39 (SEQ ID NO: 1) but which contain a lesser number of amino acid residues yet still retain antimicrobial activity. The most preferred peptide compound is PR-26, SEQ ID NO: 2. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention.
DRAMP13227	LKLLKKLLKLLKKLGK	16	Sequence 2 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13228	KGGLKKLLKLLKKLLKL	17	Sequence 3 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13229	LKLLKKLLKLLKKLGGK	17	Sequence 4 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13230	KGGGLKKLLKLLKKLLKL	18	Sequence 5 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13231	LKLLKKLLKLLKKLGGGK	18	Sequence 6 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13232	LKKLLKKLKKLKKLLKL	17	Sequence 7 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13233	LKKLLKLLKKLLKL	14	Sequence 8 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13234	LKKLLKL	7	Sequence 9 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13235	VFAKGFKKASHLFKGIG	17	Sequence 17 from Patent US 5847047	Synthetic construct	Antimicrobial	US 5847047 A	Granted Patent	1998##12##8	WO1995000547A1	Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type.	Novel polymer-bound oligopeptides exhibiting antimicrobial activity have been develop. The oligopeptides are unique amino acid sequences that form amphiphilic helices.
DRAMP13236	GRRCCGWGPGRRYCVRWC	18	Sequence 1 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13237	GRRCCNWGPGRRYCKRWC	18	Sequence 2 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13238	GPGRKYCKRWC	11	Sequence 3 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13239	GRRCCGWGPGRRYCRRWC	18	Sequence 4 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13240	GPGRRY	6	Sequence 5 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13241	QWGRRCCGWGPGRRYCVRWC	20	Sequence 10 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13242	QYGRRCCNWGPGRRYCKRWC	20	Sequence 11 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13243	QYRHRCCAWGPGRKYCKRWC	20	Sequence 12 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13244	QWGRRCCGWGPGRRYCRRWC	20	Sequence 13 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13245	ANAEEAAAAIPEASEELAQEEAPVYSED	28	Sequence 14 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13246	QNAEEAAAAIPEATEKAQEAPVYSED	26	Sequence 15 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13247	QNAEEAAAAVAIPEASEKAQEGPVYSED	28	Sequence 16 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13248	SNAADEVATPEDVEPG	16	Sequence 17 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13249	HNAAEEATLKAFEEEAAREQPVYSED	26	Sequence 18 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13250	KPNPTKEEEPAKKPDEVSVKSGGPEVSED	29	Sequence 19 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13251	QSAEEAAAFQAGEVTASLMLIMFKACPCMGPVPSV	35	Sequence 20 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13252	MVQKGVVFGVLLILFICSTLTSADS	25	Sequence 21 from Patent US 5861480	Synthetic construct	Antimicrobial	US 5861480 A	Granted Patent	1999##1##19	CA2180353A1, CN1143978A, CN1313387A, DE69525529D1, DE69525529T2, EP0749485A1, EP0749485B1, US6150588, WO1995024486A1	Antimicrobial proteins from aralia and impatiens.	Antimicrobial proteins capable of isolation from seeds of Aralia or Impatiens show a wide range of antifungal activity and some antibacterial activity. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commerical application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance. The invention further provides a method of expressing polyproteins in transgenic plants using DNA constructs based on the structure of the gene encoding the Impatiens antimicrobial proteins.
DRAMP13253	RSGRGECRRQCLRRHEGQPWETQECMRRCRRRGG	34	Sequence 1 from Patent US 5905187	Synthetic construct	Antimicrobial	US 5905187 A	Granted Patent	1999##5##18	CA2042448A1, DE69132357D1, DE69132357T2, EP0465009A1, EP0465009B1	Antimicrobial peptides and plant disease resistance based thereon.	CMIII, a small, basic maize seed peptide has been found to have antimicrobial properties. In a preferred embodiment, plant resistance to diseases caused by plant pathogens which are susceptible to CMIII is produced by inserting into the cells of a plant a gene whose expression causes production CMIII in antimicrobial amounts.
DRAMP13254	LVLLKKLMKKYKKLKKLGGL	20	Sequence 1 from Patent US 5969098	Synthetic construct	Antimicrobial	US 5969098 A	Granted Patent	1999##10##19	Unknown	Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use.	The invention is directed to compounds having the following sequences: Leu Val Leu Leu Lys Lys Leu Met Lys Lys Tyr Lys Lys Leu Lys Lys Leu Gly Gly Leu as set forth in SEQ. ID. No. 1; Leu Leu Leu Leu Lys Leu Leu Leu Lys Lys Asn Pro Lys Leu Lys Lys Leu Ile Gly Val as set forth in SEQ. ID. No. 2; Leu Leu Leu Leu Lys Lys Leu Leu Lys Leu Met Asn Leu Leu Lys Lys Leu Gly His Tyr as set forth in SEQ. ID. No. 3; and Lys Lys Ile Lys Glu Lys Tyr Asp Lys Met Lys Lys as set forth in SEQ. ID. No. 4.
DRAMP13255	LLLLKLLLKKNPKLKKLIGV	20	Sequence 2 from Patent US 5969098	Synthetic construct	Antimicrobial	US 5969098 A	Granted Patent	1999##10##19	Unknown	Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use.	The invention is directed to compounds having the following sequences: Leu Val Leu Leu Lys Lys Leu Met Lys Lys Tyr Lys Lys Leu Lys Lys Leu Gly Gly Leu as set forth in SEQ. ID. No. 1; Leu Leu Leu Leu Lys Leu Leu Leu Lys Lys Asn Pro Lys Leu Lys Lys Leu Ile Gly Val as set forth in SEQ. ID. No. 2; Leu Leu Leu Leu Lys Lys Leu Leu Lys Leu Met Asn Leu Leu Lys Lys Leu Gly His Tyr as set forth in SEQ. ID. No. 3; and Lys Lys Ile Lys Glu Lys Tyr Asp Lys Met Lys Lys as set forth in SEQ. ID. No. 4.
DRAMP13256	LLLLKKLLKLMNLLKKLGHY	20	Sequence 3 from Patent US 5969098	Synthetic construct	Antimicrobial	US 5969098 A	Granted Patent	1999##10##19	Unknown	Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use.	The invention is directed to compounds having the following sequences: Leu Val Leu Leu Lys Lys Leu Met Lys Lys Tyr Lys Lys Leu Lys Lys Leu Gly Gly Leu as set forth in SEQ. ID. No. 1; Leu Leu Leu Leu Lys Leu Leu Leu Lys Lys Asn Pro Lys Leu Lys Lys Leu Ile Gly Val as set forth in SEQ. ID. No. 2; Leu Leu Leu Leu Lys Lys Leu Leu Lys Leu Met Asn Leu Leu Lys Lys Leu Gly His Tyr as set forth in SEQ. ID. No. 3; and Lys Lys Ile Lys Glu Lys Tyr Asp Lys Met Lys Lys as set forth in SEQ. ID. No. 4.
DRAMP13257	KKIKEKYDKMKK	12	Sequence 4 from Patent US 5969098	Synthetic construct	Antimicrobial	US 5969098 A	Granted Patent	1999##10##19	Unknown	Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use.	The invention is directed to compounds having the following sequences: Leu Val Leu Leu Lys Lys Leu Met Lys Lys Tyr Lys Lys Leu Lys Lys Leu Gly Gly Leu as set forth in SEQ. ID. No. 1; Leu Leu Leu Leu Lys Leu Leu Leu Lys Lys Asn Pro Lys Leu Lys Lys Leu Ile Gly Val as set forth in SEQ. ID. No. 2; Leu Leu Leu Leu Lys Lys Leu Leu Lys Leu Met Asn Leu Leu Lys Lys Leu Gly His Tyr as set forth in SEQ. ID. No. 3; and Lys Lys Ile Lys Glu Lys Tyr Asp Lys Met Lys Lys as set forth in SEQ. ID. No. 4.
DRAMP13258	VRRFPWWWPFLRR	13	Sequence 1 from Patent US 5994308	Synthetic construct	Antimicrobial	US 5994308 A	Granted Patent	1999##11##30	CA2248320A1, EP0889903A1, EP0889903A4, US6262243, WO1997031942A1	Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use.	Peptides exhibiting antibacterial and/or antifungal activity are provided which comprise a tryptophan triplet and are between 10-34 amino acid residues in length. Pharmaceutical and non-pharmaceutical compositions containing the peptides, as well as methods of using the peptides as antimicrobials are also disclosed.
DRAMP13259	RRRFPWWWPFLRRR	14	Sequence 2 from Patent US 5994308	Synthetic construct	Antimicrobial	US 5994308 A	Granted Patent	1999##11##30	CA2248320A1, EP0889903A1, EP0889903A4, US6262243, WO1997031942A1	Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use.	Peptides exhibiting antibacterial and/or antifungal activity are provided which comprise a tryptophan triplet and are between 10-34 amino acid residues in length. Pharmaceutical and non-pharmaceutical compositions containing the peptides, as well as methods of using the peptides as antimicrobials are also disclosed.
DRAMP13260	RFPWWWPFLR	10	Sequence 3 from Patent US 5994308	Synthetic construct	Antimicrobial	US 5994308 A	Granted Patent	1999##11##30	CA2248320A1, EP0889903A1, EP0889903A4, US6262243, WO1997031942A1	Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use.	Peptides exhibiting antibacterial and/or antifungal activity are provided which comprise a tryptophan triplet and are between 10-34 amino acid residues in length. Pharmaceutical and non-pharmaceutical compositions containing the peptides, as well as methods of using the peptides as antimicrobials are also disclosed.
DRAMP13261	FPWWWPF	7	Sequence 4 from Patent US 5994308	Synthetic construct	Antimicrobial	US 5994308 A	Granted Patent	1999##11##30	CA2248320A1, EP0889903A1, EP0889903A4, US6262243, WO1997031942A1	Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use.	Peptides exhibiting antibacterial and/or antifungal activity are provided which comprise a tryptophan triplet and are between 10-34 amino acid residues in length. Pharmaceutical and non-pharmaceutical compositions containing the peptides, as well as methods of using the peptides as antimicrobials are also disclosed.
DRAMP13262	AHNFATGIVPQXCLECICKTESGCR	25	Sequence 1 from Patent US 6133010	Synthetic construct	Antimicrobial	US 6133010 A	Granted Patent	2000##10##17	CA2378537A1, CA2378537C, DE60040668D1, EP1196607A1, EP1196607B1, WO2001004328A1	Chlamysin B antibacterial protein, a protein gene for and an expression system for same.	This invention relates to the novel antibacterial protein Chlamysin B, a novel protein gene encoding the Chlamysin B protein and an expression system using such gene in E. coli.
DRAMP13263	MSRYIGHTSCSRTCESYARLHNGGPPGCE	29	Sequence 2 from Patent US 6133010	Synthetic construct	Antimicrobial	US 6133010 A	Granted Patent	2000##10##17	CA2378537A1, CA2378537C, DE60040668D1, EP1196607A1, EP1196607B1, WO2001004328A1	Chlamysin B antibacterial protein, a protein gene for and an expression system for same.	This invention relates to the novel antibacterial protein Chlamysin B, a novel protein gene encoding the Chlamysin B protein and an expression system using such gene in E. coli.
DRAMP13266	RLSRIVVIRVCR	12	Sequence 3 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13268	RRCPIVVIRVCR	12	Sequence 5 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13269	RICRIVVIRCIR	12	Sequence 6 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13270	RLCPRVRIRVCR	12	Sequence 7 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13271	KKCPIVVIRVCK	12	Sequence 8 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13272	RRRCPIVVIRVCRR	14	Sequence 9 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13273	RRRLCPIVIRVCRR	14	Sequence 10 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13274	RRLCRIVVIRVCRR	14	Sequence 11 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13275	RLCRIVPVIRVCR	13	Sequence 12 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13276	RLCRIVWVIRVCR	13	Sequence 13 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13277	RRLCRIVWVIRVCRR	15	Sequence 14 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13278	RRCPIVWVIRVCR	13	Sequence 15 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13279	RRCPIVWVIPVCRR	14	Sequence 16 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13280	RLCRIVVIRVCRIVIVIV	18	Sequence 18 from Patent US 6172185	Synthetic construct	Antimicrobial	US 6172185 B1	Granted Patent	2001##1##9	WO1999060016A2, WO1999060016A3	Antimicrobial cationic peptide derivatives of bactenecin.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.
DRAMP13281	MKRKRAVKRVGRRLKKLARKIARLGVAF	28	Sequence 2 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13282	MLLAIAFLASVCVSSKRKRAVKRVGRRLKKLARKIARLGVAF	42	Sequence 4 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13283	MGIGKFLHSAKKFGKAFVGEIMNS	24	Sequence 6 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13284	MLLAIAFLASVCVSSMGIGKFLHSAKKFGKAFVGEIMNS	39	Sequence 8 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13285	MKIAGKIAKIAGKIAKIAGKIA	22	Sequence 10 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13286	MLLAIAFLASVCVSSKIAGKIAKIAGKIAKIAGKIA	36	Sequence 12 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13287	MGIGKFLKSAKKFGKAFVKILNS	23	Sequence 14 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13288	MLLAIAFLASVCVSSMGIGKFLKSAKKFGKAFVKILNS	38	Sequence 16 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13289	MLLAIAFLASVCVSSGMASKAGAIAGKIAKVALKAL	36	Sequence 18 from Patent US 6235973	Synthetic construct	Antimicrobial	US 6235973 B1	Granted Patent	2001##5##22	CA2299615A1, EP0990033A1, WO1999006564A1	Expression of magainin and PGL classes of antimicrobial peptide genes in plants, and their use in creating resistance to multiple plant patho	The invention provides antimicrobial peptides, nucleic acid constructs encoding them, methods for transforming plant cells, and transgenic plant tissue that expresses the antimicrobial peptide genes and thereby exhibit improved resistance to plant pathogens.
DRAMP13290	MQPTIMEELTKEQVLEELGAYKQIIASAATRDRGELLRTVIEAVARPRPRPCIRAGGYCNILNVCCAGLTCEEHDIQDAVCV	82	Sequence 3 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13291	MAKVATLTLLAVVVVAVLLFETPTTEAVTCSAVQLSPCAPAIMSNQTPTSACCAKLREQKPCLCGYYKNPTLRPYINSPGAKRVASTCKVSVSC	94	Sequence 5 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13292	AINCGLVSQSLAACLGFLENGQGPNAACCNGVKTLRNLTPTTQDKRTACRCMKSAASAIPGINHKYSAALPGKCGVSIPGPVGPQADCSQIH	92	Sequence 6 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13293	ITCGLVASKLAPCIGYLQGAPGPSAGCCGGIKGLNSAAASPADRKTACTCLKSAATSMKGINYGKAASLPRQCGVSIPYAISPNTNCNAIH	91	Sequence 7 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13294	SGECNMYGRCPPGYCCSKFGYCGVGRAYCG	30	Sequence 9 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13295	AICKKPSKFFKGACGRDADCEKACDQENWPGGVCVPFLRCECQRSC	46	Sequence 10 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13296	ATCRKPSMYFSGACFSDTNCQKACNREDWPNGKCLVGFKCECQRPC	46	Sequence 11 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13297	RCIPCGQDCISSRNCCSPCKCNFGPPVPRCTN	32	Sequence 12 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13298	MMKSFVIVMLVMSMMVATSMASGECNMYGRCPPGYCCSKFGYCGVGRAYCGDAEQKVEDHPSNDADVPEFVGAGAP	76	Sequence 14 from Patent US 6242574	Synthetic construct	Antimicrobial	US 6242574 B1	Granted Patent	2001##6##5	CA2238967A1, EP0870031A1, WO1997023617A1	Antimicrobial proteins.	Isolated proteins having anti-fungal activity against at least Cercospora spp. The proteins contain an amino acid sequence which has at least 95% sequence identity to any of the following sequences: SEQ ID NO:3 wherein the amino acid in position 80 is alanine instead of valine, SEQ ID NO:5 and SEQ ID NO:6. Recombinant DNA molecules encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
DRAMP13299	GIGDPVTXLKSGAIXHPVFXPRRYKQIGGXGLPXTKXXXX	40	Sequence 1 from Patent US 6255279	Synthetic construct	Antimicrobial	US 6255279 B1	Granted Patent	2001##7##3	EP0866804A2, EP0866804B1, WO1997022624A2, WO1997022624A3	Cosmetic preparations containing vertebrate proteins and having antibacterial, antimycotical and antiviral action.	A peptide which is a monomer, homodimer, heterodimer, homotrimer, heterotrimer, homotetramer or heterotetramer, and is based on the following amino acid sequence: Gly Ile Gly Asp Pro Val Thr Xaa Leu Lys 1               5                   10 Ser Gly Ala Ile Xaa His Pro Val Phe Xaa                 15                  20 Pro Arg Arg Tyr Lys Gln Ile Gly Gly Xaa                 25                  30 Gly Leu Pro Xaa Thr Lys Xaa Xaa Xaa Xaa                 35                  40 which has been designated SEQ ID NO.: 1, or a variant of said amino acid sequence, as a homomonomer or heteromonomer. In the forgoing amino acid sequence, each Xaa independently represents an amino acid selected from the group consisting of essential and non-es
DRAMP13300	GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTTCCKKP	41	Sequence 2 from Patent US 6255279	Synthetic construct	Antimicrobial	US 6255279 B1	Granted Patent	2001##7##3	EP0866804A2, EP0866804B1, WO1997022624A2, WO1997022624A3	Cosmetic preparations containing vertebrate proteins and having antibacterial, antimycotical and antiviral action.	A peptide which is a monomer, homodimer, heterodimer, homotrimer, heterotrimer, homotetramer or heterotetramer, and is based on the following amino acid sequence: Gly Ile Gly Asp Pro Val Thr Xaa Leu Lys 1               5                   10 Ser Gly Ala Ile Xaa His Pro Val Phe Xaa                 15                  20 Pro Arg Arg Tyr Lys Gln Ile Gly Gly Xaa                 25                  30 Gly Leu Pro Xaa Thr Lys Xaa Xaa Xaa Xaa                 35                  40 which has been designated SEQ ID NO.: 1, or a variant of said amino acid sequence, as a homomonomer or heteromonomer. In the forgoing amino acid sequence, each Xaa independently represents an amino acid selected from the group consisting of essential and non-es
DRAMP13301	VKLKVXPLKVKLXP	14	Sequence 1 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13302	XKLKVXPLKVKLXP	14	Sequence 2 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13303	VXLKVXPLKVKLXP	14	Sequence 3 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13304	VKXKVXPLKVKLXP	14	Sequence 4 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13305	VKLXVXPLKVKLXP	14	Sequence 5 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13306	VKLKXXPLKVKLXP	14	Sequence 6 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13307	VKLKVYPLKVKLXP	14	Sequence 7 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13308	VKLKVXXLKVKLXP	14	Sequence 8 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13309	VKLKVXPXKVKLXP	14	Sequence 9 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13310	VKLKVXPLXVKLXP	14	Sequence 10 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13311	VKLKVXPLKXKLXP	14	Sequence 11 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13312	VKLKVXPLKVXLXP	14	Sequence 12 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13313	VKLKVXPLKVKXXP	14	Sequence 13 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13314	VKLKVXPLKVKLYP	14	Sequence 14 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13315	VKLKVXPLKVKLXX	14	Sequence 15 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13316	VXLXVXPLKVKLXP	14	Sequence 16 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13317	VXLXVXPLXVXLXP	14	Sequence 17 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13318	BKAXVXPAKVKAXP	14	Sequence 18 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13319	AKLXAXPLKAKLXP	14	Sequence 19 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13320	AKAXAXPAKAKAXP	14	Sequence 20 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13321	LKLXLXPLKLKLXP	14	Sequence 21 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13322	VKLVKXPLKVLKXP	14	Sequence 24 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13323	LVLKKXPKKVLVXP	14	Sequence 25 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13324	KVKLKXPKVKLKXP	14	Sequence 26 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13325	XVKLKXPKVKLKXP	14	Sequence 27 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13326	KXKLKXPKVKLKXP	14	Sequence 28 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13327	XPVKLKXPKVKL	12	Sequence 29 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13328	XPLKVKXPKLKV	12	Sequence 30 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13329	XPVXLXXPXVXL	12	Sequence 32 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13330	XPLXLXXPXLXL	12	Sequence 33 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13331	VXLFPVXLFP	10	Sequence 34 from Patent US 6358921	Synthetic construct	Antimicrobial	US 6358921 B1	Granted Patent	2002##3##19	EP0932620A1, WO1998016549A1	Antimicrobial peptide compositions and method.	The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
DRAMP13332	GRLRKKWKAFKKFLKILAC	19	Sequence 1 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13333	GKWKLFKKAFKKFLKILAC	19	Sequence 2 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13334	GKWKAFKKAFKKFAKILAG	19	Sequence 3 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13335	GKWKLFKKAFKKFLKILAG	19	Sequence 4 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13336	CGGGGGGGGGKWKAFKKAFKKFAKILACG	29	Sequence 5 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13337	GKLKKKWKAAKKFLKKCS	18	Sequence 6 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13338	GKWKLFKKAAKKFLKKCS	18	Sequence 7 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13339	GKWKAFKKAAKKFAKKCS	18	Sequence 8 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13340	IKISGKWKAQKRFLKMSGC	19	Sequence 9 from Patent US 6624140	Synthetic construct	Antimicrobial	US 6624140 B1	Granted Patent	2003##9##23	CA2298101A1, DE69736359D1, EP0988314A1, EP0988314B1, US20040049011, WO1999006440A1, WO1999006440A8	Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.	A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable α-helix and has the following structure comprising at least 12 amino acids R 1 -R 2 -A 1 -B 1 -(A 2 -B 2 -C 1 -A 3 ) m -(C 2 ) n -R 3 , wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A 2 -B 2 -C 1 -A 3 ) have the retro orientation and the remaining repetitive motifs (A 2 -B 2 -C 1 -A 3 ) have the orientation as presented in the formula and wherein, R 1 -R 2 - and R 3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in t
DRAMP13342	KRLFKELKKSLRKY	14	Sequence 3 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13343	KRLFKELLKSLRKY	14	Sequence 4 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13349	KRLFKELFFSLRKY	14	Sequence 10 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13350	KRKFHEKHHSHRGYC	15	Sequence 12 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13351	YGRHSHHKEHFKRKC	15	Sequence 13 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13353	GMASKGAIAGKIAKVALKAL	20	Sequence 19 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13354	SSSKEENRIIPGGI	14	Sequence 20 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13355	LLASDEEIQDVSGTWYLKA	19	Sequence 21 from Patent US 6638531	Synthetic construct	Antimicrobial	US 6638531 B1	Granted Patent	2003##10##28	CA2319094A1, CA2319094C, DE69920877D1, DE69920877T2, EP1051433A2, EP1051433B1, WO1999037678A2, WO1999037678A3	Antimicrobial peptides.	The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.
DRAMP13356	MRLVVCLVFLASFALVCQGEAYRGGYTGPIPRPPPIGRPPFRPVCNACYRLSVSDARNCCIKFGSCCHLVKG	72	Sequence 2 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13357	MRLVVCLVFLASFALVCQGQVYKGGYTRPIPRPPPFVRPLPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYSG	82	Sequence 4 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13358	YRGGYTGPIPRPPPIGRPPLRLVVCACYRLSVSDARNCCIKFGSCCHLVK	50	Sequence 5 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13359	YRGGYTGPIPRPPPIGRPPFRPVCNACYRLSVSDARNCCIKFGSCCHLVK	50	Sequence 6 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13360	EVYKGGYTRPIPRPPPFVRPLPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYS	62	Sequence 7 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13361	PXPXPXP	7	Sequence 15 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13362	PXPXPXPXXXPXX	13	Sequence 17 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13363	PXPXPXPXXXPXPXXPXXP	19	Sequence 18 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13364	PXPXPP	6	Sequence 19 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13365	PXPXPPXXXPXX	12	Sequence 21 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13366	PXPXPPXXXPXPXXPXXP	18	Sequence 22 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13367	MRLVVCLVFLASFALVCQGQVYKGGYTRPVPRPPPFVRPLPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYSG	82	Sequence 23 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13368	MRLVVCLVFLASFALVCQGQVYKGGYTRPIPRPPFVRPVPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYSG	81	Sequence 24 from Patent US 6642203	Synthetic construct	Antimicrobial	US 6642203 B1	Granted Patent	2003##11##4	DE69827262D1, EP1000153A2, EP1000153B1, WO1999005270A2, WO1999005270A3	Crustacean antimicrobial peptides.	The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.
DRAMP13369	YXXIQXWXHYR	11	Sequence 1 from Patent US 6696559	Synthetic construct	Antimicrobial	US 6696559 B1	Granted Patent	2004##2##24	CA2242660A1, EP0880356A1, EP0880356A4, US6008195, WO1997029765A1	Antimicrobial peptides and methods of use.	Novel antimicrobial peptides from bovine and murine neutrophils are provided. The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A are also provided. A synthetic version of BGP-A and MGP-A is also provided. The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.
DRAMP13370	YKIIQQWFHWRRV	13	Sequence 6 from Patent US 6696559	Synthetic construct	Antimicrobial	US 6696559 B1	Granted Patent	2004##2##24	CA2242660A1, EP0880356A1, EP0880356A4, US6008195, WO1997029765A1	Antimicrobial peptides and methods of use.	Novel antimicrobial peptides from bovine and murine neutrophils are provided. The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A are also provided. A synthetic version of BGP-A and MGP-A is also provided. The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.
DRAMP13371	YQVIQSWEHWRE	12	Sequence 7 from Patent US 6696559	Synthetic construct	Antimicrobial	US 6696559 B1	Granted Patent	2004##2##24	CA2242660A1, EP0880356A1, EP0880356A4, US6008195, WO1997029765A1	Antimicrobial peptides and methods of use.	Novel antimicrobial peptides from bovine and murine neutrophils are provided. The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A are also provided. A synthetic version of BGP-A and MGP-A is also provided. The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.
DRAMP13372	GFASFLGKALKALKAALKIGANALGGAPQQ	30	Sequence 46 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13373	GKPRPYSPRPTSHPRPIAV	19	Sequence 48 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13374	MGIGKFLKKAKKFGKAFVKILKK	23	Sequence 56 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13375	GVLSNVIGIGYLKKLGTGALNAVLKQ	26	Sequence 60 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13376	GAGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY	40	Sequence 66 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13377	GTRSSRAGLQFPVGRVHRLLRK	22	Sequence 68 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13378	GRAGLQFPVGRVHRLLRK	18	Sequence 70 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13379	GRAGLQFPVGRLLRRLLRRLLR	22	Sequence 72 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13380	MCGIVGIAGVMPVNQSIYDALTVLQHRGQDAAGIITIDANNCFRLRKANGLVSDVFEARHM	61	Sequence 74 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13381	MCGIVGIAGVMPVNQSIYDALTVLQHRGQDAAGIITIDANNCFRLRKANALVSDVFEAN	59	Sequence 76 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13382	MCGIVGIAGVMPVNQSIYDALTVLQHRGQDAAGIITIDANNCFRLRKANALVSDVFEAAHAN	62	Sequence 78 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13383	MCGIVGIAGVMPVNQSIYDALTVLQHRGQDAAGIITIDANNCFRLRKANALVSDVFEARHM	61	Sequence 80 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13384	MQRLQGNMGIGHVRYPTAGSSSASEAQPFYVNSPYGITLAHIGNLTNAHELRKKLFEEKRRHINTTSDSEILLNIFASELDNFRHYPLEADN	92	Sequence 88 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP13385	MLAEIKGLNEECGVFGIWGHEEAPQITYYGLHSLQHRGQEGAGN	44	Sequence 90 from Patent US 6699689	Synthetic construct	Antimicrobial	US 6699689 B1	Granted Patent	2004##3##2	CA2301044A1, CA2301044C, CN1201010C, CN1273605A, EP1002107A1, WO1999064611A1	Mass production method of antimicrobial peptide and DNA construct and expression system thereof.	The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
DRAMP18841	VPKCCKPV	8	Sequence 11 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18840	VPKCXKPV	8	Sequence 10 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18839	VPKCCKPV	8	Sequence 9 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18838	VPKCCKPV	8	Sequence 8 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18837	VPKXXKPV	8	Sequence 7 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18836	VPKXCKPV	8	Sequence 6 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18835	CKPV	4	Sequence 5 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18834	VPKCCKPV	8	Sequence 4 from Patent US 7244710	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18833	SYSMEHFRWGKPV	13	Sequence 3 from Patent US 7244710	Homo sapiens 	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18832	HFRWGKPV	8	Sequence 2 from Patent US 7244710	Homo sapiens 	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP18831	MEHFRWG	7	Sequence 1 from Patent US 7244710	Homo sapiens 	Antimicrobial, Antibacterial, Antifungal	US 7244710 B2	Granted Patent	2007##7##17	US20040033955A1,  EP0234855, WO9301211, US5028592, US5891847, US20020146374A1	Treatment Of Ophthalmic Infections Using Antimicrobial Peptides	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (alpha-MSH) include alpha-MSH (1-13) which is SYSMEHFRWGKPV, alpha-MSH (4-10) which is MEHFRWG, alpha-MSH (6-13) which is HFRWGKPV, alpha-MSH (11-13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter. 
DRAMP13521	YAERLCXCSIKAEV	14	Sequence 38 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	CA2320429A1, CA2320429C, EP1056465A1, EP1056465A4, WO1999042119A1	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP13522	ALYKKKIIKKLLES	14	Sequence 39 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	CA2320429A1, CA2320429C, EP1056465A1, EP1056465A4, WO1999042119A1	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP13523	MEHFRWG	7	Sequence 1 from Patent US 6803044	Synthetic construct	Antimicrobial	US 6803044 B1	Granted Patent	2004##10##12	Unknown	Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus.	The present invention is directed to a method and pharmaceuticals for treating HIV and secondary infection. One aspect of this invention involves the use of one or more polypeptides with an amino acid sequence including KPV, MEHFRWG, HFRWGKPV, or SYSMEHFRWGKPV for treatment of HIV. HIV is accompanied by infections, inflammation or both. In one preferred embodiment of the invention, the one or more polypeptides are used for treatment of HIV itself via medication taken orally or parentally. In another preferred embodiment of the invention, the treatment is for secondary infections arising from Staphylococcus aureus and Candidia albicans and can be taken either orally or parentally. In another preferred embodiment of the invention, treatment is carried out by local application of the polypeptides through a carrier onto the site of S. aureus or C. albicans infection.
DRAMP13524	HFRWGKPV	8	Sequence 2 from Patent US 6803044	Synthetic construct	Antimicrobial	US 6803044 B1	Granted Patent	2004##10##12	Unknown	Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus.	The present invention is directed to a method and pharmaceuticals for treating HIV and secondary infection. One aspect of this invention involves the use of one or more polypeptides with an amino acid sequence including KPV, MEHFRWG, HFRWGKPV, or SYSMEHFRWGKPV for treatment of HIV. HIV is accompanied by infections, inflammation or both. In one preferred embodiment of the invention, the one or more polypeptides are used for treatment of HIV itself via medication taken orally or parentally. In another preferred embodiment of the invention, the treatment is for secondary infections arising from Staphylococcus aureus and Candidia albicans and can be taken either orally or parentally. In another preferred embodiment of the invention, treatment is carried out by local application of the polypeptides through a carrier onto the site of S. aureus or C. albicans infection.
DRAMP13525	SYSMEHFRWGKPV	13	Sequence 3 from Patent US 6803044	Synthetic construct	Antimicrobial	US 6803044 B1	Granted Patent	2004##10##12	Unknown	Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus.	The present invention is directed to a method and pharmaceuticals for treating HIV and secondary infection. One aspect of this invention involves the use of one or more polypeptides with an amino acid sequence including KPV, MEHFRWG, HFRWGKPV, or SYSMEHFRWGKPV for treatment of HIV. HIV is accompanied by infections, inflammation or both. In one preferred embodiment of the invention, the one or more polypeptides are used for treatment of HIV itself via medication taken orally or parentally. In another preferred embodiment of the invention, the treatment is for secondary infections arising from Staphylococcus aureus and Candidia albicans and can be taken either orally or parentally. In another preferred embodiment of the invention, treatment is carried out by local application of the polypeptides through a carrier onto the site of S. aureus or C. albicans infection.
DRAMP13526	CKPV	4	Sequence 4 from Patent US 6803044	Synthetic construct	Antimicrobial	US 6803044 B1	Granted Patent	2004##10##12	Unknown	Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus.	The present invention is directed to a method and pharmaceuticals for treating HIV and secondary infection. One aspect of this invention involves the use of one or more polypeptides with an amino acid sequence including KPV, MEHFRWG, HFRWGKPV, or SYSMEHFRWGKPV for treatment of HIV. HIV is accompanied by infections, inflammation or both. In one preferred embodiment of the invention, the one or more polypeptides are used for treatment of HIV itself via medication taken orally or parentally. In another preferred embodiment of the invention, the treatment is for secondary infections arising from Staphylococcus aureus and Candidia albicans and can be taken either orally or parentally. In another preferred embodiment of the invention, treatment is carried out by local application of the polypeptides through a carrier onto the site of S. aureus or C. albicans infection.
DRAMP13527	NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD	85	Sequence 1 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13528	AELR	4	Sequence 2 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13529	AELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDES	68	Sequence 3 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13530	YAELR	5	Sequence 4 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13531	AGDES	5	Sequence 5 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13532	NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDES	83	Sequence 6 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13533	LRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD	68	Sequence 12 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13534	AELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD	70	Sequence 13 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13535	MAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDES	69	Sequence 14 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13536	MNLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDES	84	Sequence 15 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13537	MGHHHHHHHHHHSSGHIEGRHMYLRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD	91	Sequence 16 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13538	MGHHHHHHHHHHSSGHIEGRHMYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAI	93	Sequence 17 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13539	MNLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD	86	Sequence 18 from Patent US 6838435	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2005##1##4	WO1999015548A2, WO1999015548A3, WO1999015548B1	Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2(TC-2) or variants thereof.	The present invention relates to isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in FIG. 1 indicated by the label TC-1 and TC-2, and have antimicrobial activity against gram-positive and gram-negative bacteria, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermis , and Staphylococcus aureus , and/or against fungi, for example Candida albicans, C. glabarata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus , and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the preparation of a medicament for the treatment of bacterial or fungal infections, such as endocarditis, in humans and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or fungal infections in humans and animals.
DRAMP13540	MKLQATARVAGLLFLVLLLALPSLRVSMAGSGFCDGKCAVRCSKASRHDDCLKYCGICCATCNCVPSGTAGNKDECPCYRDMTTGHGNRTRPKCP	95	Sequence 38 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13541	MAVAKPPLQTAAVLLLLLLVVAAASWLQTVDAASGFCSSKCSVRCGRAASARARGACMRSCGLCCEECNCVPTRPPRDVNECPCYRDMLTAGPRKRPKCP	100	Sequence 40 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13542	MKAIPVALLLLVLVAAASSFKHLAEAADGGAVPDGVCDGKCRSRCSLKKAGRCMGLCMMCCGKCQGCVPSGPYASKDECPCYRDMKSPKNQRPKCP	96	Sequence 42 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13543	MAKASSRLLFSLSLVVLLLLVETTTSPHGQADAIDCGASCSYRCSKSGRPKMCLRACGTCCQRCGCVPPGTSGNEDVCPCYANMKTHDGQHKCP	94	Sequence 44 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13544	MGGGNGGAGGGGKLKPWECSSKCSSRCSGTQYKKACLTYCNKCCATCLCVPPGTYGNKGACPCYNNWKTKEGGPKCP	77	Sequence 46 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13545	MKKLRTTTLALLLLLVFLAASSLRAAMAGSAFCDGKCGVRCSKASRHDDCLKYCGICCAECNCVPSGTAGNKDECPCYRDKTTGHGARKRPKCP	94	Sequence 47 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13546	MKKLRTTTATTTLALILLLVLIAATSLRVAMAGSAFCDSKCGVRCSKAGRHDDCLKYCGICCAECNCVPSGTAGNKDECPCYRDKTTGHGARTRPKCP	98	Sequence 48 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13547	MSKPSRCRAVQTQVALLLLLLVAASLLQAGDAASGFCAGKCAVRCGRSRAKRGACMKYCGLCCXECACVPTGRSGSRDECPCYRDMLTAGPRKRPKCP	98	Sequence 50 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13548	MAGGRGRGGGGGGGVAGGGNLRPWECSPKCAGRCSNTQYKKACLTFCNKCCAKCLCVPPGTYGNKGACPCYNNWKTKEGGPKCP	84	Sequence 54 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13549	MKVAFVAVLLICLVLSSSLFEVSMAGSAFCSSKCAKRCSRAGMKDRCTRFCGICCSKCRCVPSGTYGNKHECPCYRDMKNSKGKPKCP	88	Sequence 55 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13550	MKVAFAAVLLICLVLSSSLFEVSMAGSAFCSSKCSKRCSRAGMKDRCMKFCGICCSKCNCVPSGTYGNKHECPCYRDMKNSKGKAKCP	88	Sequence 56 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13551	MKLEFANVLLLCLVLSSSFLEISMAGSPFCDSKCAQRCAKAGVQDRCLRFCGICCEKCNCVPSGTYGNKDECPCYRDMKNSKGKDKCP	88	Sequence 57 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13552	MKLVFATLLLCSLLLSSSFLEPVIAYEDSSYCSNKCSDRCSSAGVKDRCLRYCGICCAECKCVPSGTYGNKHQCPCYRDKLNKKGKPKCP	90	Sequence 58 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13553	MKLVFGTLLLCSLLLSFSFLEPVIAYEDSSYCSNKCADRCSSAGVKDRCVKYCGICCAECKCVPSGTYGNKHECPCYRDKLNKKGKPKCP	90	Sequence 59 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13554	MAISKSTVVVVILCFILIQELGIYGEDPHMDAAKKIDCGGKCNSRCSKARRQKMCIRACNSCCKKCRCVPPGTSGNRDLCPCYARLTTHGGKLKCP	96	Sequence 60 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13555	MALSKLIIASLLASLLLLHFVDADQSAHAQTQGSLLQQIDCNGACAARCRLSSRPRLCQRACGTCCRRCNCVPPGTAGNQEVCPCYASLTTHGGKRKCP	99	Sequence 64 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13556	MAARSYSPIMVALSLLLLVTFSNVAEAYTRSGTLRPSDCKPKCTYRCSATSHKKPCMFFCQKCCAKCLCVPPGTYGNKQICPCYNSWKTKEGGPKCP	97	Sequence 72 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13557	HEVQHIDCNAACAARCRLASRQRMCHRACGTCCRRCNCVPPGTSGNQEVCPCYASLATHGGRRKCP	66	Sequence 73 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13558	MKLFLLTLLLVTLVITPSLIQTTMAGSNFCDSKCKLRCSKAGLADRCLKYCGVCCEECKCVPSGTYGNKHECPCYRDKKNSKGKSKCP	88	Sequence 74 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13559	SKINCGAACKARCRLSSRPNLCHRACGTCCARCRCVPPGTSGNQKVCPCYYNMTTHGGRRKCP	63	Sequence 75 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13560	KSYQCGGQCTRRCSNTKYHKPCMFFCQKCCAKCLCVPPGTYGNKQVCPCYNNWKTQQGGPKCP	63	Sequence 76 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13561	MAKSGYNASFLLLISMFLILLTFSNVVEGYNKLRPTDCKPRCTYRCSATSHKKPCMFFCQKCCATCLCVPKGVYGNKQSCPCYNNWKTQEGKPKCP	96	Sequence 77 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13562	MANCIRRNALFFLTLLFLLSVSNLVQAARGGGKLKPQQCNSKCSYRCSATSHKKPCMFFCLKCCKKCLCVPPGTFGNKQTCPCYNNWKTKEGRPKCP	97	Sequence 80 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13563	MAIFRSTLVLLLILFCLTTFELHVHAAEDSQVGEGVVKIDCGGRCKGRCSKSSRPNLCLRACNSCCYRCNCVPPGTAGNHHLCPCYASITTRGGRLKCP	99	Sequence 82 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13564	MAVFRSTLVLLLIIVCLTTYELHVHAADGAKVGEGVVKIDCGGRCKDRCSKSSRTKLCLRACNSCCSRCNCVPPGTSGNTHLCPCYASITTHGGRLKCP	99	Sequence 83 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13565	MAISKALIASLLISLLVLQLVQADVESSQKKNGYAKKIDCGSACVARCRLSRRPRLCHRACGTCCYRCNCVPPGTYGNYDKCQCYASLTTHGGRRKCP	98	Sequence 84 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13566	MMMISLLVFNPVEADGVVVNYGQHASLLAKIDCGGACKARCRLSSRPHLCKRACGTCCQRCSCVPPGTAGNYDVCPCYATLTTHGGKRKCP	91	Sequence 87 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13567	MKLVVVQFFIISLLLTSSFSVLSSADSSCGGKCNVRCSKAGQHEECLKYCNICCQKCNCVPSGTFGHKDECPCYRDMKNSKGGSKCP	87	Sequence 90 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13568	MAVFRVLLASLLISLLVLDFVHADMVRCSLSSRPNLCHRACGTCCARCNCVAPGTSGNYDKCPCYGSLTTHGGRRKEVKEFSFFTHGS	88	Sequence 93 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13569	MAISKALIASLLISLLVLQLVQADVENSQKKNGYAKKIDCGSACVARCRLSRRPRLCHRACGTCCYRCNCVPPGTYGNYDKCQCYASLTTHGGRRKCP	98	Sequence 94 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13570	MKLNTTTTLALLLLLLLASSSLQVSMAGSDFCDGKCKVRCSKASRHDDCLKYCGVCCASCNCVPSGTAGNKDECPCYRDMTTGHGARKRPKCP	93	Sequence 95 from Patent US 7166769	Synthetic construct	Antimicrobial	US 7166769 B1	Granted Patent	2005##4##5	CA2422041A1, DE60137587D1, EP1379658A2, EP1379658B1, EP2039769A2, EP2039769A3, US6875907, US7393999, US7803989, US7807876, US20020166141, WO2002022821	Antimicrobial peptides and methods of use.	The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants.
DRAMP13571	NAEEGTAVPYVPGYHKKNEIEFQKDIDRFV	30	Sequence 3 from Patent US 6881720	Synthetic construct	Antimicrobial	US 6881720 B1	Granted Patent	2005##4##19	CA2351894A1, CA2351894C, CN1335855A, CN100406469C, DE60040835D1, EP1132400A1, EP1132400A4, EP1132400B1, US7232673, US20050288224, WO2001021657A1	Antimicrobial protein from Lyophyllum shimeji.	The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone the gene of this protein. According to the present invention, an antimicrobial protein which can be obtained from a fraction of an aqueous extract of Lyophyllum shimeji precipitated by the ammonium sulfate precipitation method, has an antimicrobial activity at least against Rhizoctonia solani or Pyricularia oryzae, and shows the presence of components of about 70 kDa and/or about 65 kDa in molecular weight in the SDS-PAGE method. A gene encoding this protein and a method of using the same are provided.
DRAMP13572	EFDESIRHTLVLRSLQDAYKDRQR	24	Sequence 4 from Patent US 6881720	Synthetic construct	Antimicrobial	US 6881720 B1	Granted Patent	2005##4##19	CA2351894A1, CA2351894C, CN1335855A, CN100406469C, DE60040835D1, EP1132400A1, EP1132400A4, EP1132400B1, US7232673, US20050288224, WO2001021657A1	Antimicrobial protein from Lyophyllum shimeji.	The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone the gene of this protein. According to the present invention, an antimicrobial protein which can be obtained from a fraction of an aqueous extract of Lyophyllum shimeji precipitated by the ammonium sulfate precipitation method, has an antimicrobial activity at least against Rhizoctonia solani or Pyricularia oryzae, and shows the presence of components of about 70 kDa and/or about 65 kDa in molecular weight in the SDS-PAGE method. A gene encoding this protein and a method of using the same are provided.
DRAMP13573	AERLIGTSTKEFDESIRHTLVLRSLQDAY	29	Sequence 5 from Patent US 6881720	Synthetic construct	Antimicrobial	US 6881720 B1	Granted Patent	2005##4##19	CA2351894A1, CA2351894C, CN1335855A, CN100406469C, DE60040835D1, EP1132400A1, EP1132400A4, EP1132400B1, US7232673, US20050288224, WO2001021657A1	Antimicrobial protein from Lyophyllum shimeji.	The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone the gene of this protein. According to the present invention, an antimicrobial protein which can be obtained from a fraction of an aqueous extract of Lyophyllum shimeji precipitated by the ammonium sulfate precipitation method, has an antimicrobial activity at least against Rhizoctonia solani or Pyricularia oryzae, and shows the presence of components of about 70 kDa and/or about 65 kDa in molecular weight in the SDS-PAGE method. A gene encoding this protein and a method of using the same are provided.
DRAMP13574	AERLIGTSTKEFDESIRHTLVLRSLQDAYKDRQR	34	Sequence 6 from Patent US 6881720	Synthetic construct	Antimicrobial	US 6881720 B1	Granted Patent	2005##4##19	CA2351894A1, CA2351894C, CN1335855A, CN100406469C, DE60040835D1, EP1132400A1, EP1132400A4, EP1132400B1, US7232673, US20050288224, WO2001021657A1	Antimicrobial protein from Lyophyllum shimeji.	The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone the gene of this protein. According to the present invention, an antimicrobial protein which can be obtained from a fraction of an aqueous extract of Lyophyllum shimeji precipitated by the ammonium sulfate precipitation method, has an antimicrobial activity at least against Rhizoctonia solani or Pyricularia oryzae, and shows the presence of components of about 70 kDa and/or about 65 kDa in molecular weight in the SDS-PAGE method. A gene encoding this protein and a method of using the same are provided.
DRAMP13576	KVHGSLARAGKVRGQTPK	18	Sequence 2 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13577	TGRAKRRMQYNRR	13	Sequence 3 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13578	KVAKQEKKKKKT	12	Sequence 4 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13579	KVAKQEKKKKKTGRAKRR	18	Sequence 5 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13580	AKVAKQEKKKKKTGRAKRRA	20	Sequence 6 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13581	TGRAKRR	7	Sequence 7 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13582	FVNVVPTFGKKKGPNANS	18	Sequence 8 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13583	MQYNRR	6	Sequence 9 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13584	KVHGSLARAGKVRGQTPKVAKQ	22	Sequence 10 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13585	AGKVRGQTPKVAKQEKKKKKT	21	Sequence 11 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine.
DRAMP13586	MKATILLAVLVAVFVAGTEAHSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSRVNNPFRVNQVAKSINDLDYTPIMKSMENLDNGMDML	96	Sequence 2 from Patent US 6911524	Synthetic construct	Antimicrobial	US 6911524 B1	Granted Patent	2005##6##28	CA2378452A1, EP1194550A1, WO2001004294A1	Antimicrobial peptides derived from mollusks.	The invention concerns an antimicrobial peptide, called myticin, characterised in that it can be obtained from a bivalve mollusc shellfish, and its molecular mass is about 4.5 kDa; its pI is about 8.7; it comprises 8 cystein radicals. The invention also concerns its preparation and its uses. The invention further concerns a nucleic acid coding for said peptide.
DRAMP13587	MKATMLLAVVVAVFVAGTEAHPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSRVKFPFGATQDAKSMNELEYTPIMKSMENLDNGMDML	96	Sequence 4 from Patent US 6911524	Synthetic construct	Antimicrobial	US 6911524 B1	Granted Patent	2005##6##28	CA2378452A1, EP1194550A1, WO2001004294A1	Antimicrobial peptides derived from mollusks.	The invention concerns an antimicrobial peptide, called myticin, characterised in that it can be obtained from a bivalve mollusc shellfish, and its molecular mass is about 4.5 kDa; its pI is about 8.7; it comprises 8 cystein radicals. The invention also concerns its preparation and its uses. The invention further concerns a nucleic acid coding for said peptide.
DRAMP13588	HXHXCTSYXCXKFCGTAXCTXYXCRXLHXGKXCXCXHCSR	40	Sequence 5 from Patent US 6911524	Synthetic construct	Antimicrobial	US 6911524 B1	Granted Patent	2005##6##28	CA2378452A1, EP1194550A1, WO2001004294A1	Antimicrobial peptides derived from mollusks.	The invention concerns an antimicrobial peptide, called myticin, characterised in that it can be obtained from a bivalve mollusc shellfish, and its molecular mass is about 4.5 kDa; its pI is about 8.7; it comprises 8 cystein radicals. The invention also concerns its preparation and its uses. The invention further concerns a nucleic acid coding for said peptide.
DRAMP13589	HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR	40	Sequence 6 from Patent US 6911524	Synthetic construct	Antimicrobial	US 6911524 B1	Granted Patent	2005##6##28	CA2378452A1, EP1194550A1, WO2001004294A1	Antimicrobial peptides derived from mollusks.	The invention concerns an antimicrobial peptide, called myticin, characterised in that it can be obtained from a bivalve mollusc shellfish, and its molecular mass is about 4.5 kDa; its pI is about 8.7; it comprises 8 cystein radicals. The invention also concerns its preparation and its uses. The invention further concerns a nucleic acid coding for said peptide.
DRAMP13590	HPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR	40	Sequence 7 from Patent US 6911524	Synthetic construct	Antimicrobial	US 6911524 B1	Granted Patent	2005##6##28	CA2378452A1, EP1194550A1, WO2001004294A1	Antimicrobial peptides derived from mollusks.	The invention concerns an antimicrobial peptide, called myticin, characterised in that it can be obtained from a bivalve mollusc shellfish, and its molecular mass is about 4.5 kDa; its pI is about 8.7; it comprises 8 cystein radicals. The invention also concerns its preparation and its uses. The invention further concerns a nucleic acid coding for said peptide.
DRAMP13591	VRGSIPLQASAAFPKAARLLKTDEFSSVFRLRPWRRTAHFVIYGKPTGRDARLGLVIGKKYAARAVTRNLVKRLAREAFRTRRAEFAGWDILLRLHA	97	Sequence 59 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13592	LRLLTPSQFTFVFRIGLTVAKKNVRRAHERNRIKRLTRESFRLRQHELDFVVVAKKGVADLDNRALSEALE	71	Sequence 61 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13593	LRLLTPKHFNFVFRIGLTIAKKNVKRAHERNRIKRLAREYFRLHQHQLDFVVLVRKGVAELDNHQLTEVLG	71	Sequence 62 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13594	LRLLTPIQFKNVFRLGLTVAKKHLKRAHERNRIKRLVRESFRLSQHRLDFVFVAKNGIGKLDNNTFAQILE	71	Sequence 63 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13595	KNLLTPRHFKAVFRLGLVIGKKSVKLAVQRNRLKRLMRDSFRLNQQLLDIVIVARKGLGEIENPELHQHFG	71	Sequence 64 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13596	SKLLKSTNFQYVFRLGLSISRKNIKHAYRRNKIKRLIRETFRLLQHRLDFVVIAKKNIVYLNNKKIVNILE	71	Sequence 65 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13597	LRLLTPAHFTFVFRIGLTVAKKNVRRAHERXRIKRLTRESFRLRQHELDFVVVAKKGVADLDNRALSEALE	71	Sequence 66 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13598	LRLLTPSHFTFVFRIGLTVAKKHVKRAHERNRIKRLTRESFRLHQHALDFVVLVKKGVADLDNRALTEALE	71	Sequence 67 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13599	LRLLTPSHFTFVFRIGLTVAKKNVKRAHERNRIKRLTRESFRLRQHELDFVVVAKRGVADLDNRALSEALE	71	Sequence 68 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13600	IRLPATSTRIGLTVAKKNVRRAHERNRIKRLTRESFRLRQHELDFVVVAKKGVADLDNRALSEALE	66	Sequence 69 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13601	LRLLTPEHYQKVFRLGLAVPKKQIKTAVGRNRFKRICRESFRLHQNQLDFVVIAKKSAQDLSNEELFNLLG	71	Sequence 70 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13602	KRLLTARQFSAVFRLGLVIGKKNVKLAVQRNRLKRLIRESFRHNQETLDIVVIARKGLGELENPELHQQFG	71	Sequence 71 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13603	LRLLTPAQFKSVFRLGLTVAKRYVKRANQRNRIKRVIRDSFRLNQHNIDIVVLVRNGVMEMENAELNGLIE	71	Sequence 72 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13604	WRIRTTAEFRRIYRLGVVASKRNVRKAVWRNRVRRVVKEAFRIRKKDLDIVVVAKASSVEADNKELYECIN	71	Sequence 73 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13605	TSLKNQKEFELINLGIKVSRKLNKKAVVRNKIKRRIRHLMRIIVNDSAIIIIPKKGFEEINFSHLQYELS	70	Sequence 74 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13606	ERLRKRPDFLLAARVGFTATKKIGGAVERNRAKRRLREAARLVLPLDYVFIARGGTGTREWARLLDDVKTALI	73	Sequence 75 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13607	DSLKNKSEFDRVYKLGLSVSKKVGNAVKRNLIKRRLRSLTLKHAALCALVFVPRSDCYHLDFWALEKHFLEMLT	74	Sequence 76 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13608	DSLKNKSEFDRVYKLGLSVSKKVGNAVKRNLIKRRLRSLVTRHAALCALVFVPRSDCYHLDFWALEKHFLEMLT	74	Sequence 77 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13609	DKFSTNEEFSSVYKIAVVASKKVGKAVVRNRSKRILRALFAKFERYLKYIFVAKNEITELSFSRLEKNLKWGLK	74	Sequence 78 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13610	YRLLKTDDFSSVFRIGLVVGKKTAKRANERNYMKRVIRDWFRLNKNRLDFVVRVRRKFDRATAKQARAELA	71	Sequence 79 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13611	YRLLKTDDFSSVFRIGLVVGEKTAKRANERNYMKRVIRDWFRLNKNRLDFVVRVRRKFDRATAKQARAELA	71	Sequence 80 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13612	ARLHRPSEFAAALRLGLVIAKRFAARAVTRNTLKRVIREAFRARRLALDYVVRLHSKLTPASLTALKRSARAEVD	75	Sequence 81 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13613	DRLRQKVAIQRTLRLGLAVSRKVGNAVVRNRIKRRLREAFRQQSVRTDVLVVARPSARQLSMRAMGAYLQ	70	Sequence 82 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13614	NRLRRREDFATAVRAGFVVSKAVGGAVVRNQVKRRLKHLVCDRLSALLVVVRALPGAGDADHAQLARDLD	70	Sequence 83 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13615	NRLRRREDFATAVRAGFVVSKAVGVAVVRNKVKRRLRHLMRDRIDLLLVVVRALPGAGDADHAQLARDLD	70	Sequence 84 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13616	RRVRTPAEFRHLGRAGFVVSKAVGNAVTRNRVKRRLRAVVAEQMRLVLVQVRALPAAAEADYALLRRETVGALG	74	Sequence 85 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13617	NRMRRSADFETTVRVGLIIAKSVGSAVERHRVARRLRHVAGSIVKELDHVVIRALPSSRHVSSARLEQQLR	71	Sequence 86 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13618	NRMRRSSEFDATVHVGLIIAKTVGSAVERHRVARRLRHVARTMLGELDQVVIRALPSSRNVSSAWLAQQLR	71	Sequence 87 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13619	NRMTRSTEFDATVRVGLVVGKAVGTAVQRHRVARRLRHVARALLGELDRLVIRALPGSRTASSARLAQELQ	71	Sequence 89 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13620	HKLSQFRATIRFGLVVSKAVGNAVTRHRVSRQLRHFHVVELRADVQAALD	50	Sequence 90 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13621	KNE	3	Sequence 91 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13622	NRLKRSDDFRKVFRVGLSVSKKIGNAVMRNRIKRLIRQFFQEHEQALDYIIIARKPAADMTYEETKKSLQ	70	Sequence 92 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13623	HRIKKNDEFSRVFRVLSVSKKIGNAVTRNRVKRLIRTSITELKDEIDYVIIARKPCAEMTYEQVKGSLW	69	Sequence 93 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13624	HRIKKNFEFQTVFRIGLSVSKKIGNAVVRNRIKRMIRQILKQNISEIDFVILVRKSVLELKYAELKKSLI	70	Sequence 94 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13625	RVIKDRKEFQEIIKYGISVGKKIGNAVIRNKVKRQIRMIMREQFCNIDIIIIINQGFLELTFKTLSKLLI	70	Sequence 95 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13626	HHLRERKVFAALLRAAVSISKTKYKLAVERNLIRRQVKAIFQQISNNLDVLVIVNKGFIELTFKEKQTIFL	71	Sequence 96 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13627	HSLRREKVFTTILRVAISIAKTKYKLAVQRNLIKRQIRSVIMALGHQLDILVIARKGVESLEYQEKQKLFL	71	Sequence 97 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13628	VKSDKDFQAIFRVGISVGKKIGNAVTRNAVKRKIRHVLMELGPYLDFVVIARKGVEELDYSELQQNLH	68	Sequence 98 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13629	YRVKREKDFQAIFRVGLSVGKRLGNAVVRNAIKRKLRHIIQNAKGSLDFVVIARKGVETLGYATMKKNLV	70	Sequence 99 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13630	FRVKKNADFKAIFRVGLSVSKKLGNAVTRNQIKRRIRHNFKVHKSHLDFVVIARQPAKDMTTLEMEKNLL	70	Sequence 100 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13631	YRIKKNADFQRIYRLGISVSKKLGNAVLRNKIKRAIRENFKVHKSHIDIIVIARQPAKDMTTLQIQNSLE	70	Sequence 101 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13632	YRIKKDSDFQRIYRLGISVSKKLGNAVLRNKIKRAIREAYRLNIDEKIDIIVIARVSSKDIDKQIQNSLE	70	Sequence 102 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13633	KGLKNSEDFRKVYRVGISVSKKVGKAITRNRVRRLIKEVVIAMKDQIDIVFVRAIPPAATASYESIKNLV	70	Sequence 103 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13634	LRLKHWQDFQTVYRFGITVSQKVSKKATVRNRLKRQIRAVINHFQPQIDVVIIVLPQGIGCNYERFLRELE	71	Sequence 104 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13635	NRLRRREDFAKVYRIGIVVSKKVSKLAVTRNRFKRQLRAIFRQLLSQLQIVVTVTTVASKPNYQELGDDLK	71	Sequence 105 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13636	ISLKSKIEIQKIFRILVTFSKGFRGSVKRNRIRRLFKEAFRKRLELLDIIFVVSYGKLTLTYFSIESLMK	70	Sequence 106 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13637	ERLRGSCRVRAVFRFLATFRRGYGKAVARNRARRLSKEAYRALKSSLDLVLLVSVVEDSLAAYQRLLCVLC	71	Sequence 107 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13638	ARLLKRKQFVYVQKVGITVSKKFGKAHQRNRFKRIVREAFRHVRPNLQVVISPRGNSQPDFLKLSEELLQRIP	73	Sequence 108 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13639	ARLLKRKQFVYVQKVGVTVSKKFGKAHQRNRFKRIVREAFRHVRPNLQVVVSPKGGTLPNFGKLSADLLKHIP	73	Sequence 109 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13640	SRVLKRKQFLYITRMGITVSKKFGKAHERNSFKRVVREVFRHVRHQLQIVVFPKGHKQRPVFSKLLQDFINQIP	74	Sequence 110 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13641	ERLRLRRDFLLIFRLGIVVKRKFGKATRRNKLKRWVREIFRRNKGVIDIVVIPRKKLSEEFERVDFWTVREKLL	74	Sequence 111 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13642	ERLYLRDEINTVFSMLVSVAKKRFRRAVKRNRVRRLVREAYRLNKHLLDVLQERQIYATIAFMVVSDELPDFRTVERA	78	Sequence 112 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13643	LRGEREFRKVRRIGLVVSKKTLKHAVKRNRARRRVREALRTMPPELRAILMLNPGVLTVPFPELQAALAQALQRGAG	77	Sequence 113 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13644	ARLKGGFLLLIRVLFTVGKKLVPRAVDRNRIKRLMREAYRLEKNILDHQVMLAFLYRARADAIPSLERFRAIRHM	75	Sequence 114 from Patent US 7001924	Synthetic construct	Antimicrobial	US 7001924 B2	Granted Patent	2006##2##21	EP1435932A2, EP1435932A4, US20030134904, WO2003024407A2, WO2003024407A3	Inhibitors of RNase P proteins as antibacterial compounds.	"The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: 
Y—(NR′)k—U1—(NR″)I—A—(NR1)m—U2—(NR2)n—Z  I with substituents as described herein."
DRAMP13646	GIGAVLKVLTTGLPALISWIGGGGGG	26	Sequence 2 from Patent US 7022319	Synthetic construct	Antimicrobial	US 7022319 B1	Granted Patent	2006##4##4	DE69627644D1, DE69627644T2, EP0817858A1, EP0817858B1, WO1996028563A1	Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy.	The present invention relates to recombinant vectors carrying sequences encoding naturally occurring antimicrobial peptides or derivatives thereof for the treatment of mammalian tumours and viral infections such as HIV infections and bacterial and fungal infections. In particular the present invention relates to retroviral vectors. Furthermore, the present invention relates to retroviral vectors which undergo promoter conversion (Procon vectors) carrying such sequences. Since these vectors also carry tumour or virus specific regulatory elements, the therapeutic antimicrobial peptide will be delivered and expressed only in relevant, affected cells and not in innocent bystander cells.
DRAMP13649	KIAHGVKKYGPTVLRIIRIAG	21	Sequence 3 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13650	LGRKIAHGVKKYGPTVLRII	20	Sequence 4 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13651	RGLRRLGRKIAHGVKKYG	18	Sequence 5 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13652	KNIRRIIRKIIHIIKKYG	18	Sequence 6 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13653	NLRRIIRKIIHIIKKY	16	Sequence 9 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13654	NIRRIIRKIIHIIKKY	16	Sequence 10 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13655	LRRIIRKIIHIIKK	14	Sequence 11 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13656	IRRIIRKIIHIIKK	14	Sequence 13 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13657	LRRIIRKIIHIIK	13	Sequence 15 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13658	RRIIRKIIHIIKK	13	Sequence 16 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13659	RRIIRKIIHIIK	12	Sequence 17 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13660	GLRKRLRKFRNKIKEKLKKIG	21	Sequence 19 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13661	KRLRKFRNKIKEKLKKIG	18	Sequence 20 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13662	RKRLRKFRNKIKEKLKKIGQKI	22	Sequence 21 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13663	LRKFRNKIKEKLKKIGQKI	19	Sequence 22 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13664	LRKFRNKIKEKLKKIGQKIQG	21	Sequence 23 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13665	RKFRNKIKEKLKKIG	15	Sequence 24 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13666	KIKEKLKKIGQKIQG	15	Sequence 25 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13667	KIKEKLKKIGQKIQGLL	17	Sequence 26 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13668	KNLRRIIRKIIHIIKKYGPTILRIIRIIG	29	Sequence 28 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13669	RGLRALGRKIAHGVKAYG	18	Sequence 29 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13670	RRIIRKIIHII	11	Sequence 32 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13671	RIIRKIIHIIK	11	Sequence 33 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13672	RIIRKIIHII	10	Sequence 34 from Patent US 7071293	Synthetic construct	Antimicrobial	US 7071293 B1	Granted Patent	2006##7##4	Unknown	Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt.	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP13673	VPKCCKPV	8	Sequence 4 from Patent US 7244710	Synthetic construct	Antimicrobial	US 7244710 B2	Granted Patent	2007##7##17	US20040033955, WO2004103315A2, WO2004103315A3	Treatment of ophthalmic infections using antimicrobial peptides.	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.
DRAMP13674	VPKXCKPV	8	Sequence 6 from Patent US 7244710	Synthetic construct	Antimicrobial	US 7244710 B2	Granted Patent	2007##7##17	US20040033955, WO2004103315A2, WO2004103315A3	Treatment of ophthalmic infections using antimicrobial peptides.	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.
DRAMP13675	VPKXXKPV	8	Sequence 7 from Patent US 7244710	Synthetic construct	Antimicrobial	US 7244710 B2	Granted Patent	2007##7##17	US20040033955, WO2004103315A2, WO2004103315A3	Treatment of ophthalmic infections using antimicrobial peptides.	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.
DRAMP13676	VPKCXKPV	8	Sequence 10 from Patent US 7244710	Synthetic construct	Antimicrobial	US 7244710 B2	Granted Patent	2007##7##17	US20040033955, WO2004103315A2, WO2004103315A3	Treatment of ophthalmic infections using antimicrobial peptides.	The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.
DRAMP13677	ESGLDIAVFEYSDR	14	Sequence 9 from Patent US 7329517	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7329517 B2	Granted Patent	2008##2##12	US20060051337	Escapin protein, a broadly antimicrobial compound from ink of the sea hare Aplysia californica, and uses thereof.	The present invention provides an isolated polypeptide (escapin), and fragments thereof, from the sea hare Aplysia californica that have antimicrobial action directed against fungi, yeast, bacteria, and cyanobacteria. Further, the present invention provides an isolated nucleic acid, and fragments thereof, that encode the polypeptide and fragments thereof. Also provided are primers for detecting the nucleic acids of the present invention. A method of inhibiting microbial growth and inhibiting biofilm formation on a surface is also provided.
DRAMP13678	VFMTFDQPWWLQNER	15	Sequence 10 from Patent US 7329517	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 7329517 B2	Granted Patent	2008##2##12	US20060051337	Escapin protein, a broadly antimicrobial compound from ink of the sea hare Aplysia californica, and uses thereof.	The present invention provides an isolated polypeptide (escapin), and fragments thereof, from the sea hare Aplysia californica that have antimicrobial action directed against fungi, yeast, bacteria, and cyanobacteria. Further, the present invention provides an isolated nucleic acid, and fragments thereof, that encode the polypeptide and fragments thereof. Also provided are primers for detecting the nucleic acids of the present invention. A method of inhibiting microbial growth and inhibiting biofilm formation on a surface is also provided.
DRAMP13679	KKVVFKVKFK	10	Sequence 1 from Patent US 7494980	Synthetic construct	Antimicrobial	US 7494980 B2	Granted Patent	2009##2##24	CA2518608A1, EP1617855A2, EP1617855A4, US20040224897, WO2004101599A2, WO2004101599A3	Antimicrobial peptide and methods of use thereof.	A method of preventing biofilm formation in an environment including the steps of administering to the environment an effective amount of a peptide having the amino acid sequence NH2-lys-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1] The method is useful in preventing the formation of biofilms in various environments including a home, workplace, laboratory, industrial environment, aquatic environment, animal body or human body. A method of inhibiting the growth of oral microorganisms including the steps of administering to an oral environment an effective amount of a peptide having the amino acid sequence NH2-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1].
DRAMP13680	LYPQPYQPQYQQYTF	15	Sequence 2 from Patent US 7494980	Synthetic construct	Antimicrobial	US 7494980 B2	Granted Patent	2009##2##24	CA2518608A1, EP1617855A2, EP1617855A4, US20040224897, WO2004101599A2, WO2004101599A3	Antimicrobial peptide and methods of use thereof.	A method of preventing biofilm formation in an environment including the steps of administering to the environment an effective amount of a peptide having the amino acid sequence NH2-lys-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1] The method is useful in preventing the formation of biofilms in various environments including a home, workplace, laboratory, industrial environment, aquatic environment, animal body or human body. A method of inhibiting the growth of oral microorganisms including the steps of administering to an oral environment an effective amount of a peptide having the amino acid sequence NH2-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1].
DRAMP13681	HPLKQYWWRPSI	12	Sequence 1 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13682	PIWWKHSGGPIL	12	Sequence 2 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13683	YWWRDAPVSQGR	12	Sequence 3 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13684	SYPTDKWWIKPG	12	Sequence 4 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13685	VQWWRPT	7	Sequence 5 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13686	NWWRPLP	7	Sequence 6 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13687	GKWWVFD	7	Sequence 7 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13688	VPTKPWW	7	Sequence 8 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13689	PWWKTSK	7	Sequence 9 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13690	PWWKASS	7	Sequence 10 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13691	TPTWWRT	7	Sequence 11 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13692	APTWWKS	7	Sequence 12 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13693	WWTSASR	7	Sequence 13 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13694	SARWWQPS	8	Sequence 14 from Patent US 7550558	Synthetic construct	Antimicrobial	US 7550558 B2	Granted Patent	2009##6##23	EP1262556A2, EP1262556A3, EP1892246A2, EP1892246A3, US20030148397	Antimicrobial peptides and methods for identifying and using such peptides.	This invention relates to a method for identifying peptides having antimicrobial activity and to the antimicrobial peptides identified thereby and methods for their use.
DRAMP13695	RFKLVRRIVLAXXXXXXXX	19	Sequence 3 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13696	RFKLVRRIVLAXXXXXXXXXXXX	23	Sequence 4 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13697	RFKLVKRIVLAXXXXXXXX	19	Sequence 5 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13698	RFKLVKRIVLAXXXXXXXXXXXX	23	Sequence 6 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13699	RFKLVKKIVLAXXXXXXXX	19	Sequence 7 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13700	RFKLVKKIVLAXXXXXXXXXXXX	23	Sequence 8 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13701	KFKLVKKIVLAXXXXXXXX	19	Sequence 9 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13702	KFKLVKKIVLAXXXXXXXXXXXX	23	Sequence 10 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13703	RFRLFRRILVGXXXXXXXX	19	Sequence 11 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13704	RFRLFRRILVGXXXXXXXXXXXX	23	Sequence 12 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13705	RFKLFRRILVGXXXXXXXX	19	Sequence 13 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13706	RFKLFRRILVGXXXXXXXXXXXX	23	Sequence 14 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13707	RFKLFKRILVGXXXXXXXX	19	Sequence 15 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13708	RFKLFKRILVGXXXXXXXXXXXX	23	Sequence 16 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13709	RFKLFKKILVGXXXXXXXX	19	Sequence 17 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13710	RFKLFKKILVGXXXXXXXXXXXX	23	Sequence 18 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13711	KFKLFKKILVGXXXXXXXX	19	Sequence 19 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13712	KFKLFKKILVGXXXXXXXXXXXX	23	Sequence 20 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13713	RFRGVRRILVGXXXXXXXX	19	Sequence 21 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13714	RFRGVRRILVGXXXXXXXXXXXX	23	Sequence 22 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13715	RFRGVKRILVGXXXXXXXX	19	Sequence 23 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13716	RFRGVKRILVGXXXXXXXXXXXX	23	Sequence 24 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13717	RFRGVKKILVGXXXXXXXX	19	Sequence 25 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13718	RFRGVKKILVGXXXXXXXXXXXX	23	Sequence 26 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13719	KFRGVKKILVGXXXXXXXX	19	Sequence 27 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13720	KFRGVKKILVGXXXXXXXXXXXX	23	Sequence 28 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13721	RWRIGRRIVLAXXXXXXXX	19	Sequence 29 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13722	RWRIGRRIVLAXXXXXXXXXXXX	23	Sequence 30 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13723	RWRIGKKIVLAXXXXXXXX	19	Sequence 31 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13724	RWRIGKKIVLAXXXXXXXXXXXX	23	Sequence 32 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13725	KWRIGKKIVLAXXXXXXXX	19	Sequence 33 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13726	KWRIGKKIVLAXXXXXXXXXXXX	23	Sequence 34 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13727	KWKIGKKIVLAXXXXXXXX	19	Sequence 35 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13728	KWKIGKKIVLAXXXXXXXXXXXX	23	Sequence 36 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13729	RWRLFRRIGIGXXXXXXXX	19	Sequence 37 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13730	RWRLFRRIGIGXXXXXXXXXXXX	23	Sequence 38 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13731	RWRLFKRIGIGXXXXXXXX	19	Sequence 39 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13732	RWRLFKRIGIGXXXXXXXXXXXX	23	Sequence 40 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13733	RWRLFKKIGIGXXXXXXXX	19	Sequence 41 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13734	RWRLFKKIGIGXXXXXXXXXXXX	23	Sequence 42 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13735	RWKLFKKIGIGXXXXXXXX	19	Sequence 43 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13736	RWKLFKKIGIGXXXXXXXXXXXX	23	Sequence 44 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13737	KWKLFKKIGIGXXXXXXXX	19	Sequence 45 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13738	KWKLFKKIGIGXXXXXXXXXXXX	23	Sequence 46 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13739	RFRVIRRILVGXXXXXXXX	19	Sequence 47 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13740	RFRVIRRILVGXXXXXXXXXXXX	23	Sequence 48 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13741	RFRVIRKILVGXXXXXXXX	19	Sequence 49 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13742	RFRVIRKILVGXXXXXXXXXXXX	23	Sequence 50 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13743	RFRVIKKILVGXXXXXXXX	19	Sequence 51 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13744	RFRVIKKILVGXXXXXXXXXXXX	23	Sequence 52 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13745	KFKVIKKILVGXXXXXXXX	19	Sequence 53 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13746	KFKVIKKILVGXXXXXXXXXXXX	23	Sequence 54 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13747	KWKLFKKIGIGRLLKRGLRKLLK	23	Sequence 55 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13748	KWKLFKKIGIGRLLRRLLRRLLR	23	Sequence 56 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13749	RWRLFKRIGIGRLLKRGLR	19	Sequence 57 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13750	RWKLFKKIEKVGRNVRDGLIKAGPAIAVIGQAKSL	35	Sequence 58 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13751	IEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSKWKLFKKIGIGRLLKRGLRKLLK	67	Sequence 66 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13752	RFKLFKKIPRLLRRGLRKVLK	21	Sequence 68 from Patent US 7629438	Synthetic construct	Antimicrobial	US 7629438 B2	Granted Patent	2009##12##8	CN1269837C, CN1398897A, EP1541584A1, EP1541584A4, EP1541584B1, US20080070279, WO2004020461A1	Group of synthetic antimicrobial peptides.	A group of new synthetic antimicrobial peptides are disclosed, which demonstrate stronger bactericidal activity than native antimicrobial peptides. The present synthetic antimicrobial peptides can be produced by solid-phase chemical synthesis or gene expression and be used to prepare the medicines for treating the diseases induced by bacteria, viruses and fungi, as well as the anticancer drugs.
DRAMP13753	XLCEXASXTWXGNCGNTXXCXXXCXXWEXAXHGACHXRXGKXXCFCYFNC	50	Sequence 1 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13754	QXLCXXPSXTWSGVCXNXNACKNQCIXLEXAXHGSCNYXFPAHKCICYXPC	51	Sequence 2 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13755	XLCEXXSXTWXGXCGNTKHCDXQCXXWEXAXHGACHXRXGKXKCFCYFXC	50	Sequence 3 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13756	VXLCEXXSXTWXGXCGNTKHCDXQCXXWEXAXHGACHXRXGKXKCFCYFXC	51	Sequence 4 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13757	GVXLCEXXSXTWXGXCGNTKHCDXQCXXWEXAXHGACHXRXGKXKCFCYFXC	52	Sequence 5 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13758	DGVXLCEXXSXTWXGXCGNTKHCDXQCXXWEXAXHGACHXRXGKXKCFCYFXC	53	Sequence 6 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13759	NLCERASKTWSGNCGNTKHCDNQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 7 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13760	QKLCQRPSRTWSGVCGNSNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 8 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13761	DGVKLCERASQTWTGHCGNTKHCDKQCKNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 9 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13762	XLCEXASKTWXGNCGNTKHCDXQCXXWEXAXHGACHXRXGKXKCFCYFNC	50	Sequence 10 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13763	DGVKLCEXXSXTWXGXCGNTKHCDXQCXXWEXAXHGACHXRXGKWKCFCYFNC	53	Sequence 11 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13764	PGAAHY	6	Sequence 12 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13765	IEDGR	5	Sequence 13 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13766	MGFVLFSQLPSFLLVSTLLLFLVISHSCRA	30	Sequence 15 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13767	IEGRQKLC	8	Sequence 17 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13768	HYNLC	5	Sequence 18 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13769	QKLCERPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 20 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13770	QKLCQKPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 21 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13771	QKLCQRSSRTWSGVCGNSNACKNQCIRLEGARHGSCNYVFPAHKCICYFPC	51	Sequence 22 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13772	QKLCQRPSRTWSGVCGNSNACKNQCINLEGAKHGSCNYRFPAHKCICYVPC	51	Sequence 23 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13773	QKLCERPSGTWSGVCGNSNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 24 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13774	QKLCQRPSGTWSGVCMNNNACKNQCIRLEKAKHGSCNYVFPAHKCICYFPC	51	Sequence 25 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13775	QKLCERPSRTWSGVCGNSNACKNQCINLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 26 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13776	QKLCERPSGTWSGVCGNSNACKNQCIRLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 27 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13777	QKLCEKPSGTWSGVCGNSNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 28 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13778	QKLCQRPSGTWSGVCGNNNACKNQCIRLEGAKHGSCNYIFPAHKCICYFPC	51	Sequence 29 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13779	QKLCQRPSRTWSGVCGNSNACKNQCINLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 30 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13780	QKLCQRSSRTWSGVCGNNNACKNQCIRLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 31 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13782	QKLCQRPSRTWSGVCMNNNACKNQCIRLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 33 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13783	QKLCERPSGTWSGVCMNSNACKNQCIRLEGARHGSCNYVFPAHKCICYFPC	51	Sequence 34 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13784	QKLCQKPSRTWSGVCGNSNACKNQCIRLEKARHGSCNYVFPAHKCICYVPC	51	Sequence 36 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13785	QKLCQRPSGTWSGVCGNNNACKNQCINLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 37 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13786	QKLCQRPSGTWSGVCMNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 38 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13787	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYVPC	51	Sequence 39 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13788	QKLCERSSRTWSGVCGNSNACKNQCIRLEGARHGSCNYVFPAHKCICYFPC	51	Sequence 40 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13789	QKLCQRPSGTWSGVCGNSNACKNQCIRLEGARHGSCNYRFPAHKCICYFPC	51	Sequence 41 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13790	QKLCQRPSRTWSGVCMNSNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 42 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13791	QQLCQRPSRTWSGVCMNNNACKNQCIRLEGARHGSCNYRFPAHKCICYVPC	51	Sequence 43 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13792	QKLCEKPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYVPC	51	Sequence 44 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13793	NLCERASLTWTGNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 45 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13794	ELCEKASKTWSGNCGNTKHCDNQCRSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 46 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13795	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 47 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13796	NLCERASKTWSGNCGNTKHCDDQCKSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 48 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13797	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHVRSGKHMCFCYFNC	50	Sequence 49 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13798	KLCERASKTWSGNCGNTKHCDDQCKNWESAAHGACHVRSGNHKCFCYFNC	50	Sequence 50 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13799	NLCEKASLTWTGNCGNTKHCDTQCKNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 51 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13800	NLCEKASLTWTGNCGNTKHCDTQCKNWEGAKHGACHVRNGNHKCFCYFNC	50	Sequence 52 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13801	ELCERASLTWTGNCGNTKHCDTQCKNWEGAAHGACHVCSGKHKCFCYFNC	50	Sequence 53 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13802	NLCEKASLTWSGNCGNTKHCDNKCKNWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 54 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13803	NLCERASLTWSGNCGNTKHCDTQCKSWESAKHGACHVRSGKHMCFCYFNC	50	Sequence 55 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13804	NLCEKASLTWSGNCGNTRHCDTQCRSWEGAAHGACHVRSGNHKCFCYFNC	50	Sequence 56 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13805	KLCERASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRSGKWMCFCYFNC	50	Sequence 57 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13806	NLCEKASLTWSGNCGNTKHCDDQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 58 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13807	ELCEKASKTWSGNCGNTKHCDTQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 59 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13808	ELCEKASKTWSGNCGNTKHCDTKCKNWEGAKHGACHKRNGKWMCFCYFNC	50	Sequence 60 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13809	ELCEKASKTWTGNCGNTKHCDTQCKNWESAKHGACHVRNGKHKCFCYFNC	50	Sequence 61 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13810	NLCERASKTWTGNCGNTGHCDNKCKSWEGAKHGACHVRNGKWMCFCYFNC	50	Sequence 62 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13811	NLCEKASKTWSGNCGNTKHCDDQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 63 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13812	NLCERASKTWSGNCGNTKHCDTQCKNWEGAKHGACHKRSGKWMCFCYFNC	50	Sequence 64 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13813	ELCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHKRSGKWMCFCYFNC	50	Sequence 65 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13814	ELCEKASKTWSGNCGNTKHCDNQCKSWEGAKHGACHKRSGKHKCFCYFNC	50	Sequence 66 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13815	NLCERASKTWTGNCGNTKHCDTQCKNWESAKHGACHVRSGKHKCFCYFNC	50	Sequence 67 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13816	NLCERASKTWSGNCGNTKHCDTQCRNWESAAHGACHKRNGKWKCFCYFNC	50	Sequence 68 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13817	NLCERASKTWTGNCGNTGHCNNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 69 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13818	NLCERASKTWSGNCGNTKHCDTQCRKWEGAKHGACHKRNGKWMCFCYFNC	50	Sequence 70 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13819	NLCERASKTWTGNCGNTKHCDTQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 71 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13820	NLCERASLTWTGNCGNTGHCDTKCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 72 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13821	NLCERASKTWTGNCGNTKHCDTKCRSWESAKHGACHKRNGKWKCFCYFNC	50	Sequence 73 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13822	NLCEKASKTWTGNCGNTKHCDTQCKSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 74 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13823	NLCERASKTWTGNCGNTKHCDTQCKSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 75 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13824	NLCEKASKTWTGNCGNTGHCDTQCRNWEGAKHGACHKRNGKHKCFCYFNC	50	Sequence 76 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13825	ELCEKASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 77 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13826	NLCERASKTWTGNCGNTKHCDTQCKSWESAKHGACHVRSGKHKCFCYFNC	50	Sequence 78 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13827	ELCEKASLTWTGNCGNTKHCDTQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 79 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13828	NLCEKASKTWTGNCGNTKHCDNQCRNWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 80 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13829	NLCERASKTWTGNCGNTKHCDTQCKIWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 81 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13830	NLCEKASKTWTGNCGNTKHCDNQCKNWESAAHGACHKRNGKWKCFCYFNC	50	Sequence 82 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13831	NLCERASLTWSGNCGNTKHCDDQCKSWESAKHGACHKRNGKHKCFCYFNC	50	Sequence 83 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13832	NLCERASKTWSGNCGNTKHCDDKCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 84 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13833	ELCERASKTWTGNCGNTKHCDNQCRSWESAAHGACHKRSGKWKCFCYFNC	50	Sequence 85 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13834	NLCERASKTWTGNCGNTGHCDTQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 86 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13835	NLCERASKTWTGNCGNTKHCDTQCKNWEGAKHGACHVRSGKHMCFCYFNC	50	Sequence 87 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13836	NLCEKASKTWTGNCGNTKHCDDQCKNWEGAKHGACHKRNGKWMCFCYFNC	50	Sequence 88 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13837	NLCERASKTWSGNCGNTKHCDTQCKNWESAKHGACHKRNGKHKCFCYFNC	50	Sequence 89 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13838	ELCERASLTWTGNCGNTKHCDTQCKSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 90 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13839	KLCERASLTWSGNCGNTKHCDTKCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 91 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13840	NLCERASKTWTGNCGNTKHCDNQCRNWESAAHGACHKRSGKWKCFCYFNC	50	Sequence 92 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13841	NLWEKASLTWTGNCGNTKHCDNQCKNWESAAHGACHKRSGKWMCFCYFNC	50	Sequence 93 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13842	NLCERASKTWTGNCGNTGHCDNKCKSWEGAKHGACHVRSGKWMCFCYFNC	50	Sequence 94 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13843	ELCERASKTWSGNCGNTKHCDTQCRNWESAKHGACHVRSGKWKCFCYFNC	50	Sequence 95 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13844	KLCEKASKTWTGNCGNTKHCDTQCKSWEGAKHGACHKRNGKWMCFCYFNC	50	Sequence 96 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13845	NLCEKASKTWTGNCGNTGHCDNKCKSWEGAKHGACHIRSGKWKCFCYFNC	50	Sequence 97 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13846	NLCEKASLTWSGNCGNTKHCDTQCKSWESAAHGACHKRSGKHKCFCYFNC	50	Sequence 98 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13847	NLCERASKTWSGNCGNTKHCDTQCRSWEGAAHGACHKRSGKHMCFCYFNC	50	Sequence 99 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13848	ELCEKASKTWSGNCGNTKHCDTKCKSWESAKHGACHKRSGNWKCFCYFNC	50	Sequence 100 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13849	ELCEKASKTWTGNCGNTKHCDTQCKSWEGAAHGACHKRNGKWMCFCYFNC	50	Sequence 101 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13850	NLCERASLTWTGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 102 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13851	ELCERASKTWTGNCGNTKHCDTQCKSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 103 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13852	ELCEKASLTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWMCFCYFNC	50	Sequence 104 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13853	NLCERASLTWTGNCGNTGHCDTQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 105 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13854	NLCEKASKTWSGNCGNTKHCDTQCRNWESAAHGACHKRNGKWKCFCYFNC	50	Sequence 106 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13855	NLCERASKTWSGNCGNTKHCDNKCKNWESAAHGACHVRNGKHMCFCYFNC	50	Sequence 107 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13856	NLCERASKTWSGNCGNTKHCDDQCRSWEGAKHGACHKRSGKWMCFCYFNC	50	Sequence 108 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13857	NLCEKASKTWTGNCGNTKHCDTQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 109 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13858	NLCEKASKTWSGNCGNTKHCDTQCRNWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 110 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13859	NLCEKASKTWSGNCGNTGHCDTQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 111 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13860	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 112 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13861	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 113 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13862	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 114 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13863	NLCERASKTWSGNCGNTKHCDTKCRSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 115 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13864	NLCEKASKTWTGNCGNTKHCDTQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 116 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13865	NLCERASKTWSGNCGNTKHCDTQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 117 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13866	NLCERASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRSGKHKCFCYFNC	50	Sequence 118 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13867	NLCERASKTWTGNCGNTKHCDTQCKSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 119 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13868	NLCEKASKTWTGNCGNTKHCDTQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 120 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13869	NLCERASKTWTGNCGNTKHCDTQCRSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 121 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13870	NLCERASKTWTGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 122 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13871	NLCERASKTWSGNCGNTKHCDTQCKSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 123 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13872	NLCERASKTWSGNCGNTKHCDTQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 124 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13873	NLCERASKTWTGNCGNTKHCDTQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 125 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13874	NLCERASKTWTGNCGNTKHCDTQCKNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 126 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13875	NLCERASKTWSGNCGNTGHCDTQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 127 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13876	NLCERASKTWTGNCGNTKHCDTQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 128 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13877	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 129 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13878	NLCEKASKTWSGNCGNTKHCDTKCRNWEGAKHGACHVRNGKWMCFCYFNC	50	Sequence 130 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13879	NLCERASKTWSGNCGNTKHCDNQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 131 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13880	NLCERASKTWSGNCGNTGHCDTQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 132 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13881	NLCEKASKTWTGNCGNTKHCDTQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 134 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13882	NLCERASKTWTGNCGNTKHCDTQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 135 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13883	NLCERASKTWSGNCGNTKHCDNQCRSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 136 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13884	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 137 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13885	NLCERASKTWSGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHMCFCYFNC	50	Sequence 138 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13886	NLCEKASKTWTGNCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 139 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13887	NLCEKASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 140 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13888	NLCERASKTWSGNCGNTGHCDTQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 141 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13889	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 142 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13890	NLCEKASKTWSGNCGNTGHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 143 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13891	NLCERASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 144 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13892	NLCERASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 145 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13893	NLCEKASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 146 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13894	NLCERASKTWSGNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 147 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13895	NLCERASKTWTGNCGNTKHCDNQCRSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 148 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13896	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 149 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13897	NLCERASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 150 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13898	NLCERASKTWSGNCGNTKHCDTQCRNWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 151 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13899	NLCEKASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 152 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13900	NLCERASKTWSGNCGNTKHCDTQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 153 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13901	NLCEKASKTWTGNCGNTKHCDTQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 154 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13902	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 155 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13903	NLCERASKTWTGNCGNTKHCDNQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 157 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13904	NLCERASKTWSGNCGNTKHCDTQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 158 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13905	NLCERASKTWSGNCGNTKHCDNQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 159 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13906	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 160 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13907	NLCEKASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 161 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13908	NLCEKASKTWTGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 162 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13909	NLCERASKTWTGNCGNTKHCDTQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 163 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13910	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 164 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13911	NLCERASKTWSGNCGNTKNCDNQCRNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 165 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13912	NLCERASKTWTGNCGNTKHCDNQCKSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 166 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13913	NLCERASKTWTGNCGNTKHCDTQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 169 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13914	NLCEKASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 170 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13915	NLCERASKTWTGNCGNTKHCDNQCRNWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 171 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13916	NLCERASKTWTGNCGNTKHCDNQCKNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 172 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13917	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 173 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13918	NLCERASKTWTGNCGNTKHCDTQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 174 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13919	NLCEKASKTWTGNCGNTKHCDNQCRNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 175 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13920	NLCERASKTWSGNCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 176 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13921	NLCERASKTWSGNCGNTKHCDTQCKNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 177 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13922	NLCERASKTWTGNCGNTKHCDTQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 178 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13923	NLCERASKTWSGNCGNTKHCDNQCRNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 179 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13924	NLCERASKTWSGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 181 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13925	NLCERASKTWTGNCGNTKHCDTQCRSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 182 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13926	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 183 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13927	NLCEKASKTWSGNCGNTKHCDNQCRNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 184 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13928	NLCERASKTWTGNCGNTKHCDNQCRSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 185 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13929	NLCEKASKTWTGNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 186 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13930	NLCEKASKTWSGNCGNTKHCDNQCKNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 187 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13931	NLCERASKTWTGNCGNTKHCDTQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 188 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13932	NLCEKASKTWSGNCGNTKHCDTQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 189 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13933	NLCERASKTWTGNCGNTKHCDNQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 190 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13934	NLCERASKTWTGNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 191 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13935	NLCERASKTWSGNCGNTKHCDTQCKNWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 193 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13936	NLCERASKTWTGNCGNTKHCDNQCRNWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 195 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13937	NLCERASKTWSGNCGNTKHCDNQCKNWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 196 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13938	NLCERASKTWSGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 197 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13939	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 198 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13940	NLCEKASKTWSGNCGNTKHCDNQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 199 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13941	NLCEKASKTWTGNCGNTKHCDTQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 200 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13942	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 201 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13943	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 202 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13944	NLCERASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 204 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13945	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 205 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13946	NLCERASKTWSGNCGNTKHCDTQCKNWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 206 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13947	NLCERASKTWSGNCGNTKHCDTQCRSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 207 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13948	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 208 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13949	NLCERASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 209 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13950	NLCERASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 210 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13951	NLCEKASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 212 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13952	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 213 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13953	NLCERASKTWSGNCGNTKHCDTQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 214 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13954	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 215 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13955	NLCEKASKTWTGNCGNTKHCDTQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 216 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13956	NLCERASKTWSGNCGNTKHCDNQCRNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 217 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13957	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 218 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13958	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 219 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13959	NLCEKASKTWTGNCGNTKHCDNQCRNWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 220 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13960	NLCERASKTWSGNCGNTKHCDTQCRSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 221 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13961	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 222 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13962	NLCERASKTWSGNCGNTKHCDTQCRSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 223 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13963	NLCEKASKTWTGNCGNTKHCDTQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 224 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP16575	LEANISQSLEQAQIQQEKNMYELQKLNSW	29	Sequence 217 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16576	LEANISQSLEQAQIQQEKNMYELQKLNS	28	Sequence 218 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16577	LEANISQSLEQAQIQQEKNMYELQKLN	27	Sequence 219 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16578	LEANISQSLEQAQIQQEKNMYELQKL	26	Sequence 220 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16579	LEANISQSLEQAQIQQEKNMYELQK	25	Sequence 221 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16580	LEANISQSLEQAQIQQEKNMYELQ	24	Sequence 222 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16581	LEANISQSLEQAQIQQEKNMYEL	23	Sequence 223 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16582	LEANISQSLEQAQIQQEKNMYE	22	Sequence 224 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16583	LEANISQSLEQAQIQQEKNMY	21	Sequence 225 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16584	LEANISQSLEQAQIQQEKNM	20	Sequence 226 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16585	LEANISQSLEQAQIQQEKN	19	Sequence 227 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16586	LEANISQSLEQAQIQQEK	18	Sequence 228 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16587	LEANISQSLEQAQIQQE	17	Sequence 229 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16588	LEANISQSLEQAQIQQ	16	Sequence 230 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16589	LEANISQSLEQAQIQ	15	Sequence 231 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16590	LEANISQSLEQAQI	14	Sequence 232 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16591	LEANISQSLEQAQ	13	Sequence 233 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16592	LEANISQSLEQA	12	Sequence 234 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16593	LEANISQSLEQ	11	Sequence 235 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16594	LEANISQSLE	10	Sequence 236 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16595	LEANISQSL	9	Sequence 237 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16596	LEANISQS	8	Sequence 238 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16597	LEANISQ	7	Sequence 239 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16598	LEANIS	6	Sequence 240 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16599	EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	35	Sequence 241 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16600	ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	34	Sequence 242 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16601	NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	33	Sequence 243 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16602	ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	32	Sequence 244 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16603	SQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	31	Sequence 245 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16604	QSLEQAQIQQEKNMYELQKLNSWDVFTNWL	30	Sequence 246 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16605	SLEQAQIQQEKNMYELQKLNSWDVFTNWL	29	Sequence 247 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16606	LEQAQIQQEKNMYELQKLNSWDVFTNWL	28	Sequence 248 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16607	EQAQIQQEKNMYELQKLNSWDVFTNWL	27	Sequence 249 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16608	QAQIQQEKNMYELQKLNSWDVFTNWL	26	Sequence 250 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16609	AQIQQEKNMYELQKLNSWDVFTNWL	25	Sequence 251 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16610	QIQQEKNMYELQKLNSWDVFTNWL	24	Sequence 252 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16611	IQQEKNMYELQKLNSWDVFTNWL	23	Sequence 253 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16612	QQEKNMYELQKLNSWDVFTNWL	22	Sequence 254 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16613	QEKNMYELQKLNSWDVFTNWL	21	Sequence 255 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16614	EKNMYELQKLNSWDVFTNWL	20	Sequence 256 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16615	KNMYELQKLNSWDVFTNWL	19	Sequence 257 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16616	NMYELQKLNSWDVFTNWL	18	Sequence 258 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16617	MYELQKLNSWDVFTNWL	17	Sequence 259 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16618	YELQKLNSWDVFTNWL	16	Sequence 260 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16619	ELQKLNSWDVFTNWL	15	Sequence 261 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16620	LQKLNSWDVFTNWL	14	Sequence 262 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16621	QKLNSWDVFTNWL	13	Sequence 263 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16622	KLNSWDVFTNWL	12	Sequence 264 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16623	LNSWDVFTNWL	11	Sequence 265 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16624	NSWDVFTNWL	10	Sequence 266 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16625	SWDVFTNWL	9	Sequence 267 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16626	WDVFTNWL	8	Sequence 268 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16627	DVFTNWL	7	Sequence 269 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16628	VFTNWL	6	Sequence 270 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16629	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQS	47	Sequence 271 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16630	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQ	46	Sequence 272 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16631	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLM	45	Sequence 273 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16632	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLL	44	Sequence 274 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16633	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL	43	Sequence 275 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16634	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQ	42	Sequence 276 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16635	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEL	41	Sequence 277 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16636	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE	40	Sequence 278 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16637	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVT	39	Sequence 279 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16638	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV	38	Sequence 280 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16639	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA	37	Sequence 281 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16640	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN	36	Sequence 282 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16641	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYK	35	Sequence 283 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16642	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKY	34	Sequence 284 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16643	YTSVITIELSNIKENKCNGTDAKVKLIKQELDK	33	Sequence 285 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16644	YTSVITIELSNIKENKCNGTDAKVKLIKQELD	32	Sequence 286 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16645	YTSVITIELSNIKENKCNGTDAKVKLIKQEL	31	Sequence 287 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16646	YTSVITIELSNIKENKCNGTDAKVKLIKQE	30	Sequence 288 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16647	YTSVITIELSNIKENKCNGTDAKVKLIKQ	29	Sequence 289 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16648	YTSVITIELSNIKENKCNGTDAKVKLIK	28	Sequence 290 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16649	YTSVITIELSNIKENKCNGTDAKVKLI	27	Sequence 291 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16650	YTSVITIELSNIKENKCNGTDAKVKL	26	Sequence 292 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16651	YTSVITIELSNIKENKCNGTDAKVK	25	Sequence 293 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16652	YTSVITIELSNIKENKCNGTDAKV	24	Sequence 294 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16653	YTSVITIELSNIKENKCNGTDAK	23	Sequence 295 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16654	YTSVITIELSNIKENKCNGTDA	22	Sequence 296 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16655	YTSVITIELSNIKENKCNGTD	21	Sequence 297 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16656	YTSVITIELSNIKENKCNGT	20	Sequence 298 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16657	YTSVITIELSNIKENKCNG	19	Sequence 299 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16658	YTSVITIELSNIKENKCN	18	Sequence 300 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16659	YTSVITIELSNIKENKC	17	Sequence 301 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16660	YTSVITIELSNIKENK	16	Sequence 302 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16661	YTSVITIELSNIKEN	15	Sequence 303 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16662	YTSVITIELSNIKE	14	Sequence 304 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16663	YTSVITIELSNIK	13	Sequence 305 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16664	YTSVITIELSNI	12	Sequence 306 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16665	YTSVITIELSN	11	Sequence 307 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16666	YTSVITIELS	10	Sequence 308 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16667	YTSVITIEL	9	Sequence 309 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16668	YTSVITIE	8	Sequence 310 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16669	YTSVITI	7	Sequence 311 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16670	YTSVIT	6	Sequence 312 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16671	TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	47	Sequence 313 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16672	SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	46	Sequence 314 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16673	VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	45	Sequence 315 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16674	ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	44	Sequence 316 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16675	TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	43	Sequence 317 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16676	ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	41	Sequence 319 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16677	LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	40	Sequence 320 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16678	SNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	39	Sequence 321 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16679	NIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	38	Sequence 322 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16680	IKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	37	Sequence 323 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16681	KENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	36	Sequence 324 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16682	NKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	34	Sequence 325 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16683	KCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	33	Sequence 326 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16684	CNGTDAKVKLIKQELDKYKNAVTELQLLMQST	32	Sequence 327 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16685	NGTDAKVKLIKQELDKYKNAVTELQLLMQST	31	Sequence 328 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16686	GTDAKVKLIKQELDKYKNAVTELQLLMQST	30	Sequence 329 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16687	TDAKVKLIKQELDKYKNAVTELQLLMQST	29	Sequence 330 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16688	DAKVKLIKQELDKYKNAVTELQLLMQST	28	Sequence 331 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16689	AKVKLIKQELDKYKNAVTELQLLMQST	27	Sequence 332 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16690	KVKLIKQELDKYKNAVTELQLLMQST	26	Sequence 333 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16691	VKLIKQELDKYKNAVTELQLLMQST	25	Sequence 334 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16692	KLIKQELDKYKNAVTELQLLMQST	24	Sequence 335 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16693	LIKQELDKYKNAVTELQLLMQST	23	Sequence 336 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16694	IKQELDKYKNAVTELQLLMQST	22	Sequence 337 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16695	KQELDKYKNAVTELQLLMQST	21	Sequence 338 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16696	QELDKYKNAVTELQLLMQST	20	Sequence 339 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16697	ELDKYKNAVTELQLLMQST	19	Sequence 340 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16698	LDKYKNAVTELQLLMQST	18	Sequence 341 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16699	DKYKNAVTELQLLMQST	17	Sequence 342 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16700	KYKNAVTELQLLMQST	16	Sequence 343 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16701	YKNAVTELQLLMQST	15	Sequence 344 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16702	KNAVTELQLLMQST	14	Sequence 345 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16703	NAVTELQLLMQST	13	Sequence 346 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16704	AVTELQLLMQST	12	Sequence 347 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16705	VTELQLLMQST	11	Sequence 348 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16706	TELQLLMQST	10	Sequence 349 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16707	ELQLLMQST	9	Sequence 350 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16708	LQLLMQST	8	Sequence 351 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16709	QLLMQST	7	Sequence 352 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16710	LLMQST	6	Sequence 353 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16711	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL	36	Sequence 355 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16712	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD	34	Sequence 357 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16713	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKS	33	Sequence 358 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16714	FYDPLVFPSDEFDASISQVNEKINQSLAFIRK	32	Sequence 359 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16715	FYDPLVFPSDEFDASISQVNEKINQSLAFIR	31	Sequence 360 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16716	FYDPLVFPSDEFDASISQVNEKINQSLAFI	30	Sequence 361 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16717	FYDPLVFPSDEFDASISQVNEKINQSLAF	29	Sequence 362 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16718	FYDPLVFPSDEFDASISQVNEKINQSLA	28	Sequence 363 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16719	FYDPLVFPSDEFDASISQVNEKINQSL	27	Sequence 364 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16720	FYDPLVFPSDEFDASISQVNEKINQS	26	Sequence 365 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16721	FYDPLVFPSDEFDASISQVNEKINQ	25	Sequence 366 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16722	FYDPLVFPSDEFDASISQVNEKIN	24	Sequence 367 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16723	FYDPLVFPSDEFDASISQVNEKI	23	Sequence 368 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16724	FYDPLVFPSDEFDASISQVNEK	22	Sequence 369 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16725	FYDPLVFPSDEFDASISQVNE	21	Sequence 370 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16726	FYDPLVFPSDEFDASISQVN	20	Sequence 371 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16727	FYDPLVFPSDEFDASISQV	19	Sequence 372 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16728	FYDPLVFPSDEFDASISQ	18	Sequence 373 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16729	FYDPLVFPSDEFDASIS	17	Sequence 374 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16730	FYDPLVFPSDEFDASI	16	Sequence 375 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16731	FYDPLVFPSDEFDAS	15	Sequence 376 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16732	FYDPLVFPSDEFDA	14	Sequence 377 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16733	FYDPLVFPSDEFD	13	Sequence 378 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16734	FYDPLVFPSDEF	12	Sequence 379 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16735	FYDPLVFPSDE	11	Sequence 380 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16736	FYDPLVFPSD	10	Sequence 381 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16737	FYDPLVFPS	9	Sequence 382 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16738	FYDPLVFP	8	Sequence 383 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16739	FYDPLVF	7	Sequence 384 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16740	FYDPLV	6	Sequence 385 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16741	YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	36	Sequence 386 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16742	PLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	34	Sequence 388 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16743	LVFPSDEFDASISQVNEKINQSLAFIRKSDELL	33	Sequence 389 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16744	VFPSDEFDASISQVNEKINQSLAFIRKSDELL	32	Sequence 390 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16745	FPSDEFDASISQVNEKINQSLAFIRKSDELL	31	Sequence 391 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16746	PSDEFDASISQVNEKINQSLAFIRKSDELL	30	Sequence 392 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16747	SDEFDASISQVNEKINQSLAFIRKSDELL	29	Sequence 393 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16748	EFDASISQVNEKINQSLAFIRKSDELL	27	Sequence 395 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16749	FDASISQVNEKINQSLAFIRKSDELL	26	Sequence 396 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16750	DASISQVNEKINQSLAFIRKSDELL	25	Sequence 397 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16751	ASISQVNEKINQSLAFIRKSDELL	24	Sequence 398 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16752	SISQVNEKINQSLAFIRKSDELL	23	Sequence 399 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16753	ISQVNEKINQSLAFIRKSDELL	22	Sequence 400 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16754	SQVNEKINQSLAFIRKSDELL	21	Sequence 401 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16755	QVNEKINQSLAFIRKSDELL	20	Sequence 402 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16756	VNEKINQSLAFIRKSDELL	19	Sequence 403 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16757	NEKINQSLAFIRKSDELL	18	Sequence 404 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16758	EKINQSLAFIRKSDELL	17	Sequence 405 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16759	KINQSLAFIRKSDELL	16	Sequence 406 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16760	INQSLAFIRKSDELL	15	Sequence 407 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16761	NQSLAFIRKSDELL	14	Sequence 408 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16762	QSLAFIRKSDELL	13	Sequence 409 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16763	SLAFIRKSDELL	12	Sequence 410 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16764	LAFIRKSDELL	11	Sequence 411 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16765	AFIRKSDELL	10	Sequence 412 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16766	FIRKSDELL	9	Sequence 413 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16767	IRKSDELL	8	Sequence 414 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16768	RKSDELL	7	Sequence 415 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16769	KSDELL	6	Sequence 416 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16770	ITLNNSVALDPIDISIELNKAKSDLEESKEWIRR	34	Sequence 418 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16771	ITLNNSVALDPIDISIELNKAKSDLEESKEWIR	33	Sequence 419 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16772	ITLNNSVALDPIDISIELNKAKSDLEESKEWI	32	Sequence 420 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16773	ITLNNSVALDPIDISIELNKAKSDLEESKEW	31	Sequence 421 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16774	ITLNNSVALDPIDISIELNKAKSDLEESKE	30	Sequence 422 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16775	ITLNNSVALDPIDISIELNKAKSDLEESK	29	Sequence 423 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16776	ITLNNSVALDPIDISIELNKAKSDLEES	28	Sequence 424 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16777	ITLNNSVALDPIDISIELNKAKSDLEE	27	Sequence 425 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16778	ITLNNSVALDPIDISIELNKAKSDLE	26	Sequence 426 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16779	ITLNNSVALDPIDISIELNKAKSDL	25	Sequence 427 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16780	ITLNNSVALDPIDISIELNKAKSD	24	Sequence 428 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16781	ITLNNSVALDPIDISIELNKAKS	23	Sequence 429 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16782	ITLNNSVALDPIDISIELNKAK	22	Sequence 430 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16783	ITLNNSVALDPIDISIELNKA	21	Sequence 431 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16784	ITLNNSVALDPIDISIELNK	20	Sequence 432 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16785	ITLNNSVALDPIDISIELN	19	Sequence 433 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16786	ITLNNSVALDPIDISIEL	18	Sequence 434 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16787	ITLNNSVALDPIDISIE	17	Sequence 435 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16788	ITLNNSVALDPIDISI	16	Sequence 436 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16789	ITLNNSVALDPIDIS	15	Sequence 437 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16790	ITLNNSVALDPIDI	14	Sequence 438 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16791	ITLNNSVALDPID	13	Sequence 439 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16792	ITLNNSVALDPI	12	Sequence 440 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16793	ITLNNSVALDP	11	Sequence 441 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16794	ITLNNSVALD	10	Sequence 442 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16795	ITLNNSVAL	9	Sequence 443 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16796	ITLNNSVA	8	Sequence 444 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16797	ITLNNSV	7	Sequence 445 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16798	ITLNNS	6	Sequence 446 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16799	TLNNSVALDPIDISIELNKAKSDLEESKEWIRRS	34	Sequence 447 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16800	LNNSVALDPIDISIELNKAKSDLEESKEWIRRS	33	Sequence 448 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16801	NNSVALDPIDISIELNKAKSDLEESKEWIRRS	32	Sequence 449 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16802	NSVALDPIDISIELNKAKSDLEESKEWIRRS	31	Sequence 450 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16803	SVALDPIDISIELNKAKSDLEESKEWIRRS	30	Sequence 451 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16804	VALDPIDISIELNKAKSDLEESKEWIRRS	29	Sequence 452 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16805	ALDPIDISIELNKAKSDLEESKEWIRRS	28	Sequence 453 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16806	LDPIDISIELNKAKSDLEESKEWIRRS	27	Sequence 454 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16807	DPIDISIELNKAKSDLEESKEWIRRS	26	Sequence 455 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16808	PIDISIELNKAKSDLEESKEWIRRS	25	Sequence 456 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16809	IDISIELNKAKSDLEESKEWIRRS	24	Sequence 457 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16810	DISIELNKAKSDLEESKEWIRRS	23	Sequence 458 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16811	ISIELNKAKSDLEESKEWIRRS	22	Sequence 459 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16812	SIELNKAKSDLEESKEWIRRS	21	Sequence 460 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16813	IELNKAKSDLEESKEWIRRS	20	Sequence 461 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16814	ELNKAKSDLEESKEWIRRS	19	Sequence 462 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16815	LNKAKSDLEESKEWIRRS	18	Sequence 463 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16816	NKAKSDLEESKEWIRRS	17	Sequence 464 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16817	KAKSDLEESKEWIRRS	16	Sequence 465 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16818	AKSDLEESKEWIRRS	15	Sequence 466 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16819	KSDLEESKEWIRRS	14	Sequence 467 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16820	SDLEESKEWIRRS	13	Sequence 468 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16821	DLEESKEWIRRS	12	Sequence 469 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16822	LEESKEWIRRS	11	Sequence 470 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16823	EESKEWIRRS	10	Sequence 471 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16824	ESKEWIRRS	9	Sequence 472 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16825	SKEWIRRS	8	Sequence 473 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16826	KEWIRRS	7	Sequence 474 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16827	EWIRRS	6	Sequence 475 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16828	ALGVATSAQITAAVALVEAKQARSDIEKLKEAI	33	Sequence 477 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16829	ALGVATSAQITAAVALVEAKQARSDIEKLKEA	32	Sequence 478 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16830	ALGVATSAQITAAVALVEAKQARSDIEKLKE	31	Sequence 479 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16831	ALGVATSAQITAAVALVEAKQARSDIEKLK	30	Sequence 480 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16832	ALGVATSAQITAAVALVEAKQARSDIEKL	29	Sequence 481 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16833	ALGVATSAQITAAVALVEAKQARSDIEK	28	Sequence 482 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16834	ALGVATSAQITAAVALVEAKQARSDIE	27	Sequence 483 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16835	ALGVATSAQITAAVALVEAKQARSDI	26	Sequence 484 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16836	ALGVATSAQITAAVALVEAKQARSD	25	Sequence 485 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16837	ALGVATSAQITAAVALVEAKQARS	24	Sequence 486 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16838	ALGVATSAQITAAVALVEAKQAR	23	Sequence 487 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16839	ALGVATSAQITAAVALVEAKQA	22	Sequence 488 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16840	ALGVATSAQITAAVALVEAKQ	21	Sequence 489 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16841	ALGVATSAQITAAVALVEAK	20	Sequence 490 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16842	ALGVATSAQITAAVALVEA	19	Sequence 491 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16843	ALGVATSAQITAAVALVE	18	Sequence 492 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16844	ALGVATSAQITAAVALV	17	Sequence 493 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16845	ALGVATSAQITAAVAL	16	Sequence 494 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16846	ALGVATSAQITAAVA	15	Sequence 495 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16847	ALGVATSAQITAAV	14	Sequence 496 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16848	ALGVATSAQITAA	13	Sequence 497 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16849	ALGVATSAQITA	12	Sequence 498 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16850	ALGVATSAQIT	11	Sequence 499 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16851	ALGVATSAQI	10	Sequence 500 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16852	ALGVATSAQ	9	Sequence 501 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16853	ALGVATSA	8	Sequence 502 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16854	ALGVATS	7	Sequence 503 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16855	ALGVAT	6	Sequence 504 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16856	LGVATSAQITAAVALVEAKQARSDIEKLKEAIRD	34	Sequence 505 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16857	GVATSAQITAAVALVEAKQARSDIEKLKEAIRD	33	Sequence 506 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16858	VATSAQITAAVALVEAKQARSDIEKLKEAIRD	32	Sequence 507 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16859	ATSAQITAAVALVEAKQARSDIEKLKEAIRD	31	Sequence 508 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16860	TSAQITAAVALVEAKQARSDIEKLKEAIRD	30	Sequence 509 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16861	SAQITAAVALVEAKQARSDIEKLKEAIRD	29	Sequence 510 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16862	AQITAAVALVEAKQARSDIEKLKEAIRD	28	Sequence 511 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16863	QITAAVALVEAKQARSDIEKLKEAIRD	27	Sequence 512 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16864	ITAAVALVEAKQARSDIEKLKEAIRD	26	Sequence 513 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16865	TAAVALVEAKQARSDIEKLKEAIRD	25	Sequence 514 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16866	AAVALVEAKQARSDIEKLKEAIRD	24	Sequence 515 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16867	AVALVEAKQARSDIEKLKEAIRD	23	Sequence 516 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16868	VALVEAKQARSDIEKLKEAIRD	22	Sequence 517 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16869	ALVEAKQARSDIEKLKEAIRD	21	Sequence 518 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16870	LVEAKQARSDIEKLKEAIRD	20	Sequence 519 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16871	VEAKQARSDIEKLKEAIRD	19	Sequence 520 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16872	EAKQARSDIEKLKEAIRD	18	Sequence 521 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16873	AKQARSDIEKLKEAIRD	17	Sequence 522 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16874	KQARSDIEKLKEAIRD	16	Sequence 523 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16875	QARSDIEKLKEAIRD	15	Sequence 524 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16876	ARSDIEKLKEAIRD	14	Sequence 525 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16877	RSDIEKLKEAIRD	13	Sequence 526 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16878	SDIEKLKEAIRD	12	Sequence 527 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16879	DIEKLKEAIRD	11	Sequence 528 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16880	IEKLKEAIRD	10	Sequence 529 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16881	EKLKEAIRD	9	Sequence 530 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16882	KLKEAIRD	8	Sequence 531 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16883	LKEAIRD	7	Sequence 532 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16884	KEAIRD	6	Sequence 533 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16885	YTGLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 534 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16886	YTNLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 535 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16887	YTSIIHSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 536 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16888	YTSLIYSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 537 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16889	YTSLIHRLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 538 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16890	YTSLIHNLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 539 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16891	YTSLIHTLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 540 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16892	YTSLIHSLLEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 541 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16893	SNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 542 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16894	NNLLRAIDAQQHLLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 543 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16895	NNLLRAIQAQQHLLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 544 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16896	NNLLRAIEAQQHMLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 545 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16897	KETWETWWTE	10	Sequence 1 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16898	GALFLGFLGAAGSTMGAWSQPKSKRKV	27	Sequence 2 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16899	GFLGAA	6	Sequence 3 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16900	GFLGAAGSTMGAWSQKETWETWWTE	25	Sequence 4 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16901	RGTKALTEVIPLTED	15	Sequence 5 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16902	GALFLGFLGAAKETWETWWTE	21	Sequence 6 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16903	KETWEAWWTE	10	Sequence 7 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16904	KETWEAWWME	10	Sequence 8 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16905	KETWETWWIE	10	Sequence 9 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16906	KETWETWWAE	10	Sequence 10 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16907	REIWEQWWDN	10	Sequence 11 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16908	RETWDQWWTD	10	Sequence 12 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16909	KETWEXWWTX	10	Sequence 13 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16910	KETWEXWWME	10	Sequence 14 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16911	KETWEAWWTD	10	Sequence 15 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16912	KETWEXWWXX	10	Sequence 16 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16913	KETWDTWWTE	10	Sequence 17 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16914	KETWEVWWTE	10	Sequence 18 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16915	RETWETWWAD	10	Sequence 19 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16916	RXXWEQWWDX	10	Sequence 20 from Patent US 7790171	Synthetic construct	Antimicrobial, Antiviral	US 7790171 B1	Granted Patent	2010##9##7	DE60137340D1, EP1311538A2, EP1311538B1, US20110064793, WO2002015661A2, WO2002015661A3, WO2002015661A8	Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase.	The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
DRAMP16917	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	41	Sequence 1 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16918	CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	45	Sequence 2 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16919	GKGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	44	Sequence 3 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16920	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA	41	Sequence 4 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16921	CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA	45	Sequence 5 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16922	IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	41	Sequence 6 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16923	CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	45	Sequence 7 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16924	IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA	41	Sequence 8 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16925	CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA	45	Sequence 9 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16926	IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL	48	Sequence 10 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16927	GGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL	50	Sequence 11 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16928	GCCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL	53	Sequence 12 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16929	CCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL	52	Sequence 13 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16930	IEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL	48	Sequence 14 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16931	CCGGIEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL	52	Sequence 15 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16932	IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	62	Sequence 16 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16933	GKGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	65	Sequence 17 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16934	CCGGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	66	Sequence 18 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16935	IEKKIEEIEKKIEEIEKKIEEIEEKISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	62	Sequence 19 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16936	CCGGIKKKIEAIEKLLQLTVWGIKQLQARIL	31	Sequence 20 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16937	SGGCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	48	Sequence 21 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16938	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWDIKQLQARIL	41	Sequence 22 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16939	RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL	45	Sequence 23 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16940	RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL	52	Sequence 24 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16941	RMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	66	Sequence 25 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16942	CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL	49	Sequence 26 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16943	CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKALAAAIA	49	Sequence 27 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16944	CCGG	4	Sequence 28 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16945	YGGIEKKIEAIEKKIEAIEKKIEAIEKKIEA	31	Sequence 29 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16946	RMKQIEDKIEEILSKQYHIENEIARIKKLIGER	33	Sequence 30 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16947	IKKEIEAIKKEQEAIKKKIEAIEK	24	Sequence 31 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16948	IEKKIEEIEKKIEEIEKKIEEIEK	24	Sequence 32 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16949	IEKKIEA	7	Sequence 33 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16950	IEKKIEE	7	Sequence 34 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16951	RMKQIEDKIEEIESKQKKIENEIARIKKL	29	Sequence 35 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16952	KQKKIENEIAAIKKL	15	Sequence 36 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16953	KIKKIENEIARIKKL	15	Sequence 37 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16954	KIEEIESKQKKIENEIARIKKL	22	Sequence 38 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16955	KIEEIESKIKKIENEIARIKK	21	Sequence 39 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16956	IKKEIEAIKKEQEAIKK	17	Sequence 40 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16957	IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL	34	Sequence 41 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16958	CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL	38	Sequence 42 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16959	IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILGGCC	38	Sequence 43 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16960	LLQLTVWGIKQLQARIL	17	Sequence 44 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16961	IKKKIEAIEK	10	Sequence 45 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16962	IEAQQHLLQLTVWGIKQLQARIL	23	Sequence 48 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16963	AVERYLK	7	Sequence 49 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16964	LLQLTVWGIKQLQARILAVERYLK	24	Sequence 50 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16965	IEAQQHLLQLTVWGIKQLQARILAVERYLK	30	Sequence 51 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16966	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK	43	Sequence 52 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16967	ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK	48	Sequence 53 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16968	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK	48	Sequence 54 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16969	IEKKIEEIEKKIEEIEKKIEEIEEKLLQLTVWGIKQLQARILAVERYLK	49	Sequence 55 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16970	RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARILAVERYLK	52	Sequence 56 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16971	IKKEIEAIKKEQEAIKKEIEAQQHLLQLTVWGIKQLQARIL	41	Sequence 57 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16972	IKKEIEAIKKEQEAIKKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	55	Sequence 58 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16973	IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILAVERYLK	41	Sequence 59 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16974	LLQLTVWGIKALAAAIA	17	Sequence 60 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16975	CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKALAAAIA	38	Sequence 61 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16976	AGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQTRVS	36	Sequence 62 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16977	QSLANATAAQQNVLEATYAMVQHVAKGVRILEARVA	36	Sequence 63 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16978	QTLANATAAQQDALEATYAMVQHVAKGVRILEARVA	36	Sequence 64 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16979	ATHQETIEKVTEALKINNLRLVTLEHQVLVIGLKVE	36	Sequence 65 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16980	NHTFEVENSTLNGMDLIERQIKILYAMILQTHADVQ	36	Sequence 66 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16981	ERVVQNVSYIAQTQDQFTHLFRNINNRLNVLHRRVS	36	Sequence 67 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16982	GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	46	Sequence 68 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16983	GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	46	Sequence 69 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16984	GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA	46	Sequence 70 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16985	GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA	46	Sequence 71 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16986	IKKEIEAIKKEQEAIKKKIEAIEKALQLTVWGIKQLQARIL	41	Sequence 72 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16987	IKKEIEAIKKEQEAIKKKIEAIEKLLALTVWGIKQLQARIL	41	Sequence 73 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16988	IKKEIEAIKKEQEAIKKKIEAIEKLLQATVWGIKQLQARIL	41	Sequence 74 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16989	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTAWGIKQLQARIL	41	Sequence 75 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16990	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVAGIKQLQARIL	41	Sequence 76 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16991	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIAQLQARIL	41	Sequence 77 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16992	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALQARIL	41	Sequence 78 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16993	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLAARIL	41	Sequence 79 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16994	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQAAIL	41	Sequence 80 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16995	IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIA	41	Sequence 81 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16996	GGCC	4	Sequence 82 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16997	IKKKIEAIEKLLQLTVWGIKQLQARILGGCC	31	Sequence 83 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16998	ASQLL	5	Sequence 84 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP16999	LIQLIVWGIKQIQARIL	17	Sequence 85 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17000	IKKKIEAIEKLIQLIVWGIKQIQARIL	27	Sequence 86 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17001	CCGGIKKKIEAIEKLIQLIVWGIKQIQARIL	31	Sequence 87 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17002	IKKKIEAIEKLIQLIVWGIKQIQARILGGCC	31	Sequence 88 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17003	IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL	34	Sequence 89 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17004	CCGGIKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL	38	Sequence 90 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17005	IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARILGGCC	38	Sequence 91 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17006	IKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK	34	Sequence 92 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17007	CCGGLLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI	44	Sequence 93 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17008	LLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI	40	Sequence 94 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17009	CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQ	41	Sequence 95 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17010	CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQIKKEIEAI	47	Sequence 96 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17011	IEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	41	Sequence 97 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17012	CCGGIEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	45	Sequence 98 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17013	IEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	34	Sequence 99 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17014	CCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	38	Sequence 100 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17015	IEKKIEAIEKLLQLTVWGIKQLQARIL	27	Sequence 101 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17016	CCGGIEKKIEAIEKLLQLTVWGIKQLQARIL	31	Sequence 102 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17017	CCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	46	Sequence 103 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17018	GGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL	44	Sequence 104 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17019	CCCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	39	Sequence 105 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17020	GGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL	37	Sequence 106 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17021	IEEKIEEIEE	10	Sequence 107 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17022	IEEKIEEIEELLQLTVWGIKQLQARIL	27	Sequence 108 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17023	CCGGIEEKIEEIEELLQLTVWGIKQLQARIL	31	Sequence 109 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17024	GGGIEEKIEEIEELLQLTVWGIKQLQARIL	30	Sequence 110 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17025	CCCGGIEEKIEEIEELLQLTVWGIKQLQARIL	32	Sequence 111 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17026	IEKKIEAIEKKIEAIEKKIEAIEK	24	Sequence 112 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17027	IEKKIEAIEK	10	Sequence 113 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17028	IEKKIEEIEKKIEEIEK	17	Sequence 114 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17029	IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	34	Sequence 115 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17030	CCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	38	Sequence 116 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17031	IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARILGGCC	38	Sequence 117 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17032	IEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL	34	Sequence 118 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17033	IEKKIEEIEEKIEEIEK	17	Sequence 119 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17034	CCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL	38	Sequence 120 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17035	GGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	44	Sequence 121 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17036	CCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	46	Sequence 122 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17037	GGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL	37	Sequence 123 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17038	CCCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL	39	Sequence 124 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17039	GGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	37	Sequence 125 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17040	CCCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL	39	Sequence 126 from Patent US 7811577	Synthetic construct	Antimicrobial, Antiviral	US 7811577 B2	Granted Patent	2010##10##12	CA2567030A1, EP1755667A2, EP1755667A4, EP2354153A2, EP2354153A3, US20070224212, WO2005118886A2, WO2005118886A3	Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity.	Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and ar
DRAMP17041	RWRQTWSGPGTTKRFPETVLARCVKYTEIH	30	Sequence 1 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17042	NTRKSHIGPGRAFYTTGIIGDIRQAH	26	Sequence 2 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17043	TRPNNNTRKSIIGPGRAFYTTGQIIGDIRQAH	32	Sequence 3 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17044	TRPNNNTRRSIRIGPGQAFYATGDIIGDIRQAH	33	Sequence 4 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17045	TRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAH	33	Sequence 5 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17046	TRPYNRQRTPIGLGQALYTTRYTTRIIGQAY	31	Sequence 6 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17047	TRPSNNTRTSRIGPGRVFYKTGDIIGDIRKAY	32	Sequence 7 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17048	TRPGNNTGGQVQIGPAMTFYNIEKIVGDRQAY	32	Sequence 8 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17049	RPGVQEIIGPMAWYSMGLNNSRAY	24	Sequence 9 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17050	RPGNNTRGQIGPGMTFYNIENIVGDTRA	28	Sequence 10 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17051	KRPGNKTVVPITLMSGLVFHSQPINRPRQAW	31	Sequence 11 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17052	RQTWSGPGTTKRFPETVLARCVKYTEIH	28	Sequence 13 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17053	RWRQTWSGPGTTK	13	Sequence 14 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17054	SGPGTTKRFPETVLARCVKYTEIH	24	Sequence 15 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17055	RWRQQWSGPGTTKRFPETVLARCVKYTEIH	30	Sequence 16 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17056	RQQWSGPGTTKRFPETVLARCVKYTEIH	28	Sequence 17 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17057	GPGTTK	6	Sequence 18 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17058	NTRKSIIGPGRAFYTTGQIIGDIRQAH	27	Sequence 20 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17059	SGPGTTKRFPETVLACVKYTEIH	23	Sequence 21 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17060	KNIYRPDKFLQCVKNPEDSSCTSEI	25	Sequence 22 from Patent US 8080633	Synthetic construct	Antimicrobial, Antiviral	US 8080633 B2	Granted Patent	2011##12##20	US7553926, US8030444, US20040116653, WO2003091275A2, WO2003091275A3	Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides.	Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
DRAMP17061	MRGSHHHHHHAIDVIEGRWQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWFG	58	Sequence 2 from Patent WO 2002103026	Synthetic construct	Antimicrobial, Antiviral	WO 2002103026 A2	Patent Application	2002##12##27	CA2450548A1, CA2450548C, CN1255548C, CN1516738A, EP1402050A2, US6858410, US7348423, US20030104581, WO2002103026A3	Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments.	A process for the production of an antifusogenic peptide of a length of about 10 to 50 amino acids in a prokaryotic host cell, characterized in that, under such conditions that inclusion bodies of said non-fusion antifusogenic peptide or said fusion peptide are formed, a) in said host cell there is expressed a nucleic acid encoding said antifusogenic peptide as a non-fusion peptide or encoding a fusion peptide of a length of about 14 to 70 amino acids consisting of said antifusogenic peptide N-terminally linked to a further peptide of a length of about 4 to 30 amino acids; b) said host cell is cultivated; c) said inclusion bodies are recovered and solubilized; d) in the case of said fusion peptide said antifusogenic peptide is cleaved off from said further peptide; and e) said antifusogenic peptide is isolated.
DRAMP17062	NQNVEPSAGDIV	12	Sequence 1 from Patent US 20020147148	Xenorhabdus Wi	Insecticidal	US 2002/0147148 A1	Patent Application	2002##10##10	CA2263794A1, CN1137137C, CN1229413A, DE69837906D1, DE69837906T2, EP0915909A1, EP0915909B1, US6048838, US6379946, WO1998050427A1	Insecticidal protein toxins from xenorhabdus.	Proteins from the genus Xenorhabdus are toxic to insects upon oral exposure. These protein toxins can be applied to insect larvae food and plants for insect control.
DRAMP17063	SQNVYRYP	8	Sequence 2 from Patent US 20020147148	Xenorhabdus Wi	Insecticidal	US 2002/0147148 A1	Patent Application	2002##10##10	CA2263794A1, CN1137137C, CN1229413A, DE69837906D1, DE69837906T2, EP0915909A1, EP0915909B1, US6048838, US6379946, WO1998050427A1	Insecticidal protein toxins from xenorhabdus.	Proteins from the genus Xenorhabdus are toxic to insects upon oral exposure. These protein toxins can be applied to insect larvae food and plants for insect control.
DRAMP17064	MTKQEYL	7	Sequence 3 from Patent US 20020147148	Xenorhabdus Wi	Insecticidal	US 2002/0147148 A1	Patent Application	2002##10##10	CA2263794A1, CN1137137C, CN1229413A, DE69837906D1, DE69837906T2, EP0915909A1, EP0915909B1, US6048838, US6379946, WO1998050427A1	Insecticidal protein toxins from xenorhabdus.	Proteins from the genus Xenorhabdus are toxic to insects upon oral exposure. These protein toxins can be applied to insect larvae food and plants for insect control.
DRAMP17065	MYSTAVLLNKI	11	Sequence 4 from Patent US 20020147148	Xenorhabdus Wi	Insecticidal	US 2002/0147148 A1	Patent Application	2002##10##10	CA2263794A1, CN1137137C, CN1229413A, DE69837906D1, DE69837906T2, EP0915909A1, EP0915909B1, US6048838, US6379946, WO1998050427A1	Insecticidal protein toxins from xenorhabdus.	Proteins from the genus Xenorhabdus are toxic to insects upon oral exposure. These protein toxins can be applied to insect larvae food and plants for insect control.
DRAMP17066	AGFQLNEYSTXG	12	Sequence 5 from Patent US 20020147148	Xenorhabdus Wi	Insecticidal	US 2002/0147148 A1	Patent Application	2002##10##10	CA2263794A1, CN1137137C, CN1229413A, DE69837906D1, DE69837906T2, EP0915909A1, EP0915909B1, US6048838, US6379946, WO1998050427A1	Insecticidal protein toxins from xenorhabdus.	Proteins from the genus Xenorhabdus are toxic to insects upon oral exposure. These protein toxins can be applied to insect larvae food and plants for insect control.
DRAMP17067	MAPTVMMASSATAVAPFLGLKSTASLPVARRSSRSLGNVSNGGRIRCMQVWPYGNKKFETLSYLPPLSTGGRIRCMQAM	79	Sequence 26 from Patent US 20030115630	Synthetic construct	Insecticidal	US 2003/0115630 A1	Patent Application	2003##6##19	US6501009, US6943281, US7408096, US8101826, US20050273882, US20090019609, US20110277180	Expression of Cry3B insecticidal protein in plants.	The present invention discloses methods and compositions comprising a group of novel expression cassettes which provide significantly improved levels of accumulation of Coleopteran inhibitory Cry3B and Cry3B variant amino acid sequences when these are expressed in plants. The preferred embodiments of the invention provide at least up to ten fold higher levels of insect controlling protein relative to the highest levels obtained using prior compositions. In particular, transgenic maize expressing higher levels of a protein designed to exhibit increased toxicity toward Coleopteran pests deliver superior levels of insect protection and are less likely to sponsor development of populations of target insects that are resistant to the insecticidally active protein.
DRAMP17068	MAPTVMMASSATAVAPFLGLKSTASLPVARRSSRSLGNVSNGGRIRCMQ	49	Sequence 27 from Patent US 20030115630	Synthetic construct	Insecticidal	US 2003/0115630 A1	Patent Application	2003##6##19	US6501009, US6943281, US7408096, US8101826, US20050273882, US20090019609, US20110277180	Expression of Cry3B insecticidal protein in plants.	The present invention discloses methods and compositions comprising a group of novel expression cassettes which provide significantly improved levels of accumulation of Coleopteran inhibitory Cry3B and Cry3B variant amino acid sequences when these are expressed in plants. The preferred embodiments of the invention provide at least up to ten fold higher levels of insect controlling protein relative to the highest levels obtained using prior compositions. In particular, transgenic maize expressing higher levels of a protein designed to exhibit increased toxicity toward Coleopteran pests deliver superior levels of insect protection and are less likely to sponsor development of populations of target insects that are resistant to the insecticidally active protein.
DRAMP17069	VWPYGNKKFETLSYLPPLSTGGRIRCMQAM	30	Sequence 28 from Patent US 20030115630	Synthetic construct	Insecticidal	US 2003/0115630 A1	Patent Application	2003##6##19	US6501009, US6943281, US7408096, US8101826, US20050273882, US20090019609, US20110277180	Expression of Cry3B insecticidal protein in plants.	The present invention discloses methods and compositions comprising a group of novel expression cassettes which provide significantly improved levels of accumulation of Coleopteran inhibitory Cry3B and Cry3B variant amino acid sequences when these are expressed in plants. The preferred embodiments of the invention provide at least up to ten fold higher levels of insect controlling protein relative to the highest levels obtained using prior compositions. In particular, transgenic maize expressing higher levels of a protein designed to exhibit increased toxicity toward Coleopteran pests deliver superior levels of insect protection and are less likely to sponsor development of populations of target insects that are resistant to the insecticidally active protein.
DRAMP17070	FIQGYSDLFGN	11	Sequence 1 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17071	MQDSPEVSITTW	12	Sequence 2 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17072	SESLFTQTLKEARRDALVA	19	Sequence 3 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17073	ASPLSTSELTSKLN	14	Sequence 4 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17074	AGDTANIGD	9	Sequence 5 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17075	LGGAATLLDLLLPQI	15	Sequence 6 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17076	MLSTMEKQLNE	11	Sequence 7 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17077	MNLASPLIS	9	Sequence 8 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17078	MINLDINEQNKIMVVS	16	Sequence 9 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17079	AAKDVKFGSDARVKMLRGVN	20	Sequence 10 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17080	LIGYNNQFSGXA	12	Sequence 13 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17081	MQNSQTFSVGEL	12	Sequence 14 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17082	AQDGNQDTFFSGNT	14	Sequence 15 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17083	MQNSL	5	Sequence 16 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17084	AFNIDDVSLF	10	Sequence 17 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17085	FIVYTSLGVNPNNSSN	16	Sequence 18 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17086	ISDLVTTSPLSEAIGSLQLFI	21	Sequence 19 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17087	MYYIQAQQLLGP	12	Sequence 20 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17088	GIDAVLSMETQNIQEPQLGAGTYVQL	26	Sequence 21 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17089	ISNPININTGIDSAK	15	Sequence 22 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17090	TYLTSFEQVANLK	13	Sequence 23 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17091	VLGTENVIALYSENNGVQYMQI	22	Sequence 24 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17092	RYYNLSDEELSQFIGK	16	Sequence 38 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17093	GTATDVSGPVEINTAISPAK	20	Sequence 39 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17094	ANSLYALFLPQ	11	Sequence 40 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17095	LRSANTLTDLFLPQ	14	Sequence 41 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17096	DDSGDDDKVTNTDIHR	16	Sequence 44 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17097	DVXGSEKANEKLK	13	Sequence 45 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17098	NIGGD	5	Sequence 62 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17099	CLRGNSPTNPDKDGIFAQVA	20	Sequence 63 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17100	CYTPDQTPSFYETAFRSADG	20	Sequence 64 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17101	HGQSYNDNNYCNFTLSINT	19	Sequence 65 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17102	CVDPKTLQRQQAGGDGTGSS	20	Sequence 66 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17103	CYKAPQRQEDGDSNAVTYDK	20	Sequence 67 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17104	CYNENPSSEDKKWYFSSKDD	20	Sequence 68 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17105	CFDSYSQLYEENINAGEQRA	20	Sequence 69 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17106	CNPNNSSNKLMFYPVYQYSGNT	22	Sequence 70 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17107	VSQGSGSAGSGNNNLAFGAG	20	Sequence 71 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17108	MQDSPEVAITTL	12	Sequence 72 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17109	MQRSSEVS	8	Sequence 73 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17110	MQDIPEVQLN	10	Sequence 74 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17111	MQDSPEVSVTQN	12	Sequence 75 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17112	SESLFTQSLKEARRD	15	Sequence 76 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17113	MNLIEAKLQENRDA	14	Sequence 77 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17114	MLSTMEKQLNESQRD	15	Sequence 78 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17115	MLDIMEKQLNESERD	15	Sequence 79 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17116	MQDSREVS	8	Sequence 80 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17117	LRSAXSALTTLL	12	Sequence 81 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17118	LKLADNGYFNEPLNV	15	Sequence 82 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17119	LKLADNSYFNEPLN	14	Sequence 83 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17120	SKDESKADSQLVYHT	15	Sequence 84 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17121	MKKRGLTTNAGAPV	14	Sequence 85 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17122	MLNPIVRKFEYGEHT	15	Sequence 86 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17123	AEIYNKDGNKLDLYG	15	Sequence 87 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17124	NLIEATLEQNLRDA	14	Sequence 88 from Patent US 20030207806	Synthetic construct	Insecticidal	US 2003/0207806 A1	Patent Application	2003##11##6	US7569748	Insecticidal protein toxins from Photorhabdus.	Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens ) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
DRAMP17125	SIAALEAALTRDVHLFTWLKRVDFWTNTIYQDLRFLSANKIGFSYTNSSAMQESGIYGSSGFGSNLTHQIQLNSNVYKTSITDTSSPSNRVT	92	Sequence 7 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17126	FSFEKAESLYTRAPHLFTWLKGFRFVTNSISYWTFLSGGQNKYSYTNNSSINEGSFRGQDTDYGGTSSTINIPSNSYVYNLWTENYEYIYPWGDPVNIT	99	Sequence 8 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17127	YQDL	4	Sequence 33 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17128	NNII	4	Sequence 34 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17129	SYWT	4	Sequence 42 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17130	YPWGD	5	Sequence 43 from Patent US 20050124803	Bacillus thuringiensis	Insecticidal	US 2005/0124803 A1	Patent Application	2005##6##9	US7393922	Insecticidal crystal proteins with enhanced toxicity.	The present invention relates generally to modified Bt insecticidal crystal proteins, also referred to as mutant toxins, with enhanced toxicity against a variety of insect genera, particularly mosquitos. The invention provides modified Bt Cry4Ba and Cry19Aa proteins, or mutant toxins, which have toxicity-enhancing sequence modifications at one or more positions within the amino acid sequence of the protein. The invention also provides polynucleotides encoding modified Cry4Ba and Cry19Aa proteins. The invention also provides insecticidal compositions comprising mutant toxins with a new or broadened insecticidal spectrum, and insecticidal compositions comprising polynucleotides encoding the modified Cry4Ba and Cry19Aa proteins.
DRAMP17134	YKDNSY	6	Sequence 1 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17135	YKDISY	6	Sequence 2 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17136	DNFKSY	6	Sequence 3 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17137	ANKYSY	6	Sequence 4 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17138	YYCDSY	6	Sequence 5 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17139	YHYYSY	6	Sequence 6 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17140	ANYYSY	6	Sequence 7 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17141	YEYQSY	6	Sequence 8 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17142	LIFASY	6	Sequence 9 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17143	YKEFSY	6	Sequence 10 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17144	CAYCSY	6	Sequence 11 from Patent US 20060216778	Synthetic construct	Insecticidal	US 2006/0216778 A1	Patent Application	2006##9##28	US7348403, WO2004052918A2, WO2004052918A3	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides.	This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
DRAMP17145	MASMTGGQQMGRGSTSNGRQCAGIRPYDGRQQHRG	35	Sequence 126 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17146	MTSNGRQCAGIRPYDGRQQHRG	22	Sequence 127 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17147	MYDGRQQHRG	10	Sequence 128 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17148	MTSNGRQCAGIRP	13	Sequence 129 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17149	MCAGIRP	7	Sequence 130 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17150	MKETAAAKFERQHMDSPDLGTLVPRGSMADIGSTTSNGRQCAGIRPYDGRQQHRG	55	Sequence 131 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17151	MASMTGGQQMGRGS	14	Sequence 132 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17152	YDGRQQHRG	9	Sequence 133 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17153	TSNGRQCAGIRP	12	Sequence 134 from Patent US 20100017914	Synthetic construct	Insecticidal	US 2010/0017914 A1	Patent Application	2010##1##21	CA2682227A1, CN101679491A, EP2137211A1, EP2137211A4, US8309516, WO2008121633A1	Insecticidal proteins.	Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
DRAMP17154	EPDEICRARMTHKEFNYKSNVCNGCGDQVAACEAECFRNDVYTACHEAQK	50	Sequence 3 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17155	MKLQLMICLVLLPCFFCEPDEICRARMTHKEFNYKSNVCNGCGDQVAACEAECFRNDVYTACHEAQKG	68	Sequence 4 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17156	MKLQLMICLVLLPCFFC	17	Sequence 6 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17157	EPDEICRARMTNKEFTYKSNVCNNCGDQVAACEAECFRNDVYTACHEAQK	50	Sequence 9 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17158	MKLQLMICLVLLPCFFCEPDEICRARMTNKEFTYKSNVCNNCGDQVAACEAECFRNDVYTACHEAQKG	68	Sequence 10 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17159	MKLQLMICLVLLPCFFCEPDEICRARMTNKEFTYKSNVCNGCGDQVAACEAECFRNDVYTACHEAQKG	68	Sequence 13 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17160	EPDEICRARMTNKEFTYKSNVCNGCGDQVAACEAECFRNDVYTACHEAQK	50	Sequence 14 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17161	EPDEIXRARMTHKEFNYKSNVXNGXGDQVAAXEAEXFRNDVYTAXHEAQKA	51	Sequence 15 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17162	EPDEIXRARMTHKEFNYKSNVXNGXGDQVAAXEAEXFRNDVYTAXHEAQK	50	Sequence 16 from Patent US 5741669	Tegenaria spider venom	Insecticidal	US 5741669 A	Granted Patent	1998##4##21	CA2128250A1, CA2128250C, CN1074936A, EP0625193A1, EP0625193A4, US5441934, WO1993015192A1	Insecticidally effective peptides.	This invention provides a family of insecticidally effective peptides which may be isolated from Tegenaria spider venom, DNA encoding such insecticidally effective peptides and methods for controlling invertebrate pests.
DRAMP17163	AKDGDVEGPAGCKKYDVECDSGECCXKQYLWYKWRPLDCRCLKSGFFSSKCVCRDV	56	Sequence 1 from Patent US 5658563	Diguetia spider venom	Insecticidal	US 5658563 A	Granted Patent	1997##8##19	US5461032, US5658781	Insecticidally effective peptides.	The invention provides insecticidally effective peptides isolatable from Diguetia spider venom, methods for preparing and using insecticides, and DNA encoding such insecticidally effective peptides.
DRAMP17164	AKDGDVKGPAGCMKYKSGDCRGKTCCDQQYLWYKWRNLACRCFTVEVFKKDCWCNDIS	58	Sequence 3 from Patent US 5658563	Diguetia spider venom	Insecticidal	US 5658563 A	Granted Patent	1997##8##19	US5461032, US5658781	Insecticidally effective peptides.	The invention provides insecticidally effective peptides isolatable from Diguetia spider venom, methods for preparing and using insecticides, and DNA encoding such insecticidally effective peptides.
DRAMP17165	AKDGDFEGPPGXLKMGELXKGGTXXTKVYKYWKWRKLECLGKNDGWFKKKFICDERXNPXXX	62	Sequence 5 from Patent US 5658563	Diguetia spider venom	Insecticidal	US 5658563 A	Granted Patent	1997##8##19	US5461032, US5658781	Insecticidally effective peptides.	The invention provides insecticidally effective peptides isolatable from Diguetia spider venom, methods for preparing and using insecticides, and DNA encoding such insecticidally effective peptides.
DRAMP17166	MKVFVVLLCLSLAAVYALEERLDKDADIMLDSPADMER	38	Sequence 7 from Patent US 5658563	Diguetia spider venom	Insecticidal	US 5658563 A	Granted Patent	1997##8##19	US5461032, US5658781	Insecticidally effective peptides.	The invention provides insecticidally effective peptides isolatable from Diguetia spider venom, methods for preparing and using insecticides, and DNA encoding such insecticidally effective peptides.
DRAMP17167	KEXKPDGEQXGITDHNDXXNAXVXPDGPFMR	31	Sequence 1 from Patent US 5674846	Segestria sp. spider veno	Insecticidal	US 5674846 A	Granted Patent	1997##10##7	EP1018875A1, EP1018875A4, WO1998009522A1	Insecticidal peptides from Segestria sp. spider venom.	This invention relates to an insecticidally effective peptide isolated from the spider, Segestria sp., characterized by its paralytic effect on insect pests and low mammalian toxicity. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
DRAMP17168	CISARYPCSNSKDCCSGNCGTFWTCYIRKDPCSKECLAP	39	Sequence 1 from Patent US 5688764	Spider venom	Insecticidal	US 5688764 A	Granted Patent	1997##11##18	CA2213443A1, EP0812129A1, EP0812129A4, WO1996025041A1	Insecticidal peptides from spider venom.	This invention relates to the purification of a family of insecticidally effective peptides isolated from the spider, Calisoga sp., characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for three of these peptides have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
DRAMP17169	CISARYPCSNSKDCCSGNCGTFWTCFIRKDPCSKECLAP	39	Sequence 2 from Patent US 5688764	Spider venom	Insecticidal	US 5688764 A	Granted Patent	1997##11##18	CA2213443A1, EP0812129A1, EP0812129A4, WO1996025041A1	Insecticidal peptides from spider venom.	This invention relates to the purification of a family of insecticidally effective peptides isolated from the spider, Calisoga sp., characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for three of these peptides have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
DRAMP17170	CISARYPCSNSKDCCSGSCGIFWTCYLRKDPCSKECLAP	39	Sequence 3 from Patent US 5688764	Spider venom	Insecticidal	US 5688764 A	Granted Patent	1997##11##18	CA2213443A1, EP0812129A1, EP0812129A4, WO1996025041A1	Insecticidal peptides from spider venom.	This invention relates to the purification of a family of insecticidally effective peptides isolated from the spider, Calisoga sp., characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for three of these peptides have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
DRAMP17171	DGIVGKASSYAAL	13	Sequence 1 from Patent US 5756459	Phidippus spider venom	Insecticidal	US 5756459 A	Granted Patent	1998##5##26	Unknown	Insecticidally effective peptides isolatable from phidippus spider venom.	This invention provides a family of insecticidally effective proteins and particular members of that family which may be isolated from the venom of the spider Phidippus audax, DNA encoding such proteins, insecticidal compositions of these proteins or the DNA encoding them, and methods for controlling invertebrate pests. Recombinant expression vectors and host cells and methods for producing insecticidally effective peptides are also provided.
DRAMP17172	DCSQDCAACSILARPAELNTETCILECEGKLSSNDTEGGLCKEFLHPSKVDLPR	54	Sequence 1 from Patent US 8003754	Synthetic construct	Insecticidal	US 8003754 B2	Granted Patent	2011##8##23	US7119168, US7273850, US7745588, US8338136, US20050181992, US20070020251, US20080045458, US20080081784, US20080081785, US20100305029, US20110288030	Paralytic peptide for use as a insecticide.	The invention relates to a method of killing or immobilizing an insect comprising administering to the insect a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina. The invention further relates to an insecticide composition comprising such a peptide.
DRAMP17173	DCSQDCAACSILARPAELNTETCILECAGKLSSNDTEGGLCKEFLHPSKVDLPR	54	Sequence 2 from Patent US 8003754	Synthetic construct	Insecticidal	US 8003754 B2	Granted Patent	2011##8##23	US7119168, US7273850, US7745588, US8338136, US20050181992, US20070020251, US20080045458, US20080081784, US20080081785, US20100305029, US20110288030	Paralytic peptide for use as a insecticide.	The invention relates to a method of killing or immobilizing an insect comprising administering to the insect a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina. The invention further relates to an insecticide composition comprising such a peptide.
DRAMP17183	IWLTALKFLGKHAAKHLAKQQLSKL	25	Sequence 1 from Patent US 8334366	Lycosa carolinensis	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17184	IWLTALKFLGKHAAKHLAKQQLSPW	25	Sequence 2 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17185	IWLTALKHLGKHAAKHLAKQQLSPW	25	Sequence 3 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17186	IWLTALKFLQKHAAKHLAKQQLSPW	25	Sequence 4 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17187	IWLTALKFSGKHAAKHLAKQQLSPW	25	Sequence 5 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17188	IWLTALKFLQKHAAKHLAKHSLSPW	25	Sequence 6 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17189	DDDKIWLTALKFLGKHAAKHLAKQQLSPW	29	Sequence 7 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17190	HHHHHHDDDKIWLTALKFLGKHAAKHLAKQQLSPW	35	Sequence 14 from Patent US 8334366	Synthetic construct	Insecticidal	US 8334366 B1	Granted Patent	2012##12##18	Unknown	Mutant lycotoxin-1 peptide sequences for insecticidal and cell membrane altering properties.	Lycotoxin-1 peptide mutant peptides which exhibit increased insecticidal activity are produced by substitution of both a proline for the lysine at amino acid position 24 and a tryptophan for the leucine at amino acid position 25 of the wild-type amino acid sequence for lycotoxin-1. Further substitution of amino acids 8, 9 or 10 of the lycotoxin-1 wild-type amino acid sequence, specifically substituting a histidine for the phenylalanine at amino acid position 8, a glutamine for the glycine at amino acid position 10, or a serine for the leucine at amino acid position 9, provides an even greater increase in insecticidal activity. In addition to changes in the lycotoxin-1 amino acid sequence, the addition of an enterokinase K recognition site, DDDK, to the N-terminus of the lycotoxin-1 peptide increases insecticidal activity further still. Isolated nucleic acid sequences encoding the mutant lycotoxin-1 peptides, expression vectors containing these sequences, microorganisms or other host cells transfor
DRAMP17191	IPPQFMXF	8	Sequence 2 from Patent WO 1998033906	Kassina maculata	Insecticidal	WO 1998/033906 A1	Patent Application	1998##8##6	CA2279579A1, EP1015581A1	Insecticidal gene and peptide.	The present invention relates to FMRF amide type peptides and their non-amidated precursors, to recombinant nucleic acids encoding for such peptides, to the use of these nucleic acids, in forms substantially isolated from other nucleic acid or when incorporated into vectors, to transform organisms in order to render them capable of producing these peptides, to the use of such peptides, nucleic acid and vectors as pesticidal agents, eg. insecticidal, acaricidal and helminthecidal agents and to compositions comprising one or more of these. A peptide or salt thereof comprising an amino acid sequence Pro-Pro-(Xaa1)n-Phe-Xaa2-Arg-Xaa3 or a conservatively substituted analogue thereof, wherein the N terminal of said peptide may be free amino or protected amino and the C-terminal of said peptide, which is the C-terminal -Xaa3 of the above sequence, may consist of that residue with a free carboxylic acid group or with an amidated carboxyl of the formula CONR1R2 wherein R1 and R2 are independently selected 
DRAMP17192	MKSAIAFVMVLAGLAVATESAPNNTPDLEARFCPVGKTCATDRECGSCHCNNWKGKCEN	59	Sequence 7 from Patent WO 1999041393	Beauveria bassiana	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17193	FCPVGKTCATDRECGSCHCNNWKGKCEN	28	Sequence 8 from Patent WO 1999041393	Synthetic construct	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17194	MVNRSVAFSAFVLILFVLAISDIASVSG	28	Sequence 9 from Patent WO 1999041393	Dahlia sp.	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17195	MAKFASIIALLFAALVLFAAFEAPTMVEA	29	Sequence 11 from Patent WO 1999041393	Raphanus sativus	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17196	MVNRSVAFSAFVLILFVLAISDIASVSGFCPVGKTCATDRECGSCHCNNWKGKCEN	56	Sequence 30 from Patent WO 1999041393	Synthetic construct	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17197	MAKFASIIALLFAALVLFAAFEAPTMVEAFCPVGKTCATDRECGSCHCNNWKGKCEN	57	Sequence 31 from Patent WO 1999041393	Synthetic construct	Insecticidal	WO 1999/041393 A1	Patent Application	1999##8##19	EP1054987A1	Insecticidal peptides.	Insecticidal peptides comprising the amino acid sequence CX1X2X3RECGSCX4CNX5WKGKCEX6 (SEQ ID NO 1), where X1, X2, X3, X4, X5 and X6 are any amino acid; or a fragment thereof, or a homologue or variant or derivative of any of these are described and claimed together with nucleotide sequences encoding these peptides. They may be applied as insecticidal compounds in the form of compositions, or expressed in host cells in particular plant cells. Transgenic plants which express peptides of the invention are described.
DRAMP17198	GCLGEGEKCADWSGPSCCDGFYCSCRSMPYCRCRNNS	37	Sequence 7 from Patent WO 2001070773	Paracoelotes luctuosus	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17199	ACVGDGQRCASWSGPYCCDGYYCSCRSMPYCRCRNNS	37	Sequence 8 from Patent WO 2001070773	Paracoelotes luctuosus	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17200	ADCLNEGDWCADWSGPSCCGEMWCSCPGFGKCRCKK	36	Sequence 9 from Patent WO 2001070773	Paracoelotes luctuosus	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17201	ACATKNQRCASWAGPYCCDGFYCSCRSYPGCMCRPNS	37	Sequence 10 from Patent WO 2001070773	Paracoelotes luctuosus	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17202	ECIGGGGGCSVFSGPSCCGGTCKCKFVLIFPKGCHCT	37	Sequence 11 from Patent WO 2001070773	Xysticus acerbus	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17203	MYKLTVFLMFIAFVIIAEAGCLGEGEKCADWSGPSCCDGFYCSCRSMPYCRCRNNS	56	Sequence 17 from Patent WO 2001070773	Synthetic construct	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17204	MYKLTVFLMFIAFVIIAEAACVGDGQRCASWSGPYCCDGYYCSCRSMPYCRCRNNS	56	Sequence 18 from Patent WO 2001070773	Synthetic construct	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17205	MYKLTVFLMFIAFVIIAEAADCLNEGDWCADWSGPSCCGEMWCSCPGFGKCRCKK	55	Sequence 19 from Patent WO 2001070773	Synthetic construct	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17206	MYKLTVFLMFIAFVIIAEAACATKNQRCASWAGPYCCDGFYCSCRSYPGCMCRPNS	56	Sequence 20 from Patent WO 2001070773	Synthetic construct	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17207	MYKLTVFLMFIAFVIIAEAECIGGGGGCSVFSGPSCCGGTCKCKFVLIFPKGCHCT	56	Sequence 21 from Patent WO 2001070773	Synthetic construct	Insecticidal	WO 2001/070773 A3	Patent Application	2001##9##27	US20020197689, WO2001070773A2	Insecticidal peptides and methods for using same.	This invention relates to the purification of a group of insecticidally effective toxin peptides isolated from the venoms of the Paracoelotes and Xysticus species of spiders. The toxin peptides are characterized by their neurotoxic effect on insect pest and potential for little, if any, toxicity in mammals. Coding polynucleotide sequences for the toxin peptides are described, as are methods and vectors for production and targeted delivery of recombinant toxin peptides. Methods for the use of the toxin peptides as insecticides are also provided.
DRAMP17208	PIRLSKEKINDLLQRSQGDLTSSQHEIVH	29	Sequence 3 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17209	PIRLSKEKINDLLQRSQGDLTSSQHEIVHFTDVFIAGSGPISCTYARHIIDNTSTTK	57	Sequence 4 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17210	VYMAEIGSQDNPVIGAHHK	19	Sequence 5 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17211	FVNIINGALQPISISPSDTYQPTLAVAAWAPPIDPAEGQLVIMGHNPNQEAGLNLPGSAVT	61	Sequence 6 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17212	RTVGGMATHWTCACPTPHDEERVNNPVDK	29	Sequence 7 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17213	QEFDALLERAKTLLNVHSDQYDDSIRQIVVK	31	Sequence 8 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17214	ETLQQTLDASRGVTTLPLGVERRTDNPIYVTWTGADTVLGDVPKSPRFALVTETRVTK	58	Sequence 9 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17215	LIVSETNPTQVVAALLRNLNTSNDELVVAK	30	Sequence 10 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17216	SFVIACGAVCTPQILWNSNIRPYALGRYLSEQSMTFCQIVLKRGIVDAIATDPRFAAK	58	Sequence 11 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17217	VEAHKKKHPDDVLPIPFHEPEPQVMIPYTSDFPWHVQVHRDAFSYGDVGPK	51	Sequence 12 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17218	ADPRVVVDLRFFGKSDIVEENRVTFGPNPK	30	Sequence 13 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17219	LREWEAGVTDTYGMPQPTFHVKRTNADGDRDQRMMNDMTNVANMLGGYLP	50	Sequence 14 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17220	GSYPQFMAPGLVLHITGTTRIGTDDQTSVADPTSK	35	Sequence 15 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17221	VHNFNNLWVGGNGCIPDATACNPTRTSVAYALK	33	Sequence 16 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17222	GAEAVVNYLGVS	12	Sequence 17 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17223	NSIKFQKDIDKFVNIINGALQP	22	Sequence 18 from Patent US 20020137896	Synthetic construct	Antitumor	US 2002/0137896 A1	Patent Application	2008##1##1	US6291648, US6762296	Antitumor protein and gene encoding same.	An objective of the present invention is to provide an antitumor protein and a gene encoding the same. The specification discloses a protein comprising (a) an amino acid sequence of SEQ ID No.1 or (b) a modified amino acid sequence of SEQ ID No.1 which have antitumor activity wherein one or more amino acids are added and/or inserted into the amino acid sequence of SEQ ID No.1 and/or one or more amino acids in the amino acid sequence of SEQ ID No.1 are substituted and/or deleted.
DRAMP17224	AAVLLPVLLAAP	12	Sequence 1 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17225	SVYDFFVWL	9	Sequence 2 from Patent US 20030077289	Human	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17226	RQIKIWFQNRRMKWKK	16	Sequence 3 from Patent US 20030077289	Drosophila	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17228	YARAAARQARA	11	Sequence 5 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17229	YARAARRAARR	11	Sequence 6 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17230	AAVALLPAVLLALLAP	16	Sequence 7 from Patent US 20030077289	Human	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17231	GALFLGWLGAAGSTMGAWSQPKKKRKV	27	Sequence 8 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17232	PLSSIFSRIGDP	12	Sequence 9 from Patent US 20030077289	Hepatitis B virus	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17233	GWTLNSAGYLLKINLKALAALAKKIL	26	Sequence 10 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17235	DAATATRGRSAASRPTERPRAPARSASRPRRPVE	34	Sequence 12 from Patent US 20030077289	Herpes simplex virus 1	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17236	KETWWETWWTEWSQPKKKRKV	21	Sequence 13 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17237	KKKKKKGGFLGFWRGENGRKTRSAYERMCNILKGK	35	Sequence 14 from Patent US 20030077289	Synthetic construct	Antitumor	US 2003/0077289 A1	Patent Application	2003##4##24	CN1309417C, CN1503628A, WO2002064057A2, WO2002064057A3	Use of cell-penetrating peptides to generate antitumor immunity.	The present invention is directed to methods and compositions for enhancing an immune response in an animal to a disease by administering an immune effector cell comprising a cell penetrating peptide associated with an antigen for the disease. In a specific embodiment, the immune effector cell is a dendritic cell comprising a cell penetrating peptide associated with an antitumor antigen for cancer immunotherapy.
DRAMP17238	ELKCYTCKEPMTSASCRTIT	20	Sequence 1 from Patent US 20050239703	Synthetic construct	Anticancer	US 2005/0239703 A1	Patent Application	2005##10##27	US7326679, WO2005042001A1	Anticancer peptide compositions.	The invention provides compositions and methods for inhibiting angiogenesis associated with tumors and reducing tumor growth.
DRAMP17239	ELKCYTCKEPMTSAACRTIT	20	Sequence 3 from Patent US 20050239703	Synthetic construct	Anticancer	US 2005/0239703 A1	Patent Application	2005##10##27	US7326679, WO2005042001A1	Anticancer peptide compositions.	The invention provides compositions and methods for inhibiting angiogenesis associated with tumors and reducing tumor growth.
DRAMP17240	YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLE	32	Sequence 1 from Patent US 20060100147	Synthetic construct	Anticancer	US 2006/0100147 A1	Patent Application	2006##5##11	US20090203594	Anticancer peptide.	A polypeptide and methods of using the polypeptide for treating malignancy by administering to a subject a composition of the polypeptide. Pharmaceutical compositions of the polypeptide.
DRAMP17241	EXAGIGILX	9	Sequence 1 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17242	EVDPIGHVY	9	Sequence 2 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17243	VPLDCVLYR	9	Sequence 3 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17244	TPRLPSSADVEF	12	Sequence 4 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17245	MPFATPMEA	9	Sequence 5 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17246	TAEEAAGIGILTV	13	Sequence 6 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17247	EAAGIGILTVIL	12	Sequence 7 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17248	EAAGIGILTV	10	Sequence 8 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17249	EAAGIGILTY	10	Sequence 9 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17250	EAAGIGILY	9	Sequence 10 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17251	EPAGIGILTY	10	Sequence 11 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17252	EPAGIGILTV	10	Sequence 12 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17253	VPLDCVLYRY	10	Sequence 13 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17254	TPRLPSSADVEFCL	14	Sequence 14 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17255	LAMPFATPMEAEL	13	Sequence 15 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17256	LAMPFATPMEAE	12	Sequence 16 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17257	MPFATPMEAEL	11	Sequence 17 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17258	MPFATPMEAE	10	Sequence 18 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17259	EVDPIGHLY	9	Sequence 19 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17260	PLDCVLYRY	9	Sequence 20 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17261	TTAEEAAGIGIL	12	Sequence 21 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17262	AAGIGILTV	9	Sequence 22 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17263	EAAGIGILT	9	Sequence 23 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17264	QVPLDCVLYR	10	Sequence 24 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17265	TPRLPSSADVEFC	13	Sequence 25 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17266	TPRLPSSADVE	11	Sequence 26 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17267	PRLPSSADVEFCL	13	Sequence 27 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17268	TPRLPSSADV	10	Sequence 28 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17269	LPSSADVEF	9	Sequence 29 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17270	LPSSADVEFC	10	Sequence 30 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17271	LAMPFATPM	9	Sequence 31 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17272	FATPMEAEL	9	Sequence 32 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17273	EPAGIGILY	9	Sequence 33 from Patent US 20060122119	Synthetic construct	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17274	ILDTAGQEEY	10	Sequence 34 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17275	ILDTAGREEY	10	Sequence 35 from Patent US 20060122119	Homo sapiens	Antitumor	US 2006/0122119 A1	Patent Application	2006##6##8	CA2477762A1, EP1481009A2, WO2003074565A2, WO2003074565A3	Peptides for use in antitumor immunotherapy.	The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects.
DRAMP17276	VRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG	66	Sequence 1 from Patent US 20060252676	Scorpion	Antitumor	US 2006/0252676 A1	Patent Application	2006##11##9	CN1325514C, CN1341662A, DE60233064D1, EP1443053A1, EP1443053A4, EP1443053B1, US7592309, WO2003037922A1	Analgesic antitumor peptide from scorpion and method of producing it.	The present invention relates to a peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof having analgesic and antitumor activity, and preparation method and use thereof. The peptide having analgesic and antitumor activity is obtained by extraction, isolation and purification from the scorpion or scorpion venom. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof can be obtained by chemical synthesis method or bioengineering method. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof is used as the analgesic and antitumor drugs.
DRAMP17277	MGSSHHHHHHSSGLVPGSHMVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG	86	Sequence 3 from Patent US 20060252676	Scorpion	Antitumor	US 2006/0252676 A1	Patent Application	2006##11##9	CN1325514C, CN1341662A, DE60233064D1, EP1443053A1, EP1443053A4, EP1443053B1, US7592309, WO2003037922A1	Analgesic antitumor peptide from scorpion and method of producing it.	The present invention relates to a peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof having analgesic and antitumor activity, and preparation method and use thereof. The peptide having analgesic and antitumor activity is obtained by extraction, isolation and purification from the scorpion or scorpion venom. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof can be obtained by chemical synthesis method or bioengineering method. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof is used as the analgesic and antitumor drugs.
DRAMP17278	MVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGGLEHHHHHH	75	Sequence 4 from Patent US 20060252676	Scorpion	Antitumor	US 2006/0252676 A1	Patent Application	2006##11##9	CN1325514C, CN1341662A, DE60233064D1, EP1443053A1, EP1443053A4, EP1443053B1, US7592309, WO2003037922A1	Analgesic antitumor peptide from scorpion and method of producing it.	The present invention relates to a peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof having analgesic and antitumor activity, and preparation method and use thereof. The peptide having analgesic and antitumor activity is obtained by extraction, isolation and purification from the scorpion or scorpion venom. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof can be obtained by chemical synthesis method or bioengineering method. The peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof is used as the analgesic and antitumor drugs.
DRAMP17279	GLPPDVQRV	9	Sequence 1 from Patent US 20070264275	Homo sapiens	Antitumor	US 2007/0264275 A1	Patent Application	2007##11##15	CA2529943A1, EP1635862A1, US7629439, WO2005000342A1	Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy.	The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.
DRAMP17280	LGLPPDVQRV	10	Sequence 2 from Patent US 20070264275	Homo sapiens	Antitumor	US 2007/0264275 A1	Patent Application	2007##11##15	CA2529943A1, EP1635862A1, US7629439, WO2005000342A1	Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy.	The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.
DRAMP17281	LPPDVQRV	8	Sequence 3 from Patent US 20070264275	Homo sapiens	Antitumor	US 2007/0264275 A1	Patent Application	2007##11##15	CA2529943A1, EP1635862A1, US7629439, WO2005000342A1	Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy.	The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.
DRAMP17282	GLPPDVQR	8	Sequence 4 from Patent US 20070264275	Homo sapiens	Antitumor	US 2007/0264275 A1	Patent Application	2007##11##15	CA2529943A1, EP1635862A1, US7629439, WO2005000342A1	Peptides Derived from the Protein Mmp-2, and the Use Thereof in Antitumoral Immunotherapy.	The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.
DRAMP17283	CREKA	5	Sequence 1 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17284	CPGPEGAGC	9	Sequence 2 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17285	GRKKRRQRRRPPQ	13	Sequence 4 from Patent US 20100279918	Human immunodeficiency vi	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17286	DAATATRGRSAASRPTERPRAPARSASRPRRVD	33	Sequence 5 from Patent US 20100279918	Herpes simplex virus type	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17287	LLIILRRRIRKQAHAHSK	18	Sequence 6 from Patent US 20100279918	Murinae gen. sp.	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17288	RVIRVWFQNKRCKDKK	16	Sequence 7 from Patent US 20100279918	Rattus sp.	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17289	LGTYTQDFNKFHTFPQTAIGVGAP	24	Sequence 8 from Patent US 20100279918	Homo sapiens	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17291	MANLGYWLLALFVTMWTDVGLCKKRPKP	28	Sequence 10 from Patent US 20100279918	Mus sp.	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17293	AGYLLGKINLKALAALAKKIL	21	Sequence 12 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17295	KETWFETWFTEWSQPKKKRKV	21	Sequence 16 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17296	GALFLGWLGAAGSTMGAPKKKRKV	24	Sequence 17 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17297	WEAKLAKALAKALAKHLAKALAKALKACEA	30	Sequence 18 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP17298	GLFKALLKLLKSLWKLLLKA	20	Sequence 19 from Patent US 20100279918	Synthetic construct	Anticancer	US 2010/0279918 A1	Patent Application	2010##11##4	DE602007011901D1, EP1991586A1, EP1991586B1, WO2007108749A1, WO2007108749A8	Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.	A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
DRAMP08191	RWWKIWVIRWWD	12	Sequence 1769 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08192	RWWKIWVIRWWE	12	Sequence 1770 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08193	RWWKIWVIRWWF	12	Sequence 1771 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08194	RWWKIWVIRWWG	12	Sequence 1772 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08195	RWWKIWVIRWWH	12	Sequence 1773 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08196	RWWKIWVIRWWI	12	Sequence 1774 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08197	RWWKIWVIRWWK	12	Sequence 1775 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08198	RWWKIWVIRWWL	12	Sequence 1776 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08199	RWWKIWVIRWWM	12	Sequence 1777 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08200	RWWKIWVIRWWN	12	Sequence 1778 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08201	RWWKIWVIRWWP	12	Sequence 1779 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08202	RWWKIWVIRWWQ	12	Sequence 1780 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08203	RWWKIWVIRWWS	12	Sequence 1781 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08204	RWWKIWVIRWWT	12	Sequence 1782 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08205	RWWKIWVIRWWV	12	Sequence 1783 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08206	RWWKIWVIRWWW	12	Sequence 1784 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08207	RWWKIWVIRWWY	12	Sequence 1785 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08208	ARAAVVLIVIRR	12	Sequence 1786 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08209	CRAAVVLIVIRR	12	Sequence 1787 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08210	DRAAVVLIVIRR	12	Sequence 1788 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08211	ERAAVVLIVIRR	12	Sequence 1789 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08212	FRAAVVLIVIRR	12	Sequence 1790 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08213	GRAAVVLIVIRR	12	Sequence 1791 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08214	HRAAVVLIVIRR	12	Sequence 1792 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08215	IRAAVVLIVIRR	12	Sequence 1793 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08216	KRAAVVLIVIRR	12	Sequence 1794 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08217	LRAAVVLIVIRR	12	Sequence 1795 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08218	MRAAVVLIVIRR	12	Sequence 1796 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08219	NRAAVVLIVIRR	12	Sequence 1797 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08220	PRAAVVLIVIRR	12	Sequence 1798 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08221	QRAAVVLIVIRR	12	Sequence 1799 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08222	SRAAVVLIVIRR	12	Sequence 1800 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08223	TRAAVVLIVIRR	12	Sequence 1801 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08224	VRAAVVLIVIRR	12	Sequence 1802 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08225	WRAAVVLIVIRR	12	Sequence 1803 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08226	YRAAVVLIVIRR	12	Sequence 1804 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08227	RAAAVVLIVIRR	12	Sequence 1805 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08228	RCAAVVLIVIRR	12	Sequence 1806 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08229	RDAAVVLIVIRR	12	Sequence 1807 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08230	REAAVVLIVIRR	12	Sequence 1808 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08231	RFAAVVLIVIRR	12	Sequence 1809 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08232	RGAAVVLIVIRR	12	Sequence 1810 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08233	RHAAVVLIVIRR	12	Sequence 1811 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08234	RIAAVVLIVIRR	12	Sequence 1812 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08235	RKAAVVLIVIRR	12	Sequence 1813 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08236	RLAAVVLIVIRR	12	Sequence 1814 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08237	RMAAVVLIVIRR	12	Sequence 1815 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08238	RNAAVVLIVIRR	12	Sequence 1816 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08239	RPAAVVLIVIRR	12	Sequence 1817 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08240	RQAAVVLIVIRR	12	Sequence 1818 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08241	RSAAVVLIVIRR	12	Sequence 1819 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08242	RTAAVVLIVIRR	12	Sequence 1820 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08243	RVAAVVLIVIRR	12	Sequence 1821 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08244	RWAAVVLIVIRR	12	Sequence 1822 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08245	RYAAVVLIVIRR	12	Sequence 1823 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08246	RRCAVVLIVIRR	12	Sequence 1824 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08247	RRDAVVLIVIRR	12	Sequence 1825 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08248	RREAVVLIVIRR	12	Sequence 1826 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08249	RRFAVVLIVIRR	12	Sequence 1827 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08250	RRGAVVLIVIRR	12	Sequence 1828 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08251	RRHAVVLIVIRR	12	Sequence 1829 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08252	RRIAVVLIVIRR	12	Sequence 1830 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08253	RRKAVVLIVIRR	12	Sequence 1831 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08254	RRLAVVLIVIRR	12	Sequence 1832 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08255	RRMAVVLIVIRR	12	Sequence 1833 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08256	RRNAVVLIVIRR	12	Sequence 1834 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08257	RRPAVVLIVIRR	12	Sequence 1835 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08258	RRQAVVLIVIRR	12	Sequence 1836 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08259	RRRAVVLIVIRR	12	Sequence 1837 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08260	RRSAVVLIVIRR	12	Sequence 1838 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08261	RRTAVVLIVIRR	12	Sequence 1839 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08262	RRVAVVLIVIRR	12	Sequence 1840 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08263	RRWAVVLIVIRR	12	Sequence 1841 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08264	RRYAVVLIVIRR	12	Sequence 1842 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08265	RRACVVLIVIRR	12	Sequence 1843 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08266	RRADVVLIVIRR	12	Sequence 1844 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08267	RRAEVVLIVIRR	12	Sequence 1845 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08268	RRAFVVLIVIRR	12	Sequence 1846 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08269	RRAGVVLIVIRR	12	Sequence 1847 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08270	RRAHVVLIVIRR	12	Sequence 1848 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08271	RRAIVVLIVIRR	12	Sequence 1849 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08272	RRAKVVLIVIRR	12	Sequence 1850 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08273	RRALVVLIVIRR	12	Sequence 1851 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08274	RRAMVVLIVIRR	12	Sequence 1852 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08275	RRANVVLIVIRR	12	Sequence 1853 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08276	RRAPVVLIVIRR	12	Sequence 1854 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08277	RRAQVVLIVIRR	12	Sequence 1855 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08278	RRARVVLIVIRR	12	Sequence 1856 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08279	RRASVVLIVIRR	12	Sequence 1857 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08280	RRATVVLIVIRR	12	Sequence 1858 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08281	RRAVVVLIVIRR	12	Sequence 1859 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08282	RRAWVVLIVIRR	12	Sequence 1860 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08283	RRAYVVLIVIRR	12	Sequence 1861 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08284	RRAAAVLIVIRR	12	Sequence 1862 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08285	RRAACVLIVIRR	12	Sequence 1863 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08286	RRAADVLIVIRR	12	Sequence 1864 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08287	RRAAEVLIVIRR	12	Sequence 1865 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08288	RRAAFVLIVIRR	12	Sequence 1866 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08289	RRAAGVLIVIRR	12	Sequence 1867 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08290	RRAAHVLIVIRR	12	Sequence 1868 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08291	RRAAIVLIVIRR	12	Sequence 1869 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08292	RRAAKVLIVIRR	12	Sequence 1870 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08293	RRAALVLIVIRR	12	Sequence 1871 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08294	RRAAMVLIVIRR	12	Sequence 1872 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08295	RRAANVLIVIRR	12	Sequence 1873 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08296	RRAAPVLIVIRR	12	Sequence 1874 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08297	RRAAQVLIVIRR	12	Sequence 1875 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08298	RRAARVLIVIRR	12	Sequence 1876 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08299	RRAASVLIVIRR	12	Sequence 1877 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08300	RRAATVLIVIRR	12	Sequence 1878 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08301	RRAAWVLIVIRR	12	Sequence 1879 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08302	RRAAYVLIVIRR	12	Sequence 1880 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08303	RRAAVALIVIRR	12	Sequence 1881 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08304	RRAAVCLIVIRR	12	Sequence 1882 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08305	RRAAVDLIVIRR	12	Sequence 1883 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08306	RRAAVELIVIRR	12	Sequence 1884 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08307	RRAAVFLIVIRR	12	Sequence 1885 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08308	RRAAVGLIVIRR	12	Sequence 1886 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08309	RRAAVHLIVIRR	12	Sequence 1887 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08310	RRAAVILIVIRR	12	Sequence 1888 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08311	RRAAVKLIVIRR	12	Sequence 1889 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08312	RRAAVLLIVIRR	12	Sequence 1890 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08313	RRAAVMLIVIRR	12	Sequence 1891 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08314	RRAAVNLIVIRR	12	Sequence 1892 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08315	RRAAVPLIVIRR	12	Sequence 1893 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08316	RRAAVQLIVIRR	12	Sequence 1894 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08317	RRAAVRLIVIRR	12	Sequence 1895 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08318	RRAAVSLIVIRR	12	Sequence 1896 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08319	RRAAVTLIVIRR	12	Sequence 1897 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08320	RRAAVWLIVIRR	12	Sequence 1898 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08321	RRAAVYLIVIRR	12	Sequence 1899 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08322	RRAAVVAIVIRR	12	Sequence 1900 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08323	RRAAVVCIVIRR	12	Sequence 1901 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08324	RRAAVVDIVIRR	12	Sequence 1902 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08325	RRAAVVEIVIRR	12	Sequence 1903 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08326	RRAAVVFIVIRR	12	Sequence 1904 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08327	RRAAVVGIVIRR	12	Sequence 1905 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08328	RRAAVVHIVIRR	12	Sequence 1906 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08329	RRAAVVIIVIRR	12	Sequence 1907 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08330	RRAAVVKIVIRR	12	Sequence 1908 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08331	RRAAVVMIVIRR	12	Sequence 1909 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08332	RRAAVVNIVIRR	12	Sequence 1910 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08333	RRAAVVPIVIRR	12	Sequence 1911 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08334	RRAAVVQIVIRR	12	Sequence 1912 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08335	RRAAVVRIVIRR	12	Sequence 1913 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08336	RRAAVVSIVIRR	12	Sequence 1914 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08337	RRAAVVTIVIRR	12	Sequence 1915 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08338	RRAAVVVIVIRR	12	Sequence 1916 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08339	RRAAVVWIVIRR	12	Sequence 1917 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08340	RRAAVVYIVIRR	12	Sequence 1918 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08341	RRAAVVLAVIRR	12	Sequence 1919 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08342	RRAAVVLCVIRR	12	Sequence 1920 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08343	RRAAVVLDVIRR	12	Sequence 1921 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08344	RRAAVVLEVIRR	12	Sequence 1922 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08345	RRAAVVLFVIRR	12	Sequence 1923 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08346	RRAAVVLGVIRR	12	Sequence 1924 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08347	RRAAVVLHVIRR	12	Sequence 1925 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08348	RRAAVVLKVIRR	12	Sequence 1926 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08349	RRAAVVLLVIRR	12	Sequence 1927 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08350	RRAAVVLMVIRR	12	Sequence 1928 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08351	RRAAVVLNVIRR	12	Sequence 1929 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08352	RRAAVVLPVIRR	12	Sequence 1930 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08353	RRAAVVLQVIRR	12	Sequence 1931 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08354	RRAAVVLRVIRR	12	Sequence 1932 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08355	RRAAVVLSVIRR	12	Sequence 1933 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08356	RRAAVVLTVIRR	12	Sequence 1934 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08357	RRAAVVLVVIRR	12	Sequence 1935 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08358	RRAAVVLWVIRR	12	Sequence 1936 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08359	RRAAVVLYVIRR	12	Sequence 1937 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08360	RRAAVVLIAIRR	12	Sequence 1938 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08361	RRAAVVLICIRR	12	Sequence 1939 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08362	RRAAVVLIDIRR	12	Sequence 1940 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08363	RRAAVVLIEIRR	12	Sequence 1941 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08364	RRAAVVLIFIRR	12	Sequence 1942 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08365	RRAAVVLIGIRR	12	Sequence 1943 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08366	RRAAVVLIHIRR	12	Sequence 1944 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08367	RRAAVVLIIIRR	12	Sequence 1945 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08368	RRAAVVLIKIRR	12	Sequence 1946 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08369	RRAAVVLILIRR	12	Sequence 1947 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08370	RRAAVVLIMIRR	12	Sequence 1948 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08371	RRAAVVLINIRR	12	Sequence 1949 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08372	RRAAVVLIPIRR	12	Sequence 1950 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08373	RRAAVVLIQIRR	12	Sequence 1951 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08374	RRAAVVLIRIRR	12	Sequence 1952 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08375	RRAAVVLISIRR	12	Sequence 1953 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08376	RRAAVVLITIRR	12	Sequence 1954 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08377	RRAAVVLIWIRR	12	Sequence 1955 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08378	RRAAVVLIYIRR	12	Sequence 1956 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08379	RRAAVVLIVARR	12	Sequence 1957 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08380	RRAAVVLIVCRR	12	Sequence 1958 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08381	RRAAVVLIVDRR	12	Sequence 1959 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08382	RRAAVVLIVERR	12	Sequence 1960 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08383	RRAAVVLIVFRR	12	Sequence 1961 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08384	RRAAVVLIVGRR	12	Sequence 1962 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08385	RRAAVVLIVHRR	12	Sequence 1963 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08386	RRAAVVLIVKRR	12	Sequence 1964 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08387	RRAAVVLIVLRR	12	Sequence 1965 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08388	RRAAVVLIVMRR	12	Sequence 1966 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08389	RRAAVVLIVNRR	12	Sequence 1967 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08390	RRAAVVLIVPRR	12	Sequence 1968 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08391	RRAAVVLIVQRR	12	Sequence 1969 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08392	RRAAVVLIVRRR	12	Sequence 1970 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08393	RRAAVVLIVSRR	12	Sequence 1971 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08394	RRAAVVLIVTRR	12	Sequence 1972 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08395	RRAAVVLIVVRR	12	Sequence 1973 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08396	RRAAVVLIVWRR	12	Sequence 1974 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08397	RRAAVVLIVYRR	12	Sequence 1975 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08398	RRAAVVLIVIAR	12	Sequence 1976 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08399	RRAAVVLIVICR	12	Sequence 1977 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08400	RRAAVVLIVIDR	12	Sequence 1978 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08401	RRAAVVLIVIER	12	Sequence 1979 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08402	RRAAVVLIVIFR	12	Sequence 1980 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08403	RRAAVVLIVIGR	12	Sequence 1981 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08404	RRAAVVLIVIHR	12	Sequence 1982 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08405	RRAAVVLIVIIR	12	Sequence 1983 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08406	RRAAVVLIVIKR	12	Sequence 1984 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08407	RRAAVVLIVILR	12	Sequence 1985 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08408	RRAAVVLIVIMR	12	Sequence 1986 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08409	RRAAVVLIVINR	12	Sequence 1987 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08410	RRAAVVLIVIPR	12	Sequence 1988 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08411	RRAAVVLIVIQR	12	Sequence 1989 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08412	RRAAVVLIVISR	12	Sequence 1990 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08413	RRAAVVLIVITR	12	Sequence 1991 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08414	RRAAVVLIVIVR	12	Sequence 1992 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08415	RRAAVVLIVIWR	12	Sequence 1993 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08416	RRAAVVLIVIYR	12	Sequence 1994 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08417	RRAAVVLIVIRA	12	Sequence 1995 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08418	RRAAVVLIVIRC	12	Sequence 1996 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08419	RRAAVVLIVIRD	12	Sequence 1997 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08420	RRAAVVLIVIRE	12	Sequence 1998 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08421	RRAAVVLIVIRF	12	Sequence 1999 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08422	RRAAVVLIVIRG	12	Sequence 2000 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08423	RRAAVVLIVIRH	12	Sequence 2001 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08424	RRAAVVLIVIRI	12	Sequence 2002 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08425	RRAAVVLIVIRK	12	Sequence 2003 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08426	RRAAVVLIVIRL	12	Sequence 2004 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08427	RRAAVVLIVIRM	12	Sequence 2005 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08428	RRAAVVLIVIRN	12	Sequence 2006 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08429	RRAAVVLIVIRP	12	Sequence 2007 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08430	RRAAVVLIVIRQ	12	Sequence 2008 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08431	RRAAVVLIVIRS	12	Sequence 2009 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08432	RRAAVVLIVIRT	12	Sequence 2010 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08433	RRAAVVLIVIRV	12	Sequence 2011 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08434	RRAAVVLIVIRW	12	Sequence 2012 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08435	RRAAVVLIVIRY	12	Sequence 2013 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08436	AIWVIWRR	8	Sequence 2014 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08437	CIWVIWRR	8	Sequence 2015 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08438	DIWVIWRR	8	Sequence 2016 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08439	EIWVIWRR	8	Sequence 2017 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08440	FIWVIWRRFIWVIWRR	16	Sequence 2018 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08441	GIWVIWRR	8	Sequence 2019 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08442	HIWVIWRR	8	Sequence 2020 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08443	IIWVIWRR	8	Sequence 2021 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08444	KIWVIWRR	8	Sequence 2022 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08445	LIWVIWRR	8	Sequence 2023 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08446	MIWVIWRR	8	Sequence 2024 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08447	NIWVIWRR	8	Sequence 2025 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08448	PIWVIWRR	8	Sequence 2026 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08449	QIWVIWRR	8	Sequence 2027 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08450	SIWVIWRR	8	Sequence 2028 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08451	TIWVIWRR	8	Sequence 2029 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08452	VIWVIWRR	8	Sequence 2030 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08453	WIWVIWRR	8	Sequence 2031 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08454	YIWVIWRR	8	Sequence 2032 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08455	RAWVIWRR	8	Sequence 2033 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08456	RCWVIWRR	8	Sequence 2034 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08457	RDWVIWRR	8	Sequence 2035 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08458	REWVIWRR	8	Sequence 2036 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08459	RFWVIWRR	8	Sequence 2037 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08460	RGWVIWRR	8	Sequence 2038 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08461	RHWVIWRR	8	Sequence 2039 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08462	RKWVIWRR	8	Sequence 2040 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08463	RLWVIWRR	8	Sequence 2041 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08464	RMWVIWRR	8	Sequence 2042 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08465	RNWVIWRR	8	Sequence 2043 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08466	RPWVIWRR	8	Sequence 2044 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08467	RQWVIWRR	8	Sequence 2045 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08468	RSWVIWRR	8	Sequence 2047 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08469	RTWVIWRR	8	Sequence 2048 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08470	RVWVIWRR	8	Sequence 2049 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08471	RWWVIWRR	8	Sequence 2050 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08472	RYWVIWRR	8	Sequence 2051 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08473	RIAVIWRR	8	Sequence 2052 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08474	RICVIWRR	8	Sequence 2053 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08475	RIDVIWRR	8	Sequence 2054 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08476	RIEVIWRR	8	Sequence 2055 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08477	RIFVIWRR	8	Sequence 2056 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08478	RIGVIWRR	8	Sequence 2057 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08479	RIHVIWRR	8	Sequence 2058 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08480	RIIVIWRR	8	Sequence 2059 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08481	RIKVIWRR	8	Sequence 2060 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08482	RILVIWRR	8	Sequence 2061 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08483	RIMVIWRR	8	Sequence 2062 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08484	RINVIWRR	8	Sequence 2063 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08485	RIPVIWRR	8	Sequence 2064 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08486	RIQVIWRR	8	Sequence 2065 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08487	RIRVIWRR	8	Sequence 2066 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08488	RISVIWRR	8	Sequence 2067 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08489	RITVIWRR	8	Sequence 2068 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08490	RIVVIWRR	8	Sequence 2069 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08491	RIYVIWRR	8	Sequence 2070 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08492	RIWAIWRR	8	Sequence 2071 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08493	RIWCIWRR	8	Sequence 2072 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08494	RIWDIWRR	8	Sequence 2073 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08495	RIWEIWRR	8	Sequence 2074 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08496	RIWFIWRR	8	Sequence 2075 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08497	RIWGIWRR	8	Sequence 2076 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08498	RIWHIWRR	8	Sequence 2077 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08499	RIWIIWRR	8	Sequence 2078 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08500	RIWKIWRR	8	Sequence 2079 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08501	RIWLIWRR	8	Sequence 2080 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08502	RIWMIWRR	8	Sequence 2081 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08503	RIWNIWRR	8	Sequence 2082 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08504	RIWPIWRR	8	Sequence 2083 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08505	RIWQIWRR	8	Sequence 2084 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08506	RIWRIWRR	8	Sequence 2085 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08507	RIWSIWRR	8	Sequence 2086 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08508	RIWTIWRR	8	Sequence 2087 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08509	RIWWIWRR	8	Sequence 2088 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08510	RIWYIWRR	8	Sequence 2089 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08511	RIWVAWRR	8	Sequence 2090 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08512	RIWVCWRR	8	Sequence 2091 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08513	RIWVDWRR	8	Sequence 2092 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08514	RIWVEWRR	8	Sequence 2093 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08515	RIWVFWRR	8	Sequence 2094 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08516	RIWVGWRR	8	Sequence 2095 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08517	RIWVHWRR	8	Sequence 2096 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08518	RIWVKWRR	8	Sequence 2097 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08519	RIWVLWRR	8	Sequence 2098 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08520	RIWVMWRR	8	Sequence 2099 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08521	RIWVNWRR	8	Sequence 2100 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08522	RIWVPWRR	8	Sequence 2101 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08523	RIWVQWRR	8	Sequence 2102 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08524	RIWVRWRR	8	Sequence 2103 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08525	RIWVSWRR	8	Sequence 2104 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08526	RIWVTWRR	8	Sequence 2105 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08527	RIWVVWRR	8	Sequence 2106 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08528	RIWVWWRR	8	Sequence 2107 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08529	RIWVYWRR	8	Sequence 2108 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08530	RIWVIARR	8	Sequence 2109 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08531	RIWVICRR	8	Sequence 2110 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08532	RIWVIDRR	8	Sequence 2111 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08533	RIWVIERR	8	Sequence 2112 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08534	RIWVIFRR	8	Sequence 2113 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08535	RIWVIGRR	8	Sequence 2114 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08536	RIWVIHRR	8	Sequence 2115 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08537	RIWVIIRR	8	Sequence 2116 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08538	RIWVIKRR	8	Sequence 2117 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08539	RIWVILRR	8	Sequence 2118 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08540	RIWVIMRR	8	Sequence 2119 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08541	RIWVINRR	8	Sequence 2120 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08542	RIWVIPRR	8	Sequence 2121 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08543	RIWVIQRR	8	Sequence 2122 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08544	RIWVIRRR	8	Sequence 2123 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08545	RIWVISRR	8	Sequence 2124 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08546	RIWVITRR	8	Sequence 2125 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08547	RIWVIVRR	8	Sequence 2126 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08548	RIWVIYRR	8	Sequence 2127 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08549	RIWVIWAR	8	Sequence 2128 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08550	RIWVIWCR	8	Sequence 2129 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08551	RIWVIWDR	8	Sequence 2130 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08552	RIWVIWER	8	Sequence 2131 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08553	RIWVIWFR	8	Sequence 2132 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08554	RIWVIWGR	8	Sequence 2133 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08555	RIWVIWHR	8	Sequence 2134 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08556	RIWVIWIR	8	Sequence 2135 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08557	RIWVIWKR	8	Sequence 2136 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08558	RIWVIWLR	8	Sequence 2137 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08559	RIWVIWMR	8	Sequence 2138 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08560	RIWVIWNR	8	Sequence 2139 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08561	RIWVIWPR	8	Sequence 2140 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08562	RIWVIWQR	8	Sequence 2141 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08563	RIWVIWSR	8	Sequence 2142 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08564	RIWVIWTR	8	Sequence 2143 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08565	RIWVIWVR	8	Sequence 2144 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08566	RIWVIWWR	8	Sequence 2145 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08567	RIWVIWYR	8	Sequence 2146 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08568	RIWVIWRA	8	Sequence 2147 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08569	RIWVIWRC	8	Sequence 2148 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08570	RIWVIWRD	8	Sequence 2149 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08571	RIWVIWRE	8	Sequence 2150 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08572	RIWVIWRF	8	Sequence 2151 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08573	RIWVIWRG	8	Sequence 2152 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08574	RIWVIWRH	8	Sequence 2153 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08575	RIWVIWRI	8	Sequence 2154 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08576	RIWVIWRK	8	Sequence 2155 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08577	RIWVIWRL	8	Sequence 2156 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08578	RIWVIWRM	8	Sequence 2157 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08579	RIWVIWRN	8	Sequence 2158 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08580	RIWVIWRP	8	Sequence 2159 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08581	RIWVIWRQ	8	Sequence 2160 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08582	RIWVIWRS	8	Sequence 2161 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08583	RIWVIWRT	8	Sequence 2162 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08584	RIWVIWRV	8	Sequence 2163 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08585	RIWVIWRW	8	Sequence 2164 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08586	RIWVIWRY	8	Sequence 2165 from Patent US 2008020752	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08587	RAVRIVVIRALR	12	Sequence 2166 from Patent US 2008020752	Synthetic construct	Antimicrobial	US 2008/0207522 A1	Patent Application	2008##8##28	CA2629751A1, EP1824976A1, EP1824976A4, EP2116603A2, EP2116603A3, WO2006050611A1	Antimicrobial Peptides.	A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.
DRAMP08588	GLLRRLRKKIGKKLKKIGQKIKPIRILVP	29	Sequence 3 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08589	GLLRRLRGKIGKKLKKIGQKIKAIRKLVP	29	Sequence 4 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08590	GLLRRFRKKIGGKLKKYGQIIKHLRILVP	29	Sequence 5 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08591	GLLRRLRRKIGGKLKKFGQKIKPLRKLVP	29	Sequence 6 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08592	GLLRRLRKKIGKKLKKFGQKIKHIRILVP	29	Sequence 7 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08593	GLLKRLGRKIGKKLKKFGQKIKAIRKLVP	29	Sequence 8 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08594	GRFKRFWKKIGRKFKKIGQMLKPIRILVP	29	Sequence 9 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08595	GLLKRLRKKIGKKLKKIGPKIKHIRKLVP	29	Sequence 10 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08596	GLLRRFWMKIGGKLKKFGQMIKHLRKLVP	29	Sequence 11 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08597	GRLRRLRRKIGEKLKKFGQVIKALRILVP	29	Sequence 12 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08598	GLLRRLWRKIGRKLKKYGQKIKALRKLVP	29	Sequence 13 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08599	GRFRRFRKKIGKKLKKIGLVIKHIRILVP	29	Sequence 14 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08600	GLLRRLRRKIGKKLKKFGQKIKHIRILVP	29	Sequence 15 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08601	GLLRRLRNKIRKKLKKFGQKIKAIRILVP	29	Sequence 16 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08602	GRLRRLWRKIGRKLKKYGQVIKHLRILVP	29	Sequence 17 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08603	GLFKRLRKKIGKKLKKFGQKIKPLRKLVP	29	Sequence 18 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08604	GLLRRFGRKIGKKFKKFGPKIKHLRKLVP	29	Sequence 19 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08605	GLFRRFRRKIGKKLKKFGQKIKPLRKLVP	29	Sequence 20 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08606	GLLRRFRRKIGRKLKKYGLMIKPLRKLVP	29	Sequence 21 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08607	GLLKRFRGKIGKKLKKYGQLIKAIRILVP	29	Sequence 22 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08608	GLFRRLRKKIGKKLKKIGQLIKAIRILVP	29	Sequence 23 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08609	GLLRRFGKKIGKKFKKYGQKIKNLRILVP	29	Sequence 24 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08610	GLLKRLRKKIGKKLKKIGQKIKPIRKLVP	29	Sequence 25 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08611	GRLRRLRRKIRKKLKKYGQKIKAIRKLVP	29	Sequence 27 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08612	GRFRRFRKKIGGKLKKIGQVIKDIRILVP	29	Sequence 28 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08613	GRFRRFRKKIGKKFKKFGQMIKALRILVP	29	Sequence 29 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08614	GRLRRFRKKIGKKLKKIGQMIKHIRILVP	29	Sequence 30 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08615	GLVRRFRRKIGKKLKKIGQIIKAIRKLVP	29	Sequence 31 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08616	GLLRRLRRKIGKKFKKIGQVIKHLRKLVP	29	Sequence 32 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08617	GLFRRLRGKIGKKLKKIGQKIKAIRILVP	29	Sequence 33 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08618	GLFRRLGKKIGKKLKKFGQVIKHIRILVP	29	Sequence 34 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08619	GLLRRLGKKIGKKFKKFGQVIKALRILVP	29	Sequence 35 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08620	GLFRRLGRKIGKKLKKIGQVIKHIRILVP	29	Sequence 36 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08621	GLLRRLRKKIEKKLKKYGPKIKALRKLVP	29	Sequence 37 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08622	GRIKRVGEKIGKKLKKIGQVIKHLRILVP	29	Sequence 38 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08623	GLFRRFGKKIGKKLKKIGQVIKALRILVP	29	Sequence 39 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08624	GRLRRFGKKIGKKLKKFGQLIKALRILVP	29	Sequence 40 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08625	GLLRRFWKKIGKKLKKFGQKIKPLPKLVP	29	Sequence 41 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08626	GRFRRLGRKIGEKLKKFGQVIKAIRILVP	29	Sequence 42 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08627	GLFRRFGKKIGKKLKKIGQKIKPIHKLVP	29	Sequence 43 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08628	GLLKRLRKKIGKKLKKIGQMIKHIRILVP	29	Sequence 44 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08629	GLLRRFREKIGKKLKKYGQKIKHLRKLVP	29	Sequence 45 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08630	GLFRRLRRKIGKKFKKFGQKIKPLRKLVP	29	Sequence 46 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08631	GLFRRFWKKIGRKLKKIGQKIKPLQILVP	29	Sequence 47 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08632	GLLRRLWKKIGRKFKKYGQVIKHIRKLVP	29	Sequence 48 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08633	GLLRRLGRKIGKKLKKIGQKIKAIRILVP	29	Sequence 49 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08634	GLLRRFRNKIGKKLKKIGQKIKPIRKLVP	29	Sequence 50 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08635	GRFKRLRKKIGKKFKKIGQKIKDIRKLVP	29	Sequence 51 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08636	GLFRRIRRKIGKKFKKFGQVIKPLRKLVP	29	Sequence 52 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08637	GRLRRLGKKIGEKLKKFGQMIKHIRILVP	29	Sequence 53 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08638	GLLRRLGKKIGKKFKKCGQVIKAIRILVP	29	Sequence 54 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08639	GLLRRFRKKIGEKFKKFGQKIKNIRILVP	29	Sequence 55 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08640	GLLRRLRKKIGKKLKKIGQKIKPIRKLVP	29	Sequence 56 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08641	GLLRRFRKKIGKKLKKYGQKIKHLRILVP	29	Sequence 57 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08642	GXXXRXXXKIXXKXXKXXR	19	Sequence 58 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08643	GLLRRLRKKIGKKLKKIAR	19	Sequence 59 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08644	GLFRRLKRKIGRKFKKIAR	19	Sequence 60 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08645	GLLKRLGRKIGKKFKKIAR	19	Sequence 61 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08646	GLLRRFRKKIGKKLKKIAR	19	Sequence 62 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08647	GLLRRLRKKIGKKLKKITR	19	Sequence 63 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08648	GLFRRLRKKIGKKLKKIAR	19	Sequence 64 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08649	GLFRRLKRKIGKKLKKIAR	19	Sequence 65 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08650	GLLKRLGRKIGKKLKKIAR	19	Sequence 66 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08651	GLLRRFRKKIGKKLKKITR	19	Sequence 67 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08652	GLLRRLRKKIGRKFKKIAR	19	Sequence 68 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08653	GLFRRLRKKIGKKFKKIAR	19	Sequence 69 from Patent US 20080213430	Synthetic construct	Antimicrobial	US 2008/0213430 A1	Patent Application	2008##9##4	CA2529062A1, CA2529062C, CN1816561A, CN1820019A, CN100497375C, CN100497376C, DE602004023624D1, EP1664096A1, EP1664096B1, US7829524, WO2004108752A1	Antimicrobial Peptides.	The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
DRAMP08654	AAAXAAAAAXAAXAAXAAA	19	Sequence 42 from Patent US 20080234188	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0234188 A1	Patent Application	2008##9##25	Unknown	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) Bn1-Z; (b) Bn1-Z-Bn2; and (c) Z-Bn1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP08655	AAAXAAAAAXAAWAAXAAA	19	Sequence 43 from Patent US 20080234188	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0234188 A1	Patent Application	2008##9##25	Unknown	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) Bn1-Z; (b) Bn1-Z-Bn2; and (c) Z-Bn1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP08656	FEFXRIVXRIKXFLRXLV	18	Sequence 1 from Patent US 20080249022	Synthetic construct	Antimicrobial	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08657	FEFKRIVQRIKDFLRNLV	18	Sequence 2 from Patent US 20080249022	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08658	IGKEFKRIVQRIKDFLRNLVPRTE	24	Sequence 3 from Patent US 20080249022	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08659	IGKEFKRIVERIKRFLRELVRPLR	24	Sequence 4 from Patent US 20080249022	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08660	PRTE	4	Sequence 5 from Patent US 20080249022	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08661	RPLR	4	Sequence 6 from Patent US 20080249022	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0249022 A1	Patent Application	2008##10##9	CA2574959A1, CN101018563A, EP1621205A1, EP1784206A2, EP2221061A1, US7803756, US20110053835, WO2006011792A2, WO2006011792A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.
DRAMP08662	MRLHHLLLALLFLVLSAGSGFTQGVRNSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK	64	Sequence 1 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08663	MYKGIFLCVLLAVICANSLATPSSDADEDNDEVERYVRGWASKIGQTLGKIAKVGLKELIQPKREAMLRSAEAQGKRPWIL	81	Sequence 3 from Patent US 20080269122	Xenopus laevis	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08664	MNFVRILSFVFALVLALGAVSAAPEPRWKLFKKIEKVGRNVRDGLIKAGPAIAVIGQAKSLGK	63	Sequence 9 from Patent US 20080269122	Bombyx mori	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08665	MNFAKILSFVFALVLALSMTSAAPEPRWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK	63	Sequence 10 from Patent US 20080269122	Bombyx mori	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08666	MNFYKIFVFVALILAISIGQSEAGWLKKLGKRIERIGQHTRDATIQGLGIAQQAANVAATARG	63	Sequence 11 from Patent US 20080269122	Drosophila melanogaster	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08668	RGGRLCYCRRRFCVCVGRX	19	Sequence 17 from Patent US 20080269122	Sus scrofa	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08669	GGRLCYCRRRFCICVG	16	Sequence 18 from Patent US 20080269122	Sus scrofa	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08670	MKFFVFALILALMLSMTGADSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN	51	Sequence 19 from Patent US 20080269122	Homo sapiens	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08671	ALWFTMLKKLGTMALHAGKAALGAAANTISQGTQ	34	Sequence 22 from Patent US 20080269122	Phyllomedusa sauvagei	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08672	ALWKNMLKGIGKLAGKAALGAVKKLVGAES	30	Sequence 23 from Patent US 20080269122	Phyllomedusa sauvagei	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08673	GIGAVLKVLTTGLPALISWISRKKRQQ	27	Sequence 25 from Patent US 20080269122	Apis mellifera	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08674	GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE	33	Sequence 26 from Patent US 20080269122	Pardachirus pavoninus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08675	GFFALIPKIISSPIFKTLLSAVGSALSSSGGQE	33	Sequence 27 from Patent US 20080269122	Pardachirus pavoninus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08676	SIGSALKKALPVAKKIGKIALPIAKAALP	29	Sequence 30 from Patent US 20080269122	Ceratitis capitata	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08677	VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV	33	Sequence 41 from Patent US 20080269122	Homo sapiens	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08678	GICACRRRFCPNSERFSGYCRVNGARYVRCCSRR	34	Sequence 44 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08679	GRCVCRKQLLCSYRERRIGDCKIRGVRFPFCCPR	34	Sequence 45 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08680	VSCTCRRFSCGFGERASGSCTVNGGVRHTLCCRR	34	Sequence 46 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08681	VFCTCRGFLCGSGERASGSCTINGVRHTLCCRR	33	Sequence 47 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08682	CSCRYSSCRFGERLLSGACRLNGRIYRLCC	30	Sequence 49 from Patent US 20080269122	Rattus norvegicus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08683	ACTCRIGACVSGERLTGACGLNGRIYRLCCR	31	Sequence 50 from Patent US 20080269122	Rattus norvegicus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08684	RCICTRGFCRCLCRRGVC	18	Sequence 53 from Patent US 20080269122	Macaca mulatta	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08685	MKSSMKMFAALLLVVMCLLANEMGGPLVVEARTCESQSHKFKGTCLSDTNCANVCHSERFSGGKCRGFRRRCFCTTHC	78	Sequence 54 from Patent US 20080269122	Helianthus annuus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08686	ACYCRIPACLAGERRYGTCFYMGRVWAFCC	30	Sequence 56 from Patent US 20080269122	Macaca mulatta	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08687	GFGCPFNQGACHRHCRSIRRRGGYCAGLFKQTCTCYR	37	Sequence 57 from Patent US 20080269122	Androctonus australis hec	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08688	GFGCPNNYQCHRHCKSIPGRCGGYCGGXHRLRCTCYRC	38	Sequence 58 from Patent US 20080269122	Mytilus galloprovincialis	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08690	NLCERASLTWTGNCGNTGHCDTQCRNWESAKHGACHKRGNWKCFCYFNC	49	Sequence 60 from Patent US 20080269122	Clitoria ternatea	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08691	MKKLVLLFALVLLAFQVQADSIQNTDEETKTEEQPGEKDQAVSVSFGDPQGSALQDAALGWGRRCPQCPRCPSCPSCPRCPRCPRCKCNPK	91	Sequence 61 from Patent US 20080269122	Mus musculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08692	QGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	40	Sequence 62 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08693	QGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPRIKCCR	40	Sequence 63 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08694	QGVRNHVTCRIYGGFCVPIRCPGRTRQIGTCFGRPVKCCRRW	42	Sequence 64 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08695	QVVRNPQSCRWNMGVCIPISCPGNMRQIGTCFGPRVPCCR	40	Sequence 65 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08696	QRVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPCCRR	41	Sequence 66 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08697	QGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	42	Sequence 67 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08698	QGVRSYLSCWGNRGICLLNRCPGRMRQIGTCLAPRVKCCR	40	Sequence 68 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08699	SGISGPLSCGRNGGVCIPIRCPVPMRQIGTCFGRPVKCCRSW	42	Sequence 69 from Patent US 20080269122	Bos taurus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08700	SLQGGAPNFPQPSQQNGGWQVSPDLGRDDKGNTRGQIEIQNKGKDHDFNAGWGKVIRGPNKAKPTWHVGGTYRR	74	Sequence 71 from Patent US 20080269122	Zophobas atratus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08701	ATCDLLSGFGVGDSACAAHCIARGNRGGYCNSKKVCVCRN	40	Sequence 73 from Patent US 20080269122	Aedes aegypti	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08702	GFGCPNDYPCHRHCKSIPGRYGGYCGGXHRLRCTC	35	Sequence 74 from Patent US 20080269122	Mytilus edulis	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08703	ATCDLLSGIGVQHSACALHCVFRGNRGGYCTGKGICVCRN	40	Sequence 75 from Patent US 20080269122	Sarcophaga peregrina	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08704	MRTLALLAAILLVALQAQAEHVSVSIDEVVDQQPPQAEDQDVAIYVKEHESSALEALGVKAGVVCACRRALCLPRERRAGFCRIRGRIHPLCCRR	95	Sequence 76 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08705	MKPLVLLSALVLLSFQVQADPIQNTDEETKTEEQSGEEDQAVSVSFGDREGASLQEESLRDLVCYCRTRGCKRRERMNGTCRKGHLMYTLCC	92	Sequence 77 from Patent US 20080269122	Mus musculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08706	MKTFVLLSALVLLAFQVQADPIHKTDEETNTEEQPGEEDQAVSISFGGQEGSALHEELSKKLICYCRIRGCKRRERVFGTCRNLFLTFVFCCS	93	Sequence 78 from Patent US 20080269122	Mus musculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08707	LRDLVCYCRARGCKGRERMNGTCRKGHLLYMLCCR	35	Sequence 79 from Patent US 20080269122	Mus musculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08708	ATCDILSFQSQWVTPNHAGCALHCVIKGYKGGQCKITVCHCRR	43	Sequence 80 from Patent US 20080269122	Pyrrhocoris apterus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08709	VTCSCRTSSCRFGERLSGACRLNGRIYRLCC	31	Sequence 82 from Patent US 20080269122	Rattus norvegicus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08710	GICACRRRFCLNFEQFSGYCRVNGARYVRCCSRR	34	Sequence 83 from Patent US 20080269122	Oryctolagus cuniculus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08711	MRVLYLLFSFLFIFLMPLPGVFGGISDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	64	Sequence 84 from Patent US 20080269122	Pan troglodytes	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08712	MRLHHLLLVLFFLVLSAGSGFTQGIRSRRSCHRNKGVCALTRCPRNMRQIGTCFGPPVKCCRKK	64	Sequence 87 from Patent US 20080269122	Capra hircus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08713	MRLHHLLLALFFLVLSAGSGFTQGIINHRSCYRNKGVCAPARCPRNMRQIGTCHGPPVKCCRKK	64	Sequence 88 from Patent US 20080269122	Capra hircus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08714	MRTLVILAAILLVALQAQAEPLQARTDEATAAQEQIPTDNPEVVVSLAWDESLAPKDSVPGLRKNMACYCRIPACLAGERRYGTCFYRRRVWAFCC	96	Sequence 89 from Patent US 20080269122	Macaca mulatta	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08715	MRTLVILAAILLVALQAQAEPLQARTDEATAAQEQIPTDNPEVVVSLAWDESLAPKDSVPGLRKNMACYCRIPACLAGERRYGTCFYLGRVWAFCC	96	Sequence 90 from Patent US 20080269122	Macaca mulatta	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08716	VTCFCRRRGCASRERHIGYCRFGNTIYRLCCRR	33	Sequence 91 from Patent US 20080269122	Mesocricetus auratus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08717	CFCKRPVCDSGETQIGYCRLGNTFYRLCCRQ	31	Sequence 92 from Patent US 20080269122	Mesocricetus auratus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08718	GRKSDCFRKNGFCAFLKCPYLTLISGKCSRFHLCCKRIW	39	Sequence 93 from Patent US 20080269122	Gallus gallus	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08719	VTCDLLSFEAKGFAANHSLCAAHCLAIGRRGGSCERGVCICRR	43	Sequence 94 from Patent US 20080269122	Allomyrina dichotoma	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08720	XCXCRXCXERXCXGXCCX	18	Sequence 96 from Patent US 20080269122	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2008/0269122 A1	Patent Application	2008##10##30	CA2525961A1, WO2004110143A2, AU2004247012A1, US20050014932A1, WO2004110143A3	Antimicrobial Peptides Derived From Cap18.	The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as
DRAMP08721	DRVYIHPF	8	Sequence 1 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08722	DRXYXHPF	8	Sequence 2 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08723	RPPGFSPFR	9	Sequence 3 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08724	RPPGXXPXR	9	Sequence 4 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08725	GGFMTSEKSQTPLVT	15	Sequence 5 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08726	GGXMXSEXSQXPLXT	15	Sequence 6 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08727	KFLHKFRKLLR	11	Sequence 28 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08729	LKRFLKWFKRF	11	Sequence 32 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08730	KLFKRWKHLFR	11	Sequence 33 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08731	RLLKRFKHLFK	11	Sequence 34 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08732	FKTFLKWLHRF	11	Sequence 35 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08733	IKQLLHFFQRF	11	Sequence 36 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08734	KLLQTFKQIFR	11	Sequence 37 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08735	RILKELKNLFK	11	Sequence 38 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08736	LKQFVHFIHRF	11	Sequence 39 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08737	VKTLLHIFQRF	11	Sequence 40 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08738	KLVEQLKEIFR	11	Sequence 41 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08739	RVLQEIKQILK	11	Sequence 42 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08740	VKNLAELVHRF	11	Sequence 43 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08741	ATHLLHALQRF	11	Sequence 44 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08742	KLAENVKEILR	11	Sequence 45 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08743	RALHEAKEALK	11	Sequence 46 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08744	FHYFWHWFHRF	11	Sequence 47 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08745	LYHFLHWFQRF	11	Sequence 48 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08746	YLFQTWQHLFR	11	Sequence 49 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08747	YLLTEFQHLFK	11	Sequence 50 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08748	FKTFLQWLHRF	11	Sequence 51 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08749	IKTLLHFFQRF	11	Sequence 52 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08750	KLLQTFNQIFR	11	Sequence 53 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08751	TILQSLKNIFK	11	Sequence 54 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08752	LKQFVKFIHRF	11	Sequence 55 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08753	VKQLLKIFNRF	11	Sequence 56 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08754	KLVQQLKNIFR	11	Sequence 57 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08755	RVLNQVKQILK	11	Sequence 58 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08756	VKKLAKLVRRF	11	Sequence 59 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08757	AKRLLKVLKRF	11	Sequence 60 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08758	KLAQKVKRVLR	11	Sequence 61 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08759	RALKRIKHVLK	11	Sequence 62 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08760	AQAAHQAAHAAHQF	14	Sequence 63 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08761	KLKKLLKKLKKLLK	14	Sequence 64 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08762	LKLLKKLLKLLKKF	14	Sequence 65 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08763	LQLLKQLLKLLKQF	14	Sequence 66 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08764	AQAAKQAAKAAKQF	14	Sequence 67 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08765	RWRRWWRHFHHFFH	14	Sequence 68 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08766	KLKKLLKRWRRWWR	14	Sequence 69 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08767	RWRRLLKKLHHLLH	14	Sequence 70 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08768	KLKKLLKHLHHLLH	14	Sequence 71 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08769	RRRRWWW	7	Sequence 72 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08770	RRWWRRW	7	Sequence 73 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08771	RRRWWWR	7	Sequence 74 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08772	RWRWRWR	7	Sequence 75 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08773	RRRFWWR	7	Sequence 76 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08774	RRWWRRF	7	Sequence 77 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08775	RRRWWWF	7	Sequence 78 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08776	RWRWRWF	7	Sequence 79 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08777	RRRRWWK	7	Sequence 80 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08778	RRWWRRK	7	Sequence 81 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08779	RRRWWWK	7	Sequence 82 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08780	RWRWRWK	7	Sequence 83 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08781	RRRKWWK	7	Sequence 84 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08782	RRWKRRK	7	Sequence 85 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08783	RWRKRWK	7	Sequence 87 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08784	FKKFWKWFRRFGGGRWRRLLKKLHHLLH	28	Sequence 88 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08785	IKQLLHFFQRFGGGRWRRLLKKLHHLLH	28	Sequence 89 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08786	RWRRLLKKLHHLLHGGGFKKFWKWFRRF	28	Sequence 90 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08787	RWRRLLKKLHHLLHGGGIKQLLHFFQRF	28	Sequence 91 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08788	RRRWWWFRRRWWWF	14	Sequence 92 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08789	RWRWRWFRWRWRWF	14	Sequence 93 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08790	RRRWWWFASASARRRWWWF	19	Sequence 94 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08791	RRRWWWFPSGSPRRRWWWF	19	Sequence 95 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08792	RRRWWWFGGGRRRWWWF	17	Sequence 96 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08793	RWRWRWFASASARWRWRWF	19	Sequence 97 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08794	RWRWRWFPSGSPRWRWRWF	19	Sequence 98 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08795	RWRWRWFGGGRWRWRWF	17	Sequence 99 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08796	FKKFWKWFRRFGGGRWRWRWF	21	Sequence 100 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08797	IKQLLHFFQRFGGGRWRWRWF	21	Sequence 101 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08798	LKRFLKWFKRFGGGRWRWRWF	21	Sequence 102 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08799	RWRWRWFGGGFKKFWKWFRRF	21	Sequence 103 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08800	RWRWRWFGGGIKQLLHFFQWRF	22	Sequence 104 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08801	RWRWRWFGGGLKRFLKWFKRF	21	Sequence 105 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08803	HHFFHHFHHFFHHF	14	Sequence 109 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08804	FHFFHHFFHFFHHF	14	Sequence 110 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08805	KLLKGATFHFFHHFFHFFHHF	21	Sequence 111 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08806	KLLKFHFFHHFFHFFHHF	18	Sequence 112 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08807	FHFFHHFFHFFHHFKLLK	18	Sequence 113 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08808	LKQKLKILF	9	Sequence 116 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08809	LKQLKAGIY	9	Sequence 117 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08810	VGKCVKLLY	9	Sequence 118 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08811	KFVKLILAY	9	Sequence 119 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08812	KLVKLVFLY	9	Sequence 120 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08813	IKVFAKQKY	9	Sequence 121 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08814	RFRHFQERY	9	Sequence 122 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08815	FVFRHKWVWKHRFLF	15	Sequence 123 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08816	VFIVWVHKHVLF	12	Sequence 124 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08817	WRWRARWRWRLRWRF	15	Sequence 125 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08818	WRXHLRARLHVKFRF	15	Sequence 126 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08819	LRIHARFKVHIRLKF	15	Sequence 127 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08820	FHIKFRVHLKVRFHF	15	Sequence 128 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08821	FHVKXHFRLHVKFHF	15	Sequence 129 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08822	LHIHAHFHVHIHLHF	15	Sequence 130 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08823	FKIHFRLKVHIRFKF	15	Sequence 131 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08824	FKAHIRFKLRVKFHF	15	Sequence 132 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08825	LKAKIKFKVKLKIKF	15	Sequence 133 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08826	WIWKHKFLHRHFLF	14	Sequence 134 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08827	VFLHRHVIKHKLVF	14	Sequence 135 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08828	FLHKHVLRHRIVF	13	Sequence 136 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08829	VFKHKIVHRHILF	13	Sequence 137 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08830	FLFKHLFLHRIFF	13	Sequence 138 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08831	LFKHILIHRVIF	12	Sequence 139 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08832	FLHKHLFKHKLF	12	Sequence 140 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08833	VFRHRFIHRHVF	12	Sequence 141 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08834	FIHKLVHKHVLF	12	Sequence 142 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08835	VLRHLFRHRIVF	12	Sequence 143 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08836	LVHKLILRHLLF	12	Sequence 144 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08837	VFKRVLIHKLIF	12	Sequence 145 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08838	IVRKFLFRHKVF	12	Sequence 146 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08839	VLKHVIAHKRLF	12	Sequence 147 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08840	FIRKFLFKHLF	11	Sequence 148 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08841	VIRHVWVRKLF	11	Sequence 149 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08842	FLFRHRFRHRLVF	13	Sequence 150 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08843	LFLHKHAKHKFLF	13	Sequence 151 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08844	FKHKFKHKFIF	11	Sequence 152 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08845	LRHRLRHRLIF	11	Sequence 153 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08846	LILKFLFKFVF	11	Sequence 154 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08847	VLIRILVRVIF	11	Sequence 155 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08848	FRHRFRHRF	9	Sequence 156 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08849	LKHKLKHKF	9	Sequence 157 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08850	FKFKHKLIF	9	Sequence 158 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08851	LRLRHRVLF	9	Sequence 159 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08852	FKFLFKFLF	9	Sequence 160 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08853	LRLFLRWLF	9	Sequence 161 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08854	FKFLFKHKF	9	Sequence 162 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08855	LRLFLRHRF	9	Sequence 163 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08856	FKFLFKF	7	Sequence 164 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08857	LRLFLRF	7	Sequence 165 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08858	KLLK	4	Sequence 166 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08859	GAT	3	Sequence 167 from Patent US 20080286210	Synthetic construct	Antimicrobial, Antibacterial	US 2008/0286210 A1	Patent Application	2008##11##20	CN101622271A, EP2118122A2, EP2118122A4, US7713927, US20110085989, WO2008140834A2, WO2008140834A3	Novel antimicrobial peptides.	This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.
DRAMP08860	KWKSFLKTFKSAVKTVLHTALKAISS	26	Sequence 1 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08861	KWKSFLKTFKSALKTVLHTALKAISS	26	Sequence 2 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08862	KWKSFLKTFKSAAKTVLHTALKAISS	26	Sequence 4 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08863	KWKSFLKTFKSASKTVLHTALKAISS	26	Sequence 5 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08864	KWKSFLKTFKSAKKTVLHTALKAISS	26	Sequence 6 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08865	KWKSFLKTFKSAGKTVLHTALKAISS	26	Sequence 12 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08866	KWKSFLKTFKLAVKTVLHTALKAISS	26	Sequence 13 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08867	KWKSFLKTFKAAVKTVLHTALKAISS	26	Sequence 14 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08868	KWKSFLKTFKVAVKTVLHTALKAISS	26	Sequence 16 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08869	KWKSFLKTFKKAVKTVLHTALKAISS	26	Sequence 17 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08870	KWKSFLKTFKGAVKTVLHTALKAISS	26	Sequence 23 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08871	ELEKGGLEGEKGGKELEK	18	Sequence 26 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08872	KWKSFLKTKKSAVKTVLHTALKAISS	26	Sequence 27 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08873	KWKSKLKTFKSAVKTVLHTALKAISS	26	Sequence 28 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08874	KWKSFLKTAKSAVKTVLHTALKAISS	26	Sequence 29 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08875	KWKSALKTFKSAVKTVLHTALKAISS	26	Sequence 30 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08876	KWKSFLKTFKSARKTVLHTALKAISS	26	Sequence 31 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08877	KWKSFAKTFKSAVKTVLHTAAKAISS	26	Sequence 32 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08878	KWKSFKKTFKSAVKTVLHTAKKAISS	26	Sequence 33 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08879	WKSFLKTFKSAVKTVLHTALKAISS	25	Sequence 34 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08880	KSFLKTFKSAVKTVLHTALKAISS	24	Sequence 35 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08881	KWKSFLKTFKSAVKTVLHTALKAI	24	Sequence 36 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08882	KWKSFLKTFKSAVKTVLHTALKA	23	Sequence 37 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08883	KIKSALKTLKSFKKTAAHTLFKVWSS	26	Sequence 38 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08884	SWSKFLKKFTKAKSHVLTTALSAIKK	26	Sequence 39 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08885	KWKSFLKTFKXAXKTVLHTALKAISS	26	Sequence 40 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08886	KHAVIKWSIKSSVKFKISTAFKATTI	26	Sequence 41 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08887	HWSKLLKSFTKALKKFAKAITSVVST	26	Sequence 42 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08888	KWKSFLKTFKXAVKTVLHTALKAISS	26	Sequence 43 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08889	KWKSFLKTFKSAXKTVLHTALKAISS	26	Sequence 44 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08890	KWKSFLKTFKSAKKTVLHTALKLISS	26	Sequence 45 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08891	KWKSFLKTFKSLKKTVLHTALKAISS	26	Sequence 46 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08892	KWKSFLKTFKSAKKTVLHTLLKAISS	26	Sequence 47 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08893	KWKSFLKTFKSLKKTVLHTALKLISS	26	Sequence 48 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08894	KWKSFLKTFKSLKKTVLHTLLKAISS	26	Sequence 49 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08895	KWKSFLKTFKSLKKTVLHTLLKLISS	26	Sequence 50 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08896	KSFLKTFKSAKLKTVLHTALKA	22	Sequence 51 from Patent US 20090005300	Synthetic construct	Antimicrobial	US 2009/0005300 A1	Patent Application	2009##1##1	CA2633435A1, CN101111256A, CN101111256B, EP1838331A2, EP1838331A4, US8252737, US20130035469, WO2006065977A2, WO2006065977A3	Antimicrobial Peptides and Methods of Use.	Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration. Modified peptide analogs herein can d
DRAMP08897	TLKERCLQVVRSLVK	15	Sequence 1 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08898	SLQYLCRFVIRQYTR	15	Sequence 2 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08899	SLQHICRMSIRRVMS	15	Sequence 3 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08900	TLLSLCRVAVRRALG	15	Sequence 4 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08901	TLKKRCLQVVRKLVK	15	Sequence 5 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08902	TLHQQCIRVLKNNID	15	Sequence 6 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08903	TLQHLCRKTVNGHLD	15	Sequence 7 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08904	SLQHICRTVICNCTT	15	Sequence 8 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08905	SLQYICRAVICRCTT	15	Sequence 9 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08906	SLQHLCRFRIRQLVR	15	Sequence 10 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08907	SLKHLCRKALRSFLT	15	Sequence 11 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08908	PLAHLCRLRVRKAIG	15	Sequence 12 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08909	SLTHLCRLEIRSSIK	15	Sequence 13 from Patent US 20090030179	Synthetic construct	Antimicrobial	US 2009/0030179 A1	Patent Application	2009##1##29	EP1849474A1, EP1849474A4, WO2006088010A1	Antimicrobial peptide and use thereof.	Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the alpha-domain of human-derived VHL protein. In addition, several antimicrobial peptides have a partial amino acid sequence of SOCS-box of a certain SOCS-box protein.
DRAMP08910	NSQIRPLPDKGLDLSIRDASIKIRGKWKARKNFIK	35	Sequence 2 from Patent US 20090048160	Bos sp.	Antimicrobial, Antibacterial	US 2009/0048160 A1	Patent Application	2009##2##19	WO2009026155A2, WO2009026155A3	Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis	The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI65-99), 142-169 (bBPI142-169), or the combination of amino acids 90-99 and 148-161 (bBPI90-99,148-161) of bBPI. The bBPI90-99,148-161 peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 µg/ml against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp, and 64-128 µg/ml against Pseudomonas aeruginosa. None of the peptides exhibited any growth inhibitory effect on Serratia marcescens. The antimicrobial activity of bBPI90-99,148-161 was inhibited in milk, but preserved in serum. Finally, both bBPI142-169 and bBPI90-99,148-161 were demonstrated to completely neutralize LPS. The peptide bBPI90-99,148-161 is a potent neutrali
DRAMP08911	VRIHISGSSLGWLIQLFRKRIESLLQKS	28	Sequence 3 from Patent US 20090048160	Bos sp.	Antimicrobial, Antibacterial	US 2009/0048160 A1	Patent Application	2009##2##19	WO2009026155A2, WO2009026155A3	Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis	The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI65-99), 142-169 (bBPI142-169), or the combination of amino acids 90-99 and 148-161 (bBPI90-99,148-161) of bBPI. The bBPI90-99,148-161 peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 µg/ml against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp, and 64-128 µg/ml against Pseudomonas aeruginosa. None of the peptides exhibited any growth inhibitory effect on Serratia marcescens. The antimicrobial activity of bBPI90-99,148-161 was inhibited in milk, but preserved in serum. Finally, both bBPI142-169 and bBPI90-99,148-161 were demonstrated to completely neutralize LPS. The peptide bBPI90-99,148-161 is a potent neutrali
DRAMP08912	KWKARKNFIKGSSLGWLIQLFRKR	24	Sequence 4 from Patent US 20090048160	Bos sp.	Antimicrobial, Antibacterial	US 2009/0048160 A1	Patent Application	2009##2##19	WO2009026155A2, WO2009026155A3	Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis	The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI65-99), 142-169 (bBPI142-169), or the combination of amino acids 90-99 and 148-161 (bBPI90-99,148-161) of bBPI. The bBPI90-99,148-161 peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 µg/ml against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp, and 64-128 µg/ml against Pseudomonas aeruginosa. None of the peptides exhibited any growth inhibitory effect on Serratia marcescens. The antimicrobial activity of bBPI90-99,148-161 was inhibited in milk, but preserved in serum. Finally, both bBPI142-169 and bBPI90-99,148-161 were demonstrated to completely neutralize LPS. The peptide bBPI90-99,148-161 is a potent neutrali
DRAMP08913	MCHWAGGASNTGDARGDVFGKQAG	24	Sequence 5 from Patent US 20090048160	Bos sp.	Antimicrobial, Antibacterial	US 2009/0048160 A1	Patent Application	2009##2##19	WO2009026155A2, WO2009026155A3	Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis	The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI65-99), 142-169 (bBPI142-169), or the combination of amino acids 90-99 and 148-161 (bBPI90-99,148-161) of bBPI. The bBPI90-99,148-161 peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 µg/ml against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp, and 64-128 µg/ml against Pseudomonas aeruginosa. None of the peptides exhibited any growth inhibitory effect on Serratia marcescens. The antimicrobial activity of bBPI90-99,148-161 was inhibited in milk, but preserved in serum. Finally, both bBPI142-169 and bBPI90-99,148-161 were demonstrated to completely neutralize LPS. The peptide bBPI90-99,148-161 is a potent neutrali
DRAMP08914	FDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	50	Sequence 1 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08915	DISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	49	Sequence 2 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08916	ISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	48	Sequence 3 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08917	SCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	47	Sequence 4 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08918	CDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	46	Sequence 5 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08919	DKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	45	Sequence 6 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08920	KDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	44	Sequence 7 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08921	DNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	43	Sequence 8 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08922	NKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	42	Sequence 9 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08923	KRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	41	Sequence 10 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08924	RFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	40	Sequence 11 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08925	FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	39	Sequence 12 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08926	ALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	38	Sequence 13 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08927	GDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	35	Sequence 16 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08928	DFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	34	Sequence 17 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08929	FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	33	Sequence 18 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08930	FRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	32	Sequence 19 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08931	SKEKIGKEFKRIVQRIKDFLRNLVPRTES	29	Sequence 22 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08932	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTE	36	Sequence 23 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08933	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRT	35	Sequence 24 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08934	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR	34	Sequence 25 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08935	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVP	33	Sequence 26 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08936	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLV	32	Sequence 27 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08937	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNL	31	Sequence 28 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08938	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN	30	Sequence 29 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08939	LLGDFFRKSKEKIGKEFKRIVQRIKDFLR	29	Sequence 30 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08940	LLGDFFRKSKEKIGKEFKRIVQRIKDFL	28	Sequence 31 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08941	LLGDFFRKSKEKIGKEFKRIVQRIKDF	27	Sequence 32 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08942	LLGDFFRKSKEKIGKEFKRIVQRIKD	26	Sequence 33 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08943	LLGDFFRKSKEKIGKEFKRIVQRIK	25	Sequence 34 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08944	LLGDFFRKSKEKIGKEFKRIVQRI	24	Sequence 35 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08945	LLGDFFRKSKEKIGKEFKRIVQR	23	Sequence 36 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08946	LLGDFFRKSKEKIGKEFKRIVQ	22	Sequence 37 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08947	LLGDFFRKSKEKIGKEFKRIV	21	Sequence 38 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08948	LLGDFFRKSKEKIGKEFKRI	20	Sequence 39 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08949	EFKRIV	6	Sequence 40 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08950	KEFKRIVQ	8	Sequence 41 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08951	GKEFKRIVQR	10	Sequence 42 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08952	IGKEFKRIVQRI	12	Sequence 43 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08953	KIGKEFKRIVQRIK	14	Sequence 44 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08954	EKIGKEFKRIVQRIKD	16	Sequence 45 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08955	KEKIGKEFKRIVQRIKDF	18	Sequence 46 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08956	SKEKIGKEFKRIVQRIKDFL	20	Sequence 47 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08957	KSKEKIGKEFKRIVQRIKDFLR	22	Sequence 49 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08958	RKSKEKIGKEFKRIVQRIKDFLRN	24	Sequence 50 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08959	FRKSKEKIGKEFKRIVQRIKDFLRNL	26	Sequence 51 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08960	FFRKSKEKIGKEFKRIVQRIKDFLRNLV	28	Sequence 52 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08961	DFFRKSKEKIGKEFKRIVQRIKDFLRNLVP	30	Sequence 53 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08962	GDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR	32	Sequence 54 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08963	LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRT	34	Sequence 55 from Patent US 20090048167	Homo sapiens	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08964	GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ	34	Sequence 61 from Patent US 20090048167	Mus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08965	MEVGWYRSPFSRVVHLYRNGK	21	Sequence 62 from Patent US 20090048167	Mus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08966	RLGNFFRKVKEKIGGGLKKVGQKIKDFLGNLVPRTAS	37	Sequence 63 from Patent US 20090048167	Macaca mulatta	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08967	GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY	37	Sequence 64 from Patent US 20090048167	Synthetic constructn	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08968	GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE	33	Sequence 65 from Patent US 20090048167	Mus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08969	GLVRKGGEKFGEKLRKIGQKIKEFFQKLALEIEQ	34	Sequence 66 from Patent US 20090048167	Rattus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08972	RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLGPFP	43	Sequence 69 from Patent US 20090048167	Bos sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08973	GRFKRFRKKFKKLFKKLSPVIPLLHL	26	Sequence 71 from Patent US 20090048167	Bos sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08974	GGLRSLGRKILRAWKKYGPIIVPIIRI	27	Sequence 72 from Patent US 20090048167	Bos sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08975	GLFRRLRDSIRRGQQKILEKARRIGERIKDIFR	33	Sequence 73 from Patent US 20090048167	Bos sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08976	GLPWILLRWLFFR	13	Sequence 76 from Patent US 20090048167	Bubalus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08977	RYCRIIFLRVCR	12	Sequence 77 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08978	RGLRRLGRKIAHGVKKYGPTVLRIIRIA	28	Sequence 78 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08979	GLFGRLRDSLQRGGQKILEKAERIWCKIKDIFR	33	Sequence 79 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08980	RFRPPIRRPPIRPPFRPPFRPPVRPPIRPPFRPPFRPPIGPFP	43	Sequence 80 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08981	RRLRPRHQHFPSERPWPKPLPLPLPRPGPRPWPKPLPLPLPRPGLRPWPKPL	52	Sequence 81 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08982	RRLRPRRPRLPRPRPRPRPRPRSLPLPRPQPRRIPRPILLPWRPPRPIPRPQIQPIPRWL	60	Sequence 82 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08983	RRLRPRRPRLPRPRPRPRPRPRSLPLPRPKPRPIPRPLPLPRPRPKPIPRPLPLPRPRPRRIPRPLPLPRPRPRPIPRPLPLPQPQPSPIPRPL	94	Sequence 83 from Patent US 20090048167	Ovis sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08984	RFRPPIRRPPIRPPFNPPFRPPVRPPFRPPFRPPFRPPIGPFP	43	Sequence 84 from Patent US 20090048167	Capra sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08985	KRFGRLAKSFLRMRILLPRRKILLAS	26	Sequence 85 from Patent US 20090048167	Equus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08986	KRRHWFPLSFQEFLEQLRRFRDQLPFP	27	Sequence 86 from Patent US 20090048167	Equus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08987	KRFHSVGSLIQRHQQMIRDKSEATRHGIRIITRPKLLLAS	40	Sequence 87 from Patent US 20090048167	Equus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08988	AFPPPNVPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPPFPPPIFPGPWFPPPPPFRPPPFGPPRFP	79	Sequence 89 from Patent US 20090048167	Sus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08989	AFPPPNVPGPRFPPPNVPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPPFPPPIFPGPWFPPPPPFRPPPFGPPRFP	79	Sequence 90 from Patent US 20090048167	Sus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP08992	GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGC	35	Sequence 97 from Patent US 20090048167	Sus sp.	Antimicrobial	US 8202835 B2	Granted Patent	2012##6##19	US8426366, US20090048167, US20120277157	Disease treatment via antimicrobial peptides or their inhibitors.	The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
DRAMP09007	RWWRWWRRWWRR	12	Sequence 14 from Patent US 8071540	Synthetic construct	Antimicrobial	US 8071540 B2	Granted Patent	2011##12##6	EP2176420A2, EP2176420A4, US20090099533, WO2009012143A2, WO2009012143A3	Virus derived antimicrobial peptides.	Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.
DRAMP09008	WRRWWRRWWRWWRRWWRR	18	Sequence 15 from Patent US 8071540	Synthetic construct	Antimicrobial	US 8071540 B2	Granted Patent	2011##12##6	EP2176420A2, EP2176420A4, US20090099533, WO2009012143A2, WO2009012143A3	Virus derived antimicrobial peptides.	Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.
DRAMP09009	RRWWRRWRRWWRRWWRWWRRWWRR	24	Sequence 16 from Patent US 8071540	Synthetic construct	Antimicrobial	US 8071540 B2	Granted Patent	2011##12##6	EP2176420A2, EP2176420A4, US20090099533, WO2009012143A2, WO2009012143A3	Virus derived antimicrobial peptides.	Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.
DRAMP09010	RRQRRTSKLMKR	12	Sequence 17 from Patent US 8071540	Synthetic construct	Antimicrobial	US 8071540 B2	Granted Patent	2011##12##6	EP2176420A2, EP2176420A4, US20090099533, WO2009012143A2, WO2009012143A3	Virus derived antimicrobial peptides.	Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.
DRAMP09011	RRQRRTSKLMKRRRWVRRVRRVWRVVRVVRRWVRR	35	Sequence 18 from Patent US 8071540	Synthetic construct	Antimicrobial	US 8071540 B2	Granted Patent	2011##12##6	EP2176420A2, EP2176420A4, US20090099533, WO2009012143A2, WO2009012143A3	Virus derived antimicrobial peptides.	Described herein are peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides, designated LBU, WLBU and WR, are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The antimicrobial peptides are monomers or multimers of peptides referred to as the Lytic Base Unit (LBU) peptides, derived from the LLP1 analogs and also having antimicrobial activity. Also described herein are using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. Methods of killing fungi, such as Candida and Cryptococcus species, and bacteria, such as B. anthracis, are provided herein. Methods of neutralizing enveloped viruses, such as poxvirus, herpesvirus, rhabdovirus, hepadnavirus, baculovirus, orthomyxovirus, paramyxovirus, retrovirus, togavirus, bunyavirus and flavivirus, including influenza virus and HIV-1 also are provided herein. Solid phase substrates and peptide-cargo complexes comprising the peptides also are provided.
DRAMP09017	KENAGEDPGLARQAPKPRKQRSSL	24	Sequence 7 from Patent US 8329865	Synthetic construct	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09027	SSLLEKGLDGAKKAVGGLGKLG	22	Sequence 18 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09028	SSLLEKGLDGAKKAVGGLGKL	21	Sequence 19 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09029	SSLLEKGLDGAKKAVGGLGK	20	Sequence 20 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09030	SSLLEKGLDGAKKAVGGLG	19	Sequence 21 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09031	SSLLEKGLDGAKKAVGGL	18	Sequence 22 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09032	SSLLEKGLDGAKKAVGG	17	Sequence 23 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09033	SSLLEKGLDGAKKAVG	16	Sequence 24 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09034	SSLLEKGLDGAKKAV	15	Sequence 25 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09035	SSLLEKGLDGAKKA	14	Sequence 26 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09036	SSLLEKGLDGAKK	13	Sequence 27 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09037	SSLLEKGLDGAK	12	Sequence 28 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09039	SSLLEKGLDG	10	Sequence 30 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09040	SSLLEKGLD	9	Sequence 31 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09041	SSLLEKGL	8	Sequence 32 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09042	SSLLEKG	7	Sequence 33 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP09043	SSLLEK	6	Sequence 34 from Patent US 8329865	Homo sapiens	Antimicrobial	US 8329865 B2	Granted Patent	2012##12##11	US20090124546	Antimicrobially active peptides.	An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.
DRAMP18842	KNLRRIIRKIIHIIKKYG	18	Sequence 1 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18843	RGLRRLGRKIAHGVKKYGPTVLRIIRIAG	29	Sequence 2 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 19, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18844	KNIRRIIRKIIHIIKKYG	18	Sequence 7 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 20, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18845	KNLRRIIRKIIHIIKKYG	18	Sequence 8 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 21, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18846	LRRIIRKIIHIIKK	14	Sequence 12 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 22, but which contain a lesser number ofmino acid residues yet still retain bacter
DRAMP18847	IRRIIRKIIHIIKK	14	Sequence 14 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 23, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18848	GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY	37	Sequence 18 from Patent US 7071293	Oryctolagus cuniculus 	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 24, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18849	RGLRRLGRKIAHGVKKYGPTVLRIIRIA	28	Sequence 27 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 25, but which contain a lesser number ofmino acid residues yet still retain bacter
DRAMP18850	NLRRIIRKIIHIIKKY	16	Sequence 30 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 26, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18851	NIRRIIRKIIHIIKKY	16	Sequence 31 from Patent US 7071293	Ovis aries	Antimicrobial, Antiproliferative	US 7071293 B1	Granted Patent	2006##7##4	US5618675, US20050277176A1,  EP1359930A2, WO9402589	Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt	The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 27, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.
DRAMP18870	KKWWRRALQGLKTAGPAIQSVLNK	24	Sequence 19 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO20). Also provided are methods for inhibiti2936, , true utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18871	KKWWKAQKAVNSGPNALQTLAQ	22	Sequence 20 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO21). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18872	KKWWKAKKFANSGPNALQTLAQ	22	Sequence 21 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO22). Also provided are methods for inhibiti
DRAMP18873	KKWWKFIKKAVNSGTTGLQTLAS	23	Sequence 22 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO23). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18874	KKSFFKKLTSVASSVLS	17	Sequence 23 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO24). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18875	WKVFKSFIKKASSFAQSVLD	20	Sequence 24 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO25). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18876	KWKSFIKK	8	Sequence 34 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO26). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18877	KKWWRRXXXGLKTAGPAIQSVLNK	24	Sequence 35 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO27). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18878	KWKLFKKIGIGAVLKVLTTGLPALIS	26	Sequence 36 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO28). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject..
DRAMP18879	KWKLFKKIGIGAVLKVLTTGLPALKKTK	28	Sequence 37 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOH (SEQ ID NO,1) and NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH (SEQ ID NO29). Also provided are methods for inhibiti the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18880	RVIRVVQRACRAIRHIVRRIRQGLRRIL	28	Sequence 1 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2 	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18881	RVIRVVQRACRAIRHIVRRIRQGLRRILRVV	31	Sequence 2 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2 	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP2) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18882	RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV	31	Sequence 3 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP3) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18883	RVVRVVRRVVRR	12	Sequence 4 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP4) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18884	RRVVRRVRRVVRRVVRVVRRVVRR	24	Sequence 5 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP5) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18885	VRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	36	Sequence 6 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP6) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18886	RRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	42	Sequence 7 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP7) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18887	RVVRVVRRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	48	Sequence 8 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP8) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18888	RVVRVVRRWVRR	12	Sequence 9 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP9) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18889	RRWVRRVRRVWRRVVRVVRRWVRR	24	Sequence 10 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LL10) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18890	VRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	36	Sequence 11 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LL11) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18891	RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWRVV	48	Sequence 12 from Patent US 6887847	Synthetic construct	Antimicrobial, Antibacterial	US 6887847 B2	Granted Patent	2005##5##3	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LL12) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18892	KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS	59	Sequence 1 from Patent US 6884776	Synthetic construct	Antimicrobial	US 6884776 B1	Granted Patent	2005##4##26	CA2291894A1, DE69840024D1, EP1003854A1, EP1003854B1, WO1998054314A1	Antimicrobial peptides derived from ubiquicidine.	The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 713 amino acids from the amino acid sequence of ubiquicidine.
DRAMP18893	GIGKFLHSAGKFGKAFVGEIMKS	23	Sequence 1 from Patent US 6872705	Xenopus laevis	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18894	GIGKFLHSAKKFGKAFVGEIMNS	23	Sequence 2 from Patent US 6872705	Xenopus laevis	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18895	GIGKFLKKAKKFGKAFVKILKX	22	Sequence 3 from Patent US 6872705	Synthetic construct	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18896	GIGKFLKKAKKFGKAFVKILKK	22	Sequence 4 from Patent US 6872705	Synthetic construct	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18897	KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK	37	Sequence 5 from Patent US 6872705	Bombyx mori	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18898	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG	36	Sequence 6 from Patent US 6872705	Bombyx mori	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18899	MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG	38	Sequence 7 from Patent US 6872705	Synthetic construct	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18900	ACYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 8 from Patent US 6872705	Homo sapiens 	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18901	CYCRIPACIAGERRYGTCIYQGRLWAFCC	29	Sequence 9 from Patent US 6872705	Homo sapiens 	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18902	DCYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 10 from Patent US 6872705	Homo sapiens 	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18903	VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR	33	Sequence 11 from Patent US 6872705	Oryctolagus cuniculus	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18904	RLCRVVIRVCR	11	Sequence 12 from Patent US 6872705	Bos taurus	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18905	KWKLFKKIGIGAVLKVLTTGLPALIX	26	Sequence 13 from Patent US 6872705	Synthetic construct	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18906	KWKGIGAVLKVLTTGX	16	Sequence 14 from Patent US 6872705	Synthetic construct	Antimicrobial	US 6872705 B2	Granted Patent	2005##3##29	US4525346, US6372234, US6482799	Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP18907	RVIRVVQRACRAIRHIVRRIRQGLRRIL	28	Sequence 1 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1 	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18908	RVIRVVQRACRAIRHIVRRIRQGLRRILRVV	31	Sequence 2 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1 	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP2) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18909	RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV	31	Sequence 3 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP3) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18910	RVVRVVRRVVRR	12	Sequence 4 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP4) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18911	RRVVRRVRRVVRRVVRVVRRVVRR	24	Sequence 5 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP5) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18912	VRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	36	Sequence 6 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP6) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18913	RRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	42	Sequence 7 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP7) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18914	RVVRVVRRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	48	Sequence 8 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP8) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18915	RVVRVVRRWVRR	12	Sequence 9 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP9) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18916	RRWVRRVRRVWRRVVRVVRRWVRR	24	Sequence 10 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LL10) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18917	VRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	36	Sequence 11 from Patent US 6835713	Synthetic construct	Antimicrobial	US 6838435 B1	Granted Patent	2004##12##28	US5714577, US5945507	Virus Derived Antimicrobial Peptides	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LL11) amino acid sequence. The invention is further directed tpeptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP18918	WRWWKVVWRWVKW	13	Sequence 121 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2 	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175  	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18919	WRWWKVWRWVKW	12	Sequence 120 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2 	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175  	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18920	ILRWPWWPWRRK	12	Sequence 119 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18921	RLARIVVIRVAR	12	Sequence 118 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18922	GKPRPYSPIPTSPRPIRY	18	Sequence 117 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18923	KWKLFIKKLTPAVKKVLLTGLPALIS	26	Sequence 116 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18924	KWKSFIKKLTSAAKKVLTTGLPALIS	26	Sequence 115 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18925	KWKLFKKIGIGAVLKVLTTGLPALKLTK	28	Sequence 112 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18926	KKWWRRALQALKNGLPALIS	20	Sequence 109 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18927	WXWWXPXWXWPXW	13	Sequence 105 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18928	WXWWXVAWXWVXW	13	Sequence 103 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18929	WRWWKVAWRWVKW	13	Sequence 100 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18930	WRWWKPKWRWPKW	13	Sequence 99 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18931	RRIWKPKWRLPKR	13	Sequence 97 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18932	ILRWPWWPWRRA	12	Sequence 96 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18933	ILRWPWWPWRAK	12	Sequence 95 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18934	ILRWPWWPWARK	12	Sequence 94 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18935	ILRWPWWPARRK	12	Sequence 93 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18936	ILRWPWWAWRRK	12	Sequence 92 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18937	ILRWPWAPWRRK	12	Sequence 91 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18938	ILRWPAWPWRRK	12	Sequence 90 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18939	ILRWAWWPWRRK	12	Sequence 89 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18940	ILRAPWWPWRRK	12	Sequence 88 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18941	ILAWPWWPWRRK	12	Sequence 87 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18942	IARWPWWPWRRK	12	Sequence 86 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18943	ALRWPWWPWRRK	12	Sequence 85 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18944	RWWWPWRRK	9	Sequence 84 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18945	WPWWPWRRK	9	Sequence 83 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18946	LRWPWWPW	8	Sequence 82 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18947	LRWWWPWRRK	10	Sequence 81 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18948	LWPWWPWRRK	10	Sequence 80 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18949	ILKKWPWWPWR	11	Sequence 79 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18950	ILKKWPWWPWK	11	Sequence 78 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18951	ILKKWPWWPWRR	12	Sequence 77 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18952	ILKKWPWWPRRK	12	Sequence 76 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18953	ILKKWPWWWRRK	12	Sequence 75 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18954	ILKKWWWPWRRK	12	Sequence 74 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18955	ILKKPWWPWRRK	12	Sequence 73 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18956	IKKWPWWPWRRK	12	Sequence 72 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18957	WVRLWWRRVW	10	Sequence 71 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18958	RLWVWWVWRR	10	Sequence 70 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18959	RLVVWVVWRR	10	Sequence 68 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18960	RLFVWWVFRR	10	Sequence 67 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18961	RLVVWWVVRR	10	Sequence 66 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18962	RLWWVVWWRR	10	Sequence 65 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18963	RLGGGWVWWVWRR	13	Sequence 64 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18964	RLWVWWVWRRK	11	Sequence 62 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18965	ILRWWVWWVWWRRK	14	Sequence 61 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18966	ILRRWVWWVWRRK	13	Sequence 60 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18967	KRRWVWWVWRLI	12	Sequence 59 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18968	ILRWVWWVWRRK	12	Sequence 58 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18969	ILKKWVWWPWRRK	13	Sequence 57 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18970	ILKKWPWWVWRRK	13	Sequence 56 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18971	ILKKWVWWVWRRK	13	Sequence 55 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18972	ILKKWPWWPWRRK	13	Sequence 54 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18973	CLRWPWWPWRRK	12	Sequence 51 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18974	WRIWKPKWRLPKW	13	Sequence 50 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18975	ILKKWPWWWRK	11	Sequence 49 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18976	ILKKWWWPWRK	11	Sequence 48 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18977	ILKKWPWWPWRRIM	14	Sequence 47 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18978	ILKKWPWWPWRRKM	14	Sequence 45 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18979	ILKKWPW	7	Sequence 44 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18980	WWPWRRK	7	Sequence 43 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18981	ILKKWPWWPWRRIMILKKAGS	21	Sequence 42 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18982	ILKKWPWWPWRRMILKKAGS	20	Sequence 41 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18983	ILKKWPWWPWRRKMILKKAGS	21	Sequence 40 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18984	PWWPWRRK	8	Sequence 39 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18985	LKKWPWWPWRRK	12	Sequence 38 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18986	WWKKWPWWPWRRK	13	Sequence 37 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18987	ILKKWPWWAWRRK	13	Sequence 36 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18988	ILKKWAWWPWRRK	13	Sequence 35 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18989	ILKWVWWVWRRK	12	Sequence 34 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18990	KRKWPWWPWRLI	12	Sequence 33 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18991	ILRWPWWPWRRKILMRWPWWPWRRKMAA	28	Sequence 32 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18992	ILRWPWRRWPWRRK	14	Sequence 31 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18993	ILRWPWWPWRRKDMILKKAGS	21	Sequence 30 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18994	ILRWPWWPWRRKMILKKAGS	20	Sequence 29 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18995	ILRWPWWPWRRKIMILKKAGS	21	Sequence 28 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18996	ILKKWPWWPWKKK	13	Sequence 27 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18997	ILRRWPWWPWRRR	13	Sequence 26 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18998	ILWPWWPWRRK	11	Sequence 25 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP18999	KRRWPWWPWRLI	12	Sequence 24 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19000	ILKWPWWPWRK	11	Sequence 22 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19001	ILKKWPWWPWRK	12	Sequence 21 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19002	ILKWPWWPWRRK	12	Sequence 20 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19003	ILRRWPWWPWRK	12	Sequence 19 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19004	ILRRWPWWPWRRK	13	Sequence 18 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19005	WWRWPWWPWRRK	12	Sequence 17 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19006	ILRWPWWPWWPWRRK	15	Sequence 16 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19007	ILRYVYYVYRRK	12	Sequence 15 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19008	ILKKFPFWPWRRK	13	Sequence 14 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19009	ILKKFPWFPWRRK	13	Sequence 13 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19010	ILKKYPWYPWRRK	13	Sequence 12 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19011	ILKKWPWPWRRK	12	Sequence 11 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19012	ILKKYPYYPYRRK	13	Sequence 10 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19013	ILKKIPIIPIRRK	13	Sequence 9 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19014	ILKKFPFFPFRRK	13	Sequence 8 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19015	KRRWPWWPWKKLI	13	Sequence 7 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19016	KKAAAKAAAAAKAAWAAKAAAKKKK	25	Sequence 2 from Patent US 6835536	Synthetic construct	Antimicrobial	US 6835536 B2	Granted Patent	2004##12##28	US4510132, US6503881, US6538106, EP590070, WO9112815, WO0000214, WO0071175	Antimicrobial Cationic Peptides And Formulations Thereof	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP19017	ALWKTMLKKLGTMALHAGKAALGAAADTISQTQ	33	Sequence 23 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2 	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19018	SIGSAFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 21 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2 	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,16). Also provided are methods for inhibiting thegrowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19019	ALWKTMLKKAAHVGKHVGKAALGAAARRRK	30	Sequence 20 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,17). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19020	GWGSFFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 19 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,18). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19021	SIGSAFKKAAHVGKHVGKAALTHYL	25	Sequence 18 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,19). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19022	ALWKTMLKKAAHVGKHVGKAALTHYL	26	Sequence 17 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,20). Also provided are methods for inhibiting the
DRAMP19023	KGWGSFFKKAAHVGKHVGKAALTHYL	26	Sequence 16 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,21). Also provided are methods for inhibiting the
DRAMP19024	KKWKKFIKKIGIGAVLTTPGAKK	23	Sequence 12 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,22). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19025	KWKKFIKKIGIGAVLKVLTTGLPALKLTKK	30	Sequence 11 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,23). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19026	KWKSFIKKLTSAAKKVTTAAKPLTK	25	Sequence 10 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,24). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19027	KLWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	33	Sequence 9 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,25). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19028	KWKFKKIGIGAVLKVLKVLTTGLPALKLTLK	31	Sequence 8 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,26). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19029	KLFKKIGIGAVLKVLKVLTTGLPALKLTLK	30	Sequence 7 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,27). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19030	KWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	32	Sequence 6 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,28). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19031	KWKKFIKSLTKSAAKTVVKTAKKPLIV	27	Sequence 5 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,29). Also provided are methods for inhibiting the
DRAMP19032	KWKSFIKKLTKAAKKVVTTAKKPLIV	26	Sequence 4 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,30). Also provided are methods for inhibiting the
DRAMP19033	KWKSFIKKLTSAAKKVVTTAKPLALIS	27	Sequence 3 from Patent US 6818407	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6818407 B2	Granted Patent	2004##11##16	WO8900199, WO9638473	Antiendotoxic Antimicrobial Cationic Peptides And Methods Of Use Therfor	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO,3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO,31). Also provided are methods for inhibiting therowth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP19034	HIFR	4	Sequence 5 from Patent US 6753407	Synthetic construct	Antimicrobial	US 6753407 B2 	Granted Patent	2004##6##22	WO8900199, WO9421672	Antimicrobial Peptides Isolated From Fish	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis
DRAMP19035	FFRHLFRGAKAIFRGARQGXRAHKVVSRYRNRDVPETDNNQEEP	44	Sequence 4 from Patent US 6753407	Morone saxitilis x Morone	Antimicrobial	US 6753407 B2 	Granted Patent	2004##6##22	WO8900199, WO9421672	Antimicrobial Peptides Isolated From Fish	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2501 Da from the gills of hybrid striped bass (Morone saxitilis
DRAMP19036	FFHHIFRGIVHVGKTIHRLVTG	22	Sequence 2 from Patent US 6753407	Morone saxitilis x Morone	Antimicrobial	US 6753407 B2	Granted Patent	2004##6##22	WO8900199, WO9421672	Antimicrobial Peptides Isolated From Fish	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2502 Da from the gills of hybrid striped bass (Morone saxitilis
DRAMP19037	FIHHIFRGIVHAGRSIGRFLTG	22	Sequence 1 from Patent US 6753407	Morone saxitilis x Morone	Antimicrobial	US 6753407 B2	Granted Patent	2004##6##22	WO8900199, WO9421672	Antimicrobial Peptides Isolated From Fish	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2503 Da from the gills of hybrid striped bass (Morone saxitilis
DRAMP19038	RRWCFRVCYRGXFCYRKCR	19	Sequence 19 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2 	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19039	RRWCXRVCYXGFCYRKCR	18	Sequence 18 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2 	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,12). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19040	RXWCXXXCYRGFCXXXCR	18	Sequence 17 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,13). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19041	RRWCFXVCXRGXCYXXCRX	19	Sequence 16 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,14). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19042	XRWCFRVCYXGXCXXXCR	18	Sequence 15 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,15). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19043	WCFXVCXRGXCRXKCRR	17	Sequence 14 from Patent US 6747007	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,16). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19044	RRWCFRVCYRGRFCYRKCR	19	Sequence 11 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,17). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19045	RRWCRRVCYAGFCYRKCR	18	Sequence 10 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,18). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19046	RVWCRYRCYRGFCRRFCR	18	Sequence 9 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,19). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19047	RVWCRRRCYRGFCRYFCR	18	Sequence 8 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,20). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19048	RRWCFIVCRRGRCYVACRR	19	Sequence 7 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,21). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19049	RRWCFIVCRRGACYRRCR	18	Sequence 6 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,22). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19050	RRWCFRVCYRGFCRYFCR	18	Sequence 5 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,23). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19051	RRWCFRVCYKGFCRYKCR	18	Sequence 4 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,24). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19052	FRWCFRVCYKGRCRYKCR	18	Sequence 3 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,25). Also provided are meth
DRAMP19053	WCFAVCYRGRCRRKCRR	17	Sequence 2 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,26). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19054	WCFAVCRRGRCRYKCRR	17	Sequence 1 from Patent US 6747007	Limulus polyphemus 	Antimicrobial, Antibacterial, Antifungal	US 6747007 B2	Granted Patent	2004##6##8	US5593866, US6191254, US6337317, EP0563844, WO9510534, WO9803192	Antimicrobial Peptides And Methods Of Use Thereof	A class of cationic, polyphemusinlike peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO,3), RRWCFRVCYKGFCRYKCR (SEQ ID NO,4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO,27). Also provided are meths for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP19055	ANLIATKKNGRKLCL	15	Sequence 29 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1 	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19056	KFDKSKLKKTETQEKNPL	18	Sequence 28 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1 	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19057	EGVNDNEEGFFSA	13	Sequence 27 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19058	ADSGEGDFLAEGGGVRKLIK	20	Sequence 26 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19059	ADSGEGDFLAEGGGVR	16	Sequence 25 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19060	SWVQEYVYDLEL	12	Sequence 24 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19061	EWVQKYVSDLELSAWKKILK	20	Sequence 23 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19062	KWVREYINSLEMSKKGLAG	19	Sequence 22 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19063	PRIKKIVQKKLAG	13	Sequence 21 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19064	KWKWWWWWKWK	11	Sequence 20 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19065	KGYFYFLFKFK	11	Sequence 19 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19066	KFKHYFFWKYK	11	Sequence 18 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19067	YAERLCTCSIKAEV	14	Sequence 17 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19068	SAIHPSSILKLEVICIGVLQ	20	Sequence 16 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19069	RFEKSKIK	8	Sequence 15 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19070	ATKKNGRKLCLDLQAAL	17	Sequence 14 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19071	ALYKRLFKKLKKF	13	Sequence 13 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19072	GLYKRLFKKLLKS	13	Sequence 12 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19073	ALYKKLFKKLLKR	13	Sequence 11 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19074	KLYKKWKNKLKRSLKRLG	18	Sequence 10 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19075	ALYKKWKNKLLKS	13	Sequence 9 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19076	KLYKKWKKKLLKLK	14	Sequence 8 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19077	ARYRKFRNKILRS	13	Sequence 7 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19078	ARYRKFKNKILKS	13	Sequence 6 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19079	KLYRKFKNKLLKLK	14	Sequence 5 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19080	ARYKKFKKKLLKS	13	Sequence 4 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19081	ALYKKFKKKLLKSLKRLG	18	Sequence 3 from Patent US 6743769	Synthetic construct	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19082	SDDPKESEGDLHCVCVKTTSLVRPGHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 2 from Patent US 6743769	Oryctolagus cuniculus 	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19083	SDDPKESEGDLHCVCVKTTSLVRPRHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 1 from Patent US 6743769	Oryctolagus cuniculus 	Antimicrobial	US 6743769 B1	Granted Patent	2004##6##1	US5409898, US5834430, WO9942119, WO0018922, WO0022170, WO0031263	Antimicrobial Peptides And Derived Metapeptides	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP19084	RHFCGGALIHARYVMTAASS	20	Sequence 58 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19085	RHYCGGALIHARFVMTAASS	20	Sequence 57 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19086	RHFCGGALIHARFAMTAASS	20	Sequence 56 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19087	RHFCGGALIHARFIMTAASS	20	Sequence 55 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19088	RHFCGGALIHARFLMTAASS	20	Sequence 54 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19089	RHFCAAALIHARFVMTAASS	20	Sequence 53 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19090	RHFCGAALIHARFVMTAASS	20	Sequence 52 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19091	RHFCAGALIHARFVMTAASS	20	Sequence 51 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19092	RHFSGGALIHARYVMTAASC	20	Sequence 50 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19093	RHYSGGALIHARFVMTAASC	20	Sequence 49 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19094	RHFSGGALIHARFAMTAASC	20	Sequence 48 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19095	RHFSGGALIHARFIMTAASC	20	Sequence 47 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19096	RHFSGGALIHARFLMTAASC	20	Sequence 46 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19097	RHFSAAALIHARFVMTAASC	20	Sequence 45 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19098	RHFSGAALIHARFVMTAASC	20	Sequence 44 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19099	RHFSAGALIHARFVMTAASC	20	Sequence 43 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19100	NQGRHFCGGALIHARFVMTAASCYQ	25	Sequence 42 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19101	NQGRHYCGGALIHARFVMTAASCFQ	25	Sequence 40 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19102	NQGRHFCGGALIHARFAMTAASCFQ	25	Sequence 39 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19103	NQGRHFCGGALIHARFIMTAASCFQ	25	Sequence 38 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19104	NQGRHFCGGALIHARFLMTAASCFQ	25	Sequence 37 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19105	NQGRHFCGGALIHARFVMTAATCFQ	25	Sequence 36 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19106	NQGRHFCAAALIHARFVMTAASSFQ	25	Sequence 35 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19107	NQGRHFCGAALIHARFVMTAASSFQ	25	Sequence 34 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19108	NQGRHFCAGALIHARFVMTAASSFQ	25	Sequence 33 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19109	NQGRHFSAAALIHARFVMTAASCFQ	25	Sequence 32 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19110	NQGRHFSGAALIHARFVMTAASCFQ	25	Sequence 31 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19111	NQGRHFSAGALIHARFVMTAASCFQ	25	Sequence 30 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19112	NQGRHFCAAALIHARFVMTAASCFQ	25	Sequence 29 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19113	NQGRHFCGAALIHARFVMTAASCFQ	25	Sequence 28 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19114	NQGRHFCAGALIHARFVMTAASCFQ	25	Sequence 27 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19115	RHFCGGALIHARFVMTAAKS	20	Sequence 26 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19116	RHFCGGALIHARFVMTAARS	20	Sequence 25 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19117	RHFCGGALIHARFVMTAAHS	20	Sequence 24 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19118	RHFSGGALIHARFVMTAAKC	20	Sequence 23 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19119	RHFSGGALIHARFVMTAARC	20	Sequence 22 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19120	RHFSGGALIHARFVMTAAHC	20	Sequence 21 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19121	NQGRHFCGGALIHARFVMTAAKSFQ	25	Sequence 20 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19122	NQGRHFCGGALIHARFVMTAARSFQ	25	Sequence 19 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19123	NQGRHFCGGALIHARFVMTAAHSFQ	25	Sequence 18 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19124	NQGRHFSGGALIHARFVMTAAKCFQ	25	Sequence 17 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19125	NQGRHFSGGALIHARFVMTAARCFQ	25	Sequence 16 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19126	NQGRHFSGGALIHARFVMTAAHCFQ	25	Sequence 15 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19127	RHFCGGALIHARFVMTAAKC	20	Sequence 14 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19128	RHFCGGALIHARFVMTAARC	20	Sequence 13 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19129	RHFCGGALIHARFVMTAAHC	20	Sequence 12 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19130	NQGRHFCGGALIHARFVMTAAKCFQ	25	Sequence 11 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19131	NQGRHFCGGALIHARFVMTAARCFQ	25	Sequence 10 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19132	RHFSGGALIHARFVMTAASS	20	Sequence 9 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19133	NQGRHFSGGALIHARFVMTAASSFQ	25	Sequence 7 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19134	RHFCGGALIHARFVMTAASS	20	Sequence 6 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19135	NQGRHFCGGALIHARFVMTAASSFQ	25	Sequence 5 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19136	RHFSGGALIHARFVMTAASC	20	Sequence 4 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19137	NQGRHFSGGALIHARFVMTAASCFQ	25	Sequence 3 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19138	RHFCGGALIHARFVMTAASC	20	Sequence 2 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19139	NQGRHFCGGALIHARFVMTAASCFQ	25	Sequence 1 from Patent US 6730659	Homo Sapiens 	Antimicrobial, Antibacterial	US 6730659 B2	Granted Patent	2004##5##4	US4652639, US5877151, US6107460	Antimicrobial Peptides And Methods Of Use Thereof	Novel peptide analogs derived from the native sequences of CAP37 peptides 2044 and 2342, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP19140	NHRSCYRNKGVCAPARCPRNMRQIGTCHGPPVKCCR	36	Sequence 88 from Patent US 6696238	Capra hircus	Antimicrobial, Antibacterial	US 6696238 B2	Granted Patent	2004##2##24	US4543252, US6045990, US6258341, EP 140498	Transplant Media	The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.
DRAMP19141	SRRSCHRNKGVCALTRCPRNMRQIGTCFGPPVKCCR	36	Sequence 87 from Patent US 6696238	Capra hircus	Antimicrobial, Antibacterial	US 6696238 B2	Granted Patent	2004##2##24	US4543252, US6045990, US6258341, EP 140498	Transplant Media	The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.
DRAMP19142	MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	64	Sequence 85 from Patent US 6696238	Homo sapiens	Antimicrobial, Antibacterial	US 6696238 B2	Granted Patent	2004##2##24	US4543252, US6045990, US6258341, EP 140498	Transplant Media	The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.
DRAMP19143	MRVLYLLFSFLFIFLMPLPGVFGGISDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	64	Sequence 84 from Patent US 6696238	Pan troglodytes	Antimicrobial, Antibacterial	US 6696238 B2	Granted Patent	2004##2##24	US4543252, US6045990, US6258341, EP 140498	Transplant Media	The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.
DRAMP19144	MRLHHLLLALLFLVLSAGSGFTQGVRNSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK	64	Sequence 1 from Patent US 6696238	Bos taurus	Antimicrobial, Antibacterial	US 6696238 B2	Granted Patent	2004##2##24	US4543252, US6045990, US6258341, EP 140498	Transplant Media	The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.
DRAMP19145	RRLRRIIRKGIRIIKKYG	18	Sequence 37 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19146	KRLRRIIRKGIHIIKKYG	18	Sequence 35 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19147	KNLRRIIRKGIRIIKKYG	18	Sequence 33 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19148	KNLRRIIRKGIHIIKKYG	18	Sequence 31 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19149	KNLRRIIRKIAHIIKKYG	18	Sequence 29 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19150	KNLRRIIRKIDHIIKKYG	18	Sequence 28 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19151	KNLRRIIRKIEHIIKKYG	18	Sequence 27 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19152	KNLRRIIRKISHIIKKYG	18	Sequence 26 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19153	KNLRRIIRKITHIIKKYG	18	Sequence 25 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19154	KNLRRIIRKIGHIIKKYG	18	Sequence 24 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19155	KNLRRIIRKAIHIIKKYG	18	Sequence 22 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19156	KNLRRIIRKDIHIIKKYG	18	Sequence 21 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19157	KNLRRIIRKEIHIIKKYG	18	Sequence 20 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19158	KNLRRIIRKSIHIIKKYG	18	Sequence 19 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19159	KNLRRIIRKTIHIIKKYG	18	Sequence 18 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19160	KNLRRIARKIIHIIKKYG	18	Sequence 15 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19161	KNLRRIDRKIIHIIKKYG	18	Sequence 14 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19162	KNLRRIERKIIHIIKKYG	18	Sequence 13 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19163	KNLRRISRKIIHIIKKYG	18	Sequence 12 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19164	KNLRRITRKIIHIIKKYG	18	Sequence 11 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19165	KNLRRIGRKIIHIIKKYG	18	Sequence 10 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19166	KNLRRAIRKIIHIIKKYG	18	Sequence 8 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19167	KNLRRDIRKIIHIIKKYG	18	Sequence 7 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19168	KNLRREIRKIIHIIKKYG	18	Sequence 6 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19169	KNLRRSIRKIIHIIKKYG	18	Sequence 5 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19170	KNLRRTIRKIIHIIKKYG	18	Sequence 4 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19171	KNLRRGIRKIIHIIKKYG	18	Sequence 3 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19172	KNLRRXXRKXXHIIKKYG	18	Sequence 1 from Patent US 6492328	Synthetic construct	Antimicrobial, Anitibacterial, AnitiGram	US 6492328 B2	Granted Patent	2002##12##10		Novispirins, Antimicrobial Peptides	Novispirin peptides are antimicrobial agents with potent activity against Gramnegative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were welltolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gramnegative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gramnegative bacterial infections.
DRAMP19173	MRLHHLLLALLFLVLSAWSGFTQGVGNPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK	64	Sequence 30 from Patent US 6399370	Synthetic construct	Antimicrobial	US 6399370 B1	Granted Patent	2002##6##4	US4954487, US5240846, US5550109, US5625128, WO9428938	Compositions And Methods For Use Of Defensin	The invention relates to mammalian beta defensin and methods of use thereof for treatment of microbial infection.
DRAMP19174	NSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCR	36	Sequence 8 from Patent US 6399370	Synthetic construct	Antimicrobial	US 6399370 B1	Granted Patent	2002##6##4	US4954487, US5240846, US5550109, US5625128, WO9428938	Compositions And Methods For Use Of Defensin	The invention relates to mammalian beta defensin and methods of use thereof for treatment of microbial infection.
DRAMP19175	MKTHYFLLVMICFLFSQMEPGVGILTSLGRRTDQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	69	Sequence 7 from Patent US 6399370	Synthetic construct	Antimicrobial	US 6399370 B1	Granted Patent	2002##6##4	US4954487, US5240846, US5550109, US5625128, WO9428938	Compositions And Methods For Use Of Defensin	The invention relates to mammalian beta defensin and methods of use thereof for treatment of microbial infection.
DRAMP19176	DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	36	Sequence 4 from Patent US 6399370	Synthetic construct	Antimicrobial	US 6399370 B1	Granted Patent	2002##6##4	US4954487, US5240846, US5550109, US5625128, WO9428938	Compositions And Methods For Use Of Defensin	The invention relates to mammalian beta defensin and methods of use thereof for treatment of microbial infection.
DRAMP19177	PTHG	4	Sequence 20 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19178	PVPMR	5	Sequence 19 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19179	NGGVCIPIR	9	Sequence 18 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19180	QIGTCFGRPVL	11	Sequence 17 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19181	EGVRSYLSCWGNRGICLLNRCPGRMRQIGTCLAPRVKCCR	40	Sequence 10 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19182	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	40	Sequence 9 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19183	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPRIKCCR	40	Sequence 7 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19184	EGVRNHVTCRIYGGFCVPIRCPGRTRQIGTCFGRPVKCCRRW	42	Sequence 6 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19185	EVVRNPQSCRWNMGVCIPISCPGNMRQIGTCFGPRVPCCR	40	Sequence 5 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19186	ERVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPCCRR	41	Sequence 4 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19187	EGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	42	Sequence 3 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19188	DFASCHTNGGICLPNRCPGHMIQIGICFRPRVLCCRSW	38	Sequence 1 from Patent US 6211148	Synthetic construct	Antimicrobial	US 6211148 B1	Granted Patent	2001##4##3	WO9207873	Antimicrobial Peptides From Bovine Neutrophis	The present invention provides a new family of cysteinerich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granulerich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP19189	ILKKWPWWPWPPFFRRK	17	Sequence 42 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19190	ILKKWPWWPWPPRRK	15	Sequence 41 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19191	ILKKWPWWPWRRWWK	15	Sequence 40 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19192	ILKKWPWWPWRWWRR	15	Sequence 39 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19193	ILKKWPWWPWWPWRRK	16	Sequence 38 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19194	FFKKFPFFPFKKK	13	Sequence 37 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19195	FFKKFPFFPFRRK	13	Sequence 36 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19196	FFKKWPWWPWRRK	13	Sequence 35 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19197	ILKKFPFFPFKKK	13	Sequence 29 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19198	ILKKWPWWRWRR	12	Sequence 27 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19199	ILPWKWPPWPPWPWRR	16	Sequence 22 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19200	ILPWKWFFPPWPWRR	15	Sequence 21 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19201	IKWPWYVWL	9	Sequence 20 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19202	ILPWKWPWYVRR	12	Sequence 19 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19203	ILKKWPWWPWKWKK	14	Sequence 18 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19204	ILKKWPWWPWKRR	13	Sequence 17 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19205	TLPCLWPWWPWSI	13	Sequence 15 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19206	IVPWKWTLWPWRR	13	Sequence 14 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19207	ILPWICPWRPSKAN	14	Sequence 13 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19208	ILPWKWPWWPWWKKPWRR	18	Sequence 12 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19209	ILPWKWPWWPWWPWRR	16	Sequence 11 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19210	ILPWKWPWRR	10	Sequence 10 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19211	PWKWPWWPWRR	11	Sequence 9 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19212	ILPWKWPWWPWKKWK	15	Sequence 8 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19213	ILPWKWPWWPWRRWR	15	Sequence 7 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19214	ILPWKWPWWPWRKWR	15	Sequence 6 from Patent US 6191254	Synthetic construct	Antimicrobial	US 6191254 B1	Granted Patent	2001##2##20	US4810777, US5547939, US5635594, CA12060510, EP0356409, WO8911290,  WO9522338	Antimicrobial Cationic Peptides	"A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas, wherein, m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine
 X3 represents Arginine or Lysine;  X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity."
DRAMP19215	CTVAGWGRVSMRRGT	15	Sequence 39 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19216	RPGLTLCTVAGWG	13	Sequence 38 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19217	HPLYNQR	7	Sequence 37 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19218	HPEYNQR	7	Sequence 36 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19219	HPNYNQR	7	Sequence 35 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19220	HPQFNQR	7	Sequence 34 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19221	HPQKNTY	7	Sequence 33 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19222	HPQANQR	7	Sequence 32 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19223	HHQYNQR	7	Sequence 31 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19224	HPQYNPQ	7	Sequence 30 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19225	IIGGV	5	Sequence 29 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19226	IIGGH	5	Sequence 28 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19227	APQYNQR	7	Sequence 27 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19228	GKSSGVPPEVFTRFVSSFLPWIRTTMR	27	Sequence 26 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19229	FKGDSGGPLLCNNVAHGIVSY	21	Sequence 25 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19230	GSYDPRRQICVGDRRERKAA	20	Sequence 24 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19231	DTLREVQLRVQRDRQCLRIF	20	Sequence 23 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19232	RPGTLCTVAGWGRVSMRRGT	20	Sequence 22 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19233	RVRRNRNVNPVALPRAQEGL	20	Sequence 21 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19234	HPQYNQRTIQNDIMLLQLSR	20	Sequence 20 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19235	RRENTQQHITARRAIRHPQY	20	Sequence 19 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19236	TAAHCWGSNINVTLGAHNIQ	20	Sequence 18 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19237	QSPAGQSRCGGFLVREDFVL	20	Sequence 17 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19238	IIGGRESRPHSRPYMAYLQI	20	Sequence 16 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19239	RHPQYNQR	8	Sequence 13 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19240	HPQYNQ	6	Sequence 12 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19241	HAQYNQR	7	Sequence 11 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19242	HPQYR	7	Sequence 10 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19243	HPQYNQA	7	Sequence 9 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19244	HPQYAQR	7	Sequence 8 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19245	HPAYNQR	7	Sequence 7 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19246	HPAYNPR	7	Sequence 6 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19247	HPAYNPK	7	Sequence 5 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19248	HXXXXXX	7	Sequence 4 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19249	HPQYNQR	7	Sequence 3 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19250	IVGGR	5	Sequence 2 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19251	IIGGR	5	Sequence 1 from Patent US 5798336	Synthetic construct	Antimicrobial, Anitibacterial	US 5798336 A	Granted Patent	1998##8##25	US4725576	Antimicrobial Peptides	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO,22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO,19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO,26) also exhibited potent activity against P. aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO,1) and IVGGR (SEQ ID NO,2) act against both gramnegative and grampositive bacterial strains. HPQYNQR (SEQ ID NO,3) and certain related peptides are also active against both gramnegative and grampositive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical compos
DRAMP19252	EGRERDHELRHRRHHHQSPKSHFELPHYPGLLAHQKPFIRKSYKCLHKRCR	51	Sequence 1 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 20 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC7D1 protein. These peptides are useful as antifungal and antibacterial agents. A method of using these peptides as antifungal and antibacterial agents is also disclosed.
DRAMP19253	RERDHELRHRRHHHQ	15	Sequence 2 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 21 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC_x0005__x0005__x0005__x0001_ҫ_x0005__x0004__x0001__x0013_
DRAMP19254	SPKSHFELPHYPGLLAHQKPFIRKSYKCLHKRCR	34	Sequence 3 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 22 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19255	LAHQKPFIRKSYKCLHKRCR	20	Sequence 4 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 23 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19256	KPFIRKSYKCLHKRCR	16	Sequence 5 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 24 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19257	RKSYKCLHKRCR	12	Sequence 6 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 25 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19258	KSYKCLHKRCR	11	Sequence 7 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 26 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19259	SYKCLHKRCR	10	Sequence 8 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 27 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19260	KCLHKRCR	8	Sequence 9 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 28 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19261	LAHQKPFI	8	Sequence 10 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 29 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19262	AASYKCLHKRCR	12	Sequence 11 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 30 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19263	AASYACLHAACA	12	Sequence 12 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 31 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19264	RKSYKALHKRAR	12	Sequence 13 from Patent US 6790833	Homo sapiens	Antimicrobial, Anitibacterial, Antifunga	US 6790833 B2	Granted Patent	2004##9##14		Antifungal And Antibacterial Agents	The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 32 amino acids in length and have a net positive charge. The peptides are obtained from the Cterminus of the MUC
DRAMP19265	VLKKAYRVKSDKDFQAIFTEGRSVANRKFWYSLEKDQSHYRVGLSVGKRLGNAWRNAIKRKLRHVLMELGPYLGTQDFWIARKGVEELDYSTMKKNLVHV	119	Sequence 20 from Patent US 6936432	Streptococcus mutans UAB1	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19266	WKLAFPRELRLLTPSHFTFVFQQPQRAGTPQITIL6RLNSLGHPRIGLTVAKKNVKRAHERNRIKRLTRESFRLRQHELPPMDFVWAKRGVADLDNRALS	119	Sequence 21 from Patent US 6936432	Klebsiella pneumoniae M6B	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19267	VTFVNSRSFHIRLPATSTGCTPQITILGRLNSLGHPRIGLTVAKKNVRRAHERNRIKRLTRESFRLRQHELPAMDFVWAKKGVADLDNRALSEALEKLWR	110	Sequence 22 from Patent US 6936432	Salmonella paratyphi A AZ	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19268	WSRDPDRDKRLLTARQPSAVFDSPTGKVPGKHVLLLARENGLDHPRLGLVIGKKNVKLAVQRNRLKRLIRESFRHNQETLA6WDIWIARKGLGELENPEL	135	Sequence 23 from Patent US 6936432	Pseudomonas aeruginosa PA	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19269	VTLTSSNRTTVLPSQHKLSNSEQFRATIRKGKRAGRSTWLHFYAEATAGNLATAGGPRFGLWSKAVGNAVTRHRVSRQLRHWIAMKDQFPASSHWVRAIP	129	Sequence 24 from Patent US 6936432	Corynebacterium diphtheri	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19270	VHRLTLPKSARLLKRKQFVYVQRCGQYCRTDQATLRIVPSRHSNIRKVGVTVSKKFGKAHQRNRFKRIVREAFRHVRPNLPACQVWSPKGGTLPNF6KLS	119	Sequence 25 from Patent US 6936432	Chlamydia trachomatis MoP	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19271	SRIILSTYAFNRELRLLTPEHYQKVFQQAHSAGSPHLTIIARANNLSHPRLGLAVPKKQIKTAVGRNRFKRICRESFRLHQNQLAMKDFWIAKKSAQDLS	122	Sequence 26 from Patent US 6936432	Vibrio cholerae serotype 	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19272	VILDYRFGRQYRLLKTDDFSSVFAFRNRRSRDLIiQVSRSNGNGLDHPRIGLWGKKTAKRANERNYMKRVIRDWFRLNKNRLPPQDFWRVRRKFDRATAK	123	Sequence 27 from Patent US 6936432	Neisseria gonorrhoea FA 1	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19273	VILDYRFGRQYRLLKTDDFSSVFAFRNRRSRDLLQVSRSNGNGLDHPRIGLWGKKTAKRANERNYMKRVIRDWFRLNKNRLPPQDFWRVRRKFDRATAKQ	123	Sequence 28 from Patent US 6936432	Neisseria meningitidis se	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19274	VKREKOFQAIFKDGKSTANRKFVIYHLNRGQDBFRVGISVGKKIGNAVTRNAVKRKIRHVIHALGHQLKSEDFWIARKGVESLEYQELQQNLHHVLKLAQ	113	Sequence 29 from Patent US 6936432	Streptococcus pyogenes M1	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19275	MPRATLPAEARLHRPSEFAAALKGRRLARGAFFIVSASPCAPADDQPARARLGLVIAKRFAARAVTRNTLKRVIREAFRARRLALPAQDYWRLHSKLTPA	123	Sequence 30 from Patent US 6936432	Bordetella pertussis Toha	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19276	MTSPPTFGLSKSEKLYLRDEINTVFGEGKAFWYPLRWYRLGSEHRVAYSSMLVSVAKKRFRRAVKRNRVKRLVREAYRLNKHLLNDVLQBRQIYATIAFH	137	Sequence 31 from Patent US 6936432	Porphyromonas gingivalis 	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19277	VLKKNFRVKREKDFKAIFKEGTSFANRKFWYQLENQKNRFRVGLSVSKKLGNAVTRNQIKRRIRHIIQNAKGSLVEDVDFWIARKGVETLGYAEMEKHLL	124	Sequence 32 from Patent US 6936432	Streptococcus pneumoniae 	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19278	MDFNRTKGLKKDSDFRKVYKHGKSFANKYLVIYILKNKSDYSRVGISVSKKVGKAITRNRVRRLIKBAYRLNIDEKIKPGYDIVFIARVSSKDATFKDID	114	Sequence 33 from Patent US 6936432	Clostridium difficile 630	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19279	VKNFDKFSTNEEFSSVYKVGKKWHCEGVIIFYLNSYEKKIAWASKKVGKAWRNRSKRILRALFAKFERYLQDGKYIFVAKNEITELSFSRLEKNLKHGLK	108	Sequence 34 from Patent US 6936432	Camphylobacter jejuni NCT	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19280	MKJOKHRIKKNDErQTVFQKGKSNANRQrwyQLDKEEQPNFRIGLSVSKKIGNAWRNRIKRMIRQSITELKDEIDSGKDPVIXAHKPCAEMTYEEIiKKS	119	Sequence 35 from Patent US 6936432	Bacillus anthracis Ames	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19281	VLPARNRMTRSTEFDATVKHGTRMAQPDIWHLRRDSEPDDESAGPRVGLWGKAVGTAVQRHRVARRLRHVARALLGELEPSDRLVIRALP6SRTASSARL	119	Sequence 36 from Patent US 6936432	Mycobacterium avium 104	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19282	HLLEKAYRIKKNADFQRIYKKGHSVANRQFWYTCNNKEIDHFRLGISVSKKLGNAVLRNKIKRAIRENFKVHKSHILAKDIIVIARQPAKDMTTLQIQNS	117	Sequence 37 from Patent US 6936432	Staphylococcus aureus NCT	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19283	MLLEKAYRIKKNADFQRIYKKGHSVANRQFWYTCNNKEIDHFRLGISVSKKLGNAVLRNKIKRAIRENFKVHKSHLAKDIXVIARQPAKDMTTLQIQNSL	117	Sequence 38 from Patent US 6936432	Staphylococcus aureus COL	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19284	VIKLNFSRELRLLTPLHFKYVFEQPFRASTPELTILARPNNLAHPRLGLTVAKKHLKKAHDRNRIKRLCRESFRLAQYKLPNCDFVIVAKQGIGKLDNRT	119	Sequence 50 from Patent US 6936432	Pasteurella multocida PM7	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19285	VNKLTFSRELRLLAPIQFKAVFEQPYRASTAELTILARQNCVNTPRLGLTVAKKHLKRAHDRNRIKRIVRESFRLKQHQLPNFDFVFVAKHGIGKLDNAT	123	Sequence 51 from Patent US 6936432	Haemophilus ducreyi strai	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19286	MHRLTLPKSARLLKRKQFVYVQRCGQYCRTDQATLRIVPSRHSNIRKVGVTVSKKFGKAHQRNRFKRIVREAFRHVRPNLPACQVWSPKGGTLPNFGKLS	119	Sequence 52 from Patent US 6936432	Chlamydia muridarum 	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19287	VHRSTLPKYARVLKRKQFLYISRAGSHCQGSQVIFHVAPSRYSGCCKLGITVSKKFGKAjHKRNYFKRIVREAFRKKRHSLPACQIWMPKNKQQPKFEDL	139	Sequence 53 from Patent US 6936432	Chlamydophila psittaci	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19288	VSNFTFSGEERLRDRSCIKAVPQKGLKLSLNGVSLLILPNGLEYNRFIiCTFRRGFGSAVMRNRSRRISKEAYRHIKHRLKTGNDIILLVFSEKDSYSIi	108	Sequence 54 from Patent US 6936432	Treponema denticola	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19289	MKKSYRVKKEKEFQQVFHKKQSCANRRFWYVLEKPQQAHFRVGISVGKKIGNAVTRNAVKRKIRASLFQLKDRISPEIDFIVIARPGLEKLSSEEVKANL	118	Sequence 55 from Patent US 6936432	Enterococcus faecalis	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19290	QPHRLLKKNHFDFVFQSAKKIPTDDFIFLFRENKLGYARL6LALSKKMIAKABDRNRIKRLLRESFRHTNLPAVDIIILARPGLAKKTNL6INTKLHKTW	109	Sequence 56 from Patent US 6936432	Legionella pneumophila 	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19291	MEKAYRIKRNSDFQAIYKNGKSVANRQFWYTYKNRDLKHFRLGISVSKKL6NAVTRNRIKRAIRENFKVHKQMIIAKDIIVIARQPAKDMNTLEIQSSLE	115	Sequence 57 from Patent US 6936432	Staphylococcus epidermis	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19292	VLPARNRMRRSAEFSVTVSRGVRAAQPDVWHALRLESNAGNAGDDGDDGDANGPRIGLIVSKAVGNAVGRHRVSRRLRHVAKTFVSGLDPADLIVIRARP	130	Sequence 58 from Patent US 6936432	Mycobacterium smegmatis	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19293	VRGSIPLQASAAFPKAARLLKTDEFSSVFRLRPWRRTAHFVIYGKPTGRDARLGLVIGKKYAARAVTRNLVKRLAREAFRTRRAEFAGWDILLRLHA	97	Sequence 59 from Patent US 6936432	Burkholderia pseudomallei	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19294	MANFISLKKNEDILDTIKKQQKIHSNQIWYFRKTNLKNVRLAISISKKKFKLATQRNRIRYDIWLVKPSFIDGSFVLNCNNLKIILQRIINKEKR	113	Sequence 60 from Patent US 6936432	Ureaplasma urealyticum	Antimicrobial	US 6936432 B2	Granted Patent	2005##8##30	EP0811688, WO9818931, WO9911653	Bacterial Rnase P Proteins And Their Use In Identifying Antibacterial Compounds	The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
DRAMP19295	CKNQCIRLEKARHGS	15	Sequence 1 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP19296	CIRLEKARHGSCNYV	15	Sequence 2 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19297	EKARHGSCNYVFPAH	15	Sequence 3 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19298	HGSCNYVFPAHKCIC	15	Sequence 4 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19299	CNYVFPAHKC	10	Sequence 5 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19300	FPAHKC	6	Sequence 6 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19301	AHKCIC	6	Sequence 7 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19302	HKCICY	6	Sequence 8 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19303	QCIRLEKAR	9	Sequence 9 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19304	CIRLEKARH	9	Sequence 10 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19305	RHGSCNYVF	9	Sequence 11 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19306	CNYVFPAHK	9	Sequence 12 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19307	FPAHKCICY	9	Sequence 13 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19308	PAHKCICYF	9	Sequence 14 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19309	AHKCICYFP	9	Sequence 15 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19310	HKCICYFPC	9	Sequence 16 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19311	CIRLEKARHGSC	12	Sequence 17 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19312	EKARHGSCNYVF	12	Sequence 18 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19313	KARHGSCNYVFP	12	Sequence 19 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19314	RHGSCNYVFPAH	12	Sequence 20 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		_x000b__x000b_"
DRAMP19315	HGSCNYVFPAHK	12	Sequence 21 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19316	ARHGSCNYVFPAHKCICYF	19	Sequence 22 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19317	ASHGACHKRENHWKCFCYF	19	Sequence 23 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19318	AAHGACHVRNGKHMCFCYF	19	Sequence 24 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19319	QKLCERPSGTWSGVCGNNCKNQCINLEKARHGSCNYVFPAHKCICYFPC	49	Sequence 34 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19320	QKLCQRPSGTWSGVCGNNCKNQCIRLEKARHGSCNYVFPAHKCICYFPC	49	Sequence 35 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19321	KLCERSSGTWSGVCGNNCKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	48	Sequence 36 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19322	QKLCERSSGTWSGVCGNNCKNQCINLEGARHGSCNYIFPYHRCICYFPC	49	Sequence 37 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19323	QKLCERPSGTWSGVCGNNCKNQCINLEK	28	Sequence 40 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19324	QKLCERPSGTWSGVCGNNCKN	21	Sequence 41 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19325	QKLCERPSGTWSGVCGNNCKNQC	23	Sequence 42 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19326	QKLCQRPSGTWSGVCGNNCRNQCI	24	Sequence 43 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19327	QKLCERPSGTWSGVCGNSCKNQCIN	25	Sequence 44 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19328	QKLCQRPSGTWSGVC	15	Sequence 46 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19329	QRPSGTWSGVCGNNN	15	Sequence 47 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19330	GTWSGVCGNNCKN	13	Sequence 48 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19331	GVCGNNCKNQCIR	13	Sequence 49 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19332	NNCKNQCIRLEKA	13	Sequence 50 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19333	NYVFPAHKCICYFPC	15	Sequence 55 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
		
_x000b_"
DRAMP19334	DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC	54	Sequence 56 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19335	LCNERPSQTWSGNCGNTAHCDKQCQDWEKASHGACHKRENHWKCFCYFNC	50	Sequence 57 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19336	ELCEKASKTWSGNCGNTGHCDNQCKSWEGAAHGACHVRNGKHMCFCYFNC	50	Sequence 58 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19337	CICYFP	6	Sequence 129 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19338	ICYFPC	6	Sequence 130 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19339	VFPAHKCICYFP	12	Sequence 131 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19340	FPAHKCICYFPC	12	Sequence 132 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001_
DRAMP19341	QKLCQR	6	Sequence 133 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19342	KLCQRP	6	Sequence 134 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19343	LCQRPS	6	Sequence 135 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19344	QKLCQRPSG	9	Sequence 136 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0001__x0001__x0001__x0001__x0001__x0004__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0001__x0008_
_x0006_
"
DRAMP19345	KLCQRPSGT	9	Sequence 137 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19346	LCQRPSGTW	9	Sequence 138 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19347	QKLCQRPSGTWS	12	Sequence 139 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19348	KLCQRPSGTWSG	12	Sequence 140 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_	
			_x000b_"
DRAMP19349	LCQRPSGTWSGV	12	Sequence 141 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169, WO9524486	Antifungal peptides and composition thereof.	"Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the RsAFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptid_x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008__x0006__x0008_	_x000b_					_x000b_"
DRAMP19350	RLCERPSGTWSGVCGNNNACRNQCRNLERAEHGSCNYVFPAHKCICYFPC	50	Sequence 2 from Patent US 6653280	Synthetic construct	Antimicrobial, Antifungal	US 6653280 B2	Granted Patent	2003##11##25	US4940840, US5421839, US5538525, EP0448511, WO9518229	Antifungal Polypeptide Alyafp From Alyssum And Methods For Controlling Plant Pathogenic Fungi	An antifungal polypeptide, AlyAFP, that controls fungal damage to plants is provided. DNA encoding this polypeptide can be cloned into vectors for transformation of plantcolonizing microorganisms or plants, thereby providing a method of inhibiting fungal growth on plants. The polypeptide can be formulated into compositions that can be used to control undesired fungi on plants and elsewhere.
DRAMP19351	MAKFATIISLLFAALVLFAAFEAPTMVDARLCERPSGTWSGVCGNNNACRNQCRNLERAEHGSCNYVFPAHKCICYFPC	79	Sequence 15 from Patent US 6653280	Synthetic construct	Antimicrobial, Antifungal	US 6653280 B2	Granted Patent	2003##11##25	US4940840, US5421839, US5538525, EP0448511, WO9518229	Antifungal Polypeptide Alyafp From Alyssum And Methods For Controlling Plant Pathogenic Fungi	An antifungal polypeptide, AlyAFP, that controls fungal damage to plants is provided. DNA encoding this polypeptide can be cloned into vectors for transformation of plantcolonizing microorganisms or plants, thereby providing a method of inhibiting fungal growth on plants. The polypeptide can be formulated into compositions that can be used to control undesired fungi on plants and elsewhere.
DRAMP19352	MAKFASIIALLFAALVLFAAFEAETMVEAQKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	80	Sequence 20 from Patent US 6653280	Synthetic construct	Antimicrobial, Antifungal	US 6653280 B2	Granted Patent	2003##11##25	US4940840, US5421839, US5538525, EP0448511, WO9518229	Antifungal Polypeptide Alyafp From Alyssum And Methods For Controlling Plant Pathogenic Fungi	An antifungal polypeptide, AlyAFP, that controls fungal damage to plants is provided. DNA encoding this polypeptide can be cloned into vectors for transformation of plantcolonizing microorganisms or plants, thereby providing a method of inhibiting fungal growth on plants. The polypeptide can be formulated into compositions that can be used to control undesired fungi on plants and elsewhere.
DRAMP19353	XEDXXXXXXXRGXGXGXXXX	20	Sequence 1 from Patent US 6743598	Synthetic construct	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine6phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds use in the isolation of new classes of antifungal drugs, wherein the compounds have the ability to inhibit fungal glucose utilization.
DRAMP19354	NXPAXXXYXXXGX	13	Sequence 2 from Patent US 6743598	Synthetic construct	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine7phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19355	IEDISVAKSEQGKKLGYYLV	20	Sequence 3 from Patent US 6743598	Candida albicans	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine8phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19356	NVGFYEKCGY	10	Sequence 4 from Patent US 6743598	Candida albicans	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine9phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19357	IEDIAVNSKYQGQGLGKLLIPRT	23	Sequence 5 from Patent US 6743598	Saccharomyces cerevisiae	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine10phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19358	NVKFYEKCGF	10	Sequence 6 from Patent US 6743598	Saccharomyces cerevisiae	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine11phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19359	VEDVVVSDECRGKQLGKLLL	20	Sequence 7 from Patent US 6743598	Mus musculus	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine12phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19360	NVGFYKKFDY	10	Sequence 8 from Patent US 6743598	Mus musculus	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine13phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19361	LEDFFVMSDYRGFGIGSEIL	20	Sequence 9 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine14phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19362	NEPSINFYKRRGA	13	Sequence 10 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine15phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19363	YSTGMVHLLLQVTIDGRNYI	20	Sequence 11 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine16phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19364	IEAYFERIGY	10	Sequence 12 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine17phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19365	LFHLSVDNEHRGQGIAKALV	20	Sequence 13 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine18phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19366	QLSAMGLYQSLGF	13	Sequence 14 from Patent US 6743598	Homo sapiens	Antimicrobial, Antifungal	US 6743598 B2	Granted Patent	2004##6##1	US5945315, US6346252, WO9810656	Methods For The Identification Of Fungal Glucose Utilization Inhibitors And Antifungal Agents	The present invention provides methods for simultaneously assessing microbial phosphoglucose isomerase, ketolisomerase and glucosamine19phosphate acetyltransferase activities, by measuring the production of Coenzyme A (CoA). The present invention finds
DRAMP19367	RVCMKGSAGFKGLCMRDQNCAQVCLQEGWGGGNCDGVMRQCKCIRQC	47	Sequence 21 from Patent US 6864068	Sorghum bicolor	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076 	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP19368	QKLCMRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 22 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076 	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP3 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19369	QKLCQRPSGGWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 23 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP4 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19370	QKLCQRPSGTSSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 24 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP5 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19371	QKLCQRPSGTWSGVCMNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 25 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP6 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19372	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKWRHGSCNYVFPAHKCICYFPC	51	Sequence 26 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP7 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19373	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNGVFPAHKCICYFPC	51	Sequence 27 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP8 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19374	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVMPAHKCICYFPC	51	Sequence 28 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAFP9 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19375	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHQCICYFPC	51	Sequence 29 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF10 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19376	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPPAHKCICIFPC	51	Sequence 30 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF11 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inricultural, pharmaceutical or preservative applications.
DRAMP19377	QKLCQRPSGAWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 31 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF12 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19378	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARAGSCNYVFPAHKCICYFPC	51	Sequence 32 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF13 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19379	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCVFPAHKCICYFPC	49	Sequence 33 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF14 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19380	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVAPAHKCICYFPC	51	Sequence 34 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF15 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19381	QKLCQRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	50	Sequence 35 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF16 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19382	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPAHKCICYFPC	50	Sequence 36 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF17 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19383	QKLCQRRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 37 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF18 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19384	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 38 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF19 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19385	QKLCQRPSGTWRGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 39 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF20 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases in
DRAMP19386	QKLCQRPSGTWSGVCGNNNACKNQCRRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 40 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF21 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19387	QKLCQRPSGTWSGVCGNNNACKNQCIRREKARHGSCNYVFPAHKCICYFPC	51	Sequence 41 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF22 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19388	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCRYVFPAHKCICYFPC	51	Sequence 42 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF23 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19389	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 43 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF24 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19390	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPRHKCICYFPC	51	Sequence 44 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF25 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inricultural, pharmaceutical or preservative applications.
DRAMP19391	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCRCYFPC	51	Sequence 45 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF26 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inҫ
DRAMP19392	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYRPC	51	Sequence 46 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF27 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases inricultural, pharmaceutical or preservative applications.
DRAMP19393	QKLCERPSRTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 57 from Patent US 6864068	Raphanus sativus	Antimicrobial, Antifungal	US 6864068 B2	Granted Patent	2005##3##8	US5919918, WO8703303, WO9416076	Antifungal Proteins	Antifungal proteins which are analogues of the RsAF28 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salttolerant antifungal activity. The proteins are useful for combating fungal diseases in
DRAMP19394	GKVWDWIKSTAKKLWNSEPVKELKNTALNAAKNFVAEKIGATPS	44	Sequence 128 from Patent US 7939500	Opistophthalmus carinatus	Antimicrobial, Antifungal	US 7939500 B2	Granted Patent	2011##5##10	US4342751A, US6294183B1, US7335400B2, US20050147579A1, CN1031387, EP1174439, GB2249311, JP5247378, WO2004055044	Antifungal Paints And Coatings	Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.
DRAMP19395	GLLDSIKGMAISAGKGALQNLLKVASCKLDKTC	33	Sequence 143 from Patent US 7939500	Rana nigromaculata	Antimicrobial, Antifungal	US 7939500 B2	Granted Patent	2011##5##10	US4342751A, US6294183B1, US7335400B2, US20050147579A1, CN1031387, EP1174439, GB2249311, JP5247378, WO2004055044	Antifungal Paints And Coatings	Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.
DRAMP19396	FLPAIAGMAAKFLPKIFCAISKKC	24	Sequence 119 from Patent US 7939500	Rana berlandieri	Antimicrobial, Antifungal	US 7939500 B2	Granted Patent	2011##5##10	US4342751A, US6294183B1, US7335400B2, US20050147579A1, CN1031387, EP1174439, GB2249311, JP5247378, WO2004055044	Antifungal Paints And Coatings	Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.
DRAMP19397	GKVWDWIKSTAKKLWNSEPVKELKNTALNAAKNFVAEKIGATPS	44	Sequence 128 from Patent US 7932230	Opistophthalmus carinatus	Antimicrobial, Antifungal	US 7932230 B2	Granted Patent	2011##4##26	US20050147579, CN1031387, EP1174439, JP5247378, WO2004055044	Antifungal paints and coatings 	"Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.

"
DRAMP19398	GLLDSIKGMAISAGKGALQNLLKVASCKLDKTC	33	Sequence 143 from Patent US 7932230	Rana nigromaculata	Antimicrobial, Antifungal	US 7932230 B2	Granted Patent	2011##4##26	US20050147579, CN1031387, EP1174439, JP5247378, WO2004055044	Antifungal paints and coatings 	"Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.

"
DRAMP19399	FLPAIAGMAAKFLPKIFCAISKKC	24	Sequence 119 from Patent US 7932230	Rana berlandieri	Antimicrobial, Antifungal	US 7932230 B2	Granted Patent	2011##4##26	US20050147579, CN1031387, EP1174439, JP5247378, WO2004055044	Antifungal paints and coatings 	"Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.

"
DRAMP19400	GILDSFKQFAKGVGKDLIKGAAQGVLSTMSCKLAKTC	37	Sequence 762 from Patent US 7862826	Rana rugosa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19401	GLLNTFKDWAISIAKGAGKGVLTTLSCKLDKSC	33	Sequence 760 from Patent US 7862826	Rana rugosa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19402	GIWGTALKWGVKLLPKLVGMAQTKKQ	26	Sequence 710 from Patent US 7862826	Pachycondyla goeldii	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19403	FWGALAKGALKLIPSLFSSFSKKD	24	Sequence 662 from Patent US 7862826	Pandinus imperator	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19404	GKVWDWIKSTAKKLWNSEPVKELKNTALAKNFVAEKIGATPS	42	Sequence 660 from Patent US 7862826	Opistophthalmus carinatus	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19405	GILDTIKSIASKVWNSKTVQDLKRKGINWVANKLGVSPQAA	41	Sequence 516 from Patent US 7862826	Hadrurus aztecus	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19406	MFTLKKSLLLLFFLGTISLSLCEEERDEEEKRDVEVEKRFLGALFKVASKVLPSVFCAITKKC	63	Sequence 504 from Patent US 7862826	Rana rugosa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19407	GLFSILRGAAKFASKGLGKDLTKLGVDLVACKISKQC	37	Sequence 494 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19408	MFTMKKSLLLFFFLGTISLSLCQEERDEDDGEMTEEEKRGILDTLKHLAKTAGKGALQSLLNHASCKLSGQC	72	Sequence 258 from Patent US 7862826	Rana temporaria	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19409	MFTMKKSLLLIFFLGTISLSLCQEERDDDDGEMTEEEKRGIMDTLKNLAKTAGKGALQSLVKMASCKLSGQC	72	Sequence 256 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19410	GILDSLKNLAKGQILLNKASCKLSGQC	27	Sequence 254 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19411	GILDTLKNLAKTAGKGALQGLVKMASCKLSGQC	33	Sequence 252 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19412	GIMDTLKNLAKTAGKGALQSLLNKASCKLSGQC	33	Sequence 250 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19413	FLPVVAGLAAKVLPSIICAVTKKC	24	Sequence 246 from Patent US 7862826	Rana sylvatica	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19414	FLPAIVGAAGKFLPKIFCAISKKC	24	Sequence 244 from Patent US 7862826	Rana sphenocephala	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19415	FLPIIASVAAKVFPKIFCAISKKC	24	Sequence 242 from Patent US 7862826	Rana pipiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19416	FLPIIASVAAKVFSKIFCAISKKC	24	Sequence 240 from Patent US 7862826	Rana pipiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19417	FLPIIAGVAAKVFPKIFCAISKKC	24	Sequence 238 from Patent US 7862826	Rana pipiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19418	FLPMLAGLAASMVPKLVCLITKKC	24	Sequence 236 from Patent US 7862826	Rana luteiventris	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19419	MFTLKKSMLLLFFLGTINLSLCEEERDADEEERRDNPDESEVEVEKRFLPLLAGLAANFLPKIFCKITRKC	71	Sequence 232 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19420	FLPAIVGAAAKFLPKIFCVISKKC	24	Sequence 230 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19421	FLPFIAGVAAKFLPKIFCAISKKC	24	Sequence 228 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19422	FLPFIAGMAAKFLPKIFCAISKKC	24	Sequence 226 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19423	FWGALIKGAAKLIPSVVGLFKKKQ	24	Sequence 711 from Patent US 7862826	Pachycondyla goeldii	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19424	GIWGTLAKIGIKAVPRVISMLKKKKQ	26	Sequence 709 from Patent US 7862826	Pachycondyla goeldii	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19425	GKVWDWIKSAAKKIWSSEPVSQLKGQVLAKNYVAEKIGATPT	42	Sequence 661 from Patent US 7862826	Pandinus imperator	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19426	FLPLLAGLAANFLPTIICKISYKC	24	Sequence 505 from Patent US 7862826	Rana rugosa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19427	MFTMKKSLLFLFFLGTISLSLCEEERSADEDDGGEMTEEEVKRGILDTLKQFAKGVGKDLVKGAAQGVLSTVSCKLAKTC	80	Sequence 503 from Patent US 7862826	Rana rugosa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19428	GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC	37	Sequence 497 from Patent US 7862826	Rana pipiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19429	GLLSGLKKVGKHVAKNVAVSLMDSLKCKISGDC	33	Sequence 257 from Patent US 7862826	Rana temporaria	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19430	GIFDKLKNFAKGVAQSLLNKASCKLSGQC	29	Sequence 255 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19431	GILLDKLKNFAKTAGKGVLQSLLNTASCKLSGQC	34	Sequence 253 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19432	GILDTLKNLAISAAKGAAQGLVNKASCKLSGQC	33	Sequence 251 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19433	GLLDSLKGFAATAGKGVLQSLLSTASCKLAKTC	33	Sequence 249 from Patent US 7862826	Rana  brevipoda	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19434	FFPIVAGVAGQVLKKIYCTISKKC	24	Sequence 245 from Patent US 7862826	Rana sphenocephala	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19435	FLPAIVGAAGQFLPKIFCAISKKC	24	Sequence 243 from Patent US 7862826	Rana sphenocephala	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19436	FLPIIASVAANVFSKIFCAISKKC	24	Sequence 241 from Patent US 7862826	Rana pipiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19437	FLPMLAGLAASMVPKFVCLITKKC	24	Sequence 237 from Patent US 7862826	Rana luteiventris	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19438	FLPAIFRMAAKVVPTIICSITKKC	24	Sequence 233 from Patent US 7862826	Rana esculenta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19439	FLPFIAGMAANFLPKIFCAISKKC	24	Sequence 231 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19440	FLPAIAGVAAKFLPKIFCAISKKC	24	Sequence 229 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19441	FLPAIAGMAAKFLPKIFCAISKKC	24	Sequence 227 from Patent US 7862826	Rana berlandieri	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19442	FLPVLAGIAAKVVPALFCKITKKC	24	Sequence 225 from Patent US 7862826	Rana  brevipoda	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19443	MKVVIFIFALLATICAAFAYVPLPNVPQPGRRPFPTFPGQGPFNPKIKWPQGY	53	Sequence 78 from Patent US 7862826	Homo sapiens	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19444	GINTLKKVIQGLHEVIKLVSNHE	23	Sequence 728 from Patent US 7862826	Pseudis paradoxa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	"The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.

"
DRAMP19445	GLNTLKKVFQGLHEAIKLINNHVQ	24	Sequence 726 from Patent US 7862826	Pseudis paradoxa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19446	MWHLKLFAVLVICLLLAVQVHGSPIPELSSAKRRPRRITPFWRAVSLRPIGASCRDDSECLTRLCRKRRCSLSVAQE	77	Sequence 552 from Patent US 7862826	Sus scrofa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	"The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.

"
DRAMP19447	MWHLKLFAVLVICLLLAVQVHGSPIPELSSAKRRPRRMTPFWRAVSLRPIGASCRDDSECLTRLCRKRRCSLSVAQE	77	Sequence 550 from Patent US 7862826	Sus scrofa	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19448	MWHLKLCAVLMIFLLLLGQTDGSPIPEVSSAKRRPRRMTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLSVAQE	77	Sequence 548 from Patent US 7862826	Macaca mulatta	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	"The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.

"
DRAMP19449	MKLQNTLILIGCLFLMGAMIGDAYSRCQLQGFNCVVRSYGLPTIPCCRGLTCRSYFPGSTYGRCQRY	67	Sequence 793 from Patent US 7862826	Tachypleus tridentatus	Antimicrobial	US 7862826 B2	Granted Patent	2011##1##4	"US20090298741A1, US11214372, US60604912, US20070207209, WO
0209738"	Trophic factor combinations for nervous system treatment 	The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
DRAMP19450	ILRWPWWPWRRK	12	Sequence 23 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19451	KRKWPWWPWRLI	12	Sequence 33 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19452	ILKWVWWVWRRK	12	Sequence 34 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19453	ILKKWPWWPWRRK	13	Sequence 54 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19454	ILRWVWWVWRRK	12	Sequence 58 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19455	ILRRWVWWVWRRK	13	Sequence 60 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19456	RLWVWWVWRRK	11	Sequence 62 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19457	RLWVWWVWRR	10	Sequence 63 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19458	RLGGGWVWWVWRR	13	Sequence 64 from Patent US 8927487	Synthetic construct	Antimicrobial	US 8927487 B2	Granted Patent	2015##1##6	US20130296227A1, US13421018, US10865687, US10225087, US60314232, US8466102, EP0930065, WO 03015809	Antimicrobial cationic peptides and formulations thereof 	"Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

"
DRAMP19459	KFSDQIDKGQDALKDKLGDL	20	Sequence 1063 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19460	LSEMERRRLRKRA	13	Sequence 1064 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19461	RRGCTERLRRMARRNAWDLYAEHFY	25	Sequence 1065 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19462	SKFKVLRKIIIKEYKGELMLSIQKQR	26	Sequence 1066 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19463	FELVDWLETNLGKILKSKSA	20	Sequence 1067 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19464	LVLRICTDLFTFIKWTIKQRKS	22	Sequence 1068 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19465	VYSFLYVLVIVRKLLSMKKRIERL	24	Sequence 1069 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19466	GIVLIGLKLIPLLANVLR	18	Sequence 1070 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19467	VMQSLYVKPPLILVTKLAQQN	21	Sequence 1071 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19468	SFMPEIQKNTIPTQMK	16	Sequence 1072 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19469	LGLTAGVAYAAQPTNQPTNQPTNQPTNQPTNQPTNQPRW	39	Sequence 1073 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19470	CGKLLEQKNFFLKTR	15	Sequence 1074 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19471	ASKQASKQASKQASKQASKQASRSLKNHLL	30	Sequence 1075 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19472	PDAPRTCYHKPILAALSRIVVTDR	24	Sequence 1076 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19473	NYAVVSHT	8	Sequence 1077 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19474	FQKPFTGEEVEDFQDDDEIPTII	23	Sequence 1078 from Patent US 8754039	Synthetic construct	Antimicrobial	US 8754039 B2	Granted Patent	2014##6##17	US20110039761A1, US7018637B2, US20020082195A1, US20130108575A1, WO2008030988, WO2010080836	Targeted Antimicrobial Moieties	This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
DRAMP19475	RFGRFLRKIRRFRPKVTITIQGSARFG	27	Sequence 1 from Patent US 9006174	Gallus gallus	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant."
DRAMP19476	RFGRFLRKIRRF	12	Sequence 2 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP28 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19477	RFGRFLRKIRRFR	13	Sequence 3 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP29 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19478	RFGRFLRKIRRFRPK	15	Sequence 4 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP30 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19479	RFGRFLRKIRRFRPKVT	17	Sequence 5 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP31 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19480	RFGRFLRKIRRFRPKVTITIQ	21	Sequence 6 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP32 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19481	RFGRFLRKIRRFRPKVTITIQGSARF	26	Sequence 7 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP33 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19482	RFGRFLRKIRRFRPKVTITIQGSARF	26	Sequence 8 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP34 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19483	RFGRFLRKIRRFRGKVTITIQGSARF	26	Sequence 9 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP35 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19484	RFGRFLRKIRRFRLKVTITIQGSARF	26	Sequence 10 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP36 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19485	RFGRFLRKIRRFRPKVTITIQ	21	Sequence 11 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP37 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19486	RFGRFLRKIRRFRPK	15	Sequence 12 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP38 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19487	RLGRFLRKIRRFRPK	15	Sequence 13 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP39 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19488	RFGRLLRKIRRFRPK	15	Sequence 14 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP40 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19489	RFGRFLRKIRRLRPK	15	Sequence 15 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP41 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt	_x0002__x0004__x0006_	_x0002__x0004__x0006_	_x0002__x0004__x0006_	_x0002__x0004__x0006_	_x0002__x0004__x0006_	_x0002_"
DRAMP19490	RLGRLLRKIRRLRPK	15	Sequence 16 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP42 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19491	RWGRFLRKIRRFRPK	15	Sequence 17 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP43 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19492	RFGRWLRKIRRFRPK	15	Sequence 18 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP44 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19493	RFGRFLRKIRRWRPK	15	Sequence 19 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP45 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19494	RWGRWLRKIRRWRPK	15	Sequence 20 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP46 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19495	RFGRFLRKIRRFR	13	Sequence 21 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP47 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19496	RFGRFLRKIRRF	12	Sequence 22 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP48 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19497	RFGRFLRKIRR	11	Sequence 23 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP49 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19498	RFGRFLRKIR	10	Sequence 24 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP50 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19499	FGRFLRKIRRFRPK	14	Sequence 25 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP51 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19500	GRFLRKIRRFRPK	13	Sequence 26 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP52 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19501	RFLRKIRRFRPK	12	Sequence 27 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP53 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19502	FLRKIRRFRPK	11	Sequence 28 from Patent US 9006174	Synthetic construct	Antimicrobial	US 9006174 B2	Granted Patent	2015##4##14	WO2007064903	Antimicrobial Peptides Based On Cmap27	"
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wildtype CMAP54 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Furt"
DRAMP19503	QRLRIRVAVIRA	12	Sequence 1 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19504	VQLRIRVAVIRA	12	Sequence 2 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19505	VRFRIRVAVIRA	12	Sequence 3 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19506	VRWRIRVAVIRA	12	Sequence 4 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19507	VRLWIRVAVIRA	12	Sequence 5 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19508	VRLRIRVWVIRA	12	Sequence 6 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19509	VRLRIRVAVRRA	12	Sequence 7 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19510	VRLRIRVAVIRK	12	Sequence 8 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19511	VQLRIRVRVIRK	12	Sequence 9 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19512	KRFRIRVAVRRA	12	Sequence 10 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19513	VRLRIRVRVIRK	12	Sequence 11 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19514	KQFRIRVRVIRK	12	Sequence 12 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19515	HQFRFRFRVRRK	12	Sequence 13 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19516	HQWRIRVAVRRH	12	Sequence 14 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19517	KRFRIRVRVIRK	12	Sequence 15 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19518	KRWRIRVRVIRK	12	Sequence 16 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19519	KIWVRWK	7	Sequence 17 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19520	IWVIWRR	7	Sequence 18 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19521	ALPWKWPWWPWRR	13	Sequence 19 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19522	IAPWKWPWWPWRR	13	Sequence 20 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19523	ILAWKWPWWPWRR	13	Sequence 21 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19524	ILPAKWPWWPWRR	13	Sequence 22 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19525	ILPWAWPWWPWRR	13	Sequence 23 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19526	ILPWKAPWWPWRR	13	Sequence 24 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19527	ILPWKWAWWPWRR	13	Sequence 25 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19528	ILPWKWPAWPWRR	13	Sequence 26 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19529	ILPWKWPWAPWRR	13	Sequence 27 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19530	ILPWKWPWWAWRR	13	Sequence 28 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19531	ILPWKWPWWPARR	13	Sequence 29 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19532	ILPWKWPWWPWAR	13	Sequence 30 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19533	ILPWKWPWWPWRA	13	Sequence 31 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19534	DLPWKWPWWPWRR	13	Sequence 32 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19535	IDPWKWPWWPWRR	13	Sequence 33 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19536	ILDWKWPWWPWRR	13	Sequence 34 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19537	ILPDKWPWWPWRR	13	Sequence 35 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19538	ILPWDWPWWPWRR	13	Sequence 36 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19539	ILPWKDPWWPWRR	13	Sequence 37 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19540	ILPWKWDWWPWRR	13	Sequence 38 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19541	ILPWKWPDWPWRR	13	Sequence 39 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19542	ILPWKWPWDPWRR	13	Sequence 40 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19543	ILPWKWPWWDWRR	13	Sequence 41 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19544	ILPWKWPWWPDRR	13	Sequence 42 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19545	ILPWKWPWWPWDR	13	Sequence 43 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19546	ILPWKWPWWPWRD	13	Sequence 44 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19547	ELPWKWPWWPWRR	13	Sequence 45 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19548	IEPWKWPWWPWRR	13	Sequence 46 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19549	ILEWKWPWWPWRR	13	Sequence 47 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19550	ILPEKWPWWPWRR	13	Sequence 48 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19551	ILPWEWPWWPWRR	13	Sequence 49 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19552	ILPWKEPWWPWRR	13	Sequence 50 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19553	ILPWKWEWWPWRR	13	Sequence 51 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19554	ILPWKWPEWPWRR	13	Sequence 52 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19555	ILPWKWPWEPWRR	13	Sequence 53 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19556	ILPWKWPWWEWRR	13	Sequence 54 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19557	ILPWKWPWWPERR	13	Sequence 55 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19558	ILPWKWPWWPWER	13	Sequence 56 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19559	ILPWKWPWWPWRE	13	Sequence 57 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19560	FLPWKWPWWPWRR	13	Sequence 58 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19561	IFPWKWPWWPWRR	13	Sequence 59 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19562	ILFWKWPWWPWRR	13	Sequence 60 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19563	ILPFKWPWWPWRR	13	Sequence 61 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19564	ILPWFWPWWPWRR	13	Sequence 62 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19565	ILPWKFPWWPWRR	13	Sequence 63 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19566	ILPWKWFWWPWRR	13	Sequence 64 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19567	ILPWKWPFWPWRR	13	Sequence 65 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19568	ILPWKWPWFPWRR	13	Sequence 66 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19569	ILPWKWPWWFWRR	13	Sequence 67 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19570	ILPWKWPWWPFRR	13	Sequence 68 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19571	ILPWKWPWWPWFR	13	Sequence 69 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19572	ILPWKWPWWPWRF	13	Sequence 70 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19573	GLPWKWPWWPWRR	13	Sequence 71 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19574	IGPWKWPWWPWRR	13	Sequence 72 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19575	ILGWKWPWWPWRR	13	Sequence 73 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19576	ILPGKWPWWPWRR	13	Sequence 74 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19577	ILPWGWPWWPWRR	13	Sequence 75 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19578	ILPWKGPWWPWRR	13	Sequence 76 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19579	ILPWKWGWWPWRR	13	Sequence 77 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19580	ILPWKWPGWPWRR	13	Sequence 78 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19581	ILPWKWPWGPWRR	13	Sequence 79 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19582	ILPWKWPWWGWRR	13	Sequence 80 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19583	ILPWKWPWWPGRR	13	Sequence 81 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19584	ILPWKWPWWPWGR	13	Sequence 82 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19585	ILPWKWPWWPWRG	13	Sequence 83 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19586	HLPWKWPWWPWRR	13	Sequence 84 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19587	IHPWKWPWWPWRR	13	Sequence 85 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19588	ILHWKWPWWPWRR	13	Sequence 86 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19589	ILPHKWPWWPWRR	13	Sequence 87 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19590	ILPWHWPWWPWRR	13	Sequence 88 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19591	ILPWKHPWWPWRR	13	Sequence 89 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19592	ILPWKWHWWPWRR	13	Sequence 90 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19593	ILPWKWPHWPWRR	13	Sequence 91 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19594	ILPWKWPWHPWRR	13	Sequence 92 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19595	ILPWKWPWWHWRR	13	Sequence 93 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19596	ILPWKWPWWPHRR	13	Sequence 94 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19597	ILPWKWPWWPWHR	13	Sequence 95 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19598	ILPWKWPWWPWRH	13	Sequence 96 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19599	IIPWKWPWWPWRR	13	Sequence 97 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19600	ILIWKWPWWPWRR	13	Sequence 98 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19601	ILPIKWPWWPWRR	13	Sequence 99 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19602	ILPWIWPWWPWRR	13	Sequence 100 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19603	ILPWKIPWWPWRR	13	Sequence 101 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19604	ILPWKWIWWPWRR	13	Sequence 102 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19605	ILPWKWPIWPWRR	13	Sequence 103 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19606	ILPWKWPWIPWRR	13	Sequence 104 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19607	ILPWKWPWWIWRR	13	Sequence 105 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19608	ILPWKWPWWPIRR	13	Sequence 106 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19609	ILPWKWPWWPWIR	13	Sequence 107 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19610	ILPWKWPWWPWRI	13	Sequence 108 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19611	KLPWKWPWWPWRR	13	Sequence 109 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19612	IKPWKWPWWPWRR	13	Sequence 110 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19613	ILKWKWPWWPWRR	13	Sequence 111 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19614	ILPKKWPWWPWRR	13	Sequence 112 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19615	ILPWKKPWWPWRR	13	Sequence 113 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19616	ILPWKWKWWPWRR	13	Sequence 114 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19617	ILPWKWPKWPWRR	13	Sequence 115 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19618	ILPWKWPWKPWRR	13	Sequence 116 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19619	ILPWKWPWWKWRR	13	Sequence 117 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19620	ILPWKWPWWPKRR	13	Sequence 118 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19621	ILPWKWPWWPWKR	13	Sequence 119 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19622	ILPWKWPWWPWRK	13	Sequence 120 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19623	LLPWKWPWWPWRR	13	Sequence 121 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19624	ILLWKWPWWPWRR	13	Sequence 122 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19625	ILPLKWPWWPWRR	13	Sequence 123 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19626	ILPWLWPWWPWRR	13	Sequence 124 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19627	ILPWKLPWWPWRR	13	Sequence 125 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19628	ILPWKWLWWPWRR	13	Sequence 126 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19629	ILPWKWPLWPWRR	13	Sequence 127 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19630	ILPWKWPWLPWRR	13	Sequence 128 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19631	ILPWKWPWWLWRR	13	Sequence 129 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19632	ILPWKWPWWPLRR	13	Sequence 130 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19633	ILPWKWPWWPWLR	13	Sequence 131 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19634	ILPWKWPWWPWRL	13	Sequence 132 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19635	MLPWKWPWWPWRR	13	Sequence 133 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19636	IMPWKWPWWPWRR	13	Sequence 134 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19637	ILMWKWPWWPWRR	13	Sequence 135 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19638	ILPMKWPWWPWRR	13	Sequence 136 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19639	ILPWMWPWWPWRR	13	Sequence 137 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19640	ILPWKMPWWPWRR	13	Sequence 138 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19641	ILPWKWMWWPWRR	13	Sequence 139 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19642	ILPWKWPMWPWRR	13	Sequence 140 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19643	ILPWKWPWMPWRR	13	Sequence 141 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19644	ILPWKWPWWMWRR	13	Sequence 142 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19645	ILPWKWPWWPMRR	13	Sequence 143 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19646	ILPWKWPWWPWMR	13	Sequence 144 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19647	ILPWKWPWWPWRM	13	Sequence 145 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19648	NLPWKWPWWPWRR	13	Sequence 146 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19649	INPWKWPWWPWRR	13	Sequence 147 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19650	ILNWKWPWWPWRR	13	Sequence 148 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19651	ILPNKWPWWPWRR	13	Sequence 149 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19652	ILPWNWPWWPWRR	13	Sequence 150 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19653	ILPWKNPWWPWRR	13	Sequence 151 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19654	ILPWKWNWWPWRR	13	Sequence 152 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19655	ILPWKWPNWPWRR	13	Sequence 153 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19656	ILPWKWPWNPWRR	13	Sequence 154 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19657	ILPWKWPWWNWRR	13	Sequence 155 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19658	ILPWKWPWWPNRR	13	Sequence 156 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19659	ILPWKWPWWPWNR	13	Sequence 157 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19660	ILPWKWPWWPWRN	13	Sequence 158 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19661	PLPWKWPWWPWRR	13	Sequence 159 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19662	IPPWKWPWWPWRR	13	Sequence 160 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19663	ILPPKWPWWPWRR	13	Sequence 161 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19664	ILPWPWPWWPWRR	13	Sequence 162 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19665	ILPWKPPWWPWRR	13	Sequence 163 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19666	ILPWKWPPWPWRR	13	Sequence 164 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19667	ILPWKWPWPPWRR	13	Sequence 165 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19668	ILPWKWPWWPPRR	13	Sequence 166 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19669	ILPWKWPWWPWPR	13	Sequence 167 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19670	ILPWKWPWWPWRP	13	Sequence 168 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19671	QLPWKWPWWPWRR	13	Sequence 169 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19672	IQPWKWPWWPWRR	13	Sequence 170 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19673	ILQWKWPWWPWRR	13	Sequence 171 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19674	ILPQKWPWWPWRR	13	Sequence 172 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19675	ILPWQWPWWPWRR	13	Sequence 173 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19676	ILPWKQPWWPWRR	13	Sequence 174 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19677	ILPWKWQWWPWRR	13	Sequence 175 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19678	ILPWKWPQWPWRR	13	Sequence 176 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19679	ILPWKWPWQPWRR	13	Sequence 177 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19680	ILPWKWPWWQWRR	13	Sequence 178 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19681	ILPWKWPWWPQRR	13	Sequence 179 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19682	ILPWKWPWWPWQR	13	Sequence 180 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19683	ILPWKWPWWPWRQ	13	Sequence 181 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19684	RLPWKWPWWPWRR	13	Sequence 182 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19685	IRPWKWPWWPWRR	13	Sequence 183 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19686	ILRWKWPWWPWRR	13	Sequence 184 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19687	ILPRKWPWWPWRR	13	Sequence 185 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19688	ILPWRWPWWPWRR	13	Sequence 186 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19689	ILPWKRPWWPWRR	13	Sequence 187 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19690	ILPWKWRWWPWRR	13	Sequence 188 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19691	ILPWKWPRWPWRR	13	Sequence 189 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19692	ILPWKWPWRPWRR	13	Sequence 190 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19693	ILPWKWPWWRWRR	13	Sequence 191 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19694	ILPWKWPWWPRRR	13	Sequence 192 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19695	SLPWKWPWWPWRR	13	Sequence 193 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19696	ISPWKWPWWPWRR	13	Sequence 194 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19697	ILSWKWPWWPWRR	13	Sequence 195 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19698	ILPSKWPWWPWRR	13	Sequence 196 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19699	ILPWSWPWWPWRR	13	Sequence 197 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19700	ILPWKSPWWPWRR	13	Sequence 198 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19701	ILPWKWSWWPWRR	13	Sequence 199 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19702	ILPWKWPSWPWRR	13	Sequence 200 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19703	ILPWKWPWSPWRR	13	Sequence 201 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19704	ILPWKWPWWSWRR	13	Sequence 202 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19705	ILPWKWPWWPSRR	13	Sequence 203 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19706	ILPWKWPWWPWSR	13	Sequence 204 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19707	ILPWKWPWWPWRS	13	Sequence 205 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19708	TLPWKWPWWPWRR	13	Sequence 206 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19709	ITPWKWPWWPWRR	13	Sequence 207 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19710	ILTWKWPWWPWRR	13	Sequence 208 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19711	ILPTKWPWWPWRR	13	Sequence 209 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19712	ILPWTWPWWPWRR	13	Sequence 210 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19713	ILPWKTPWWPWRR	13	Sequence 211 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19714	ILPWKWTWWPWRR	13	Sequence 212 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19715	ILPWKWPTWPWRR	13	Sequence 213 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19716	ILPWKWPWTPWRR	13	Sequence 214 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19717	ILPWKWPWWTWRR	13	Sequence 215 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19718	ILPWKWPWWPTRR	13	Sequence 216 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19719	ILPWKWPWWPWTR	13	Sequence 217 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19720	ILPWKWPWWPWRT	13	Sequence 218 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19721	VLPWKWPWWPWRR	13	Sequence 219 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19722	IVPWKWPWWPWRR	13	Sequence 220 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19723	ILVWKWPWWPWRR	13	Sequence 221 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19724	ILPVKWPWWPWRR	13	Sequence 222 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19725	ILPWVWPWWPWRR	13	Sequence 223 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19726	ILPWKVPWWPWRR	13	Sequence 224 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19727	ILPWKWVWWPWRR	13	Sequence 225 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19728	ILPWKWPVWPWRR	13	Sequence 226 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19729	ILPWKWPWVPWRR	13	Sequence 227 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19730	ILPWKWPWWVWRR	13	Sequence 228 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19731	ILPWKWPWWPVRR	13	Sequence 229 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19732	ILPWKWPWWPWVR	13	Sequence 230 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19733	ILPWKWPWWPWRV	13	Sequence 231 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19734	WLPWKWPWWPWRR	13	Sequence 232 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19735	IWPWKWPWWPWRR	13	Sequence 233 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19736	ILWWKWPWWPWRR	13	Sequence 234 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19737	ILPWWWPWWPWRR	13	Sequence 235 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19738	ILPWKWWWWPWRR	13	Sequence 236 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19739	ILPWKWPWWWWRR	13	Sequence 237 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19740	ILPWKWPWWPWWR	13	Sequence 238 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19741	ILPWKWPWWPWRW	13	Sequence 239 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19742	YLPWKWPWWPWRR	13	Sequence 240 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19743	IYPWKWPWWPWRR	13	Sequence 241 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19744	ILYWKWPWWPWRR	13	Sequence 242 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19745	ILPYKWPWWPWRR	13	Sequence 243 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19746	ILPWYWPWWPWRR	13	Sequence 244 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19747	ILPWKYPWWPWRR	13	Sequence 245 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19748	ILPWKWYWWPWRR	13	Sequence 246 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19749	ILPWKWPYWPWRR	13	Sequence 247 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19750	ILPWKWPWYPWRR	13	Sequence 248 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19751	ILPWKWPWWYWRR	13	Sequence 249 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19752	ILPWKWPWWPYRR	13	Sequence 250 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19753	ILPWKWPWWPWYR	13	Sequence 251 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19754	ILPWKWPWWPWRY	13	Sequence 252 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19755	ARLRIRVAVIRA	12	Sequence 253 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19756	DRLRIRVAVIRA	12	Sequence 254 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19757	ERLRIRVAVIRA	12	Sequence 255 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19758	FRLRIRVAVIRA	12	Sequence 256 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19759	GRLRIRVAVIRA	12	Sequence 257 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19760	HRLRIRVAVIRA	12	Sequence 258 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19761	IRLRIRVAVIRA	12	Sequence 259 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19762	KRLRIRVAVIRA	12	Sequence 260 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19763	LRLRIRVAVIRA	12	Sequence 261 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19764	MRLRIRVAVIRA	12	Sequence 262 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19765	NRLRIRVAVIRA	12	Sequence 263 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19766	PRLRIRVAVIRA	12	Sequence 264 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19767	RRLRIRVAVIRA	12	Sequence 265 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19768	SRLRIRVAVIRA	12	Sequence 266 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19769	TRLRIRVAVIRA	12	Sequence 267 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19770	WRLRIRVAVIRA	12	Sequence 268 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19771	YRLRIRVAVIRA	12	Sequence 269 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19772	VALRIRVAVIRA	12	Sequence 270 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19773	VDLRIRVAVIRA	12	Sequence 271 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19774	VELRIRVAVIRA	12	Sequence 272 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19775	VFLRIRVAVIRA	12	Sequence 273 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19776	VGLRIRVAVIRA	12	Sequence 274 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19777	VHLRIRVAVIRA	12	Sequence 275 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19778	VILRIRVAVIRA	12	Sequence 276 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19779	VKLRIRVAVIRA	12	Sequence 277 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19780	VLLRIRVAVIRA	12	Sequence 278 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19781	VMLRIRVAVIRA	12	Sequence 279 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19782	VNLRIRVAVIRA	12	Sequence 280 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19783	VPLRIRVAVIRA	12	Sequence 281 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19784	VSLRIRVAVIRA	12	Sequence 282 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19785	VTLRIRVAVIRA	12	Sequence 283 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19786	VVLRIRVAVIRA	12	Sequence 284 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19787	VWLRIRVAVIRA	12	Sequence 285 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19788	VYLRIRVAVIRA	12	Sequence 286 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19789	VRARIRVAVIRA	12	Sequence 287 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19790	VRDRIRVAVIRA	12	Sequence 288 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19791	VRERIRVAVIRA	12	Sequence 289 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19792	VRGRIRVAVIRA	12	Sequence 290 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19793	VRHRIRVAVIRA	12	Sequence 291 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19794	VRIRIRVAVIRA	12	Sequence 292 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19795	VRKRIRVAVIRA	12	Sequence 293 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19796	VRMRIRVAVIRA	12	Sequence 294 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19797	VRNRIRVAVIRA	12	Sequence 295 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19798	VRPRIRVAVIRA	12	Sequence 296 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19799	VRQRIRVAVIRA	12	Sequence 297 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19800	VRRRIRVAVIRA	12	Sequence 298 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19801	VRSRIRVAVIRA	12	Sequence 299 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19802	VRTRIRVAVIRA	12	Sequence 300 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19803	VRVRIRVAVIRA	12	Sequence 301 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19804	VRYRIRVAVIRA	12	Sequence 302 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19805	VRLAIRVAVIRA	12	Sequence 303 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19806	VRLDIRVAVIRA	12	Sequence 304 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19807	VRLEIRVAVIRA	12	Sequence 305 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19808	VRLFIRVAVIRA	12	Sequence 306 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19809	VRLGIRVAVIRA	12	Sequence 307 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19810	VRLHIRVAVIRA	12	Sequence 308 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19811	VRLIIRVAVIRA	12	Sequence 309 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19812	VRLKIRVAVIRA	12	Sequence 310 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19813	VRLLIRVAVIRA	12	Sequence 311 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19814	VRLMIRVAVIRA	12	Sequence 312 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19815	VRLNIRVAVIRA	12	Sequence 313 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19816	VRLPIRVAVIRA	12	Sequence 314 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19817	VRLQIRVAVIRA	12	Sequence 315 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19818	VRLSIRVAVIRA	12	Sequence 316 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19819	VRLTIRVAVIRA	12	Sequence 317 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19820	VRLVIRVAVIRA	12	Sequence 318 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19821	VRLYIRVAVIRA	12	Sequence 319 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19822	VRLRARVAVIRA	12	Sequence 320 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19823	VRLRDRVAVIRA	12	Sequence 321 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19824	VRLRERVAVIRA	12	Sequence 322 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19825	VRLRFRVAVIRA	12	Sequence 323 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19826	VRLRGRVAVIRA	12	Sequence 324 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19827	VRLRHRVAVIRA	12	Sequence 325 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19828	VRLRKRVAVIRA	12	Sequence 326 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19829	VRLRLRVAVIRA	12	Sequence 327 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19830	VRLRMRVAVIRA	12	Sequence 328 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19831	VRLRNRVAVIRA	12	Sequence 329 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19832	VRLRPRVAVIRA	12	Sequence 330 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19833	VRLRQRVAVIRA	12	Sequence 331 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19834	VRLRRRVAVIRA	12	Sequence 332 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19835	VRLRSRVAVIRA	12	Sequence 333 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19836	VRLRTRVAVIRA	12	Sequence 334 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19837	VRLRVRVAVIRA	12	Sequence 335 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19838	VRLRWRVAVIRA	12	Sequence 336 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19839	VRLRYRVAVIRA	12	Sequence 337 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19840	VRLRIAVAVIRA	12	Sequence 338 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19841	VRLRIDVAVIRA	12	Sequence 339 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19842	VRLRIEVAVIRA	12	Sequence 340 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19843	VRLRIFVAVIRA	12	Sequence 341 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19844	VRLRIGVAVIRA	12	Sequence 342 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19845	VRLRIHVAVIRA	12	Sequence 343 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19846	VRLRIIVAVIRA	12	Sequence 344 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19847	VRLRIKVAVIRA	12	Sequence 345 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19848	VRLRILVAVIRA	12	Sequence 346 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19849	VRLRIMVAVIRA	12	Sequence 347 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19850	VRLRINVAVIRA	12	Sequence 348 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19851	VRLRIPVAVIRA	12	Sequence 349 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19852	VRLRIQVAVIRA	12	Sequence 350 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19853	VRLRISVAVIRA	12	Sequence 351 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19854	VRLRITVAVIRA	12	Sequence 352 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19855	VRLRIVVAVIRA	12	Sequence 353 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19856	VRLRIWVAVIRA	12	Sequence 354 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19857	VRLRIYVAVIRA	12	Sequence 355 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19858	VRLRIRAAVIRA	12	Sequence 356 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19859	VRLRIRDAVIRA	12	Sequence 357 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19860	VRLRIREAVIRA	12	Sequence 358 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19861	VRLRIRFAVIRA	12	Sequence 359 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19862	VRLRIRGAVIRA	12	Sequence 360 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19863	VRLRIRHAVIRA	12	Sequence 361 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19864	VRLRIRIAVIRA	12	Sequence 362 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19865	VRLRIRKAVIRA	12	Sequence 363 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19866	VRLRIRLAVIRA	12	Sequence 364 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19867	VRLRIRMAVIRA	12	Sequence 365 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19868	VRLRIRNAVIRA	12	Sequence 366 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19869	VRLRIRPAVIRA	12	Sequence 367 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19870	VRLRIRQAVIRA	12	Sequence 368 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19871	VRLRIRRAVIRA	12	Sequence 369 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19872	VRLRIRSAVIRA	12	Sequence 370 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19873	VRLRIRTAVIRA	12	Sequence 371 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19874	VRLRIRWAVIRA	12	Sequence 372 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19875	VRLRIRYAVIRA	12	Sequence 373 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19876	VRLRIRVDVIRA	12	Sequence 374 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19877	VRLRIRVEVIRA	12	Sequence 375 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19878	VRLRIRVFVIRA	12	Sequence 376 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19879	VRLRIRVGVIRA	12	Sequence 377 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19880	VRLRIRVHVIRA	12	Sequence 378 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19881	VRLRIRVIVIRA	12	Sequence 379 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19882	VRLRIRVKVIRA	12	Sequence 380 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19883	VRLRIRVLVIRA	12	Sequence 381 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19884	VRLRIRVMVIRA	12	Sequence 382 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19885	VRLRIRVNVIRA	12	Sequence 383 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19886	VRLRIRVPVIRA	12	Sequence 384 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19887	VRLRIRVQVIRA	12	Sequence 385 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19888	VRLRIRVRVIRA	12	Sequence 386 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19889	VRLRIRVSVIRA	12	Sequence 387 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19890	VRLRIRVTVIRA	12	Sequence 388 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19891	VRLRIRVVVIRA	12	Sequence 389 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19892	VRLRIRVYVIRA	12	Sequence 390 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19893	VRLRIRVAAIRA	12	Sequence 391 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19894	VRLRIRVADIRA	12	Sequence 392 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19895	VRLRIRVAEIRA	12	Sequence 393 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19896	VRLRIRVAFIRA	12	Sequence 394 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19897	VRLRIRVAGIRA	12	Sequence 395 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19898	VRLRIRVAHIRA	12	Sequence 396 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19899	VRLRIRVAIIRA	12	Sequence 397 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19900	VRLRIRVAKIRA	12	Sequence 398 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19901	VRLRIRVAKIRA	12	Sequence 399 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19902	VRLRIRVAKIRA	12	Sequence 400 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19903	VRLRIRVANIRA	12	Sequence 401 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19904	VRLRIRVAPIRA	12	Sequence 402 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19905	VRLRIRVAQIRA	12	Sequence 403 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19906	VRLRIRVARIRA	12	Sequence 404 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19907	VRLRIRVASIRA	12	Sequence 405 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19908	VRLRIRVATIRA	12	Sequence 406 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19909	VRLRIRVAWIRA	12	Sequence 407 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19910	VRLRIRVAYIRA	12	Sequence 408 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19911	VRLRIRVAVARA	12	Sequence 409 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19912	VRLRIRVAVDRA	12	Sequence 410 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19913	VRLRIRVAVERA	12	Sequence 411 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19914	VRLRIRVAVFRA	12	Sequence 412 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19915	VRLRIRVAVGRA	12	Sequence 413 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19916	VRLRIRVAVHRA	12	Sequence 414 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19917	VRLRIRVAVKRA	12	Sequence 415 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19918	VRLRIRVAVLRA	12	Sequence 416 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19919	VRLRIRVAVMRA	12	Sequence 417 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19920	VRLRIRVAVNRA	12	Sequence 418 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19921	VRLRIRVAVPRA	12	Sequence 419 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19922	VRLRIRVAVQRA	12	Sequence 420 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19923	VRLRIRVAVSRA	12	Sequence 421 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19924	VRLRIRVAVTRA	12	Sequence 422 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19925	VRLRIRVAVVRA	12	Sequence 423 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19926	VRLRIRVAVWRA	12	Sequence 424 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19927	VRLRIRVAVYRA	12	Sequence 425 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19928	VRLRIRVAVIAA	12	Sequence 426 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19929	VRLRIRVAVIDA	12	Sequence 427 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19930	VRLRIRVAVIEA	12	Sequence 428 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19931	VRLRIRVAVIFA	12	Sequence 429 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19932	VRLRIRVAVIGA	12	Sequence 430 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19933	VRLRIRVAVIHA	12	Sequence 431 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19934	VRLRIRVAVIIA	12	Sequence 432 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19935	VRLRIRVAVIKA	12	Sequence 433 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19936	VRLRIRVAVILA	12	Sequence 434 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19937	VRLRIRVAVIMA	12	Sequence 435 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19938	VRLRIRVAVINA	12	Sequence 436 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19939	VRLRIRVAVIPA	12	Sequence 437 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19940	VRLRIRVAVIQA	12	Sequence 438 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19941	VRLRIRVAVISA	12	Sequence 439 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19942	VRLRIRVAVITA	12	Sequence 440 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19943	VRLRIRVAVIVA	12	Sequence 441 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19944	VRLRIRVAVIWA	12	Sequence 442 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19945	VRLRIRVAVIYA	12	Sequence 443 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19946	VRLRIRVAVIRD	12	Sequence 444 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19947	VRLRIRVAVIRE	12	Sequence 445 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19948	VRLRIRVAVIRF	12	Sequence 446 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19949	VRLRIRVAVIRG	12	Sequence 447 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19950	VRLRIRVAVIRH	12	Sequence 448 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19951	VRLRIRVAVIRI	12	Sequence 449 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19952	VRLRIRVAVIRL	12	Sequence 450 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19953	VRLRIRVAVIRM	12	Sequence 451 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19954	VRLRIRVAVIRN	12	Sequence 452 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19955	VRLRIRVAVIRP	12	Sequence 453 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19956	VRLRIRVAVIRQ	12	Sequence 454 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19957	VRLRIRVAVIRR	12	Sequence 455 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19958	VRLRIRVAVIRS	12	Sequence 456 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19959	VRLRIRVAVIRT	12	Sequence 457 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19960	VRLRIRVAVIRV	12	Sequence 458 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19961	VRLRIRVAVIRW	12	Sequence 459 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19962	VRLRIRVAVIRY	12	Sequence 460 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19963	RRRRVKWWR	9	Sequence 461 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19964	WLRKKQGRL	9	Sequence 462 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19965	KWVRVYLRW	9	Sequence 463 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19966	GKVMISIVR	9	Sequence 464 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19967	IKVVRWRWR	9	Sequence 465 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19968	RRRRRWVRR	9	Sequence 466 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19969	HMNRFRTVY	9	Sequence 467 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19970	VRKRGSWRM	9	Sequence 468 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19971	RIIRTYKRG	9	Sequence 469 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19972	WWRWRLRLI	9	Sequence 470 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19973	WLNRLYIRL	9	Sequence 471 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19974	IWRWTKWFW	9	Sequence 472 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19975	RFKGSWKYR	9	Sequence 473 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19976	VWVIRKKKW	9	Sequence 474 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19977	RGRRVWRLF	9	Sequence 475 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19978	WRWRKVKQW	9	Sequence 476 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19979	WWKYWRKVI	9	Sequence 477 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19980	WLVRIRKRI	9	Sequence 478 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19981	WWRWWQRRW	9	Sequence 479 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19982	RKKWWWKIR	9	Sequence 480 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19983	WVRKKIRRR	9	Sequence 481 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19984	RYRRRWYIR	9	Sequence 482 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19985	LYRWVWKVG	9	Sequence 483 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19986	VRRRWFKWL	9	Sequence 484 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19987	RRLWWWKWL	9	Sequence 485 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19988	WRFKWTRRG	9	Sequence 486 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19989	KWWRHRRMW	9	Sequence 487 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19990	RRKRWWWRT	9	Sequence 488 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19991	WRRKIVRVW	9	Sequence 489 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19992	KLRRGSLWR	9	Sequence 490 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19993	RVIWWWRRK	9	Sequence 491 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19994	TWRVWKVRW	9	Sequence 492 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19995	QRGIVIWRK	9	Sequence 493 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19996	GKWWKWGIW	9	Sequence 494 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19997	RVRRWWFVR	9	Sequence 495 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19998	FWRRRVKWR	9	Sequence 496 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP19999	FRRYQNIVR	9	Sequence 497 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20000	RFWRWIFKW	9	Sequence 498 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20001	KRNVKRNWK	9	Sequence 499 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20002	WYSLIIFKR	9	Sequence 500 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20003	RKNRRIRVV	9	Sequence 501 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20004	FFRKRRWRI	9	Sequence 502 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20005	WKIRKVIKW	9	Sequence 503 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20006	IKWYWRKKK	9	Sequence 504 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20007	KRGWRKRWW	9	Sequence 505 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20008	RKWMGRRIR	9	Sequence 506 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20009	WKGKKRRVI	9	Sequence 507 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20010	KVIRYKVYI	9	Sequence 508 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20011	RRTRKWILR	9	Sequence 509 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20012	YNWNWLRRW	9	Sequence 510 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20013	KWKHWRWQW	9	Sequence 511 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20014	RKIVVKVRV	9	Sequence 512 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20015	QYLGWRFKW	9	Sequence 513 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20016	KIKTRKVKY	9	Sequence 514 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20017	VWIRWRRRW	9	Sequence 515 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20018	WGVRVRRLI	9	Sequence 516 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20019	WWKRVWKFI	9	Sequence 517 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20020	YWIYSRLRR	9	Sequence 518 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20021	RRYWKFKRR	9	Sequence 519 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20022	IVRRVIIRV	9	Sequence 520 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20023	ARRRGLKVW	9	Sequence 521 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20024	RRWVRRWWR	9	Sequence 522 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20025	WKWKWKWQS	9	Sequence 523 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20026	RWKVKQRRR	9	Sequence 524 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20027	YWTKFRLRI	9	Sequence 525 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20028	WVIKVRIRW	9	Sequence 526 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20029	ARVQVYKYR	9	Sequence 527 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20030	KWRWHWVYV	9	Sequence 528 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20031	KVKYKFRRW	9	Sequence 529 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20032	RFRKRKNRI	9	Sequence 530 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20033	MFRRRFIWK	9	Sequence 531 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20034	WRLRRFRLW	9	Sequence 532 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20035	WIQRIRIWV	9	Sequence 533 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20036	RRYHWRIYI	9	Sequence 534 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20037	SRFWRRWRK	9	Sequence 535 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20038	YRVWIIRRK	9	Sequence 536 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20039	WRVSWLIWR	9	Sequence 537 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20040	RFVKRKIVW	9	Sequence 538 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20041	RIYKIRWII	9	Sequence 539 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20042	RKFWHRGTI	9	Sequence 540 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20043	AWVVWRKRW	9	Sequence 541 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20044	WVWGKVRWG	9	Sequence 542 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20045	FGIRFRRMV	9	Sequence 543 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20046	FWIRKVFRI	9	Sequence 544 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20047	KRWKVRVVW	9	Sequence 545 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20048	KIRIWRIWV	9	Sequence 546 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20049	RGRWKRIKK	9	Sequence 547 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20050	RLWFLVLRR	9	Sequence 548 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20051	IIRVTRWTK	9	Sequence 549 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20052	AMWRWKWRK	9	Sequence 550 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20053	TRKYFGRFV	9	Sequence 551 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20054	ARRVKKKRR	9	Sequence 552 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20055	RWWKIWKRR	9	Sequence 553 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20056	RWRYKIQKW	9	Sequence 554 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20057	RVGIKIKMK	9	Sequence 555 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20058	WVLKLRYKW	9	Sequence 556 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20059	FRRKWIFKK	9	Sequence 557 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20060	WIQKLWRQR	9	Sequence 558 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20061	RIVRLHVRK	9	Sequence 559 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20062	VRIGWRRVK	9	Sequence 560 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20063	RRRIGIKRF	9	Sequence 561 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20064	RRRRKKVRI	9	Sequence 562 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20065	KLWRYKRWR	9	Sequence 563 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20066	RIRRFIKKW	9	Sequence 564 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20067	LWHKKKKIW	9	Sequence 565 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20068	LTRRFWLRR	9	Sequence 566 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20069	RRRYVIRRR	9	Sequence 567 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20070	WGWRWIWIK	9	Sequence 568 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20071	RWRWQRGRF	9	Sequence 569 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20072	RRKKWKVRI	9	Sequence 570 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20073	KMKLYKGSM	9	Sequence 571 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20074	GTIRWWRRR	9	Sequence 572 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20075	SLRRYIWRF	9	Sequence 573 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20076	GRYWKKWRR	9	Sequence 574 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20077	WIRQFRWKK	9	Sequence 575 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20078	AKVRRIKHW	9	Sequence 576 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20079	YSRRKTWWI	9	Sequence 577 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20080	RGRWWIRRQ	9	Sequence 578 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20081	WVFRWVWWR	9	Sequence 579 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20082	VYRVWWLKW	9	Sequence 580 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20083	WWVRRRVGW	9	Sequence 581 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20084	WFKIKRLYL	9	Sequence 582 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20085	WKMWKRGWT	9	Sequence 583 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20086	RWWRKSRRL	9	Sequence 584 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20087	FWRIRWWRW	9	Sequence 585 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20088	VWWFGKRTT	9	Sequence 586 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20089	VRIIWWIWR	9	Sequence 587 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20090	WWVRIWRWM	9	Sequence 588 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20091	RKWKKWFHR	9	Sequence 589 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20092	RKWKFWGYK	9	Sequence 590 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20093	FWYIWSKRV	9	Sequence 591 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20094	YWRQFRRKQ	9	Sequence 592 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20095	WWWKVKSRR	9	Sequence 593 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20096	WRLWIWWIR	9	Sequence 594 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20097	QFRVNRRKY	9	Sequence 595 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20098	RYRFWWVRR	9	Sequence 596 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20099	THIWLRRRR	9	Sequence 597 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20100	RRRFRKRRM	9	Sequence 598 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20101	LYTRVRRYS	9	Sequence 599 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20102	WSIRRLWWL	9	Sequence 600 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20103	YKIKRRRYG	9	Sequence 601 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20104	WKRIQFRRK	9	Sequence 602 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20105	HKKRRIWRK	9	Sequence 603 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20106	WRLIRWWIR	9	Sequence 604 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20107	LRKNWWWRR	9	Sequence 605 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20108	VKRIRIWML	9	Sequence 606 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20109	IRYRNWKWL	9	Sequence 607 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20110	GRILSRRWK	9	Sequence 608 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20111	KHWKIHVRW	9	Sequence 609 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20112	WIYWKVWRR	9	Sequence 610 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20113	KLWKVRNRR	9	Sequence 611 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20114	RRVYYYKWV	9	Sequence 612 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20115	WRWGVFRLR	9	Sequence 613 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20116	IWRVLKKRV	9	Sequence 614 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20117	AKKFWRNWI	9	Sequence 615 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20118	RQWRKVVKK	9	Sequence 616 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20119	GWKRWWVML	9	Sequence 617 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20120	KWRRTRRRK	9	Sequence 618 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20121	FRRMKRFLR	9	Sequence 619 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20122	RSWNWWWIR	9	Sequence 620 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20123	WRRRIWINR	9	Sequence 621 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20124	RWKWFYLKR	9	Sequence 622 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20125	RKRTIWRII	9	Sequence 623 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20126	RRRVWWRRR	9	Sequence 624 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20127	KWRFKWWKR	9	Sequence 625 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20128	KWIWGWRRW	9	Sequence 626 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20129	WIKRKWKMR	9	Sequence 627 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20130	MWKKVLRRV	9	Sequence 628 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20131	WRWRIFHWL	9	Sequence 629 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20132	KIQRWKGKR	9	Sequence 630 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20133	LWYKYWRWR	9	Sequence 631 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20134	YVRRIWKIT	9	Sequence 632 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20135	RWRQYRSRW	9	Sequence 633 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20136	VGRWKRRRW	9	Sequence 634 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20137	KSSRIYILF	9	Sequence 635 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20138	AKWWWYRKI	9	Sequence 636 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20139	FYWWRWFRV	9	Sequence 637 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20140	RTRWLRYRR	9	Sequence 638 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20141	WNIIWWIRR	9	Sequence 639 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20142	KRGFWWWRI	9	Sequence 640 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20143	RRRKKYIIR	9	Sequence 641 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20144	VWKVGWYYR	9	Sequence 642 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20145	LKFSTGRVR	9	Sequence 643 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20146	RRVWVRRKR	9	Sequence 644 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20147	RFWYMWKYV	9	Sequence 645 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20148	WYVRWMGRR	9	Sequence 646 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20149	WKRRMRRRK	9	Sequence 647 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20150	RVLRRVSWV	9	Sequence 648 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20151	RRLRKKWGW	9	Sequence 649 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20152	WYKKIRLII	9	Sequence 650 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20153	IYIIIWRTK	9	Sequence 651 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20154	TWRMRVKVS	9	Sequence 652 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20155	AWWKIRWRI	9	Sequence 653 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20156	RVRRYRWSW	9	Sequence 654 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20157	IWRIRRFRI	9	Sequence 655 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20158	KIRRKWWWF	9	Sequence 656 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20159	RRFWWIKIR	9	Sequence 657 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20160	WYWWRVRRV	9	Sequence 658 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20161	WYKLWRRKV	9	Sequence 659 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20162	WWFSWRWRV	9	Sequence 660 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20163	RFKTRRGWR	9	Sequence 661 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20164	WIWIVRRRV	9	Sequence 662 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20165	RRFKKWMYW	9	Sequence 663 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20166	RWYRVIRWK	9	Sequence 664 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20167	YRWMVRWVR	9	Sequence 665 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20168	KVRRYNRRR	9	Sequence 666 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20169	WFVWNRRVV	9	Sequence 667 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20170	RWKWRWRWY	9	Sequence 668 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20171	ARWRVRKWW	9	Sequence 669 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20172	KIKFWIIRR	9	Sequence 670 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20173	WYWRVRLQW	9	Sequence 671 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20174	YWWWKRRRR	9	Sequence 672 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20175	FIKRVRRRW	9	Sequence 673 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20176	VSVVFRRRY	9	Sequence 674 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20177	KFRVMVRVL	9	Sequence 675 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20178	WMYYKRRRR	9	Sequence 676 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20179	IWIWWRWRW	9	Sequence 677 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20180	WKKKKIIRV	9	Sequence 678 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20181	RRGWRRRRR	9	Sequence 679 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20182	WRWRKIWKW	9	Sequence 680 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20183	WWRWKRRII	9	Sequence 681 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20184	WKVRWKIRR	9	Sequence 682 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20185	RFWVRGRRS	9	Sequence 683 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20186	RRWVLWRRR	9	Sequence 684 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20187	KYIWKKRRY	9	Sequence 685 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20188	KWQWIRKIR	9	Sequence 686 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20189	YWIRRRWRL	9	Sequence 687 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20190	RVKWIKWLH	9	Sequence 688 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20191	YVRQWKKRR	9	Sequence 689 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20192	WKIVGVFRV	9	Sequence 690 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20193	VIKYVRMWW	9	Sequence 691 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20194	RRRRVWRVR	9	Sequence 692 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20195	RRRKIRVYR	9	Sequence 693 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20196	RRNRWRRIR	9	Sequence 694 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20197	IRKWIWRRV	9	Sequence 695 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20198	QRWRVRRRY	9	Sequence 696 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20199	WWMIIKIRN	9	Sequence 697 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20200	ARRRGRRVM	9	Sequence 698 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20201	RRWHWRKRK	9	Sequence 699 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20202	KRFLRKRRF	9	Sequence 700 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20203	RWKGWYLRT	9	Sequence 701 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20204	WSWRGRRKF	9	Sequence 702 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20205	KIIMKRRRW	9	Sequence 703 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20206	VWKRFLHWR	9	Sequence 704 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20207	RLKRRKKWR	9	Sequence 705 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20208	AVRKFRRVT	9	Sequence 706 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20209	IKQRFWWRT	9	Sequence 707 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20210	WKIVVWIIK	9	Sequence 708 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20211	LYRWIVWKR	9	Sequence 709 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20212	WWWRWRIRK	9	Sequence 710 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20213	RLWRKWQWN	9	Sequence 711 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20214	RVKLRWGWR	9	Sequence 712 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20215	AWRYKRRIF	9	Sequence 713 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20216	KRWQIRGIT	9	Sequence 714 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20217	KRWRWRWRW	9	Sequence 715 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20218	KRWVYKYRV	9	Sequence 716 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20219	VHWRWRFWK	9	Sequence 717 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20220	FVGKTKRKR	9	Sequence 718 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20221	RLRFGWFLF	9	Sequence 719 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20222	AKRWIWIQV	9	Sequence 720 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20223	RKYVRRWVY	9	Sequence 721 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20224	YRVYWWWWR	9	Sequence 722 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20225	KRRKKRRVR	9	Sequence 723 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20226	KKVRFTITW	9	Sequence 724 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20227	KLWYWKKVV	9	Sequence 725 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20228	WRWGLRWWQ	9	Sequence 726 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20229	AFFYRWWIR	9	Sequence 727 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20230	WYWRRRRLK	9	Sequence 728 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20231	YKFRWRIYI	9	Sequence 729 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20232	WLRKVWNWR	9	Sequence 730 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20233	RVRFKVYRV	9	Sequence 731 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20234	RWLSKIWKV	9	Sequence 732 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20235	RRRLGWRRG	9	Sequence 733 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20236	KKWGGGLVK	9	Sequence 734 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20237	YWWLWRKKR	9	Sequence 735 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20238	WIRLWVKWR	9	Sequence 736 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20239	GRRSTHWRI	9	Sequence 737 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20240	KKKLFINTW	9	Sequence 738 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20241	VYRRRRVKG	9	Sequence 739 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20242	KGWIIWKIV	9	Sequence 740 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20243	VFHRIRRIK	9	Sequence 741 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20244	RLRLWKSKR	9	Sequence 742 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20245	RRKVFKLRR	9	Sequence 743 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20246	VWLKVYWFK	9	Sequence 744 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20247	VRWGRRRWV	9	Sequence 745 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20248	RYNWVRRKK	9	Sequence 746 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20249	KIRWRKYHL	9	Sequence 747 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20250	VIWRWRKFY	9	Sequence 748 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20251	RRWWKWWWR	9	Sequence 749 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20252	WRVKGKRSK	9	Sequence 750 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20253	RWRTRRNIV	9	Sequence 751 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20254	WWFSIRLWR	9	Sequence 752 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20255	YTWYIKKKR	9	Sequence 753 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20256	VWRRKKYWR	9	Sequence 754 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20257	YLTRFVKYF	9	Sequence 755 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20258	KRWKHIRRI	9	Sequence 756 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20259	WIVWIRKRI	9	Sequence 757 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20260	RRWVIRIYK	9	Sequence 758 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20261	WFWRRKMIR	9	Sequence 759 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20262	RYRRWVRKR	9	Sequence 760 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20263	RKWWWKWRR	9	Sequence 761 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20264	RIWMFKIFR	9	Sequence 762 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20265	IVRVGIFRL	9	Sequence 763 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20266	IIRLIKWWR	9	Sequence 764 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20267	WVRRYQMRR	9	Sequence 765 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20268	WQVVMRYRR	9	Sequence 766 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20269	KKWKVWRFG	9	Sequence 767 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20270	WRYWWTRRI	9	Sequence 768 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20271	RIRKGWKWG	9	Sequence 769 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20272	KKRRGNRVR	9	Sequence 770 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20273	VMRKLRRRW	9	Sequence 771 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20274	RNRTHWWRK	9	Sequence 772 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20275	RFTWWWRKF	9	Sequence 773 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20276	KRIRYKRWH	9	Sequence 774 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20277	RWRRYGRVY	9	Sequence 775 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20278	TVVKKRVKK	9	Sequence 776 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20279	RKYRRRYRR	9	Sequence 777 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20280	YFRWWKRWI	9	Sequence 778 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20281	WWQWIVWRK	9	Sequence 779 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20282	RKRLYRWIK	9	Sequence 780 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20283	GWWKNWRWW	9	Sequence 781 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20284	KWWWYWYRR	9	Sequence 782 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20285	RFKWFIRRF	9	Sequence 783 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20286	RIRRLWNIV	9	Sequence 784 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20287	ARWMWRRWR	9	Sequence 785 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20288	LVRWVWGKR	9	Sequence 786 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20289	KRWLKWWRV	9	Sequence 787 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20290	FVYRGWRRK	9	Sequence 788 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20291	RRRWKIYKW	9	Sequence 789 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20292	KRWWQWRWF	9	Sequence 790 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20293	KRVKVRWVT	9	Sequence 791 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20294	RFKYWRWWQ	9	Sequence 792 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20295	KRQWWRVFK	9	Sequence 793 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20296	FKIVWWRRR	9	Sequence 794 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20297	QWWWKYRWK	9	Sequence 795 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20298	RWLRIRKVY	9	Sequence 796 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20299	RYKRVVYRH	9	Sequence 797 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20300	KVRWKWWGW	9	Sequence 798 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20301	IWKVRIFKR	9	Sequence 799 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20302	AIWHKTRRL	9	Sequence 800 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20303	IRQRVRWRW	9	Sequence 801 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20304	MKVWIRWRI	9	Sequence 802 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20305	QRRWWGRFK	9	Sequence 803 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20306	NKRVWFIYR	9	Sequence 804 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20307	RVVNWKGGL	9	Sequence 805 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20308	RYRRFRVRW	9	Sequence 806 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20309	KKVRRVIWW	9	Sequence 807 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20310	WFTRWKWRW	9	Sequence 808 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20311	KWVWFRWRK	9	Sequence 809 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20312	KYLRSVIFY	9	Sequence 810 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20313	FKRSWVQIV	9	Sequence 811 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20314	RWWFIRKWW	9	Sequence 812 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20315	IRRWKRVWW	9	Sequence 813 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20316	QKWYRQRRN	9	Sequence 814 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20317	VWRKWYRVK	9	Sequence 815 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20318	KKKLWRKFR	9	Sequence 816 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20319	RRWWWWRFN	9	Sequence 817 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20320	WFFKSKVYW	9	Sequence 818 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20321	RVVNLNWRW	9	Sequence 819 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20322	RWRRNWMTK	9	Sequence 820 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20323	WKIWKIRWF	9	Sequence 821 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20324	WWFWVIRKY	9	Sequence 822 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20325	RYVKIRWVR	9	Sequence 823 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20326	RIWILSWRW	9	Sequence 824 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20327	KSWRKLFIW	9	Sequence 825 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20328	VWVRWKIWY	9	Sequence 826 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20329	KKRRFKRRY	9	Sequence 827 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20330	RFWKKIRRH	9	Sequence 828 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20331	RKVWWRVFY	9	Sequence 829 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20332	YWRRKWRRK	9	Sequence 830 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20333	KRIRRWKWW	9	Sequence 831 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20334	YWRYLWIRF	9	Sequence 832 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20335	IIYKWRWYW	9	Sequence 833 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20336	QTVYLIFRR	9	Sequence 834 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20337	AKKIKWLVW	9	Sequence 835 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20338	YRFVRRWIV	9	Sequence 836 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20339	VWRRYWWYR	9	Sequence 837 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20340	ARKWKYWRF	9	Sequence 838 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20341	RKRVIKRWR	9	Sequence 839 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20342	RSFWWMWFK	9	Sequence 840 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20343	WRINIFKRI	9	Sequence 841 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20344	RWRVLKRRK	9	Sequence 842 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20345	RWWVIWWWK	9	Sequence 843 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20346	KLIRIWWWW	9	Sequence 844 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20347	FKRKRWWGI	9	Sequence 845 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20348	VWHWWRWRW	9	Sequence 846 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20349	WKRWLIIGR	9	Sequence 847 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20350	AYRWWTRFK	9	Sequence 848 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20351	SWWWIWLKK	9	Sequence 849 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20352	FVIWKYIRV	9	Sequence 850 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20353	RWVRTRRRR	9	Sequence 851 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20354	RRSWWYKRR	9	Sequence 852 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20355	RKYVWWKSI	9	Sequence 853 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20356	WWKRYIVKK	9	Sequence 854 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20357	WFIRVWRYR	9	Sequence 855 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20358	WKMWLRKHW	9	Sequence 856 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20359	RRFFWKKGI	9	Sequence 857 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20360	KRWTFWSRR	9	Sequence 858 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20361	AVQRWRWVV	9	Sequence 859 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20362	IWKYGWRYK	9	Sequence 860 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20363	IIKWWRRWR	9	Sequence 861 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20364	AFRKVKRWG	9	Sequence 862 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20365	MGFTRKWQF	9	Sequence 863 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20366	NWIRWRKWR	9	Sequence 864 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20367	RIGRKLRIR	9	Sequence 865 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20368	RWWRWRHVI	9	Sequence 866 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20369	RLVSKRRRK	9	Sequence 867 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20370	RRKYWKKYR	9	Sequence 868 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20371	IILWWYRRK	9	Sequence 869 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20372	IYFWWWRIR	9	Sequence 870 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20373	HKRKWWRFR	9	Sequence 871 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20374	IGRFWRRWL	9	Sequence 872 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20375	RIRRVLVYV	9	Sequence 873 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20376	WWLRGRRWL	9	Sequence 874 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20377	VRIRKRRWR	9	Sequence 875 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20378	WWRRKWWRR	9	Sequence 876 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20379	WWWRSFRKR	9	Sequence 877 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20380	VGQKWRKRT	9	Sequence 878 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20381	FRRRYRVYR	9	Sequence 879 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20382	RIRRKRKGR	9	Sequence 880 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20383	WKWVTRMYI	9	Sequence 881 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20384	KVVRKKRLR	9	Sequence 882 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20385	RKRRKHWRY	9	Sequence 883 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20386	RVTRTWQRW	9	Sequence 884 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20387	RRRITRKRI	9	Sequence 885 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20388	RLILIKKKW	9	Sequence 886 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20389	WKRRWSRSR	9	Sequence 887 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20390	MWWWFLWRR	9	Sequence 888 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20391	RWVRIWKKK	9	Sequence 889 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20392	KRRVWRMWR	9	Sequence 890 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20393	WHWWIRWWR	9	Sequence 891 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20394	WWRRLRWLV	9	Sequence 892 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20395	KWWIWKRRR	9	Sequence 893 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20396	RYGRKWMIW	9	Sequence 894 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20397	RVKKIKLFI	9	Sequence 895 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20398	RIRYIQRVW	9	Sequence 896 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20399	RLIRWWRKR	9	Sequence 897 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20400	QRGRWLRRG	9	Sequence 898 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20401	RRRRWIRKK	9	Sequence 899 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20402	LGRRWRYRR	9	Sequence 900 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20403	FKIVHVKVR	9	Sequence 901 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20404	FRKKYRVRR	9	Sequence 902 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20405	WKYKYRIRL	9	Sequence 903 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20406	HVRRWWRII	9	Sequence 904 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20407	RFKWWRRYW	9	Sequence 905 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20408	RRRRMRKKI	9	Sequence 906 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20409	RRIRGRVGR	9	Sequence 907 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20410	AFWRWIRFK	9	Sequence 908 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20411	VKKRKIVIY	9	Sequence 909 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20412	KRVKWTWRK	9	Sequence 910 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20413	TGVGRGYRI	9	Sequence 911 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20414	LSWKWWRRV	9	Sequence 912 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20415	IKTFIKRWR	9	Sequence 913 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20416	KMRLKWKRR	9	Sequence 914 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20417	WRWYVTRRK	9	Sequence 915 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20418	IYRRRRKLR	9	Sequence 916 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20419	VWWKWWRWW	9	Sequence 917 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20420	KYKKGWRVV	9	Sequence 918 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20421	KWRRWYYWR	9	Sequence 919 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20422	RRWVFGRRY	9	Sequence 920 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20423	GFTWKKKRR	9	Sequence 921 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20424	YKKIRIKRR	9	Sequence 922 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20425	VWIRRIKRR	9	Sequence 923 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20426	WWKWIRKIV	9	Sequence 924 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20427	WRRKWWSRW	9	Sequence 925 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20428	VTRRRTRIK	9	Sequence 926 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20429	RKRWFVYIW	9	Sequence 927 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20430	IIKWKRIMI	9	Sequence 928 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20431	FNRWWWKKI	9	Sequence 929 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20432	RYKSRRVRR	9	Sequence 930 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20433	VKVIKKFVR	9	Sequence 931 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20434	KWKWLQGRR	9	Sequence 932 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20435	KVRWWYNIK	9	Sequence 933 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20436	FWFRIRKLK	9	Sequence 934 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20437	KRRKQRKYR	9	Sequence 935 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20438	AKNSKRRLW	9	Sequence 936 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20439	RNRRIFRYS	9	Sequence 937 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20440	RWTKWFLVR	9	Sequence 938 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20441	RIRRTRRTR	9	Sequence 939 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20442	KIRWWRISI	9	Sequence 940 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20443	YKGRWGRRW	9	Sequence 941 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20444	MYYRIKQKW	9	Sequence 942 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20445	WRIQRWRWQ	9	Sequence 943 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20446	IRRWSYRRW	9	Sequence 944 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20447	VRIWKIIWW	9	Sequence 945 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20448	RWRWWWLWK	9	Sequence 946 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20449	TKRRWIWIT	9	Sequence 947 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20450	RRWHYWKGW	9	Sequence 948 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20451	WRIRKWWMR	9	Sequence 949 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20452	KRRTRWWVR	9	Sequence 950 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20453	RKWRVWKRR	9	Sequence 951 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20454	WRVWKIRVR	9	Sequence 952 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20455	KYWGIGGWR	9	Sequence 953 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20456	RLISRRRKK	9	Sequence 954 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20457	VSRRIVRRM	9	Sequence 955 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20458	ITKWWRKRR	9	Sequence 956 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20459	KWKIQLWKI	9	Sequence 957 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20460	KKWTWWYVI	9	Sequence 958 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20461	SWKKNRKIW	9	Sequence 959 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20462	HKRQYRKWF	9	Sequence 960 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20463	IFKWFYRRK	9	Sequence 961 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20464	RLARIVVIRVAR	12	Sequence 962 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20465	ILPWKWPWWPWRR	13	Sequence 963 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20466	VRLRIRVAVIRA	12	Sequence 964 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20467	ILKWKWPWWKWRR	13	Sequence 965 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20468	ILPWKWRWWKWRR	13	Sequence 966 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20469	FLPKKFRWWKYRK	13	Sequence 967 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20470	FIKWKFRWWKWRK	13	Sequence 968 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20471	KWPWWPWRR	9	Sequence 969 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20472	KWPWWPWRK	9	Sequence 970 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20473	KFPWWPWRR	9	Sequence 971 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20474	KKPWWPWRR	9	Sequence 972 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20475	KWRWWPWRR	9	Sequence 973 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20476	KWPKWPWRR	9	Sequence 974 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20477	KWPWKPWRR	9	Sequence 975 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20478	KWPWWKWRR	9	Sequence 976 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20479	KWPWWPKRR	9	Sequence 977 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20480	KFRWWPWRR	9	Sequence 978 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20481	KFRWWKWRR	9	Sequence 979 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20482	KWRWWKKRR	9	Sequence 980 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20483	KKKWWKWRR	9	Sequence 981 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20484	KFHWWIWRK	9	Sequence 982 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20485	KFHWWKWRK	9	Sequence 983 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20486	KFKWWKYRK	9	Sequence 984 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20487	KFKFFKYRK	9	Sequence 985 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20488	KFKFFKFRK	9	Sequence 986 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20489	PWWPWRR	7	Sequence 987 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20490	KWWPWRR	7	Sequence 988 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20491	KWWPWRR	7	Sequence 989 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20492	RWWPWRR	7	Sequence 990 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20493	PKWPWRR	7	Sequence 991 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20494	PWKPWRR	7	Sequence 992 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20495	PWWPKRR	7	Sequence 993 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20496	PWWPWRK	7	Sequence 994 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20497	RWWKWRR	7	Sequence 995 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20498	RWWKWRK	7	Sequence 996 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20499	RFWKWRR	7	Sequence 997 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20500	RWWIKRR	7	Sequence 998 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20501	RWWIYRR	7	Sequence 999 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20502	RFFKFRR	7	Sequence 1000 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20503	KWWKWKK	7	Sequence 1001 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20504	KFFKFKK	7	Sequence 1002 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20505	RWRWKRWWW	9	Sequence 1003 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20506	RWRRWKWWW	9	Sequence 1004 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20507	RWWRWRKWW	9	Sequence 1005 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20508	RWRRKWWWW	9	Sequence 1006 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20509	RWRWWKRWY	9	Sequence 1007 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20510	RRKRWWWWW	9	Sequence 1008 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20511	RWRIKRWWW	9	Sequence 1009 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20512	KIWWWWRKR	9	Sequence 1010 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20513	RWRRWKWWL	9	Sequence 1011 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20514	KRWWKWIRW	9	Sequence 1012 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20515	KRWWWWWKR	9	Sequence 1013 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20516	IRWWKRWWR	9	Sequence 1014 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20517	IKRWWRWWR	9	Sequence 1015 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20518	RRKWWWRWW	9	Sequence 1016 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20519	RKWWRWWRW	9	Sequence 1017 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20520	KRWWWWRFR	9	Sequence 1018 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20521	IKRWWWRRW	9	Sequence 1019 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20522	KRWWWVWKR	9	Sequence 1020 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20523	KWRRWKRWW	9	Sequence 1021 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20524	WRWWKIWKR	9	Sequence 1022 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20525	WRWRWWKRW	9	Sequence 1023 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20526	WKRWKWWKR	9	Sequence 1024 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20527	RIKRWWWWR	9	Sequence 1025 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20528	IWKRWWRRW	9	Sequence 1026 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20529	KWWKIWWKR	9	Sequence 1027 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20530	RKRWLWRWW	9	Sequence 1028 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20531	KRWRWWRWW	9	Sequence 1029 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20532	KKRWLWWWR	9	Sequence 1030 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20533	RWWRKWWIR	9	Sequence 1031 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20534	KWWRWWRKW	9	Sequence 1032 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20535	KRWWIRWWR	9	Sequence 1033 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20536	KIWWWWRRR	9	Sequence 1034 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20537	RRRKWWIWW	9	Sequence 1035 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20538	RRRWWWWWW	9	Sequence 1036 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20539	RWWIRKWWR	9	Sequence 1037 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20540	KRWWKWWRR	9	Sequence 1038 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20541	KRWWRKWWR	9	Sequence 1039 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20542	RRIWRWWWW	9	Sequence 1040 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20543	IRRRKWWWW	9	Sequence 1041 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20544	KRKIWWWIR	9	Sequence 1042 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20545	RKIWWWRIR	9	Sequence 1043 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20546	KRWWIWRIR	9	Sequence 1044 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20547	RWFRWWKRW	9	Sequence 1045 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20548	WRWWWKKWR	9	Sequence 1046 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20549	WKRWWKKWR	9	Sequence 1047 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20550	WKRWRWIRW	9	Sequence 1048 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20551	WRWWKWWRR	9	Sequence 1049 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20552	WKKWWKRRW	9	Sequence 1050 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20553	WRWYWWKKR	9	Sequence 1051 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20554	WRRWWKWWR	9	Sequence 1052 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20555	IRMWVKRWR	9	Sequence 1053 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20556	RIWYWYKRW	9	Sequence 1054 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20557	FRRWWKWFK	9	Sequence 1055 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20558	RVRWWKKRW	9	Sequence 1056 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20559	RLKKVRWWW	9	Sequence 1057 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20560	RWWLKIRKW	9	Sequence 1058 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20561	LRWWWIKRI	9	Sequence 1059 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20562	TRKVWWWRW	9	Sequence 1060 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20563	KRFWIWFWR	9	Sequence 1061 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20564	KKRWVWVIR	9	Sequence 1062 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20565	KRWVWYRYW	9	Sequence 1063 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20566	IRKWRRWWK	9	Sequence 1064 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20567	RHWKTWWKR	9	Sequence 1065 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20568	RRFKKWYWY	9	Sequence 1066 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20569	RIKVIWWWR	9	Sequence 1067 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20570	RKRLKWWIY	9	Sequence 1068 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20571	LVFRKYWKR	9	Sequence 1069 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20572	RRRWWWIIV	9	Sequence 1070 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20573	KKRWVWIRY	9	Sequence 1071 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20574	RWRIKFKRW	9	Sequence 1072 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20575	KWKIFRRWW	9	Sequence 1073 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20576	IWKRWRKRL	9	Sequence 1074 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20577	RRRKWWIWG	9	Sequence 1075 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20578	RWLVLRKRW	9	Sequence 1076 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20579	RKWIWRWFL	9	Sequence 1077 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20580	KRRRIWWWK	9	Sequence 1078 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20581	IWWKWRRWV	9	Sequence 1079 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20582	LRWRWWKIK	9	Sequence 1080 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20583	RWKMWWRWV	9	Sequence 1081 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20584	VKRYYWRWR	9	Sequence 1082 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20585	RWYRKRWSW	9	Sequence 1083 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20586	KRKLIRWWW	9	Sequence 1084 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20587	RWRWWIKII	9	Sequence 1085 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20588	KFRKRVWWW	9	Sequence 1086 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20589	IWIWRKLRW	9	Sequence 1087 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20590	LRFILWWKR	9	Sequence 1088 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20591	RVWFKRRWW	9	Sequence 1089 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20592	RRWFVKWWY	9	Sequence 1090 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20593	KWWLVWKRK	9	Sequence 1091 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20594	RWILWWWRI	9	Sequence 1092 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20595	KRWLTWRFR	9	Sequence 1093 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20596	RKWRWRWLK	9	Sequence 1094 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20597	IRRRWWWIV	9	Sequence 1095 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20598	IKWWWRMRI	9	Sequence 1096 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20599	RWKIFIRWW	9	Sequence 1097 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20600	IRQWWRRWW	9	Sequence 1098 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20601	RRRKTWYWW	9	Sequence 1099 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20602	RRWWMRWWV	9	Sequence 1100 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20603	RRWWMRWWV	9	Sequence 1101 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20604	RRFKFIRWW	9	Sequence 1102 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20605	INRKRRLRW	9	Sequence 1103 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20606	RRMKKLRRK	9	Sequence 1104 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20607	RKVRWKIRV	9	Sequence 1105 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20608	VRIVRVRIR	9	Sequence 1106 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20609	IKRVKRRKR	9	Sequence 1107 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20610	RVKTWRVRT	9	Sequence 1108 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20611	RVFVKIRMK	9	Sequence 1109 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20612	IRGRIIFWV	9	Sequence 1110 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20613	ATWIWVFRR	9	Sequence 1111 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20614	KKSKQLWKR	9	Sequence 1112 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20615	MINRVRLRW	9	Sequence 1113 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20616	GGIRRLRWY	9	Sequence 1114 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20617	RLVHWIRRV	9	Sequence 1115 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20618	AWKIKKGRI	9	Sequence 1116 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20619	FVVMKRIVW	9	Sequence 1117 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20620	GIKWRSRRW	9	Sequence 1118 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20621	RWMVSKIWY	9	Sequence 1119 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20622	IVVRVWVVR	9	Sequence 1120 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20623	RWIGVIIKY	9	Sequence 1121 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20624	WIRKRSRIF	9	Sequence 1122 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20625	GWKILRKRK	9	Sequence 1123 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20626	YQRLFVRIR	9	Sequence 1124 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20627	AVWKFVKRV	9	Sequence 1125 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20628	IRKKRRRWT	9	Sequence 1126 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20629	ILRVISKRR	9	Sequence 1127 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20630	AWRFKNIRK	9	Sequence 1128 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20631	HYKFQRWIK	9	Sequence 1129 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20632	RRIRRVRWG	9	Sequence 1130 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20633	VLVKKRRRR	9	Sequence 1131 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20634	RWRGIVHIR	9	Sequence 1132 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20635	WRNRKVVWR	9	Sequence 1133 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20636	KFWWWNYLK	9	Sequence 1134 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20637	KRIMKLKMR	9	Sequence 1135 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20638	IRRRKKRIK	9	Sequence 1136 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20639	RKWMGRFLM	9	Sequence 1137 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20640	RRVQRGKWW	9	Sequence 1138 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20641	WHGVRWWKW	9	Sequence 1139 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20642	WVRFVYRYW	9	Sequence 1140 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20643	RKRTKVTWI	9	Sequence 1141 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20644	IRRIVRRKI	9	Sequence 1142 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20645	KIRRKVRWG	9	Sequence 1143 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20646	AIRRWRIRK	9	Sequence 1144 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20647	WRFKVLRQR	9	Sequence 1145 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20648	RSGKKRWRR	9	Sequence 1146 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20649	FMWVYRYKK	9	Sequence 1147 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20650	RGKYIRWRK	9	Sequence 1148 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20651	WVKVWKYTW	9	Sequence 1149 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20652	VVLKIVRRF	9	Sequence 1150 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20653	GKFYKVWVR	9	Sequence 1151 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20654	SWYRTRKRV	9	Sequence 1152 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20655	KNRGRWFSH	9	Sequence 1153 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20656	AFRGSRHRM	9	Sequence 1154 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20657	GRNGWYRIN	9	Sequence 1155 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20658	AGGMRKRTR	9	Sequence 1156 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20659	ATRKGYSKF	9	Sequence 1157 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20660	SSGVRWSWR	9	Sequence 1158 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20661	RVWRNGYSR	9	Sequence 1159 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20662	WGRTRWSSR	9	Sequence 1160 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20663	GKRVWGRGR	9	Sequence 1161 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20664	SFNWKRSGK	9	Sequence 1162 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20665	WGRGGWTNR	9	Sequence 1163 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20666	ANRWGRGIR	9	Sequence 1164 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20667	WGGHKRRGW	9	Sequence 1165 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20668	WHGGQKWRK	9	Sequence 1166 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20669	FVWQKGTNR	9	Sequence 1167 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20670	HGVWGNRKR	9	Sequence 1168 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20671	TRGWSLGTR	9	Sequence 1169 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20672	GRRVMNQKR	9	Sequence 1170 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20673	RNKFGGNWR	9	Sequence 1171 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20674	GVRVQRNSK	9	Sequence 1172 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20675	NQKWSGRRR	9	Sequence 1173 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20676	RQNGVWRVF	9	Sequence 1174 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20677	GRMRLWNGR	9	Sequence 1175 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20678	WHYRSQVGR	9	Sequence 1176 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20679	GWNTMGRRW	9	Sequence 1177 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20680	RRMGNGGFR	9	Sequence 1178 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20681	SKNVRTWRQ	9	Sequence 1179 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20682	ARGRWINGR	9	Sequence 1180 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20683	GSRRSVWVF	9	Sequence 1181 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20684	WSQNVRTRI	9	Sequence 1182 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20685	GMRRWRGKN	9	Sequence 1183 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20686	RGRTSNWKM	9	Sequence 1184 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20687	WGKRRGWNT	9	Sequence 1185 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20688	WGKRRGWNT	9	Sequence 1186 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20689	AMLGGRQWR	9	Sequence 1187 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20690	QRNKGLRHH	9	Sequence 1188 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20691	ARGKSIKNR	9	Sequence 1189 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20692	NRRNGQMRR	9	Sequence 1190 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20693	RGRRQIGKF	9	Sequence 1191 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20694	ASKRVGVRN	9	Sequence 1192 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20695	GRIGGKNVR	9	Sequence 1193 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20696	NKTGYRWRN	9	Sequence 1194 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20697	VSGNWRGSR	9	Sequence 1195 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20698	GWGGKRRNF	9	Sequence 1196 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20699	KNNRRWQGR	9	Sequence 1197 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20700	GRTMGNGRW	9	Sequence 1198 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20701	GRQISWGRT	9	Sequence 1199 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20702	GGRGTRWHG	9	Sequence 1200 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20703	GVRSWSQRT	9	Sequence 1201 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20704	GSRRFGWNR	9	Sequence 1202 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20705	LVRAIQVRAVIR	12	Sequence 1203 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20706	VQRWLIVWRIRK	12	Sequence 1204 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20707	IVWKIKRWWVGR	12	Sequence 1205 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20708	RFWKVRVKYIRF	12	Sequence 1206 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20709	VQLRIRVAV	9	Sequence 1207 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20710	VQLRIWVRR	9	Sequence 1208 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20711	WNRVKWIRR	9	Sequence 1209 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20712	RIKWIVRFR	9	Sequence 1210 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20713	AIRVVRARLVRR	12	Sequence 1211 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20714	IRWRIRVWVRRI	12	Sequence 1212 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20715	RRWVVWRIVQRR	12	Sequence 1213 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20716	IFWRRIVIVKKF	12	Sequence 1214 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20717	VRLRIRVAV	9	Sequence 1215 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20718	RQVIVRRW	8	Sequence 1216 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20719	VLIRWNGKK	9	Sequence 1217 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20720	LRIRWIFKR	9	Sequence 1218 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20721	KRIVRRLVARIV	12	Sequence 1219 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20722	VRLIVAVRIWRR	12	Sequence 1220 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20723	IVVWRRQLVKNK	12	Sequence 1221 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20724	VRLRIRWWVLRK	12	Sequence 1222 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20725	LRIRVIVWR	9	Sequence 1223 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20726	IRVWVLRQR	9	Sequence 1224 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20727	RIRVIVLKK	9	Sequence 1225 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20728	RRIVKKFQIVRR	12	Sequence 1226 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20729	VQWRIRVRVIKK	12	Sequence 1227 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20730	KKQVSRVKVWRK	12	Sequence 1228 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20731	LIQRIRVRNIVK	12	Sequence 1229 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20732	KQFRIRVRV	9	Sequence 1230 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20733	FRIRVRVIR	9	Sequence 1231 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20734	WRWRVRVWR	9	Sequence 1232 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20735	IRVRVIWRK	9	Sequence 1233 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20736	RRVIVKKFRIRR	12	Sequence 1234 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20737	KQFRNRLRIVKK	12	Sequence 1235 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20738	KRWRWIVRNIRR	12	Sequence 1236 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20739	VQFRIRVIVIRK	12	Sequence 1237 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20740	KRFRIRVRV	9	Sequence 1238 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20741	IVVRRVIRK	9	Sequence 1239 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20742	IWVIRRVWR	9	Sequence 1240 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20743	FQVVKIKVR	9	Sequence 1241 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20744	VIWIRWR	7	Sequence 1242 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20745	IVWIWRR	7	Sequence 1243 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20746	WIVIWRR	7	Sequence 1244 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20747	RRWIVWI	7	Sequence 1245 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20748	RWWRIVI	7	Sequence 1246 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20749	WIRVIRW	7	Sequence 1247 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20750	IIRRWWV	7	Sequence 1248 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20751	IRWVIRW	7	Sequence 1249 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20752	ILRWKWRWWRWRR	13	Sequence 1250 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20753	RWRWWRWRR	9	Sequence 1251 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20754	KWKWWKWKK	9	Sequence 1252 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20755	RWWRWRR	7	Sequence 1253 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20756	RIRVAV	6	Sequence 1254 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20757	WKWPWWPW	8	Sequence 1255 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20758	KIWVIRWWR	9	Sequence 1256 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP20759	RLCRIVVIRVCR	12	Sequence 1257 from Patent US 9017656	Synthetic construct	Antimicrobial	US 9017656 B2	Granted Patent	2015##4##28	WO9522338A1, WO9958141A1, WO2005025607A1, WO2005068492A2	Small Cationic Antimicrobial Peptides	"
The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides."
DRAMP27560	DCWSAMIRLHAKYNQV	16	Sequence 4 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27561	NRIVQQRTSSR	11	Sequence 5 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27562	YDKGFGLFKKM	11	Sequence 6 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27563	KIRLHRKRLRK	11	Sequence 7 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27564	KKRLHRKRLRK	11	Sequence 8 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27565	KLRLHAKRLRK	11	Sequence 9 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27566	RKWRAMIRLHAKRLRK	16	Sequence 10 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27567	RKWRAMIRLHAKWLRK	16	Sequence 11 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27568	WIRLHWKRLRK	11	Sequence 12 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27569	WWRLHAKKKLW	11	Sequence 13 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27570	WWRLHAKRKLW	11	Sequence 14 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27571	WWRLHAKWKLW	11	Sequence 15 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27572	KLKRAMIRLHAKKRLK	16	Sequence 16 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27573	KLKRAMIRLHAKKWRW	16	Sequence 17 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27574	RLKRAMIRLHAKKWRW	16	Sequence 18 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27575	RWWRAMIRLHAKKWRW	16	Sequence 19 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27576	WWRLHAAKKIL	11	Sequence 20 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27577	WWRLHAKKKCW	11	Sequence 21 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27578	WWRLHAKKKFW	11	Sequence 22 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27579	WWRLHAKKKIW	11	Sequence 23 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27580	WWRLHAKKKRW	11	Sequence 24 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27581	WWRLHAKKKWR	11	Sequence 25 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27582	WWRLHAKKKWW	11	Sequence 26 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27583	WWRLHAKLKLW	11	Sequence 27 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27584	WWRLHAKRKRW	11	Sequence 28 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27585	WWRLHAKWRWR	11	Sequence 29 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27586	WWRLHARKRWW	11	Sequence 30 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27587	WWRLHAWKWRR	11	Sequence 31 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27588	KWIVWRWRFKR	11	Sequence 32 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27589	RRIVKLRWFKR	11	Sequence 34 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27590	RRLIWRRFKWLR	12	Sequence 35 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27591	KRIVRWRTRKR	11	Sequence 36 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27592	KRIVRWRWRKR	11	Sequence 37 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27593	KRIVRWRKLKRK	12	Sequence 38 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27594	WRILRWRKLKR	11	Sequence 39 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27595	WRIVRWRKLKR	11	Sequence 40 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27596	WRIVQWRKLKR	11	Sequence 41 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27597	KRIVRRRTFKR	11	Sequence 42 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27598	KRWRKWRLFKR	11	Sequence 43 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27599	NRIVLLRTFKR	11	Sequence 44 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27600	NRIVKKRTFKR	11	Sequence 45 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27601	RKIVKRRTFKR	11	Sequence 46 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27602	RKIVWWRTFKR	11	Sequence 47 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27603	RLIVRRRTFKR	11	Sequence 48 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27604	RRIVRKKTFKR	11	Sequence 49 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27605	RRIVWRRTFKR	11	Sequence 50 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27606	RWIVQRRTFKR	11	Sequence 51 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27607	RVIVRRRTFKR	11	Sequence 52 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27608	WKIVKKRTRRR	11	Sequence 53 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27609	WRIVRRRTFKR	11	Sequence 54 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27610	IIKRFRLFKKL	11	Sequence 55 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27611	ILKRWWLFKKL	11	Sequence 56 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27612	IWKRFRLFKKR	11	Sequence 57 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27613	IWKRFRLFKKW	11	Sequence 58 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27614	RLKWFWLRKLK	11	Sequence 59 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27615	RLKRWRLFRKR	11	Sequence 60 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27616	RLKWFWLFRKR	11	Sequence 61 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27617	RLKWFLLFRKR	11	Sequence 62 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27618	WRKWFWLFKKR	11	Sequence 63 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27619	KRKWRWLFKKL	11	Sequence 64 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27620	KLKWFWLFKKR	11	Sequence 65 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27621	KLKKFKLFKKR	11	Sequence 66 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27622	RLKRFRLFRKRK	12	Sequence 67 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27623	KRKRFRLFKKR	11	Sequence 68 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27624	RLKRFRLFKKL	11	Sequence 69 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27625	RRKRFRLFKKM	11	Sequence 70 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27626	RRKRFRLFRRK	11	Sequence 71 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27627	RWKRFRLFKKR	11	Sequence 72 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27628	RWKRFRLFKKW	11	Sequence 73 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27629	WKKGFGLFKKM	11	Sequence 74 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27630	WKKRFRLFKKL	11	Sequence 75 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27631	WLRRFRLFRRL	11	Sequence 76 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27632	RLKRFLLFRKRL	12	Sequence 77 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27633	KRKWFWLFKKL	11	Sequence 78 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27634	KLKRFRLFKKR	11	Sequence 79 from Patent US 10457709	Synthetic construct	Antimicrobial	US 10457709 B2	Granted Patent	2019##10##29	WO2017001730A1, CN108026155A, US20180186843A1, JP2018530516A, EP3423476A1, EP3423476B1	Antimicrobial Peptides, Their Variants And Uses	The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
DRAMP27637	KWKW	4	Sequence 1 from Patent US 10301354	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 10301354 B2	Granted Patent	2019##5##28	WO2013100721A1, KR20130078561A, KR101345333B1, US20140309162A1, US20180179251	Antibacterial And Fungicidal Peptide In Which Lysine And Tryptophan Residues Are Repeated, And Use Thereof	The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative.
DRAMP27638	KWKWKW	6	Sequence 2 from Patent US 10301354	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 10301354 B2	Granted Patent	2019##5##28	WO2013100721A1, KR20130078561A, KR101345333B1, US20140309162A1, US20180179251	Antibacterial And Fungicidal Peptide In Which Lysine And Tryptophan Residues Are Repeated, And Use Thereof	The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative.
DRAMP27639	KWKWKWKW	8	Sequence 3 from Patent US 10301354	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 10301354 B2	Granted Patent	2019##5##28	WO2013100721A1, KR20130078561A, KR101345333B1, US20140309162A1, US20180179251	Antibacterial And Fungicidal Peptide In Which Lysine And Tryptophan Residues Are Repeated, And Use Thereof	The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative.
DRAMP27640	KWKWKWKWKW	10	Sequence 4 from Patent US 10301354	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 10301354 B2	Granted Patent	2019##5##28	WO2013100721A1, KR20130078561A, KR101345333B1, US20140309162A1, US20180179251	Antibacterial And Fungicidal Peptide In Which Lysine And Tryptophan Residues Are Repeated, And Use Thereof	The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative.
DRAMP27641	WWWLSRIW	8	Sequence 1 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27642	WWWLKRIW	8	Sequence 2 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27643	WWWLRKIW	8	Sequence 3 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27644	WWWLKKIW	8	Sequence 4 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27645	WWWLRRIW	8	Sequence 5 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27646	FFFLSRIF	8	Sequence 7 from Patent US 20190048052	Pelophylax saharicus	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27647	KRWWKWWRRC	10	Sequence 8 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27649	RWWLRRIW	8	Sequence 10 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27650	WRWLRRIW	8	Sequence 11 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27651	WWRLRRIW	8	Sequence 12 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27652	WWWRRRIW	8	Sequence 13 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27653	WWWLRRRW	8	Sequence 14 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27654	WWWLRRIR	8	Sequence 15 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27655	WWWXXXXW	8	Sequence 16 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27656	WWWLXXXW	8	Sequence 17 from Patent US 20190048052	Synthetic construct	Antimicrobial	US 2019/0048052 A1	Patent Application	2019##2##14	US20180051061A1, US10144767B2	Anti-microbial Peptides And Coatings	Antimicrobial peptides and methods of use are provided.
DRAMP27657	RRGMKQYERISRDANRSYRR	20	Sequence 1 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27658	RQYMRQIEQALRYGYRISRR	20	Sequence 2 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27659	RKYMRQYEEAIRDGNRSIRR	20	Sequence 3 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27660	RQYMRYLEQAERYVNRNLRR	20	Sequence 4 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27661	RKLMEMYEEAFRYFNRISRR	20	Sequence 5 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27662	RSIMELYKQASRSFNRGIRR	20	Sequence 6 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27663	RQIYESIEQALRRGYRSYRR	20	Sequence 7 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27664	RSYYEAYERALRKGQRGIRR	20	Sequence 8 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27665	RAYMEALRQAERLGNRTARR	20	Sequence 9 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27666	RYLMEYAEQAKRDAKRAYRR	20	Sequence 10 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27667	RQLMELIEQAERYGNRFYRR	20	Sequence 11 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27668	RKLMELYEQAIRYGKRSYRR	20	Sequence 12 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27669	RRYMECYEQAERYFRRFGRR	20	Sequence 13 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27670	RSFMKCYEQASRYGNRILRR	20	Sequence 14 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27671	RKLVECYERAERDANRSGRR	20	Sequence 15 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27672	RQLMECYEQAARRGARSYRR	20	Sequence 16 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27673	RYMMKIYEQAERYFNRVGRR	20	Sequence 17 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27674	RRYYEQLEQASRKGNRGFRR	20	Sequence 18 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27675	RSVMEQYEQAARDAYRSARR	20	Sequence 19 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27676	RQYMECIEKALRDGYRSYRR	20	Sequence 20 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27677	RYYMKCYKQAARYIYRGYRR	20	Sequence 21 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27678	RSAYEYYRRAYRDGNRGYRR	20	Sequence 22 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27679	RYGMRQFEQASRDGNRSFRR	20	Sequence 23 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27680	RKGYRGYEQALRYGKRYGRR	20	Sequence 24 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27681	RYGMRCLEEALRYGNRGYRR	20	Sequence 25 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27682	RQYREIIEQARRVGNRGARR	20	Sequence 26 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27683	RQGMEVYERASRQGNRSLRR	20	Sequence 27 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27684	RRIMEQYEEAERDGNRVYRR	20	Sequence 28 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27685	RQVMEAYEQFYRDGNRAYRR	20	Sequence 29 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27686	RQLMEQYEQAYRYAARGYRR	20	Sequence 30 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27687	RYIMEIYEQAIRKGNRSYRR	20	Sequence 31 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27688	RKYMELYEKASRRGYRGYRR	20	Sequence 32 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27689	RQYLEQYENAERYIYRAYRR	20	Sequence 33 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27690	RQYMKCYEQAYRYGRRGYRR	20	Sequence 34 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27691	RQYAEQYEEAIRDGNRSVRR	20	Sequence 35 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27692	RSYMEMLEQIERYGNRVGRR	20	Sequence 36 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27693	RQYMEFVEQAERYGRRGSRR	20	Sequence 37 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27694	RSYMEQYEEAIRRGYRSYRR	20	Sequence 38 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27695	RQYMKYYEEAERYGNRAYRR	20	Sequence 39 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27696	RAYMEYYEQFYRMGKRASRR	20	Sequence 40 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27697	RQYMEQVEQALRDGYRSGRR	20	Sequence 41 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27698	RSYMESIEQALRIGNRSYRR	20	Sequence 42 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27699	RSYMEIYEQASRAGNRAYRR	20	Sequence 43 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27700	RQYMEYYEQVFRAGYRSARR	20	Sequence 44 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27701	RYYMECYEQAVRYGRRWYRR	20	Sequence 45 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27702	RQGMECYEQALRYGQRGIRR	20	Sequence 46 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27703	RSFMEQGEQAFRDGYRMYRR	20	Sequence 47 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27704	RKYMEIYEKASRYGNRSYRR	20	Sequence 48 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27705	RQYKEAYEEIYRYGNRMGRR	20	Sequence 49 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27706	RRYMECYEQAERDGNRMYRR	20	Sequence 50 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27707	RAYMECLEQAERYGNRAYRR	20	Sequence 51 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27708	RQVMETYEQLERYGNRSARR	20	Sequence 52 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27709	RQIRECYEQASRYGNRSYRR	20	Sequence 53 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27710	RQYMEVYEQAERAGNRVYRR	20	Sequence 54 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27711	RSYMEQYEQAFRRGNRSYRR	20	Sequence 55 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27712	RHFMECYEQASRDGNRSLRR	20	Sequence 56 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27713	RKAMEQYEEAERDGARSYRR	20	Sequence 57 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27714	RQYMKGYEQAERHAYRSYRR	20	Sequence 58 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27715	RQYMEQAEQAERDGNRSVRR	20	Sequence 59 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27716	RSIMEYYEQIERDGNRSYRR	20	Sequence 60 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27717	RYLKECYEQASRIGYRGLRR	20	Sequence 61 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27718	RQGMEAYEQAERLGNRGIRR	20	Sequence 62 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27719	RQYMECYKQIYRYGNRSYRR	20	Sequence 63 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27720	RSYREYAEQALRYGNRGYRR	20	Sequence 64 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27721	RSGMEYYKQAFRAGYRVTRR	20	Sequence 65 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27722	RSAMECYEKAERYWYRGSRR	20	Sequence 66 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27723	RSYMECYEQASRKGNRSIRR	20	Sequence 67 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27724	RQYMELYEQAMRYGNRGYRR	20	Sequence 68 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27725	RQYIECYEQAARYGKRGYRR	20	Sequence 69 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27726	RQWAEYYEQLERYGNRSYRR	20	Sequence 70 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27727	RSYMEAYEQASRDGYRLYRR	20	Sequence 71 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27728	RQYMEQYEQFERAGNRVYRR	20	Sequence 72 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27729	RYYMEYYEKASRYGNRGIRR	20	Sequence 73 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27730	RYYMEYYEQLERYGNRLYRR	20	Sequence 74 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27731	RQYMECYEQAARYGNRSYRR	20	Sequence 75 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27732	RQYMEIYEQASRYGNRSYRR	20	Sequence 76 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27733	RQYMEQYEQAMRDGNRGYRR	20	Sequence 77 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27734	RQYMEYYEQFSRLGNRSYRR	20	Sequence 78 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27735	RSGMKVYEQAERYGNRSYRR	20	Sequence 79 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27736	RSAMECYEKASRDGNRGSRR	20	Sequence 80 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27737	RYYKEYYEKAERIGNRGYRR	20	Sequence 81 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27738	RSYMECYEQAFRYGKRSSRR	20	Sequence 82 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27739	RQYMECYKQAERYGNRGYRR	20	Sequence 83 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27740	RSVMEYYEQAYRYGNRGSRR	20	Sequence 84 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27741	RQGMEAYEQAERYGNRSYRR	20	Sequence 85 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27742	RAYQEAYEQAYRDGNRSYRR	20	Sequence 86 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27743	RSYMEQYEQASRKGYRSYRR	20	Sequence 87 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27744	RSYAECYEQISRYGNRGYRR	20	Sequence 88 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27745	RSYMEAYEQAERYGNRGYRR	20	Sequence 89 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27746	SQRVEQYVRRLYDDYRNYMR	20	Sequence 90 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27747	RSYIEQYEQLERDGARSYRR	20	Sequence 91 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27748	SQRLERYVERSFDDYRKSGR	20	Sequence 92 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27749	RSYMEYYEQASRDGARGYRR	20	Sequence 93 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27750	SKRVGQGVERSYKKYRNYIR	20	Sequence 94 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27751	GQRVEQLVERYGDDLRNSVR	20	Sequence 95 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27752	YQRVEQYVQRSYDAYRNYAR	20	Sequence 96 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27753	SQRVEQYVERYADGYRNYLR	20	Sequence 97 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27754	YQRVEQYVQRYHDDLRNYSR	20	Sequence 98 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27755	YQRVEQYVQRSYDDYRNVGR	20	Sequence 99 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27756	TQRVEQYVERSSDKYRNLGR	20	Sequence 100 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27757	SSRMECYEQAERYGYGGYGG	20	Sequence 101 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27758	RYGYGGYGGGRYGGGYGSGR	20	Sequence 102 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27759	YGYGGYGGGRYGGGYGSGRG	20	Sequence 103 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27760	GQPVGQGVERSHDDNRNQPR	20	Sequence 104 from Patent US 20190279741	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0279741 A1	Patent Application	2020##9##12	WO2019178056A1	Computational Platform For In Silico Combinatorial Sequence Space Exploration And Artificial Evolution Of Peptides	Disclosed herein are methods of designing peptides having at least one property of interest, such as α-helical propensity, higher net charge, hydrophobicity, and/or hydrophobic moment. Also disclosed herein are novel artificially evolved peptides (e.g., antimicrobial peptides), which may be designed according to the methods described herein, and methods of use thereof.
DRAMP27763	FFHHIFRPIVHVGKTIHRLVTG	22	Sequence 2 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27764	FFHHIFRGKVHVGKTIHRLVTG	22	Sequence 3 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27765	FFHHIFRGIVHKGKTIHRLVTG	22	Sequence 4 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27766	FFHHIFRGIVHVKKTIHRLVTG	22	Sequence 5 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27767	ALWMTLLKKVLKAAAKALNAVLVGANA	27	Sequence 6 from Patent US 10221222	Phyllomedusa sauvagii	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27768	ALWMTLKKKVLKAAAKALNAVLVGANA	27	Sequence 7 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27769	ALWMTLLKKVLKAKAKALNAVLVGANA	27	Sequence 8 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27770	ALWMTLKKKVLKAKAKALNAVLVGANA	27	Sequence 9 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27772	ALWMTLLKKVLKAAAKAALNAVLVGANA	28	Sequence 11 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27773	ALWMTLKKKVLKAKAKAALNAVLVGANA	28	Sequence 12 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27774	ALWMTLKKKVLKAKAK	16	Sequence 13 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27775	ALWMTKLKKVLKAKAKALNAVLVGANA	27	Sequence 14 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27776	ALWMTLKKKVLKAKAKALNAVLSGANA	27	Sequence 15 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27777	ALWMTLKKKVLKAKAKALNAVLKGANA	27	Sequence 16 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27778	ALWMTLKKKVLKAKAKALNAVLAGVNA	27	Sequence 17 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27779	ALWMTLKKKVLKAKAKLLNAVLVGANA	27	Sequence 18 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27780	ALWMTLKKKVLKAKAKALNAVLVGLNA	27	Sequence 19 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27781	ALWMTLKKKVLKAKAKLLNAVLVGLNA	27	Sequence 20 from Patent US 10221222	Synthetic construct	Antimicrobial, Antibacterial	US 10221222 B2	Granted Patent	2019##3##5	WO2015112980A2, US20160333062A1, EP3096616A2, US20190202877A1, EP3096616B1, EP3096616A4, US20190202877A1, US10428126B2, EP3096616B1	Dermaseptin-type And Piscidin-type Antimicrobial Peptides	Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
DRAMP27782	GLLSLLSLLGKLL	13	Sequence 1 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27783	GLLPLLSLLGKLL	13	Sequence 2 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27784	GIIPIISIIGKII	13	Sequence 3 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27785	GVVPVVSVVGKVV	13	Sequence 4 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27786	FFGSVLKLIPKIL	13	Sequence 5 from Patent US 10723764	Hylarana picturata	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27787	FFGSVLKLIPKIL	13	Sequence 6 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27788	FFGSLLKLLPKLL	13	Sequence 7 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27789	LLGSLLKLLPKLL	13	Sequence 8 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27790	FFGKVLKLIRKIF	13	Sequence 9 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27791	FVQWFSKFLGRIL	13	Sequence 11 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27792	FFPVIGRILNGIL	13	Sequence 12 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27793	NFLGTLINLAKKIM	14	Sequence 13 from Patent US 10723764	Rana luteiventris	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27794	FLPLIGRVLSGIL	13	Sequence 14 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27795	VLPIIGNLLNSLL	13	Sequence 16 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27796	LSPNLLKSLL	10	Sequence 17 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27797	LLPIVGNLLNSLL	13	Sequence 18 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27798	LLPIVGNLLKSLL	13	Sequence 19 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27799	LLPNLLKSLL	10	Sequence 20 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27800	LLPILGNLLNGLL	13	Sequence 21 from Patent US 10723764	Rana temporaria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27801	VDKPDYRPRPRPPNM	15	Sequence 22 from Patent US 10723764	Palomena prasina	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27802	FLFPLITSFLSKVL	14	Sequence 23 from Patent US 10723764	Rana catesbeiana	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27803	INLKAIAALAKKLL	14	Sequence 24 from Patent US 10723764	Vespa mandarinia	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27804	FRPALIVRTKGTRL	14	Sequence 25 from Patent US 10723764	Phyllomedusa hypochondria	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27808	VFQFLGRIIHHVGNFVHGFSHVF	23	Sequence 29 from Patent US 10723764	Styela clava	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27810	GFGKAFHSVSNFAKKHKTA	19	Sequence 31 from Patent US 10723764	Styela clava	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27811	LLKELWTKIKGAGKAVLGKIKGLL	24	Sequence 32 from Patent US 10723764	Pachycondyla goeldii	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27812	HVDKKVADKVLLLKQLRIMRLLTRL	25	Sequence 33 from Patent US 10723764	Pseudacanthotermes spinig	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27816	KGRGKQGGKVRAKAKTRSS	19	Sequence 38 from Patent US 10723764	Silurus asotus	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27817	GIWDTIKSMGKVFAGKILQNL	21	Sequence 39 from Patent US 10723764	Rana septentrionalis	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27818	GLLGLLGSVVSHVVPAIVGHF	21	Sequence 40 from Patent US 10723764	Litoria eucnemis	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27819	SWKSMAKKLKEYMEKLKQRA	20	Sequence 41 from Patent US 10723764	Lachesana tarabaevi	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27820	GAWKNFWSSLRKGFYDGEAGRAIRR	25	Sequence 42 from Patent US 10723764	Lactobacillus plantarum	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27821	GFKDLLKGAAKALVKTVLF	19	Sequence 43 from Patent US 10723764	Ascaphus truei	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27822	GLADFLNKAVGKVVDFVKS	19	Sequence 44 from Patent US 10723764	Crinia deserticola	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27823	GFLSILKKVLPKVMAHMK	18	Sequence 45 from Patent US 10723764	Melecta albifrons	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27825	IKWKKLLRAAKRIL	14	Sequence 47 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27826	GWFDVVKHIAKRF	13	Sequence 48 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27827	NLVSGLIEARKYLEQLHRKLKNRKV	25	Sequence 49 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27828	SLSRFLRFLKIVYRRAF	17	Sequence 50 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27829	IWLTALKFLGKHAAKHLAKQQL	22	Sequence 51 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27830	IWLTALKFLGKHAAKHLL	18	Sequence 52 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27831	FFGRVLRLIRRIF	13	Sequence 53 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27832	KIGKEFKRIVQRIKDFLRNLVP	22	Sequence 54 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27833	GKEFKRIVQRIKDFLRNLVPR	21	Sequence 55 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27834	GFKRIVQRIKDFLRNLV	17	Sequence 56 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27835	GXKRLVQRLKDXLRNLV	17	Sequence 58 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27836	GFKRLVQRLKDFLRNLV	17	Sequence 59 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27837	GXKRLVQRLKDFLRNLV	17	Sequence 60 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27838	XXXXLLXLLXXLL	13	Sequence 63 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27839	FKRIVQRIKDFLRNLVPRTE	20	Sequence 64 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27840	EKIGKEFKRIVQRIKDFLRN	20	Sequence 65 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27841	GFKRIVQRIKDFLRNL	16	Sequence 66 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27842	GRFKRFRKKFKKLFKKLS	18	Sequence 67 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27843	GFKRLVQRLKDXLRNLV	17	Sequence 68 from Patent US 10723764	Synthetic construct	Antimicrobial, Antibacterial	US 10723764 B2	Granted Patent	2020##7##28	US20150259382A1	Anti-microbial Peptides And Methods Of Use Thereof	Anti-microbial peptides and methods of use are provided.
DRAMP27844	CKXXXXC	7	Sequence 1 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27845	LIAGLAANFLPKLFCKITK	19	Sequence 2 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27846	FLPLLAGLAANFLPKIFCKITRK	23	Sequence 3 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27847	LPLLAGLAANFLPKIFCKITRK	22	Sequence 4 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27848	FLPFIAGMAAKFLPKIFCAISKK	23	Sequence 5 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27849	LIAGLAANFLPQILCKIARKC	21	Sequence 6 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27850	GLFSILKIGAKVIGKNLLKQAGKAGMEYAACKATNQC	37	Sequence 7 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27851	GLFSILKIGAEVIGKNLLKQAGKAGMEYAACKAANQC	37	Sequence 8 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27852	GLFSILKIGAKVIGKSLLKQAGKAGMEYAACKATNQC	37	Sequence 9 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27853	GLFSILKIGAKVIGKNLLKQAGKAGMEYAACKAANQC	37	Sequence 10 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27854	FFGPLIKIATGVLPNLICKALGKC	24	Sequence 11 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27855	FFGPLIKIATGVLPSLICKALGKC	24	Sequence 12 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27856	FFGPLIKIATGVLPSLICRALGKC	24	Sequence 13 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27857	GIGSMLLGLAKNVGMSLLNKAQCKISGKC	29	Sequence 14 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27858	GFMGDTLKGIARNAALALMNAAQCKLSGKC	30	Sequence 15 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27859	GLGSMFLGLAKNLGMTLLNKAQCKLSGKC	29	Sequence 16 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27860	GFMGDTLKGIAKNAALALMNAAQCKLSGKC	30	Sequence 17 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27861	GFMNTAMNTATNIARTLVDKVKCKFKGGC	29	Sequence 18 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27862	NALVGCWTKSYPPKPCLG	18	Sequence 19 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27863	NALVRCWTKSYPPKPCLG	18	Sequence 20 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27864	TVLRGCWTFTFPPKPCVGKR	20	Sequence 21 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27865	IAGLAANFLPKLFCKITK	18	Sequence 23 from Patent WO 2019077634 	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/077634 A2	Patent Application	2019##4##25	WO2019077634A3	Therapeutic Compositions Of Antimicrobial Peptides	The present invention provides L-peptides and synthetic D-amino acid substituted peptides isolated, purified and characterized from frogs Clinotarsus curtipes and Hylarana temporalis of the Western Ghats, Kerala region of India. Peptides profiles are herein described according to their killing kinetics of Gram-positive and gram-negative bacteria, red blood cell haemolysis and cytotoxic effect on cultured mammalian cells.
DRAMP27866	ATCYCRTGR	9	Sequence 1 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27867	RGTRCYCTA	9	Sequence 2 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27868	VCSCRLVFCRR	11	Sequence 3 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27869	RRCFVLRCSCV	11	Sequence 4 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27870	ATCYCRTGRCATRESLSGVCEISGRLYRLCCR	32	Sequence 9 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27871	ATCYCRTGRCATRESLSGVCEISGRLYRL	29	Sequence 10 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27872	CRTGRCATRESLSGVCEISGRLYRLCCR	28	Sequence 11 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27873	ATCYCRTGRCATRESLSGVCEISGRLYR	28	Sequence 12 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27874	ATCYCRTGRCATRESLSGVCEISGRLY	27	Sequence 13 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27875	TGRCATRESLSGVCEISGRLYRLCCR	26	Sequence 14 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27876	ATCYCRTGRCATRESLSGVCEISGRL	26	Sequence 15 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27877	CRTGRCATRESLSGVCEISGRLYRL	25	Sequence 16 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27878	ATCYCRTGRCATRESLSGVCEISGR	25	Sequence 17 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27879	CRTGRCATRESLSGVCEISGRLYR	24	Sequence 18 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27880	CATRESLSGVCEISGRLYRLCCR	23	Sequence 19 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27881	CRTGRCATRESLSGVCEISGRLY	23	Sequence 20 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27882	TGRCATRESLSGVCEISGRLYR	22	Sequence 21 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27883	CRTGRCATRESLSGVCEISGRL	22	Sequence 22 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27884	TGRCATRESLSGVCEISGRLY	21	Sequence 23 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27885	CRTGRCATRESLSGVCEISGR	21	Sequence 24 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27886	ESLSGVCEISGRLYRLCCR	19	Sequence 25 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27887	CATRESLSGVCEISGRLYR	19	Sequence 26 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27888	TGRCATRESLSGVCEISGR	19	Sequence 27 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27889	CATRESLSGVCEISGRLY	18	Sequence 28 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27890	SGVCEISGRLYRLCCR	16	Sequence 29 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27891	ATCYCRTGRCATRESL	16	Sequence 30 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27892	ESLSGVCEISGRLYR	15	Sequence 31 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27893	CATRESLSGVCEISGR	16	Sequence 32 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27894	ESLSGVCEISGRLY	14	Sequence 33 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27895	ATCYCRTGRCATR	13	Sequence 34 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27896	SGVCEISGRLYRL	13	Sequence 35 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27897	CRTGRCATRESL	12	Sequence 36 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27898	ESLSGVCEISGR	12	Sequence 37 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27899	SGVCEISGRLY	11	Sequence 38 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27900	CRTGRCATR	9	Sequence 39 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27901	SGVCEISGRL	10	Sequence 40 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27902	LYRLCCR	7	Sequence 41 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27903	YRLCCR	6	Sequence 42 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27904	TGRCATR	7	Sequence 43 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27905	ATCYCR	6	Sequence 44 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27906	RLCCR	5	Sequence 45 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27907	CRTGR	5	Sequence 46 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27908	AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL	32	Sequence 47 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27909	TCHCRRSCYSTEYSYGTCTVMGINHRFCCL	30	Sequence 48 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27910	AFTCHCRRSCYSTEYSYGTCTVMGINHRF	29	Sequence 49 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27911	AFTCHCRRSCYSTEYSYGTCTVMGINHR	28	Sequence 50 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27912	TCHCRRSCYSTEYSYGTCTVMGINHRF	27	Sequence 51 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27913	TCHCRRSCYSTEYSYGTCTVMGINHR	26	Sequence 52 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27914	RSCYSTEYSYGTCTVMGINHRFCCL	25	Sequence 53 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27915	SCYSTEYSYGTCTVMGINHRFCCL	24	Sequence 54 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27916	AFTCHCRRSCYSTEYSYGTCTVM	23	Sequence 55 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27917	RSCYSTEYSYGTCTVMGINHRF	22	Sequence 56 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27918	TCHCRRSCYSTEYSYGTCTVM	21	Sequence 57 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27919	RSCYSTEYSYGTCTVMGINHR	21	Sequence 58 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27920	SCYSTEYSYGTCTVMGINHRF	21	Sequence 59 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27921	STEYSYGTCTVMGINHRFCCL	21	Sequence 60 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27922	SCYSTEYSYGTCTVMGINHR	20	Sequence 61 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27923	AFTCHCRRSCYSTEYSY	17	Sequence 62 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27924	STEYSYGTCTVMGINHRF	18	Sequence 63 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27925	STEYSYGTCTVMGINHR	17	Sequence 64 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27926	SYGTCTVMGINHRFCCL	17	Sequence 65 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27927	TCHCRRSCYSTEYSY	15	Sequence 66 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27928	AFTCHCRRSCYSTEY	15	Sequence 67 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27929	GTCTVMGINHRFCCL	15	Sequence 68 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27930	TCHCRRSCYSTEY	13	Sequence 69 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27931	SYGTCTVMGINHRF	14	Sequence 70 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27932	SYGTCTVMGINHR	13	Sequence 71 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27933	AFTCHCRRSCY	11	Sequence 72 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27934	STEYSYGTCTVM	12	Sequence 73 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27935	GTCTVMGINHRF	12	Sequence 74 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27936	RSCYSTEYSY	10	Sequence 75 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27937	GTCTVMGINHR	11	Sequence 76 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27938	TCHCRRSCY	9	Sequence 77 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27939	SCYSTEYSY	9	Sequence 78 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27940	GINHRFCCL	9	Sequence 79 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27941	RSCYSTEY	8	Sequence 80 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27942	AFTCHCRR	8	Sequence 81 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27943	SYGTCTVM	8	Sequence 82 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27944	SCYSTEY	7	Sequence 83 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27945	AFTCHCR	7	Sequence 84 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27946	TCHCRR	6	Sequence 85 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27947	STEYSY	6	Sequence 86 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27948	GINHRF	6	Sequence 87 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27949	TCHCR	5	Sequence 88 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27950	GTCTVM	6	Sequence 89 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27951	RSCY	4	Sequence 90 from Patent WO 2020144166	Homo sapiens	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27952	ATXYCRTGR	9	Sequence 91 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27953	ATCYXRTGR	9	Sequence 92 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27954	ATXYXRTGR	9	Sequence 93 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27955	ATCYCXTGR	9	Sequence 94 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27956	ATCYCRTGX	9	Sequence 95 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27957	ATCYCXTGX	9	Sequence 96 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27958	CTRATYCRG	9	Sequence 98 from Patent WO 2020144166	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/144166 A1	Patent Application	2020##7##16	/	Defensin Fragments For Use In Therapy Or Prophylaxis	The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfaces and/or for use as an antimicrobial agent in a human or other mammals, as well as to medicaments containing these peptides.
DRAMP27961	RARKGGRRRARKGGRRKK	18	Sequence 3 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27962	RARKGRRRARKGRRKK	16	Sequence 4 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27963	RARKARRRARKARRKK	16	Sequence 5 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27964	RARKAARRRARKAARRKK	18	Sequence 6 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27965	RARKRRRARKRRKK	14	Sequence 7 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27966	RGRKGGRRRGRKGGRRKK	18	Sequence 8 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27967	RGRKGRRRGRKGRRKK	16	Sequence 10 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27968	RGRKRRRGRKRRKK	14	Sequence 11 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27969	RGRKAARRRGRKAARRKK	18	Sequence 12 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27970	RGRKARRRGRKARRKK	16	Sequence 13 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27971	RGRKGGRRRGRKGGRRKKRRGGKRGR	26	Sequence 14 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27972	RGRKGRRRGRKGRRKKRRGKRGR	23	Sequence 15 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27973	RGRKRRRGRKRRKKRRKRGR	20	Sequence 16 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27974	RGRKWRRRGRKWRRKK	16	Sequence 17 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27975	RRKRRRRKRRKK	12	Sequence 18 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27976	RRKRRRRKRRKKRRKRR	17	Sequence 19 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27978	RGRKAARR	8	Sequence 22 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27979	RGRKGGRR	8	Sequence 23 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27986	AGRKVVRR	8	Sequence 30 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27987	RARKVVRR	8	Sequence 31 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27988	RGAKVVRR	8	Sequence 32 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27989	RGRAVVRR	8	Sequence 33 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27990	RGRKVARR	8	Sequence 34 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27991	RGRKVVAR	8	Sequence 36 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27992	RGRKVVRA	8	Sequence 37 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27993	RGAAVVRR	8	Sequence 38 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27994	RGRKVVAA	8	Sequence 39 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27995	RGAKAVRR	8	Sequence 40 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27996	RGAAAVRR	8	Sequence 42 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27997	RGAKAARR	8	Sequence 43 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27998	RGRAAARR	8	Sequence 44 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP27999	RGAAAARR	8	Sequence 45 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP28000	RGRKAAAA	8	Sequence 46 from Patent WO 2020168265	Synthetic construct	Antimicrobial, Antibacterial	WO 2020/168265 A1	Patent Application	2020##8##20	/	Antibacterial Compositions	Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic.
DRAMP28001	ILGTILGLLKSL	12	Sequence 1 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28002	ALGTILGLLKSL	12	Sequence 2 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28003	IAGTILGLLKSL	12	Sequence 3 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28004	ILATILGLLKSL	12	Sequence 4 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28005	ILGAILGLLKSL	12	Sequence 5 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28006	ILGTALGLLKSL	12	Sequence 6 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28007	ILGTIAGLLKSL	12	Sequence 7 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28008	ILGTILALLKSL	12	Sequence 8 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28009	ILGTILGALKSL	12	Sequence 9 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28010	ILGTILGLAKSL	12	Sequence 10 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28011	ILGTILGLLASL	12	Sequence 11 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28012	ILGTILGLLKAL	12	Sequence 12 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28013	ILGTILGLLKSA	12	Sequence 13 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28014	ILGTLLGLKKSL	12	Sequence 14 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28015	ILGTKLGLLKSL	12	Sequence 15 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28016	ILGKILGLLKSL	12	Sequence 16 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28017	ILGTILKLLKSL	12	Sequence 17 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28018	ILGTILGLFKSL	12	Sequence 18 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28019	ILGTILGLLKS	11	Sequence 19 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28020	ILETKLGLLKSE	12	Sequence 20 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28021	GLGTILGLLKSL	12	Sequence 21 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28022	SLLSLIRKLLT	11	Sequence 22 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28023	ALGTILKLLKSL	12	Sequence 23 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28024	CLGTILKLLKSL	12	Sequence 24 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28025	DLGTILKLLKSL	12	Sequence 25 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28026	ELGTILKLLKSL	12	Sequence 26 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28027	FLGTILKLLKSL	12	Sequence 27 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28028	GLGTILKLLKSL	12	Sequence 28 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28029	HLGTILKLLKSL	12	Sequence 29 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28030	KLGTILKLLKSL	12	Sequence 30 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28031	LLGTILKLLKSL	12	Sequence 31 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28032	MLGTILKLLKSL	12	Sequence 32 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28033	NLGTILKLLKSL	12	Sequence 33 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28034	PLGTILKLLKSL	12	Sequence 34 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28035	QLGTILKLLKSL	12	Sequence 35 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28036	RLGTILKLLKSL	12	Sequence 36 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28037	SLGTILKLLKSL	12	Sequence 37 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28038	TLGTILKLLKSL	12	Sequence 38 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28039	VLGTILKLLKSL	12	Sequence 39 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28040	WLGTILKLLKSL	12	Sequence 40 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28041	YLGTILKLLKSL	12	Sequence 41 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28042	IAGTILKLLKSL	12	Sequence 42 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28043	ICGTILKLLKSL	12	Sequence 43 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28044	IDGTILKLLKSL	12	Sequence 44 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28045	IEGTILKLLKSL	12	Sequence 45 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28046	IFGTILKLLKSL	12	Sequence 46 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28047	IGGTILKLLKSL	12	Sequence 47 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28048	IHGTILKLLKSL	12	Sequence 48 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28049	IIGTILKLLKSL	12	Sequence 49 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28050	IKGTILKLLKSL	12	Sequence 50 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28051	IMGTILKLLKSL	12	Sequence 51 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28052	INGTILKLLKSL	12	Sequence 52 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28053	IPGTILKLLKSL	12	Sequence 53 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28054	IQGTILKLLKSL	12	Sequence 54 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28055	IRGTILKLLKSL	12	Sequence 55 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28056	ISGTILKLLKSL	12	Sequence 56 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28057	ITGTILKLLKSL	12	Sequence 57 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28058	IVGTILKLLKSL	12	Sequence 58 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28059	IWGTILKLLKSL	12	Sequence 59 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28060	IYGTILKLLKSL	12	Sequence 60 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28061	ILATILKLLKSL	12	Sequence 61 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28062	ILCTILKLLKSL	12	Sequence 62 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28063	ILDTILKLLKSL	12	Sequence 63 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28064	ILETILKLLKSL	12	Sequence 64 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28065	ILFTILKLLKSL	12	Sequence 65 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28066	ILHTILKLLKSL	12	Sequence 66 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28067	ILITILKLLKSL	12	Sequence 67 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28068	ILKTILKLLKSL	12	Sequence 68 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28069	ILLTILKLLKSL	12	Sequence 69 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28070	ILMTILKLLKSL	12	Sequence 70 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28071	ILNTILKLLKSL	12	Sequence 71 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28072	ILPTILKLLKSL	12	Sequence 72 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28073	ILQTILKLLKSL	12	Sequence 73 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28074	ILRTILKLLKSL	12	Sequence 74 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28075	ILSTILKLLKSL	12	Sequence 75 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28076	ILTTILKLLKSL	12	Sequence 76 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28077	ILVTILKLLKSL	12	Sequence 77 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28078	ILWTILKLLKSL	12	Sequence 78 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28079	ILYTILKLLKSL	12	Sequence 79 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28080	ILGAILKLLKSL	12	Sequence 80 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28081	ILGCILKLLKSL	12	Sequence 81 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28082	ILGDILKLLKSL	12	Sequence 82 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28083	ILGEILKLLKSL	12	Sequence 83 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28084	ILGFILKLLKSL	12	Sequence 84 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28085	ILGGILKLLKSL	12	Sequence 85 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28086	ILGHILKLLKSL	12	Sequence 86 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28087	ILGIILKLLKSL	12	Sequence 87 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28088	ILGKILKLLKSL	12	Sequence 88 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28089	ILGLILKLLKSL	12	Sequence 89 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28090	ILGMILKLLKSL	12	Sequence 90 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28091	ILGNILKLLKSL	12	Sequence 91 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28092	ILGPILKLLKSL	12	Sequence 92 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28093	ILGQILKLLKSL	12	Sequence 93 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28094	ILGRILKLLKSL	12	Sequence 94 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28095	ILGSILKLLKSL	12	Sequence 95 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28096	ILGVILKLLKSL	12	Sequence 96 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28097	ILGWILKLLKSL	12	Sequence 97 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28098	ILGYILKLLKSL	12	Sequence 98 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28099	ILGTIAKLLKSL	12	Sequence 99 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28100	ILGTICKLLKSL	12	Sequence 100 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28101	ILGTIDKLLKSL	12	Sequence 101 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28102	ILGTIEKLLKSL	12	Sequence 102 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28103	ILGTIFKLLKSL	12	Sequence 103 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28104	ILGTIGKLLKSL	12	Sequence 104 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28105	ILGTIHKLLKSL	12	Sequence 105 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28106	ILGTIIKLLKSL	12	Sequence 106 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28107	ILGTIKKLLKSL	12	Sequence 107 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28108	ILGTIMKLLKSL	12	Sequence 108 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28109	ILGTINKLLKSL	12	Sequence 109 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28110	ILGTIPKLLKSL	12	Sequence 110 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28111	ILGTIQKLLKSL	12	Sequence 111 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28112	ILGTIRKLLKSL	12	Sequence 112 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28113	ILGTISKLLKSL	12	Sequence 113 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28114	ILGTITKLLKSL	12	Sequence 114 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28115	ILGTIVKLLKSL	12	Sequence 115 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28116	ILGTIWKLLKSL	12	Sequence 116 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28117	ILGTIYKLLKSL	12	Sequence 117 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28118	ILGTILKALKSL	12	Sequence 118 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28119	ILGTILKCLKSL	12	Sequence 119 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28120	ILGTILKDLKSL	12	Sequence 120 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28121	ILGTILKELKSL	12	Sequence 121 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28122	ILGTILKFLKSL	12	Sequence 122 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28123	ILGTILKGLKSL	12	Sequence 123 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28124	ILGTILKHLKSL	12	Sequence 124 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28125	ILGTILKILKSL	12	Sequence 125 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28126	ILGTILKKLKSL	12	Sequence 126 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28127	ILGTILKMLKSL	12	Sequence 127 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28128	ILGTILKNLKSL	12	Sequence 128 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28129	ILGTILKPLKSL	12	Sequence 129 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28130	ILGTILKQLKSL	12	Sequence 130 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28131	ILGTILKRLKSL	12	Sequence 131 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28132	ILGTILKSLKSL	12	Sequence 132 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28133	ILGTILKTLKSL	12	Sequence 133 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28134	ILGTILKVLKSL	12	Sequence 134 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28135	ILGTILKWLKSL	12	Sequence 135 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28136	ILGTILKYLKSL	12	Sequence 136 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28137	ILGTILKLAKSL	12	Sequence 137 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28138	ILGTILKLCKSL	12	Sequence 138 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28139	ILGTILKLDKSL	12	Sequence 139 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28140	ILGTILKLEKSL	12	Sequence 140 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28141	ILGTILKLFKSL	12	Sequence 141 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28142	ILGTILKLGKSL	12	Sequence 142 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28143	ILGTILKLHKSL	12	Sequence 143 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28144	ILGTILKLIKSL	12	Sequence 144 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28145	ILGTILKLKKSL	12	Sequence 145 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28146	ILGTILKLMKSL	12	Sequence 146 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28147	ILGTILKLNKSL	12	Sequence 147 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28148	ILGTILKLPKSL	12	Sequence 148 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28149	ILGTILKLQKSL	12	Sequence 149 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28150	ILGTILKLRKSL	12	Sequence 150 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28151	ILGTILKLSKSL	12	Sequence 151 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28152	ILGTILKLTKSL	12	Sequence 152 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28153	ILGTILKLVKSL	12	Sequence 153 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28154	ILGTILKLWKSL	12	Sequence 154 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28155	ILGTILKLYKSL	12	Sequence 155 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28156	ILGTILKLLASL	12	Sequence 156 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28157	ILGTILKLLCSL	12	Sequence 157 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28158	ILGTILKLLDSL	12	Sequence 158 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28159	ILGTILKLLESL	12	Sequence 159 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28160	ILGTILKLLFSL	12	Sequence 160 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28161	ILGTILKLLGSL	12	Sequence 161 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28162	ILGTILKLLHSL	12	Sequence 162 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28163	ILGTILKLLISL	12	Sequence 163 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28164	ILGTILKLLLSL	12	Sequence 164 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28165	ILGTILKLLMSL	12	Sequence 165 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28166	ILGTILKLLNSL	12	Sequence 166 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28167	ILGTILKLLPSL	12	Sequence 167 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28168	ILGTILKLLQSL	12	Sequence 168 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28169	ILGTILKLLRSL	12	Sequence 169 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28170	ILGTILKLLSSL	12	Sequence 170 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28171	ILGTILKLLTSL	12	Sequence 171 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28172	ILGTILKLLVSL	12	Sequence 172 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28173	ILGTILKLLWSL	12	Sequence 173 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28174	ILGTILKLLYSL	12	Sequence 174 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28175	ILGTILKLLKAL	12	Sequence 175 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28176	ILGTILKLLKCL	12	Sequence 176 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28177	ILGTILKLLKDL	12	Sequence 177 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28178	ILGTILKLLKEL	12	Sequence 178 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28179	ILGTILKLLKFL	12	Sequence 179 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28180	ILGTILKLLKGL	12	Sequence 180 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28181	ILGTILKLLKHL	12	Sequence 181 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28182	ILGTILKLLKIL	12	Sequence 182 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28183	ILGTILKLLKKL	12	Sequence 183 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28184	ILGTILKLLKLL	12	Sequence 184 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28185	ILGTILKLLKML	12	Sequence 185 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28186	ILGTILKLLKNL	12	Sequence 186 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28187	ILGTILKLLKPL	12	Sequence 187 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28188	ILGTILKLLKQL	12	Sequence 188 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28189	ILGTILKLLKRL	12	Sequence 189 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28190	ILGTILKLLKTL	12	Sequence 190 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28191	ILGTILKLLKVL	12	Sequence 191 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28192	ILGTILKLLKWL	12	Sequence 192 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28193	ILGTILKLLKYL	12	Sequence 193 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28194	ILGTILKLLKSA	12	Sequence 194 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28195	ILGTILKLLKSC	12	Sequence 195 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28196	ILGTILKLLKSD	12	Sequence 196 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28197	ILGTILKLLKSE	12	Sequence 197 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28198	ILGTILKLLKSF	12	Sequence 198 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28199	ILGTILKLLKSG	12	Sequence 199 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28200	ILGTILKLLKSH	12	Sequence 200 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28201	ILGTILKLLKSI	12	Sequence 201 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28202	ILGTILKLLKSK	12	Sequence 202 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28203	ILGTILKLLKSM	12	Sequence 203 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28204	ILGTILKLLKSN	12	Sequence 204 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28205	ILGTILKLLKSP	12	Sequence 205 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28206	ILGTILKLLKSQ	12	Sequence 206 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28207	ILGTILKLLKSR	12	Sequence 207 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28208	ILGTILKLLKSS	12	Sequence 208 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28209	ILGTILKLLKST	12	Sequence 209 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28210	ILGTILKLLKSV	12	Sequence 210 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28211	ILGTILKLLKSW	12	Sequence 211 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28212	ILGTILKLLKSY	12	Sequence 212 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28213	ALLSLIRKLLT	11	Sequence 213 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28214	CLLSLIRKLLT	11	Sequence 214 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28215	DLLSLIRKLLT	11	Sequence 215 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28216	ELLSLIRKLLT	11	Sequence 216 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28217	FLLSLIRKLLT	11	Sequence 217 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28218	GLLSLIRKLLT	11	Sequence 218 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28219	HLLSLIRKLLT	11	Sequence 219 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28220	ILLSLIRKLLT	11	Sequence 220 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28221	KLLSLIRKLLT	11	Sequence 221 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28222	LLLSLIRKLLT	11	Sequence 222 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28223	MLLSLIRKLLT	11	Sequence 223 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28224	NLLSLIRKLLT	11	Sequence 224 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28225	PLLSLIRKLLT	11	Sequence 225 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28226	QLLSLIRKLLT	11	Sequence 226 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28227	RLLSLIRKLLT	11	Sequence 227 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28228	TLLSLIRKLLT	11	Sequence 228 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28229	VLLSLIRKLLT	11	Sequence 229 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28230	WLLSLIRKLLT	11	Sequence 230 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28231	YLLSLIRKLLT	11	Sequence 231 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28232	SALSLIRKLLT	11	Sequence 232 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28233	SCLSLIRKLLT	11	Sequence 233 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28234	SDLSLIRKLLT	11	Sequence 234 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28235	SELSLIRKLLT	11	Sequence 235 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28236	SFLSLIRKLLT	11	Sequence 236 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28237	SGLSLIRKLLT	11	Sequence 237 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28238	SHLSLIRKLLT	11	Sequence 238 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28239	SILSLIRKLLT	11	Sequence 239 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28240	SKLSLIRKLLT	11	Sequence 240 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28241	SMLSLIRKLLT	11	Sequence 241 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28242	SNLSLIRKLLT	11	Sequence 242 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28243	SPLSLIRKLLT	11	Sequence 243 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28244	SQLSLIRKLLT	11	Sequence 244 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28245	SRLSLIRKLLT	11	Sequence 245 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28246	SSLSLIRKLLT	11	Sequence 246 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28247	STLSLIRKLLT	11	Sequence 247 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28248	SVLSLIRKLLT	11	Sequence 248 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28249	SWLSLIRKLLT	11	Sequence 249 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28250	SYLSLIRKLLT	11	Sequence 250 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28251	SLASLIRKLLT	11	Sequence 251 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28252	SLCSLIRKLLT	11	Sequence 252 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28253	SLDSLIRKLLT	11	Sequence 253 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28254	SLESLIRKLLT	11	Sequence 254 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28255	SLFSLIRKLLT	11	Sequence 255 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28256	SLGSLIRKLLT	11	Sequence 256 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28257	SLHSLIRKLLT	11	Sequence 257 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28258	SLISLIRKLLT	11	Sequence 258 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28259	SLKSLIRKLLT	11	Sequence 259 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28260	SLMSLIRKLLT	11	Sequence 260 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28261	SLNSLIRKLLT	11	Sequence 261 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28262	SLPSLIRKLLT	11	Sequence 262 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28263	SLQSLIRKLLT	11	Sequence 263 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28264	SLRSLIRKLLT	11	Sequence 264 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28265	SLSSLIRKLLT	11	Sequence 265 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28266	SLTSLIRKLLT	11	Sequence 266 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28267	SLVSLIRKLLT	11	Sequence 267 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28268	SLWSLIRKLLT	11	Sequence 268 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28269	SLYSLIRKLLT	11	Sequence 269 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28270	SLLALIRKLLT	11	Sequence 270 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28271	SLLCLIRKLLT	11	Sequence 271 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28272	SLLDLIRKLLT	11	Sequence 272 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28273	SLLELIRKLLT	11	Sequence 273 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28274	SLLFLIRKLLT	11	Sequence 274 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28275	SLLGLIRKLLT	11	Sequence 275 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28276	SLLHLIRKLLT	11	Sequence 276 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28277	SLLILIRKLLT	11	Sequence 277 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28278	SLLKLIRKLLT	11	Sequence 278 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28279	SLLLLIRKLLT	11	Sequence 279 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28280	SLLMLIRKLLT	11	Sequence 280 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28281	SLLNLIRKLLT	11	Sequence 281 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28282	SLLPLIRKLLT	11	Sequence 282 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28283	SLLQLIRKLLT	11	Sequence 283 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28284	SLLRLIRKLLT	11	Sequence 284 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28285	SLLTLIRKLLT	11	Sequence 285 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28286	SLLVLIRKLLT	11	Sequence 286 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28287	SLLWLIRKLLT	11	Sequence 287 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28288	SLLYLIRKLLT	11	Sequence 288 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28289	SLLSAIRKLLT	11	Sequence 289 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28290	SLLSCIRKLLT	11	Sequence 290 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28291	SLLSDIRKLLT	11	Sequence 291 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28292	SLLSEIRKLLT	11	Sequence 292 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28293	SLLSFIRKLLT	11	Sequence 293 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28294	SLLSGIRKLLT	11	Sequence 294 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28295	SLLSHIRKLLT	11	Sequence 295 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28296	SLLSIIRKLLT	11	Sequence 296 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28297	SLLSKIRKLLT	11	Sequence 297 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28298	SLLSMIRKLLT	11	Sequence 298 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28299	SLLSNIRKLLT	11	Sequence 299 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28300	SLLSPIRKLLT	11	Sequence 300 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28301	SLLSQIRKLLT	11	Sequence 301 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28302	SLLSRIRKLLT	11	Sequence 302 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28303	SLLSSIRKLLT	11	Sequence 303 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28304	SLLSTIRKLLT	11	Sequence 304 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28305	SLLSVIRKLLT	11	Sequence 305 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28306	SLLSWIRKLLT	11	Sequence 306 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28307	SLLSYIRKLLT	11	Sequence 307 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28308	SLLSLARKLLT	11	Sequence 308 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28309	SLLSLCRKLLT	11	Sequence 309 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28310	SLLSLDRKLLT	11	Sequence 310 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28311	SLLSLERKLLT	11	Sequence 311 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28312	SLLSLFRKLLT	11	Sequence 312 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28313	SLLSLGRKLLT	11	Sequence 313 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28314	SLLSLHRKLLT	11	Sequence 314 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28315	SLLSLKRKLLT	11	Sequence 315 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28316	SLLSLLRKLLT	11	Sequence 316 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28317	SLLSLMRKLLT	11	Sequence 317 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28318	SLLSLNRKLLT	11	Sequence 318 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28319	SLLSLPRKLLT	11	Sequence 319 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28320	SLLSLQRKLLT	11	Sequence 320 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28321	SLLSLRRKLLT	11	Sequence 321 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28322	SLLSLSRKLLT	11	Sequence 322 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28323	SLLSLTRKLLT	11	Sequence 323 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28324	SLLSLVRKLLT	11	Sequence 324 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28325	SLLSLWRKLLT	11	Sequence 325 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28326	SLLSLYRKLLT	11	Sequence 326 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28327	SLLSLIAKLLT	11	Sequence 327 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28328	SLLSLICKLLT	11	Sequence 328 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28329	SLLSLIDKLLT	11	Sequence 329 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28330	SLLSLIEKLLT	11	Sequence 330 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28331	SLLSLIFKLLT	11	Sequence 331 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28332	SLLSLIGKLLT	11	Sequence 332 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28333	SLLSLIHKLLT	11	Sequence 333 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28334	SLLSLIIKLLT	11	Sequence 334 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28335	SLLSLIKKLLT	11	Sequence 335 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28336	SLLSLILKLLT	11	Sequence 336 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28337	SLLSLIMKLLT	11	Sequence 337 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28338	SLLSLINKLLT	11	Sequence 338 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28339	SLLSLIPKLLT	11	Sequence 339 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28340	SLLSLIQKLLT	11	Sequence 340 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28341	SLLSLISKLLT	11	Sequence 341 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28342	SLLSLITKLLT	11	Sequence 342 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28343	SLLSLIVKLLT	11	Sequence 343 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28344	SLLSLIWKLLT	11	Sequence 344 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28345	SLLSLIYKLLT	11	Sequence 345 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28346	SLLSLIRKALT	11	Sequence 346 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28347	SLLSLIRKCLT	11	Sequence 347 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28348	SLLSLIRKDLT	11	Sequence 348 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28349	SLLSLIRKELT	11	Sequence 349 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28350	SLLSLIRKFLT	11	Sequence 350 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28351	SLLSLIRKGLT	11	Sequence 351 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28352	SLLSLIRKHLT	11	Sequence 352 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28353	SLLSLIRKILT	11	Sequence 353 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28354	SLLSLIRKKLT	11	Sequence 354 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28355	SLLSLIRKMLT	11	Sequence 355 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28356	SLLSLIRKNLT	11	Sequence 356 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28357	SLLSLIRKPLT	11	Sequence 357 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28358	SLLSLIRKQLT	11	Sequence 358 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28359	SLLSLIRKRLT	11	Sequence 359 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28360	SLLSLIRKSLT	11	Sequence 360 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28361	SLLSLIRKTLT	11	Sequence 361 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28362	SLLSLIRKVLT	11	Sequence 362 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28363	SLLSLIRKWLT	11	Sequence 363 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28364	SLLSLIRKYLT	11	Sequence 364 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28365	SLLSLIRKLLA	11	Sequence 365 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28366	SLLSLIRKLLC	11	Sequence 366 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28367	SLLSLIRKLLD	11	Sequence 367 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28368	SLLSLIRKLLE	11	Sequence 368 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28369	SLLSLIRKLLF	11	Sequence 369 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28370	SLLSLIRKLLG	11	Sequence 370 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28371	SLLSLIRKLLH	11	Sequence 371 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28372	SLLSLIRKLLI	11	Sequence 372 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28373	SLLSLIRKLLK	11	Sequence 373 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28374	SLLSLIRKLLL	11	Sequence 374 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28375	SLLSLIRKLLM	11	Sequence 375 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28376	SLLSLIRKLLN	11	Sequence 376 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28377	SLLSLIRKLLP	11	Sequence 377 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28378	SLLSLIRKLLQ	11	Sequence 378 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28379	SLLSLIRKLLR	11	Sequence 379 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28380	SLLSLIRKLLS	11	Sequence 380 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28381	SLLSLIRKLLV	11	Sequence 381 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28382	SLLSLIRKLLW	11	Sequence 382 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28383	SLLSLIRKLLY	11	Sequence 383 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28384	CILGTILKLLKSLC	14	Sequence 384 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28385	CSLLSLIRKLLTC	13	Sequence 385 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28386	ILGTILGLLKGL	12	Sequence 386 from Patent WO 2020061306	Synthetic construct	Antimicrobial	WO 2020/061306 A1	Patent Application	2020##3##26	WO2020061306A8	Methods Of Physicochemical-guided Peptide Design And Novel Peptides Derived Therefrom	Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
DRAMP28387	DSHAKRHHGYKRKFHEKHHSHRGY	24	Sequence 1 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28388	DSHARRHHGYKRKFHEKHHSHRGY	24	Sequence 2 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28389	DSHALRHHGYKRKFHEKHHSHRGY	24	Sequence 3 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28390	DSHAKRHHGYRRKFHEKHHSHRGY	24	Sequence 4 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28391	DSHAKRHHGYLRKFHEKHHSHRGY	24	Sequence 5 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28392	DSHAKRHHGYKRRFHEKHHSHRGY	24	Sequence 6 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28393	DSHAKRHHGYKRLFHEKHHSHRGY	24	Sequence 7 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28394	DSHAKRHHGYKRKFHERHHSHRGY	24	Sequence 8 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28395	DSHAKRHHGYKRKFHELHHSHRGY	24	Sequence 9 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28396	DSHAKRHHGYRRKFHERHHSHRGY	24	Sequence 10 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28397	DSHAKRHHGYKRKFHRKHHSHRGY	24	Sequence 11 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28398	DSHAKRHHGYKRKFHLKHHSHRGY	24	Sequence 12 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28399	DSHAKRHHGYKREFHEKHHSHRGY	24	Sequence 13 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28400	DSHAKRHHGYKRHFHEKHHSHRGY	24	Sequence 14 from Patent US 10464977	Synthetic construct	Antimicrobial, Antifungal	US 10464977 B2	Granted Patent	2019##11##5	US20170291930A1	Histatin-5 Based Synthetic Peptides And Uses Thereof	Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
DRAMP28401	FFWLSRRTK	9	Sequence 1 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28402	FFWSRRTK	8	Sequence 2 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28403	FFWRRTK	7	Sequence 3 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28404	FFWLRRXK	8	Sequence 4 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28405	FFWRRXK	7	Sequence 5 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28406	XFWRRXK	7	Sequence 6 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28407	FFXWRRXK	8	Sequence 7 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28408	XFXRRXK	7	Sequence 8 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28409	FFXRRXK	7	Sequence 9 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28410	FFWRRVK	7	Sequence 12 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28411	XFXRRVK	7	Sequence 13 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28412	MLIFVHIIAPVISGCAIAFFSYWLSRRNTK	30	Sequence 15 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28413	MLIFVHIIAPVISGCAIA	18	Sequence 16 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28414	FFSYWLSRRNTK	12	Sequence 17 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28415	FFSYWLSRRTK	11	Sequence 18 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28416	FFSWLSRRTK	10	Sequence 19 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28417	FFWLSRTK	8	Sequence 21 from Patent US 10220112	Synthetic construct	Antimicrobial, Antibacterial	US 10220112 B2	Granted Patent	2019##3##5	CA2963050A1, WO2016066784A1, EP3212661A1, US20170319738A1, JP2018500283A, JP6742999B2, JP2020158513A	Cyclic Antimicrobial Pseudopeptides And Uses Thereof	The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or treating an infection or contamination caused by such microorganisms.
DRAMP28418	FIGAIARLLSKIF	13	Sequence 1 from Patent US 10548948	Mesobuthus martensii	Antimicrobial, Antifungal	US 10548948 B2	Granted Patent	2020##2##4	US20180250362A1, WO2018160577A1, US20200108121A1	Methods Of Treating Fungal Infections	
DRAMP28419	FIKRIARLLRKIF	13	Sequence 2 from Patent US 10548948	Synthetic construct	Antimicrobial, Antifungal	US 10548948 B2	Granted Patent	2020##2##4	US20180250362A1, WO2018160577A1, US20200108121A1	Methods Of Treating Fungal Infections	
DRAMP28421	MFTLKKCMLLIFFLGTINLSLCQEESNAEEERRDDDDDQMNVEVEKRFFPGIIKVASAILPTAICAITKRC	71	Sequence 5 from Patent US 20190298796	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0298796 A1	Patent Application	2019##10##3	WO2017216810A1, EP3471751A1	Therapeutic Compositions From The Brevinin-1 Family Of Peptides And Uses Thereof	The invention is directed to peptides and methods of making and using antimicrobial compositions for the treatment of a bacterium, wherein the composition comprises: a pharmaceutically effective amount of a modified brevinin-1 peptide, as well as modified and truncated versions thereof, disposed in a pharmaceutical carrier.
DRAMP28422	MFTLKKPLLLIFFLGTINLSLCQEESNAEEERRDDDDDQMNVEVEKRFFPGIIKVAGAILPTAICAITKRC	71	Sequence 6 from Patent US 20190298796	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0298796 A1	Patent Application	2019##10##3	WO2017216810A1, EP3471751A1	Therapeutic Compositions From The Brevinin-1 Family Of Peptides And Uses Thereof	The invention is directed to peptides and methods of making and using antimicrobial compositions for the treatment of a bacterium, wherein the composition comprises: a pharmaceutically effective amount of a modified brevinin-1 peptide, as well as modified and truncated versions thereof, disposed in a pharmaceutical carrier.
DRAMP28423	FFPGIIKVASAILPTAICAITKRC	24	Sequence 7 from Patent US 20190298796	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0298796 A1	Patent Application	2019##10##3	WO2017216810A1, EP3471751A1	Therapeutic Compositions From The Brevinin-1 Family Of Peptides And Uses Thereof	The invention is directed to peptides and methods of making and using antimicrobial compositions for the treatment of a bacterium, wherein the composition comprises: a pharmaceutically effective amount of a modified brevinin-1 peptide, as well as modified and truncated versions thereof, disposed in a pharmaceutical carrier.
DRAMP28424	FFPGIIKVAGAILPTAICAITKRC	24	Sequence 10 from Patent US 20190298796	Synthetic construct	Antimicrobial, Antibacterial	US 2019/0298796 A1	Patent Application	2019##10##3	WO2017216810A1, EP3471751A1	Therapeutic Compositions From The Brevinin-1 Family Of Peptides And Uses Thereof	The invention is directed to peptides and methods of making and using antimicrobial compositions for the treatment of a bacterium, wherein the composition comprises: a pharmaceutically effective amount of a modified brevinin-1 peptide, as well as modified and truncated versions thereof, disposed in a pharmaceutical carrier.
DRAMP28425	HAHSGHGQSTQRGSRTAGR	19	Sequence 1 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28426	GRHGSGLGHSSSHGQHGSGSGR	22	Sequence 2 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28427	GRRGSGLGRSSSRGGRGSGSGR	22	Sequence 4 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28428	GRRGSGLGRSSSRGQRGSGSGR	22	Sequence 5 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28429	GRRGSGLGRSSSR	13	Sequence 6 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28430	GRRGGGGGRGGGRGGRGGGGGR	22	Sequence 7 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28431	HGSRSGQSSRGERHGSSSGSSSH	23	Sequence 8 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28432	RGSRSGQSSRGERR	14	Sequence 9 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28433	RGSRSGQSSRGERRGSSSGSSSR	23	Sequence 10 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28434	GXGX	4	Sequence 11 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28435	GRGR	4	Sequence 13 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28436	GRRGGR	6	Sequence 14 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28437	GRRGGRGGR	9	Sequence 15 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28438	GRRGGRGGRGR	11	Sequence 16 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28439	GRRGGRGGRGRGR	13	Sequence 17 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28440	SHHRCCRSHRCRR	13	Sequence 20 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28441	SHHRHFRSHQCRR	13	Sequence 22 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28442	GRRGGRGGRGRGRC	14	Sequence 25 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28443	GKGK	4	Sequence 26 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28444	HTHSGHTHGQSGSQHGESESIIHDR	25	Sequence 31 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28445	HTHSGHTHGQARSQHGESESIVHER	25	Sequence 32 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28446	HTHSGHTHSQARSQHGESESTVHKR	25	Sequence 33 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28447	HTHSGHTHGQAGSHYPESGSSVHER	25	Sequence 34 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28448	HTHSGHAHGQAGSQHGESGSSVHER	25	Sequence 35 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28449	HAHSGHGQSTQR	12	Sequence 36 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28450	HAHSGHGQSTQRGSR	15	Sequence 37 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28451	HAHSGHGQSTQRGSRTAGRRGSGH	24	Sequence 38 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28452	HGQSTQRGSRTAGRRGSGH	19	Sequence 39 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28453	GSRTAGRRGSGH	12	Sequence 40 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28454	TAGRRGSGH	9	Sequence 41 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28455	HAHYGYGQSTQRGSRTTGRRGSGH	24	Sequence 42 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28456	QGSHHEQSVNRSGHSGSHHSHTTSQGR	27	Sequence 43 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28457	GHHGGHGGHGHGH	13	Sequence 44 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28458	HGH	3	Sequence 45 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28459	HGHGH	5	Sequence 46 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28460	HGHGHGH	7	Sequence 47 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28461	HGHGHGHGH	9	Sequence 48 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28462	RGR	3	Sequence 49 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28463	RGRGR	5	Sequence 50 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28464	RGRGRGR	7	Sequence 51 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28465	RGRGRGRGR	9	Sequence 52 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28466	HGSRSGQSSGGGRHGSSSGSSSH	23	Sequence 55 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28467	GGSRSGQSSRGERHGSSSGSSSH	23	Sequence 56 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28468	HGSRSGQSSRGERGGSSSGSSSH	23	Sequence 57 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28469	HGSRSGQSSRGERHGSSSGSSSG	23	Sequence 58 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28470	HGSGSGQSSRGERHGSSSGSSSH	23	Sequence 59 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28471	HGSRSGQSSGGERHGSSSGSSSH	23	Sequence 60 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28472	HGSRSGQSSRGEGHGSSSGSSSH	23	Sequence 61 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28473	GSGSRQSSGHGRQGSGSGQ	19	Sequence 63 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28474	GRHGSGLGHSSSHGQHGSGSGRSSSRGPY	29	Sequence 64 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28475	GGHGSGLGHSSSHGQHGSGSGRSSSRGPY	29	Sequence 65 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28476	GRHGSGLGHSSSHGQHGSGSGGSSSRGPY	29	Sequence 66 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28477	GRHGSGLGHSSSHGQHGSGSGRSSSGGPY	29	Sequence 67 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28478	GRGGSGLGGSSSGGQGGSGSGRSSSRGPY	29	Sequence 68 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28479	SRRSSSLSRSSSRSSRSSSSSR	22	Sequence 69 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28480	GRRGSGGGRSSSRGGRGSGSGR	22	Sequence 70 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28481	GRHGSGGGHSSSHGGHGSGSGR	22	Sequence 71 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28482	GRHGGGGGHGGGHGGHGGGGGR	22	Sequence 72 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28483	GHHGGGGGHGGGHGGHGGGGGH	22	Sequence 73 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28484	LRHGSGLGHSSSHGQHGSGSGR	22	Sequence 76 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28485	GRHGSGLGHSSSHGQH	16	Sequence 77 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28486	RHGSGLGHSSSHGQH	15	Sequence 78 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28487	RHGSGLGHSSSH	12	Sequence 79 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28488	LGHSSSHGQHGSGSGRSSSRGPYESRLGH	29	Sequence 80 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28489	GRHGSGLGHSSSH	13	Sequence 81 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28490	HSSSHGQHGSGSGR	14	Sequence 82 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28491	HGSSSGSSSHYGQHGSGSR	19	Sequence 83 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28492	HGSGLGHSSSHGQHGSGSGR	20	Sequence 84 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28493	GSGSRQSPSYGRHGSGSGRSSSSGQH	26	Sequence 85 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28494	RQSPSYGRHGSGSGR	15	Sequence 86 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28495	SRQSPSYGRHGSGR	14	Sequence 87 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28496	HSQRGSGSRQSPSYGRH	17	Sequence 88 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28497	GSGSRQSPSHGRHGSGSGR	19	Sequence 89 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28498	GSGSRQSLSYGRHGSGSGR	19	Sequence 90 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28499	GSGSRQSPSYGRQGSGSGR	19	Sequence 91 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28500	GSGSRQSPSRGRHGSGSGR	19	Sequence 92 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28501	GSGSRQSSSYGRHGSGSGR	19	Sequence 93 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28502	GSGSRQSPSYGR	12	Sequence 94 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28503	GRHGSGSGQSSSYGPYRSGSGWSSSRGPY	29	Sequence 95 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28504	GRHGSGSGQSSSYGPYGSGSGWSSSRGPY	29	Sequence 96 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28505	GRHGSGSGHSSSHGQHGSGSGR	22	Sequence 97 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28506	SQHKSSSGQSSGYSQHGSGSGHSSGYGQHGSRSGQSSRGDRHRSSSGSSSSYGQHGSGSRQSL	63	Sequence 98 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28507	GRHGSGSGQSSSYSPYGSGSGWSSSR	26	Sequence 99 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28508	GRHGSGSGQSSSYSPYGSGSGWSSSRGPY	29	Sequence 100 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28509	GHGRQGSGSRQSPSHVRHGSGSGHSSSHGQHGSGSSYSYSRGHYESGSGQTSGFGQHESGSGQSSGY	67	Sequence 101 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28510	GHKSSSGQSSGYTQHGSGSGHSSSYEQHGSRSGQSSRSEQHGSSSGSSSSYGQHGSGSRQSL	62	Sequence 102 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28511	LGHGQHGSGSGQSPSPSRGRHGSGSGQSSSYGPYRSGSGWSSSRGPYESGSGHSSGLGHRER	62	Sequence 103 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28512	GKKGGKGGKGKGK	13	Sequence 104 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28513	SHHRRRRSHCH	11	Sequence 105 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28514	SHHRPRLFHRHRH	13	Sequence 106 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28515	SHHRPRLFHRRRH	13	Sequence 107 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28516	SHHRCRRSHRC	11	Sequence 108 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28517	SHHRHFRSHQCR	12	Sequence 109 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28518	SHHRHFRSHQCRRQRSNSCDR	21	Sequence 110 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28519	NHHRRHHRCR	10	Sequence 111 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28520	GXXGGXGGXGXGX	13	Sequence 114 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28521	RGSGSGHQGHSSSHGLGSGHRG	22	Sequence 122 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28522	THEHEQSHQRRDRQTHEDKQNRQR	24	Sequence 123 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28523	SLSSGHGSGHGHQRGGHRSGSG	22	Sequence 124 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28524	CGQHGATSSGQSSSHGQHGSGSSQSSGYGR	30	Sequence 125 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28525	GRHGSGSGQSSGFGHHESSSWQSSGC	26	Sequence 126 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28526	SGHSSVFGQHESGSGHSSAYSQHGSGSGHFC	31	Sequence 127 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28527	GQHGSSSGHSSTHGQHGSTSGQSSSC	26	Sequence 128 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28528	CGQHGATSGQSSSHGQHGSGSSQSSR	26	Sequence 129 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28529	GQHGSSSGHSSTHGQHGSASGQSSSC	26	Sequence 130 from Patent US 20200115426	Synthetic construct	Antimicrobial, Antibacterial	US 2020/0115426 A1	Patent Application	2020##4##16	EP3323827A1, WO2018091523A1, EP3541831A1	Cationic Intrinsically Disordered Antimicrobial Peptides	The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.
DRAMP28530	SGSWLRDVWTWLQSKL	16	Sequence 1 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28531	GSSWLRDVWTWLQSKL	16	Sequence 2 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28532	GSSWLRDVWTWLQSAL	16	Sequence 3 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28533	GSSWLRDVWTKLQSWL	16	Sequence 4 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28534	GSSWLRDIWTKLQSWL	16	Sequence 5 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28535	GSSWLRDIWTALQSWL	16	Sequence 6 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28536	GSSWLRDILTALQSLL	16	Sequence 7 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28537	AGSWLRDIWTWLQSAL	16	Sequence 1 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28538	AGSWLRDILTLLQSAL	16	Sequence 9 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28540	SWLRDIWDWICEVLSDFK	18	Sequence 11 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28541	XXSWLRDXXTXLQSXL	16	Sequence 12 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28542	TWLQSKL	7	Sequence 20 from Patent US 10351604	Synthetic construct	Anti-infective	US 10351604 B2	Granted Patent	2019##7##16	CA2989399A1, WO2016209173A1, AU2016281477A1, KR20180037185A, CN107922461A, EP3313862A1, US20180186837A1, BR112017028190A2, HK1248248A1, JP2018531880A,	Broad-spectrum Anti-infective Peptides	Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.
DRAMP28543	LKLKSIVSWAKKVL	14	Sequence 1 from Patent US 20190276505	Synthetic construct	Antimicrobial	US 2019/0276505 A1	Patent Application	2019##9##12	WO2018084807A1, SG10201609136RA, SG11201903961RA, EP3519426A1, JP2019534297A, EP3519426A4	Antimicrobial Peptides Comprising Epsilon Lysine Residues	The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods
DRAMP28545	KRKRKRKRKRKR	12	Sequence 3 from Patent US 20190276505	Synthetic construct	Antimicrobial	US 2019/0276505 A1	Patent Application	2019##9##12	WO2018084807A1, SG10201609136RA, SG11201903961RA, EP3519426A1, JP2019534297A, EP3519426A4	Antimicrobial Peptides Comprising Epsilon Lysine Residues	The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one α-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods
DRAMP28548	HFRW	4	Sequence 1 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28549	RRWQQR	6	Sequence 2 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28550	RRWCR	5	Sequence 3 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28551	RWCFR	5	Sequence 4 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28552	YCRRF	5	Sequence 5 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28553	ACRRRF	6	Sequence 6 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28555	KKFKKFFKKLK	11	Sequence 9 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28556	RRFRRFFRRLR	11	Sequence 10 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28557	VRLIVAVR	8	Sequence 11 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28558	VRIWRR	6	Sequence 12 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28559	VRLIVA	6	Sequence 13 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28560	KKFKKFF	7	Sequence 14 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28561	RRFRRFF	7	Sequence 15 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28562	FFKKLK	6	Sequence 16 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28563	FFRRLR	6	Sequence 17 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28564	KKFKKFFKK	9	Sequence 18 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28565	RRFRRFFRR	9	Sequence 19 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28566	KKFFKKLK	8	Sequence 20 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28567	RRFFRRLR	8	Sequence 21 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28578	CYFQNCPRG	9	Sequence 35 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28579	RKPWIL	6	Sequence 36 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28580	FGGGGF	6	Sequence 37 from Patent US 10351599	Synthetic construct	Antimicrobial	US 10351599 B2	Granted Patent	2019##7##16	WO2016044683A1, EP3194422A1, US20170247414A1, EP3194422A4, US20200109171A1, EP3194422B1	Anti-microbial Peptides	Described herein are anti-microbial peptides having enhanced activity and transport.
DRAMP28581	CYFQNCPRG	9	Sequence 1 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28582	RKPWIL	6	Sequence 2 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28583	FGGGGF	6	Sequence 3 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28584	RRIRPRPRLPRPRPRPLPFPRPGPRPIPRPLPFP	34	Sequence 4 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28586	PRPRPRP	7	Sequence 6 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28587	PRPZPRP	7	Sequence 8 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28588	PRPGPRP	7	Sequence 9 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28589	PRPLPRP	7	Sequence 10 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28590	PRPWPRP	7	Sequence 11 from Patent WO 2019169504	Synthetic construct	Antimicrobial, Antibacterial	WO 2019/169504 A1	Patent Application	2019##9##12	CA3092264A1	Short Proline-rich Lipopeptide Potentiates Minocycline And Rifampicin Against Multidrug-and Extensively Drug-resistant Pseudomonas Aeruginosa	We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP motif apparent in longer PRAMPs. We assessed the potential of these SPRLPs to serve as adjuvants in combination with clinically-used antibiotics against P. aeruginosa. Our results revealed an amphiphilic non-hemolytic non-cytotoxic L-lipopeptide lead sequence that strongly potentiates minocycline and rifampicin against MDR/XDR P. aeruginosa. Furthermore, the adjuvant potency is retained in its enantiomeric D-SPRLP counterpart.
DRAMP28591	GLLLLLKLLLLLLG	14	Sequence 1 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28592	GLLDLLKLLLKLLG	14	Sequence 2 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28593	GLLDLLKLLLKAAG	14	Sequence 3 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28594	GLLDLLHLLLKAAG	14	Sequence 4 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28595	GLADLAKLLLKLLGW	15	Sequence 5 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28596	GLLDLLKLLLKLAGW	15	Sequence 6 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28597	GLDDLAKLLLKLAGW	15	Sequence 7 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28598	GLDDLLKALLKAAGW	15	Sequence 8 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28599	GLLDDAKLLAKLAGW	15	Sequence 9 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28600	GLLDLPKALAKALGW	15	Sequence 10 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28601	GLADAAKLLLKAAGW	15	Sequence 11 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28602	GLLDAAKLLAKAAGW	15	Sequence 12 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28604	GILDAIKAIAKAAG	14	Sequence 14 from Patent WO	Hypsiboas punctatus	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28605	GILDPIKAFAKAAG	14	Sequence 15 from Patent WO	Hyla simplex	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28606	GLLSLLSLLGKLL	13	Sequence 16 from Patent WO	Synthetic construct	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28607	GLLGTLGNLLNGLGL	15	Sequence 17 from Patent WO	Litoria infrafrenata	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28608	GLFDIIKKIAESI	13	Sequence 18 from Patent WO	Litoria aurea	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28609	GLFDIIKNIVSTL	13	Sequence 19 from Patent WO	Litoria dahlii	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28610	GLLDLAKHVIGIASKL	16	Sequence 20 from Patent WO	Litoria fallax	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28611	GWFDVVKHIASAV	13	Sequence 21 from Patent WO	Litoria ewingii	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28612	GIGAVLKVL	9	Sequence 23 from Patent WO	Apis mellifera	Antimicrobial	US 2020/0048303 A1	Patent Application	2020##2##13	WO2018165655A1	Antimicrobial Peptides And Methods Of Making And Using Same	The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
DRAMP28613	IPLRGAFINGRWDSQCHRFSNGAIACA	27	Sequence 1 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28614	SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC	37	Sequence 2 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28615	SFVTKLKDVAIGVAKGAGLGILKTLTCKLDNSCA	34	Sequence 3 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28616	SFITKLKDVAIGVAKGAGLGILKTLTCKLDNSCA	34	Sequence 4 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28617	APLRGAFINGRWDSQCHRFSNGAIACA	27	Sequence 5 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28618	IALRGAFINGRWDSQCHRFSNGAIACA	27	Sequence 6 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28619	IPARGAFINGRWDSQCHRFSNGAIACA	27	Sequence 7 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28620	IPLAGAFINGRWDSQCHRFSNGAIACA	27	Sequence 8 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28621	IPLRAAFINGRWDSQCHRFSNGAIACA	27	Sequence 9 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28622	IPLRGAAINGRWDSQCHRFSNGAIACA	27	Sequence 10 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28623	IPLRGAFANGRWDSQCHRFSNGAIACA	27	Sequence 11 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28624	IPLRGAFIAGRWDSQCHRFSNGAIACA	27	Sequence 12 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28625	IPLRGAFINARWDSQCHRFSNGAIACA	27	Sequence 13 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28626	IPLRGAFINGAWDSQCHRFSNGAIACA	27	Sequence 14 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28627	IPLRGAFINGRADSQCHRFSNGAIACA	27	Sequence 15 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28628	IPLRGAFINGRWASQCHRFSNGAIACA	27	Sequence 16 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28629	IPLRGAFINGRWDAQCHRFSNGAIACA	27	Sequence 17 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28630	IPLRGAFINGRWDSACHRFSNGAIACA	27	Sequence 18 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28631	IPLRGAFINGRWDSQAHRFSNGAIACA	27	Sequence 19 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28632	IPLRGAFINGRWDSQCARFSNGAIACA	27	Sequence 20 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28633	IPLRGAFINGRWDSQCHAFSNGAIACA	27	Sequence 21 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28634	IPLRGAFINGRWDSQCHRASNGAIACA	27	Sequence 22 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28635	IPLRGAFINGRWDSQCHRFANGAIACA	27	Sequence 23 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28636	IPLRGAFINGRWDSQCHRFSAGAIACA	27	Sequence 24 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28637	IPLRGAFINGRWDSQCHRFSNAAIACA	27	Sequence 25 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28638	IPLRGAFINGRWDSQCHRFSNGAAACA	27	Sequence 26 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28639	IPLRGAFINGRWDSQCHRFSNGAIAAA	27	Sequence 27 from Patent US 20190367567	Synthetic construct	Antimicrobial, Antiviral	US 2019/0367567 A1	Patent Application	2019##12##5	WO2018102753A1, EP3548056A1, EP3548056A4	Peptides And Uses For Managing Viral Infections	It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same.
DRAMP28640	NYWXXGXWTIGS	12	Sequence 1 from Patent US 10738093	Brevibacillus laterosporu	Antimicrobial, Antibacterial	US 10738093 B2	Granted Patent	2020##8##11	US20190225663A1, CN110078790	Discovery Of Cationic Nonribosomal Peptides As Gram-negative Antibiotics Through Global Genome Mining	Pharmacological compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof are described. Further, methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof are provided.
DRAMP28641	SYWXXGXWTINGG	13	Sequence 2 from Patent US 10738093	Brevibacillus laterosporu	Antimicrobial, Antibacterial	US 10738093 B2	Granted Patent	2020##8##11	US20190225663A1, CN110078790	Discovery Of Cationic Nonribosomal Peptides As Gram-negative Antibiotics Through Global Genome Mining	Pharmacological compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof are described. Further, methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof are provided.
DRAMP28642	GIGKFLHXAKKFXKAFVXEIMNS	23	Sequence 1 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28646	GFFKKAWRKVKHAGRRVLKKGVGRHYVNNWLK	32	Sequence 6 from Patent US 10464975	Myxine glutinosa	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28648	ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ	34	Sequence 9 from Patent US 10464975	Phyllomedusa sp.	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28649	GLFKVLGSVAKHLLPHVVPVIAEKL	25	Sequence 10 from Patent US 10464975	Litoria chloris	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28650	KIKWFKTMKSIAKFIAKEQMKKHLGGE	27	Sequence 13 from Patent US 10464975	Unspecified	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28651	GFGPAFHSVSNFAKKHKTA	19	Sequence 14 from Patent US 10464975	Unspecified	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28654	GWGSFFKKAAHXGKHVGKXALTHYL	25	Sequence 18 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28655	GFFALIPKIISXPLFKTLXSAVGSALSSSGEQE	33	Sequence 19 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28656	GFFKKAWRKVKHAXRRVLKKXVGRHYVNNWLK	32	Sequence 20 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28657	GVLSNVIGYLKKLXTGALNAXLKQ	24	Sequence 21 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28658	TRSSRAGLQFPXGRVHRLXRK	21	Sequence 22 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28659	ALWKTMLKKLGTMXLHAGKAXLGAAADTISQGTQ	34	Sequence 23 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28660	GLFKVLGSVAKHLXPHVVPVXAEKL	25	Sequence 24 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28661	GIGAVLKVLTTGXPALISWXKRKRQQ	26	Sequence 25 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28662	KWKXFKKIEKXGQNIRDGIIKAGPAVAVVGQATQIAK	37	Sequence 26 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28663	KIKWFKTXKSIAKFXAKEQMKKHLGGE	27	Sequence 27 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28664	GFGPXFHSVSNXAKKHKTA	19	Sequence 28 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28665	VFQFXGRIIHHXGNFVHGFSHVF	23	Sequence 29 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28666	IXKKWPWWXWRRK	13	Sequence 30 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28667	SSLLEKGLDGXKKAVGGXGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	48	Sequence 31 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28668	GIGKFLHSAKKFGKAXVGEXXNK	23	Sequence 32 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28669	GIGKFLHSAKKFGKAXVGEXXKS	23	Sequence 33 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28670	GIGKFLHSAKKFGKAXVGEXKNS	23	Sequence 34 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28671	GIGKFLHSAKKFGKAXVGKXXNS	23	Sequence 35 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28672	GIGKFLHSAKKFGKAXVKEXXNS	23	Sequence 36 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28673	GIGKFLHSAKKFGKAXKGEXXNS	23	Sequence 37 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28674	GIGKFLHSAKKFGKKXVGEXXNS	23	Sequence 38 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28675	GIGKFLHSAKKFKKAXVGEXXNS	23	Sequence 39 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28676	GIGKFLHSAKKKGKAXVGEXXNS	23	Sequence 40 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28677	GIGKFLHSKKKFGKAXVGEXXNS	23	Sequence 41 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28678	GIGKFLHKAKKFGKAXVGEXXNS	23	Sequence 42 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28679	GIGKFLKSAKKFGKAXVGEXXNS	23	Sequence 43 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28680	GIGKFKHSAKKFGKAXVGEXXNS	23	Sequence 44 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28681	GIGKKLHSAKKFGKAXVGEXXNS	23	Sequence 45 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28682	GIKKFLHSAKKFGKAXVGEXXNS	23	Sequence 46 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28683	GKGKFLHSAKKFGKAXVGEXXNS	23	Sequence 47 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28684	KIGKFLHSAKKFGKAXVGEXXNS	23	Sequence 48 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28685	EIGKFLHSAKKFGKAXVGEXXNS	23	Sequence 49 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28686	GEGKFLHSAKKFGKAXVGEXXNS	23	Sequence 50 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28687	GIEKFLHSAKKFGKAXVGEXXNS	23	Sequence 51 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28688	GIGEFLHSAKKFGKAXVGEXXNS	23	Sequence 52 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28689	GIGKELHSAKKFGKAXVGEXXNS	23	Sequence 53 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28690	GIGKFEHSAKKFGKAXVGEXXNS	23	Sequence 54 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28691	GIGKFLESAKKFGKAXVGEXXNS	23	Sequence 55 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28692	GIGKFLHEAKKFGKAXVGEXXNS	23	Sequence 56 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28693	GIGKFLHSEKKFGKAXVGEXXNS	23	Sequence 57 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28694	GIGKFLHSAEKFGKAXVGEXXNS	23	Sequence 58 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28695	GIGKFLHSAKEFGKAXVGEXXNS	23	Sequence 59 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28696	GIGKFLHSAKKEGKAXVGEXXNS	23	Sequence 60 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28697	GIGKFLHSAKKFEKAXVGEXXNS	23	Sequence 61 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28698	GIGKFLHSAKKFGEAXVGEXXNS	23	Sequence 62 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28699	GIGKFLHSAKKFGKEXVGEXXNS	23	Sequence 63 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28700	GIGKFLHSAKKFGKAXEGEXXNS	23	Sequence 64 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28701	GIGKFLHSAKKFGKAXVEEXXNS	23	Sequence 65 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28702	GIGKFLHSAKKFGKAXVGEXENS	23	Sequence 66 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28703	GIGKFLHSAKKFGKAXVGEXXES	23	Sequence 67 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28704	GIGKFLHSAKKFGKAXVGEXXNE	23	Sequence 68 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28705	XIGKXLHSAKKFGKAFVGEIXNS	23	Sequence 69 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28706	GIGKFLHSAKKFGKAFVGXIXNX	23	Sequence 70 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28707	GXGKFXHSKKKFGKAXVGEXXNS	23	Sequence 71 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28708	GIXKFLXSKKKFGKAXVGEXXNS	23	Sequence 72 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28709	GIHKFLHSAKKFGKAXVGEXXNS	23	Sequence 73 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28710	GIGKFLHHAKKFGKAXVGEXXNS	23	Sequence 74 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28711	GIGKFLHSAKKFGKHXVGEXXNS	23	Sequence 75 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28712	GIGKFLHSAKKFGKAXVHEXXNS	23	Sequence 76 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28713	GIGKFLHSAKKFXKAXVGEXXNS	23	Sequence 77 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28714	GIGKFLHSAKKFPKAXVGEXXNS	23	Sequence 78 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28715	GIGKFLHSAKKFAKAXVGEXXNS	23	Sequence 80 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28716	GIGKFLHSAKXFGKAFVXEIXNK	23	Sequence 83 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28717	GIGKFLHSAKXFGKAFVXEIXKS	23	Sequence 84 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28718	GIGKFLHSAKXFGKAFVXEIKNS	23	Sequence 85 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28719	GIGKFLHSAKXFGKAFVXEKXNS	23	Sequence 86 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28720	GIGKFLHSAKXFGKAFVXKIXNS	23	Sequence 87 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28721	GIGKFLHSAKXFGKAFKXEIXNS	23	Sequence 88 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28722	GIGKFLHSAKXFGKAKVXEIXNS	23	Sequence 89 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28723	GIGKFLHSAKXFGKKFVXEIXNS	23	Sequence 90 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28724	GIGKFLHSAKXFKKAFVXEIXNS	23	Sequence 91 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28725	GIGKFLHSAKXKGKAFVXEIXNS	23	Sequence 92 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28726	GIGKFLHSKKXFGKAFVXEIXNS	23	Sequence 93 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28727	GIGKFLHKAKXFGKAFVXEIXNS	23	Sequence 94 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28728	GIGKFLKSAKXFGKAFVXEIXNS	23	Sequence 95 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28729	GIGKFKHSAKXFGKAFVXEIXNS	23	Sequence 96 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28730	GIGKKLHSAKXFGKAFVXEIXNS	23	Sequence 97 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28731	GIKKFLHSAKXFGKAFVXEIXNS	23	Sequence 98 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28732	GKGKFLHSAKXFGKAFVXEIXNS	23	Sequence 99 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28733	KIGKFLHSAKXFGKAFVXEIXNS	23	Sequence 100 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28734	EIGKFLHSAKXFGKAFVXEIXNS	23	Sequence 101 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28735	GEGKFLHSAKXFGKAFVXEIXNS	23	Sequence 102 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28736	GIEKFLHSAKXFGKAFVXEIXNS	23	Sequence 103 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28737	GIGEFLHSAKXFGKAFVXEIXNS	23	Sequence 104 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28738	GIGKELHSAKXFGKAFVXEIXNS	23	Sequence 105 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28739	GIGKFEHSAKXFGKAFVXEIXNS	23	Sequence 106 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28740	GIGKFLESAKXFGKAFVXEIXNS	23	Sequence 107 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28741	GIGKFLHEAKXFGKAFVXEIXNS	23	Sequence 108 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28742	GIGKFLHSEKXFGKAFVXEIXNS	23	Sequence 109 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28743	GIGKFLHSAEXFGKAFVXEIXNS	23	Sequence 110 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28744	GIGKFLHSAKXEGKAFVXEIXNS	23	Sequence 111 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28745	GIGKFLHSAKXFEKAFVXEIXNS	23	Sequence 112 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28746	GIGKFLHSAKXFGEAFVXEIXNS	23	Sequence 113 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28747	GIGKFLHSAKXFGKEFVXEIXNS	23	Sequence 114 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28748	GIGKFLHSAKXFGKAEVXEIXNS	23	Sequence 115 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28749	GIGKFLHSAKXFGKAFEXEIXNS	23	Sequence 116 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28750	GIGKFLHSAKXFGKAFVXEEXNS	23	Sequence 117 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28751	GIGKFLHSAKXFGKAFVXEIENS	23	Sequence 118 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28752	GIGKFLHSAKXFGKAFVXEIXES	23	Sequence 119 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28753	GIGKFLHSAKXFGKAFVXEIXNE	23	Sequence 120 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28754	GIGKFLHSAKKFGKAXVGEIXNX	23	Sequence 121 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28755	XIGKFLHXAKKFGKAFVGEIXNS	23	Sequence 122 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28756	GXGKFXHSKKXFGKAFVXEIXNS	23	Sequence 123 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28757	GIXKFLXSKKXFGKAFVXEIXNS	23	Sequence 124 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28758	GIHKFLHSAKXFGKAFVXEIXNS	23	Sequence 125 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28759	GIGKFLHHAKXFGKAFVXEIXNS	23	Sequence 126 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28760	GIGKFLHSAKXFGKHFVXEIXNS	23	Sequence 127 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28761	GIGKFLHSAKXFXKAFVXEIXNS	23	Sequence 128 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28762	GIGKFLHSAKXFPKAFVXEIXNS	23	Sequence 129 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28763	GIGKFLHSAKXFAKAFVXEIXNS	23	Sequence 131 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28764	GIGKFLHSAKKFGKAFVGEIXNS	23	Sequence 134 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28765	GXGKFXHSAKKFGKAFVGEIXNS	23	Sequence 135 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28766	GIXKFLXSAKKFGKAFVGEIXNS	23	Sequence 136 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28767	GIGXFLHXAKKFGKAFVGEIXNS	23	Sequence 137 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28768	GIGKXLHSXKKFGKAFVGEIXNS	23	Sequence 138 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28769	GIGKFXHSAXKFGKAFVGEIXNS	23	Sequence 139 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28770	GIGKFLXSAKXFGKAFVGEIXNS	23	Sequence 140 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28771	GIGKFLHXAKKXGKAFVGEIXNS	23	Sequence 141 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28772	GIGKFLHSXKKFXKAFVGEIXNS	23	Sequence 142 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28773	GIGKFLHSAXKFGXAFVGEIXNS	23	Sequence 143 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28774	GIGKFLHSAKXFGKXFVGEIXNS	23	Sequence 144 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28775	GIGKFLHSAKKXGKAXVGEIXNS	23	Sequence 145 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28776	GIGKFLHSAKKFXKAFXGEIXNS	23	Sequence 146 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28777	GIGKFLHSAKKFGXAFVXEIXNS	23	Sequence 147 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28778	GIGKFLHSAKKFGKXFVGXIXNS	23	Sequence 148 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28779	GIGKFLHSAKKFGKAXVGEXXNS	23	Sequence 149 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28780	GIGKFLHSAKKFGKAFXGEIXNS	23	Sequence 150 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28781	GIGKFLHSAKKFGKAFVXEIXXS	23	Sequence 151 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28782	GIXKFLXSKKKFGKAXVGEXXNS	23	Sequence 154 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28783	GXGKFLHSXKKFGKAFVGEIXNS	23	Sequence 155 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28784	GIXKFLHSAXKFGKAFVGEIXNS	23	Sequence 156 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28785	GIGXFLHSAKXFGKAFVGEIXNS	23	Sequence 157 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28786	GIGKXLHSAKKXGKAFVGEIXNS	23	Sequence 158 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28787	GIGKFXHSAKKFXKAFVGEIXNS	23	Sequence 159 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28788	GIGKFLXSAKKFGXAFVGEIXNS	23	Sequence 160 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28789	GIGKFLHXAKKFGKXFVGEIXNS	23	Sequence 161 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28790	GIGKFLHSXKKFGKAXVGEIXNS	23	Sequence 162 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28791	GIGKFLHSAXKFGKAFXGEIXNS	23	Sequence 163 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28792	GIGKFLHSAKXFGKAFVXEIXNS	23	Sequence 164 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28793	GIGKFLHSAKKXGKAFVGXIXNS	23	Sequence 165 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28794	GIGKFLHSAKKFXKAFVGEXXNS	23	Sequence 166 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28795	GIGKFLHSAKKFAXAFVGEIXNS	23	Sequence 167 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28796	GIGKFLHSAKKFAKXFVGEIXXS	23	Sequence 168 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28798	GKXKFLXSKKKFGKAXVHEXXNS	23	Sequence 170 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28799	GKXKFLXSHKKFGKAXVGEXXNS	23	Sequence 171 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28800	GKXKFLXSHKKFGKAXVGEXXES	23	Sequence 172 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28801	GKXKFLXSHKKFGKAXVHEXXES	23	Sequence 173 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28802	GXGKFXHSKKKFGKAXVHEXXES	23	Sequence 174 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28803	GXGSFXKKAAHVGKHXGKAXLTHYL	25	Sequence 176 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28804	GXGSFXKKKAHVGKHXGKAXLTHYL	25	Sequence 177 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28805	GIGKFLXAAKKFAXAFVAEIXNS	23	Sequence 178 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28806	GIGKFLHXAKKFAKXFVAEIXNS	23	Sequence 179 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28807	GIGKFLHAXKKFAKAXVAEIXNS	23	Sequence 180 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28808	GIGKFLHAAXKFAKAFXAEIXNS	23	Sequence 181 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28809	GIGKFLHAAKXFAKAFVXEIXNS	23	Sequence 182 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28810	GIGKFLHAAKKXAKAFVAXIXNS	23	Sequence 183 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28811	GIGKFLHAAKKFXKAFVAEXXNS	23	Sequence 184 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28812	GIGKFLKXAKKFGKXFVKILKK	22	Sequence 185 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28813	GIGKFLKKAKXFGKAFVXILKK	22	Sequence 186 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28814	GIGKFLKKAKKXGKAFVKXLKK	22	Sequence 187 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28815	GIGKFLHAAKKFAXAFVAEIXNS	23	Sequence 195 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28816	GIGKFLHAAKKFAKXFVAEIXXS	23	Sequence 196 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28817	GIGKFLHAAKKFAKAXVAEIXNX	23	Sequence 197 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28818	GIGKFXHAAKKFXKAFVAEIXNS	23	Sequence 198 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28819	GIGKXLHAAKKXAKAFVAEIXNS	23	Sequence 199 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28820	GIGXFLHAAKXFAKAFVAEIXNS	23	Sequence 200 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28821	GIXKFLHAAXKFAKAFVAEIXNS	23	Sequence 201 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28822	GXGKFLHAXKKFAKAFVAEIXNS	23	Sequence 202 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28823	XIGKFLHXAKKFAKAFVAEIXNS	23	Sequence 203 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28824	XIGKXLHAAKKFAKAFVAEIXNS	23	Sequence 204 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28825	GXGKFXHAAKKFAKAFVAEIXNS	23	Sequence 205 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28826	GIXKFLXAAKKFAKAFVAEIXNS	23	Sequence 206 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28827	GIGXFLHXAKKFAKAFVAEIXNS	23	Sequence 207 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28828	GIGKXLHAXKKFAKAFVAEIXNS	23	Sequence 208 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28829	GIGKFXHAAXKFAKAFVAEIXNS	23	Sequence 209 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28830	GIGKFLXAAKXFAKAFVAEIXNS	23	Sequence 210 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28831	GIGKFLHXAKKXAKAFVAEIXNS	23	Sequence 211 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28832	GIGKFLHAXKKFXKAFVAEIXNS	23	Sequence 212 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28833	GIGKFLHAAXKFAXAFVAEIXNS	23	Sequence 213 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28834	GIGKFLHAAKXFAKXFVAEIXNS	23	Sequence 214 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28835	GIGKFLHAAKKXAKAXVAEIXNS	23	Sequence 215 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28836	GIGKFLHAAKKFXKAFXAEIXNS	23	Sequence 216 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28837	GIGKFLHAAKKFAXAFVXEIXNS	23	Sequence 217 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28838	GIGKFLHAAKKFAKXFVAXIXNS	23	Sequence 218 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28839	GIGKFLHAAKKFAKAXVAEXXNS	23	Sequence 219 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28840	GIGKFLHAAKKFAKAFXAEIXNS	23	Sequence 220 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28841	GIGKFLHAAKKFAKAFVXEIXXS	23	Sequence 221 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28842	GIGKFLHAAKKFAKAFVAXIXNX	23	Sequence 222 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28843	XIGXFLHAAKKFAKAFVAEIXNS	23	Sequence 223 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28844	GXGKXLHAAKKFAKAFVAEIXNS	23	Sequence 224 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28845	GIXKFXHAAKKFAKAFVAEIXNS	23	Sequence 225 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28846	GIGXFLXAAKKFAKAFVAEIXNS	23	Sequence 226 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28847	GIGKXLHXAKKFAKAFVAEIXNS	23	Sequence 227 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28848	GIGKFXHAXKKFAKAFVAEIXNS	23	Sequence 228 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28849	GIGKFLXAAXKFAKAFVAEIXNS	23	Sequence 229 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28850	GIGKFLHXAKXFAKAFVAEIXNS	23	Sequence 230 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28851	GIGKFLHAXKKXAKAFVAEIXNS	23	Sequence 231 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28852	GIGKFLHAAXKFXKAFVAEIXNS	23	Sequence 232 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28853	GIGKFLHAAKXFAXAFVAEIXNS	23	Sequence 233 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28854	GIGKFLHAAKKXAKXFVAEIXNS	23	Sequence 234 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28855	GIGKFLHAAKKFXKAXVAEIXNS	23	Sequence 235 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28856	GIGKFLHAAKKFAXAFXAEIXNS	23	Sequence 236 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28857	GIGKFLHAAKKFAKXFVXEIXNS	23	Sequence 237 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28858	GIGKFLHAAKKFAKAXVAXIXNS	23	Sequence 238 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28859	GIGKFLHAAKKFAKAFXAEXXNS	23	Sequence 239 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28860	GIGKFLHAAKKFAKAFVXEIXNS	23	Sequence 240 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28861	GIGKFLHAAKKFAKAFVAXIXXS	23	Sequence 241 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28862	GIGKFLHAAKKFAKAFVAEXXNX	23	Sequence 242 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28863	GXGKXLHAAKKXAKAFVAXIXNS	23	Sequence 243 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28864	GIXKFXHAAKXFAKAFVXEIXNS	23	Sequence 244 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28865	GIXKFLXAAKKFXKAFXAEIXNS	23	Sequence 245 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28866	GIGXFLHXAKKFXKAFXAEIXNS	23	Sequence 246 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28867	GXGKFXHAAKKFXKAFVAEXXNS	23	Sequence 247 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28868	GXGKFLHAXKKFAKAXVAEIXNX	23	Sequence 248 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28869	GIXKFLHAAXKFAKXFVAEIXXS	23	Sequence 249 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28870	XIGKFLHXAKKFAKAFXAEIXNS	23	Sequence 250 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28871	GXGKFLHAXKKFAKAXVAEXXNS	23	Sequence 251 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28872	GIXKFLHAAXKFAKXFVAXIXNS	23	Sequence 252 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28873	XIGKFLKXAKKFGKAFVKILKK	22	Sequence 253 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28874	XIGKFXKKAKKFGKAFVKILKK	22	Sequence 254 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28875	XIGKXLKKAKKFGKAFVKILKK	22	Sequence 255 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28876	XIGKFLKXAKKFGKXFVKILKX	22	Sequence 256 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28877	XIGKFXKKAKKFGKAFXKILKX	22	Sequence 257 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28878	XIGKXLKKAKKFGKAFVXILKX	22	Sequence 258 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28879	XXXKXXKKXKKXXKXXXKXXKK	22	Sequence 259 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28880	GIGKFLHSAKKXGKXFVGXIXN	22	Sequence 260 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28881	GIGKFLHSAKKXGKAXVGEXXN	22	Sequence 261 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28882	GIGKFLHSAKKXGKAFVGEIMN	22	Sequence 262 from Patent US 10464975	Synthetic construct	Antimicrobial	US 10464975 B2	Granted Patent	2019##11##5	CA2989311A1, WO2017004591A2, US20170015716A1, WO2017004591A3, AU2016287754A1, IL256395D0, KR20180022971A, MX2017016251A, EP3317294A2, CN108026146A, BR	Stabilized Anti-microbial Peptides	The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
DRAMP28883	QHGYGAGGHGQQGYGSQHSSHAPQGGHVVREQGFSGHVHEQQAGHHHEAGHHEQAGHHEQSGQQVHGQGHGYKSHGY	77	Sequence 1 from Patent US 10266842	Lucilia sericata	Antimicrobial, Antifungal	US 10266842 B2	Granted Patent	2019##4##23	WO2014124786A1, KR20150117254A, CN105102476A, EP2956474A1, US20160002663A1, JP2016507541A, EP2956474B1, JP6396330B2, ES2693036T3, CN105102476B, KR1021	Polypeptides Against Plant Pathogenic Fungi	The present invention discloses polypeptides comprising an amino acid sequence being identical with at least 12 contiguous amino acid residues of SEQ ID No 2. The polypeptides according to the invention are effective against fungi, especially against fungi causing plant diseases, and against fungi colonizing agricultural products. The invention further discloses processes for preparing such polypeptides, and nucleic acids coding for such polypeptides. In addition, the invention relates to processes and preparations for treating plants using the polypeptides according to the invention, and to the use of the nucleic acids according to the invention for producing crops that are protected against damage from fungi.
DRAMP28884	QHGYGAGGHGQQGYGSQHSSHAPQGGHVVREQGFSGHVHEQQAGHHHEAGHHEQAGHHEQSGQQVHGQGHGYK	73	Sequence 2 from Patent US 10266842	Lucilia sericata	Antimicrobial, Antifungal	US 10266842 B2	Granted Patent	2019##4##23	WO2014124786A1, KR20150117254A, CN105102476A, EP2956474A1, US20160002663A1, JP2016507541A, EP2956474B1, JP6396330B2, ES2693036T3, CN105102476B, KR1021	Polypeptides Against Plant Pathogenic Fungi	The present invention discloses polypeptides comprising an amino acid sequence being identical with at least 12 contiguous amino acid residues of SEQ ID No 2. The polypeptides according to the invention are effective against fungi, especially against fungi causing plant diseases, and against fungi colonizing agricultural products. The invention further discloses processes for preparing such polypeptides, and nucleic acids coding for such polypeptides. In addition, the invention relates to processes and preparations for treating plants using the polypeptides according to the invention, and to the use of the nucleic acids according to the invention for producing crops that are protected against damage from fungi.
DRAMP28885	SHGY	4	Sequence 8 from Patent US 10266842	Lucilia sericata	Antimicrobial, Antifungal	US 10266842 B2	Granted Patent	2019##4##23	WO2014124786A1, KR20150117254A, CN105102476A, EP2956474A1, US20160002663A1, JP2016507541A, EP2956474B1, JP6396330B2, ES2693036T3, CN105102476B, KR1021	Polypeptides Against Plant Pathogenic Fungi	The present invention discloses polypeptides comprising an amino acid sequence being identical with at least 12 contiguous amino acid residues of SEQ ID No 2. The polypeptides according to the invention are effective against fungi, especially against fungi causing plant diseases, and against fungi colonizing agricultural products. The invention further discloses processes for preparing such polypeptides, and nucleic acids coding for such polypeptides. In addition, the invention relates to processes and preparations for treating plants using the polypeptides according to the invention, and to the use of the nucleic acids according to the invention for producing crops that are protected against damage from fungi.
DRAMP28887	SGRGKTGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYAHRVGAGAPVYL	51	Sequence 2 from Patent US 20200308236	Hippoglossus hippoglossus	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28888	KAKSRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYL	39	Sequence 3 from Patent US 20200308236	Himantura pastinacoides	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28889	SGRGKTGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYL	51	Sequence 4 from Patent US 20200308236	Oncorhynchus mykiss	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28890	MSGRGKGGKTKAKAKSRSSRAGLQFPVGRIHRLLRKGNYA	40	Sequence 5 from Patent US 20200308236	Haliotis discus	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28891	MSGRGKGGKVKGKAKSRSSRAGLQFPVGRIHRLLRKGNYA	40	Sequence 6 from Patent US 20200308236	Azumapecten farreri	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28893	KLNKKAASGE	10	Sequence 8 from Patent US 20200308236	Homo sapiens	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28894	KLNKKAASGEAKPKA	15	Sequence 9 from Patent US 20200308236	Homo sapiens	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28895	KAKSPKKAKA	10	Sequence 10 from Patent US 20200308236	Homo sapiens	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28896	DSHAKRKKGYKRKFHEKHHSHRGY	24	Sequence 11 from Patent US 20200308236	Homo sapiens	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28899	GWXSFFXKAAHXGKHXGKAALTHYL	25	Sequence 14 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28900	GWGSFFKKXAHVXKHVGKXALTXYL	25	Sequence 15 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28901	SGRXKTGGKAXAKAKTRSSRAGLQFPVGRVHRLLRKGNYAHRVGAGAPVYL	51	Sequence 16 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28902	SGRGKTGGKXRAKXKTRSSRAGLQFPXGRVXRLLRKGNYAHRVGAGAPVYL	51	Sequence 17 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28903	KAKSRXSRAXLQFPVGRVHRLLRKGNYAXRVGAGAXVYL	39	Sequence 18 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28904	KAKSRSSRAGLXFPVXRVHRLLRKGNYXERVGAGXPVYL	39	Sequence 19 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28905	SGRGKTGGKARAKAKTRSSXAGLQFPXGRVHRLLRXGNYAERXGAGAPVYL	51	Sequence 20 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28906	SGRGKTGGKXRAKAKTXSSRAGLQFPVGRVHRLXRKGNYAXRVGAGAPVYL	51	Sequence 21 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28907	MSGRGKGXKTKAKAXSRSSRAGLQFPVGRIHRLLRKGNYA	40	Sequence 22 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28908	MSGRGKGGKTKAKAKSRSSRAGLQFPXGRIHRLXRKGNYA	40	Sequence 23 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28909	XSGRGKGXKVKGKAKSRSSRAGLQFPVGRIHRLLRKGNYA	40	Sequence 24 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28910	MSGRGKGGKVKGKXKSRSSRXGLQFPVGRIHRLLRKGNYA	40	Sequence 25 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28911	TRSSRAGLQFPXGRXHRLLRK	21	Sequence 26 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28912	TRSSRAGLQFPVGRXHRLXRK	21	Sequence 27 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28913	KXNKKXASGEAKPKA	15	Sequence 29 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28914	KAXSPKKAKX	10	Sequence 30 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28915	DSHAXRKKGYKRXFHEKHHSHRGY	24	Sequence 31 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28916	DSXAKRXKGYKRKXHEKHHSXRGY	24	Sequence 32 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28917	XKPRPYSXRPTSHPRPIRV	19	Sequence 33 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28918	GKPRPYXPRPTSHXRPIRV	19	Sequence 34 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28919	GNNRPXYIPQPRXPHPRL	18	Sequence 35 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28920	GNNXPVYXPQPRPPXPRX	18	Sequence 36 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28921	TRSSRAGLQWPVGRVHALLRA	21	Sequence 37 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28922	TRSSRAGLQWPVGRVARLLAK	21	Sequence 38 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28923	TRSSRAGLQWPVGRAHRLARK	21	Sequence 39 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28924	TRSSRAGLQWPVGAVHRALRK	21	Sequence 40 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28925	TRSSRAGLQWPVARVHALLRK	21	Sequence 41 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28926	TRSSRAGLQWPAGRVARLLRK	21	Sequence 42 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28927	TRSSRAGLAWPVARVHRLLRK	21	Sequence 43 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28928	TRSSRAGAQWPAGRVHRLLRK	21	Sequence 44 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28929	TRSSAAGLAWPVGRVHRLLRK	21	Sequence 45 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28930	TRSARAGAQWPVGRVHRLLRK	21	Sequence 46 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28931	TRASRAALQWPVGRVHRLLRK	21	Sequence 47 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28932	TASSRAGLQWPVGRVHRLLRK	21	Sequence 48 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28933	ARSSAAGLQWPVGRVHRLLRK	21	Sequence 49 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28934	TRSSRAGLQWPVGAVHRLLRA	21	Sequence 50 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28935	TRSSRAGLQWPVARVHRLLAK	21	Sequence 51 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28936	TRSSRAGLQWPAGRVHRLARK	21	Sequence 52 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28937	TRSSRAGLAWPVGRVARLLRK	21	Sequence 53 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28938	TRSSRAGAQWPVGRAHRLLRK	21	Sequence 54 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28939	TRSSRAALQWPVGAVHRLLRK	21	Sequence 55 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28940	TRSSRAGLQWPVARVHRLLRK	21	Sequence 56 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28941	TRSSAAGLQWPAGRVHRLLRK	21	Sequence 57 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28942	TASSRAGLAWPVGRVHRLLRK	21	Sequence 58 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28943	ARSSRAGAQWPVGRVHRLLRK	21	Sequence 59 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28944	TRSSRAGLQWPVGRVHRLLRK	21	Sequence 60 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28945	LQFPVG	6	Sequence 61 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28946	LQWPVG	6	Sequence 62 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28947	AGLQFP	6	Sequence 63 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28948	AGLQWP	6	Sequence 64 from Patent US 20200308236	Synthetic construct	Antimicrobial	US 2020/0308236 A1	Patent Application	2020##10##1	US20170247423A1, CA3014442A1, WO2017151617A1, AU2017228333A1, CN109069578A, EP3423075A1, JP2019513696A, EP3423075A4	Stapled Intracellular-targeting Antimicrobial Peptides To Treat Infection	Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
DRAMP28949	ILKPGGGTSGGLLGGLLGKVTSVIPGLNNI	30	Sequence 1 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28950	ILKKWWXXXXGLLGXLLGXVXXVIKXLXXI	30	Sequence 2 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28951	ILKKWWGTSGGLLGGLLGKVTSVIKGLNNI	30	Sequence 3 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28952	ILKKWWKTSGGLLGGLLGKVTSVIKGLNNI	30	Sequence 4 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28953	ILKKWWKTSKGLLGGLLGKVTSVIKGLNNI	30	Sequence 5 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28954	ILKKWWKTSKGLLGGLLGKVTSVIKGLKNI	30	Sequence 6 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28955	ILKKWWKTSKGLLGGLLGGVTSVIKKLKKI	30	Sequence 7 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28956	ILKKWWKTSKGLLGGLLGGVTSVIKKLKKI	30	Sequence 8 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28957	ILKKWWKTVKGLLGGLLGGVTSVIKKLKKI	30	Sequence 9 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28958	ILKKWWKKVKGLLGKLLGGVKSVIKGLNNI	30	Sequence 10 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28959	ILKKWWKKVKGLLGKLLGGVKKVIKGLNNI	30	Sequence 11 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28960	LKKWWKXXKGLLGGLLGKVXXVIK	24	Sequence 12 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28961	LKKWWKTSKGLLGGLLGKVTSVIK	24	Sequence 13 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28962	LKKWWKTVKGLLGGLLGKVTSVIK	24	Sequence 14 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28963	LKKWWKKVKGLLGGLLGKVTSVIK	24	Sequence 15 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28964	LKKWWKKVKGLLGGLLGKVKSVIK	24	Sequence 16 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28965	LKKWWKKVKGLLGGLLGKVKKVIK	24	Sequence 17 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28966	XKKXXKKXKGXLGGLXGK	18	Sequence 18 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28967	LKKWWKKVKGLLGGLLGK	18	Sequence 19 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28968	LKKLLKKVKGWLGGLWGK	18	Sequence 20 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28969	VKKLLKKVKGWLGGLWGK	18	Sequence 21 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28970	GKKLLKKVKGWLGGLWGK	18	Sequence 22 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28971	GKKLLKKGKGWLGGLWGK	18	Sequence 23 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28972	GVKKKWKKKLGLKLWLKISGVVLG	24	Sequence 24 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28973	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLLPRTES	37	Sequence 25 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28974	RRWVRRVRRVWRRVVRVVRRWVRR	24	Sequence 26 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28975	KLWKKGKGGKLTKSLTWVLVGILV	24	Sequence 27 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28976	VWKWGKLGKLLKLGKLGK	18	Sequence 28 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28977	KKLGKKVVGKLGTSKVWKLIGWLL	24	Sequence 29 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28978	LKKWWKKVLGLLGGLKGKVTSVIK	24	Sequence 30 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28979	LKKWLKKVLGLKGGLWGKVTSVIK	24	Sequence 31 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28980	RRWVRRXRRVWRRVXRXVRRWXRR	24	Sequence 32 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28981	RRWVRRXRRXWRRVXRXXRRWXRR	24	Sequence 33 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP28982	RRWXRRXRRXWRRXXRXXRRWXRR	24	Sequence 34 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2020/0079827 A1	Patent Application	2020##3##12	WO2018094403A1, CN109996554A, EP3541405A1, EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
DRAMP29363	MFTMKKSLLLLFFLGTISLSLCEQERNADDDQGEVIEQKVKR	42	Sequence 1 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29364	AFLSTVKNTLTNVAGTMIDTFKCKITGVC	29	Sequence 2 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29365	VLLYLIITVSFPRRDANDEDGGEVTKEVVKR	31	Sequence 3 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29366	SLSGCWTKSFPRKPCLRNR	19	Sequence 4 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29367	MSSFCEITNVALTISLSSPRRGADEEEGNGEKEIKR	36	Sequence 5 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29368	SMLSVLKNLGKVGLGFVACKINKQC	25	Sequence 6 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29369	MTQSTQKWFKTKYWRVRNRPAMSPDLNPIEHLWRDLKKVVGKR	43	Sequence 7 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29370	NPSNLRALEELVKEECSEIPVERCKKLIYGYRK	33	Sequence 8 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29371	MRKRMTMRRMMKKKKSEKERRERGKR	26	Sequence 9 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29372	MMRVMRRKTKVIWEKKDFIGLYSID	25	Sequence 10 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29373	MFFMSSPRRDADEVKEVKR	19	Sequence 11 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29374	GFLDIIKNLGKTFAGHMLDKIKCTIGTCPPSP	32	Sequence 12 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29375	MITVSSPRRDADGDEGEVEEVKR	23	Sequence 13 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29376	GFLDIIKDTGKEFAVKILNNLKCKLAGGCPP	31	Sequence 14 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29377	MFTMKKSLLLFFFLGTISLSLCEEERDADDDQGEVVKKEVKRAFFTTVKNLVTNVAGTVIDKMKCKLTGQC	71	Sequence 15 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29378	MFTMKKSLLLLFFLGTISLSLCEQERNADDDQGEVIEQKVKRAFLSTVKNTLTNVAGTMIDTFKCKITGVC	71	Sequence 16 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29379	MFTLKKSLLLLFFLGTITLSLCEQERGADEEEGNGEKEIKRSMLSVLKNLGKVGLGFVACKINKQC	66	Sequence 17 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29380	MSSFCEITNVALTISLSSPRRGADEEEGNGEKEIKRSMLSVLKNLGKVGLGFVACKINKQC	61	Sequence 18 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29381	MFFMSSPRRDADEVKEVKRGFLDIIKNLGKTFAGHMLDKIKCTIGTCPPSP	51	Sequence 19 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29382	MFTMKKSLLLLFFLGTISLSLCEPQRDADEVKEVKRGFLDIIKNLGKTFAGHMLDKIKCTIGTCPPSP	68	Sequence 20 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29383	MFTLKKSLLLLFFLGTINLSLCEEERDAEEERRDNPDERDVEVEKRFLPFIARLAAKVFPSIICSVTKKC	70	Sequence 21 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29384	MFTMKKSLLLLFFLGTISLSLCEQERNADDDQGEVIEQKVKRAFLSTVKNTLTNVAGTMIDTFKCKITGVC	71	Sequence 22 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29385	MFTLKKSLLLLFFLGTITLSLCEQERGADEDNGGEMTEEEVKRGLFLDTLKGAAKDVAGKLLEGLKCKITGCKP	74	Sequence 23 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29386	MFTMKKSLLLLFFLGIISLSLCEQERDANDEEDGGEVTKEVVKRSLRGCWTKSFPPQPCLGKRLNMN	67	Sequence 24 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29387	MFTLKKSLLLLFFFGIISLSFCEQERDANDEEDGGEVTKEVVKRSLRGCWTKSYPPQPCLGKR	63	Sequence 25 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29388	VLLYLIITVSFPRRDANDEDGGEVTKEVVKRSLSGCWTKSFPRKPCLRNR	50	Sequence 26 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29389	MFTMKKSEKERRERGKRMMRVMRRKTKVIWEKKDFIGLYSID	42	Sequence 27 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29390	MRKRMTMRRMMKKKKSEKERRERGKRMMRVMRRKTKVIWEKKDFIGLYSID	51	Sequence 28 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29391	MFTMKKSLLLLFFLGTISLSLCEQERDADGDEGEVEEVKRGFLDIIKDTGKEFAVKILNNLKCKLAGGCPP	71	Sequence 29 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29392	MITVSSPRRDADGDEGEVEEVKRGFLDIIKDTGKEFAVKILNNLKCKLAGGCPP	54	Sequence 30 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29393	MIPQLRKWMAIFVMCIVLIHQLEGAPMNSNDGSKTALRLRRMTPFWRGLSLRPVGASCRDDTECLTRLCRNQRCSLKTFAD	81	Sequence 33 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29394	MTPQLRKWTAIFVICIVLIHQLEGAPMSNTAGSKTLLRLRRMTPFWRGLSLRPVGASCRDDTECLTRLCRKERCSLKTFAD	81	Sequence 34 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29395	FYFPVSRKFGGK	12	Sequence 35 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29396	FPFPVSRKRGGK	12	Sequence 36 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29397	FFPRVLPLANKFLPTIYCALPKSVGN	26	Sequence 37 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29398	FFPRVLRLANKFLPKIYCALPKSVGN	26	Sequence 38 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29399	GLLDIIKDTGKTTGILMDTLKCQMTGRCPPSS	32	Sequence 39 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29400	GLLDIIKKTGKTTGILMDTLKCCMTGRCPPSS	32	Sequence 40 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29401	GLLDIIKTTGKDFAVKILDNLKCKLAGGCPP	31	Sequence 41 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29402	GLLDIIKTTGKDFAVKILDNLKCKLAGGCPK	31	Sequence 42 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29403	FFPIIARLAAKVIPSLVCAVTKKC	24	Sequence 43 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29404	FFPIIARLAAKVIPSLVCKVTKKC	24	Sequence 44 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29405	GLWETIKTTGKSIALNLLDKIKCKIAGGCPP	31	Sequence 45 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29406	GLWETIKTTGKKIALNLLDKIKCKIAGGCPP	31	Sequence 46 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29407	ATAWRIPPPGMQPIIPIRIRPLCGKQ	26	Sequence 47 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29408	ATAWMIPPRGMQPIIPIRIRPLCGKQ	26	Sequence 48 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29409	FPAIICKVSKNC	12	Sequence 49 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29410	FPAIICKVSKKC	12	Sequence 50 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29411	FLTKPGMTFGKLLGK	15	Sequence 51 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29412	SNRDFFKVNIFRLCG	15	Sequence 52 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29413	SNRKFFKVRIFRLCG	15	Sequence 53 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29414	ALVAKIQKFPVFNTLKLCKLELEII	25	Sequence 54 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29415	ALVAKIQKFPVFNTLKLCKLKLRII	25	Sequence 55 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29416	IAGQVAAAKQKHI	13	Sequence 56 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29417	IAGQKARAKQKHI	13	Sequence 57 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29418	IQRLPVINMLKLWKLELEII	20	Sequence 58 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29419	IQRLPVIKMLKLWKLELKII	20	Sequence 59 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29420	IQRLPVIVILPSLYCVICRTC	21	Sequence 60 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29421	IQRLPVIVILPSLYCVICRKK	21	Sequence 61 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29422	LRCPTPHYNFENGIGNHLMWNIIWLNAQQMSYKNK	35	Sequence 62 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29423	LRCPTPHYRFENGIGNHLMWNIIWLNAQQMSYCNK	35	Sequence 63 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29424	SNRDFFMVNIFGLCGPFGIMERKRR	25	Sequence 64 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29425	SNRKFFMVNIFGLCGPFGIMKRKRR	25	Sequence 65 from Patent US 2022/0125873	Synthetic construct	Antimicrobial	US 2022/0125873 A1	Patent Application	2022##4##28	WO 2020/118427 A1##CA 3123101 A1##BR 112021011276 A2##EP 3897128 A1##JP 2022523896 A##US 2022/0125873 A1##EP 3897128 A4	Antimicrobial Peptides	Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) catesbeiana ) genome, and a bioinformatics approach is used to develop new AMPs. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.
DRAMP29426	LGLKLLWSAYKHRKTL	16	Sequence 1 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29427	LTKRHKYASWLLKLGL	16	Sequence 2 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29428	LGIKILWSAYKHRKTI	16	Sequence 3 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29429	ITKRHKYASWLIKIGL	16	Sequence 4 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29430	SVPTSVYTLGIKILWSAYKHRKTIEKSFNKGFYH	34	Sequence 5 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29431	SVPTSVYTLGIKILWS	16	Sequence 6 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29432	VPTSVYTLGIKILWSA	16	Sequence 7 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1##WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29433	PTSVYTLGIKILWSAY	16	Sequence 8 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1##WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29434	TSVYTLGIKILWSAYK	16	Sequence 9 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29435	SVYTLGIKILWSAYKH	16	Sequence 10 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29436	VYTLGIKILWSAYKHR	16	Sequence 11 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29437	YTLGIKILWSAYKHRK	16	Sequence 12 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29438	TLGIKILWSAYKHRKT	16	Sequence 13 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29439	GIKILWSAYKHRKTIE	16	Sequence 14 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29440	IKILWSAYKHRKTIEK	16	Sequence 15 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29441	KILWSAYKHRKTIEKS	16	Sequence 16 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29442	ILWSAYKHRKTIEKSF	16	Sequence 17 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29443	LWSAYKHRKTIEKSFN	16	Sequence 18 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29444	WSAYKHRKTIEKSFNK	16	Sequence 10 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29445	SAYKHRKTIEKSFNKG	16	Sequence 20 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29446	AYKHRKTIEKSFNKGF	16	Sequence 21 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29447	YKHRKTIEKSFNKGFY	16	Sequence 22 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29448	KHRKTIEKSFNKGFYH	16	Sequence 23 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29449	LGIKILRSAYKHRKTIEK	18	Sequence 24 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29450	LGIKILRSAYKHRKTIEKSFNK	22	Sequence 25 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29451	LGQKILRSARKFGKTIEKSF	20	Sequence 26 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29452	LGQKILRSARKFGKDIEKSF	20	Sequence 27 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29453	LGIKILRSARKFGKVIEKSF	20	Sequence 28 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29454	LGIKILWSARKFGKVIEKSF	20	Sequence 29 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29455	LLGIKILWSARKFGKVIEKSF	21	Sequence 30 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29456	LLGIKILWKARKFGKVIEKSF	21	Sequence 31 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29457	KILWSAYKHR	10	Sequence 32 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29458	ILWSAYKHR	9	Sequence 33 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29459	LWSAYKHR	8	Sequence 34 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29460	WSAYKHR	7	Sequence 35 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29461	WSAYKH	6	Sequence 36 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29462	WSAYK	5	Sequence 37 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29463	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	37	Sequence 38 from Patent WO 2023/075675	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	WO 2023/075675 A1	Patent Application	2023##5##4	SE 2151338 A1,WO 2023/075675 A1	Antibacterial Peptide	The present document is directed to an antimicrobial peptide, pharmaceutical and non- pharmaceutical compositions comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or an amino acid sequence having at least 85% or at least 90%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, and medical and non- medical use the antimicrobial peptide
DRAMP29464	ALLRL	5	Sequence 1 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29465	ALLRLI	6	Sequence 2 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29466	ALLR	4	Sequence 3 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29467	LLRL	4	Sequence 4 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29468	LRLLA	5	Sequence 5 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29469	MDTLTQKLTVLIAVLELLVALLRLIDLLK	29	Sequence 6 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29470	MQKLTVLIAVLELLVALLRLIDLLK	25	Sequence 7 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29471	MVLIAVLELLVALLRLIDLLK	21	Sequence 8 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29472	MLELLVALLRLIDLLK	16	Sequence 9 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29473	MDTLTQKLTVLIAVLELLVALLRL	24	Sequence 10 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29474	MDTLTQKLTVLIAVLELLV	19	Sequence 11 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29475	MDTLTQKLTVLIAVLELLVIDLLK	24	Sequence 12 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1##JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29476	LELLVALLRL	10	Sequence 13 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1##JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29477	VALLRL	6	Sequence 14 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29478	ALLKL	5	Sequence 15 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29479	ALLHL	5	Sequence 16 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29480	ALLRA	5	Sequence 17 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29481	ALLRI	5	Sequence 18 from Patent JP 2020152640 A	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	JP 2020152640 A	Patent Application	2020##9##24	WO 2019/009426 A1,JP 2020152640 A	Antibacterial or Antifungal Peptides and Antibacterial or Antifungal Drugs	To provide low molecular weight peptides having a potent antibacterial or antifungal activity not affected by salt concentrations and extremely low toxicity to eukaryotic cells, and antibacterial or antifungal drugs using the same.SOLUTION: A peptide of the following (a), (b) or (c), or a derivative or salt thereof is provided: (a) a peptide comprising a specific amino acid sequence; (b) a peptide comprising the specific amino acid sequence but with deletion, substitution or addition of one or more amino acids therein and having an antibacterial or antifungal activity; (c) a peptide comprising an amino acid sequence having 80% or more identity to the specific amino acid sequence and having an antibacterial or antifungal activity.SELECTED DRAWING: None
DRAMP29482	CIGAVLKVLTTGLPALISWIKRKRQQ 	27	Sequence 1 from Patent AU 2021100565A4	Synthetic construct	Antimicrobial	AU 2021/100565 A4	Limited Patent	2021##4##22		ACID-ACTIVATED CSP TARGETED ANTIMICROBIAL PEPTIDE AND PREPARATION AND APPLICATION THEREOF 	The present disclosure provides an acid-activated CSP targeted antimicrobial peptide, which is prepared from the reaction of 2,3-dimethylmaleic anhydride, antimicrobial peptide melittin, and 5 CSP target molecules. In addition, the present disclosure provides a preparation method and two applications of the acid-activated CSP targeted antimicrobial peptide. For the acid-activated CSP targeted antimicrobial peptide provided by the present disclosure, CSP target molecules can be utilized to enhance the selectivity of the antimicrobial peptide and the aggregation of the antimicrobial peptide on the surface of SM bacteria, meanwhile 2,3-dimethylmaleic anhydride 10 (DMMAn) is utilized to protect the amino groups so as to decrease the toxicity of the antimicrobial peptide melittin. When such a CSP targeted antimicrobial peptide gets into decayed tooth, it may be activated by acidic conditions in the microenvironment, thus exhibiting an antimicrobial activity. 15 FIG. 1 1/1
DRAMP29483	AAWKLLKALAKA	12	Sequence 1 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29484	LLWKLLKLLLK	11	Sequence 2 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29485	LLWKLLKKLLK	11	Sequence 3 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29486	LLWKLLKKL	9	Sequence 4 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29487	KLALKLLKLL	10	Sequence 5 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29488	KAAAKAAKAA	10	Sequence 6 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29489	KLLLKLLKLL	10	Sequence 7 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29490	KLLLKLLKKLL	11	Sequence 8 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29491	KLLKKLLKLL	10	Sequence 9 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29492	KWLLKLLKKL	10	Sequence 10 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29493	LKWLLKLLKLK	11	Sequence 11 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29494	AATKPKKAGAAP	12	Sequence 12 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29495	KPAKKQTKKKP	11	Sequence 13 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29496	KLLK	4	Sequence 14 from Patent US 20180141984	Synthetic construct	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29497	AATKPKKAGAGAAPKKPAKKQTKKKPAKKAGGKKKPKRAGAKKAKK	46	Sequence 15 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29498	AATAKKGAKKADAPAKPKKATKPKSPKKAAKKAGAKKGVKRAGKKGAKKTTKAKK	55	Sequence 16 from Patent US 20180141984	Crassostrea gigas	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29499	AATKPKKAGAEAAPKKPAKKQTKKKPAKKAGGKKKPKRAGAKKAKK	46	Sequence 17 from Patent US 20180141984	Haliotis discus	Antimicrobial	US 2018/0141984 A1	Patent Application	2018##5##24	US10077293B2,KR101899552B1,KR20180056226A,WO2018092955A1,US20180141984A1	ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME	The present disclosure relates to an antimicrobial peptide analogue derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
DRAMP29500	NKVKEWIKYLKSLFS	15	Sequence 1 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 23 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29501	NKVKEWWKWLKSLFS	15	Sequence 2 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 24 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29502	NKVKEWIKYLKSLFK	15	Sequence 3 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 25 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29503	NKVKEWIKYLKSKFS	15	Sequence 4 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 26 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29504	NKVKEWWKWLKSLFK	15	Sequence 5 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 27 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29505	NKVKEWIKYLKSKFK	15	Sequence 6 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 28 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29506	NKVKEWWKWLKSL	13	Sequence 7 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 29 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29507	NKVKEWIKYLKKL	13	Sequence 8 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 30 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29508	NKVKEWWKWLKKL	13	Sequence 9 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 31 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29509	NKVKEWWKWLK	11	Sequence 10 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 32 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29510	NTVKETIKYLKSLFSHAFEVVKT	23	Sequence 11 from Patent US 10150795	Synthetic construct	Antimicrobial, Antibacterial	US 10150795 B2	Granted Patent	2018##12##11	JP6820251B2,JP2019523211A,US10150795B2,US20180170965A1,KR101847051B1,KR20170122026A,WO2017188498A1	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same	An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (−) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 33 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
DRAMP29511	KKIIKKIWKW	10	Sequence 1 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 10, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29512	KKIWKKWIKI	10	Sequence 2 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 11, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29513	WIKKIWKKIK	10	Sequence 3 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 12, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29514	RRIIRRIWRW	10	Sequence 4 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 13, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29515	RRIWRRWIRI	10	Sequence 5 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 14, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29516	WIRRIWRRIR	10	Sequence 6 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 15, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29517	KKIIKKIIKKIWKW	14	Sequence 7 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 16, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29518	KKIWKKWIKKIIKI	14	Sequence 8 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 17, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29519	WIKKIWKKIIKKIK	14	Sequence 9 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 18, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29520	WIKKIWKKIIKEIK	14	Sequence 10 from Patent KR 101983679	Synthetic construct	Antimicrobial, Antifungal	KR 101983679 B1	Granted Patent	2019##5##31	KR20180117258A	Alpha-helical peptide having antimicrobial actvity against drug-resistant bacteria and biofilm and antimicrobial composition comprising the s	The present invention relates to an alpha-helical peptide having antimicrobial activity against drug-resistant bacteria and an antimicrobial composition containing the same. More particularly, the present invention relates to an alpha-helical peptide having an antifungal activity, 1, 2, 3, 4, 5, 6, 7, 8 or 9 synthesized in an amphipathic structure existing on the surface having different hydrophilicity and hydrophobicity by using as a hydrophobic amino acid a novel antimicrobial active peptide , Lysine and arginine as the cationic amino acids of SEQ ID NO: 19, isoleucine and tryptophan as hydrophobic amino acids, and glutamic acid as an anionic amino acid, and a new antibacterial composition synthesized with an amphipathic structure having hydrophilic and hydrophobic faces Active peptides and the compounds containing them It relates to compositions for. Since the antimicrobial active peptide of the present invention has no cytotoxicity and exhibits excellent antimicrobial activity, it can be effec
DRAMP29521	GLRRLLRKIRGRWK	14	Sequence 1 from Patent KR 101838208	Synthetic construct	Antimicrobial, Antiinflammatory	KR 101838208 B1	Granted Patent	2018##3##13	KR20160128904A	Antimicrobial peptide with improved specificity to gram-negative pathogen and antimicrobial composition comprising the same	The present invention relates to a novel antimicrobial peptide and an antimicrobial composition containing the antimicrobial peptide. More particularly, the present invention relates to an antimicrobial peptide having an antimicrobial activity and an antiinflammatory activity with enhanced specificity against gram-negative bacteria and an antimicrobial composition containing the same . The antimicrobial peptide according to the present invention exhibits high specificity and low cytotoxicity against Gram-negative bacteria and has excellent anti-inflammatory and antibacterial activity by inactivating LPS by binding to LPS acting as endotoxin, It can be usefully utilized as a composition for antibiosis specific for a pathogen.
DRAMP29522	RKVRGPP	7	Sequence 2 from Patent KR 101838208	Synthetic construct	Antimicrobial, Antiinflammatory	KR 101838208 B1	Granted Patent	2018##3##13	KR20160128904A	Antimicrobial peptide with improved specificity to gram-negative pathogen and antimicrobial composition comprising the same	The present invention relates to a novel antimicrobial peptide and an antimicrobial composition containing the antimicrobial peptide. More particularly, the present invention relates to an antimicrobial peptide having an antimicrobial activity and an antiinflammatory activity with enhanced specificity against gram-negative bacteria and an antimicrobial composition containing the same . The antimicrobial peptide according to the present invention exhibits high specificity and low cytotoxicity against Gram-negative bacteria and has excellent anti-inflammatory and antibacterial activity by inactivating LPS by binding to LPS acting as endotoxin, It can be usefully utilized as a composition for antibiosis specific for a pathogen.
DRAMP29523	NIKISGKWKAQKRFLK	16	Sequence 3 from Patent KR 101838208	Synthetic construct	Antimicrobial, Antiinflammatory	KR 101838208 B1	Granted Patent	2018##3##13	KR20160128904A	Antimicrobial peptide with improved specificity to gram-negative pathogen and antimicrobial composition comprising the same	The present invention relates to a novel antimicrobial peptide and an antimicrobial composition containing the antimicrobial peptide. More particularly, the present invention relates to an antimicrobial peptide having an antimicrobial activity and an antiinflammatory activity with enhanced specificity against gram-negative bacteria and an antimicrobial composition containing the same . The antimicrobial peptide according to the present invention exhibits high specificity and low cytotoxicity against Gram-negative bacteria and has excellent anti-inflammatory and antibacterial activity by inactivating LPS by binding to LPS acting as endotoxin, It can be usefully utilized as a composition for antibiosis specific for a pathogen.
DRAMP29524	RLLRPLLQLLKQKLR	15	Sequence 4 from Patent KR 101838208	Synthetic construct	Antimicrobial, Antiinflammatory	KR 101838208 B1	Granted Patent	2018##3##13	KR20160128904A	Antimicrobial peptide with improved specificity to gram-negative pathogen and antimicrobial composition comprising the same	The present invention relates to a novel antimicrobial peptide and an antimicrobial composition containing the antimicrobial peptide. More particularly, the present invention relates to an antimicrobial peptide having an antimicrobial activity and an antiinflammatory activity with enhanced specificity against gram-negative bacteria and an antimicrobial composition containing the same . The antimicrobial peptide according to the present invention exhibits high specificity and low cytotoxicity against Gram-negative bacteria and has excellent anti-inflammatory and antibacterial activity by inactivating LPS by binding to LPS acting as endotoxin, It can be usefully utilized as a composition for antibiosis specific for a pathogen.
DRAMP29525	WNLLRQAQEKFGKDKSP	17	Sequence 1 from Patent KR 20200056194	Homo sapiens	Antimicrobial	KR 20200056194 A	Patent Application	2020##5##22	KR102146468B1	Antimicrobial peptide with increased antimicrobial activity and antimicrobial composition comprising the same as effective component	The present invention relates to an antimicrobial peptide having an increased antimicrobial activity, a gene coding the antimicrobial peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, a method for producing the antimicrobial peptide by transforming the host cell with the recombinant vector, and an antimicrobial composition comprising the antimicrobial peptide with increased antimicrobial activity as an active ingredient.
DRAMP29526	WNLLRRAQEKFGKDKSK	17	Sequence 2 from Patent KR 20200056194	Synthetic construct	Antimicrobial	KR 20200056194 A	Patent Application	2020##5##22	KR102146468B1	Antimicrobial peptide with increased antimicrobial activity and antimicrobial composition comprising the same as effective component	The present invention relates to an antimicrobial peptide having an increased antimicrobial activity, a gene coding the antimicrobial peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, a method for producing the antimicrobial peptide by transforming the host cell with the recombinant vector, and an antimicrobial composition comprising the antimicrobial peptide with increased antimicrobial activity as an active ingredient.
DRAMP29527	WNLLRRAQEKFGKDKSP	17	Sequence 3 from Patent KR 20200056194	Synthetic construct	Antimicrobial	KR 20200056194 A	Patent Application	2020##5##22	KR102146468B1	Antimicrobial peptide with increased antimicrobial activity and antimicrobial composition comprising the same as effective component	The present invention relates to an antimicrobial peptide having an increased antimicrobial activity, a gene coding the antimicrobial peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, a method for producing the antimicrobial peptide by transforming the host cell with the recombinant vector, and an antimicrobial composition comprising the antimicrobial peptide with increased antimicrobial activity as an active ingredient.
DRAMP29528	WNLLRQAQEKFGKDKSK	17	Sequence 4 from Patent KR 20200056194	Synthetic construct	Antimicrobial	KR 20200056194 A	Patent Application	2020##5##22	KR102146468B1	Antimicrobial peptide with increased antimicrobial activity and antimicrobial composition comprising the same as effective component	The present invention relates to an antimicrobial peptide having an increased antimicrobial activity, a gene coding the antimicrobial peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, a method for producing the antimicrobial peptide by transforming the host cell with the recombinant vector, and an antimicrobial composition comprising the antimicrobial peptide with increased antimicrobial activity as an active ingredient.
DRAMP29529	WKLLSKAQEKFGKNKSR	17	Sequence 5 from Patent KR 20200056194	Bos taurus	Antimicrobial	KR 20200056194 A	Patent Application	2020##5##22	KR102146468B1	Antimicrobial peptide with increased antimicrobial activity and antimicrobial composition comprising the same as effective component	The present invention relates to an antimicrobial peptide having an increased antimicrobial activity, a gene coding the antimicrobial peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, a method for producing the antimicrobial peptide by transforming the host cell with the recombinant vector, and an antimicrobial composition comprising the antimicrobial peptide with increased antimicrobial activity as an active ingredient.
DRAMP29530	SCSSLTTLRPCG  	12	Sequence 1 from Patent KR 20190019309	Synthetic construct	Antimicrobial	KR 20190019309 A	Patent Application	2019##2##27	KR101977800B1	Pseudomonas specific antimicrobial peptide and antimicrobial composition comprising the same	The present invention relates to an antimicrobial peptide specific to a Pseudomonas sp. strain and an antimicrobial composition containing the same. The antimicrobial peptide according to the present invention has a specific antimicrobial effect on the Pseudomonas sp. strain, thus can be utilized as a pharmaceutical composition for antimicrobial use, a food preservative, a cosmetic additive and a feed additive in medicine, cosmetics and food area. In addition, the antimicrobial peptide can provide a substitute for conventional antibiotics and a method of using the antibiotic peptide as a therapeutic agent for new infection.
DRAMP29531	SQRKLAAKLTSK	12	Sequence 2 from Patent KR 20190019309	Synthetic construct	Antimicrobial	KR 20190019309 A	Patent Application	2019##2##27	KR101977800B1	Pseudomonas specific antimicrobial peptide and antimicrobial composition comprising the same	The present invention relates to an antimicrobial peptide specific to a Pseudomonas sp. strain and an antimicrobial composition containing the same. The antimicrobial peptide according to the present invention has a specific antimicrobial effect on the Pseudomonas sp. strain, thus can be utilized as a pharmaceutical composition for antimicrobial use, a food preservative, a cosmetic additive and a feed additive in medicine, cosmetics and food area. In addition, the antimicrobial peptide can provide a substitute for conventional antibiotics and a method of using the antibiotic peptide as a therapeutic agent for new infection.
DRAMP29532	VILTGPEAEYFW	12	Sequence 3 from Patent KR 20190019309	Synthetic construct	Antimicrobial	KR 20190019309 A	Patent Application	2019##2##27	KR101977800B1	Pseudomonas specific antimicrobial peptide and antimicrobial composition comprising the same	The present invention relates to an antimicrobial peptide specific to a Pseudomonas sp. strain and an antimicrobial composition containing the same. The antimicrobial peptide according to the present invention has a specific antimicrobial effect on the Pseudomonas sp. strain, thus can be utilized as a pharmaceutical composition for antimicrobial use, a food preservative, a cosmetic additive and a feed additive in medicine, cosmetics and food area. In addition, the antimicrobial peptide can provide a substitute for conventional antibiotics and a method of using the antibiotic peptide as a therapeutic agent for new infection.
DRAMP29533	RLLRPLLQLLKQKLR	15	Sequence 4 from Patent KR 20190019309	Synthetic construct	Antimicrobial	KR 20190019309 A	Patent Application	2019##2##27	KR101977800B1	Pseudomonas specific antimicrobial peptide and antimicrobial composition comprising the same	The present invention relates to an antimicrobial peptide specific to a Pseudomonas sp. strain and an antimicrobial composition containing the same. The antimicrobial peptide according to the present invention has a specific antimicrobial effect on the Pseudomonas sp. strain, thus can be utilized as a pharmaceutical composition for antimicrobial use, a food preservative, a cosmetic additive and a feed additive in medicine, cosmetics and food area. In addition, the antimicrobial peptide can provide a substitute for conventional antibiotics and a method of using the antibiotic peptide as a therapeutic agent for new infection.
DRAMP29534	RQGRTLYGFGG	11	Sequence 1 from Patent KR 20170022961	Octopus variabilis	Antimicrobial	KR 20170022961 A	Patent Application	2017##3##2	KR101720539B1	Antimicrobial peptide analogues Ov1-1, Ov1-2 derived from Octopus variabilis and antimicrobial composition containing the same	The present invention relates to antimicrobial peptide analogs Ov1-1 and Ov1-2 derived from a small octopus, and to an antimicrobial composition containing the same. The antimicrobial peptide analogs, according to the present invention, derive from the small octopus and are newly designed to have peptide with superior antimicrobial activity and enable commercialization. Namely, the number of amino acids was suitably designed to enable commercialization and the antimicrobial activity is excellently achieved at both inside and outside of a body, thereby solving a problem of remarkably reduced antimicrobial activity of parent peptide at the outside body of the small octopus. Furthermore, despite a synthesis process by the commercialization, the present invention solved a problem of reduced antimicrobial activity due to a structural change by the synthesis.
DRAMP29535	RLLRTLYRFLR  	11	Sequence 2 from Patent KR 20170022961	Synthetic construct	Antimicrobial	KR 20170022961 A	Patent Application	2017##3##2	KR101720539B1	Antimicrobial peptide analogues Ov1-1, Ov1-2 derived from Octopus variabilis and antimicrobial composition containing the same	The present invention relates to antimicrobial peptide analogs Ov1-1 and Ov1-2 derived from a small octopus, and to an antimicrobial composition containing the same. The antimicrobial peptide analogs, according to the present invention, derive from the small octopus and are newly designed to have peptide with superior antimicrobial activity and enable commercialization. Namely, the number of amino acids was suitably designed to enable commercialization and the antimicrobial activity is excellently achieved at both inside and outside of a body, thereby solving a problem of remarkably reduced antimicrobial activity of parent peptide at the outside body of the small octopus. Furthermore, despite a synthesis process by the commercialization, the present invention solved a problem of reduced antimicrobial activity due to a structural change by the synthesis.
DRAMP29536	LAKHAVKKALKAV	13	Sequence 3 from Patent KR 20170022961	Synthetic construct	Antimicrobial	KR 20170022961 A	Patent Application	2017##3##2	KR101720539B1	Antimicrobial peptide analogues Ov1-1, Ov1-2 derived from Octopus variabilis and antimicrobial composition containing the same	The present invention relates to antimicrobial peptide analogs Ov1-1 and Ov1-2 derived from a small octopus, and to an antimicrobial composition containing the same. The antimicrobial peptide analogs, according to the present invention, derive from the small octopus and are newly designed to have peptide with superior antimicrobial activity and enable commercialization. Namely, the number of amino acids was suitably designed to enable commercialization and the antimicrobial activity is excellently achieved at both inside and outside of a body, thereby solving a problem of remarkably reduced antimicrobial activity of parent peptide at the outside body of the small octopus. Furthermore, despite a synthesis process by the commercialization, the present invention solved a problem of reduced antimicrobial activity due to a structural change by the synthesis.
DRAMP29537	RQGRTLYGFGG	11	Sequence 4 from Patent KR 20170022961	Synthetic construct	Antimicrobial	KR 20170022961 A	Patent Application	2017##3##2	KR101720539B1	Antimicrobial peptide analogues Ov1-1, Ov1-2 derived from Octopus variabilis and antimicrobial composition containing the same	The present invention relates to antimicrobial peptide analogs Ov1-1 and Ov1-2 derived from a small octopus, and to an antimicrobial composition containing the same. The antimicrobial peptide analogs, according to the present invention, derive from the small octopus and are newly designed to have peptide with superior antimicrobial activity and enable commercialization. Namely, the number of amino acids was suitably designed to enable commercialization and the antimicrobial activity is excellently achieved at both inside and outside of a body, thereby solving a problem of remarkably reduced antimicrobial activity of parent peptide at the outside body of the small octopus. Furthermore, despite a synthesis process by the commercialization, the present invention solved a problem of reduced antimicrobial activity due to a structural change by the synthesis.
DRAMP29538	LPGELAKHAVSEGTKAVTKYTSSK	24	Sequence 5 from Patent KR 20170022961	Octopus variabilis	Antimicrobial	KR 20170022961 A	Patent Application	2017##3##2	KR101720539B1	Antimicrobial peptide analogues Ov1-1, Ov1-2 derived from Octopus variabilis and antimicrobial composition containing the same	The present invention relates to antimicrobial peptide analogs Ov1-1 and Ov1-2 derived from a small octopus, and to an antimicrobial composition containing the same. The antimicrobial peptide analogs, according to the present invention, derive from the small octopus and are newly designed to have peptide with superior antimicrobial activity and enable commercialization. Namely, the number of amino acids was suitably designed to enable commercialization and the antimicrobial activity is excellently achieved at both inside and outside of a body, thereby solving a problem of remarkably reduced antimicrobial activity of parent peptide at the outside body of the small octopus. Furthermore, despite a synthesis process by the commercialization, the present invention solved a problem of reduced antimicrobial activity due to a structural change by the synthesis.
DRAMP29539	HTSRLKARKHSKRRVR	16	Sequence 1 from Patent DE 102018113988	Synthetic construct	Antimicrobial	DE 102018113988 A1	Patent Application	2019##12##12		Antimicrobial CLEC3A peptide fragment	The present invention relates to an antimicrobial peptide fragment of C-type lectin domain family 3 member A (CLEC3A) or an antimicrobial variant thereof having one or more conservative substitutions, a pharmaceutical composition comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof, the antimicrobial peptide fragment and / or an antimicrobial variant thereof for use as an antimicrobial agent, the use of the antimicrobial peptide fragment and / or an antimicrobial variant thereof for coating or incorporating in a solid, a solid coated with the antimicrobial peptide fragment and / or an antimicrobial variant thereof or in which the antimicrobial peptide fragment and / or an antimicrobial variant thereof is incorporated, and a kit comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof.
DRAMP29540	HTSRLKARKHSKRRVRDKDGDLKTQIEKLWTEVNALKE	38	Sequence 2 from Patent DE 102018113988	Synthetic construct	Antimicrobial	DE 102018113988 A1	Patent Application	2019##12##12		Antimicrobial CLEC3A peptide fragment	The present invention relates to an antimicrobial peptide fragment of C-type lectin domain family 3 member A (CLEC3A) or an antimicrobial variant thereof having one or more conservative substitutions, a pharmaceutical composition comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof, the antimicrobial peptide fragment and / or an antimicrobial variant thereof for use as an antimicrobial agent, the use of the antimicrobial peptide fragment and / or an antimicrobial variant thereof for coating or incorporating in a solid, a solid coated with the antimicrobial peptide fragment and / or an antimicrobial variant thereof or in which the antimicrobial peptide fragment and / or an antimicrobial variant thereof is incorporated, and a kit comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof.
DRAMP29541	HTSRLKARKHSKRRVRDKDGDLKTQIEKLWTEVNALKEIQALQTVCL	47	Sequence 3 from Patent DE 102018113988	Synthetic construct	Antimicrobial	DE 102018113988 A1	Patent Application	2019##12##12		Antimicrobial CLEC3A peptide fragment	The present invention relates to an antimicrobial peptide fragment of C-type lectin domain family 3 member A (CLEC3A) or an antimicrobial variant thereof having one or more conservative substitutions, a pharmaceutical composition comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof, the antimicrobial peptide fragment and / or an antimicrobial variant thereof for use as an antimicrobial agent, the use of the antimicrobial peptide fragment and / or an antimicrobial variant thereof for coating or incorporating in a solid, a solid coated with the antimicrobial peptide fragment and / or an antimicrobial variant thereof or in which the antimicrobial peptide fragment and / or an antimicrobial variant thereof is incorporated, and a kit comprising the antimicrobial peptide fragment and / or an antimicrobial variant thereof.
DRAMP29542	GIHDILKYGKPS	12	Sequence 1 from Patent WO 2017048028	Myxine glutinosa	Antimicrobial	WO 2017/048028 A1	Patent Application	2017##5##11	US10919935B2,US20200231628A1,KR101734064B1,KR20170032689A	Novel Antimicrobial Peptide Derived From Myxinidin Peptide, and Use Thereof	The present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a use thereof. Specifically, the present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a novel antimicrobial peptide synthesized from the mushroom of a hagfish epidermis, Peptides (mycidine 2 and mycinidin 3) have excellent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and antibiotic-resistant bacteria, and have inhibitory activity against biofilms. Toxicity, the novel antimicrobial peptide of the present invention can be effectively used as an active ingredient of antibiotics for antimicrobial use, cosmetic composition, food additive, feed additive and biocidal pesticide.
DRAMP29543	GIHHILKYGKPS	12	Sequence 2 from Patent WO 2017048028	Synthetic construct	Antimicrobial	WO 2017/048028 A1	Patent Application	2017##5##11	US10919935B2,US20200231628A1,KR101734064B1,KR20170032689A	Novel Antimicrobial Peptide Derived From Myxinidin Peptide, and Use Thereof	The present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a use thereof. Specifically, the present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a novel antimicrobial peptide synthesized from the mushroom of a hagfish epidermis, Peptides (mycidine 2 and mycinidin 3) have excellent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and antibiotic-resistant bacteria, and have inhibitory activity against biofilms. Toxicity, the novel antimicrobial peptide of the present invention can be effectively used as an active ingredient of antibiotics for antimicrobial use, cosmetic composition, food additive, feed additive and biocidal pesticide.
DRAMP29544	KIKWILKYWKWS	12	Sequence 3 from Patent WO 2017048028	Synthetic construct	Antimicrobial,Anti-inflammatory 	WO 2017/048028 A1	Patent Application	2017##5##11	US10919935B2,US20200231628A1,KR101734064B1,KR20170032689A	Novel Antimicrobial Peptide Derived From Myxinidin Peptide, and Use Thereof	The present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a use thereof. Specifically, the present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a novel antimicrobial peptide synthesized from the mushroom of a hagfish epidermis, Peptides (mycidine 2 and mycinidin 3) have excellent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and antibiotic-resistant bacteria, and have inhibitory activity against biofilms. Toxicity, the novel antimicrobial peptide of the present invention can be effectively used as an active ingredient of antibiotics for antimicrobial use, cosmetic composition, food additive, feed additive and biocidal pesticide.
DRAMP29545	RIRWILRYWRWS	12	Sequence 4 from Patent WO 2017048028	Synthetic construct	Antimicrobial,Anti-inflammatory 	WO 2017/048028 A1	Patent Application	2017##5##11	US10919935B2,US20200231628A1,KR101734064B1,KR20170032689A	Novel Antimicrobial Peptide Derived From Myxinidin Peptide, and Use Thereof	The present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a use thereof. Specifically, the present invention relates to a novel antimicrobial peptide derived from a mycidine peptide and a novel antimicrobial peptide synthesized from the mushroom of a hagfish epidermis, Peptides (mycidine 2 and mycinidin 3) have excellent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and antibiotic-resistant bacteria, and have inhibitory activity against biofilms. Toxicity, the novel antimicrobial peptide of the present invention can be effectively used as an active ingredient of antibiotics for antimicrobial use, cosmetic composition, food additive, feed additive and biocidal pesticide.
DRAMP29546	LGPQLNKGCATCSIGAACLVDGPIPDEIAG	30	Sequence 1 from Patent KR 20170115824	Bacillus subtilis SN7	Antimicrobial	KR 20170115824 A	Patent Application	2017##10##18	KR101865461B1	A ANTIMICROBIAL PEPTIDE AND A ANTIMICROBIAL COMPOSITION CONTAINING THE SAME	The invention of the antimicrobial composition, and specifically food poisoning organisms as microorganisms to, incorporated in soy sauce production process organisms own bar sealer three cereus (Bacillus cereus) to cause food poisoning containing a peptide and this active ingredient having antimicrobial activity A novel Bacillus subtilis SN7 strain ( Bacillus sp .) With excellent antimicrobial activity and having an accession number KACC 91935P which maintains antimicrobial activity in a temperature and pH range that can be varied during the production of intestinal products Antimicrobial composition comprising a novel peptide, said peptide having an antimicrobial activity as the active ingredient to produce a subtilis SN7), antimicrobial food comprising a pharmaceutical composition or the peptides for antibacterial containing the peptide as an active ingredient as an active ingredient ≪ / RTI >
DRAMP29547	GILGKLWEGVKSIF	14	Sequence 1 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29548	ILGKLWEGVKSI	12	Sequence 2 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29549	ILKKLWEGVKSI	12	Sequence 3 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29550	ILKKLLEGVKSI	12	Sequence 4 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29551	ILKKLLKGVKSI	12	Sequence 5 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29552	ILKKLLKKVKSI	12	Sequence 6 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29553	ILKKLLKKVKKI	12	Sequence 7 from Patent KR 20190033837	Synthetic construct	Antimicrobial	KR 20190033837 A	Patent Application	2019##4##1	US11117931B2,US20200216497A1,KR101998106B1,WO2019059709A3,WO2019059709A2	Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof	The present invention relates to an antimicrobial peptide in which i) first and fourteenth amino acids are deleted, ii) fourth and eighth amino acids are substituted with lysine (K), iii) seventh amino acid is substituted with leucine (L), iv) ninth amino acid is glycine (G) or is substituted with lysine (K), and v) twelfth amino acid is serine (S) or is substituted with lysine (K) in an Hp1404 peptide consisting of the amino acid sequence of SEQ ID NO: 1, and to uses thereof. The antimicrobial peptide of the present invention shows excellent antimicrobial activity against gram positive bacteria, gram negative bacteria, and antibiotic resistant bacteria, and has low cytotoxicity against cells derived from mice and human beings, thereby being useful as an active ingredient of antimicrobial antibiotics, cosmetic compositions, food additives, feed additives, and biopesticides.
DRAMP29554	MNFGKILFFVMACLAALSLTTASPRWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVKG	62	Sequence 1 from Patent KR 101099558	Synthetic construct	Antimicrobial	KR 101099558 B1	Granted Patent	2011##12##28	KR20100100246A	ANTIMICROBIAL PEPTIDE GENE AND ANTIMICROBIAL PEPTIDE ISOLATED FROM LARVAE OF SWALLOWTAIL BUTTERFLY	The present invention relates to a gene and an antimicrobial peptide of a new antimicrobial peptide isolated by inducing an immune response from a larva butterfly belonging to Lepidoptera insects.Swallowtail butterfly, larva, antibacterial peptide, antibiotic The antimicrobial peptide of the present invention exhibits antimicrobial activity against various bacteria, such as gram-negative bacteria and gram-positive bacteria, and has antimicrobial activity against resistant bacteria as well as fungi that cause candidiasis, and has no cytotoxicity, and thus is useful as a natural antibiotic for preventing and treating bacterial diseases. Can be used.
DRAMP29555	RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVKG	38	Sequence 2 from Patent KR 101099558	Synthetic construct	Antimicrobial	KR 101099558 B1	Granted Patent	2011##12##28	KR20100100246A	ANTIMICROBIAL PEPTIDE GENE AND ANTIMICROBIAL PEPTIDE ISOLATED FROM LARVAE OF SWALLOWTAIL BUTTERFLY	The present invention relates to a gene and an antimicrobial peptide of a new antimicrobial peptide isolated by inducing an immune response from a larva butterfly belonging to Lepidoptera insects. The antimicrobial peptide of the present invention exhibits antimicrobial activity against various bacteria, such as gram-negative bacteria and gram-positive bacteria, and has antimicrobial activity against resistant bacteria as well as fungi that cause candidiasis, and has no cytotoxicity, and thus is useful as a natural antibiotic for preventing and treating bacterial diseases. Can be used.
DRAMP29556	YEPGQVRCCLMPA	13	Sequence 1 from Patent KR 101976573	Okamejei kenojei	Antimicrobial	KR 101976573 B1	Granted Patent	2019##5##9	US11077170B2,US20200254057A1,WO2019059572A3,KR20190033836A,WO2019059572A2	Novel antimicrobial peptide from Skate skin and uses thereof	The present invention relates to a novel antimicrobial peptide derived from a skipjacker and a use thereof. Specifically, the skimmer-derived antimicrobial peptide comprising the amino acid sequence of SEQ ID NO: 1 has an excellent antimicrobial effect against gram-positive and gram- , The novel antimicrobial peptide of the present invention can be effectively used as an active ingredient of antibiotics for antimicrobial use, cosmetic composition, food additive, feed additive and biocidal pesticide.
DRAMP29557	KETWWETWWTEWSQPKKKPKV	21	Sequence 1 from Patent KR 100811745	Synthetic construct	Antimicrobial	KR 100811745 B1	Granted Patent	2008##3##11	KR20080004997A	1 A novel antimicrobial peptide Pep-1-K designed from the cell-penetrating peptide Pep-1 and uses thereof	The present invention relates to a novel antimicrobial peptide Pep-1-K using Pep-1, which is a cell permeable peptide, and its use. Specifically, the second, sixth and eleventh amino acids of Pep-1, known as cell permeable peptide, The present invention relates to an antimicrobial peptide Pep-1-K prepared by replacing glutamic acid (Glu) with lysine (Lys) and a use thereof. Pep-1-K of the present invention not only exhibits strong antimicrobial activity in various strains, especially gram-positive bacteria, gram-negative bacteria and strains resistant to antibiotics, but also does not show any hemolytic activity in human erythrocyte cells. It can be usefully used as a preservative and cosmetic additive.Cell Permeable Peptides, Pep-1, Pep-1-K
DRAMP29558	KETWWKTWWTKWSQPKKKPKV	21	Sequence 2 from Patent KR 100811745	Synthetic construct	Antimicrobial	KR 100811745 B1	Granted Patent	2008##3##11	KR20080004997A	1 A novel antimicrobial peptide Pep-1-K designed from the cell-penetrating peptide Pep-1 and uses thereof	The present invention relates to a novel antimicrobial peptide Pep-1-K using Pep-1, which is a cell permeable peptide, and its use. Specifically, the second, sixth and eleventh amino acids of Pep-1, known as cell permeable peptide, The present invention relates to an antimicrobial peptide Pep-1-K prepared by replacing glutamic acid (Glu) with lysine (Lys) and a use thereof. Pep-1-K of the present invention not only exhibits strong antimicrobial activity in various strains, especially gram-positive bacteria, gram-negative bacteria and strains resistant to antibiotics, but also does not show any hemolytic activity in human erythrocyte cells. It can be usefully used as a preservative and cosmetic additive.Cell Permeable Peptides, Pep-1, Pep-1-K
DRAMP29559	RRRPRPPTLPRPRPPPFFPPRLPPRIGFPPRFPPRFP	37	Sequence 1 from Patent JP 2007314432	Synthetic construct	Antimicrobial	JP 2007314432 A	Patent Application	2007##12##6		NEW ANTIMICROBIAL PEPTIDE AND SERUM-FREE MEDIUM CONTAINING THE ANTIMICROBIAL PEPTIDE AS ACTIVE INGREDIENT	<P>PROBLEM TO BE SOLVED: To obtain a new peptide that performs high antibacterial effect, cell growth promoting action and bone differentiation inducing action so as to be a substitute for an autologous serum or bovine fetal calf serum and is contained as an active ingredient in a serum-free medium. <P>SOLUTION: The antimicrobial peptide comprises a specific amino acid sequence. The antifungal agent comprises the peptide. The composition having sterilization and/or growth inhibitory action contains an effective amount of the peptide as an active ingredient. The medical device and apparatus contain the peptide and have antimicrobial property. The method for sterilization and/or growth inhibition of fungi comprises administration of the peptide. The cell growth promoting factor comprises the antimicrobial peptide. The bone differentiation inducing factor comprises the antimicrobial peptide. The serum-free medium comprises the antimicrobial peptide. <P>COPYRIGHT: (C)2008,JPO&INPIT
DRAMP29560	LLWIALRKK	9	Sequence 1 from Patent WO 2020013527	Synthetic construct	Antimicrobial	WO 2020/013527 A1	Patent Application	2020##1##16		ANTIMICROBIAL PEPTIDE DERIVATIVE HAVING ENHANCED ANTIMICROBIAL ACTIVITY, HEMOLYTIC STABILITY AND STABILITY IN BLOOD SERUM	The present invention relates to an antimicrobial peptide derivative having enhanced antimicrobial activity, hemolytic stability and stability in blood serum. More specifically, the present invention relates to an antimicrobial peptide derivative, having enhanced antimicrobial activity, hemolytic stability and stability in blood serum, on the basis of Coprisin-induced CopW peptide (LLWIALRKK-NH₂).
DRAMP29561	HRRSVAHQEEASLHVKTDELPSPDTVREQL	30	Sequence 1 from Patent JP 2008106057	Ascaris suum	Antimicrobial	JP 2008106057 A	Patent Application	2008##5##8	JP5158538B2	ANTIMICROBIAL ACTIVITY-ENHANCING PEPTIDE AND ANTIMICROBIAL AGENT CONTAINING THE SAME	<P>PROBLEM TO BE SOLVED: To provide an anti-microbial activity-enhancing peptide capable of enhancing the antimicrobial activity of a peptide-based antimicrobial substance but having almost no antimicrobial activity as itself. <P>SOLUTION: This anti-microbial activity-enhancing peptide prepared by modifying the amino acid sequence of precursor region peptide of an antimicrobial peptide precursor is provided by converting carboxyl group which is an acidic amino acid residue contained in the precursor region peptide, to amide group. <P>COPYRIGHT: (C)2008,JPO&INPIT
DRAMP29562	HRRSVAHQQQASLHVKTNQLPSPNTVRQQL	30	Sequence 2 from Patent JP 2008106057	Synthetic construct	Antimicrobial	JP 2008106057 A	Patent Application	2008##5##8	JP5158538B2	ANTIMICROBIAL ACTIVITY-ENHANCING PEPTIDE AND ANTIMICROBIAL AGENT CONTAINING THE SAME	<P>PROBLEM TO BE SOLVED: To provide an anti-microbial activity-enhancing peptide capable of enhancing the antimicrobial activity of a peptide-based antimicrobial substance but having almost no antimicrobial activity as itself. <P>SOLUTION: This anti-microbial activity-enhancing peptide prepared by modifying the amino acid sequence of precursor region peptide of an antimicrobial peptide precursor is provided by converting carboxyl group which is an acidic amino acid residue contained in the precursor region peptide, to amide group. <P>COPYRIGHT: (C)2008,JPO&INPIT
DRAMP29563	WLPPAGLLGRCGRWFRPWLLWLQSGAQYKWLGNLFGLGPK	40	Sequence 1 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29564	YGXGV	5	Sequence 2	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29565	GKYYGNGVSCNKKGCSVDWGRAIGIIGNNSAANLATGGAAGWKSGGGASGRDIAMAIGTLSGQFVAGGIGAAAGGVAGGAIYDYASTHKPNPAMSPSGLG	135	Sequence 3 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29566	MISSHQKTLTDKELALISGGKTHYPTNAWKSLWKGFWESLRYTDGF	46	Sequence 4 from US 20230416797	Lactobacillus acidophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29567	MISMISSHQKTLTDKELALISGGKTYYGTNGVHCTKKSLWGKVRLKNVIPGTLCRKQSLPIKQDLKILLGWATGAFGKTFH	81	Sequence 5 from US 20230416797	Lactobacillus acidophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29568	MDKKTKILFEVLYIICIIGPQFILFVTAKNNMYQLVGSFVGIVWFSYIFWYIFFKQHKKM	60	Sequence 6 from US 20230416797	Lactobacillus acidophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29569	MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACALGGAAIGGYLGYKSN	65	Sequence 7 from US 20230416797	Lactobacillus gasseri	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29570	MSWLNFLKYIAKYGKKAVSAAWKYKGKVLEWLNVGPTLEWVWQKLKKIAGL	51	Sequence 8 from US 20230416797	Staphylococcus aureus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29571	MTRSKKLNLREMKNVVGGTYYGNGVSCNKKGCSVDWGKAISIIGNNSAANLATGGAAGWKS	61	Sequence 9 from US 20230416797	Enterococcus avium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29572	MKKKLVICGIIGIGFTALGTNVEAATYYGNGLYCNKQKCWVDWNKASREIGKIIVNGWVQHGPWAPR	67	Sequence 10 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29573	MKEQNSFNLLQEVTESELDLILGAKGGSGVIHTISHEVIYNSWNFVFTCCS	51	Sequence 11 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29574	MKKKVLKHCVILGILGTCLAGIGTGIKVDAATYYGNGLYCNKEKCWVDWNQAKGEIGKIIVNGWVNHGPWAPRR	74	Sequence 12 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29575	MQKPEIISADLGLCAVNEFVALAAIPGGAATFAVCQMPNLDEIVSNAAYV	50	Sequence 13 from US 20230416797	Clostridium botulinum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29576	MMNATENQIFVETVSDQELEMLIGGADRGWIKTLTKDCPNVISSICAGTIITACKNCA	58	Sequence 14 from US 20230416797	Streptococcus equinus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29577	MHKVKKLNNQELQQIVGGYSSKDCLKDIGKGIGAGTVAGAAGGGLAAGLGAIPGAFVGAHFGVIGGSAACIGGLLGN	77	Sequence 15 from US 20230416797	Brochothrix campestris	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29578	MSKKQIMSNCISIALLIALIPNIYFIADKMGIQLAPAWYQDIVNWVSAGGTLTTGFAIIVGVTVPAWIAEAAAAFGIASA	80	Sequence 16 from US 20230416797	Butyrivibrio fibrisolvens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29579	MNKELNALTNPIDEKELEQILGGGNGVIKTISHECHMNTWQFIFTCCS	48	Sequence 17 from US 20230416797	Butyrivibrio fibrisolvens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29580	MNSVKELNVKEMKQLHGGVNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP	66	Sequence 18 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29581	MKSVKELNKKEMQQINGGAISYGNGVYCNKEKCWVNKAENKQAITGIVIGGWASSLAGMGH	61	Sequence 19 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29582	MNNVKELSIKEMQQVTGGDQMSDGVNYGKGSSLSKGGAKCGLGIVGGLATIPSGPLGWLAGAAGVINSCMK	71	Sequence 20 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29583	MLYELVAYGIAQGTAEKVVSLINAGLTVGSIISILGGVTVGLSGVFTAVKAAIAKQGIKKAIQL	64	Sequence 21 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29584	MENLQMLTEEELMEIEGGGWWNSWGKCVAGTIGGAGTGGLGGAAAGSAVPVIGTGIGGAIGGVSGGLTGAATFC	74	Sequence 22 from US 20230416797	Bacillus cereus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29585	MTASILQQSVVDADFRAALLENPAAFGASAAALPTPVEAQDQASLDFWTKDIAATEAFACRQSCSFGPFTFVCDGNTK	78	Sequence 23 from US 20230416797	Streptomyces griseovertic	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29586	MSLLALVAGTLGVSQSIATTVVSIVLTGSTLISIILGITAILSGGVDAILEIGWSAFVATVKKIVAERGKAAAIAW	76	Sequence 24 from US 20230416797	Geobacillus kaustophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29587	MKKIEKLTEKEMANIIGGKYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGTHKC	62	Sequence 25 from US 20230416797	Bacillus coagulans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29588	MRTLTLNELDSVSGGASGRDIAMAIGTLSGQFVAGGIGAAAGGVAGGAIYDYASTHKPNPAMSPSGLGGTIKQKPEGIPSEAWNYAAGRLCNWSPNNLSD	103	Sequence 26 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29589	MMNATENQIFVETVSDQELEMLIGGAGRGWIKTLTKDCPNVISSICAGTIITACKNCA	58	Sequence 27 from US 20230416797	Enterococcus columbae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29590	MNNVKELSMTELQTITGGARSYGNGVYCNNKKCWVNRGEATQSIIGGMISGWASGLAGM	59	Sequence 28 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29591	MRSEMTLTSTNSAEALAAQDFANTVLSAAAPGFHADCETPAMATPATPTVAQFVIQGSTICLVC	64	Sequence 29 from US 20230416797	Streptomyces albogriseolu	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29592	MVNSKDLRNPEFRKAQGLQFVDEVNEKELSSLAGSGDVHAQTTWPCATVGVSVALCPTTKCTSQC	65	Sequence 30 from US 20230416797	Bacillus halodurans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29593	MKNLKEGSYTAVNTDELKSINGGTKYYGNGVYCNSKKCWVDWGQASGCIGQTVVGGWLGGAIPGKC	66	Sequence 31 from US 20230416797	Carnobacterium divergens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29594	MIKREKNRTISSLGYEEISNHKLQEIQGGKGILGKLGVVQAGVDFVSGVWAGIKQSAKDHPNA	63	Sequence 32 from US 20230416797	Carnobacterium divergens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29595	MKKQILKGLVIVVCLSGATFFSTPQQASAAAPKITQKQKNCVNGQLGGMLAGALGGPGGVVLGGIGGAIAGGCFN	75	Sequence 33 from US 20230416797	Carnobacterium divergens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29596	MQTIKELNTMELQEIIGGENDHRMPYELNRPNNLSKGGAKCAAGILGAGLGAVGGGPGGFISAGISAVLGCM	72	Sequence 34 from US 20230416797	Enterococcus durans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29597	MQTIKELNTMELQKIIGGENDHRMPYELNRPNNLSKGGAKCAAGILGAGLGAVGGGPGGFISAGISAVLGCM	72	Sequence 35 from US 20230416797	Enterococcus durans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29598	MKQYKVLNEKEMKKPIGGESVFSKIGNAVGPAAYWILKGLGNMSDVNQADRINRKKH	57	Sequence 36 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29599	MGAIAKLVAKFGWPIVKKYYKQIMQFIGEGWAINKIIDWIKKHI	44	Sequence 37 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29600	MGAIAKLVAKFGWPFIKKFYKQIMQFIGQGWTIDQIEKWLKRH	43	Sequence 38 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29601	MLNKKLLENGVVNAVTIDELDAQFGGMSKRDCNLMKACCAGQAVTYAIHSLLNRLGGDSSDPAGCNDIVRKYCK	74	Sequence 39 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29602	MKHLKILSIKETQLIYGGTTHSGKYYGNGVYCTKNKCTVDWAKATTCIAGMSIGGFLGGAIPGKC	65	Sequence 40 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29603	MVKENKFSKIFILMALSFLGLALFSASLQFLPIAHMAKEFGIPAAVAGTVLNVVEAGGWVTTIVSILTAVGSGGLSLLAAAGRESIKAYLKKEIKKKGKR	105	Sequence 41 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29604	MQNVKELSTKEMKQIIGGENDHRMPNELNRPNNLSKGGAKCGAAIAGGLFGIPKGPLAWAAGLANVYSKCN	71	Sequence 42 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29605	MKKLTSKEMAQVVGGKYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS	58	Sequence 43 from US 20230416797	Enterococcus mundtii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29606	MLAKIKAMIKKFPNPYTLAAKLTTYEINWYKQQYGRYPWERPVA	44	Sequence 44 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29607	MRKKLFSLALIGIFGLVVTNFGTKVDAATRSYGNGVYCNNSKCWVNWGEAKENIAGIVISGWASGLAGMGH	71	Sequence 45 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29608	MNFLKNGIAKWMTGAELQAYKKKYGCLPWEKISC	34	Sequence 46 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29609	MKKKLVKGLVICGMIGIGFTALGTNVEAATYYGNGVYCNKQKCWVDWSRARSEIIDRGVKAYVNGFTKVLGGIGGR	76	Sequence 47 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29610	MKKEELVGMAKEDFLNVICENDNKLENSGAKCPWWNLSCHLGNDGKICTYSHECTAGCNA	60	Sequence 48 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29611	MTELNKRLQLKRDVSTENSLKKISNTDETHGGVTTSIPCTVMVSAAVCPTLVCSNKCGGRG	61	Sequence 49 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29612	MQNVKEVSVKEMKQIIGGSNDSLWYGVGQFMGKQANCITNHPVKHMIIPGYCLSKILG	58	Sequence 50 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29613	MKKYNELSKKELLQIQGGIAPIIVAGLGYLVKDAWDHSDQIISGFKKGWNGGRRK	55	Sequence 51 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29614	MENKKDLFDLEIKKDNMENNNELEAQSLGPAIKATRQVCPKATRFVTVSCKKSDCQ	56	Sequence 52 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29615	MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA	51	Sequence 53 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29616	MEAVKEKNDLFNLDVKVNAKESNDSGAEPRIASKFICTPGCAKTGSFNSYCC	52	Sequence 54 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29617	MNNSLFDLNLNKGVETQKSDLSPQSASVLKTSIKVSKKYCKGVTLTCGCNITGGK	55	Sequence 55 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29618	MEAVKEKNELFDLDVKVNAKESNDSGAEPRIASKFLCTPGCAKTGSFNSYCC	52	Sequence 56 from US 20230416797	Staphylococcus gallinarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29619	MENNNYTVLSDEELQKIDGGIGGALGNALNGLGTWANMMNGGGFVNQWQVYANKGKINQYRPY	63	Sequence 57 from US 20230416797	Lactococcus garvieae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29620	MFDLVATGMAAGVAKTIVNAVSAGMDIATALSLFSGAFTAAGGIMALIKKYAQKKLWKQLIAA	63	Sequence 58 from US 20230416797	Lactococcus garvieae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29621	MVTKYGRNLGLNKVELFAIWAVLVVALLLTTANIYWIADQFGIHLATGTARKLLDAMASGASLGTAFAAILGVTLPAWALAAAGALGATAA	91	Sequence 59 from US 20230416797	Lactobacillus gasseri	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29622	MKNFNTLSFETLANIVGGRNNWAANIGGVGGATVAGWALGNAVCGPACGFVGAHYVPIAWAGVTAATGGFGKIRK	75	Sequence 60 from US 20230416797	Lactobacillus gasseri	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29623	MSKLVKTLTISEISKAQNNGGKPAWCWYTLAMCGAGYDSGTCDYMYSHCFGIKHHSSGSSSYHC	64	Sequence 61 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29624	MKKKVLKHCVILGILGTCLAGIGTGIKVDAATYYGNGLYCNKEKCWVDWNQAKGEIGKIIVNGWVNHGPWAPRR	74	Sequence 62 from US 20230416797	Enterococcus hirae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29625	MKQFNYLSHKDLAVVVGGRNNWQTNVGGAVGSAMIGATVGGTICGPACAVAGAHYLPILWTAVTAATGGFGKIRK	75	Sequence 63 from US 20230416797	Lactobacillus johnsonii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29626	MKLNDKELSKIVGGNRWGDTVLSAASGAGTGIKACKSFGPWGMAICGVGGAAIGGYFGYTHN	62	Sequence 64 from US 20230416797	Lactobacillus johnsonii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29627	MNKNEIETQPVTWLEEVSDQNFDEDVFGACSTNTFSLSDYWGNNGAWCTLTHECMAWCK	59	Sequence 65 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29628	MKEKNMKKNDTIELQLGKYLEDDMIELAEGDESHGGTTPATPAISILSAYISTNTCPTTKCTRAC	65	Sequence 66 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29629	MKEQNSFNLLQEVTESELDLILGAKGGSGVIHTISHECNMNSWQFVFTCCS	51	Sequence 67 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29630	MAGFLKVVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVSKIKQILGIK	53	Sequence 68 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29631	MAGFLKVVQILAKYGSKAVQWAWANKGKILDWINAGQAIDWVVEKIKQILGIK	53	Sequence 69 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29632	MKQLNSEQLQNIIGGNRWTNAYSAALGCAVPGVKYGKKLGGVWGAVIGGVGGAAVCGLAGYVRKG	65	Sequence 70 from US 20230416797	Lactobacillus amylovorus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29633	MKTEKKVLDELSLHASAKMGARDVESSMNADSTPVLASVAVSMELLPTASVLYSDVAGCFKYSAKHHC	68	Sequence 71 from US 20230416797	Lactobacillus sakei L45	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29634	MKTKSLVLALSAVTLFSAGGIVAQAEGTWQHGYGVSSAYSNYHHGSKTHSATVVNNNTGRQGKDTQRAGVWAKATVGRNLTEKASFYYNFW	91	Sequence 72 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29635	MKNQLNFNIVSDEELSEANGGKLTFIQSTAAGDLYYNTNTHKYVYQQTQNAFGAAANTIVNGWMGGAAGGFGLHH	75	Sequence 73 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29636	MKNQLNFNIVSDEELAEVNGGSLQYVMSAGPYTWYKDTRTGKTICKQTIDTASYTFGVMAEGWGKTFH	68	Sequence 74 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29637	MKLIDHLGAPRWAVDTILGAIAVGNLASWVLALVPGPGWAVKAGLATAAAIVKHQGKAAAAAW	63	Sequence 75 from US 20230416797	Lactococcus sp. QU 12	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29638	MACQCPDAISGWTHTDYQCHGLENKMYRHVYAICMNGTQVYCRTEWGSSC	50	Sequence 76 from US 20230416797	Brevibacillus sp. GI-9	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29639	MNKEYNSISNFKKITNKDLQNINGGFIGRAIGDFVYFGAKGLRESGKLLNYYYKHKH	57	Sequence 77 from US 20230416797	Leuconostoc pseudomesente	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29640	MKNQLMSFEVISEKELSTVQGGKGLGKLIGIDWLLGQAKDAVKQYKKDYKRWH	53	Sequence 78 from US 20230416797	Leuconostoc pseudomesente	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29641	MMNMKPTESYEQLDNSALEQVVGGKYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW	61	Sequence 79 from US 20230416797	Leuconostoc gelidum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29642	MNNMKSADNYQQLDNNALEQVVGGKYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW	61	Sequence 80 from US 20230416797	Leuconostoc carnosum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29643	MFLVNQLGISKSLANTILGAIAVGNLASWLLALVPGPGWATKAALATAETIVKHEGKAAAIAW	63	Sequence 81 from US 20230416797	Leuconostoc mesenteroides	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29644	MSKKEMILSWKNPMYRTESSYHPAGNILKELQEEEQHSIAGGTITLSTCAILSKPLGNNGYLCTVTKECMPSCN	74	Sequence 82 from US 20230416797	Bacillus licheniformis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29645	MKKAALKFIIVIAILGFSFSFFSIQSEAKSYGNGVQCNKKKCWVDWGSAISTIGNNSAANWATGGAAGWKS	71	Sequence 83 from US 20230416797	Listeria innocua	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29646	MSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMDKLVGAGDMEAACTFTLPGGGGVCTLTSECIC	68	Sequence 84 from US 20230416797	Bacillus amyloliquefacien	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29647	MTNMKSVEAYQQLDNQNLKKVVGGKYYGNGVHCTKSGCSVNWGEAASAGIHRLANGGNGFW	61	Sequence 85 from US 20230416797	Leuconostoc mesenteroides	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29648	MNDILETETPVMVSPRWDMLLDAGEDTSPSVQTQIDAEFRRVVSPYMSSSGWLCTLTIECGTIICACR	68	Sequence 86 from US 20230416797	Clavibacter michiganensis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29649	MELKASEFGVVLSVDALKLSRQSPLGVGIGGGGGGGGGGSCGGQGGGCGGCSNGCSGGNGGSGGSGSHI	69	Sequence 87 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29650	MRTGNAN	7	Sequence 88 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29651	MREISQKDLNLAFGAGETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVPIPVLIGPSWNGSGSGYNSATSSSGSGS	99	Sequence 89 from US 20230416797	Klebsiella pneumoniae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29652	MREITESQLRYISGAGGAPATSANAAGAAAIVGALAGIPGGPLGVVVGAVSAGLTTAIGSTVGSGSASSSAGGGS	75	Sequence 90 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29653	MIKHFHFNKLSSGKKNNVPSPAKGVIQIKKSASQLTKGGAGHVPEYFVGIGTPISFYG	58	Sequence 91 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29654	MYMRELDREELNCVGGAGDPLADPNSQIVRQIMSNAAWGPPLVPERFRGMAVGAAGGVTQTVLQGAAAHMPVNVPIPKVPMGPSWNGSKG	90	Sequence 92 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29655	MSQVVGGKYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS	50	Sequence 93 from US 20230416797	Enterococcus mundtii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29656	MKKLTSKEMAQVVGGKYYGNGLSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS	58	Sequence 94 from US 20230416797	Enterococcus mundtii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29657	MSNTQLLEVLGTETFDVQEDLFAFDTTDTTIVASNDDPDTRFKSWSLCTPGCARTGSFNSYCC	63	Sequence 95 from US 20230416797	Streptococcus mutans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29658	MNKLNSNAVVSLNEVSDSELDTILGGNRWWQGVVPTVSYECRMNSWQHVFTCC	53	Sequence 96 from US 20230416797	Streptococcus mutans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29659	MSTKDFNLDLVSVSKKDSGASPRITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK	57	Sequence 97 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29660	MSTKDFNLDLVSVSKKDSGASPRITSISLCTPGCKTGALMGCNMKTATCNCSVHVSK	57	Sequence 98 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29661	MSTKDFNLDLVSVSKTDSGASTRITSISLCTPGCKTGVLMGCNLKTATCNCSVHVSK	57	Sequence 99 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29662	MNNEDFNLDLIKISKENNSGASPRITSKSLCTPGCKTGILMTCPLKTATCGCHFG	55	Sequence 100 from US 20230416797	Streptococcus uberis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29663	MSTKDFNLDLVSVSKKDSGASPRITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK	57	Sequence 101 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29664	MENSKVMKDIEVANLLEEVQEDELNEVLGAKKKSGVIPTVSHDCHMNSFQFVFTCCS	57	Sequence 102 from US 20230416797	Staphylococcus warneri	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29665	MAENLFDLDIQVNKSQGSVEPQVLSIVACSSGCGSGKTAASCVETCGNRCFTNVGSLC	58	Sequence 103 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29666	MKKIEKLTEKEMANIIGGKYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGNHKC	62	Sequence 104 from US 20230416797	Pediococcus acidilactici	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29667	MTEIKVLNDKELKNVVGGKYYGNGVHCGKKTCYVDWGQATASIGKIIVNGWTQHGPWAHR	60	Sequence 105 from US 20230416797	Pediococcus pentosaceus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29668	MKNNKNLFDLEIKKETSQNTDELEPQTAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK	60	Sequence 106 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29669	MKTVKELSVKEMQLTTGGKYYGNGVSCNKNGCTVDWSKAIGIIGNNAAANLTTGGAAGWNKG	62	Sequence 107 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29670	MYKELTVDELALIDGGKKKKKKVACTWGNAATAAASGAVXGILGGPTGALAGAIWGVSQCASNNLHGMH	69	Sequence 108 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29671	MMKKIEKLTEKEMANIIGGKYYGNGVTCGKHSCSVNWGQAFSCSVSHLANFGHGKC	56	Sequence 109 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29672	MSKLVKTLTVDEISKIQTNGGKPAWCWYTLAMCGAGYDSGTCDYMYSHCFGVKHSSGGGGSYHC	64	Sequence 110 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29673	MLQFEKLQYSRLPQKKLAKISGGFNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR	56	Sequence 111 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29674	MKKFLVLRDRELNAISGGVFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG	52	Sequence 112 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29675	MTVNKMIKDLDVVDAFAPISNNKLNGVVGGGAWKNFWSSLRKGFYDGEAGRAIRR	55	Sequence 113 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29676	MKIKLTVLNEFEELTADAEKNISGGRRSRKNGIGYAIGYAFGAVERAVLGGSRDYNK	57	Sequence 114 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29677	MDKFEKISTSNLEKISGGDLTTKLWSSWGYYLGKKARWNLKHPYVQF	47	Sequence 115 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29678	MNNLNKFSTLGKSSLSQIEGGSVPTSVYTLGIKILWSAYKHRKTIEKSFNKGFYH	55	Sequence 116 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29679	MNNALSFEQQFTDFSTLSDSELESVEGGRNKLAYNMGHYAGKATIFGLAAWALLA	55	Sequence 117 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29680	MDKIIKFQGISDDQLNAVIGGKKKKQSWYAAAGDAIVSFGEGFLNAW	47	Sequence 118 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29681	MKISKIEAQARKDFFKKIDTNSNLLNVNGAKCKWWNISCDLGNNGHVCTLSHECQVSCN	59	Sequence 119 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29682	MTKTSRRKNAIANYLEPVDEKSINESFGAGDPEARSGIPCTIGAAVAASIAVCPTTKCSKRCGKRKK	67	Sequence 120 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29683	MKIQIKGMKQLSNKEMQKIVGGKSSAYSLQMGATAIKQVKKLFKKWGW	48	Sequence 121 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29684	MKKTLLRSGTIALATAAAFGASLAAAPSAMAVPGGCTYTRSNRDVIGTCKTGSGQFRIRLDCNNAPDKTSVWAKPKVMVSVHCLVGQPRSISFETK	96	Sequence 122 from US 20230416797	Propionibacterium thoenii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29685	MRNDVLTLTNPMEEKELEQILGGGNGVLKTISHECNMNTWQFLFTCC	47	Sequence 123 from US 20230416797	[Ruminococcus] gnavus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29686	MKNAKSLTIQEMKSITGGKYYGNGVSCNSHGCSVNWGQAWTCGVNHLANGGHGVC	55	Sequence 124 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29687	MNNVKELSMTELQTITGGARSYGNGVYCNNKKCWVNRGEATQSIIGGMISGWASGLAGM	59	Sequence 125 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29688	MEKFIELSLKEVTAITGGKYYGNGVHCGKHSCTVDWGTAIGNIGNNAAANWATGGNAGWNK	61	Sequence 126 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29689	MKSTNNQSIAEIAAVNSLQEVSMEELDQIIGAGNGVVLTLTHECNLATWTKKLKCC	56	Sequence 127 from US 20230416797	Streptococcus salivarius	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29690	MSFMKNSKDILTNAIEEVSEKELMEVAGGKKGSGWFATITDDCPNSVFVCC	51	Sequence 128 from US 20230416797	Streptococcus pyogenes se	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29691	MKNSKDVLNNAIEEVSEKELMEVAGGKKGPGWIATITDDCPNSIFVCC	48	Sequence 129 from US 20230416797	Streptococcus salivarius	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29692	MKNSKDILNNAIEEVSEKELMEVAGGKRGSGWIATITDDCPNSVFVCC	48	Sequence 130 from US 20230416797	Streptococcus salivarius	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29693	MKSSFLEKDIEEQVTWFEEVSEQEFDDDIFGACSTNTFSLSDYWGNKGNWCTATHECMSWCK	62	Sequence 131 from US 20230416797	Staphylococcus aureus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29694	MKNELGKFLEENELELGKFSESDMLEITDDEVYAAGTPLALLGGAATGVIGYISNQTCPTTACTRAC	67	Sequence 132 from US 20230416797	Staphylococcus aureus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29695	MNNTIKDFDLDLKTNKKDTATPYVGSRYLCTPGSCWKLVCFTTTVK	46	Sequence 133 from US 20230416797	Streptococcus pyogenes	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29696	MEKNNEVINSIQEVSLEELDQIIGAGKNGVFKTISHECHLNTWAFLATCCS	51	Sequence 134 from US 20230416797	Streptococcus pyogenes	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29697	MTKEHEIINSIQEVSLEELDQIIGAGKNGVFKTISHECHLNTWAFLATCCS	51	Sequence 135 from US 20230416797	Streptococcus pyogenes se	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29698	MEKLFKEVKLEELENQKGSGLGKAQCAALWLQCASGGTIGCGGGAVACQNYRQFCR	56	Sequence 136 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29699	MSKFDDFDLDVVKVSKQDSKITPQWKSESLCTPGCVTGALQTCFLQTLTCNCKISK	56	Sequence 137 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29700	MKLPVQQVYSVYGGKDLPKGHSHSTMPFLSKLQFLTKIYLLDIHTQPFFI	50	Sequence 138 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29701	MKKAVIVENKGCATCSIGAACLVDGPIPDFEIAGATGLFGLWG	43	Sequence 139 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29702	MMNATENQIFVETVSDQELEMLIGGADRGWIKTLTKDCPNVISSICAGTIITACKNCA	58	Sequence 140 from US 20230416797	Streptococcus thermophilu	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29703	MKQYNGFEVLHELDLANVTGGQINWGSVVGHCIGGAIIGGAFSGGAAAGVGCLVGSGKAIINGL	64	Sequence 141 from US 20230416797	Streptococcus thermophilu	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29704	MNTITICKFDVLDAELLSTVEGGYSGKDCLKDMGGYALAGAGSGALWGAPAGGVGALPGAFVGAHVGAIAGGFACMGGMIGNKFN	85	Sequence 142 from US 20230416797	Streptococcus thermophilu	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29705	MSEIKKALNTLEIEDFDAIEMVDVDAMPENEALEIMGASCTTCVCTCSCCTT	52	Sequence 143 from US 20230416797	Bacillus cereus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29706	MEVMNNALITKVDEEIGGNAACVIGCIGSCVISEGIGSLVGTAFTLG	47	Sequence 144 from US 20230416797	Bacillus cereus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29707	MEVLNKQNVNIIPESEEVGGWVACVGACGTVCLASGGVGTEFAAASYFL	49	Sequence 145 from US 20230416797	Bacillus cereus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29708	METPVVQPRDWTCWSCLVCAACSVELLNLVTAATGASTAS	40	Sequence 146 from US 20230416797	Bacillus thuringiensis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29709	MDNKVAKNVEVKKGSIKATFKAAVLKSKTKVDIGGSRQGCVA	42	Sequence 147 from US 20230416797	Rhizobium leguminosarum b	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29710	MNTIEKFENIKLFSLKKIIGGKTVNYGNGLYCNQKKCWVNWSETATTIVNNSIMNGLTGGNAGWHSGGRA	70	Sequence 148 from US 20230416797	Streptococcus uberis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29711	MDILLELAGYTGIASGTAKKVVDAIDKGAAAFVIISIISTVISAGALGAVSASADFIILTVKNYISRNLKAQAVIW	76	Sequence 149 from US 20230416797	Streptococcus uberis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29712	MDSELFKLMATQGAFAILFSYLLFYVLKENSKREDKYQNIIEELTELLPKIKEDVEDIKEKLNK	64	Sequence 150 from US 20230416797	Clostridium perfringens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29713	MTNAFQALDEVTDAELDAILGGGSGVIPTISHECHMNSFQFVFTCCS	47	Sequence 151 from US 20230416797	Kocuria varians	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29714	ANCSCSTASDYCPILTFCTTGTACSYTPTGCGTGWVYCACNGNFY	45	Sequence 152 from US 20230416797	Myxococcus fulvus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29715	CANSCSYGPLTWSCDGNTK	19	Sequence 153 from US 20230416797	Streptomyces griseoluteus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29716	CKQSCSFGPFTFVCDGNTK	19	Sequence 154 from US 20230416797	Streptomyces griseovertic	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29717	GSEIQPR	7	Sequence 155 from US 20230416797	Carnobacterium sp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29718	GTWDDIGQGIGRVAYWVGKAMGNMSDVNQASRINRKKKH	39	Sequence 156 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29719	KKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI	35	Sequence 157 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29720	CVQSCSFGPLTWSCDGNTK	19	Sequence 158 from US 20230416797	Streptomyces albogriseolu	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29721	SSGWVCTLTIECGTVICAC	19	Sequence 159 from US 20230416797	Actinoplanes liguriensis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29722	YTAKQCLQAIGSCGIAGTGAGAAGGPAGAFVGAXVVXI	38	Sequence 160 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29723	TKYYGNGVYCNSKKCWVDWGQAAGGIGQTVVXGWLGGAIPGK	42	Sequence 161 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29724	FKSWSFCTPGCAKTGSFNSYCC	22	Sequence 162 from US 20230416797	Streptococcus mutans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29725	KYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWSK	43	Sequence 163 from US 20230416797	Enterococcus mundtii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29726	KYYGNGVHXGKHSXTVDWGTAIGNIGNNAAANXATGXNAGG	41	Sequence 164 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29727	GMSGYIQGIPDFLKGYLHGISAANKHKKGRL	31	Sequence 165 from US 20230416797	Lactobacillus paracasei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29728	KGKGFWSWASKATSWLTGPQQPGSPLLKKHR	31	Sequence 166 from US 20230416797	Leuconostoc mesenteroides	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29729	KNYGNGVHCTKKGCSVDWGYAWTNIANNSVMNGLTGGNAGWHN	43	Sequence 167 from US 20230416797	Leuconostoc mesenteroides	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29730	AIKLVQSPNGNFAASFVLDGTKWIFKSKYYDSSKGYWVGIYEVWDRK	47	Sequence 168 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29731	ISLEICXIFHDN	12	Sequence 169 from US 20230416797	Bacillus licheniformis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29732	TSYGNGVHCNKSKCWIDVSELETYKAGTVSNPKDILW	37	Sequence 170 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29733	DYHHGVRVL	9	Sequence 171 from US 20230416797	Serratia plymuthica	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29734	DIDITGCSACKYAAG	15	Sequence 172 from US 20230416797	Halobacterium sp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29735	XXKEIXHIFHDN	12	Sequence 173 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29736	TPVVNPPFLQQT	12	Sequence 174 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29737	VAPFPEQFLX	10	Sequence 175 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29738	NIPQLTPTP	9	Sequence 176 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29739	DWTXWSXLVXAACSVELL	18	Sequence 177 from US 20230416797	Bacillus thuringiensis se	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29740	AYPGNGVHCGKYSCTVDKQTAIGNIGNNAA	30	Sequence 178 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29741	TKYYGNGVYCNSKKCWVDWGTAQGCIDVVIGQLGGGIPGKGKC	43	Sequence 179 from US 20230416797	Carnobacterium divergens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29742	NRWYCNSAAGGVGGAAVCGLAGYVGEAKENIAGEVRKGWGMAGGFTHNKACKSFPGSGWASG	62	Sequence 180 from US 20230416797	Enterococcus sp. 4062	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29743	TTKNYGNGVCNSVNWCQCGNVWASCNLATGCAAWLCKLA	39	Sequence 181 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29744	ASIIKTTIKVSKAVCKTLTCICTGSCSNCK	30	Sequence 182 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29745	SASIVKTTIKASKKLCRGFTLTCGCHFTGKK	31	Sequence 183 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29746	KYYGNGVSCNKKGCSVDWGKAIGIIGNNAAANLTTGGKAAWAC	43	Sequence 184 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29747	ATYYGNGLYCNKQKHYTWVDWNKASREIGKITVNGWVQH	39	Sequence 185 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29748	VNYGNGVSCSKTKCSVNWGIITHQAFRVTSGVASG	35	Sequence 186 from US 20230416797	Bacillus circulans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29749	FVYGNGVTSILVQAQFLVNGQRRFFYTPDK	30	Sequence 187 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29750	FVYGNGVTSILVQAQFLVNGQRRFFYTPDK	13	Sequence 188 from US 20230416797	Lactobacillus rhamnosus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29751	MKNSAAREAFKGANHPAGMVSEEELKALVGGNDVNPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC	69	Sequence 189 from US 20230416797	Bacillus licheniformis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29752	KYYGNGLSCSKKGCTVNWGQAFSCGVNRVATAGHGK	36	Sequence 190 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29753	GNPKVAHCASQIGRSTAWGAVSGA	24	Sequence 191 from US 20230416797	Lactobacillus acidophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29754	WLPPAGLLGRCGRWFRPWLLWLQSGAQYKWLGNLFGLGPK	40	Sequence 192 from US 20230416797	Enterococcus faecalis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29755	NLDQWLTEQVHEFQDMYLEPQAISNQDITFKLSDLDFIHN	40	Sequence 193 from US 20230416797	Anabaena variabilis 0441	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29756	NLDQWLTEQVHEFQDMYLEPQAISNQDITFKLSDLDFIHN	40	Sequence 194 from US 20230416797	Nostoc sp	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29757	HREKKSA	7	Sequence 195 from US 20230416797	'Nostoc azollae' 0708	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29758	TSNNWLAKNYLSMWNKKSSNPNL	23	Sequence 196 from US 20230416797	Acaryochloris marina	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29759	FRYFWW	6	Sequence 197 from US 20230416797	Cyanothece sp. ATCC 51142	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29760	CGEKWRIFS	9	Sequence 198 from US 20230416797	Cyanothece sp. ATCC 51142	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29761	FRLQLWQF	8	Sequence 199 from US 20230416797	Cyanothece sp. ATCC 51142	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29762	LGCNQSSIWSIFFWNH	16	Sequence 200 from US 20230416797	Cyanothece sp. ATCC 51142	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29763	YNLQGLPAIESEDCIPDSVAPSDDWFSGVSSLFNRLTGLG	40	Sequence 201 from US 20230416797	Coleofasciculus chthonopl	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29764	WMAIRRILRCHPFHPGGYDPVPELGEHCCHHDSGNKG	37	Sequence 202 from US 20230416797	Nostoc sp	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29765	WMGIRRILRCHPFHPGGYDPVPEVGEHCCHHDSGK	35	Sequence 203 from US 20230416797	Anabaena variabilis 0441	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29766	WMATRRILRCHPFHPGGYDPVPEVKHNCCDQHLSDSGKQTTEDHHKGS	48	Sequence 204 from US 20230416797	Nodularia spumigena	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29767	WMATLRILRCHPFHPGGYDPVPGLAEKSCCDHHD	34	Sequence 205 from US 20230416797	'Nostoc azollae' 0708	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29768	WLTAKRFCRCHPLHPGGYDPVPEKKSVL	28	Sequence 206 from US 20230416797	Synechococcus elongatus P	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29769	WLTLRRLSRCHPFTPCGCDPVPD	23	Sequence 207 from US 20230416797	Prochlorococcus marinus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29770	MSYKKLYQLTAIFSLPLTILLVSLSSLRIVGEGNSYVDVFLSFIIFLGFIELIHGIRKILVWSGWKNGS	69	Sequence 208 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29771	MSYKKLYQLTAIFSLPLTILLVSLSSLRIVGEGNSYVDVFLSFIIFLGFIELIHGIRKILVWSGWKNGS	85	Sequence 209 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29772	MSLRYYIKNILFGLYCTLIYIYLITKNSEGYYFLVSDKMLYAIVISTILCPYSKYAIEYIAFNFIKKDFFERRKNLNNAPVAKLNLFMLYNLLCLVLAIP	113	Sequence 210 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29773	MGLKLHIHWFDKKTEEFKGGEYSKDFGDDGSVIESLGMPLKDNINNGWFDVEKPWVSILQPHFKNVIDISKFDYFVSFVYRDGNW	85	Sequence 211 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29774	MELKHSISDYTEAEFLEFVKKICRAEGATEEDDNKLVREFERLTEHPDGSDLIYYPRDDREDSPEGIVKEIKEWRAANGKSGFKQG	86	Sequence 212 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29775	MMNEHSIDTDNRKANNALYLFIIIGLIPLLCIFVVYYKTPDALLLRKIATSTENLPSITSSYNPLMTKVMDIYCKTAPFLALILYILTFKIRKLINNTDR	178	Sequence 213 from US 20230416797	Citrobacter freundii	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29776	MNRKYYFNNMWWGWVTGGYMLYMSWDYEFKYRLLFWCISLCGMVLYPVAKWYIEDTALKFTRPDFWNSGFFADTPGKMGLLAVYTGTVFILSLPLSMIYI	111	Sequence 214 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29777	MKLDISVKYLLKSLIPILIILTVFYLGWKDNQENARMFYAFIGCIISAITFPFSMRIIQKMVIRFTGKEFWQKDFFTNPVGGSLTAIFELFCFVISVPVV	115	Sequence 215 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29778	MHNTLLEKIIAYLSLPGFHSLNNPPLSEAFNLYVHTAPLAATSLFIFTHKELELKPKSSPLRALKILTPFTILYISMIYCFLLTDTELTLSSKTFVLIVK	131	Sequence 216 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29779	MELKNSISDYTETEFKKIIEDIINCEGDEKKQDDNLEHFISVTEHPSGSDLIYYPEGNNDGSPEAVIKEIKEWRAANGKSGFKQG	85	Sequence 217 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29780	MKKKQIEFENELRSMLATALEKDISQEERNALNIAEKALDNSEYLPKIILNLRKALTPLAINRTLNHDLSELYKFITSSKASNKNLGGGLIMSWGRLF	98	Sequence 218 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29781	MKKKQIEFENELRSMLATALEKDISQEERNALNIAEKALDNSEYLPKIILNLRKALTPLAINRTLNHDLSELYKFITSSKASNKNLGGGLIMSWGRLF	98	Sequence 219 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29782	MNKMAMIDLAKLFLASKITAIEFSERICVERRRLYGVKDLSPNILNCGEELFMAAERFEPDADRANYEIDDNGLKVEVRSILEKFKL	87	Sequence 220 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29783	MKLSPKAAIEVCNEAAKKGLWILGIDGGHWLNPGFRIDSSASWTYDMPEEYKSKIPENNRLAIENIKDDIENGYTAFIITLKM	83	Sequence 221 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29784	MGLKLHINWFDKRTEEFKGGEYSKDFGDDGSVIERLGMPFKDNINNGWFDVIAEWVPLLQPYFNHQIDISDNEYFVSFDYRDGDW	85	Sequence 222 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29785	MELKKSIGDYTETEFKKIIENIINCEGDEKKQDDNLEHFISVTEHPSGSDLIYYPEGNNDGSPEAVIKEIKEWRAANGKSGFKQG	85	Sequence 223 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29786	MELKHSISDYTEAEFLQLVTTICNADTSSEEELVKLVTHFEEMTEHPSGSDLIYYPKEGDDDSPSGIVNTVKQWRAANGKSGFKQG	86	Sequence 224 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29787	MLTLYGYIRNVFLYRMNDRSCGDFMKVISMKFIFILTIIALAAVFFWSEDKGPACYQVSDEQARTFVKNDYLQRMKRWDNDVQLLGTEIPKITWEKIERS	141	Sequence 225 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29788	MTSNKDKNKKANEILYAFSIIGIIPLMAILILRINDPYSQVLYYLYNKVAFLPSITSLHDPVMTTLMSNYNKTAPVMGILVFLCTYKTREIIKPVTRKLV	175	Sequence 226 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29789	MDRKRTKLELLFAFIINATAIYIALAIYDCVFRGKDFLSMHTFCFSALMSAICYFVGDNYYSISDKIKRRSYENSDSK	78	Sequence 227 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29790	MSLRYYIKNILFGLYCALIYIYLITKNNEGYYFLASDKMLYAIVISTILCPYSKYAIEHIFFKFIKKDFFRKRKNLNKCPRGKIKPYLCVYNLLCLVLAI	113	Sequence 228 from US 20230416797	Shigella sonnei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29791	MSLRYYIKNILFGLYCTLIYIYLITKNSEEYYFLVTDKMLYAIVISTILCPYSKYAIEHIAFNFIKKHFFERRKNLNNAPVAKLNLFMLYNLLCLVLAIP	113	Sequence 229 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29792	MRKNNILLDDAKIYTNKLYLLLIDRKDDAGYGDICDVLFQVSKKLDSTKNVEALINRLVNYIRITASTNRIKFSKDEEAVIIELGVIGQKAGLNGQYMAD	113	Sequence 230 from US 20230416797	Leuconostoc gelidum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29793	MKKKVDTEKQITSWASDLASKNETKVQEKLILSSYIQDIENHVYFPKAMISLEKKLRDQNNICALSKEVNQFYFKVVEVNQRKSWMVGLIV	91	Sequence 231 from US 20230416797	Lactococcus lactis subsp.	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29794	MNKTKSEHIKQQALDLFTRLQFLLQKHDTIEPYQYVLDILETGISKTKHNQQTPERQARVVYNKIASQALVDKLHFTAEENKVLAAINELAHSQKGWGEF	112	Sequence 232 from US 20230416797	Pediococcus acidilactici	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29795	MIKDEKINKIYALVKSALDNTDVKNDKKLSLLLMRIQETSINGELFYDYKKELQPAISMYSIQHNFRVPDDLVKLLALVQTPKAWSGF	88	Sequence 233 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29796	MDIKSQTLYLNLSEAYKDPEVKANEFLSKLVVQCAGKLTASNSENSYIEVISLLSRGISSYYLSHKRIIPSSMLTIYTQIQKDIKNGNIDTEKLRKYEIA	111	Sequence 234 from US 20230416797	Carnobacterium maltaromat	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29797	MSPAQRRILLYILSFIFVIGAVVYFVKSDYLFTLIFIAIAILFGMRARKADSR	53	Sequence 235 from US 20230416797	Bacillus subtilis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29798	MELKNSISDYTEAEFVQLLKEIEKENVAATDDVLDVLLEHFVKITEHPDGTDLIYYPSDNRDDSPEGIVKEIKEWRAANGKPGFKQG	87	Sequence 236 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29799	MKSKISEYTEKEFLEFVEDIYTNNKKKFPTEESHIQAVLEFKKLTEHPSGSDLLYYPNENREDSPAGVVKEVKEWRASKGLPGFKAG	87	Sequence 237 from US 20230416797	Pseudomonas aeruginosa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29800	MKSKISEYTEKEFLEFVKDIYTNNKKKFPTEESHIQAVLEFKKLTEHPSGSDLLYYPNENREDSPAGVVKEVKEWRASKGLPGFKAG	87	Sequence 238 from US 20230416797	Pseudomonas aeruginosa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29801	MDFTKEEKLLNAISKVYNEATIDDYPDLKEKLFLYSKEISEGKSVGEVSMKLSSFLGRYILKHKFGLPKSLIELQEIVSKESQVYRGWASIGIWS	95	Sequence 239 from US 20230416797	Enterococcus hirae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29802	MKKKYRYLEDSKNYTSTLYSLLVDNVDKPGYSDICDVLLQVSKKLDNTQSVEALINRLVNYIRITASTYKIIFSKKEEELIIKLGVIGQKAGLNGQYMAD	113	Sequence 240 from US 20230416797	Leuconostoc mesenteroides	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29803	MSFLNFAFSPVFFSIMACYFIVWRNKRNEFVCNRLLSIIIISFLICFIYPWLNYKIEVKYYIFEQFYLFCFLSSLVAVVINLIVYFILYRRCI	93	Sequence 241 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29804	MHLKYYLHNLPESLIPWILILIFNDNDNTPLLFIFISSIHVLLYPYSKLTISRYIKENTKLKKEPWYLCKLSALFYLLMAIPVGLPSFIYYTLKRN	96	Sequence 242 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29805	MKADYKKINSILTYTSTALKNPKIIKDKDLVVLLTIIQEEAKQNRIFYDYKRKFRPAVTRFTIDNNFEIPDCLVKLLSAVETPKAWSGFS	90	Sequence 243 from US 20230416797	Lactobacillus sakei	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29806	MKLSPKAAIEVCNEAAKKGLWILGIDGGHWLNPGFRIDSSASWTYDMPEEYKSKTPENNRLAIENIKDDIENGYTAFIITLKM	83	Sequence 244 from US 20230416797	Escherichia coli	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29807	MTLLSFGFSPVFFSVMAFCIISRSKFYPQRTRNKVIVLILLTFFICFLYPLTKVYLVGSYGIFDKFYLFCFISTLIAIAINVVILTINGAKNERN	95	Sequence 245 from US 20230416797	Klebsiella pneumoniae	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29808	NIPQLTPTP	9	Sequence 246 from US 20230416797	Lactobacillus curvatus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29809	DWTXWSXLVXAACSVELL	18	Sequence 247 from US 20230416797	Bacillus thuringiensis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29810	AYPGNGVHCGKYSCTVDKQTAIGNIGNNAA	30	Sequence 248 from US 20230416797	Lactobacillus curvatus L4	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29811	TKYYGNGVYCNSKKCWVDWGTAQGCIDVVIGQLGGGIPGKGKC	43	Sequence 249 from US 20230416797	Carnobacterium divergens	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29812	VTSWSLCTPGCTSPGGGSNCSFCC	24	Sequence 250 from US 20230416797	Microbispora sp. (strain 	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29813	NRWYCNSAAGGVGGAAVCGLAGYVGEAKENIAGEVRKGWGMAGGFTHNKACKSFPGSGWASG	62	Sequence 251 from US 20230416797	Enterococcus sp. 4062	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29814	TTKNYGNGVCNSVNWCQCGNVWASCNLATGCAAWLCKLA	39	Sequence 252 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29815	ASIIKTTIKVSKAVCKTLTCICTGSCSNCK	30	Sequence 253 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29816	SASIVKTTIKASKKLCRGFTLTCGCHFTGKK	31	Sequence 254 from US 20230416797	Staphylococcus epidermidi	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29817	MEKLTVKEMSQVVGGKYYGNGVSCNKKGCSVDWGKAIGIIGNNAAANLTTGGKAGWKG	58	Sequence 255 from US 20230416797	Enterococcus faecium	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29818	ATYYGNGLYCNKQKHYTWVDWNKASREIGKITVNGWVQH	39	Sequence 256 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29819	VNYGNGVSCSKTKCSVNWGIITHQAFRVTSGVASG	35	Sequence 257 from US 20230416797	Bacillus circulans	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29820	FVYGNGVTSILVQAQFLVNGQRRFFYTPDK	30	Sequence 258 from US 20230416797	Paenibacillus polymyxa	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29821	AVPAVRKTNETLD	13	Sequence 259 from US 20230416797	Lactobacillus rhamnosus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29822	MKNSAAREAFKGANHPAGMVSEEELKALVGGNDVNPETTPATTSSWTCITAGVTVSASLC	60	Sequence 260 from US 20230416797	Bacillus licheniformis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29823	KYYGNGLSCSKKGCTVNWGQAFSCGVNRVATAGHGK	36	Sequence 261 from US 20230416797	Lactobacillus plantarum	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29824	MKTILRFVAGYDIASHKKKTGGYPWERGKA	30	Sequence 262 from US 20230416797	Lactococcus lactis	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29825	GNPKVAHCASQIGRSTAWGAVSGA	24	Sequence 263 from US 20230416797	Lactobacillus acidophilus	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29826	MFFNFMKKVDVKKNFGYKEVSRKDLAKVNGGKRKKHRCRVYNNGMPTGMYRWC	53	Sequence 264 from US 20230416797	Lactobacillus salivarius 	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29827	DVADL	5	Sequence 265 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29828	DVADI	5	Sequence 266 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29829	FHWWQTSPAHFS	12	Sequence 267 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29830	WPFAHWPWQYPR	12	Sequence 268 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29831	GDSVCASYF	9	Sequence 269 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29832	SVCASYF	7	Sequence 270 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29833	SKADT	5	Sequence 271 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29834	SKPAD	5	Sequence 272 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29835	QNSAAAFAAWA	11	Sequence 273 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29836	QNSAAAFGQWA	11	Sequence 274 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29837	YSTCFIM	7	Sequence 275 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP29838	STCAFIM	7	Sequence 276 from US 20230416797	Synthetic construct	Antimicrobial	US 2023/0416797 A1	Patent Application	2023##12##28	JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1	MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE	Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
DRAMP31728	KLlLKlLkkLLKlLKKK	17	Lytic	Transferrin receptor (TfR	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	2011##12##29	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP31729	THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK	32	Transferrin receptor (TfR)-lytic hybrid	Transferrin receptor (TfR	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	2011##12##29	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP31749	KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK	33	IL-4Rα-lytic peptide	Interleukin-4 receptor a 	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	2011##12##29	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32389	VKDGYIVDDKNCAYFCGRNAYCDDECEKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGRCNG	65	VKVR	Scorpion	Antimicrobial, Anticancer	CN102690342B	Granted Patent	2014##10##29	CN102690342B	Anti-cancer analgesic peptide VKVR, its preparation method and application  	Concerning the technical field of biomedicine, the invention relates to an anticancer analgesic peptide VKVR obtained by extraction, separation and purification of natural materials and its preparation method, a method for obtaining the anti-cancer analgesic peptide VKVR through a genetic engineering technology, the structure of anti-cancer analgesic peptide VKVR derivatives, analogues, and active fragments and a preparation method thereof, as well as application of the anticancer analgesic peptide VKVR and its derivatives, analogues, and active fragments as analgesic and anti-cancer drugs in the medical field. The anticancer analgesic peptide VKVR and its derivatives or analogues or active fragments can be mixed with a pharmaceutically acceptable carrier to prepare clinically acceptable injections, oral preparations, transdermal absorption preparations, and mucosal absorption preparations. The anticancer analgesic peptide VKVR and its derivatives, analogues, and active fragments in the invention 
DRAMP32390	YALPAH	6	YALPAH	Yellow crucian carp prote	Antimicrobial, Anticancer	CN103665103B	Granted Patent	2014##4##6	CN103665103B	Method for separating out prostatic cancer (PC)-3 anticancer peptide by utilizing thermal reactant of setipinna taty antibacterial peptide li	The present invention relates to a kind of method and the anticancer peptide thereof that utilize yellow crucian carp albumen antibacterial peptide liquid thermal response thing separation prostate cancer PC-3 anticancer peptide, it is characterized in that step is: 1) prepare yellow crucian carp albumen antibacterial peptide liquid, regulate pH value to 5.0 ~ 7.0 of yellow crucian carp albumen antibacterial peptide liquid; 2) to the thermal treatment of yellow crucian carp albumen antibacterial peptide liquid, in 100 ~ 121 DEG C of cannery retort, 30 ~ 60min is heated, with the thermal response product of obtained yellow crucian carp albumen antibacterial peptide liquid; 3) from yellow crucian carp albumen antibacterial peptide liquid thermal response product, anticancer peptide is separated.Compared with prior art, the invention has the advantages that: with yellow crucian carp albumen antibacterial peptide liquid for the substrate that sets out, be separated through two step gels, be separated 
DRAMP32391	GNKKWEQKQVQIKTLEGEFSVTMWSS	26	OPB	YY1 protein	Antimicrobial, Anticancer	CN105601724B	Granted Patent	2019##6##7	CN105601724B	Anticancer active OPB (oligopeptidase B) oligopeptide and expression vector and application thereof  	A kind of OPB oligopeptides and its expression vector and application with anticancer activity, it is related to a kind of oligopeptides with anticancer activity and its expression vector and application.Sequence of the invention is Gly-Asn-Lys-Lys-Trp-Glu-Gln-Lys-Gln-Val-Gln-Ile-Lys-Thr- Leu-Glu-Gly-Glu-Phe-Ser-Val-Thr-Met-Trp-Ser-Ser.It is used to prepare anticancer drug.The present invention constructs pMBP-2xOPB expression vector.The present invention has the effect of that inhibition growth of tumour cell is proliferated using the peptide fragment that OPB sequent synthesis goes out, and shows that peptide fragment and its derivative based on OPB are a kind of drugs of potential treating cancer.
DRAMP32392	KFKKFFKFMVKKKKF	15	CMAP-L-252	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32393	KKFFKKMKKFVKKFF	15	CMAP-L-25	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32394	KKFFKKMKKFVKKFL	15	CMAP-L-242	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32395	KKFFKKMKKLVKKFF	15	CMAP-L-24	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32396	KKFFKKMKSFFKKFF	15	CMAP-L-23	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32397	KKFFKKMSFFFFKKK	15	CMAP-L-232	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32398	KKFFKLVKKKMKKFF	15	CMAP-L-241	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32399	KKFFSKMKSFFKKFF	15	CMAP-L-20	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32400	KKFFSKSMKSFFFFKK	16	CMAP-L-202	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32401	KKKKFFMFVFFKKKK	15	CMAP-L-253	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32402	KKKKFFMLVKKKKFF	15	CMAP-L-243	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32403	KKKKFFMSFFFKKKF	15	CMAP-L-233	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32404	KKKKFFSMSFFKKFF	15	CMAP-L-201	Not available	Antimicrobial, Anticancer	CN106831946A	Granted Patent	2017##6##13	CN106831946B	Anticancer peptide as well as preparation method and application thereof  	The present invention relates to biomedicine field, in particular to a kind of anticancer peptide.The anticancer peptide is selected from one or two in following group of sequence：A), with SEQ ID NO：Amino acid sequence shown in 1；B), with SEQ ID NO：Amino acid sequence shown in 2.The anticancer peptide has especially significant active anticancer, and small toxicity, safer to human body.Application the invention further relates to the preparation method of the anticancer peptide and its in cancer therapy drug is prepared.
DRAMP32406	MADIKQEHDTELDQNYSLGSNTDPKNMQELTQYVQTLLQSVQDKFQTMSDQILNRIDEMGSRIDDLEKNISDLMTQAGVEGPDK	84	ALT614	Antlion	Antimicrobial, Anticancer	CN109485711A	Patent Application	2019##3##19	CN109485711B	Antlion micromolecular peptide and separation and purification method and application thereof	The invention discloses a kind of ant lion small-molecular peptides and its isolation and purification method and applications.The ant lion small-molecular peptides category class I type heat shock factor conjugated protein, relative molecular mass 9.6kDa, isoelectric point 4.0, total number of atnino acid is 84, and amino acid sequence is as shown in SEQ ID NO:1.The present invention isolates and purifies the component polypeptides with anticancer activity using ion exchange technique from ant lion, it is found that two component ALT1 and ALT6 therein have obvious depression effect to stomach cancer cell MKN28.Further isolated and purified to obtain component ALT614 with highest anticancer activity using technologies such as ultrafiltration, ion exchange, molecular sieves to component ALT6, it is found by NCBI sequence alignment, the ant lion small-molecular peptides ALT614 and heat shock factor conjugated protein HSBP1 has homology, similarity 50~70%.The ant lion small-molecular peptides can be 
DRAMP32407	ADGAPRPGAPLA	12	SEQ ID NO 19 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32408	APRPG	5	SEQ ID NO 17 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32409	ASSSYPLIHWRPWAR	15	SEQ ID NO 6 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32410	DRWRPALP	8	SEQ ID NO 13 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32411	DRWRPALPVVLFPLH	15	SEQ ID NO 5 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32412	HARPW	5	SEQ ID NO 33 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32413	HWAPW	5	SEQ ID NO 34 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32414	HWRAW	5	SEQ ID NO 35 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32415	HWRP	4	SEQ ID NO 29 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32416	HWRPW	5	SEQ ID NO 16 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32417	IHWRPWAR	8	SEQ ID NO 14 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32418	LFPLH	5	SEQ ID NO 24 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32419	PVVLFLH	7	SEQ ID NO 21 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32420	RWRP	4	SEQ ID NO 28 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32421	WRP	3	SEQ ID NO 32 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32422	WRPA	4	SEQ ID NO 30 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32423	WRPW	4	SEQ ID NO 31 from EP1783140A3	Screen of phage display p	Antimicrobial, Anticancer	EP1783140A3	Search Report	2007##7##17	EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262	Neovascular-specific peptides	Angiogenesis-specific peptides which home selectively to neovascular tissues and comprise one of the peptides having the amino acid sequences shown in SEQ ID NOS: 1 to 17 and dendrimers thereof. These peptides are applicable to DDS preparations whereby drugs can be transported selectively to target cancer tissues and are useful as diagnostics for cancer, remedies for cancer, etc. which contribute to the improvement in the therapeutic effects on cancer.
DRAMP32424	LNQEDARKSE	10	SEQ ID NO: 2 from EP2716297B1	Screen of phage display p	Antimicrobial, Anticancer	EP2524926B1	Granted Patent	2016##3##9	EP2524926A4##EP2524926B1##KR101815322B1##KR20110082954A##WO2011087222A2##WO2011087222A3	Anticancer Peptide Sequence	The present invention relates to an anticancer peptide derived from ROR , a gene encoding the anticancer peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, and a method of producing an anticancer drug using the host cell. The anticancer peptide is useful for the treatment and prevent of cancers, particularly prostate cancer and colorectal cancer.
DRAMP32425	LNQEEARKSE	10	SEQ ID NO: 3 from EP2716297B1	Screen of phage display p	Antimicrobial, Anticancer	EP2524926B1	Granted Patent	2016##3##9	EP2524926A4##EP2524926B1##KR101815322B1##KR20110082954A##WO2011087222A2##WO2011087222A3	Anticancer Peptide Sequence	The present invention relates to an anticancer peptide derived from ROR , a gene encoding the anticancer peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, and a method of producing an anticancer drug using the host cell. The anticancer peptide is useful for the treatment and prevent of cancers, particularly prostate cancer and colorectal cancer.
DRAMP32426	LNQESARKSE	10	SEQ ID NO: 1 from EP2716297B1	Screen of phage display p	Antimicrobial, Anticancer	EP2524926B1	Granted Patent	2016##3##9	EP2524926A4##EP2524926B1##KR101815322B1##KR20110082954A##WO2011087222A2##WO2011087222A3	Anticancer Peptide Sequence	The present invention relates to an anticancer peptide derived from ROR , a gene encoding the anticancer peptide, a recombinant vector containing the gene, a host cell transformed with the recombinant vector, and a method of producing an anticancer drug using the host cell. The anticancer peptide is useful for the treatment and prevent of cancers, particularly prostate cancer and colorectal cancer.
DRAMP32427	TeATITGLEPGTEYTITVIAL	21	D-Glu-Fniii14	Not available	Antimicrobial, Anticancer	EP2716297B1	Granted Patent	2017##9##27	EP2716297A4##EP2716297B1##JP5924593B2##JPWO2012124641A1##US2014005120A1##US9327013B2##WO2012124641A1	D-Glu-Fniii14 Polypeptide for Use in Treating Cancer	An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.
DRAMP32428	TEATITGLEPGTEYTITVIAL	21	Not available	Not available	Antimicrobial, Anticancer	EP2716297B1	Granted Patent	2017##9##27	EP2716297A4##EP2716297B1##JP5924593B2##JPWO2012124641A1##US2014005120A1##US9327013B2##WO2012124641A1	D-Glu-Fniii14 Polypeptide for Use in Treating Cancer	An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.
DRAMP32429	GKCSTRGRKCCRRKK	15	hBD3-3	Not available	Antimicrobial, Anticancer	EP3111951B1	Granted Patent	2019##12##11	EP3111951A4##EP3111951B1##ES2773755T3##KR101693533B1##KR20160115314A##US2017042963A1##US9993519B2##WO2016153185A1	Anticancer Functional Peptide for the Treatment of Breast Cancer	The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-kB which is overexpressed specifically in cancer stem cells present in tumors.
DRAMP32430	GKCSTRGRKCMRRKK	15	hBD3-3 M1	Not available	Antimicrobial, Anticancer	EP3111951B1	Granted Patent	2019##12##11	EP3111951A4##EP3111951B1##ES2773755T3##KR101693533B1##KR20160115314A##US2017042963A1##US9993519B2##WO2016153185A1	Anticancer Functional Peptide for the Treatment of Breast Cancer	The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-kB which is overexpressed specifically in cancer stem cells present in tumors.
DRAMP32431	GKCSTRGRKMCRRKK	15	hBD3-3 M2	Not available	Antimicrobial, Anticancer	EP3111951B1	Granted Patent	2019##12##11	EP3111951A4##EP3111951B1##ES2773755T3##KR101693533B1##KR20160115314A##US2017042963A1##US9993519B2##WO2016153185A1	Anticancer Functional Peptide for the Treatment of Breast Cancer	The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-kB which is overexpressed specifically in cancer stem cells present in tumors.
DRAMP32432	CLQKTPKQC	9	PBP-1	Not available	Antimicrobial, Anticancer	EP3725799A1	Patent Application	2020##12##21	EP3725799A4##KR102150419B1##KR20190072466A##US2021163534A1	Peptide Bound to Pl-L1 and Use Thereof	The present invention relates to a peptide bound to PD-L1 and uses for cancer immunotherapy and anticancer using the same, and the peptide of the present invention specifically binds to PD-L1 and inhibits it, thereby activating the function of immune cells against cancer cells and exhibiting anticancer effects. The peptides of the present invention selected two peptides (PD-L1Pep-1 and PD-L1Pep-2) that bind well to cells with high expression of human PD-L1 protein using phage peptide display technology and it was confirmed that it inhibits its function by binding to PD-L1 in humans and mice. The peptide of the present invention showed an effect similar level to that of an antibody and is relatively stable in blood, indicating a high potential as a cancer immunotherapy in the future.
DRAMP32433	CVRARTR	7	PBP-2	Not available	Antimicrobial, Anticancer	EP3725799A1	Patent Application	2020##12##21	EP3725799A4##KR102150419B1##KR20190072466A##US2021163534A1	Peptide Bound to Pl-L1 and Use Thereof	The present invention relates to a peptide bound to PD-L1 and uses for cancer immunotherapy and anticancer using the same, and the peptide of the present invention specifically binds to PD-L1 and inhibits it, thereby activating the function of immune cells against cancer cells and exhibiting anticancer effects. The peptides of the present invention selected two peptides (PD-L1Pep-1 and PD-L1Pep-2) that bind well to cells with high expression of human PD-L1 protein using phage peptide display technology and it was confirmed that it inhibits its function by binding to PD-L1 in humans and mice. The peptide of the present invention showed an effect similar level to that of an antibody and is relatively stable in blood, indicating a high potential as a cancer immunotherapy in the future.
DRAMP32434	CNEWQLKSC	9	v6Pep-2	Screen of phage display p	Antimicrobial, Anticancer	EP3733685A1	Patent Application	2020##11##4	EP3733685A4##KR102194025B1##KR20190072467A##US2021163535A1	Peptides Binding to Cd44v6 and Use Thereof	The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.
DRAMP32435	CNLNTIDTC	9	v6Pep-1	Screen of phage display p	Antimicrobial, Anticancer	EP3733685A1	Patent Application	2020##11##4	EP3733685A4##KR102194025B1##KR20190072467A##US2021163535A1	Peptides Binding to Cd44v6 and Use Thereof	The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.
DRAMP32436	WLWKAIWKLLK	11	HDH-LGBP-A2	Not available	Antimicrobial, Anticancer	KR101749548B1	Granted Patent	2017##6##21	JP2017077236A##JP6045678B1##KR101749548B1	Antimicrobial Peptide Derived From Abalone Lipopolysaccharide and Beta-Glucan Binding Protein Nucleic Acid Encoding the Peptide and Uses Ther	The present invention relates to peptides having anticancer properties and anticancer properties as novel physiological activities, nucleic acids encoding the peptides, and applications of the peptides or nucleic acids. The peptide synthesized according to the present invention or a vector into which a nucleic acid encoding the peptide is inserted can be used as an active ingredient to be used as an antibacterial and / or anticancer composition such as a pharmaceutical composition, a cosmetic composition and / or a food additive .
DRAMP32437	WLWKAIWKLLT	11	HDH-LGBP-A1	Not available	Antimicrobial, Anticancer	KR101749548B1	Granted Patent	2017##6##21	JP2017077236A##JP6045678B1##KR101749548B1	Antimicrobial Peptide Derived From Abalone Lipopolysaccharide and Beta-Glucan Binding Protein Nucleic Acid Encoding the Peptide and Uses Ther	The present invention relates to peptides having anticancer properties and anticancer properties as novel physiological activities, nucleic acids encoding the peptides, and applications of the peptides or nucleic acids. The peptide synthesized according to the present invention or a vector into which a nucleic acid encoding the peptide is inserted can be used as an active ingredient to be used as an antibacterial and / or anticancer composition such as a pharmaceutical composition, a cosmetic composition and / or a food additive .
DRAMP32438	FWPGLILKGLGAL	13	PvVCP	Not available	Antimicrobial, Anticancer	KR101990437B1	Granted Patent	2019##6##19	KR101990437B1  	Peptide from Parapolybia varia having antitumor activity and uses thereof	The present invention relates to peptibodies derived from snake-bite monkeys having anticancer activity and uses thereof.  The peptide according to the present invention possesses excellent anticancer activity without hemolytic activity against normal cells and thus can be usefully used as an anticancer therapeutic agent.
DRAMP32439	GRPPGFSPFRSG	12	PvVespk	Not available	Antimicrobial, Anticancer	KR101990437B1	Granted Patent	2019##6##19	KR101990437B1  	Peptide from Parapolybia varia having antitumor activity and uses thereof	The present invention relates to peptibodies derived from snake-bite monkeys having anticancer activity and uses thereof.  The peptide according to the present invention possesses excellent anticancer activity without hemolytic activity against normal cells and thus can be usefully used as an anticancer therapeutic agent.
DRAMP32440	AEQAA	5	p53 TAD(50-54) Ala-substituted peptide	p57 protein	Antimicrobial, Anticancer	KR20050098766A	Patent Application	2005##12##12	KR100788928B1##US2009030181A1##US8598127B2##WO2005097820A1	Peptides for Inhibiting Mdm2 Function	The present invention relates to a peptide that inhibits mdm2-mediated function and a pharmaceutical composition comprising the same.
DRAMP32441	IEQWF	5	p53 TAD(50-54)	p53 protein	Antimicrobial, Anticancer	KR20050098766A	Patent Application	2005##12##12	KR100788928B1##US2009030181A1##US8598127B2##WO2005097820A1	Peptides for Inhibiting Mdm2 Function	The present invention relates to a peptide that inhibits mdm2-mediated function and a pharmaceutical composition comprising the same.
DRAMP32442	WEQWW	5	p53 TAD(50-54) Trp-substituted peptide	p61 protein	Antimicrobial, Anticancer	KR20050098766A	Patent Application	2005##12##12	KR100788928B1##US2009030181A1##US8598127B2##WO2005097820A1	Peptides for Inhibiting Mdm2 Function	The present invention relates to a peptide that inhibits mdm2-mediated function and a pharmaceutical composition comprising the same.
DRAMP32443	NYPQRPCRGDKGPDC	15	ACP52C	Not available	Antimicrobial, Anticancer	KR20200116394A	Patent Application	2020##10##12	KR102261371B1	CP2c Anticancer peptide for targeting CP2c	The present invention relates to a CP2c target peptide-based anticancer agent which has secured stability capable of lasting for a long time in vivo and, more specifically, to a CP2c target peptide-based anticancer agent which is a CP2c target peptide-fatty acid conjugate including: transcription factor CP2c target peptide; linker peptide; cell membrane penetrating peptide (CPP); and fatty acid.
DRAMP32471	ATWLPPRGGGKLlLKlLkkLLKlLKKK	27	VEGFR2-Lytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32472	GRVPYPRGGLLkLLKklLKKLlKL	24	Sema3A(aa371-377) -nLytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##EP2370107B1##EP2370107B8##EP3228632A1##EP3228633A1##JP2010154842A##JP2012510287A##JP2015172050A##JP5734865B2##JP5837712B2##	Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32473	LLkLLKklLKKLlKL	15	nLytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32474	NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKlLKKK	35	Sema3A(aa363-377) -kLytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A4	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32475	NYQWVPYQGRVPYPRGGLLkLLKklLKKLlKL	32	Sema3A(aa363-377) -nLytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A5	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32476	WHSDMEWWYLLGGGGKLlLKlLkkLLKlLKKK	32	Sequence 16 from Patent US 20110319336	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A6	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32477	YCDGFYACYMDVGGGKLlLKlLkkLLKlLKKK	32	Sequence 15 from Patent US 20110319336	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A7	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32478	YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK	32	EB-lytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A8	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32479	YHWYGYTPQNVIGGGLLkLLKklLKKLlKL	30	Sequence 42 from Patent US 20110319336	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A9	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32480	YRWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK	32	EB(H2R)-lytic	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	2011##12##19	CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3	Selective anticancer chimeric peptide.	It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
DRAMP32487	RRWVRRvRRVWRRVvRvVRRWvRR	24	Sequence 32 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	Not availabl	WO2018094403A1##CN109996554A##EP3541405A1##EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	Not available
DRAMP32488	RRWVRRvRRvWRRVvRvvRRWvRR	24	Sequence 33 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	Not availabl	WO2018094403A1##CN109996554A##EP3541405A1##EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	Not available
DRAMP32489	RRWvRRvRRvWRRvvRvvRRWvRR	24	Sequence 34 from Patent US 20200079827	Synthetic construct	Antimicrobial, Anticancer	US 2011/0319336 A1	Granted Patent	Not availabl	WO2018094403A1##CN109996554A##EP3541405A1##EP3541405A4	Novel Antimicrobial And Anti-cancer Therapy	Not available
DRAMP32490	RNRVKLVNLXFATLREX	17	H04	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32491	RNRVKXVNLXFATLREH	17	H02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32492	RRRRRRRRVKLVNLXFATLREXVP	24	IDP-H14-CPP	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32493	RVKLVNLXFAALREXVP	17	IDP-H14-A09	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32494	RVKLVNLXFATLRAXVP	17	IDP-H14-A12	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32495	RVKLVNLXFATLREXVF	17	IDP-H14-F14	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32496	RVKLVNLXFATLREXVP	17	H14	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32497	RVKLVNLXFATLREXVQ	17	IDP-H14-Q15	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32498	RVKLVNLXFATLREXVS	17	IDP-H14-S15	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32499	RVKLVNLXFATLRFXVP	17	IDP-H14-F12	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32500	RVKLVNLXFATLRQXVP	17	IDP-H14-Q13	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A3	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32501	RVKLVNLXFQALRQXVP	17	IDP-H14-H2-01	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A3	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32502	RVKLVNLXFQTLREXVP	17	IDP-H14-Q9	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A3	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32503	RVKLVQLXFATLREXVP	17	IDP-H14-Q6	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A3	Patent Application	Not availabl	AU2018305923A1##CA3070874A1##CN111263768A##EP3658576A1##JP2020528458A##KR20200032183A##WO2019020649A1	Anticancer Peptides	Not available
DRAMP32504	KKKKKKXXKKWRKWLAKK	18	K6-Nal2-S1	Cationic antimicrobial pe	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	TW201716428A##TWI619731B##US10093699B2	Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use o	Not available
DRAMP32505	KKKKRRXXKKWRKWLAKK	18	K4R2-Nal2-S1	Cationic antimicrobial pe	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	TW201716428A##TWI619731B##US10093699B2	Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use o	Not available
DRAMP32506	KKWRKWLAK	9	S1	Cationic antimicrobial pe	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	TW201716428A##TWI619731B##US10093699B2	Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use o	Not available
DRAMP32507	Nal-Nal-KKWRKWLAKK	18	Nal2-S1	Cationic antimicrobial pe	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	TW201716428A##TWI619731B##US10093699B2	Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use o	Not available
DRAMP32508	FLSaIVaMLaKLF	13	peptide6	analogs of antimicrobial 	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	US10550155B2	Anticancer peptides	Not available
DRAMP32509	FLSaIVaMLGKLF	13	peptide5	analogs of antimicrobial 	Antimicrobial, Anticancer	US 2011/0319336 A3	Granted Patent	Not availabl	US10550155B2	Anticancer peptides	Not available
DRAMP32510	FLSaIVGMLGKLF	13	peptide2	analogs of antimicrobial 	Antimicrobial, Anticancer	US 2011/0319336 A4	Granted Patent	Not availabl	US10550155B2	Anticancer peptides	Not available
DRAMP32511	FLSGIVaMLGKLF	13	peptide3	analogs of antimicrobial 	Antimicrobial, Anticancer	US 2011/0319336 A4	Granted Patent	Not availabl	US10550155B2	Anticancer peptides	Not available
DRAMP32512	FLSGIVGMLaKLF	13	peptide4	analogs of antimicrobial 	Antimicrobial, Anticancer	US 2011/0319336 A4	Granted Patent	Not availabl	US10550155B2	Anticancer peptides	Not available
DRAMP32513	FAFAKIIAKIAKKII	15	FLAK50 Z9	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32514	FAFGKGIGKIGKKGL	15	FLAK50 Z7	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32515	FAFGKGIGKVGKKLL	15	FLAK50 Z2	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32516	FAKAIAKIAFGKGIGKVGKKLL	22	FLAK50 Z3	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32517	FAKALAKLAKKLL	13	FLAK50B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32518	FAKALKALLKALKAL	15	FLAK 17 C	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32519	FAKFLAKFLKKAL	13	FLAK50 Q1	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A4	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32520	FAKGVGKVGKKAL	13	FLAK50 Z6	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32521	FAKIIAKIAKIAKKIL	16	FLAK50 Z8	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32522	FAKIIAKIAKKI	12	FLAK50 Z10	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32523	FAKKALKALKKL	12	FLAK77	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32524	FAKKLAKALL	10	FLAK81	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32525	FAKKLAKKAKLAKKL	15	FLAK 72	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32526	FAKKLAKKLAKAAL	14	FLAK 58	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32527	FAKKLAKKLAKAL	13	FLAK 54	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32528	FAKKLAKKLAKLAL	14	FLAK57	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32529	FAKKLAKKLAKLL	13	FLAK 56	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A5	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32530	FAKKLAKKLKKLAKKLAK	18	Shiva 10(1-18 AC)	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32531	FAKKLAKKLKKLAKKLAKKWKL	22	SHIVA 10 PEPTIDE 71 + KWKL	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32532	FAKKLAKKLKKLAKKLAKKWKL	22	SHIVA 10 PEPTIDE 71 + KWKL	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32533	FAKKLAKKLKKLAKKLAKKWKL	22	SHIVA DERIV P69 + KWKL	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32534	FAKKLAKKLKKLAKKLAKKWKL	22	SHIVA DERIV P69 + KWKL	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32535	FAKKLAKKLKKLAKKLAKLAKKL	23	Anubis-2	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32536	FAKKLAKKLKKLAKKLAKLALAL	23	SHIVA 10 AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32537	FAKKLAKKLKKLAKKLAKLALALKALALKAL	31	Shiva-11	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32538	FAKKLAKKLKKLAKKLIGAVLKV	23	SHIVA 11[(1-16)ME(2-9]-COOH	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32539	FAKKLAKKLKKLAKLALAK	19	FLAK 06R-AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A6	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32540	FAKKLAKKLKKLAKLALAL	19	FLAK06 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32541	FAKKLAKKLKKLAKLALAL	19	FLAK06 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32542	FAKKLAKKLKKLAKLALAL	19	FLAK06 R-AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32543	FAKKLAKKLKKLAKLALAL	19	FLAK06 R-AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32544	FAKKLAKKLL	10	FLAK82	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32545	FAKKLAKLAKKALAL	15	FLAK44 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32546	FAKKLAKLAKKL	12	FLAG26-D1	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32547	FAKKLAKLAKKLAKAL	16	FLAK26-D2	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32548	FAKKLAKLAKKLAKLAL	17	FLAK 26 Ac	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32549	FAKKLAKLAKKLAKLAL	17	FLAK 26 Ac	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A7	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32550	FAKKLAKLAKKLAKLAL	17	FLAK 26 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32551	FAKKLAKLAKKLAKLAL	17	FLAK 26 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32552	VAKALKALLKALKAL	15	FLAK 17 CV	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32553	FAKKLAKLAKKLAKLALAL	19	FLAK 25 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32554	FAKKLAKLAKKLLAL	15	FLAK43 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32555	FAKKLAKLALKLAKL	15	FLAK51	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32556	FAKKLKKLAKKL	12	FLAK 75	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32557	FAKKLKKLAKLAKKL	15	FLAK71	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32558	FAKKLLAKALKL	12	FLAG26-D3	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32559	FAKLA	5	FLAK90	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A8	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32560	FAKLAKKALAKLL	13	FLAK91B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32561	FAKLAKKLL	9	FLAK83M	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32562	FAKLF	5	FLAK91	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32563	FAKLFAKAFKKAL	13	FLAK50 Q5	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32564	FAKLFAKLAKKFAL	14	FLAK50 Q9	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32565	FAKLLAKAFKKAL	13	FLAK50 Q4	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32566	FAKLLAKALKKAL	13	FLAK 50O	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32567	FAKLLAKALKKFAL	14	FLAK50 Q7	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32568	FAKLLAKALKKFL	13	FLAK50 Q6	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32569	FAKLLAKALKKL	12	FLAK 50P	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A9	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32570	FAKLLAKALKKLL	13	FLAK50D	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32571	FAKLLAKALKLKL	13	FLAK 50N	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32572	FAKLLAKFLKKAL	13	FLAK50 Q3	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32573	FAKLLAKKLL	10	FLAK80	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32574	FAKLLAKLAK	10	FLAK50 T1	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32575	FAKLLAKLAKAKA	13	FLAK50K	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32576	FAKLLAKLAKAKG	13	FLAK50L	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32577	FAKLLAKLAKAKL	13	FLAK 50H	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32578	FAKLLAKLAKK	11	FLAK50T6	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32579	FAKLLAKLAKKAA	13	FLAK50J	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32580	FAKLLAKLAKKAL	13	FLAK50C	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32581	FAKLLAKLAKKEL	13	FLAK50 T4	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32582	FAKLLAKLAKKFAL	14	FLAK50 Q8	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32583	FAKLLAKLAKKGL	13	FLAK50T7	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32584	FAKLLAKLAKKIL	13	FLAK50 T3	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32585	FAKLLAKLAKKL	12	FLAK50F	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32586	FAKLLAKLAKKLL	13	FLAK50	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32587	FAKLLAKLAKKSL	13	FLAK50 T5	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32588	FAKLLAKLAKKVL	13	FLAK50 T2	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32589	FAKLLAKLAKLKL	13	FLAK 50G	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32590	FAKLLALALKLKL	13	FLAK50I	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32591	FAKLLFKALKKAL	13	FLAK50 Q2	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32592	FAKLLKLAAKKLL	13	FLAK 50E	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32593	FAKLWAKLAFGKGIGKVGKKLL	22	FLAK50 Z4	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32594	FAKLWAKLAKKL	12	FLAK50 Z5	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32595	FALA	4	FLAK-120B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32596	FALAAKALKKLAKKLKKLAKKAL	23	FLAK01 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32597	FALAKALKKAL	11	FLAK121	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32598	FALAKKALKKAKKAL	15	FLAK62 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32599	FALAKLAKKAKAKLKKALKAL	21	FLAK05 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32600	FALALKA	7	FLAK94	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32601	FALALKAKKL	10	FLAK-120C	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32602	FALALKALKK	10	FLAK96F	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32603	FALALKALKKA	11	Flak 96H	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32604	FALALKALKKAL	12	FLAK96	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32605	FALALKALKKALkkLKKALKKAL	23	HECATE 2DAc	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32606	FALALKALKKL	11	FLAK120	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32607	FALALKALKKLAKKLKKLAKKAL	23	FLAK04 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32608	FALALKALKKLKKALKKAL	19	FLAK06 AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32609	FALALKALKKLKKALKKAL	19	FLAK06 AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32610	FALALKALKKLKKALKKAL	19	FLAK06 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32611	FALALKALKKLKKALKKAL	19	FLAK06 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32612	FALALKALKKLLKKLKKLAKKAL	23	FLAK03 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32613	FALALKKALKALKKAL	16	FLAK 17 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32614	FALALKLAKKAL	12	FLAK96B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32615	FALALKLAKKL	11	Flak 96J	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32616	FALALKLKKL	10	FLAK-120D	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32617	FALKALKK	8	FLAK97	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32618	FALKALKKAL	10	FLAK96C	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32619	FALKALKKLKKALKKAL	17	FLAK95	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32620	FALLKALKKAL	11	FLAK96D	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32621	FALLKALLKKAL	12	Flak 96I	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32622	FALLKL	6	FLAK96G	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32623	FGKGIGKVGKKLL	13	FLAK50 Z1	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32624	FKLAFKLAKKAFL	13	FLAK50 Q10	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32625	FKRLAKIKVLRLAKIKR	17	FKRLA	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32626	FKVKFKVKVK	10	KSL-7	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32627	KWKLFKKKTKLFKKFAKKLAKKL	23	CA (1-7) Shiva10 (1-16)-COOH	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32628	KWKLFKKKTKLFKKFAKKLAKKL	23	CA (1-7) Shiva10 (1-16)-COOH	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32629	KAKLAKKALAKLL	13	FLAK92B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32630	KAKLF	5	FLAK92	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32631	KFKKLAKKF	9	Modelin-8D	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32632	KFKKLAKKW	9	Modelin-8E	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32633	KIAKVALAKLGIGAVLKVLTTGL	23	PYL-ME	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32634	KLAKKLAKLAKLAKAL	16	Modelin-5	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32635	KLAKKLAKLAKLAKAL	16	Modelin-5	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32636	KLAKKLAKLAKLAKAL	16	Modelin-5-CO2H	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32637	KLAKKLAKLAKLAKAL	16	Modelin-5-CO2H	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32638	KLALKLALKALKAAKLA	17	FLAK99	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32639	KLLKLLLKLYKKLLKLL	17	FLAK100-CO2H	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32640	KTKLFKKFAKKLAKKLKKLAKKL	23	SHIVA 10 (1-16)	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32641	KWKKLAKKW	9	FLAK120	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32642	KWKLAKKALALL	12	FLAK93B	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32643	KWKLF	5	FLAK93	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32644	KWKLFKKALKKLKKALKKAL	20	CA(1-& HECATE(11/23)	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32645	KWKLFKKKTKLFKKFAKKLAKKL	23	CA (1-7) Shiva10 (1-16)	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32646	KWKLFKKKTKLFKKFAKKLAKKL	23	CA (1-7) Shiva10 (1-16)	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32647	KYKKALKKLAKLL	13	FLAK98	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32648	LKKLAKLALAF	11	Flak 96L	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32649	LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	38	LSB-37	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32650	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	38	SB-37 AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32651	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	38	SB-37 AC	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32652	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	38	SB-37 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32653	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	38	SB-37 AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32654	VAKFLAKFLKKAL	13	FLAK50 Q1V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32655	VAKKFAKKFKKFAKKFAKFAFAF	23	D2A21V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32656	VAKKLAKLAKKLAKLAL	17	FLAK26V AM	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32657	VAKKLAKLAKKLAKLALAL	19	FLAK 25 AM V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32658	VAKKLAKLAKKLLAL	15	FLAK43 AM V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32659	VAKLLAKALKKLL	13	FLAK50D V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32660	VAKLLAKLAKKLL	13	FLAK50V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32661	VAKLLAKLAKKVL	13	FLAK50T8	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32662	VALALKALKKALKKLKKALKKAL	23	Hecate AC V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32663	VALALKALKKALKKLKKALKKAL	23	Hecate AC V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32664	VALALKALKKALKKLKKALKKAL	23	Hecate AM V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32665	VALALKALKKALKKLKKALKKAL	23	Hecate AM V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32666	VALALKALKKL	11	FLAK-120G	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32667	VALALKALKKLAKKLKKLAKKAL	23	FLAK04 AM V	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32668	WALAL	5	FLAK-120F	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32669	YAKLLAKLAKKAL	13	FLAK50T9	FLAK peptides	Antimicrobial, Anticancer	US 2011/0319336 A1	Patent Application	Not availabl	Not available	Short bioactive peptides and methods for their use	Not available
DRAMP32670	YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLERRRRRRRRR	41	pDBD * 4R9	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US2009203594A1	Anticancer peptide	Not available
DRAMP32671	lKKllKKllKKl	12	DDA-DL6K6-22	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32672	lKKllKKllKKl	12	DDA-DL6K6-22	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32673	lKKllKKllKKl	12	DDA-DL6K6-22	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32674	lKKllKKllKKl	12	DDA-DL6K6-22	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32675	lRRllRRllRRl	12	DDA-DL6R6-25	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32676	lKKllKKllKKl	12	DL6K6	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32677	lKKllKKllKKl	12	DL6K6	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32678	lKKllKKllKKl	12	DL6K6	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32679	lKKllKKllKKl	12	DL6K6	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32680	lKKllKKllKKl	12	MA-DL6K6-23	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32681	lKKllKKllKKl	12	MA-DL6K6-23	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32682	lKKllKKllKKl	12	MA-DL6K6-23	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32683	lKKllKKllKKl	12	MA-DL6K6-23	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32684	lKKllKKllKKl	12	PA-DL6K6-24	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32685	lKKllKKllKKl	12	PA-DL6K6-24	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32686	lKKllKKllKKl	12	PA-DL6K6-24	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32687	lKKllKKllKKl	12	PA-DL6K6-24	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2004246909A1##AU2004246909B2##CA2529125A1##EP1633380A2##EP1633380A4##US2010160213A1##US7671011B2##US8445636B2##WO2004110341A2##WO2004110341A3	Antimicrobial and anticancer lipopeptides	Not available
DRAMP32688	WRYMVm	6	SEQ ID NO: 4	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CA2634902A1##CA2634902C##CN101370510A##CN101370510B##EP1976545A1##EP1976545B1##JP2009520812A##JP4880700B2##KR101040299B1##KR20080071194A##US2007219139	Immune-Modulating Peptide	Not available
DRAMP32689	EARPALLTSRLRFIPK	16	pep1	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN106456697A##CN106456697B##EP3130345A1##EP3130345A4##EP3130345B1##JP2017513941A##JP2018193384A##JP6420459B2##JP6748155B2##KR20160135358A##US201820724	Peptide Having Fibrosis Inhibitory Activity and Composition Containing Same	Not available
DRAMP32690	AQTGTGKT	8	AQTGTGKT	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10233221B2##US10239924B2##US2018079792A1##WO2016099188A1	Peptide Having Eight Amino Acid Sequences Derived From Cage and Retaining Anticancer Activity and Activity to Promote Anticancer Drug Sensiti	Not available
DRAMP32691	D-AQTGTGKT	10	D-AQTGTGKT	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10233221B2##US10239924B2##US2018079792A1##WO2016099188A1	Peptide Having Eight Amino Acid Sequences Derived From Cage and Retaining Anticancer Activity and Activity to Promote Anticancer Drug Sensiti	Not available
DRAMP32692	GTGKA	5	Not available	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10716826B2 	Compositions for Overcoming Anti-Cancer Drug-Resistance or Compositions for Anti-Cancer Activity Employing Cage-Derived Peptides	Not available
DRAMP32693	GTGKT	5	Not available	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10716826B2 	Compositions for Overcoming Anti-Cancer Drug-Resistance or Compositions for Anti-Cancer Activity Employing Cage-Derived Peptides	Not available
DRAMP32694	GSNKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDS	91	Kr1(1-91 ActiveZone)frag SEQ ID NO: 19	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10905750B2  	Grp78 Antagonist That Block Binding of Receptor Tyrosine Kinase Orphan Receptors as Immunotherapy Anticancer Agents	Not available
DRAMP32695	NHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSCD	89	Kr1(3-91 ActiveZone)frag-Fc SEQ ID NO: 	Not available	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US10905750B2  	Grp78 Antagonist That Block Binding of Receptor Tyrosine Kinase Orphan Receptors as Immunotherapy Anticancer Agents	Not available
DRAMP32696	AAKVVILKKATEYVES	16	IDP-wtLN10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32697	AAXVVILKKXTEYVHS	16	IDP-NS10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32698	APKVVILXKALEYLXA	16	IDP-LS17	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32699	APKVVXLSKALEXLQA	16	IDP-LS16	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32700	RKRRNDLRSRFLALRDQ	17	IDP-wtL05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32701	RKRRNDLRSXFLALRDX	17	IDP-LS15	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32702	RKRRNDLXSRFLALXDQ	17	IDP-LS13	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32703	RKRXNDLRSRXLALRDQ	17	IDP-LS05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32704	RQRRNDLXSSFLTLXDH	17	IDP-NS16	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32705	RQRRNKLRSKFLTLRDH	17	IDP-NS02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32706	RRNDLRSXFLALRDXVP	17	IDP-La05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32707	RRNDLRSXFLTLRDXVP	17	Na05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32708	RRRRRRRAAKVVILKKATEYVHS	23	IDP-intwtLN10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32709	RRRRRRRRKRRNDLRSRFLALRDQ	24	IDP-intwtL05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32710	RRRRRRRRQRRNDLRSSFLTLRDHVP	26	NLCa02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32711	RRRRRRRRVKLVNLGFATLREHVP	24	LH02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32712	RRRRRRRSKAPKVVILSKALEYLQA	25	IDP-LLCb01	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32713	RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA	25	IDP-LLCb02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32714	RVKLVNLGFATLREHVP	17	LH01	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32715	SKAPKXVILSKAXEYL	16	IDP-Lb06	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32716	SKAPXVVILSKXLEYL	16	IDP-Lb05	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32717	SKAXKVVILSXALEYL	16	IDP-Lb04	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32718	SKXPKVVILXKALEYL	16	IDP-Lb03	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32719	SXAPKVVIXSKALEYL	16	IDP-Lb02	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32720	XKAPKVVXLSKALEYL	16	IDP-Lb01	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AU2018311129A1##CA3071601A1##CN111436200A##EP3661947A1##JP2020529429A##KR20200032730A##WO2019025432A1	Anticancer Peptides	Not available
DRAMP32721	KWKKLLKKPPPLLKKLLKKL	20	Synthetic peptide	Synthetic	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	KR100438416B1##KR20030024961A##US6800727B2 	Peptides with increased + charge and hydrophobicity by substituting one or more amino acids of CA-MA peptide and pharmaceutical compositions 	Not available
DRAMP32722	LMXYLK	6	SEQ ID NO: 18	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32723	LMXTYLK	7	SEQ ID NO: 8	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2  	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32724	LMXTYLK	7	SEQ ID NO: 8	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2  	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32725	LMXTYLK	7	SEQ ID NO: 9	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32726	LMXTYLK	7	SEQ ID NO: 9	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32727	LMYXYLK	7	SEQ ID NO: 10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32728	LMYXYLK	7	SEQ ID NO: 10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32729	LMYXYLK	7	SEQ ID NO: 10	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32730	LMYXTYLK	8	SEQ ID NO: 3	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2  	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32731	LMYXYLK	7	SEQ ID NO: 12	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32732	LMYXYLK	7	SEQ ID NO: 12	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32733	LMYXYLK	7	SEQ ID NO: 12	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32734	LMYXYLK	7	SEQ ID NO: 13	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32735	LMYXYLK	7	SEQ ID NO: 13	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32736	LMYXYLK	7	SEQ ID NO: 13	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32737	MXYL	4	SEQ ID NO: 14	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32738	MXYL	4	SEQ ID NO: 14	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32739	MXYL	4	SEQ ID NO: 14	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32740	MXYL	4	SEQ ID NO: 16	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32741	MXYL	4	SEQ ID NO: 16	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32742	MXYL	4	SEQ ID NO: 16	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32743	MXYL	4	SEQ ID NO: 17	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32744	MXYL	4	SEQ ID NO: 17	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32745	MXYL	4	SEQ ID NO: 17	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Granted Patent	Not availabl	US7060678B2	Peptides comprising furanoid sugar amino acids for the treatment of cancer	Not available
DRAMP32746	KWKLFKKIGIGRLLKRGLRKLLKLLR	26	GK-2	AMPs	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	AT528316T##AU2003293296A1##CN1269837C##CN1398897A##EP1541584A1##EP1541584A4##EP1541584B1##US2008070279A1##US7629438B2	A Group of Novel Synthetic Antibiotic Peptides	Not available
DRAMP32747	KAMKSIAKFIAK	12	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32748	KGWFKAMKSIAKFIAKEKLKEHL	23	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32749	KGWFKAMKSIAKFIAKEKMKEHL	23	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32750	RKGWFKAMKSIAKFIAKEKLKEHL	24	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32751	WFKAMKSIAKFIAKEKLK	18	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32752	YRPWGSGSGF	10	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32753	YRPWGSGSGFG	11	Not available	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	CN100590130C##CN101168563A##EP2184295A1##EP2184295A4##EP2184295B1##JP2010534689A##JP5707594B2##US2010145012A1##US8207122B2	Polypeptides Having Anticancer Activity	Not available
DRAMP32754	GQVWEATATVNAIRGSVTPAVSQFNARTAD	30	MB30	Derived from the MPT63 se	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	WO2012042540A9##EP2621510A2##EP2621510A4##JP2013543493A##JP5873499B2##US2014051643A1##US9624277B2	Anticancer Agent	Not available
DRAMP32755	NHFTLKCPKTALTEPPTLAY	20	TG20	Derived from the SAG1 sur	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	WO2012042540A9##EP2621510A2##EP2621510A4##JP2013543493A##JP5873499B2##US2014051643A1##US9624277B2	Anticancer Agent	Not available
DRAMP32756	TAGIKLTVPIEKFPVTTQTFWG	22	TG23	Derived from the SAG1 sur	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	WO2012042540A9##EP2621510A2##EP2621510A4##JP2013543493A##JP5873499B2##US2014051643A1##US9624277B2	Anticancer Agent	Not available
DRAMP32757	GRKKRRQRRRPQ	12	PIER4 (Tat-PIER1)	AMPs	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	US201261606551P20120305	Hsp90 Inhibitor for the Treatment of Cancer and Inflammatory Diseases	Not available
DRAMP32758	CRKRLDRCGGGKLAKLAKKLAKLAK	25	IL4RPep1KLA	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	JP2018521998A##JP6720227B2##KR101741594B1##KR20170003203A##US2018201651A1	Pharmaceutical Composition That Is Anticancer and Suppresses Cancer Metastasis, Containing, as Active Ingredient, Fusion Peptide Simultaneous	Not available
DRAMP32759	ISGGNDKQGFPM	12	RPS6 subunit anticancer peptide	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	JP2018521998A##JP6720227B2##KR101741594B1##KR20170003203A##US2018201651A1	Pharmaceutical Composition That Is Anticancer and Suppresses Cancer Metastasis, Containing, as Active Ingredient, Fusion Peptide Simultaneous	Not available
DRAMP32760	AVPSP	5	ANS-1	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	KR102241134B1##KR20210017560A  	Anticancer Virus Expressing Fgf2- or Api5-Derived Peptide, and Use Thereof	Not available
DRAMP32761	AVPSPPPAS	9	ANS-2	Synthetics	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	KR102241134B1##KR20210017560A  	Anticancer Virus Expressing Fgf2- or Api5-Derived Peptide, and Use Thereof	Not available
DRAMP32762	KRTGQYKLGSKT	12	FGF2 derived peptides	API13 derived peptides	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	KR102241134B1##KR20210017560A  	Anticancer Virus Expressing Fgf2- or Api5-Derived Peptide, and Use Thereof	Not available
DRAMP32763	LEDVTGEEF	9	API5 derived peptides	API5 derived peptides	Antimicrobial, Anticancer	US 2011/0319336 A2	Patent Application	Not availabl	KR102241134B1##KR20210017560A  	Anticancer Virus Expressing Fgf2- or Api5-Derived Peptide, and Use Thereof	Not available
DRAMP33233	FLSGIVGMLGKLE	13	Temporin-1Sa, SEQ ID NO:1 for Patent EP	Pelophylax saharicus (Sah	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33234	FLKGIVGMLGKLE	13	Temporin-1Sa [S3K], SEQ ID NO:29 for Pa	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33235	KGIVGMLGKLE	11	Temporin-1Sa [S3K] (3-13), SEQ ID NO:30	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33236	FLKGIKGMLGKLF	13	Temporin-1Sa [S3K,V6K], SEQ ID NO:3 for	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33237	FLKGIVGKLGKLF	13	Temporin-1Sa [S3K,M8K], SEQ ID NO:4 for	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33238	FLKGIVGMLGKLL	13	Temporin-1Sa [S3K,F13L], SEQ ID NO:5 fo	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33239	FLKGIKGMLGKLL	13	Temporin-1Sa [S3K,V6K,F13L], SEQ ID NO:	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33240	FLKGIVGMLGKLW	13	Temporin-1Sa [S3K,F13W], SEQ ID NO:6 fo	Synthetic (Derived from T	Antimicrobial, Anticancer	EP 2853538 A1	Patent Application	2015##4##1	BR112016006424A2##CA2924035A1##EP3049432A1##EP3049432B1##ES2691323T3##JP2016539658A##JP6669656B2##US2016280749A1##US9932376B2##WO2015044356A1	Analogues of temporin-SHa and uses thereof	The present invention relates to novel antimicrobial peptides, to pharmaceutical compositions comprising said peptides, and to the uses thereof, in particular as antimicrobial drugs, disinfectants, pesticides or preservatives. The present invention also relates to a transgenic plant expressing said novel peptides.
DRAMP33333	RRPKGRGKRRREKQRP	16	P6 (SEQ ID NO:1 for Patent US 200301868	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33334	RRPKGRGKRRREKQRPCDKPRR	22	P6V8 (SEQ ID NO:4 for Patent US 2003018	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33335	RRPKGRGKRRREKQRPSDKPRR	22	P6V8CS (SEQ ID NO:5 for Patent US 20030	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33336	RRPKGRGKRRREKQRPDAVPRR	22	P6P7 (SEQ ID NO:7 for Patent US 2003018	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33337	CKGRGKRCREKQRPSDKPRR	20	P6V8-3NCS1-7CC (SEQ ID NO:12 for Patent	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33338	KGRGKRRREKQRPCDKPRR	19	P6V8-3N (SEQ ID NO:13 for Patent US 200	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33339	RRREKQRPCDKPRR	14	P6V8-8N (SEQ ID NO:14 for Patent US 200	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33340	KGRGKRRREKQRPSDKPR	18	P6V8-3NCS-1C (SEQ ID NO:17 for Patent U	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33341	KGRGKRRREKQRPSDKP	17	P6V8-3NCS-2C (SEQ ID NO:18 for Patent U	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33342	KGRGKRRREKQRPSDKPRR	19	P6V8-3NCS (SEQ ID NO:20 for Patent US 2	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33343	RRPKGRAAARREKQRPSDKPRR	22	AS-2 (SEQ ID NO:22 for Patent US 200301	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33344	RRPKGRGKRAAAKQRPSDKPRR	22	AS-3 (SEQ ID NO:23 for Patent US 200301	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33345	AGRGKRRREKQRPSDKPRR	19	P6V8-3NCSA1 (SEQ ID NO:24 for Patent US	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33346	KGRGARRREKQRPSDKPRR	19	P6V8-3NCSA5 (SEQ ID NO:25 for Patent US	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33347	KGAGKRRREKQRPSDKPRR	19	P6V8-3NCSA3 (SEQ ID NO:27 for Patent US	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33348	KGRGKARREKQRPSDKPRR	19	P6V8-3NCSA6 (SEQ ID NO:28 for Patent US	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33349	KGRGKRRREKQGPSDKPRR	19	P6V8-3NRGCS (SEQ ID NO:31 for Patent US	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33350	KGRGKRRREKQRPSDAPAA	19	P6V8-3NCSA16,18,19 (SEQ ID NO:32 for Pa	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33351	KGRGKRAAEAQRPSDKPRR	19	P6V8-3NCSA7,8,10 (SEQ ID NO:33 for Pate	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33352	KGRGKRAAEKQAPSDKPRR	19	P6V8-3NCSA7,8,12 (SEQ ID NO:34 for Pate	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33353	AGRGARAAEAQRPSDKPRR	19	P6V8-3NCSA1,5,7,8,10 (SEQ ID NO:35 for 	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP33354	RRPKGRGKRRREKQRPSDAAAR	22	AS-5 (SEQ ID NO:39 for Patent US 200301	Synthetic	Antimicrobial, Anticancer	US 20030186868 A1	Patent Application	2003##10##2	AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3	Anti-angiogenic peptides	Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth. 
DRAMP35729	LLCLDGTRKPVTEAQSCHLAVAPNHAVVSR	30	Lactotransferrin (590-619), Lactofungin	Synthetic	Antimicrobial, Anticancer	Not available	Not available	2020##2##11	Not available	Not available	Not available
DRAMP36006	AEIEADRSY	9	SEQ ID NO: 531 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	Not availabl	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36035	ALARQPLTGSPPNERAFFCSSLRR	24		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36036	AWYRGAAPPKQEFLDIEDP	19	aa 176-194	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Patent Application	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36045	CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFAC	40	aa 128-167; partial loop-4+loop-5+loop-	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Patent Application	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36046	CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSC	48	AA 128-175; loop-4+loop-5+loop-6	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Patent Application	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36047	CLWMDWVTEKNINGHQAKFFAC	22	aa 146-167; loop-5	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Patent Application	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36048	DDDDKRAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV	40		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36055	ECLWMDWVTEKNINGHQAKFFACI	24	Loop 6	Synthetic	Antimicrobial, Anticancer	US8431396B2	Granted Patent	2013##4##13	Not available	Anti-angiogenic peptides	A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.
DRAMP36079	IARALFEKKV	10		Synthetic	Antimicrobial, Anticancer	US7365159B2	Granted Patent	2008##4##29	Not available	Angiostatin protein	The present invention provides plasminogen fragments containing kringle region domains having anti-angiogenic activity and termed angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.
DRAMP36081	INEFLERSGIPRQRNQ	16		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36082	INGSLDKRLLPDVET	15		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36083	INGSLDKRVQDCYHG	15		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36084	INLEACLGRTLMD	13		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36085	INLEACLKRGRT	12		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36092	KITRCPMIPC	10	aa 129-138; partial loop-4+loop-5	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Granted Patent	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36093	KITRCPMIPCYISSPDE	17	aa 129-145; partial loop-4+loop-5	Synthetic	Antimicrobial, Anticancer	US20020086420A1	Granted Patent	2002##7##4	Not available	Novel antiangiogenic peptides	The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition. 
DRAMP36112	LVPRGSRAGSPSGGPFCALARQPLTGARLMSGLFFALHET	40		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36116	MFSPILSLEIILALATLQSVFAQPVICTTVGSAAEGS	37		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36129	RAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV	35		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36130	RCRLAERRQIAK	12		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36149	SVSGGGHHHHHHGGG	15		Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36150	SVSRAGSPSGGPFC	14	synVB1	Synthetic	Antimicrobial, Anticancer	US6057122A	Patent Application	2000##5##2	Not available	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis	Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
DRAMP36156	TRCPMIPCYI	10	Loop 5	Synthetic	Antimicrobial, Anticancer	US8431396B2	Granted Patent	2013##4##30	Not available	Anti-angiogenic peptides	A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.
DRAMP36167	YPYDVPDYASL	11	SEQ ID NO:48 of US7365159B2	Synthetic	Antimicrobial, Anticancer	US 7365159 B2	Patent Application	2008##4##29	Not available	Angiostatin protein	The present invention provides plasminogen fragments containing kringle region domains having anti-angiogenic activity and termed angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.
DRAMP36173	CGAYDLRRRERQSRLRRRERQSR	23	DPV15b	Protein derived	Antimicrobial, Anticancer	US20090186802A1	Granted Patent	2009##7##23	Not available	Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell	The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.
DRAMP36174	RKKRRRESRKKRRRESC	17	DPV3	Protein derived	Antimicrobial, Anticancer	US20090186802A1	Granted Patent	2009##7##23	Not available	Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell	The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.
DRAMP36175	CVKRGLKLRHVRPRVTRDV	19	DPV1048	Protein derived	Antimicrobial, Anticancer	US20090186802A1	Granted Patent	2009##7##23	Not available	Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell	The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.
DRAMP36176	RILQQLLFIHFRIGCRHSRI	20	LR20	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36177	RILQQLLFIHFRIGCRH	17	LR17	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36178	RILQQLLFIHFRIGC	15	LR15	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36179	RIFIHFRIGC	10	LR15DL	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36180	RIFIRIGC	8	LR8DHF	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36181	RILQQLLFIHF	11	LR11	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36182	RIFIGC	6	LR8DHFRI	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36183	FIRIGC	6	LR8DRIHF	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36184	DTWAGVEAIIRILQQLLFIHFR	22	C45D18	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36185	IGCRH	5	Penetration	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36186	GYGRKKRRGRRRTHRLPRRRRRR	23	YM-3	Synthetic	Antimicrobial, Anticancer	US 20100203611A1	Granted Patent	2010##8##12	Not available	NOVEL NUCLEAR TRANSLOCATION PEPTIDE	The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
DRAMP36187	GLWRALWRLLRSLWRLLWKA	20	CADY-1 (SEQ ID No: 2)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36188	GLWRALWRALWRSLWKLKRKV	21	CADY-1b (SEQ ID No: 3)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36189	GLWRALWRALRSLWKLKRKV	20	CADY-1c (SEQ ID No: 4)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36190	GLWRALWRGLRSLWKLKRKV	20	CADY-1d (SEQ ID No: 5)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36191	GLWRALWRGLRSLWKKKRKV	20	CADY-1e (SEQ ID No: 6)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36192	GLWRALWRALWRSLWKLKWKV	21	CADY-2 (SEQ ID No: 8)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36193	GLWRALWRALWRSLWKSKRKV	21	CADY-2b (SEQ ID No: 9)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36194	GLWRALWRALWRSLWKKKRKV	21	CADY-2c (SEQ ID No: 10)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36195	GLWRALWRLLRSLWRLLWSQPKKKRKV	27	CADY-2e (SEQ ID No: 12)	Synthetic	Antimicrobial, Anticancer	US7943581B2	Granted Patent	2011##5##17	Not available	Cell penetrating peptides for intracellular delivery of molecules	The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
DRAMP36196	PARAARRAARR	11	CTP501	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36197	YPRAARRAARR	11	CTP502	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36198	YRRAARRAARA	11	CTP503	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36199	YGRAARRAARR	11	CTP504	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36200	YAREARRAARR	11	CTP505	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36201	YEREARRAARR	11	CTP506	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36202	YKRAARRAARR	11	CTP507	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36203	YARKARRAARR	11	CTP508	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36204	YKRKARRAARR	11	CTP509	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36205	YGRRARRAARR	11	CTP510	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36206	YGRRARRRARR	11	CTP511	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36207	YGRRARRRRRR	11	CTP512	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36208	YGRRRRRRRRR	11	CTP513	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36209	YRRRRRRRRRR	11	CTP514	Synthetic	Antimicrobial, Anticancer	US7101844B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36210	CWKKK	5	AlkCWK3 (SEQ ID NO:4)	Synthetic	Antimicrobial, Anticancer	US7112442B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36211	CWKKKKKKKK	10	AlkCWK8 (SEQ ID NO:5)	Synthetic	Antimicrobial, Anticancer	US7112442B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36212	CWKKKKKKKKKKKKK	15	AlkCWK13 (SEQ ID NO:6)	Synthetic	Antimicrobial, Anticancer	US7112442B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36213	CWKKKKKKKKKKKKKKKKKK	20	AlkCWK18 (SEQ ID NO:3)	Synthetic	Antimicrobial, Anticancer	US7112442B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36214	KKKKKKKKKKKKKKKKKKK	19	Polylysine19 (SEQ ID NO:2)	Synthetic	Antimicrobial, Anticancer	US7112442B2	Granted Patent	2006##9##5	Not available	Cytoplasmic transduction peptides and uses thereof	The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
DRAMP36215	AGYXLLGKTNLKALAALAKKIL	22	NF 1	Protein derived	Antimicrobial, Anticancer	EP2491952A1	Granted Patent	2012##8##29	Not available	A system for cargo delivery into the cells	The present invention relates to a system for intracellular cargo delivery, named NickFect, comprising at least one component A, which is attached covalently to cell penetrating peptide B and/or peptide or non-peptide construct C. The said delivery system NickFect relates to chemically modified new cell-penetrating peptides (CPP) non-covalently or covalently complexed with cargo for efficient cellular.
DRAMP36216	AGYLLGKTXNLKALAALAKKIL	22	NF 2	Protein derived	Antimicrobial, Anticancer	EP2491952A1	Granted Patent	2012##8##29	Not available	A system for cargo delivery into the cells	The present invention relates to a system for intracellular cargo delivery, named NickFect, comprising at least one component A, which is attached covalently to cell penetrating peptide B and/or peptide or non-peptide construct C. The said delivery system NickFect relates to chemically modified new cell-penetrating peptides (CPP) non-covalently or covalently complexed with cargo for efficient cellular.
DRAMP36217	AGYXLLGKTXNLKALAALAKKIL	23	NF 3	Protein derived	Antimicrobial, Anticancer	EP2491952A1	Granted Patent	2012##8##29	Not available	A system for cargo delivery into the cells	The present invention relates to a system for intracellular cargo delivery, named NickFect, comprising at least one component A, which is attached covalently to cell penetrating peptide B and/or peptide or non-peptide construct C. The said delivery system NickFect relates to chemically modified new cell-penetrating peptides (CPP) non-covalently or covalently complexed with cargo for efficient cellular.
DRAMP36218	AGYXLLGKINLKALAALAKKIL	22	NF 5	Protein derived	Antimicrobial, Anticancer	EP2491952A1	Granted Patent	2012##8##29	Not available	A system for cargo delivery into the cells	The present invention relates to a system for intracellular cargo delivery, named NickFect, comprising at least one component A, which is attached covalently to cell penetrating peptide B and/or peptide or non-peptide construct C. The said delivery system NickFect relates to chemically modified new cell-penetrating peptides (CPP) non-covalently or covalently complexed with cargo for efficient cellular.
DRAMP36219	RKKRKKKRXRHXRHXRHXR	19	Pepfect 1	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36220	MVTVLFRRLRIRRACGPPRVRV	22	Pepfect 2	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36221	MVTVLFRRLRIRRACGPPRVRV	22	Pepfect 2	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36222	AGYLLGXINLKALAALAKKIL	21	Pepfect 4	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36223	AGYLLGXINLKALAALAKKIL	21	Pepfect 4	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36224	AGYLLGXINLKALAALAKKIL	21	Pepfect 4	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36225	AGYLLGXINLKALAALAKKIL	21	Pepfect 4	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36226	AGYLLGXINLKALAALAKKIL	21	Pepfect 5	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36227	AGYLLGXINLKALAALAKKIL	21	Pepfect 5	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36228	AGYLLGXINLKALAALAKKIL	21	Pepfect 5	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36229	AGYLLGXINLKALAALAKKIL	21	Pepfect 5	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36230	AGYLLGXINLKALAALAKKIL	21	Pepfect 6	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36231	AGYLLGXINLKALAALAKKIL	21	Pepfect 6	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36232	AGYLLGXINLKALAALAKKIL	21	Pepfect 6	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36233	AGYLLGXINLKALAALAKKIL	21	Pepfect 6	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36234	LLOOLAAAALOOLL	14	Pepfect 14	Synthetic	Antimicrobial, Anticancer	US20140140929A1	Granted Patent	2014##5##22	Not available	CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS	The present invention relates to a system for intracellular delivery of a cargo comprising at least one component A chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from N, S, O and P, wherein component(s) A is (are) attached to a cell penetrating peptide B and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material. Finally it relates to novel peptides.
DRAMP36315	KALKALKKALKALKDGR	17		Synthetic	Antimicrobial, Anticancer	CN114805493A	Granted Patent	2022##7##29	Not available	Preparation and anti-tumor effect of RGD/KLA integrated lipopeptide	The invention relates to an anticancer lipopeptide C 8 H 15 The preparation of O-Lys-Ala-Leu-Lys-Ala-Leu-Lys-Lys-Ala-Leu-Lys-Ala-Leu-Lys-Asp-Gly-Arg and the application thereof in the anti-tumor treatment belong to the field of biological medicine. The anticancer lipopeptides are prepared based on key biological features of membrane-cleavable peptides (positive charge, alpha-helical structure and amphiphilicity). The invention provides a solid-phase synthesis method of the anticancer lipopeptide. The anticancer lipopeptide has the characteristics of low hemolytic activity and good serum stability, can effectively make up the defect of high hemolytic toxicity of most anticancer peptides, and solves the problem of high hemolytic toxicity of the anticancer peptidesThe problem of poor in vivo stability of peptide drugs. In vitro anticancer experiments and in vivo antitumor experiments prove that the anticancer lipopeptide has good antitumor effect and good application prospect.
DRAMP36316	KLLKFIWRI	9	SEQ ID NO.1 of Patent CN114409737A	Synthetic	Antimicrobial, Anticancer	CN114409737A	Patent Application	2022##4##29	Not available	Novel anti-tumor peptide and application thereof	The invention discloses a novel anti-tumor peptide and application thereof, wherein the anti-tumor peptide is safe and nontoxic to normal human cells and can effectively inhibit the activity of tumor cells. The amino acid sequence (N-terminal to C-terminal) of the anti-tumor peptide is as follows: Lys-Leu-Leu-Lys-Phe-Ile-Trp-Arg-Ile.
DRAMP36317	FLWSRILFRLRK	12	Ped4	Synthetic	Antimicrobial, Anticancer	CN114989259A	Patent Application	2022##90##2	Not available	Small molecule peptide Ped4 and application	The invention provides a small molecular peptide Ped4 and application thereof. The amino acid sequence of the small molecule peptide Ped4 is FLWSRILFRLRK. The small molecular peptide Ped4 provided by the invention has the effects of inhibiting glioma cell activity, inhibiting glioma cell metastasis and inhibiting glioma cell proliferation. The small molecular peptide Ped4 has the advantages of small molecular weight, easy synthesis, high selectivity, low toxicity and the like, has obvious inhibition effect on glioma cells, the metastasis of glioma cells and the proliferation of glioma cells, and can be used as a candidate molecule of a substitute drug or an auxiliary drug of the existing anticancer drug.
DRAMP36318	LLRHVVKILKYLHGVSGHGQHGVHG	25	SEQ ID NO.01 of Patent CN 113234128A	Synthetic	Antimicrobial, Anticancer	CN113234128A	Patent Application	2021##8##10	Not available	Anti-tumor active polypeptide and application thereof	The invention discloses an anti-tumor active polypeptide and application thereof, wherein the amino acid sequence of the polypeptide is shown as SEQ ID NO. 01. The anti-tumor active polypeptide and the modified variant thereof have strong tumor cell inhibition capability and low killing effect on normal cells.
DRAMP36319	HFEYWEERHK	10		Synthetic	Antimicrobial, Anticancer	CN113292635A	Patent Application	2021##8##24	Not available	CD47 targeting polypeptide and application thereof	The invention provides a polypeptide targeting CD47 and application thereof. The polypeptide of the invention can specifically recognize and bind to CD47 protein. The invention also provides the polypeptide, a bivalent body, a multivalent body and a polypeptide conjugate formed by the polypeptide, and application of the polypeptide in preparing a diagnosis and treatment agent and an imaging agent for targeting and killing tumor cells. The polypeptide is synthesized by a chemical method, is simple to prepare, strong in specificity, high in selectivity, safe and reliable, overcomes the defects of long production cycle of an antibody biological preparation and the like, and can be used for preparing a cancer-targeted probe. The invention can carry out immune blocking on the CD47 protein by an immunotherapy method, thereby activating the recognition and phagocytosis of an in-vivo immune system on tumor cells, effectively inhibiting the growth and the metastasis of tumors and realizing good anti-tumor 
DRAMP36320	ELQSTGRKVA	10	PEP01	Synthetic	Antimicrobial, Anticancer	CN113354711A	Patent Application	2021##9##7	Not available	Anti-cancer bioactive peptide and synthesis method thereof	The invention discloses an anticancer bioactive peptide, which comprises an amino acid sequence shown as SEQ ID NO. 1. The anticancer bioactive peptide is safe and effective, and has an obvious effect.
DRAMP36321	DASTKKLSECLRRIGDELDS	20	Bax-BH3	Synthetic	Antimicrobial, Anticancer	CN113549143A	Patent Application	2021##10##26	Not available	Anti-tumor polypeptide Bax-BH3, fluorescent polymer nano-micelle as well as preparation method and application of fluorescent polymer nano-mi	The invention provides an anti-tumor polypeptide Bax-BH3, a fluorescent polymer nano micelle, and a preparation method and application thereof, and belongs to the technical field of medicines, wherein the amino acid sequence of the anti-tumor polypeptide Bax-BH3 is shown as SEQ ID No. 1; the fluorescent polymer nano micelle comprises the antitumor polypeptide Bax-BH 3and a polymer carrier, wherein the polymer carrier is a block copolymer RGD-PHPMA-b-Poly (MMA-alt- (Rhob-MA)). The anti-tumor polypeptide Bax-BH3 has good biocompatibility and biological activity; the fluorescent polymer nano-micelle wraps the antitumor polypeptide Bax-BH3 by using a block copolymer RGD-PHPMA-b-Poly (MMA-alt- (Rhob-MA)), so that the encapsulating rate and the drug loading are high, and the release performance is good.
DRAMP36329	QRDMHSHRDFQPVLVALNSPLSGGMRDRG	29	SEQ ID NO.1 of Patent CN113912739A	Synthetic	Antimicrobial, Anticancer	CN113912739A	Patent Application	2022##1##11	Not available	Endostatin 33 peptide with anti-tumor activity and application thereof	The invention discloses an endostatin 33 peptide with anti-tumor activity and application thereof. The endothelial chalone 33 peptide is composed of 24 peptide which forms the anti-angiogenesis activity of the endothelial chalone, RGDRD sequence and QRD sequence, and the amino acid sequence is shown as SEQ ID NO. 1. Experiments prove that the endostatin 33 peptide has broad-spectrum anti-tumor activity, especially on high-expression alpha6β1Specific anticancer function of subtype prostate cancer tissue. The invention provides a method for solving the problem that the curative effect is poor when the prior 30 peptide endostatin is used for treating tumors with integrin subtypes which cannot be identified by RGD sequenceThe treatment of prostate cancer provides a new and effective technical means.
DRAMP36330	DSDVWWGGRRLLRRLRRL	18		Synthetic	Antimicrobial, Anticancer	CN114014911A	Patent Application	2022##2##8	Not available	Preparation of anti-cancer lipopeptide and application of anti-cancer lipopeptide in anti-tumor treatment	The invention relates to an anticancer lipopeptide C8H15The preparation of O-Asp-Ser-Asp-Val-Trp-Trp-Gly-Gly-Arg-Arg-Leu-Leu-Arg-Arg-Arg-Leu and the application thereof in the anti-tumor treatment, belonging to the field of biological medicine. The anticancer lipopeptides are prepared based on key biological features of membrane-cleavable peptides (positive charge, alpha-helical structure and amphiphilicity). The invention provides a solid-phase synthesis method of the anticancer lipopeptide. The anticancer lipopeptide applianceHas the characteristics of small hydrophobic moment, low hemolytic activity and good serum stability, can effectively make up the defect of high hemolytic toxicity of most anticancer peptides, and solves the problem of poor in-vivo stability of peptide drugs. In vitro anticancer experiments and in vivo antitumor experiments prove that the anticancer lipopeptide has good antitumor effect and good application prospect.
DRAMP36331	XGFFYKD	7		Synthetic	Antimicrobial, Anticancer	CN114159581A	Patent Application	2022##3##11	Not available	Polypeptide hydrogel and application thereof in preparation of tumor treatment medicine	The invention discloses a polypeptide hydrogel and application thereof in preparing a tumor treatment drug, and belongs to the technical field of biological medicines. The invention adopts a solid-phase synthesis method to synthesize a drug polypeptide conjugate LND-GFFYKD which covalently connects anticancer drug lonidamine to polypeptide molecules, and adjusts pH to lead the drug polypeptide conjugate to be self-assembled into glue or to be assembled with synergist verapamil to form hydrogel. The hydrogel can improve the solubility of the drug, reduce the toxic and side effects of the drug on the whole body, and has obviously better growth inhibition effect on brain glioma cells than the pure lonidamine drug.
DRAMP36332	FSLNWRPPCLFYGRKKRRQRRR	22	TAT-WLP	Synthetic	Antimicrobial, Anticancer	CN114457052A	Patent Application	2022##5##10	Not available	Anti-tumor polypeptide composition and application thereof	The invention provides an anti-tumor polypeptide composition and application thereof, and particularly relates to the field of anti-cancer drugs. The invention provides an anti-tumor polypeptide composition, which comprises a WLP targeting peptide; the amino acid sequence of the WLP targeting peptide is shown as SEQ ID No. 1. The polypeptide composition can effectively inhibit the proliferation of cancer cells, thereby achieving the aim of treating cancer.
DRAMP36346	RAGLQFPVGKLLKKLLKKLLK	21	LXP-7	Synthetic	Antimicrobial, Anticancer	CN114605517A	Patent Application	2022##6##10	Not available	Polypeptide LXP-7 with broad-spectrum anticancer effect and application thereof	The invention provides a polypeptide LXP-7 with broad-spectrum anticancer effect and application thereof, belonging to the technical field of medicines. The amino acid sequence of the polypeptide LXP-7 with broad-spectrum anticancer effect is shown as SEQ ID NO. 1. The polypeptide LXP-7 of the invention can effectively kill various tumor cells, including lung cancer, colorectal cancer, liver cancer, stomach cancer, breast cancer, esophageal cancer and prostate cancer, has anticancer effect on various tumors, and can be used for preparing broad-spectrum tumor treatment medicines. Meanwhile, the LXP-7 has a remarkable killing effect on paclitaxel-resistant prostate cancer cells (PC 3/Tax), and can be used for preparing paclitaxel-resistant prostate cancer treatment medicines.
DRAMP36347	YGRKKRRQRRRLPDWHIPV	19	TAT-LP8	Synthetic	Antimicrobial, Anticancer	CN114634551A	Patent Application	2022##6##17	Not available	Polypeptide and application thereof in preparation of anti-cancer drug for antagonizing combination of wild type p53 and MDM2	The invention belongs to the field of nasopharyngeal carcinoma medicaments, and particularly discloses a nasopharyngeal carcinoma-resistant p53-MDM2 antagonistic polypeptide medicament which is a compound with a structural formula 1. The invention also discloses application of the nasopharyngeal carcinoma resisting polypeptide and the derivative polypeptide (with a structural formula of formula 2) thereof as a nasopharyngeal carcinoma metastasis resisting drug. The compounds shown in the formula 1 and the formula 2 have unexpected effect on resisting nasopharyngeal carcinoma metastasis, and can inhibit metastasis and invasion of nasopharyngeal carcinoma cells in vitro and in vivo.
DRAMP36348	MSL	3	MSL	Chilli seeds	Antimicrobial, Anticancer	CN114835774A	Patent Application	2022##8##2	Not available	Oligopeptide MSL separated from chilli seeds and application of oligopeptide MSL in prevention or treatment of cancer	The oligopeptide MSL is obtained by separating the chilli seeds, has an anti-tumor effect, particularly can effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
DRAMP36349	MEDEI	5	MEDEI	Chilli seeds	Antimicrobial, Anticancer	CN114835780A	Patent Application	2022##8##2	Not available	Oligopeptide MEDEI separated from chili seeds and application of oligopeptide MEDEI in prevention or treatment of cancers	The oligopeptide MEDEI separated from the chilli seeds is separated from the chilli seeds, has an anti-tumor effect, can particularly effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
DRAMP36350	GLWKSLFKNVGKAAGKAALNAVTDMVNQ	28	DMS-PS1	South America frog Phy l 	Antimicrobial, Anticancer	CN114835791A	Patent Application	2022##8##2	Not available	Anticancer peptide DMS-PS1 of South America frog and application thereof	The invention discloses a rana amurensis frog anticancer peptide DMS-PS1 and application thereof, which can be used in the fields of anticancer drugs and health care products and preparation, wherein rana amurensis frog Phy l lomedusa sauuvagi i is used as a material, a novel natural anticancer peptide DMS-PS1 is obtained by separating from frog skin secretion, open reading frames of the polypeptide consist of 76 amino acids, the polypeptide contains a highly conserved signal peptide consisting of 22 amino acid residues, and acidic amino acids such as rich aspartic acid, glutamic acid and the like, the molecular weight of the polypeptide is 2931.43 daltons, the C end of the polypeptide contains amidation modification, and the polypeptide is amphiphilic cationic peptide with an alpha-helix structure, the invention discloses that the natural anticancer peptide DMS-PS1 shows spectral anticancer activity and shows certain selectivity to prostate cancer cells, researches show that the peptide has antic
DRAMP36351	FTLE	4	FTLE	Chilli seeds	Antimicrobial, Anticancer	CN114853847A	Patent Application	2022##8##5	Not available	Oligopeptide FTLE separated from chilli seeds and application of oligopeptide FTLE in prevention or treatment of cancers	The oligopeptide is obtained by separating the chilli seeds, has an anti-tumor effect, particularly can effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
DRAMP36352	XGFLGGIGAVLKVLTTGLPALISWIKRKRQQ	31	MTX-GFLG-Melittin	Synthetic	Antimicrobial, Anticancer	CN115317622A	Patent Application	2022##11##11	Not available	Preparation and application of anti-tumor polypeptide coupling medicine	The invention discloses an anti-tumor polypeptide conjugate drug and application thereof. The molecular sequence of the polypeptide coupled drug is as follows: MTX-Gly-Phe-Leu-Gly-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH 2 Wherein the Gly-Phe-Leu-Gly sequence linked to MTX is cleaved by cathepsin-B or the like. The antitumor polypeptide provided by the invention has membrane penetrability, and can be used as a carrier of a small-molecule antitumor drug to prepare a polypeptide coupled drug, so that the antitumor drug can be promoted to penetrate a cell membrane of a tumor cell, the release of the small-molecule drug is completed, and the tumor treatment is carried out.
DRAMP36353	KKCGIQDTNDKKQSD	15		Synthetic	Antimicrobial, Anticancer	CN115433287A	Patent Application	2022##12##6	Not available	Small molecule peptide and application thereof as agonist and in anti-cancer drugs	The invention discloses a small molecular peptide and application thereof as an agonist and in an anti-cancer drug, and mainly relates to the field of bioengineering. And (2) taking an amino acid sequence 270-284 of PD-L1 as a template, and fusing with green fluorescent protein to construct and obtain the PD-L1 protein S279D hyperphosphorylation small Peptide. Can be used as an agonist to competitively inhibit the protein level interaction of PD-L1 and IGFBP3 so as to maintain the cancer inhibition function of the IGFBP3 protein.
DRAMP36354	WAVLL	5	coloy(Trp-Ala-Val-Leu-Leu)	Frog fecal mildew	Antimicrobial, Anticancer	CN115536734A	Patent Application	2022##12##30	Not available	Cyclochrome-propyl-valine-leucine-leucine with hepatoma carcinoma cytotoxicity and alpha-glucosidase inhibitory activity and preparation meth	The invention relates to a cyclo-c-v-l-Leu peptide (Trp-Ala-Val-Leu-Leu cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to biological productsThe technical field of extraction and preparation. The cyclo-tryptophan-alanine-valine-leucine peptide is a pentadecatomic cyclic pentapeptide which is formed by connecting tryptophan, alanine, valine, leucine and leucine through an amide bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure cyclochrome-C-valine-bright peptide is white powder, and has half Inhibitory Concentration (IC) on liver cancer cell HepG2 50 ) Comprises the following steps: 91.15 μ g/mL, half inhibitory concentration of alpha-glucosidase (IC) 50 ) Comprises the following steps: 50.09. Mu.g/mL. The compound can be used as a potential drug for treating liver cancer and 
DRAMP36355	WVVAIF	6	coloy(Trp-Val-Val-Ala-Ile-Phe)	Frog fecal mildew	Antimicrobial, Anticancer	CN115572324A	Patent Application	2023##1##6	Not available	Cyclochrome-valine-valine-propyl-bright-phenylalanine with hepatoma carcinoma cytotoxicity and alpha-glucosidase inhibitory activity and prep	The invention relates to a cyclo-chromo-valine-propyl-leucin-phenylpropyl peptide (Trp-Val-Val-Ala-Ile-Phe cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclo-tryptophan-valine-alanine-leucine-phenylalanine peptide is a pentadecane cyclic pentapeptide formed by connecting tryptophan, valine, alanine, leucine and phenylalanine by an amido bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure product of the cyclo-valine-propyl-leucine-phenylpropanoid is white powder, and has half Inhibitory Concentration (IC) on hepatoma carcinoma cell HepG2 50 ) Comprises the following steps: 96.64 μ g/mL, half inhibitory concentration of alpha-glucosidase (IC) 50 ) Comprises the following steps: 54.44. Mu.g/mL. The 
DRAMP36356	WTYIF	5	coloy(Trp-Thr-Tyr-Ile-Phe)	Frog fecal mildew	Antimicrobial, Anticancer	CN115636869A	Patent Application	2023##1##24	Not available	Cyclic cyclo chrosurotyroisoleucine with hepatoma carcinoma cytotoxicity and alpha-glucosidase inhibitory activity and preparation method of 	The invention relates to a cyclo-threo casein iso-brilliant phenylpropanoid peptide (cyclo-Trp-Thr-Tyr-Ile-Phe cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibition activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclic cyclo-chromo-threo-casein-isoleucin-phenylpropanoid is prepared from cyclo-tryptophan, threonine, tyrosine, isoleucine and phenylalanine, and is a pentadecatomic cyclic pentapeptide formed by connecting amide bonds. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure product of the cyclocyclo-chromo-threo-casein-isoleucin is white powder and has half Inhibition Concentration (IC) on hepatoma carcinoma cell HepG2 50 ) Comprises the following steps: 111.07. Mu.g/mL, half inhibitory concentration of alpha-glucosidase (IC) 50 ) Comprises the foll
DRAMP36357	WTVLL	5	coloy(Trp-Thr-Val-Leu-Leu)	Frog fecal mildew	Antimicrobial, Anticancer	CN115636870A	Patent Application	2023##1##24	Not available	Cyclochrome-threo-valine-leucine-leucine peptide with hepatoma carcinoma cytotoxicity and alpha-glucosidase inhibitory activity and preparati	The invention relates to a cyclo-chromo-threo-valine-bright-leucine peptide (Trp-Thr-Val-Leu-Leu cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclotryptophan-threo-valine-leucine peptide is composed of tryptophan, threonine and valineLeucine and leucine, and pentadecane pentapeptide connected via amide bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure product of the cyclo-threo-valine-leucine peptide is white powder, and has half-Inhibitory Concentration (IC) on liver cancer cell HepG2 50 ) Comprises the following steps: 51.50. Mu.g/mL, half inhibitory concentration of alpha-glucosidase (IC) 50 ) Comprises the following steps: 140.81. Mu.g/mL. The compound can be used as a potential drug for tr
DRAMP36358	WAVIL	5	coloy(Trp-Ala-Val-Ile-Leu)	Frog fecal mildew	Antimicrobial, Anticancer	CN115651067A	Patent Application	2023##1##24	Not available	Cyclochrome-propyl-valine-isoleucine-leucine with hepatoma carcinoma cytotoxicity and alpha-glucosidase inhibitory activity and preparation m	The invention relates to a cyclo-chromo-threo-valine-bright-leucine peptide (Trp-Thr-Val-Leu-Leu cyclic peptide) with hepatotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclotryptophan-threo-valine-leucine peptide is composed of tryptophan, threonine and valineLeucine and leucine, and pentadecane pentapeptide connected via amide bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure product of the cyclo-threo-valine-leucine peptide is white powder, and has half-Inhibitory Concentration (IC) on liver cancer cell HepG2 50 ) Comprises the following steps: 51.50. Mu.g/mL, half inhibitory concentration of alpha-glucosidase (IC) 50 ) Comprises the following steps: 140.81. Mu.g/mL. The compound can be used as a potential drug for tr
DRAMP36359	MQDAITAV	8		Phycocyanin 	Antimicrobial, Anticancer	CN115716870A	Patent Application	2023##2##28	Not available	Phycocyanin anti-tumor peptide as well as preparation method and application thereof	The invention relates to a phycocyanin antitumor peptide and application thereof, which mainly introduce a preparation method, a separation method and a purification method of phycocyanin enzymolysis peptide, and screen the separated peptide through molecular docking to obtain MQDAITAV peptide, and detect the MQDAITAV peptide through a cck-8 kit and a cell migration experiment, wherein the MQDAITAV peptide has a good inhibition effect on non-small cell lung cancer cells.
DRAMP36360	DLMAQMQGPYNFIQSMLDFENQTL	24	SEQ ID NO: 1 of Patent CN113135987A	Synthetic (Derived from C	Antimicrobial, Anticancer	CN113135987A	Patent Application	2021##7##20	Not available	Active peptide derived from Caprin1 and application thereof	The invention designs active peptides derived from Caprin1, which can competitively bind with G3BP1 protein, specifically block the interaction between Caprin1 and G3BP1 protein, inhibit the generation of stress particles, and further treat SGs generation-related diseases, such as tumors or neurodegenerative diseases.
DRAMP36361	DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTL	35	SEQ ID NO: 2 of Patent CN113135987A	Synthetic (Derived from C	Antimicrobial, Anticancer	CN113135987A	Patent Application	2021##7##20	Not available	Active peptide derived from Caprin1 and application thereof	The invention designs active peptides derived from Caprin1, which can competitively bind with G3BP1 protein, specifically block the interaction between Caprin1 and G3BP1 protein, inhibit the generation of stress particles, and further treat SGs generation-related diseases, such as tumors or neurodegenerative diseases.
DRAMP36362	DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTLDPAIV	40	SEQ ID NO: 3 of Patent CN113135987A	Synthetic (Derived from C	Antimicrobial, Anticancer	CN113135987A	Patent Application	2021##7##20	Not available	Active peptide derived from Caprin1 and application thereof	The invention designs active peptides derived from Caprin1, which can competitively bind with G3BP1 protein, specifically block the interaction between Caprin1 and G3BP1 protein, inhibit the generation of stress particles, and further treat SGs generation-related diseases, such as tumors or neurodegenerative diseases.
DRAMP36363	DLMAQMQGPYNPIQDSMLDPENQTLDPAIV	30	SEQ ID NO: 4 of Patent CN113135987A	Synthetic (Derived from C	Antimicrobial, Anticancer	CN113135987A	Patent Application	2021##7##20	Not available	Active peptide derived from Caprin1 and application thereof	The invention designs active peptides derived from Caprin1, which can competitively bind with G3BP1 protein, specifically block the interaction between Caprin1 and G3BP1 protein, inhibit the generation of stress particles, and further treat SGs generation-related diseases, such as tumors or neurodegenerative diseases.
DRAMP36364	CIELLQAR	8		Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36365	CIELLQARX	9	HA-Pep-DTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36366	CIELLQARX	9	HA-Pep-DTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36367	CIELLQARX	9	HA-Pep-DTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36368	CIELLQARX	9	HA-Pep-DTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36369	CIELLQARX	9	HA-Pep-SN38	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36370	CIELLQARX	9	HA-Pep-SN38	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36371	CIELLQARX	9	HA-Pep-SN38	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36372	CIELLQARX	9	HA-Pep-SN38	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36373	CIELLQARX	9	HA-Pep-PTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36374	CIELLQARX	9	HA-Pep-PTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36375	CIELLQARX	9	HA-Pep-PTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36376	CIELLQARX	9	HA-Pep-PTX	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36377	CIELLQARX	9	HA-Pep-PODP	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36378	CIELLQARX	9	HA-Pep-PODP	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36379	CIELLQARX	9	HA-Pep-PODP	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36380	CIELLQARX	9	HA-Pep-PODP	Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36381	IELLQARC	8		Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36382	CRAQLLEI	8		Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36383	RAQLLEIC	8		Synthetic	Antimicrobial, Anticancer	CN113171342A	Patent Application	2021##7##21	Not available	Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle	The invention provides a tumor targeting nano micelle based on hyaluronic acid, and a preparation method and application thereof. The invention connects E selectin peptide ligand with chemotherapeutic drugs such as taxanes, camptothecins, podophyllotoxin and the like through disulfide bonds, then connects the conjugate to carboxyl of hyaluronic acid, and the formed amphiphilic polymer can be self-assembled in aqueous solution to form a primary nano targeting micelle and can be further loaded with other functional molecules, such as chemotherapeutic drugs and/or photosensitizer indocyanine green, to form a multifunctional nano micelle: the micelle has the active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and the passive targeting effect mediated by nano micelle EPR effect, has the characteristic of the synergistic effect of photothermal photodynamic and chemotherapy, and can competitively inhibit the adhesion of vascular endothelial cells and tumor cells mediated
DRAMP36384	ciellqar	8		Synthetic	Antimicrobial, Anticancer	CN113171343A	Patent Application	2021##7##21	Not available	Amikacin sulfate multivesicular liposome for local injection and preparation method of amikacin sulfate multivesicular liposome	The invention provides an amikacin sulfate multivesicular liposome for local injection and a preparation method thereof. The amikacin sulfate multivesicular liposome comprises the following raw materials in parts by weight: 35-180 parts of amikacin sulfate; 35-300 parts of a lipid material; 195-410 parts of an osmotic pressure regulator; 0.50-35.50 parts of auxiliary emulsifier material; the lipid material is prepared from phospholipid, cholesterol, triglyceride and a membrane stabilizer in a mass ratio of (5-7.5): (3-5.5): (3-6): (1.0-3.0), wherein the membrane stabilizer comprises at least one of negatively charged phosphatidyl glycerol, fatty acid or stearyl amine. The amikacin sulfate multivesicular liposome provided by the invention has the characteristics of high encapsulation efficiency, large drug loading rate and uniform particle size, and can be prepared into powder injection for injection, so that the sustained-release effect is better, the bioavailability of the drug is favorably impro
DRAMP36385	iellqarc	8		Synthetic	Antimicrobial, Anticancer	CN113171343A	Patent Application	2021##7##21	Not available	Amikacin sulfate multivesicular liposome for local injection and preparation method of amikacin sulfate multivesicular liposome	The invention provides an amikacin sulfate multivesicular liposome for local injection and a preparation method thereof. The amikacin sulfate multivesicular liposome comprises the following raw materials in parts by weight: 35-180 parts of amikacin sulfate; 35-300 parts of a lipid material; 195-410 parts of an osmotic pressure regulator; 0.50-35.50 parts of auxiliary emulsifier material; the lipid material is prepared from phospholipid, cholesterol, triglyceride and a membrane stabilizer in a mass ratio of (5-7.5): (3-5.5): (3-6): (1.0-3.0), wherein the membrane stabilizer comprises at least one of negatively charged phosphatidyl glycerol, fatty acid or stearyl amine. The amikacin sulfate multivesicular liposome provided by the invention has the characteristics of high encapsulation efficiency, large drug loading rate and uniform particle size, and can be prepared into powder injection for injection, so that the sustained-release effect is better, the bioavailability of the drug is favorably impro
DRAMP36386	craqllei	8		Synthetic	Antimicrobial, Anticancer	CN113171343A	Patent Application	2021##7##21	Not available	Amikacin sulfate multivesicular liposome for local injection and preparation method of amikacin sulfate multivesicular liposome	The invention provides an amikacin sulfate multivesicular liposome for local injection and a preparation method thereof. The amikacin sulfate multivesicular liposome comprises the following raw materials in parts by weight: 35-180 parts of amikacin sulfate; 35-300 parts of a lipid material; 195-410 parts of an osmotic pressure regulator; 0.50-35.50 parts of auxiliary emulsifier material; the lipid material is prepared from phospholipid, cholesterol, triglyceride and a membrane stabilizer in a mass ratio of (5-7.5): (3-5.5): (3-6): (1.0-3.0), wherein the membrane stabilizer comprises at least one of negatively charged phosphatidyl glycerol, fatty acid or stearyl amine. The amikacin sulfate multivesicular liposome provided by the invention has the characteristics of high encapsulation efficiency, large drug loading rate and uniform particle size, and can be prepared into powder injection for injection, so that the sustained-release effect is better, the bioavailability of the drug is favorably impro
DRAMP36387	raqlleic	8		Synthetic	Antimicrobial, Anticancer	CN113171343A	Patent Application	2021##7##21	Not available	Amikacin sulfate multivesicular liposome for local injection and preparation method of amikacin sulfate multivesicular liposome	The invention provides an amikacin sulfate multivesicular liposome for local injection and a preparation method thereof. The amikacin sulfate multivesicular liposome comprises the following raw materials in parts by weight: 35-180 parts of amikacin sulfate; 35-300 parts of a lipid material; 195-410 parts of an osmotic pressure regulator; 0.50-35.50 parts of auxiliary emulsifier material; the lipid material is prepared from phospholipid, cholesterol, triglyceride and a membrane stabilizer in a mass ratio of (5-7.5): (3-5.5): (3-6): (1.0-3.0), wherein the membrane stabilizer comprises at least one of negatively charged phosphatidyl glycerol, fatty acid or stearyl amine. The amikacin sulfate multivesicular liposome provided by the invention has the characteristics of high encapsulation efficiency, large drug loading rate and uniform particle size, and can be prepared into powder injection for injection, so that the sustained-release effect is better, the bioavailability of the drug is favorably impro
DRAMP36388	CLHELLEHLHELLEHCLKKLLKLLKKLLKL	30	ALK-1	Synthetic	Antimicrobial, Anticancer	CN110862458A	Patent Application	2020##3##6	Not available	Combined peptide with acid-activated anti-tumor activity and clinical application of combined peptide	The invention discloses a combined peptide with acid-activated antitumor activity, which belongs to the technical field of biological medicine, wherein a plurality of anion shielding peptides LE are designed and synthesized by taking a pH sensitive peptide LH as a template, and the LE is coupled with LK through disulfide bonds to synthesize the combined peptide, wherein the combined peptide has lower activity under normal physiological conditions, and can effectively kill tumor cells by activating the activity under tumor acidic conditions.
DRAMP36389	CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH	30	ALK-2	Synthetic	Antimicrobial, Anticancer	CN110862458A	Patent Application	2020##3##6	Not available	Combined peptide with acid-activated anti-tumor activity and clinical application of combined peptide	The invention discloses a combined peptide with acid-activated antitumor activity, which belongs to the technical field of biological medicine, wherein a plurality of anion shielding peptides LE are designed and synthesized by taking a pH sensitive peptide LH as a template, and the LE is coupled with LK through disulfide bonds to synthesize the combined peptide, wherein the combined peptide has lower activity under normal physiological conditions, and can effectively kill tumor cells by activating the activity under tumor acidic conditions.
DRAMP36390	CLKKLLKLLKKLLKLCLEELLHHLEELLHH	30	ALK-3	Synthetic	Antimicrobial, Anticancer	CN110862458A	Patent Application	2020##3##6	Not available	Combined peptide with acid-activated anti-tumor activity and clinical application of combined peptide	The invention discloses a combined peptide with acid-activated antitumor activity, which belongs to the technical field of biological medicine, wherein a plurality of anion shielding peptides LE are designed and synthesized by taking a pH sensitive peptide LH as a template, and the LE is coupled with LK through disulfide bonds to synthesize the combined peptide, wherein the combined peptide has lower activity under normal physiological conditions, and can effectively kill tumor cells by activating the activity under tumor acidic conditions.
DRAMP36391	nAVPNLRGDLQVLAQKVART	20	SEQ ID: 7 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36392	nKVPNLRGDLQVLAQKVART	20	SEQ ID: 8 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36393	nXVPNLRGDLQVLAQKVART	20	SEQ ID: 8 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36394	nKVPNLRGDLQVLAQKVAR	19	SEQ ID: 9 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36395	nXVPNLRGDLQVLAQKVARt	20	SEQ ID: 9 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36396	nAVPNLRGDLQVLAQKVARt	20	SEQ ID: 10 of Patent CN110662759A	Synthetic	Antimicrobial, Anticancer	CN110662759A	Granted Patent	2020##1##7	Not available	Tumour-Targeting Peptide Variants	The present invention provides peptides that selectively bind to α v β 6 integrin, said peptides having a motif comprising X1BnRGDLX2X3X4ZmX5Wherein X is1Is any D-amino acid, BnIs any sequence of n amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where n is a number from 1 to 10, X2And X3Independently selected from any amino acid, X4Is Leu or Ile, ZmIs a sequence of any m amino acids, which may be natural or non-natural, D-or L-and may be identical or different, where m is a number from 1 to 10, X5Is any L-or D-amino acid. Also provided are conjugates comprising the peptides,pharmaceutical compositions comprising said peptides or said conjugates and uses of said peptides, conjugates or compositions for the treatment, imaging and/or diagnosis of α v β 6 expressing tumors in a mammalian subject, for example.
DRAMP36397	FHIVELLA	8	LT1-3	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36398	FHAVELLA	8	LT-A3	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36399	ASAIYSVETINDGNFHIVELLA	22	LT-1	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36400	FHIVELLALDQSLSLSVDGGNPKIIT	26	LT-2	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36401	KIITNLSKQSTLNFDSPLYVGG	22	LT-3	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36402	GGMPGKSNVASLRQAPGQNGTSF	23	LT-4	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36403	LRQAPGQNGTSFHGCIRNLYINSE	24	LT-5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36404	FKAVELLA	8	LT-K2	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36405	FRAVELLA	8	LT-R2	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36406	FHAVDLLA	8	LT-D5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36407	FHAVHLLA	8	LT-H5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36408	FHAVOLLA	8	LT-Orn5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36409	AHAVELLA	8	LT-A13	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36410	FHAAELLA	8	LT-A34	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36411	FHAVEALA	8	LT-A36	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36412	FHAAEALA	8	LT-A346	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36413	FAIVALLA	8	LT-A25	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36414	FEAVHLLA	8	LT-E2H5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36415	YHAVELLA	8	LT-Y1	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36416	WHAVELLA	8	LT-W1	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36417	FHAVELSA	8	LT-S7	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36418	FHAVELLS	8	LT-S8	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36419	DGNFHIVELLA	11	LT-11AA	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36420	DGNFHIVELLA	11	LT-11AA	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36421	AHIVELLA	8	LT-A1	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36422	FAIVELLA	8	LT-A2	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36423	FHIAELLA	8	LT-A4	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36424	FHIVALLA	8	LT-A5	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36425	FHIVEALA	8	LT-A6	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36426	FHIVELAA	8	LT-A7	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36427	DGNFHIVELLA	11	cLT-11AA	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36428	DGNFHIVELLA	11	cLT-11AA	Synthetic (Derived from S	Antimicrobial, Anticancer	CN111032679A	Granted Patent	2020##4##17	Not available	Peptides for Cancer Treatment	The present invention relates to the field of cancer treatment or prevention. In particular, the invention provides peptide fragments from the SLIT2 protein and their use in inhibiting cancer growth, invasion and metastasis.
DRAMP36429	TLPNSNHIKQGL	12	SEQ ID NO:1 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36430	LNKQTHGLIPNS	12	SEQ ID NO:3 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36431	NQHSKNTLLIGP	12	SEQ ID NO:4 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36432	LKQGNHINLPS	11	SEQ ID NO:5 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36433	YSPLNIHNGQKL	12	SEQ ID NO:6 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36434	LPNSNHIKQGL	11	SEQ ID NO:7 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36435	YLPNSNHIKQGL	12	SEQ ID NO:8 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36436	FLPNSNHIKQGL	12	SEQ ID NO:9 of Patent CN111225679A	Synthetic	Antimicrobial, Anticancer	CN111225679A	Granted Patent	2020##6##2	Not available	Novel Peptide-Based Cancer Imaging Agents	The present invention discloses compositions and methods relating to novel tumor targeting peptides.
DRAMP36454	CAYHRLRRC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36455	CDCRGDCFC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36456	CPIEDRPMC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36457	CNRRTKAGC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36458	CGTKRKC	7		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36459	CRGDGWC	7		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36460	CVSNPRWKC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36461	CHVLWSTRC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36462	CLDGGRPKC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36463	GCSVSSVGALCTHV	14		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36464	CVNHPAFAC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36465	CRGDRGPDC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36466	CRGDKTTNC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36467	CRGDHAGDC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36468	CLSYYPSYC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36469	CTPSPPFSHC	10		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36470	CPHSKPCLC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36471	CSDSWHYWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36472	CSDWQHPWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36473	CSDYNHHWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36474	CSDGQHYWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36475	CYDSWHYWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36476	CFDGNHIWC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36477	CTDFPRSFC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36478	CTQDRQHPC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36479	CLSRYLDQC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36480	CRGDCF	6		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36481	CGNSNPKSC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36482	CPHNLTKLC	9		Synthetic	Antimicrobial, Anticancer	CN111344298A	Granted Patent	2020##6##26	Not available	Anti-cancer agent	An anticancer agent is provided comprising a tumor targeting peptide having or having been modified to present two cysteine residues with an arsenic atom between them such that the tumor targeting peptide is cyclized to produce an arsenic-containing anticancer agent. This allows selection of appropriate tumor targeting peptides for treatment of a given cancer, whereby subsequent agents provide more targeted delivery of arsenic to the tumor microenvironment.
DRAMP36484	RKRRNDLⓍSRFLALⓍDQ	17	IDP-LS13	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36485	RKRRNDLRSⓍFLALRDⓍ	17	IDP-LS15	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36486	APKVVⓍLSKALEⓍLQA	16	IDP-LS16	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36487	APKVVILⓍKALEYLⓍA	16	IDP-LS17	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36488	ⓍKAPKVVⓍLSKALEYL	16	IDP-Lb01	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36489	SⓍAPKVVIⓍSKALEYL	16	IDP-Lb02	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36490	SKⓍPKVVILⓍKALEYL	16	IDP-Lb03	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36492	SKAPⓍVVILSKⓍLEYL	16	IDP-Lb05	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36493	SKAPKⓍVILSKAⓍEYL	16	IDP-Lb06	Synthetic	Antimicrobial, Anticancer	CN111511761A	Granted Patent	2020##8##7	Not available	Anticancer Peptides	The present invention provides a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and fusion peptides and pharmaceutical compositions comprising the peptide of formula (I) or a pharmaceutically acceptable salt thereof; or, alternatively, the peptide or pharmaceutically acceptable salt thereof is a peptide having an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO: 25. 26, 27 or 28, or a pharmaceutically acceptable salt thereof, having from 85% to 95% identity. The peptides of the present invention show anticancer activity.
DRAMP36494	TCRSSGRYCRSPYDRRRRYCRRITDACV	28	GexIVA[1,2]	Alpha O-conotoxin	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36495	TCRSSGRYCRSPYDRRRRYCRRITDACV	28	GexIVA[1,2]	Alpha O-conotoxin	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36496	ACRSSGRYCRSPYDRRRRYCRRITDACV	28	[T1A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36497	ACRSSGRYCRSPYDRRRRYCRRITDACV	28	[T1A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36498	TCASSGRYCRSPYDRRRRYCRRITDACV	28	[R3A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36499	TCASSGRYCRSPYDRRRRYCRRITDACV	28	[R3A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36500	TCRASGRYCRSPYDRRRRYCRRITDACV	28	[S4A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36501	TCRASGRYCRSPYDRRRRYCRRITDACV	28	[S4A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36502	TCRSAGRYCRSPYDRRRRYCRRITDACV	28	[S5A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36503	TCRSAGRYCRSPYDRRRRYCRRITDACV	28	[S5A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36504	TCRSSARYCRSPYDRRRRYCRRITDACV	28	[G6A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36505	TCRSSARYCRSPYDRRRRYCRRITDACV	28	[G6A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36506	TCRSSGAYCRSPYDRRRRYCRRITDACV	28	[R7A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36507	TCRSSGAYCRSPYDRRRRYCRRITDACV	28	[R7A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36508	TCRSSGRACRSPYDRRRRYCRRITDACV	28	[Y8A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36509	TCRSSGRACRSPYDRRRRYCRRITDACV	28	[Y8A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36510	TCRSSGRYCASPYDRRRRYCRRITDACV	28	[R10A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36511	TCRSSGRYCASPYDRRRRYCRRITDACV	28	[R10A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36512	TCRSSGRYCRAPYDRRRRYCRRITDACV	28	[S11A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36513	TCRSSGRYCRAPYDRRRRYCRRITDACV	28	[S11A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36514	TCRSSGRYCRSAYDRRRRYCRRITDACV	28	[P12A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36515	TCRSSGRYCRSAYDRRRRYCRRITDACV	28	[P12A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36516	TCRSSGRYCRSPADRRRRYCRRITDACV	28	[Y13A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36517	TCRSSGRYCRSPADRRRRYCRRITDACV	28	[Y13A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36518	TCRSSGRYCRSPYARRRRYCRRITDACV	28	[D14A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36519	TCRSSGRYCRSPYARRRRYCRRITDACV	28	[D14A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36520	TCRSSGRYCRSPYDARRRYCRRITDACV	28	[R15A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36521	TCRSSGRYCRSPYDARRRYCRRITDACV	28	[R15A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36522	TCRSSGRYCRSPYDRARRYCRRITDACV	28	R16A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36523	TCRSSGRYCRSPYDRARRYCRRITDACV	28	R16A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36524	TCRSSGRYCRSPYDRRARYCRRITDACV	28	[R17A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36525	TCRSSGRYCRSPYDRRARYCRRITDACV	28	[R17A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36526	TCRSSGRYCRSPYDRRRAYCRRITDACV	28	[R18A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36527	TCRSSGRYCRSPYDRRRAYCRRITDACV	28	[R18A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36528	TCRSSGRYCRSPYDRRRRACRRITDACV	28	[Y19A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36529	TCRSSGRYCRSPYDRRRRACRRITDACV	28	[Y19A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36530	TCRSSGRYCRSPYDRRRRYCARITDACV	28	[R21A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36531	TCRSSGRYCRSPYDRRRRYCARITDACV	28	[R21A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36532	TCRSSGRYCRSPYDRRRRYCRAITDACV	28	[R22A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36533	TCRSSGRYCRSPYDRRRRYCRAITDACV	28	[R22A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36534	TCRSSGRYCRSPYDRRRRYCRRATDACV	28	[I23A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36535	TCRSSGRYCRSPYDRRRRYCRRATDACV	28	[I23A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36536	TCRSSGRYCRSPYDRRRRYCRRIADACV	28	[T24A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36537	TCRSSGRYCRSPYDRRRRYCRRIADACV	28	[T24A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36538	TCRSSGRYCRSPYDRRRRYCRRITAACV	28	[D25A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36539	TCRSSGRYCRSPYDRRRRYCRRITAACV	28	[D25A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36540	TCRSSGRYCRSPYDRRRRYCRRITDACA	28	[V28A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36541	TCRSSGRYCRSPYDRRRRYCRRITDACA	28	[V28A]GexIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36542	TCRSSGRYCRSPYDRRRRYCRRITDACV	28	GexIVA[1,4]	Alpha O-conotoxin	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36543	TCRSSGRYCRSPYDRRRRYCRRITDACV	28	GexIVA[1,4]	Alpha O-conotoxin	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36544	ACRSSGRYCRSPYDRRRRYCRRITDACV	28	[T1A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36545	ACRSSGRYCRSPYDRRRRYCRRITDACV	28	[T1A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36546	TCASSGRYCRSPYDRRRRYCRRITDACV	28	[R3A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36547	TCASSGRYCRSPYDRRRRYCRRITDACV	28	[R3A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36548	TCRASGRYCRSPYDRRRRYCRRITDACV	28	[S4A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36549	TCRASGRYCRSPYDRRRRYCRRITDACV	28	[S4A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36550	TCRSAGRYCRSPYDRRRRYCRRITDACV	28	[S5A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36551	TCRSAGRYCRSPYDRRRRYCRRITDACV	28	[S5A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36552	TCRSSARYCRSPYDRRRRYCRRITDACV	28	[G6A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36553	TCRSSARYCRSPYDRRRRYCRRITDACV	28	[G6A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36554	TCRSSGAYCRSPYDRRRRYCRRITDACV	28	[R7A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36555	TCRSSGAYCRSPYDRRRRYCRRITDACV	28	[R7A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36556	TCRSSGRACRSPYDRRRRYCRRITDACV	28	[Y8A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36557	TCRSSGRACRSPYDRRRRYCRRITDACV	28	[Y8A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36558	TCRSSGRYCASPYDRRRRYCRRITDACV	28	[R10A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36559	TCRSSGRYCASPYDRRRRYCRRITDACV	28	[R10A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36560	TCRSSGRYCRAPYDRRRRYCRRITDACV	28	[S11A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36561	TCRSSGRYCRAPYDRRRRYCRRITDACV	28	[S11A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36562	TCRSSGRYCRSAYDRRRRYCRRITDACV	28	[P12A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36563	TCRSSGRYCRSAYDRRRRYCRRITDACV	28	[P12A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36564	TCRSSGRYCRSPADRRRRYCRRITDACV	28	[Y13A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36565	TCRSSGRYCRSPADRRRRYCRRITDACV	28	[Y13A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36566	TCRSSGRYCRSPYARRRRYCRRITDACV	28	[D14A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36567	TCRSSGRYCRSPYARRRRYCRRITDACV	28	[D14A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36568	TCRSSGRYCRSPYDARRRYCRRITDACV	28	[R15A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36569	TCRSSGRYCRSPYDARRRYCRRITDACV	28	[R15A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36570	TCRSSGRYCRSPYDRARRYCRRITDACV	28	R16A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36571	TCRSSGRYCRSPYDRARRYCRRITDACV	28	R16A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36572	TCRSSGRYCRSPYDRRARYCRRITDACV	28	[R17A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36573	TCRSSGRYCRSPYDRRARYCRRITDACV	28	[R17A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36574	TCRSSGRYCRSPYDRRRAYCRRITDACV	28	[R18A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36575	TCRSSGRYCRSPYDRRRAYCRRITDACV	28	[R18A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36576	TCRSSGRYCRSPYDRRRRACRRITDACV	28	[Y19A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36577	TCRSSGRYCRSPYDRRRRACRRITDACV	28	[Y19A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36578	TCRSSGRYCRSPYDRRRRYCARITDACV	28	[R21A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36579	TCRSSGRYCRSPYDRRRRYCARITDACV	28	[R21A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36580	TCRSSGRYCRSPYDRRRRYCRAITDACV	28	[R22A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36581	TCRSSGRYCRSPYDRRRRYCRAITDACV	28	[R22A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36582	TCRSSGRYCRSPYDRRRRYCRRATDACV	28	[I23A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36583	TCRSSGRYCRSPYDRRRRYCRRATDACV	28	[I23A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36584	TCRSSGRYCRSPYDRRRRYCRRIADACV	28	[T24A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36585	TCRSSGRYCRSPYDRRRRYCRRIADACV	28	[T24A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36586	TCRSSGRYCRSPYDRRRRYCRRITAACV	28	[D25A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36587	TCRSSGRYCRSPYDRRRRYCRRITAACV	28	[D25A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36588	TCRSSGRYCRSPYDRRRRYCRRITDACA	28	[V28A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36589	TCRSSGRYCRSPYDRRRRYCRRITDACA	28	[V28A]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36590	TCASSGAYCASPYDAAAAYCAAITDACV	28	[R3A/R7A/R10A/R15A/R16A/R17A/R18A/R21A/	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36591	TCRSSGRYCRSPYDAAAAYCRRITDACV	28	[R15A/R16A/R17A/R18A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36592	TCASSGAYCASPYDRRRRYCRRITDACV	28	[R3A/R7A/R10A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36593	TCASSGAYCRSPYDRRRRYCRRITDACV	28	[R3A, R7A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36594	TCASSGRYCASPYDRRRRYCRRITDACV	28	[R3A, R10A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36595	TCRSSGAYCASPYDRRRRYCRRITDACV	28	[R7A, R10A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36596	TCRSSGRYCRSPYDAARRYCRRITDACV	28	[R15A, R16A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36597	TCRSSGRYCRSPYDARARYCRRITDACV	28	[R15A, R17A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36598	TCRSSGRYCRSPYDARRAYCRRITDACV	28	[R15A, R18A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36599	TCRSSGRYCRSPYDRAARYCRRITDACV	28	[R16A, R17A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36600	TCRSSGRYCRSPYDRARAYCRRITDACV	28	[R16A, R18A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36601	TCRSSGRYCRSPYDRRAAYCRRITDACV	28	[R17A, R18A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36602	TCRSSGRYCRSPYDRRRRYCAAITDACV	28	[R21A, R22A]GeXIVA[1,2]	Synthetic	Antimicrobial, Anticancer	CN112010959A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36603	GRYCRSPYDRRRRYCRR	17	Δ6-22GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010960A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36604	RSPYDRRRRY	10	Δ10-19GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010961A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36605	RSPYDRRRRY	10	Δ10-19GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010961A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36606	ASPYDRRRRY	10	Δ10-19[R1A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010962A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36607	RAPYDRRRRY	10	Δ10-19[S2A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010963A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36608	RSAYDRRRRY	10	Δ10-19[P3A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010964A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36609	RSPADRRRRY	10	Δ10-19[Y4A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010965A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36610	RSPYARRRRY	10	Δ10-19[D5A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010966A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36611	RSPYARRRRY	10	Δ10-19[D5A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010966A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36612	RSPYDARRRY	10	Δ10-19[R6A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010967A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36613	RSPYDRARRY	10	Δ10-19[R7A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010968A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36614	RSPYDRRARY	10	Δ10-19[R8A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010969A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36615	RSPYDRRRAY	10	Δ10-19[R9A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010970A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36616	RSPYDRRRRA	10	Δ10-19[Y10A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010971A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36617	RSPYDRRRRY	10	Δ10-19GeXIVA#	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36618	RSPYDRRRRY	10	Δ10-19GeXIVA#	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36619	RSPYARRRRY	10	Δ10-19[D5A]GeXIVA#	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36620	RSPYARRRRY	10	Δ10-19[D5A]GeXIVA#	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36621	RYCRSPYDRRRRYCRR	16	Δ7-22GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36622	TARSSGRYARSPYDRRRRYCRRITDACV	28	[C2A, C9A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36623	TSRSSGRYSRSPYDRRRRYCRRITDACV	28	[C2S, C9S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36624	TCRSSGRYCRSPYDRRRRYARRITDAAV	28	[C20A, C27A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36625	TCRSSGRYCRSPYDRRRRYSRRITDASV	28	[C20S, C27S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36626	TARSSGRYCRSPYDRRRRYCRRITDAAV	28	[C2A, C27A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36627	TSRSSGRYCRSPYDRRRRYCRRITDASV	28	[C2S, C27S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36628	TCRSSGRYARSPYDRRRRYARRITDACV	28	[C9A, C20A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36629	TCRSSGRYSRSPYDRRRRYSRRITDACV	28	[C9S, C20S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36630	TARSSGRYARSPYDRRRRYARRITDAAV	28	[C2A, C9A, C20A, C27A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36631	TSRSSGRYSRSPYDRRRRYSRRITDASV	28	[C2S, C9S, C20S, C27S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36632	TARSSGRYARSPYDRRRRYSRRITDASV	28	[C2A, C9A, C20S, C27S]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36633	TSRSSGRYSRSPYDRRRRYARRITDAAV	28	[C2S, C9S, C20A, C27A]GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36634	tCRSSGRYCRSPYDRRRRYCRRITDACV	28	1t-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36635	TCRSSGRYCRSPYDRRRRYCRRITDACv	28	28v-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36636	tCRSSGRYCRSPYDRRRRYCRRITDACv	28	1t, 28v-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36637	TCRSSGRYCRSPYDrrRRYCRRITDACV	28	GeMT, Mt-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36638	TCRSSGRYCRSPYDrrrrYCRRITDACV	28	GeMF, Mf-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36639	TCrSSGrYCrSPYDrrrrYCrrITDACV	28	GeArg-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36640	tCrSSGrYCrSPYDrrrrYCrrITDACv	28	GeFlex-GeXIVA	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36641	DCRSSGRYCRSPYDRRRRYCRRITDACV	28	[T1D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36642	TCDSSGRYCRSPYDRRRRYCRRITDACV	28	[R3D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36643	TCRDSGRYCRSPYDRRRRYCRRITDACV	28	[S4D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36644	TCRSDGRYCRSPYDRRRRYCRRITDACV	28	[S5D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36645	TCRSSDRYCRSPYDRRRRYCRRITDACV	28	[G6D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36646	TCRSSGDYCRSPYDRRRRYCRRITDACV	28	[R7D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36647	TCRSSGRDCRSPYDRRRRYCRRITDACV	28	[Y8D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36648	TCRSSGRYCDSPYDRRRRYCRRITDACV	28	[R10D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36649	TCRSSGRYCRDPYDRRRRYCRRITDACV	28	[S11D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36650	TCRSSGRYCRSDYDRRRRYCRRITDACV	28	[P12D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36651	TCRSSGRYCRSPDDRRRRYCRRITDACV	28	[Y13D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36652	TCRSSGRYCRSPYDDRRRYCRRITDACV	28	[R15D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36653	TCRSSGRYCRSPYDRDRRYCRRITDACV	28	[R16D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36654	TCRSSGRYCRSPYDRRDRYCRRITDACV	28	[R17D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36655	TCRSSGRYCRSPYDRRRDYCRRITDACV	28	[R18D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36656	TCRSSGRYCRSPYDRRRRDCRRITDACV	28	[Y19D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36657	TCRSSGRYCRSPYDRRRRYCDRITDACV	28	[R21D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36658	TCRSSGRYCRSPYDRRRRYCRDITDACV	28	[R22D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36659	TCRSSGRYCRSPYDRRRRYCRRDTDACV	28	[I23D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36660	TCRSSGRYCRSPYDRRRRYCRRIDDACV	28	[T24D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36661	TCRSSGRYCRSPYDRRRRYCRRITDDCV	28	[A26D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36662	TCRSSGRYCRSPYDRRRRYCRRITDACD	28	[V28D]GexIVA[1,4]	Synthetic	Antimicrobial, Anticancer	CN112010972A	Granted Patent	2020##12##1	Not available	Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof	The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
DRAMP36663	QYDPTPLTW	9	SEQ ID NO: 1 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36664	VWSNVTPLKF	10	SEQ ID NO: 2 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36665	YLEKFYGL	8	SEQ ID NO: 3 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36666	SYEKVINYL	9	SEQ ID NO: 4 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36667	RYMKKDYLI	9	SEQ ID NO: 5 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36668	KYKDYFPVI	9	SEQ ID NO: 6 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36669	VQQWSVAVF	9	SEQ ID NO: 7 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36670	PFLPPAACFF	10	SEQ ID NO: 8 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36671	RILRFPWQL	9	SEQ ID NO: 9 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36672	VWSDVTPLNF	10	SEQ ID NO: 10 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36673	YYSKSVGFMQW	11	SEQ ID NO: 11 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36674	STIRGELFFF	10	SEQ ID NO: 12 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36675	HYTYILEVF	9	SEQ ID NO: 13 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36676	SYSSCYSF	8	SEQ ID NO: 14 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36677	KYALLLQDL	9	SEQ ID NO: 15 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36678	TYNPDFSSL	9	SEQ ID NO: 16 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36679	YYADKKTFIVL	11	SEQ ID NO: 17 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36680	DYIGSVEKW	9	SEQ ID NO: 18 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36681	ILKEDPFLF	9	SEQ ID NO: 19 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36682	EFTTVLYNF	9	SEQ ID NO: 20 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36683	SYEVRSTF	8	SEQ ID NO: 21 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36684	TQPGDWTLF	9	SEQ ID NO: 22 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36685	KFIISDWRF	9	SEQ ID NO: 23 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36686	MYPDLSELLM	10	SEQ ID NO: 24 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36687	SYNGYVFYL	9	SEQ ID NO: 25 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36688	KTPTNYYLF	9	SEQ ID NO: 26 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36689	NYTLYPITF	9	SEQ ID NO: 27 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36690	YYSIISHTL	9	SEQ ID NO: 28 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36691	VYPLLSRLYW	10	SEQ ID NO: 29 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36692	QYLPGWTVLF	10	SEQ ID NO: 30 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36693	QYQNVLTLW	9	SEQ ID NO: 31 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36694	SLPDLTPTF	9	SEQ ID NO: 32 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36695	KSSVIASLLF	10	SEQ ID NO: 33 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36696	MQPRMFFLF	9	SEQ ID NO: 34 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36697	KYLEESVWL	9	SEQ ID NO: 35 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36698	KQMEDGHTLF	10	SEQ ID NO: 36 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36699	QWPWQASLQF	10	SEQ ID NO: 37 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36700	KYTNWKAFL	9	SEQ ID NO: 38 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36701	LIFMLANVF	9	SEQ ID NO: 39 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36702	QYEPPSAPSTTF	12	SEQ ID NO: 40 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36703	VIYFMGAIF	9	SEQ ID NO: 41 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36704	TLPNTIYRF	9	SEQ ID NO: 42 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36705	IQMDEPMAF	9	SEQ ID NO: 43 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36706	AYLSAVGTF	9	SEQ ID NO: 44 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36707	KYFVPPQLF	9	SEQ ID NO: 45 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36708	AFPVTSIFHTF	11	SEQ ID NO: 46 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36709	KYADYFLEV	9	SEQ ID NO: 47 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36710	VFIDHPVHLKF	11	SEQ ID NO: 48 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36711	LYISEVRNI	9	SEQ ID NO: 49 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36712	SYPELVKMVW	10	SEQ ID NO: 50 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36713	KYALLLQEL	9	SEQ ID NO: 51 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36714	KYMKIFHKF	9	SEQ ID NO: 52 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36715	KYITNLEDL	9	SEQ ID NO: 53 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36716	LLIKLLQTF	9	SEQ ID NO: 54 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36717	RWMDQRLVF	9	SEQ ID NO: 55 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36718	VYMIEPLEL	9	SEQ ID NO: 56 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36719	YPSIIQEF	8	SEQ ID NO: 57 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36720	QFAAPLRGIYF	11	SEQ ID NO: 58 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36721	KYSTTFFMV	9	SEQ ID NO: 59 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36722	TYLSIFDQL	9	SEQ ID NO: 60 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36723	NYAENILTI	9	SEQ ID NO: 61 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36724	LYQEILAQL	9	SEQ ID NO: 62 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36725	VMPSDSFFF	9	SEQ ID NO: 63 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36726	NYAIFDEGHML	11	SEQ ID NO: 64 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36727	VYPASKMFPFI	11	SEQ ID NO: 65 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36728	IYFRDSSFL	9	SEQ ID NO: 66 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36729	RYPGKFYRV	9	SEQ ID NO: 67 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36730	IYQQIIQTY	9	SEQ ID NO: 68 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36731	IMPEKFEFW	9	SEQ ID NO: 69 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36732	PYTNYTFDF	9	SEQ ID NO: 70 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36733	SYMVLAPVF	9	SEQ ID NO: 71 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36734	RYEGILYTI	9	SEQ ID NO: 72 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36735	SYIGLPLTL	9	SEQ ID NO: 73 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36736	VYDQYFITL	9	SEQ ID NO: 74 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36737	NYIYSISVF	9	SEQ ID NO: 75 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36738	WYGWHFPEL	9	SEQ ID NO: 76 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36739	AYTLLGHEFV	10	SEQ ID NO: 77 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36740	TWFPKTPMLF	10	SEQ ID NO: 78 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36741	RYLADLPTL	9	SEQ ID NO: 79 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36742	YYSPLRDLL	9	SEQ ID NO: 80 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36743	LYPEGLRLL	9	SEQ ID NO: 81 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36744	RFLPSPVVI	9	SEQ ID NO: 82 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36745	TYCQNIKEF	9	SEQ ID NO: 83 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36746	YVDINTFRL	9	SEQ ID NO: 84 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36747	YIDEFQSLV	9	SEQ ID NO: 85 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36748	FVIDGFDEL	9	SEQ ID NO: 86 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36749	TLYPYQISQL	10	SEQ ID NO: 87 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36750	VQMVITEAQKV	11	SEQ ID NO: 88 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36751	ILSTTMVTV	9	SEQ ID NO: 89 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36752	FLLMHPSI	8	SEQ ID NO: 90 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36753	FALPGLLHA	9	SEQ ID NO: 91 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36754	NLRDLLSEV	9	SEQ ID NO: 92 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36755	TLQEKILQV	9	SEQ ID NO: 93 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36756	VLPDIETLIGV	11	SEQ ID NO: 94 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36757	ITIGVLARV	9	SEQ ID NO: 95 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36758	HLVGGLHTV	9	SEQ ID NO: 96 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36759	VLALVNSTV	9	SEQ ID NO: 97 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36760	LQSSGLTLLL	10	SEQ ID NO: 98 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36761	FLKEKVPGI	9	SEQ ID NO: 99 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36762	RQYPTPFQL	9	SEQ ID NO: 100 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36763	FIISDWRFVL	10	SEQ ID NO: 101 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36764	SLLEQAIAL	9	SEQ ID NO: 102 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36765	FLYYPDPVL	9	SEQ ID NO: 103 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36766	GMLDIFWGV	9	SEQ ID NO: 104 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36767	SLLTHIPTA	9	SEQ ID NO: 105 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36768	FIIDTTYPAYV	11	SEQ ID NO: 106 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36769	LLQGAIESV	9	SEQ ID NO: 107 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36770	MIIALSLYI	9	SEQ ID NO: 108 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36771	LLLGSIGLLGV	11	SEQ ID NO: 109 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36772	LLADFQALL	9	SEQ ID NO: 110 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36773	ALCLLLHLL	9	SEQ ID NO: 111 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36774	SVSDGIHSV	9	SEQ ID NO: 112 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36775	AVLTGLVEV	9	SEQ ID NO: 113 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36776	ILDERQVLL	9	SEQ ID NO: 114 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36777	MLLETQDALYV	11	SEQ ID NO: 115 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36778	VLMEENSKL	9	SEQ ID NO: 116 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36779	FLDPNARPLV	10	SEQ ID NO: 117 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36780	ALSSVLHSI	9	SEQ ID NO: 118 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36781	RTADITVTV	9	SEQ ID NO: 119 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36782	ALLANLPAV	9	SEQ ID NO: 120 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36783	ALVDTLTGI	9	SEQ ID NO: 121 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36784	ALLEMFPEITV	11	SEQ ID NO: 122 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36785	LMAFFLAVV	9	SEQ ID NO: 123 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36786	SVASVLLYL	9	SEQ ID NO: 124 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36787	VLQPFLPSI	9	SEQ ID NO: 125 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36788	FLSTVTSV	8	SEQ ID NO: 126 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36789	GLDGSLVFL	9	SEQ ID NO: 127 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36790	FLGTTPTL	8	SEQ ID NO: 128 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36791	VLYDKDAVYV	10	SEQ ID NO: 129 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36792	NLWGGQGLLGV	11	SEQ ID NO: 130 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36793	LLKEFVQRV	9	SEQ ID NO: 131 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36794	ALWLVDPLTV	10	SEQ ID NO: 132 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36795	MTLPVDAVISV	11	SEQ ID NO: 133 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36796	AAEIGDKSWLY	11	SEQ ID NO: 134 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36797	ASEDSVLLY	9	SEQ ID NO: 135 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36798	ATDLVVLDRY	10	SEQ ID NO: 136 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36799	ATSKFMEFY	9	SEQ ID NO: 137 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36800	DSDSCHFNY	9	SEQ ID NO: 138 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36801	ECDMAFHIY	9	SEQ ID NO: 139 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36802	ESDREELNY	9	SEQ ID NO: 140 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36803	ESDVGVVVY	9	SEQ ID NO: 141 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36804	EVAEPSVLFDLY	12	SEQ ID NO: 142 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36805	FIDYPKKEDY	10	SEQ ID NO: 143 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36806	FLDSQNLSAY	10	SEQ ID NO: 144 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36807	FVDKPVAY	8	SEQ ID NO: 145 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36808	GLNTGSALSY	10	SEQ ID NO: 146 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36809	GSSDSSTLPKL	11	SEQ ID NO: 147 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36810	GTEFTTILY	9	SEQ ID NO: 148 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36811	GTEFTTVLY	9	SEQ ID NO: 149 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36812	GTELLSLVY	9	SEQ ID NO: 150 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36813	HSDLKVGEY	9	SEQ ID NO: 151 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36814	HTDSLHLLI	9	SEQ ID NO: 152 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36815	KLDRSVFTAY	10	SEQ ID NO: 153 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36816	LLDISQKNLY	10	SEQ ID NO: 154 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36817	LLDPNPHMY	9	SEQ ID NO: 155 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36818	LLDSLREQY	9	SEQ ID NO: 156 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36819	LMDRPIFY	8	SEQ ID NO: 157 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36820	LSDLLKQGY	9	SEQ ID NO: 158 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36821	LSDTSVIQFY	10	SEQ ID NO: 159 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36822	LTEAVLNRY	9	SEQ ID NO: 160 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36823	LVDDGTHGQY	10	SEQ ID NO: 161 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36824	LVDNSIRELQY	11	SEQ ID NO: 162 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36825	NSDSSLTLREFY	12	SEQ ID NO: 163 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36826	NTDNNLAVY	9	SEQ ID NO: 164 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36827	NTDPTAPPY	9	SEQ ID NO: 165 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36828	NTQITDIGRY	10	SEQ ID NO: 166 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36829	QSDPGTSVLGY	11	SEQ ID NO: 167 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36830	QTDHPQPILDRY	12	SEQ ID NO: 168 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36831	RLDTPLYFSY	10	SEQ ID NO: 169 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36832	RSDDTAVYY	9	SEQ ID NO: 170 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36833	RSDPVTLNVLY	11	SEQ ID NO: 171 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36834	RTDSCSSAQAQY	12	SEQ ID NO: 172 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36835	RTEFNLNQY	9	SEQ ID NO: 173 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36836	SADDIRGIQSLY	12	SEQ ID NO: 174 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36837	SDVTPLTF	8	SEQ ID NO: 175 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36838	SRTINVSNLY	10	SEQ ID NO: 176 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36839	SSDEVNFLVY	10	SEQ ID NO: 177 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36840	SSDSSTLPKL	10	SEQ ID NO: 178 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36841	STAKSATWTY	10	SEQ ID NO: 179 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36842	STDPWIQMAY	10	SEQ ID NO: 180 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36843	TADGKTYYY	9	SEQ ID NO: 181 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36844	TDYHVRVY	8	SEQ ID NO: 182 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36845	TLEDIATSHLY	11	SEQ ID NO: 183 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36846	TSAHPEDSSFY	11	SEQ ID NO: 184 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36847	TSDSNLNKY	9	SEQ ID NO: 185 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36848	TTDIIEKY	8	SEQ ID NO: 186 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36849	VADLHLYLY	9	SEQ ID NO: 187 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36850	VSDAKLDKY	9	SEQ ID NO: 188 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36851	VSDSECLSRY	10	SEQ ID NO: 189 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36852	VTDGINPLIDRY	12	SEQ ID NO: 190 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36853	VTDGSLYEGVAY	12	SEQ ID NO: 191 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36854	VTEESFDSKFY	11	SEQ ID NO: 192 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36855	VTEFSLNTY	9	SEQ ID NO: 193 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36856	VVADTKMIEY	10	SEQ ID NO: 194 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36857	VVDSVGGYLY	10	SEQ ID NO: 195 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36858	WMFFVINY	8	SEQ ID NO: 196 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36859	YADTVRPEFY	10	SEQ ID NO: 197 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36860	YLDPVQRDLY	10	SEQ ID NO: 198 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36861	YLPQHTIETY	10	SEQ ID NO: 199 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36862	YSDEDVTKY	9	SEQ ID NO: 200 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36863	YVGKEHMFY	9	SEQ ID NO: 201 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36864	KLAELEGALQK	11	SEQ ID NO: 202 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36865	KVKDTPGLGK	10	SEQ ID NO: 203 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36866	AVFDKFIRY	9	SEQ ID NO: 204 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36867	SLDGAARPK	9	SEQ ID NO: 205 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36868	KLIDLSQVMY	10	SEQ ID NO: 206 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36869	RSFNGLLTMY	10	SEQ ID NO: 207 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36870	GLASRILDAK	10	SEQ ID NO: 208 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36871	RTQIPMSEK	9	SEQ ID NO: 209 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36872	ATSGVPVYK	9	SEQ ID NO: 210 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36873	TVNPVAIHK	9	SEQ ID NO: 211 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36874	KAYEQVMHY	9	SEQ ID NO: 212 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36875	LNINMTSPMGTK	12	SEQ ID NO: 213 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36876	RTMSEAALVRK	11	SEQ ID NO: 214 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36877	MMFSGPQILKL	11	SEQ ID NO: 215 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36878	KLYAWELAF	9	SEQ ID NO: 216 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36879	RILNQILYY	9	SEQ ID NO: 217 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36880	KTLVAELLILK	11	SEQ ID NO: 218 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36881	RLRSSLVFK	9	SEQ ID NO: 219 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36882	SPSVSQLSVL	10	SEQ ID NO: 220 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36883	VPDVAQFVL	9	SEQ ID NO: 221 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36884	NPFYPEVEL	9	SEQ ID NO: 222 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36885	YPKDIYSSF	9	SEQ ID NO: 223 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36886	GPQPWHAAL	9	SEQ ID NO: 224 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36887	LPFDGPGGIL	10	SEQ ID NO: 225 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36888	SPRMSGLLSQT	11	SEQ ID NO: 226 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36889	YPRGNHWAVGH	11	SEQ ID NO: 227 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36890	YPRGNHWAVGHL	12	SEQ ID NO: 228 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36891	VPLPAGGGTV	10	SEQ ID NO: 229 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36892	VPLPAGGGTVL	11	SEQ ID NO: 230 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36893	RPRALRDLQL	10	SEQ ID NO: 231 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36894	RPRALRDLQLL	11	SEQ ID NO: 232 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36895	KPYQGNPTF	9	SEQ ID NO: 233 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36896	RAKNAGVTI	9	SEQ ID NO: 234 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36897	MPLKHYLLL	9	SEQ ID NO: 235 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36898	RVRGGEDGDRAL	12	SEQ ID NO: 236 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36899	RPAATAVISL	10	SEQ ID NO: 237 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36900	KPGPPWAAF	9	SEQ ID NO: 238 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36901	YVPSASLFM	9	SEQ ID NO: 239 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36902	LSPREVTTVL	10	SEQ ID NO: 240 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36903	SARLATDAL	9	SEQ ID NO: 241 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36904	SPRWLPVSL	9	SEQ ID NO: 242 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36905	RPIENRILIL	10	SEQ ID NO: 243 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36906	FPYVRDFVM	9	SEQ ID NO: 244 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36907	RIREHVPQL	9	SEQ ID NO: 245 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36908	TPLPAVIVL	9	SEQ ID NO: 246 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36909	RALLARLLL	9	SEQ ID NO: 247 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36910	IPNWARQDL	9	SEQ ID NO: 248 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36911	VPSSRILQL	9	SEQ ID NO: 249 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36912	SPRDFLSGL	9	SEQ ID NO: 250 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36913	VPRSSGQTV	9	SEQ ID NO: 251 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36914	SPDIRNTTV	9	SEQ ID NO: 252 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36915	RVIDAVRFTL	10	SEQ ID NO: 253 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36916	NPFPHLITL	9	SEQ ID NO: 254 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36917	MPLLENLYL	9	SEQ ID NO: 255 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36918	SPRVPSIEL	9	SEQ ID NO: 256 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36919	LPRIPFADV	9	SEQ ID NO: 257 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36920	LPRGPLASL	9	SEQ ID NO: 258 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36921	RPPAAGLRGISL	12	SEQ ID NO: 259 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36922	YPQHPGLNA	9	SEQ ID NO: 260 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36923	APSARVGVC	9	SEQ ID NO: 261 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36924	SAYPQRLEI	9	SEQ ID NO: 262 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36925	HPAPYGDLL	9	SEQ ID NO: 263 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36926	RPILIIITL	9	SEQ ID NO: 264 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36927	SPRQPPRLV	9	SEQ ID NO: 265 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36928	HAYPPGPGL	9	SEQ ID NO: 266 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36929	HPELVNHIVF	10	SEQ ID NO: 267 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36930	YPLFRGINL	9	SEQ ID NO: 268 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36931	APRAPRLML	9	SEQ ID NO: 269 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36932	APGPRFLVT	9	SEQ ID NO: 270 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36933	MPLPWSLALP	10	SEQ ID NO: 271 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36934	MPLPWSLALPL	11	SEQ ID NO: 272 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36935	MPLLWLRGF	9	SEQ ID NO: 273 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36936	TPYQEHVAL	9	SEQ ID NO: 274 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36937	APHPPLSVV	9	SEQ ID NO: 275 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36938	LPRAGGAFL	9	SEQ ID NO: 276 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36939	MPLFEPRVF	9	SEQ ID NO: 277 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36940	HPMIDINGIIVF	12	SEQ ID NO: 278 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36941	SPARASPAL	9	SEQ ID NO: 279 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36942	VPISEEGTPVL	11	SEQ ID NO: 280 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36943	RPRAPVTPA	9	SEQ ID NO: 281 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36944	MPQIETRVIL	10	SEQ ID NO: 282 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36945	RPHSLSSEL	9	SEQ ID NO: 283 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36946	FPVTSIFHTF	10	SEQ ID NO: 284 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36947	FPSFLTNSL	9	SEQ ID NO: 285 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36948	VPTLRSEL	8	SEQ ID NO: 286 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36949	APREEQQRSL	10	SEQ ID NO: 287 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36950	FPQKFIDLL	9	SEQ ID NO: 288 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36951	VPENHSVAL	9	SEQ ID NO: 289 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36952	APYRPPDISL	10	SEQ ID NO: 290 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36953	SPQRLRGLL	9	SEQ ID NO: 291 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36954	SPQRLRGLLL	10	SEQ ID NO: 292 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36955	RPRSALPRLLLP	12	SEQ ID NO: 293 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36956	GPTPNTGAAL	10	SEQ ID NO: 294 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36957	KPEGTRIAV	9	SEQ ID NO: 295 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36958	MPMQDIKM	8	SEQ ID NO: 296 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36959	RAQLKLVAL	9	SEQ ID NO: 297 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36960	FNKRKPLSL	9	SEQ ID NO: 298 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36961	MAQFKEISL	9	SEQ ID NO: 299 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36962	VASPKHCVL	9	SEQ ID NO: 300 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36963	YMHKLLVL	8	SEQ ID NO: 301 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36964	HLLQKQTSI	9	SEQ ID NO: 302 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36965	LPFPKFTV	8	SEQ ID NO: 303 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36966	ELKKLYCQI	9	SEQ ID NO: 304 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36967	ALKLRVAVL	9	SEQ ID NO: 305 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36968	ILKVKVGL	8	SEQ ID NO: 306 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36969	ILLPRTVSL	9	SEQ ID NO: 307 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36970	MLKQKVEEL	9	SEQ ID NO: 308 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36971	DAIQRKYSC	9	SEQ ID NO: 309 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36972	LPPKKFVL	8	SEQ ID NO: 310 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36973	EIRIRVVQM	9	SEQ ID NO: 311 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36974	EAMLRNKEL	9	SEQ ID NO: 312 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36975	ELKKKEYEEL	10	SEQ ID NO: 313 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36976	AIISRLVAL	9	SEQ ID NO: 314 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36977	DIYQRALNL	9	SEQ ID NO: 315 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36978	VIKEKALTL	9	SEQ ID NO: 316 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36979	LVKVKVLL	8	SEQ ID NO: 317 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36980	EAAIRSVEL	9	SEQ ID NO: 318 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36981	AEMLERVIKNY	11	SEQ ID NO: 319 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36982	MEVDPIGHVYIF	12	SEQ ID NO: 320 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36983	AEMLESVIKNY	11	SEQ ID NO: 321 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36984	KEVDPAGHSY	10	SEQ ID NO: 322 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36985	SEFMQVIF	8	SEQ ID NO: 323 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36986	TDSIHAWTF	9	SEQ ID NO: 324 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36987	QEQDVDLVQKY	11	SEQ ID NO: 325 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36988	QEMQHFLGL	9	SEQ ID NO: 326 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36989	YEIEARNQVF	10	SEQ ID NO: 327 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36990	FEYDFLLQRI	10	SEQ ID NO: 328 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36991	NEHPSNNW	8	SEQ ID NO: 329 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36992	KEGDLGGKQW	10	SEQ ID NO: 330 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36993	EDAQGHIW	8	SEQ ID NO: 331 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36994	MEVPVIKI	8	SEQ ID NO: 332 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36995	AETLSTIQI	9	SEQ ID NO: 333 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36996	AEDEPAAAHL	10	SEQ ID NO: 334 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36997	KELEATKQY	9	SEQ ID NO: 335 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36998	ASSSGPMRWW	10	SEQ ID NO: 336 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP36999	TENRYCVQL	9	SEQ ID NO: 337 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37000	SEGSEPALLHSW	12	SEQ ID NO: 338 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37001	SEPALLHSW	9	SEQ ID NO: 339 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37002	TEFSLNTY	8	SEQ ID NO: 340 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37003	EEIEGKGSFTYF	12	SEQ ID NO: 341 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37004	HEFSSPSHL	9	SEQ ID NO: 342 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37005	TEFTTVLY	8	SEQ ID NO: 343 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37006	EEATGQFHVY	10	SEQ ID NO: 344 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37007	IEFIHPQAF	9	SEQ ID NO: 345 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37008	VEAPGPVHVYW	11	SEQ ID NO: 346 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37009	ALNPYQYQY	9	SEQ ID NO: 347 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37010	AEIQGNINHV	10	SEQ ID NO: 348 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37011	AEQDMRELTY	10	SEQ ID NO: 349 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37012	GECDVFKEIL	10	SEQ ID NO: 350 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37013	EEVNYINTF	9	SEQ ID NO: 351 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37014	NEVLTYIKF	9	SEQ ID NO: 352 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37015	GEIIMQNNW	9	SEQ ID NO: 353 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37016	TEDPTILRI	9	SEQ ID NO: 354 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37017	SDMVRFHLF	9	SEQ ID NO: 355 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37018	EEGRVYLF	8	SEQ ID NO: 356 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37019	RELENCFQIQ	10	SEQ ID NO: 357 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37020	KEADIHFLI	9	SEQ ID NO: 358 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37021	DELFSIALY	9	SEQ ID NO: 359 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37022	AEVPTGVII	9	SEQ ID NO: 360 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37023	SENLFFASF	9	SEQ ID NO: 361 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37024	SEKGVIQVY	9	SEQ ID NO: 362 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37025	AELDKLTSV	9	SEQ ID NO: 363 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37026	AETPIQNVI	9	SEQ ID NO: 364 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37027	SEMNVNMKY	9	SEQ ID NO: 365 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37028	AENLFRAF	8	SEQ ID NO: 366 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37029	GEVHPSEMI	9	SEQ ID NO: 367 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37030	GEFPVRVQV	9	SEQ ID NO: 368 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37031	EEIERFFKL	9	SEQ ID NO: 369 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37032	YEDLSQKY	8	SEQ ID NO: 370 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37033	GELALKKKI	9	SEQ ID NO: 371 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37034	TEGIIMKDF	9	SEQ ID NO: 372 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37035	MEMQKSPVF	9	SEQ ID NO: 373 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37036	DEVNFLVY	8	SEQ ID NO: 374 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37037	VYSDLHAFYY	10	SEQ ID NO: 375 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37038	KYVKDFHKF	9	SEQ ID NO: 376 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37039	VYVGAVNRI	9	SEQ ID NO: 377 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37040	KFLGPAEHLTF	11	SEQ ID NO: 378 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37041	NYIVPDKQIF	10	SEQ ID NO: 379 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37042	VFQEKHHVI	9	SEQ ID NO: 380 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37043	TYSKKHFRI	9	SEQ ID NO: 381 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37044	IYHSHHPTL	9	SEQ ID NO: 382 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37045	RYKQDVERF	9	SEQ ID NO: 383 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37046	KYVKVFDKF	9	SEQ ID NO: 384 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37047	MYINEVERL	9	SEQ ID NO: 385 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37048	VYNDHSIYVW	10	SEQ ID NO: 386 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37049	RWLPQKNAAQF	11	SEQ ID NO: 387 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37050	FSIPEGALVAV	11	SEQ ID NO: 388 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37051	TLMEQPLTTL	10	SEQ ID NO: 389 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37052	HIMPTVHTV	9	SEQ ID NO: 390 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37053	SLIDMRGIETV	11	SEQ ID NO: 391 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37054	SLFKDQMEL	9	SEQ ID NO: 392 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37055	ILLPYLQTL	9	SEQ ID NO: 393 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37056	ASEAEMRLFY	10	SEQ ID NO: 394 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37057	ASEASRLAHY	10	SEQ ID NO: 395 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37058	ASEFGNHYLY	10	SEQ ID NO: 396 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37059	ASEITSKGASLY	12	SEQ ID NO: 397 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37060	ASEQQALHTVQY	12	SEQ ID NO: 398 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37061	ATDIPCLLY	9	SEQ ID NO: 399 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37062	ATDISRQNEY	10	SEQ ID NO: 400 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37063	DSDESYMEKSLY	12	SEQ ID NO: 401 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37064	DTDSQRLAY	9	SEQ ID NO: 402 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37065	ELDSKVEVLTY	11	SEQ ID NO: 403 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37066	ETARKFLYY	9	SEQ ID NO: 404 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37067	ETEEGIYWRY	10	SEQ ID NO: 405 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37068	ETEQTKFWDY	10	SEQ ID NO: 406 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37069	FSDNDKLYLY	10	SEQ ID NO: 407 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37070	FTEQWTDGY	9	SEQ ID NO: 408 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37071	FVDPLVTNY	9	SEQ ID NO: 409 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37072	GSDHQSPSSSSY	12	SEQ ID NO: 410 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37073	GTVYEDLRY	9	SEQ ID NO: 411 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37074	ILDEVIMGY	9	SEQ ID NO: 412 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37075	ISDRYYTALY	10	SEQ ID NO: 413 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37076	KTDESLTKY	9	SEQ ID NO: 414 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37077	LLDPRSYHTY	10	SEQ ID NO: 415 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37078	LLDTAQKNLY	10	SEQ ID NO: 416 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37079	LLEDKHFQSY	10	SEQ ID NO: 417 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37080	LSDPSGPKSY	10	SEQ ID NO: 418 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37081	LSELKPMSY	9	SEQ ID NO: 419 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37082	LTEDKETLQY	10	SEQ ID NO: 420 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37083	LTELLERAAFY	11	SEQ ID NO: 421 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37084	MIDVTKSYY	9	SEQ ID NO: 422 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37085	NLDAVHDITVAY	12	SEQ ID NO: 423 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37086	NLDEEKQLLY	10	SEQ ID NO: 424 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37087	NLDIIQQEY	9	SEQ ID NO: 425 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37088	NLDQATRVAY	10	SEQ ID NO: 426 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37089	NSDEQKITEMVY	12	SEQ ID NO: 427 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37090	NSELSCQLY	9	SEQ ID NO: 428 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37091	NTEDSSMSGYLY	12	SEQ ID NO: 429 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37092	NTEGLHHLY	9	SEQ ID NO: 430 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37093	NTSDMMGRMSY	11	SEQ ID NO: 431 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37094	NVDPVQHTY	9	SEQ ID NO: 432 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37095	QIDTGENLY	9	SEQ ID NO: 433 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37096	QTDCAPNNGY	10	SEQ ID NO: 434 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37097	QTDDTWRTEY	10	SEQ ID NO: 435 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37098	QTETGTPYMLY	11	SEQ ID NO: 436 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37099	STDGKHWWEY	10	SEQ ID NO: 437 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37100	STDNFNCKY	9	SEQ ID NO: 438 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37101	TLDAGKFQIY	10	SEQ ID NO: 439 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37102	TLDENPGVRY	10	SEQ ID NO: 440 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37103	TLDSALNAASYY	12	SEQ ID NO: 441 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37104	TSDFSRFTNY	10	SEQ ID NO: 442 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37105	TTDFPSESSFEY	12	SEQ ID NO: 443 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37106	TTDTVIRSY	9	SEQ ID NO: 444 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37107	VLDQGKITEY	10	SEQ ID NO: 445 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37108	VTAQVVGTERY	11	SEQ ID NO: 446 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37109	VVDEDHELIY	10	SEQ ID NO: 447 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37110	YLDIPNPRY	9	SEQ ID NO: 448 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37111	YLDRGTGNVSFY	12	SEQ ID NO: 449 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37112	YSDDGQKWTVY	11	SEQ ID NO: 450 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37113	YSDSLVQKGY	10	SEQ ID NO: 451 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37114	YVDAVLGKGHQY	12	SEQ ID NO: 452 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37115	AINTSIKNK	9	SEQ ID NO: 453 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37116	KVYTPSISK	9	SEQ ID NO: 454 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37117	RIADIFVKK	9	SEQ ID NO: 455 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37118	SMFTAILKK	9	SEQ ID NO: 456 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37119	SINKPTSER	9	SEQ ID NO: 457 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37120	GIADFVLKY	9	SEQ ID NO: 458 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37121	RPMQQARAQL	10	SEQ ID NO: 459 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37122	MPMAGDMNGL	10	SEQ ID NO: 460 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37123	RPILIIVTL	9	SEQ ID NO: 461 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37124	RPFHTRATV	9	SEQ ID NO: 462 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37125	TPKAGPTL	8	SEQ ID NO: 463 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37126	YPRPGTPAA	9	SEQ ID NO: 464 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37127	VPRPIFSQL	9	SEQ ID NO: 465 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37128	APYKSVTSL	9	SEQ ID NO: 466 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37129	KPFSSFTSM	9	SEQ ID NO: 467 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37130	SPMYGQAGL	9	SEQ ID NO: 468 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37131	YPENGVVQM	9	SEQ ID NO: 469 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37132	SPNSYFRVL	9	SEQ ID NO: 470 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37133	KPRPDVTNEL	10	SEQ ID NO: 471 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37134	NPRATDAQL	9	SEQ ID NO: 472 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37135	LPRALLSSL	9	SEQ ID NO: 473 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37136	LPRLLPAL	8	SEQ ID NO: 474 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37137	RPHKPGLYL	9	SEQ ID NO: 475 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37138	AEEEIMKKI	9	SEQ ID NO: 476 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37139	QENSYQSRL	9	SEQ ID NO: 477 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37140	SEIEQEIGSL	10	SEQ ID NO: 478 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37141	AEIQPQTQV	9	SEQ ID NO: 479 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37142	GEVSGLTKDF	10	SEQ ID NO: 480 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37143	RELQHEHSL	9	SEQ ID NO: 481 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37144	TEREWADEW	9	SEQ ID NO: 482 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37145	EENDQSTHKW	10	SEQ ID NO: 483 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37146	AEVGFVRFF	9	SEQ ID NO: 484 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37147	SEIEDSTKQVF	11	SEQ ID NO: 485 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37148	SEDDPILQI	9	SEQ ID NO: 486 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37149	AEDQLHHSF	9	SEQ ID NO: 487 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37150	TEFPIIKMY	9	SEQ ID NO: 488 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37151	SEIGKAVGF	9	SEQ ID NO: 489 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37152	SYVKVLHHL	9	SEQ ID NO: 490 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37153	KYLEKYYNL	9	SEQ ID NO: 491 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37154	NYEDHFPLL	9	SEQ ID NO: 492 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37155	TYKYVDINTF	10	SEQ ID NO: 493 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37156	RYLEKFYGL	9	SEQ ID NO: 494 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37157	SYNDALLTF	9	SEQ ID NO: 495 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37158	VFMKDGFFYF	10	SEQ ID NO: 496 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37159	NYPKSIHSF	9	SEQ ID NO: 497 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37160	EYIRALQQL	9	SEQ ID NO: 498 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37161	VYFVAPAKF	9	SEQ ID NO: 499 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37162	VWSDVTPLTF	10	SEQ ID NO: 500 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37163	GYIDNVTLI	9	SEQ ID NO: 501 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37164	SVHKITSTF	9	SEQ ID NO: 502 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37165	VHFEDTGKTLLF	12	SEQ ID NO: 503 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37166	VYEKNGYIYF	10	SEQ ID NO: 504 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37167	AYISGLDVF	9	SEQ ID NO: 505 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37168	RYVFPLPYL	9	SEQ ID NO: 506 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37169	VYIAELEKI	9	SEQ ID NO: 507 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37170	IYVTGGHLF	9	SEQ ID NO: 508 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37171	ALLEEEEGV	9	SEQ ID NO: 509 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37172	KVLEHVVRV	9	SEQ ID NO: 510 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37173	KIWEELSVLEV	11	SEQ ID NO: 511 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37174	VLGEEQEGV	9	SEQ ID NO: 512 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37175	KLVELEHTL	9	SEQ ID NO: 513 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37176	VQLDSIEDLEV	11	SEQ ID NO: 514 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37177	KIFEMLEGV	9	SEQ ID NO: 515 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37178	YTFSGDVQL	9	SEQ ID NO: 516 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37179	TLYNPERTITV	11	SEQ ID NO: 517 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37180	GLLEDERALQL	11	SEQ ID NO: 518 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37181	KIQEILTQV	9	SEQ ID NO: 519 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37182	KIQEMQHFL	9	SEQ ID NO: 520 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37183	FVYGEPREL	9	SEQ ID NO: 521 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37184	TLDEKVAEL	9	SEQ ID NO: 522 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37185	HLIAEIHTA	9	SEQ ID NO: 523 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37186	KVWSDVTPL	9	SEQ ID NO: 524 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37187	RLDDLKMTV	9	SEQ ID NO: 525 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37188	VLSPFILTL	9	SEQ ID NO: 526 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37189	LLDSVSRL	8	SEQ ID NO: 527 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37190	RLLDSVSRL	9	SEQ ID NO: 528 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37191	HPSAHDVIL	9	SEQ ID NO: 529 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.
DRAMP37192	APAAWLRSAA	10	SEQ ID NO: 530 of Patent CN110785183A	Synthetic	Antimicrobial, Anticancer	CN110785183A	Patent Application	2020##2##11	Not available	Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention also relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine composition transferred into the patient. Peptides that bind to Major Histocompatibility Complex (MHC) molecules or peptides of the same may also be targets for antibodies, soluble T cell receptors and other binding molecules.